[
    {
        "_id": "PIBARDGJJAGJAJ-NQIIRXRSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 118323590,
                "inchl_key": "PIBARDGJJAGJAJ-NQIIRXRSSA-N",
                "generic_name": "(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide",
                "designated_date": "11/02/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Alexion Pharmaceuticals, Inc|300 George Street|New Haven|Connecticut|6511|United States",
                "orphan_designation": {
                    "original_text": "Treatment of paroxysmal nocturnal hemoglobinuria",
                    "umls_id": "C0024790",
                    "parsed_text": "Paroxysmal nocturnal hemoglobinuria"
                }
            },
            {
                "compound_id": 118323590,
                "inchl_key": "PIBARDGJJAGJAJ-NQIIRXRSSA-N",
                "generic_name": "(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide",
                "designated_date": "12/14/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Alexion Pharmaceuticals, Inc|300 George Street|New Haven|Connecticut|6511|United States",
                "orphan_designation": {
                    "original_text": "Treatment of C3 glomerulopathy (C3G)",
                    "umls_id": "C4521256",
                    "parsed_text": "Glomerulopathy"
                }
            }
        ]
    },
    {
        "_id": "CIWBSHSKHKDKBQ-JLAZNSOCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 54670067,
                "inchl_key": "CIWBSHSKHKDKBQ-JLAZNSOCSA-N",
                "generic_name": "ascorbic acid",
                "designated_date": "05/11/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Murigenetics SAS|Faculte de Medecine Timone|13005 Marseille|France",
                "orphan_designation": {
                    "original_text": "Treatment of Charcot-Marie-Tooth disease type 1A.",
                    "umls_id": "C0270911",
                    "parsed_text": "Charcot-Marie-Tooth Disease Type 1A"
                }
            },
            {
                "compound_id": 54670067,
                "inchl_key": "CIWBSHSKHKDKBQ-JLAZNSOCSA-N",
                "generic_name": "ascorbic acid",
                "designated_date": "07/30/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Renovion, Inc.|112 South Duke Street|Durham|North Carolina|27701|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            },
            {
                "compound_id": 54670067,
                "inchl_key": "CIWBSHSKHKDKBQ-JLAZNSOCSA-N",
                "generic_name": "ascorbic acid",
                "trade_name": "Ascor",
                "designated_date": "08/31/2007",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "for the treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administrtaion is not possible, insufficient or contraindicated",
                "marketing_approval_date": "\u00a010/02/2017\u00a0",
                "exclusivity_end_date": "\u00a010/02/2024\u00a0",
                "exclusivity_protected_indication": "for the treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administrtaion is not possible, insufficient or contraindicated",
                "sponsor": "McGuff Pharmaceuticals Inc.|2921 W. MacArthur Blvd.|Suite 141|Santa Ana|California|92704|United States",
                "orphan_designation": {
                    "original_text": "Treatment of scurvy",
                    "umls_id": "C0036474",
                    "parsed_text": "Scurvy"
                }
            }
        ]
    },
    {
        "_id": "GJPICJJJRGTNOD-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 104865,
                "inchl_key": "GJPICJJJRGTNOD-UHFFFAOYSA-N",
                "generic_name": "bosentan",
                "trade_name": "Tracleer",
                "designated_date": "10/06/2000",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of pulmonary arterial hypertension.",
                "marketing_approval_date": "\u00a011/20/2001\u00a0",
                "exclusivity_end_date": "\u00a011/20/2008\u00a0",
                "sponsor": "Actelion Pharmaceuticals Ltd|1840 Gateway Drive|Suite 300|Cherry Hill|New Jersey|8002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            },
            {
                "compound_id": 104865,
                "inchl_key": "GJPICJJJRGTNOD-UHFFFAOYSA-N",
                "generic_name": "bosentan",
                "trade_name": "Tracleer",
                "designated_date": "10/06/2000",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability",
                "marketing_approval_date": "\u00a009/05/2017\u00a0",
                "exclusivity_end_date": "\u00a009/05/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability",
                "sponsor": "Actelion Pharmaceuticals Ltd|1840 Gateway Drive|Suite 300|Cherry Hill|New Jersey|8002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            },
            {
                "compound_id": 104865,
                "inchl_key": "GJPICJJJRGTNOD-UHFFFAOYSA-N",
                "generic_name": "bosentan",
                "designated_date": "06/07/2010",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Actelion Ltd.|Gewerbestrasse 16|Allschwil|Switzerland",
                "orphan_designation": {
                    "original_text": "Reduction of the number (treatment) of new digital ulcers in patients with systemic sclerosis",
                    "umls_id": "C0036421,C0041582",
                    "parsed_text": "Systemic sclerosis , Ulcers"
                }
            },
            {
                "compound_id": 104865,
                "inchl_key": "GJPICJJJRGTNOD-UHFFFAOYSA-N",
                "generic_name": "bosentan",
                "designated_date": "09/30/2008",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Actelion Pharmaceuticals Ltd|Gewerbestrasse 16|Allschwil|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic pulmonary fibrosis",
                    "umls_id": "C1800706",
                    "parsed_text": "Idiopathic Pulmonary Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "VOVIALXJUBGFJZ-KWVAZRHASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5281004,
                "inchl_key": "VOVIALXJUBGFJZ-KWVAZRHASA-N",
                "generic_name": "budesonide",
                "designated_date": "12/20/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Takeda Pharmaceuticals U.S.A., Inc.|95 Hayden Avenue|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with eosinophilic esophagitis",
                    "umls_id": "C0341106",
                    "parsed_text": "Eosinophilic esophagitis"
                }
            },
            {
                "compound_id": 5281004,
                "inchl_key": "VOVIALXJUBGFJZ-KWVAZRHASA-N",
                "generic_name": "budesonide",
                "designated_date": "05/06/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santarus, Inc.|3611 Valley Centre Drive, Suite 400|San Diego|California|92130|United States",
                "orphan_designation": {
                    "original_text": "Treat of ulcerative colitis in pediatric patients aged 0 through 16 years.",
                    "umls_id": "C0009324",
                    "parsed_text": "Ulcerative Colitis"
                }
            },
            {
                "compound_id": 5281004,
                "inchl_key": "VOVIALXJUBGFJZ-KWVAZRHASA-N",
                "generic_name": "budesonide",
                "designated_date": "02/11/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Calliditas Therapeutics AB|26B Wallingatan|Norrmalm|Stockholms l\u4b8d|Sweden",
                "orphan_designation": {
                    "original_text": "Treatment of primary biliary cholangitis",
                    "umls_id": "C0008312",
                    "parsed_text": "Primary Biliary Cholangitis"
                }
            },
            {
                "compound_id": 5281004,
                "inchl_key": "VOVIALXJUBGFJZ-KWVAZRHASA-N",
                "generic_name": "budesonide",
                "designated_date": "02/01/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Calliditas Therapeutics AB|26B Wallingatan|Norrmalm|Stockholms l\u4b8d|Sweden",
                "orphan_designation": {
                    "original_text": "Treatment of Autoimmune Hepatitis",
                    "umls_id": "C0241910",
                    "parsed_text": "Autoimmune hepatitis"
                }
            },
            {
                "compound_id": 5281004,
                "inchl_key": "VOVIALXJUBGFJZ-KWVAZRHASA-N",
                "generic_name": "budesonide",
                "designated_date": "05/17/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Calliditas Therapeutics AB|26B Wallingatan|Norrmalm|Stockholms l\u4b8d|Sweden",
                "orphan_designation": {
                    "original_text": "To slow the progression of immunoglobulin A nephropathy & delay kidney failure in patients affected by the disease.",
                    "umls_id": "C0017661,C0035078",
                    "parsed_text": "Immunoglobulin A Nephropathy , Kidney Failure"
                }
            },
            {
                "compound_id": 5281004,
                "inchl_key": "VOVIALXJUBGFJZ-KWVAZRHASA-N",
                "generic_name": "budesonide",
                "designated_date": "05/08/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Salix Pharmaceuticals, Inc., division of Valeant Pharmaceuticals North America|400 Somerset Corporate Boulevard|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of eosinophilic esophagitis",
                    "umls_id": "C0341106",
                    "parsed_text": "Eosinophilic esophagitis"
                }
            }
        ]
    },
    {
        "_id": "PQAPVTKIEGUPRN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11455910,
                "inchl_key": "PQAPVTKIEGUPRN-UHFFFAOYSA-N",
                "generic_name": "N-[4-[[2-(1,1-Dimethylethyl)phenyl]sulfonyl]phenyl]-2,3,4-trihydroxy-5-[[2-(1-methylethyl)phenyl]methyl]benzamide",
                "designated_date": "09/14/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oxular Ltd|Magadalen Centre|1 Robert Robinson Avenue|Oxford|OX4 4GA|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of retinoblastoma",
                    "umls_id": "C0035335",
                    "parsed_text": "Retinoblastoma"
                }
            }
        ]
    },
    {
        "_id": "CPKVUHPKYQGHMW-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 410087,
                "inchl_key": "CPKVUHPKYQGHMW-UHFFFAOYSA-N",
                "generic_name": "povidone iodine",
                "designated_date": "11/27/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Veloce BioPharma LLC|7008 Lafayette Avenue|Fort Washington|Pennsylvania|19034|United States",
                "orphan_designation": {
                    "original_text": "Treatment of endophthalmitis",
                    "umls_id": "C0014236",
                    "parsed_text": "Endophthalmitis"
                }
            },
            {
                "compound_id": 410087,
                "inchl_key": "CPKVUHPKYQGHMW-UHFFFAOYSA-N",
                "generic_name": "povidone iodine",
                "designated_date": "11/30/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cumulus Pharmaceutical LLC|1712 Pioneer Avenue|Suite 1377|Cheyenne|Wyoming|82001|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Endophthalmitis",
                    "umls_id": "C0014236",
                    "parsed_text": "Endophthalmitis"
                }
            }
        ]
    },
    {
        "_id": "WRFHGDPIDHPWIQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10257882,
                "inchl_key": "WRFHGDPIDHPWIQ-UHFFFAOYSA-N",
                "generic_name": "sparsentan",
                "designated_date": "01/11/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Travere Therapeutics, Inc.|3611 Valley Centre Drive, Suite 300|San Diego|California|92130|United States",
                "orphan_designation": {
                    "original_text": "Treatment of immunoglobulin A (IgA) nephropathy",
                    "umls_id": "C0022658",
                    "parsed_text": "Nephropathy"
                }
            },
            {
                "compound_id": 10257882,
                "inchl_key": "WRFHGDPIDHPWIQ-UHFFFAOYSA-N",
                "generic_name": "sparsentan",
                "designated_date": "01/05/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Travere Therapeutics, Inc.|3611 Valley Centre Drive, Suite 300|San Diego|California|92130|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Focal Segmental Glomerulosclerosis",
                    "umls_id": "C0017668",
                    "parsed_text": "Focal segmental glomerulosclerosis"
                }
            }
        ]
    },
    {
        "_id": "GFJCILQBXUTOGN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 15942270,
                "inchl_key": "GFJCILQBXUTOGN-UHFFFAOYSA-N",
                "generic_name": "((4-(3-benzyl-4-hydroxybenzyl)-3,5-dimethylphenoxy)methyl)phosphonic acid",
                "designated_date": "12/05/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Viking Therapeutics, Inc.|12340 El Camino Real|Suite 250|San Diego|California|92130|United States",
                "orphan_designation": {
                    "original_text": "Treatment of X-linked adrenoleukodystrophy",
                    "umls_id": "C0162309",
                    "parsed_text": "X-Linked Adrenoleukodystrophy"
                }
            }
        ]
    },
    {
        "_id": "WEQLWGNDNRARGE-DJIMGWMZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 14580381,
                "inchl_key": "WEQLWGNDNRARGE-DJIMGWMZSA-N",
                "generic_name": "(+)-alpha-dihydrotetrabenazine",
                "designated_date": "12/05/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Adeptio Pharmaceuticals, Ltd|22 Bedford Row|WC1R 4JS|London|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of Huntington's disease.",
                    "umls_id": "C0020179",
                    "parsed_text": "Huntington's Disease"
                }
            }
        ]
    },
    {
        "_id": "PFTAWBLQPZVEMU-ZFWWWQNUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 182232,
                "inchl_key": "PFTAWBLQPZVEMU-ZFWWWQNUSA-N",
                "generic_name": "(+)-Epicatechin",
                "designated_date": "04/06/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Epirium Bio Inc.|9171 Towne Centre Dr.,|Suite 270|San Diego|California|92122|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Duchenne and Becker muscular dystrophy",
                    "umls_id": "C3542021",
                    "parsed_text": "Duchenne and Becker Muscular Dystrophy"
                }
            }
        ]
    },
    {
        "_id": "ZFPZEYHRWGMJCV-ZHALLVOQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9926832,
                "inchl_key": "ZFPZEYHRWGMJCV-ZHALLVOQSA-N",
                "generic_name": "(-)-(3aR,4S,7aR)-4-Hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester",
                "designated_date": "10/12/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X syndrome",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "ZRJBHWIHUMBLCN-MEBBXXQBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6565233,
                "inchl_key": "ZRJBHWIHUMBLCN-MEBBXXQBSA-N",
                "generic_name": "(-)-huperzine A",
                "designated_date": "06/15/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Supernus Pharmaceuticals, Inc.|9715 Key West Avenue|Rockville|Maryland|20850|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Lennox-Gastaut Syndrome",
                    "umls_id": "C0238111",
                    "parsed_text": "Lennox-Gastaut syndrome"
                }
            },
            {
                "compound_id": 6565233,
                "inchl_key": "ZRJBHWIHUMBLCN-MEBBXXQBSA-N",
                "generic_name": "Huperzine A",
                "designated_date": "04/12/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biscayne Neurotherapeutics, Inc.|4770 Biscayne Boulevard|Suite 660|Miami|Florida|33137|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Dravet syndrome",
                    "umls_id": "C0751122",
                    "parsed_text": "Dravet Syndrome"
                }
            }
        ]
    },
    {
        "_id": "ZRJBHWIHUMBLCN-QDEBKDIKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5912039,
                "inchl_key": "ZRJBHWIHUMBLCN-QDEBKDIKSA-N",
                "generic_name": "(-)-huperzine A",
                "designated_date": "06/15/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Supernus Pharmaceuticals, Inc.|9715 Key West Avenue|Rockville|Maryland|20850|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Lennox-Gastaut Syndrome",
                    "umls_id": "C0238111",
                    "parsed_text": "Lennox-Gastaut syndrome"
                }
            },
            {
                "compound_id": 5912039,
                "inchl_key": "ZRJBHWIHUMBLCN-QDEBKDIKSA-N",
                "generic_name": "Huperzine A",
                "designated_date": "04/12/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biscayne Neurotherapeutics, Inc.|4770 Biscayne Boulevard|Suite 660|Miami|Florida|33137|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Dravet syndrome",
                    "umls_id": "C0751122",
                    "parsed_text": "Dravet Syndrome"
                }
            }
        ]
    },
    {
        "_id": "ZRJBHWIHUMBLCN-HNWKQCISSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71308731,
                "inchl_key": "ZRJBHWIHUMBLCN-HNWKQCISSA-N",
                "generic_name": "(-)-huperzine A",
                "designated_date": "06/15/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Supernus Pharmaceuticals, Inc.|9715 Key West Avenue|Rockville|Maryland|20850|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Lennox-Gastaut Syndrome",
                    "umls_id": "C0238111",
                    "parsed_text": "Lennox-Gastaut syndrome"
                }
            },
            {
                "compound_id": 71308731,
                "inchl_key": "ZRJBHWIHUMBLCN-HNWKQCISSA-N",
                "generic_name": "Huperzine A",
                "designated_date": "04/12/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biscayne Neurotherapeutics, Inc.|4770 Biscayne Boulevard|Suite 660|Miami|Florida|33137|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Dravet syndrome",
                    "umls_id": "C0751122",
                    "parsed_text": "Dravet Syndrome"
                }
            }
        ]
    },
    {
        "_id": "ZRJBHWIHUMBLCN-JYXJEATCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44461111,
                "inchl_key": "ZRJBHWIHUMBLCN-JYXJEATCSA-N",
                "generic_name": "(-)-huperzine A",
                "designated_date": "06/15/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Supernus Pharmaceuticals, Inc.|9715 Key West Avenue|Rockville|Maryland|20850|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Lennox-Gastaut Syndrome",
                    "umls_id": "C0238111",
                    "parsed_text": "Lennox-Gastaut syndrome"
                }
            },
            {
                "compound_id": 44461111,
                "inchl_key": "ZRJBHWIHUMBLCN-JYXJEATCSA-N",
                "generic_name": "Huperzine A",
                "designated_date": "04/12/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biscayne Neurotherapeutics, Inc.|4770 Biscayne Boulevard|Suite 660|Miami|Florida|33137|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Dravet syndrome",
                    "umls_id": "C0751122",
                    "parsed_text": "Dravet Syndrome"
                }
            }
        ]
    },
    {
        "_id": "ZRJBHWIHUMBLCN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 1253,
                "inchl_key": "ZRJBHWIHUMBLCN-UHFFFAOYSA-N",
                "generic_name": "(-)-huperzine A",
                "designated_date": "06/15/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Supernus Pharmaceuticals, Inc.|9715 Key West Avenue|Rockville|Maryland|20850|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Lennox-Gastaut Syndrome",
                    "umls_id": "C0238111",
                    "parsed_text": "Lennox-Gastaut syndrome"
                }
            },
            {
                "compound_id": 1253,
                "inchl_key": "ZRJBHWIHUMBLCN-UHFFFAOYSA-N",
                "generic_name": "Huperzine A",
                "designated_date": "04/12/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biscayne Neurotherapeutics, Inc.|4770 Biscayne Boulevard|Suite 660|Miami|Florida|33137|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Dravet syndrome",
                    "umls_id": "C0751122",
                    "parsed_text": "Dravet Syndrome"
                }
            }
        ]
    },
    {
        "_id": "ZRJBHWIHUMBLCN-YQEJDHNASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 854026,
                "inchl_key": "ZRJBHWIHUMBLCN-YQEJDHNASA-N",
                "generic_name": "(-)-huperzine A",
                "designated_date": "06/15/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Supernus Pharmaceuticals, Inc.|9715 Key West Avenue|Rockville|Maryland|20850|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Lennox-Gastaut Syndrome",
                    "umls_id": "C0238111",
                    "parsed_text": "Lennox-Gastaut syndrome"
                }
            },
            {
                "compound_id": 854026,
                "inchl_key": "ZRJBHWIHUMBLCN-YQEJDHNASA-N",
                "generic_name": "Huperzine A",
                "designated_date": "04/12/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biscayne Neurotherapeutics, Inc.|4770 Biscayne Boulevard|Suite 660|Miami|Florida|33137|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Dravet syndrome",
                    "umls_id": "C0751122",
                    "parsed_text": "Dravet Syndrome"
                }
            }
        ]
    },
    {
        "_id": "ZRJBHWIHUMBLCN-ZUZCIYMTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 449069,
                "inchl_key": "ZRJBHWIHUMBLCN-ZUZCIYMTSA-N",
                "generic_name": "(-)-huperzine A",
                "designated_date": "06/15/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Supernus Pharmaceuticals, Inc.|9715 Key West Avenue|Rockville|Maryland|20850|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Lennox-Gastaut Syndrome",
                    "umls_id": "C0238111",
                    "parsed_text": "Lennox-Gastaut syndrome"
                }
            },
            {
                "compound_id": 449069,
                "inchl_key": "ZRJBHWIHUMBLCN-ZUZCIYMTSA-N",
                "generic_name": "Huperzine A",
                "designated_date": "04/12/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biscayne Neurotherapeutics, Inc.|4770 Biscayne Boulevard|Suite 660|Miami|Florida|33137|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Dravet syndrome",
                    "umls_id": "C0751122",
                    "parsed_text": "Dravet Syndrome"
                }
            }
        ]
    },
    {
        "_id": "ZRJBHWIHUMBLCN-SEQYCRGISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 907504,
                "inchl_key": "ZRJBHWIHUMBLCN-SEQYCRGISA-N",
                "generic_name": "(-)-huperzine A",
                "designated_date": "06/15/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Supernus Pharmaceuticals, Inc.|9715 Key West Avenue|Rockville|Maryland|20850|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Lennox-Gastaut Syndrome",
                    "umls_id": "C0238111",
                    "parsed_text": "Lennox-Gastaut syndrome"
                }
            },
            {
                "compound_id": 907504,
                "inchl_key": "ZRJBHWIHUMBLCN-SEQYCRGISA-N",
                "generic_name": "Huperzine A",
                "designated_date": "04/12/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biscayne Neurotherapeutics, Inc.|4770 Biscayne Boulevard|Suite 660|Miami|Florida|33137|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Dravet syndrome",
                    "umls_id": "C0751122",
                    "parsed_text": "Dravet Syndrome"
                }
            }
        ]
    },
    {
        "_id": "DVZQUMSQEGOYMX-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 122540907,
                "inchl_key": "DVZQUMSQEGOYMX-UHFFFAOYSA-N",
                "generic_name": "(1-hydroxy-2-oxopiperidin-3-yl)phosphonic acid",
                "designated_date": "08/09/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "The University of Texas MD Anderson Cancer Center|1515 Holcombe Blvd #2|Houston|Texas|77030|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Glioblastoma",
                    "umls_id": "C0017636",
                    "parsed_text": "Glioblastoma"
                }
            }
        ]
    },
    {
        "_id": "OEBIHOVSAMBXIB-SJKOYZFVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 129103609,
                "inchl_key": "OEBIHOVSAMBXIB-SJKOYZFVSA-N",
                "generic_name": "(13E,14E,22R,6R)-35-fluoro-6-methyl-7-aza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one",
                "designated_date": "09/24/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bayer Healthcare Pharmaceuticals, Inc.|100 Bayer Blvd.|Whippany|New Jersey|7981|United States",
                "orphan_designation": {
                    "original_text": "Treatment of solid tumors with neurotrophic tyrosine receptor kinase (NTRK)-fusion proteins",
                    "umls_id": "C0280100",
                    "parsed_text": "solid tumors"
                }
            }
        ]
    },
    {
        "_id": "JQUBXCDDRXAMLF-IXPVHAAZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16735504,
                "inchl_key": "JQUBXCDDRXAMLF-IXPVHAAZSA-N",
                "generic_name": "(2R,3R,4S)-2-(2-chloro-6-(3-chlorobenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol",
                "designated_date": "02/01/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Future Medicine Co., Ltd.|Rm616, LH Business Growth Center, 54 Changeop-ro, Sujeong-gu|Seongnam|Gyeonggi-do|South Korea",
                "orphan_designation": {
                    "original_text": "Treatment of Primary Biliary Cholangitis",
                    "umls_id": "C0008312",
                    "parsed_text": "Primary Biliary Cholangitis"
                }
            }
        ]
    },
    {
        "_id": "UFPFGVNKHCLJJO-SSKFGXFMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24737642,
                "inchl_key": "UFPFGVNKHCLJJO-SSKFGXFMSA-N",
                "generic_name": "(2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide",
                "designated_date": "06/28/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Paul Maher, MD|10644 Weymouth Street|Suite 104|Bethesda|Maryland|20814|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "HCZQIIVHWYFIPW-UKKRHICBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9859470,
                "inchl_key": "HCZQIIVHWYFIPW-UKKRHICBSA-N",
                "generic_name": "(2S,3R,4R,5S)-2-(hydroxymethyl)-1-pentylpiperidine-3,4,5-triol",
                "designated_date": "08/01/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Idorsia Pharmaceuticals Ltd|91 Hegenheimermattweg|Allschwil|Basel-Landschaft|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of GM2 gangliosidosis",
                    "umls_id": "C0268274",
                    "parsed_text": "GM2 Gangliosidosis"
                }
            }
        ]
    },
    {
        "_id": "PDWGVXJIDIRQME-DCNFBYMVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71812122,
                "inchl_key": "PDWGVXJIDIRQME-DCNFBYMVSA-N",
                "generic_name": "(3R,3aS,9R,9aS,9bS)-3-((dimethylamino)methyl)-9-hydroxy-6,9-dimethyl-3,3a,4,5,7,8,9,9a-octahydroazuleno[4,5-b]furan-2(9bH)-one fumarate",
                "designated_date": "11/08/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Accendatech USA Incorporated|3730 Kirby Drive|Suite 1200|Houston|Texas|77098|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioblastoma multiforme",
                    "umls_id": "C0017636",
                    "parsed_text": "Glioblastoma multiforme"
                }
            }
        ]
    },
    {
        "_id": "HWSLMIXAPNOWGU-AWEZNQCLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 22869857,
                "inchl_key": "HWSLMIXAPNOWGU-AWEZNQCLSA-N",
                "generic_name": "(3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one",
                "designated_date": "12/09/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Centre National de la Recherche Scientifique (CNRS)|3 Rue Michel-Ange|Paris|France",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X Syndrome.",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "UOKSXAOZBSWROR-DOELHFPHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 146048056,
                "inchl_key": "UOKSXAOZBSWROR-DOELHFPHSA-N",
                "generic_name": "(E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)oct-2-enediamide phosphate",
                "designated_date": "08/26/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CrystalGenomics, Inc.|5th F. Bldg.A, Korea Bio Park|700 Daewangpangyoro, Bundanggu, Seongnamsi|Gyeonggido|South Korea",
                "orphan_designation": {
                    "original_text": "Treatment of Pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "XDAOLTSRNUSPPH-XMMPIXPASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6480466,
                "inchl_key": "XDAOLTSRNUSPPH-XMMPIXPASA-N",
                "generic_name": "(R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole",
                "designated_date": "07/12/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Otsuka Pharmaceutical Company, Ltd|2-9, Kanda-Tsukasamachi|Tokyo|Japan",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary tuberculosis.",
                    "umls_id": "C0041327",
                    "parsed_text": "Pulmonary tuberculosis"
                }
            }
        ]
    },
    {
        "_id": "OLDWOVJAXRWCGT-FBHGDYMESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 124081779,
                "inchl_key": "OLDWOVJAXRWCGT-FBHGDYMESA-N",
                "generic_name": "(R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride",
                "designated_date": "11/19/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Basilea Pharmaceutical International Ltd.|Grenzacherstrasse 487|P.O. Box|Basel|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of cholangiocarcinoma.",
                    "umls_id": "C0206698",
                    "parsed_text": "Cholangiocarcinoma"
                }
            }
        ]
    },
    {
        "_id": "GFVBDLIBPSGFDL-ZOWNYOTGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 131801108,
                "inchl_key": "GFVBDLIBPSGFDL-ZOWNYOTGSA-N",
                "generic_name": "(R)-Azasetron besylate",
                "designated_date": "08/16/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sensorion SA|375 Rue du Professeur Joseph Blayac|Montpellier|Languedoc-Roussillon|France",
                "orphan_designation": {
                    "original_text": "Prevention of platinum-induced ototoxicity in pediatric patients",
                    "umls_id": "C0235280",
                    "parsed_text": "Ototoxicity"
                }
            }
        ]
    },
    {
        "_id": "SJHNWSAWWOAWJH-MRXNPFEDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 118224491,
                "inchl_key": "SJHNWSAWWOAWJH-MRXNPFEDSA-N",
                "generic_name": "(R)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide",
                "designated_date": "04/05/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Curis, Inc.|128 Spring Street, Building C, Suite 500|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "FSVJFNAIGNNGKK-KRWDZBQOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 445900,
                "inchl_key": "FSVJFNAIGNNGKK-KRWDZBQOSA-N",
                "generic_name": "(R)-praziquantel",
                "designated_date": "06/27/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Tongli Biomedical Co., Ltd. (TLB)|Guotaibei Road|Room 401, Building D|Zhangjiagang|Jiangsu|China",
                "orphan_designation": {
                    "original_text": "Treatment of schistosomiasis",
                    "umls_id": "C0036323",
                    "parsed_text": "Schistosomiasis"
                }
            }
        ]
    },
    {
        "_id": "KXMZDGSRSGHMMK-VWLOTQADSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 46215462,
                "inchl_key": "KXMZDGSRSGHMMK-VWLOTQADSA-N",
                "generic_name": "(S)-1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine",
                "designated_date": "11/05/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "BerGenBio AS|Jonas Lies vei 91|Bergen|Norway",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "QUMWKKVIZAIAHU-LBPRGKRZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 70675172,
                "inchl_key": "QUMWKKVIZAIAHU-LBPRGKRZSA-N",
                "generic_name": "(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile",
                "designated_date": "01/26/2015",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Almirall S.A.|Ronda General Mitre, 151|Barcelona|Spain",
                "orphan_designation": {
                    "original_text": "Treatment of pemphigus vulgaris",
                    "umls_id": "C0030809",
                    "parsed_text": "Pemphigus Vulgaris"
                }
            }
        ]
    },
    {
        "_id": "HVFWCHDZDIRYBZ-MQZJHDQISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 72710874,
                "inchl_key": "HVFWCHDZDIRYBZ-MQZJHDQISA-N",
                "generic_name": "(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride",
                "designated_date": "11/17/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Khondrion BV|Philips van Leydenlaan 15|Ex Nijmegen|Netherlands",
                "orphan_designation": {
                    "original_text": "Treatment of inherited mitochondrial respiratory chain diseases",
                    "umls_id": "C1325653",
                    "parsed_text": "mitochondrial respiratory chain"
                }
            }
        ]
    },
    {
        "_id": "RSIWALKZYXPAGW-NSHDSACASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 58111426,
                "inchl_key": "RSIWALKZYXPAGW-NSHDSACASA-N",
                "generic_name": "(S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one",
                "designated_date": "04/29/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Incyte Corporation|1801 Augustine Cut-Off|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Hodgkin lymphoma",
                    "umls_id": "C0019829",
                    "parsed_text": "Hodgkin Lymphoma"
                }
            }
        ]
    },
    {
        "_id": "MGTLGARADRIKNV-GFCCVEGCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 56846912,
                "inchl_key": "MGTLGARADRIKNV-GFCCVEGCSA-N",
                "generic_name": "(s)-perillyl alcohol temozolomide carbamate",
                "designated_date": "02/28/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NeOnc Technologies, Inc.|8335 Sunset Blvd., #240|Los Angeles|California|90069|United States",
                "orphan_designation": {
                    "original_text": "Treatment of intracranially located metastases from breast cancer",
                    "umls_id": "C0027627,C0678222",
                    "parsed_text": "Metastases , Breast cancer"
                }
            },
            {
                "compound_id": 56846912,
                "inchl_key": "MGTLGARADRIKNV-GFCCVEGCSA-N",
                "generic_name": "(s)-perillyl alcohol temozolomide carbamate",
                "designated_date": "07/27/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NeOnc Technologies, Inc.|8335 Sunset Blvd., #240|Los Angeles|California|90069|United States",
                "orphan_designation": {
                    "original_text": "Treatment of nasopharyngeal carcinoma",
                    "umls_id": "C2931822",
                    "parsed_text": "Nasopharyngeal carcinoma"
                }
            }
        ]
    },
    {
        "_id": "NEBUOXBYNAHKFV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 51357549,
                "inchl_key": "NEBUOXBYNAHKFV-UHFFFAOYSA-N",
                "generic_name": "1'-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3-f][1,3]benzodioxole-7,3'-indol]-2'(1'H)-one",
                "designated_date": "11/19/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Flexion Therapeutics, Inc.|10 Mall Road, Suite 301|Burlington|Massachusetts|1803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of erythromelalgia",
                    "umls_id": "C0014804",
                    "parsed_text": "Erythromelalgia"
                }
            }
        ]
    },
    {
        "_id": "AAFJXZWCNVJTMK-GUCUJZIJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 15942827,
                "inchl_key": "AAFJXZWCNVJTMK-GUCUJZIJSA-N",
                "generic_name": "1,2:5,6-dianhydrogalactitol",
                "designated_date": "04/19/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "DelMar Pharmaceuticals, Inc. (Clinical Operations)|3475 Edison Way|Suite R|Menlo Park|California|94025|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer.",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "compound_id": 15942827,
                "inchl_key": "AAFJXZWCNVJTMK-GUCUJZIJSA-N",
                "generic_name": "1,2:5,6-dianhydrogalactitol",
                "designated_date": "03/10/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "DelMar Pharmaceuticals, Inc.|3475 Edison Way|Suite R|Menlo Park|California|94025|United States",
                "orphan_designation": {
                    "original_text": "Treatment of medulloblastoma.",
                    "umls_id": "C0025149",
                    "parsed_text": "Medulloblastoma"
                }
            }
        ]
    },
    {
        "_id": "SKDNPCDRIUQGAL-XTJCVSPVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 89584363,
                "inchl_key": "SKDNPCDRIUQGAL-XTJCVSPVSA-N",
                "generic_name": "1-(((Z)-hexadec-1-en-1-yl)oxy)-3-((2-oxido-1,3,2-oxazaphospholidin-2-yl)oxy)propan-2-yl (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate",
                "designated_date": "08/08/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Med-Life Discoveries, LP|407-15 Innovation Boulevard|Saskatoon|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of Rhizomelic Chondrodysplasia Punctata",
                    "umls_id": "C0282529",
                    "parsed_text": "Rhizomelic chondrodysplasia punctata"
                }
            }
        ]
    },
    {
        "_id": "TZOWVYPYWJLZTK-IMTBSYHQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 57524523,
                "inchl_key": "TZOWVYPYWJLZTK-IMTBSYHQSA-N",
                "generic_name": "1-(2-chlorophenyl)-1-(S)-hydroxy-2-(S)-carbamoyloxy-propane",
                "designated_date": "03/20/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bio-Pharm Solutions, Co., Ltd.|6F, C Bldg., Advanced Institute of Convergence Technology|145 Gwanggyo-Ro, Yeongtong-Gu|Suwon|Gyeonggi-Do|South Korea",
                "orphan_designation": {
                    "original_text": "Treatment of infantile spasms",
                    "umls_id": "C3887898",
                    "parsed_text": "Infantile spasms"
                }
            },
            {
                "compound_id": 57524523,
                "inchl_key": "TZOWVYPYWJLZTK-IMTBSYHQSA-N",
                "generic_name": "1-(2-chlorophenyl)-1-(S)-hydroxy-2-(S)-carbamoyloxy-propane",
                "designated_date": "07/07/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bio-Pharm Solutions Co., Ltd.|Advanced Institute of Convergence Technology|6F, C Bldg|Yeongtong Suwon|Gyeonggi-do|South Korea",
                "orphan_designation": {
                    "original_text": "Treatment of status epilepticus",
                    "umls_id": "C0038220",
                    "parsed_text": "Status Epilepticus"
                }
            }
        ]
    },
    {
        "_id": "RDALZZCKQFLGJP-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 73051434,
                "inchl_key": "RDALZZCKQFLGJP-UHFFFAOYSA-N",
                "generic_name": "1-(4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide",
                "designated_date": "07/08/2015",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cleave Biosciences, Inc.|866 Malcolm Road|Suite 100|Burlingame|California|94010|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "VCPMZDWBEWTGNW-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4988454,
                "inchl_key": "VCPMZDWBEWTGNW-UHFFFAOYSA-N",
                "generic_name": "1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one",
                "designated_date": "09/26/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Zalicus Pharmaceuticals Ltd.|245 First Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Management of postherpetic neuralgia",
                    "umls_id": "C0032768",
                    "parsed_text": "Postherpetic neuralgia"
                }
            }
        ]
    },
    {
        "_id": "OQDQIFQRNZIEEJ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 68677842,
                "inchl_key": "OQDQIFQRNZIEEJ-UHFFFAOYSA-N",
                "generic_name": "1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid",
                "designated_date": "03/31/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Inventiva Pharma|50 rue de Dijon|Daix 21121|France",
                "orphan_designation": {
                    "original_text": "Treatment of systemic sclerosis",
                    "umls_id": "C0036421",
                    "parsed_text": "Systemic sclerosis"
                }
            }
        ]
    },
    {
        "_id": "LOLPPWBBNUVNQZ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135398495,
                "inchl_key": "LOLPPWBBNUVNQZ-UHFFFAOYSA-N",
                "generic_name": "1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea",
                "designated_date": "11/12/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Astex Therapeutics Ltd|436 Cambridge Science Park|Milton|Cambridge|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "ZOAIEFWMQLYMTF-PEHXSSJGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11570943,
                "inchl_key": "ZOAIEFWMQLYMTF-PEHXSSJGSA-N",
                "generic_name": "18-(p-[124I]-iodophenyl)octadecyl phosphocholine",
                "designated_date": "04/30/2014",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cellectar Biosciences, Inc.|3301 Agriculture Drive|Madison|Wisconsin|53716|United States",
                "orphan_designation": {
                    "original_text": "Diagnostic for the management of glioma",
                    "umls_id": "C0017638",
                    "parsed_text": "Glioma"
                }
            }
        ]
    },
    {
        "_id": "AUFUWRKPQLGTGF-QRMSVCKNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 60004399,
                "inchl_key": "AUFUWRKPQLGTGF-QRMSVCKNSA-N",
                "generic_name": "2',3',5'-tri-o-acetyluridine",
                "designated_date": "01/13/2003",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Repligen Corporation|41 Seyon Street|Building 1, Suite 100|Waltham|Massachusetts|2453|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mitochondrial disease",
                    "umls_id": "C0751651",
                    "parsed_text": "Mitochondrial disease"
                }
            }
        ]
    },
    {
        "_id": "AUFUWRKPQLGTGF-ZRJCITRHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6547277,
                "inchl_key": "AUFUWRKPQLGTGF-ZRJCITRHSA-N",
                "generic_name": "2',3',5'-tri-o-acetyluridine",
                "designated_date": "01/13/2003",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Repligen Corporation|41 Seyon Street|Building 1, Suite 100|Waltham|Massachusetts|2453|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mitochondrial disease",
                    "umls_id": "C0751651",
                    "parsed_text": "Mitochondrial disease"
                }
            }
        ]
    },
    {
        "_id": "AUFUWRKPQLGTGF-ZZVYKPCYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 990800,
                "inchl_key": "AUFUWRKPQLGTGF-ZZVYKPCYSA-N",
                "generic_name": "2',3',5'-tri-o-acetyluridine",
                "designated_date": "01/13/2003",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Repligen Corporation|41 Seyon Street|Building 1, Suite 100|Waltham|Massachusetts|2453|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mitochondrial disease",
                    "umls_id": "C0751651",
                    "parsed_text": "Mitochondrial disease"
                }
            }
        ]
    },
    {
        "_id": "AUFUWRKPQLGTGF-RWDKGTSBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44629990,
                "inchl_key": "AUFUWRKPQLGTGF-RWDKGTSBSA-N",
                "generic_name": "2',3',5'-tri-o-acetyluridine",
                "designated_date": "01/13/2003",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Repligen Corporation|41 Seyon Street|Building 1, Suite 100|Waltham|Massachusetts|2453|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mitochondrial disease",
                    "umls_id": "C0751651",
                    "parsed_text": "Mitochondrial disease"
                }
            }
        ]
    },
    {
        "_id": "AUFUWRKPQLGTGF-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 254731,
                "inchl_key": "AUFUWRKPQLGTGF-UHFFFAOYSA-N",
                "generic_name": "2',3',5'-tri-o-acetyluridine",
                "designated_date": "01/13/2003",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Repligen Corporation|41 Seyon Street|Building 1, Suite 100|Waltham|Massachusetts|2453|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mitochondrial disease",
                    "umls_id": "C0751651",
                    "parsed_text": "Mitochondrial disease"
                }
            }
        ]
    },
    {
        "_id": "AUFUWRKPQLGTGF-FMKGYKFTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 20058,
                "inchl_key": "AUFUWRKPQLGTGF-FMKGYKFTSA-N",
                "generic_name": "2',3',5'-tri-o-acetyluridine",
                "designated_date": "01/13/2003",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Repligen Corporation|41 Seyon Street|Building 1, Suite 100|Waltham|Massachusetts|2453|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mitochondrial disease",
                    "umls_id": "C0751651",
                    "parsed_text": "Mitochondrial disease"
                }
            },
            {
                "compound_id": 20058,
                "inchl_key": "AUFUWRKPQLGTGF-FMKGYKFTSA-N",
                "generic_name": "uridine triacetate",
                "designated_date": "05/01/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the emergency treatment of adult and pediatric patients following a fluorouracil or capecitabine overdose regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration",
                "marketing_approval_date": "\u00a012/11/2015\u00a0",
                "exclusivity_end_date": "\u00a012/11/2022\u00a0",
                "exclusivity_protected_indication": "For the emergency treatment of adult and pediatric patients following a fluorouracil or capecitabine overdose regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration",
                "sponsor": "Wellstat Therapeutics Corp.|14200 Shady Grove Road|Suite 600|Rockville|Maryland|20850|United States",
                "orphan_designation": {
                    "original_text": "An antidote in the treatment of 5-fluorouracil or capecitabine poisoning",
                    "umls_id": "C0032343",
                    "parsed_text": "Poisoning"
                }
            },
            {
                "compound_id": 20058,
                "inchl_key": "AUFUWRKPQLGTGF-FMKGYKFTSA-N",
                "generic_name": "uridine triacetate",
                "designated_date": "08/09/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of hereditary orotic aciduria",
                "marketing_approval_date": "\u00a009/04/2015\u00a0",
                "exclusivity_end_date": "\u00a009/04/2022\u00a0",
                "exclusivity_protected_indication": "Treatment of hereditary orotic aciduria",
                "sponsor": "Wellstat Therapeutics, Inc.|14200 Shady Grove Road|Suite 600|Rockville|Maryland|20850|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hereditary orotic aciduria",
                    "umls_id": "C0268130",
                    "parsed_text": "OROTIC ACIDURIA"
                }
            }
        ]
    },
    {
        "_id": "CKTSBUTUHBMZGZ-SHYZEUOFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 13711,
                "inchl_key": "CKTSBUTUHBMZGZ-SHYZEUOFSA-N",
                "generic_name": "2'-deoxycytidine",
                "designated_date": "09/09/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Grant, Steven M.D.|Massey Cancer Center, VCU|P.O. Box 980230|Richmond|Virginia|23298|United States",
                "orphan_designation": {
                    "original_text": "As a host-protective agent in the treatment of acute myelogenous leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "VUAXHMVRKOTJKP-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11684,
                "inchl_key": "VUAXHMVRKOTJKP-UHFFFAOYSA-N",
                "generic_name": "2,2-dimethylbutanoic acid",
                "designated_date": "12/10/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "HemoShear Therapeutics, LLC|501 Locust Avenue|Charlottesville|Virginia|22902|United States",
                "orphan_designation": {
                    "original_text": "Treatment of propionic acidemia",
                    "umls_id": "C0268579",
                    "parsed_text": "Propionic acidemia"
                }
            },
            {
                "compound_id": 11684,
                "inchl_key": "VUAXHMVRKOTJKP-UHFFFAOYSA-N",
                "generic_name": "2,2-dimethylbutanoic acid",
                "designated_date": "12/10/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "HemoShear Therapeutics, LLC|501 Locust Avenue|Charlottesville|Virginia|22902|United States",
                "orphan_designation": {
                    "original_text": "Treatment of methylmalonic acidemia",
                    "umls_id": "C0268583",
                    "parsed_text": "Methylmalonic acidemia"
                }
            }
        ]
    },
    {
        "_id": "UFBJCMHMOXMLKC-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 1493,
                "inchl_key": "UFBJCMHMOXMLKC-UHFFFAOYSA-N",
                "generic_name": "2,4 dinitrophenol",
                "designated_date": "09/08/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mitochon Phannaceuticals, Inc.|970 Cross Lane|Blue Bell|Pennsylvania|19422|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Amyotrophic Lateral Sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            },
            {
                "compound_id": 1493,
                "inchl_key": "UFBJCMHMOXMLKC-UHFFFAOYSA-N",
                "generic_name": "2,4-dinitrophenol",
                "designated_date": "02/11/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mitochon Pharmaceuticals, Inc.|970 Cross Lane|Blue Bell|Pennsylvania|19422|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Huntington disease",
                    "umls_id": "C0020179",
                    "parsed_text": "Huntington Disease"
                }
            }
        ]
    },
    {
        "_id": "OMPATGZMNFWVOH-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24986824,
                "inchl_key": "OMPATGZMNFWVOH-UHFFFAOYSA-N",
                "generic_name": "2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)nicotinic acid",
                "designated_date": "08/16/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ASLAN Pharmaceuticals Pte, Ltd.|83 Clemenceau Avenue|#12-03|Singapore|Singapore",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "XLXXBYJYWULGGD-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 69619483,
                "inchl_key": "XLXXBYJYWULGGD-UHFFFAOYSA-N",
                "generic_name": "2-(4-(2,4-dichlorophenethyl)-3,6-dioxo-1-(2-(thiophen-2-yl)ethyl)piperazin-2-yl)-N-(2-(5-methoxy-1H-indol-3-yl)ethyl) acetamide",
                "designated_date": "12/14/2017",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Spiral Therapeutics|1467 Dolores Street|San Francisco|California|94110|United States",
                "orphan_designation": {
                    "original_text": "Prevention of platinum-induced ototoxicity in pediatric patients",
                    "umls_id": "C0235280",
                    "parsed_text": "Ototoxicity"
                }
            }
        ]
    },
    {
        "_id": "ORQGHAJIWGGFJK-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 132260161,
                "inchl_key": "ORQGHAJIWGGFJK-UHFFFAOYSA-N",
                "generic_name": "2-(4-oxo-3-((5-(trifluoromethyl)benzo[d]thiazol-2-yl)methyl)-3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid",
                "designated_date": "05/23/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Applied Therapeutics Inc.|340 Madison Avenue, 19th Floor|New York,|New York|10173|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Galactosemia",
                    "umls_id": "C0016952",
                    "parsed_text": "Galactosemia"
                }
            },
            {
                "compound_id": 132260161,
                "inchl_key": "ORQGHAJIWGGFJK-UHFFFAOYSA-N",
                "generic_name": "2-(4-oxo-3-((5-(trifluoromethyl)benzo[d]thiazol-2-yl)methyl)-3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid",
                "designated_date": "09/21/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Applied Therapeutics Inc.|340 Madison Avenue|19th Floor|New York|New York|10173|United States",
                "orphan_designation": {
                    "original_text": "Treatment of phosphomannomutase 2 deficiency",
                    "umls_id": "C0349653",
                    "parsed_text": "Phosphomannomutase 2 deficiency"
                }
            }
        ]
    },
    {
        "_id": "XRPSUWYWZUQALB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 86298861,
                "inchl_key": "XRPSUWYWZUQALB-UHFFFAOYSA-N",
                "generic_name": "2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl)acetamide",
                "designated_date": "05/13/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Flatley Discovery Lab|529 Main Street|Suite 115|Charlestown|Massachusetts|2129|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "HYHJFNXFVPGMBI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 100773,
                "inchl_key": "HYHJFNXFVPGMBI-UHFFFAOYSA-N",
                "generic_name": "2-chloroethyl-3-sarcosinamide-1-nitrosourea",
                "designated_date": "08/03/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Lawrence Panasci, MD|Professor of Medicine, McGill University|3755 Cote Ste Catherine|Montreal, Quebec H3T 1E2|Canada",
                "orphan_designation": {
                    "original_text": "Treatment for malignant gliomas",
                    "umls_id": "C0555198",
                    "parsed_text": "malignant gliomas"
                }
            },
            {
                "compound_id": 100773,
                "inchl_key": "HYHJFNXFVPGMBI-UHFFFAOYSA-N",
                "generic_name": "2-chloroethyl-3-sarcosinamide-1-nitrosourea",
                "designated_date": "11/15/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pangene Corporation|5500 Stewart Avenue|Fremont|California|94538|United States",
                "orphan_designation": {
                    "original_text": "Treatment for malignant glioma",
                    "umls_id": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            }
        ]
    },
    {
        "_id": "GOWDQYRMBCOOJR-JHMJKTBASA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 145711124,
                "inchl_key": "GOWDQYRMBCOOJR-JHMJKTBASA-M",
                "generic_name": "2-hydroxy-N,N,N-trimethylethan-1-aminium (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoate",
                "designated_date": "09/11/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.|3013 Science Park Road|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pancreatic Cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "WWVANQJRLPIHNS-ZKWXMUAHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 128878,
                "inchl_key": "WWVANQJRLPIHNS-ZKWXMUAHSA-N",
                "generic_name": "2-iminobiotin",
                "designated_date": "02/24/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neurophyxia B.V.|Onderwijsboulevard 219|5223 DE 's-Hertogenbosch|Netherlands",
                "orphan_designation": {
                    "original_text": "Treatment of perinatal asphyxia.",
                    "umls_id": "C0559477",
                    "parsed_text": "Perinatal asphyxia"
                }
            }
        ]
    },
    {
        "_id": "AJFWITSBVLLDCC-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 91820639,
                "inchl_key": "AJFWITSBVLLDCC-UHFFFAOYSA-N",
                "generic_name": "2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione",
                "designated_date": "04/16/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NeuroVive Pharmaceutical AB|Medicon Village|Lund|Sweden",
                "orphan_designation": {
                    "original_text": "Treatment of inherited mitochondrial respiratory chain disease",
                    "umls_id": "C0012634,C1325653",
                    "parsed_text": "Disease , mitochondrial respiratory chain"
                }
            }
        ]
    },
    {
        "_id": "CQOQDQWUFQDJMK-SSTWWWIQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 66414,
                "inchl_key": "CQOQDQWUFQDJMK-SSTWWWIQSA-N",
                "generic_name": "2-methoxyestradiol",
                "designated_date": "04/04/2005",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EntreMed, Inc.|Research Triangle Park Center|4819 Emperor Blvd., Suite 400|Durham|North Carolina|27703|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "compound_id": 66414,
                "inchl_key": "CQOQDQWUFQDJMK-SSTWWWIQSA-N",
                "generic_name": "2-methoxyestradiol",
                "designated_date": "06/16/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EntreMed, Inc.|Research Triangle Park Center|4819 Emperor Blvd., Suite 400|Durham|North Carolina|27703|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiforme glioblastoma",
                    "umls_id": "C0017636",
                    "parsed_text": "Glioblastoma"
                }
            },
            {
                "compound_id": 66414,
                "inchl_key": "CQOQDQWUFQDJMK-SSTWWWIQSA-N",
                "generic_name": "2-methoxyestradiol",
                "designated_date": "07/10/2001",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EntreMed, Inc.|Research Triangle Park Center|Suite 400|Durham|North Carolina|27703|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            },
            {
                "compound_id": 66414,
                "inchl_key": "CQOQDQWUFQDJMK-SSTWWWIQSA-N",
                "generic_name": "2-methoxyestradiol",
                "designated_date": "04/11/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PR Pharmaceuticals, Inc.|1716 Heath Parkway|Fort Collins|Colorado|80524|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "WTPZYIZNHQOCOQ-VQIWEWKSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 78324948,
                "inchl_key": "WTPZYIZNHQOCOQ-VQIWEWKSSA-N",
                "generic_name": "2-{4-[(9R)-9-Hydroxy-2-(3-hydroxy-3-methylbutyloxy)-9-(trifluoromethyl)-9H-fluoren-4-yl]-1H-pyrazol-1-yl}-2-methylpropanamide monohydrate",
                "designated_date": "01/23/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Akros Pharma Inc.|302 Carnegie Center|Suite 300|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "NKDFYOWSKOHCCO-YPVLXUMRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5459840,
                "inchl_key": "NKDFYOWSKOHCCO-YPVLXUMRSA-N",
                "generic_name": "20-hydroxyecdysone",
                "designated_date": "05/10/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biophytis SA|14 Avenue de lOpera|Paris|France",
                "orphan_designation": {
                    "original_text": "Treatment of Duchenne Muscular Dystrophy",
                    "umls_id": "C0013264",
                    "parsed_text": "DUCHENNE MUSCULAR DYSTROPHY"
                }
            }
        ]
    },
    {
        "_id": "FCKJYANJHNLEEP-SRLFHJKTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6434253,
                "inchl_key": "FCKJYANJHNLEEP-SRLFHJKTSA-N",
                "generic_name": "24,25 dihydroxycholecalciferol",
                "designated_date": "02/27/1987",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Lemmon Company|1510 Delp Drive|Kulpsville|Pennsylvania|19443|United States",
                "orphan_designation": {
                    "original_text": "Treatment of uremic osteodystrophy.",
                    "umls_id": "C0543799",
                    "parsed_text": "uremic osteodystrophy"
                }
            }
        ]
    },
    {
        "_id": "XMAYWYJOQHXEEK-ZEQKJWHPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 47576,
                "inchl_key": "XMAYWYJOQHXEEK-ZEQKJWHPSA-N",
                "generic_name": "2S,4R ketoconazole",
                "designated_date": "03/09/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Strongbridge Dublin Limited|Suite 206, Fitzwilliam Hall|Dublin 2|D02 T292|Ireland",
                "orphan_designation": {
                    "original_text": "Treatment of endogenous Cushing's syndrome",
                    "umls_id": "C0010481",
                    "parsed_text": "Cushing's Syndrome"
                }
            },
            {
                "compound_id": 47576,
                "inchl_key": "XMAYWYJOQHXEEK-ZEQKJWHPSA-N",
                "generic_name": "Ketoconazole",
                "designated_date": "03/27/1991",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmedic Company|28101 Ballard Road|Lake Forest|Illinois|60045|United States",
                "orphan_designation": {
                    "original_text": "For use with cyclosporine A to diminish the nephrotoxicity induced by cyclosporine in organ transplantation.",
                    "umls_id": "C0595916",
                    "parsed_text": "nephrotoxicity"
                }
            }
        ]
    },
    {
        "_id": "OYTKINVCDFNREN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5918,
                "inchl_key": "OYTKINVCDFNREN-UHFFFAOYSA-N",
                "generic_name": "3,4-diaminopyridine",
                "designated_date": "03/30/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Jacobus Pharmaceutical Co., Inc.|37 Cleveland Lane|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of congenital myasthenic syndrome (CMS)",
                    "umls_id": "C0751882",
                    "parsed_text": "congenital myasthenic syndrome"
                }
            },
            {
                "compound_id": 5918,
                "inchl_key": "OYTKINVCDFNREN-UHFFFAOYSA-N",
                "generic_name": "amifampridine",
                "trade_name": "Ruzurgi",
                "designated_date": "12/18/1990",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RUZURGI is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age.",
                "marketing_approval_date": "\u00a005/06/2019\u00a0",
                "exclusivity_end_date": "\u00a005/06/2026\u00a0",
                "exclusivity_protected_indication": "Treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age.",
                "sponsor": "Jacobus Pharmaceutical Company, Inc.|37 Cleveland Lane|P.O. Box 5290|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Lambert-Eaton myasthenic syndrome.",
                    "umls_id": "C0022972",
                    "parsed_text": "Lambert-Eaton Myasthenic Syndrome"
                }
            }
        ]
    },
    {
        "_id": "WONYMNWUJVKVII-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 160565,
                "inchl_key": "WONYMNWUJVKVII-UHFFFAOYSA-N",
                "generic_name": "3,5-diiodothyropropionic acid",
                "designated_date": "07/28/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Prizm, LLC|3377 S. Price Road, Suite 3031|Chandler|Arizona|85248|United States",
                "orphan_designation": {
                    "original_text": "Treatment of monocarboxylate transporter (MCT) 8 deficiency (Allan-Herndon-Dudley syndrome)",
                    "umls_id": "C0795889",
                    "parsed_text": "Allan-Herndon-Dudley syndrome"
                }
            },
            {
                "compound_id": 160565,
                "inchl_key": "WONYMNWUJVKVII-UHFFFAOYSA-N",
                "generic_name": "3,5-diiodothyropropionic acid",
                "designated_date": "05/14/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Zarion Pharmaceuticals P/L|8 Grandview Grove|Sassafras 3787|Victoria|Australia",
                "orphan_designation": {
                    "original_text": "Treatment of Allan-Herndon-Dudley syndrome",
                    "umls_id": "C0795889",
                    "parsed_text": "Allan-Herndon-Dudley syndrome"
                }
            }
        ]
    },
    {
        "_id": "LOMMPXLFBTZENJ-ZACQAIPSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 117947097,
                "inchl_key": "LOMMPXLFBTZENJ-ZACQAIPSSA-N",
                "generic_name": "3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile",
                "designated_date": "06/24/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.|One Merck Drive|Whitehouse Station|New Jersey|8889|United States",
                "orphan_designation": {
                    "original_text": "Treatment of von Hippel-Lindau disease",
                    "umls_id": "C0019562",
                    "parsed_text": "von Hippel-Lindau Disease"
                }
            }
        ]
    },
    {
        "_id": "IWMJORKECAFMRX-USANWJRDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 137254226,
                "inchl_key": "IWMJORKECAFMRX-USANWJRDSA-N",
                "generic_name": "3-(1-butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-N-butylimide methyl ester",
                "designated_date": "12/06/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Photolitec, LLC|6220 Creekhaven Drive|East Amherst|New York|14051|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioma",
                    "umls_id": "C0017638",
                    "parsed_text": "Glioma"
                }
            }
        ]
    },
    {
        "_id": "BVJRNKXVSYLNFD-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 60199173,
                "inchl_key": "BVJRNKXVSYLNFD-UHFFFAOYSA-N",
                "generic_name": "3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride",
                "designated_date": "09/19/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diffuse large B-cell lymphoma",
                    "umls_id": "C1332201",
                    "parsed_text": "Diffuse Large B-Cell Lymphoma"
                }
            },
            {
                "compound_id": 60199173,
                "inchl_key": "BVJRNKXVSYLNFD-UHFFFAOYSA-N",
                "generic_name": "3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride",
                "designated_date": "07/03/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma (HCC)",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            }
        ]
    },
    {
        "_id": "XMYKNCNAZKMVQN-WCIBSUBMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5468049,
                "inchl_key": "XMYKNCNAZKMVQN-WCIBSUBMSA-N",
                "generic_name": "3-aminopyridine-2-carboxaldehyde thiosemicarbazone",
                "designated_date": "11/08/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "National Cancer Institute, Div of Cancer Treatment & Diagnosis (DCTD)|9609 Medical Center Drive|Room 5-W520, MSC 9740|Rockville|Maryland|20850|United States",
                "orphan_designation": {
                    "original_text": "Treatment of stage 1B to IV cervical cancer",
                    "umls_id": "C4048328",
                    "parsed_text": "cervical cancer"
                }
            }
        ]
    },
    {
        "_id": "XMYKNCNAZKMVQN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3006315,
                "inchl_key": "XMYKNCNAZKMVQN-UHFFFAOYSA-N",
                "generic_name": "3-aminopyridine-2-carboxaldehyde thiosemicarbazone",
                "designated_date": "11/08/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "National Cancer Institute, Div of Cancer Treatment & Diagnosis (DCTD)|9609 Medical Center Drive|Room 5-W520, MSC 9740|Rockville|Maryland|20850|United States",
                "orphan_designation": {
                    "original_text": "Treatment of stage 1B to IV cervical cancer",
                    "umls_id": "C4048328",
                    "parsed_text": "cervical cancer"
                }
            }
        ]
    },
    {
        "_id": "XMYKNCNAZKMVQN-NYYWCZLTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9571836,
                "inchl_key": "XMYKNCNAZKMVQN-NYYWCZLTSA-N",
                "generic_name": "3-aminopyridine-2-carboxaldehyde thiosemicarbazone",
                "designated_date": "11/08/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "National Cancer Institute, Div of Cancer Treatment & Diagnosis (DCTD)|9609 Medical Center Drive|Room 5-W520, MSC 9740|Rockville|Maryland|20850|United States",
                "orphan_designation": {
                    "original_text": "Treatment of stage 1B to IV cervical cancer",
                    "umls_id": "C4048328",
                    "parsed_text": "cervical cancer"
                }
            }
        ]
    },
    {
        "_id": "PRRZDZJYSJLDBS-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 70684,
                "inchl_key": "PRRZDZJYSJLDBS-UHFFFAOYSA-N",
                "generic_name": "3-bromo-2-oxopropanoic acid",
                "designated_date": "05/01/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NewG Lab Pharma, Inc.|701 E Pratt St.|Baltimore|Maryland|21202|United States",
                "orphan_designation": {
                    "original_text": "Treatment of stage IIb-IV melanoma",
                    "umls_id": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "PRRZDZJYSJLDBS-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 6994776,
                "inchl_key": "PRRZDZJYSJLDBS-UHFFFAOYSA-M",
                "generic_name": "3-bromopyruvate",
                "designated_date": "04/29/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PreScience Labs, LLC|9500 Reach Road|Potomac|Maryland|20854|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 6994776,
                "inchl_key": "PRRZDZJYSJLDBS-UHFFFAOYSA-M",
                "generic_name": "3-bromopyruvate",
                "designated_date": "03/05/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "KoDiscovery, LLC|Columbus Center|701 East Pratt Street|Baltimore|Maryland|21202|United States",
                "orphan_designation": {
                    "original_text": "Treatment of liver and intrahepatic bile duct cancer",
                    "umls_id": "C0279000",
                    "parsed_text": "Liver and Intrahepatic Bile Duct Cancer"
                }
            }
        ]
    },
    {
        "_id": "CNSJWSLXKSJQFE-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 46944243,
                "inchl_key": "CNSJWSLXKSJQFE-UHFFFAOYSA-M",
                "generic_name": "3-pentylbenzenacetic acid sodium salt",
                "designated_date": "02/11/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Liminal BioSciences Limited|Unit 1, Iconix Park, London Road|Sawston|Cambridge|CB22 3EG|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic pulmonary fibrosis.",
                    "umls_id": "C1800706",
                    "parsed_text": "Idiopathic Pulmonary Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "ZXRVKCBLGJOCEE-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3448,
                "inchl_key": "ZXRVKCBLGJOCEE-UHFFFAOYSA-N",
                "generic_name": "4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol",
                "designated_date": "09/06/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ovid Therapeutics|1460 Broadway|New York|New York|10036|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Angelman syndrome.",
                    "umls_id": "C0162635",
                    "parsed_text": "Angelman Syndrome"
                }
            },
            {
                "compound_id": 3448,
                "inchl_key": "ZXRVKCBLGJOCEE-UHFFFAOYSA-N",
                "generic_name": "Gaboxadol",
                "designated_date": "10/03/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ovid Therapeutics|1460 Broadway|New York|New York|10036|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X syndrome",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "MUDCDMMNYVJLEB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9871944,
                "inchl_key": "MUDCDMMNYVJLEB-UHFFFAOYSA-N",
                "generic_name": "4,5-dibromorhodamine 123",
                "designated_date": "04/10/2003",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kiadis Pharma Canada, Inc.|2525 Marie-Curie|Saint-Laurent (Quebec)|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of chronic myelogenous leukemia",
                    "umls_id": "C0023473",
                    "parsed_text": "Chronic myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "WCXAUCDLLSWGQS-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 126485502,
                "inchl_key": "WCXAUCDLLSWGQS-UHFFFAOYSA-N",
                "generic_name": "4-(((3-chloro-1,4-dioxo-1,4 dihydronaphthalen-2-yl)amino)methyl)-N-(pyridine-3-yl)benzamide",
                "designated_date": "02/28/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sino-American Cancer Foundation|4978 Santa Anita Ave|Suite 104|Temple City|California|91780|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Multiple Myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "RMGPNQKZEPTAOC-QMMMGPOBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 54274194,
                "inchl_key": "RMGPNQKZEPTAOC-QMMMGPOBSA-N",
                "generic_name": "4-((L-valyl)oxy)butanoic acid",
                "designated_date": "06/12/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "XWPharma Incorporated|19F-1, No. 99, Sec. 1|Xintai 5th Road|New Taipei City|Xizhi District|Taiwan",
                "orphan_designation": {
                    "original_text": "Treatment of Narcolepsy",
                    "umls_id": "C0027404",
                    "parsed_text": "Narcolepsy"
                }
            }
        ]
    },
    {
        "_id": "LQBVNQSMGBZMKD-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 49846579,
                "inchl_key": "LQBVNQSMGBZMKD-UHFFFAOYSA-N",
                "generic_name": "4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide",
                "designated_date": "03/27/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AbbVie|Research and Development|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diffuse large B-cell lymphoma.",
                    "umls_id": "C1332201",
                    "parsed_text": "Diffuse Large B-Cell Lymphoma"
                }
            },
            {
                "compound_id": 49846579,
                "inchl_key": "LQBVNQSMGBZMKD-UHFFFAOYSA-N",
                "generic_name": "Venetoclax",
                "designated_date": "10/26/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute lymphoblastic leukemia",
                    "umls_id": "C0023449",
                    "parsed_text": "Acute lymphoblastic leukemia"
                }
            },
            {
                "compound_id": 49846579,
                "inchl_key": "LQBVNQSMGBZMKD-UHFFFAOYSA-N",
                "generic_name": "venetoclax",
                "trade_name": "VENCLEXTA",
                "designated_date": "09/20/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "VENCLEXTA (venetoclax) indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.",
                "marketing_approval_date": "\u00a006/08/2018\u00a0",
                "exclusivity_end_date": "\u00a006/08/2025\u00a0",
                "exclusivity_protected_indication": "For treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), without 17p deletion, who have received at least one prior therapy.",
                "sponsor": "AbbVie, Inc|1 North Waukegan Road|Dept. PA72, Bldg. AP30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "compound_id": 49846579,
                "inchl_key": "LQBVNQSMGBZMKD-UHFFFAOYSA-N",
                "generic_name": "venetoclax",
                "trade_name": "VENCLEXTA",
                "designated_date": "09/20/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy",
                "marketing_approval_date": "\u00a004/11/2016\u00a0",
                "exclusivity_end_date": "\u00a004/11/2023\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy",
                "sponsor": "AbbVie, Inc|1 North Waukegan Road|Dept. PA72, Bldg. AP30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "compound_id": 49846579,
                "inchl_key": "LQBVNQSMGBZMKD-UHFFFAOYSA-N",
                "generic_name": "venetoclax",
                "designated_date": "08/29/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AbbVie Inc.|Regualtory Affairs|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            },
            {
                "compound_id": 49846579,
                "inchl_key": "LQBVNQSMGBZMKD-UHFFFAOYSA-N",
                "generic_name": "venetoclax",
                "trade_name": "VENCLEXTA",
                "designated_date": "09/20/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "VENCLEXTA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).",
                "marketing_approval_date": "\u00a005/15/2019\u00a0",
                "exclusivity_end_date": "\u00a005/15/2026\u00a0",
                "exclusivity_protected_indication": "Treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)",
                "sponsor": "AbbVie, Inc|1 North Waukegan Road|Dept. PA72, Bldg. AP30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "compound_id": 49846579,
                "inchl_key": "LQBVNQSMGBZMKD-UHFFFAOYSA-N",
                "generic_name": "venetoclax",
                "designated_date": "08/31/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mantle cell lymphoma",
                    "umls_id": "C4721414",
                    "parsed_text": "Mantle cell lymphoma"
                }
            },
            {
                "compound_id": 49846579,
                "inchl_key": "LQBVNQSMGBZMKD-UHFFFAOYSA-N",
                "generic_name": "venetoclax",
                "trade_name": "VENCLEXTA",
                "designated_date": "02/04/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "VENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
                "marketing_approval_date": "\u00a011/21/2018\u00a0",
                "exclusivity_end_date": "\u00a011/21/2025\u00a0",
                "exclusivity_protected_indication": "VENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Dept PA72, Bldg. AP30-4|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "compound_id": 49846579,
                "inchl_key": "LQBVNQSMGBZMKD-UHFFFAOYSA-N",
                "generic_name": "Venetoclax",
                "designated_date": "11/05/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080-4990|United States",
                "orphan_designation": {
                    "original_text": "Treatment for small cell lung cancer",
                    "umls_id": "C3540630",
                    "parsed_text": "Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 49846579,
                "inchl_key": "LQBVNQSMGBZMKD-UHFFFAOYSA-N",
                "generic_name": "Venetoclax",
                "designated_date": "06/12/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Dept #PA72, Bldg. AP30-4|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndromes",
                    "umls_id": "C3463824",
                    "parsed_text": "Myelodysplastic Syndromes"
                }
            }
        ]
    },
    {
        "_id": "NUKYPUAOHBNCPY-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 1727,
                "inchl_key": "NUKYPUAOHBNCPY-UHFFFAOYSA-N",
                "generic_name": "4-Aminopyridine",
                "designated_date": "12/14/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Acorda Therapeutics, Inc.|420 Saw Mill River Road|Ardsley|New York|10502|United States",
                "orphan_designation": {
                    "original_text": "Treatment chronic functional motor and sensory deficits from Guillain-Barre syndrome",
                    "umls_id": "C0018378",
                    "parsed_text": "Guillain-Barre Syndrome"
                }
            },
            {
                "compound_id": 1727,
                "inchl_key": "NUKYPUAOHBNCPY-UHFFFAOYSA-N",
                "generic_name": "Fampridine",
                "designated_date": "06/02/1997",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Acorda Therapeutics, Inc.|15 Skyline Dr.|Hawthorne|New York|10532|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic, incomplete spinal cord injury.",
                    "umls_id": "C4545488",
                    "parsed_text": "Incomplete spinal cord injury"
                }
            },
            {
                "compound_id": 1727,
                "inchl_key": "NUKYPUAOHBNCPY-UHFFFAOYSA-N",
                "generic_name": "dalfampridine",
                "designated_date": "11/25/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Magnum Therapeutics|243 W. 259th Street|Riverdale|New York|10471|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Transverse Myelitis",
                    "umls_id": "C0026976",
                    "parsed_text": "Transverse myelitis"
                }
            },
            {
                "compound_id": 1727,
                "inchl_key": "NUKYPUAOHBNCPY-UHFFFAOYSA-N",
                "generic_name": "dalfampridine",
                "trade_name": "Ampyra",
                "designated_date": "06/02/1987",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment to improve walking in patients with multiple sclerosis",
                "marketing_approval_date": "\u00a001/22/2010\u00a0",
                "exclusivity_end_date": "\u00a001/22/2017\u00a0",
                "sponsor": "Acorda Therapeutics|15 Skyline Dr.|Hawthorne|New York|10532|United States",
                "orphan_designation": {
                    "original_text": "Relief of symptoms of multiple sclerosis",
                    "umls_id": "C0026769",
                    "parsed_text": "Multiple Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "WUBBRNOQWQTFEX-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4649,
                "inchl_key": "WUBBRNOQWQTFEX-UHFFFAOYSA-N",
                "generic_name": "4-aminosalicylic acid",
                "designated_date": "12/13/1989",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Beeken, Warren M.D.|University Of Vermont|Given C-317|Burlington|Vermont|5405|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mild to moderate ulcerative colitis in patients intolerant to sulfasalazine.",
                    "umls_id": "C0009324",
                    "parsed_text": "Ulcerative Colitis"
                }
            },
            {
                "compound_id": 4649,
                "inchl_key": "WUBBRNOQWQTFEX-UHFFFAOYSA-N",
                "generic_name": "4-aminosalicylic acid",
                "designated_date": "04/26/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Jacobus Pharmaceutical Co., Inc.|37 Cleveland Lane|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute flares in pediatric patients with ileo-cecal Crohn's disease",
                    "umls_id": "C0010346",
                    "parsed_text": "Crohn's Disease"
                }
            },
            {
                "compound_id": 4649,
                "inchl_key": "WUBBRNOQWQTFEX-UHFFFAOYSA-N",
                "generic_name": "Aminosalicylate sodium",
                "designated_date": "04/06/1993",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Syncom Pharmaceuticals, Inc.|66 Hanover Road|Florham Park|New Jersey|7932|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Crohn's disease.",
                    "umls_id": "C0010346",
                    "parsed_text": "Crohn's Disease"
                }
            },
            {
                "compound_id": 4649,
                "inchl_key": "WUBBRNOQWQTFEX-UHFFFAOYSA-N",
                "generic_name": "Aminosalicylic acid",
                "trade_name": "Paser Granules",
                "designated_date": "02/19/1992",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of tuberculosis",
                "marketing_approval_date": "\u00a006/30/1994\u00a0",
                "exclusivity_end_date": "\u00a006/30/2001\u00a0",
                "sponsor": "Jacobus Pharmaceutical Company|37 Cleveland Lane|P.O. Box 5290|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of tuberculosis infections",
                    "umls_id": "C0041296",
                    "parsed_text": "Tuberculosis"
                }
            }
        ]
    },
    {
        "_id": "ZJUUIXYKTPSIOH-LEZJFEBPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16126905,
                "inchl_key": "ZJUUIXYKTPSIOH-LEZJFEBPSA-N",
                "generic_name": "4-demethyl-4-cholesteryloxycarbonylpenclomedine",
                "designated_date": "09/19/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "DEKK-TEC, Inc.|725 Topaz Street|New Orleans|Louisiana|70124|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-small cell lung cancer with CNS metastases",
                    "umls_id": "C0686377,C3539721",
                    "parsed_text": "CNS metastases , Non-Small Cell Lung Cancer"
                }
            }
        ]
    },
    {
        "_id": "HSHNITRMYYLLCV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5280567,
                "inchl_key": "HSHNITRMYYLLCV-UHFFFAOYSA-N",
                "generic_name": "4-Methylumbelliferone",
                "designated_date": "03/13/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenefly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pancreatic Cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 5280567,
                "inchl_key": "HSHNITRMYYLLCV-UHFFFAOYSA-N",
                "generic_name": "4-Methylumbelliferone",
                "designated_date": "04/20/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenefly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Esophageal Carcinoma",
                    "umls_id": "C0152018",
                    "parsed_text": "Esophageal carcinoma"
                }
            },
            {
                "compound_id": 5280567,
                "inchl_key": "HSHNITRMYYLLCV-UHFFFAOYSA-N",
                "generic_name": "4-Methylumbelliferone",
                "designated_date": "03/30/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenefly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            }
        ]
    },
    {
        "_id": "XAKLYHGHEFMDAP-UNMCSNQZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 57887037,
                "inchl_key": "XAKLYHGHEFMDAP-UNMCSNQZSA-N",
                "generic_name": "5(S)-(2'-hydroxy ethoxy)-20(S)-Camptothecin",
                "designated_date": "06/15/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Dr. Reddy's Laboratories, Inc.|200 Somerset Corporate Blvd|Building II, 7th Floor|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of osteosarcoma (bone cancer)",
                    "umls_id": "C0279530",
                    "parsed_text": "Bone Cancer"
                }
            }
        ]
    },
    {
        "_id": "JYHHQTRVJFMEGR-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 57411069,
                "inchl_key": "JYHHQTRVJFMEGR-UHFFFAOYSA-N",
                "generic_name": "5,5-dimethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione",
                "designated_date": "06/12/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Autifony Therapeutics Limited|Gunnels Wood Road|Stevenage|England|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of fragile X syndrome",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "LJIRBXZDQGQUOO-KVTDHHQDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 99681,
                "inchl_key": "LJIRBXZDQGQUOO-KVTDHHQDSA-N",
                "generic_name": "5,6-dihydro-5-azacytidine",
                "designated_date": "05/11/1992",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ILEX Oncology, Inc.|4545 Horizon Hill Blvd.|San Antonio|Texas|78229|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant mesothelioma.",
                    "umls_id": "C0345967",
                    "parsed_text": "Malignant mesothelioma"
                }
            }
        ]
    },
    {
        "_id": "FVWAMONNJGNNHY-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44472513,
                "inchl_key": "FVWAMONNJGNNHY-UHFFFAOYSA-N",
                "generic_name": "5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride",
                "designated_date": "04/18/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mithridion, Inc.|505 Science Drive|Madison|Wisconsin|53711|United States",
                "orphan_designation": {
                    "original_text": "Treatment of progressive supranuclear palsy.",
                    "umls_id": "C0038868",
                    "parsed_text": "Progressive supranuclear palsy"
                }
            }
        ]
    },
    {
        "_id": "STWVLEKJQQRGMO-GUYCJALGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 126642132,
                "inchl_key": "STWVLEKJQQRGMO-GUYCJALGSA-N",
                "generic_name": "5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine",
                "designated_date": "02/25/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Galapagos NV|Generaal De Wittelaan L11 A3|Mechelen|2800|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic pulmonary fibrosis",
                    "umls_id": "C1800706",
                    "parsed_text": "Idiopathic Pulmonary Fibrosis"
                }
            },
            {
                "compound_id": 126642132,
                "inchl_key": "STWVLEKJQQRGMO-GUYCJALGSA-N",
                "generic_name": "5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine",
                "designated_date": "01/14/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Galapagos NV|Generaal De Wittelaan L11 A3|Mechelen|2800|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of sarcoidosis",
                    "umls_id": "C0036202",
                    "parsed_text": "Sarcoidosis"
                }
            }
        ]
    },
    {
        "_id": "ZGXJTSGNIOSYLO-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 137,
                "inchl_key": "ZGXJTSGNIOSYLO-UHFFFAOYSA-N",
                "generic_name": "5-aminolevulinic acid",
                "trade_name": "Gleolan",
                "designated_date": "01/15/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery",
                "marketing_approval_date": "\u00a006/06/2017\u00a0",
                "exclusivity_end_date": "\u00a006/06/2024\u00a0",
                "exclusivity_protected_indication": "Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery",
                "sponsor": "NX Development Corporation|1827 South Bayshore Lane|Miami|Florida|33133|United States",
                "orphan_designation": {
                    "original_text": "Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV)",
                    "umls_id": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            },
            {
                "compound_id": 137,
                "inchl_key": "ZGXJTSGNIOSYLO-UHFFFAOYSA-N",
                "generic_name": "5-aminolevulinic acid",
                "designated_date": "11/12/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NX Development Corp.|870 Corporate Drive|Suite 403|Lexington|Kentucky|40503|United States",
                "orphan_designation": {
                    "original_text": "Diagnostic for the visualization of tumor tissue in patients undergoing surgical resection for meningioma",
                    "umls_id": "C0025286",
                    "parsed_text": "Meningioma"
                }
            },
            {
                "compound_id": 137,
                "inchl_key": "ZGXJTSGNIOSYLO-UHFFFAOYSA-N",
                "generic_name": "5-Aminolevulinic Acid",
                "designated_date": "03/29/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hemerion Therapeutics|12 rue Denis Papin|NEO 2 - Building A|Villeneuve dAscq|59650|France",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls_id": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            }
        ]
    },
    {
        "_id": "XAUDJQYHKZQPEU-KVQBGUIXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 451668,
                "inchl_key": "XAUDJQYHKZQPEU-KVQBGUIXSA-N",
                "generic_name": "5-aza-2'-deoxycytidine",
                "designated_date": "08/03/1987",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SuperGen, Inc.|4140 Dublin Blvd.|Suite 200|Dublin|California|94568|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute leukemia.",
                    "umls_id": "C0085669",
                    "parsed_text": "Acute leukemia"
                }
            },
            {
                "compound_id": 451668,
                "inchl_key": "XAUDJQYHKZQPEU-KVQBGUIXSA-N",
                "generic_name": "decitabine",
                "trade_name": "Dacogen",
                "designated_date": "03/08/1999",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups",
                "marketing_approval_date": "\u00a005/02/2006\u00a0",
                "exclusivity_end_date": "\u00a005/02/2013\u00a0",
                "sponsor": "Otsuka Pharmaceutical Development|and Commercialization, Inc.|508 Carnegie Center Drive|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndromes.",
                    "umls_id": "C3463824",
                    "parsed_text": "Myelodysplastic Syndromes"
                }
            },
            {
                "compound_id": 451668,
                "inchl_key": "XAUDJQYHKZQPEU-KVQBGUIXSA-N",
                "generic_name": "decitabine",
                "designated_date": "09/09/2002",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Otsuka Pharmaceutical Development &|Commercialization, Inc.|508 Carnegie Center Drive|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sickle cell anemia",
                    "umls_id": "C0002895",
                    "parsed_text": "SICKLE CELL ANEMIA"
                }
            },
            {
                "compound_id": 451668,
                "inchl_key": "XAUDJQYHKZQPEU-KVQBGUIXSA-N",
                "generic_name": "decitabine",
                "designated_date": "08/04/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Otsuka Pharmaceutical Development &|Commercialization, Inc.|508 Carnegie Center Drive|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "compound_id": 451668,
                "inchl_key": "XAUDJQYHKZQPEU-KVQBGUIXSA-N",
                "generic_name": "decitabine",
                "designated_date": "03/08/1999",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Otsuka Pharmaceutical Development &|Commercialization, Inc.|508 Carnegie Center Drive|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic myelogenous leukemia.",
                    "umls_id": "C0023473",
                    "parsed_text": "Chronic myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "NOEGNKMFWQHSLB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 237332,
                "inchl_key": "NOEGNKMFWQHSLB-UHFFFAOYSA-N",
                "generic_name": "5-hydroxymethyl-2-furfuraldehyde",
                "designated_date": "05/26/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Baxalta US, Inc.|ONe Baxter Way|Westlake Village|California|91362|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sickle cell disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            }
        ]
    },
    {
        "_id": "XIJXHOVKJAXCGJ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 14326905,
                "inchl_key": "XIJXHOVKJAXCGJ-UHFFFAOYSA-N",
                "generic_name": "5-iodo-2-pyrimidinone-2'-deoxyribose",
                "designated_date": "05/26/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hana Biosciences, Inc.|7000 Shoreline Court|Suite 370|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malginant glioma",
                    "umls_id": "C0017638",
                    "parsed_text": "Glioma"
                }
            }
        ]
    },
    {
        "_id": "XIJXHOVKJAXCGJ-XLPZGREQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9840777,
                "inchl_key": "XIJXHOVKJAXCGJ-XLPZGREQSA-N",
                "generic_name": "5-iodo-2-pyrimidinone-2'-deoxyribose",
                "designated_date": "05/26/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hana Biosciences, Inc.|7000 Shoreline Court|Suite 370|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malginant glioma",
                    "umls_id": "C0017638",
                    "parsed_text": "Glioma"
                }
            },
            {
                "compound_id": 9840777,
                "inchl_key": "XIJXHOVKJAXCGJ-XLPZGREQSA-N",
                "generic_name": "ropidoxuridine",
                "designated_date": "05/19/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EMEK, Inc.|196 Channel View|Warwick|Rhode Island|2889|United States",
                "orphan_designation": {
                    "original_text": "Radiosensitizer to be used during radiation treatment of glioma",
                    "umls_id": "C0017638",
                    "parsed_text": "Glioma"
                }
            }
        ]
    },
    {
        "_id": "YGCADXGQGUPFOA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 154925881,
                "inchl_key": "YGCADXGQGUPFOA-UHFFFAOYSA-N",
                "generic_name": "5-methyl cromolyn",
                "designated_date": "09/23/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Vitalgenics|820 Grape St|Denver|Colorado|80220|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pancreatic Cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "BOIAUNVCOPGNOT-STOTURBNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71461381,
                "inchl_key": "BOIAUNVCOPGNOT-STOTURBNSA-N",
                "generic_name": "6'-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)- paromamine sulfate",
                "designated_date": "11/03/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eloxx Pharmaceuticals, Ltd.|Weizmann Science Park|7 Golda Meir Street|Ness Ziona|Center District|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Rett syndrome",
                    "umls_id": "C0035372",
                    "parsed_text": "Rett Syndrome"
                }
            }
        ]
    },
    {
        "_id": "ZYRLHJIMTROTBO-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24770514,
                "inchl_key": "ZYRLHJIMTROTBO-UHFFFAOYSA-N",
                "generic_name": "6,8-bis(benzylthio)octanoic acid",
                "designated_date": "02/28/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rafael Pharmaceuticals, Inc.|1 Duncan Drive|Cranbury Township|New Jersey|8512|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Peripheral T-cell Lymphoma (PTCL)",
                    "umls_id": "C0079774",
                    "parsed_text": "Peripheral T-Cell Lymphoma"
                }
            },
            {
                "compound_id": 24770514,
                "inchl_key": "ZYRLHJIMTROTBO-UHFFFAOYSA-N",
                "generic_name": "6,8-bis(benzylthio)octanoic acid",
                "designated_date": "01/25/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rafael Pharmaceuticals, Inc.|1 Duncan Drive|Cranbury Township|New Jersey|8512|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Burkitts Lymphoma (BL)",
                    "umls_id": "C0006413",
                    "parsed_text": "Burkitts Lymphoma"
                }
            },
            {
                "compound_id": 24770514,
                "inchl_key": "ZYRLHJIMTROTBO-UHFFFAOYSA-N",
                "generic_name": "Devimistat",
                "designated_date": "10/26/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rafael Pharmaceuticals, Inc.|1 Duncan Drive|Cranbury|New Jersey|8512|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissues sarcoma.",
                    "umls_id": "C1261473",
                    "parsed_text": "Sarcoma"
                }
            }
        ]
    },
    {
        "_id": "XIIOFHFUYBLOLW-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134436906,
                "inchl_key": "XIIOFHFUYBLOLW-UHFFFAOYSA-N",
                "generic_name": "6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile",
                "designated_date": "10/10/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Loxo Oncology, Inc.|701 Gateway Blvd, Suite 420|South San Francisco,|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer.",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 134436906,
                "inchl_key": "XIIOFHFUYBLOLW-UHFFFAOYSA-N",
                "generic_name": "selpercatinib",
                "trade_name": "RETEVMO",
                "designated_date": "11/21/2019",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RETEVMO is indicated for the treatment of: Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)",
                "marketing_approval_date": "\u00a005/08/2020\u00a0",
                "exclusivity_end_date": "\u00a005/08/2027\u00a0",
                "exclusivity_protected_indication": "For the treatment of: adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; and, adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).",
                "sponsor": "Loxo Oncolocy at Lilly|701 Gateway Boulevard, Suite 420|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of RET fusion-positive or RET mutant thyroid cancers including poorly differentiated thyroid cancer, undifferentiated or anaplastic thyroid cancer, medullary thyroid cancer, and locally advanced or metastatic follicular or papillary thyroid canc",
                    "umls_id": "C0238461,C0238462,C0549473,C1337013",
                    "parsed_text": "anaplastic thyroid cancer , Thyroid cancer, medullary , Thyroid Cancers , Differentiated Thyroid Cancer"
                }
            },
            {
                "compound_id": 134436906,
                "inchl_key": "XIIOFHFUYBLOLW-UHFFFAOYSA-N",
                "generic_name": "selpercatinib",
                "trade_name": "RETEVMO",
                "designated_date": "10/30/2019",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RETEVMO is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC)",
                "marketing_approval_date": "\u00a005/08/2020\u00a0",
                "exclusivity_end_date": "\u00a005/08/2027\u00a0",
                "exclusivity_protected_indication": "For the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC)",
                "sponsor": "Loxo Oncolocy at Lilly|701 Gateway Boulevard, Suite 420|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of RET-fusion-positive non-small cell lung cancer",
                    "umls_id": "C3539721",
                    "parsed_text": "Non-Small Cell Lung Cancer"
                }
            }
        ]
    },
    {
        "_id": "JTQBMTFVGGUDPN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25400580,
                "inchl_key": "JTQBMTFVGGUDPN-UHFFFAOYSA-N",
                "generic_name": "6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-bensoxazin-4-one",
                "designated_date": "06/18/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sixera Pharma AB|Erik Dahlbergsgaten 11a2t|Vastra Gotaland 41126|Sweden",
                "orphan_designation": {
                    "original_text": "Treatment of Netherton syndrome",
                    "umls_id": "C0265962,C0265962",
                    "parsed_text": "Netherton Syndrome , Netherton Syndrome"
                }
            }
        ]
    },
    {
        "_id": "NICJCIQSJJKZAH-AWEZNQCLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 148189,
                "inchl_key": "NICJCIQSJJKZAH-AWEZNQCLSA-N",
                "generic_name": "6-hydroxymethylacylfulvene",
                "designated_date": "04/06/1999",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eisai, Inc.|300 Tice Blvd|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of histologically confirmed advanced or metastatic pancreatic cancer.",
                    "umls_id": "C0346976",
                    "parsed_text": "metastatic pancreatic cancer"
                }
            },
            {
                "compound_id": 148189,
                "inchl_key": "NICJCIQSJJKZAH-AWEZNQCLSA-N",
                "generic_name": "irofulven",
                "designated_date": "07/27/1999",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eisai, Inc.|300 Tice Blvd|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma.",
                    "umls_id": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            },
            {
                "compound_id": 148189,
                "inchl_key": "NICJCIQSJJKZAH-AWEZNQCLSA-N",
                "generic_name": "irofulven",
                "designated_date": "07/06/1999",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eisai, Inc.|300 Tice Blvd|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer.",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "CLEFVPILGAPOTG-NSHDSACASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 146591762,
                "inchl_key": "CLEFVPILGAPOTG-NSHDSACASA-N",
                "generic_name": "6-{(1S)-1-[(2-Amino-6-fluoroquinolin-3-yl)oxy]ethyl}-5-(1H-pyrazol-1-yl)pyridin-2(1H)-one",
                "designated_date": "09/18/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer, Inc.|500 Arcola Road|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "Treatment for Sickle Cell Disease.",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            }
        ]
    },
    {
        "_id": "VLULRUCCHYVXOH-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 73777259,
                "inchl_key": "VLULRUCCHYVXOH-UHFFFAOYSA-N",
                "generic_name": "7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one",
                "designated_date": "06/04/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Chimerix, Inc.|2505 Meridian Parkway, Suite 100|Durham|North Carolina|27713|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls_id": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            }
        ]
    },
    {
        "_id": "FFBDFADSZUINTG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 1329,
                "inchl_key": "FFBDFADSZUINTG-UHFFFAOYSA-N",
                "generic_name": "8 Cyclopentyl 1,3-dipropylxanthine",
                "designated_date": "03/24/1997",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SciClone Pharmaceuticals, Inc.|901 Mariner's Island Boulevard|San Mateo|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis.",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "FMMOOAYVCKXGMF-XMCVDNGOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 124037379,
                "inchl_key": "FMMOOAYVCKXGMF-XMCVDNGOSA-N",
                "generic_name": "9-cis, 12-cis-11,11-d2-linoleic acid ethyl ester",
                "designated_date": "05/23/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Retrotope, Inc.|4300 El Camino Real|Suite 201|Los Altos|California|94022|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Friedreich's Ataxia",
                    "umls_id": "C0016719",
                    "parsed_text": "Friedreich's Ataxia"
                }
            }
        ]
    },
    {
        "_id": "SHGAZHPCJJPHSC-ZVCIMWCZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 449171,
                "inchl_key": "SHGAZHPCJJPHSC-ZVCIMWCZSA-N",
                "generic_name": "9-cis-retinoic acid",
                "designated_date": "01/02/1997",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92623|United States",
                "orphan_designation": {
                    "original_text": "Prevention of retinal detachment due to proliferative vitreoretinopathy.",
                    "umls_id": "C0035305,C0344290",
                    "parsed_text": "Retinal Detachment , Vitreoretinopathy"
                }
            },
            {
                "compound_id": 449171,
                "inchl_key": "SHGAZHPCJJPHSC-ZVCIMWCZSA-N",
                "generic_name": "Alitretinoin",
                "trade_name": "Panretin",
                "designated_date": "03/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.",
                "marketing_approval_date": "\u00a002/02/1999\u00a0",
                "exclusivity_end_date": "\u00a002/02/2006\u00a0",
                "sponsor": "Eisai, Inc|300 Tice Blvd|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of AIDS-related Kaposi's sarcoma.",
                    "umls_id": "C0276535",
                    "parsed_text": "AIDS-related Kaposi's sarcoma"
                }
            },
            {
                "compound_id": 449171,
                "inchl_key": "SHGAZHPCJJPHSC-ZVCIMWCZSA-N",
                "generic_name": "alitretinoin",
                "designated_date": "01/12/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Galephar Pharmaceutical Research, Inc.|Carr 925 Km 6.1 Bo. Junquito|HC-04 BOX 4540|Humacao|Puerto Rico|791|United States",
                "orphan_designation": {
                    "original_text": "Treatment of systemic (non-cutaneous) kaposi sarcoma",
                    "umls_id": "C0036220",
                    "parsed_text": "Kaposi Sarcoma"
                }
            },
            {
                "compound_id": 449171,
                "inchl_key": "SHGAZHPCJJPHSC-ZVCIMWCZSA-N",
                "generic_name": "Alitretinoin",
                "designated_date": "04/10/1992",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ligand Pharmaceuticals, Inc.|10275 Science Center Dr.|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute promyelocytic leukemia",
                    "umls_id": "C0023487",
                    "parsed_text": "Acute Promyelocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "RTRQQBHATOEIAF-UUOKFMHZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 17513,
                "inchl_key": "RTRQQBHATOEIAF-UUOKFMHZSA-N",
                "generic_name": "acadesine",
                "designated_date": "03/03/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Avanced In Vitro Cell Technologies, S.L.|(Advancell)|Barcelona|Spain",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "compound_id": 17513,
                "inchl_key": "RTRQQBHATOEIAF-UUOKFMHZSA-N",
                "generic_name": "acadesine",
                "designated_date": "05/04/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Advancell-Advanced In Vitro Cell Technologies S.A.|Via Augusta 59, 3rd floor, door 313|Barcelona|Spain",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "WDENQIQQYWYTPO-IBGZPJMESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71226662,
                "inchl_key": "WDENQIQQYWYTPO-IBGZPJMESA-N",
                "generic_name": "acalabrutinib",
                "trade_name": "CALQUENCE",
                "designated_date": "09/21/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy",
                "marketing_approval_date": "\u00a010/31/2017\u00a0",
                "exclusivity_end_date": "\u00a010/31/2024\u00a0",
                "exclusivity_protected_indication": "treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy",
                "sponsor": "Acerta Pharma, LLC (a member of the AstraZeneca Group)|121 Oyster Point Boulevard|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mantle cell lymphoma.",
                    "umls_id": "C4721414",
                    "parsed_text": "Mantle cell lymphoma"
                }
            },
            {
                "compound_id": 71226662,
                "inchl_key": "WDENQIQQYWYTPO-IBGZPJMESA-N",
                "generic_name": "acalabrutinib",
                "designated_date": "10/22/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Acerta Pharma, LLC (a member of the AstraZeneca Group)|121 Oyster Point Boulevard|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Waldenstrom macroglobulinemia.",
                    "umls_id": "C0024419",
                    "parsed_text": "Waldenstrom Macroglobulinemia"
                }
            },
            {
                "compound_id": 71226662,
                "inchl_key": "WDENQIQQYWYTPO-IBGZPJMESA-N",
                "generic_name": "acalabrutinib",
                "designated_date": "05/13/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).",
                "marketing_approval_date": "\u00a011/21/2019\u00a0",
                "exclusivity_end_date": "\u00a011/21/2026\u00a0",
                "exclusivity_protected_indication": "Indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).",
                "sponsor": "Acerta Pharma, LLC (a member of the AstraZeneca Group)|121 Oyster Point Boulevard|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia (CLL).",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "AFCGFAGUEYAMAO-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71158,
                "inchl_key": "AFCGFAGUEYAMAO-UHFFFAOYSA-N",
                "generic_name": "acamprosate",
                "designated_date": "03/25/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Confluence Pharmaceuticals, LLC|Box 528|351 West 10th Street|Indianapolis|Indiana|46202|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fragile X syndrome",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "KBGAYAKRZNYFFG-BOHATCBPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 14017587,
                "inchl_key": "KBGAYAKRZNYFFG-BOHATCBPSA-N",
                "generic_name": "aceneuramic acid",
                "designated_date": "09/23/2011",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ultragenyx Pharmaceutical, Inc.|60 Leveroni Court|Suite 200|Novato|California|94949|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hereditary inclusion body myopathy",
                    "umls_id": "C1853926",
                    "parsed_text": "Hereditary inclusion body myopathy"
                }
            }
        ]
    },
    {
        "_id": "MDQMFOHHSFMREL-YIYMUJAPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134819826,
                "inchl_key": "MDQMFOHHSFMREL-YIYMUJAPSA-N",
                "generic_name": "acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-cysteinyl-D-glutaminyl-D-cysteinyl-D-arginyl-D-arginyl-D-lysyl-Dasparaginylamide disulfide",
                "designated_date": "02/18/2011",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genus Oncology, LLC|2458 N. Racine Avenue|Chicago|Illinois|60614|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer.",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "RDHQFKQIGNGIED-MRVPVSSYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 7045767,
                "inchl_key": "RDHQFKQIGNGIED-MRVPVSSYSA-N",
                "generic_name": "acetyl-l-carnitine",
                "designated_date": "07/24/2012",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Leadiant Biosciences, Inc.|9841 Washingtonian Blvd.|Suite 500|Gaithersburg|Maryland|20878|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X syndrome",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "PWKSKIMOESPYIA-BYPYZUCNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 12035,
                "inchl_key": "PWKSKIMOESPYIA-BYPYZUCNSA-N",
                "generic_name": "Acetylcysteine",
                "designated_date": "08/13/1987",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Intravenous treatment of patients presenting with moderate to severe acetaminophen overdose.",
                    "umls_id": "C0572025",
                    "parsed_text": "Acetaminophen overdose"
                }
            },
            {
                "compound_id": 12035,
                "inchl_key": "PWKSKIMOESPYIA-BYPYZUCNSA-N",
                "generic_name": "acetylcysteine",
                "trade_name": "Acetadote",
                "designated_date": "10/19/2001",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the use of Acetadote(registered TM) Injection, administered intravenously within 8 to 10 hours after ingestion of a potentially heptotoxic quantity of acetaminophen, to prevent or lessen hepatic injur",
                "marketing_approval_date": "\u00a001/23/2004\u00a0",
                "exclusivity_end_date": "\u00a001/23/2011\u00a0",
                "sponsor": "Cumberland Pharmaceuticals, Inc.|209 10th Street South|Suite 332|Nashville|Tennessee|37203|United States",
                "orphan_designation": {
                    "original_text": "For the intravenous treatment of moderate to severe acetaminophen overdose",
                    "umls_id": "C0572025",
                    "parsed_text": "Acetaminophen overdose"
                }
            },
            {
                "compound_id": 12035,
                "inchl_key": "PWKSKIMOESPYIA-BYPYZUCNSA-N",
                "generic_name": "N-acetylcysteine",
                "designated_date": "09/09/2002",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cumberland Pharmaceuticals, Inc.|2525 West End Ave.|Suite 950|Nashville|Tennessee|37203|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute liver failure",
                    "umls_id": "C0162557",
                    "parsed_text": "Acute liver failure"
                }
            },
            {
                "compound_id": 12035,
                "inchl_key": "PWKSKIMOESPYIA-BYPYZUCNSA-N",
                "generic_name": "N-acetylcysteine",
                "designated_date": "07/19/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Edward A. Neuwelt, MD|3181 SW Sam Jackson Park Road|Portland|Oregon|97239|United States",
                "orphan_designation": {
                    "original_text": "Prevention of ototoxicity caused by platinum-based chemotherapeutic agents used to treat pediatric cancers",
                    "umls_id": "C0006826,C0235280",
                    "parsed_text": "Cancers , Ototoxicity"
                }
            },
            {
                "compound_id": 12035,
                "inchl_key": "PWKSKIMOESPYIA-BYPYZUCNSA-N",
                "generic_name": "N-acetylcysteine",
                "designated_date": "10/21/2010",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Galleon Pharmaceuticals|213 Witmer Road|Horsham|Pennsylvania|19044|United States",
                "orphan_designation": {
                    "original_text": "Treatment of apnea of prematurity",
                    "umls_id": "C0475715",
                    "parsed_text": "Apnea of prematurity"
                }
            }
        ]
    },
    {
        "_id": "MDFXJBQEWLCGHP-MFOYZWKCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5391612,
                "inchl_key": "MDFXJBQEWLCGHP-MFOYZWKCSA-N",
                "generic_name": "Aconiazide",
                "designated_date": "06/20/1988",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Lincoln Diagnostics|P.O. Box 1128|Decatur|Illinois|62525|United States",
                "orphan_designation": {
                    "original_text": "Treatment of tuberculosis.",
                    "umls_id": "C0041296",
                    "parsed_text": "Tuberculosis"
                }
            }
        ]
    },
    {
        "_id": "MKUXAQIIEYXACX-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135398513,
                "inchl_key": "MKUXAQIIEYXACX-UHFFFAOYSA-N",
                "generic_name": "acyclovir",
                "designated_date": "05/03/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cumulus Pharmaceuticals LLC|1712 Pioneer Avenue|Suite 1377|Cheyenne|Wyoming|82001|United States",
                "orphan_designation": {
                    "original_text": "Treatment of herpetic keratitis.",
                    "umls_id": "C0022568",
                    "parsed_text": "Keratitis"
                }
            },
            {
                "compound_id": 135398513,
                "inchl_key": "MKUXAQIIEYXACX-UHFFFAOYSA-N",
                "generic_name": "acyclovir",
                "designated_date": "09/16/2010",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "GlaxoSmithKline|One Franklin Plaza|Philadelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of herpetic keratitis",
                    "umls_id": "C0019357",
                    "parsed_text": "Herpetic keratitis"
                }
            },
            {
                "compound_id": 135398513,
                "inchl_key": "MKUXAQIIEYXACX-UHFFFAOYSA-N",
                "generic_name": "acyclovir",
                "trade_name": "Avaclyr",
                "designated_date": "12/13/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "AVACLYR is a sterile topical antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus.",
                "marketing_approval_date": "\u00a003/29/2019\u00a0",
                "exclusivity_end_date": "\u00a003/29/2026\u00a0",
                "exclusivity_protected_indication": "AVACLYR is a sterile topical antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus.",
                "sponsor": "Fera Pharmaceuticals|134 Birch Hill Road|Locust Valley|New York|11560|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute herpetic keratitis caused by Herpes Simplex Virus type 1 and 2",
                    "umls_id": "C0019357",
                    "parsed_text": "Herpetic keratitis"
                }
            }
        ]
    },
    {
        "_id": "OIRDTQYFTABQOQ-KQYNXXCUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 60961,
                "inchl_key": "OIRDTQYFTABQOQ-KQYNXXCUSA-N",
                "generic_name": "Adenosine",
                "designated_date": "08/01/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medco Research, Inc.|8455 Beverly Boulevard|Suite 308|Los Angeles|California|90048|United States",
                "orphan_designation": {
                    "original_text": "For use in conjunction with BCNU in the treatment of brain tumors.",
                    "umls_id": "C0006118",
                    "parsed_text": "Brain Tumors"
                }
            }
        ]
    },
    {
        "_id": "UAHFGYDRQSXQEB-LEBBXHLNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16197727,
                "inchl_key": "UAHFGYDRQSXQEB-LEBBXHLNSA-N",
                "generic_name": "afamelanotide",
                "designated_date": "12/11/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinuvel, Inc.|30 Broad Street|Suites 1407 and 1408|New York|New York|10004|United States",
                "orphan_designation": {
                    "original_text": "Treatment of solar urticaria",
                    "umls_id": "C0263610",
                    "parsed_text": "Solar urticaria"
                }
            },
            {
                "compound_id": 16197727,
                "inchl_key": "UAHFGYDRQSXQEB-LEBBXHLNSA-N",
                "generic_name": "afamelanotide",
                "designated_date": "05/14/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinuvel, Inc.|40 Worth Street|10th Floor - Suite 1053|New York|New York|10013|United States",
                "orphan_designation": {
                    "original_text": "Treatment of familial benign chronic pemphigus (Hailey-Hailey disease)",
                    "umls_id": "C0085106",
                    "parsed_text": "Familial Benign Chronic Pemphigus"
                }
            },
            {
                "compound_id": 16197727,
                "inchl_key": "UAHFGYDRQSXQEB-LEBBXHLNSA-N",
                "generic_name": "afamelanotide",
                "trade_name": "SCENESSE",
                "designated_date": "07/17/2008",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "SCENESSE is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)",
                "marketing_approval_date": "\u00a010/08/2019\u00a0",
                "exclusivity_end_date": "\u00a010/08/2026\u00a0",
                "exclusivity_protected_indication": "Indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).",
                "sponsor": "Clinuvel Inc.|P. O. Box 94026|Menlo Park|California|94026|United States",
                "orphan_designation": {
                    "original_text": "Treatment of erythropoietic porphyrias",
                    "umls_id": "C0162530",
                    "parsed_text": "Erythropoietic Porphyrias"
                }
            },
            {
                "compound_id": 16197727,
                "inchl_key": "UAHFGYDRQSXQEB-LEBBXHLNSA-N",
                "generic_name": "afamelanotide",
                "designated_date": "02/04/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinuvel Inc.|40 Worth Street|Suite 1053|New York|New York|10013|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cutaneous variants of porphyria (which includes treatment and prevention of cutaneous manifestations of disease)",
                    "umls_id": "C0032708",
                    "parsed_text": "Porphyria"
                }
            }
        ]
    },
    {
        "_id": "ULXXDDBFHOBEHA-CWDCEQMOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10184653,
                "inchl_key": "ULXXDDBFHOBEHA-CWDCEQMOSA-N",
                "generic_name": "afatinib",
                "designated_date": "07/09/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Boehringer Ingelheim Pharmaceuticals, Inc.|900 Ridgebury Road|P. O. Box 368|Ridgefield|Connecticut|6877|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 10184653,
                "inchl_key": "ULXXDDBFHOBEHA-CWDCEQMOSA-N",
                "generic_name": "afatinib",
                "designated_date": "06/04/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Boehringer Ingelheim Pharmaceuticals, Inc.|900 Ridgebury Road|P. O. Box 368|Ridgefield|Connecticut|6877|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant brain and central nervous system tumors",
                    "umls_id": "C0085136",
                    "parsed_text": "central nervous system tumors"
                }
            },
            {
                "compound_id": 10184653,
                "inchl_key": "ULXXDDBFHOBEHA-CWDCEQMOSA-N",
                "generic_name": "afatinib",
                "trade_name": "Gilotrif",
                "designated_date": "12/03/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.",
                "marketing_approval_date": "\u00a007/12/2013\u00a0",
                "exclusivity_end_date": "\u00a007/12/2020\u00a0",
                "exclusivity_protected_indication": "First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.",
                "sponsor": "Boehringer Ingelheim Pharmaceuticals, Inc.|900 Ridgebury Road|P. O. Box 368|Ridgefield|Connecticut|6877|United States",
                "orphan_designation": {
                    "original_text": "Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).",
                    "umls_id": "C0007131",
                    "parsed_text": "Non-Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 10184653,
                "inchl_key": "ULXXDDBFHOBEHA-CWDCEQMOSA-N",
                "generic_name": "afatinib",
                "trade_name": "Gilotrif",
                "designated_date": "08/03/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with metastatic, squamous, non-small cell lung cancer progressing after platinum-based chemotherapy",
                "marketing_approval_date": "\u00a004/15/2016\u00a0",
                "exclusivity_end_date": "\u00a004/15/2023\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with metastatic, squamous, non-small cell lung cancer progressing after platinum-based chemotherapy",
                "sponsor": "Boehringer Ingelheim Pharmaceuticals, Inc.|900 Ridgebury Road|P. O. Box 368|Ridgefield|Connecticut|6877|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-small cell lung cancer with squamous histology.",
                    "umls_id": "C0007131",
                    "parsed_text": "non-small cell lung cancer"
                }
            },
            {
                "compound_id": 10184653,
                "inchl_key": "ULXXDDBFHOBEHA-CWDCEQMOSA-N",
                "generic_name": "afatinib",
                "trade_name": "Gilotrif",
                "designated_date": "12/03/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.",
                "marketing_approval_date": "\u00a001/12/2018\u00a0",
                "exclusivity_end_date": "\u00a001/12/2025\u00a0",
                "exclusivity_protected_indication": "GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations other than exon 19 deletions or exon 21 (L858R) substiution mutationas as detected by an FDA-approved test.",
                "sponsor": "Boehringer Ingelheim Pharmaceuticals, Inc.|900 Ridgebury Road|P. O. Box 368|Ridgefield|Connecticut|6877|United States",
                "orphan_designation": {
                    "original_text": "Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).",
                    "umls_id": "C0007131",
                    "parsed_text": "Non-Small Cell Lung Cancer"
                }
            }
        ]
    },
    {
        "_id": "HXHWSAZORRCQMX-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2082,
                "inchl_key": "HXHWSAZORRCQMX-UHFFFAOYSA-N",
                "generic_name": "Albendazole",
                "trade_name": "Albenza",
                "designated_date": "01/17/1996",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.",
                "marketing_approval_date": "\u00a006/11/1996\u00a0",
                "exclusivity_end_date": "\u00a006/11/2003\u00a0",
                "sponsor": "Impax Laboratories, LLC|400 Crossing Boulevard|Third Floor|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).",
                    "umls_id": "C0013502,C0152069,C4553297",
                    "parsed_text": "Hydatid disease , Alveolar echinococcosis , Hydatid Disease"
                }
            },
            {
                "compound_id": 2082,
                "inchl_key": "HXHWSAZORRCQMX-UHFFFAOYSA-N",
                "generic_name": "Albendazole",
                "trade_name": "Albenza",
                "designated_date": "01/18/1996",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.",
                "marketing_approval_date": "\u00a006/11/1996\u00a0",
                "exclusivity_end_date": "\u00a006/11/2003\u00a0",
                "sponsor": "Impax Laboratories, LLC|400 Crossing Boulevard|Third Floor|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocys",
                    "umls_id": "C0010709,C0014544,C0338437",
                    "parsed_text": "Cysts , Epilepsy , Neurocysticercosis"
                }
            }
        ]
    },
    {
        "_id": "NDAUXUAQIAJITI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2083,
                "inchl_key": "NDAUXUAQIAJITI-UHFFFAOYSA-N",
                "generic_name": "Albuterol",
                "designated_date": "03/12/2002",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MotoGen, Inc.|3 Pine View Road|Mount Kisco|New York|10549|United States",
                "orphan_designation": {
                    "original_text": "Prevention of paralysis due to spinal cord injury",
                    "umls_id": "C0037929,C0522224",
                    "parsed_text": "Spinal Cord Injury , Paralysis"
                }
            }
        ]
    },
    {
        "_id": "OBMJQRLIQQTJLR-USGQOSEYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9810709,
                "inchl_key": "OBMJQRLIQQTJLR-USGQOSEYSA-N",
                "generic_name": "aldoxorubicin",
                "designated_date": "09/24/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ImmunityBio, Inc.|9920 Jefferson Boulevard|Culver City|California|90232|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioblastoma multiforme",
                    "umls_id": "C0017636",
                    "parsed_text": "Glioblastoma multiforme"
                }
            },
            {
                "compound_id": 9810709,
                "inchl_key": "OBMJQRLIQQTJLR-USGQOSEYSA-N",
                "generic_name": "aldoxorubicin",
                "designated_date": "09/24/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ImmunityBio, Inc.|9920 Jefferson Boulevard|Culver City|California|90232|United States",
                "orphan_designation": {
                    "original_text": "Treatment of small cell lung cancer",
                    "umls_id": "C3540630",
                    "parsed_text": "Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 9810709,
                "inchl_key": "OBMJQRLIQQTJLR-USGQOSEYSA-N",
                "generic_name": "aldoxorubicin",
                "designated_date": "09/24/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ImmunityBio, Inc.|9920 Jefferson Boulevard|Culver City|California|90232|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "compound_id": 9810709,
                "inchl_key": "OBMJQRLIQQTJLR-USGQOSEYSA-N",
                "generic_name": "Aldoxorubicin",
                "designated_date": "06/29/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ImmunityBio, Inc.|9920 Jefferson Boulevard|Culver City|California|90232|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcoma",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            },
            {
                "compound_id": 9810709,
                "inchl_key": "OBMJQRLIQQTJLR-USGQOSEYSA-N",
                "generic_name": "Aldoxorubicin",
                "designated_date": "04/18/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ImmunityBio, Inc.|9920 Jefferson Boulevard|Culver City|California|90232|United States",
                "orphan_designation": {
                    "original_text": "Treatment of adenocarcinoma of the pancreas.",
                    "umls_id": "C0281361",
                    "parsed_text": "adenocarcinoma of the pancreas"
                }
            }
        ]
    },
    {
        "_id": "KDGFLJKFZUIJMX-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 49806720,
                "inchl_key": "KDGFLJKFZUIJMX-UHFFFAOYSA-N",
                "generic_name": "alectinib",
                "trade_name": "Alecensa",
                "designated_date": "01/27/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "ALECENSA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.",
                "marketing_approval_date": "\u00a011/06/2017\u00a0",
                "exclusivity_end_date": "\u00a011/06/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small-cell lung cancer (NSCLC) as detected by an FDA-approved test, excluding patients who have progressed on or are intolerant to crizotinib.",
                "sponsor": "Hoffmann-La Roche, Inc. (c/o Genentech, Inc.)|1 DNA Way, MS #355E|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ALK-positive non-small cell lung cancer",
                    "umls_id": "C3539721",
                    "parsed_text": "Non-Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 49806720,
                "inchl_key": "KDGFLJKFZUIJMX-UHFFFAOYSA-N",
                "generic_name": "alectinib",
                "trade_name": "Alecensa",
                "designated_date": "01/27/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "ALECENSA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.",
                "marketing_approval_date": "\u00a012/11/2015\u00a0",
                "exclusivity_end_date": "\u00a012/11/2022\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), who have progressed on or are intolerant to crizotinib",
                "sponsor": "Hoffmann-La Roche, Inc. (c/o Genentech, Inc.)|1 DNA Way, MS #355E|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ALK-positive non-small cell lung cancer",
                    "umls_id": "C3539721",
                    "parsed_text": "Non-Small Cell Lung Cancer"
                }
            }
        ]
    },
    {
        "_id": "OGSPWJRAVKPPFI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2088,
                "inchl_key": "OGSPWJRAVKPPFI-UHFFFAOYSA-N",
                "generic_name": "alendronate",
                "designated_date": "03/31/2003",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Merck, Sharpe & Dohme Corp.|126 East Lincoln Ave.|RY 33-212|Rahway|New Jersey|7065|United States",
                "orphan_designation": {
                    "original_text": "Treatment of osteogenesis imperfecta in pediatric patients 4 years of age and older",
                    "umls_id": "C0029434",
                    "parsed_text": "Osteogenesis Imperfecta"
                }
            }
        ]
    },
    {
        "_id": "CAKRAHQRJGUPIG-UHFFFAOYSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 91997073,
                "inchl_key": "CAKRAHQRJGUPIG-UHFFFAOYSA-L",
                "generic_name": "Alendronate disodium",
                "designated_date": "02/13/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Richard J. Wenstrup, M.D.|Division of Human Genetics|Children's Hospital Research Foundation|Cincinnati|Ohio|45229|United States",
                "orphan_designation": {
                    "original_text": "Treatment of the bone manifestations of Gaucher disease",
                    "umls_id": "C0017205",
                    "parsed_text": "Gaucher Disease"
                }
            }
        ]
    },
    {
        "_id": "LMWOPQOPFYJQLI-UHFFFAOYSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 14157383,
                "inchl_key": "LMWOPQOPFYJQLI-UHFFFAOYSA-L",
                "generic_name": "Alendronate disodium",
                "designated_date": "02/13/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Richard J. Wenstrup, M.D.|Division of Human Genetics|Children's Hospital Research Foundation|Cincinnati|Ohio|45229|United States",
                "orphan_designation": {
                    "original_text": "Treatment of the bone manifestations of Gaucher disease",
                    "umls_id": "C0017205",
                    "parsed_text": "Gaucher Disease"
                }
            }
        ]
    },
    {
        "_id": "IDBPHNDTYPBSNI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 51263,
                "inchl_key": "IDBPHNDTYPBSNI-UHFFFAOYSA-N",
                "generic_name": "Alfentanil",
                "designated_date": "08/09/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cinergen, LLC|146 Medinah Drive|Blue Bell|Pennsylvania|19422|United States",
                "orphan_designation": {
                    "original_text": "Treatment of painful HIV-associated neuropathy",
                    "umls_id": "C0019682,C0442874",
                    "parsed_text": "HIV , Neuropathy"
                }
            },
            {
                "compound_id": 51263,
                "inchl_key": "IDBPHNDTYPBSNI-UHFFFAOYSA-N",
                "generic_name": "Alfentanil",
                "designated_date": "07/08/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cinergen, LLC|146 Medinah Drive|Blue Bell|Pennsylvania|19422|United States",
                "orphan_designation": {
                    "original_text": "Management of postherpetic neuralgia",
                    "umls_id": "C0032768",
                    "parsed_text": "Postherpetic neuralgia"
                }
            }
        ]
    },
    {
        "_id": "ZMJWRJKGPUDEOX-LMXUULCNSA-A",
        "Orphan Drug Designations": [
            {
                "compound_id": 16197725,
                "inchl_key": "ZMJWRJKGPUDEOX-LMXUULCNSA-A",
                "generic_name": "alicaforsen",
                "designated_date": "06/24/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Atlantic Clinica Ltd.|Atlantic House|10 Rose & Crown Walk|Saffron Walden|Essex|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of pouchitis.",
                    "umls_id": "C0376620",
                    "parsed_text": "Pouchitis"
                }
            }
        ]
    },
    {
        "_id": "POHUROFYRXELIO-YUMQZZPRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 121488179,
                "inchl_key": "POHUROFYRXELIO-YUMQZZPRSA-N",
                "generic_name": "Alidornase alfa",
                "designated_date": "07/21/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SarcoMed USA, Inc.|1300 Post Oak Boulevard|Suite 760|Houston|Texas|77056|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sarcoidosis",
                    "umls_id": "C0036202",
                    "parsed_text": "Sarcoidosis"
                }
            }
        ]
    },
    {
        "_id": "ZLHFILGSQDJULK-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24771867,
                "inchl_key": "ZLHFILGSQDJULK-UHFFFAOYSA-N",
                "generic_name": "alisertib",
                "designated_date": "07/12/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of small cell lung cancer",
                    "umls_id": "C3540630",
                    "parsed_text": "Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 24771867,
                "inchl_key": "ZLHFILGSQDJULK-UHFFFAOYSA-N",
                "generic_name": "alisertib",
                "designated_date": "05/14/2012",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of peripheral T-cell lymphoma",
                    "umls_id": "C0079774",
                    "parsed_text": "Peripheral T-Cell Lymphoma"
                }
            }
        ]
    },
    {
        "_id": "MBMBGCFOFBJSGT-KUBAVDMBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 445580,
                "inchl_key": "MBMBGCFOFBJSGT-KUBAVDMBSA-N",
                "generic_name": "all-cis-docosa-4,7,10,13,16,19-hexaenoic acid",
                "designated_date": "05/21/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Natac Pharma, S.L.|C/ Faraday 7|28049|Madrid|Spain",
                "orphan_designation": {
                    "original_text": "Treatment of retinitis pigmentosa",
                    "umls_id": "C0035334",
                    "parsed_text": "Retinitis Pigmentosa"
                }
            },
            {
                "compound_id": 445580,
                "inchl_key": "MBMBGCFOFBJSGT-KUBAVDMBSA-N",
                "generic_name": "docosahexaenoic acid",
                "designated_date": "04/27/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Micelle BioPharma, Inc.|3874 Fiscal Ct., #200|Riviera Beach|Florida|33404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sickle cell disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            },
            {
                "compound_id": 445580,
                "inchl_key": "MBMBGCFOFBJSGT-KUBAVDMBSA-N",
                "generic_name": "docosahexaenoic acid",
                "designated_date": "06/01/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Micelle BioPharma, Inc.|3874 Fiscal Ct., #200|Riviera Beach|Florida|33404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of short bowel syndrome",
                    "umls_id": "C0036992",
                    "parsed_text": "Short Bowel Syndrome"
                }
            }
        ]
    },
    {
        "_id": "POJWUDADGALRAB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 204,
                "inchl_key": "POJWUDADGALRAB-UHFFFAOYSA-N",
                "generic_name": "allantoin",
                "designated_date": "11/21/2002",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Scioderm, Inc.|1007 Slater Road|Suite 170|Durham|North Carolina|27703|United States",
                "orphan_designation": {
                    "original_text": "Treatment of skin blistering and erosions associated with inherited epidermolysis bullosa",
                    "umls_id": "C0014527,C2220104",
                    "parsed_text": "Epidermolysis Bullosa , Skin blistering"
                }
            }
        ]
    },
    {
        "_id": "AURFZBICLPNKBZ-FFWOKMQNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134688930,
                "inchl_key": "AURFZBICLPNKBZ-FFWOKMQNSA-N",
                "generic_name": "allopregnanolone",
                "designated_date": "04/20/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sage Therapeutics|215 First Street|Suite 220|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of status epilepticus",
                    "umls_id": "C0038220",
                    "parsed_text": "Status Epilepticus"
                }
            },
            {
                "compound_id": 134688930,
                "inchl_key": "AURFZBICLPNKBZ-FFWOKMQNSA-N",
                "generic_name": "allopregnanolone",
                "designated_date": "07/12/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company, Inc.|10182 Telesis Court|6th Floor, Suite 600|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Neimann-Pick disease, type C",
                    "umls_id": "C0028064",
                    "parsed_text": "neimann-pick disease"
                }
            }
        ]
    },
    {
        "_id": "AURFZBICLPNKBZ-JITSNLRCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 21139953,
                "inchl_key": "AURFZBICLPNKBZ-JITSNLRCSA-N",
                "generic_name": "allopregnanolone",
                "designated_date": "04/20/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sage Therapeutics|215 First Street|Suite 220|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of status epilepticus",
                    "umls_id": "C0038220",
                    "parsed_text": "Status Epilepticus"
                }
            },
            {
                "compound_id": 21139953,
                "inchl_key": "AURFZBICLPNKBZ-JITSNLRCSA-N",
                "generic_name": "allopregnanolone",
                "designated_date": "07/12/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company, Inc.|10182 Telesis Court|6th Floor, Suite 600|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Neimann-Pick disease, type C",
                    "umls_id": "C0028064",
                    "parsed_text": "neimann-pick disease"
                }
            }
        ]
    },
    {
        "_id": "AURFZBICLPNKBZ-LOPWJTSLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9883500,
                "inchl_key": "AURFZBICLPNKBZ-LOPWJTSLSA-N",
                "generic_name": "allopregnanolone",
                "designated_date": "04/20/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sage Therapeutics|215 First Street|Suite 220|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of status epilepticus",
                    "umls_id": "C0038220",
                    "parsed_text": "Status Epilepticus"
                }
            },
            {
                "compound_id": 9883500,
                "inchl_key": "AURFZBICLPNKBZ-LOPWJTSLSA-N",
                "generic_name": "allopregnanolone",
                "designated_date": "07/12/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company, Inc.|10182 Telesis Court|6th Floor, Suite 600|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Neimann-Pick disease, type C",
                    "umls_id": "C0028064",
                    "parsed_text": "neimann-pick disease"
                }
            }
        ]
    },
    {
        "_id": "AURFZBICLPNKBZ-MHPDUSGUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6708605,
                "inchl_key": "AURFZBICLPNKBZ-MHPDUSGUSA-N",
                "generic_name": "allopregnanolone",
                "designated_date": "04/20/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sage Therapeutics|215 First Street|Suite 220|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of status epilepticus",
                    "umls_id": "C0038220",
                    "parsed_text": "Status Epilepticus"
                }
            },
            {
                "compound_id": 6708605,
                "inchl_key": "AURFZBICLPNKBZ-MHPDUSGUSA-N",
                "generic_name": "allopregnanolone",
                "designated_date": "07/12/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company, Inc.|10182 Telesis Court|6th Floor, Suite 600|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Neimann-Pick disease, type C",
                    "umls_id": "C0028064",
                    "parsed_text": "neimann-pick disease"
                }
            }
        ]
    },
    {
        "_id": "AURFZBICLPNKBZ-SRJHXTLLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 104881,
                "inchl_key": "AURFZBICLPNKBZ-SRJHXTLLSA-N",
                "generic_name": "allopregnanolone",
                "designated_date": "04/20/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sage Therapeutics|215 First Street|Suite 220|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of status epilepticus",
                    "umls_id": "C0038220",
                    "parsed_text": "Status Epilepticus"
                }
            },
            {
                "compound_id": 104881,
                "inchl_key": "AURFZBICLPNKBZ-SRJHXTLLSA-N",
                "generic_name": "allopregnanolone",
                "designated_date": "07/12/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company, Inc.|10182 Telesis Court|6th Floor, Suite 600|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Neimann-Pick disease, type C",
                    "umls_id": "C0028064",
                    "parsed_text": "neimann-pick disease"
                }
            }
        ]
    },
    {
        "_id": "AURFZBICLPNKBZ-JMTGGFPBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 22833567,
                "inchl_key": "AURFZBICLPNKBZ-JMTGGFPBSA-N",
                "generic_name": "allopregnanolone",
                "designated_date": "04/20/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sage Therapeutics|215 First Street|Suite 220|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of status epilepticus",
                    "umls_id": "C0038220",
                    "parsed_text": "Status Epilepticus"
                }
            },
            {
                "compound_id": 22833567,
                "inchl_key": "AURFZBICLPNKBZ-JMTGGFPBSA-N",
                "generic_name": "allopregnanolone",
                "designated_date": "07/12/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company, Inc.|10182 Telesis Court|6th Floor, Suite 600|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Neimann-Pick disease, type C",
                    "umls_id": "C0028064",
                    "parsed_text": "neimann-pick disease"
                }
            }
        ]
    },
    {
        "_id": "AURFZBICLPNKBZ-YZRLXODZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 31402,
                "inchl_key": "AURFZBICLPNKBZ-YZRLXODZSA-N",
                "generic_name": "allopregnanolone",
                "designated_date": "04/20/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sage Therapeutics|215 First Street|Suite 220|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of status epilepticus",
                    "umls_id": "C0038220",
                    "parsed_text": "Status Epilepticus"
                }
            },
            {
                "compound_id": 31402,
                "inchl_key": "AURFZBICLPNKBZ-YZRLXODZSA-N",
                "generic_name": "allopregnanolone",
                "designated_date": "07/12/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company, Inc.|10182 Telesis Court|6th Floor, Suite 600|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Neimann-Pick disease, type C",
                    "umls_id": "C0028064",
                    "parsed_text": "neimann-pick disease"
                }
            }
        ]
    },
    {
        "_id": "AURFZBICLPNKBZ-SUZPBREPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16760287,
                "inchl_key": "AURFZBICLPNKBZ-SUZPBREPSA-N",
                "generic_name": "allopregnanolone",
                "designated_date": "04/20/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sage Therapeutics|215 First Street|Suite 220|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of status epilepticus",
                    "umls_id": "C0038220",
                    "parsed_text": "Status Epilepticus"
                }
            },
            {
                "compound_id": 16760287,
                "inchl_key": "AURFZBICLPNKBZ-SUZPBREPSA-N",
                "generic_name": "allopregnanolone",
                "designated_date": "07/12/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company, Inc.|10182 Telesis Court|6th Floor, Suite 600|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Neimann-Pick disease, type C",
                    "umls_id": "C0028064",
                    "parsed_text": "neimann-pick disease"
                }
            }
        ]
    },
    {
        "_id": "AURFZBICLPNKBZ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 262961,
                "inchl_key": "AURFZBICLPNKBZ-UHFFFAOYSA-N",
                "generic_name": "allopregnanolone",
                "designated_date": "04/20/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sage Therapeutics|215 First Street|Suite 220|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of status epilepticus",
                    "umls_id": "C0038220",
                    "parsed_text": "Status Epilepticus"
                }
            },
            {
                "compound_id": 262961,
                "inchl_key": "AURFZBICLPNKBZ-UHFFFAOYSA-N",
                "generic_name": "allopregnanolone",
                "designated_date": "07/12/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company, Inc.|10182 Telesis Court|6th Floor, Suite 600|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Neimann-Pick disease, type C",
                    "umls_id": "C0028064",
                    "parsed_text": "neimann-pick disease"
                }
            }
        ]
    },
    {
        "_id": "AURFZBICLPNKBZ-FZCSVUEKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 92787,
                "inchl_key": "AURFZBICLPNKBZ-FZCSVUEKSA-N",
                "generic_name": "allopregnanolone",
                "designated_date": "04/20/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sage Therapeutics|215 First Street|Suite 220|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of status epilepticus",
                    "umls_id": "C0038220",
                    "parsed_text": "Status Epilepticus"
                }
            },
            {
                "compound_id": 92787,
                "inchl_key": "AURFZBICLPNKBZ-FZCSVUEKSA-N",
                "generic_name": "allopregnanolone",
                "designated_date": "07/12/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company, Inc.|10182 Telesis Court|6th Floor, Suite 600|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Neimann-Pick disease, type C",
                    "umls_id": "C0028064",
                    "parsed_text": "neimann-pick disease"
                }
            }
        ]
    },
    {
        "_id": "AURFZBICLPNKBZ-SYBPFIFISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 92786,
                "inchl_key": "AURFZBICLPNKBZ-SYBPFIFISA-N",
                "generic_name": "allopregnanolone",
                "designated_date": "04/20/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sage Therapeutics|215 First Street|Suite 220|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of status epilepticus",
                    "umls_id": "C0038220",
                    "parsed_text": "Status Epilepticus"
                }
            },
            {
                "compound_id": 92786,
                "inchl_key": "AURFZBICLPNKBZ-SYBPFIFISA-N",
                "generic_name": "allopregnanolone",
                "designated_date": "07/12/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company, Inc.|10182 Telesis Court|6th Floor, Suite 600|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Neimann-Pick disease, type C",
                    "umls_id": "C0028064",
                    "parsed_text": "neimann-pick disease"
                }
            }
        ]
    },
    {
        "_id": "KFQUAMTWOJHPEJ-DAGMQNCNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135407110,
                "inchl_key": "KFQUAMTWOJHPEJ-DAGMQNCNSA-N",
                "generic_name": "Allopurinol riboside",
                "designated_date": "12/04/1985",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Burroughs Wellcome Company|3030 Cornwallis Road|P.O. Box 12700|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "1. Treatment of Chagas' disease 2. Treatment of cutaneous and visceral leishmaniasis",
                    "umls_id": "C0023290,C0041234",
                    "parsed_text": "Visceral leishmaniasis , Chagas' disease"
                }
            }
        ]
    },
    {
        "_id": "PTJRZVJXXNYNLN-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 70691471,
                "inchl_key": "PTJRZVJXXNYNLN-UHFFFAOYSA-M",
                "generic_name": "Allopurinol sodium",
                "trade_name": "Aloprim for Injection",
                "designated_date": "10/16/1992",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.",
                "marketing_approval_date": "\u00a005/17/1996\u00a0",
                "exclusivity_end_date": "\u00a005/17/2003\u00a0",
                "sponsor": "Catalytica Pharmaceuticals, Inc|PO Box 1887|Greenville|North Carolina|27835|United States",
                "orphan_designation": {
                    "original_text": "Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.",
                    "umls_id": "C0006826,C0023418,C0024299,C0280099",
                    "parsed_text": "MALIGNANCIES , leukemia , Lymphoma , Solid Tumor"
                }
            },
            {
                "compound_id": 70691471,
                "inchl_key": "PTJRZVJXXNYNLN-UHFFFAOYSA-M",
                "generic_name": "Allopurinol sodium",
                "trade_name": "Aloprim for Injection",
                "designated_date": "10/16/1992",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.",
                "marketing_approval_date": "\u00a005/17/1996\u00a0",
                "exclusivity_end_date": "\u00a005/17/2003\u00a0",
                "sponsor": "Catalytica Pharmaceuticals, Inc|PO Box 1887|Greenville|North Carolina|27835|United States",
                "orphan_designation": {
                    "original_text": "Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.",
                    "umls_id": "C0006826,C0023418,C0024299,C0280099",
                    "parsed_text": "MALIGNANCIES , leukemia , Lymphoma , Solid Tumor"
                }
            }
        ]
    },
    {
        "_id": "PTJRZVJXXNYNLN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135534565,
                "inchl_key": "PTJRZVJXXNYNLN-UHFFFAOYSA-N",
                "generic_name": "Allopurinol sodium",
                "trade_name": "Aloprim for Injection",
                "designated_date": "10/16/1992",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.",
                "marketing_approval_date": "\u00a005/17/1996\u00a0",
                "exclusivity_end_date": "\u00a005/17/2003\u00a0",
                "sponsor": "Catalytica Pharmaceuticals, Inc|PO Box 1887|Greenville|North Carolina|27835|United States",
                "orphan_designation": {
                    "original_text": "Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.",
                    "umls_id": "C0006826,C0023418,C0024299,C0280099",
                    "parsed_text": "MALIGNANCIES , leukemia , Lymphoma , Solid Tumor"
                }
            }
        ]
    },
    {
        "_id": "STUWGJZDJHPWGZ-LBPRGKRZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 56649450,
                "inchl_key": "STUWGJZDJHPWGZ-LBPRGKRZSA-N",
                "generic_name": "alpelisib",
                "designated_date": "11/18/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of PIK3CA-related overgrowth spectrum",
                    "umls_id": "C1849265",
                    "parsed_text": "Overgrowth"
                }
            }
        ]
    },
    {
        "_id": "WHNFPRLDDSXQCL-UAZQEYIDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44273719,
                "inchl_key": "WHNFPRLDDSXQCL-UAZQEYIDSA-N",
                "generic_name": "Alpha-melanocyte stimulating hormone",
                "designated_date": "08/19/1997",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "National Institute of Diabetes, and Digestive and Kidney Diseases|National Institutes of Health, 31 Center Drive MSC|Building 31, Room 9N-222|Bethesda|Maryland|20892|United States",
                "orphan_designation": {
                    "original_text": "Prevention and treatment of intrinsic acute renal failure due to ischemia.",
                    "umls_id": "C1828256",
                    "parsed_text": "Acute renal failure due to ischemia"
                }
            }
        ]
    },
    {
        "_id": "LTVDFSLWFKLJDQ-IEOSBIPESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2734086,
                "inchl_key": "LTVDFSLWFKLJDQ-IEOSBIPESA-N",
                "generic_name": "Alpha-tocopherol quinone",
                "designated_date": "03/28/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Penwest Pharmaceuticals Company|39 Old Ridgebury Road|Suite 11|Danbury|Connecticut|6810|United States",
                "orphan_designation": {
                    "original_text": "Treatment of inherited mitochondrial respiratory chain diseases",
                    "umls_id": "C1325653",
                    "parsed_text": "mitochondrial respiratory chain"
                }
            }
        ]
    },
    {
        "_id": "LNOVHERIIMJMDG-XZXLULOTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 46184405,
                "inchl_key": "LNOVHERIIMJMDG-XZXLULOTSA-N",
                "generic_name": "alpha-tocotrienol quinone",
                "designated_date": "10/21/2010",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PTC Therapeutics, Inc.|100 Corporate Court|South Plainfield|New Jersey|7080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of inherited mitochondrial respiratory chain diseases",
                    "umls_id": "C1325653",
                    "parsed_text": "mitochondrial respiratory chain"
                }
            },
            {
                "compound_id": 46184405,
                "inchl_key": "LNOVHERIIMJMDG-XZXLULOTSA-N",
                "generic_name": "vatiquinone",
                "designated_date": "01/31/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PTC Therapeutics, Inc.|100 Corporate Court|South Plainfield|New Jersey|7080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Friedreich's ataxia",
                    "umls_id": "C0016719",
                    "parsed_text": "Friedreich's Ataxia"
                }
            },
            {
                "compound_id": 46184405,
                "inchl_key": "LNOVHERIIMJMDG-XZXLULOTSA-N",
                "generic_name": "vatiquinone",
                "designated_date": "08/10/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PTC Therapeutics, Inc.|100 Corporate Court|South Plainfield|New Jersey|7080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mitochondrial disease",
                    "umls_id": "C0751651",
                    "parsed_text": "Mitochondrial disease"
                }
            },
            {
                "compound_id": 46184405,
                "inchl_key": "LNOVHERIIMJMDG-XZXLULOTSA-N",
                "generic_name": "vatiquinone",
                "designated_date": "11/17/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PTC Therapeutics, Inc.|100 Corporate Court|South Plainfield|New Jersey|7080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Rett syndrome",
                    "umls_id": "C0035372",
                    "parsed_text": "Rett Syndrome"
                }
            },
            {
                "compound_id": 46184405,
                "inchl_key": "LNOVHERIIMJMDG-XZXLULOTSA-N",
                "generic_name": "vatiquinone",
                "designated_date": "06/04/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PTC Therapeutics, Inc.|100 Corporate Court|South Plainfield|New Jersey|7080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Leigh Syndrome",
                    "umls_id": "C0023264",
                    "parsed_text": "Leigh Syndrome"
                }
            },
            {
                "compound_id": 46184405,
                "inchl_key": "LNOVHERIIMJMDG-XZXLULOTSA-N",
                "generic_name": "vatiquinone",
                "designated_date": "10/18/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PTC Therapeutics, Inc.|100 Corporate Court|South Plainfield|New Jersey|7080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pontocerebellar hypoplasia",
                    "umls_id": "C0266468",
                    "parsed_text": "Pontocerebellar Hypoplasia"
                }
            }
        ]
    },
    {
        "_id": "GMVPRGQOIOIIMI-DWKJAMRDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5280723,
                "inchl_key": "GMVPRGQOIOIIMI-DWKJAMRDSA-N",
                "generic_name": "Alprostadil",
                "designated_date": "10/20/1993",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Schwarz Pharma, Inc.|P.O. Box 2038|Milwaukee|Wisconsin|53201|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe peripheral arterial occlusive disease (critical limb ischemia) in patients where other procedures, grafts or angioplasty, are not indicated.",
                    "umls_id": "C1142264,C1306889",
                    "parsed_text": "critical limb ischemia , Peripheral arterial occlusive disease"
                }
            }
        ]
    },
    {
        "_id": "GNNDEPIMDAZHRQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 54576299,
                "inchl_key": "GNNDEPIMDAZHRQ-UHFFFAOYSA-N",
                "generic_name": "altiratinib",
                "designated_date": "08/19/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Deciphera Pharmaceuticals, LLC|643 Massachusetts|Suite 200|Lawrence|Kansas|66044|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioblastoma multiforme.",
                    "umls_id": "C0017636",
                    "parsed_text": "Glioblastoma multiforme"
                }
            }
        ]
    },
    {
        "_id": "UUVWYPNAQBNQJQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2123,
                "inchl_key": "UUVWYPNAQBNQJQ-UHFFFAOYSA-N",
                "generic_name": "Altretamine",
                "trade_name": "Hexalen",
                "designated_date": "02/09/1984",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Single agent palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent based combination.",
                "marketing_approval_date": "\u00a012/26/1990\u00a0",
                "exclusivity_end_date": "\u00a012/26/1997\u00a0",
                "sponsor": "Medimmune Oncology, Inc.|One Tower Bridge|100 Front Street, Suite 400|West Conshohocken|Pennsylvania|19428|United States",
                "orphan_designation": {
                    "original_text": "Treatment of advanced adenocarcinoma of the ovary.",
                    "umls_id": "C0948216,C5204526",
                    "parsed_text": "Adenocarcinoma of the Ovary , Advanced Adenocarcinoma"
                }
            }
        ]
    },
    {
        "_id": "BIIVYFLTOXDAOV-YVEFUNNKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5287969,
                "inchl_key": "BIIVYFLTOXDAOV-YVEFUNNKSA-N",
                "generic_name": "alvocidib",
                "designated_date": "04/21/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sumitomo Dainippon Pharma Oncology, Inc.|640 Memorial Drive|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "compound_id": 5287969,
                "inchl_key": "BIIVYFLTOXDAOV-YVEFUNNKSA-N",
                "generic_name": "Alvocidib",
                "designated_date": "04/13/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sumitomo Dainippon Pharma Oncology, Inc.|640 Memorial Drive|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Teatment of B-cell chronic lymphocytic leukemia (B-CLL) or prolymphocytic leukemia arising from CLL.",
                    "umls_id": "C0023434,C0023486",
                    "parsed_text": "B-cell chronic lymphocytic leukemia , Prolymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "WOLHOYHSEKDWQH-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 64150,
                "inchl_key": "WOLHOYHSEKDWQH-UHFFFAOYSA-N",
                "generic_name": "Amantadine HCl",
                "designated_date": "07/20/2015",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Osmotica Pharmaceutical Corporation|Regulatory, Clinical Operations & Legal|Lumina Station #2, Suite 209-A|Wilmington|North Carolina|28403|United States",
                "orphan_designation": {
                    "original_text": "Treatment of levodopa-induced dyskinesia",
                    "umls_id": "C0013384",
                    "parsed_text": "Dyskinesia"
                }
            },
            {
                "compound_id": 64150,
                "inchl_key": "WOLHOYHSEKDWQH-UHFFFAOYSA-N",
                "generic_name": "Amantadine hydrochloride",
                "trade_name": "Gocovri",
                "designated_date": "04/09/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy with or without concomitant dopminergic medications",
                "marketing_approval_date": "\u00a008/24/2017\u00a0",
                "exclusivity_end_date": "\u00a008/24/2024\u00a0",
                "exclusivity_protected_indication": "treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy with or without concomitant dopminergic medications",
                "sponsor": "Adamas Pharmaceuticals, Inc.|1900 Powell Street|Suite 750|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of levodopa-induced dyskinesia",
                    "umls_id": "C0013384",
                    "parsed_text": "Dyskinesia"
                }
            }
        ]
    },
    {
        "_id": "OUJTZYPIHDYQMC-LJQANCHMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6918493,
                "inchl_key": "OUJTZYPIHDYQMC-LJQANCHMSA-N",
                "generic_name": "ambrisentan",
                "trade_name": "Letairis",
                "designated_date": "07/16/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of pulmonary arterial hypertension (WHO group I) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening",
                "marketing_approval_date": "\u00a006/15/2007\u00a0",
                "exclusivity_end_date": "\u00a006/15/2014\u00a0",
                "sponsor": "Gilead Colorado|7575 West 103rd Avenue|Suite 102|Westminister|Colorado|80021|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            },
            {
                "compound_id": 6918493,
                "inchl_key": "OUJTZYPIHDYQMC-LJQANCHMSA-N",
                "generic_name": "ambrisentan",
                "designated_date": "12/23/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gilead Sciences, Inc.|199 East Blaine Street|Seattle|Washington|98102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic pulmonary fibrosis",
                    "umls_id": "C1800706",
                    "parsed_text": "Idiopathic Pulmonary Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "JBDGDEWWOUBZPM-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2132,
                "inchl_key": "JBDGDEWWOUBZPM-UHFFFAOYSA-N",
                "generic_name": "ambroxol",
                "designated_date": "06/29/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Zywie LLC|155 Lambert Drive|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Gaucher disease",
                    "umls_id": "C0017205",
                    "parsed_text": "Gaucher Disease"
                }
            }
        ]
    },
    {
        "_id": "KAICRBBQCRKMPO-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9920716,
                "inchl_key": "KAICRBBQCRKMPO-UHFFFAOYSA-N",
                "generic_name": "amifampridine phosphate",
                "designated_date": "03/03/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Catalyst Pharmaceuticals|(dba Catalyst Pharmaceutical Partner, Inc)|Suite 1500|Coral Gables|Florida|33134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of congenital myasthenic syndromes",
                    "umls_id": "C0751882",
                    "parsed_text": "congenital myasthenic syndromes"
                }
            },
            {
                "compound_id": 9920716,
                "inchl_key": "KAICRBBQCRKMPO-UHFFFAOYSA-N",
                "generic_name": "amifampridine phosphate",
                "designated_date": "08/31/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Catalyst Pharmaceuticals, Inc.|355 Alhambra Circle|Suite 1250|Coral Gables|Florida|33134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myasthenia gravis",
                    "umls_id": "C0026896",
                    "parsed_text": "Myasthenia Gravis"
                }
            },
            {
                "compound_id": 9920716,
                "inchl_key": "KAICRBBQCRKMPO-UHFFFAOYSA-N",
                "generic_name": "amifampridine phosphate",
                "trade_name": "FIRDAPSE",
                "designated_date": "11/12/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "FIRDAPSE is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.",
                "marketing_approval_date": "\u00a011/28/2018\u00a0",
                "exclusivity_end_date": "\u00a011/28/2025\u00a0",
                "exclusivity_protected_indication": "FIRDAPSE is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.",
                "sponsor": "Catalyst Pharmaceuticals, Inc.|355 Alhambra Circle|Suite 1250|Coral Gables|Florida|33134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Lambert-Eaton Myasthenic Syndrome",
                    "umls_id": "C0022972",
                    "parsed_text": "Lambert-Eaton Myasthenic Syndrome"
                }
            }
        ]
    },
    {
        "_id": "JKOQGQFVAUAYPM-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2141,
                "inchl_key": "JKOQGQFVAUAYPM-UHFFFAOYSA-N",
                "generic_name": "Amifostine",
                "designated_date": "05/30/1990",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "For use as a chemoprotective agent for cyclophosphamide in the treatment of advanced ovarian carcinoma.",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian carcinoma"
                }
            },
            {
                "compound_id": 2141,
                "inchl_key": "JKOQGQFVAUAYPM-UHFFFAOYSA-N",
                "generic_name": "Amifostine",
                "trade_name": "Ethyol",
                "designated_date": "05/30/1990",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "To reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer.",
                "marketing_approval_date": "\u00a012/08/1995\u00a0",
                "exclusivity_end_date": "\u00a012/08/2002\u00a0",
                "sponsor": "Medimmune Oncology, Inc.|One Tower Bridge|100 Front Street, Suite 400|West Conshohocken|Pennsylvania|19428|United States",
                "orphan_designation": {
                    "original_text": "For use as a chemoprotective agent for cisplatin in the treatment of advanced ovarian carcinoma.",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian carcinoma"
                }
            },
            {
                "compound_id": 2141,
                "inchl_key": "JKOQGQFVAUAYPM-UHFFFAOYSA-N",
                "generic_name": "Amifostine",
                "trade_name": "Ethyol",
                "designated_date": "05/12/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands.",
                "marketing_approval_date": "\u00a006/24/1999\u00a0",
                "exclusivity_end_date": "\u00a006/24/2006\u00a0",
                "sponsor": "Medimmune Oncology, Inc.|One Tower Bridge|100 Front Street, Suite 400|West Conshohocken|Pennsylvania|19428|United States",
                "orphan_designation": {
                    "original_text": "Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.",
                    "umls_id": "C0043352",
                    "parsed_text": "Xerostomia"
                }
            },
            {
                "compound_id": 2141,
                "inchl_key": "JKOQGQFVAUAYPM-UHFFFAOYSA-N",
                "generic_name": "Amifostine",
                "designated_date": "11/24/1998",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "For the reduction of the incidence and severity of toxicities associated with cisplatin administration.",
                    "umls_id": "C0600688",
                    "parsed_text": "toxicities"
                }
            },
            {
                "compound_id": 2141,
                "inchl_key": "JKOQGQFVAUAYPM-UHFFFAOYSA-N",
                "generic_name": "Amifostine",
                "designated_date": "05/30/1990",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "For use as a chemoprotective agent for cisplatin in the treatment of metastatic melanoma.",
                    "umls_id": "C0278883",
                    "parsed_text": "Metastatic melanoma"
                }
            },
            {
                "compound_id": 2141,
                "inchl_key": "JKOQGQFVAUAYPM-UHFFFAOYSA-N",
                "generic_name": "Amifostine",
                "designated_date": "10/04/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndromes.",
                    "umls_id": "C3463824",
                    "parsed_text": "Myelodysplastic Syndromes"
                }
            },
            {
                "compound_id": 2141,
                "inchl_key": "JKOQGQFVAUAYPM-UHFFFAOYSA-N",
                "generic_name": "Ethiofos",
                "designated_date": "08/01/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "U.S. Bioscience|100 Front Street|West Conshohocken|Pennsylvania|19428|United States",
                "orphan_designation": {
                    "original_text": "Use as a chemoprotective agent for cisplatin and cyclophosphamide in the treatment of ovarian cancer.",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "HIBICIOPDUTNRR-XTHCGPPUSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 86619108,
                "inchl_key": "HIBICIOPDUTNRR-XTHCGPPUSA-L",
                "generic_name": "amikacin sulfate",
                "designated_date": "01/05/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PlumeStars s.r.l.|Via Lago Scuro11|Parma|Italy",
                "orphan_designation": {
                    "original_text": "Management of cystic fibrosis patients with Pseudomonas aeruginosa lung infections",
                    "umls_id": "C0010674,C0033809,C3714514",
                    "parsed_text": "Cystic Fibrosis , Pseudomonas aeruginosa , Infections"
                }
            }
        ]
    },
    {
        "_id": "HIBICIOPDUTNRR-XTHCGPPUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5458175,
                "inchl_key": "HIBICIOPDUTNRR-XTHCGPPUSA-N",
                "generic_name": "amikacin sulfate",
                "designated_date": "01/05/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PlumeStars s.r.l.|Via Lago Scuro11|Parma|Italy",
                "orphan_designation": {
                    "original_text": "Management of cystic fibrosis patients with Pseudomonas aeruginosa lung infections",
                    "umls_id": "C0010674,C0033809,C3714514",
                    "parsed_text": "Cystic Fibrosis , Pseudomonas aeruginosa , Infections"
                }
            }
        ]
    },
    {
        "_id": "LKCWBDHBTVXHDL-RMDFUYIESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 37768,
                "inchl_key": "LKCWBDHBTVXHDL-RMDFUYIESA-N",
                "generic_name": "amikacin sulfate",
                "designated_date": "01/05/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PlumeStars s.r.l.|Via Lago Scuro11|Parma|Italy",
                "orphan_designation": {
                    "original_text": "Management of cystic fibrosis patients with Pseudomonas aeruginosa lung infections",
                    "umls_id": "C0010674,C0033809,C3714514",
                    "parsed_text": "Cystic Fibrosis , Pseudomonas aeruginosa , Infections"
                }
            }
        ]
    },
    {
        "_id": "FXKSEJFHKVNEFI-GCZBSULCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 38351,
                "inchl_key": "FXKSEJFHKVNEFI-GCZBSULCSA-N",
                "generic_name": "amikacin sulfate",
                "designated_date": "01/05/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PlumeStars s.r.l.|Via Lago Scuro11|Parma|Italy",
                "orphan_designation": {
                    "original_text": "Management of cystic fibrosis patients with Pseudomonas aeruginosa lung infections",
                    "umls_id": "C0010674,C0033809,C3714514",
                    "parsed_text": "Cystic Fibrosis , Pseudomonas aeruginosa , Infections"
                }
            }
        ]
    },
    {
        "_id": "SLXKOJJOQWFEFD-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 564,
                "inchl_key": "SLXKOJJOQWFEFD-UHFFFAOYSA-N",
                "generic_name": "Aminocaproic acid",
                "designated_date": "01/06/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eastern Virginia Medical School|Department of Ophthalomology|880 Kempsville Road, Suite 2500|Norfolk|Virginia|23502|United States",
                "orphan_designation": {
                    "original_text": "For the topical treatment of traumatic hyphema of the eye.",
                    "umls_id": "C0339335",
                    "parsed_text": "Traumatic hyphema"
                }
            }
        ]
    },
    {
        "_id": "ZLHFONARZHCSET-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 123608,
                "inchl_key": "ZLHFONARZHCSET-UHFFFAOYSA-N",
                "generic_name": "aminolevulinic acid hydrochloride",
                "designated_date": "03/20/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "DUSA Pharmaceuticals, Inc.|25 Upton Place|Wilmington|Massachusetts|1887|United States",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal dysplasia",
                    "umls_id": "C0586354",
                    "parsed_text": "Esophageal dysplasia"
                }
            },
            {
                "compound_id": 123608,
                "inchl_key": "ZLHFONARZHCSET-UHFFFAOYSA-N",
                "generic_name": "Aminolevulinic acid hydrochloride",
                "designated_date": "09/09/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SonALAsense, Inc.|2600 Tenth Street|Suite 435|Berkeley|California|94710|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls_id": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            }
        ]
    },
    {
        "_id": "WUBBRNOQWQTFEX-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 54690315,
                "inchl_key": "WUBBRNOQWQTFEX-UHFFFAOYSA-M",
                "generic_name": "Aminosalicylate sodium",
                "designated_date": "04/06/1993",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Syncom Pharmaceuticals, Inc.|66 Hanover Road|Florham Park|New Jersey|7932|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Crohn's disease.",
                    "umls_id": "C0010346",
                    "parsed_text": "Crohn's Disease"
                }
            }
        ]
    },
    {
        "_id": "FVVDKUPCWXUVNP-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16051922,
                "inchl_key": "FVVDKUPCWXUVNP-UHFFFAOYSA-N",
                "generic_name": "Aminosalicylate sodium",
                "designated_date": "04/06/1993",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Syncom Pharmaceuticals, Inc.|66 Hanover Road|Florham Park|New Jersey|7932|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Crohn's disease.",
                    "umls_id": "C0010346",
                    "parsed_text": "Crohn's Disease"
                }
            }
        ]
    },
    {
        "_id": "GMUQJDAYXZXBOT-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 16211148,
                "inchl_key": "GMUQJDAYXZXBOT-UHFFFAOYSA-M",
                "generic_name": "Aminosalicylate sodium",
                "designated_date": "04/06/1993",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Syncom Pharmaceuticals, Inc.|66 Hanover Road|Florham Park|New Jersey|7932|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Crohn's disease.",
                    "umls_id": "C0010346",
                    "parsed_text": "Crohn's Disease"
                }
            }
        ]
    },
    {
        "_id": "FVVDKUPCWXUVNP-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 2724368,
                "inchl_key": "FVVDKUPCWXUVNP-UHFFFAOYSA-M",
                "generic_name": "Aminosalicylate sodium",
                "designated_date": "04/06/1993",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Syncom Pharmaceuticals, Inc.|66 Hanover Road|Florham Park|New Jersey|7932|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Crohn's disease.",
                    "umls_id": "C0010346",
                    "parsed_text": "Crohn's Disease"
                }
            }
        ]
    },
    {
        "_id": "UOZODPSAJZTQNH-LSWIJEOBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 165580,
                "inchl_key": "UOZODPSAJZTQNH-LSWIJEOBSA-N",
                "generic_name": "Aminosidine",
                "designated_date": "05/14/1993",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kanyok, Thomas P. Pharm.D.|University Of Illinois At Chicago College of Pharm|833 South Wood Street (m/c886) Rm. 176|Chicago|Illinois|60612|United States",
                "orphan_designation": {
                    "original_text": "Treatment of tuberculosis.",
                    "umls_id": "C0041296",
                    "parsed_text": "Tuberculosis"
                }
            },
            {
                "compound_id": 165580,
                "inchl_key": "UOZODPSAJZTQNH-LSWIJEOBSA-N",
                "generic_name": "Aminosidine",
                "designated_date": "09/09/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kanyok, Thomas P. Pharm.D.|University of Illinois at Chicago College of Pharm|833 South Wood Street (m/c886) Rm. 176|Chicago|Illinois|60612|United States",
                "orphan_designation": {
                    "original_text": "Treatment of visceral leishmaniasis (kala-azar).",
                    "umls_id": "C0023290",
                    "parsed_text": "Visceral leishmaniasis"
                }
            },
            {
                "compound_id": 165580,
                "inchl_key": "UOZODPSAJZTQNH-LSWIJEOBSA-N",
                "generic_name": "Aminosidine",
                "designated_date": "11/15/1993",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kanyok, Thomas P. Pharm.D.|University Of Illinois At Chicago College of Pharm|833 South Wood Street (m/c886) Rm. 176|Chicago|Illinois|60612|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Mycobacterium avium complex.",
                    "umls_id": "C0026914",
                    "parsed_text": "Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 165580,
                "inchl_key": "UOZODPSAJZTQNH-LSWIJEOBSA-N",
                "generic_name": "aminosidine",
                "designated_date": "03/29/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "The Institute for One World Health|50 California Street|Suite 500|San Francisco|California|94111|United States",
                "orphan_designation": {
                    "original_text": "Treatment of visceral leishmaniasis",
                    "umls_id": "C0023290",
                    "parsed_text": "Visceral leishmaniasis"
                }
            },
            {
                "compound_id": 165580,
                "inchl_key": "UOZODPSAJZTQNH-LSWIJEOBSA-N",
                "generic_name": "paromomycin",
                "designated_date": "02/11/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "The Surgeon General, Dept. of the Army|USAMRMC|ATTN: MCMR-ORA|Ft. Detrick|Maryland|21702|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cutaneous leishmaniasis (Old World and New World)",
                    "umls_id": "C0023283",
                    "parsed_text": "Cutaneous leishmaniasis"
                }
            }
        ]
    },
    {
        "_id": "IYIKLHRQXLHMJQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2157,
                "inchl_key": "IYIKLHRQXLHMJQ-UHFFFAOYSA-N",
                "generic_name": "Amiodarone",
                "designated_date": "08/17/1993",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Academic Pharmaceuticals, Inc.|21 N. Skokie Valley Highway|Suite G3|Lake Bluff|Illinois|60044|United States",
                "orphan_designation": {
                    "original_text": "Treatment of incessant ventricular tachycardia.",
                    "umls_id": "C0042514",
                    "parsed_text": "Ventricular tachycardia"
                }
            }
        ]
    },
    {
        "_id": "ITPDYQOUSLNIHG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 441325,
                "inchl_key": "ITPDYQOUSLNIHG-UHFFFAOYSA-N",
                "generic_name": "Amiodarone HCl",
                "trade_name": "Cordarone",
                "designated_date": "03/16/1994",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy.",
                "marketing_approval_date": "\u00a008/03/1995\u00a0",
                "exclusivity_end_date": "\u00a008/03/2002\u00a0",
                "sponsor": "Wyeth-Ayerst Laboratories|P.O. Box 8299|Philadelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "For the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation.",
                    "umls_id": "C0042510,C0042514",
                    "parsed_text": "Ventricular Fibrillation , Ventricular tachycardia"
                }
            }
        ]
    },
    {
        "_id": "KRMDCWKBEZIMAB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2160,
                "inchl_key": "KRMDCWKBEZIMAB-UHFFFAOYSA-N",
                "generic_name": "Amitriptyline",
                "designated_date": "05/27/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Algo Therapeutix S.A.S|49 rue des Nouvelles|Suresnes|France",
                "orphan_designation": {
                    "original_text": "Treatment of Erythromelalgia",
                    "umls_id": "C0014804",
                    "parsed_text": "Erythromelalgia"
                }
            }
        ]
    },
    {
        "_id": "ZKKLPDLKUGTPME-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 15251598,
                "inchl_key": "ZKKLPDLKUGTPME-UHFFFAOYSA-N",
                "generic_name": "Ammonium tetrathiomolybdate",
                "designated_date": "01/31/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pipex Pharmaceuticals, Inc.|3930 Varsity Drive|Ann Arbor|Michigan|48108|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wilson's disease.",
                    "umls_id": "C0019202",
                    "parsed_text": "Wilson's Disease"
                }
            },
            {
                "compound_id": 15251598,
                "inchl_key": "ZKKLPDLKUGTPME-UHFFFAOYSA-N",
                "generic_name": "ammonium tetrathiomolybdate",
                "designated_date": "05/05/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pipex Pharmaceuticals, Inc.|3930 Varsity Drive|Ann Arbor|Michigan|48108|United States",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic pulmonary fibrosis",
                    "umls_id": "C1800706",
                    "parsed_text": "Idiopathic Pulmonary Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "JNZBHHQBPHSOMU-WNQIDUERSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10216431,
                "inchl_key": "JNZBHHQBPHSOMU-WNQIDUERSA-N",
                "generic_name": "Amonafide L-malate",
                "designated_date": "12/20/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Xanthus Pharmaceuticals, Inc.|An Antisoma Group Company|300 Technology Square|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "APKFDSVGJQXUKY-INPOYWNPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5280965,
                "inchl_key": "APKFDSVGJQXUKY-INPOYWNPSA-N",
                "generic_name": "amphotericin B",
                "designated_date": "09/15/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "iCo Therapeutics Inc.|760-777 Hornby Street|Vancouver|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of visceral leishmaniasis.",
                    "umls_id": "C0023290",
                    "parsed_text": "Visceral leishmaniasis"
                }
            },
            {
                "compound_id": 5280965,
                "inchl_key": "APKFDSVGJQXUKY-INPOYWNPSA-N",
                "generic_name": "amphotericin B",
                "designated_date": "09/15/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "iCo Therapeutics Inc.|760-777 Hornby Street|Vancouver|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of visceral leishmaniasis.",
                    "umls_id": "C0023290",
                    "parsed_text": "Visceral leishmaniasis"
                }
            },
            {
                "compound_id": 5280965,
                "inchl_key": "APKFDSVGJQXUKY-INPOYWNPSA-N",
                "generic_name": "Liposomal amphotericin B",
                "trade_name": "AmBisome",
                "designated_date": "12/10/1996",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of disseminated cryptococcosis including meningitis.",
                "marketing_approval_date": "\u00a008/11/1997\u00a0",
                "exclusivity_end_date": "\u00a008/11/2004\u00a0",
                "sponsor": "Fujisawa USA, Inc.|3 Parkway North Center|Deerfield|Illinois|60015|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cryptococcal meningitis.",
                    "umls_id": "C0085436",
                    "parsed_text": "Cryptococcal meningitis"
                }
            },
            {
                "compound_id": 5280965,
                "inchl_key": "APKFDSVGJQXUKY-INPOYWNPSA-N",
                "generic_name": "Liposomal amphotericin B",
                "trade_name": "AmBisome",
                "designated_date": "12/06/1996",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of visceral leishmaniasis.",
                "marketing_approval_date": "\u00a008/11/1997\u00a0",
                "exclusivity_end_date": "\u00a008/11/2004\u00a0",
                "sponsor": "Fujisawa USA, Inc.|3 Parkway North Center|Deerfield|Illinois|60015|United States",
                "orphan_designation": {
                    "original_text": "Treatment of visceral leishmaniasis.",
                    "umls_id": "C0023290",
                    "parsed_text": "Visceral leishmaniasis"
                }
            },
            {
                "compound_id": 5280965,
                "inchl_key": "APKFDSVGJQXUKY-INPOYWNPSA-N",
                "generic_name": "Liposomal amphotericin B",
                "designated_date": "12/10/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Fujisawa USA, Inc.|3 Parkway North Center|Deerfield|Illinois|60015|United States",
                "orphan_designation": {
                    "original_text": "Treatment of histoplasmosis.",
                    "umls_id": "C0019655",
                    "parsed_text": "Histoplasmosis"
                }
            }
        ]
    },
    {
        "_id": "APKFDSVGJQXUKY-VTPNKFOWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 118705500,
                "inchl_key": "APKFDSVGJQXUKY-VTPNKFOWSA-N",
                "generic_name": "Amphotericin B lipid complex",
                "designated_date": "06/27/1996",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "The Liposome Company, Inc.|One Research Way|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of invasive candidiasis.",
                    "umls_id": "C1609535",
                    "parsed_text": "Invasive Candidiasis"
                }
            },
            {
                "compound_id": 118705500,
                "inchl_key": "APKFDSVGJQXUKY-VTPNKFOWSA-N",
                "generic_name": "Amphotericin B lipid complex",
                "trade_name": "Abelcet",
                "designated_date": "12/05/1991",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy.",
                "marketing_approval_date": "\u00a010/18/1996\u00a0",
                "exclusivity_end_date": "\u00a010/18/2003\u00a0",
                "sponsor": "Liposome Company, Inc.|One Research Way|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of invasive fungal infections.",
                    "umls_id": "C1262313",
                    "parsed_text": "Invasive Fungal Infections"
                }
            },
            {
                "compound_id": 118705500,
                "inchl_key": "APKFDSVGJQXUKY-VTPNKFOWSA-N",
                "generic_name": "Amphotericin B lipid complex",
                "designated_date": "05/06/1996",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "The Liposome Company, Inc.|One Research Way|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of invasive zygomycosis.",
                    "umls_id": "C0043541",
                    "parsed_text": "Zygomycosis"
                }
            },
            {
                "compound_id": 118705500,
                "inchl_key": "APKFDSVGJQXUKY-VTPNKFOWSA-N",
                "generic_name": "Amphotericin B lipid complex",
                "designated_date": "08/21/1996",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "The Liposome Company, Inc.|One Research Way|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of invasive protothecosis.",
                    "umls_id": "C0033735",
                    "parsed_text": "Protothecosis"
                }
            },
            {
                "compound_id": 118705500,
                "inchl_key": "APKFDSVGJQXUKY-VTPNKFOWSA-N",
                "generic_name": "Amphotericin B lipid complex",
                "designated_date": "09/23/1996",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "The Liposome Company, Inc.|One Research Way|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of invasive sporotrichosis.",
                    "umls_id": "C0038034",
                    "parsed_text": "Sporotrichosis"
                }
            },
            {
                "compound_id": 118705500,
                "inchl_key": "APKFDSVGJQXUKY-VTPNKFOWSA-N",
                "generic_name": "Amphotericin B lipid complex",
                "designated_date": "05/06/1996",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "The Liposome Company, Inc.|One Research Way|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of invasive coccidioidomycosis.",
                    "umls_id": "C0009186",
                    "parsed_text": "Coccidioidomycosis"
                }
            }
        ]
    },
    {
        "_id": "VJZITPJGSQKZMX-XDPRQOKASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3035016,
                "inchl_key": "VJZITPJGSQKZMX-XDPRQOKASA-N",
                "generic_name": "amrubicin",
                "designated_date": "03/10/2008",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Celgene Corporation|9225 Indian Creek Parkway|Suite 900|Overland Park|Kansas|66210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of small cell lung cancer",
                    "umls_id": "C3540630",
                    "parsed_text": "Small Cell Lung Cancer"
                }
            }
        ]
    },
    {
        "_id": "XCPGHVQEEXUHNC-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2179,
                "inchl_key": "XCPGHVQEEXUHNC-UHFFFAOYSA-N",
                "generic_name": "Amsacrine",
                "designated_date": "12/07/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Warner-Lambert Company|2800 Plymouth Road|Ann Arbor|Michigan|48106|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute adult leukemia.",
                    "umls_id": "C0023418,C1547229",
                    "parsed_text": "leukemia , Acute"
                }
            }
        ]
    },
    {
        "_id": "WMGFVAGNIYUEEP-WUYNJSITSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 439207,
                "inchl_key": "WMGFVAGNIYUEEP-WUYNJSITSA-N",
                "generic_name": "amylopectin",
                "designated_date": "03/24/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Voltera Pharmaceuticals, LLC|9322 SW 41st Ln|Gainesville|Florida|32608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glycogen storage disease types Ia and Ib",
                    "umls_id": "C0017919",
                    "parsed_text": "Glycogen Storage Disease"
                }
            }
        ]
    },
    {
        "_id": "OTBXOEAOVRKTNQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135409400,
                "inchl_key": "OTBXOEAOVRKTNQ-UHFFFAOYSA-N",
                "generic_name": "Anagrelide",
                "trade_name": "Agrylin",
                "designated_date": "01/27/1988",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with essential thrombocythemia to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms.",
                "marketing_approval_date": "\u00a003/14/1997\u00a0",
                "exclusivity_end_date": "\u00a003/14/2004\u00a0",
                "sponsor": "Takeda Development Center Americas, Inc.|95 Hayden Avenue|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of essential thrombocythemia.",
                    "umls_id": "C0040028",
                    "parsed_text": "ESSENTIAL THROMBOCYTHEMIA"
                }
            },
            {
                "compound_id": 135409400,
                "inchl_key": "OTBXOEAOVRKTNQ-UHFFFAOYSA-N",
                "generic_name": "Anagrelide",
                "designated_date": "06/11/1985",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Roberts Pharmaceutical Corp.|Meridian Center II|Four Industrial Way West|Eatontown|New Jersey|7724|United States",
                "orphan_designation": {
                    "original_text": "Treatment of polycythemia vera.",
                    "umls_id": "C0032463",
                    "parsed_text": "Polycythemia Vera"
                }
            },
            {
                "compound_id": 135409400,
                "inchl_key": "OTBXOEAOVRKTNQ-UHFFFAOYSA-N",
                "generic_name": "Anagrelide",
                "designated_date": "07/14/1986",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Roberts Pharmaceutical Corp.|Meridian Center II|Four Industrial Way West|Eatontown|New Jersey|7724|United States",
                "orphan_designation": {
                    "original_text": "Treatment of thrombocytosis in chronic myelogenous leukemia.",
                    "umls_id": "C0023473,C0836924",
                    "parsed_text": "Chronic myelogenous leukemia , Thrombocytosis"
                }
            }
        ]
    },
    {
        "_id": "HMLGSIZOMSVISS-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 139595263,
                "inchl_key": "HMLGSIZOMSVISS-UHFFFAOYSA-N",
                "generic_name": "anakinra",
                "trade_name": "Kineret",
                "designated_date": "08/19/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of neonatal-onset multisystem inflammatory disease (NOMID)",
                "marketing_approval_date": "\u00a012/21/2012\u00a0",
                "exclusivity_end_date": "\u00a012/21/2019\u00a0",
                "sponsor": "Swedish Orphan Biovitrum AB (publ)|SE-011276|Stockholm|Sweden",
                "orphan_designation": {
                    "original_text": "Treatment of cryopyrin-associated periodic syndromes",
                    "umls_id": "C0039082",
                    "parsed_text": "Syndromes"
                }
            }
        ]
    },
    {
        "_id": "ZXFWJPKXEMFBOG-LWVMDMHWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 118984442,
                "inchl_key": "ZXFWJPKXEMFBOG-LWVMDMHWSA-N",
                "generic_name": "Anaritide acetate",
                "designated_date": "08/27/1992",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Scios, Inc.|2450 Bayshore Parkway|Mountain View|California|94043|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with acute renal failure.",
                    "umls_id": "C0022660",
                    "parsed_text": "Acute renal failure"
                }
            }
        ]
    },
    {
        "_id": "XUHBBTKJWIBQMY-MHZLTWQESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9831652,
                "inchl_key": "XUHBBTKJWIBQMY-MHZLTWQESA-N",
                "generic_name": "Anatibant",
                "designated_date": "04/15/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Xytis, Inc.|400 South El Camino Real|Suite 1200|San Mateo|California|94402|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients having experienced a severe traumatic brain injury (Glasgow Coma Scale 3 to 8) in order to decrease early mortality and improve long-term functional and neurological outcome",
                    "umls_id": "C0876926",
                    "parsed_text": "Traumatic Brain Injury"
                }
            }
        ]
    },
    {
        "_id": "PVHLMTREZMEJCG-GDTLVBQBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 123805,
                "inchl_key": "PVHLMTREZMEJCG-GDTLVBQBSA-N",
                "generic_name": "Angiotensin (1-7)",
                "designated_date": "09/01/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Constant Therapeutics LLC|303 Congress St, c/o Casner & Edwards|Boston|Massachusetts|2210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of recessive dystrophic epidermolysis bullosa (RDEB).",
                    "umls_id": "C0079474",
                    "parsed_text": "Recessive dystrophic epidermolysis bullosa"
                }
            },
            {
                "compound_id": 123805,
                "inchl_key": "PVHLMTREZMEJCG-GDTLVBQBSA-N",
                "generic_name": "Angiotensin (1-7)",
                "designated_date": "02/08/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Constant Therapeutics LLC|303 Congress St, c/o Casner & Edwards|Boston|Massachusetts|2210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of LAMA2-related muscular dystrophy",
                    "umls_id": "C0026850",
                    "parsed_text": "Muscular Dystrophy"
                }
            },
            {
                "compound_id": 123805,
                "inchl_key": "PVHLMTREZMEJCG-GDTLVBQBSA-N",
                "generic_name": "Angiotensin (1-7)",
                "designated_date": "11/26/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Constant Therapeutics LLC|303 Congress St, c/o Casner & Edwards|Boston|Massachusetts|2210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of limb-girdle muscular dystrophy",
                    "umls_id": "C0686353",
                    "parsed_text": "Limb-girdle muscular dystrophy"
                }
            },
            {
                "compound_id": 123805,
                "inchl_key": "PVHLMTREZMEJCG-GDTLVBQBSA-N",
                "generic_name": "angiotensin 1-7",
                "designated_date": "06/17/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Tarix Pharmaceuticals, Ltd.|12 Bow Street|Cambridge|Massachusetts|2138|United States",
                "orphan_designation": {
                    "original_text": "To accelerate engraftment of hematopoietic cells (treatment of neutropenia, thrombocytopenia, lymphoma, and aneima)in hematopoietic stem cell transplants.",
                    "umls_id": "C0024299,C0027947,C0040034",
                    "parsed_text": "Lymphoma , Neutropenia , Thrombocytopenia"
                }
            },
            {
                "compound_id": 123805,
                "inchl_key": "PVHLMTREZMEJCG-GDTLVBQBSA-N",
                "generic_name": "Angiotensin 1-7",
                "designated_date": "08/03/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Tarix Pharmaceuticals, Ltd|12 Bow Street|Cambridge|Massachusetts|2138|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndrome",
                    "umls_id": "C3463824",
                    "parsed_text": "MYELODYSPLASTIC SYNDROME"
                }
            },
            {
                "compound_id": 123805,
                "inchl_key": "PVHLMTREZMEJCG-GDTLVBQBSA-N",
                "generic_name": "Angiotensin 1-7",
                "designated_date": "02/16/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Tarix Pharmaceuticals Ltd|12 Bow Street|Cambridge|Massachusetts|2138|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neutropenia associated with autologous bone marrow transplantation.",
                    "umls_id": "C0027947",
                    "parsed_text": "Neutropenia"
                }
            },
            {
                "compound_id": 123805,
                "inchl_key": "PVHLMTREZMEJCG-GDTLVBQBSA-N",
                "generic_name": "angiotensin 1-7",
                "designated_date": "01/29/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "W. Jeffrey Petty, MD|Wake Forest University Health Sciences|Winston-Salem|North Carolina|27157|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sarcoma.",
                    "umls_id": "C1261473",
                    "parsed_text": "Sarcoma"
                }
            },
            {
                "compound_id": 123805,
                "inchl_key": "PVHLMTREZMEJCG-GDTLVBQBSA-N",
                "generic_name": "Angiotensin-(1-7)",
                "designated_date": "09/13/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "US Biotest, Inc.|231 Bonetti Drive|San Luis Obispo|California|93401|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension.",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            },
            {
                "compound_id": 123805,
                "inchl_key": "PVHLMTREZMEJCG-GDTLVBQBSA-N",
                "generic_name": "TXA127",
                "designated_date": "10/25/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "US Biotest, Inc.|231 Bonetti Drive|San Luis Obispo|California|93401|United States",
                "orphan_designation": {
                    "original_text": "Treament of acute radiation syndrome",
                    "umls_id": "C0520799",
                    "parsed_text": "Acute Radiation Syndrome"
                }
            }
        ]
    },
    {
        "_id": "KHPXUQMNIQBQEV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 970,
                "inchl_key": "KHPXUQMNIQBQEV-UHFFFAOYSA-N",
                "generic_name": "anhydrous enol-oxaloacetate",
                "designated_date": "03/07/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Terra Biological LLC|3830 Valley Centre Drive|Suite 705-561|San Diego|California|92130|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            },
            {
                "compound_id": 970,
                "inchl_key": "KHPXUQMNIQBQEV-UHFFFAOYSA-N",
                "generic_name": "oxaloacetate",
                "designated_date": "07/24/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Terra Biological LLC|3830 Valley Centre Drive|Suite 705-561|San Diego|California|92130|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gliomas",
                    "umls_id": "C0017638",
                    "parsed_text": "gliomas"
                }
            },
            {
                "compound_id": 970,
                "inchl_key": "KHPXUQMNIQBQEV-UHFFFAOYSA-N",
                "generic_name": "oxaloacetic acid",
                "designated_date": "11/18/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Terra Biological LLC|3830 Valley Centre Drive|Suite 705-561|San Diego|California|92130|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "KSMZEXLVHXZPEF-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25017411,
                "inchl_key": "KSMZEXLVHXZPEF-UHFFFAOYSA-N",
                "generic_name": "Anlotinib",
                "designated_date": "06/19/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Advenchen Laboratories, LLC|887 Patriot Drive|Suite A|Moorpark|California|93021|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcoma",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            }
        ]
    },
    {
        "_id": "UUAKQNIPIXQZFN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 57380530,
                "inchl_key": "UUAKQNIPIXQZFN-UHFFFAOYSA-N",
                "generic_name": "anlotinib hydrochloride",
                "designated_date": "12/31/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Advenchen Laboratories, LLC|887 Patriot Drive|Suite A|Moorpark|California|93021|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "BLPUOQGPBJPXRL-FNORWQNLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 641115,
                "inchl_key": "BLPUOQGPBJPXRL-FNORWQNLSA-N",
                "generic_name": "Antiepilepsirine",
                "designated_date": "03/23/1989",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Children's Hospital|700 Children's Drive|Columbus|Ohio|43205|United States",
                "orphan_designation": {
                    "original_text": "Treatment of drug resistant generalized tonic-clonic epilepsy in children and adults.",
                    "umls_id": "C0014549,C3826394",
                    "parsed_text": "Tonic-Clonic Epilepsy , Epilepsy in children"
                }
            }
        ]
    },
    {
        "_id": "LJTSIMVOOOLKOL-FNRDIUJOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24875259,
                "inchl_key": "LJTSIMVOOOLKOL-FNRDIUJOSA-N",
                "generic_name": "antroquinonol",
                "designated_date": "07/23/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Golden Biotechnology Corporation|10F, No. 9, Ln. 3|Tamsui Dist.,|New Taipei City 251|Taiwan",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            },
            {
                "compound_id": 24875259,
                "inchl_key": "LJTSIMVOOOLKOL-FNRDIUJOSA-N",
                "generic_name": "antroquinonol",
                "designated_date": "01/21/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Golden Biotechnology Corp.|10F., No. 9, Ln 3|Tamsui Dist.|New Taipei City 251|Taiwan",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 24875259,
                "inchl_key": "LJTSIMVOOOLKOL-FNRDIUJOSA-N",
                "generic_name": "antroquinonol",
                "designated_date": "04/30/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Golden Biotechnology Corporation|10F, No. 9, Ln. 3, Sec. 1, Zhong-Zheng E. Rd|New Taipei City 251|Taiwan",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "FYJROXRIVQPKRY-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 45139106,
                "inchl_key": "FYJROXRIVQPKRY-UHFFFAOYSA-N",
                "generic_name": "apatinib mesylate",
                "designated_date": "06/15/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Elevar Therapeutics, Inc.|2825 E Cottonwood Parkway|Suite 180|Salt Lake City|Utah|84121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastric cancer",
                    "umls_id": "C0024623",
                    "parsed_text": "Gastric Cancer"
                }
            }
        ]
    },
    {
        "_id": "NOFOAYPPHIUXJR-APNQCZIXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 457964,
                "inchl_key": "NOFOAYPPHIUXJR-APNQCZIXSA-N",
                "generic_name": "aphidicolin",
                "designated_date": "04/20/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biospherics.net LLC|Department of Pharmaceutical Sciences|University of Kentucky|Nicholasville|Kentucky|40356|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Ebola virus infection",
                    "umls_id": "C0282687",
                    "parsed_text": "Ebola Virus Infection"
                }
            }
        ]
    },
    {
        "_id": "GAJWNIKZLYZYSY-OKUPSQOASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11527330,
                "inchl_key": "GAJWNIKZLYZYSY-OKUPSQOASA-N",
                "generic_name": "apilimod dimesylate",
                "designated_date": "07/01/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AI Therapeutics, Inc.|530 Old Whitfield Street|Guilford|Connecticut|6437|United States",
                "orphan_designation": {
                    "original_text": "Treatment of follicular lymphoma",
                    "umls_id": "C0024301",
                    "parsed_text": "follicular lymphoma"
                }
            }
        ]
    },
    {
        "_id": "VMWNQDUVQKEIOC-CYBMUJFWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6005,
                "inchl_key": "VMWNQDUVQKEIOC-CYBMUJFWSA-N",
                "generic_name": "Apomorphine",
                "designated_date": "07/17/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pentech Pharmaceuticals, Inc.|1110 Lake Cook Rd.|Suite 257|Buffalo Grove|Illinois|60089|United States",
                "orphan_designation": {
                    "original_text": "Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.",
                    "umls_id": "C0030567",
                    "parsed_text": "Parkinson's Disease"
                }
            },
            {
                "compound_id": 6005,
                "inchl_key": "VMWNQDUVQKEIOC-CYBMUJFWSA-N",
                "generic_name": "Apomorphine",
                "designated_date": "10/20/1997",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Scherer DDS|Frankland Road|Swindon SN5 8RU|Wiltshire|United Kingdom",
                "orphan_designation": {
                    "original_text": "For use as rescue treatment for early morning motor dysfunction in late-stage Parkinson's disease.",
                    "umls_id": "C0030567,C0521654",
                    "parsed_text": "Parkinson's Disease , Motor dysfunction"
                }
            },
            {
                "compound_id": 6005,
                "inchl_key": "VMWNQDUVQKEIOC-CYBMUJFWSA-N",
                "generic_name": "Apomorphine hydrochloride",
                "designated_date": "05/23/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NeuroHealing Pharmaceuticals, Inc.|50 Undine Road|Newton|Massachusetts|2135|United States",
                "orphan_designation": {
                    "original_text": "For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous)",
                    "umls_id": "C0751699,C0876926,C0917808",
                    "parsed_text": "Minimally Conscious State , Traumatic Brain Injury , Vegetative State"
                }
            }
        ]
    },
    {
        "_id": "SKYZYDSNJIOXRL-BTQNPOSSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9410,
                "inchl_key": "SKYZYDSNJIOXRL-BTQNPOSSSA-N",
                "generic_name": "Apomorphine HCl",
                "trade_name": "Apokyn",
                "designated_date": "04/22/1993",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the acute, intermittent treatment of hypomobility, \"off\" episodes (\"end-of-dose-wearing-off\" and unpredictable :on/off\" episodes) associated with advanced Parkinson's disease",
                "marketing_approval_date": "\u00a004/20/2004\u00a0",
                "exclusivity_end_date": "\u00a004/20/2011\u00a0",
                "sponsor": "MDD US Operations, LLC, a subsidiary of Supernus Pharmaceuticals, Inc.|9715 Key West Avenue|Rockville|Maryland|20850|United States",
                "orphan_designation": {
                    "original_text": "Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.",
                    "umls_id": "C0030567",
                    "parsed_text": "Parkinson's Disease"
                }
            },
            {
                "compound_id": 9410,
                "inchl_key": "SKYZYDSNJIOXRL-BTQNPOSSSA-N",
                "generic_name": "Apomorphine hydrochloride",
                "designated_date": "05/23/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NeuroHealing Pharmaceuticals, Inc.|50 Undine Road|Newton|Massachusetts|2135|United States",
                "orphan_designation": {
                    "original_text": "For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous)",
                    "umls_id": "C0751699,C0876926,C0917808",
                    "parsed_text": "Minimally Conscious State , Traumatic Brain Injury , Vegetative State"
                }
            }
        ]
    },
    {
        "_id": "SKYZYDSNJIOXRL-BTQNPOSSSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 44358405,
                "inchl_key": "SKYZYDSNJIOXRL-BTQNPOSSSA-M",
                "generic_name": "Apomorphine hydrochloride",
                "designated_date": "05/23/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NeuroHealing Pharmaceuticals, Inc.|50 Undine Road|Newton|Massachusetts|2135|United States",
                "orphan_designation": {
                    "original_text": "For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous)",
                    "umls_id": "C0751699,C0876926,C0917808",
                    "parsed_text": "Minimally Conscious State , Traumatic Brain Injury , Vegetative State"
                }
            }
        ]
    },
    {
        "_id": "CXWQXGNFZLHLHQ-DPFCLETOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25058166,
                "inchl_key": "CXWQXGNFZLHLHQ-DPFCLETOSA-N",
                "generic_name": "Apomorphine hydrochloride",
                "designated_date": "05/23/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NeuroHealing Pharmaceuticals, Inc.|50 Undine Road|Newton|Massachusetts|2135|United States",
                "orphan_designation": {
                    "original_text": "For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous)",
                    "umls_id": "C0751699,C0876926,C0917808",
                    "parsed_text": "Minimally Conscious State , Traumatic Brain Injury , Vegetative State"
                }
            },
            {
                "compound_id": 25058166,
                "inchl_key": "CXWQXGNFZLHLHQ-DPFCLETOSA-N",
                "generic_name": "Apomorphine hydrochloride",
                "designated_date": "05/23/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NeuroHealing Pharmaceuticals, Inc.|50 Undine Road|Newton|Massachusetts|2135|United States",
                "orphan_designation": {
                    "original_text": "For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous)",
                    "umls_id": "C0751699,C0876926,C0917808",
                    "parsed_text": "Minimally Conscious State , Traumatic Brain Injury , Vegetative State"
                }
            }
        ]
    },
    {
        "_id": "DQQCJDBYNZMPOA-FFXKMJQXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6852399,
                "inchl_key": "DQQCJDBYNZMPOA-FFXKMJQXSA-N",
                "generic_name": "Apomorphine hydrochloride",
                "designated_date": "05/23/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NeuroHealing Pharmaceuticals, Inc.|50 Undine Road|Newton|Massachusetts|2135|United States",
                "orphan_designation": {
                    "original_text": "For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous)",
                    "umls_id": "C0751699,C0876926,C0917808",
                    "parsed_text": "Minimally Conscious State , Traumatic Brain Injury , Vegetative State"
                }
            }
        ]
    },
    {
        "_id": "MAFITCMHQZUUQZ-VZUYHUTRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135390845,
                "inchl_key": "MAFITCMHQZUUQZ-VZUYHUTRSA-N",
                "generic_name": "apomorphine palmitate",
                "designated_date": "06/04/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Leukos Biotech|Muntaner 383, 32|Barcelona|Catalonia|Spain",
                "orphan_designation": {
                    "original_text": "Treatment of Acute Myeloid Leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "IMOZEMNVLZVGJZ-QGZVFWFLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11561674,
                "inchl_key": "IMOZEMNVLZVGJZ-QGZVFWFLSA-N",
                "generic_name": "apremilast",
                "designated_date": "01/17/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Amgen Inc.|One Amgen Center Drive|Mailstop 27-2-D|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients with ulcerative colitis",
                    "umls_id": "C0009324",
                    "parsed_text": "Ulcerative Colitis"
                }
            },
            {
                "compound_id": 11561674,
                "inchl_key": "IMOZEMNVLZVGJZ-QGZVFWFLSA-N",
                "generic_name": "apremilast",
                "trade_name": "OTEZLA",
                "designated_date": "01/17/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "OTEZLA is indicated for the treatment of adult patients with oral ulcers associated with Beh\u7974s Disease.",
                "marketing_approval_date": "\u00a007/19/2019\u00a0",
                "exclusivity_end_date": "\u00a007/19/2026\u00a0",
                "exclusivity_protected_indication": "For the treatment of adult patients with oral ulcers associated with Beh\u7974s disease",
                "sponsor": "Amgen Inc.|One Amgen Center Drive|Mailstop: 27-2-D|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Behcet's disease",
                    "umls_id": "C0004943",
                    "parsed_text": "Behcet Syndrome"
                }
            }
        ]
    },
    {
        "_id": "ZPNFWUPYTFPOJU-IAUBLLHJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 129627711,
                "inchl_key": "ZPNFWUPYTFPOJU-IAUBLLHJSA-N",
                "generic_name": "Aprotinin",
                "trade_name": "Trasylol",
                "designated_date": "11/17/1993",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a012/29/1993\u00a0",
                "exclusivity_end_date": "\u00a012/29/2000\u00a0",
                "sponsor": "Bayer Corporation|Pharmaceutical Division|400 Morgan Lane|West Haven|Connecticut|6516|United States",
                "orphan_designation": {
                    "original_text": "For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary c",
                    "umls_id": "C0019080",
                    "parsed_text": "Blood loss"
                }
            }
        ]
    },
    {
        "_id": "ZPNFWUPYTFPOJU-YSFZTAPISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 53487898,
                "inchl_key": "ZPNFWUPYTFPOJU-YSFZTAPISA-N",
                "generic_name": "Aprotinin",
                "trade_name": "Trasylol",
                "designated_date": "11/17/1993",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a012/29/1993\u00a0",
                "exclusivity_end_date": "\u00a012/29/2000\u00a0",
                "sponsor": "Bayer Corporation|Pharmaceutical Division|400 Morgan Lane|West Haven|Connecticut|6516|United States",
                "orphan_designation": {
                    "original_text": "For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary c",
                    "umls_id": "C0019080",
                    "parsed_text": "Blood loss"
                }
            }
        ]
    },
    {
        "_id": "ZPNFWUPYTFPOJU-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 22833874,
                "inchl_key": "ZPNFWUPYTFPOJU-UHFFFAOYSA-N",
                "generic_name": "Aprotinin",
                "trade_name": "Trasylol",
                "designated_date": "11/17/1993",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a012/29/1993\u00a0",
                "exclusivity_end_date": "\u00a012/29/2000\u00a0",
                "sponsor": "Bayer Corporation|Pharmaceutical Division|400 Morgan Lane|West Haven|Connecticut|6516|United States",
                "orphan_designation": {
                    "original_text": "For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary c",
                    "umls_id": "C0019080",
                    "parsed_text": "Blood loss"
                }
            }
        ]
    },
    {
        "_id": "ZPNFWUPYTFPOJU-LPYSRVMUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16130295,
                "inchl_key": "ZPNFWUPYTFPOJU-LPYSRVMUSA-N",
                "generic_name": "Aprotinin",
                "trade_name": "Trasylol",
                "designated_date": "11/17/1993",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a012/29/1993\u00a0",
                "exclusivity_end_date": "\u00a012/29/2000\u00a0",
                "sponsor": "Bayer Corporation|Pharmaceutical Division|400 Morgan Lane|West Haven|Connecticut|6516|United States",
                "orphan_designation": {
                    "original_text": "For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary c",
                    "umls_id": "C0019080",
                    "parsed_text": "Blood loss"
                }
            }
        ]
    },
    {
        "_id": "ZPNFWUPYTFPOJU-VKTQZXOTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 146027575,
                "inchl_key": "ZPNFWUPYTFPOJU-VKTQZXOTSA-N",
                "generic_name": "Aprotinin",
                "trade_name": "Trasylol",
                "designated_date": "11/17/1993",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a012/29/1993\u00a0",
                "exclusivity_end_date": "\u00a012/29/2000\u00a0",
                "sponsor": "Bayer Corporation|Pharmaceutical Division|400 Morgan Lane|West Haven|Connecticut|6516|United States",
                "orphan_designation": {
                    "original_text": "For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary c",
                    "umls_id": "C0019080",
                    "parsed_text": "Blood loss"
                }
            }
        ]
    },
    {
        "_id": "ZVEMACCDKBQNGX-KALODSIISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 23622962,
                "inchl_key": "ZVEMACCDKBQNGX-KALODSIISA-N",
                "generic_name": "Arginine butyrate",
                "designated_date": "05/25/1994",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Vertex Pharmaceuticals Inc.|130 Waverly Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sickle cell disease and beta thalassemia.",
                    "umls_id": "C0002895,C0005283",
                    "parsed_text": "Sickle Cell Disease , beta Thalassemia"
                }
            },
            {
                "compound_id": 23622962,
                "inchl_key": "ZVEMACCDKBQNGX-KALODSIISA-N",
                "generic_name": "Arginine butyrate",
                "designated_date": "04/07/1992",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Perrine, Susan P., M.D.|Boston University|Cancer Research Center|Boston|Massachusetts|2118|United States",
                "orphan_designation": {
                    "original_text": "Treatment of beta-hemoglobinopathies and beta-thalassemia.",
                    "umls_id": "C0005283,C0019045",
                    "parsed_text": "BETA-THALASSEMIA , Hemoglobinopathies"
                }
            }
        ]
    },
    {
        "_id": "SGEIEGAXKLMUIZ-YZGLPLCXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 92461203,
                "inchl_key": "SGEIEGAXKLMUIZ-YZGLPLCXSA-N",
                "generic_name": "arimoclomol",
                "designated_date": "03/29/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orphazyme ApS|Ole Maales Vej 3|Copenhagen|Kbenhavn|Denmark",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            },
            {
                "compound_id": 92461203,
                "inchl_key": "SGEIEGAXKLMUIZ-YZGLPLCXSA-N",
                "generic_name": "arimoclomol",
                "designated_date": "11/02/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orphazyme ApS|Ole Maaloes Vej 3|Copenhagen|Kbenhavn|Denmark",
                "orphan_designation": {
                    "original_text": "Treatment of inclusion body myositis",
                    "umls_id": "C0238190",
                    "parsed_text": "INCLUSION BODY MYOSITIS"
                }
            }
        ]
    },
    {
        "_id": "SGEIEGAXKLMUIZ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 53427024,
                "inchl_key": "SGEIEGAXKLMUIZ-UHFFFAOYSA-N",
                "generic_name": "arimoclomol",
                "designated_date": "03/29/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orphazyme ApS|Ole Maales Vej 3|Copenhagen|Kbenhavn|Denmark",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            },
            {
                "compound_id": 53427024,
                "inchl_key": "SGEIEGAXKLMUIZ-UHFFFAOYSA-N",
                "generic_name": "arimoclomol",
                "designated_date": "11/02/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orphazyme ApS|Ole Maaloes Vej 3|Copenhagen|Kbenhavn|Denmark",
                "orphan_designation": {
                    "original_text": "Treatment of inclusion body myositis",
                    "umls_id": "C0238190",
                    "parsed_text": "INCLUSION BODY MYOSITIS"
                }
            }
        ]
    },
    {
        "_id": "SGEIEGAXKLMUIZ-ZPTIMJQQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6507255,
                "inchl_key": "SGEIEGAXKLMUIZ-ZPTIMJQQSA-N",
                "generic_name": "arimoclomol",
                "designated_date": "03/29/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orphazyme ApS|Ole Maales Vej 3|Copenhagen|Kbenhavn|Denmark",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            },
            {
                "compound_id": 6507255,
                "inchl_key": "SGEIEGAXKLMUIZ-ZPTIMJQQSA-N",
                "generic_name": "arimoclomol",
                "designated_date": "11/02/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orphazyme ApS|Ole Maaloes Vej 3|Copenhagen|Kbenhavn|Denmark",
                "orphan_designation": {
                    "original_text": "Treatment of inclusion body myositis",
                    "umls_id": "C0238190",
                    "parsed_text": "INCLUSION BODY MYOSITIS"
                }
            }
        ]
    },
    {
        "_id": "SGEIEGAXKLMUIZ-CYBMUJFWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 208924,
                "inchl_key": "SGEIEGAXKLMUIZ-CYBMUJFWSA-N",
                "generic_name": "arimoclomol",
                "designated_date": "03/29/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orphazyme ApS|Ole Maales Vej 3|Copenhagen|Kbenhavn|Denmark",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            },
            {
                "compound_id": 208924,
                "inchl_key": "SGEIEGAXKLMUIZ-CYBMUJFWSA-N",
                "generic_name": "arimoclomol",
                "designated_date": "11/02/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orphazyme ApS|Ole Maaloes Vej 3|Copenhagen|Kbenhavn|Denmark",
                "orphan_designation": {
                    "original_text": "Treatment of inclusion body myositis",
                    "umls_id": "C0238190",
                    "parsed_text": "INCLUSION BODY MYOSITIS"
                }
            }
        ]
    },
    {
        "_id": "SGEIEGAXKLMUIZ-XUVDNFPMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9568077,
                "inchl_key": "SGEIEGAXKLMUIZ-XUVDNFPMSA-N",
                "generic_name": "arimoclomol",
                "designated_date": "03/29/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orphazyme ApS|Ole Maales Vej 3|Copenhagen|Kbenhavn|Denmark",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            },
            {
                "compound_id": 9568077,
                "inchl_key": "SGEIEGAXKLMUIZ-XUVDNFPMSA-N",
                "generic_name": "arimoclomol",
                "designated_date": "11/02/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orphazyme ApS|Ole Maaloes Vej 3|Copenhagen|Kbenhavn|Denmark",
                "orphan_designation": {
                    "original_text": "Treatment of inclusion body myositis",
                    "umls_id": "C0238190",
                    "parsed_text": "INCLUSION BODY MYOSITIS"
                }
            }
        ]
    },
    {
        "_id": "XSENLDLUMVYRET-BTQNPOSSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 72710735,
                "inchl_key": "XSENLDLUMVYRET-BTQNPOSSSA-N",
                "generic_name": "arimoclomol citrate",
                "designated_date": "01/13/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orphazyme ApS|Ole Maaloes Vej 3|Copenhagen|Kbenhavn|Denmark",
                "orphan_designation": {
                    "original_text": "Treatment of Neimann-Pick disease, type C",
                    "umls_id": "C0028064",
                    "parsed_text": "neimann-pick disease"
                }
            }
        ]
    },
    {
        "_id": "CEUORZQYGODEFX-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 60795,
                "inchl_key": "CEUORZQYGODEFX-UHFFFAOYSA-N",
                "generic_name": "Aripiprazole",
                "designated_date": "07/22/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Perlara PBC|2625 Alcatraz Ave, #435|Berkeley|California|94705|United States",
                "orphan_designation": {
                    "original_text": "Treatment of N-glycanase 1 (NGLY1) deficiency",
                    "umls_id": "C1425023",
                    "parsed_text": "N-GLYCANASE 1"
                }
            },
            {
                "compound_id": 60795,
                "inchl_key": "CEUORZQYGODEFX-UHFFFAOYSA-N",
                "generic_name": "aripiprazole",
                "trade_name": "Abilify",
                "designated_date": "01/25/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of pediatric patients with Tourette's",
                "marketing_approval_date": "\u00a012/12/2014\u00a0",
                "exclusivity_end_date": "\u00a012/12/2021\u00a0",
                "exclusivity_protected_indication": "Treatment of pediatric patients with Tourette's",
                "sponsor": "Otsuka Pharmaceutical Development|and Commercialization|1st Floor|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Tourette's syndrome",
                    "umls_id": "C0040517",
                    "parsed_text": "Tourette's Syndrome"
                }
            }
        ]
    },
    {
        "_id": "RQNWIZPPADIBDY-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5359596,
                "inchl_key": "RQNWIZPPADIBDY-UHFFFAOYSA-N",
                "generic_name": "arsenic",
                "designated_date": "11/02/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.|145 Brandywine Parkway|West Chester|Pennsylvania|19380|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelocytic leukemia subtypes M0, M1, M2, M4, M5, M6 and M7",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myelocytic leukemia"
                }
            }
        ]
    },
    {
        "_id": "QTLQKAJBUDWPIB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 14888,
                "inchl_key": "QTLQKAJBUDWPIB-UHFFFAOYSA-N",
                "generic_name": "Arsenic trioxide",
                "designated_date": "03/04/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.|145 Brandywine Parkway|West Chester|Pennsylvania|19380|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls_id": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            },
            {
                "compound_id": 14888,
                "inchl_key": "QTLQKAJBUDWPIB-UHFFFAOYSA-N",
                "generic_name": "arsenic trioxide",
                "designated_date": "10/18/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.|145 Brandywine Parkway|West Chester|Pennsylvania|19380|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic myeloid leukemia",
                    "umls_id": "C0023473",
                    "parsed_text": "Chronic myeloid leukemia"
                }
            },
            {
                "compound_id": 14888,
                "inchl_key": "QTLQKAJBUDWPIB-UHFFFAOYSA-N",
                "generic_name": "Arsenic trioxide",
                "trade_name": "Trisenox",
                "designated_date": "03/03/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.",
                "marketing_approval_date": "\u00a001/12/2018\u00a0",
                "exclusivity_end_date": "\u00a001/12/2025\u00a0",
                "exclusivity_protected_indication": "In combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.",
                "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.|41 Moores Road|Frazer|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute promyelocytic leukemia.",
                    "umls_id": "C0023487",
                    "parsed_text": "Acute Promyelocytic Leukemia"
                }
            },
            {
                "compound_id": 14888,
                "inchl_key": "QTLQKAJBUDWPIB-UHFFFAOYSA-N",
                "generic_name": "Arsenic trioxide",
                "designated_date": "04/28/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "TEVA Branded Pharmaceutical Products R & D, Inc.|145 Brandywine Parkway|West Chester|Pennsylvania|19380|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma.",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            },
            {
                "compound_id": 14888,
                "inchl_key": "QTLQKAJBUDWPIB-UHFFFAOYSA-N",
                "generic_name": "arsenic trioxide",
                "designated_date": "07/17/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.|145 Brandywine Parkway|West Chester|Pennsylvania|19380|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndrome.",
                    "umls_id": "C3463824",
                    "parsed_text": "MYELODYSPLASTIC SYNDROME"
                }
            },
            {
                "compound_id": 14888,
                "inchl_key": "QTLQKAJBUDWPIB-UHFFFAOYSA-N",
                "generic_name": "arsenic trioxide",
                "designated_date": "07/30/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medsenic|204 avenue de Colmar|Strasbourg|Grand Est|France",
                "orphan_designation": {
                    "original_text": "Treatment of Graft-versus-host disease",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 14888,
                "inchl_key": "QTLQKAJBUDWPIB-UHFFFAOYSA-N",
                "generic_name": "Arsenic trioxide",
                "designated_date": "05/13/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.|145 Brandywine Parkway|West Chester|Pennsylvania|19380|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "compound_id": 14888,
                "inchl_key": "QTLQKAJBUDWPIB-UHFFFAOYSA-N",
                "generic_name": "arsenic trioxide",
                "designated_date": "06/13/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.|145 Brandywine Parkway|West Chester|Pennsylvania|19380|United States",
                "orphan_designation": {
                    "original_text": "Treatment of liver cancer",
                    "umls_id": "C0220630",
                    "parsed_text": "Liver Cancer"
                }
            },
            {
                "compound_id": 14888,
                "inchl_key": "QTLQKAJBUDWPIB-UHFFFAOYSA-N",
                "generic_name": "Arsenic trioxide",
                "trade_name": "Trisenox",
                "designated_date": "03/03/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation of PML/RAR-alpha gene expression.",
                "marketing_approval_date": "\u00a009/25/2000\u00a0",
                "exclusivity_end_date": "\u00a009/25/2007\u00a0",
                "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.|41 Moores Road|Frazer|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute promyelocytic leukemia.",
                    "umls_id": "C0023487",
                    "parsed_text": "Acute Promyelocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "FDMUNKXWYMSZIR-NQWKWHCYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11531457,
                "inchl_key": "FDMUNKXWYMSZIR-NQWKWHCYSA-N",
                "generic_name": "artemisone",
                "designated_date": "07/19/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Artemis Therapeutics, Inc.|18 East 16th Street|Suite 307|New York|New York|10003|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            }
        ]
    },
    {
        "_id": "FIHJKUPKCHIPAT-PNDUOAGUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 129009911,
                "inchl_key": "FIHJKUPKCHIPAT-PNDUOAGUSA-N",
                "generic_name": "artesunate",
                "designated_date": "03/28/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "marketing_approval_date": "\u00a005/26/2020\u00a0",
                "exclusivity_end_date": "\u00a005/26/2027\u00a0",
                "exclusivity_protected_indication": "For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "sponsor": "Amivas LLC|3216 Park View Rd|Chevy Chase|Maryland|20815|United States",
                "orphan_designation": {
                    "original_text": "Immediate treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 129009911,
                "inchl_key": "FIHJKUPKCHIPAT-PNDUOAGUSA-N",
                "generic_name": "artesunate",
                "designated_date": "07/22/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company|4550 Towne Centre Court|San Diego,|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 129009911,
                "inchl_key": "FIHJKUPKCHIPAT-PNDUOAGUSA-N",
                "generic_name": "Artesunate",
                "designated_date": "09/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Guilin Pharmaceutical Co., Ltd.|No. 43 Qilidian Road|Guilin Guangxi|Shanghai Shi|China",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 129009911,
                "inchl_key": "FIHJKUPKCHIPAT-PNDUOAGUSA-N",
                "generic_name": "Artesunate",
                "designated_date": "07/19/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "World Health Organization|Special Programme for Research and Training in Tro|Via Appia ,|Geneva 27|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of malaria.",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            }
        ]
    },
    {
        "_id": "FIHJKUPKCHIPAT-XIIQFBLFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 91746179,
                "inchl_key": "FIHJKUPKCHIPAT-XIIQFBLFSA-N",
                "generic_name": "artesunate",
                "designated_date": "03/28/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "marketing_approval_date": "\u00a005/26/2020\u00a0",
                "exclusivity_end_date": "\u00a005/26/2027\u00a0",
                "exclusivity_protected_indication": "For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "sponsor": "Amivas LLC|3216 Park View Rd|Chevy Chase|Maryland|20815|United States",
                "orphan_designation": {
                    "original_text": "Immediate treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 91746179,
                "inchl_key": "FIHJKUPKCHIPAT-XIIQFBLFSA-N",
                "generic_name": "artesunate",
                "designated_date": "07/22/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company|4550 Towne Centre Court|San Diego,|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 91746179,
                "inchl_key": "FIHJKUPKCHIPAT-XIIQFBLFSA-N",
                "generic_name": "Artesunate",
                "designated_date": "09/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Guilin Pharmaceutical Co., Ltd.|No. 43 Qilidian Road|Guilin Guangxi|Shanghai Shi|China",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 91746179,
                "inchl_key": "FIHJKUPKCHIPAT-XIIQFBLFSA-N",
                "generic_name": "Artesunate",
                "designated_date": "07/19/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "World Health Organization|Special Programme for Research and Training in Tro|Via Appia ,|Geneva 27|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of malaria.",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            }
        ]
    },
    {
        "_id": "FIHJKUPKCHIPAT-WNZKYHKJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 60196289,
                "inchl_key": "FIHJKUPKCHIPAT-WNZKYHKJSA-N",
                "generic_name": "artesunate",
                "designated_date": "03/28/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "marketing_approval_date": "\u00a005/26/2020\u00a0",
                "exclusivity_end_date": "\u00a005/26/2027\u00a0",
                "exclusivity_protected_indication": "For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "sponsor": "Amivas LLC|3216 Park View Rd|Chevy Chase|Maryland|20815|United States",
                "orphan_designation": {
                    "original_text": "Immediate treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 60196289,
                "inchl_key": "FIHJKUPKCHIPAT-WNZKYHKJSA-N",
                "generic_name": "artesunate",
                "designated_date": "07/22/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company|4550 Towne Centre Court|San Diego,|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 60196289,
                "inchl_key": "FIHJKUPKCHIPAT-WNZKYHKJSA-N",
                "generic_name": "Artesunate",
                "designated_date": "09/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Guilin Pharmaceutical Co., Ltd.|No. 43 Qilidian Road|Guilin Guangxi|Shanghai Shi|China",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 60196289,
                "inchl_key": "FIHJKUPKCHIPAT-WNZKYHKJSA-N",
                "generic_name": "Artesunate",
                "designated_date": "07/19/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "World Health Organization|Special Programme for Research and Training in Tro|Via Appia ,|Geneva 27|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of malaria.",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            }
        ]
    },
    {
        "_id": "FIHJKUPKCHIPAT-RUYKMDFCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 49769200,
                "inchl_key": "FIHJKUPKCHIPAT-RUYKMDFCSA-N",
                "generic_name": "artesunate",
                "designated_date": "03/28/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "marketing_approval_date": "\u00a005/26/2020\u00a0",
                "exclusivity_end_date": "\u00a005/26/2027\u00a0",
                "exclusivity_protected_indication": "For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "sponsor": "Amivas LLC|3216 Park View Rd|Chevy Chase|Maryland|20815|United States",
                "orphan_designation": {
                    "original_text": "Immediate treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 49769200,
                "inchl_key": "FIHJKUPKCHIPAT-RUYKMDFCSA-N",
                "generic_name": "artesunate",
                "designated_date": "07/22/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company|4550 Towne Centre Court|San Diego,|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 49769200,
                "inchl_key": "FIHJKUPKCHIPAT-RUYKMDFCSA-N",
                "generic_name": "Artesunate",
                "designated_date": "09/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Guilin Pharmaceutical Co., Ltd.|No. 43 Qilidian Road|Guilin Guangxi|Shanghai Shi|China",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 49769200,
                "inchl_key": "FIHJKUPKCHIPAT-RUYKMDFCSA-N",
                "generic_name": "Artesunate",
                "designated_date": "07/19/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "World Health Organization|Special Programme for Research and Training in Tro|Via Appia ,|Geneva 27|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of malaria.",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            }
        ]
    },
    {
        "_id": "FIHJKUPKCHIPAT-MFMTXCBGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 146160078,
                "inchl_key": "FIHJKUPKCHIPAT-MFMTXCBGSA-N",
                "generic_name": "artesunate",
                "designated_date": "03/28/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "marketing_approval_date": "\u00a005/26/2020\u00a0",
                "exclusivity_end_date": "\u00a005/26/2027\u00a0",
                "exclusivity_protected_indication": "For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "sponsor": "Amivas LLC|3216 Park View Rd|Chevy Chase|Maryland|20815|United States",
                "orphan_designation": {
                    "original_text": "Immediate treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 146160078,
                "inchl_key": "FIHJKUPKCHIPAT-MFMTXCBGSA-N",
                "generic_name": "artesunate",
                "designated_date": "07/22/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company|4550 Towne Centre Court|San Diego,|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 146160078,
                "inchl_key": "FIHJKUPKCHIPAT-MFMTXCBGSA-N",
                "generic_name": "Artesunate",
                "designated_date": "09/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Guilin Pharmaceutical Co., Ltd.|No. 43 Qilidian Road|Guilin Guangxi|Shanghai Shi|China",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 146160078,
                "inchl_key": "FIHJKUPKCHIPAT-MFMTXCBGSA-N",
                "generic_name": "Artesunate",
                "designated_date": "07/19/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "World Health Organization|Special Programme for Research and Training in Tro|Via Appia ,|Geneva 27|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of malaria.",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            }
        ]
    },
    {
        "_id": "FIHJKUPKCHIPAT-RVBFJZMGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 129317578,
                "inchl_key": "FIHJKUPKCHIPAT-RVBFJZMGSA-N",
                "generic_name": "artesunate",
                "designated_date": "03/28/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "marketing_approval_date": "\u00a005/26/2020\u00a0",
                "exclusivity_end_date": "\u00a005/26/2027\u00a0",
                "exclusivity_protected_indication": "For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "sponsor": "Amivas LLC|3216 Park View Rd|Chevy Chase|Maryland|20815|United States",
                "orphan_designation": {
                    "original_text": "Immediate treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 129317578,
                "inchl_key": "FIHJKUPKCHIPAT-RVBFJZMGSA-N",
                "generic_name": "artesunate",
                "designated_date": "07/22/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company|4550 Towne Centre Court|San Diego,|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 129317578,
                "inchl_key": "FIHJKUPKCHIPAT-RVBFJZMGSA-N",
                "generic_name": "Artesunate",
                "designated_date": "09/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Guilin Pharmaceutical Co., Ltd.|No. 43 Qilidian Road|Guilin Guangxi|Shanghai Shi|China",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 129317578,
                "inchl_key": "FIHJKUPKCHIPAT-RVBFJZMGSA-N",
                "generic_name": "Artesunate",
                "designated_date": "07/19/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "World Health Organization|Special Programme for Research and Training in Tro|Via Appia ,|Geneva 27|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of malaria.",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            }
        ]
    },
    {
        "_id": "FIHJKUPKCHIPAT-DRVUCALVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 126963478,
                "inchl_key": "FIHJKUPKCHIPAT-DRVUCALVSA-N",
                "generic_name": "artesunate",
                "designated_date": "03/28/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "marketing_approval_date": "\u00a005/26/2020\u00a0",
                "exclusivity_end_date": "\u00a005/26/2027\u00a0",
                "exclusivity_protected_indication": "For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "sponsor": "Amivas LLC|3216 Park View Rd|Chevy Chase|Maryland|20815|United States",
                "orphan_designation": {
                    "original_text": "Immediate treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 126963478,
                "inchl_key": "FIHJKUPKCHIPAT-DRVUCALVSA-N",
                "generic_name": "artesunate",
                "designated_date": "07/22/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company|4550 Towne Centre Court|San Diego,|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 126963478,
                "inchl_key": "FIHJKUPKCHIPAT-DRVUCALVSA-N",
                "generic_name": "Artesunate",
                "designated_date": "09/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Guilin Pharmaceutical Co., Ltd.|No. 43 Qilidian Road|Guilin Guangxi|Shanghai Shi|China",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 126963478,
                "inchl_key": "FIHJKUPKCHIPAT-DRVUCALVSA-N",
                "generic_name": "Artesunate",
                "designated_date": "07/19/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "World Health Organization|Special Programme for Research and Training in Tro|Via Appia ,|Geneva 27|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of malaria.",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            }
        ]
    },
    {
        "_id": "FIHJKUPKCHIPAT-AXFKQHSWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9821433,
                "inchl_key": "FIHJKUPKCHIPAT-AXFKQHSWSA-N",
                "generic_name": "artesunate",
                "designated_date": "03/28/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "marketing_approval_date": "\u00a005/26/2020\u00a0",
                "exclusivity_end_date": "\u00a005/26/2027\u00a0",
                "exclusivity_protected_indication": "For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "sponsor": "Amivas LLC|3216 Park View Rd|Chevy Chase|Maryland|20815|United States",
                "orphan_designation": {
                    "original_text": "Immediate treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 9821433,
                "inchl_key": "FIHJKUPKCHIPAT-AXFKQHSWSA-N",
                "generic_name": "artesunate",
                "designated_date": "07/22/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company|4550 Towne Centre Court|San Diego,|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 9821433,
                "inchl_key": "FIHJKUPKCHIPAT-AXFKQHSWSA-N",
                "generic_name": "Artesunate",
                "designated_date": "09/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Guilin Pharmaceutical Co., Ltd.|No. 43 Qilidian Road|Guilin Guangxi|Shanghai Shi|China",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 9821433,
                "inchl_key": "FIHJKUPKCHIPAT-AXFKQHSWSA-N",
                "generic_name": "Artesunate",
                "designated_date": "07/19/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "World Health Organization|Special Programme for Research and Training in Tro|Via Appia ,|Geneva 27|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of malaria.",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            }
        ]
    },
    {
        "_id": "FIHJKUPKCHIPAT-OQYNCAMDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 53486426,
                "inchl_key": "FIHJKUPKCHIPAT-OQYNCAMDSA-N",
                "generic_name": "artesunate",
                "designated_date": "03/28/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "marketing_approval_date": "\u00a005/26/2020\u00a0",
                "exclusivity_end_date": "\u00a005/26/2027\u00a0",
                "exclusivity_protected_indication": "For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "sponsor": "Amivas LLC|3216 Park View Rd|Chevy Chase|Maryland|20815|United States",
                "orphan_designation": {
                    "original_text": "Immediate treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 53486426,
                "inchl_key": "FIHJKUPKCHIPAT-OQYNCAMDSA-N",
                "generic_name": "artesunate",
                "designated_date": "07/22/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company|4550 Towne Centre Court|San Diego,|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 53486426,
                "inchl_key": "FIHJKUPKCHIPAT-OQYNCAMDSA-N",
                "generic_name": "Artesunate",
                "designated_date": "09/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Guilin Pharmaceutical Co., Ltd.|No. 43 Qilidian Road|Guilin Guangxi|Shanghai Shi|China",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 53486426,
                "inchl_key": "FIHJKUPKCHIPAT-OQYNCAMDSA-N",
                "generic_name": "Artesunate",
                "designated_date": "07/19/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "World Health Organization|Special Programme for Research and Training in Tro|Via Appia ,|Geneva 27|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of malaria.",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            }
        ]
    },
    {
        "_id": "FIHJKUPKCHIPAT-RLQWWVEOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16394563,
                "inchl_key": "FIHJKUPKCHIPAT-RLQWWVEOSA-N",
                "generic_name": "artesunate",
                "designated_date": "03/28/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "marketing_approval_date": "\u00a005/26/2020\u00a0",
                "exclusivity_end_date": "\u00a005/26/2027\u00a0",
                "exclusivity_protected_indication": "For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "sponsor": "Amivas LLC|3216 Park View Rd|Chevy Chase|Maryland|20815|United States",
                "orphan_designation": {
                    "original_text": "Immediate treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 16394563,
                "inchl_key": "FIHJKUPKCHIPAT-RLQWWVEOSA-N",
                "generic_name": "artesunate",
                "designated_date": "07/22/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company|4550 Towne Centre Court|San Diego,|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 16394563,
                "inchl_key": "FIHJKUPKCHIPAT-RLQWWVEOSA-N",
                "generic_name": "Artesunate",
                "designated_date": "09/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Guilin Pharmaceutical Co., Ltd.|No. 43 Qilidian Road|Guilin Guangxi|Shanghai Shi|China",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 16394563,
                "inchl_key": "FIHJKUPKCHIPAT-RLQWWVEOSA-N",
                "generic_name": "Artesunate",
                "designated_date": "07/19/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "World Health Organization|Special Programme for Research and Training in Tro|Via Appia ,|Geneva 27|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of malaria.",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            }
        ]
    },
    {
        "_id": "FIHJKUPKCHIPAT-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 105031,
                "inchl_key": "FIHJKUPKCHIPAT-UHFFFAOYSA-N",
                "generic_name": "artesunate",
                "designated_date": "03/28/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "marketing_approval_date": "\u00a005/26/2020\u00a0",
                "exclusivity_end_date": "\u00a005/26/2027\u00a0",
                "exclusivity_protected_indication": "For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "sponsor": "Amivas LLC|3216 Park View Rd|Chevy Chase|Maryland|20815|United States",
                "orphan_designation": {
                    "original_text": "Immediate treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 105031,
                "inchl_key": "FIHJKUPKCHIPAT-UHFFFAOYSA-N",
                "generic_name": "artesunate",
                "designated_date": "07/22/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company|4550 Towne Centre Court|San Diego,|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 105031,
                "inchl_key": "FIHJKUPKCHIPAT-UHFFFAOYSA-N",
                "generic_name": "Artesunate",
                "designated_date": "09/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Guilin Pharmaceutical Co., Ltd.|No. 43 Qilidian Road|Guilin Guangxi|Shanghai Shi|China",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 105031,
                "inchl_key": "FIHJKUPKCHIPAT-UHFFFAOYSA-N",
                "generic_name": "Artesunate",
                "designated_date": "07/19/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "World Health Organization|Special Programme for Research and Training in Tro|Via Appia ,|Geneva 27|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of malaria.",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            }
        ]
    },
    {
        "_id": "FIHJKUPKCHIPAT-HXMLZIBGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 156252,
                "inchl_key": "FIHJKUPKCHIPAT-HXMLZIBGSA-N",
                "generic_name": "artesunate",
                "designated_date": "03/28/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "marketing_approval_date": "\u00a005/26/2020\u00a0",
                "exclusivity_end_date": "\u00a005/26/2027\u00a0",
                "exclusivity_protected_indication": "For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "sponsor": "Amivas LLC|3216 Park View Rd|Chevy Chase|Maryland|20815|United States",
                "orphan_designation": {
                    "original_text": "Immediate treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 156252,
                "inchl_key": "FIHJKUPKCHIPAT-HXMLZIBGSA-N",
                "generic_name": "artesunate",
                "designated_date": "07/22/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company|4550 Towne Centre Court|San Diego,|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 156252,
                "inchl_key": "FIHJKUPKCHIPAT-HXMLZIBGSA-N",
                "generic_name": "Artesunate",
                "designated_date": "09/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Guilin Pharmaceutical Co., Ltd.|No. 43 Qilidian Road|Guilin Guangxi|Shanghai Shi|China",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 156252,
                "inchl_key": "FIHJKUPKCHIPAT-HXMLZIBGSA-N",
                "generic_name": "Artesunate",
                "designated_date": "07/19/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "World Health Organization|Special Programme for Research and Training in Tro|Via Appia ,|Geneva 27|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of malaria.",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            }
        ]
    },
    {
        "_id": "FIHJKUPKCHIPAT-JQXDXKTESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5464098,
                "inchl_key": "FIHJKUPKCHIPAT-JQXDXKTESA-N",
                "generic_name": "artesunate",
                "designated_date": "03/28/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "marketing_approval_date": "\u00a005/26/2020\u00a0",
                "exclusivity_end_date": "\u00a005/26/2027\u00a0",
                "exclusivity_protected_indication": "For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "sponsor": "Amivas LLC|3216 Park View Rd|Chevy Chase|Maryland|20815|United States",
                "orphan_designation": {
                    "original_text": "Immediate treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 5464098,
                "inchl_key": "FIHJKUPKCHIPAT-JQXDXKTESA-N",
                "generic_name": "artesunate",
                "designated_date": "07/22/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company|4550 Towne Centre Court|San Diego,|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 5464098,
                "inchl_key": "FIHJKUPKCHIPAT-JQXDXKTESA-N",
                "generic_name": "Artesunate",
                "designated_date": "09/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Guilin Pharmaceutical Co., Ltd.|No. 43 Qilidian Road|Guilin Guangxi|Shanghai Shi|China",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 5464098,
                "inchl_key": "FIHJKUPKCHIPAT-JQXDXKTESA-N",
                "generic_name": "Artesunate",
                "designated_date": "07/19/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "World Health Organization|Special Programme for Research and Training in Tro|Via Appia ,|Geneva 27|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of malaria.",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            }
        ]
    },
    {
        "_id": "FIHJKUPKCHIPAT-NKHDUEHSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 65664,
                "inchl_key": "FIHJKUPKCHIPAT-NKHDUEHSSA-N",
                "generic_name": "artesunate",
                "designated_date": "03/28/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "marketing_approval_date": "\u00a005/26/2020\u00a0",
                "exclusivity_end_date": "\u00a005/26/2027\u00a0",
                "exclusivity_protected_indication": "For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "sponsor": "Amivas LLC|3216 Park View Rd|Chevy Chase|Maryland|20815|United States",
                "orphan_designation": {
                    "original_text": "Immediate treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 65664,
                "inchl_key": "FIHJKUPKCHIPAT-NKHDUEHSSA-N",
                "generic_name": "artesunate",
                "designated_date": "07/22/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company|4550 Towne Centre Court|San Diego,|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 65664,
                "inchl_key": "FIHJKUPKCHIPAT-NKHDUEHSSA-N",
                "generic_name": "Artesunate",
                "designated_date": "09/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Guilin Pharmaceutical Co., Ltd.|No. 43 Qilidian Road|Guilin Guangxi|Shanghai Shi|China",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 65664,
                "inchl_key": "FIHJKUPKCHIPAT-NKHDUEHSSA-N",
                "generic_name": "Artesunate",
                "designated_date": "07/19/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "World Health Organization|Special Programme for Research and Training in Tro|Via Appia ,|Geneva 27|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of malaria.",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            }
        ]
    },
    {
        "_id": "FIHJKUPKCHIPAT-AHIGJZGOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6917864,
                "inchl_key": "FIHJKUPKCHIPAT-AHIGJZGOSA-N",
                "generic_name": "artesunate",
                "designated_date": "03/28/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "marketing_approval_date": "\u00a005/26/2020\u00a0",
                "exclusivity_end_date": "\u00a005/26/2027\u00a0",
                "exclusivity_protected_indication": "For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.",
                "sponsor": "Amivas LLC|3216 Park View Rd|Chevy Chase|Maryland|20815|United States",
                "orphan_designation": {
                    "original_text": "Immediate treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 6917864,
                "inchl_key": "FIHJKUPKCHIPAT-AHIGJZGOSA-N",
                "generic_name": "artesunate",
                "designated_date": "07/22/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Company|4550 Towne Centre Court|San Diego,|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 6917864,
                "inchl_key": "FIHJKUPKCHIPAT-AHIGJZGOSA-N",
                "generic_name": "Artesunate",
                "designated_date": "09/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Guilin Pharmaceutical Co., Ltd.|No. 43 Qilidian Road|Guilin Guangxi|Shanghai Shi|China",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 6917864,
                "inchl_key": "FIHJKUPKCHIPAT-AHIGJZGOSA-N",
                "generic_name": "Artesunate",
                "designated_date": "07/19/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "World Health Organization|Special Programme for Research and Training in Tro|Via Appia ,|Geneva 27|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of malaria.",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            }
        ]
    },
    {
        "_id": "VOVZXURTCKPRDQ-CQSZACIVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 72165228,
                "inchl_key": "VOVZXURTCKPRDQ-CQSZACIVSA-N",
                "generic_name": "asciminib",
                "designated_date": "02/27/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceutical Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic myelogenous leukemia",
                    "umls_id": "C0023473",
                    "parsed_text": "Chronic myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "BSYNRYMUTXBXSQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2244,
                "inchl_key": "BSYNRYMUTXBXSQ-UHFFFAOYSA-N",
                "generic_name": "aspirin",
                "designated_date": "09/18/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rhoshan Pharmaceuticals Inc.|6 Bethel Road|Glen Mills|Pennsylvania|19342|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Kawasaki Disease",
                    "umls_id": "C0026691",
                    "parsed_text": "Kawasaki Disease"
                }
            }
        ]
    },
    {
        "_id": "OOUGLTULBSNHNF-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11219835,
                "inchl_key": "OOUGLTULBSNHNF-UHFFFAOYSA-N",
                "generic_name": "ataluren",
                "designated_date": "03/10/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PTC Therapeutics, Inc.|100 Corporate Court|South Plainfield|New Jersey|7080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of spinal muscular atrophy",
                    "umls_id": "C0026847",
                    "parsed_text": "Spinal Muscular Atrophy"
                }
            },
            {
                "compound_id": 11219835,
                "inchl_key": "OOUGLTULBSNHNF-UHFFFAOYSA-N",
                "generic_name": "ataluren",
                "designated_date": "09/01/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PTC Therapeutics, Inc.|100 Corporate Court|South Plainfield|New Jersey|7080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of aniridia",
                    "umls_id": "C0003076",
                    "parsed_text": "Aniridia"
                }
            },
            {
                "compound_id": 11219835,
                "inchl_key": "OOUGLTULBSNHNF-UHFFFAOYSA-N",
                "generic_name": "ataluren",
                "designated_date": "12/10/2014",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PTC Therapeutics, Inc.|100 Corporate Court|South Plainfield|New Jersey|7080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mucopolysaccharidosis type I",
                    "umls_id": "C0023786",
                    "parsed_text": "Mucopolysaccharidosis Type I"
                }
            },
            {
                "compound_id": 11219835,
                "inchl_key": "OOUGLTULBSNHNF-UHFFFAOYSA-N",
                "generic_name": "ataluren",
                "designated_date": "01/10/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PTC Therapeutics, Inc.|100 Corporate Court|South Plainfield|New Jersey|7080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Muscular Dystrophy resulting from premature stop mutations in the dystrohin gene",
                    "umls_id": "C0026850",
                    "parsed_text": "Muscular Dystrophy"
                }
            },
            {
                "compound_id": 11219835,
                "inchl_key": "OOUGLTULBSNHNF-UHFFFAOYSA-N",
                "generic_name": "ataluren",
                "designated_date": "09/01/2004",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PTC Therapeutics, Inc.|100 Corporate Court|South Plainfield|New Jersey|7080|United States",
                "orphan_designation": {
                    "original_text": "For use in the treatment of cystic fibrosis resulting fron a nonsense (premature stopcodon) mutation in the cystic bibrosis transmembrane conductance regulatory gene",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "LUCXVPAZUDVVBT-UNTBIKODSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 54840,
                "inchl_key": "LUCXVPAZUDVVBT-UNTBIKODSA-N",
                "generic_name": "Atomoxetine hydrochloride",
                "designated_date": "08/26/2003",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eli Lilly & Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Tourette's Syndrome",
                    "umls_id": "C0040517",
                    "parsed_text": "Tourette's Syndrome"
                }
            }
        ]
    },
    {
        "_id": "BSJMWHQBCZFXBR-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 74989,
                "inchl_key": "BSJMWHQBCZFXBR-UHFFFAOYSA-N",
                "generic_name": "Atovaquone",
                "trade_name": "Mepron",
                "designated_date": "09/10/1990",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the acute oral treatment of mild to moderate Pneumocystis carinii pneumonia in patients who are intolerant to trimethoprim-sulfamethoxazole.",
                "marketing_approval_date": "\u00a011/25/1992\u00a0",
                "exclusivity_end_date": "\u00a011/25/1999\u00a0",
                "sponsor": "Glaxo Wellcome Inc.|5 Moore Drive|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Treatment of AIDS associated Pneumocystis Carinii Pneumonia.",
                    "umls_id": "C0001175,C1535939",
                    "parsed_text": "AIDS , Pneumocystis carinii Pneumonia"
                }
            },
            {
                "compound_id": 74989,
                "inchl_key": "BSJMWHQBCZFXBR-UHFFFAOYSA-N",
                "generic_name": "Atovaquone",
                "trade_name": "Mepron",
                "designated_date": "08/14/1991",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prevention of PCP in patients who are intolerant to trimethoprim-sulfamethoxazole.",
                "marketing_approval_date": "\u00a001/05/1999\u00a0",
                "exclusivity_end_date": "\u00a001/05/2006\u00a0",
                "sponsor": "Glaxo Wellcome Research and Development|5 Moore Drive|PO Box 13398|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3.",
                    "umls_id": "C0019682,C1535939",
                    "parsed_text": "HIV , Pneumocystis carinii Pneumonia"
                }
            },
            {
                "compound_id": 74989,
                "inchl_key": "BSJMWHQBCZFXBR-UHFFFAOYSA-N",
                "generic_name": "Atovaquone",
                "designated_date": "03/16/1993",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "GlaxoSmithKline, Inc.|5 Moore Drive|PO Box 13398|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Treatment and suppression of Toxoplasma gondii encephalitis.",
                    "umls_id": "C0085315",
                    "parsed_text": "toxoplasma gondii encephalitis"
                }
            },
            {
                "compound_id": 74989,
                "inchl_key": "BSJMWHQBCZFXBR-UHFFFAOYSA-N",
                "generic_name": "Atovaquone",
                "designated_date": "03/16/1993",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "GlaxoSmithKline, Inc.|5 Moore Drive|PO Box 13398|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Primary prophylaxis of HIV-infected persons at high risk for developing Toxoplasma gondii encephalitis.",
                    "umls_id": "C0019682,C0085315",
                    "parsed_text": "HIV , toxoplasma gondii encephalitis"
                }
            }
        ]
    },
    {
        "_id": "MOTJMGVDPWRKOC-QPVYNBJUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 159594,
                "inchl_key": "MOTJMGVDPWRKOC-QPVYNBJUSA-N",
                "generic_name": "Atrasentan",
                "designated_date": "09/29/2016",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AbbVie Inc.|Regulatory Affairs|1 North Waukegan Road|North Chicago|Illinois|60044|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric nephrotic syndrome",
                    "umls_id": "C0027726",
                    "parsed_text": "Nephrotic Syndrome"
                }
            }
        ]
    },
    {
        "_id": "IRPYFWIZKIOHQN-XTZHGVARSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 138402869,
                "inchl_key": "IRPYFWIZKIOHQN-XTZHGVARSA-N",
                "generic_name": "auranofin",
                "designated_date": "04/30/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ctr for Discovery & Innovation in Parasitic Diseas|U. of CA, San Francisco|QB3, Byers Hall 508B|San Francisco|California|94158|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amebiasis",
                    "umls_id": "C0013370",
                    "parsed_text": "amebiasis"
                }
            },
            {
                "compound_id": 138402869,
                "inchl_key": "IRPYFWIZKIOHQN-XTZHGVARSA-N",
                "generic_name": "auranofin",
                "designated_date": "04/30/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ctr for Discovery & Innovation in Parasitic Diseas|U. of CA, San Francisco|QB3, Byers Hall 508B|San Francisco|California|94158|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amebiasis",
                    "umls_id": "C0013370",
                    "parsed_text": "amebiasis"
                }
            }
        ]
    },
    {
        "_id": "AUJRCFUBUPVWSZ-JMYRMHIVSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 124081048,
                "inchl_key": "AUJRCFUBUPVWSZ-JMYRMHIVSA-M",
                "generic_name": "auranofin",
                "designated_date": "04/30/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ctr for Discovery & Innovation in Parasitic Diseas|U. of CA, San Francisco|QB3, Byers Hall 508B|San Francisco|California|94158|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amebiasis",
                    "umls_id": "C0013370",
                    "parsed_text": "amebiasis"
                }
            }
        ]
    },
    {
        "_id": "AUJRCFUBUPVWSZ-BQWBZISASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 57417071,
                "inchl_key": "AUJRCFUBUPVWSZ-BQWBZISASA-N",
                "generic_name": "auranofin",
                "designated_date": "04/30/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ctr for Discovery & Innovation in Parasitic Diseas|U. of CA, San Francisco|QB3, Byers Hall 508B|San Francisco|California|94158|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amebiasis",
                    "umls_id": "C0013370",
                    "parsed_text": "amebiasis"
                }
            }
        ]
    },
    {
        "_id": "AUJRCFUBUPVWSZ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6333901,
                "inchl_key": "AUJRCFUBUPVWSZ-UHFFFAOYSA-N",
                "generic_name": "auranofin",
                "designated_date": "04/30/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ctr for Discovery & Innovation in Parasitic Diseas|U. of CA, San Francisco|QB3, Byers Hall 508B|San Francisco|California|94158|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amebiasis",
                    "umls_id": "C0013370",
                    "parsed_text": "amebiasis"
                }
            }
        ]
    },
    {
        "_id": "AUJRCFUBUPVWSZ-XTZHGVARSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 6918453,
                "inchl_key": "AUJRCFUBUPVWSZ-XTZHGVARSA-M",
                "generic_name": "auranofin",
                "designated_date": "04/30/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ctr for Discovery & Innovation in Parasitic Diseas|U. of CA, San Francisco|QB3, Byers Hall 508B|San Francisco|California|94158|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amebiasis",
                    "umls_id": "C0013370",
                    "parsed_text": "amebiasis"
                }
            },
            {
                "compound_id": 6918453,
                "inchl_key": "AUJRCFUBUPVWSZ-XTZHGVARSA-M",
                "generic_name": "auranofin",
                "designated_date": "04/30/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ctr for Discovery & Innovation in Parasitic Diseas|U. of CA, San Francisco|QB3, Byers Hall 508B|San Francisco|California|94158|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amebiasis",
                    "umls_id": "C0013370",
                    "parsed_text": "amebiasis"
                }
            }
        ]
    },
    {
        "_id": "AUJRCFUBUPVWSZ-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 24199313,
                "inchl_key": "AUJRCFUBUPVWSZ-UHFFFAOYSA-M",
                "generic_name": "auranofin",
                "designated_date": "04/30/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ctr for Discovery & Innovation in Parasitic Diseas|U. of CA, San Francisco|QB3, Byers Hall 508B|San Francisco|California|94158|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amebiasis",
                    "umls_id": "C0013370",
                    "parsed_text": "amebiasis"
                }
            }
        ]
    },
    {
        "_id": "PUKBOVABABRILL-YZNIXAGQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 49841217,
                "inchl_key": "PUKBOVABABRILL-YZNIXAGQSA-N",
                "generic_name": "avacopan",
                "designated_date": "11/17/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ChemoCentryx, Inc.|850 Maude Avenue|Mountain View|California|94043|United States",
                "orphan_designation": {
                    "original_text": "Treatment of atypical hemolytic uremic syndrome",
                    "umls_id": "C2931788",
                    "parsed_text": "Atypical Hemolytic Uremic Syndrome"
                }
            },
            {
                "compound_id": 49841217,
                "inchl_key": "PUKBOVABABRILL-YZNIXAGQSA-N",
                "generic_name": "avacopan",
                "designated_date": "03/20/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ChemoCentryx, Inc.|850 Maude Avenue|Mountain View|California|94043|United States",
                "orphan_designation": {
                    "original_text": "Treatment of C3 glomerulopathy",
                    "umls_id": "C4521256",
                    "parsed_text": "Glomerulopathy"
                }
            },
            {
                "compound_id": 49841217,
                "inchl_key": "PUKBOVABABRILL-YZNIXAGQSA-N",
                "generic_name": "avacopan",
                "designated_date": "06/02/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ChemoCentryx, Inc.|850 Maude Avenue|Mountain View|California|94043|United States",
                "orphan_designation": {
                    "original_text": "Treatment of anti-neutrophil cytoplasmic autoantibodies associated vasculitides (granulomatosis with polyangiitis or Wegener's granulomatosis), microscopic polyangiitis, and Churg-Strauss syndrome.",
                    "umls_id": "C0008728,C0042384,C2347126,C3495801,C4050407",
                    "parsed_text": "Churg-Strauss Syndrome , Vasculitides , Microscopic Polyangiitis , Granulomatosis with polyangiitis , Wegener Granulomatosis"
                }
            }
        ]
    },
    {
        "_id": "DWYRIWUZIJHQKQ-SANMLTNESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 118023034,
                "inchl_key": "DWYRIWUZIJHQKQ-SANMLTNESA-N",
                "generic_name": "avapritinib",
                "designated_date": "01/21/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Blueprint Medicines Corporation|45 Sidney Street|Suite 200|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mastocytosis",
                    "umls_id": "C0024899",
                    "parsed_text": "Mastocytosis"
                }
            },
            {
                "compound_id": 118023034,
                "inchl_key": "DWYRIWUZIJHQKQ-SANMLTNESA-N",
                "generic_name": "avapritinib",
                "trade_name": "Ayvakit",
                "designated_date": "01/06/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "AYVAKIT is indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations",
                "marketing_approval_date": "\u00a001/09/2020\u00a0",
                "exclusivity_end_date": "\u00a001/09/2027\u00a0",
                "sponsor": "Blueprint Medicines Corporation|45 Sidney Street|Suite 200|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastrointestinal stromal tumors",
                    "umls_id": "C0238198",
                    "parsed_text": "Gastrointestinal Stromal Tumors"
                }
            }
        ]
    },
    {
        "_id": "MISPBGHDNZYFNM-BTJKTKAUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9918581,
                "inchl_key": "MISPBGHDNZYFNM-BTJKTKAUSA-N",
                "generic_name": "avatrombopag maleate",
                "designated_date": "12/19/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Dova Pharmaceuticals, Inc.|240 Leigh Farm Road|Suite 245|Durham|North Carolina|27707|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chemotherapy-induced thrombocytopenia",
                    "umls_id": "C0040034",
                    "parsed_text": "Thrombocytopenia"
                }
            },
            {
                "compound_id": 9918581,
                "inchl_key": "MISPBGHDNZYFNM-BTJKTKAUSA-N",
                "generic_name": "avatrombopag maleate",
                "designated_date": "09/01/2011",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "DOPTELET is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment",
                "marketing_approval_date": "\u00a006/26/2019\u00a0",
                "exclusivity_end_date": "\u00a006/26/2026\u00a0",
                "exclusivity_protected_indication": "For the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment",
                "sponsor": "Dova Pharmaceuticals, Inc.|240 Leigh Farm Road|Suite 245|Durham|North Carolina|27707|United States",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic thrombocytopenic purpura",
                    "umls_id": "C0398650",
                    "parsed_text": "IDIOPATHIC THROMBOCYTOPENIC PURPURA"
                }
            }
        ]
    },
    {
        "_id": "HKEDBKXRDHFCFB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3216,
                "inchl_key": "HKEDBKXRDHFCFB-UHFFFAOYSA-N",
                "generic_name": "avicin d",
                "designated_date": "03/24/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Avicin Therapeutics Ltd.|Westpark Corporate Center|4634 S. Alston Avenue|Durham|North Carolina|27713|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "HKEDBKXRDHFCFB-LUAQNYIXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44566777,
                "inchl_key": "HKEDBKXRDHFCFB-LUAQNYIXSA-N",
                "generic_name": "avicin d",
                "designated_date": "03/24/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Avicin Therapeutics Ltd.|Westpark Corporate Center|4634 S. Alston Avenue|Durham|North Carolina|27713|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "VBUWHHLIZKOSMS-RIWXPGAOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 53314964,
                "inchl_key": "VBUWHHLIZKOSMS-RIWXPGAOSA-N",
                "generic_name": "Aviptadil",
                "designated_date": "07/23/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AdVita Lifescience GmbH|Alte Bundesstra\u07e5 20|Gundelfingen|79194|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of sarcoidosis",
                    "umls_id": "C0036202",
                    "parsed_text": "Sarcoidosis"
                }
            },
            {
                "compound_id": 53314964,
                "inchl_key": "VBUWHHLIZKOSMS-RIWXPGAOSA-N",
                "generic_name": "aviptadil",
                "designated_date": "02/22/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mondobiotech Laboratories AG|Herrengasse 21|Furstentum Liechtenstein|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            },
            {
                "compound_id": 53314964,
                "inchl_key": "VBUWHHLIZKOSMS-RIWXPGAOSA-N",
                "generic_name": "Vasoactive intestinal peptide",
                "designated_date": "03/09/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "mondoBIOTECH|Europark|FL - 9490 Vaduz|Liechtenstein|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of Acute Respiratory Distress Syndrome.",
                    "umls_id": "C0035222",
                    "parsed_text": "Acute respiratory distress syndrome"
                }
            }
        ]
    },
    {
        "_id": "RITAVMQDGBJQJZ-FMIVXFBMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6450551,
                "inchl_key": "RITAVMQDGBJQJZ-FMIVXFBMSA-N",
                "generic_name": "axitinib",
                "designated_date": "05/31/2007",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer, Inc.|10646 Science Center Drive|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "NMUSYJAQQFHJEW-KVTDHHQDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9444,
                "inchl_key": "NMUSYJAQQFHJEW-KVTDHHQDSA-N",
                "generic_name": "azacitidine",
                "trade_name": "Vidaza",
                "designated_date": "12/03/2001",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia and requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia",
                "marketing_approval_date": "\u00a005/19/2004\u00a0",
                "exclusivity_end_date": "\u00a005/19/2011\u00a0",
                "sponsor": "Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States",
                "orphan_designation": {
                    "original_text": "Treatament of myelodysplastic syndromes",
                    "umls_id": "C3463824",
                    "parsed_text": "Myelodysplastic Syndromes"
                }
            },
            {
                "compound_id": 9444,
                "inchl_key": "NMUSYJAQQFHJEW-KVTDHHQDSA-N",
                "generic_name": "Azacitidine",
                "trade_name": "ONUREG",
                "designated_date": "06/18/2008",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "ONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy",
                "marketing_approval_date": "\u00a009/01/2020\u00a0",
                "exclusivity_end_date": "\u00a009/01/2027\u00a0",
                "exclusivity_protected_indication": "ONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy",
                "sponsor": "Bristol-Myers Squibb|86 Morris Ave|Summit|New Jersey|7901|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "LMEKQMALGUDUQG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2265,
                "inchl_key": "LMEKQMALGUDUQG-UHFFFAOYSA-N",
                "generic_name": "Azathioprine",
                "designated_date": "09/14/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oral Solutions, Inc.|787 Seventh Ave., 48th Floor|New York|New York|10019|United States",
                "orphan_designation": {
                    "original_text": "Treatment of oral manifestations of graft-versus-host disease.",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            }
        ]
    },
    {
        "_id": "WZPBZJONDBGPKJ-HMTIBFNOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 86741379,
                "inchl_key": "WZPBZJONDBGPKJ-HMTIBFNOSA-N",
                "generic_name": "aztreonam",
                "designated_date": "05/15/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gilead Sciences, Inc.|2025 1st Avenue|Seattle|Washington|98121|United States",
                "orphan_designation": {
                    "original_text": "Improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.",
                    "umls_id": "C0006267,C0037090",
                    "parsed_text": "Bronchiectasis , Respiratory symptoms"
                }
            },
            {
                "compound_id": 86741379,
                "inchl_key": "WZPBZJONDBGPKJ-HMTIBFNOSA-N",
                "generic_name": "aztreonam",
                "trade_name": "Cayston",
                "designated_date": "03/12/2002",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "To improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa",
                "marketing_approval_date": "\u00a002/22/2010\u00a0",
                "exclusivity_end_date": "\u00a002/22/2017\u00a0",
                "sponsor": "Gilead Sciences (formerly Corus Pharma)|199 East Blaine St|Seattle|Washington|98102|United States",
                "orphan_designation": {
                    "original_text": "Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "WZPBZJONDBGPKJ-NACOFCMISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 22842006,
                "inchl_key": "WZPBZJONDBGPKJ-NACOFCMISA-N",
                "generic_name": "aztreonam",
                "designated_date": "05/15/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gilead Sciences, Inc.|2025 1st Avenue|Seattle|Washington|98121|United States",
                "orphan_designation": {
                    "original_text": "Improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.",
                    "umls_id": "C0006267,C0037090",
                    "parsed_text": "Bronchiectasis , Respiratory symptoms"
                }
            },
            {
                "compound_id": 22842006,
                "inchl_key": "WZPBZJONDBGPKJ-NACOFCMISA-N",
                "generic_name": "aztreonam",
                "trade_name": "Cayston",
                "designated_date": "03/12/2002",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "To improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa",
                "marketing_approval_date": "\u00a002/22/2010\u00a0",
                "exclusivity_end_date": "\u00a002/22/2017\u00a0",
                "sponsor": "Gilead Sciences (formerly Corus Pharma)|199 East Blaine St|Seattle|Washington|98102|United States",
                "orphan_designation": {
                    "original_text": "Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "WZPBZJONDBGPKJ-PSGLRMFWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 56842327,
                "inchl_key": "WZPBZJONDBGPKJ-PSGLRMFWSA-N",
                "generic_name": "aztreonam",
                "designated_date": "05/15/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gilead Sciences, Inc.|2025 1st Avenue|Seattle|Washington|98121|United States",
                "orphan_designation": {
                    "original_text": "Improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.",
                    "umls_id": "C0006267,C0037090",
                    "parsed_text": "Bronchiectasis , Respiratory symptoms"
                }
            },
            {
                "compound_id": 56842327,
                "inchl_key": "WZPBZJONDBGPKJ-PSGLRMFWSA-N",
                "generic_name": "aztreonam",
                "trade_name": "Cayston",
                "designated_date": "03/12/2002",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "To improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa",
                "marketing_approval_date": "\u00a002/22/2010\u00a0",
                "exclusivity_end_date": "\u00a002/22/2017\u00a0",
                "sponsor": "Gilead Sciences (formerly Corus Pharma)|199 East Blaine St|Seattle|Washington|98102|United States",
                "orphan_designation": {
                    "original_text": "Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "WZPBZJONDBGPKJ-CAOOACKPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5466987,
                "inchl_key": "WZPBZJONDBGPKJ-CAOOACKPSA-N",
                "generic_name": "aztreonam",
                "designated_date": "05/15/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gilead Sciences, Inc.|2025 1st Avenue|Seattle|Washington|98121|United States",
                "orphan_designation": {
                    "original_text": "Improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.",
                    "umls_id": "C0006267,C0037090",
                    "parsed_text": "Bronchiectasis , Respiratory symptoms"
                }
            },
            {
                "compound_id": 5466987,
                "inchl_key": "WZPBZJONDBGPKJ-CAOOACKPSA-N",
                "generic_name": "aztreonam",
                "trade_name": "Cayston",
                "designated_date": "03/12/2002",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "To improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa",
                "marketing_approval_date": "\u00a002/22/2010\u00a0",
                "exclusivity_end_date": "\u00a002/22/2017\u00a0",
                "sponsor": "Gilead Sciences (formerly Corus Pharma)|199 East Blaine St|Seattle|Washington|98102|United States",
                "orphan_designation": {
                    "original_text": "Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "WZPBZJONDBGPKJ-FSPLSTOPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 54117,
                "inchl_key": "WZPBZJONDBGPKJ-FSPLSTOPSA-N",
                "generic_name": "aztreonam",
                "designated_date": "05/15/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gilead Sciences, Inc.|2025 1st Avenue|Seattle|Washington|98121|United States",
                "orphan_designation": {
                    "original_text": "Improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.",
                    "umls_id": "C0006267,C0037090",
                    "parsed_text": "Bronchiectasis , Respiratory symptoms"
                }
            },
            {
                "compound_id": 54117,
                "inchl_key": "WZPBZJONDBGPKJ-FSPLSTOPSA-N",
                "generic_name": "aztreonam",
                "trade_name": "Cayston",
                "designated_date": "03/12/2002",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "To improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa",
                "marketing_approval_date": "\u00a002/22/2010\u00a0",
                "exclusivity_end_date": "\u00a002/22/2017\u00a0",
                "sponsor": "Gilead Sciences (formerly Corus Pharma)|199 East Blaine St|Seattle|Washington|98102|United States",
                "orphan_designation": {
                    "original_text": "Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "WZPBZJONDBGPKJ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2274,
                "inchl_key": "WZPBZJONDBGPKJ-UHFFFAOYSA-N",
                "generic_name": "aztreonam",
                "designated_date": "05/15/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gilead Sciences, Inc.|2025 1st Avenue|Seattle|Washington|98121|United States",
                "orphan_designation": {
                    "original_text": "Improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.",
                    "umls_id": "C0006267,C0037090",
                    "parsed_text": "Bronchiectasis , Respiratory symptoms"
                }
            },
            {
                "compound_id": 2274,
                "inchl_key": "WZPBZJONDBGPKJ-UHFFFAOYSA-N",
                "generic_name": "aztreonam",
                "trade_name": "Cayston",
                "designated_date": "03/12/2002",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "To improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa",
                "marketing_approval_date": "\u00a002/22/2010\u00a0",
                "exclusivity_end_date": "\u00a002/22/2017\u00a0",
                "sponsor": "Gilead Sciences (formerly Corus Pharma)|199 East Blaine St|Seattle|Washington|98102|United States",
                "orphan_designation": {
                    "original_text": "Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "WZPBZJONDBGPKJ-IYZXUIDESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5459211,
                "inchl_key": "WZPBZJONDBGPKJ-IYZXUIDESA-N",
                "generic_name": "aztreonam",
                "designated_date": "05/15/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gilead Sciences, Inc.|2025 1st Avenue|Seattle|Washington|98121|United States",
                "orphan_designation": {
                    "original_text": "Improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.",
                    "umls_id": "C0006267,C0037090",
                    "parsed_text": "Bronchiectasis , Respiratory symptoms"
                }
            },
            {
                "compound_id": 5459211,
                "inchl_key": "WZPBZJONDBGPKJ-IYZXUIDESA-N",
                "generic_name": "aztreonam",
                "trade_name": "Cayston",
                "designated_date": "03/12/2002",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "To improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa",
                "marketing_approval_date": "\u00a002/22/2010\u00a0",
                "exclusivity_end_date": "\u00a002/22/2017\u00a0",
                "sponsor": "Gilead Sciences (formerly Corus Pharma)|199 East Blaine St|Seattle|Washington|98102|United States",
                "orphan_designation": {
                    "original_text": "Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "WZPBZJONDBGPKJ-VEHQQRBSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5742832,
                "inchl_key": "WZPBZJONDBGPKJ-VEHQQRBSSA-N",
                "generic_name": "aztreonam",
                "designated_date": "05/15/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gilead Sciences, Inc.|2025 1st Avenue|Seattle|Washington|98121|United States",
                "orphan_designation": {
                    "original_text": "Improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.",
                    "umls_id": "C0006267,C0037090",
                    "parsed_text": "Bronchiectasis , Respiratory symptoms"
                }
            },
            {
                "compound_id": 5742832,
                "inchl_key": "WZPBZJONDBGPKJ-VEHQQRBSSA-N",
                "generic_name": "aztreonam",
                "trade_name": "Cayston",
                "designated_date": "03/12/2002",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "To improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa",
                "marketing_approval_date": "\u00a002/22/2010\u00a0",
                "exclusivity_end_date": "\u00a002/22/2017\u00a0",
                "sponsor": "Gilead Sciences (formerly Corus Pharma)|199 East Blaine St|Seattle|Washington|98102|United States",
                "orphan_designation": {
                    "original_text": "Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "KPYSYYIEGFHWSV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2284,
                "inchl_key": "KPYSYYIEGFHWSV-UHFFFAOYSA-N",
                "generic_name": "baclofen",
                "designated_date": "10/28/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Piramal Critical Care, Inc.|261 Brodhead Road|Suite 221|Bethlehem|Pennsylvania|18017|United States",
                "orphan_designation": {
                    "original_text": "Treatment of complex regional pain syndrome",
                    "umls_id": "C0458219",
                    "parsed_text": "Complex regional pain syndrome"
                }
            },
            {
                "compound_id": 2284,
                "inchl_key": "KPYSYYIEGFHWSV-UHFFFAOYSA-N",
                "generic_name": "Baclofen",
                "designated_date": "09/26/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medtronic, Inc.|800 53rd Avenue N.E.|P.O. 1250|Minneapolis|Minnesota|55440|United States",
                "orphan_designation": {
                    "original_text": "Treatment of spasticity associated with cerebral palsy.",
                    "umls_id": "C0007789,C0026838",
                    "parsed_text": "Cerebral Palsy , Spasticity"
                }
            },
            {
                "compound_id": 2284,
                "inchl_key": "KPYSYYIEGFHWSV-UHFFFAOYSA-N",
                "generic_name": "baclofen",
                "trade_name": "Lioresal Intrathecal",
                "designated_date": "11/10/1987",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Management of severe spasticity of spinal cord origin in patients who are unresponsive to oral baclofen therapy or experience intolerable CNS side effects at effective doses.",
                "marketing_approval_date": "\u00a006/25/1992\u00a0",
                "exclusivity_end_date": "\u00a006/25/1999\u00a0",
                "sponsor": "Medtronic, Inc.|800 53rd Avenue N.E.|Minneapolis|Minnesota|55432|United States",
                "orphan_designation": {
                    "original_text": "Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy).",
                    "umls_id": "C0022116,C0026769,C0026838,C0026976,C0037929,C0037930,C0037933,C0270780,C1384641",
                    "parsed_text": "Ischemia , Multiple Sclerosis , Spasticity , Transverse myelitis , Spinal Cord Injury , Spinal tumor , Spinal Diseases , Degenerative myelopathy , Cervical spondylosis"
                }
            },
            {
                "compound_id": 2284,
                "inchl_key": "KPYSYYIEGFHWSV-UHFFFAOYSA-N",
                "generic_name": "baclofen",
                "trade_name": "OZOBAX",
                "designated_date": "12/16/1991",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "OZOBAX is indicated for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity.",
                "marketing_approval_date": "\u00a009/18/2019\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Metacel Pharmaceuticals, LLC|244 E Washington Street|Athens|Georgia|30601|United States",
                "orphan_designation": {
                    "original_text": "Treatment of intractable spasticity due to multiple sclerosis or spinal cord injury.",
                    "umls_id": "C0026769,C0026838,C0037929",
                    "parsed_text": "Multiple Sclerosis , Spasticity , Spinal Cord Injury"
                }
            },
            {
                "compound_id": 2284,
                "inchl_key": "KPYSYYIEGFHWSV-UHFFFAOYSA-N",
                "generic_name": "baclofen",
                "designated_date": "12/02/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medtronic Neurological|710 Medtronic Parkway NE|Minneapolis|Minnesota|55432|United States",
                "orphan_designation": {
                    "original_text": "Treatment of dystonia",
                    "umls_id": "C0013421",
                    "parsed_text": "Dystonia"
                }
            },
            {
                "compound_id": 2284,
                "inchl_key": "KPYSYYIEGFHWSV-UHFFFAOYSA-N",
                "generic_name": "baclofen",
                "designated_date": "12/31/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Saol Therapeutics Research Limited|Peter Street, Unit G04|Adelaide Chambers|Dublin|8|Ireland",
                "orphan_designation": {
                    "original_text": "Prevention of baclofen withdrawal syndrome",
                    "umls_id": "C0038587",
                    "parsed_text": "Withdrawal Syndrome"
                }
            }
        ]
    },
    {
        "_id": "KVHRYLNQDWXAGI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 46848915,
                "inchl_key": "KVHRYLNQDWXAGI-UHFFFAOYSA-N",
                "generic_name": "Balipodect",
                "designated_date": "06/19/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Millennium Pharmaceuticals, Inc.|40 Landsdowne St.|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of CDKL5 deficiency disorder",
                    "umls_id": "C0012634",
                    "parsed_text": "Disorder"
                }
            },
            {
                "compound_id": 46848915,
                "inchl_key": "KVHRYLNQDWXAGI-UHFFFAOYSA-N",
                "generic_name": "Balipodect",
                "designated_date": "06/13/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Millennium Pharmaceuticals, Inc.|40 Landsdowne St.|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X Syndrome",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "IBRSMMVMVMCYCS-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135430840,
                "inchl_key": "IBRSMMVMVMCYCS-UHFFFAOYSA-N",
                "generic_name": "Balsalazide disodium",
                "trade_name": "Colazal",
                "designated_date": "08/12/2005",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Safety and Effectiveness of Colazal beyond 8 weeks in children (ages 5-17) and 12 weeks in adults have not been established.",
                "marketing_approval_date": "\u00a012/20/2006\u00a0",
                "exclusivity_end_date": "\u00a012/20/2013\u00a0",
                "sponsor": "Salix Pharmaceuticals, Inc.|400 Somerset Corporate Blvd|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients with ulcerative colitis",
                    "umls_id": "C0009324",
                    "parsed_text": "Ulcerative Colitis"
                }
            }
        ]
    },
    {
        "_id": "UANPKWBWEAQNQY-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 136040192,
                "inchl_key": "UANPKWBWEAQNQY-UHFFFAOYSA-N",
                "generic_name": "Balsalazide disodium",
                "trade_name": "Colazal",
                "designated_date": "08/12/2005",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Safety and Effectiveness of Colazal beyond 8 weeks in children (ages 5-17) and 12 weeks in adults have not been established.",
                "marketing_approval_date": "\u00a012/20/2006\u00a0",
                "exclusivity_end_date": "\u00a012/20/2013\u00a0",
                "sponsor": "Salix Pharmaceuticals, Inc.|400 Somerset Corporate Blvd|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients with ulcerative colitis",
                    "umls_id": "C0009324",
                    "parsed_text": "Ulcerative Colitis"
                }
            }
        ]
    },
    {
        "_id": "WLYZKTXOAMAVEO-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135515521,
                "inchl_key": "WLYZKTXOAMAVEO-UHFFFAOYSA-N",
                "generic_name": "Balsalazide disodium",
                "trade_name": "Colazal",
                "designated_date": "08/12/2005",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Safety and Effectiveness of Colazal beyond 8 weeks in children (ages 5-17) and 12 weeks in adults have not been established.",
                "marketing_approval_date": "\u00a012/20/2006\u00a0",
                "exclusivity_end_date": "\u00a012/20/2013\u00a0",
                "sponsor": "Salix Pharmaceuticals, Inc.|400 Somerset Corporate Blvd|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients with ulcerative colitis",
                    "umls_id": "C0009324",
                    "parsed_text": "Ulcerative Colitis"
                }
            }
        ]
    },
    {
        "_id": "IPOKCKJONYRRHP-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 54585,
                "inchl_key": "IPOKCKJONYRRHP-UHFFFAOYSA-N",
                "generic_name": "Balsalazide disodium",
                "trade_name": "Colazal",
                "designated_date": "08/12/2005",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Safety and Effectiveness of Colazal beyond 8 weeks in children (ages 5-17) and 12 weeks in adults have not been established.",
                "marketing_approval_date": "\u00a012/20/2006\u00a0",
                "exclusivity_end_date": "\u00a012/20/2013\u00a0",
                "sponsor": "Salix Pharmaceuticals, Inc.|400 Somerset Corporate Blvd|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients with ulcerative colitis",
                    "umls_id": "C0009324",
                    "parsed_text": "Ulcerative Colitis"
                }
            }
        ]
    },
    {
        "_id": "XDCNKOBSQURQOZ-UHFFFAOYSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 135414247,
                "inchl_key": "XDCNKOBSQURQOZ-UHFFFAOYSA-L",
                "generic_name": "Balsalazide disodium",
                "trade_name": "Colazal",
                "designated_date": "08/12/2005",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Safety and Effectiveness of Colazal beyond 8 weeks in children (ages 5-17) and 12 weeks in adults have not been established.",
                "marketing_approval_date": "\u00a012/20/2006\u00a0",
                "exclusivity_end_date": "\u00a012/20/2013\u00a0",
                "sponsor": "Salix Pharmaceuticals, Inc.|400 Somerset Corporate Blvd|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients with ulcerative colitis",
                    "umls_id": "C0009324",
                    "parsed_text": "Ulcerative Colitis"
                }
            }
        ]
    },
    {
        "_id": "CKMOQBVBEGCJGW-UHFFFAOYSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 135413496,
                "inchl_key": "CKMOQBVBEGCJGW-UHFFFAOYSA-L",
                "generic_name": "Balsalazide disodium",
                "trade_name": "Colazal",
                "designated_date": "08/12/2005",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Safety and Effectiveness of Colazal beyond 8 weeks in children (ages 5-17) and 12 weeks in adults have not been established.",
                "marketing_approval_date": "\u00a012/20/2006\u00a0",
                "exclusivity_end_date": "\u00a012/20/2013\u00a0",
                "sponsor": "Salix Pharmaceuticals, Inc.|400 Somerset Corporate Blvd|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients with ulcerative colitis",
                    "umls_id": "C0009324",
                    "parsed_text": "Ulcerative Colitis"
                }
            }
        ]
    },
    {
        "_id": "TXGZJQLMVSIZEI-UQMAOPSPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 400010,
                "inchl_key": "TXGZJQLMVSIZEI-UQMAOPSPSA-N",
                "generic_name": "Bardoxolone",
                "designated_date": "08/06/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Reata Pharmaceuticals, Inc.|2801 Gateway Drive|Irving|Texas|75063|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 400010,
                "inchl_key": "TXGZJQLMVSIZEI-UQMAOPSPSA-N",
                "generic_name": "bardoxolone",
                "designated_date": "03/30/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Reata Pharmaceuticals, Inc.|2801 Gateway Dr.|Suite 150|Irving|Texas|75063|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "WPTTVJLTNAWYAO-OYWPANLISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 133109022,
                "inchl_key": "WPTTVJLTNAWYAO-OYWPANLISA-N",
                "generic_name": "bardoxolone methyl",
                "designated_date": "06/03/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Reata Pharmaceuticals, Inc.|2801 Gateway Dr.|Suite 150|Irving|Texas|75063|United States",
                "orphan_designation": {
                    "original_text": "Treatment of autosomal dominant polycystic kidney disease",
                    "umls_id": "C0085413",
                    "parsed_text": "Autosomal dominant polycystic kidney disease"
                }
            },
            {
                "compound_id": 133109022,
                "inchl_key": "WPTTVJLTNAWYAO-OYWPANLISA-N",
                "generic_name": "bardoxolone methyl",
                "designated_date": "07/03/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Reata Pharmaceuticals, Inc.|2801 Gateway Dr.|Suite 150|Irving|Texas|75063|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Alport Syndrome",
                    "umls_id": "C1567741",
                    "parsed_text": "Alport Syndrome"
                }
            }
        ]
    },
    {
        "_id": "WPTTVJLTNAWYAO-ZREYCQBLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 131632414,
                "inchl_key": "WPTTVJLTNAWYAO-ZREYCQBLSA-N",
                "generic_name": "bardoxolone methyl",
                "designated_date": "06/03/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Reata Pharmaceuticals, Inc.|2801 Gateway Dr.|Suite 150|Irving|Texas|75063|United States",
                "orphan_designation": {
                    "original_text": "Treatment of autosomal dominant polycystic kidney disease",
                    "umls_id": "C0085413",
                    "parsed_text": "Autosomal dominant polycystic kidney disease"
                }
            },
            {
                "compound_id": 131632414,
                "inchl_key": "WPTTVJLTNAWYAO-ZREYCQBLSA-N",
                "generic_name": "bardoxolone methyl",
                "designated_date": "07/03/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Reata Pharmaceuticals, Inc.|2801 Gateway Dr.|Suite 150|Irving|Texas|75063|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Alport Syndrome",
                    "umls_id": "C1567741",
                    "parsed_text": "Alport Syndrome"
                }
            }
        ]
    },
    {
        "_id": "WPTTVJLTNAWYAO-OROHISIGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24896135,
                "inchl_key": "WPTTVJLTNAWYAO-OROHISIGSA-N",
                "generic_name": "bardoxolone methyl",
                "designated_date": "06/03/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Reata Pharmaceuticals, Inc.|2801 Gateway Dr.|Suite 150|Irving|Texas|75063|United States",
                "orphan_designation": {
                    "original_text": "Treatment of autosomal dominant polycystic kidney disease",
                    "umls_id": "C0085413",
                    "parsed_text": "Autosomal dominant polycystic kidney disease"
                }
            },
            {
                "compound_id": 24896135,
                "inchl_key": "WPTTVJLTNAWYAO-OROHISIGSA-N",
                "generic_name": "bardoxolone methyl",
                "designated_date": "07/03/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Reata Pharmaceuticals, Inc.|2801 Gateway Dr.|Suite 150|Irving|Texas|75063|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Alport Syndrome",
                    "umls_id": "C1567741",
                    "parsed_text": "Alport Syndrome"
                }
            }
        ]
    },
    {
        "_id": "WPTTVJLTNAWYAO-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 53315588,
                "inchl_key": "WPTTVJLTNAWYAO-UHFFFAOYSA-N",
                "generic_name": "bardoxolone methyl",
                "designated_date": "06/03/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Reata Pharmaceuticals, Inc.|2801 Gateway Dr.|Suite 150|Irving|Texas|75063|United States",
                "orphan_designation": {
                    "original_text": "Treatment of autosomal dominant polycystic kidney disease",
                    "umls_id": "C0085413",
                    "parsed_text": "Autosomal dominant polycystic kidney disease"
                }
            },
            {
                "compound_id": 53315588,
                "inchl_key": "WPTTVJLTNAWYAO-UHFFFAOYSA-N",
                "generic_name": "bardoxolone methyl",
                "designated_date": "07/03/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Reata Pharmaceuticals, Inc.|2801 Gateway Dr.|Suite 150|Irving|Texas|75063|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Alport Syndrome",
                    "umls_id": "C1567741",
                    "parsed_text": "Alport Syndrome"
                }
            }
        ]
    },
    {
        "_id": "WPTTVJLTNAWYAO-UFHYVYMVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 49827815,
                "inchl_key": "WPTTVJLTNAWYAO-UFHYVYMVSA-N",
                "generic_name": "bardoxolone methyl",
                "designated_date": "06/03/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Reata Pharmaceuticals, Inc.|2801 Gateway Dr.|Suite 150|Irving|Texas|75063|United States",
                "orphan_designation": {
                    "original_text": "Treatment of autosomal dominant polycystic kidney disease",
                    "umls_id": "C0085413",
                    "parsed_text": "Autosomal dominant polycystic kidney disease"
                }
            },
            {
                "compound_id": 49827815,
                "inchl_key": "WPTTVJLTNAWYAO-UFHYVYMVSA-N",
                "generic_name": "bardoxolone methyl",
                "designated_date": "07/03/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Reata Pharmaceuticals, Inc.|2801 Gateway Dr.|Suite 150|Irving|Texas|75063|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Alport Syndrome",
                    "umls_id": "C1567741",
                    "parsed_text": "Alport Syndrome"
                }
            }
        ]
    },
    {
        "_id": "WPTTVJLTNAWYAO-FUARBKCBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 70700216,
                "inchl_key": "WPTTVJLTNAWYAO-FUARBKCBSA-N",
                "generic_name": "bardoxolone methyl",
                "designated_date": "06/03/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Reata Pharmaceuticals, Inc.|2801 Gateway Dr.|Suite 150|Irving|Texas|75063|United States",
                "orphan_designation": {
                    "original_text": "Treatment of autosomal dominant polycystic kidney disease",
                    "umls_id": "C0085413",
                    "parsed_text": "Autosomal dominant polycystic kidney disease"
                }
            },
            {
                "compound_id": 70700216,
                "inchl_key": "WPTTVJLTNAWYAO-FUARBKCBSA-N",
                "generic_name": "bardoxolone methyl",
                "designated_date": "07/03/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Reata Pharmaceuticals, Inc.|2801 Gateway Dr.|Suite 150|Irving|Texas|75063|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Alport Syndrome",
                    "umls_id": "C1567741",
                    "parsed_text": "Alport Syndrome"
                }
            }
        ]
    },
    {
        "_id": "WPTTVJLTNAWYAO-KPOXMGGZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 400769,
                "inchl_key": "WPTTVJLTNAWYAO-KPOXMGGZSA-N",
                "generic_name": "bardoxolone methyl",
                "designated_date": "06/03/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Reata Pharmaceuticals, Inc.|2801 Gateway Dr.|Suite 150|Irving|Texas|75063|United States",
                "orphan_designation": {
                    "original_text": "Treatment of autosomal dominant polycystic kidney disease",
                    "umls_id": "C0085413",
                    "parsed_text": "Autosomal dominant polycystic kidney disease"
                }
            },
            {
                "compound_id": 400769,
                "inchl_key": "WPTTVJLTNAWYAO-KPOXMGGZSA-N",
                "generic_name": "bardoxolone methyl",
                "designated_date": "07/03/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Reata Pharmaceuticals, Inc.|2801 Gateway Dr.|Suite 150|Irving|Texas|75063|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Alport Syndrome",
                    "umls_id": "C1567741",
                    "parsed_text": "Alport Syndrome"
                }
            }
        ]
    },
    {
        "_id": "XUZMWHLSFXCVMG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44205240,
                "inchl_key": "XUZMWHLSFXCVMG-UHFFFAOYSA-N",
                "generic_name": "baricitinib",
                "designated_date": "11/02/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric systemic lupus erythematosus",
                    "umls_id": "C0024141",
                    "parsed_text": "SYSTEMIC LUPUS ERYTHEMATOSUS"
                }
            }
        ]
    },
    {
        "_id": "UPZWINBEAHDTLA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11438771,
                "inchl_key": "UPZWINBEAHDTLA-UHFFFAOYSA-N",
                "generic_name": "basimglurant",
                "designated_date": "03/09/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X Syndrome",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "NBMKJKDGKREAPL-DVTGEIKXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 20469,
                "inchl_key": "NBMKJKDGKREAPL-DVTGEIKXSA-N",
                "generic_name": "beclomethasone",
                "designated_date": "03/04/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Aptalis Pharma US, Inc.|100 Somerset corporate Blvd|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatriac patients with ulcerative colitis",
                    "umls_id": "C0009324",
                    "parsed_text": "Ulcerative Colitis"
                }
            }
        ]
    },
    {
        "_id": "KUVIULQEHSCUHY-XYWKZLDCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 21700,
                "inchl_key": "KUVIULQEHSCUHY-XYWKZLDCSA-N",
                "generic_name": "beclomethasone dipropionate",
                "designated_date": "03/27/1998",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Soligenix, Inc.|29 Emmons Drive|Suite B-10|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "For oral administration in the treatment of intestinal graft-versus-host disease.",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            }
        ]
    },
    {
        "_id": "QUIJNHUBAXPXFS-XLJNKUFUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5388906,
                "inchl_key": "QUIJNHUBAXPXFS-XLJNKUFUSA-N",
                "generic_name": "bedaquiline",
                "trade_name": "SIRTURO",
                "designated_date": "01/10/2005",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Reserve SIRTURO for use when an effective treatment regimen cannot otherwise be provided.",
                "marketing_approval_date": "\u00a005/27/2020\u00a0",
                "exclusivity_end_date": "\u00a005/27/2027\u00a0",
                "exclusivity_protected_indication": "As part of combination therapy in the treatment of pediatric patients 5 years and older to less than 12 years of age and weighing at least 15 kg with pulmonary multi-drug resistant tuberculosis (MDR-TB)",
                "sponsor": "Janssen Research & Development, LLC|920 Route 202 South|Raritan|New Jersey|8869|United States",
                "orphan_designation": {
                    "original_text": "Treatment of active tuberculosis",
                    "umls_id": "C0041296",
                    "parsed_text": "Active Tuberculosis"
                }
            },
            {
                "compound_id": 5388906,
                "inchl_key": "QUIJNHUBAXPXFS-XLJNKUFUSA-N",
                "generic_name": "bedaquiline",
                "trade_name": "SIRTURO",
                "designated_date": "01/10/2005",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Part of combination therapy in adults (greater than or equal to 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB).",
                "marketing_approval_date": "\u00a012/28/2012\u00a0",
                "exclusivity_end_date": "\u00a012/28/2019\u00a0",
                "sponsor": "Janssen Research & Development, LLC|920 Route 202 South|Raritan|New Jersey|8869|United States",
                "orphan_designation": {
                    "original_text": "Treatment of active tuberculosis",
                    "umls_id": "C0041296",
                    "parsed_text": "Active Tuberculosis"
                }
            },
            {
                "compound_id": 5388906,
                "inchl_key": "QUIJNHUBAXPXFS-XLJNKUFUSA-N",
                "generic_name": "Bedaquiline",
                "designated_date": "07/27/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Janssen Research & Development, LLC|125 Trenton-Harbourton Road|Titusville|New Jersey|8560|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Nontuberculosis Mycobacteria infection",
                    "umls_id": "C0009450,C0026912",
                    "parsed_text": "Infection , Mycobacteria"
                }
            },
            {
                "compound_id": 5388906,
                "inchl_key": "QUIJNHUBAXPXFS-XLJNKUFUSA-N",
                "generic_name": "bedaquiline",
                "trade_name": "SIRTURO",
                "designated_date": "01/10/2005",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (12 to less than 18 years of age and weighing at least 30 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Reserve SIRTURO for use when an effective treatment regimen cannot otherwise be provided.",
                "marketing_approval_date": "\u00a008/09/2019\u00a0",
                "exclusivity_end_date": "\u00a008/09/2026\u00a0",
                "exclusivity_protected_indication": "As part of combination therapy in the treatment of pediatric patients (12 to less than 18 years of age and weighing at least 30 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB)",
                "sponsor": "Janssen Research & Development, LLC|920 Route 202 South|Raritan|New Jersey|8869|United States",
                "orphan_designation": {
                    "original_text": "Treatment of active tuberculosis",
                    "umls_id": "C0041296",
                    "parsed_text": "Active Tuberculosis"
                }
            }
        ]
    },
    {
        "_id": "NCNRHFGMJRPRSK-MDZDMXLPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6918638,
                "inchl_key": "NCNRHFGMJRPRSK-MDZDMXLPSA-N",
                "generic_name": "Belinostat",
                "trade_name": "Beleodaq",
                "designated_date": "09/03/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with relapsed or refractory peripheral T-cell lymphoma",
                "marketing_approval_date": "\u00a007/03/2014\u00a0",
                "exclusivity_end_date": "\u00a007/03/2021\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with relapsed or refractory peripheral T-cell lymphoma",
                "sponsor": "Acrotech Biopharma LLC|279 Princeton Hightstown Road|East Windsor|New Jersey|8520|United States",
                "orphan_designation": {
                    "original_text": "Treatment of peripheral T-cell lymphoma (PTCL).",
                    "umls_id": "C0079774",
                    "parsed_text": "Peripheral T-Cell Lymphoma"
                }
            }
        ]
    },
    {
        "_id": "ZEZFKUBILQRZCK-MJSCXXSSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6918502,
                "inchl_key": "ZEZFKUBILQRZCK-MJSCXXSSSA-N",
                "generic_name": "beloranib",
                "designated_date": "01/15/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Zafgen, Inc.|175 Portland Street|4th Floor|Boston|Massachusetts|2114|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Prader-Willi syndrome",
                    "umls_id": "C0032897",
                    "parsed_text": "Prader-Willi Syndrome"
                }
            }
        ]
    },
    {
        "_id": "GKHIVNAUVKXIIY-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11950170,
                "inchl_key": "GKHIVNAUVKXIIY-UHFFFAOYSA-N",
                "generic_name": "Belumosudil",
                "designated_date": "09/04/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kadmon Corporation|450 East 29th Street|New York|New York|10016|United States",
                "orphan_designation": {
                    "original_text": "Treatment of systemic sclerosis",
                    "umls_id": "C0036421",
                    "parsed_text": "Systemic sclerosis"
                }
            }
        ]
    },
    {
        "_id": "HYHMLYSLQUKXKP-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10472693,
                "inchl_key": "HYHMLYSLQUKXKP-UHFFFAOYSA-N",
                "generic_name": "bempedoic acid",
                "designated_date": "04/05/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Esperion Therapeutics, Inc.|3891 Ranchero Drive, Suite 150|Ann Arbor|Michigan|48108|United States",
                "orphan_designation": {
                    "original_text": "Treatment of homozygous familial hypercholesterolemia",
                    "umls_id": "C0020445",
                    "parsed_text": "FAMILIAL HYPERCHOLESTEROLEMIA"
                }
            }
        ]
    },
    {
        "_id": "YTKUWDBFDASYHO-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 65628,
                "inchl_key": "YTKUWDBFDASYHO-UHFFFAOYSA-N",
                "generic_name": "bendamustine",
                "designated_date": "06/22/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Paul Maher, MD|10644 Weymouth Street|Suite 104|Bethesda|Maryland|20814|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "ZHSKUOZOLHMKEA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 77082,
                "inchl_key": "ZHSKUOZOLHMKEA-UHFFFAOYSA-N",
                "generic_name": "Bendamustine hydrochloride",
                "trade_name": "Treanda",
                "designated_date": "08/17/2007",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with chronic lymphocytic leukemia",
                "marketing_approval_date": "\u00a003/20/2008\u00a0",
                "exclusivity_end_date": "\u00a003/20/2015\u00a0",
                "sponsor": "Cephalon, Inc.|41 Moores Road|Frazer|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "compound_id": 77082,
                "inchl_key": "ZHSKUOZOLHMKEA-UHFFFAOYSA-N",
                "generic_name": "bendamustine hydrochloride",
                "trade_name": "Treanda",
                "designated_date": "11/26/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.",
                "marketing_approval_date": "\u00a010/31/2008\u00a0",
                "exclusivity_end_date": "\u00a010/31/2015\u00a0",
                "sponsor": "Cephalon, Inc.|A wholly owned subsidiary of Teva Pharmaceuticals|PO Box 4011|Frazer|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively",
                    "umls_id": "C0024301,C0024419,C0242647,C0349632,C0855139,C1955690",
                    "parsed_text": "follicular lymphoma , lymphoplasmacytic lymphoma , Mucosa-associated lymphoma , Splenic marginal zone lymphoma , Nodal Marginal Zone Lymphoma , Extranodal marginal zone B-cell lymphoma"
                }
            }
        ]
    },
    {
        "_id": "CULUWZNBISUWAS-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 31593,
                "inchl_key": "CULUWZNBISUWAS-UHFFFAOYSA-N",
                "generic_name": "benznidazole",
                "designated_date": "04/14/2014",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of Chagas disease (American trypanosomiasis), caused by Trypanosoma cruzi, in pediatric patients 2 to 12 years of age.",
                "marketing_approval_date": "\u00a008/29/2017\u00a0",
                "exclusivity_end_date": "\u00a008/29/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of Chagas disease (American trypanosomiasis), caused by Trypanosoma cruzi, in pediatric patients 2 to 12 years of age.",
                "sponsor": "Chemo Research, S.L.|Edificio Nectar|c/Quintanapalla, 2, 3 planta|Madrid|Spain",
                "orphan_designation": {
                    "original_text": "Treatment of Chagas disease",
                    "umls_id": "C0041234",
                    "parsed_text": "Chagas Disease"
                }
            },
            {
                "compound_id": 31593,
                "inchl_key": "CULUWZNBISUWAS-UHFFFAOYSA-N",
                "generic_name": "benznidazole",
                "designated_date": "07/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Humanigen, Inc.|533 Airport Boulevard|Suite 400|Burlingame|California|94010|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Chagas disease",
                    "umls_id": "C0041234",
                    "parsed_text": "Chagas Disease"
                }
            }
        ]
    },
    {
        "_id": "WPYMKLBDIGXBTP-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 242,
                "inchl_key": "WPYMKLBDIGXBTP-UHFFFAOYSA-M",
                "generic_name": "benzoate",
                "designated_date": "07/06/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SyneuRx International (Taiwan) Corp.|1380 S. Marengo Ave|Pasadena|California|91106|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric schizophrenia",
                    "umls_id": "C0036341",
                    "parsed_text": "Schizophrenia"
                }
            }
        ]
    },
    {
        "_id": "HNNIWKQLJSNAEQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 65464,
                "inchl_key": "HNNIWKQLJSNAEQ-UHFFFAOYSA-N",
                "generic_name": "Benzydamine hydrochloride",
                "designated_date": "05/18/1998",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Angelini Pharmaceuticals, Inc.|70 Grand Avenue|River Edge|New Jersey|7661|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.",
                    "umls_id": "C1568868,C3887461",
                    "parsed_text": "Oral Mucositis , Head and Neck Cancer"
                }
            }
        ]
    },
    {
        "_id": "CTPOHARTNNSRSR-SEYXRHQNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 45358438,
                "inchl_key": "CTPOHARTNNSRSR-SEYXRHQNSA-N",
                "generic_name": "Beraprost",
                "designated_date": "04/29/1999",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "LungRx, Inc.|1040 Spring Street|Silver Spring|Maryland|20910|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "CTPOHARTNNSRSR-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2352,
                "inchl_key": "CTPOHARTNNSRSR-UHFFFAOYSA-N",
                "generic_name": "Beraprost",
                "designated_date": "04/29/1999",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "LungRx, Inc.|1040 Spring Street|Silver Spring|Maryland|20910|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "CTPOHARTNNSRSR-APJZLKAGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6917951,
                "inchl_key": "CTPOHARTNNSRSR-APJZLKAGSA-N",
                "generic_name": "Beraprost",
                "designated_date": "04/29/1999",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "LungRx, Inc.|1040 Spring Street|Silver Spring|Maryland|20910|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "CTPOHARTNNSRSR-OUKQBFOZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5282428,
                "inchl_key": "CTPOHARTNNSRSR-OUKQBFOZSA-N",
                "generic_name": "Beraprost",
                "designated_date": "04/29/1999",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "LungRx, Inc.|1040 Spring Street|Silver Spring|Maryland|20910|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "CTPOHARTNNSRSR-NOQAJONNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10501053,
                "inchl_key": "CTPOHARTNNSRSR-NOQAJONNSA-N",
                "generic_name": "beraprost sodium 314d",
                "designated_date": "12/22/2011",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Lung Biotechnology PBC|1040 Spring Street|Silver Spring|Maryland|20910|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "YTCZZXIRLARSET-ZTWNIFTGSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 71587534,
                "inchl_key": "YTCZZXIRLARSET-ZTWNIFTGSA-M",
                "generic_name": "beraprost sodium 314d",
                "designated_date": "12/22/2011",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Lung Biotechnology PBC|1040 Spring Street|Silver Spring|Maryland|20910|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "UXNXMBYCBRBRFD-MUUNZHRXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 137528262,
                "inchl_key": "UXNXMBYCBRBRFD-MUUNZHRXSA-N",
                "generic_name": "berotralstat",
                "trade_name": "ORLADEYO",
                "designated_date": "11/01/2017",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older",
                "marketing_approval_date": "\u00a012/03/2020\u00a0",
                "exclusivity_end_date": "\u00a012/03/2027\u00a0",
                "exclusivity_protected_indication": "prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older",
                "sponsor": "BioCryst Pharmaceuticals, Inc.|4505 Emperor Blvd|Suite 200|Durham|North Carolina|27703|United States",
                "orphan_designation": {
                    "original_text": "Treatment of C1-inhibitor-dependent angioedema (including prevention and treatment of attacks)",
                    "umls_id": "C0002994",
                    "parsed_text": "Angioedema"
                }
            }
        ]
    },
    {
        "_id": "FIGNGSHKNAHTSH-JJMFXPFOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9874592,
                "inchl_key": "FIGNGSHKNAHTSH-JJMFXPFOSA-N",
                "generic_name": "Berubicin",
                "designated_date": "06/09/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CNS Pharmaceuticals, Inc.|2100 West Loop South|Suite 900|Houston|Texas|77027|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls_id": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            }
        ]
    },
    {
        "_id": "WELIVEBWRWAGOM-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 69532,
                "inchl_key": "WELIVEBWRWAGOM-UHFFFAOYSA-N",
                "generic_name": "Beta alethine",
                "designated_date": "03/24/1997",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Dovetail Technologies, Inc.|Bldg. 337, Paint Branch Drive|College Park|Maryland|20742|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma.",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            },
            {
                "compound_id": 69532,
                "inchl_key": "WELIVEBWRWAGOM-UHFFFAOYSA-N",
                "generic_name": "Beta alethine",
                "designated_date": "03/24/1997",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Dovetail Technologies, Inc.|Bldg. 337, Paint Branch Drive|College Park|Maryland|20742|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic melanoma.",
                    "umls_id": "C0278883",
                    "parsed_text": "Metastatic melanoma"
                }
            }
        ]
    },
    {
        "_id": "XVDFMHARQUBJRE-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 68643,
                "inchl_key": "XVDFMHARQUBJRE-UHFFFAOYSA-N",
                "generic_name": "Betahistine dihydrochloride",
                "designated_date": "11/08/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Auris Medical Inc.|500 North Michigan Avenue|Suite 600|Chicago|Illinois|60611|United States",
                "orphan_designation": {
                    "original_text": "Treatment of obesity associated with Prader Willi syndrome",
                    "umls_id": "C0028754,C0032897",
                    "parsed_text": "Obesity , Prader Willi syndrome"
                }
            }
        ]
    },
    {
        "_id": "KWIUHFFTVRNATP-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 247,
                "inchl_key": "KWIUHFFTVRNATP-UHFFFAOYSA-N",
                "generic_name": "Betaine",
                "trade_name": "Cystadane",
                "designated_date": "05/16/1994",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of homocystinuria to decrease elevated homocysteine blood levels.",
                "marketing_approval_date": "\u00a010/25/1996\u00a0",
                "exclusivity_end_date": "\u00a010/25/2003\u00a0",
                "sponsor": "Orphan Europe SARL|70 Avenue du G\u9ba9ral de Gaulle|Puteaux|\u03ace-de-France|France",
                "orphan_designation": {
                    "original_text": "Treatment of homocystinuria.",
                    "umls_id": "C0019880",
                    "parsed_text": "Homocystinuria"
                }
            }
        ]
    },
    {
        "_id": "UREBDLICKHMUKA-DVTGEIKXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9782,
                "inchl_key": "UREBDLICKHMUKA-DVTGEIKXSA-N",
                "generic_name": "betamethasone",
                "designated_date": "10/07/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Grace Therapeutics, LLC|675 U.S. 1|North Brunswick Township|New Jersey|8902|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Ataxia Telangiectasia.",
                    "umls_id": "C0004135",
                    "parsed_text": "Ataxia Telangiectasia"
                }
            }
        ]
    },
    {
        "_id": "YTIJUXVIZLYQTB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16048622,
                "inchl_key": "YTIJUXVIZLYQTB-UHFFFAOYSA-N",
                "generic_name": "Bethanidine sulfate",
                "designated_date": "11/24/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medco Research, Inc.|8455 Beverly Blvd.|Suite 308|Los Angeles|California|90048|United States",
                "orphan_designation": {
                    "original_text": "Prevention of recurrence of primary ventricular fibrillation.",
                    "umls_id": "C0042510",
                    "parsed_text": "Ventricular Fibrillation"
                }
            },
            {
                "compound_id": 16048622,
                "inchl_key": "YTIJUXVIZLYQTB-UHFFFAOYSA-N",
                "generic_name": "Bethanidine sulfate",
                "designated_date": "11/24/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medco Research, Inc.|8455 Beverly Blvd.|Suite 308|Los Angeles|California|90048|United States",
                "orphan_designation": {
                    "original_text": "Prevention of recurrence of primary ventricular fibrillation.",
                    "umls_id": "C0042510",
                    "parsed_text": "Ventricular Fibrillation"
                }
            },
            {
                "compound_id": 16048622,
                "inchl_key": "YTIJUXVIZLYQTB-UHFFFAOYSA-N",
                "generic_name": "Bethanidine sulfate",
                "designated_date": "11/24/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medco Research, Inc.|8455 Beverly Blvd.|Suite 308|Los Angeles|California|90048|United States",
                "orphan_designation": {
                    "original_text": "Prevention of recurrence of primary ventricular fibrillation.",
                    "umls_id": "C0042510",
                    "parsed_text": "Ventricular Fibrillation"
                }
            },
            {
                "compound_id": 16048622,
                "inchl_key": "YTIJUXVIZLYQTB-UHFFFAOYSA-N",
                "generic_name": "Bethanidine sulfate",
                "designated_date": "09/20/1988",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medco Research, Inc.|8455 Beverly Blvd.|Suite 308|Los Angeles|California|90048|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary ventricular fibrillation.",
                    "umls_id": "C0042510",
                    "parsed_text": "Ventricular Fibrillation"
                }
            },
            {
                "compound_id": 16048622,
                "inchl_key": "YTIJUXVIZLYQTB-UHFFFAOYSA-N",
                "generic_name": "Bethanidine sulfate",
                "designated_date": "09/20/1988",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medco Research, Inc.|8455 Beverly Blvd.|Suite 308|Los Angeles|California|90048|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary ventricular fibrillation.",
                    "umls_id": "C0042510",
                    "parsed_text": "Ventricular Fibrillation"
                }
            },
            {
                "compound_id": 16048622,
                "inchl_key": "YTIJUXVIZLYQTB-UHFFFAOYSA-N",
                "generic_name": "Bethanidine sulfate",
                "designated_date": "09/20/1988",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medco Research, Inc.|8455 Beverly Blvd.|Suite 308|Los Angeles|California|90048|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary ventricular fibrillation.",
                    "umls_id": "C0042510",
                    "parsed_text": "Ventricular Fibrillation"
                }
            }
        ]
    },
    {
        "_id": "WDLCALUKNKNIDF-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 23615599,
                "inchl_key": "WDLCALUKNKNIDF-UHFFFAOYSA-N",
                "generic_name": "Bethanidine sulfate",
                "designated_date": "11/24/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medco Research, Inc.|8455 Beverly Blvd.|Suite 308|Los Angeles|California|90048|United States",
                "orphan_designation": {
                    "original_text": "Prevention of recurrence of primary ventricular fibrillation.",
                    "umls_id": "C0042510",
                    "parsed_text": "Ventricular Fibrillation"
                }
            },
            {
                "compound_id": 23615599,
                "inchl_key": "WDLCALUKNKNIDF-UHFFFAOYSA-N",
                "generic_name": "Bethanidine sulfate",
                "designated_date": "09/20/1988",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medco Research, Inc.|8455 Beverly Blvd.|Suite 308|Los Angeles|California|90048|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary ventricular fibrillation.",
                    "umls_id": "C0042510",
                    "parsed_text": "Ventricular Fibrillation"
                }
            }
        ]
    },
    {
        "_id": "NIVZHWNOUVJHKV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2368,
                "inchl_key": "NIVZHWNOUVJHKV-UHFFFAOYSA-N",
                "generic_name": "Bethanidine sulfate",
                "designated_date": "11/24/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medco Research, Inc.|8455 Beverly Blvd.|Suite 308|Los Angeles|California|90048|United States",
                "orphan_designation": {
                    "original_text": "Prevention of recurrence of primary ventricular fibrillation.",
                    "umls_id": "C0042510",
                    "parsed_text": "Ventricular Fibrillation"
                }
            },
            {
                "compound_id": 2368,
                "inchl_key": "NIVZHWNOUVJHKV-UHFFFAOYSA-N",
                "generic_name": "Bethanidine sulfate",
                "designated_date": "09/20/1988",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medco Research, Inc.|8455 Beverly Blvd.|Suite 308|Los Angeles|California|90048|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary ventricular fibrillation.",
                    "umls_id": "C0042510",
                    "parsed_text": "Ventricular Fibrillation"
                }
            }
        ]
    },
    {
        "_id": "QGJZLNKBHJESQX-FZFNOLFKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 64971,
                "inchl_key": "QGJZLNKBHJESQX-FZFNOLFKSA-N",
                "generic_name": "Betulinic acid",
                "designated_date": "08/09/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Advanced Life Sciences, Inc. (ALS)|1440 Davey Road|Woodridge|Illinois|60517|United States",
                "orphan_designation": {
                    "original_text": "Topical treatment of metastatic melanoma",
                    "umls_id": "C0278883",
                    "parsed_text": "Metastatic melanoma"
                }
            }
        ]
    },
    {
        "_id": "NAVMQTYZDKMPEU-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 82146,
                "inchl_key": "NAVMQTYZDKMPEU-UHFFFAOYSA-N",
                "generic_name": "Bexarotene",
                "trade_name": "Targretin",
                "designated_date": "06/18/1999",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.",
                "marketing_approval_date": "\u00a012/29/1999\u00a0",
                "exclusivity_end_date": "\u00a012/29/2006\u00a0",
                "sponsor": "Eisai, Inc.|300 Tice Blvd|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cutaneous T-cell lymphoma.",
                    "umls_id": "C0079773",
                    "parsed_text": "cutaneous T-cell lymphoma"
                }
            }
        ]
    },
    {
        "_id": "IIBYAHWJQTYFKB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 39042,
                "inchl_key": "IIBYAHWJQTYFKB-UHFFFAOYSA-N",
                "generic_name": "bezafibrate",
                "designated_date": "07/24/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Barth Sydrome Foundation, Inc.|P. O. Box 618|Larchmont|New York|10538|United States",
                "orphan_designation": {
                    "original_text": "For therapeutic treatment of Barth syndrome",
                    "umls_id": "C0574083",
                    "parsed_text": "Barth Syndrome"
                }
            }
        ]
    },
    {
        "_id": "MTHORRSSURHQPZ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71354,
                "inchl_key": "MTHORRSSURHQPZ-UHFFFAOYSA-N",
                "generic_name": "Bindarit",
                "designated_date": "02/03/1998",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Angelini Pharmaceuticals, Inc.|70 Grand Avenue|Suite 109|River Edge|New Jersey|7661|United States",
                "orphan_designation": {
                    "original_text": "Treatment of lupus nephritis.",
                    "umls_id": "C0024143",
                    "parsed_text": "Lupus Nephritis"
                }
            }
        ]
    },
    {
        "_id": "ACWZRVQXLIRSDF-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10288191,
                "inchl_key": "ACWZRVQXLIRSDF-UHFFFAOYSA-N",
                "generic_name": "binimetinib",
                "designated_date": "07/31/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Array Biopharma, Inc.|3200 Walnut Street|Boulder|Colorado|80301|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "compound_id": 10288191,
                "inchl_key": "ACWZRVQXLIRSDF-UHFFFAOYSA-N",
                "generic_name": "binimetinib",
                "designated_date": "11/19/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Array BioPharma, Inc.|125 Cambridge Park Drive|Suite 301|Cambridge|Massachusetts|2140|United States",
                "orphan_designation": {
                    "original_text": "Treatment Stage IIB-IV melanoma.",
                    "umls_id": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "YBJHBAHKTGYVGT-ZKWXMUAHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 171548,
                "inchl_key": "YBJHBAHKTGYVGT-ZKWXMUAHSA-N",
                "generic_name": "Biotin",
                "designated_date": "09/08/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MedDay Pharmaceuticals|6880 Commerce Blvd.|Canton|Michigan|48187|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Charcot-Marie-Tooth disease",
                    "umls_id": "C0007959",
                    "parsed_text": "Charcot-Marie-Tooth Disease"
                }
            }
        ]
    },
    {
        "_id": "SCTZUZTYRMOMKT-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 216327,
                "inchl_key": "SCTZUZTYRMOMKT-UHFFFAOYSA-N",
                "generic_name": "Bis(4-fluorophenyl)phenylacetamide",
                "designated_date": "03/02/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ICAgen Inc.|Ion Channel Advances|PO Box 14487|Durham|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sickle cell disease.",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            }
        ]
    },
    {
        "_id": "FSWNJZRQQVVVJT-UHFFFAOYSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 18442052,
                "inchl_key": "FSWNJZRQQVVVJT-UHFFFAOYSA-L",
                "generic_name": "bis-choline tetrathiomolybdate",
                "designated_date": "06/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Alexion Pharmaceutical Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Amyotrophic Lateral Sclerosis (ALS)",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            },
            {
                "compound_id": 18442052,
                "inchl_key": "FSWNJZRQQVVVJT-UHFFFAOYSA-L",
                "generic_name": "bis-choline tetrathiomolybdate",
                "designated_date": "04/06/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary biliary cholangitis",
                    "umls_id": "C0008312",
                    "parsed_text": "Primary Biliary Cholangitis"
                }
            }
        ]
    },
    {
        "_id": "KINULKKPVJYRON-PVNXHVEDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6917792,
                "inchl_key": "KINULKKPVJYRON-PVNXHVEDSA-N",
                "generic_name": "bisantrene HCl",
                "designated_date": "02/14/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Race Oncology, Ltd|50 Kings Park Road|Level 2|West Perth|WA|Australia",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "YUUGYIUSCYNSQR-LBPRGKRZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24946690,
                "inchl_key": "YUUGYIUSCYNSQR-LBPRGKRZSA-N",
                "generic_name": "bitopertin",
                "designated_date": "08/16/2017",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoffmann-La Roche Inc.|c/o Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of \u07edthalassemia",
                    "umls_id": "C0039730",
                    "parsed_text": "thalassemia"
                }
            }
        ]
    },
    {
        "_id": "OIRCOABEOLEUMC-GEJPAHFPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16129704,
                "inchl_key": "OIRCOABEOLEUMC-GEJPAHFPSA-N",
                "generic_name": "bivalirudin",
                "designated_date": "11/02/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "The Medicines Company|8 Sylvan Way|Parsippany|New Jersey|7054|United States",
                "orphan_designation": {
                    "original_text": "For use as an anticoagulant in patients with or at risk of heparin-induced thrombocytopenia/heparin-induced thrombocytopenia thrombosis syndrome",
                    "umls_id": "C0040034,C0272285,C0302148",
                    "parsed_text": "Thrombocytopenia , Heparin-induced thrombocytopenia , Thrombosis"
                }
            }
        ]
    },
    {
        "_id": "OYVAGSVQBOHSSS-QRQYLRPSSA-O",
        "Orphan Drug Designations": [
            {
                "compound_id": 456190,
                "inchl_key": "OYVAGSVQBOHSSS-QRQYLRPSSA-O",
                "generic_name": "Bleomycin",
                "designated_date": "12/20/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CIRJ Company Ltd.|1800 Loma Vista St.|Pasadena|California|91004|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer.",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 456190,
                "inchl_key": "OYVAGSVQBOHSSS-QRQYLRPSSA-O",
                "generic_name": "Bleomycin",
                "designated_date": "02/09/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genetronics, Inc.|11199 Sorrento Valley Rd.|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer.",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "OYVAGSVQBOHSSS-UHFFFAOYSA-O",
        "Orphan Drug Designations": [
            {
                "compound_id": 84068,
                "inchl_key": "OYVAGSVQBOHSSS-UHFFFAOYSA-O",
                "generic_name": "Bleomycin",
                "designated_date": "12/20/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CIRJ Company Ltd.|1800 Loma Vista St.|Pasadena|California|91004|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer.",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 84068,
                "inchl_key": "OYVAGSVQBOHSSS-UHFFFAOYSA-O",
                "generic_name": "Bleomycin",
                "designated_date": "02/09/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genetronics, Inc.|11199 Sorrento Valley Rd.|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer.",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 84068,
                "inchl_key": "OYVAGSVQBOHSSS-UHFFFAOYSA-O",
                "generic_name": "Bleomycin sulfate",
                "trade_name": "Blenoxane",
                "designated_date": "09/17/1993",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of malignant pleural effusion.",
                "marketing_approval_date": "\u00a002/20/1996\u00a0",
                "exclusivity_end_date": "\u00a002/20/2003\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|P.O. Box 4000|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant pleural effusion.",
                    "umls_id": "C0080032",
                    "parsed_text": "malignant pleural effusion"
                }
            }
        ]
    },
    {
        "_id": "OYVAGSVQBOHSSS-UAPAGMARSA-O",
        "Orphan Drug Designations": [
            {
                "compound_id": 5460769,
                "inchl_key": "OYVAGSVQBOHSSS-UAPAGMARSA-O",
                "generic_name": "Bleomycin",
                "designated_date": "12/20/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CIRJ Company Ltd.|1800 Loma Vista St.|Pasadena|California|91004|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer.",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 5460769,
                "inchl_key": "OYVAGSVQBOHSSS-UAPAGMARSA-O",
                "generic_name": "Bleomycin",
                "designated_date": "02/09/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genetronics, Inc.|11199 Sorrento Valley Rd.|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer.",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "OYVAGSVQBOHSSS-WXFSZRTFSA-O",
        "Orphan Drug Designations": [
            {
                "compound_id": 5360373,
                "inchl_key": "OYVAGSVQBOHSSS-WXFSZRTFSA-O",
                "generic_name": "Bleomycin",
                "designated_date": "12/20/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CIRJ Company Ltd.|1800 Loma Vista St.|Pasadena|California|91004|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer.",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 5360373,
                "inchl_key": "OYVAGSVQBOHSSS-WXFSZRTFSA-O",
                "generic_name": "Bleomycin",
                "designated_date": "02/09/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genetronics, Inc.|11199 Sorrento Valley Rd.|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer.",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 5360373,
                "inchl_key": "OYVAGSVQBOHSSS-WXFSZRTFSA-O",
                "generic_name": "Bleomycin sulfate",
                "trade_name": "Blenoxane",
                "designated_date": "09/17/1993",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of malignant pleural effusion.",
                "marketing_approval_date": "\u00a002/20/1996\u00a0",
                "exclusivity_end_date": "\u00a002/20/2003\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|P.O. Box 4000|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant pleural effusion.",
                    "umls_id": "C0080032",
                    "parsed_text": "malignant pleural effusion"
                }
            }
        ]
    },
    {
        "_id": "OYVAGSVQBOHSSS-ITQDJCQPSA-O",
        "Orphan Drug Designations": [
            {
                "compound_id": 122172957,
                "inchl_key": "OYVAGSVQBOHSSS-ITQDJCQPSA-O",
                "generic_name": "Bleomycin sulfate",
                "trade_name": "Blenoxane",
                "designated_date": "09/17/1993",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of malignant pleural effusion.",
                "marketing_approval_date": "\u00a002/20/1996\u00a0",
                "exclusivity_end_date": "\u00a002/20/2003\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|P.O. Box 4000|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant pleural effusion.",
                    "umls_id": "C0080032",
                    "parsed_text": "malignant pleural effusion"
                }
            }
        ]
    },
    {
        "_id": "WUIABRMSWOKTOF-OYALTWQYSA-O",
        "Orphan Drug Designations": [
            {
                "compound_id": 71587153,
                "inchl_key": "WUIABRMSWOKTOF-OYALTWQYSA-O",
                "generic_name": "Bleomycin sulfate",
                "trade_name": "Blenoxane",
                "designated_date": "09/17/1993",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of malignant pleural effusion.",
                "marketing_approval_date": "\u00a002/20/1996\u00a0",
                "exclusivity_end_date": "\u00a002/20/2003\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|P.O. Box 4000|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant pleural effusion.",
                    "umls_id": "C0080032",
                    "parsed_text": "malignant pleural effusion"
                }
            }
        ]
    },
    {
        "_id": "WUIABRMSWOKTOF-FOBMNYSPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 57336513,
                "inchl_key": "WUIABRMSWOKTOF-FOBMNYSPSA-N",
                "generic_name": "Bleomycin sulfate",
                "trade_name": "Blenoxane",
                "designated_date": "09/17/1993",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of malignant pleural effusion.",
                "marketing_approval_date": "\u00a002/20/1996\u00a0",
                "exclusivity_end_date": "\u00a002/20/2003\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|P.O. Box 4000|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant pleural effusion.",
                    "umls_id": "C0080032",
                    "parsed_text": "malignant pleural effusion"
                }
            }
        ]
    },
    {
        "_id": "WUIABRMSWOKTOF-NUAMMRKQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 54608728,
                "inchl_key": "WUIABRMSWOKTOF-NUAMMRKQSA-N",
                "generic_name": "Bleomycin sulfate",
                "trade_name": "Blenoxane",
                "designated_date": "09/17/1993",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of malignant pleural effusion.",
                "marketing_approval_date": "\u00a002/20/1996\u00a0",
                "exclusivity_end_date": "\u00a002/20/2003\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|P.O. Box 4000|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant pleural effusion.",
                    "umls_id": "C0080032",
                    "parsed_text": "malignant pleural effusion"
                }
            }
        ]
    },
    {
        "_id": "OYVAGSVQBOHSSS-NHOVFDEISA-O",
        "Orphan Drug Designations": [
            {
                "compound_id": 46930982,
                "inchl_key": "OYVAGSVQBOHSSS-NHOVFDEISA-O",
                "generic_name": "Bleomycin sulfate",
                "trade_name": "Blenoxane",
                "designated_date": "09/17/1993",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of malignant pleural effusion.",
                "marketing_approval_date": "\u00a002/20/1996\u00a0",
                "exclusivity_end_date": "\u00a002/20/2003\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|P.O. Box 4000|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant pleural effusion.",
                    "umls_id": "C0080032",
                    "parsed_text": "malignant pleural effusion"
                }
            }
        ]
    },
    {
        "_id": "WUIABRMSWOKTOF-PATWWPTKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 46930981,
                "inchl_key": "WUIABRMSWOKTOF-PATWWPTKSA-N",
                "generic_name": "Bleomycin sulfate",
                "trade_name": "Blenoxane",
                "designated_date": "09/17/1993",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of malignant pleural effusion.",
                "marketing_approval_date": "\u00a002/20/1996\u00a0",
                "exclusivity_end_date": "\u00a002/20/2003\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|P.O. Box 4000|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant pleural effusion.",
                    "umls_id": "C0080032",
                    "parsed_text": "malignant pleural effusion"
                }
            }
        ]
    },
    {
        "_id": "WUIABRMSWOKTOF-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 21864427,
                "inchl_key": "WUIABRMSWOKTOF-UHFFFAOYSA-N",
                "generic_name": "Bleomycin sulfate",
                "trade_name": "Blenoxane",
                "designated_date": "09/17/1993",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of malignant pleural effusion.",
                "marketing_approval_date": "\u00a002/20/1996\u00a0",
                "exclusivity_end_date": "\u00a002/20/2003\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|P.O. Box 4000|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant pleural effusion.",
                    "umls_id": "C0080032",
                    "parsed_text": "malignant pleural effusion"
                }
            }
        ]
    },
    {
        "_id": "WUIABRMSWOKTOF-OCBSMOPSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 72466,
                "inchl_key": "WUIABRMSWOKTOF-OCBSMOPSSA-N",
                "generic_name": "Bleomycin sulfate",
                "trade_name": "Blenoxane",
                "designated_date": "09/17/1993",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of malignant pleural effusion.",
                "marketing_approval_date": "\u00a002/20/1996\u00a0",
                "exclusivity_end_date": "\u00a002/20/2003\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|P.O. Box 4000|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant pleural effusion.",
                    "umls_id": "C0080032",
                    "parsed_text": "malignant pleural effusion"
                }
            }
        ]
    },
    {
        "_id": "GXJABQQUPOEUTA-RDJZCZTQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 387447,
                "inchl_key": "GXJABQQUPOEUTA-RDJZCZTQSA-N",
                "generic_name": "bortezomib",
                "designated_date": "07/05/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "BioXcel Corporation|780 East Main Street|Suite 2|Branford|Connecticut|6405|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neurofibromatosis type 2 (NF2)",
                    "umls_id": "C0027832",
                    "parsed_text": "Neurofibromatosis Type 2"
                }
            },
            {
                "compound_id": 387447,
                "inchl_key": "GXJABQQUPOEUTA-RDJZCZTQSA-N",
                "generic_name": "bortezomib",
                "trade_name": "Velcade",
                "designated_date": "01/15/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of multiple myeloma patients who have received at least one prior therapy",
                "marketing_approval_date": "\u00a003/25/2005\u00a0",
                "exclusivity_end_date": "\u00a003/25/2012\u00a0",
                "sponsor": "Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            },
            {
                "compound_id": 387447,
                "inchl_key": "GXJABQQUPOEUTA-RDJZCZTQSA-N",
                "generic_name": "bortezomib",
                "trade_name": "Velcade",
                "designated_date": "01/15/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy",
                "marketing_approval_date": "\u00a005/13/2003\u00a0",
                "exclusivity_end_date": "\u00a005/13/2010\u00a0",
                "sponsor": "Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            },
            {
                "compound_id": 387447,
                "inchl_key": "GXJABQQUPOEUTA-RDJZCZTQSA-N",
                "generic_name": "bortezomib",
                "designated_date": "01/04/2011",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of follicular non-Hodgkin lymphoma",
                    "umls_id": "C0024301",
                    "parsed_text": "follicular non-Hodgkin lymphoma"
                }
            },
            {
                "compound_id": 387447,
                "inchl_key": "GXJABQQUPOEUTA-RDJZCZTQSA-N",
                "generic_name": "bortezomib",
                "designated_date": "02/03/2015",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute lymphoblastic leukemia",
                    "umls_id": "C0023449",
                    "parsed_text": "Acute lymphoblastic leukemia"
                }
            },
            {
                "compound_id": 387447,
                "inchl_key": "GXJABQQUPOEUTA-RDJZCZTQSA-N",
                "generic_name": "bortezomib",
                "trade_name": "Velcade",
                "designated_date": "01/15/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "First-line therapy of multiple myeloma.",
                "marketing_approval_date": "\u00a006/20/2008\u00a0",
                "exclusivity_end_date": "\u00a006/20/2015\u00a0",
                "sponsor": "Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            },
            {
                "compound_id": 387447,
                "inchl_key": "GXJABQQUPOEUTA-RDJZCZTQSA-N",
                "generic_name": "bortezomib",
                "trade_name": "Velcade",
                "designated_date": "05/30/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.",
                "marketing_approval_date": "\u00a012/08/2006\u00a0",
                "exclusivity_end_date": "\u00a012/08/2013\u00a0",
                "sponsor": "Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mantle cell lymphoma.",
                    "umls_id": "C4721414",
                    "parsed_text": "Mantle cell lymphoma"
                }
            },
            {
                "compound_id": 387447,
                "inchl_key": "GXJABQQUPOEUTA-RDJZCZTQSA-N",
                "generic_name": "bortezomib",
                "trade_name": "Velcade",
                "designated_date": "05/30/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with mantle cell lymphoma.",
                "marketing_approval_date": "\u00a010/08/2014\u00a0",
                "exclusivity_end_date": "\u00a010/08/2021\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with mantle cell lymphoma who have not received at least 1 prior therapy",
                "sponsor": "Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mantle cell lymphoma.",
                    "umls_id": "C4721414",
                    "parsed_text": "Mantle cell lymphoma"
                }
            }
        ]
    },
    {
        "_id": "UBPYILGKFZZVDX-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5328940,
                "inchl_key": "UBPYILGKFZZVDX-UHFFFAOYSA-N",
                "generic_name": "bosutinib",
                "trade_name": "Bosulif",
                "designated_date": "02/24/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "BOSULIF is indicated for the treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML).",
                "marketing_approval_date": "\u00a012/19/2017\u00a0",
                "exclusivity_end_date": "\u00a012/19/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).",
                "sponsor": "Pfizer Inc.|445 Eastern Point Road|Groton|Connecticut|6340|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic myelogenous leukemia",
                    "umls_id": "C0023473",
                    "parsed_text": "Chronic myelogenous leukemia"
                }
            },
            {
                "compound_id": 5328940,
                "inchl_key": "UBPYILGKFZZVDX-UHFFFAOYSA-N",
                "generic_name": "bosutinib",
                "trade_name": "Bosulif",
                "designated_date": "02/24/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy",
                "marketing_approval_date": "\u00a009/04/2012\u00a0",
                "exclusivity_end_date": "\u00a009/04/2019\u00a0",
                "sponsor": "Pfizer Inc.|445 Eastern Point Road|Groton|Connecticut|6340|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic myelogenous leukemia",
                    "umls_id": "C0023473",
                    "parsed_text": "Chronic myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "STWTUEAWRAIWJG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135565042,
                "inchl_key": "STWTUEAWRAIWJG-UHFFFAOYSA-N",
                "generic_name": "Branaplam",
                "designated_date": "10/19/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|07936-1080|United States",
                "orphan_designation": {
                    "original_text": "treatment of Huntingtons disease",
                    "umls_id": "C0020179",
                    "parsed_text": "huntingtons disease"
                }
            },
            {
                "compound_id": 135565042,
                "inchl_key": "STWTUEAWRAIWJG-UHFFFAOYSA-N",
                "generic_name": "branaplam",
                "designated_date": "01/23/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|1 Health Plaza|Office #310-2132B|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of spinal muscular atrophy (SMA)",
                    "umls_id": "C0026847",
                    "parsed_text": "Spinal Muscular Atrophy"
                }
            }
        ]
    },
    {
        "_id": "JPBOABGEVHVPNM-LPEULFRDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 15965874,
                "inchl_key": "JPBOABGEVHVPNM-LPEULFRDSA-N",
                "generic_name": "Brevenal",
                "designated_date": "04/02/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Silurian Pharmaceuticals, Inc.|6490 Doyle Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "JPBOABGEVHVPNM-ANYVIMDKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11490752,
                "inchl_key": "JPBOABGEVHVPNM-ANYVIMDKSA-N",
                "generic_name": "Brevenal",
                "designated_date": "04/02/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Silurian Pharmaceuticals, Inc.|6490 Doyle Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "JPBOABGEVHVPNM-KGIMXCGWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11227586,
                "inchl_key": "JPBOABGEVHVPNM-KGIMXCGWSA-N",
                "generic_name": "Brevenal",
                "designated_date": "04/02/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Silurian Pharmaceuticals, Inc.|6490 Doyle Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "JPBOABGEVHVPNM-GFIBHCGLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 46886836,
                "inchl_key": "JPBOABGEVHVPNM-GFIBHCGLSA-N",
                "generic_name": "Brevenal",
                "designated_date": "04/02/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Silurian Pharmaceuticals, Inc.|6490 Doyle Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "AILRADAXUVEEIR-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 68165256,
                "inchl_key": "AILRADAXUVEEIR-UHFFFAOYSA-N",
                "generic_name": "brigatinib",
                "trade_name": "Alunbrig",
                "designated_date": "04/28/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "ALUNBRIG (brigatinib) is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.",
                "marketing_approval_date": "\u00a005/22/2020\u00a0",
                "exclusivity_end_date": "\u00a005/22/2027\u00a0",
                "exclusivity_protected_indication": "For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test, not including patients who have progressed on or are intolerant to crizotinib.",
                "sponsor": "ARIAD Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of anaplastic lymphoma kinase-positive (ALK+), c-ros 1 oncogene positive (ROS1+), or epidermal growth factor receptor positive (EGFR+) non-small cell lung cancer (NSCLC).",
                    "umls_id": "C0007131,C3539721",
                    "parsed_text": "Non-Small Cell Lung Cancer , Non-Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 68165256,
                "inchl_key": "AILRADAXUVEEIR-UHFFFAOYSA-N",
                "generic_name": "brigatinib",
                "trade_name": "Alunbrig",
                "designated_date": "04/28/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib",
                "marketing_approval_date": "\u00a004/28/2017\u00a0",
                "exclusivity_end_date": "\u00a004/28/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib",
                "sponsor": "ARIAD Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of anaplastic lymphoma kinase-positive (ALK+), c-ros 1 oncogene positive (ROS1+), or epidermal growth factor receptor positive (EGFR+) non-small cell lung cancer (NSCLC).",
                    "umls_id": "C0007131,C3539721",
                    "parsed_text": "Non-Small Cell Lung Cancer , Non-Small Cell Lung Cancer"
                }
            }
        ]
    },
    {
        "_id": "XYLJNLCSTIOKRM-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2435,
                "inchl_key": "XYLJNLCSTIOKRM-UHFFFAOYSA-N",
                "generic_name": "brimonidine",
                "designated_date": "08/03/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ocugen, Inc.|5 Great Valley Parkway|Suite 160|Malvern|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ocular graft versus host disease",
                    "umls_id": "C5203917",
                    "parsed_text": "Ocular Graft Versus Host Disease"
                }
            },
            {
                "compound_id": 2435,
                "inchl_key": "XYLJNLCSTIOKRM-UHFFFAOYSA-N",
                "generic_name": "Brimonidine",
                "designated_date": "02/07/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Allergan, Inc.|2525 Dupont Dr.|Irvine|California|92612|United States",
                "orphan_designation": {
                    "original_text": "Treatment of anterior ischemic optic neuropathy.",
                    "umls_id": "C0751711",
                    "parsed_text": "Anterior Ischemic Optic Neuropathy"
                }
            }
        ]
    },
    {
        "_id": "WXJFKKQWPMNTIM-VWLOTQADSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 483477,
                "inchl_key": "WXJFKKQWPMNTIM-VWLOTQADSA-N",
                "generic_name": "brincidofovir",
                "designated_date": "06/05/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Chimerix, Inc.|2505 Meridian Parkway|Suite 100|Durham|North Carolina|27713|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Smallpox",
                    "umls_id": "C0037356",
                    "parsed_text": "smallpox"
                }
            }
        ]
    },
    {
        "_id": "LTEJRLHKIYCEOX-OCCSQVGLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11154925,
                "inchl_key": "LTEJRLHKIYCEOX-OCCSQVGLSA-N",
                "generic_name": "brivanib alaninate",
                "designated_date": "03/18/2011",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb|P. O. Box 4000|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            }
        ]
    },
    {
        "_id": "MSYKRHVOOPPJKU-BDAKNGLRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9837243,
                "inchl_key": "MSYKRHVOOPPJKU-BDAKNGLRSA-N",
                "generic_name": "brivaracetam",
                "designated_date": "10/05/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "UCB Pharma, Inc.|1950 Lake Park Drive|Smyra|Georgia|30080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of symptomatic myoclonus",
                    "umls_id": "C0393619",
                    "parsed_text": "Symptomatic myoclonus"
                }
            },
            {
                "compound_id": 9837243,
                "inchl_key": "MSYKRHVOOPPJKU-BDAKNGLRSA-N",
                "generic_name": "brivaracetam",
                "designated_date": "12/03/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "UCB, Inc.|1950 Lake Park Drive|Building 2100|Smyrna|Georgia|30080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Juvenile Absence Epilepsy",
                    "umls_id": "C4317339",
                    "parsed_text": "Juvenile Absence Epilepsy"
                }
            },
            {
                "compound_id": 9837243,
                "inchl_key": "MSYKRHVOOPPJKU-BDAKNGLRSA-N",
                "generic_name": "brivaracetam",
                "designated_date": "12/03/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "UCB, Inc.|1950 Lake Park Drive|Building 2100|Smyrna|Georgia|30080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Childhood Absence Epilepsy",
                    "umls_id": "C0014553",
                    "parsed_text": "childhood absence epilepsy"
                }
            }
        ]
    },
    {
        "_id": "ODZBBRURCPAEIQ-PIXDULNESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 446727,
                "inchl_key": "ODZBBRURCPAEIQ-PIXDULNESA-N",
                "generic_name": "Brivudin",
                "designated_date": "11/15/2007",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SciClone Pharmaceuticals, Inc.|901 Mariner's Island Blvd.|San Mateo|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Adjunct treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "OJGDCBLYJGHCIH-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2442,
                "inchl_key": "OJGDCBLYJGHCIH-UHFFFAOYSA-N",
                "generic_name": "Bromhexine",
                "designated_date": "05/15/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Boehringer Ingelheim Pharmaceuticals, Inc.|900 Ridgebury Road, Box 368|Ridgefield|Connecticut|6877|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mild to moderate keratoconjunctivitis sicca in patients with Sjogren's syndrome.",
                    "umls_id": "C0022575,C1527336",
                    "parsed_text": "Keratoconjunctivitis Sicca , Sjogren Syndrome"
                }
            }
        ]
    },
    {
        "_id": "WOVKYSAHUYNSMH-RRKCRQDMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6035,
                "inchl_key": "WOVKYSAHUYNSMH-RRKCRQDMSA-N",
                "generic_name": "Broxuridine",
                "designated_date": "09/18/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NeoPharm, Inc.|225 East Deerpath, Suite 250|Lake Forest|Illinois|60045|United States",
                "orphan_designation": {
                    "original_text": "Radiation sensitizer in the treatment of primary brain tumors.",
                    "umls_id": "C0750974",
                    "parsed_text": "primary brain tumors"
                }
            }
        ]
    },
    {
        "_id": "MJQUEDHRCUIRLF-DDYLLZMUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134817197,
                "inchl_key": "MJQUEDHRCUIRLF-DDYLLZMUSA-N",
                "generic_name": "bryostatin 1",
                "designated_date": "03/31/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neurotrope BioScience, Inc.|50 Park Place|Suite 1401|Newark|New Jersey|7102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X Syndrome.",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "MJQUEDHRCUIRLF-IBMAKELESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 133635911,
                "inchl_key": "MJQUEDHRCUIRLF-IBMAKELESA-N",
                "generic_name": "bryostatin 1",
                "designated_date": "03/31/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neurotrope BioScience, Inc.|50 Park Place|Suite 1401|Newark|New Jersey|7102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X Syndrome.",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "MJQUEDHRCUIRLF-JGGKDZLHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 124918436,
                "inchl_key": "MJQUEDHRCUIRLF-JGGKDZLHSA-N",
                "generic_name": "bryostatin 1",
                "designated_date": "03/31/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neurotrope BioScience, Inc.|50 Park Place|Suite 1401|Newark|New Jersey|7102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X Syndrome.",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "MJQUEDHRCUIRLF-PXXLITNBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 122173102,
                "inchl_key": "MJQUEDHRCUIRLF-PXXLITNBSA-N",
                "generic_name": "bryostatin 1",
                "designated_date": "03/31/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neurotrope BioScience, Inc.|50 Park Place|Suite 1401|Newark|New Jersey|7102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X Syndrome.",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "MJQUEDHRCUIRLF-ZVHDYJKJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 14078847,
                "inchl_key": "MJQUEDHRCUIRLF-ZVHDYJKJSA-N",
                "generic_name": "bryostatin 1",
                "designated_date": "03/31/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neurotrope BioScience, Inc.|50 Park Place|Suite 1401|Newark|New Jersey|7102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X Syndrome.",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            },
            {
                "compound_id": 14078847,
                "inchl_key": "MJQUEDHRCUIRLF-ZVHDYJKJSA-N",
                "generic_name": "bryostatin-1",
                "designated_date": "12/03/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "GPC Biotech, Inc.|610 Lincoln Street|Waltham|Massachusetts|2451|United States",
                "orphan_designation": {
                    "original_text": "For use in combination with paclitaxel in the treatment of esophageal cancer",
                    "umls_id": "C0014859",
                    "parsed_text": "esophageal cancer"
                }
            }
        ]
    },
    {
        "_id": "MJQUEDHRCUIRLF-JYXSRQLPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 146159872,
                "inchl_key": "MJQUEDHRCUIRLF-JYXSRQLPSA-N",
                "generic_name": "bryostatin 1",
                "designated_date": "03/31/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neurotrope BioScience, Inc.|50 Park Place|Suite 1401|Newark|New Jersey|7102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X Syndrome.",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "MJQUEDHRCUIRLF-MDGOTRLRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16760328,
                "inchl_key": "MJQUEDHRCUIRLF-MDGOTRLRSA-N",
                "generic_name": "bryostatin 1",
                "designated_date": "03/31/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neurotrope BioScience, Inc.|50 Park Place|Suite 1401|Newark|New Jersey|7102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X Syndrome.",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "MJQUEDHRCUIRLF-SGXMQRQHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6473739,
                "inchl_key": "MJQUEDHRCUIRLF-SGXMQRQHSA-N",
                "generic_name": "bryostatin 1",
                "designated_date": "03/31/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neurotrope BioScience, Inc.|50 Park Place|Suite 1401|Newark|New Jersey|7102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X Syndrome.",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            },
            {
                "compound_id": 6473739,
                "inchl_key": "MJQUEDHRCUIRLF-SGXMQRQHSA-N",
                "generic_name": "bryostatin-1",
                "designated_date": "12/03/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "GPC Biotech, Inc.|610 Lincoln Street|Waltham|Massachusetts|2451|United States",
                "orphan_designation": {
                    "original_text": "For use in combination with paclitaxel in the treatment of esophageal cancer",
                    "umls_id": "C0014859",
                    "parsed_text": "esophageal cancer"
                }
            }
        ]
    },
    {
        "_id": "MJQUEDHRCUIRLF-BXOMOELISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6435419,
                "inchl_key": "MJQUEDHRCUIRLF-BXOMOELISA-N",
                "generic_name": "bryostatin 1",
                "designated_date": "03/31/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neurotrope BioScience, Inc.|50 Park Place|Suite 1401|Newark|New Jersey|7102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X Syndrome.",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "MJQUEDHRCUIRLF-DECOFNLXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5884629,
                "inchl_key": "MJQUEDHRCUIRLF-DECOFNLXSA-N",
                "generic_name": "bryostatin 1",
                "designated_date": "03/31/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neurotrope BioScience, Inc.|50 Park Place|Suite 1401|Newark|New Jersey|7102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X Syndrome.",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "MJQUEDHRCUIRLF-KOWVOJLTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5477635,
                "inchl_key": "MJQUEDHRCUIRLF-KOWVOJLTSA-N",
                "generic_name": "bryostatin 1",
                "designated_date": "03/31/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neurotrope BioScience, Inc.|50 Park Place|Suite 1401|Newark|New Jersey|7102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X Syndrome.",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "MJQUEDHRCUIRLF-VUHCRTQMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5458769,
                "inchl_key": "MJQUEDHRCUIRLF-VUHCRTQMSA-N",
                "generic_name": "bryostatin 1",
                "designated_date": "03/31/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neurotrope BioScience, Inc.|50 Park Place|Suite 1401|Newark|New Jersey|7102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X Syndrome.",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "MJQUEDHRCUIRLF-YCVQJEHTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44277532,
                "inchl_key": "MJQUEDHRCUIRLF-YCVQJEHTSA-N",
                "generic_name": "bryostatin 1",
                "designated_date": "03/31/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neurotrope BioScience, Inc.|50 Park Place|Suite 1401|Newark|New Jersey|7102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X Syndrome.",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "MJQUEDHRCUIRLF-MEBWOBETSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 22524140,
                "inchl_key": "MJQUEDHRCUIRLF-MEBWOBETSA-N",
                "generic_name": "bryostatin 1",
                "designated_date": "03/31/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neurotrope BioScience, Inc.|50 Park Place|Suite 1401|Newark|New Jersey|7102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X Syndrome.",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "MJQUEDHRCUIRLF-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 433902,
                "inchl_key": "MJQUEDHRCUIRLF-UHFFFAOYSA-N",
                "generic_name": "bryostatin 1",
                "designated_date": "03/31/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neurotrope BioScience, Inc.|50 Park Place|Suite 1401|Newark|New Jersey|7102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X Syndrome.",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "MJQUEDHRCUIRLF-TVIXENOKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5280757,
                "inchl_key": "MJQUEDHRCUIRLF-TVIXENOKSA-N",
                "generic_name": "bryostatin 1",
                "designated_date": "03/31/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neurotrope BioScience, Inc.|50 Park Place|Suite 1401|Newark|New Jersey|7102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X Syndrome.",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            },
            {
                "compound_id": 5280757,
                "inchl_key": "MJQUEDHRCUIRLF-TVIXENOKSA-N",
                "generic_name": "bryostatin-1",
                "designated_date": "12/03/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "GPC Biotech, Inc.|610 Lincoln Street|Waltham|Massachusetts|2451|United States",
                "orphan_designation": {
                    "original_text": "For use in combination with paclitaxel in the treatment of esophageal cancer",
                    "umls_id": "C0014859",
                    "parsed_text": "esophageal cancer"
                }
            }
        ]
    },
    {
        "_id": "VUAFHZCUKUDDBC-BYPYZUCNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 656604,
                "inchl_key": "VUAFHZCUKUDDBC-BYPYZUCNSA-N",
                "generic_name": "bucillamine",
                "designated_date": "10/22/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Revive Therapeutics, Ltd.|5 Director Court|Suite 105|Vaughan|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of cystinuria",
                    "umls_id": "C0010691",
                    "parsed_text": "Cystinuria"
                }
            }
        ]
    },
    {
        "_id": "LEBVLXFERQHONN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2474,
                "inchl_key": "LEBVLXFERQHONN-UHFFFAOYSA-N",
                "generic_name": "bupivacaine",
                "designated_date": "06/18/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "DURECT Corporation|10260 Bubb Road|Cupertino|California|95014|United States",
                "orphan_designation": {
                    "original_text": "Relief of persistent pain associated with postherpetic neuralgia",
                    "umls_id": "C0030193,C0032768",
                    "parsed_text": "Pain , Postherpetic neuralgia"
                }
            }
        ]
    },
    {
        "_id": "SIEYLFHKZGLBNX-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 64737,
                "inchl_key": "SIEYLFHKZGLBNX-UHFFFAOYSA-N",
                "generic_name": "bupivacaine hydrochloride",
                "designated_date": "05/31/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Grace Therapeutics, LLC|675 U.S. 1|North Brunswick Township|New Jersey|8902|United States",
                "orphan_designation": {
                    "original_text": "treatment of pain associated with postherpetic neuralgia.",
                    "umls_id": "C0030193,C0032768",
                    "parsed_text": "Pain , Postherpetic neuralgia"
                }
            }
        ]
    },
    {
        "_id": "UAIXRPCCYXNJMQ-RZIPZOSSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 45265653,
                "inchl_key": "UAIXRPCCYXNJMQ-RZIPZOSSSA-N",
                "generic_name": "Buprenorphine hydrochloride",
                "designated_date": "06/15/1994",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Indivior, Inc.|10710 Midlothian Turnpike|Suite 125|North Chesterfield|Virginia|23235|United States",
                "orphan_designation": {
                    "original_text": "Treatment of opiate addiction in opiate users.",
                    "umls_id": "C0524662",
                    "parsed_text": "Opiate Addiction"
                }
            },
            {
                "compound_id": 45265653,
                "inchl_key": "UAIXRPCCYXNJMQ-RZIPZOSSSA-N",
                "generic_name": "Buprenorphine hydrochloride",
                "designated_date": "06/15/1994",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Indivior, Inc.|10710 Midlothian Turnpike|Suite 125|North Chesterfield|Virginia|23235|United States",
                "orphan_designation": {
                    "original_text": "Treatment of opiate addiction in opiate users.",
                    "umls_id": "C0524662",
                    "parsed_text": "Opiate Addiction"
                }
            },
            {
                "compound_id": 45265653,
                "inchl_key": "UAIXRPCCYXNJMQ-RZIPZOSSSA-N",
                "generic_name": "Buprenorphine hydrochloride",
                "designated_date": "06/15/1994",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Indivior, Inc.|10710 Midlothian Turnpike|Suite 125|North Chesterfield|Virginia|23235|United States",
                "orphan_designation": {
                    "original_text": "Treatment of opiate addiction in opiate users.",
                    "umls_id": "C0524662",
                    "parsed_text": "Opiate Addiction"
                }
            },
            {
                "compound_id": 45265653,
                "inchl_key": "UAIXRPCCYXNJMQ-RZIPZOSSSA-N",
                "generic_name": "Buprenorphine hydrochloride",
                "designated_date": "06/15/1994",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Indivior, Inc.|10710 Midlothian Turnpike|Suite 125|North Chesterfield|Virginia|23235|United States",
                "orphan_designation": {
                    "original_text": "Treatment of opiate addiction in opiate users.",
                    "umls_id": "C0524662",
                    "parsed_text": "Opiate Addiction"
                }
            }
        ]
    },
    {
        "_id": "COVZYZSDYWQREU-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2478,
                "inchl_key": "COVZYZSDYWQREU-UHFFFAOYSA-N",
                "generic_name": "Busulfan",
                "designated_date": "03/05/2001",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SuperGen, Inc.|4140 Dublin Boulevard|Dublin|California|94568|United States",
                "orphan_designation": {
                    "original_text": "Intrathecal therapy for neoplastic meningitis",
                    "umls_id": "C0220654",
                    "parsed_text": "neoplastic meningitis"
                }
            },
            {
                "compound_id": 2478,
                "inchl_key": "COVZYZSDYWQREU-UHFFFAOYSA-N",
                "generic_name": "Busulfan",
                "designated_date": "07/07/1997",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SuperGen, Inc.|4140 Dublin Blvd.|Suite 200|Dublin|California|94568|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary brain malignancies.",
                    "umls_id": "C0006826",
                    "parsed_text": "MALIGNANCIES"
                }
            },
            {
                "compound_id": 2478,
                "inchl_key": "COVZYZSDYWQREU-UHFFFAOYSA-N",
                "generic_name": "Busulfan",
                "designated_date": "04/21/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sparta Pharmaceuticals, Inc.|111 Rock Road|Horsham|Pennsylvania|19044|United States",
                "orphan_designation": {
                    "original_text": "For use as preparative therapy for malignancies treated with bone marrow transplantation.",
                    "umls_id": "C0006826",
                    "parsed_text": "MALIGNANCIES"
                }
            },
            {
                "compound_id": 2478,
                "inchl_key": "COVZYZSDYWQREU-UHFFFAOYSA-N",
                "generic_name": "Busulfan",
                "trade_name": "Busulfex",
                "designated_date": "07/28/1994",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia.",
                "marketing_approval_date": "\u00a002/04/1999\u00a0",
                "exclusivity_end_date": "\u00a002/04/2006\u00a0",
                "sponsor": "Otsuka Pharmaceutical Company, Ltd|2-9, Kanda-Tsukasamachi|Tokyo|Japan",
                "orphan_designation": {
                    "original_text": "As preparative therapy in the treatment of malignancies with bone marrow transplantation.",
                    "umls_id": "C0006826",
                    "parsed_text": "MALIGNANCIES"
                }
            }
        ]
    },
    {
        "_id": "KJQFBVYMGADDTQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 21157,
                "inchl_key": "KJQFBVYMGADDTQ-UHFFFAOYSA-N",
                "generic_name": "Buthionine sulfoxamine",
                "designated_date": "10/05/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "USC-CHLA Institute for Pediatric Clinical Research|Children's Hospital Los Angeles|MS 55|Los Angeles|California|90027|United States",
                "orphan_designation": {
                    "original_text": "For use in children as a modulator of chemotherapy for the treatment of pediatric patients with neuroblastoma",
                    "umls_id": "C0027819",
                    "parsed_text": "Neuroblastoma"
                }
            },
            {
                "compound_id": 21157,
                "inchl_key": "KJQFBVYMGADDTQ-UHFFFAOYSA-N",
                "generic_name": "Buthionine sulfoxamine",
                "designated_date": "10/05/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "USC-CHLA Institute for Pediatric Clinical Research|Children's Hospital Los Angeles|MS 55|Los Angeles|California|90027|United States",
                "orphan_designation": {
                    "original_text": "Use as a modulator of chemotherapy for the treatment of pediatric patients with primary malignant brain tumors",
                    "umls_id": "C0750979",
                    "parsed_text": "Primary Malignant Brain Tumors"
                }
            }
        ]
    },
    {
        "_id": "WMBOCUXXNSOQHM-DHZHZOJOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5352899,
                "inchl_key": "WMBOCUXXNSOQHM-DHZHZOJOSA-N",
                "generic_name": "butylidenephthalide",
                "designated_date": "08/05/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Everfront Biotech, Inc.|11F., No. 31, Ln. 169, Kangning St.|New Taipei City 221|Taiwan",
                "orphan_designation": {
                    "original_text": "Treatment of Malignant Glioma",
                    "umls_id": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            }
        ]
    },
    {
        "_id": "WMBOCUXXNSOQHM-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 62368,
                "inchl_key": "WMBOCUXXNSOQHM-UHFFFAOYSA-N",
                "generic_name": "butylidenephthalide",
                "designated_date": "08/05/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Everfront Biotech, Inc.|11F., No. 31, Ln. 169, Kangning St.|New Taipei City 221|Taiwan",
                "orphan_designation": {
                    "original_text": "Treatment of Malignant Glioma",
                    "umls_id": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            }
        ]
    },
    {
        "_id": "WMBOCUXXNSOQHM-FLIBITNWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 642376,
                "inchl_key": "WMBOCUXXNSOQHM-FLIBITNWSA-N",
                "generic_name": "butylidenephthalide",
                "designated_date": "08/05/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Everfront Biotech, Inc.|11F., No. 31, Ln. 169, Kangning St.|New Taipei City 221|Taiwan",
                "orphan_designation": {
                    "original_text": "Treatment of Malignant Glioma",
                    "umls_id": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            }
        ]
    },
    {
        "_id": "ONIQOQHATWINJY-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25102847,
                "inchl_key": "ONIQOQHATWINJY-UHFFFAOYSA-N",
                "generic_name": "cabozantinib",
                "trade_name": "Cometriq",
                "designated_date": "11/29/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of progressive, metastatic medullary thyroid cancer (MTC).",
                "marketing_approval_date": "\u00a011/29/2012\u00a0",
                "exclusivity_end_date": "\u00a011/29/2019\u00a0",
                "sponsor": "Exelixis, Inc.|1851 Harbor Bay Parkway|Alameda|California|94502|United States",
                "orphan_designation": {
                    "original_text": "Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer.",
                    "umls_id": "C0238461,C0238463",
                    "parsed_text": "Anaplastic thyroid carcinoma , papillary thyroid cancer"
                }
            },
            {
                "compound_id": 25102847,
                "inchl_key": "ONIQOQHATWINJY-UHFFFAOYSA-N",
                "generic_name": "cabozantinib",
                "trade_name": "CABOMETYX",
                "designated_date": "03/02/2017",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "CABOMETYX is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.",
                "marketing_approval_date": "\u00a001/14/2019\u00a0",
                "exclusivity_end_date": "\u00a001/14/2026\u00a0",
                "exclusivity_protected_indication": "CABOMETYX is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.",
                "sponsor": "Exelixis, Inc.|1851 Harbor Bay Parkway|Alameda|California|94502|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma.",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            }
        ]
    },
    {
        "_id": "XWFCFMXQTBGXQW-GOSISDBHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44242317,
                "inchl_key": "XWFCFMXQTBGXQW-GOSISDBHSA-N",
                "generic_name": "cadazolid",
                "designated_date": "08/08/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Actelion Pharmaceuticals Ltd|16 Gewerbestrasse|Allschwil|Basel-Landschaft|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of clostridium difficile infection in pediatric patients",
                    "umls_id": "C0343386",
                    "parsed_text": "Clostridium difficile infection"
                }
            }
        ]
    },
    {
        "_id": "RYYVLZVUVIJVGH-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2519,
                "inchl_key": "RYYVLZVUVIJVGH-UHFFFAOYSA-N",
                "generic_name": "Caffeine",
                "trade_name": "Cafcit",
                "designated_date": "09/20/1988",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Short term treatment of apnea of prematurity in infants between 28 and less than 33 weeks gestational age.",
                "marketing_approval_date": "\u00a009/21/1999\u00a0",
                "exclusivity_end_date": "\u00a009/21/2006\u00a0",
                "sponsor": "O.P.R. Development, L.P.|1501 Wakarusa Drive|Lawrence|Kansas|66047|United States",
                "orphan_designation": {
                    "original_text": "Treatment of apnea of prematurity.",
                    "umls_id": "C0475715",
                    "parsed_text": "Apnea of prematurity"
                }
            }
        ]
    },
    {
        "_id": "JWBPVFVNISJVEM-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 23669229,
                "inchl_key": "JWBPVFVNISJVEM-UHFFFAOYSA-M",
                "generic_name": "caffeine and sodium benzoate",
                "designated_date": "08/22/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Luitpold Pharmaceuticals, Inc.|One Luitpold Drive|P. O. Box 9001|Shirley|New York|11967|United States",
                "orphan_designation": {
                    "original_text": "Treatment of seizure prolongation in patients undergoing electroconvulsive therapy",
                    "umls_id": "C0036572",
                    "parsed_text": "Seizure"
                }
            }
        ]
    },
    {
        "_id": "IHRNYHWGJUMPFJ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44562555,
                "inchl_key": "IHRNYHWGJUMPFJ-UHFFFAOYSA-N",
                "generic_name": "Caflanone",
                "designated_date": "09/25/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Flavocure Biotech|701 East Pratt Street|Suite 2033|Baltimore|Maryland|21202|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pancreatic Cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "VSGNNIFQASZAOI-UHFFFAOYSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 6116,
                "inchl_key": "VSGNNIFQASZAOI-UHFFFAOYSA-L",
                "generic_name": "Calcium acetate",
                "trade_name": "Phos-Lo",
                "designated_date": "12/22/1988",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a012/10/1990\u00a0",
                "exclusivity_end_date": "\u00a012/10/1997\u00a0",
                "sponsor": "Fresenius Medical Care North America|920 Winter Street|Waltham|Massachusetts|2451|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hyperphosphatemia in end stage renal failure.",
                    "umls_id": "C0022661,C0085681",
                    "parsed_text": "End stage renal failure , Hyperphosphatemia"
                }
            },
            {
                "compound_id": 6116,
                "inchl_key": "VSGNNIFQASZAOI-UHFFFAOYSA-L",
                "generic_name": "Calcium acetate",
                "designated_date": "06/27/1989",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmedic Company|28101 Ballard Road, Suite F|Lake Forest|Illinois|60045|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hyperphosphatemia in end stage renal disease.",
                    "umls_id": "C0022661,C0085681",
                    "parsed_text": "End stage renal disease , Hyperphosphatemia"
                }
            }
        ]
    },
    {
        "_id": "VTYYLEPIZMXCLO-UHFFFAOYSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 10112,
                "inchl_key": "VTYYLEPIZMXCLO-UHFFFAOYSA-L",
                "generic_name": "Calcium carbonate",
                "designated_date": "06/06/1990",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "R & D Laboratories, Inc.|4204 Glencoe Avenue|Marina Del Rey|California|90292|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hyperphosphatemia in patients with end stage renal disease.",
                    "umls_id": "C0022661,C0085681",
                    "parsed_text": "End stage renal disease , Hyperphosphatemia"
                }
            }
        ]
    },
    {
        "_id": "XASIMHXSUQUHLV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2536,
                "inchl_key": "XASIMHXSUQUHLV-UHFFFAOYSA-N",
                "generic_name": "camostat",
                "designated_date": "05/18/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NIXS Corporation|Nichi-Iko Pharmaceutical Co., Ltd.|7th Floor - NOF Nihonbashi Honcho Bldg|Tokyo|Japan",
                "orphan_designation": {
                    "original_text": "Treatment of chronic pancreatitis",
                    "umls_id": "C0149521",
                    "parsed_text": "Chronic pancreatitis"
                }
            }
        ]
    },
    {
        "_id": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 644019,
                "inchl_key": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
                "generic_name": "cannabidiol",
                "trade_name": "EPIDIOLEX",
                "designated_date": "02/27/2014",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex (TSC) in patients 1 year of age and older.",
                "marketing_approval_date": "\u00a007/31/2020\u00a0",
                "exclusivity_end_date": "\u00a007/31/2027\u00a0",
                "exclusivity_protected_indication": "treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients between 1 and 2 years of age",
                "sponsor": "GW Research Ltd.|Sovereign House|Histon|Cambridge|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of Lennox-Gastaut syndrome",
                    "umls_id": "C0238111",
                    "parsed_text": "Lennox-Gastaut syndrome"
                }
            },
            {
                "compound_id": 644019,
                "inchl_key": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
                "generic_name": "cannabidiol",
                "designated_date": "11/29/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kalytera Therapeutics Israel, Ltd.|Technological Building|Road 4 Katzrin|Qatsrin|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Graft versus Host Disease",
                    "umls_id": "C0018133",
                    "parsed_text": "GRAFT VERSUS HOST DISEASE"
                }
            },
            {
                "compound_id": 644019,
                "inchl_key": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
                "generic_name": "cannabidiol",
                "designated_date": "11/05/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Revive Therapeutics Ltd.|5 Director Court|Suite 105|Vaughan|Canada",
                "orphan_designation": {
                    "original_text": "Prevention of ischemia/reperfusion Injury resulting from solid organ transplantation",
                    "umls_id": "C0022116,C0035126",
                    "parsed_text": "Ischemia , Reperfusion Injury"
                }
            },
            {
                "compound_id": 644019,
                "inchl_key": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
                "generic_name": "cannabidiol",
                "designated_date": "04/20/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Tetra Bio-Pharma Inc.|365 St.-Jean Street|Suite 122|Longueuil|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of Epidermolysis Bullosa",
                    "umls_id": "C0014527",
                    "parsed_text": "Epidermolysis Bullosa"
                }
            },
            {
                "compound_id": 644019,
                "inchl_key": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
                "generic_name": "cannabidiol",
                "designated_date": "04/28/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Diverse Biotech, Inc.|3805 Old Easton Road, Suite 111|Doylestown|Pennsylvania|18902|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioblastoma",
                    "umls_id": "C0017636",
                    "parsed_text": "Glioblastoma"
                }
            },
            {
                "compound_id": 644019,
                "inchl_key": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
                "generic_name": "cannabidiol",
                "designated_date": "09/24/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Benuvia Therapeutics Inc.|444 South Ellis Street|Chandler|Alaska|85224|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioma",
                    "umls_id": "C0017638",
                    "parsed_text": "Glioma"
                }
            },
            {
                "compound_id": 644019,
                "inchl_key": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
                "generic_name": "cannabidiol",
                "designated_date": "11/17/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Benuvia Therapeutics Inc.|444 South Ellis Street|Chandler|Alaska|85224|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric schizophrenia (pediatrics is defined as 0 through 16 years of age)",
                    "umls_id": "C0036341",
                    "parsed_text": "Schizophrenia"
                }
            },
            {
                "compound_id": 644019,
                "inchl_key": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
                "generic_name": "cannabidiol",
                "designated_date": "02/23/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Zynerba Pharmaceuticals, Inc.|80 West Lancaster Avenue|Suite 300|Devon|Pennsylvania|19333|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X syndrome",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            },
            {
                "compound_id": 644019,
                "inchl_key": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
                "generic_name": "cannabidiol",
                "trade_name": "Epidiolex",
                "designated_date": "02/27/2014",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2 years of age and older.",
                "marketing_approval_date": "\u00a009/28/2018\u00a0",
                "exclusivity_end_date": "\u00a009/28/2025\u00a0",
                "exclusivity_protected_indication": "EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.",
                "sponsor": "GW Research Ltd.|Sovereign House|Histon|Cambridge|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of Lennox-Gastaut syndrome",
                    "umls_id": "C0238111",
                    "parsed_text": "Lennox-Gastaut syndrome"
                }
            },
            {
                "compound_id": 644019,
                "inchl_key": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
                "generic_name": "cannabidiol",
                "trade_name": "Epidiolex",
                "designated_date": "11/14/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2 years of age and older.",
                "marketing_approval_date": "\u00a009/28/2018\u00a0",
                "exclusivity_end_date": "\u00a009/28/2025\u00a0",
                "exclusivity_protected_indication": "EPIDIOLEX is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients 2 years of age and older.",
                "sponsor": "GW Research Ltd.|Sovereign House|Histon|Cambridge|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of Dravet syndrome",
                    "umls_id": "C0751122",
                    "parsed_text": "Dravet Syndrome"
                }
            },
            {
                "compound_id": 644019,
                "inchl_key": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
                "generic_name": "cannabidiol",
                "trade_name": "Epidiolex",
                "designated_date": "04/19/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older",
                "marketing_approval_date": "\u00a007/31/2020\u00a0",
                "exclusivity_end_date": "\u00a007/31/2027\u00a0",
                "exclusivity_protected_indication": "treatment of seizures associated with tuberous sclerosis complex (TSC) in patients 1 year of age and older",
                "sponsor": "GW Research Ltd.|Sovereign House|Histon|Cambridge|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of tuberous sclerosis complex.",
                    "umls_id": "C0041341",
                    "parsed_text": "Tuberous Sclerosis Complex"
                }
            },
            {
                "compound_id": 644019,
                "inchl_key": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
                "generic_name": "cannabidiol",
                "designated_date": "07/23/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Radius Pharmaceuticals, Inc.|950 Winter Street|Waltham|Massachusetts|2451|United States",
                "orphan_designation": {
                    "original_text": "Treatment of infantile spasms",
                    "umls_id": "C3887898",
                    "parsed_text": "Infantile spasms"
                }
            },
            {
                "compound_id": 644019,
                "inchl_key": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
                "generic_name": "cannabidiol",
                "trade_name": "EPIDIOLEX",
                "designated_date": "11/14/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older.",
                "marketing_approval_date": "\u00a007/31/2020\u00a0",
                "exclusivity_end_date": "\u00a007/31/2027\u00a0",
                "exclusivity_protected_indication": "treatment of seizures associated with Dravet syndrome (DS) in patients between 1 and 2 years of age",
                "sponsor": "GW Research Ltd.|Sovereign House|Histon|Cambridge|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of Dravet syndrome",
                    "umls_id": "C0751122",
                    "parsed_text": "Dravet Syndrome"
                }
            },
            {
                "compound_id": 644019,
                "inchl_key": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
                "generic_name": "cannabidiol",
                "designated_date": "08/21/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Radius Pharmaceuticals, Inc.|950 Winter Street|Waltham|Massachusetts|2451|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Prader Willi Syndrome",
                    "umls_id": "C0032897",
                    "parsed_text": "Prader Willi syndrome"
                }
            },
            {
                "compound_id": 644019,
                "inchl_key": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
                "generic_name": "cannabidiol",
                "designated_date": "08/20/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Benuvia Therapeutics Inc.|444 South Ellis Street|Chandler|Alaska|85224|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioblastoma multiforme",
                    "umls_id": "C0017636",
                    "parsed_text": "Glioblastoma multiforme"
                }
            },
            {
                "compound_id": 644019,
                "inchl_key": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
                "generic_name": "cannabidiol",
                "designated_date": "04/22/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "GW Pharma Ltd.|15 T.W. Alexander Drive|P. O. Box 13547|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neonatal hypoxic ischemic encephalopathy",
                    "umls_id": "C3898147",
                    "parsed_text": "Neonatal Hypoxic Ischemic Encephalopathy"
                }
            },
            {
                "compound_id": 644019,
                "inchl_key": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
                "generic_name": "cannabidiol",
                "designated_date": "08/15/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Radius Pharmaceuticals, Inc.|950 Winter Street|Waltham|Massachusetts|2451|United States",
                "orphan_designation": {
                    "original_text": "Treatment of childhood absence epilepsy",
                    "umls_id": "C0014553",
                    "parsed_text": "childhood absence epilepsy"
                }
            },
            {
                "compound_id": 644019,
                "inchl_key": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
                "generic_name": "cannabidiol",
                "designated_date": "07/01/2014",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Insys Development Company, Inc.|1333 S. Spectrum Blvd|Suite 100|Chandler|Alaska|85286|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Dravet syndrome",
                    "umls_id": "C0751122",
                    "parsed_text": "Dravet Syndrome"
                }
            },
            {
                "compound_id": 644019,
                "inchl_key": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
                "generic_name": "cannabidiol",
                "designated_date": "07/14/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kalytera Therapeutics Israel, Ltd.|Technological Building|Road 4 Katzrin|Qatsrin|Israel",
                "orphan_designation": {
                    "original_text": "Prevention of Graft versus Host Disease (GVHD).",
                    "umls_id": "C0018133",
                    "parsed_text": "GRAFT VERSUS HOST DISEASE"
                }
            },
            {
                "compound_id": 644019,
                "inchl_key": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
                "generic_name": "cannabidiol",
                "designated_date": "06/23/2014",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Insys Development Company, Inc.|1333 S. Spectrum Blvd|Suite 100|Chandler|Alaska|85286|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Lennox-Gastaut syndrome",
                    "umls_id": "C0238111",
                    "parsed_text": "Lennox-Gastaut syndrome"
                }
            },
            {
                "compound_id": 644019,
                "inchl_key": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
                "generic_name": "cannabidiol",
                "designated_date": "06/13/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "GW Research Ltd.|Sovereign House|Histon|Cambridge|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of infantile spasms",
                    "umls_id": "C3887898",
                    "parsed_text": "Infantile spasms"
                }
            },
            {
                "compound_id": 644019,
                "inchl_key": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
                "generic_name": "Cannabidiol",
                "designated_date": "03/22/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biom Therapeutics|2203 Industrial Blvd.|Sarasota|Florida|34239|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Angelman syndrome",
                    "umls_id": "C0162635",
                    "parsed_text": "Angelman Syndrome"
                }
            },
            {
                "compound_id": 644019,
                "inchl_key": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
                "generic_name": "cannabidiol",
                "designated_date": "12/21/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AXIUM Pharmaceuticals, Inc.|265 Eastchester Drive|Suite 133, #201|High Point|North Carolina|27262|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Dravet syndrome",
                    "umls_id": "C0751122",
                    "parsed_text": "Dravet Syndrome"
                }
            },
            {
                "compound_id": 644019,
                "inchl_key": "QHMBSVQNZZTUGM-ZWKOTPCHSA-N",
                "generic_name": "cannabidiol",
                "designated_date": "06/25/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Revive Therapeutics Ltd.|5 Director Court|Suite 105|Vaughan|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of autoimmune hepatitis",
                    "umls_id": "C0241910",
                    "parsed_text": "Autoimmune hepatitis"
                }
            }
        ]
    },
    {
        "_id": "REOZWEGFPHTFEI-JKSUJKDBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11601669,
                "inchl_key": "REOZWEGFPHTFEI-JKSUJKDBSA-N",
                "generic_name": "cannabidivarin",
                "designated_date": "11/30/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "GW Research Ltd.|Sovereign House|Histon|Cambridge|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of Rett syndrome",
                    "umls_id": "C0035372",
                    "parsed_text": "Rett Syndrome"
                }
            },
            {
                "compound_id": 11601669,
                "inchl_key": "REOZWEGFPHTFEI-JKSUJKDBSA-N",
                "generic_name": "Cannabidivarin",
                "designated_date": "06/06/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "GW Research Ltd.|Sovereign House|Histon|Cambridge|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X syndrome",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "DHZBEENLJMYSHQ-XCVPVQRUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5944,
                "inchl_key": "DHZBEENLJMYSHQ-XCVPVQRUSA-N",
                "generic_name": "cantharidin",
                "designated_date": "07/24/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orenova Group, LLC|10 New King Street|Suite 106|White Plains|New York|10604|United States",
                "orphan_designation": {
                    "original_text": "Treatment of perforating diseases, including Kyrle's disease, reactive perforating collangenosis, perforating folliculitis and elastosis perforans serpiginosa",
                    "umls_id": "C0016436,C0221271,C0263382",
                    "parsed_text": "Folliculitis , Elastosis perforans serpiginosa , Kyrle's disease"
                }
            }
        ]
    },
    {
        "_id": "JFVVPUGGRUGRBJ-AVRDEDQJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 129851403,
                "inchl_key": "JFVVPUGGRUGRBJ-AVRDEDQJSA-N",
                "generic_name": "cantrixil",
                "designated_date": "04/20/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kazia Therapeutics Limited|20 George Street|Suite 207|Hornsby|New South Wales|Australia",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "LIOLIMKSCNQPLV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25145656,
                "inchl_key": "LIOLIMKSCNQPLV-UHFFFAOYSA-N",
                "generic_name": "capmatinib",
                "designated_date": "03/15/2019",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Tabrecta (capmatinib) is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.",
                "marketing_approval_date": "\u00a005/06/2020\u00a0",
                "exclusivity_end_date": "\u00a005/06/2027\u00a0",
                "exclusivity_protected_indication": "For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-small cell lung cancer with MET genomic tumor aberrations",
                    "umls_id": "C0027651,C3539721",
                    "parsed_text": "Tumor , Non-Small Cell Lung Cancer"
                }
            }
        ]
    },
    {
        "_id": "YKPUWZUDDOIDPM-SOFGYWHQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 1548943,
                "inchl_key": "YKPUWZUDDOIDPM-SOFGYWHQSA-N",
                "generic_name": "capsaicin",
                "designated_date": "10/23/2002",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Averitas Pharma, Inc.|360 Mount Kemble Avenue|Morristown|New Jersey|7960|United States",
                "orphan_designation": {
                    "original_text": "Treatment of erythromelalgia",
                    "umls_id": "C0014804",
                    "parsed_text": "Erythromelalgia"
                }
            },
            {
                "compound_id": 1548943,
                "inchl_key": "YKPUWZUDDOIDPM-SOFGYWHQSA-N",
                "generic_name": "Capsaicin",
                "designated_date": "08/03/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "TheraQuest Biosciences, LLC|146 Medinah Drive|Blue Bell|Pennsylvania|19422|United States",
                "orphan_designation": {
                    "original_text": "Treatment of postherpetic neuralgia.",
                    "umls_id": "C0032768",
                    "parsed_text": "Postherpetic neuralgia"
                }
            },
            {
                "compound_id": 1548943,
                "inchl_key": "YKPUWZUDDOIDPM-SOFGYWHQSA-N",
                "generic_name": "capsaicin",
                "designated_date": "09/29/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Centrexion Corporation|509 S. Exeter Street|Suite 202|Baltimore|Maryland|21202|United States",
                "orphan_designation": {
                    "original_text": "Treatment of intermetatarsal neuroma (Morton's Neuroma) that does not respond to conservative treatment and requires either neurectomy or neurolysis",
                    "umls_id": "C0311337",
                    "parsed_text": "Intermetatarsal Neuroma"
                }
            },
            {
                "compound_id": 1548943,
                "inchl_key": "YKPUWZUDDOIDPM-SOFGYWHQSA-N",
                "generic_name": "capsaicin",
                "designated_date": "05/02/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Averitas Pharma, Inc.|360 Mount Kemble Avenue|Morristown|New Jersey|7960|United States",
                "orphan_designation": {
                    "original_text": "Treatment of painful HIV-associated neuropathy",
                    "umls_id": "C0019682,C0442874",
                    "parsed_text": "HIV , Neuropathy"
                }
            },
            {
                "compound_id": 1548943,
                "inchl_key": "YKPUWZUDDOIDPM-SOFGYWHQSA-N",
                "generic_name": "capsaicin",
                "trade_name": "Qutenza",
                "designated_date": "05/22/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Management of neuropathic pain associated with postherpetic neuralgia",
                "marketing_approval_date": "\u00a011/16/2009\u00a0",
                "exclusivity_end_date": "\u00a011/16/2016\u00a0",
                "sponsor": "Averitas Pharma, Inc.|360 Mount Kemble Avenue|Morristown|New Jersey|7960|United States",
                "orphan_designation": {
                    "original_text": "Management of neuropathic pain in patients with postherpetic neuralgia",
                    "umls_id": "C0027796,C0032768",
                    "parsed_text": "Neuropathic Pain , Postherpetic neuralgia"
                }
            }
        ]
    },
    {
        "_id": "OBZHEBDUNPOCJG-HLWLYVGMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134689748,
                "inchl_key": "OBZHEBDUNPOCJG-HLWLYVGMSA-N",
                "generic_name": "carbenoxolone",
                "designated_date": "07/02/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oxalys Pharmaceuticals, Inc.|4 Mollard Road|Toronto|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of Huntington's Disease",
                    "umls_id": "C0020179",
                    "parsed_text": "Huntington's Disease"
                }
            }
        ]
    },
    {
        "_id": "OBZHEBDUNPOCJG-IBEOWVBCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134613184,
                "inchl_key": "OBZHEBDUNPOCJG-IBEOWVBCSA-N",
                "generic_name": "carbenoxolone",
                "designated_date": "07/02/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oxalys Pharmaceuticals, Inc.|4 Mollard Road|Toronto|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of Huntington's Disease",
                    "umls_id": "C0020179",
                    "parsed_text": "Huntington's Disease"
                }
            }
        ]
    },
    {
        "_id": "OBZHEBDUNPOCJG-KNJYOZPASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 146036893,
                "inchl_key": "OBZHEBDUNPOCJG-KNJYOZPASA-N",
                "generic_name": "carbenoxolone",
                "designated_date": "07/02/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oxalys Pharmaceuticals, Inc.|4 Mollard Road|Toronto|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of Huntington's Disease",
                    "umls_id": "C0020179",
                    "parsed_text": "Huntington's Disease"
                }
            }
        ]
    },
    {
        "_id": "OBZHEBDUNPOCJG-SMVPYXKTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 56965767,
                "inchl_key": "OBZHEBDUNPOCJG-SMVPYXKTSA-N",
                "generic_name": "carbenoxolone",
                "designated_date": "07/02/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oxalys Pharmaceuticals, Inc.|4 Mollard Road|Toronto|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of Huntington's Disease",
                    "umls_id": "C0020179",
                    "parsed_text": "Huntington's Disease"
                }
            }
        ]
    },
    {
        "_id": "OBZHEBDUNPOCJG-SZTGPWMUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 46936354,
                "inchl_key": "OBZHEBDUNPOCJG-SZTGPWMUSA-N",
                "generic_name": "carbenoxolone",
                "designated_date": "07/02/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oxalys Pharmaceuticals, Inc.|4 Mollard Road|Toronto|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of Huntington's Disease",
                    "umls_id": "C0020179",
                    "parsed_text": "Huntington's Disease"
                }
            }
        ]
    },
    {
        "_id": "OBZHEBDUNPOCJG-WZCASOPNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 21913,
                "inchl_key": "OBZHEBDUNPOCJG-WZCASOPNSA-N",
                "generic_name": "carbenoxolone",
                "designated_date": "07/02/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oxalys Pharmaceuticals, Inc.|4 Mollard Road|Toronto|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of Huntington's Disease",
                    "umls_id": "C0020179",
                    "parsed_text": "Huntington's Disease"
                }
            }
        ]
    },
    {
        "_id": "OBZHEBDUNPOCJG-ILYNEHRHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5311038,
                "inchl_key": "OBZHEBDUNPOCJG-ILYNEHRHSA-N",
                "generic_name": "carbenoxolone",
                "designated_date": "07/02/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oxalys Pharmaceuticals, Inc.|4 Mollard Road|Toronto|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of Huntington's Disease",
                    "umls_id": "C0020179",
                    "parsed_text": "Huntington's Disease"
                }
            }
        ]
    },
    {
        "_id": "OBZHEBDUNPOCJG-WBXJDKIVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 636403,
                "inchl_key": "OBZHEBDUNPOCJG-WBXJDKIVSA-N",
                "generic_name": "carbenoxolone",
                "designated_date": "07/02/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oxalys Pharmaceuticals, Inc.|4 Mollard Road|Toronto|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of Huntington's Disease",
                    "umls_id": "C0020179",
                    "parsed_text": "Huntington's Disease"
                }
            }
        ]
    },
    {
        "_id": "CURLTUGMZLYLDI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 280,
                "inchl_key": "CURLTUGMZLYLDI-UHFFFAOYSA-N",
                "generic_name": "carbon dioxide",
                "designated_date": "12/17/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Capnia, Inc.|3 Twin Dolphin Drive|Suite 160|Redwood City|California|94065|United States",
                "orphan_designation": {
                    "original_text": "Treatment of trigeminal neuralgia",
                    "umls_id": "C0040997",
                    "parsed_text": "Trigeminal Neuralgia"
                }
            }
        ]
    },
    {
        "_id": "UGFAIRIUMAVXCW-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 281,
                "inchl_key": "UGFAIRIUMAVXCW-UHFFFAOYSA-N",
                "generic_name": "carbon monoxide",
                "designated_date": "08/16/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Proterris, Inc.|197 West Springfield Street|Boston|Massachusetts|2118|United States",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic pulmonary fibrosis (IPF).",
                    "umls_id": "C0034069,C1800706",
                    "parsed_text": "IPF , Idiopathic Pulmonary Fibrosis"
                }
            },
            {
                "compound_id": 281,
                "inchl_key": "UGFAIRIUMAVXCW-UHFFFAOYSA-N",
                "generic_name": "carbon monoxide",
                "designated_date": "04/14/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Proterris, Inc.|197 West Springfield Street|Boston|Massachusetts|2118|United States",
                "orphan_designation": {
                    "original_text": "Prevention of Primary Graft Dysfunction in transplant recipients receiving a lung or heart+ lung transplant.",
                    "umls_id": "C0948031",
                    "parsed_text": "Primary Graft Dysfunction"
                }
            },
            {
                "compound_id": 281,
                "inchl_key": "UGFAIRIUMAVXCW-UHFFFAOYSA-N",
                "generic_name": "carbon monoxide",
                "designated_date": "09/28/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hillhurst Biopharmaceuticals, Inc.|2029 Verdugo Blvd|Suite 125|Montrose|California|91020|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sickle cell disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            }
        ]
    },
    {
        "_id": "XSSYCIGJYCVRRK-NKWVEPMBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135538685,
                "inchl_key": "XSSYCIGJYCVRRK-NKWVEPMBSA-N",
                "generic_name": "Carbovir",
                "designated_date": "12/13/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Glaxo Wellcome Inc.|5 Moore Drive|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Treatment of persons with AIDS and in patients with symptomatic HIV infection and a CD4 count less than 200/mm3.",
                    "umls_id": "C0001175,C0019693",
                    "parsed_text": "AIDS , HIV infection"
                }
            }
        ]
    },
    {
        "_id": "XSSYCIGJYCVRRK-RQJHMYQMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135433604,
                "inchl_key": "XSSYCIGJYCVRRK-RQJHMYQMSA-N",
                "generic_name": "Carbovir",
                "designated_date": "12/13/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Glaxo Wellcome Inc.|5 Moore Drive|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Treatment of persons with AIDS and in patients with symptomatic HIV infection and a CD4 count less than 200/mm3.",
                    "umls_id": "C0001175,C0019693",
                    "parsed_text": "AIDS , HIV infection"
                }
            }
        ]
    },
    {
        "_id": "XSSYCIGJYCVRRK-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135403630,
                "inchl_key": "XSSYCIGJYCVRRK-UHFFFAOYSA-N",
                "generic_name": "Carbovir",
                "designated_date": "12/13/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Glaxo Wellcome Inc.|5 Moore Drive|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Treatment of persons with AIDS and in patients with symptomatic HIV infection and a CD4 count less than 200/mm3.",
                    "umls_id": "C0001175,C0019693",
                    "parsed_text": "AIDS , HIV infection"
                }
            }
        ]
    },
    {
        "_id": "WEUITFNOCGSIHW-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 154732136,
                "inchl_key": "WEUITFNOCGSIHW-UHFFFAOYSA-N",
                "generic_name": "carboxyamidotriazole orotate",
                "designated_date": "05/10/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Tactical Therapeutics, Inc.|48 Wall Street, 12th Floor|New York|New York|10005|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls_id": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            }
        ]
    },
    {
        "_id": "BLMPQMFVWMYDKT-NZTKNTHTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11556711,
                "inchl_key": "BLMPQMFVWMYDKT-NZTKNTHTSA-N",
                "generic_name": "carfilzomib",
                "designated_date": "01/21/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Amgen Inc.|One Amgen Center Drive|Mail Stop 27-2-D|Thousand Oaks|California|91320-1799|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Acute Lymphoblastic Leukemia",
                    "umls_id": "C0023449",
                    "parsed_text": "Acute lymphoblastic leukemia"
                }
            },
            {
                "compound_id": 11556711,
                "inchl_key": "BLMPQMFVWMYDKT-NZTKNTHTSA-N",
                "generic_name": "carfilzomib",
                "trade_name": "Kyprolis",
                "designated_date": "01/18/2008",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.",
                "marketing_approval_date": "\u00a007/20/2012\u00a0",
                "exclusivity_end_date": "\u00a007/20/2019\u00a0",
                "sponsor": "Onyx Therapeutics, Inc.|249 East Grand Avenue|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            },
            {
                "compound_id": 11556711,
                "inchl_key": "BLMPQMFVWMYDKT-NZTKNTHTSA-N",
                "generic_name": "carfilzomib",
                "trade_name": "KYPROLIS",
                "designated_date": "01/18/2008",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "KYPROLIS is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with daratumumab and dexamethasone.",
                "marketing_approval_date": "\u00a008/20/2020\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Onyx Therapeutics, Inc.|249 East Grand Avenue|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "LCQLHJZYVOQKHU-VKHMYHEASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 121396,
                "inchl_key": "LCQLHJZYVOQKHU-VKHMYHEASA-N",
                "generic_name": "carglumic acid",
                "trade_name": "Carbaglu",
                "designated_date": "01/20/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "As an adjunctive therapy for the treatment of acute hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS) and as manitenance therapy for chronic hyperammonemia due to NAGS deficiency",
                "marketing_approval_date": "\u00a003/18/2010\u00a0",
                "exclusivity_end_date": "\u00a003/18/2017\u00a0",
                "sponsor": "Orphan Europe SARL|Immeuble Le Wilson|70 avenue du General de Gaulle|Puteaux|France",
                "orphan_designation": {
                    "original_text": "Treatment of N-acetylglutamate synthetase deficiency.",
                    "umls_id": "C0268543",
                    "parsed_text": "N-acetylglutamate synthetase deficiency"
                }
            },
            {
                "compound_id": 121396,
                "inchl_key": "LCQLHJZYVOQKHU-VKHMYHEASA-N",
                "generic_name": "carglumic acid",
                "trade_name": "Carbaglu",
                "designated_date": "06/17/2014",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA) in pediatric and adult patients",
                "marketing_approval_date": "\u00a001/22/2021\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Recordati Rare Diseases|Immeuble Le Wilson|70 avenue du General de Gaulle|Puteaux|France",
                "orphan_designation": {
                    "original_text": "Treatment of organic acidemias",
                    "umls_id": "C1829844",
                    "parsed_text": "Organic acidemias"
                }
            }
        ]
    },
    {
        "_id": "OLBWFRRUHYQABZ-MRVPVSSYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6918474,
                "inchl_key": "OLBWFRRUHYQABZ-MRVPVSSYSA-N",
                "generic_name": "carisbamate",
                "designated_date": "08/02/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SK Life Sciences, Inc.|22-10 New Jersey 208 South|Fair Lawn|New Jersey|7410|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Lennox-Gastaut syndrome",
                    "umls_id": "C0238111",
                    "parsed_text": "Lennox-Gastaut syndrome"
                }
            },
            {
                "compound_id": 6918474,
                "inchl_key": "OLBWFRRUHYQABZ-MRVPVSSYSA-N",
                "generic_name": "carisbamate",
                "designated_date": "03/16/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SK Life Science, Inc.|22-10 Route 208 South|Fair Lawn|New Jersey|7410|United States",
                "orphan_designation": {
                    "original_text": "Management of patients with infantile spasms",
                    "umls_id": "C3887898",
                    "parsed_text": "Infantile spasms"
                }
            }
        ]
    },
    {
        "_id": "DLGOEMSEDOSKAD-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2578,
                "inchl_key": "DLGOEMSEDOSKAD-UHFFFAOYSA-N",
                "generic_name": "Carmustine",
                "designated_date": "07/03/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Direct Therapeutics, Inc.|460 Seaport Court|Suite 220|Redwood|California|94063|United States",
                "orphan_designation": {
                    "original_text": "Treatment of intracranial malignancies.",
                    "umls_id": "C0006826",
                    "parsed_text": "MALIGNANCIES"
                }
            }
        ]
    },
    {
        "_id": "GPEYTRIZYSZRRK-MHZLTWQESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 100951591,
                "inchl_key": "GPEYTRIZYSZRRK-MHZLTWQESA-N",
                "generic_name": "Ceclazepide",
                "designated_date": "05/12/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Trio Medicines Ltd.|Pavillion View|19 New Road|Brighton|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of gastric neuroendocrine tumors (gastric NETs).",
                    "umls_id": "C0206754",
                    "parsed_text": "Neuroendocrine Tumors"
                }
            }
        ]
    },
    {
        "_id": "XXJWYDDUDKYVKI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9933475,
                "inchl_key": "XXJWYDDUDKYVKI-UHFFFAOYSA-N",
                "generic_name": "cediranib",
                "designated_date": "12/13/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "National Institutes of Health|National Cancer Institute|9609 Medical Center Dr.|Bethesda|Maryland|20892|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioblastoma",
                    "umls_id": "C0017636",
                    "parsed_text": "Glioblastoma"
                }
            }
        ]
    },
    {
        "_id": "YOBPSXOHCHDCMU-FDDQUTDISA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 137705394,
                "inchl_key": "YOBPSXOHCHDCMU-FDDQUTDISA-M",
                "generic_name": "Ceftriaxone sodium",
                "designated_date": "03/28/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mass General Hospital|Merit E. Cudkowicz, MD, MSc|Building 149 13th Street, Room 2274|Charlestown|Massachusetts|2129|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "VAAUVRVFOQPIGI-ONNSZKPLSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 98042587,
                "inchl_key": "VAAUVRVFOQPIGI-ONNSZKPLSA-L",
                "generic_name": "Ceftriaxone sodium",
                "designated_date": "03/28/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mass General Hospital|Merit E. Cudkowicz, MD, MSc|Building 149 13th Street, Room 2274|Charlestown|Massachusetts|2129|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "VUGBLGCUPUUDOI-GNXCPKRQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 87900910,
                "inchl_key": "VUGBLGCUPUUDOI-GNXCPKRQSA-N",
                "generic_name": "Ceftriaxone sodium",
                "designated_date": "03/28/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mass General Hospital|Merit E. Cudkowicz, MD, MSc|Building 149 13th Street, Room 2274|Charlestown|Massachusetts|2129|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "XKYJAZULGNDPLX-IXIFSOOLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 87060529,
                "inchl_key": "XKYJAZULGNDPLX-IXIFSOOLSA-N",
                "generic_name": "Ceftriaxone sodium",
                "designated_date": "03/28/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mass General Hospital|Merit E. Cudkowicz, MD, MSc|Building 149 13th Street, Room 2274|Charlestown|Massachusetts|2129|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "XMCDZRXQAGFWAK-PMCOHIMVSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 60196280,
                "inchl_key": "XMCDZRXQAGFWAK-PMCOHIMVSA-L",
                "generic_name": "Ceftriaxone sodium",
                "designated_date": "03/28/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mass General Hospital|Merit E. Cudkowicz, MD, MSc|Building 149 13th Street, Room 2274|Charlestown|Massachusetts|2129|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "VAAUVRVFOQPIGI-DAMLXXHOSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 24867842,
                "inchl_key": "VAAUVRVFOQPIGI-DAMLXXHOSA-L",
                "generic_name": "Ceftriaxone sodium",
                "designated_date": "03/28/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mass General Hospital|Merit E. Cudkowicz, MD, MSc|Building 149 13th Street, Room 2274|Charlestown|Massachusetts|2129|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "FDRNWTJTHBSPMW-UYIJMJIKSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 12971800,
                "inchl_key": "FDRNWTJTHBSPMW-UYIJMJIKSA-L",
                "generic_name": "Ceftriaxone sodium",
                "designated_date": "03/28/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mass General Hospital|Merit E. Cudkowicz, MD, MSc|Building 149 13th Street, Room 2274|Charlestown|Massachusetts|2129|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "XKYJAZULGNDPLX-VKZZUTNHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9894479,
                "inchl_key": "XKYJAZULGNDPLX-VKZZUTNHSA-N",
                "generic_name": "Ceftriaxone sodium",
                "designated_date": "03/28/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mass General Hospital|Merit E. Cudkowicz, MD, MSc|Building 149 13th Street, Room 2274|Charlestown|Massachusetts|2129|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "YOBPSXOHCHDCMU-IXIFSOOLSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 86287429,
                "inchl_key": "YOBPSXOHCHDCMU-IXIFSOOLSA-L",
                "generic_name": "Ceftriaxone sodium",
                "designated_date": "03/28/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mass General Hospital|Merit E. Cudkowicz, MD, MSc|Building 149 13th Street, Room 2274|Charlestown|Massachusetts|2129|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "YOBPSXOHCHDCMU-OOUOULNMSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 77906400,
                "inchl_key": "YOBPSXOHCHDCMU-OOUOULNMSA-M",
                "generic_name": "Ceftriaxone sodium",
                "designated_date": "03/28/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mass General Hospital|Merit E. Cudkowicz, MD, MSc|Building 149 13th Street, Room 2274|Charlestown|Massachusetts|2129|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "YOBPSXOHCHDCMU-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 53394792,
                "inchl_key": "YOBPSXOHCHDCMU-UHFFFAOYSA-M",
                "generic_name": "Ceftriaxone sodium",
                "designated_date": "03/28/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mass General Hospital|Merit E. Cudkowicz, MD, MSc|Building 149 13th Street, Room 2274|Charlestown|Massachusetts|2129|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "KTAVBOYXMBQFGR-MAODNAKNSA-J",
        "Orphan Drug Designations": [
            {
                "compound_id": 11953897,
                "inchl_key": "KTAVBOYXMBQFGR-MAODNAKNSA-J",
                "generic_name": "Ceftriaxone sodium",
                "designated_date": "03/28/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mass General Hospital|Merit E. Cudkowicz, MD, MSc|Building 149 13th Street, Room 2274|Charlestown|Massachusetts|2129|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "FDRNWTJTHBSPMW-ZJTMPOFJSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 9601224,
                "inchl_key": "FDRNWTJTHBSPMW-ZJTMPOFJSA-L",
                "generic_name": "Ceftriaxone sodium",
                "designated_date": "03/28/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mass General Hospital|Merit E. Cudkowicz, MD, MSc|Building 149 13th Street, Room 2274|Charlestown|Massachusetts|2129|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "FDRNWTJTHBSPMW-JQVQFYFGSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 59844,
                "inchl_key": "FDRNWTJTHBSPMW-JQVQFYFGSA-L",
                "generic_name": "Ceftriaxone sodium",
                "designated_date": "03/28/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mass General Hospital|Merit E. Cudkowicz, MD, MSc|Building 149 13th Street, Room 2274|Charlestown|Massachusetts|2129|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "FDRNWTJTHBSPMW-PHCXSBOASA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 11957491,
                "inchl_key": "FDRNWTJTHBSPMW-PHCXSBOASA-L",
                "generic_name": "Ceftriaxone sodium",
                "designated_date": "03/28/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mass General Hospital|Merit E. Cudkowicz, MD, MSc|Building 149 13th Street, Room 2274|Charlestown|Massachusetts|2129|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "FDRNWTJTHBSPMW-GNXCPKRQSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 5362369,
                "inchl_key": "FDRNWTJTHBSPMW-GNXCPKRQSA-L",
                "generic_name": "Ceftriaxone sodium",
                "designated_date": "03/28/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mass General Hospital|Merit E. Cudkowicz, MD, MSc|Building 149 13th Street, Room 2274|Charlestown|Massachusetts|2129|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "FDRNWTJTHBSPMW-BBJOQENWSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 9570985,
                "inchl_key": "FDRNWTJTHBSPMW-BBJOQENWSA-L",
                "generic_name": "Ceftriaxone sodium",
                "designated_date": "03/28/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mass General Hospital|Merit E. Cudkowicz, MD, MSc|Building 149 13th Street, Room 2274|Charlestown|Massachusetts|2129|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "VAAUVRVFOQPIGI-SPQHTLEESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5479530,
                "inchl_key": "VAAUVRVFOQPIGI-SPQHTLEESA-N",
                "generic_name": "Ceftriaxone sodium",
                "designated_date": "03/28/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mass General Hospital|Merit E. Cudkowicz, MD, MSc|Building 149 13th Street, Room 2274|Charlestown|Massachusetts|2129|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "YOBPSXOHCHDCMU-IXIFSOOLSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 23709629,
                "inchl_key": "YOBPSXOHCHDCMU-IXIFSOOLSA-M",
                "generic_name": "Ceftriaxone sodium",
                "designated_date": "03/28/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mass General Hospital|Merit E. Cudkowicz, MD, MSc|Building 149 13th Street, Room 2274|Charlestown|Massachusetts|2129|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "YOBPSXOHCHDCMU-VKZZUTNHSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 23679441,
                "inchl_key": "YOBPSXOHCHDCMU-VKZZUTNHSA-M",
                "generic_name": "Ceftriaxone sodium",
                "designated_date": "03/28/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mass General Hospital|Merit E. Cudkowicz, MD, MSc|Building 149 13th Street, Room 2274|Charlestown|Massachusetts|2129|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "RZEKVGVHFLEQIL-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2662,
                "inchl_key": "RZEKVGVHFLEQIL-UHFFFAOYSA-N",
                "generic_name": "Celecoxib",
                "designated_date": "07/30/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Upex-Med Co., Ltd.|Rm1117, Geumgangpenterium IT Tower B|Hagui-ro 282, Dongan-gu, Anyang-si,|Gyeonggi-do|South Korea",
                "orphan_designation": {
                    "original_text": "Treatment of hemophilic arthropathy",
                    "umls_id": "C0263725",
                    "parsed_text": "Hemophilic arthropathy"
                }
            }
        ]
    },
    {
        "_id": "JOATXPAWOHTVSZ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2663,
                "inchl_key": "JOATXPAWOHTVSZ-UHFFFAOYSA-N",
                "generic_name": "celiprolol",
                "designated_date": "01/05/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Acer Therapeutics, Inc.|222 Third Street|Suite 2240|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Ehlers-Danlos syndrome",
                    "umls_id": "C0013720",
                    "parsed_text": "Ehlers-Danlos Syndrome"
                }
            }
        ]
    },
    {
        "_id": "YVPXVXANRNDGTA-WDYNHAJCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10206,
                "inchl_key": "YVPXVXANRNDGTA-WDYNHAJCSA-N",
                "generic_name": "Cepharanthine",
                "designated_date": "09/22/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenafly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of immune thrombocytopenia (ITP)",
                    "umls_id": "C0242584,C0398650",
                    "parsed_text": "Immune thrombocytopenia , Immune Thrombocytopenia"
                }
            },
            {
                "compound_id": 10206,
                "inchl_key": "YVPXVXANRNDGTA-WDYNHAJCSA-N",
                "generic_name": "Cepharanthine",
                "designated_date": "01/14/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sairiyo Therapeutics Inc.|77 King Street West, Suite 2905|Toronto|Ontario|M5K 1H1|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of Esophageal Cancer",
                    "umls_id": "C0014859",
                    "parsed_text": "esophageal cancer"
                }
            }
        ]
    },
    {
        "_id": "BGLPECHZZQDNCD-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44595079,
                "inchl_key": "BGLPECHZZQDNCD-UHFFFAOYSA-N",
                "generic_name": "cerdulatinib",
                "designated_date": "09/21/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Portola Pharmaceuticals, Inc.|270 East Grand Avenue|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of peripheral T-cell lymphoma (PTCL).",
                    "umls_id": "C0079774",
                    "parsed_text": "Peripheral T-Cell Lymphoma"
                }
            }
        ]
    },
    {
        "_id": "VERWOWGGCGHDQE-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 57379345,
                "inchl_key": "VERWOWGGCGHDQE-UHFFFAOYSA-N",
                "generic_name": "ceritinib",
                "trade_name": "ZYKADIA",
                "designated_date": "09/27/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test",
                "marketing_approval_date": "\u00a005/26/2017\u00a0",
                "exclusivity_end_date": "\u00a005/26/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive",
                    "umls_id": "C0007131,C3539721",
                    "parsed_text": "Non-Small Cell Lung Cancer , Non-Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 57379345,
                "inchl_key": "VERWOWGGCGHDQE-UHFFFAOYSA-N",
                "generic_name": "ceritinib",
                "trade_name": "ZYKADIA",
                "designated_date": "09/27/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "ZYKADIA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic nonsmall cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.",
                "marketing_approval_date": "\u00a004/29/2014\u00a0",
                "exclusivity_end_date": "\u00a004/29/2021\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with anaplastic lymphoma kinase (ALK) positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive",
                    "umls_id": "C0007131,C3539721",
                    "parsed_text": "Non-Small Cell Lung Cancer , Non-Small Cell Lung Cancer"
                }
            }
        ]
    },
    {
        "_id": "WHTVZRBIWZFKQO-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2719,
                "inchl_key": "WHTVZRBIWZFKQO-UHFFFAOYSA-N",
                "generic_name": "chloroquine",
                "designated_date": "05/20/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "DualTpharma B.,V.|Boschstraat 111-D01|Maastricht|Netherlands",
                "orphan_designation": {
                    "original_text": "Treatment of glioblastoma multiforme.",
                    "umls_id": "C0017636",
                    "parsed_text": "Glioblastoma multiforme"
                }
            }
        ]
    },
    {
        "_id": "QNTASHOAVRSLMD-FCARAQADSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 21763506,
                "inchl_key": "QNTASHOAVRSLMD-FCARAQADSA-N",
                "generic_name": "cholest-4-en-3-one, oxime",
                "designated_date": "02/17/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|A Roche Group Member|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of spinal muscular atrophy.",
                    "umls_id": "C0026847",
                    "parsed_text": "Spinal Muscular Atrophy"
                }
            }
        ]
    },
    {
        "_id": "QNTASHOAVRSLMD-SIWSWZRQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9930827,
                "inchl_key": "QNTASHOAVRSLMD-SIWSWZRQSA-N",
                "generic_name": "cholest-4-en-3-one, oxime",
                "designated_date": "02/17/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|A Roche Group Member|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of spinal muscular atrophy.",
                    "umls_id": "C0026847",
                    "parsed_text": "Spinal Muscular Atrophy"
                }
            }
        ]
    },
    {
        "_id": "QNTASHOAVRSLMD-GYKMGIIDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 76971721,
                "inchl_key": "QNTASHOAVRSLMD-GYKMGIIDSA-N",
                "generic_name": "cholest-4-en-3-one, oxime",
                "designated_date": "02/17/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|A Roche Group Member|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of spinal muscular atrophy.",
                    "umls_id": "C0026847",
                    "parsed_text": "Spinal Muscular Atrophy"
                }
            }
        ]
    },
    {
        "_id": "SCZVLDHREVKTSH-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5280666,
                "inchl_key": "SCZVLDHREVKTSH-UHFFFAOYSA-N",
                "generic_name": "chrysoeriol",
                "designated_date": "06/22/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Flavocure Biotech|701 East Pratt Street|Suite 2033|Baltimore|Maryland|21202|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "VDHAWDNDOKGFTD-MRXNPFEDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 156419,
                "inchl_key": "VDHAWDNDOKGFTD-MRXNPFEDSA-N",
                "generic_name": "cinacalcet",
                "trade_name": "Sensipar",
                "designated_date": "04/30/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "0",
                "marketing_approval_date": "\u00a002/25/2011\u00a0",
                "exclusivity_end_date": "\u00a002/25/2018\u00a0",
                "sponsor": "Amgen, Inc.|One Amgen Center Drive|Bldg 17, 1A-4-4, Mail Stop 17-1-B|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery",
                    "umls_id": "C0221002",
                    "parsed_text": "Primary hyperparathyroidism"
                }
            },
            {
                "compound_id": 156419,
                "inchl_key": "VDHAWDNDOKGFTD-MRXNPFEDSA-N",
                "generic_name": "cinacalcet",
                "trade_name": "Sensipar",
                "designated_date": "05/12/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of hypercalcemia in patients with parathyroid carcinoma",
                "marketing_approval_date": "\u00a003/08/2004\u00a0",
                "exclusivity_end_date": "\u00a003/08/2011\u00a0",
                "sponsor": "Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hypercalcemia in patients with parathyroid carcinoma",
                    "umls_id": "C0687150",
                    "parsed_text": "Parathyroid Carcinoma"
                }
            },
            {
                "compound_id": 156419,
                "inchl_key": "VDHAWDNDOKGFTD-MRXNPFEDSA-N",
                "generic_name": "cinacalcet",
                "trade_name": "Sensipar",
                "designated_date": "04/30/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of hypercalcemia in adult patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy.",
                "marketing_approval_date": "\u00a011/21/2014\u00a0",
                "exclusivity_end_date": "\u00a011/21/2021\u00a0",
                "exclusivity_protected_indication": "Treatment of less severe hypercalcemia (serum calcium >11.2 mg/dl and <= 12.5 mg/dl) in adult patients with primary hyperparathyroidism (HPT) for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy.",
                "sponsor": "Amgen, Inc.|One Amgen Center Drive|Bldg 17, 1A-4-4, Mail Stop 17-1-B|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery",
                    "umls_id": "C0221002",
                    "parsed_text": "Primary hyperparathyroidism"
                }
            },
            {
                "compound_id": 156419,
                "inchl_key": "VDHAWDNDOKGFTD-MRXNPFEDSA-N",
                "generic_name": "cinacalcet",
                "designated_date": "09/07/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Amgen, Inc.|One Amgen Center Drive|Bldg 17, 1A-4-4, Mail Stop 17-1-B|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Treatment of secondary hyperparathyroidism (HPT) in pediatric patients with chronic kidney disease receiving dialysis",
                    "umls_id": "C0020503,C1384672,C1561643",
                    "parsed_text": "Secondary hyperparathyroidism , HPT , Chronic Kidney Disease"
                }
            }
        ]
    },
    {
        "_id": "YKPUWZUDDOIDPM-VURMDHGXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 1548942,
                "inchl_key": "YKPUWZUDDOIDPM-VURMDHGXSA-N",
                "generic_name": "civamide",
                "designated_date": "02/17/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Winston Laboratories, Inc.|100 Fairway Drive|Vernon Hills|Illinois|60061|United States",
                "orphan_designation": {
                    "original_text": "Treatment of postherpetic neuralgia.",
                    "umls_id": "C0032768",
                    "parsed_text": "Postherpetic neuralgia"
                }
            },
            {
                "compound_id": 1548942,
                "inchl_key": "YKPUWZUDDOIDPM-VURMDHGXSA-N",
                "generic_name": "civamide",
                "designated_date": "12/09/2002",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Winston Laboratories, Inc.|100 Fairway Drive, Suite 134|Vernon Hills|Illinois|60061|United States",
                "orphan_designation": {
                    "original_text": "Treatment of postherpetic neuralgia of the trigeminal nerve",
                    "umls_id": "C0032768",
                    "parsed_text": "Postherpetic neuralgia"
                }
            }
        ]
    },
    {
        "_id": "PTOAARAWEBMLNO-KVQBGUIXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 20279,
                "inchl_key": "PTOAARAWEBMLNO-KVQBGUIXSA-N",
                "generic_name": "Cladribine",
                "designated_date": "04/19/1993",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Janssen Research & Development, LLC|920 Route 202 South|Raritan|New Jersey|8869|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin's lymphoma.",
                    "umls_id": "C0024305",
                    "parsed_text": "Non-Hodgkin's Lymphoma"
                }
            },
            {
                "compound_id": 20279,
                "inchl_key": "PTOAARAWEBMLNO-KVQBGUIXSA-N",
                "generic_name": "cladribine",
                "designated_date": "03/19/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Chord Therapeutics S.a.r.l.|15 Avenue De Secheron|Geneva|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder",
                    "umls_id": "C0027873",
                    "parsed_text": "Neuromyelitis Optica"
                }
            },
            {
                "compound_id": 20279,
                "inchl_key": "PTOAARAWEBMLNO-KVQBGUIXSA-N",
                "generic_name": "Cladribine",
                "designated_date": "07/20/1990",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Janssen Research & Development, LLC|920 Route 202 South|Raritan|New Jersey|8869|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "compound_id": 20279,
                "inchl_key": "PTOAARAWEBMLNO-KVQBGUIXSA-N",
                "generic_name": "cladribine",
                "designated_date": "12/31/1990",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Janssen Research & Development, LLC|920 Route 202 South|Raritan|New Jersey|8869|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "compound_id": 20279,
                "inchl_key": "PTOAARAWEBMLNO-KVQBGUIXSA-N",
                "generic_name": "Cladribine",
                "designated_date": "04/19/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Johnson & Johnson Pharmaceutical R & D, LLC|920 Route 202|PO Box 300|Raritan|New Jersey|8869|United States",
                "orphan_designation": {
                    "original_text": "Treatment of the chronic progressive form of multiple sclerosis.",
                    "umls_id": "C0026769",
                    "parsed_text": "Multiple Sclerosis"
                }
            },
            {
                "compound_id": 20279,
                "inchl_key": "PTOAARAWEBMLNO-KVQBGUIXSA-N",
                "generic_name": "Cladribine",
                "trade_name": "Leustatin Injection",
                "designated_date": "11/15/1990",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a002/26/1993\u00a0",
                "exclusivity_end_date": "\u00a002/26/2000\u00a0",
                "sponsor": "R. W. Johnson Pharmaceutical Research Institute|Route 202, P.O. Box 300|Raritan|New Jersey|8869|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hairy cell leukemia.",
                    "umls_id": "C0023443",
                    "parsed_text": "Hairy Cell Leukemia"
                }
            }
        ]
    },
    {
        "_id": "STJMRWALKKWQGH-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2783,
                "inchl_key": "STJMRWALKKWQGH-UHFFFAOYSA-N",
                "generic_name": "clenbuterol",
                "designated_date": "10/02/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Duke University Medical Center|Department of Pediatrics|Box 103856|Durham|North Carolina|27710|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            },
            {
                "compound_id": 2783,
                "inchl_key": "STJMRWALKKWQGH-UHFFFAOYSA-N",
                "generic_name": "Clenbuterol",
                "designated_date": "01/09/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Dwight D. Koeberl, MD, PhD|Duke University Medical Center|Pediatrics Dept., Div. of Genetics|Durham|North Carolina|27710|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pompe disease (glycogen storage disease type II)",
                    "umls_id": "C0017921,C0342751",
                    "parsed_text": "Pompe Disease , Pompe disease"
                }
            },
            {
                "compound_id": 2783,
                "inchl_key": "STJMRWALKKWQGH-UHFFFAOYSA-N",
                "generic_name": "clenbuterol",
                "designated_date": "10/27/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Duke University Medical Center|Department of Pediatrics|Box 103856|Durham|North Carolina|27710|United States",
                "orphan_designation": {
                    "original_text": "Adjunctive therapy with enzyme replacement therapy in the treatment of Pompe disease",
                    "umls_id": "C0017921",
                    "parsed_text": "Pompe Disease"
                }
            }
        ]
    },
    {
        "_id": "CXOXHMZGEKVPMT-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2789,
                "inchl_key": "CXOXHMZGEKVPMT-UHFFFAOYSA-N",
                "generic_name": "clobazam",
                "trade_name": "Onfi",
                "designated_date": "12/18/2007",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome inpatients 2 years of age or older",
                "marketing_approval_date": "\u00a010/21/2011\u00a0",
                "exclusivity_end_date": "\u00a010/21/2018\u00a0",
                "sponsor": "Lundbeck, Inc.|Four Parkway North|Deerfield|Illinois|60015|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Lennox-Gastaut Syndrome",
                    "umls_id": "C0238111",
                    "parsed_text": "Lennox-Gastaut syndrome"
                }
            }
        ]
    },
    {
        "_id": "WDDPHFBMKLOVOX-AYQXTPAHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 119182,
                "inchl_key": "WDDPHFBMKLOVOX-AYQXTPAHSA-N",
                "generic_name": "clofarabine",
                "designated_date": "01/24/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Boyen Therapeutics, Inc.|148 Section 4, Zhongxiao East Road|Suite 404|Taipei|Taipei City|Taiwan",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "compound_id": 119182,
                "inchl_key": "WDDPHFBMKLOVOX-AYQXTPAHSA-N",
                "generic_name": "clofarabine",
                "designated_date": "03/14/2002",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genzyme Corp (Ilex Products, Inc.)|4545 Horizon Hill Blvd.|San Antonio|Texas|78229|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelogenous leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            },
            {
                "compound_id": 119182,
                "inchl_key": "WDDPHFBMKLOVOX-AYQXTPAHSA-N",
                "generic_name": "clofarabine",
                "trade_name": "Clolar",
                "designated_date": "02/07/2002",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens",
                "marketing_approval_date": "\u00a012/28/2004\u00a0",
                "exclusivity_end_date": "\u00a012/28/2011\u00a0",
                "sponsor": "Genzyme Corporation|4545 Horizon Hill Blvd.|San Antonio|Texas|78229|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute lymphoblastic leukemia",
                    "umls_id": "C0023449",
                    "parsed_text": "Acute lymphoblastic leukemia"
                }
            }
        ]
    },
    {
        "_id": "DGBIGWXXNGSACT-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2802,
                "inchl_key": "DGBIGWXXNGSACT-UHFFFAOYSA-N",
                "generic_name": "Clonazepam",
                "designated_date": "08/04/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hyperekplexia (startle disease).",
                    "umls_id": "C0234166",
                    "parsed_text": "Hyperekplexia"
                }
            }
        ]
    },
    {
        "_id": "ACTIUHUUMQJHFO-UPTCCGCDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5281915,
                "inchl_key": "ACTIUHUUMQJHFO-UPTCCGCDSA-N",
                "generic_name": "Coenzyme Q10",
                "designated_date": "03/05/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Integrative Therapeutics, Inc.|825 Challenger Drive|Green Bay|Wisconsin|54311|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Huntington's disease",
                    "umls_id": "C0020179",
                    "parsed_text": "Huntington's Disease"
                }
            },
            {
                "compound_id": 5281915,
                "inchl_key": "ACTIUHUUMQJHFO-UPTCCGCDSA-N",
                "generic_name": "Ubiquinone",
                "designated_date": "12/14/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gel-Tec, Division of Tishcon Corp.|30 New York Avenue|P. O. Box 331|Westbury|New York|11590|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mitochondrial cytopathies.",
                    "umls_id": "C0162670",
                    "parsed_text": "mitochondrial cytopathies"
                }
            },
            {
                "compound_id": 5281915,
                "inchl_key": "ACTIUHUUMQJHFO-UPTCCGCDSA-N",
                "generic_name": "ubidecarenone",
                "designated_date": "11/08/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Berg, LLC|500 Old Connecticut Path|Building B|Framingham|Massachusetts|1701|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 5281915,
                "inchl_key": "ACTIUHUUMQJHFO-UPTCCGCDSA-N",
                "generic_name": "ubidecarenone",
                "designated_date": "04/16/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Berg, LLC (BERG)|500 Old Connecticut Path|Building B|Framingham|Massachusetts|1701|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Epidermolysis Bullosa",
                    "umls_id": "C0014527",
                    "parsed_text": "Epidermolysis Bullosa"
                }
            }
        ]
    },
    {
        "_id": "IQWHCHZFYPIVRV-UHFFFAOYSA-I",
        "Orphan Drug Designations": [
            {
                "compound_id": 216258,
                "inchl_key": "IQWHCHZFYPIVRV-UHFFFAOYSA-I",
                "generic_name": "colistimethate sodium",
                "designated_date": "03/19/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EnBiotix, Inc.|197 W. Springfield St.|Boston|Massachusetts|2118|United States",
                "orphan_designation": {
                    "original_text": "Treatment of respiratory infection in patients with Cystic Fibrosis",
                    "umls_id": "C0010674,C0035243",
                    "parsed_text": "Cystic Fibrosis , respiratory infection"
                }
            }
        ]
    },
    {
        "_id": "WDOGQTQEKVLZIJ-WAYWQWQTSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 21159388,
                "inchl_key": "WDOGQTQEKVLZIJ-WAYWQWQTSA-L",
                "generic_name": "Combretastatin A4 Phosphate",
                "designated_date": "07/23/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mateon Therapeutics, Inc.|701 Gateway Boulevard|Suite 210|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer",
                    "umls_id": "C0206682,C0238461,C0238462",
                    "parsed_text": "follicular thyroid cancer , anaplastic thyroid cancer , Thyroid cancer, medullary"
                }
            },
            {
                "compound_id": 21159388,
                "inchl_key": "WDOGQTQEKVLZIJ-WAYWQWQTSA-L",
                "generic_name": "Combretastatin A4 phosphate",
                "designated_date": "05/08/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mateon Therapeutics, Inc.|701 Gateway Blvd|Suite 210|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "WDOGQTQEKVLZIJ-WAYWQWQTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5351387,
                "inchl_key": "WDOGQTQEKVLZIJ-WAYWQWQTSA-N",
                "generic_name": "Combretastatin A4 Phosphate",
                "designated_date": "07/23/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mateon Therapeutics, Inc.|701 Gateway Boulevard|Suite 210|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer",
                    "umls_id": "C0206682,C0238461,C0238462",
                    "parsed_text": "follicular thyroid cancer , anaplastic thyroid cancer , Thyroid cancer, medullary"
                }
            },
            {
                "compound_id": 5351387,
                "inchl_key": "WDOGQTQEKVLZIJ-WAYWQWQTSA-N",
                "generic_name": "Combretastatin A4 phosphate",
                "designated_date": "05/08/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mateon Therapeutics, Inc.|701 Gateway Blvd|Suite 210|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "UTQHLYJFMFKSGI-ZUMWLQPESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 101205708,
                "inchl_key": "UTQHLYJFMFKSGI-ZUMWLQPESA-N",
                "generic_name": "Contulakin-G",
                "designated_date": "07/07/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cognetix, Inc.|421 Wakara Way|Salt Lake City|Utah|84108|United States",
                "orphan_designation": {
                    "original_text": "Intrathecal treatment of neuropathic pain associated with spinal cord injury",
                    "umls_id": "C0027796,C0037929",
                    "parsed_text": "Neuropathic Pain , Spinal Cord Injury"
                }
            }
        ]
    },
    {
        "_id": "UTQHLYJFMFKSGI-UBINZTMLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 56928166,
                "inchl_key": "UTQHLYJFMFKSGI-UBINZTMLSA-N",
                "generic_name": "Contulakin-G",
                "designated_date": "07/07/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cognetix, Inc.|421 Wakara Way|Salt Lake City|Utah|84108|United States",
                "orphan_designation": {
                    "original_text": "Intrathecal treatment of neuropathic pain associated with spinal cord injury",
                    "umls_id": "C0027796,C0037929",
                    "parsed_text": "Neuropathic Pain , Spinal Cord Injury"
                }
            }
        ]
    },
    {
        "_id": "MWYDSXOGIBMAET-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135565596,
                "inchl_key": "MWYDSXOGIBMAET-UHFFFAOYSA-N",
                "generic_name": "copanlisib",
                "designated_date": "02/07/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bayer HealthCare Pharmaceuticals, Inc.|100 Bayer Boulevard|P. O. Box 915|Hanover|New Jersey|7981|United States",
                "orphan_designation": {
                    "original_text": "Treatment of extranodal marginal zone lymphoma",
                    "umls_id": "C1367654",
                    "parsed_text": "Marginal zone lymphoma"
                }
            },
            {
                "compound_id": 135565596,
                "inchl_key": "MWYDSXOGIBMAET-UHFFFAOYSA-N",
                "generic_name": "copanlisib",
                "designated_date": "02/07/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bayer HealthCare Pharmaceuticals, Inc.|100 Bayer Boulevard|P. O. Box 915|Hanover|New Jersey|7981|United States",
                "orphan_designation": {
                    "original_text": "Treatment of splenic marginal zone lymphoma",
                    "umls_id": "C0349632",
                    "parsed_text": "Splenic marginal zone lymphoma"
                }
            },
            {
                "compound_id": 135565596,
                "inchl_key": "MWYDSXOGIBMAET-UHFFFAOYSA-N",
                "generic_name": "copanlisib",
                "trade_name": "ALIQOPA",
                "designated_date": "02/05/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies",
                "marketing_approval_date": "\u00a009/14/2017\u00a0",
                "exclusivity_end_date": "\u00a009/14/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies",
                "sponsor": "Bayer US LLC|100 Bayer Boulevard|P. O. Box 915|Hanover|New Jersey|7981|United States",
                "orphan_designation": {
                    "original_text": "Treatment of follicular lymphoma",
                    "umls_id": "C0024301",
                    "parsed_text": "follicular lymphoma"
                }
            },
            {
                "compound_id": 135565596,
                "inchl_key": "MWYDSXOGIBMAET-UHFFFAOYSA-N",
                "generic_name": "copanlisib",
                "designated_date": "02/07/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bayer HealthCare Pharmaceuticals, Inc.|100 Bayer Boulevard|P. O. Box 915|Hanover|New Jersey|7981|United States",
                "orphan_designation": {
                    "original_text": "Treatment of nodal marginal zone lymphoma",
                    "umls_id": "C0242647",
                    "parsed_text": "Nodal marginal zone lymphoma"
                }
            }
        ]
    },
    {
        "_id": "QEEJLLNYQOBRRM-KSHGRFHLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16132344,
                "inchl_key": "QEEJLLNYQOBRRM-KSHGRFHLSA-N",
                "generic_name": "Corticorelin ovine triflutate",
                "trade_name": "Acthrel",
                "designated_date": "11/24/1989",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "To differentiate between pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome.",
                "marketing_approval_date": "\u00a005/23/1996\u00a0",
                "exclusivity_end_date": "\u00a005/23/2003\u00a0",
                "sponsor": "Ferring Laboratories, Inc.|400 Rella Boulevard, Suite 201|Suffern|New York|10901|United States",
                "orphan_designation": {
                    "original_text": "For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushings syndrome.",
                    "umls_id": "C0010481",
                    "parsed_text": "CUSHINGS SYNDROME"
                }
            }
        ]
    },
    {
        "_id": "ZOEFCCMDUURGSE-CQVUSSRSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16129617,
                "inchl_key": "ZOEFCCMDUURGSE-CQVUSSRSSA-N",
                "generic_name": "cosyntropin",
                "designated_date": "07/06/2017",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mallinckrodt ARD Inc.|675 McDonnell Boulevard|Hazelwood|Missouri|63042|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Duchenne muscular dystrophy.",
                    "umls_id": "C0013264",
                    "parsed_text": "DUCHENNE MUSCULAR DYSTROPHY"
                }
            },
            {
                "compound_id": 16129617,
                "inchl_key": "ZOEFCCMDUURGSE-CQVUSSRSSA-N",
                "generic_name": "cosyntropin",
                "designated_date": "08/02/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "West Therapeutic Development, LLC|540 Ziegler Drive|Grayslake|Illinois|60030|United States",
                "orphan_designation": {
                    "original_text": "Treatment of infantile spasms.",
                    "umls_id": "C3887898",
                    "parsed_text": "Infantile spasms"
                }
            }
        ]
    },
    {
        "_id": "KTEIFNKAUNYNJU-GFCCVEGCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11626560,
                "inchl_key": "KTEIFNKAUNYNJU-GFCCVEGCSA-N",
                "generic_name": "crizotinib",
                "trade_name": "Xalkori",
                "designated_date": "09/28/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive",
                "marketing_approval_date": "\u00a001/14/2021\u00a0",
                "exclusivity_end_date": "\u00a001/14/2028\u00a0",
                "exclusivity_protected_indication": "treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.",
                "sponsor": "Pfizer, Inc.|10646 Science Center Drive|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of anaplastic large cell lymphoma",
                    "umls_id": "C0024302",
                    "parsed_text": "large cell lymphoma"
                }
            },
            {
                "compound_id": 11626560,
                "inchl_key": "KTEIFNKAUNYNJU-GFCCVEGCSA-N",
                "generic_name": "crizotinib",
                "trade_name": "Xalkori",
                "designated_date": "09/13/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with locally advanced or metastatic non-small cell lungcancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDAapprovedtest",
                "marketing_approval_date": "\u00a008/26/2011\u00a0",
                "exclusivity_end_date": "\u00a008/26/2018\u00a0",
                "sponsor": "Pfizer, Inc.|10646 Science Center Drive|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer",
                    "umls_id": "C3539721",
                    "parsed_text": "Non-Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 11626560,
                "inchl_key": "KTEIFNKAUNYNJU-GFCCVEGCSA-N",
                "generic_name": "crizotinib",
                "trade_name": "Xalkori",
                "designated_date": "09/13/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with metastatic NSCLC whose tumors are ROS1-positive",
                "marketing_approval_date": "\u00a003/11/2016\u00a0",
                "exclusivity_end_date": "\u00a003/11/2023\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with metastatic NSCLC whose tumors are ROS1-positive",
                "sponsor": "Pfizer, Inc.|10646 Science Center Drive|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer",
                    "umls_id": "C3539721",
                    "parsed_text": "Non-Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 11626560,
                "inchl_key": "KTEIFNKAUNYNJU-GFCCVEGCSA-N",
                "generic_name": "crizotinib",
                "designated_date": "10/31/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer, Inc.|10646 Science Center Drive|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuroblastoma",
                    "umls_id": "C0027819",
                    "parsed_text": "Neuroblastoma"
                }
            }
        ]
    },
    {
        "_id": "RCBJUJRVBGYTEO-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71587716,
                "inchl_key": "RCBJUJRVBGYTEO-UHFFFAOYSA-N",
                "generic_name": "CT-2584 Mesylate",
                "designated_date": "04/16/1999",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cell Therapeutics, Inc.|501 Elliott Ave. West|Suite 400|Seattle|Washington|98119|United States",
                "orphan_designation": {
                    "original_text": "Treatment of adult soft tissue sarcoma.",
                    "umls_id": "C0220613",
                    "parsed_text": "Adult Soft Tissue Sarcoma"
                }
            },
            {
                "compound_id": 71587716,
                "inchl_key": "RCBJUJRVBGYTEO-UHFFFAOYSA-N",
                "generic_name": "CT-2584 mesylate",
                "designated_date": "04/16/1999",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cell Therapeutics, Inc.|501 Elliott Ave. West|Suite 400|Seattle|Washington|98119|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant mesothelioma.",
                    "umls_id": "C0345967",
                    "parsed_text": "Malignant mesothelioma"
                }
            }
        ]
    },
    {
        "_id": "OGMADIBCHLQMIP-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9082,
                "inchl_key": "OGMADIBCHLQMIP-UHFFFAOYSA-N",
                "generic_name": "Cysteamine hydrochloride",
                "trade_name": "Cystaran",
                "designated_date": "08/19/1997",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of corneal cystine crystal accumulation in patients with cystinosis",
                "marketing_approval_date": "\u00a010/02/2012\u00a0",
                "exclusivity_end_date": "\u00a010/02/2019\u00a0",
                "sponsor": "Leadiant Biosciences, Inc.|9841 Washingtonian Blvd|Suite 500|Gaithersburg|Maryland|20878|United States",
                "orphan_designation": {
                    "original_text": "Treatment of corneal cystine crystal accumulation in cystinosis patients.",
                    "umls_id": "C4316899",
                    "parsed_text": "Cystinosis"
                }
            }
        ]
    },
    {
        "_id": "UIBPZXXSPHGPDS-UXLZJAPBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71587612,
                "inchl_key": "UIBPZXXSPHGPDS-UXLZJAPBSA-N",
                "generic_name": "D-peptide of the sequence AKRHHGYKRKFH - NH2",
                "designated_date": "10/23/2002",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Demegen, Inc.|100 Technology Drive|Suite 440 B|Pittsburgh|Pennsylvania|15219|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "LKDRXBCSQODPBY-OEXCPVAWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 439312,
                "inchl_key": "LKDRXBCSQODPBY-OEXCPVAWSA-N",
                "generic_name": "D-tagatose",
                "designated_date": "01/19/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biospherics.net LLC|Department of Pharmaceutical Sciences|University of Kentucky|Nicholasville|Kentucky|40356|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Prader-Willi Syndrome",
                    "umls_id": "C0032897",
                    "parsed_text": "Prader-Willi Syndrome"
                }
            }
        ]
    },
    {
        "_id": "BOFQWVMAQOTZIW-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 214348,
                "inchl_key": "BOFQWVMAQOTZIW-UHFFFAOYSA-N",
                "generic_name": "deferasirox",
                "trade_name": "Exjade; Jadenu Sprinkles",
                "designated_date": "02/24/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of chronic iron overload in patients 10 years of age and older with non-transfusion dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and serum ferritin greater than 300 mcg/L.",
                "marketing_approval_date": "\u00a001/23/2013\u00a0",
                "exclusivity_end_date": "\u00a001/23/2020\u00a0",
                "exclusivity_protected_indication": "Treatment of chronic iron overload in patients 10 years of age and older with non-transfusion dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and serum ferritin greater than 300 mcg/L.",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic iron overload in alpha-thalassemia",
                    "umls_id": "C0002312,C0282193",
                    "parsed_text": "alpha-Thalassemia , Iron Overload"
                }
            },
            {
                "compound_id": 214348,
                "inchl_key": "BOFQWVMAQOTZIW-UHFFFAOYSA-N",
                "generic_name": "Deferasirox",
                "trade_name": "Exjade; Jadenu Sprinkles",
                "designated_date": "11/21/2002",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age or older",
                "marketing_approval_date": "\u00a011/02/2005\u00a0",
                "exclusivity_end_date": "\u00a011/02/2012\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza|East Hanover|New Hampshire|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic iron overload in patients with transfusion-dependent anemias",
                    "umls_id": "C0002871,C0282193",
                    "parsed_text": "Anemias , Iron Overload"
                }
            },
            {
                "compound_id": 214348,
                "inchl_key": "BOFQWVMAQOTZIW-UHFFFAOYSA-N",
                "generic_name": "Deferasirox",
                "trade_name": "Exjade; Jadenu Sprinkles",
                "designated_date": "11/21/2002",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older",
                "marketing_approval_date": "\u00a005/18/2017\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza|East Hanover|New Hampshire|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic iron overload in patients with transfusion-dependent anemias",
                    "umls_id": "C0002871,C0282193",
                    "parsed_text": "Anemias , Iron Overload"
                }
            },
            {
                "compound_id": 214348,
                "inchl_key": "BOFQWVMAQOTZIW-UHFFFAOYSA-N",
                "generic_name": "deferasirox",
                "trade_name": "Exjade; Jadenu Sprinkles",
                "designated_date": "02/24/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and a serum ferritin greater than 300 mcg/L.",
                "marketing_approval_date": "\u00a005/18/2017\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic iron overload in alpha-thalassemia",
                    "umls_id": "C0002312,C0282193",
                    "parsed_text": "alpha-Thalassemia , Iron Overload"
                }
            }
        ]
    },
    {
        "_id": "JNWFIPVDEINBAI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135565962,
                "inchl_key": "JNWFIPVDEINBAI-UHFFFAOYSA-N",
                "generic_name": "Defibrotide",
                "designated_date": "07/05/1985",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Crinos International|Via Belvedere 1|Villa Guardia, Italy|22079|United States",
                "orphan_designation": {
                    "original_text": "Treatment of thrombotic thrombocytopenic purpura.",
                    "umls_id": "C0857305",
                    "parsed_text": "Thrombocytopenic purpura"
                }
            },
            {
                "compound_id": 135565962,
                "inchl_key": "JNWFIPVDEINBAI-UHFFFAOYSA-N",
                "generic_name": "defibrotide",
                "designated_date": "05/14/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Jazz Pharmaceuticals Ireland Limited|5th Floor Waterloo Exchange|Waterloo Road|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Prevention of acute graft versus host disease",
                    "umls_id": "C0856825",
                    "parsed_text": "Acute Graft Versus Host Disease"
                }
            },
            {
                "compound_id": 135565962,
                "inchl_key": "JNWFIPVDEINBAI-UHFFFAOYSA-N",
                "generic_name": "defibrotide",
                "designated_date": "01/08/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Jazz Pharmaceuticals, Inc.|3180 Porter Drive|Palo Alto|California|94304|United States",
                "orphan_designation": {
                    "original_text": "For the prevention of hepatic veno-occlusive disease.",
                    "umls_id": "C0019156",
                    "parsed_text": "Hepatic Veno-Occlusive Disease"
                }
            },
            {
                "compound_id": 135565962,
                "inchl_key": "JNWFIPVDEINBAI-UHFFFAOYSA-N",
                "generic_name": "defibrotide",
                "trade_name": "Defitelio",
                "designated_date": "05/21/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT).",
                "marketing_approval_date": "\u00a003/30/2016\u00a0",
                "exclusivity_end_date": "\u00a003/30/2023\u00a0",
                "exclusivity_protected_indication": "For the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT).",
                "sponsor": "Jazz Pharmaceuticals, Inc.|3180 Porter Drive|Palo Alto|California|94304|United States",
                "orphan_designation": {
                    "original_text": "For the treatment of hepatic veno-occlusive disease",
                    "umls_id": "C0019156",
                    "parsed_text": "Hepatic Veno-Occlusive Disease"
                }
            }
        ]
    },
    {
        "_id": "FBHSPRKOSMHSIF-GRMWVWQJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 189821,
                "inchl_key": "FBHSPRKOSMHSIF-GRMWVWQJSA-N",
                "generic_name": "deflazacort",
                "trade_name": "Emflaza",
                "designated_date": "08/16/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of Duchenne Muscular Dystrophy in patients 5 years of age and older",
                "marketing_approval_date": "\u00a002/09/2017\u00a0",
                "exclusivity_end_date": "\u00a002/09/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of Duchenne Muscular Dystrophy in patients 5 years of age and older",
                "sponsor": "PTC Therapeutics, Inc.|100 Corporate Court|South Plainfield|New Jersey|7080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Duchenne muscular dystrophy",
                    "umls_id": "C0013264",
                    "parsed_text": "DUCHENNE MUSCULAR DYSTROPHY"
                }
            },
            {
                "compound_id": 189821,
                "inchl_key": "FBHSPRKOSMHSIF-GRMWVWQJSA-N",
                "generic_name": "deflazacort",
                "designated_date": "09/16/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "University of Rochester Medical Center|1351 Mt. Hope Avenue|Suite 203|Rochester|New York|14620|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Duchenne muscular dystrophy",
                    "umls_id": "C0013264",
                    "parsed_text": "DUCHENNE MUSCULAR DYSTROPHY"
                }
            },
            {
                "compound_id": 189821,
                "inchl_key": "FBHSPRKOSMHSIF-GRMWVWQJSA-N",
                "generic_name": "deflazacort",
                "trade_name": "Emflaza",
                "designated_date": "08/16/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "EMFLAZA is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.",
                "marketing_approval_date": "\u00a006/07/2019\u00a0",
                "exclusivity_end_date": "\u00a006/07/2026\u00a0",
                "exclusivity_protected_indication": "For the treatment of Duchene muscular dystrophy in patients 2 years of age to less than 5 years of age",
                "sponsor": "PTC Therapeutics, Inc.|100 Corporate Court|South Plainfield|New Jersey|7080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Duchenne muscular dystrophy",
                    "umls_id": "C0013264",
                    "parsed_text": "DUCHENNE MUSCULAR DYSTROPHY"
                }
            },
            {
                "compound_id": 189821,
                "inchl_key": "FBHSPRKOSMHSIF-GRMWVWQJSA-N",
                "generic_name": "deflazacort",
                "designated_date": "10/22/2015",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PTC Therapeutics, Inc.|100 Corporate Court|South Plainfield|New Jersey|7080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric (0 through 16 years of age) juvenile idiopathis arthritis (JIA) International League of Associations for Rheumatology (ILAR) categories excluding systemic JIA.",
                    "umls_id": "C0003864,C3495559",
                    "parsed_text": "Arthritis , JIA"
                }
            }
        ]
    },
    {
        "_id": "FMGSKLZLMKYGDP-USOAJAOKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5881,
                "inchl_key": "FMGSKLZLMKYGDP-USOAJAOKSA-N",
                "generic_name": "Dehydroepiandrosterone (DHEA)",
                "designated_date": "08/19/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Paladin Labs, Inc.|6111 Royalmount Avenue, Suite 102|Montreal|Canada",
                "orphan_designation": {
                    "original_text": "Replacement therapy in individuals with adrenal insufficiency",
                    "umls_id": "C0001623",
                    "parsed_text": "Adrenal Insufficiency"
                }
            },
            {
                "compound_id": 5881,
                "inchl_key": "FMGSKLZLMKYGDP-USOAJAOKSA-N",
                "generic_name": "Dehydroepiandrosterone",
                "designated_date": "07/13/1994",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "GlaxoSmithKline|P. O. Box 13398|Five Moore Drive|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Treatment of systemic lupus erythematosus (SLE) and the reduction in the use of steroids in steroid-dependent SLE patients.",
                    "umls_id": "C0014060,C0024141",
                    "parsed_text": "SLE , SYSTEMIC LUPUS ERYTHEMATOSUS"
                }
            }
        ]
    },
    {
        "_id": "VFLDPWHFBUODDF-FCXRPNKRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 969516,
                "inchl_key": "VFLDPWHFBUODDF-FCXRPNKRSA-N",
                "generic_name": "diferuloylmethane",
                "designated_date": "06/13/2003",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Allertein Therapeutics, LLC|640 Sasco Hill Road|Fairfield|Connecticut|6824|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "VHBABGAFHUKREU-ICKLFXEKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11977455,
                "inchl_key": "VHBABGAFHUKREU-ICKLFXEKSA-N",
                "generic_name": "dihydroartemisinin and piperaquine",
                "designated_date": "01/08/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Alfasigma S.p.A|223 Viale Sarca|Milano|Lombardia|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of uncomplicated malaria caused by \"Plasmodium falciparum,\" Plasmodium vivax,\" Plasmodium malariae,\" or \"Plasmodium ovale.\"",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            }
        ]
    },
    {
        "_id": "LDCRTTXIJACKKU-ONEGZZNKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 637568,
                "inchl_key": "LDCRTTXIJACKKU-ONEGZZNKSA-N",
                "generic_name": "dimethyl fumarate",
                "designated_date": "09/11/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ixchel Pharma, LLC|608 12th Street|Davis|California|95616|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Friedreich's Ataxia",
                    "umls_id": "C0016719",
                    "parsed_text": "Friedreich's Ataxia"
                }
            }
        ]
    },
    {
        "_id": "LZXMUJCJAWVHPZ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44557636,
                "inchl_key": "LZXMUJCJAWVHPZ-UHFFFAOYSA-N",
                "generic_name": "dipraglurant",
                "designated_date": "12/29/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Addex Pharma SA|Chemin des Aulx 14|1228 Plan-Les-Ouates|Geneva|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of levodopa-induced dyskinesias",
                    "umls_id": "C1970038",
                    "parsed_text": "Levodopa-induced dyskinesias"
                }
            }
        ]
    },
    {
        "_id": "ZLVMAMIPILWYHQ-INIZCTEOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71137,
                "inchl_key": "ZLVMAMIPILWYHQ-INIZCTEOSA-N",
                "generic_name": "docarpamine",
                "designated_date": "04/14/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Martin Pharmaceuticals, Inc.|233 Broadway|Suite 1750|New York|New York|10279|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ascites due to all etiologies except cancer",
                    "umls_id": "C0003962,C0006826",
                    "parsed_text": "Ascites , Cancer"
                }
            }
        ]
    },
    {
        "_id": "RZHKDBRREKOZEW-AAXZNHDCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 158782,
                "inchl_key": "RZHKDBRREKOZEW-AAXZNHDCSA-N",
                "generic_name": "Edotreotide",
                "designated_date": "07/28/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Molecular Insight Pharmaceuticals, Inc. (Progenics Subsidiary)|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of somatostatin receptor-positive neuroendocrine gastroenteropancreatic tumors",
                    "umls_id": "C0027651",
                    "parsed_text": "Tumors"
                }
            }
        ]
    },
    {
        "_id": "VLCYCQAOQCDTCN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3009,
                "inchl_key": "VLCYCQAOQCDTCN-UHFFFAOYSA-N",
                "generic_name": "eflornithine",
                "designated_date": "11/23/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cancer Prevention Pharmaceuticals|1760 E. River Road|Suite 250|Tucson|Alaska|85718|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuroblastoma",
                    "umls_id": "C0027819",
                    "parsed_text": "Neuroblastoma"
                }
            },
            {
                "compound_id": 3009,
                "inchl_key": "VLCYCQAOQCDTCN-UHFFFAOYSA-N",
                "generic_name": "Eflornithine",
                "designated_date": "09/29/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orbus Therapeutics, Inc.|1043 Via Tornasol|Aptos|California|95003|United States",
                "orphan_designation": {
                    "original_text": "Treatment of anaplastic glioma",
                    "umls_id": "C4287997",
                    "parsed_text": "Anaplastic Glioma"
                }
            },
            {
                "compound_id": 3009,
                "inchl_key": "VLCYCQAOQCDTCN-UHFFFAOYSA-N",
                "generic_name": "eflornithine",
                "designated_date": "02/04/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cancer Prevention Pharmaceuticals|1760 E. River Road #250|Tucson|Alaska|85718|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Familial Adenomatous Polyposis",
                    "umls_id": "C0032580",
                    "parsed_text": "Familial Adenomatous Polyposis"
                }
            },
            {
                "compound_id": 3009,
                "inchl_key": "VLCYCQAOQCDTCN-UHFFFAOYSA-N",
                "generic_name": "eflornithine",
                "designated_date": "11/22/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "USWM, LLC|4441 Springdale Rd|Louisville|Kentucky|40241|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuroblastoma",
                    "umls_id": "C0027819",
                    "parsed_text": "Neuroblastoma"
                }
            },
            {
                "compound_id": 3009,
                "inchl_key": "VLCYCQAOQCDTCN-UHFFFAOYSA-N",
                "generic_name": "eflornithine",
                "designated_date": "12/14/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cancer Prevention Pharmaceutical, Inc.|1760 East River Road|Suite 250|Tucson|Alaska|85718|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer.",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "JOZGNYDSEBIJDH-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 43157,
                "inchl_key": "JOZGNYDSEBIJDH-UHFFFAOYSA-N",
                "generic_name": "eniluracil",
                "designated_date": "12/15/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Adherex Technologies, Inc.|501 Eastowne Drive|Suite 140|Chapel Hill|North Carolina|27514|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma.",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            }
        ]
    },
    {
        "_id": "XSMSNFMDVXXHGJ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 59473233,
                "inchl_key": "XSMSNFMDVXXHGJ-UHFFFAOYSA-N",
                "generic_name": "entospletinib",
                "designated_date": "08/10/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kronos Bio, Inc.|1300 S. El Camino Real, Suite 300|San Mateo|California|94402|United States",
                "orphan_designation": {
                    "original_text": "Prevention of chronic graft-versus-host disease",
                    "umls_id": "C0867389",
                    "parsed_text": "Chronic graft-versus-host disease"
                }
            },
            {
                "compound_id": 59473233,
                "inchl_key": "XSMSNFMDVXXHGJ-UHFFFAOYSA-N",
                "generic_name": "entospletinib",
                "designated_date": "04/14/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kronos Bio, Inc.|1300 S. El Camino Real, Suite 300|San Mateo|California|94402|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "compound_id": 59473233,
                "inchl_key": "XSMSNFMDVXXHGJ-UHFFFAOYSA-N",
                "generic_name": "entospletinib",
                "designated_date": "06/15/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kronos Bio, Inc.|1300 S. El Camino Real, Suite 300|San Mateo|California|94402|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "AXRCEOKUDYDWLF-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 176167,
                "inchl_key": "AXRCEOKUDYDWLF-UHFFFAOYSA-N",
                "generic_name": "enzastaurin",
                "designated_date": "03/04/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Denovo Biopharma LLC|6331 Nancy Ridge Drive|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diffuse large B-cell lymphoma",
                    "umls_id": "C1332201",
                    "parsed_text": "Diffuse Large B-Cell Lymphoma"
                }
            },
            {
                "compound_id": 176167,
                "inchl_key": "AXRCEOKUDYDWLF-UHFFFAOYSA-N",
                "generic_name": "Enzastaurin",
                "designated_date": "09/19/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Denovo Biopharma LLC|6331 Nancy Ridge Drive|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioblastoma multiforme",
                    "umls_id": "C0017636",
                    "parsed_text": "Glioblastoma multiforme"
                }
            }
        ]
    },
    {
        "_id": "LMHIPJMTZHDKEW-XQYLJSSYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 21158562,
                "inchl_key": "LMHIPJMTZHDKEW-XQYLJSSYSA-N",
                "generic_name": "epoprostenol",
                "designated_date": "04/20/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Aurora Research Institute, LLC|960 N 12th St|Discovery Lab|Milwaukee|Wisconsin|53233|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Frostbite",
                    "umls_id": "C0016736",
                    "parsed_text": "Frostbite"
                }
            },
            {
                "compound_id": 21158562,
                "inchl_key": "LMHIPJMTZHDKEW-XQYLJSSYSA-N",
                "generic_name": "Epoprostenol",
                "trade_name": "Flolan",
                "designated_date": "09/25/1985",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Long-term intravenous treatment of primary pulmonary hypertension in NYHA Class III and Class IV patients.",
                "marketing_approval_date": "\u00a009/20/1995\u00a0",
                "exclusivity_end_date": "\u00a009/20/2002\u00a0",
                "sponsor": "Glaxo Wellcome Inc.|5 Moore Drive|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary pulmonary hypertension.",
                    "umls_id": "C3203102",
                    "parsed_text": "Primary Pulmonary Hypertension"
                }
            },
            {
                "compound_id": 21158562,
                "inchl_key": "LMHIPJMTZHDKEW-XQYLJSSYSA-N",
                "generic_name": "epoprostenol",
                "trade_name": "Flolan",
                "designated_date": "03/22/1999",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "0",
                "marketing_approval_date": "\u00a004/14/2000\u00a0",
                "exclusivity_end_date": "\u00a004/14/2007\u00a0",
                "sponsor": "GlaxoSmithKline|2301 Renaissance Blvd|P. O. Box 61540|King of Prussia|Pennsylvania|19406|United States",
                "orphan_designation": {
                    "original_text": "Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.",
                    "umls_id": "C0042373,C0264936",
                    "parsed_text": "Vascular Disease , Secondary pulmonary hypertension"
                }
            }
        ]
    },
    {
        "_id": "WHVPOEPABJZBBY-XQYLJSSYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 67548346,
                "inchl_key": "WHVPOEPABJZBBY-XQYLJSSYSA-N",
                "generic_name": "epoprostenol",
                "designated_date": "04/20/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Aurora Research Institute, LLC|960 N 12th St|Discovery Lab|Milwaukee|Wisconsin|53233|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Frostbite",
                    "umls_id": "C0016736",
                    "parsed_text": "Frostbite"
                }
            },
            {
                "compound_id": 67548346,
                "inchl_key": "WHVPOEPABJZBBY-XQYLJSSYSA-N",
                "generic_name": "Epoprostenol",
                "trade_name": "Flolan",
                "designated_date": "09/25/1985",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Long-term intravenous treatment of primary pulmonary hypertension in NYHA Class III and Class IV patients.",
                "marketing_approval_date": "\u00a009/20/1995\u00a0",
                "exclusivity_end_date": "\u00a009/20/2002\u00a0",
                "sponsor": "Glaxo Wellcome Inc.|5 Moore Drive|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary pulmonary hypertension.",
                    "umls_id": "C3203102",
                    "parsed_text": "Primary Pulmonary Hypertension"
                }
            },
            {
                "compound_id": 67548346,
                "inchl_key": "WHVPOEPABJZBBY-XQYLJSSYSA-N",
                "generic_name": "epoprostenol",
                "trade_name": "Flolan",
                "designated_date": "03/22/1999",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "0",
                "marketing_approval_date": "\u00a004/14/2000\u00a0",
                "exclusivity_end_date": "\u00a004/14/2007\u00a0",
                "sponsor": "GlaxoSmithKline|2301 Renaissance Blvd|P. O. Box 61540|King of Prussia|Pennsylvania|19406|United States",
                "orphan_designation": {
                    "original_text": "Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.",
                    "umls_id": "C0042373,C0264936",
                    "parsed_text": "Vascular Disease , Secondary pulmonary hypertension"
                }
            }
        ]
    },
    {
        "_id": "LMHIPJMTZHDKEW-XQYLJSSYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 6364626,
                "inchl_key": "LMHIPJMTZHDKEW-XQYLJSSYSA-M",
                "generic_name": "epoprostenol",
                "designated_date": "04/20/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Aurora Research Institute, LLC|960 N 12th St|Discovery Lab|Milwaukee|Wisconsin|53233|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Frostbite",
                    "umls_id": "C0016736",
                    "parsed_text": "Frostbite"
                }
            },
            {
                "compound_id": 6364626,
                "inchl_key": "LMHIPJMTZHDKEW-XQYLJSSYSA-M",
                "generic_name": "Epoprostenol",
                "trade_name": "Flolan",
                "designated_date": "09/25/1985",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Long-term intravenous treatment of primary pulmonary hypertension in NYHA Class III and Class IV patients.",
                "marketing_approval_date": "\u00a009/20/1995\u00a0",
                "exclusivity_end_date": "\u00a009/20/2002\u00a0",
                "sponsor": "Glaxo Wellcome Inc.|5 Moore Drive|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary pulmonary hypertension.",
                    "umls_id": "C3203102",
                    "parsed_text": "Primary Pulmonary Hypertension"
                }
            },
            {
                "compound_id": 6364626,
                "inchl_key": "LMHIPJMTZHDKEW-XQYLJSSYSA-M",
                "generic_name": "epoprostenol",
                "trade_name": "Flolan",
                "designated_date": "03/22/1999",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "0",
                "marketing_approval_date": "\u00a004/14/2000\u00a0",
                "exclusivity_end_date": "\u00a004/14/2007\u00a0",
                "sponsor": "GlaxoSmithKline|2301 Renaissance Blvd|P. O. Box 61540|King of Prussia|Pennsylvania|19406|United States",
                "orphan_designation": {
                    "original_text": "Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.",
                    "umls_id": "C0042373,C0264936",
                    "parsed_text": "Vascular Disease , Secondary pulmonary hypertension"
                }
            }
        ]
    },
    {
        "_id": "KAQKFAOMNZTLHT-OZUDYXHBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5282411,
                "inchl_key": "KAQKFAOMNZTLHT-OZUDYXHBSA-N",
                "generic_name": "epoprostenol",
                "designated_date": "04/20/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Aurora Research Institute, LLC|960 N 12th St|Discovery Lab|Milwaukee|Wisconsin|53233|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Frostbite",
                    "umls_id": "C0016736",
                    "parsed_text": "Frostbite"
                }
            },
            {
                "compound_id": 5282411,
                "inchl_key": "KAQKFAOMNZTLHT-OZUDYXHBSA-N",
                "generic_name": "Epoprostenol",
                "trade_name": "Flolan",
                "designated_date": "09/25/1985",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Long-term intravenous treatment of primary pulmonary hypertension in NYHA Class III and Class IV patients.",
                "marketing_approval_date": "\u00a009/20/1995\u00a0",
                "exclusivity_end_date": "\u00a009/20/2002\u00a0",
                "sponsor": "Glaxo Wellcome Inc.|5 Moore Drive|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary pulmonary hypertension.",
                    "umls_id": "C3203102",
                    "parsed_text": "Primary Pulmonary Hypertension"
                }
            },
            {
                "compound_id": 5282411,
                "inchl_key": "KAQKFAOMNZTLHT-OZUDYXHBSA-N",
                "generic_name": "epoprostenol",
                "trade_name": "Flolan",
                "designated_date": "03/22/1999",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "0",
                "marketing_approval_date": "\u00a004/14/2000\u00a0",
                "exclusivity_end_date": "\u00a004/14/2007\u00a0",
                "sponsor": "GlaxoSmithKline|2301 Renaissance Blvd|P. O. Box 61540|King of Prussia|Pennsylvania|19406|United States",
                "orphan_designation": {
                    "original_text": "Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.",
                    "umls_id": "C0042373,C0264936",
                    "parsed_text": "Vascular Disease , Secondary pulmonary hypertension"
                }
            }
        ]
    },
    {
        "_id": "KGWDUNBJIMUFAP-KVVVOXFISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5282489,
                "inchl_key": "KGWDUNBJIMUFAP-KVVVOXFISA-N",
                "generic_name": "Ethanolamine oleate",
                "trade_name": "Ethamolin",
                "designated_date": "03/22/1984",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a012/22/1988\u00a0",
                "exclusivity_end_date": "\u00a012/22/1995\u00a0",
                "sponsor": "QOL Medical|4445 North Highway A1A, 241|Vero Beach|Florida|32963|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with esophageal varices that have recently bled, to prevent rebleeding.",
                    "umls_id": "C0014867",
                    "parsed_text": "Esophageal Varices"
                }
            }
        ]
    },
    {
        "_id": "NGOGFTYYXHNFQH-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3547,
                "inchl_key": "NGOGFTYYXHNFQH-UHFFFAOYSA-N",
                "generic_name": "Fasudil",
                "designated_date": "09/09/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Woolsey Pharmaceuticals, Inc.Woolsey Pharmaceuticals, Inc.|233 Broadway|Suite 1750|New York|New York|10279|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Frontotemporal Dementia",
                    "umls_id": "C0338451",
                    "parsed_text": "Frontotemporal dementia"
                }
            },
            {
                "compound_id": 3547,
                "inchl_key": "NGOGFTYYXHNFQH-UHFFFAOYSA-N",
                "generic_name": "fasudil",
                "designated_date": "09/05/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Aneuryst, Inc.|211 East 43rd Street|Suite 710|New York|New York|10017-8601|United States",
                "orphan_designation": {
                    "original_text": "Treatment of subarachnoid hemorrhage",
                    "umls_id": "C0038525",
                    "parsed_text": "Subarachnoid Hemorrhage"
                }
            },
            {
                "compound_id": 3547,
                "inchl_key": "NGOGFTYYXHNFQH-UHFFFAOYSA-N",
                "generic_name": "Fasudil",
                "designated_date": "01/15/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Woolsey Pharmaceuticals, Inc.|233 Broadway|Suite 1750|New York|New York|10279|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Amyotrophic Lateral Sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            },
            {
                "compound_id": 3547,
                "inchl_key": "NGOGFTYYXHNFQH-UHFFFAOYSA-N",
                "generic_name": "Fasudil",
                "designated_date": "12/21/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Woolsey Pharmaceuticals, Inc.|233 Broadway, Suite 1750|New York|New York|10279|United States",
                "orphan_designation": {
                    "original_text": "Treatment of progressive supranuclear palsy",
                    "umls_id": "C0038868",
                    "parsed_text": "Progressive supranuclear palsy"
                }
            }
        ]
    },
    {
        "_id": "LFVPBERIVUNMGV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 163751,
                "inchl_key": "LFVPBERIVUNMGV-UHFFFAOYSA-N",
                "generic_name": "fasudil HCL",
                "designated_date": "08/25/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Woolsey Pharmaceuticals, Inc.|233 Broadway|Suite 1750|New York|New York|10279|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Huntingtons Disease",
                    "umls_id": "C0020179",
                    "parsed_text": "huntingtons disease"
                }
            },
            {
                "compound_id": 163751,
                "inchl_key": "LFVPBERIVUNMGV-UHFFFAOYSA-N",
                "generic_name": "Fasudil hydrochloride",
                "designated_date": "01/07/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Woolsey Pharmaceuticals, Inc.|233 Broadway|Suite 1750|New York|New York|10279|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Corticobasal Syndrome",
                    "umls_id": "C0039082",
                    "parsed_text": "Syndrome"
                }
            }
        ]
    },
    {
        "_id": "AKJHMTWEGVYYSE-FXILSDISSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5288209,
                "inchl_key": "AKJHMTWEGVYYSE-FXILSDISSA-N",
                "generic_name": "fenretinide",
                "designated_date": "09/04/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CerRx, Inc.|Reese Technology Center|9801 Reese Blvd, Suite 104|Lubbock|Texas|79416|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cutaneous T-cell lymphoma",
                    "umls_id": "C0079773",
                    "parsed_text": "cutaneous T-cell lymphoma"
                }
            },
            {
                "compound_id": 5288209,
                "inchl_key": "AKJHMTWEGVYYSE-FXILSDISSA-N",
                "generic_name": "fenretinide",
                "designated_date": "12/22/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SciTech Development, LLC|281 Kercheval Avenue|Grosse Pointe Farms|Michigan|48236|United States",
                "orphan_designation": {
                    "original_text": "Treatment of peripheral T-cell lymphoma (including follicular T-cell lymphoma)",
                    "umls_id": "C0079774,C2700204",
                    "parsed_text": "Peripheral T-Cell Lymphoma , Follicular T-cell lymphoma"
                }
            },
            {
                "compound_id": 5288209,
                "inchl_key": "AKJHMTWEGVYYSE-FXILSDISSA-N",
                "generic_name": "Fenretinide",
                "designated_date": "10/05/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "USC-CHLA Institute for Pediatric Clinical Research|Children's Hospital Los Angeles|MS 55|Los Angeles|California|90027|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuroblastoma",
                    "umls_id": "C0027819",
                    "parsed_text": "Neuroblastoma"
                }
            },
            {
                "compound_id": 5288209,
                "inchl_key": "AKJHMTWEGVYYSE-FXILSDISSA-N",
                "generic_name": "fenretinide",
                "designated_date": "09/04/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CerRx, Inc.|Reese Technology Center|9801 Reese Blvd, Suite 104|Lubbock|Texas|79416|United States",
                "orphan_designation": {
                    "original_text": "Treatment of peripheral T-cell lymphoma",
                    "umls_id": "C0079774",
                    "parsed_text": "Peripheral T-Cell Lymphoma"
                }
            },
            {
                "compound_id": 5288209,
                "inchl_key": "AKJHMTWEGVYYSE-FXILSDISSA-N",
                "generic_name": "fenretinide",
                "designated_date": "02/01/2007",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cancer Research UK|61 Lincoln's Inn Fields|WC2A 3PX|London|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of Ewing's sarcoma family of tumors.",
                    "umls_id": "C0027651",
                    "parsed_text": "Tumors"
                }
            },
            {
                "compound_id": 5288209,
                "inchl_key": "AKJHMTWEGVYYSE-FXILSDISSA-N",
                "generic_name": "Fenretinide",
                "designated_date": "04/07/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "McGill University|McGill University|Montreal|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis patients",
                    "umls_id": "C0010674,C0033809,C3714514",
                    "parsed_text": "Cystic Fibrosis , Pseudomonas aeruginosa , Infections"
                }
            },
            {
                "compound_id": 5288209,
                "inchl_key": "AKJHMTWEGVYYSE-FXILSDISSA-N",
                "generic_name": "fenretinide",
                "designated_date": "12/19/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SciTech Development, LLC|281 Kercheval Avenue|Grosse Pointe Farms|Michigan|48236|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cutaneous T-cell lymphoma",
                    "umls_id": "C0079773",
                    "parsed_text": "cutaneous T-cell lymphoma"
                }
            }
        ]
    },
    {
        "_id": "MIWWSGDADVMLTG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 68792,
                "inchl_key": "MIWWSGDADVMLTG-UHFFFAOYSA-N",
                "generic_name": "fexinidazole",
                "designated_date": "04/04/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sanofi US Services, Inc.|55 Corporate Drive|Mail Code 55D-225A|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of human African trypanosomiasis (HAT) or sleeping sickness",
                    "umls_id": "C0041228",
                    "parsed_text": "African Trypanosomiasis"
                }
            }
        ]
    },
    {
        "_id": "VHZXNQKVFDBFIK-DTCRIMCDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 69944058,
                "inchl_key": "VHZXNQKVFDBFIK-DTCRIMCDSA-N",
                "generic_name": "fluasterone",
                "designated_date": "03/28/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sterotherapeutics, LLC|716 North Bethlehem Pike|Suite 203|Spring House|Pennsylvania|19002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Cushing syndrome (including hyperglycemia, nonalcoholic fatty liver disease, and nonalcoholic steatosis)",
                    "umls_id": "C0010481,C0020456,C0400966,C2711227",
                    "parsed_text": "Cushing Syndrome , Hyperglycemia , Nonalcoholic Fatty Liver Disease , Steatosis"
                }
            }
        ]
    },
    {
        "_id": "VHZXNQKVFDBFIK-WYTRLKPUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 145705956,
                "inchl_key": "VHZXNQKVFDBFIK-WYTRLKPUSA-N",
                "generic_name": "fluasterone",
                "designated_date": "03/28/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sterotherapeutics, LLC|716 North Bethlehem Pike|Suite 203|Spring House|Pennsylvania|19002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Cushing syndrome (including hyperglycemia, nonalcoholic fatty liver disease, and nonalcoholic steatosis)",
                    "umls_id": "C0010481,C0020456,C0400966,C2711227",
                    "parsed_text": "Cushing Syndrome , Hyperglycemia , Nonalcoholic Fatty Liver Disease , Steatosis"
                }
            }
        ]
    },
    {
        "_id": "VHZXNQKVFDBFIK-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 21906940,
                "inchl_key": "VHZXNQKVFDBFIK-UHFFFAOYSA-N",
                "generic_name": "fluasterone",
                "designated_date": "03/28/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sterotherapeutics, LLC|716 North Bethlehem Pike|Suite 203|Spring House|Pennsylvania|19002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Cushing syndrome (including hyperglycemia, nonalcoholic fatty liver disease, and nonalcoholic steatosis)",
                    "umls_id": "C0010481,C0020456,C0400966,C2711227",
                    "parsed_text": "Cushing Syndrome , Hyperglycemia , Nonalcoholic Fatty Liver Disease , Steatosis"
                }
            }
        ]
    },
    {
        "_id": "VHZXNQKVFDBFIK-NBBHSKLNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 133967,
                "inchl_key": "VHZXNQKVFDBFIK-NBBHSKLNSA-N",
                "generic_name": "fluasterone",
                "designated_date": "03/28/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sterotherapeutics, LLC|716 North Bethlehem Pike|Suite 203|Spring House|Pennsylvania|19002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Cushing syndrome (including hyperglycemia, nonalcoholic fatty liver disease, and nonalcoholic steatosis)",
                    "umls_id": "C0010481,C0020456,C0400966,C2711227",
                    "parsed_text": "Cushing Syndrome , Hyperglycemia , Nonalcoholic Fatty Liver Disease , Steatosis"
                }
            }
        ]
    },
    {
        "_id": "GIUYCYHIANZCFB-FJFJXFQQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 30751,
                "inchl_key": "GIUYCYHIANZCFB-FJFJXFQQSA-N",
                "generic_name": "Fludarabine phosphate",
                "trade_name": "Fludara",
                "designated_date": "04/18/1989",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a004/18/1991\u00a0",
                "exclusivity_end_date": "\u00a004/18/1998\u00a0",
                "sponsor": "Berlex Laboratories, Inc.|15049 San Pablo Avenue, P.O. Box 4099|Richmond|California|94804|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL.",
                    "umls_id": "C0023434,C0278791",
                    "parsed_text": "Chronic Lymphocytic Leukemia , Refractory CLL"
                }
            },
            {
                "compound_id": 30751,
                "inchl_key": "GIUYCYHIANZCFB-FJFJXFQQSA-N",
                "generic_name": "Fludarabine phosphate",
                "designated_date": "04/18/1989",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Berlex Laboratories, Inc.|15049 San Pablo Avenue|P.O. Box 4099|Richmond|California|94804|United States",
                "orphan_designation": {
                    "original_text": "Treatment and management of patients with non-Hodgkins lymphoma.",
                    "umls_id": "C0024305",
                    "parsed_text": "Non-Hodgkins Lymphoma"
                }
            }
        ]
    },
    {
        "_id": "SMANXXCATUTDDT-QPJJXVBHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 941361,
                "inchl_key": "SMANXXCATUTDDT-QPJJXVBHSA-N",
                "generic_name": "flunarizine",
                "designated_date": "07/20/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Xenon Pharmaceuticals, Inc.|3650 Gilmore Way|Burnaby|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of hemiplegic migraine",
                    "umls_id": "C0270862",
                    "parsed_text": "Hemiplegic migraine"
                }
            },
            {
                "compound_id": 941361,
                "inchl_key": "SMANXXCATUTDDT-QPJJXVBHSA-N",
                "generic_name": "flunarizine",
                "designated_date": "11/20/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Xenon Pharmaceuticals, Inc.|200-3650 Gilmore Way|Burnaby|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of Alternating Hemiplegia",
                    "umls_id": "C0338488",
                    "parsed_text": "Alternating hemiplegia"
                }
            },
            {
                "compound_id": 941361,
                "inchl_key": "SMANXXCATUTDDT-QPJJXVBHSA-N",
                "generic_name": "flunarizine",
                "designated_date": "01/06/1986",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Janssen Research Foundation|P.O. Box 200|Titusville|New Jersey|8560|United States",
                "orphan_designation": {
                    "original_text": "Treatment of alternating hemiplegia.",
                    "umls_id": "C0018991",
                    "parsed_text": "Hemiplegia"
                }
            },
            {
                "compound_id": 941361,
                "inchl_key": "SMANXXCATUTDDT-QPJJXVBHSA-N",
                "generic_name": "flunarizine",
                "designated_date": "06/24/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Marathon Pharmaceuticals, LLC|1033 Skokie Blvd.|Suite 600|Northbrook|Illinois|60062|United States",
                "orphan_designation": {
                    "original_text": "Treatment of alternating hemiplegia",
                    "umls_id": "C0018991",
                    "parsed_text": "Hemiplegia"
                }
            }
        ]
    },
    {
        "_id": "GHASVSINZRGABV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3385,
                "inchl_key": "GHASVSINZRGABV-UHFFFAOYSA-N",
                "generic_name": "Fluorouracil",
                "designated_date": "10/27/1989",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States",
                "orphan_designation": {
                    "original_text": "For use in combination with interferon alpha-2a, recombinant, for the treatment of esophageal carcinoma.",
                    "umls_id": "C0152018",
                    "parsed_text": "Esophageal carcinoma"
                }
            },
            {
                "compound_id": 3385,
                "inchl_key": "GHASVSINZRGABV-UHFFFAOYSA-N",
                "generic_name": "Fluorouracil",
                "designated_date": "06/29/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ethypharm SA|194 Bureaux de la Colline - Batiment D|92213 Saint-Cloud Cedex|France",
                "orphan_designation": {
                    "original_text": "Treatment of glioblastoma multiforme.",
                    "umls_id": "C0017636",
                    "parsed_text": "Glioblastoma multiforme"
                }
            },
            {
                "compound_id": 3385,
                "inchl_key": "GHASVSINZRGABV-UHFFFAOYSA-N",
                "generic_name": "Fluorouracil",
                "designated_date": "04/18/1990",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States",
                "orphan_designation": {
                    "original_text": "For use in combination with interferon alpha-2a, recombinant, for the treatment of advanced colorectal carcinoma.",
                    "umls_id": "C5206582",
                    "parsed_text": "Advanced Colorectal Carcinoma"
                }
            },
            {
                "compound_id": 3385,
                "inchl_key": "GHASVSINZRGABV-UHFFFAOYSA-N",
                "generic_name": "Fluorouracil",
                "designated_date": "02/06/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Lederle Laboratories|Division of American Cyanamid Company|401 N. Middletown Road|Pearl River|New York|10965|United States",
                "orphan_designation": {
                    "original_text": "For use in combination with leucovorin for therapy of metastatic adenocarcinoma of the colon and rectum.",
                    "umls_id": "C0334277,C0338106",
                    "parsed_text": "Metastatic adenocarcinoma , adenocarcinoma of the colon"
                }
            }
        ]
    },
    {
        "_id": "RIKMMFOAQPJVMX-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3406,
                "inchl_key": "RIKMMFOAQPJVMX-UHFFFAOYSA-N",
                "generic_name": "fomepizole",
                "trade_name": "Antizole",
                "designated_date": "12/22/1988",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Use for suspected or confirmed methanol poisoning, either alone or in combination with hemodialysis",
                "marketing_approval_date": "\u00a012/08/2000\u00a0",
                "exclusivity_end_date": "\u00a012/08/2007\u00a0",
                "sponsor": "Par Pharmaceuticals, Inc|1 Ram Ridge Road|Chestnut Ridge|New York|10977|United States",
                "orphan_designation": {
                    "original_text": "Treatment of methanol or ethylene glycol poisoning.",
                    "umls_id": "C0413194",
                    "parsed_text": "Ethylene glycol poisoning"
                }
            },
            {
                "compound_id": 3406,
                "inchl_key": "RIKMMFOAQPJVMX-UHFFFAOYSA-N",
                "generic_name": "Fomepizole",
                "designated_date": "03/02/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Denver Health - Rocky Mountain Poison & Drug Safety|777 Bannock St. MC 0180|Denver|Colorado|80204|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acetaminophen overdose",
                    "umls_id": "C0572025",
                    "parsed_text": "Acetaminophen overdose"
                }
            },
            {
                "compound_id": 3406,
                "inchl_key": "RIKMMFOAQPJVMX-UHFFFAOYSA-N",
                "generic_name": "fomepizole",
                "trade_name": "Antizole",
                "designated_date": "12/22/1988",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "As an antidote to ethylene glycol (antifreeze) poisoning, or for use in suspected ethylene glycol ingestion.",
                "marketing_approval_date": "\u00a012/04/1997\u00a0",
                "exclusivity_end_date": "\u00a012/04/2004\u00a0",
                "sponsor": "Par Pharmaceuticals, Inc|1 Ram Ridge Road|Chestnut Ridge|New York|10977|United States",
                "orphan_designation": {
                    "original_text": "Treatment of methanol or ethylene glycol poisoning.",
                    "umls_id": "C0413194",
                    "parsed_text": "Ethylene glycol poisoning"
                }
            }
        ]
    },
    {
        "_id": "RNBGYGVWRKECFJ-VRPWFDPXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 172313,
                "inchl_key": "RNBGYGVWRKECFJ-VRPWFDPXSA-N",
                "generic_name": "Fructose-1,6-diphosphate",
                "designated_date": "05/29/1998",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Questcor Pharmaceuticals, Inc.|3260 Whipple Road|Union City|California|94587|United States",
                "orphan_designation": {
                    "original_text": "Treatment of painful vaso-occlusive episodes associated with sickle cell disease.",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            }
        ]
    },
    {
        "_id": "RNBGYGVWRKECFJ-ZXXMMSQZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 445557,
                "inchl_key": "RNBGYGVWRKECFJ-ZXXMMSQZSA-N",
                "generic_name": "Fructose-1,6-diphosphate",
                "designated_date": "05/29/1998",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Questcor Pharmaceuticals, Inc.|3260 Whipple Road|Union City|California|94587|United States",
                "orphan_designation": {
                    "original_text": "Treatment of painful vaso-occlusive episodes associated with sickle cell disease.",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            }
        ]
    },
    {
        "_id": "RNBGYGVWRKECFJ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 718,
                "inchl_key": "RNBGYGVWRKECFJ-UHFFFAOYSA-N",
                "generic_name": "Fructose-1,6-diphosphate",
                "designated_date": "05/29/1998",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Questcor Pharmaceuticals, Inc.|3260 Whipple Road|Union City|California|94587|United States",
                "orphan_designation": {
                    "original_text": "Treatment of painful vaso-occlusive episodes associated with sickle cell disease.",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            }
        ]
    },
    {
        "_id": "RNBGYGVWRKECFJ-JGWLITMVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 46937007,
                "inchl_key": "RNBGYGVWRKECFJ-JGWLITMVSA-N",
                "generic_name": "Fructose-1,6-diphosphate",
                "designated_date": "05/29/1998",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Questcor Pharmaceuticals, Inc.|3260 Whipple Road|Union City|California|94587|United States",
                "orphan_designation": {
                    "original_text": "Treatment of painful vaso-occlusive episodes associated with sickle cell disease.",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            }
        ]
    },
    {
        "_id": "RNBGYGVWRKECFJ-ARQDHWQXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10267,
                "inchl_key": "RNBGYGVWRKECFJ-ARQDHWQXSA-N",
                "generic_name": "Fructose-1,6-diphosphate",
                "designated_date": "05/29/1998",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Questcor Pharmaceuticals, Inc.|3260 Whipple Road|Union City|California|94587|United States",
                "orphan_designation": {
                    "original_text": "Treatment of painful vaso-occlusive episodes associated with sickle cell disease.",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            }
        ]
    },
    {
        "_id": "UGJMXCAKCUNAIE-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3446,
                "inchl_key": "UGJMXCAKCUNAIE-UHFFFAOYSA-N",
                "generic_name": "gabapentin",
                "designated_date": "07/05/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Warner-Lambert Company|Parke-Davis Pharmaceutical Research Division|2800 Plymouth Road|Ann Arbor|Michigan|48105|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            },
            {
                "compound_id": 3446,
                "inchl_key": "UGJMXCAKCUNAIE-UHFFFAOYSA-N",
                "generic_name": "gabapentin",
                "trade_name": "Gralise",
                "designated_date": "11/08/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the management of postherpetic neuralgia",
                "marketing_approval_date": "\u00a001/28/2011\u00a0",
                "exclusivity_end_date": "\u00a001/28/2018\u00a0",
                "sponsor": "Golf Acquiror LLC|44 Whippany Road|Suite 300|Morristown|New Jersey|7960|United States",
                "orphan_designation": {
                    "original_text": "Management of postherpetic neuralgia",
                    "umls_id": "C0032768",
                    "parsed_text": "Postherpetic neuralgia"
                }
            }
        ]
    },
    {
        "_id": "PGTVWKLGGCQMBR-FLBATMFCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6918305,
                "inchl_key": "PGTVWKLGGCQMBR-FLBATMFCSA-N",
                "generic_name": "ganaxolone",
                "designated_date": "03/24/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Marinus Pharmaceuticals, Inc.|3 Radnor Corporate Center|Suite 304|Radnor|Pennsylvania|19087|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Protocadherin 19 (PCDH19) female epilepsy.",
                    "umls_id": "C0014544",
                    "parsed_text": "Epilepsy"
                }
            },
            {
                "compound_id": 6918305,
                "inchl_key": "PGTVWKLGGCQMBR-FLBATMFCSA-N",
                "generic_name": "Ganaxolone",
                "designated_date": "05/25/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Marinus Pharmaceuticals, Inc.|21 Business Park Drive|Branford|Connecticut|6405|United States",
                "orphan_designation": {
                    "original_text": "Treatment of infantile spasms.",
                    "umls_id": "C3887898",
                    "parsed_text": "Infantile spasms"
                }
            },
            {
                "compound_id": 6918305,
                "inchl_key": "PGTVWKLGGCQMBR-FLBATMFCSA-N",
                "generic_name": "ganaxolone",
                "designated_date": "06/28/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Marinus Pharmaceuticals|170 North Radnor Chester Road|Suite 250|Radnor|Pennsylvania|19087|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cyclin-dependent kinase-like 5 (CDKL5) gene-related early-onset infantile epileptic encephalopathy",
                    "umls_id": "C0543888",
                    "parsed_text": "Epileptic encephalopathy"
                }
            },
            {
                "compound_id": 6918305,
                "inchl_key": "PGTVWKLGGCQMBR-FLBATMFCSA-N",
                "generic_name": "ganaxolone",
                "designated_date": "04/14/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Marinus Pharmaceuticals, Inc.|Three Radnor Corporate Center|100 Matsonford Road|Radnor|Pennsylvania|19087|United States",
                "orphan_designation": {
                    "original_text": "Treatment of status epilepticus.",
                    "umls_id": "C0038220",
                    "parsed_text": "Status Epilepticus"
                }
            },
            {
                "compound_id": 6918305,
                "inchl_key": "PGTVWKLGGCQMBR-FLBATMFCSA-N",
                "generic_name": "ganaxolone",
                "designated_date": "12/28/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Marinus Pharmaceuticals|170 North Radnor Chester Road|Suite 250|Radnor|Pennsylvania|19087|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X Syndrome",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "HUCXKZBETONXFO-NJFMWZAGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5282199,
                "inchl_key": "HUCXKZBETONXFO-NJFMWZAGSA-N",
                "generic_name": "geranylgeranylacetone",
                "designated_date": "06/26/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenefly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of spinal and bulbar muscular atrophy",
                    "umls_id": "C1839259",
                    "parsed_text": "Spinal and Bulbar Muscular Atrophy"
                }
            },
            {
                "compound_id": 5282199,
                "inchl_key": "HUCXKZBETONXFO-NJFMWZAGSA-N",
                "generic_name": "geranylgeranylacetone",
                "designated_date": "06/10/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenefly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Prevention of Acute Radiation Syndrome",
                    "umls_id": "C0520799",
                    "parsed_text": "Acute Radiation Syndrome"
                }
            },
            {
                "compound_id": 5282199,
                "inchl_key": "HUCXKZBETONXFO-NJFMWZAGSA-N",
                "generic_name": "Geranylgeranylacetone",
                "designated_date": "06/16/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenefly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Prevention of post-hepatectomy liver failure",
                    "umls_id": "C0085605",
                    "parsed_text": "Liver Failure"
                }
            }
        ]
    },
    {
        "_id": "GYQYAJJFPNQOOW-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 49803313,
                "inchl_key": "GYQYAJJFPNQOOW-UHFFFAOYSA-N",
                "generic_name": "gilteritinib",
                "trade_name": "XOSPATA",
                "designated_date": "07/13/2017",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.",
                "marketing_approval_date": "\u00a011/28/2018\u00a0",
                "exclusivity_end_date": "\u00a011/28/2025\u00a0",
                "exclusivity_protected_indication": "XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.",
                "sponsor": "Astellas Pharma US, Inc.|1 Astellas Way|Northbrook|Illinois|60062|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia (AML)",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "MASNOZXLGMXCHN-ZLPAWPGGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16132283,
                "inchl_key": "MASNOZXLGMXCHN-ZLPAWPGGSA-N",
                "generic_name": "glucagon",
                "designated_date": "12/05/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biodel, Inc.|100 Saw Mill Road|Danbury|Connecticut|6810|United States",
                "orphan_designation": {
                    "original_text": "Prevention of hypoglycemia in the congenital hyperinsulinism population",
                    "umls_id": "C0020615,C3888018",
                    "parsed_text": "Hypoglycemia , Congenital Hyperinsulinism"
                }
            }
        ]
    },
    {
        "_id": "HIZCTWCPHWUPFU-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 61156,
                "inchl_key": "HIZCTWCPHWUPFU-UHFFFAOYSA-N",
                "generic_name": "glycerol tribenzoate",
                "designated_date": "09/10/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Curyx Bio, Inc.|140 E. Ridgewood Avenue|Suite 415 South Tower|Paramus|New Jersey|7652|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Huntingtons disease",
                    "umls_id": "C0020179",
                    "parsed_text": "huntingtons disease"
                }
            },
            {
                "compound_id": 61156,
                "inchl_key": "HIZCTWCPHWUPFU-UHFFFAOYSA-N",
                "generic_name": "glyceryl tribenzoate",
                "designated_date": "10/15/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Curyx Bio, Inc.|140 E. Ridgewood Avenue|Suite 415 South Tower|Paramus|New Jersey|7652|United States",
                "orphan_designation": {
                    "original_text": "Treatment of nonketotic hyperglycinemia",
                    "umls_id": "C0751748",
                    "parsed_text": "Nonketotic Hyperglycinemia"
                }
            }
        ]
    },
    {
        "_id": "GKMPTIBZVGZJDN-RJLNLWLESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 123133491,
                "inchl_key": "GKMPTIBZVGZJDN-RJLNLWLESA-N",
                "generic_name": "H-(D)p-Benzoylphenylalanyl-(D)seryl-(D)tryptophanyl-(D)seryl-(D)pentafluorophenylalanyl-(D)cyclohexylalanyl-(D)arginyl-(D)arginyl-(D)arginyl-(D)glutaminyl-(D)arginyl-(D)arginine acetate salt",
                "designated_date": "12/22/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CanBas Company, Ltd.|2-2-1 Otemachi|Numazu City|Shizuoka|Japan",
                "orphan_designation": {
                    "original_text": "For use in combination with cisplatin and pemetrexed for the treatment of patients with mesothelioma",
                    "umls_id": "C0025500",
                    "parsed_text": "Mesothelioma"
                }
            }
        ]
    },
    {
        "_id": "SJUWEPZBTXEUMU-CTHHTMFSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 132470909,
                "inchl_key": "SJUWEPZBTXEUMU-CTHHTMFSSA-N",
                "generic_name": "halofuginone hydrobromide",
                "designated_date": "10/13/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Akashi Therapeutics, Inc.|245 First Street|18th Floor|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Duchenne Muscular Dystrophy",
                    "umls_id": "C0013264",
                    "parsed_text": "DUCHENNE MUSCULAR DYSTROPHY"
                }
            }
        ]
    },
    {
        "_id": "SJUWEPZBTXEUMU-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 62893,
                "inchl_key": "SJUWEPZBTXEUMU-UHFFFAOYSA-N",
                "generic_name": "halofuginone hydrobromide",
                "designated_date": "10/13/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Akashi Therapeutics, Inc.|245 First Street|18th Floor|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Duchenne Muscular Dystrophy",
                    "umls_id": "C0013264",
                    "parsed_text": "DUCHENNE MUSCULAR DYSTROPHY"
                }
            }
        ]
    },
    {
        "_id": "SJUWEPZBTXEUMU-LIOBNPLQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11591339,
                "inchl_key": "SJUWEPZBTXEUMU-LIOBNPLQSA-N",
                "generic_name": "halofuginone hydrobromide",
                "designated_date": "10/13/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Akashi Therapeutics, Inc.|245 First Street|18th Floor|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Duchenne Muscular Dystrophy",
                    "umls_id": "C0013264",
                    "parsed_text": "DUCHENNE MUSCULAR DYSTROPHY"
                }
            }
        ]
    },
    {
        "_id": "SJUWEPZBTXEUMU-LDXVYITESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 400771,
                "inchl_key": "SJUWEPZBTXEUMU-LDXVYITESA-N",
                "generic_name": "halofuginone hydrobromide",
                "designated_date": "10/13/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Akashi Therapeutics, Inc.|245 First Street|18th Floor|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Duchenne Muscular Dystrophy",
                    "umls_id": "C0013264",
                    "parsed_text": "DUCHENNE MUSCULAR DYSTROPHY"
                }
            }
        ]
    },
    {
        "_id": "DGTVQJOTEDTFMR-VYFXDUNUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 126970648,
                "inchl_key": "DGTVQJOTEDTFMR-VYFXDUNUSA-N",
                "generic_name": "Histrelin acetate",
                "trade_name": "Supprelin Injection",
                "designated_date": "08/10/1988",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of central precocious puberty.",
                "marketing_approval_date": "\u00a012/24/1991\u00a0",
                "exclusivity_end_date": "\u00a012/24/1998\u00a0",
                "sponsor": "Roberts Pharmaceutical Corp.|Meridian Center III|6 Industrial Way West|Eatontown|New Jersey|7724|United States",
                "orphan_designation": {
                    "original_text": "Treatment of central precocious puberty.",
                    "umls_id": "C0342543",
                    "parsed_text": "Central Precocious Puberty"
                }
            }
        ]
    },
    {
        "_id": "BKEMVGVBBDMHKL-VYFXDUNUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 56927879,
                "inchl_key": "BKEMVGVBBDMHKL-VYFXDUNUSA-N",
                "generic_name": "Histrelin acetate",
                "trade_name": "Supprelin Injection",
                "designated_date": "08/10/1988",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of central precocious puberty.",
                "marketing_approval_date": "\u00a012/24/1991\u00a0",
                "exclusivity_end_date": "\u00a012/24/1998\u00a0",
                "sponsor": "Roberts Pharmaceutical Corp.|Meridian Center III|6 Industrial Way West|Eatontown|New Jersey|7724|United States",
                "orphan_designation": {
                    "original_text": "Treatment of central precocious puberty.",
                    "umls_id": "C0342543",
                    "parsed_text": "Central Precocious Puberty"
                }
            }
        ]
    },
    {
        "_id": "HHXHVIJIIXKSOE-QILQGKCVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25077993,
                "inchl_key": "HHXHVIJIIXKSOE-QILQGKCVSA-N",
                "generic_name": "Histrelin acetate",
                "trade_name": "Supprelin Injection",
                "designated_date": "08/10/1988",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of central precocious puberty.",
                "marketing_approval_date": "\u00a012/24/1991\u00a0",
                "exclusivity_end_date": "\u00a012/24/1998\u00a0",
                "sponsor": "Roberts Pharmaceutical Corp.|Meridian Center III|6 Industrial Way West|Eatontown|New Jersey|7724|United States",
                "orphan_designation": {
                    "original_text": "Treatment of central precocious puberty.",
                    "umls_id": "C0342543",
                    "parsed_text": "Central Precocious Puberty"
                }
            },
            {
                "compound_id": 25077993,
                "inchl_key": "HHXHVIJIIXKSOE-QILQGKCVSA-N",
                "generic_name": "Histrelin",
                "designated_date": "05/03/1991",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Anderson, Karl E., M.D.|University of Texas Medical Branch at Galveston|Route J-09, 700 The Strand|Galveston|Texas|77550|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria.",
                    "umls_id": "C0162532,C0162565,C0342856",
                    "parsed_text": "Variegate Porphyria , Acute intermittent porphyria , Coproporphyria"
                }
            },
            {
                "compound_id": 25077993,
                "inchl_key": "HHXHVIJIIXKSOE-QILQGKCVSA-N",
                "generic_name": "Histrelin",
                "trade_name": "Supprelin LA",
                "designated_date": "11/18/2005",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of central precocious puberty",
                "marketing_approval_date": "\u00a005/03/2007\u00a0",
                "exclusivity_end_date": "\u00a005/03/2014\u00a0",
                "sponsor": "Endo Pharmaceuticals Solutions, Inc.|100 Endo Blvd|Chadds Ford|Pennsylvania|19317|United States",
                "orphan_designation": {
                    "original_text": "Treatment of central precocious puberty",
                    "umls_id": "C0342543",
                    "parsed_text": "Central Precocious Puberty"
                }
            }
        ]
    },
    {
        "_id": "OWAUGAMNPZHEOJ-YKZVIGSYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25084151,
                "inchl_key": "OWAUGAMNPZHEOJ-YKZVIGSYSA-N",
                "generic_name": "Histrelin acetate",
                "trade_name": "Supprelin Injection",
                "designated_date": "08/10/1988",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of central precocious puberty.",
                "marketing_approval_date": "\u00a012/24/1991\u00a0",
                "exclusivity_end_date": "\u00a012/24/1998\u00a0",
                "sponsor": "Roberts Pharmaceutical Corp.|Meridian Center III|6 Industrial Way West|Eatontown|New Jersey|7724|United States",
                "orphan_designation": {
                    "original_text": "Treatment of central precocious puberty.",
                    "umls_id": "C0342543",
                    "parsed_text": "Central Precocious Puberty"
                }
            }
        ]
    },
    {
        "_id": "VSNHCAURESNICA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3657,
                "inchl_key": "VSNHCAURESNICA-UHFFFAOYSA-N",
                "generic_name": "hydroxyurea",
                "designated_date": "03/16/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ebelle D'Ebelle Pharmaceuticals LLC|5 Witherwood Drive|Hamburg|New Jersey|7419|United States",
                "orphan_designation": {
                    "original_text": "Treatment of symptomatic sickle cell disease in pediatric patients, less than 17 years of age.",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            },
            {
                "compound_id": 3657,
                "inchl_key": "VSNHCAURESNICA-UHFFFAOYSA-N",
                "generic_name": "hydroxycarbamide (hydroxyurea)",
                "trade_name": "Siklos",
                "designated_date": "07/24/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "To reduce the frequency of painful crises and to reduce the need for blood transfusions in pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crisis",
                "marketing_approval_date": "\u00a012/21/2017\u00a0",
                "exclusivity_end_date": "\u00a012/21/2024\u00a0",
                "exclusivity_protected_indication": "To reduce the frequency of painful crises and to reduce the need for blood transfusions in pediatric patients, 2 years of age amd older, with sickle cell anemia with recurrent moderate to severe painful crisis",
                "sponsor": "Addmedica Laboratories|37 rue de Caumartin|Paris|France",
                "orphan_designation": {
                    "original_text": "Treatment of sickle cell disease in patients under 18 years of age",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            },
            {
                "compound_id": 3657,
                "inchl_key": "VSNHCAURESNICA-UHFFFAOYSA-N",
                "generic_name": "hydroxyurea",
                "designated_date": "04/15/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "UPM Pharmaceuticals, Inc.|6200 Seaforth Street|Baltimore|Maryland|21224|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients with sickle cell anemia.",
                    "umls_id": "C0002895",
                    "parsed_text": "SICKLE CELL ANEMIA"
                }
            },
            {
                "compound_id": 3657,
                "inchl_key": "VSNHCAURESNICA-UHFFFAOYSA-N",
                "generic_name": "Hydroxyurea",
                "trade_name": "Droxia",
                "designated_date": "10/01/1990",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "To reduce the frequency of painful crises and to reduce the need for blood transfusions in adult patients with sickle cell anemia with recurrent moderate to severe painful crises (generally at least 3 during the preceding 12 months).",
                "marketing_approval_date": "\u00a002/25/1998\u00a0",
                "exclusivity_end_date": "\u00a002/25/2005\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|P.O. Box 4000|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.",
                    "umls_id": "C0002895,C0037054",
                    "parsed_text": "SICKLE CELL ANEMIA , Hemoglobin S"
                }
            },
            {
                "compound_id": 3657,
                "inchl_key": "VSNHCAURESNICA-UHFFFAOYSA-N",
                "generic_name": "Hydroxyurea",
                "designated_date": "03/02/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Nova Laboratories Limited|Martin House|Gloucester Crescent|Leicester|Wigston|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of sickle cell anemia in pediatric patients",
                    "umls_id": "C0002895",
                    "parsed_text": "SICKLE CELL ANEMIA"
                }
            }
        ]
    },
    {
        "_id": "ALHBJBCQLJZYON-PFSRBDOWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71543365,
                "inchl_key": "ALHBJBCQLJZYON-PFSRBDOWSA-N",
                "generic_name": "iadademstat",
                "designated_date": "02/10/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oryzon Genomics S.A.|Carrera de San Jeronimo 15, 2 planta|Madrid|Spain|28014|Spain",
                "orphan_designation": {
                    "original_text": "Treatment of Acute Myeloid Leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "XYFPWWZEPKGCCK-GOSISDBHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24821094,
                "inchl_key": "XYFPWWZEPKGCCK-GOSISDBHSA-N",
                "generic_name": "ibrutinib",
                "trade_name": "Imbruvica",
                "designated_date": "04/06/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy",
                "marketing_approval_date": "\u00a002/12/2014\u00a0",
                "exclusivity_end_date": "\u00a002/12/2021\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy",
                "sponsor": "Pharmacyclics, LLC|995 E. Arques Avenue|Sunnyvale|California|94085|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia (CLL)",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "compound_id": 24821094,
                "inchl_key": "XYFPWWZEPKGCCK-GOSISDBHSA-N",
                "generic_name": "ibrutinib",
                "trade_name": "Imbruvica",
                "designated_date": "02/05/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.",
                "marketing_approval_date": "\u00a001/18/2017\u00a0",
                "exclusivity_end_date": "\u00a001/18/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.",
                "sponsor": "Pharmacyclics, LLC|995 E. Arques Avenue|Sunnyvale|California|94085|United States",
                "orphan_designation": {
                    "original_text": "Treatment of splenic marginal zone lymphoma",
                    "umls_id": "C0349632",
                    "parsed_text": "Splenic marginal zone lymphoma"
                }
            },
            {
                "compound_id": 24821094,
                "inchl_key": "XYFPWWZEPKGCCK-GOSISDBHSA-N",
                "generic_name": "ibrutinib",
                "trade_name": "IMBRUVICA",
                "designated_date": "05/30/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Indicated for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and indicated for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) with 17p deletion.",
                "marketing_approval_date": "\u00a005/06/2016\u00a0",
                "exclusivity_end_date": "\u00a005/06/2023\u00a0",
                "exclusivity_protected_indication": "For treatment of patients with small lymphocytic lymphoma (SLL)",
                "sponsor": "Pharmacyclics, LLC|995 E. Arques Avenue|Sunnyvale|California|94085|United States",
                "orphan_designation": {
                    "original_text": "Treatment of small lymphocytic lymphoma",
                    "umls_id": "C0023434",
                    "parsed_text": "Small Lymphocytic Lymphoma"
                }
            },
            {
                "compound_id": 24821094,
                "inchl_key": "XYFPWWZEPKGCCK-GOSISDBHSA-N",
                "generic_name": "ibrutinib",
                "trade_name": "Imbruvica",
                "designated_date": "10/15/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with Waldenstrom's macroglobulinemia",
                "marketing_approval_date": "\u00a001/29/2015\u00a0",
                "exclusivity_end_date": "\u00a001/29/2022\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with Waldenstrom's macroglobulinemia",
                "sponsor": "Pharmacyclics, LLC|995 E. Arques Avenue|Sunnyvale|California|94085|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Waldenstrom's macroglobulinemia",
                    "umls_id": "C0024419",
                    "parsed_text": "Waldenstrom's Macroglobulinemia"
                }
            },
            {
                "compound_id": 24821094,
                "inchl_key": "XYFPWWZEPKGCCK-GOSISDBHSA-N",
                "generic_name": "ibrutinib",
                "trade_name": "Imbruvica",
                "designated_date": "04/06/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion",
                "marketing_approval_date": "\u00a007/28/2014\u00a0",
                "exclusivity_end_date": "\u00a007/28/2021\u00a0",
                "exclusivity_protected_indication": "Treatment of chronic lymphocytic leukemia with 17p deletion who have not received at least one prior therapy",
                "sponsor": "Pharmacyclics, LLC|995 E. Arques Avenue|Sunnyvale|California|94085|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia (CLL)",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "compound_id": 24821094,
                "inchl_key": "XYFPWWZEPKGCCK-GOSISDBHSA-N",
                "generic_name": "ibrutinib",
                "trade_name": "Imbruvica",
                "designated_date": "04/06/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Indicated for the treatment of patients with chronic lymphocytic leukemia",
                "marketing_approval_date": "\u00a003/04/2016\u00a0",
                "exclusivity_end_date": "\u00a003/04/2023\u00a0",
                "exclusivity_protected_indication": "Indicated for the treatment of patients with chronic lymphocytic leukemia without 17p deletion who have not received at least one prior therapy (first line therapy).",
                "sponsor": "Pharmacyclics, LLC|995 E. Arques Avenue|Sunnyvale|California|94085|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia (CLL)",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "compound_id": 24821094,
                "inchl_key": "XYFPWWZEPKGCCK-GOSISDBHSA-N",
                "generic_name": "ibrutinib",
                "designated_date": "09/08/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacyclics, LLC|995 E. Arques Avenue|Sunnyvale|California|94085|United States",
                "orphan_designation": {
                    "original_text": "Treatment of follicular lymphoma",
                    "umls_id": "C0024301",
                    "parsed_text": "follicular lymphoma"
                }
            },
            {
                "compound_id": 24821094,
                "inchl_key": "XYFPWWZEPKGCCK-GOSISDBHSA-N",
                "generic_name": "ibrutinib",
                "designated_date": "03/27/2012",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacyclics, LLC|995 E. Arques Avenue|Sunnyvale|California|94085|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia (CLL).",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "compound_id": 24821094,
                "inchl_key": "XYFPWWZEPKGCCK-GOSISDBHSA-N",
                "generic_name": "ibrutinib",
                "trade_name": "Imbruvica",
                "designated_date": "02/02/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.",
                "marketing_approval_date": "\u00a001/18/2017\u00a0",
                "exclusivity_end_date": "\u00a001/18/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.",
                "sponsor": "Pharmacyclics, LLC|995 E. Arques Avenue|Sunnyvale|California|94085|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with extranodal marginal zone lymphoma (mucosa associated lymphoid tissue [MALT type] lymphoma)",
                    "umls_id": "C0024299,C0242647,C1367654",
                    "parsed_text": "Lymphoma , marginal zone lymphoma , Marginal zone lymphoma"
                }
            },
            {
                "compound_id": 24821094,
                "inchl_key": "XYFPWWZEPKGCCK-GOSISDBHSA-N",
                "generic_name": "ibrutinib",
                "trade_name": "Imbruvica",
                "designated_date": "02/05/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.",
                "marketing_approval_date": "\u00a001/18/2017\u00a0",
                "exclusivity_end_date": "\u00a001/18/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.",
                "sponsor": "Pharmacyclics, LLC|995 E. Arques Avenue|Sunnyvale|California|94085|United States",
                "orphan_designation": {
                    "original_text": "Treatment of nodal marginal zone lymphoma",
                    "umls_id": "C0242647",
                    "parsed_text": "Nodal marginal zone lymphoma"
                }
            },
            {
                "compound_id": 24821094,
                "inchl_key": "XYFPWWZEPKGCCK-GOSISDBHSA-N",
                "generic_name": "ibrutinib",
                "trade_name": "Imbruvica",
                "designated_date": "06/23/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.",
                "marketing_approval_date": "\u00a008/02/2017\u00a0",
                "exclusivity_end_date": "\u00a008/02/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.",
                "sponsor": "Pharmacyclics, LLC|995 East Arques Avenue|Sunnyvale|California|94085|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic Graft versus Host disease.",
                    "umls_id": "C0867389",
                    "parsed_text": "Chronic Graft Versus Host Disease"
                }
            },
            {
                "compound_id": 24821094,
                "inchl_key": "XYFPWWZEPKGCCK-GOSISDBHSA-N",
                "generic_name": "ibrutinib",
                "designated_date": "05/16/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacyclics, LLC|995 E. Arques Avenue|Sunnyvale|California|94085|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            },
            {
                "compound_id": 24821094,
                "inchl_key": "XYFPWWZEPKGCCK-GOSISDBHSA-N",
                "generic_name": "ibrutinib",
                "designated_date": "06/12/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacyclics, LLC|995 East Arques Avenue|Sunnyvale|California|94085|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 24821094,
                "inchl_key": "XYFPWWZEPKGCCK-GOSISDBHSA-N",
                "generic_name": "ibrutinib",
                "trade_name": "Imbruvica",
                "designated_date": "12/03/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy",
                "marketing_approval_date": "\u00a011/13/2013\u00a0",
                "exclusivity_end_date": "\u00a011/13/2020\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy",
                "sponsor": "Pharmacyclics, LLC|995 E. Arques Avenue|Sunnyvale|California|94085|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mantle cell lymphoma",
                    "umls_id": "C4721414",
                    "parsed_text": "Mantle cell lymphoma"
                }
            },
            {
                "compound_id": 24821094,
                "inchl_key": "XYFPWWZEPKGCCK-GOSISDBHSA-N",
                "generic_name": "ibrutinib",
                "designated_date": "02/01/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacyclics, LLC|995 East Arques Avenue|Sunnyvale|California|94085|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma",
                    "umls_id": "C0024623,C1332166",
                    "parsed_text": "Gastric Cancer , Gastroesophageal Junction Adenocarcinoma"
                }
            },
            {
                "compound_id": 24821094,
                "inchl_key": "XYFPWWZEPKGCCK-GOSISDBHSA-N",
                "generic_name": "ibrutinib",
                "designated_date": "10/23/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacyclics, LLC|995 E. Arques Avenue|Sunnyvale|California|94085|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diffuse large B-cell lymphoma",
                    "umls_id": "C1332201",
                    "parsed_text": "Diffuse Large B-Cell Lymphoma"
                }
            }
        ]
    },
    {
        "_id": "QURWXBZNHXJZBE-UAULPJDASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 137705994,
                "inchl_key": "QURWXBZNHXJZBE-UAULPJDASA-N",
                "generic_name": "icatibant",
                "trade_name": "Firazyr",
                "designated_date": "11/25/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of acute attacks of hereditary angioedema in adults 18 years of age and older",
                "marketing_approval_date": "\u00a008/25/2011\u00a0",
                "exclusivity_end_date": "\u00a008/25/2018\u00a0",
                "sponsor": "Takeda Development Center Americas, Inc.|95 Hayden Avenue|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of angioedema",
                    "umls_id": "C0002994",
                    "parsed_text": "Angioedema"
                }
            },
            {
                "compound_id": 137705994,
                "inchl_key": "QURWXBZNHXJZBE-UAULPJDASA-N",
                "generic_name": "icatibant",
                "designated_date": "05/05/2004",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Shire Human Genetic Therapies|700 Main Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of burn patients hospitalized with burn-induced edema",
                    "umls_id": "C0013604",
                    "parsed_text": "Edema"
                }
            }
        ]
    },
    {
        "_id": "QURWXBZNHXJZBE-JNFYKTHFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 90488794,
                "inchl_key": "QURWXBZNHXJZBE-JNFYKTHFSA-N",
                "generic_name": "icatibant",
                "trade_name": "Firazyr",
                "designated_date": "11/25/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of acute attacks of hereditary angioedema in adults 18 years of age and older",
                "marketing_approval_date": "\u00a008/25/2011\u00a0",
                "exclusivity_end_date": "\u00a008/25/2018\u00a0",
                "sponsor": "Takeda Development Center Americas, Inc.|95 Hayden Avenue|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of angioedema",
                    "umls_id": "C0002994",
                    "parsed_text": "Angioedema"
                }
            },
            {
                "compound_id": 90488794,
                "inchl_key": "QURWXBZNHXJZBE-JNFYKTHFSA-N",
                "generic_name": "icatibant",
                "designated_date": "05/05/2004",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Shire Human Genetic Therapies|700 Main Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of burn patients hospitalized with burn-induced edema",
                    "umls_id": "C0013604",
                    "parsed_text": "Edema"
                }
            }
        ]
    },
    {
        "_id": "QURWXBZNHXJZBE-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 14724482,
                "inchl_key": "QURWXBZNHXJZBE-UHFFFAOYSA-N",
                "generic_name": "icatibant",
                "trade_name": "Firazyr",
                "designated_date": "11/25/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of acute attacks of hereditary angioedema in adults 18 years of age and older",
                "marketing_approval_date": "\u00a008/25/2011\u00a0",
                "exclusivity_end_date": "\u00a008/25/2018\u00a0",
                "sponsor": "Takeda Development Center Americas, Inc.|95 Hayden Avenue|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of angioedema",
                    "umls_id": "C0002994",
                    "parsed_text": "Angioedema"
                }
            },
            {
                "compound_id": 14724482,
                "inchl_key": "QURWXBZNHXJZBE-UHFFFAOYSA-N",
                "generic_name": "icatibant",
                "designated_date": "05/05/2004",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Shire Human Genetic Therapies|700 Main Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of burn patients hospitalized with burn-induced edema",
                    "umls_id": "C0013604",
                    "parsed_text": "Edema"
                }
            }
        ]
    },
    {
        "_id": "QURWXBZNHXJZBE-MCDGZUPGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71364,
                "inchl_key": "QURWXBZNHXJZBE-MCDGZUPGSA-N",
                "generic_name": "icatibant",
                "trade_name": "Firazyr",
                "designated_date": "11/25/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of acute attacks of hereditary angioedema in adults 18 years of age and older",
                "marketing_approval_date": "\u00a008/25/2011\u00a0",
                "exclusivity_end_date": "\u00a008/25/2018\u00a0",
                "sponsor": "Takeda Development Center Americas, Inc.|95 Hayden Avenue|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of angioedema",
                    "umls_id": "C0002994",
                    "parsed_text": "Angioedema"
                }
            },
            {
                "compound_id": 71364,
                "inchl_key": "QURWXBZNHXJZBE-MCDGZUPGSA-N",
                "generic_name": "icatibant",
                "designated_date": "05/05/2004",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Shire Human Genetic Therapies|700 Main Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of burn patients hospitalized with burn-induced edema",
                    "umls_id": "C0013604",
                    "parsed_text": "Edema"
                }
            }
        ]
    },
    {
        "_id": "QURWXBZNHXJZBE-SKXRKSCCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6918173,
                "inchl_key": "QURWXBZNHXJZBE-SKXRKSCCSA-N",
                "generic_name": "icatibant",
                "trade_name": "Firazyr",
                "designated_date": "11/25/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of acute attacks of hereditary angioedema in adults 18 years of age and older",
                "marketing_approval_date": "\u00a008/25/2011\u00a0",
                "exclusivity_end_date": "\u00a008/25/2018\u00a0",
                "sponsor": "Takeda Development Center Americas, Inc.|95 Hayden Avenue|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of angioedema",
                    "umls_id": "C0002994",
                    "parsed_text": "Angioedema"
                }
            },
            {
                "compound_id": 6918173,
                "inchl_key": "QURWXBZNHXJZBE-SKXRKSCCSA-N",
                "generic_name": "icatibant",
                "designated_date": "05/05/2004",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Shire Human Genetic Therapies|700 Main Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of burn patients hospitalized with burn-induced edema",
                    "umls_id": "C0013604",
                    "parsed_text": "Edema"
                }
            }
        ]
    },
    {
        "_id": "IFSDAJWBUCMOAH-HNNXBMFYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11625818,
                "inchl_key": "IFSDAJWBUCMOAH-HNNXBMFYSA-N",
                "generic_name": "idelalisib",
                "designated_date": "10/15/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gilead Sciences, Inc.|199 E. Blaine St|Seattle|Washington|98102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of nodal marginal zone lymphoma.",
                    "umls_id": "C0242647",
                    "parsed_text": "Nodal marginal zone lymphoma"
                }
            },
            {
                "compound_id": 11625818,
                "inchl_key": "IFSDAJWBUCMOAH-HNNXBMFYSA-N",
                "generic_name": "idelalisib",
                "trade_name": "Zydelig",
                "designated_date": "10/15/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; and Zydelig is indicated for the treatment of patients with relapsed small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies.",
                "marketing_approval_date": "\u00a007/23/2014\u00a0",
                "exclusivity_end_date": "\u00a007/23/2021\u00a0",
                "exclusivity_protected_indication": "(1) Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; and (2) Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies.",
                "sponsor": "Gilead Sciences, Inc.|199 E. Blaine St|Seattle|Washington|98102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma",
                    "umls_id": "C0023434,C0855095",
                    "parsed_text": "Chronic Lymphocytic Leukemia , Small Lymphocytic Lymphoma"
                }
            },
            {
                "compound_id": 11625818,
                "inchl_key": "IFSDAJWBUCMOAH-HNNXBMFYSA-N",
                "generic_name": "idelalisib",
                "trade_name": "Zydelig",
                "designated_date": "09/26/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Zydelig is indicated for the treatment of patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) who have received at least two prior systemic therapies.",
                "marketing_approval_date": "\u00a007/23/2014\u00a0",
                "exclusivity_end_date": "\u00a007/23/2021\u00a0",
                "exclusivity_protected_indication": "Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies.",
                "sponsor": "Gilead Sciences, Inc.|199 E. Blaine St|Seattle|Washington|98102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of follicular lymphoma",
                    "umls_id": "C0024301",
                    "parsed_text": "follicular lymphoma"
                }
            },
            {
                "compound_id": 11625818,
                "inchl_key": "IFSDAJWBUCMOAH-HNNXBMFYSA-N",
                "generic_name": "idelalisib",
                "designated_date": "10/15/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gilead Sciences, Inc.|199 E. Blaine St|Seattle|Washington|98102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of extranodal marginal zone lymphoma",
                    "umls_id": "C1367654",
                    "parsed_text": "Marginal zone lymphoma"
                }
            },
            {
                "compound_id": 11625818,
                "inchl_key": "IFSDAJWBUCMOAH-HNNXBMFYSA-N",
                "generic_name": "idelalisib",
                "designated_date": "08/25/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gilead Sciences, Inc.|199 E. Blaine St.|Seattle|Washington|98102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "compound_id": 11625818,
                "inchl_key": "IFSDAJWBUCMOAH-HNNXBMFYSA-N",
                "generic_name": "idelalisib",
                "designated_date": "10/15/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gilead Sciences, Inc.|199 E. Blaine St|Seattle|Washington|98102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of splenic marginal zone lymphoma",
                    "umls_id": "C0349632",
                    "parsed_text": "Splenic marginal zone lymphoma"
                }
            },
            {
                "compound_id": 11625818,
                "inchl_key": "IFSDAJWBUCMOAH-HNNXBMFYSA-N",
                "generic_name": "idelalisib",
                "designated_date": "09/26/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gilead Sciences, Inc.|199 E. Blaine St|Seattle|Washington|98102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of lymphoplasmacytic lymphoma with or without Walenstrom's macroglobulinemia",
                    "umls_id": "C0024419,C0334633",
                    "parsed_text": "lymphoplasmacytic lymphoma , Lymphoplasmacytic Lymphoma"
                }
            }
        ]
    },
    {
        "_id": "HOMGKSMUEGBAAB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3690,
                "inchl_key": "HOMGKSMUEGBAAB-UHFFFAOYSA-N",
                "generic_name": "Ifosfamide",
                "trade_name": "Ifex",
                "designated_date": "01/20/1987",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with certain other approved antineoplastic agents, for third line chemotherapy in the treatment of germ cell testicular cancer.",
                "marketing_approval_date": "\u00a012/30/1988\u00a0",
                "exclusivity_end_date": "\u00a012/30/1995\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|5 Research Parkway, P.O. Box 5100|Wallingford|Connecticut|6492|United States",
                "orphan_designation": {
                    "original_text": "Treatment of testicular cancer.",
                    "umls_id": "C0855197",
                    "parsed_text": "Testicular Cancer"
                }
            },
            {
                "compound_id": 3690,
                "inchl_key": "HOMGKSMUEGBAAB-UHFFFAOYSA-N",
                "generic_name": "ifosfamide",
                "designated_date": "08/07/1985",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Company|P.O. Box 4000|Mail Stop D12-02|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue and bone sarcomas",
                    "umls_id": "C0029463",
                    "parsed_text": "bone sarcomas"
                }
            }
        ]
    },
    {
        "_id": "WPHKIQPVPYJNAX-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 46207586,
                "inchl_key": "WPHKIQPVPYJNAX-UHFFFAOYSA-N",
                "generic_name": "ilorasertib",
                "designated_date": "03/16/2012",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AbbVie, Inc.|1 N. Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "DOUYETYNHWVLEO-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 57469,
                "inchl_key": "DOUYETYNHWVLEO-UHFFFAOYSA-N",
                "generic_name": "Imiquimod",
                "designated_date": "12/03/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "UroGen Pharma Ltd|9 Ha'Ta'asiya Street|P. O. Box 2397|Ra'anana|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of carcinoma in situ (CIS) of the urinary bladder",
                    "umls_id": "C0007099",
                    "parsed_text": "Carcinoma in Situ"
                }
            }
        ]
    },
    {
        "_id": "QADPYRIHXKWUSV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 53235510,
                "inchl_key": "QADPYRIHXKWUSV-UHFFFAOYSA-N",
                "generic_name": "Infigratinib",
                "designated_date": "09/11/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "QED Therapeutics|8000 Marina Boulevard|Suite 400|Brisbane|California|94005|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cholangiocarcinoma",
                    "umls_id": "C0206698",
                    "parsed_text": "Cholangiocarcinoma"
                }
            }
        ]
    },
    {
        "_id": "XNACDNPGABUBFR-FKNPGSCZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 56840904,
                "inchl_key": "XNACDNPGABUBFR-FKNPGSCZSA-N",
                "generic_name": "iobenguane sulfate I-123",
                "designated_date": "10/21/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Brogan Pharmaceuticals, Inc.|9800 Connecticut Drive|c/o Purdue Technology Center|Crown Point|Indiana|46307|United States",
                "orphan_designation": {
                    "original_text": "For the detection, localization, and staging of pheochromocytomas.",
                    "umls_id": "C0031511",
                    "parsed_text": "Pheochromocytomas"
                }
            },
            {
                "compound_id": 56840904,
                "inchl_key": "XNACDNPGABUBFR-FKNPGSCZSA-N",
                "generic_name": "Iobenguane Sulfate I-123",
                "designated_date": "10/17/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Brogan Pharmaceuticals, LLC|312 Lacebark Street|Schererville|Indiana|46375|United States",
                "orphan_designation": {
                    "original_text": "For scintigraphic detection, localization and staging of neuroblastoma.",
                    "umls_id": "C0027819",
                    "parsed_text": "Neuroblastoma"
                }
            }
        ]
    },
    {
        "_id": "ULBPPCHRAVUQMC-RWOHWRPJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 70697642,
                "inchl_key": "ULBPPCHRAVUQMC-RWOHWRPJSA-N",
                "generic_name": "isofagomine tartrate",
                "designated_date": "01/10/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Amicus Therapeutics, Inc.|1 Cedarbrook Drive|Cranbury|New Jersey|8512|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Gaucher disease",
                    "umls_id": "C0017205",
                    "parsed_text": "Gaucher Disease"
                }
            }
        ]
    },
    {
        "_id": "ULBPPCHRAVUQMC-AWUBODBRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 56841032,
                "inchl_key": "ULBPPCHRAVUQMC-AWUBODBRSA-N",
                "generic_name": "isofagomine tartrate",
                "designated_date": "01/10/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Amicus Therapeutics, Inc.|1 Cedarbrook Drive|Cranbury|New Jersey|8512|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Gaucher disease",
                    "umls_id": "C0017205",
                    "parsed_text": "Gaucher Disease"
                }
            }
        ]
    },
    {
        "_id": "ULBPPCHRAVUQMC-MUMXBIPUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 23581846,
                "inchl_key": "ULBPPCHRAVUQMC-MUMXBIPUSA-N",
                "generic_name": "isofagomine tartrate",
                "designated_date": "01/10/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Amicus Therapeutics, Inc.|1 Cedarbrook Drive|Cranbury|New Jersey|8512|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Gaucher disease",
                    "umls_id": "C0017205",
                    "parsed_text": "Gaucher Disease"
                }
            }
        ]
    },
    {
        "_id": "VHVPQPYKVGDNFY-DFMJLFEVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 14179008,
                "inchl_key": "VHVPQPYKVGDNFY-DFMJLFEVSA-N",
                "generic_name": "Itraconazole",
                "designated_date": "05/19/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mayne Pharma LLC|1240 Sugg Parkway|Greenville|North Carolina|27834|United States",
                "orphan_designation": {
                    "original_text": "Treatment of basal cell carcinoma nevus syndrome.",
                    "umls_id": "C0007117,C0027962",
                    "parsed_text": "Basal cell carcinoma , Nevus"
                }
            },
            {
                "compound_id": 14179008,
                "inchl_key": "VHVPQPYKVGDNFY-DFMJLFEVSA-N",
                "generic_name": "itraconazole",
                "designated_date": "11/17/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mayne Pharma International Pty Ltd. c/o Mayne Pharma Inc.|1240 Sugg Parkway|Greenville|North Carolina|27834|United States",
                "orphan_designation": {
                    "original_text": "Treatment of coccidioidomycosis",
                    "umls_id": "C0009186",
                    "parsed_text": "Coccidioidomycosis"
                }
            }
        ]
    },
    {
        "_id": "VHVPQPYKVGDNFY-VXTATNQMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 45039617,
                "inchl_key": "VHVPQPYKVGDNFY-VXTATNQMSA-N",
                "generic_name": "Itraconazole",
                "designated_date": "05/19/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mayne Pharma LLC|1240 Sugg Parkway|Greenville|North Carolina|27834|United States",
                "orphan_designation": {
                    "original_text": "Treatment of basal cell carcinoma nevus syndrome.",
                    "umls_id": "C0007117,C0027962",
                    "parsed_text": "Basal cell carcinoma , Nevus"
                }
            },
            {
                "compound_id": 45039617,
                "inchl_key": "VHVPQPYKVGDNFY-VXTATNQMSA-N",
                "generic_name": "itraconazole",
                "designated_date": "11/17/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mayne Pharma International Pty Ltd. c/o Mayne Pharma Inc.|1240 Sugg Parkway|Greenville|North Carolina|27834|United States",
                "orphan_designation": {
                    "original_text": "Treatment of coccidioidomycosis",
                    "umls_id": "C0009186",
                    "parsed_text": "Coccidioidomycosis"
                }
            }
        ]
    },
    {
        "_id": "VHVPQPYKVGDNFY-TUJWMRSMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 14179013,
                "inchl_key": "VHVPQPYKVGDNFY-TUJWMRSMSA-N",
                "generic_name": "Itraconazole",
                "designated_date": "05/19/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mayne Pharma LLC|1240 Sugg Parkway|Greenville|North Carolina|27834|United States",
                "orphan_designation": {
                    "original_text": "Treatment of basal cell carcinoma nevus syndrome.",
                    "umls_id": "C0007117,C0027962",
                    "parsed_text": "Basal cell carcinoma , Nevus"
                }
            },
            {
                "compound_id": 14179013,
                "inchl_key": "VHVPQPYKVGDNFY-TUJWMRSMSA-N",
                "generic_name": "itraconazole",
                "designated_date": "11/17/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mayne Pharma International Pty Ltd. c/o Mayne Pharma Inc.|1240 Sugg Parkway|Greenville|North Carolina|27834|United States",
                "orphan_designation": {
                    "original_text": "Treatment of coccidioidomycosis",
                    "umls_id": "C0009186",
                    "parsed_text": "Coccidioidomycosis"
                }
            }
        ]
    },
    {
        "_id": "VHVPQPYKVGDNFY-AVQIMAJZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6917738,
                "inchl_key": "VHVPQPYKVGDNFY-AVQIMAJZSA-N",
                "generic_name": "Itraconazole",
                "designated_date": "05/19/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mayne Pharma LLC|1240 Sugg Parkway|Greenville|North Carolina|27834|United States",
                "orphan_designation": {
                    "original_text": "Treatment of basal cell carcinoma nevus syndrome.",
                    "umls_id": "C0007117,C0027962",
                    "parsed_text": "Basal cell carcinoma , Nevus"
                }
            },
            {
                "compound_id": 6917738,
                "inchl_key": "VHVPQPYKVGDNFY-AVQIMAJZSA-N",
                "generic_name": "itraconazole",
                "designated_date": "11/17/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mayne Pharma International Pty Ltd. c/o Mayne Pharma Inc.|1240 Sugg Parkway|Greenville|North Carolina|27834|United States",
                "orphan_designation": {
                    "original_text": "Treatment of coccidioidomycosis",
                    "umls_id": "C0009186",
                    "parsed_text": "Coccidioidomycosis"
                }
            }
        ]
    },
    {
        "_id": "VHVPQPYKVGDNFY-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3793,
                "inchl_key": "VHVPQPYKVGDNFY-UHFFFAOYSA-N",
                "generic_name": "Itraconazole",
                "designated_date": "05/19/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mayne Pharma LLC|1240 Sugg Parkway|Greenville|North Carolina|27834|United States",
                "orphan_designation": {
                    "original_text": "Treatment of basal cell carcinoma nevus syndrome.",
                    "umls_id": "C0007117,C0027962",
                    "parsed_text": "Basal cell carcinoma , Nevus"
                }
            },
            {
                "compound_id": 3793,
                "inchl_key": "VHVPQPYKVGDNFY-UHFFFAOYSA-N",
                "generic_name": "itraconazole",
                "designated_date": "11/17/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mayne Pharma International Pty Ltd. c/o Mayne Pharma Inc.|1240 Sugg Parkway|Greenville|North Carolina|27834|United States",
                "orphan_designation": {
                    "original_text": "Treatment of coccidioidomycosis",
                    "umls_id": "C0009186",
                    "parsed_text": "Coccidioidomycosis"
                }
            }
        ]
    },
    {
        "_id": "VHVPQPYKVGDNFY-ZPGVKDDISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 55283,
                "inchl_key": "VHVPQPYKVGDNFY-ZPGVKDDISA-N",
                "generic_name": "Itraconazole",
                "designated_date": "05/19/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mayne Pharma LLC|1240 Sugg Parkway|Greenville|North Carolina|27834|United States",
                "orphan_designation": {
                    "original_text": "Treatment of basal cell carcinoma nevus syndrome.",
                    "umls_id": "C0007117,C0027962",
                    "parsed_text": "Basal cell carcinoma , Nevus"
                }
            },
            {
                "compound_id": 55283,
                "inchl_key": "VHVPQPYKVGDNFY-ZPGVKDDISA-N",
                "generic_name": "itraconazole",
                "designated_date": "11/17/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mayne Pharma International Pty Ltd. c/o Mayne Pharma Inc.|1240 Sugg Parkway|Greenville|North Carolina|27834|United States",
                "orphan_designation": {
                    "original_text": "Treatment of coccidioidomycosis",
                    "umls_id": "C0009186",
                    "parsed_text": "Coccidioidomycosis"
                }
            }
        ]
    },
    {
        "_id": "PURKAOJPTOLRMP-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16220172,
                "inchl_key": "PURKAOJPTOLRMP-UHFFFAOYSA-N",
                "generic_name": "ivacaftor",
                "trade_name": "Kalydeco",
                "designated_date": "12/20/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cystic fibrosis (CF) in patients age 12 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.",
                "marketing_approval_date": "\u00a008/15/2018\u00a0",
                "exclusivity_end_date": "\u00a008/15/2025\u00a0",
                "exclusivity_protected_indication": "For the treatment of cystic fibrosis (CF) in patients age 12 months to less than 2 years who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data",
                "sponsor": "Vertex Pharmaceuticals, Inc.|50 Northern Avenue|Boston|Massachusetts|2210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            },
            {
                "compound_id": 16220172,
                "inchl_key": "PURKAOJPTOLRMP-UHFFFAOYSA-N",
                "generic_name": "ivacaftor",
                "trade_name": "Kalydeco",
                "designated_date": "12/20/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R.",
                "marketing_approval_date": "\u00a002/21/2014\u00a0",
                "exclusivity_end_date": "\u00a002/21/2021\u00a0",
                "exclusivity_protected_indication": "Treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R.",
                "sponsor": "Vertex Pharmaceuticals, Inc.|50 Northern Avenue|Boston|Massachusetts|2210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            },
            {
                "compound_id": 16220172,
                "inchl_key": "PURKAOJPTOLRMP-UHFFFAOYSA-N",
                "generic_name": "ivacaftor",
                "trade_name": "Kalydeco",
                "designated_date": "12/20/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.",
                "marketing_approval_date": "\u00a007/31/2017\u00a0",
                "exclusivity_end_date": "\u00a007/31/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one of the following mutations in the CFTR gene: 711+3A G, E831X, 2789+5G A, 3272-26A G, and 3849+10kbC T.",
                "sponsor": "Vertex Pharmaceuticals, Inc.|50 Northern Avenue|Boston|Massachusetts|2210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            },
            {
                "compound_id": 16220172,
                "inchl_key": "PURKAOJPTOLRMP-UHFFFAOYSA-N",
                "generic_name": "ivacaftor",
                "trade_name": "Kalydeco",
                "designated_date": "12/20/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.",
                "marketing_approval_date": "\u00a005/17/2017\u00a0",
                "exclusivity_end_date": "\u00a005/17/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one of the following mutations in the CFTR gene: E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, and D1270N.",
                "sponsor": "Vertex Pharmaceuticals, Inc.|50 Northern Avenue|Boston|Massachusetts|2210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            },
            {
                "compound_id": 16220172,
                "inchl_key": "PURKAOJPTOLRMP-UHFFFAOYSA-N",
                "generic_name": "ivacaftor",
                "trade_name": "KALYDECO",
                "designated_date": "12/20/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data",
                "marketing_approval_date": "\u00a009/24/2020\u00a0",
                "exclusivity_end_date": "\u00a009/24/2027\u00a0",
                "exclusivity_protected_indication": "treatment of cystic fibrosis (CF) in patients age 4 months to less than 6 months who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data",
                "sponsor": "Vertex Pharmaceuticals, Inc.|50 Northern Avenue|Boston|Massachusetts|2210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            },
            {
                "compound_id": 16220172,
                "inchl_key": "PURKAOJPTOLRMP-UHFFFAOYSA-N",
                "generic_name": "ivacaftor",
                "trade_name": "Kalydeco",
                "designated_date": "12/20/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene.",
                "marketing_approval_date": "\u00a001/31/2012\u00a0",
                "exclusivity_end_date": "\u00a001/31/2019\u00a0",
                "sponsor": "Vertex Pharmaceuticals, Inc.|50 Northern Avenue|Boston|Massachusetts|2210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            },
            {
                "compound_id": 16220172,
                "inchl_key": "PURKAOJPTOLRMP-UHFFFAOYSA-N",
                "generic_name": "ivacaftor",
                "trade_name": "Kalydeco",
                "designated_date": "12/20/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R; and treatment of CF in patients age 6 years and older who have an R117H mutation in the CFTR gene.",
                "marketing_approval_date": "\u00a012/29/2014\u00a0",
                "exclusivity_end_date": "\u00a012/29/2021\u00a0",
                "exclusivity_protected_indication": "Treatment of cystic fibrosis (CF) in patients age 6 years and older who have an R117H mutation in the CFTR gene.",
                "sponsor": "Vertex Pharmaceuticals, Inc.|50 Northern Avenue|Boston|Massachusetts|2210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            },
            {
                "compound_id": 16220172,
                "inchl_key": "PURKAOJPTOLRMP-UHFFFAOYSA-N",
                "generic_name": "ivacaftor",
                "trade_name": "Kalydeco",
                "designated_date": "12/20/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data",
                "marketing_approval_date": "\u00a012/21/2020\u00a0",
                "exclusivity_end_date": "\u00a012/21/2027\u00a0",
                "exclusivity_protected_indication": "treatment of cystic fibrosis (CF) in patients age 4 months and older who have one of the additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that have been identified as responsive to ivacaftor potentiation based on in vitro data and identified in the approval on December 21, 2020.",
                "sponsor": "Vertex Pharmaceuticals Inc.|50 Northern Ave|Boston|Massachusetts|2210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            },
            {
                "compound_id": 16220172,
                "inchl_key": "PURKAOJPTOLRMP-UHFFFAOYSA-N",
                "generic_name": "ivacaftor",
                "trade_name": "Kalydeco",
                "designated_date": "12/20/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 6 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data",
                "marketing_approval_date": "\u00a004/29/2019\u00a0",
                "exclusivity_end_date": "\u00a004/29/2026\u00a0",
                "exclusivity_protected_indication": "For the treatment of cystic fibrosis (CF) in patients age 6 months to less than 12 months who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data",
                "sponsor": "Vertex Pharmaceuticals, Inc.|50 Northern Avenue|Boston|Massachusetts|2210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            },
            {
                "compound_id": 16220172,
                "inchl_key": "PURKAOJPTOLRMP-UHFFFAOYSA-N",
                "generic_name": "ivacaftor",
                "trade_name": "Kalydeco",
                "designated_date": "12/20/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R ; and treatment of CF in patients age 2 years and older who have an R117H mutation in the CFTR gene.",
                "marketing_approval_date": "\u00a003/17/2015\u00a0",
                "exclusivity_end_date": "\u00a003/17/2022\u00a0",
                "exclusivity_protected_indication": "Treatment of cystic fibrosis (CF) in patients ages 2 to less than 6 years who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, and R117H.",
                "sponsor": "Vertex Pharmaceuticals, Inc.|50 Northern Avenue|Boston|Massachusetts|2210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "WIJZXSAJMHAVGX-DHLKQENFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71657455,
                "inchl_key": "WIJZXSAJMHAVGX-DHLKQENFSA-N",
                "generic_name": "ivosidenib",
                "designated_date": "05/01/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Agios Pharmaceuticals, Inc.|88 Sidney Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioma.",
                    "umls_id": "C0017638",
                    "parsed_text": "Glioma"
                }
            },
            {
                "compound_id": 71657455,
                "inchl_key": "WIJZXSAJMHAVGX-DHLKQENFSA-N",
                "generic_name": "ivosidenib",
                "designated_date": "05/20/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Agios Pharmaceuticals, Inc.|88 Sidney Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndromes",
                    "umls_id": "C3463824",
                    "parsed_text": "Myelodysplastic Syndromes"
                }
            },
            {
                "compound_id": 71657455,
                "inchl_key": "WIJZXSAJMHAVGX-DHLKQENFSA-N",
                "generic_name": "ivosidenib",
                "designated_date": "04/26/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Agios Pharmaceuticals, Inc.|88 Sidney Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cholangiocarcinoma",
                    "umls_id": "C0206698",
                    "parsed_text": "Cholangiocarcinoma"
                }
            },
            {
                "compound_id": 71657455,
                "inchl_key": "WIJZXSAJMHAVGX-DHLKQENFSA-N",
                "generic_name": "ivosidenib",
                "trade_name": "TIBSOVO",
                "designated_date": "06/09/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "TIBSOVO is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.",
                "marketing_approval_date": "\u00a007/20/2018\u00a0",
                "exclusivity_end_date": "\u00a007/20/2025\u00a0",
                "exclusivity_protected_indication": "Indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test",
                "sponsor": "Agios Pharmaceuticals, Inc.|88 Sidney Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia (AML)",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "compound_id": 71657455,
                "inchl_key": "WIJZXSAJMHAVGX-DHLKQENFSA-N",
                "generic_name": "ivosidenib",
                "trade_name": "TIBSOVO",
                "designated_date": "06/09/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "TIBSOVO is indicated for the treatment of newly-diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adult patients who are >= 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.",
                "marketing_approval_date": "\u00a005/02/2019\u00a0",
                "exclusivity_end_date": "\u00a005/02/2026\u00a0",
                "exclusivity_protected_indication": "TIBSOVO is indicated for the treatment of newly-diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adult patients who are >= 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.",
                "sponsor": "Agios Pharmaceuticals, Inc.|88 Sidney Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia (AML)",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "KPYSYYIEGFHWSV-QMMMGPOBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44602,
                "inchl_key": "KPYSYYIEGFHWSV-QMMMGPOBSA-N",
                "generic_name": "L-baclofen",
                "designated_date": "01/30/1992",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Osmotica Pharmaceutical Corp.|1205 Culbreth Drive|Suite 200|Wilmington|North Carolina|28405|United States",
                "orphan_designation": {
                    "original_text": "Treatment of intractable spasticity in children with cerebral palsy.",
                    "umls_id": "C0007789,C0026838",
                    "parsed_text": "Cerebral Palsy , Spasticity"
                }
            },
            {
                "compound_id": 44602,
                "inchl_key": "KPYSYYIEGFHWSV-QMMMGPOBSA-N",
                "generic_name": "L-baclofen",
                "designated_date": "07/13/1990",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Fromm, Gerhard M.D.|University Of Pittsburgh School of Medicine|Pittsburgh|Pennsylvania|15261|United States",
                "orphan_designation": {
                    "original_text": "Treatment of trigeminal neuralgia.",
                    "umls_id": "C0040997",
                    "parsed_text": "Trigeminal Neuralgia"
                }
            },
            {
                "compound_id": 44602,
                "inchl_key": "KPYSYYIEGFHWSV-QMMMGPOBSA-N",
                "generic_name": "L-baclofen",
                "designated_date": "01/06/1998",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Osmotica Pharmaceutical Corp.|1205 Culbreth Dr.|Suite 200|Wilmington|North Carolina|28405|United States",
                "orphan_designation": {
                    "original_text": "Treatment of trigeminal neuralgia",
                    "umls_id": "C0040997",
                    "parsed_text": "Trigeminal Neuralgia"
                }
            },
            {
                "compound_id": 44602,
                "inchl_key": "KPYSYYIEGFHWSV-QMMMGPOBSA-N",
                "generic_name": "L-baclofen",
                "designated_date": "12/17/1991",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Osmotica Pharmaceutical Corp.|1205 Culbreth Dr.|Suite 200|Wilmington|North Carolina|28405|United States",
                "orphan_designation": {
                    "original_text": "Treatment of spasticity associated with spinal cord injury or multiple sclerosis.",
                    "umls_id": "C0026769,C0026838,C0037929",
                    "parsed_text": "Multiple Sclerosis , Spasticity , Spinal Cord Injury"
                }
            }
        ]
    },
    {
        "_id": "KPYSYYIEGFHWSV-MRVPVSSYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44600,
                "inchl_key": "KPYSYYIEGFHWSV-MRVPVSSYSA-N",
                "generic_name": "L-baclofen",
                "designated_date": "01/30/1992",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Osmotica Pharmaceutical Corp.|1205 Culbreth Drive|Suite 200|Wilmington|North Carolina|28405|United States",
                "orphan_designation": {
                    "original_text": "Treatment of intractable spasticity in children with cerebral palsy.",
                    "umls_id": "C0007789,C0026838",
                    "parsed_text": "Cerebral Palsy , Spasticity"
                }
            },
            {
                "compound_id": 44600,
                "inchl_key": "KPYSYYIEGFHWSV-MRVPVSSYSA-N",
                "generic_name": "L-baclofen",
                "designated_date": "07/13/1990",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Fromm, Gerhard M.D.|University Of Pittsburgh School of Medicine|Pittsburgh|Pennsylvania|15261|United States",
                "orphan_designation": {
                    "original_text": "Treatment of trigeminal neuralgia.",
                    "umls_id": "C0040997",
                    "parsed_text": "Trigeminal Neuralgia"
                }
            },
            {
                "compound_id": 44600,
                "inchl_key": "KPYSYYIEGFHWSV-MRVPVSSYSA-N",
                "generic_name": "L-baclofen",
                "designated_date": "01/06/1998",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Osmotica Pharmaceutical Corp.|1205 Culbreth Dr.|Suite 200|Wilmington|North Carolina|28405|United States",
                "orphan_designation": {
                    "original_text": "Treatment of trigeminal neuralgia",
                    "umls_id": "C0040997",
                    "parsed_text": "Trigeminal Neuralgia"
                }
            },
            {
                "compound_id": 44600,
                "inchl_key": "KPYSYYIEGFHWSV-MRVPVSSYSA-N",
                "generic_name": "L-baclofen",
                "designated_date": "12/17/1991",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Osmotica Pharmaceutical Corp.|1205 Culbreth Dr.|Suite 200|Wilmington|North Carolina|28405|United States",
                "orphan_designation": {
                    "original_text": "Treatment of spasticity associated with spinal cord injury or multiple sclerosis.",
                    "umls_id": "C0026769,C0026838,C0037929",
                    "parsed_text": "Multiple Sclerosis , Spasticity , Spinal Cord Injury"
                }
            }
        ]
    },
    {
        "_id": "SHZGCJCMOBCMKK-DHVFOXMCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 17106,
                "inchl_key": "SHZGCJCMOBCMKK-DHVFOXMCSA-N",
                "generic_name": "L-fucose",
                "designated_date": "06/08/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orpha Labs, AG|Haldenstrasse 5|Baar|Zug|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of Leukocyte Adhesion Deficiency Type- II",
                    "umls_id": "C0272187",
                    "parsed_text": "Leukocyte adhesion deficiency"
                }
            },
            {
                "compound_id": 17106,
                "inchl_key": "SHZGCJCMOBCMKK-DHVFOXMCSA-N",
                "generic_name": "L-fucose",
                "designated_date": "01/14/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cerecor Inc.|1500 Liberty Ridge Drive|Suite 321|Wayne|Pennsylvania|19087|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Congenital Disorder of Glycosylation IIc",
                    "umls_id": "C0282577",
                    "parsed_text": "Congenital disorder of glycosylation"
                }
            }
        ]
    },
    {
        "_id": "ZDXPYRJPNDTMRX-VKHMYHEASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5961,
                "inchl_key": "ZDXPYRJPNDTMRX-VKHMYHEASA-N",
                "generic_name": "L-glutamine",
                "trade_name": "Endari",
                "designated_date": "08/01/2001",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "To reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.",
                "marketing_approval_date": "\u00a007/07/2017\u00a0",
                "exclusivity_end_date": "\u00a007/07/2024\u00a0",
                "exclusivity_protected_indication": "To reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.",
                "sponsor": "Emmaus Medical, Inc.|21250 Hawthorne Blvd., Suite 800|Torrance|California|90503|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sickle cell disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            },
            {
                "compound_id": 5961,
                "inchl_key": "ZDXPYRJPNDTMRX-VKHMYHEASA-N",
                "generic_name": "Glutamine",
                "trade_name": "NutreStore",
                "designated_date": "03/06/1995",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of short bowel syndrome in patients receiving specialized nutritional support when used in conjunction with a recombinant human growth hormone that is approved for this indication.",
                "marketing_approval_date": "\u00a006/10/2004\u00a0",
                "exclusivity_end_date": "\u00a006/10/2011\u00a0",
                "sponsor": "Emmaus Medical, Inc.|20725 S. Western Avenue|Suite 136|Torrence|California|90501|United States",
                "orphan_designation": {
                    "original_text": "For use with human growth hormone in the treatment of short bowel syndrome (nutrient malabsorption from the gastrointestinal tract resulting from an inadequate absorptive surface).",
                    "umls_id": "C0024523,C0036992",
                    "parsed_text": "Malabsorption , Short Bowel Syndrome"
                }
            }
        ]
    },
    {
        "_id": "BCFGMOOMADDAQU-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 208908,
                "inchl_key": "BCFGMOOMADDAQU-UHFFFAOYSA-N",
                "generic_name": "lapatinib",
                "designated_date": "05/29/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ErbB2 positive gastric cancer",
                    "umls_id": "C0024623",
                    "parsed_text": "Gastric Cancer"
                }
            }
        ]
    },
    {
        "_id": "PVCULFYROUOVGJ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3081349,
                "inchl_key": "PVCULFYROUOVGJ-UHFFFAOYSA-N",
                "generic_name": "laromustine",
                "designated_date": "10/21/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Vion Pharmaceuticals, Inc.|Four Science Park|New Haven|Connecticut|6511|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelogenous leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            },
            {
                "compound_id": 3081349,
                "inchl_key": "PVCULFYROUOVGJ-UHFFFAOYSA-N",
                "generic_name": "Laromustine",
                "designated_date": "03/27/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NanoSHIFT LLC|10454 Northwest 132nd Drive|Alachua|Florida|32615|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelogenous leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "GOTYRUGSSMKFNF-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 216326,
                "inchl_key": "GOTYRUGSSMKFNF-UHFFFAOYSA-N",
                "generic_name": "lenalidomide",
                "trade_name": "Revlimid",
                "designated_date": "01/04/2017",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).",
                "marketing_approval_date": "\u00a005/28/2019\u00a0",
                "exclusivity_end_date": "\u00a005/28/2026\u00a0",
                "exclusivity_protected_indication": "In combination with a rituximab product for the treatment of adult patients with previously treated nodal marginal zone lymphoma",
                "sponsor": "Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States",
                "orphan_designation": {
                    "original_text": "Treatment of nodal marginal zone lymphoma",
                    "umls_id": "C0242647",
                    "parsed_text": "Nodal marginal zone lymphoma"
                }
            },
            {
                "compound_id": 216326,
                "inchl_key": "GOTYRUGSSMKFNF-UHFFFAOYSA-N",
                "generic_name": "lenalidomide",
                "trade_name": "Revlimid",
                "designated_date": "01/04/2017",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).",
                "marketing_approval_date": "\u00a005/28/2019\u00a0",
                "exclusivity_end_date": "\u00a005/28/2026\u00a0",
                "exclusivity_protected_indication": "In combination with a rituximab product for the treatment of adult patients with previously treated splenic marginal zone lymphoma",
                "sponsor": "Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States",
                "orphan_designation": {
                    "original_text": "Treatment of splenic marginal zone lymphoma",
                    "umls_id": "C0349632",
                    "parsed_text": "Splenic marginal zone lymphoma"
                }
            },
            {
                "compound_id": 216326,
                "inchl_key": "GOTYRUGSSMKFNF-UHFFFAOYSA-N",
                "generic_name": "lenalidomide",
                "trade_name": "Revlimid",
                "designated_date": "09/17/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL).",
                "marketing_approval_date": "\u00a005/28/2019\u00a0",
                "exclusivity_end_date": "\u00a005/28/2026\u00a0",
                "exclusivity_protected_indication": "In combination with a rituximab product for the treatment of adult patients with previously treated follicular lymphoma (FL).",
                "sponsor": "Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States",
                "orphan_designation": {
                    "original_text": "Treatment of follicular lymphoma",
                    "umls_id": "C0024301",
                    "parsed_text": "follicular lymphoma"
                }
            },
            {
                "compound_id": 216326,
                "inchl_key": "GOTYRUGSSMKFNF-UHFFFAOYSA-N",
                "generic_name": "lenalidomide",
                "trade_name": "Revlimid",
                "designated_date": "04/27/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.",
                "marketing_approval_date": "\u00a006/05/2013\u00a0",
                "exclusivity_end_date": "\u00a006/05/2020\u00a0",
                "exclusivity_protected_indication": "Treatment of mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.",
                "sponsor": "Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mantle cell lymphoma",
                    "umls_id": "C4721414",
                    "parsed_text": "Mantle cell lymphoma"
                }
            },
            {
                "compound_id": 216326,
                "inchl_key": "GOTYRUGSSMKFNF-UHFFFAOYSA-N",
                "generic_name": "lenalidomide",
                "designated_date": "03/28/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diffuse large B-cell lymphoma",
                    "umls_id": "C1332201",
                    "parsed_text": "Diffuse Large B-Cell Lymphoma"
                }
            },
            {
                "compound_id": 216326,
                "inchl_key": "GOTYRUGSSMKFNF-UHFFFAOYSA-N",
                "generic_name": "lenalidomide",
                "trade_name": "Revlimid",
                "designated_date": "09/20/2001",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For use in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy",
                "marketing_approval_date": "\u00a006/29/2006\u00a0",
                "exclusivity_end_date": "\u00a006/29/2013\u00a0",
                "sponsor": "Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            },
            {
                "compound_id": 216326,
                "inchl_key": "GOTYRUGSSMKFNF-UHFFFAOYSA-N",
                "generic_name": "lenalidomide",
                "designated_date": "01/17/2007",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "compound_id": 216326,
                "inchl_key": "GOTYRUGSSMKFNF-UHFFFAOYSA-N",
                "generic_name": "lenalidomide",
                "trade_name": "Revlimid",
                "designated_date": "04/29/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).",
                "marketing_approval_date": "\u00a005/28/2019\u00a0",
                "exclusivity_end_date": "\u00a005/28/2026\u00a0",
                "exclusivity_protected_indication": "In combination with a rituximab product for the treatment of adult patients with previously treated extranodal marginal zone lymphoma",
                "sponsor": "Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States",
                "orphan_designation": {
                    "original_text": "Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue",
                    "umls_id": "C2200312",
                    "parsed_text": "marginal zone lymphoma of mucosa-associated lymphoid tissue"
                }
            },
            {
                "compound_id": 216326,
                "inchl_key": "GOTYRUGSSMKFNF-UHFFFAOYSA-N",
                "generic_name": "lenalidomide",
                "trade_name": "Revlimid",
                "designated_date": "01/29/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with transfusion dependant anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5 q cytogenetic abnormality with or without additional cytogenetic abnormalities",
                "marketing_approval_date": "\u00a012/27/2005\u00a0",
                "exclusivity_end_date": "\u00a012/27/2012\u00a0",
                "sponsor": "Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndromes",
                    "umls_id": "C3463824",
                    "parsed_text": "Myelodysplastic Syndromes"
                }
            },
            {
                "compound_id": 216326,
                "inchl_key": "GOTYRUGSSMKFNF-UHFFFAOYSA-N",
                "generic_name": "lenalidomide",
                "trade_name": "Revlimid",
                "designated_date": "09/20/2001",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "REVLIMID in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM).",
                "marketing_approval_date": "\u00a002/17/2015\u00a0",
                "exclusivity_end_date": "\u00a002/17/2022\u00a0",
                "exclusivity_protected_indication": "For use in combination with dexamethasone for the treatment of patients with multiple myeloma who have not received at least one prior therapy (first-line therapy).",
                "sponsor": "Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            },
            {
                "compound_id": 216326,
                "inchl_key": "GOTYRUGSSMKFNF-UHFFFAOYSA-N",
                "generic_name": "lenalidomide",
                "trade_name": "Revlimid",
                "designated_date": "09/20/2001",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of multiple myeloma (MM), as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT)",
                "marketing_approval_date": "\u00a002/22/2017\u00a0",
                "exclusivity_end_date": "\u00a002/22/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of multiple myeloma (MM), as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT)",
                "sponsor": "Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "WOSKHXYHFSIKNG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9823820,
                "inchl_key": "WOSKHXYHFSIKNG-UHFFFAOYSA-N",
                "generic_name": "lenvatinib",
                "designated_date": "03/26/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eisai, Inc.|155 Tice Blvd|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of stage IIB to Stage IV melanoma",
                    "umls_id": "C0025202",
                    "parsed_text": "melanoma"
                }
            },
            {
                "compound_id": 9823820,
                "inchl_key": "WOSKHXYHFSIKNG-UHFFFAOYSA-N",
                "generic_name": "lenvatinib",
                "trade_name": "Lenvima",
                "designated_date": "12/27/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine refractory differentiated thyroid cancer",
                "marketing_approval_date": "\u00a002/13/2015\u00a0",
                "exclusivity_end_date": "\u00a002/13/2022\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine refractory differentiated thyroid cancer",
                "sponsor": "Eisai, Inc.|155 Tice Blvd|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of follicullar, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer",
                    "umls_id": "C0238463",
                    "parsed_text": "papillary thyroid cancer"
                }
            },
            {
                "compound_id": 9823820,
                "inchl_key": "WOSKHXYHFSIKNG-UHFFFAOYSA-N",
                "generic_name": "lenvatinib",
                "trade_name": "LENVIMA",
                "designated_date": "03/27/2014",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)",
                "marketing_approval_date": "\u00a008/15/2018\u00a0",
                "exclusivity_end_date": "\u00a008/15/2025\u00a0",
                "exclusivity_protected_indication": "LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)",
                "sponsor": "Eisai Inc.|155 Tice Blvd|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            }
        ]
    },
    {
        "_id": "OXVFDZYQLGRLCD-USSMZTJJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 45359068,
                "inchl_key": "OXVFDZYQLGRLCD-USSMZTJJSA-N",
                "generic_name": "leriglitazone",
                "designated_date": "08/01/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Minoryx Therapeutics S.L.|TecnoCampus Mataro-Maresme. TCM3 602|Av. Ernest Lluch, 32.|Matar\udaf4\udea0|Catalunya|Spain",
                "orphan_designation": {
                    "original_text": "Treatment of Friedreichs ataxia",
                    "umls_id": "C0016719",
                    "parsed_text": "FRIEDREICHS ATAXIA"
                }
            }
        ]
    },
    {
        "_id": "OXVFDZYQLGRLCD-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4147757,
                "inchl_key": "OXVFDZYQLGRLCD-UHFFFAOYSA-N",
                "generic_name": "leriglitazone",
                "designated_date": "08/01/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Minoryx Therapeutics S.L.|TecnoCampus Mataro-Maresme. TCM3 602|Av. Ernest Lluch, 32.|Matar\udaf4\udea0|Catalunya|Spain",
                "orphan_designation": {
                    "original_text": "Treatment of Friedreichs ataxia",
                    "umls_id": "C0016719",
                    "parsed_text": "FRIEDREICHS ATAXIA"
                }
            },
            {
                "compound_id": 4147757,
                "inchl_key": "OXVFDZYQLGRLCD-UHFFFAOYSA-N",
                "generic_name": "hydroxypioglitazone",
                "designated_date": "01/30/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Minoryx Therapeutics S.L.|TecnoCampus Mataro-Maresme. TCM3 602|Av. Ernest Lluch, 32.|Matar\udaf4\udea0|Catalunya|Spain",
                "orphan_designation": {
                    "original_text": "Treatment of X-linked adrenoleukodystrophy",
                    "umls_id": "C0162309",
                    "parsed_text": "X-Linked Adrenoleukodystrophy"
                }
            }
        ]
    },
    {
        "_id": "UGFHIPBXIWJXNA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 60652,
                "inchl_key": "UGFHIPBXIWJXNA-UHFFFAOYSA-N",
                "generic_name": "liarozole",
                "designated_date": "06/18/2004",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Stiefel Laboratories, Inc.|20 T.W. Alexander Drive|P. O. Box 14910|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Treatment of congenital ichthyosis",
                    "umls_id": "C0079154",
                    "parsed_text": "congenital ichthyosis"
                }
            }
        ]
    },
    {
        "_id": "MWWSFMDVAYGXBV-RUELKSSGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 443939,
                "inchl_key": "MWWSFMDVAYGXBV-RUELKSSGSA-N",
                "generic_name": "Liposomal doxorubicin hydrochloride",
                "designated_date": "12/27/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "GP-Pharm SA|Pol. Ind. Els Vinyets els Fogars n 2,|Quinti de Mediona|Barcelona|Spain",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcomas",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft Tissue Sarcomas"
                }
            }
        ]
    },
    {
        "_id": "BKRGVLQUQGGVSM-KBXCAEBGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 28864,
                "inchl_key": "BKRGVLQUQGGVSM-KBXCAEBGSA-N",
                "generic_name": "lisuride",
                "designated_date": "01/17/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sinoxa Pharma GmbH|Thomasiusstr.13|Berlin|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "OSPNFKYGOFXGBX-YWWKUQGPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 145722609,
                "inchl_key": "OSPNFKYGOFXGBX-YWWKUQGPSA-N",
                "generic_name": "Lucinactant",
                "designated_date": "10/21/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Windtree Therapeutics, Inc.|2600 Kelly Road|Suite 100|Warrington|Pennsylvania|18976|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis.",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            },
            {
                "compound_id": 145722609,
                "inchl_key": "OSPNFKYGOFXGBX-YWWKUQGPSA-N",
                "generic_name": "Lucinactant",
                "designated_date": "10/21/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Windtree Therapeutics, Inc.|2600 Kelly Road|Suite 100|Warrington|Pennsylvania|18976|United States",
                "orphan_designation": {
                    "original_text": "Treatment of bronchopulmonary dysplasia in premature infants.",
                    "umls_id": "C0006287",
                    "parsed_text": "Bronchopulmonary Dysplasia"
                }
            },
            {
                "compound_id": 145722609,
                "inchl_key": "OSPNFKYGOFXGBX-YWWKUQGPSA-N",
                "generic_name": "Lucinactant",
                "designated_date": "05/23/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Windtree Therapeutics, Inc.|2600 Kelly Road|Suite 100|Warrington|Pennsylvania|18976|United States",
                "orphan_designation": {
                    "original_text": "Prevention of bronchopulmonary dysplasia in premature infants",
                    "umls_id": "C0006287",
                    "parsed_text": "Bronchopulmonary Dysplasia"
                }
            },
            {
                "compound_id": 145722609,
                "inchl_key": "OSPNFKYGOFXGBX-YWWKUQGPSA-N",
                "generic_name": "Lucinactant",
                "designated_date": "07/17/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Windtree Therapeutics, Inc.|2600 Kelly Road|Suite 100|Warrington|Pennsylvania|18976|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute respiratory distress syndrome in adults.",
                    "umls_id": "C0035222",
                    "parsed_text": "Acute respiratory distress syndrome"
                }
            },
            {
                "compound_id": 145722609,
                "inchl_key": "OSPNFKYGOFXGBX-YWWKUQGPSA-N",
                "generic_name": "Lucinactant",
                "designated_date": "10/18/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Windtree Therapeutics, Inc.|2600 Kelly Road|Suite 100|Warrington|Pennsylvania|18976|United States",
                "orphan_designation": {
                    "original_text": "Treatment of respiratory distress syndrome in premature infants.",
                    "umls_id": "C1968593",
                    "parsed_text": "Respiratory Distress Syndrome In Premature Infants"
                }
            },
            {
                "compound_id": 145722609,
                "inchl_key": "OSPNFKYGOFXGBX-YWWKUQGPSA-N",
                "generic_name": "Lucinactant",
                "designated_date": "07/30/1996",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Windtree Therapeutics, Inc.|2600 Kelly Road|Suite 100|Warrington|Pennsylvania|18976|United States",
                "orphan_designation": {
                    "original_text": "Treatment of meconium aspiration syndrome in newborn infants",
                    "umls_id": "C0025048",
                    "parsed_text": "of meconium aspiration"
                }
            }
        ]
    },
    {
        "_id": "JGCMEBMXRHSZKX-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16004692,
                "inchl_key": "JGCMEBMXRHSZKX-UHFFFAOYSA-N",
                "generic_name": "macitentan",
                "designated_date": "06/15/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Actelion Clinical Research, Inc.|1820 Chapel Avenue West|Suite 300|Cherry Hill|New Jersey|8002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic thromboembolic pulmonary hypertension (CTEPH)",
                    "umls_id": "C2363973",
                    "parsed_text": "Chronic thromboembolic pulmonary hypertension"
                }
            },
            {
                "compound_id": 16004692,
                "inchl_key": "JGCMEBMXRHSZKX-UHFFFAOYSA-N",
                "generic_name": "macitentan",
                "trade_name": "Opsumit",
                "designated_date": "09/03/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). Opsumit also reduced hospitalization for PAH.",
                "marketing_approval_date": "\u00a010/18/2013\u00a0",
                "exclusivity_end_date": "\u00a010/18/2020\u00a0",
                "exclusivity_protected_indication": "Treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). Opsumit also reduced hospitalization for PAH.",
                "sponsor": "Actelion Pharmaceuticals Ltd|Gewerbestrasse 16|Allschwil|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            },
            {
                "compound_id": 16004692,
                "inchl_key": "JGCMEBMXRHSZKX-UHFFFAOYSA-N",
                "generic_name": "macitentan",
                "designated_date": "04/14/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Actelion Pharmaceuticals Ltd|Gewerbestrasse 16|Allschwil|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic pulmonary fibrosis.",
                    "umls_id": "C1800706",
                    "parsed_text": "Idiopathic Pulmonary Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "STPKWKPURVSAJF-LJEWAXOPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9831643,
                "inchl_key": "STPKWKPURVSAJF-LJEWAXOPSA-N",
                "generic_name": "maralixibat",
                "designated_date": "09/04/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mirum Pharmaceuticals, Inc.|950 Tower Lane|Suite 1050|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of alagille syndrome",
                    "umls_id": "C0085280",
                    "parsed_text": "Alagille Syndrome"
                }
            },
            {
                "compound_id": 9831643,
                "inchl_key": "STPKWKPURVSAJF-LJEWAXOPSA-N",
                "generic_name": "maralixibat",
                "designated_date": "09/04/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mirum Pharmaceuticals, Inc.|950 Tower Lane|Suite 1050|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of progressive familial intrahepatic cholestasis",
                    "umls_id": "C4551898",
                    "parsed_text": "Progressive familial intrahepatic cholestasis"
                }
            },
            {
                "compound_id": 9831643,
                "inchl_key": "STPKWKPURVSAJF-LJEWAXOPSA-N",
                "generic_name": "maralixibat",
                "designated_date": "10/21/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mirum Pharmaceuticals, Inc.|950 Tower Lane|Suite 1050|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "treatment of biliary atresia",
                    "umls_id": "C0005411",
                    "parsed_text": "Biliary Atresia"
                }
            }
        ]
    },
    {
        "_id": "WESWYMRNZNDGBX-YLCXCWDSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 65329,
                "inchl_key": "WESWYMRNZNDGBX-YLCXCWDSSA-N",
                "generic_name": "mefloquine HCL",
                "trade_name": "Lariam",
                "designated_date": "04/13/1988",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs",
                "marketing_approval_date": "\u00a005/03/1989\u00a0",
                "exclusivity_end_date": "\u00a005/03/1996\u00a0",
                "sponsor": "Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States",
                "orphan_designation": {
                    "original_text": "For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs",
                    "umls_id": "C0024535,C2930826",
                    "parsed_text": "Plasmodium falciparum Malaria , Acute malaria"
                }
            },
            {
                "compound_id": 65329,
                "inchl_key": "WESWYMRNZNDGBX-YLCXCWDSSA-N",
                "generic_name": "mefloquine HCL",
                "trade_name": "Lariam",
                "designated_date": "04/13/1988",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax",
                "marketing_approval_date": "\u00a005/02/1989\u00a0",
                "exclusivity_end_date": "\u00a005/02/1996\u00a0",
                "sponsor": "Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States",
                "orphan_designation": {
                    "original_text": "For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs",
                    "umls_id": "C0024535,C2930826",
                    "parsed_text": "Plasmodium falciparum Malaria , Acute malaria"
                }
            }
        ]
    },
    {
        "_id": "DRLFMBDRBRZALE-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 896,
                "inchl_key": "DRLFMBDRBRZALE-UHFFFAOYSA-N",
                "generic_name": "melatonin",
                "designated_date": "03/02/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "WORPHMED Srl|Via Malachia Marchesi de Taddei, 21|Milan|Lombardy|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of acute acetaminophen overdose",
                    "umls_id": "C0572025",
                    "parsed_text": "Acetaminophen overdose"
                }
            },
            {
                "compound_id": 896,
                "inchl_key": "DRLFMBDRBRZALE-UHFFFAOYSA-N",
                "generic_name": "Melatonin",
                "designated_date": "07/09/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neurim Pharmaceuticals, Ltd.|8 Hanechoshet St.|Tel-Aviv|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of non-24-hour sleep-wake disorder in blind individuals without light perception",
                    "umls_id": "C0456909,C0851578",
                    "parsed_text": "Blind , Sleep-wake disorder"
                }
            },
            {
                "compound_id": 896,
                "inchl_key": "DRLFMBDRBRZALE-UHFFFAOYSA-N",
                "generic_name": "Melatonin",
                "designated_date": "11/15/1993",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sack, Robert, M.D.|Oregon Health Sciences University|3181 S.W. Sam Jackson Park Road|Portland|Oregon|97201|United States",
                "orphan_designation": {
                    "original_text": "Treatment of circadian rhythm sleep disorders in blind people with no light perception.",
                    "umls_id": "C0456909,C0877792",
                    "parsed_text": "Blind , Circadian rhythm sleep disorders"
                }
            },
            {
                "compound_id": 896,
                "inchl_key": "DRLFMBDRBRZALE-UHFFFAOYSA-N",
                "generic_name": "melatonin",
                "designated_date": "11/03/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "WORPHMED Srl|Via Malachia Marchesi de Taddei, 21|Milan|Lombardy|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of smith-magenis syndrome in combination with a beta-blocker",
                    "umls_id": "C0039082",
                    "parsed_text": "Syndrome"
                }
            },
            {
                "compound_id": 896,
                "inchl_key": "DRLFMBDRBRZALE-UHFFFAOYSA-N",
                "generic_name": "Melatonin",
                "designated_date": "04/20/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "WORPHMED Srl|Via Malachia Marchesi de Taddei, 21|Milan|Lombardy|Italy",
                "orphan_designation": {
                    "original_text": "Prevention of retinopathy of prematurity",
                    "umls_id": "C0035344",
                    "parsed_text": "Retinopathy of Prematurity"
                }
            },
            {
                "compound_id": 896,
                "inchl_key": "DRLFMBDRBRZALE-UHFFFAOYSA-N",
                "generic_name": "melatonin",
                "designated_date": "04/12/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Scharper S.p.A.|Viale Ortles 12|Milan|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of neonatal hypoxic ischemic encephalopathy",
                    "umls_id": "C3898147",
                    "parsed_text": "Neonatal Hypoxic Ischemic Encephalopathy"
                }
            },
            {
                "compound_id": 896,
                "inchl_key": "DRLFMBDRBRZALE-UHFFFAOYSA-N",
                "generic_name": "melatonin",
                "designated_date": "10/09/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "WORPHMED Srl|Via Malachia Marchesi de Taddei, 21|Milan|Lombardy|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 896,
                "inchl_key": "DRLFMBDRBRZALE-UHFFFAOYSA-N",
                "generic_name": "Melatonin",
                "designated_date": "04/22/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "WORPHMED Srl|Via Malachia Marchesi de Taddei, 21|Milan|Lombardy|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of heat stroke",
                    "umls_id": "C0038819",
                    "parsed_text": "Heat Stroke"
                }
            },
            {
                "compound_id": 896,
                "inchl_key": "DRLFMBDRBRZALE-UHFFFAOYSA-N",
                "generic_name": "melatonin",
                "designated_date": "10/22/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "WORPHMED Srl|Via Malachia Marchesi de Taddei, 21|Milan|Lombardy|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of Acute Radiation Syndrome",
                    "umls_id": "C0520799",
                    "parsed_text": "Acute Radiation Syndrome"
                }
            },
            {
                "compound_id": 896,
                "inchl_key": "DRLFMBDRBRZALE-UHFFFAOYSA-N",
                "generic_name": "melatonin",
                "designated_date": "02/14/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "WORPHMED Srl|Via Malachia Marchesi de Taddei, 21|Milan|Lombardy|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of short bowel syndrome",
                    "umls_id": "C0036992",
                    "parsed_text": "Short Bowel Syndrome"
                }
            },
            {
                "compound_id": 896,
                "inchl_key": "DRLFMBDRBRZALE-UHFFFAOYSA-N",
                "generic_name": "Melatonin",
                "designated_date": "01/22/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "WORPHMED Srl|Via Malachia Marchesi de Taddei, 21|Milan|Lombardy|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of primary intracerebral hemorrhage",
                    "umls_id": "C2937358",
                    "parsed_text": "Intracerebral Hemorrhage"
                }
            },
            {
                "compound_id": 896,
                "inchl_key": "DRLFMBDRBRZALE-UHFFFAOYSA-N",
                "generic_name": "melatonin",
                "designated_date": "03/28/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "WORPHMED Srl|Via Malachia Marchesi de Taddei, 21|Milan|Lombardy|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of subarachnoid hemorrhage",
                    "umls_id": "C0038525",
                    "parsed_text": "Subarachnoid Hemorrhage"
                }
            },
            {
                "compound_id": 896,
                "inchl_key": "DRLFMBDRBRZALE-UHFFFAOYSA-N",
                "generic_name": "melatonin",
                "designated_date": "01/25/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "WORPHMED Srl|Via Malachia Marchesi de Taddei, 21|Milan|Lombardy|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of necrotizing enterocolitis",
                    "umls_id": "C0014356",
                    "parsed_text": "Enterocolitis"
                }
            },
            {
                "compound_id": 896,
                "inchl_key": "DRLFMBDRBRZALE-UHFFFAOYSA-N",
                "generic_name": "Melatonin",
                "designated_date": "04/20/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "WORPHMED Srl|Via Malachia Marchesi de Taddei, 21|Milan|Lombardy|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of retinopathy of prematurity",
                    "umls_id": "C0035344",
                    "parsed_text": "Retinopathy of Prematurity"
                }
            },
            {
                "compound_id": 896,
                "inchl_key": "DRLFMBDRBRZALE-UHFFFAOYSA-N",
                "generic_name": "melatonin",
                "designated_date": "03/08/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "WORPHMED Srl|Via Malachia Marchesi de Taddei, 21|Milan|Lombardy|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of perinatal asphyxia",
                    "umls_id": "C0559477",
                    "parsed_text": "Perinatal asphyxia"
                }
            },
            {
                "compound_id": 896,
                "inchl_key": "DRLFMBDRBRZALE-UHFFFAOYSA-N",
                "generic_name": "melatonin",
                "designated_date": "02/28/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "WORPHMED Srl|Via Malachia Marchesi de Taddei, 21|Milan|Lombardy|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            }
        ]
    },
    {
        "_id": "OUUYBRCCFUEMLH-YDALLXLXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9927978,
                "inchl_key": "OUUYBRCCFUEMLH-YDALLXLXSA-N",
                "generic_name": "melphalan hydrochloride",
                "designated_date": "05/22/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Delcath Systems, Inc.|1301 6th Avenue|43rd Floor|New York|New York|10019|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuroendocrine tumors",
                    "umls_id": "C0206754",
                    "parsed_text": "Neuroendocrine Tumors"
                }
            },
            {
                "compound_id": 9927978,
                "inchl_key": "OUUYBRCCFUEMLH-YDALLXLXSA-N",
                "generic_name": "melphalan hydrochloride",
                "designated_date": "11/12/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Delcath Systems, Inc.|1301 6th Avenue|43rd Floor|New York|New York|10019|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with cutaneous melanoma.",
                    "umls_id": "C0025202",
                    "parsed_text": "cutaneous melanoma"
                }
            },
            {
                "compound_id": 9927978,
                "inchl_key": "OUUYBRCCFUEMLH-YDALLXLXSA-N",
                "generic_name": "melphalan hydrochloride",
                "designated_date": "09/26/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Delcath Systems, Inc.|1301 6th Avenue|43rd Floor|New York|New York|10019|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with hepatocellular carcinoma",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            },
            {
                "compound_id": 9927978,
                "inchl_key": "OUUYBRCCFUEMLH-YDALLXLXSA-N",
                "generic_name": "melphalan hydrochloride",
                "designated_date": "11/12/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Delcath Systems, Inc.|1301 6th Avenue|43rd Floor|New York|New York|10019|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with ocular (uveal) melanoma.",
                    "umls_id": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "INWLQCZOYSRPNW-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4062,
                "inchl_key": "INWLQCZOYSRPNW-UHFFFAOYSA-N",
                "generic_name": "mepivacaine",
                "designated_date": "01/08/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Relmada Therapeutics, Inc.|546 Fifth Avenue|14 Floor|New York|New York|10036|United States",
                "orphan_designation": {
                    "original_text": "Treatment of postherpetic neuralgia",
                    "umls_id": "C0032768",
                    "parsed_text": "Postherpetic neuralgia"
                }
            },
            {
                "compound_id": 4062,
                "inchl_key": "INWLQCZOYSRPNW-UHFFFAOYSA-N",
                "generic_name": "mepivacaine",
                "designated_date": "10/18/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Relmada Therapeutics, Inc.|750 3rd Avenue|9th Floor|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Treatment of painful HIV-associated neuropathy",
                    "umls_id": "C0019682,C0442874",
                    "parsed_text": "HIV , Neuropathy"
                }
            }
        ]
    },
    {
        "_id": "XNXVOSBNFZWHBV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 521874,
                "inchl_key": "XNXVOSBNFZWHBV-UHFFFAOYSA-N",
                "generic_name": "Methoxyamine hydrochloride",
                "designated_date": "10/22/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "TRACON Pharmaceuticals, Inc.|4350 La Jolla Village Dr., Suite 800|San Diego|California|92122|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls_id": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            }
        ]
    },
    {
        "_id": "VLPIATFUUWWMKC-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4178,
                "inchl_key": "VLPIATFUUWWMKC-UHFFFAOYSA-N",
                "generic_name": "mexiletine",
                "designated_date": "09/02/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "University of Rochester Medical Center|1351 Mt. Hope Ave.|Suite 203|Rochester|New York|14620|United States",
                "orphan_designation": {
                    "original_text": "Treatment of nondystrophic myotonia",
                    "umls_id": "C2931139",
                    "parsed_text": "Nondystrophic myotonia"
                }
            },
            {
                "compound_id": 4178,
                "inchl_key": "VLPIATFUUWWMKC-UHFFFAOYSA-N",
                "generic_name": "mexiletine",
                "designated_date": "03/16/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Lupin Europe GmbH|Hanauer Landstr. 139 -143|Frankfurt am Main|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of myotonic disorders",
                    "umls_id": "C0553604",
                    "parsed_text": "Myotonic Disorders"
                }
            }
        ]
    },
    {
        "_id": "HBNPJJILLOYFJU-VMPREFPWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 60663,
                "inchl_key": "HBNPJJILLOYFJU-VMPREFPWSA-N",
                "generic_name": "mibefradil",
                "designated_date": "08/25/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cavion, LLC|600 E. Water Street|Suite E|Charlottesville|Virginia|22902|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioblastoma multiforme.",
                    "umls_id": "C0017636",
                    "parsed_text": "Glioblastoma multiforme"
                }
            },
            {
                "compound_id": 60663,
                "inchl_key": "HBNPJJILLOYFJU-VMPREFPWSA-N",
                "generic_name": "mibefradil",
                "designated_date": "06/15/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cavion, LLC|600 E. Water Street|Suite E|Charlottesville|Virginia|22902|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "compound_id": 60663,
                "inchl_key": "HBNPJJILLOYFJU-VMPREFPWSA-N",
                "generic_name": "mibefradil",
                "designated_date": "10/16/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cavion, LLC|600 E. Water Street|Suite E|Charlottesville|Virginia|22902|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer.",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "DDLIGBOFAVUZHB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4192,
                "inchl_key": "DDLIGBOFAVUZHB-UHFFFAOYSA-N",
                "generic_name": "midazolam",
                "trade_name": "NAYZILAM",
                "designated_date": "10/20/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "NAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patients usual seizure pattern in patients with epilepsy 12 years of age and older.",
                "marketing_approval_date": "\u00a005/17/2019\u00a0",
                "exclusivity_end_date": "\u00a005/17/2026\u00a0",
                "exclusivity_protected_indication": "NAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patients usual seizure pattern in patients with epilepsy 12 years of age and older.",
                "sponsor": "UCB, Inc.|1950 Lake Park Drive|Building 2100|Smyrna|Georgia|30080|United States",
                "orphan_designation": {
                    "original_text": "Rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity (e.g. acute repetitive seizures, seizure clusters)",
                    "umls_id": "C0036572,C1148454,C1959629",
                    "parsed_text": "Seizures , seizure activity , Seizure"
                }
            },
            {
                "compound_id": 4192,
                "inchl_key": "DDLIGBOFAVUZHB-UHFFFAOYSA-N",
                "generic_name": "midazolam",
                "trade_name": "SEIZALAM",
                "designated_date": "02/04/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "SEIZALAM is indicated for the treatment of status epilepticus in adults.",
                "marketing_approval_date": "\u00a009/14/2018\u00a0",
                "exclusivity_end_date": "\u00a009/14/2025\u00a0",
                "exclusivity_protected_indication": "SEIZALAM is indicated for the treatment of status epilepticus in adults.",
                "sponsor": "Meridian Medical Technologies|6350 Stevens Forest Road|Suite 301|Columbia|Maryland|21046|United States",
                "orphan_designation": {
                    "original_text": "Treatment of status epilepticus",
                    "umls_id": "C0038220",
                    "parsed_text": "Status Epilepticus"
                }
            },
            {
                "compound_id": 4192,
                "inchl_key": "DDLIGBOFAVUZHB-UHFFFAOYSA-N",
                "generic_name": "midazolam",
                "designated_date": "02/18/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Takeda Development Center Americas, Inc.|95 Hayden Avenue|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of status epilepticus",
                    "umls_id": "C0038220",
                    "parsed_text": "Status Epilepticus"
                }
            },
            {
                "compound_id": 4192,
                "inchl_key": "DDLIGBOFAVUZHB-UHFFFAOYSA-N",
                "generic_name": "midazolam",
                "designated_date": "02/08/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Meridian Medical Technologies, Inc.|A Pfizer Company|6350 Stevens Forest Road|Columbia|Maryland|21046|United States",
                "orphan_designation": {
                    "original_text": "Treatment of seizures induced by organophosporous insecticide poisoning.",
                    "umls_id": "C0036572,C0413048",
                    "parsed_text": "Seizures , Insecticide poisoning"
                }
            },
            {
                "compound_id": 4192,
                "inchl_key": "DDLIGBOFAVUZHB-UHFFFAOYSA-N",
                "generic_name": "midazolam",
                "designated_date": "07/24/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Meridian Medical Technologies, Inc.|A Pfizer Company|6350 Stevens Forest Road|Columbia|Maryland|21046|United States",
                "orphan_designation": {
                    "original_text": "Treatment of nerve agent-induced seizures",
                    "umls_id": "C0036572",
                    "parsed_text": "Seizures"
                }
            },
            {
                "compound_id": 4192,
                "inchl_key": "DDLIGBOFAVUZHB-UHFFFAOYSA-N",
                "generic_name": "midazolam",
                "designated_date": "05/08/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "UCB, Inc|1950 Lake Park rive|Smyrna|Georgia|30080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of bouts of increased seizure activity in selected refractory patients with epilepsy who are on stable regimens of anti-epileptic drugs and who require intermittent use of midazolam",
                    "umls_id": "C0014544,C1148454",
                    "parsed_text": "Epilepsy , seizure activity"
                }
            },
            {
                "compound_id": 4192,
                "inchl_key": "DDLIGBOFAVUZHB-UHFFFAOYSA-N",
                "generic_name": "midazolam",
                "designated_date": "01/30/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Crossject SA|6 Rue Pauline Kergomard|Dijon|Bourgogne Franche-Comt\u934a|France",
                "orphan_designation": {
                    "original_text": "Treatment of status epilepticus",
                    "umls_id": "C0038220",
                    "parsed_text": "Status Epilepticus"
                }
            }
        ]
    },
    {
        "_id": "PQLXHQMOHUQAKB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3599,
                "inchl_key": "PQLXHQMOHUQAKB-UHFFFAOYSA-N",
                "generic_name": "miltefosine",
                "designated_date": "12/06/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Profounda, Inc.|5790 Hoffner Avenue|Suite 507|Orlando|Florida|32822|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Acanthamoeba keratitis",
                    "umls_id": "C0000880",
                    "parsed_text": "Acanthamoeba Keratitis"
                }
            },
            {
                "compound_id": 3599,
                "inchl_key": "PQLXHQMOHUQAKB-UHFFFAOYSA-N",
                "generic_name": "miltefosine",
                "designated_date": "08/02/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Profounda, Inc.|5790 Hoffner Avenue|Suite 507|Orlando|Florida|32822|United States",
                "orphan_designation": {
                    "original_text": "Treatment of schistosomiasis",
                    "umls_id": "C0036323",
                    "parsed_text": "Schistosomiasis"
                }
            },
            {
                "compound_id": 3599,
                "inchl_key": "PQLXHQMOHUQAKB-UHFFFAOYSA-N",
                "generic_name": "miltefosine",
                "designated_date": "06/19/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Profounda, Inc.|5790 Hoffner Avenue|Suite 507|Orlando|Florida|32822|United States",
                "orphan_designation": {
                    "original_text": "Treatment of disseminated amebiasis",
                    "umls_id": "C0013370",
                    "parsed_text": "amebiasis"
                }
            },
            {
                "compound_id": 3599,
                "inchl_key": "PQLXHQMOHUQAKB-UHFFFAOYSA-N",
                "generic_name": "miltefosine",
                "designated_date": "12/06/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Profounda, Inc.|5790 Hoffner Avenue|Suite 507|Orlando|Florida|32822|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary amebic encephalitis (PAM)",
                    "umls_id": "C0338427,C2931826",
                    "parsed_text": "Primary amebic encephalitis , PAM"
                }
            },
            {
                "compound_id": 3599,
                "inchl_key": "PQLXHQMOHUQAKB-UHFFFAOYSA-N",
                "generic_name": "miltefosine",
                "trade_name": "IMPAVIDO",
                "designated_date": "10/10/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of visceral leishmaniasis due to Leishmania donovani; cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis; and mucosal leishmaniasis due to Leishmania braziliensis.",
                "marketing_approval_date": "\u00a003/19/2014\u00a0",
                "exclusivity_end_date": "\u00a003/19/2021\u00a0",
                "exclusivity_protected_indication": "Treatment of visceral leishmaniasis due to Leishmania donovani; cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis; and mucosal leishmaniasis due to Leishmania braziliensis.",
                "sponsor": "Knight Therapeutics (USA)|Corporation Trust Center|1209 Orange Street|Wilmington|Delaware|19801|United States",
                "orphan_designation": {
                    "original_text": "Treatment of leishmaniasis.",
                    "umls_id": "C0023281",
                    "parsed_text": "Leishmaniasis"
                }
            },
            {
                "compound_id": 3599,
                "inchl_key": "PQLXHQMOHUQAKB-UHFFFAOYSA-N",
                "generic_name": "miltefosine",
                "designated_date": "06/19/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Profounda, Inc.|5790 Hoffner Avenue|Suite 507|Orlando|Florida|32822|United States",
                "orphan_designation": {
                    "original_text": "Treatment of granulomatous amebic encephalitis (GAE)",
                    "umls_id": "C0338428",
                    "parsed_text": "Granulomatous amebic encephalitis"
                }
            },
            {
                "compound_id": 3599,
                "inchl_key": "PQLXHQMOHUQAKB-UHFFFAOYSA-N",
                "generic_name": "miltefosine",
                "designated_date": "03/18/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ExperGen Drug Development GmbH|Hernalser|Haupstrasse 24/16|Austria",
                "orphan_designation": {
                    "original_text": "Topical treatment of cutaneous lymphoma encompassing cutaneous manifestations of T-cell lymphoma and B-cell lymphoma",
                    "umls_id": "C0079731,C0079772,C1276146",
                    "parsed_text": "B-Cell Lymphoma , T-Cell Lymphoma , Cutaneous lymphoma"
                }
            }
        ]
    },
    {
        "_id": "XAYGBKHKBBXDAK-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 59634741,
                "inchl_key": "XAYGBKHKBBXDAK-UHFFFAOYSA-N",
                "generic_name": "mitapivat",
                "designated_date": "11/12/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Agios Pharmaceuticals, Inc.|88 Sidney Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sickle cell disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            },
            {
                "compound_id": 59634741,
                "inchl_key": "XAYGBKHKBBXDAK-UHFFFAOYSA-N",
                "generic_name": "Mitapivat",
                "designated_date": "06/08/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Agios Pharmaceuticals, Inc.|88 Sidney Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of thalassemia",
                    "umls_id": "C0039730",
                    "parsed_text": "Thalassemia"
                }
            }
        ]
    },
    {
        "_id": "VFKZTMPDYBFSTM-GUCUJZIJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5284380,
                "inchl_key": "VFKZTMPDYBFSTM-GUCUJZIJSA-N",
                "generic_name": "Mitolactol",
                "designated_date": "01/23/1989",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Targent, Inc..|155 Lambert Drive|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of invasive carcinoma of the uterine cervix",
                    "umls_id": "C0302592,C1334274",
                    "parsed_text": "Carcinoma of the Uterine Cervix , Invasive Carcinoma"
                }
            },
            {
                "compound_id": 5284380,
                "inchl_key": "VFKZTMPDYBFSTM-GUCUJZIJSA-N",
                "generic_name": "Mitolactol",
                "designated_date": "07/12/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Targent, Inc.|155 Lambert Drive|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "As adjuvant therapy in the treatment of primary brain tumors.",
                    "umls_id": "C0750974",
                    "parsed_text": "primary brain tumors"
                }
            }
        ]
    },
    {
        "_id": "ZAHQPTJLOCWVPG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 51082,
                "inchl_key": "ZAHQPTJLOCWVPG-UHFFFAOYSA-N",
                "generic_name": "Mitoxantrone HCl",
                "trade_name": "Novantrone",
                "designated_date": "07/13/1987",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a012/23/1987\u00a0",
                "exclusivity_end_date": "\u00a012/23/1994\u00a0",
                "sponsor": "Lederle Laboratories|Division of American Cyanamid Company|401 N. Middletown Road|Pearl River|New York|10965|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "HRNLUBSXIHFDHP-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9865515,
                "inchl_key": "HRNLUBSXIHFDHP-UHFFFAOYSA-N",
                "generic_name": "mocetinostat",
                "designated_date": "08/07/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mirati Therapeutics, Inc.|9363 Towne Center Drive|Suite 200|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diffuse large B-cell lymphoma",
                    "umls_id": "C1332201",
                    "parsed_text": "Diffuse Large B-Cell Lymphoma"
                }
            },
            {
                "compound_id": 9865515,
                "inchl_key": "HRNLUBSXIHFDHP-UHFFFAOYSA-N",
                "generic_name": "Mocetinostat",
                "designated_date": "06/12/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mirati Therapeutics, Inc.|9363 Towne Center Drive|Suite 200|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndrome",
                    "umls_id": "C3463824",
                    "parsed_text": "MYELODYSPLASTIC SYNDROME"
                }
            }
        ]
    },
    {
        "_id": "RTGDFNSFWBGLEC-SYZQJQIISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5281078,
                "inchl_key": "RTGDFNSFWBGLEC-SYZQJQIISA-N",
                "generic_name": "Mycophenolate mofetil",
                "designated_date": "12/19/2005",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoffman-LaRoche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myasthenia gravis",
                    "umls_id": "C0026896",
                    "parsed_text": "Myasthenia Gravis"
                }
            },
            {
                "compound_id": 5281078,
                "inchl_key": "RTGDFNSFWBGLEC-SYZQJQIISA-N",
                "generic_name": "Mycophenolate mofetil",
                "designated_date": "05/26/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoffman-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pemphigus vulgaris",
                    "umls_id": "C0030809",
                    "parsed_text": "Pemphigus Vulgaris"
                }
            }
        ]
    },
    {
        "_id": "WXNXCEHXYPACJF-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 1995,
                "inchl_key": "WXNXCEHXYPACJF-UHFFFAOYSA-N",
                "generic_name": "N-acetyl-DL-leucine",
                "designated_date": "06/06/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "IntraBio Inc.|270 Devon Road|Tenafly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Spinocerebellar Ataxia (SCA)",
                    "umls_id": "C0018790,C0087012",
                    "parsed_text": "SCA , Spinocerebellar ataxia"
                }
            },
            {
                "compound_id": 1995,
                "inchl_key": "WXNXCEHXYPACJF-UHFFFAOYSA-N",
                "generic_name": "N-acetyl-DL-leucine",
                "designated_date": "03/26/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "IntraBio Inc.|270 Devon Road|Tenafly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of GM2 Gangliosidosis",
                    "umls_id": "C0268274",
                    "parsed_text": "GM2 Gangliosidosis"
                }
            },
            {
                "compound_id": 1995,
                "inchl_key": "WXNXCEHXYPACJF-UHFFFAOYSA-N",
                "generic_name": "N-acetyl-DL-leucine",
                "designated_date": "02/22/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "IntraBio Inc.|270 Devon Road|Tenafly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Niemann-Pick disease, type C",
                    "umls_id": "C0220756",
                    "parsed_text": "Niemann-Pick Disease, Type C"
                }
            }
        ]
    },
    {
        "_id": "DRHXTSWSUAJOJZ-FMDGEEDCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5289024,
                "inchl_key": "DRHXTSWSUAJOJZ-FMDGEEDCSA-N",
                "generic_name": "N-acetyl-glucosamine thiazoline",
                "designated_date": "02/06/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ExSAR Corporation|11 Deer Park Drive|Monmouth Junction|New Jersey|8852|United States",
                "orphan_designation": {
                    "original_text": "Treatment of adult Tay-Sachs disease",
                    "umls_id": "C0039373",
                    "parsed_text": "Tay-Sachs Disease"
                }
            }
        ]
    },
    {
        "_id": "NOWRLNPOENZFHP-ARHDFHRDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 445212,
                "inchl_key": "NOWRLNPOENZFHP-ARHDFHRDSA-N",
                "generic_name": "N-Methanocarbathymidine",
                "designated_date": "10/15/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "N & N Pharmaceuticals, Inc.|2400 Research Blvd|Suite 310|Rockville|Maryland|20850|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neonatal herpes",
                    "umls_id": "C2931185",
                    "parsed_text": "Neonatal herpes"
                }
            }
        ]
    },
    {
        "_id": "DQCKKXVULJGBQN-XFWGSAIBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5360515,
                "inchl_key": "DQCKKXVULJGBQN-XFWGSAIBSA-N",
                "generic_name": "naltrexone",
                "designated_date": "01/13/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "TaiwanJ Pharmaceuticals Co., Ltd.|Room 204 A, Bldg 53|195 Chung Hsing Rd., Sec 4|Chutung, Hsinchu|Taiwan",
                "orphan_designation": {
                    "original_text": "Treatment of autoimmune hepatitis",
                    "umls_id": "C0241910",
                    "parsed_text": "Autoimmune hepatitis"
                }
            },
            {
                "compound_id": 5360515,
                "inchl_key": "DQCKKXVULJGBQN-XFWGSAIBSA-N",
                "generic_name": "naltrexone",
                "designated_date": "01/19/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cytocom, Inc.|37 North Orange Avenue|Suite 607|Orlando|Florida|32801|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Crohn's disease in pediatric patients",
                    "umls_id": "C0010346",
                    "parsed_text": "Crohn's Disease"
                }
            },
            {
                "compound_id": 5360515,
                "inchl_key": "DQCKKXVULJGBQN-XFWGSAIBSA-N",
                "generic_name": "naltrexone",
                "designated_date": "02/23/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Allodynic Therapeutics LLC|1785 NE 123rd Street|North Miami|Florida|33181|United States",
                "orphan_designation": {
                    "original_text": "Treatment of postherpetic neuralgia",
                    "umls_id": "C0032768",
                    "parsed_text": "Postherpetic neuralgia"
                }
            }
        ]
    },
    {
        "_id": "NPAGDVCDWIYMMC-IZPLOLCNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9904,
                "inchl_key": "NPAGDVCDWIYMMC-IZPLOLCNSA-N",
                "generic_name": "nandrolone",
                "designated_date": "06/13/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sarcomed AB|25 St_xDE8B__xDD2C_oppsv\u49e5n|H\u49e5rsten-Liljeholmen|Stockholms l\u4b8d|Sweden",
                "orphan_designation": {
                    "original_text": "Treatment of Duchenne and Becker Muscular Dystrophy",
                    "umls_id": "C3542021",
                    "parsed_text": "Duchenne and Becker Muscular Dystrophy"
                }
            },
            {
                "compound_id": 9904,
                "inchl_key": "NPAGDVCDWIYMMC-IZPLOLCNSA-N",
                "generic_name": "nandrolone",
                "designated_date": "12/04/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sarcomed AB|25 St_xDE8B__xDD2C_oppsv\u49e5n|H\u49e5rsten-Liljeholmen|Stockholms l\u4b8d|Sweden",
                "orphan_designation": {
                    "original_text": "Treatment of limb-girdle muscular dystrophy",
                    "umls_id": "C0686353",
                    "parsed_text": "Limb-girdle muscular dystrophy"
                }
            }
        ]
    },
    {
        "_id": "DPHUWDIXHNQOSY-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10331844,
                "inchl_key": "DPHUWDIXHNQOSY-UHFFFAOYSA-N",
                "generic_name": "napabucasin",
                "designated_date": "10/25/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sumitomo Dainippon Pharma Oncology, Inc.|640 Memorial Drive|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 10331844,
                "inchl_key": "DPHUWDIXHNQOSY-UHFFFAOYSA-N",
                "generic_name": "napabucasin",
                "designated_date": "06/20/2016",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Boston Biomedical, Inc.|640 Memorial Drive|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastric cancer including gastroesophageal junction cancer.",
                    "umls_id": "C0024623",
                    "parsed_text": "Gastric Cancer"
                }
            }
        ]
    },
    {
        "_id": "YDZYKNJZCVIKPP-VWLOTQADSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9870520,
                "inchl_key": "YDZYKNJZCVIKPP-VWLOTQADSA-N",
                "generic_name": "netazepide",
                "designated_date": "09/10/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Trio Medicines Ltd.|Pavillion View|19 New Road|Brighton|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of gastric carcinoids",
                    "umls_id": "C0007095",
                    "parsed_text": "Carcinoids"
                }
            }
        ]
    },
    {
        "_id": "HHZIURLSWUIHRB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 644241,
                "inchl_key": "HHZIURLSWUIHRB-UHFFFAOYSA-N",
                "generic_name": "nilotinib",
                "trade_name": "Tasigna",
                "designated_date": "04/27/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "TASIGNA (nilotinib) is indicated for the treatment of pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase and pediatric patients greater than or equal to 1 year of age with chronic phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) therapy.",
                "marketing_approval_date": "\u00a003/22/2018\u00a0",
                "exclusivity_end_date": "\u00a003/22/2025\u00a0",
                "exclusivity_protected_indication": "TASIGNA (nilotinib) is indicated for the treatment of pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase and pediatric patients greater than or equal to 1 year of age with chronic phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) therapy.",
                "sponsor": "Novartis Pharmaceutical Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic myelogenous leukemia",
                    "umls_id": "C0023473",
                    "parsed_text": "Chronic myelogenous leukemia"
                }
            },
            {
                "compound_id": 644241,
                "inchl_key": "HHZIURLSWUIHRB-UHFFFAOYSA-N",
                "generic_name": "nilotinib",
                "designated_date": "03/20/2007",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaeuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastrointestinal stromal tumors.",
                    "umls_id": "C0238198",
                    "parsed_text": "Gastrointestinal Stromal Tumors"
                }
            },
            {
                "compound_id": 644241,
                "inchl_key": "HHZIURLSWUIHRB-UHFFFAOYSA-N",
                "generic_name": "nilotinib",
                "trade_name": "Tasigna",
                "designated_date": "04/27/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the use for chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior therapy that included imatinib.",
                "marketing_approval_date": "\u00a010/29/2007\u00a0",
                "exclusivity_end_date": "\u00a010/29/2014\u00a0",
                "sponsor": "Novartis Pharmaceutical Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic myelogenous leukemia",
                    "umls_id": "C0023473",
                    "parsed_text": "Chronic myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "UIAGMCDKSXEBJQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4497,
                "inchl_key": "UIAGMCDKSXEBJQ-UHFFFAOYSA-N",
                "generic_name": "nimodipine",
                "trade_name": "NYMALIZE",
                "designated_date": "09/16/2011",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V).",
                "marketing_approval_date": "\u00a005/10/2013\u00a0",
                "exclusivity_end_date": "\u00a005/10/2020\u00a0",
                "exclusivity_protected_indication": "Improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V).",
                "sponsor": "Arbor Pharmaceuticals, Inc.|6 Concourse Parkway|Suite 1800|Atlanta|Georgia|30328|United States",
                "orphan_designation": {
                    "original_text": "Treatment of subarachnoid hemorrhage.",
                    "umls_id": "C0038525",
                    "parsed_text": "Subarachnoid Hemorrhage"
                }
            }
        ]
    },
    {
        "_id": "PCHKPVIQAHNQLW-CQSZACIVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24958200,
                "inchl_key": "PCHKPVIQAHNQLW-CQSZACIVSA-N",
                "generic_name": "niraparib",
                "trade_name": "Zejula",
                "designated_date": "04/30/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "ZEJULA is indicated for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either, (1) a deleterious or suspected deleterious BRCA mutation, or (2) genomic instability and who have progressed more than six months after response to the last platinum-based chemotherapy",
                "marketing_approval_date": "\u00a010/23/2019\u00a0",
                "exclusivity_end_date": "\u00a010/23/2026\u00a0",
                "exclusivity_protected_indication": "Indicated for the treatment of adult patients with advanced ovarian cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation, or genomic instability and who have progressed more than six months after response to the last platinum-based chemotherapy.",
                "sponsor": "GlaxoSmithKline, LLC.|1000 Winter St.|Suite 3300|Waltham|Massachusetts|2451|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "compound_id": 24958200,
                "inchl_key": "PCHKPVIQAHNQLW-CQSZACIVSA-N",
                "generic_name": "niraparib",
                "trade_name": "Zejula",
                "designated_date": "04/30/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "ZEJULA is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy",
                "marketing_approval_date": "\u00a004/29/2020\u00a0",
                "exclusivity_end_date": "\u00a004/29/2027\u00a0",
                "exclusivity_protected_indication": "Indicated for the maintenance treatment of adult patients with advanced epithelial ovarian cancer who are in a complete or partial response to first-line platinum-based chemotherapy.",
                "sponsor": "GlaxoSmithKline, LLC.|1000 Winter St.|Suite 3300|Waltham|Massachusetts|2451|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "compound_id": 24958200,
                "inchl_key": "PCHKPVIQAHNQLW-CQSZACIVSA-N",
                "generic_name": "niraparib",
                "trade_name": "Zejula",
                "designated_date": "04/30/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Indicated for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy",
                "marketing_approval_date": "\u00a003/27/2017\u00a0",
                "exclusivity_end_date": "\u00a003/27/2024\u00a0",
                "exclusivity_protected_indication": "Indicated for maintenance treatment of adult patients with recurrent epithelial ovarian cancer who are in a complete or partial response to platinum-based chemotherapy",
                "sponsor": "GlaxoSmithKline, LLC.|1000 Winter St.|Suite 3300|Waltham|Massachusetts|2451|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "VFCRKLWBYMDAED-REWPJTCUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 46224413,
                "inchl_key": "VFCRKLWBYMDAED-REWPJTCUSA-N",
                "generic_name": "nirogacestat",
                "designated_date": "06/07/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SpringWorks Subsidiary 2, PBC|575 5th Avenue|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Treatment of desmoid tumor (aggressive fibromatosis)",
                    "umls_id": "C0079218",
                    "parsed_text": "Desmoid tumor"
                }
            }
        ]
    },
    {
        "_id": "MWUXSHHQAYIFBG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 145068,
                "inchl_key": "MWUXSHHQAYIFBG-UHFFFAOYSA-N",
                "generic_name": "Nitric oxide",
                "trade_name": "INOmax",
                "designated_date": "06/22/1993",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In conjunction with ventilatory support and other appropriate agents, in the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.",
                "marketing_approval_date": "\u00a012/23/1999\u00a0",
                "exclusivity_end_date": "\u00a012/23/2006\u00a0",
                "sponsor": "Mallinckrodt Hospital Products|1425 U.S. 206|Bedminster Township|New Jersey|7921|United States",
                "orphan_designation": {
                    "original_text": "Treatment of persistent pulmonary hypertension in the newborn.",
                    "umls_id": "C1135361",
                    "parsed_text": "Persistent pulmonary hypertension"
                }
            },
            {
                "compound_id": 145068,
                "inchl_key": "MWUXSHHQAYIFBG-UHFFFAOYSA-N",
                "generic_name": "nitric oxide",
                "designated_date": "09/23/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Advanced Inhalation Therapies, Ltd.|2 Ilan Ramon Street|Ness Ziyona|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            },
            {
                "compound_id": 145068,
                "inchl_key": "MWUXSHHQAYIFBG-UHFFFAOYSA-N",
                "generic_name": "nitric oxide",
                "designated_date": "09/11/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novoteris, LLC|7245 Garden Grove Blvd.|Suite C|Garden Grove|California|92841|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            },
            {
                "compound_id": 145068,
                "inchl_key": "MWUXSHHQAYIFBG-UHFFFAOYSA-N",
                "generic_name": "nitric oxide",
                "designated_date": "01/25/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "GeNo, LLC|2941 Oxbow Circle|Cocoa|Florida|32926|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension excluding persistent pulmonary hypertension of the newborn",
                    "umls_id": "C0031190,C3203102",
                    "parsed_text": "Persistent pulmonary hypertension of the newborn , PULMONARY ARTERIAL HYPERTENSION"
                }
            },
            {
                "compound_id": 145068,
                "inchl_key": "MWUXSHHQAYIFBG-UHFFFAOYSA-N",
                "generic_name": "nitric oxide",
                "designated_date": "12/28/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bellerophon Therapeutics|53 Frontage Road|Suite 301|Hampton|New Jersey|8827|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            },
            {
                "compound_id": 145068,
                "inchl_key": "MWUXSHHQAYIFBG-UHFFFAOYSA-N",
                "generic_name": "nitric oxide",
                "designated_date": "01/31/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "VERO Biotech|387 Technology Circle|Suite 125|Atlanta|Georgia|30313|United States",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic pulmonary fibrosis",
                    "umls_id": "C1800706",
                    "parsed_text": "Idiopathic Pulmonary Fibrosis"
                }
            },
            {
                "compound_id": 145068,
                "inchl_key": "MWUXSHHQAYIFBG-UHFFFAOYSA-N",
                "generic_name": "nitric oxide",
                "designated_date": "06/18/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "GENOSYL is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.",
                "marketing_approval_date": "\u00a012/20/2019\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "VERO BIOTECH|387 Technology Circle, Suite 125|Atlanta|Georgia|30313|United States",
                "orphan_designation": {
                    "original_text": "Treatment of persistent pulmonary hypertension in newborns",
                    "umls_id": "C1135361",
                    "parsed_text": "Persistent pulmonary hypertension"
                }
            },
            {
                "compound_id": 145068,
                "inchl_key": "MWUXSHHQAYIFBG-UHFFFAOYSA-N",
                "generic_name": "Nitric oxide",
                "designated_date": "02/16/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SensorMedics Corporation|22705 Savi Ranch Parkway|Yorba Linda|California|92887|United States",
                "orphan_designation": {
                    "original_text": "Diagnosis of sarcoidosis",
                    "umls_id": "C0036202",
                    "parsed_text": "Sarcoidosis"
                }
            },
            {
                "compound_id": 145068,
                "inchl_key": "MWUXSHHQAYIFBG-UHFFFAOYSA-N",
                "generic_name": "Nitric oxide",
                "designated_date": "09/27/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mallinckrodt Hospital Products|1425 U.S. 206|Bedminster Township|New Jersey|7921|United States",
                "orphan_designation": {
                    "original_text": "To reduce the risk of chronic lung disease in premature neonates",
                    "umls_id": "C0746102",
                    "parsed_text": "Chronic lung disease"
                }
            },
            {
                "compound_id": 145068,
                "inchl_key": "MWUXSHHQAYIFBG-UHFFFAOYSA-N",
                "generic_name": "Nitric oxide",
                "designated_date": "07/10/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mallinckrodt Hopspital Products|1425 U.S. 206|Bedminster Township|New Jersey|7921|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute respiratory distress syndrome in adults.",
                    "umls_id": "C0035222",
                    "parsed_text": "Acute respiratory distress syndrome"
                }
            },
            {
                "compound_id": 145068,
                "inchl_key": "MWUXSHHQAYIFBG-UHFFFAOYSA-N",
                "generic_name": "Nitric oxide",
                "designated_date": "09/26/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Advanced Inhalation Therapies Ltd.|2 Ilan Ramon Street|Ness Ziona|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of non-tuberculosis mycobacterial (NTM) infections",
                    "umls_id": "C0041296,C1265234,C3714514",
                    "parsed_text": "Tuberculosis , NTM , Infections"
                }
            },
            {
                "compound_id": 145068,
                "inchl_key": "MWUXSHHQAYIFBG-UHFFFAOYSA-N",
                "generic_name": "nitric oxide",
                "designated_date": "09/05/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mallinckrodt Hospital Products IP Unlimited|1425 U.S. 206|Bedminster Township|New Jersey|7921|United States",
                "orphan_designation": {
                    "original_text": "Use in combination with a drug delivery device for acute treatment of sickle cell vaso-occlusive crisis (pain crises)",
                    "umls_id": "C0030193,C0231224,C0750151",
                    "parsed_text": "Pain , crises , Vaso-Occlusive Crisis"
                }
            },
            {
                "compound_id": 145068,
                "inchl_key": "MWUXSHHQAYIFBG-UHFFFAOYSA-N",
                "generic_name": "nitric oxide",
                "designated_date": "06/05/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novoteris, LLC|7245 Garden Grove Blvd.|Suite C|Garden Grove|California|92841|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-tuberculous mycobacterial lung disease",
                    "umls_id": "C0024115,C0041296",
                    "parsed_text": "Lung Disease , Tuberculous"
                }
            }
        ]
    },
    {
        "_id": "ZVAGBRFUYHSUHA-XEKNBVSESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 122362431,
                "inchl_key": "ZVAGBRFUYHSUHA-XEKNBVSESA-N",
                "generic_name": "Obatoclax mesylate",
                "designated_date": "11/06/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gemin X, Inc.|400 Chesterfield Parkway|Suite 100|Malvern|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndrome",
                    "umls_id": "C3463824",
                    "parsed_text": "MYELODYSPLASTIC SYNDROME"
                }
            },
            {
                "compound_id": 122362431,
                "inchl_key": "ZVAGBRFUYHSUHA-XEKNBVSESA-N",
                "generic_name": "obatoclax mesylate",
                "designated_date": "10/08/2004",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.|41 Moores Road|P. O. Box 4011|Frazer|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "compound_id": 122362431,
                "inchl_key": "ZVAGBRFUYHSUHA-XEKNBVSESA-N",
                "generic_name": "Obatoclax mesylate",
                "designated_date": "12/01/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gemin X Pharmaceuticals US, Inc.|400 Chesterfield Pkwy.|Suite 100|Malvern|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelofibrosis",
                    "umls_id": "C0026987",
                    "parsed_text": "myelofibrosis"
                }
            }
        ]
    },
    {
        "_id": "ZVAGBRFUYHSUHA-QUIKYCSHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 56843157,
                "inchl_key": "ZVAGBRFUYHSUHA-QUIKYCSHSA-N",
                "generic_name": "Obatoclax mesylate",
                "designated_date": "11/06/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gemin X, Inc.|400 Chesterfield Parkway|Suite 100|Malvern|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndrome",
                    "umls_id": "C3463824",
                    "parsed_text": "MYELODYSPLASTIC SYNDROME"
                }
            },
            {
                "compound_id": 56843157,
                "inchl_key": "ZVAGBRFUYHSUHA-QUIKYCSHSA-N",
                "generic_name": "obatoclax mesylate",
                "designated_date": "10/08/2004",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.|41 Moores Road|P. O. Box 4011|Frazer|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "compound_id": 56843157,
                "inchl_key": "ZVAGBRFUYHSUHA-QUIKYCSHSA-N",
                "generic_name": "Obatoclax mesylate",
                "designated_date": "12/01/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gemin X Pharmaceuticals US, Inc.|400 Chesterfield Pkwy.|Suite 100|Malvern|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelofibrosis",
                    "umls_id": "C0026987",
                    "parsed_text": "myelofibrosis"
                }
            }
        ]
    },
    {
        "_id": "ZVAGBRFUYHSUHA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 70700268,
                "inchl_key": "ZVAGBRFUYHSUHA-UHFFFAOYSA-N",
                "generic_name": "Obatoclax mesylate",
                "designated_date": "11/06/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gemin X, Inc.|400 Chesterfield Parkway|Suite 100|Malvern|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndrome",
                    "umls_id": "C3463824",
                    "parsed_text": "MYELODYSPLASTIC SYNDROME"
                }
            },
            {
                "compound_id": 70700268,
                "inchl_key": "ZVAGBRFUYHSUHA-UHFFFAOYSA-N",
                "generic_name": "obatoclax mesylate",
                "designated_date": "10/08/2004",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.|41 Moores Road|P. O. Box 4011|Frazer|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "compound_id": 70700268,
                "inchl_key": "ZVAGBRFUYHSUHA-UHFFFAOYSA-N",
                "generic_name": "Obatoclax mesylate",
                "designated_date": "12/01/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gemin X Pharmaceuticals US, Inc.|400 Chesterfield Pkwy.|Suite 100|Malvern|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelofibrosis",
                    "umls_id": "C0026987",
                    "parsed_text": "myelofibrosis"
                }
            }
        ]
    },
    {
        "_id": "ZVAGBRFUYHSUHA-CFWFSBERSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16727411,
                "inchl_key": "ZVAGBRFUYHSUHA-CFWFSBERSA-N",
                "generic_name": "Obatoclax mesylate",
                "designated_date": "11/06/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gemin X, Inc.|400 Chesterfield Parkway|Suite 100|Malvern|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndrome",
                    "umls_id": "C3463824",
                    "parsed_text": "MYELODYSPLASTIC SYNDROME"
                }
            },
            {
                "compound_id": 16727411,
                "inchl_key": "ZVAGBRFUYHSUHA-CFWFSBERSA-N",
                "generic_name": "obatoclax mesylate",
                "designated_date": "10/08/2004",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.|41 Moores Road|P. O. Box 4011|Frazer|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "compound_id": 16727411,
                "inchl_key": "ZVAGBRFUYHSUHA-CFWFSBERSA-N",
                "generic_name": "Obatoclax mesylate",
                "designated_date": "12/01/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gemin X Pharmaceuticals US, Inc.|400 Chesterfield Pkwy.|Suite 100|Malvern|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelofibrosis",
                    "umls_id": "C0026987",
                    "parsed_text": "myelofibrosis"
                }
            }
        ]
    },
    {
        "_id": "ZVAGBRFUYHSUHA-RKMKAUCSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71816154,
                "inchl_key": "ZVAGBRFUYHSUHA-RKMKAUCSSA-N",
                "generic_name": "Obatoclax mesylate",
                "designated_date": "11/06/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gemin X, Inc.|400 Chesterfield Parkway|Suite 100|Malvern|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndrome",
                    "umls_id": "C3463824",
                    "parsed_text": "MYELODYSPLASTIC SYNDROME"
                }
            },
            {
                "compound_id": 71816154,
                "inchl_key": "ZVAGBRFUYHSUHA-RKMKAUCSSA-N",
                "generic_name": "obatoclax mesylate",
                "designated_date": "10/08/2004",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.|41 Moores Road|P. O. Box 4011|Frazer|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "compound_id": 71816154,
                "inchl_key": "ZVAGBRFUYHSUHA-RKMKAUCSSA-N",
                "generic_name": "Obatoclax mesylate",
                "designated_date": "12/01/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gemin X Pharmaceuticals US, Inc.|400 Chesterfield Pkwy.|Suite 100|Malvern|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelofibrosis",
                    "umls_id": "C0026987",
                    "parsed_text": "myelofibrosis"
                }
            }
        ]
    },
    {
        "_id": "ZVAGBRFUYHSUHA-VLJPQPJMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 46930996,
                "inchl_key": "ZVAGBRFUYHSUHA-VLJPQPJMSA-N",
                "generic_name": "Obatoclax mesylate",
                "designated_date": "11/06/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gemin X, Inc.|400 Chesterfield Parkway|Suite 100|Malvern|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndrome",
                    "umls_id": "C3463824",
                    "parsed_text": "MYELODYSPLASTIC SYNDROME"
                }
            },
            {
                "compound_id": 46930996,
                "inchl_key": "ZVAGBRFUYHSUHA-VLJPQPJMSA-N",
                "generic_name": "obatoclax mesylate",
                "designated_date": "10/08/2004",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.|41 Moores Road|P. O. Box 4011|Frazer|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "compound_id": 46930996,
                "inchl_key": "ZVAGBRFUYHSUHA-VLJPQPJMSA-N",
                "generic_name": "Obatoclax mesylate",
                "designated_date": "12/01/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gemin X Pharmaceuticals US, Inc.|400 Chesterfield Pkwy.|Suite 100|Malvern|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelofibrosis",
                    "umls_id": "C0026987",
                    "parsed_text": "myelofibrosis"
                }
            }
        ]
    },
    {
        "_id": "ZVAGBRFUYHSUHA-LZOXOEDVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16681698,
                "inchl_key": "ZVAGBRFUYHSUHA-LZOXOEDVSA-N",
                "generic_name": "Obatoclax mesylate",
                "designated_date": "11/06/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gemin X, Inc.|400 Chesterfield Parkway|Suite 100|Malvern|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndrome",
                    "umls_id": "C3463824",
                    "parsed_text": "MYELODYSPLASTIC SYNDROME"
                }
            },
            {
                "compound_id": 16681698,
                "inchl_key": "ZVAGBRFUYHSUHA-LZOXOEDVSA-N",
                "generic_name": "obatoclax mesylate",
                "designated_date": "10/08/2004",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.|41 Moores Road|P. O. Box 4011|Frazer|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "compound_id": 16681698,
                "inchl_key": "ZVAGBRFUYHSUHA-LZOXOEDVSA-N",
                "generic_name": "Obatoclax mesylate",
                "designated_date": "12/01/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gemin X Pharmaceuticals US, Inc.|400 Chesterfield Pkwy.|Suite 100|Malvern|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelofibrosis",
                    "umls_id": "C0026987",
                    "parsed_text": "myelofibrosis"
                }
            }
        ]
    },
    {
        "_id": "ZXERDUOLZKYMJM-ZWECCWDJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 447715,
                "inchl_key": "ZXERDUOLZKYMJM-ZWECCWDJSA-N",
                "generic_name": "obeticholic acid",
                "trade_name": "OCALIVA",
                "designated_date": "04/09/2008",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA",
                "marketing_approval_date": "\u00a005/27/2016\u00a0",
                "exclusivity_end_date": "\u00a005/27/2023\u00a0",
                "exclusivity_protected_indication": "Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA",
                "sponsor": "Intercept Pharmaceuticals, Inc.|4760 Eastgate Mall|San Diego|California|92122|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary biliary cirrhosis",
                    "umls_id": "C0008312",
                    "parsed_text": "Primary Biliary Cirrhosis"
                }
            }
        ]
    },
    {
        "_id": "MIMNFCVQODTQDP-NDLVEFNKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 118984458,
                "inchl_key": "MIMNFCVQODTQDP-NDLVEFNKSA-N",
                "generic_name": "oblimersen",
                "designated_date": "08/28/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genta, Inc.|200 Connell Drive|Berkeley Heights|New Jersey|7922|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "compound_id": 118984458,
                "inchl_key": "MIMNFCVQODTQDP-NDLVEFNKSA-N",
                "generic_name": "oblimersen",
                "designated_date": "08/28/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genta, Inc.|200 Connell Drive|Berkeley Heights|New Jersey|7922|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            },
            {
                "compound_id": 118984458,
                "inchl_key": "MIMNFCVQODTQDP-NDLVEFNKSA-N",
                "generic_name": "oblimersen",
                "designated_date": "07/31/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genta, Inc.|200 Connell Drive|Berkeley Heights|New Jersey|7922|United States",
                "orphan_designation": {
                    "original_text": "Treatment of advanced malignant melanoma (Stages II,III, IV).",
                    "umls_id": "C0025202",
                    "parsed_text": "Malignant Melanoma"
                }
            },
            {
                "compound_id": 118984458,
                "inchl_key": "MIMNFCVQODTQDP-NDLVEFNKSA-N",
                "generic_name": "oblimersen",
                "designated_date": "08/28/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genta, Inc.|200 Connell Drive|Berkeley Heights|New Jersey|7922|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelocytic leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myelocytic leukemia"
                }
            }
        ]
    },
    {
        "_id": "IBXPAFBDJCXCDW-MHFPCNPESA-A",
        "Orphan Drug Designations": [
            {
                "compound_id": 118984457,
                "inchl_key": "IBXPAFBDJCXCDW-MHFPCNPESA-A",
                "generic_name": "oblimersen",
                "designated_date": "08/28/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genta, Inc.|200 Connell Drive|Berkeley Heights|New Jersey|7922|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "compound_id": 118984457,
                "inchl_key": "IBXPAFBDJCXCDW-MHFPCNPESA-A",
                "generic_name": "oblimersen",
                "designated_date": "08/28/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genta, Inc.|200 Connell Drive|Berkeley Heights|New Jersey|7922|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            },
            {
                "compound_id": 118984457,
                "inchl_key": "IBXPAFBDJCXCDW-MHFPCNPESA-A",
                "generic_name": "oblimersen",
                "designated_date": "07/31/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genta, Inc.|200 Connell Drive|Berkeley Heights|New Jersey|7922|United States",
                "orphan_designation": {
                    "original_text": "Treatment of advanced malignant melanoma (Stages II,III, IV).",
                    "umls_id": "C0025202",
                    "parsed_text": "Malignant Melanoma"
                }
            },
            {
                "compound_id": 118984457,
                "inchl_key": "IBXPAFBDJCXCDW-MHFPCNPESA-A",
                "generic_name": "oblimersen",
                "designated_date": "08/28/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genta, Inc.|200 Connell Drive|Berkeley Heights|New Jersey|7922|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelocytic leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myelocytic leukemia"
                }
            }
        ]
    },
    {
        "_id": "DEQANNDTNATYII-JPZSUCLZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 138107728,
                "inchl_key": "DEQANNDTNATYII-JPZSUCLZSA-N",
                "generic_name": "Octreotide",
                "trade_name": "Sandostatin LAR",
                "designated_date": "08/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Supression of severe diarrhea and flushing associated with malignant carcinoid syndrome.",
                "marketing_approval_date": "\u00a011/25/1998\u00a0",
                "exclusivity_end_date": "\u00a011/25/2005\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.",
                    "umls_id": "C0016382,C0391970,C1443924",
                    "parsed_text": "Flushing , Malignant carcinoid tumors , Severe diarrhea"
                }
            },
            {
                "compound_id": 138107728,
                "inchl_key": "DEQANNDTNATYII-JPZSUCLZSA-N",
                "generic_name": "Octreotide",
                "trade_name": "Sandostatin LAR",
                "designated_date": "08/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of profuse watery diarrhea associated with VIPoma.",
                "marketing_approval_date": "\u00a011/25/1998\u00a0",
                "exclusivity_end_date": "\u00a011/25/2005\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).",
                    "umls_id": "C0011991,C0011993,C0027651",
                    "parsed_text": "Diarrhea , Vipoma , Tumors"
                }
            },
            {
                "compound_id": 138107728,
                "inchl_key": "DEQANNDTNATYII-JPZSUCLZSA-N",
                "generic_name": "octreotide",
                "designated_date": "08/05/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health laza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuroendocrine tumors",
                    "umls_id": "C0206754",
                    "parsed_text": "Neuroendocrine Tumors"
                }
            },
            {
                "compound_id": 138107728,
                "inchl_key": "DEQANNDTNATYII-JPZSUCLZSA-N",
                "generic_name": "Octreotide",
                "trade_name": "Sandostatin LAR",
                "designated_date": "08/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly.",
                "marketing_approval_date": "\u00a011/25/1998\u00a0",
                "exclusivity_end_date": "\u00a011/25/2005\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acromegaly.",
                    "umls_id": "C0001206",
                    "parsed_text": "Acromegaly"
                }
            }
        ]
    },
    {
        "_id": "DEQANNDTNATYII-LIXSYSMXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44311916,
                "inchl_key": "DEQANNDTNATYII-LIXSYSMXSA-N",
                "generic_name": "Octreotide",
                "trade_name": "Sandostatin LAR",
                "designated_date": "08/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Supression of severe diarrhea and flushing associated with malignant carcinoid syndrome.",
                "marketing_approval_date": "\u00a011/25/1998\u00a0",
                "exclusivity_end_date": "\u00a011/25/2005\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.",
                    "umls_id": "C0016382,C0391970,C1443924",
                    "parsed_text": "Flushing , Malignant carcinoid tumors , Severe diarrhea"
                }
            },
            {
                "compound_id": 44311916,
                "inchl_key": "DEQANNDTNATYII-LIXSYSMXSA-N",
                "generic_name": "Octreotide",
                "trade_name": "Sandostatin LAR",
                "designated_date": "08/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of profuse watery diarrhea associated with VIPoma.",
                "marketing_approval_date": "\u00a011/25/1998\u00a0",
                "exclusivity_end_date": "\u00a011/25/2005\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).",
                    "umls_id": "C0011991,C0011993,C0027651",
                    "parsed_text": "Diarrhea , Vipoma , Tumors"
                }
            },
            {
                "compound_id": 44311916,
                "inchl_key": "DEQANNDTNATYII-LIXSYSMXSA-N",
                "generic_name": "octreotide",
                "designated_date": "08/05/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health laza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuroendocrine tumors",
                    "umls_id": "C0206754",
                    "parsed_text": "Neuroendocrine Tumors"
                }
            },
            {
                "compound_id": 44311916,
                "inchl_key": "DEQANNDTNATYII-LIXSYSMXSA-N",
                "generic_name": "Octreotide",
                "trade_name": "Sandostatin LAR",
                "designated_date": "08/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly.",
                "marketing_approval_date": "\u00a011/25/1998\u00a0",
                "exclusivity_end_date": "\u00a011/25/2005\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acromegaly.",
                    "umls_id": "C0001206",
                    "parsed_text": "Acromegaly"
                }
            }
        ]
    },
    {
        "_id": "DEQANNDTNATYII-XOEBDJBESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 90488715,
                "inchl_key": "DEQANNDTNATYII-XOEBDJBESA-N",
                "generic_name": "Octreotide",
                "trade_name": "Sandostatin LAR",
                "designated_date": "08/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Supression of severe diarrhea and flushing associated with malignant carcinoid syndrome.",
                "marketing_approval_date": "\u00a011/25/1998\u00a0",
                "exclusivity_end_date": "\u00a011/25/2005\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.",
                    "umls_id": "C0016382,C0391970,C1443924",
                    "parsed_text": "Flushing , Malignant carcinoid tumors , Severe diarrhea"
                }
            },
            {
                "compound_id": 90488715,
                "inchl_key": "DEQANNDTNATYII-XOEBDJBESA-N",
                "generic_name": "Octreotide",
                "trade_name": "Sandostatin LAR",
                "designated_date": "08/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of profuse watery diarrhea associated with VIPoma.",
                "marketing_approval_date": "\u00a011/25/1998\u00a0",
                "exclusivity_end_date": "\u00a011/25/2005\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).",
                    "umls_id": "C0011991,C0011993,C0027651",
                    "parsed_text": "Diarrhea , Vipoma , Tumors"
                }
            },
            {
                "compound_id": 90488715,
                "inchl_key": "DEQANNDTNATYII-XOEBDJBESA-N",
                "generic_name": "octreotide",
                "designated_date": "08/05/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health laza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuroendocrine tumors",
                    "umls_id": "C0206754",
                    "parsed_text": "Neuroendocrine Tumors"
                }
            },
            {
                "compound_id": 90488715,
                "inchl_key": "DEQANNDTNATYII-XOEBDJBESA-N",
                "generic_name": "Octreotide",
                "trade_name": "Sandostatin LAR",
                "designated_date": "08/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly.",
                "marketing_approval_date": "\u00a011/25/1998\u00a0",
                "exclusivity_end_date": "\u00a011/25/2005\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acromegaly.",
                    "umls_id": "C0001206",
                    "parsed_text": "Acromegaly"
                }
            }
        ]
    },
    {
        "_id": "DEQANNDTNATYII-FLDZURHUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 86289069,
                "inchl_key": "DEQANNDTNATYII-FLDZURHUSA-N",
                "generic_name": "Octreotide",
                "trade_name": "Sandostatin LAR",
                "designated_date": "08/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Supression of severe diarrhea and flushing associated with malignant carcinoid syndrome.",
                "marketing_approval_date": "\u00a011/25/1998\u00a0",
                "exclusivity_end_date": "\u00a011/25/2005\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.",
                    "umls_id": "C0016382,C0391970,C1443924",
                    "parsed_text": "Flushing , Malignant carcinoid tumors , Severe diarrhea"
                }
            },
            {
                "compound_id": 86289069,
                "inchl_key": "DEQANNDTNATYII-FLDZURHUSA-N",
                "generic_name": "Octreotide",
                "trade_name": "Sandostatin LAR",
                "designated_date": "08/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of profuse watery diarrhea associated with VIPoma.",
                "marketing_approval_date": "\u00a011/25/1998\u00a0",
                "exclusivity_end_date": "\u00a011/25/2005\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).",
                    "umls_id": "C0011991,C0011993,C0027651",
                    "parsed_text": "Diarrhea , Vipoma , Tumors"
                }
            },
            {
                "compound_id": 86289069,
                "inchl_key": "DEQANNDTNATYII-FLDZURHUSA-N",
                "generic_name": "octreotide",
                "designated_date": "08/05/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health laza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuroendocrine tumors",
                    "umls_id": "C0206754",
                    "parsed_text": "Neuroendocrine Tumors"
                }
            },
            {
                "compound_id": 86289069,
                "inchl_key": "DEQANNDTNATYII-FLDZURHUSA-N",
                "generic_name": "Octreotide",
                "trade_name": "Sandostatin LAR",
                "designated_date": "08/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly.",
                "marketing_approval_date": "\u00a011/25/1998\u00a0",
                "exclusivity_end_date": "\u00a011/25/2005\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acromegaly.",
                    "umls_id": "C0001206",
                    "parsed_text": "Acromegaly"
                }
            }
        ]
    },
    {
        "_id": "DEQANNDTNATYII-MEUDYGGUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44420813,
                "inchl_key": "DEQANNDTNATYII-MEUDYGGUSA-N",
                "generic_name": "Octreotide",
                "trade_name": "Sandostatin LAR",
                "designated_date": "08/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Supression of severe diarrhea and flushing associated with malignant carcinoid syndrome.",
                "marketing_approval_date": "\u00a011/25/1998\u00a0",
                "exclusivity_end_date": "\u00a011/25/2005\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.",
                    "umls_id": "C0016382,C0391970,C1443924",
                    "parsed_text": "Flushing , Malignant carcinoid tumors , Severe diarrhea"
                }
            },
            {
                "compound_id": 44420813,
                "inchl_key": "DEQANNDTNATYII-MEUDYGGUSA-N",
                "generic_name": "Octreotide",
                "trade_name": "Sandostatin LAR",
                "designated_date": "08/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of profuse watery diarrhea associated with VIPoma.",
                "marketing_approval_date": "\u00a011/25/1998\u00a0",
                "exclusivity_end_date": "\u00a011/25/2005\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).",
                    "umls_id": "C0011991,C0011993,C0027651",
                    "parsed_text": "Diarrhea , Vipoma , Tumors"
                }
            },
            {
                "compound_id": 44420813,
                "inchl_key": "DEQANNDTNATYII-MEUDYGGUSA-N",
                "generic_name": "octreotide",
                "designated_date": "08/05/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health laza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuroendocrine tumors",
                    "umls_id": "C0206754",
                    "parsed_text": "Neuroendocrine Tumors"
                }
            },
            {
                "compound_id": 44420813,
                "inchl_key": "DEQANNDTNATYII-MEUDYGGUSA-N",
                "generic_name": "Octreotide",
                "trade_name": "Sandostatin LAR",
                "designated_date": "08/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly.",
                "marketing_approval_date": "\u00a011/25/1998\u00a0",
                "exclusivity_end_date": "\u00a011/25/2005\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acromegaly.",
                    "umls_id": "C0001206",
                    "parsed_text": "Acromegaly"
                }
            }
        ]
    },
    {
        "_id": "DEQANNDTNATYII-RRCPSWKPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6400441,
                "inchl_key": "DEQANNDTNATYII-RRCPSWKPSA-N",
                "generic_name": "Octreotide",
                "trade_name": "Sandostatin LAR",
                "designated_date": "08/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Supression of severe diarrhea and flushing associated with malignant carcinoid syndrome.",
                "marketing_approval_date": "\u00a011/25/1998\u00a0",
                "exclusivity_end_date": "\u00a011/25/2005\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.",
                    "umls_id": "C0016382,C0391970,C1443924",
                    "parsed_text": "Flushing , Malignant carcinoid tumors , Severe diarrhea"
                }
            },
            {
                "compound_id": 6400441,
                "inchl_key": "DEQANNDTNATYII-RRCPSWKPSA-N",
                "generic_name": "Octreotide",
                "trade_name": "Sandostatin LAR",
                "designated_date": "08/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of profuse watery diarrhea associated with VIPoma.",
                "marketing_approval_date": "\u00a011/25/1998\u00a0",
                "exclusivity_end_date": "\u00a011/25/2005\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).",
                    "umls_id": "C0011991,C0011993,C0027651",
                    "parsed_text": "Diarrhea , Vipoma , Tumors"
                }
            },
            {
                "compound_id": 6400441,
                "inchl_key": "DEQANNDTNATYII-RRCPSWKPSA-N",
                "generic_name": "octreotide",
                "designated_date": "08/05/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health laza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuroendocrine tumors",
                    "umls_id": "C0206754",
                    "parsed_text": "Neuroendocrine Tumors"
                }
            },
            {
                "compound_id": 6400441,
                "inchl_key": "DEQANNDTNATYII-RRCPSWKPSA-N",
                "generic_name": "Octreotide",
                "trade_name": "Sandostatin LAR",
                "designated_date": "08/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly.",
                "marketing_approval_date": "\u00a011/25/1998\u00a0",
                "exclusivity_end_date": "\u00a011/25/2005\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acromegaly.",
                    "umls_id": "C0001206",
                    "parsed_text": "Acromegaly"
                }
            }
        ]
    },
    {
        "_id": "DEQANNDTNATYII-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 383414,
                "inchl_key": "DEQANNDTNATYII-UHFFFAOYSA-N",
                "generic_name": "Octreotide",
                "trade_name": "Sandostatin LAR",
                "designated_date": "08/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Supression of severe diarrhea and flushing associated with malignant carcinoid syndrome.",
                "marketing_approval_date": "\u00a011/25/1998\u00a0",
                "exclusivity_end_date": "\u00a011/25/2005\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.",
                    "umls_id": "C0016382,C0391970,C1443924",
                    "parsed_text": "Flushing , Malignant carcinoid tumors , Severe diarrhea"
                }
            },
            {
                "compound_id": 383414,
                "inchl_key": "DEQANNDTNATYII-UHFFFAOYSA-N",
                "generic_name": "Octreotide",
                "trade_name": "Sandostatin LAR",
                "designated_date": "08/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of profuse watery diarrhea associated with VIPoma.",
                "marketing_approval_date": "\u00a011/25/1998\u00a0",
                "exclusivity_end_date": "\u00a011/25/2005\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).",
                    "umls_id": "C0011991,C0011993,C0027651",
                    "parsed_text": "Diarrhea , Vipoma , Tumors"
                }
            },
            {
                "compound_id": 383414,
                "inchl_key": "DEQANNDTNATYII-UHFFFAOYSA-N",
                "generic_name": "octreotide",
                "designated_date": "08/05/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health laza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuroendocrine tumors",
                    "umls_id": "C0206754",
                    "parsed_text": "Neuroendocrine Tumors"
                }
            },
            {
                "compound_id": 383414,
                "inchl_key": "DEQANNDTNATYII-UHFFFAOYSA-N",
                "generic_name": "Octreotide",
                "trade_name": "Sandostatin LAR",
                "designated_date": "08/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly.",
                "marketing_approval_date": "\u00a011/25/1998\u00a0",
                "exclusivity_end_date": "\u00a011/25/2005\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acromegaly.",
                    "umls_id": "C0001206",
                    "parsed_text": "Acromegaly"
                }
            }
        ]
    },
    {
        "_id": "DEQANNDTNATYII-OULOTJBUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 448601,
                "inchl_key": "DEQANNDTNATYII-OULOTJBUSA-N",
                "generic_name": "Octreotide",
                "trade_name": "Sandostatin LAR",
                "designated_date": "08/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Supression of severe diarrhea and flushing associated with malignant carcinoid syndrome.",
                "marketing_approval_date": "\u00a011/25/1998\u00a0",
                "exclusivity_end_date": "\u00a011/25/2005\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.",
                    "umls_id": "C0016382,C0391970,C1443924",
                    "parsed_text": "Flushing , Malignant carcinoid tumors , Severe diarrhea"
                }
            },
            {
                "compound_id": 448601,
                "inchl_key": "DEQANNDTNATYII-OULOTJBUSA-N",
                "generic_name": "Octreotide",
                "trade_name": "Sandostatin LAR",
                "designated_date": "08/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of profuse watery diarrhea associated with VIPoma.",
                "marketing_approval_date": "\u00a011/25/1998\u00a0",
                "exclusivity_end_date": "\u00a011/25/2005\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).",
                    "umls_id": "C0011991,C0011993,C0027651",
                    "parsed_text": "Diarrhea , Vipoma , Tumors"
                }
            },
            {
                "compound_id": 448601,
                "inchl_key": "DEQANNDTNATYII-OULOTJBUSA-N",
                "generic_name": "octreotide",
                "designated_date": "08/05/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health laza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuroendocrine tumors",
                    "umls_id": "C0206754",
                    "parsed_text": "Neuroendocrine Tumors"
                }
            },
            {
                "compound_id": 448601,
                "inchl_key": "DEQANNDTNATYII-OULOTJBUSA-N",
                "generic_name": "Octreotide",
                "trade_name": "Sandostatin LAR",
                "designated_date": "08/24/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly.",
                "marketing_approval_date": "\u00a011/25/1998\u00a0",
                "exclusivity_end_date": "\u00a011/25/2005\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acromegaly.",
                    "umls_id": "C0001206",
                    "parsed_text": "Acromegaly"
                }
            }
        ]
    },
    {
        "_id": "JRHNIQQUVJOPQC-AQNFWKISSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 216385,
                "inchl_key": "JRHNIQQUVJOPQC-AQNFWKISSA-N",
                "generic_name": "odiparcil",
                "designated_date": "08/03/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Inventiva Pharma|50 rue de Dijon|Daix 21121|France",
                "orphan_designation": {
                    "original_text": "Treatment of mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome)",
                    "umls_id": "C0026709",
                    "parsed_text": "Mucopolysaccharidosis Type VI"
                }
            }
        ]
    },
    {
        "_id": "SWZXEVABPLUDIO-WSZYKNRRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25067547,
                "inchl_key": "SWZXEVABPLUDIO-WSZYKNRRSA-N",
                "generic_name": "oprozomib",
                "designated_date": "10/28/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Onyx Therapeutics, Inc.|249 E. Grand Avenue|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            },
            {
                "compound_id": 25067547,
                "inchl_key": "SWZXEVABPLUDIO-WSZYKNRRSA-N",
                "generic_name": "oprozomib",
                "designated_date": "08/25/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Onyx Therapeutics, Inc.|249 E. Grand Avenue|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Waldenstrom's macroglobulinemia",
                    "umls_id": "C0024419",
                    "parsed_text": "Waldenstrom's Macroglobulinemia"
                }
            }
        ]
    },
    {
        "_id": "QSLJIVKCVHQPLV-PEMPUTJUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5878,
                "inchl_key": "QSLJIVKCVHQPLV-PEMPUTJUSA-N",
                "generic_name": "Oxandrolone",
                "designated_date": "07/05/1990",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bio-Technology General Corp.|70 Wood Avenue, South|Iselin|New Jersey|8830|United States",
                "orphan_designation": {
                    "original_text": "Treatment of short stature associated with Turner's syndrome.",
                    "umls_id": "C0013336,C0041408",
                    "parsed_text": "Short stature , Turner's Syndrome"
                }
            },
            {
                "compound_id": 5878,
                "inchl_key": "QSLJIVKCVHQPLV-PEMPUTJUSA-N",
                "generic_name": "Oxandrolone",
                "designated_date": "04/22/1997",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Savient Pharmaceuticals, Inc.|One Tower Center Boulevard, 12th floor|East Brunswick|New Jersey|8816|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.",
                    "umls_id": "C0013264,C0917713",
                    "parsed_text": "Duchenne's Muscular Dystrophy , Becker's Muscular Dystrophy"
                }
            },
            {
                "compound_id": 5878,
                "inchl_key": "QSLJIVKCVHQPLV-PEMPUTJUSA-N",
                "generic_name": "Oxandrolone",
                "designated_date": "09/06/1991",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bio-Technology General Corp.|One Tower Center Boulevard, 12 th floor|East Brunswick|New Jersey|8816|United States",
                "orphan_designation": {
                    "original_text": "Adjunctive therapy for AIDS patients suffering from HIV-wasting syndrome.",
                    "umls_id": "C0006625,C0019682",
                    "parsed_text": "Wasting syndrome , HIV"
                }
            },
            {
                "compound_id": 5878,
                "inchl_key": "QSLJIVKCVHQPLV-PEMPUTJUSA-N",
                "generic_name": "Oxandrolone",
                "designated_date": "10/05/1990",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bio-Technology General Corp.|70 Wood Avenue, South|Iselin|New Jersey|8830|United States",
                "orphan_designation": {
                    "original_text": "Treatment of constitutional delay of growth and puberty.",
                    "umls_id": "C0342538",
                    "parsed_text": "Constitutional delay of growth and puberty"
                }
            },
            {
                "compound_id": 5878,
                "inchl_key": "QSLJIVKCVHQPLV-PEMPUTJUSA-N",
                "generic_name": "Oxandrolone",
                "designated_date": "03/18/1994",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bio-Technology General Corp.|One Tower Center Boulevard, 12 th floor|East Brunswick|New Jersey|8816|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate/severe acute alcoholic hepatitis in the presence of moderate protein calorie malnutrition.",
                    "umls_id": "C0001306,C0033677",
                    "parsed_text": "Acute alcoholic hepatitis , protein calorie malnutrition"
                }
            }
        ]
    },
    {
        "_id": "BEZZFPOZAYTVHN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 40854,
                "inchl_key": "BEZZFPOZAYTVHN-UHFFFAOYSA-N",
                "generic_name": "oxfendazole",
                "designated_date": "07/14/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Robert H. Gilman, MD, DTMH and|Johns Hopkins School of Public Health|615 N. Wolfe St, Room W5515|Baltimore|Maryland|21205|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cysticercosis (including neurocysticercosis)",
                    "umls_id": "C0010678,C0338437",
                    "parsed_text": "Cysticercosis , Neurocysticercosis"
                }
            },
            {
                "compound_id": 40854,
                "inchl_key": "BEZZFPOZAYTVHN-UHFFFAOYSA-N",
                "generic_name": "oxfendazole",
                "designated_date": "08/07/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oxfendazole Development Group|736 Cathcart Road|Blue Bell|Pennsylvania|19422|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cysticercosis",
                    "umls_id": "C0010678",
                    "parsed_text": "Cysticercosis"
                }
            }
        ]
    },
    {
        "_id": "FPOHNWQLNRZRFC-ZHACJKMWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6918837,
                "inchl_key": "FPOHNWQLNRZRFC-ZHACJKMWSA-N",
                "generic_name": "panobinostat",
                "trade_name": "Farydak",
                "designated_date": "08/20/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "FARYDAK (panobinostat) in combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent",
                "marketing_approval_date": "\u00a002/23/2015\u00a0",
                "exclusivity_end_date": "\u00a002/23/2022\u00a0",
                "exclusivity_protected_indication": "FARYDAK (panobinostat) in combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent",
                "sponsor": "Secura Bio, Inc.|11988 El Camino Real|Suite 650|San Diego|California|92130|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            },
            {
                "compound_id": 6918837,
                "inchl_key": "FPOHNWQLNRZRFC-ZHACJKMWSA-N",
                "generic_name": "panobinostat",
                "designated_date": "09/18/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza, 105/3W038|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Hodgkin's lymphoma",
                    "umls_id": "C0019829",
                    "parsed_text": "hodgkin's lymphoma"
                }
            },
            {
                "compound_id": 6918837,
                "inchl_key": "FPOHNWQLNRZRFC-ZHACJKMWSA-N",
                "generic_name": "Panobinostat",
                "designated_date": "09/26/2007",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza, 105/3W038|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cutaneous T-cell lymphoma",
                    "umls_id": "C0079773",
                    "parsed_text": "cutaneous T-cell lymphoma"
                }
            }
        ]
    },
    {
        "_id": "VMZMNAABQBOLAK-DBILLSOUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9941444,
                "inchl_key": "VMZMNAABQBOLAK-DBILLSOUSA-N",
                "generic_name": "pasireotide",
                "trade_name": "Signifor",
                "designated_date": "07/24/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "SIGNIFOR LAR is indicated for the treatment of patients with Cushings disease for whom pituitary surgery is not an option or has not been curative.",
                "marketing_approval_date": "\u00a006/29/2018\u00a0",
                "exclusivity_end_date": "\u00a006/29/2025\u00a0",
                "exclusivity_protected_indication": "Indicated for treatment of patients with Cushings disease for whom pituitary surgery is not an option or has not been curative.",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|Bldg 104, 3K28|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Cushing's disease",
                    "umls_id": "C0010481",
                    "parsed_text": "Cushing's disease"
                }
            },
            {
                "compound_id": 9941444,
                "inchl_key": "VMZMNAABQBOLAK-DBILLSOUSA-N",
                "generic_name": "pasireotide",
                "trade_name": "Signifor",
                "designated_date": "07/24/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative",
                "marketing_approval_date": "\u00a012/14/2012\u00a0",
                "exclusivity_end_date": "\u00a012/14/2019\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|Bldg 104, 3K28|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Cushing's disease",
                    "umls_id": "C0010481",
                    "parsed_text": "Cushing's disease"
                }
            },
            {
                "compound_id": 9941444,
                "inchl_key": "VMZMNAABQBOLAK-DBILLSOUSA-N",
                "generic_name": "pasireotide",
                "designated_date": "08/25/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option",
                "marketing_approval_date": "\u00a012/15/2014\u00a0",
                "exclusivity_end_date": "\u00a012/15/2021\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|Bldg 104, 3K28|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acromegaly",
                    "umls_id": "C0001206",
                    "parsed_text": "Acromegaly"
                }
            }
        ]
    },
    {
        "_id": "HZLFFNCLTRVYJG-WWGOJCOQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25027363,
                "inchl_key": "HZLFFNCLTRVYJG-WWGOJCOQSA-N",
                "generic_name": "patidegib",
                "designated_date": "07/19/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PellePharm, Inc.|275 Middlefield Road|Menlo Park|California|94025|United States",
                "orphan_designation": {
                    "original_text": "Treatment of nevoid basal cell carcinoma syndrome (Gorlin syndrome)",
                    "umls_id": "C0004779",
                    "parsed_text": "Nevoid Basal Cell Carcinoma Syndrome"
                }
            }
        ]
    },
    {
        "_id": "CUIHSIWYWATEQL-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10113978,
                "inchl_key": "CUIHSIWYWATEQL-UHFFFAOYSA-N",
                "generic_name": "pazopanib",
                "designated_date": "05/06/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza, 337/B17.5F|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer.",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "compound_id": 10113978,
                "inchl_key": "CUIHSIWYWATEQL-UHFFFAOYSA-N",
                "generic_name": "pazopanib",
                "trade_name": "Votrient",
                "designated_date": "10/20/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Advanced soft tissue sarcoma (STS) who have received prior chemotherapy",
                "marketing_approval_date": "\u00a004/26/2012\u00a0",
                "exclusivity_end_date": "\u00a004/26/2019\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corp|1 Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcomas",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft Tissue Sarcomas"
                }
            },
            {
                "compound_id": 10113978,
                "inchl_key": "CUIHSIWYWATEQL-UHFFFAOYSA-N",
                "generic_name": "pazopanib",
                "designated_date": "10/09/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "HHT Foundation International (d/b/a Cure HHT)|8 Henderson Hill Ct|Monkton|Maryland|21111|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hereditary hemorrhagic telangiectasia",
                    "umls_id": "C0039445",
                    "parsed_text": "hereditary hemorrhagic telangiectasia"
                }
            }
        ]
    },
    {
        "_id": "QIOCQCYXBYUYLH-YACUFSJGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 76900653,
                "inchl_key": "QIOCQCYXBYUYLH-YACUFSJGSA-N",
                "generic_name": "Pelcitoclax",
                "designated_date": "09/23/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ascentage Pharma Group Inc.|800 King Farm Blvd.|Suite 300|Rockville|Maryland|20850|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Small Cell Lung Cancer",
                    "umls_id": "C3540630",
                    "parsed_text": "Small Cell Lung Cancer"
                }
            }
        ]
    },
    {
        "_id": "SZFPYBIJACMNJV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 148177,
                "inchl_key": "SZFPYBIJACMNJV-UHFFFAOYSA-N",
                "generic_name": "perifosine",
                "designated_date": "07/09/2010",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Aeterna Zentaris GmbH|Weismuellerstrasse 50|D-60314 Frankfurt Am Main|Frankfurt Am Main|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of neuroblastoma",
                    "umls_id": "C0027819",
                    "parsed_text": "Neuroblastoma"
                }
            },
            {
                "compound_id": 148177,
                "inchl_key": "SZFPYBIJACMNJV-UHFFFAOYSA-N",
                "generic_name": "perifosine",
                "designated_date": "09/03/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Aeterna Zentaris GmbH|Weismuellerstrasse 50|Frankfurt|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma.",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "NDTYTMIUWGWIMO-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10819,
                "inchl_key": "NDTYTMIUWGWIMO-UHFFFAOYSA-N",
                "generic_name": "perillyl alcohol",
                "designated_date": "04/18/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NeOnc Technologies, Inc.|10524 South La Cienega Blvd.|Inglewood|California|90304|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioma",
                    "umls_id": "C0017638",
                    "parsed_text": "Glioma"
                }
            }
        ]
    },
    {
        "_id": "DDBREPKUVSBGFI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4763,
                "inchl_key": "DDBREPKUVSBGFI-UHFFFAOYSA-N",
                "generic_name": "Phenobarbital",
                "designated_date": "02/26/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Accord Healthcare Inc.|1009 Slater Road, Suite 210-B|Durham|North Carolina|27703|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Neonatal seizures",
                    "umls_id": "C0159020",
                    "parsed_text": "Neonatal seizures"
                }
            },
            {
                "compound_id": 4763,
                "inchl_key": "DDBREPKUVSBGFI-UHFFFAOYSA-N",
                "generic_name": "phenobarbital",
                "designated_date": "10/25/2017",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Renaissance SSA, LLC|411 South State Street|Suite E100|Newtown|Pennsylvania|18940|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neonatal seizures",
                    "umls_id": "C0159020",
                    "parsed_text": "Neonatal seizures"
                }
            },
            {
                "compound_id": 4763,
                "inchl_key": "DDBREPKUVSBGFI-UHFFFAOYSA-N",
                "generic_name": "phenobarbital",
                "designated_date": "10/02/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sun Pharma Advanced Research Company Ltd.|17/B, Mahal Industrial Estate|Mahakali Caves Road|Andheri (E)|Mumbai|India",
                "orphan_designation": {
                    "original_text": "Treatment of neonatal seizures",
                    "umls_id": "C0159020",
                    "parsed_text": "Neonatal seizures"
                }
            }
        ]
    },
    {
        "_id": "WRLGYAWRGXKSKG-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 23674889,
                "inchl_key": "WRLGYAWRGXKSKG-UHFFFAOYSA-M",
                "generic_name": "Phenobarbital Sodium",
                "designated_date": "09/30/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hikma Pharmaceuticals USA, Inc.|2 Esterbrook Lane|Cherry Hill|New Jersey|8003|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neonatal seizures",
                    "umls_id": "C0159020",
                    "parsed_text": "Neonatal seizures"
                }
            },
            {
                "compound_id": 23674889,
                "inchl_key": "WRLGYAWRGXKSKG-UHFFFAOYSA-M",
                "generic_name": "Phenobarbital sodium",
                "designated_date": "03/28/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genus Lifesciences|514 North 12th Street|Allentown|Pennsylvania|18102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neonatal seizures",
                    "umls_id": "C0159020",
                    "parsed_text": "Neonatal seizures"
                }
            },
            {
                "compound_id": 23674889,
                "inchl_key": "WRLGYAWRGXKSKG-UHFFFAOYSA-M",
                "generic_name": "phenobarbital sodium",
                "designated_date": "02/26/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Accord Healthcare Inc.|1009 Slater Road, Suite 210-B|Durham|North Carolina|27703|United States",
                "orphan_designation": {
                    "original_text": "Treatment of status epilepticus",
                    "umls_id": "C0038220",
                    "parsed_text": "Status Epilepticus"
                }
            },
            {
                "compound_id": 23674889,
                "inchl_key": "WRLGYAWRGXKSKG-UHFFFAOYSA-M",
                "generic_name": "phenobarbital sodium",
                "designated_date": "02/27/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Nivagen Pharmaceuticals, Inc.|3050 Fite Circle, Suite 100|Sacramento|California|95827|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neonatal seizures",
                    "umls_id": "C0159020",
                    "parsed_text": "Neonatal seizures"
                }
            }
        ]
    },
    {
        "_id": "SONNWYBIRXJNDC-VIFPVBQESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6041,
                "inchl_key": "SONNWYBIRXJNDC-VIFPVBQESA-N",
                "generic_name": "phenylephrine",
                "designated_date": "01/31/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Luitpold Pharmaceuticals, Inc.|One Luitpold Drive|P. O. Box 9001|Shirley|New York|11967|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Tetralogy of Fallot",
                    "umls_id": "C0039685",
                    "parsed_text": "Tetralogy of Fallot"
                }
            },
            {
                "compound_id": 6041,
                "inchl_key": "SONNWYBIRXJNDC-VIFPVBQESA-N",
                "generic_name": "phenylephrine",
                "designated_date": "02/14/2002",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "S.L.A. Pharma|Unit 3, Hill Farm Industrial Estate|Leavesden, Watford|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of ileal pouch anal anastomosis related fecal incontinence",
                    "umls_id": "C0015732",
                    "parsed_text": "Fecal Incontinence"
                }
            }
        ]
    },
    {
        "_id": "VIUAUNHCRHHYNE-JTQLQIEISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44187362,
                "inchl_key": "VIUAUNHCRHHYNE-JTQLQIEISA-N",
                "generic_name": "pimasertib",
                "designated_date": "01/29/2010",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "ISWRGOKTTBVCFA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 40632,
                "inchl_key": "ISWRGOKTTBVCFA-UHFFFAOYSA-N",
                "generic_name": "pirfenidone",
                "designated_date": "11/19/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of systemic sclerosis (including the associated interstitial lung disease)",
                    "umls_id": "C0036421,C0206062",
                    "parsed_text": "Systemic sclerosis , Interstitial lung disease"
                }
            },
            {
                "compound_id": 40632,
                "inchl_key": "ISWRGOKTTBVCFA-UHFFFAOYSA-N",
                "generic_name": "pirfenidone",
                "designated_date": "07/31/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Avalyn Pharma, Inc.|701 Pike Street|Suite 1500|Seattle|Washington|98101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic pulmonary fibrosis",
                    "umls_id": "C1800706",
                    "parsed_text": "Idiopathic Pulmonary Fibrosis"
                }
            },
            {
                "compound_id": 40632,
                "inchl_key": "ISWRGOKTTBVCFA-UHFFFAOYSA-N",
                "generic_name": "pirfenidone",
                "trade_name": "ESBRIET",
                "designated_date": "03/05/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of idiopathic pulmonary fibrosis",
                "marketing_approval_date": "\u00a010/15/2014\u00a0",
                "exclusivity_end_date": "\u00a010/15/2021\u00a0",
                "exclusivity_protected_indication": "Treatment of idiopathic pulmonary fibrosis",
                "sponsor": "Genentech|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic pulmonary fibrosis",
                    "umls_id": "C1800706",
                    "parsed_text": "Idiopathic Pulmonary Fibrosis"
                }
            },
            {
                "compound_id": 40632,
                "inchl_key": "ISWRGOKTTBVCFA-UHFFFAOYSA-N",
                "generic_name": "pirfenidone",
                "designated_date": "03/11/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech Inc., A Member of the Roche Group|1 DNA Way|MS# 355F|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Unclassifiable-interstitial lung disease",
                    "umls_id": "C0206062",
                    "parsed_text": "Interstitial lung disease"
                }
            }
        ]
    },
    {
        "_id": "IOEMETRLOWNXGW-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 54368,
                "inchl_key": "IOEMETRLOWNXGW-UHFFFAOYSA-N",
                "generic_name": "Piritrexim isethionate",
                "designated_date": "06/13/1988",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Burroughs Wellcome Company|3030 Cornwallis Road|P.O. Box 12700|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Treatment of infections caused by Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium-intracellulare.",
                    "umls_id": "C0026914,C0040557,C3714514",
                    "parsed_text": "Mycobacterium avium-intracellulare , Toxoplasma gondii , Infections"
                }
            }
        ]
    },
    {
        "_id": "NNACHAUCXXVJSP-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9948102,
                "inchl_key": "NNACHAUCXXVJSP-UHFFFAOYSA-N",
                "generic_name": "pitolisant",
                "trade_name": "WAKIX",
                "designated_date": "05/17/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy",
                "marketing_approval_date": "\u00a010/13/2020\u00a0",
                "exclusivity_end_date": "\u00a010/13/2027\u00a0",
                "exclusivity_protected_indication": "treatment of cataplexy in adult patients with narcolepsy",
                "sponsor": "Harmony Biosciences, LLC|630 W Germantown Pike|Suite 215|Plymouth Meeting|Pennsylvania|19462|United States",
                "orphan_designation": {
                    "original_text": "Treatment of narcolepsy",
                    "umls_id": "C0027404",
                    "parsed_text": "Narcolepsy"
                }
            },
            {
                "compound_id": 9948102,
                "inchl_key": "NNACHAUCXXVJSP-UHFFFAOYSA-N",
                "generic_name": "Pitolisant",
                "trade_name": "WAKIX",
                "designated_date": "05/17/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "WAKIX is indicated for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy",
                "marketing_approval_date": "\u00a008/14/2019\u00a0",
                "exclusivity_end_date": "\u00a008/14/2026\u00a0",
                "exclusivity_protected_indication": "For the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy",
                "sponsor": "Harmony Biosciences, LLC|630 W Germantown Pike|Suite 215|Plymouth Meeting|Pennsylvania|19462|United States",
                "orphan_designation": {
                    "original_text": "Treatment of narcolepsy",
                    "umls_id": "C0027404",
                    "parsed_text": "Narcolepsy"
                }
            }
        ]
    },
    {
        "_id": "IEJSCSAMMLUINT-NRFANRHFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135430970,
                "inchl_key": "IEJSCSAMMLUINT-NRFANRHFSA-N",
                "generic_name": "Plevitrexed",
                "designated_date": "05/14/2007",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "BTG International Ltd|10 Fleet Place|EC4M 7SB|London|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "compound_id": 135430970,
                "inchl_key": "IEJSCSAMMLUINT-NRFANRHFSA-N",
                "generic_name": "Plevitrexed",
                "designated_date": "05/29/2007",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "BTG International Ltd|10 Fleet Place|EC4M 7SB|London|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of gastric (stomach cancer",
                    "umls_id": "C0024623",
                    "parsed_text": "stomach cancer"
                }
            }
        ]
    },
    {
        "_id": "RVGRUAULSDPKGF-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24751,
                "inchl_key": "RVGRUAULSDPKGF-UHFFFAOYSA-N",
                "generic_name": "Poloxamer 188",
                "designated_date": "02/22/1990",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CytRx Corporation|154 Technology Parkway|Norcross|Georgia|30092|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe burns requiring hospitalization.",
                    "umls_id": "C0006434",
                    "parsed_text": "Burns"
                }
            },
            {
                "compound_id": 24751,
                "inchl_key": "RVGRUAULSDPKGF-UHFFFAOYSA-N",
                "generic_name": "poloxamer 188",
                "designated_date": "11/08/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mast Therapeutics Inc.|3611 Valley Centre rive|Suite 500|San Diego|California|92130|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Acute Limb Ischemia",
                    "umls_id": "C2945695",
                    "parsed_text": "Limb ischemia"
                }
            },
            {
                "compound_id": 24751,
                "inchl_key": "RVGRUAULSDPKGF-UHFFFAOYSA-N",
                "generic_name": "Poloxamer 188",
                "designated_date": "08/05/1997",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CytRx Corporation|154 Technology Parkway|Norcross|Georgia|30092|United States",
                "orphan_designation": {
                    "original_text": "Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.",
                    "umls_id": "C0038525,C0242084",
                    "parsed_text": "Subarachnoid Hemorrhage , Ruptured cerebral aneurysm"
                }
            }
        ]
    },
    {
        "_id": "UVSMNLNDYGZFPF-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134780,
                "inchl_key": "UVSMNLNDYGZFPF-UHFFFAOYSA-N",
                "generic_name": "pomalidomide",
                "trade_name": "Pomalyst",
                "designated_date": "01/15/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.",
                "marketing_approval_date": "\u00a002/08/2013\u00a0",
                "exclusivity_end_date": "\u00a002/08/2020\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.",
                "sponsor": "Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            },
            {
                "compound_id": 134780,
                "inchl_key": "UVSMNLNDYGZFPF-UHFFFAOYSA-N",
                "generic_name": "pomalidomide",
                "designated_date": "09/21/2010",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States",
                "orphan_designation": {
                    "original_text": "Treatment of persons with myeloproliferative neoplasm-associated myelofibrosis and anemia who are red blood cell tranfusion dependent.",
                    "umls_id": "C0002871,C0026987,C1292778",
                    "parsed_text": "Anemia , Myelofibrosis , Myeloproliferative neoplasm"
                }
            },
            {
                "compound_id": 134780,
                "inchl_key": "UVSMNLNDYGZFPF-UHFFFAOYSA-N",
                "generic_name": "pomalidomide",
                "trade_name": "POMALYST",
                "designated_date": "04/04/2018",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "POMALYST (pomalidomide) is indicated for the treatment of adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART); and for the treatment of Kaposi sarcoma (KS) in adult patients who are HIV-negative.",
                "marketing_approval_date": "\u00a005/14/2020\u00a0",
                "exclusivity_end_date": "\u00a005/14/2027\u00a0",
                "exclusivity_protected_indication": "Indicated for the treatment of adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART); and for the treatment of Kaposi sarcoma (KS) in adult patients who are HIV-negative.",
                "sponsor": "Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Kaposi sarcoma",
                    "umls_id": "C0036220",
                    "parsed_text": "Kaposi Sarcoma"
                }
            },
            {
                "compound_id": 134780,
                "inchl_key": "UVSMNLNDYGZFPF-UHFFFAOYSA-N",
                "generic_name": "pomalidomide",
                "designated_date": "08/22/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States",
                "orphan_designation": {
                    "original_text": "Treatment of systemic sclerosis",
                    "umls_id": "C0036421",
                    "parsed_text": "Systemic sclerosis"
                }
            }
        ]
    },
    {
        "_id": "GBLBJPZSROAGMF-SIYOEGHHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 129073603,
                "inchl_key": "GBLBJPZSROAGMF-SIYOEGHHSA-N",
                "generic_name": "pralsetinib",
                "trade_name": "Gavreto",
                "designated_date": "05/26/2020",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of (1) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; and; (2) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)",
                "marketing_approval_date": "\u00a012/01/2020\u00a0",
                "exclusivity_end_date": "\u00a012/01/2027\u00a0",
                "exclusivity_protected_indication": "Treatment of (1) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; and; (2) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)",
                "sponsor": "Blueprint Medicines Corporation|45 Sidney Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of RET-fusion, RET-mutation, and TRKC-positive poorly differentiated thyroid cancer, undifferentiated or anaplastic thyroid cancer, medullary thyroid cancer, and locally advanced or metastatic follicular or papillary thyroid cancer",
                    "umls_id": "C0238461,C0238462,C0238463,C1337013",
                    "parsed_text": "anaplastic thyroid cancer , Thyroid cancer, medullary , papillary thyroid cancer , Differentiated Thyroid Cancer"
                }
            },
            {
                "compound_id": 129073603,
                "inchl_key": "GBLBJPZSROAGMF-SIYOEGHHSA-N",
                "generic_name": "pralsetinib",
                "trade_name": "GAVRETO",
                "designated_date": "04/11/2018",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test",
                "marketing_approval_date": "\u00a009/04/2020\u00a0",
                "exclusivity_end_date": "\u00a009/04/2027\u00a0",
                "exclusivity_protected_indication": "treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test",
                "sponsor": "Blueprint Medicines Corporation|45 Sidney Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of rearranged during transfection (RET)-rearranged non-small cell lung cancer (NSCLC), JAK1/2-positive NSCLC, or TRKC-positive NSCLC.",
                    "umls_id": "C0007131,C0694890,C3539721",
                    "parsed_text": "Non-Small Cell Lung Cancer , rearranged during transfection , Non-Small Cell Lung Cancer"
                }
            }
        ]
    },
    {
        "_id": "AQHHHDLHHXJYJD-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4946,
                "inchl_key": "AQHHHDLHHXJYJD-UHFFFAOYSA-N",
                "generic_name": "propranolol",
                "trade_name": "HEMANGEOL",
                "designated_date": "09/05/2008",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of proliferating infantile hemangioma requiring systemic therapy.",
                "marketing_approval_date": "\u00a003/14/2014\u00a0",
                "exclusivity_end_date": "\u00a003/14/2021\u00a0",
                "exclusivity_protected_indication": "Treatment of proliferating infantile hemangioma requiring systemic therapy.",
                "sponsor": "Pierre Fabre Dermatologie|8 Campus Drive, 2nd Floor|Parsippany|New Jersey|7054|United States",
                "orphan_designation": {
                    "original_text": "Treatment of proliferating infantile hemangiomas requiring systemic therapy",
                    "umls_id": "C0018916",
                    "parsed_text": "Hemangiomas"
                }
            },
            {
                "compound_id": 4946,
                "inchl_key": "AQHHHDLHHXJYJD-UHFFFAOYSA-N",
                "generic_name": "Propranolol",
                "designated_date": "08/23/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Recordati Rare Diseases, SARL|Immeuble le \"Wilson\"|70 Avenue du General de Gaulle|Puteaux|France",
                "orphan_designation": {
                    "original_text": "Treatment of retinopathy of prematurity",
                    "umls_id": "C0035344",
                    "parsed_text": "Retinopathy of Prematurity"
                }
            }
        ]
    },
    {
        "_id": "XNSAINXGIQZQOO-SRVKXCTJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 638678,
                "inchl_key": "XNSAINXGIQZQOO-SRVKXCTJSA-N",
                "generic_name": "Protirelin",
                "designated_date": "08/24/1993",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "UCB Pharma, Inc.|1950 Lake Park Drive|Smyrna|Georgia|30080|United States",
                "orphan_designation": {
                    "original_text": "Prevention of infant respiratory distress syndrome associated with prematurity.",
                    "umls_id": "C0035220",
                    "parsed_text": "infant respiratory distress syndrome"
                }
            }
        ]
    },
    {
        "_id": "QMHSXPLYMTVAMK-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5281035,
                "inchl_key": "QMHSXPLYMTVAMK-UHFFFAOYSA-N",
                "generic_name": "pyrvinium",
                "designated_date": "01/05/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "StemSynergy Therapeutics, Inc.|1951 NW 7th Avenue|Suite 300|Miami|Florida|33136|United States",
                "orphan_designation": {
                    "original_text": "Treatment of familial adenomatous polyposis",
                    "umls_id": "C0032580",
                    "parsed_text": "Familial Adenomatous Polyposis"
                }
            }
        ]
    },
    {
        "_id": "RONWGALEIBILOG-VMJVVOMYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 56927704,
                "inchl_key": "RONWGALEIBILOG-VMJVVOMYSA-N",
                "generic_name": "quinine Sulfate",
                "designated_date": "06/03/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of uncomplicated Plasmodium falciparum malaria",
                "marketing_approval_date": "\u00a008/12/2005\u00a0",
                "exclusivity_end_date": "\u00a008/12/2012\u00a0",
                "sponsor": "AR Holding Company, Inc.|1100 Orthodox Street|Philadelphia|Pennsylvania|19124|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 56927704,
                "inchl_key": "RONWGALEIBILOG-VMJVVOMYSA-N",
                "generic_name": "quinine Sulfate",
                "designated_date": "06/03/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of uncomplicated Plasmodium falciparum malaria",
                "marketing_approval_date": "\u00a008/12/2005\u00a0",
                "exclusivity_end_date": "\u00a008/12/2012\u00a0",
                "sponsor": "AR Holding Company, Inc.|1100 Orthodox Street|Philadelphia|Pennsylvania|19124|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 56927704,
                "inchl_key": "RONWGALEIBILOG-VMJVVOMYSA-N",
                "generic_name": "quinine sulfate",
                "designated_date": "12/02/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Zydus Pharmaceuticals, Inc.|210 Carnegie Center|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria excluding Plasmodium faliparum",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 56927704,
                "inchl_key": "RONWGALEIBILOG-VMJVVOMYSA-N",
                "generic_name": "quinine sulfate",
                "designated_date": "12/02/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Zydus Pharmaceuticals, Inc.|210 Carnegie Center|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria excluding Plasmodium faliparum",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            }
        ]
    },
    {
        "_id": "ZHNFLHYOFXQIOW-LPYZJUEESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16211610,
                "inchl_key": "ZHNFLHYOFXQIOW-LPYZJUEESA-N",
                "generic_name": "quinine Sulfate",
                "designated_date": "06/03/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of uncomplicated Plasmodium falciparum malaria",
                "marketing_approval_date": "\u00a008/12/2005\u00a0",
                "exclusivity_end_date": "\u00a008/12/2012\u00a0",
                "sponsor": "AR Holding Company, Inc.|1100 Orthodox Street|Philadelphia|Pennsylvania|19124|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 16211610,
                "inchl_key": "ZHNFLHYOFXQIOW-LPYZJUEESA-N",
                "generic_name": "quinine sulfate",
                "designated_date": "12/02/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Zydus Pharmaceuticals, Inc.|210 Carnegie Center|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria excluding Plasmodium faliparum",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            }
        ]
    },
    {
        "_id": "LOUPRKONTZGTKE-WZBLMQSHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3034034,
                "inchl_key": "LOUPRKONTZGTKE-WZBLMQSHSA-N",
                "generic_name": "quinine Sulfate",
                "designated_date": "06/03/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of uncomplicated Plasmodium falciparum malaria",
                "marketing_approval_date": "\u00a008/12/2005\u00a0",
                "exclusivity_end_date": "\u00a008/12/2012\u00a0",
                "sponsor": "AR Holding Company, Inc.|1100 Orthodox Street|Philadelphia|Pennsylvania|19124|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 3034034,
                "inchl_key": "LOUPRKONTZGTKE-WZBLMQSHSA-N",
                "generic_name": "quinine sulfate",
                "designated_date": "12/02/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Zydus Pharmaceuticals, Inc.|210 Carnegie Center|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria excluding Plasmodium faliparum",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            }
        ]
    },
    {
        "_id": "AKYHKWQPZHDOBW-DSXUQNDKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11949689,
                "inchl_key": "AKYHKWQPZHDOBW-DSXUQNDKSA-N",
                "generic_name": "quinine Sulfate",
                "designated_date": "06/03/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of uncomplicated Plasmodium falciparum malaria",
                "marketing_approval_date": "\u00a008/12/2005\u00a0",
                "exclusivity_end_date": "\u00a008/12/2012\u00a0",
                "sponsor": "AR Holding Company, Inc.|1100 Orthodox Street|Philadelphia|Pennsylvania|19124|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 11949689,
                "inchl_key": "AKYHKWQPZHDOBW-DSXUQNDKSA-N",
                "generic_name": "quinine sulfate",
                "designated_date": "12/02/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Zydus Pharmaceuticals, Inc.|210 Carnegie Center|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria excluding Plasmodium faliparum",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            }
        ]
    },
    {
        "_id": "QFJCIRLUMZQUOT-HPLJOQBZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5284616,
                "inchl_key": "QFJCIRLUMZQUOT-HPLJOQBZSA-N",
                "generic_name": "rapamycin",
                "designated_date": "03/20/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OncoImmune, Inc.|333 Parkland Plaza|Suite 1000|Ann Arbor|Michigan|48103|United States",
                "orphan_designation": {
                    "original_text": "Treatment of tuberous sclerosis complex",
                    "umls_id": "C0041341",
                    "parsed_text": "Tuberous Sclerosis Complex"
                }
            },
            {
                "compound_id": 5284616,
                "inchl_key": "QFJCIRLUMZQUOT-HPLJOQBZSA-N",
                "generic_name": "sirolimus",
                "designated_date": "08/26/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AI Therapeutics, Inc.|530 Old Whitfield Street|Guilford|Connecticut|6437|United States",
                "orphan_designation": {
                    "original_text": "Treatment of tuberous sclerosis complex",
                    "umls_id": "C0041341",
                    "parsed_text": "Tuberous Sclerosis Complex"
                }
            },
            {
                "compound_id": 5284616,
                "inchl_key": "QFJCIRLUMZQUOT-HPLJOQBZSA-N",
                "generic_name": "sirolimus",
                "designated_date": "03/18/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Palvella Therapeutics, Inc.|125 Strafford Avenue|Suite #360|Wayne|Pennsylvania|19087|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pachyonychia congenita",
                    "umls_id": "C0265334",
                    "parsed_text": "Pachyonychia Congenita"
                }
            },
            {
                "compound_id": 5284616,
                "inchl_key": "QFJCIRLUMZQUOT-HPLJOQBZSA-N",
                "generic_name": "sirolimus",
                "designated_date": "11/04/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen Inc.|6101 Hollis Street, Suite 125|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, noninfectious panuveitis and non-infectious, uveitis affecting the posterior of the eye (NICUPS).",
                    "umls_id": "C0009450,C0042164,C0042166,C0751437,C0751438,C4518725",
                    "parsed_text": "Infectious , Uveitis , Intermediate uveitis , Anterior , Posterior , Noninfectious panuveitis"
                }
            },
            {
                "compound_id": 5284616,
                "inchl_key": "QFJCIRLUMZQUOT-HPLJOQBZSA-N",
                "generic_name": "sirolimus",
                "designated_date": "03/13/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rare Partners srl Impresa Sociale|31 Corso Magenta|Milano|Lombardia|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of sickle cell disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            },
            {
                "compound_id": 5284616,
                "inchl_key": "QFJCIRLUMZQUOT-HPLJOQBZSA-N",
                "generic_name": "sirolimus",
                "designated_date": "06/25/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "LAM Therapeutics, Inc.|530 Old Whitfield Street|Guilford|Connecticut|6437|United States",
                "orphan_designation": {
                    "original_text": "Treatment of lymphangioleiomyomatosis",
                    "umls_id": "C0751674",
                    "parsed_text": "Lymphangioleiomyomatosis"
                }
            },
            {
                "compound_id": 5284616,
                "inchl_key": "QFJCIRLUMZQUOT-HPLJOQBZSA-N",
                "generic_name": "sirolimus",
                "designated_date": "11/17/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cote Orphan Consulting, LLC|8630 Fenton St., #222|Silver Spring|Maryland|20910|United States",
                "orphan_designation": {
                    "original_text": "Treatment of lymphangioleiomyomatosis",
                    "umls_id": "C0751674",
                    "parsed_text": "Lymphangioleiomyomatosis"
                }
            },
            {
                "compound_id": 5284616,
                "inchl_key": "QFJCIRLUMZQUOT-HPLJOQBZSA-N",
                "generic_name": "sirolimus",
                "designated_date": "02/13/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Aucta Pharmaceuticals, Inc.|675 US Highway One|North Brunswick|New Jersey|8902|United States",
                "orphan_designation": {
                    "original_text": "Treatment of tuberous sclerosis complex-related facial angiofibromas",
                    "umls_id": "C0041341,C0265319",
                    "parsed_text": "Tuberous Sclerosis Complex , Facial angiofibromas"
                }
            },
            {
                "compound_id": 5284616,
                "inchl_key": "QFJCIRLUMZQUOT-HPLJOQBZSA-N",
                "generic_name": "rapamycin",
                "designated_date": "02/24/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "DSLP|129 Hurstmere Road|Level 1, Nielsen Building|Auckland|Auckland|New Zealand",
                "orphan_designation": {
                    "original_text": "Treatment of facial angiofibromas (FA) associated with tuberous sclerosis complex (TSC).",
                    "umls_id": "C0041341,C0265319",
                    "parsed_text": "Tuberous Sclerosis Complex , Facial angiofibromas"
                }
            },
            {
                "compound_id": 5284616,
                "inchl_key": "QFJCIRLUMZQUOT-HPLJOQBZSA-N",
                "generic_name": "rapamycin",
                "designated_date": "12/21/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Aadi Bioscience, Inc.|1343 Luna Vista Drive|Los Angeles|California|90272|United States",
                "orphan_designation": {
                    "original_text": "Treatment of perivascular epithelioid cell tumors (PEComa)",
                    "umls_id": "C1300127",
                    "parsed_text": "Perivascular Epithelioid Cell Tumors"
                }
            },
            {
                "compound_id": 5284616,
                "inchl_key": "QFJCIRLUMZQUOT-HPLJOQBZSA-N",
                "generic_name": "sirolimus",
                "designated_date": "06/21/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rare Partners srl Impresa Sociale|31 Corso Magenta|Milano|Lombardia|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of beta-thalassemia.",
                    "umls_id": "C0005283",
                    "parsed_text": "BETA-THALASSEMIA"
                }
            },
            {
                "compound_id": 5284616,
                "inchl_key": "QFJCIRLUMZQUOT-HPLJOQBZSA-N",
                "generic_name": "sirolimus",
                "trade_name": "Rapamune",
                "designated_date": "10/31/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of lymphangioleiomyomatosis (LAM)",
                "marketing_approval_date": "\u00a005/28/2015\u00a0",
                "exclusivity_end_date": "\u00a005/28/2022\u00a0",
                "exclusivity_protected_indication": "Treatment of lymphangioleiomyomatosis (LAM)",
                "sponsor": "Pfizer, Inc.|500 Arcola Road|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "Treatment of lymphangioleiomyomatosis",
                    "umls_id": "C0751674",
                    "parsed_text": "Lymphangioleiomyomatosis"
                }
            },
            {
                "compound_id": 5284616,
                "inchl_key": "QFJCIRLUMZQUOT-HPLJOQBZSA-N",
                "generic_name": "sirolimus",
                "designated_date": "05/17/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NobelPharma Co., LTD|12-10 Nihonbashi-kobunacho|Chuo-ku|Tokyo-to|Japan",
                "orphan_designation": {
                    "original_text": "Treatment of angiofibroma associated with tuberous sclerosis",
                    "umls_id": "C0041341,C0206731",
                    "parsed_text": "Tuberous Sclerosis , Angiofibroma"
                }
            }
        ]
    },
    {
        "_id": "WVXNSAVVKYZVOE-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25066467,
                "inchl_key": "WVXNSAVVKYZVOE-UHFFFAOYSA-N",
                "generic_name": "Rebastinib",
                "designated_date": "09/03/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Deciphera Pharmaceuticals, LLC|643 Massachusetts|Lawrence|Kansas|66044|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Philadelphia chromosome positive chronic myeloid leukemia",
                    "umls_id": "C0279543",
                    "parsed_text": "Philadelphia Chromosome Positive Chronic Myeloid Leukemia"
                }
            },
            {
                "compound_id": 25066467,
                "inchl_key": "WVXNSAVVKYZVOE-UHFFFAOYSA-N",
                "generic_name": "rebastinib",
                "designated_date": "05/23/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genea Biocells US Inc.|11099 North Torrey Pines Road|San Diego|California|92037|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Facioscapulohumeral Muscular Dystrophy",
                    "umls_id": "C0238288",
                    "parsed_text": "Facioscapulohumeral muscular dystrophy"
                }
            }
        ]
    },
    {
        "_id": "VRNHFZYMPDKTBS-WYUJEMNCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71652162,
                "inchl_key": "VRNHFZYMPDKTBS-WYUJEMNCSA-N",
                "generic_name": "reltecimod",
                "designated_date": "10/12/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Atox Bio, Inc.|3 Golda Meir St.|Ness Ziona|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of necrotizing soft tissue infections (NSTI)",
                    "umls_id": "C0149778",
                    "parsed_text": "Soft Tissue Infections"
                }
            }
        ]
    },
    {
        "_id": "YSGASDXSLKIKOD-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 60511,
                "inchl_key": "YSGASDXSLKIKOD-UHFFFAOYSA-N",
                "generic_name": "Remacemide",
                "designated_date": "03/06/2000",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AstraZeneca LP|725 Chesterbrook Blvd.|Wayne|Pennsylvania|19087|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Huntington's disease.",
                    "umls_id": "C0020179",
                    "parsed_text": "Huntington's Disease"
                }
            }
        ]
    },
    {
        "_id": "KQDRVXQXKZXMHP-LLVKDONJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9838712,
                "inchl_key": "KQDRVXQXKZXMHP-LLVKDONJSA-N",
                "generic_name": "reparixin",
                "designated_date": "09/25/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Dompe S.p.A.|Via Campo di Pile|L'Aquila|Italy",
                "orphan_designation": {
                    "original_text": "Prevention of graft loss in pancreatic islet transplantation",
                    "umls_id": "C0877042",
                    "parsed_text": "graft loss"
                }
            }
        ]
    },
    {
        "_id": "FECGNJPYVFEKOD-VMPITWQZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11609955,
                "inchl_key": "FECGNJPYVFEKOD-VMPITWQZSA-N",
                "generic_name": "resminostat",
                "designated_date": "06/29/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "4SC AG|Am Klopferspitz 19a|Martinsried|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            },
            {
                "compound_id": 11609955,
                "inchl_key": "FECGNJPYVFEKOD-VMPITWQZSA-N",
                "generic_name": "resminostat",
                "designated_date": "09/16/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "4SC AG|Am Klopferspitz 19a|Martinsried|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of Hodgkin's lymphoma.",
                    "umls_id": "C0019829",
                    "parsed_text": "hodgkin's lymphoma"
                }
            }
        ]
    },
    {
        "_id": "OIRUWDYJGMHDHJ-AFXVCOSJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11685945,
                "inchl_key": "OIRUWDYJGMHDHJ-AFXVCOSJSA-N",
                "generic_name": "retaspimycin hydrochloride",
                "designated_date": "06/24/2008",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of melanoma stages IIb through IV.",
                    "umls_id": "C0280209",
                    "parsed_text": "melanoma stages"
                }
            }
        ]
    },
    {
        "_id": "IWUCXVSUMQZMFG-AFCXAGJDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 37542,
                "inchl_key": "IWUCXVSUMQZMFG-AFCXAGJDSA-N",
                "generic_name": "ribavirin",
                "trade_name": "REBETOL",
                "designated_date": "04/04/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of chronic hepatitis C among previously untreated pediatric patients at least three years of age or older.",
                "marketing_approval_date": "\u00a007/29/2003\u00a0",
                "exclusivity_end_date": "\u00a007/29/2010\u00a0",
                "sponsor": "Schering Corporation|2000 Galloping Hill Road|Kenilworth|New Jersey|7033|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic hepatitis C in pediatric patients",
                    "umls_id": "C0524910",
                    "parsed_text": "chronic hepatitis c"
                }
            },
            {
                "compound_id": 37542,
                "inchl_key": "IWUCXVSUMQZMFG-AFCXAGJDSA-N",
                "generic_name": "ribavirin",
                "designated_date": "04/12/1991",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Valeant Pharmaceuticals International|3300 Hyland Avenue|Costa Mesa|California|92626|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hemorrhagic fever with renal syndrome",
                    "umls_id": "C0019101",
                    "parsed_text": "Hemorrhagic Fever with Renal Syndrome"
                }
            }
        ]
    },
    {
        "_id": "HNJWVTLAOZFLEK-OOWZQQDUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 49848291,
                "inchl_key": "HNJWVTLAOZFLEK-OOWZQQDUSA-N",
                "generic_name": "ribavirin elaidate",
                "designated_date": "09/02/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Translational Therapeutics, Inc.|163 Scituate Street|Arlington|Massachusetts|2476|United States",
                "orphan_designation": {
                    "original_text": "Treatment of follicular, medullary, and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer",
                    "umls_id": "C0238461,C0238463",
                    "parsed_text": "Anaplastic thyroid carcinoma , papillary thyroid cancer"
                }
            }
        ]
    },
    {
        "_id": "ZWBTYMGEBZUQTK-SHULBWHJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 137313637,
                "inchl_key": "ZWBTYMGEBZUQTK-SHULBWHJSA-N",
                "generic_name": "Rifabutin",
                "trade_name": "Mycobutin",
                "designated_date": "12/18/1989",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections.",
                "marketing_approval_date": "\u00a012/23/1992\u00a0",
                "exclusivity_end_date": "\u00a012/23/1999\u00a0",
                "sponsor": "Adria Laboratories, Inc.|P.O. Box 16529|Columbus|Ohio|43216|United States",
                "orphan_designation": {
                    "original_text": "Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.",
                    "umls_id": "C0019693,C0026914",
                    "parsed_text": "HIV infection , Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 137313637,
                "inchl_key": "ZWBTYMGEBZUQTK-SHULBWHJSA-N",
                "generic_name": "Rifabutin",
                "designated_date": "12/18/1989",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer Inc.|235 East 42nd Street|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Treatment of disseminated Mycobacterium avium complex disease.",
                    "umls_id": "C0026914",
                    "parsed_text": "Mycobacterium avium Complex"
                }
            }
        ]
    },
    {
        "_id": "ZWBTYMGEBZUQTK-HBZSWILLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 137295261,
                "inchl_key": "ZWBTYMGEBZUQTK-HBZSWILLSA-N",
                "generic_name": "Rifabutin",
                "trade_name": "Mycobutin",
                "designated_date": "12/18/1989",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections.",
                "marketing_approval_date": "\u00a012/23/1992\u00a0",
                "exclusivity_end_date": "\u00a012/23/1999\u00a0",
                "sponsor": "Adria Laboratories, Inc.|P.O. Box 16529|Columbus|Ohio|43216|United States",
                "orphan_designation": {
                    "original_text": "Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.",
                    "umls_id": "C0019693,C0026914",
                    "parsed_text": "HIV infection , Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 137295261,
                "inchl_key": "ZWBTYMGEBZUQTK-HBZSWILLSA-N",
                "generic_name": "Rifabutin",
                "designated_date": "12/18/1989",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer Inc.|235 East 42nd Street|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Treatment of disseminated Mycobacterium avium complex disease.",
                    "umls_id": "C0026914",
                    "parsed_text": "Mycobacterium avium Complex"
                }
            }
        ]
    },
    {
        "_id": "ZWBTYMGEBZUQTK-DNEPJJHDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135925740,
                "inchl_key": "ZWBTYMGEBZUQTK-DNEPJJHDSA-N",
                "generic_name": "Rifabutin",
                "trade_name": "Mycobutin",
                "designated_date": "12/18/1989",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections.",
                "marketing_approval_date": "\u00a012/23/1992\u00a0",
                "exclusivity_end_date": "\u00a012/23/1999\u00a0",
                "sponsor": "Adria Laboratories, Inc.|P.O. Box 16529|Columbus|Ohio|43216|United States",
                "orphan_designation": {
                    "original_text": "Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.",
                    "umls_id": "C0019693,C0026914",
                    "parsed_text": "HIV infection , Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 135925740,
                "inchl_key": "ZWBTYMGEBZUQTK-DNEPJJHDSA-N",
                "generic_name": "Rifabutin",
                "designated_date": "12/18/1989",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer Inc.|235 East 42nd Street|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Treatment of disseminated Mycobacterium avium complex disease.",
                    "umls_id": "C0026914",
                    "parsed_text": "Mycobacterium avium Complex"
                }
            }
        ]
    },
    {
        "_id": "ZWBTYMGEBZUQTK-OZKAIBRQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 136257950,
                "inchl_key": "ZWBTYMGEBZUQTK-OZKAIBRQSA-N",
                "generic_name": "Rifabutin",
                "trade_name": "Mycobutin",
                "designated_date": "12/18/1989",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections.",
                "marketing_approval_date": "\u00a012/23/1992\u00a0",
                "exclusivity_end_date": "\u00a012/23/1999\u00a0",
                "sponsor": "Adria Laboratories, Inc.|P.O. Box 16529|Columbus|Ohio|43216|United States",
                "orphan_designation": {
                    "original_text": "Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.",
                    "umls_id": "C0019693,C0026914",
                    "parsed_text": "HIV infection , Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 136257950,
                "inchl_key": "ZWBTYMGEBZUQTK-OZKAIBRQSA-N",
                "generic_name": "Rifabutin",
                "designated_date": "12/18/1989",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer Inc.|235 East 42nd Street|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Treatment of disseminated Mycobacterium avium complex disease.",
                    "umls_id": "C0026914",
                    "parsed_text": "Mycobacterium avium Complex"
                }
            }
        ]
    },
    {
        "_id": "ZWBTYMGEBZUQTK-WOYMMMRKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 136053407,
                "inchl_key": "ZWBTYMGEBZUQTK-WOYMMMRKSA-N",
                "generic_name": "Rifabutin",
                "trade_name": "Mycobutin",
                "designated_date": "12/18/1989",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections.",
                "marketing_approval_date": "\u00a012/23/1992\u00a0",
                "exclusivity_end_date": "\u00a012/23/1999\u00a0",
                "sponsor": "Adria Laboratories, Inc.|P.O. Box 16529|Columbus|Ohio|43216|United States",
                "orphan_designation": {
                    "original_text": "Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.",
                    "umls_id": "C0019693,C0026914",
                    "parsed_text": "HIV infection , Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 136053407,
                "inchl_key": "ZWBTYMGEBZUQTK-WOYMMMRKSA-N",
                "generic_name": "Rifabutin",
                "designated_date": "12/18/1989",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer Inc.|235 East 42nd Street|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Treatment of disseminated Mycobacterium avium complex disease.",
                    "umls_id": "C0026914",
                    "parsed_text": "Mycobacterium avium Complex"
                }
            }
        ]
    },
    {
        "_id": "ZWBTYMGEBZUQTK-OZFKZPMASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135458645,
                "inchl_key": "ZWBTYMGEBZUQTK-OZFKZPMASA-N",
                "generic_name": "Rifabutin",
                "trade_name": "Mycobutin",
                "designated_date": "12/18/1989",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections.",
                "marketing_approval_date": "\u00a012/23/1992\u00a0",
                "exclusivity_end_date": "\u00a012/23/1999\u00a0",
                "sponsor": "Adria Laboratories, Inc.|P.O. Box 16529|Columbus|Ohio|43216|United States",
                "orphan_designation": {
                    "original_text": "Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.",
                    "umls_id": "C0019693,C0026914",
                    "parsed_text": "HIV infection , Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 135458645,
                "inchl_key": "ZWBTYMGEBZUQTK-OZFKZPMASA-N",
                "generic_name": "Rifabutin",
                "designated_date": "12/18/1989",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer Inc.|235 East 42nd Street|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Treatment of disseminated Mycobacterium avium complex disease.",
                    "umls_id": "C0026914",
                    "parsed_text": "Mycobacterium avium Complex"
                }
            }
        ]
    },
    {
        "_id": "ZWBTYMGEBZUQTK-AMWSOCTHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 136117120,
                "inchl_key": "ZWBTYMGEBZUQTK-AMWSOCTHSA-N",
                "generic_name": "Rifabutin",
                "trade_name": "Mycobutin",
                "designated_date": "12/18/1989",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections.",
                "marketing_approval_date": "\u00a012/23/1992\u00a0",
                "exclusivity_end_date": "\u00a012/23/1999\u00a0",
                "sponsor": "Adria Laboratories, Inc.|P.O. Box 16529|Columbus|Ohio|43216|United States",
                "orphan_designation": {
                    "original_text": "Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.",
                    "umls_id": "C0019693,C0026914",
                    "parsed_text": "HIV infection , Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 136117120,
                "inchl_key": "ZWBTYMGEBZUQTK-AMWSOCTHSA-N",
                "generic_name": "Rifabutin",
                "designated_date": "12/18/1989",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer Inc.|235 East 42nd Street|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Treatment of disseminated Mycobacterium avium complex disease.",
                    "umls_id": "C0026914",
                    "parsed_text": "Mycobacterium avium Complex"
                }
            }
        ]
    },
    {
        "_id": "ZWBTYMGEBZUQTK-ASBZJICESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135950975,
                "inchl_key": "ZWBTYMGEBZUQTK-ASBZJICESA-N",
                "generic_name": "Rifabutin",
                "trade_name": "Mycobutin",
                "designated_date": "12/18/1989",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections.",
                "marketing_approval_date": "\u00a012/23/1992\u00a0",
                "exclusivity_end_date": "\u00a012/23/1999\u00a0",
                "sponsor": "Adria Laboratories, Inc.|P.O. Box 16529|Columbus|Ohio|43216|United States",
                "orphan_designation": {
                    "original_text": "Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.",
                    "umls_id": "C0019693,C0026914",
                    "parsed_text": "HIV infection , Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 135950975,
                "inchl_key": "ZWBTYMGEBZUQTK-ASBZJICESA-N",
                "generic_name": "Rifabutin",
                "designated_date": "12/18/1989",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer Inc.|235 East 42nd Street|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Treatment of disseminated Mycobacterium avium complex disease.",
                    "umls_id": "C0026914",
                    "parsed_text": "Mycobacterium avium Complex"
                }
            }
        ]
    },
    {
        "_id": "ZWBTYMGEBZUQTK-PVLSIAFMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135398743,
                "inchl_key": "ZWBTYMGEBZUQTK-PVLSIAFMSA-N",
                "generic_name": "Rifabutin",
                "trade_name": "Mycobutin",
                "designated_date": "12/18/1989",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections.",
                "marketing_approval_date": "\u00a012/23/1992\u00a0",
                "exclusivity_end_date": "\u00a012/23/1999\u00a0",
                "sponsor": "Adria Laboratories, Inc.|P.O. Box 16529|Columbus|Ohio|43216|United States",
                "orphan_designation": {
                    "original_text": "Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.",
                    "umls_id": "C0019693,C0026914",
                    "parsed_text": "HIV infection , Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 135398743,
                "inchl_key": "ZWBTYMGEBZUQTK-PVLSIAFMSA-N",
                "generic_name": "Rifabutin",
                "designated_date": "12/18/1989",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer Inc.|235 East 42nd Street|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Treatment of disseminated Mycobacterium avium complex disease.",
                    "umls_id": "C0026914",
                    "parsed_text": "Mycobacterium avium Complex"
                }
            }
        ]
    },
    {
        "_id": "VDNLFJGJEQUWRB-UHFFFAOYSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 3856851,
                "inchl_key": "VDNLFJGJEQUWRB-UHFFFAOYSA-L",
                "generic_name": "rose bengal disodium",
                "designated_date": "02/11/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Provectus BioPharmaceuticals, Inc.|10025 Investment Drive|Suite 250|Knoxville|Tennessee|37932|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ocular melanoma",
                    "umls_id": "C0558356",
                    "parsed_text": "Ocular Melanoma"
                }
            },
            {
                "compound_id": 3856851,
                "inchl_key": "VDNLFJGJEQUWRB-UHFFFAOYSA-L",
                "generic_name": "Rose bengal disodium",
                "designated_date": "11/02/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Provectus BioPharmaceuticals, Inc.|10025 Investment Drive|Suite 250|Knoxville|Tennessee|37932|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Neuroblastoma",
                    "umls_id": "C0027819",
                    "parsed_text": "Neuroblastoma"
                }
            },
            {
                "compound_id": 3856851,
                "inchl_key": "VDNLFJGJEQUWRB-UHFFFAOYSA-L",
                "generic_name": "Rose Bengal Disodium",
                "designated_date": "12/21/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Provectus BioPharmaceuticals, Inc.|10025 Investment Drive|Suite 250|Knoxville|Tennessee|37932|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic melanoma",
                    "umls_id": "C0278883",
                    "parsed_text": "Metastatic melanoma"
                }
            },
            {
                "compound_id": 3856851,
                "inchl_key": "VDNLFJGJEQUWRB-UHFFFAOYSA-L",
                "generic_name": "rose bengal disodium",
                "designated_date": "04/18/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Provectus BioPharmaceuticals, Inc.|10025 Investment Drive|Suite 250|Knoxville|Tennessee|37932|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma.",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            }
        ]
    },
    {
        "_id": "YLXBBCDOUAHKIB-LJKCMNKDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 121488160,
                "inchl_key": "YLXBBCDOUAHKIB-LJKCMNKDSA-N",
                "generic_name": "Rosomidnar",
                "designated_date": "03/10/2016",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ProNAi Therapeutics, Inc.|46701 Commerce Center Drive|Plymouth|Michigan|48170|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diffuse large B-cell lymphoma.",
                    "umls_id": "C1332201",
                    "parsed_text": "Diffuse Large B-Cell Lymphoma"
                }
            }
        ]
    },
    {
        "_id": "YLXBBCDOUAHKIB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 119058033,
                "inchl_key": "YLXBBCDOUAHKIB-UHFFFAOYSA-N",
                "generic_name": "Rosomidnar",
                "designated_date": "03/10/2016",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ProNAi Therapeutics, Inc.|46701 Commerce Center Drive|Plymouth|Michigan|48170|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diffuse large B-cell lymphoma.",
                    "umls_id": "C1332201",
                    "parsed_text": "Diffuse Large B-Cell Lymphoma"
                }
            }
        ]
    },
    {
        "_id": "HFNKQEVNSGCOJV-OAHLLOKOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25126798,
                "inchl_key": "HFNKQEVNSGCOJV-OAHLLOKOSA-N",
                "generic_name": "ruxolitinib",
                "trade_name": "Jakafi",
                "designated_date": "03/26/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.",
                "marketing_approval_date": "\u00a012/04/2014\u00a0",
                "exclusivity_end_date": "\u00a012/04/2021\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.",
                "sponsor": "Incyte Corporation|1801 Augustine Cut-Off|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of polycythemia vera",
                    "umls_id": "C0032463",
                    "parsed_text": "Polycythemia Vera"
                }
            },
            {
                "compound_id": 25126798,
                "inchl_key": "HFNKQEVNSGCOJV-OAHLLOKOSA-N",
                "generic_name": "Ruxolitinib",
                "designated_date": "07/18/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Incyte Corporation|1801 Augustine Cut-off|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute lymphoblastic leukemia.",
                    "umls_id": "C0023449",
                    "parsed_text": "Acute lymphoblastic leukemia"
                }
            },
            {
                "compound_id": 25126798,
                "inchl_key": "HFNKQEVNSGCOJV-OAHLLOKOSA-N",
                "generic_name": "ruxolitinib",
                "designated_date": "08/16/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Incyte Corporation|1801 Augustine Cut-Off|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 25126798,
                "inchl_key": "HFNKQEVNSGCOJV-OAHLLOKOSA-N",
                "generic_name": "ruxolitinib",
                "trade_name": "JAKAFI",
                "designated_date": "11/03/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older.",
                "marketing_approval_date": "\u00a005/24/2019\u00a0",
                "exclusivity_end_date": "\u00a005/24/2026\u00a0",
                "exclusivity_protected_indication": "Treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older.",
                "sponsor": "Incyte Corporation|1801 Augustine Cut-Off|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of graft versus host disease",
                    "umls_id": "C0018133",
                    "parsed_text": "GRAFT VERSUS HOST DISEASE"
                }
            }
        ]
    },
    {
        "_id": "MEFKEPWMEQBLKI-AIRLBKTGSA-P",
        "Orphan Drug Designations": [
            {
                "compound_id": 56593143,
                "inchl_key": "MEFKEPWMEQBLKI-AIRLBKTGSA-P",
                "generic_name": "S-adenosylmethionine",
                "designated_date": "04/30/1998",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genopia USA, Inc.|90 Gold Street, 6N|New York|New York|10038|United States",
                "orphan_designation": {
                    "original_text": "Treatment of AIDS-myelopathy.",
                    "umls_id": "C0001175,C0005956",
                    "parsed_text": "AIDS , myelopathy"
                }
            }
        ]
    },
    {
        "_id": "MEFKEPWMEQBLKI-AIRLBKTGSA-O",
        "Orphan Drug Designations": [
            {
                "compound_id": 24762165,
                "inchl_key": "MEFKEPWMEQBLKI-AIRLBKTGSA-O",
                "generic_name": "S-adenosylmethionine",
                "designated_date": "04/30/1998",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genopia USA, Inc.|90 Gold Street, 6N|New York|New York|10038|United States",
                "orphan_designation": {
                    "original_text": "Treatment of AIDS-myelopathy.",
                    "umls_id": "C0001175,C0005956",
                    "parsed_text": "AIDS , myelopathy"
                }
            },
            {
                "compound_id": 24762165,
                "inchl_key": "MEFKEPWMEQBLKI-AIRLBKTGSA-O",
                "generic_name": "S-adenosylmethionine",
                "designated_date": "04/30/1998",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genopia USA, Inc.|90 Gold Street, 6N|New York|New York|10038|United States",
                "orphan_designation": {
                    "original_text": "Treatment of AIDS-myelopathy.",
                    "umls_id": "C0001175,C0005956",
                    "parsed_text": "AIDS , myelopathy"
                }
            }
        ]
    },
    {
        "_id": "MEFKEPWMEQBLKI-AIRLBKTGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 34755,
                "inchl_key": "MEFKEPWMEQBLKI-AIRLBKTGSA-N",
                "generic_name": "S-adenosylmethionine",
                "designated_date": "04/30/1998",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genopia USA, Inc.|90 Gold Street, 6N|New York|New York|10038|United States",
                "orphan_designation": {
                    "original_text": "Treatment of AIDS-myelopathy.",
                    "umls_id": "C0001175,C0005956",
                    "parsed_text": "AIDS , myelopathy"
                }
            }
        ]
    },
    {
        "_id": "HYHSBSXUHZOYLX-WDSKDSINSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 7059524,
                "inchl_key": "HYHSBSXUHZOYLX-WDSKDSINSA-M",
                "generic_name": "S-nitrosoglutathione",
                "designated_date": "12/28/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Salupont Consulting Ltd|The Old Quarters, Hazells Hall|Everton Road, Sandy|Bedfordshire SG19 2DD|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of severe preeclampsia",
                    "umls_id": "C0341950",
                    "parsed_text": "Severe Preeclampsia"
                }
            },
            {
                "compound_id": 7059524,
                "inchl_key": "HYHSBSXUHZOYLX-WDSKDSINSA-M",
                "generic_name": "S-nitrosoglutathione",
                "designated_date": "05/12/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "N30 PHARMAceuticals, LLC|3122 Sterling Circle|Boulder|Colorado|80301|United States",
                "orphan_designation": {
                    "original_text": "Management of cystic fibrosis patients to improve airway clearance and to improve or stabilize pulmonary function",
                    "umls_id": "C0010674,C1547996",
                    "parsed_text": "Cystic Fibrosis , Pulmonary Function"
                }
            }
        ]
    },
    {
        "_id": "HYHSBSXUHZOYLX-WDSKDSINSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 104858,
                "inchl_key": "HYHSBSXUHZOYLX-WDSKDSINSA-N",
                "generic_name": "S-nitrosoglutathione",
                "designated_date": "12/28/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Salupont Consulting Ltd|The Old Quarters, Hazells Hall|Everton Road, Sandy|Bedfordshire SG19 2DD|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of severe preeclampsia",
                    "umls_id": "C0341950",
                    "parsed_text": "Severe Preeclampsia"
                }
            },
            {
                "compound_id": 104858,
                "inchl_key": "HYHSBSXUHZOYLX-WDSKDSINSA-N",
                "generic_name": "S-nitrosoglutathione",
                "designated_date": "05/12/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "N30 PHARMAceuticals, LLC|3122 Sterling Circle|Boulder|Colorado|80301|United States",
                "orphan_designation": {
                    "original_text": "Management of cystic fibrosis patients to improve airway clearance and to improve or stabilize pulmonary function",
                    "umls_id": "C0010674,C1547996",
                    "parsed_text": "Cystic Fibrosis , Pulmonary Function"
                }
            }
        ]
    },
    {
        "_id": "OUKYUETWWIPKQR-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10302451,
                "inchl_key": "OUKYUETWWIPKQR-UHFFFAOYSA-N",
                "generic_name": "saracatinib",
                "designated_date": "03/11/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AstraZeneca Pharmaceuticals, LP|Emerging Innovations, AstraZeneca, R&D Boston|35 Gatehouse Drive|Waltham|Massachusetts|2451|United States",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic pulmonary fibrosis",
                    "umls_id": "C1800706",
                    "parsed_text": "Idiopathic Pulmonary Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "DEVSOMFAQLZNKR-RJRFIUFISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71481097,
                "inchl_key": "DEVSOMFAQLZNKR-RJRFIUFISA-N",
                "generic_name": "selinexor",
                "trade_name": "XPOVIO",
                "designated_date": "01/05/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "XPOVIO is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.",
                "marketing_approval_date": "\u00a007/03/2019\u00a0",
                "exclusivity_end_date": "\u00a007/03/2026\u00a0",
                "exclusivity_protected_indication": "Indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.",
                "sponsor": "Karyopharm Therapeutics, Inc.|85 Wells Avenue, Suite 210|Newton|Massachusetts|2459|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            },
            {
                "compound_id": 71481097,
                "inchl_key": "DEVSOMFAQLZNKR-RJRFIUFISA-N",
                "generic_name": "selinexor",
                "designated_date": "05/14/2014",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "XPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.",
                "marketing_approval_date": "\u00a006/22/2020\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Karyopharm Therapeutics, Inc.|2 Mercer Road|Natick|Massachusetts|1760|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diffuse large B-cell lymphoma",
                    "umls_id": "C1332201",
                    "parsed_text": "Diffuse Large B-Cell Lymphoma"
                }
            },
            {
                "compound_id": 71481097,
                "inchl_key": "DEVSOMFAQLZNKR-RJRFIUFISA-N",
                "generic_name": "selinexor",
                "designated_date": "07/07/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Karyopharm Therapeutics, Inc.|85 Wells Avenue|Newton|Massachusetts|2459|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcoma",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            },
            {
                "compound_id": 71481097,
                "inchl_key": "DEVSOMFAQLZNKR-RJRFIUFISA-N",
                "generic_name": "selinexor",
                "designated_date": "05/14/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Karyopharm Therapeutics, Inc.|2 Mercer Road|Natick|Massachusetts|1760|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "compound_id": 71481097,
                "inchl_key": "DEVSOMFAQLZNKR-RJRFIUFISA-N",
                "generic_name": "selinexor",
                "trade_name": "Xpovio",
                "designated_date": "01/05/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy",
                "marketing_approval_date": "\u00a012/18/2020\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Karyopharm Therapeutics, Inc.|85 Wells Avenue, Suite 210|Newton|Massachusetts|2459|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "BVLCEKWPOSAKSZ-YQMCHIOTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16132412,
                "inchl_key": "BVLCEKWPOSAKSZ-YQMCHIOTSA-N",
                "generic_name": "Sermorelin acetate",
                "trade_name": "Geref",
                "designated_date": "09/14/1988",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a009/26/1997\u00a0",
                "exclusivity_end_date": "\u00a009/26/2004\u00a0",
                "sponsor": "EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.",
                    "umls_id": "C0015544,C3898072",
                    "parsed_text": "growth failure , Organic Growth Hormone Deficiency"
                }
            },
            {
                "compound_id": 16132412,
                "inchl_key": "BVLCEKWPOSAKSZ-YQMCHIOTSA-N",
                "generic_name": "Sermorelin acetate",
                "designated_date": "12/05/1991",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States",
                "orphan_designation": {
                    "original_text": "Treatment of AIDS-associated catabolism/weight loss.",
                    "umls_id": "C0001175,C4084774",
                    "parsed_text": "AIDS , Weight loss"
                }
            },
            {
                "compound_id": 16132412,
                "inchl_key": "BVLCEKWPOSAKSZ-YQMCHIOTSA-N",
                "generic_name": "Sermorelin acetate",
                "designated_date": "02/13/1990",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States",
                "orphan_designation": {
                    "original_text": "Adjunct to gonadotropin therapy in the induction of ovulation in women with anovulatory or oligo-ovulatory infertility who fail to ovulate in response to adequate treatment with clomiphene citrate alone and gonadotropin therapy alone.",
                    "umls_id": "C0021359,C0429468",
                    "parsed_text": "Infertility , Anovulatory"
                }
            }
        ]
    },
    {
        "_id": "VPZRWNZGLKXFOE-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 5258,
                "inchl_key": "VPZRWNZGLKXFOE-UHFFFAOYSA-M",
                "generic_name": "sodium 4-phenylbutyrate",
                "designated_date": "10/18/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "GMP-Orphan SAS|7, rue du Pasteur Wagner|F-75011|Paris|France",
                "orphan_designation": {
                    "original_text": "Treatment of spinal muscular atrophy",
                    "umls_id": "C0026847",
                    "parsed_text": "Spinal Muscular Atrophy"
                }
            },
            {
                "compound_id": 5258,
                "inchl_key": "VPZRWNZGLKXFOE-UHFFFAOYSA-M",
                "generic_name": "sodium phenylbutyrate",
                "trade_name": "Buphenyl",
                "designated_date": "11/22/1993",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Adjunctive therapy in the chronic managment of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase.",
                "marketing_approval_date": "\u00a004/30/1996\u00a0",
                "exclusivity_end_date": "\u00a004/30/2003\u00a0",
                "sponsor": "Medicis Pharmaceutical Corp.|8125 N. Hayden Road|Scottsdale|Alaska|85258|United States",
                "orphan_designation": {
                    "original_text": "Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency.",
                    "umls_id": "C0154246,C0268542,C1291575",
                    "parsed_text": "Urea Cycle Disorders , Deficiency, Ornithine Transcarbamylase , synthetase deficiency"
                }
            },
            {
                "compound_id": 5258,
                "inchl_key": "VPZRWNZGLKXFOE-UHFFFAOYSA-M",
                "generic_name": "Phenylbutyrate",
                "designated_date": "01/19/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Elan Drug Delivery, Inc.|1300 Gould Dr.|Gainesville|Georgia|30504|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute promyelocytic leukemia.",
                    "umls_id": "C0023487",
                    "parsed_text": "Acute Promyelocytic Leukemia"
                }
            },
            {
                "compound_id": 5258,
                "inchl_key": "VPZRWNZGLKXFOE-UHFFFAOYSA-M",
                "generic_name": "Sodium phenylbutyrate",
                "designated_date": "01/25/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OrphaMed, Inc.|7720 N. Dobson Road|subsidiary of Medicis Pharmaceutical Corp.|Scottsdale|Alaska|85256|United States",
                "orphan_designation": {
                    "original_text": "Treatment of spinal muscular atrophy",
                    "umls_id": "C0026847",
                    "parsed_text": "Spinal Muscular Atrophy"
                }
            },
            {
                "compound_id": 5258,
                "inchl_key": "VPZRWNZGLKXFOE-UHFFFAOYSA-M",
                "generic_name": "Sodium phenylbutyrate",
                "designated_date": "03/20/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Tikvah Therapeutics, Inc.|75 5th Street, NW.|Atlanta|Georgia|30308|United States",
                "orphan_designation": {
                    "original_text": "Treatment of spinal muscular atrophy",
                    "umls_id": "C0026847",
                    "parsed_text": "Spinal Muscular Atrophy"
                }
            },
            {
                "compound_id": 5258,
                "inchl_key": "VPZRWNZGLKXFOE-UHFFFAOYSA-M",
                "generic_name": "sodium phenylbutyrate",
                "designated_date": "08/19/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Acer Therapeutics, Inc.|One Gateway Center|300 Washington Street, Suite 351|Newton|Massachusetts|2458|United States",
                "orphan_designation": {
                    "original_text": "Treatment of maple syrup urine disease",
                    "umls_id": "C0024776",
                    "parsed_text": "Maple Syrup Urine Disease"
                }
            },
            {
                "compound_id": 5258,
                "inchl_key": "VPZRWNZGLKXFOE-UHFFFAOYSA-M",
                "generic_name": "sodium phenylbutyrate",
                "designated_date": "06/06/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medunik Canada Inc|950 Boulevard Mich\u8b25-Bohec|Blainville|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of urea cycle disorders",
                    "umls_id": "C0154246",
                    "parsed_text": "Urea Cycle Disorders"
                }
            },
            {
                "compound_id": 5258,
                "inchl_key": "VPZRWNZGLKXFOE-UHFFFAOYSA-M",
                "generic_name": "sodium phenylbutyrate",
                "designated_date": "01/19/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Navinta LLC|1499 Lower Ferry Road|Ewing|New Jersey|8618|United States",
                "orphan_designation": {
                    "original_text": "Treatment of urea cycle disorder.",
                    "umls_id": "C0154246",
                    "parsed_text": "urea cycle disorder"
                }
            },
            {
                "compound_id": 5258,
                "inchl_key": "VPZRWNZGLKXFOE-UHFFFAOYSA-M",
                "generic_name": "sodium phenylbutyrate",
                "designated_date": "07/02/1992",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medicis Pharmaceutical Corp.|8125 N. Hayden Road|Scottsdale|Alaska|85258|United States",
                "orphan_designation": {
                    "original_text": "Treatment for sickling disorders, which include S-S hemoglobinopathy, S-C hemoglobinopathy, and S-thalassemia hemoglobinopathy.",
                    "umls_id": "C0019045,C0039730",
                    "parsed_text": "Hemoglobinopathy , Thalassemia"
                }
            },
            {
                "compound_id": 5258,
                "inchl_key": "VPZRWNZGLKXFOE-UHFFFAOYSA-M",
                "generic_name": "Sodium phenylbutyrate",
                "designated_date": "04/24/1998",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Elan Drug Delivery, Inc.|1300 Gould Dr.|Gainesville|Georgia|30504|United States",
                "orphan_designation": {
                    "original_text": "For use as an adjuct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.",
                    "umls_id": "C4684861",
                    "parsed_text": "Recurrent Malignant Glioma"
                }
            }
        ]
    },
    {
        "_id": "HJHVQCXHVMGZNC-XOSDQFCBSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 134694338,
                "inchl_key": "HJHVQCXHVMGZNC-XOSDQFCBSA-M",
                "generic_name": "sodium fusidate",
                "designated_date": "02/13/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Arrevus Inc.|2443 Lynn Road, Suite 210|Raleigh|North Carolina|27612|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "HJHVQCXHVMGZNC-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 44134727,
                "inchl_key": "HJHVQCXHVMGZNC-UHFFFAOYSA-M",
                "generic_name": "sodium fusidate",
                "designated_date": "02/13/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Arrevus Inc.|2443 Lynn Road, Suite 210|Raleigh|North Carolina|27612|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "HJHVQCXHVMGZNC-LOPNDLIXSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 23706209,
                "inchl_key": "HJHVQCXHVMGZNC-LOPNDLIXSA-M",
                "generic_name": "sodium fusidate",
                "designated_date": "02/13/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Arrevus Inc.|2443 Lynn Road, Suite 210|Raleigh|North Carolina|27612|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "HJHVQCXHVMGZNC-XDELSAJESA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 91873261,
                "inchl_key": "HJHVQCXHVMGZNC-XDELSAJESA-M",
                "generic_name": "sodium fusidate",
                "designated_date": "02/13/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Arrevus Inc.|2443 Lynn Road, Suite 210|Raleigh|North Carolina|27612|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "HJHVQCXHVMGZNC-DHUMWTJCSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 23690471,
                "inchl_key": "HJHVQCXHVMGZNC-DHUMWTJCSA-M",
                "generic_name": "sodium fusidate",
                "designated_date": "02/13/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Arrevus Inc.|2443 Lynn Road, Suite 210|Raleigh|North Carolina|27612|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "HJHVQCXHVMGZNC-JCJNLNMISA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 23672955,
                "inchl_key": "HJHVQCXHVMGZNC-JCJNLNMISA-M",
                "generic_name": "sodium fusidate",
                "designated_date": "02/13/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Arrevus Inc.|2443 Lynn Road, Suite 210|Raleigh|North Carolina|27612|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "LPXPTNMVRIOKMN-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 23668193,
                "inchl_key": "LPXPTNMVRIOKMN-UHFFFAOYSA-M",
                "generic_name": "sodium nitrite",
                "designated_date": "04/02/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hope Pharmaceuticals|16416 North 92nd St.|Suite 125|Scottsdale|Alaska|85260|United States",
                "orphan_designation": {
                    "original_text": "Treatment of vaso-occlusive crisis associated with sickle cell disease",
                    "umls_id": "C0002895,C0750151",
                    "parsed_text": "Sickle Cell Disease , Vaso-Occlusive Crisis"
                }
            },
            {
                "compound_id": 23668193,
                "inchl_key": "LPXPTNMVRIOKMN-UHFFFAOYSA-M",
                "generic_name": "sodium nitrite",
                "designated_date": "09/03/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hope Pharmaceuticals|16416 North 92nd St.|Suite 125|Scottsdale|Alaska|85260|United States",
                "orphan_designation": {
                    "original_text": "Prevention of ischemia reperfusion injury to donor organ tissue associated with solid organ transplantation",
                    "umls_id": "C0035126",
                    "parsed_text": "ischemia reperfusion injury"
                }
            },
            {
                "compound_id": 23668193,
                "inchl_key": "LPXPTNMVRIOKMN-UHFFFAOYSA-M",
                "generic_name": "sodium nitrite",
                "designated_date": "01/09/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hope Pharmaceuticals|16416 North 92nd St.|Suite 125|Scottsdale|Alaska|85260|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chlorine gas poisoning",
                    "umls_id": "C0017107",
                    "parsed_text": "Gas Poisoning"
                }
            },
            {
                "compound_id": 23668193,
                "inchl_key": "LPXPTNMVRIOKMN-UHFFFAOYSA-M",
                "generic_name": "sodium nitrite",
                "designated_date": "04/18/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hope Pharmaceuticals|16416 North 92nd Street|Suite 125|Scottsdale|Alaska|85260|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            },
            {
                "compound_id": 23668193,
                "inchl_key": "LPXPTNMVRIOKMN-UHFFFAOYSA-M",
                "generic_name": "sodium nitrite",
                "designated_date": "07/08/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Airess Pharmaceuticals, Inc.|(subsidiary of Mast Therapeutics, Inc)|3611 Valley Centre Drive|San Diego|California|92130|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            },
            {
                "compound_id": 23668193,
                "inchl_key": "LPXPTNMVRIOKMN-UHFFFAOYSA-M",
                "generic_name": "sodium nitrite",
                "designated_date": "01/17/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hope Pharmaceuticals|16416 North 92nd St.|Suite 125|Scottsdale|Alaska|85260|United States",
                "orphan_designation": {
                    "original_text": "Prevention of vasospasm associated with subarachnoid hemorrhage",
                    "umls_id": "C0038525",
                    "parsed_text": "Subarachnoid Hemorrhage"
                }
            },
            {
                "compound_id": 23668193,
                "inchl_key": "LPXPTNMVRIOKMN-UHFFFAOYSA-M",
                "generic_name": "Sodium Nitrite",
                "designated_date": "03/25/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AdimaBio LLC|19 Garrison Road|Wellesley|Massachusetts|2482|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Sickle Cell Disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            }
        ]
    },
    {
        "_id": "DAEPDZWVDSPTHF-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 23662274,
                "inchl_key": "DAEPDZWVDSPTHF-UHFFFAOYSA-M",
                "generic_name": "Sodium pyruvate",
                "designated_date": "03/31/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cellular Sciences, Inc|84 park Avenue|P.O. Box 968|Flemington|New Jersey|8822|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "CUEDNFKBTFCOSV-UZVLBLASSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 16683012,
                "inchl_key": "CUEDNFKBTFCOSV-UZVLBLASSA-L",
                "generic_name": "sodium stibogluconate",
                "designated_date": "10/28/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Surgeon General of the US Army|US Army Medical Research & Materiel Command|1430 Veterans Drive|Ft. Detrick|Maryland|21702|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cutaneous leishmaniasis",
                    "umls_id": "C0023283",
                    "parsed_text": "Cutaneous leishmaniasis"
                }
            },
            {
                "compound_id": 16683012,
                "inchl_key": "CUEDNFKBTFCOSV-UZVLBLASSA-L",
                "generic_name": "Sodium stibogluconate",
                "designated_date": "06/16/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "VioQuest Pharmaceuticals, Inc.|180 Mt. Airy Road|Suite 102|Basking Ridge|New Jersey|7920|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cutaneous leishmaniasis",
                    "umls_id": "C0023283",
                    "parsed_text": "Cutaneous leishmaniasis"
                }
            },
            {
                "compound_id": 16683012,
                "inchl_key": "CUEDNFKBTFCOSV-UZVLBLASSA-L",
                "generic_name": "Sodium Stibogluconate",
                "designated_date": "06/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "BioXcel Corporation|780 East Main Street|Suite 2|Branford|Connecticut|6405|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "AKHNMLFCWUSKQB-UHFFFAOYSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 24477,
                "inchl_key": "AKHNMLFCWUSKQB-UHFFFAOYSA-L",
                "generic_name": "sodium thiosulfate",
                "designated_date": "12/02/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hope Pharmaceuticals|16416 North 92nd St.|Suite 125|Scottsdale|Alaska|85260|United States",
                "orphan_designation": {
                    "original_text": "Treatment of extravasation of meclorethamine hydrochloride into subcutaneous tissues.",
                    "umls_id": "C0015376",
                    "parsed_text": "Extravasation"
                }
            },
            {
                "compound_id": 24477,
                "inchl_key": "AKHNMLFCWUSKQB-UHFFFAOYSA-L",
                "generic_name": "sodium thiosulfate",
                "designated_date": "10/28/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hope Pharmaceuticals|16416 North 92nd St.|Suite 125|Scottsdale|Alaska|85260|United States",
                "orphan_designation": {
                    "original_text": "Treatment of dermatomyositis",
                    "umls_id": "C0011633",
                    "parsed_text": "Dermatomyositis"
                }
            },
            {
                "compound_id": 24477,
                "inchl_key": "AKHNMLFCWUSKQB-UHFFFAOYSA-L",
                "generic_name": "Sodium thiosulfate",
                "designated_date": "03/17/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Fennec Pharmaceuticals, Inc.|PO Box 13628|68 T.W. Alexander Drive|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Prevention of platinum-induced ototoxicity in pediatric patients",
                    "umls_id": "C0235280",
                    "parsed_text": "Ototoxicity"
                }
            },
            {
                "compound_id": 24477,
                "inchl_key": "AKHNMLFCWUSKQB-UHFFFAOYSA-L",
                "generic_name": "sodium thiosulfate",
                "designated_date": "11/09/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hope Pharmaceuticals|16416 North 92nd St.|Suite 125|Scottsdale|Alaska|85260|United States",
                "orphan_designation": {
                    "original_text": "Treatment of uremic and non-uremic calciphylaxis",
                    "umls_id": "C0006666",
                    "parsed_text": "Calciphylaxis"
                }
            },
            {
                "compound_id": 24477,
                "inchl_key": "AKHNMLFCWUSKQB-UHFFFAOYSA-L",
                "generic_name": "sodium thiosulfate",
                "designated_date": "10/13/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hope Pharmaceuticals|16416 North 92nd St.|Suite 125|Scottsdale|Alaska|85260|United States",
                "orphan_designation": {
                    "original_text": "Prevention of platinum-induced ototoxicity in pediatric patients",
                    "umls_id": "C0235280",
                    "parsed_text": "Ototoxicity"
                }
            },
            {
                "compound_id": 24477,
                "inchl_key": "AKHNMLFCWUSKQB-UHFFFAOYSA-L",
                "generic_name": "sodium thiosulfate",
                "designated_date": "11/19/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Edinburg BioQuarter|University Medical School 47|EH16 4TJ|Edinburgh|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of calciphylaxis",
                    "umls_id": "C0006666",
                    "parsed_text": "Calciphylaxis"
                }
            },
            {
                "compound_id": 24477,
                "inchl_key": "AKHNMLFCWUSKQB-UHFFFAOYSA-L",
                "generic_name": "Sodium Thiosulfate",
                "designated_date": "02/16/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Luitpold Pharmaceuticals, Inc.|800 Adams Avenue|Suite 100|Norristown|Pennsylvania|19403|United States",
                "orphan_designation": {
                    "original_text": "Treatment of uremic and non-uremic calciphylaxis",
                    "umls_id": "C0006666",
                    "parsed_text": "Calciphylaxis"
                }
            }
        ]
    },
    {
        "_id": "TTZHDVOVKQGIBA-LVPOHEQUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 73425384,
                "inchl_key": "TTZHDVOVKQGIBA-LVPOHEQUSA-N",
                "generic_name": "sofosbuvir",
                "trade_name": "Sovaldi",
                "designated_date": "10/25/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin",
                "marketing_approval_date": "\u00a008/28/2019\u00a0",
                "exclusivity_end_date": "\u00a008/28/2026\u00a0",
                "exclusivity_protected_indication": "For the treatment of chronic hepatitis C virus (HCV) genotype 2 or 3 infection in pediatric patients between 3 years of age and 12 years of age or weighing 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric chronic hepatitis C virus infection",
                    "umls_id": "C0019196,C0524910",
                    "parsed_text": "Hepatitis C Virus Infection , chronic hepatitis c"
                }
            },
            {
                "compound_id": 73425384,
                "inchl_key": "TTZHDVOVKQGIBA-LVPOHEQUSA-N",
                "generic_name": "sofosbuvir",
                "trade_name": "Sovaldi",
                "designated_date": "10/25/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin",
                "marketing_approval_date": "\u00a004/07/2017\u00a0",
                "exclusivity_end_date": "\u00a004/07/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric chronic hepatitis C virus infection",
                    "umls_id": "C0019196,C0524910",
                    "parsed_text": "Hepatitis C Virus Infection , chronic hepatitis c"
                }
            },
            {
                "compound_id": 73425384,
                "inchl_key": "TTZHDVOVKQGIBA-LVPOHEQUSA-N",
                "generic_name": "sofosbuvir",
                "trade_name": "Sovaldi",
                "designated_date": "10/25/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin",
                "marketing_approval_date": "\u00a008/28/2019\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric chronic hepatitis C virus infection",
                    "umls_id": "C0019196,C0524910",
                    "parsed_text": "Hepatitis C Virus Infection , chronic hepatitis c"
                }
            }
        ]
    },
    {
        "_id": "TTZHDVOVKQGIBA-KVOQBTHKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 72699160,
                "inchl_key": "TTZHDVOVKQGIBA-KVOQBTHKSA-N",
                "generic_name": "sofosbuvir",
                "trade_name": "Sovaldi",
                "designated_date": "10/25/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin",
                "marketing_approval_date": "\u00a008/28/2019\u00a0",
                "exclusivity_end_date": "\u00a008/28/2026\u00a0",
                "exclusivity_protected_indication": "For the treatment of chronic hepatitis C virus (HCV) genotype 2 or 3 infection in pediatric patients between 3 years of age and 12 years of age or weighing 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric chronic hepatitis C virus infection",
                    "umls_id": "C0019196,C0524910",
                    "parsed_text": "Hepatitis C Virus Infection , chronic hepatitis c"
                }
            },
            {
                "compound_id": 72699160,
                "inchl_key": "TTZHDVOVKQGIBA-KVOQBTHKSA-N",
                "generic_name": "sofosbuvir",
                "trade_name": "Sovaldi",
                "designated_date": "10/25/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin",
                "marketing_approval_date": "\u00a004/07/2017\u00a0",
                "exclusivity_end_date": "\u00a004/07/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric chronic hepatitis C virus infection",
                    "umls_id": "C0019196,C0524910",
                    "parsed_text": "Hepatitis C Virus Infection , chronic hepatitis c"
                }
            },
            {
                "compound_id": 72699160,
                "inchl_key": "TTZHDVOVKQGIBA-KVOQBTHKSA-N",
                "generic_name": "sofosbuvir",
                "trade_name": "Sovaldi",
                "designated_date": "10/25/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin",
                "marketing_approval_date": "\u00a008/28/2019\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric chronic hepatitis C virus infection",
                    "umls_id": "C0019196,C0524910",
                    "parsed_text": "Hepatitis C Virus Infection , chronic hepatitis c"
                }
            }
        ]
    },
    {
        "_id": "TTZHDVOVKQGIBA-IECBXEDQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 129010435,
                "inchl_key": "TTZHDVOVKQGIBA-IECBXEDQSA-N",
                "generic_name": "sofosbuvir",
                "trade_name": "Sovaldi",
                "designated_date": "10/25/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin",
                "marketing_approval_date": "\u00a008/28/2019\u00a0",
                "exclusivity_end_date": "\u00a008/28/2026\u00a0",
                "exclusivity_protected_indication": "For the treatment of chronic hepatitis C virus (HCV) genotype 2 or 3 infection in pediatric patients between 3 years of age and 12 years of age or weighing 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric chronic hepatitis C virus infection",
                    "umls_id": "C0019196,C0524910",
                    "parsed_text": "Hepatitis C Virus Infection , chronic hepatitis c"
                }
            },
            {
                "compound_id": 129010435,
                "inchl_key": "TTZHDVOVKQGIBA-IECBXEDQSA-N",
                "generic_name": "sofosbuvir",
                "trade_name": "Sovaldi",
                "designated_date": "10/25/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin",
                "marketing_approval_date": "\u00a004/07/2017\u00a0",
                "exclusivity_end_date": "\u00a004/07/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric chronic hepatitis C virus infection",
                    "umls_id": "C0019196,C0524910",
                    "parsed_text": "Hepatitis C Virus Infection , chronic hepatitis c"
                }
            },
            {
                "compound_id": 129010435,
                "inchl_key": "TTZHDVOVKQGIBA-IECBXEDQSA-N",
                "generic_name": "sofosbuvir",
                "trade_name": "Sovaldi",
                "designated_date": "10/25/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin",
                "marketing_approval_date": "\u00a008/28/2019\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric chronic hepatitis C virus infection",
                    "umls_id": "C0019196,C0524910",
                    "parsed_text": "Hepatitis C Virus Infection , chronic hepatitis c"
                }
            }
        ]
    },
    {
        "_id": "TTZHDVOVKQGIBA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 91302628,
                "inchl_key": "TTZHDVOVKQGIBA-UHFFFAOYSA-N",
                "generic_name": "sofosbuvir",
                "trade_name": "Sovaldi",
                "designated_date": "10/25/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin",
                "marketing_approval_date": "\u00a008/28/2019\u00a0",
                "exclusivity_end_date": "\u00a008/28/2026\u00a0",
                "exclusivity_protected_indication": "For the treatment of chronic hepatitis C virus (HCV) genotype 2 or 3 infection in pediatric patients between 3 years of age and 12 years of age or weighing 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric chronic hepatitis C virus infection",
                    "umls_id": "C0019196,C0524910",
                    "parsed_text": "Hepatitis C Virus Infection , chronic hepatitis c"
                }
            },
            {
                "compound_id": 91302628,
                "inchl_key": "TTZHDVOVKQGIBA-UHFFFAOYSA-N",
                "generic_name": "sofosbuvir",
                "trade_name": "Sovaldi",
                "designated_date": "10/25/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin",
                "marketing_approval_date": "\u00a004/07/2017\u00a0",
                "exclusivity_end_date": "\u00a004/07/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric chronic hepatitis C virus infection",
                    "umls_id": "C0019196,C0524910",
                    "parsed_text": "Hepatitis C Virus Infection , chronic hepatitis c"
                }
            },
            {
                "compound_id": 91302628,
                "inchl_key": "TTZHDVOVKQGIBA-UHFFFAOYSA-N",
                "generic_name": "sofosbuvir",
                "trade_name": "Sovaldi",
                "designated_date": "10/25/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin",
                "marketing_approval_date": "\u00a008/28/2019\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric chronic hepatitis C virus infection",
                    "umls_id": "C0019196,C0524910",
                    "parsed_text": "Hepatitis C Virus Infection , chronic hepatitis c"
                }
            }
        ]
    },
    {
        "_id": "TTZHDVOVKQGIBA-IAAJYNJHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 45375806,
                "inchl_key": "TTZHDVOVKQGIBA-IAAJYNJHSA-N",
                "generic_name": "sofosbuvir",
                "trade_name": "Sovaldi",
                "designated_date": "10/25/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin",
                "marketing_approval_date": "\u00a008/28/2019\u00a0",
                "exclusivity_end_date": "\u00a008/28/2026\u00a0",
                "exclusivity_protected_indication": "For the treatment of chronic hepatitis C virus (HCV) genotype 2 or 3 infection in pediatric patients between 3 years of age and 12 years of age or weighing 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric chronic hepatitis C virus infection",
                    "umls_id": "C0019196,C0524910",
                    "parsed_text": "Hepatitis C Virus Infection , chronic hepatitis c"
                }
            },
            {
                "compound_id": 45375806,
                "inchl_key": "TTZHDVOVKQGIBA-IAAJYNJHSA-N",
                "generic_name": "sofosbuvir",
                "trade_name": "Sovaldi",
                "designated_date": "10/25/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin",
                "marketing_approval_date": "\u00a004/07/2017\u00a0",
                "exclusivity_end_date": "\u00a004/07/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric chronic hepatitis C virus infection",
                    "umls_id": "C0019196,C0524910",
                    "parsed_text": "Hepatitis C Virus Infection , chronic hepatitis c"
                }
            },
            {
                "compound_id": 45375806,
                "inchl_key": "TTZHDVOVKQGIBA-IAAJYNJHSA-N",
                "generic_name": "sofosbuvir",
                "trade_name": "Sovaldi",
                "designated_date": "10/25/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin",
                "marketing_approval_date": "\u00a008/28/2019\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric chronic hepatitis C virus infection",
                    "umls_id": "C0019196,C0524910",
                    "parsed_text": "Hepatitis C Virus Infection , chronic hepatitis c"
                }
            }
        ]
    },
    {
        "_id": "TTZHDVOVKQGIBA-IQWMDFIBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 45375808,
                "inchl_key": "TTZHDVOVKQGIBA-IQWMDFIBSA-N",
                "generic_name": "sofosbuvir",
                "trade_name": "Sovaldi",
                "designated_date": "10/25/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin",
                "marketing_approval_date": "\u00a008/28/2019\u00a0",
                "exclusivity_end_date": "\u00a008/28/2026\u00a0",
                "exclusivity_protected_indication": "For the treatment of chronic hepatitis C virus (HCV) genotype 2 or 3 infection in pediatric patients between 3 years of age and 12 years of age or weighing 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric chronic hepatitis C virus infection",
                    "umls_id": "C0019196,C0524910",
                    "parsed_text": "Hepatitis C Virus Infection , chronic hepatitis c"
                }
            },
            {
                "compound_id": 45375808,
                "inchl_key": "TTZHDVOVKQGIBA-IQWMDFIBSA-N",
                "generic_name": "sofosbuvir",
                "trade_name": "Sovaldi",
                "designated_date": "10/25/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin",
                "marketing_approval_date": "\u00a004/07/2017\u00a0",
                "exclusivity_end_date": "\u00a004/07/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric chronic hepatitis C virus infection",
                    "umls_id": "C0019196,C0524910",
                    "parsed_text": "Hepatitis C Virus Infection , chronic hepatitis c"
                }
            },
            {
                "compound_id": 45375808,
                "inchl_key": "TTZHDVOVKQGIBA-IQWMDFIBSA-N",
                "generic_name": "sofosbuvir",
                "trade_name": "Sovaldi",
                "designated_date": "10/25/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin",
                "marketing_approval_date": "\u00a008/28/2019\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric chronic hepatitis C virus infection",
                    "umls_id": "C0019196,C0524910",
                    "parsed_text": "Hepatitis C Virus Infection , chronic hepatitis c"
                }
            }
        ]
    },
    {
        "_id": "LKVFMOMQYXIFRK-KSVAIKAXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 91864495,
                "inchl_key": "LKVFMOMQYXIFRK-KSVAIKAXSA-N",
                "generic_name": "solnatide",
                "designated_date": "02/08/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Apeptico Forschung und Entwicklung GmbH (APEPTICO)|Mariahilferstrabe 136|Top 1150|Vienna|Austria",
                "orphan_designation": {
                    "original_text": "Treatment of generalized systemic pseudohypoaldosteronism type 1 (also known as autosomal recessive PHA-I or PHA-IB)",
                    "umls_id": "C0268436",
                    "parsed_text": "Pseudohypoaldosteronism Type 1"
                }
            },
            {
                "compound_id": 91864495,
                "inchl_key": "LKVFMOMQYXIFRK-KSVAIKAXSA-N",
                "generic_name": "solnatide",
                "designated_date": "02/04/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Apeptico Forschung und Entwicklung GmbH|c/o mingo bueros|Vienna|Austria",
                "orphan_designation": {
                    "original_text": "Treatment of primary graft dysfunction following lung transplantation",
                    "umls_id": "C0948031",
                    "parsed_text": "Primary Graft Dysfunction"
                }
            }
        ]
    },
    {
        "_id": "JACAAXNEHGBPOQ-LLVKDONJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 164509,
                "inchl_key": "JACAAXNEHGBPOQ-LLVKDONJSA-N",
                "generic_name": "talampanel",
                "designated_date": "03/24/2008",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "TEVA Neuroscience|P. O. Box 1005|425 Privet Road|Horsham|Pennsylvania|19044|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            },
            {
                "compound_id": 164509,
                "inchl_key": "JACAAXNEHGBPOQ-LLVKDONJSA-N",
                "generic_name": "talampanel",
                "designated_date": "02/17/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "TEVA Neuroscience, Inc.|425 Privet Road|Horsham|Pennsylvania|19044|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioma",
                    "umls_id": "C0017638",
                    "parsed_text": "Glioma"
                }
            }
        ]
    },
    {
        "_id": "AJKIRUJIDFJUKJ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 29566,
                "inchl_key": "AJKIRUJIDFJUKJ-UHFFFAOYSA-N",
                "generic_name": "taurolidine",
                "designated_date": "05/16/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Geistlich Pharma NA, Inc.|202 Carnegie Center Drive|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer.",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 29566,
                "inchl_key": "AJKIRUJIDFJUKJ-UHFFFAOYSA-N",
                "generic_name": "taurolidine",
                "designated_date": "02/22/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CorMedix, Inc.|1430 U.S. 206|Suite 200|Bedminster Township|New Jersey|7921|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuroblastoma",
                    "umls_id": "C0027819",
                    "parsed_text": "Neuroblastoma"
                }
            }
        ]
    },
    {
        "_id": "NSQSAUGJQHDYNO-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 66558664,
                "inchl_key": "NSQSAUGJQHDYNO-UHFFFAOYSA-N",
                "generic_name": "tazemetostat",
                "designated_date": "02/04/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Epizyme Inc.|400 Technology Square|4th Floor|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant rhabdoid tumors (MRTs)",
                    "umls_id": "C0206743",
                    "parsed_text": "Rhabdoid Tumors"
                }
            },
            {
                "compound_id": 66558664,
                "inchl_key": "NSQSAUGJQHDYNO-UHFFFAOYSA-N",
                "generic_name": "tazemetostat",
                "designated_date": "05/23/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Epizyme, Inc.|400 Technology Square|4th Floor|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chordoma",
                    "umls_id": "C0008487",
                    "parsed_text": "Chordoma"
                }
            },
            {
                "compound_id": 66558664,
                "inchl_key": "NSQSAUGJQHDYNO-UHFFFAOYSA-N",
                "generic_name": "tazemetostat",
                "designated_date": "11/14/2017",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "TAZVERIK (tazemetostat) is indicated for: the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies; and the treatment of adult patients with R/R FL who have no satisfactory alternative treatment options.",
                "marketing_approval_date": "\u00a006/18/2020\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Epizyme, Inc.|400 Technology Square|4th Floor|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of follicular lymphoma",
                    "umls_id": "C0024301",
                    "parsed_text": "follicular lymphoma"
                }
            },
            {
                "compound_id": 66558664,
                "inchl_key": "NSQSAUGJQHDYNO-UHFFFAOYSA-N",
                "generic_name": "tazemetostat",
                "designated_date": "09/28/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Epizyme Inc.|400 Technology Square|4th Floor|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mesothelioma",
                    "umls_id": "C0025500",
                    "parsed_text": "Mesothelioma"
                }
            },
            {
                "compound_id": 66558664,
                "inchl_key": "NSQSAUGJQHDYNO-UHFFFAOYSA-N",
                "generic_name": "tazemetostat",
                "designated_date": "06/15/2017",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "TAZVERIK is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.",
                "marketing_approval_date": "\u00a001/23/2020\u00a0",
                "exclusivity_end_date": "\u00a001/23/2027\u00a0",
                "sponsor": "Epizyme, Inc.|400 Technology Square|4th Floor|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcoma",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            }
        ]
    },
    {
        "_id": "BPEGJWRSRHCHSN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5394,
                "inchl_key": "BPEGJWRSRHCHSN-UHFFFAOYSA-N",
                "generic_name": "temozolomide",
                "trade_name": "Temodar",
                "designated_date": "10/05/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with refractory anaplastic astrocytoma, i.e., patients at first relapse who have experienced disease progression on a drug regimen containing a nitrosourea and procarbazine",
                "marketing_approval_date": "\u00a008/11/1999\u00a0",
                "exclusivity_end_date": "\u00a008/11/2006\u00a0",
                "sponsor": "Schering-Plough Research Institute|2000 Galloping Hill Rd.|Kenilworth|New Jersey|7033|United States",
                "orphan_designation": {
                    "original_text": "Treatment of recurrent malignant glioma.",
                    "umls_id": "C4684861",
                    "parsed_text": "Recurrent Malignant Glioma"
                }
            },
            {
                "compound_id": 5394,
                "inchl_key": "BPEGJWRSRHCHSN-UHFFFAOYSA-N",
                "generic_name": "Temozolomide",
                "designated_date": "10/14/1998",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Merck & Company|2000 Galloping Hill Rd.|Kenilworth|New Jersey|7033|United States",
                "orphan_designation": {
                    "original_text": "Treatment of advanced metastatic melanoma.",
                    "umls_id": "C0278883",
                    "parsed_text": "Metastatic melanoma"
                }
            },
            {
                "compound_id": 5394,
                "inchl_key": "BPEGJWRSRHCHSN-UHFFFAOYSA-N",
                "generic_name": "temozolomide",
                "trade_name": "Temodar",
                "designated_date": "10/05/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with newly diagnosed glioblastoma multiforme concomitatly with radiotherapy and then as maintenance treatment",
                "marketing_approval_date": "\u00a003/15/2005\u00a0",
                "exclusivity_end_date": "\u00a003/15/2012\u00a0",
                "sponsor": "Schering-Plough Research Institute|2000 Galloping Hill Rd.|Kenilworth|New Jersey|7033|United States",
                "orphan_designation": {
                    "original_text": "Treatment of recurrent malignant glioma.",
                    "umls_id": "C4684861",
                    "parsed_text": "Recurrent Malignant Glioma"
                }
            },
            {
                "compound_id": 5394,
                "inchl_key": "BPEGJWRSRHCHSN-UHFFFAOYSA-N",
                "generic_name": "Temozolomide",
                "designated_date": "10/18/2004",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Merck & Company|2000 Galloping Hill Road|Kenilworth|New Jersey|7033|United States",
                "orphan_designation": {
                    "original_text": "Treatment of newly diagnosed high grade glioma",
                    "umls_id": "C0555198",
                    "parsed_text": "High Grade Glioma"
                }
            },
            {
                "compound_id": 5394,
                "inchl_key": "BPEGJWRSRHCHSN-UHFFFAOYSA-N",
                "generic_name": "Temozolomide",
                "designated_date": "08/01/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ORPHELIA Pharma|85 Blvd Saint-Michel|Paris|France",
                "orphan_designation": {
                    "original_text": "Treatment of neuroblastoma",
                    "umls_id": "C0027819",
                    "parsed_text": "Neuroblastoma"
                }
            },
            {
                "compound_id": 5394,
                "inchl_key": "BPEGJWRSRHCHSN-UHFFFAOYSA-N",
                "generic_name": "temozolomide",
                "designated_date": "11/25/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AmpliPharm Pharmaceuticals, LLC|970 Peachtree Industrial Boulevard|Suite 100|Suwanee|Georgia|30024|United States",
                "orphan_designation": {
                    "original_text": "Treatment glioblastoma multiforme in pediatric patients",
                    "umls_id": "C0017636",
                    "parsed_text": "Glioblastoma multiforme"
                }
            }
        ]
    },
    {
        "_id": "SGOIRFVFHAKUTI-ZCFIWIBFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 464205,
                "inchl_key": "SGOIRFVFHAKUTI-ZCFIWIBFSA-N",
                "generic_name": "tenofovir",
                "trade_name": "Viread",
                "designated_date": "03/17/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of HIV infection in combination with other antiretroviral agents in patients 12 to less than 18 years of age",
                "marketing_approval_date": "\u00a003/24/2010\u00a0",
                "exclusivity_end_date": "\u00a003/24/2017\u00a0",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster city|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric HIV infection.",
                    "umls_id": "C0019693",
                    "parsed_text": "HIV infection"
                }
            }
        ]
    },
    {
        "_id": "VCMJCVGFSROFHV-VIEYUMQNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 86280652,
                "inchl_key": "VCMJCVGFSROFHV-VIEYUMQNSA-N",
                "generic_name": "tenofovir disoproxil fumarate",
                "designated_date": "09/27/2016",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Prevention of mother to child transmission of hepatitis B virus",
                    "umls_id": "C0019169,C0282474",
                    "parsed_text": "hepatitis B virus , Mother to Child Transmission"
                }
            }
        ]
    },
    {
        "_id": "JFVZFKDSXNQEJW-CQSZACIVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5481350,
                "inchl_key": "JFVZFKDSXNQEJW-CQSZACIVSA-N",
                "generic_name": "tenofovir disoproxil fumarate",
                "designated_date": "09/27/2016",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Prevention of mother to child transmission of hepatitis B virus",
                    "umls_id": "C0019169,C0282474",
                    "parsed_text": "hepatitis B virus , Mother to Child Transmission"
                }
            }
        ]
    },
    {
        "_id": "VCMJCVGFSROFHV-PFEQFJNWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5486830,
                "inchl_key": "VCMJCVGFSROFHV-PFEQFJNWSA-N",
                "generic_name": "tenofovir disoproxil fumarate",
                "designated_date": "09/27/2016",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Prevention of mother to child transmission of hepatitis B virus",
                    "umls_id": "C0019169,C0282474",
                    "parsed_text": "hepatitis B virus , Mother to Child Transmission"
                }
            }
        ]
    },
    {
        "_id": "VCMJCVGFSROFHV-WZGZYPNHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6398764,
                "inchl_key": "VCMJCVGFSROFHV-WZGZYPNHSA-N",
                "generic_name": "tenofovir disoproxil fumarate",
                "designated_date": "09/27/2016",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Prevention of mother to child transmission of hepatitis B virus",
                    "umls_id": "C0019169,C0282474",
                    "parsed_text": "hepatitis B virus , Mother to Child Transmission"
                }
            }
        ]
    },
    {
        "_id": "AHYMHWXQRWRBKT-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25171648,
                "inchl_key": "AHYMHWXQRWRBKT-UHFFFAOYSA-N",
                "generic_name": "tepotinib",
                "trade_name": "Tepmetko",
                "designated_date": "10/26/2020",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations",
                "marketing_approval_date": "\u00a002/03/2021\u00a0",
                "exclusivity_end_date": "\u00a002/03/2028\u00a0",
                "exclusivity_protected_indication": "treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations",
                "sponsor": "EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-small cell lung cancer with MET genomic tumor aberrations",
                    "umls_id": "C0027651,C3539721",
                    "parsed_text": "Tumor , Non-Small Cell Lung Cancer"
                }
            }
        ]
    },
    {
        "_id": "MUMGGOZAMZWBJJ-DYKIIFRCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6013,
                "inchl_key": "MUMGGOZAMZWBJJ-DYKIIFRCSA-N",
                "generic_name": "Testosterone",
                "designated_date": "09/22/1997",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Watson Laboratories|Research Park|417 Wakara Way|Salt Lake City|Utah|84108|United States",
                "orphan_designation": {
                    "original_text": "For use as physiologic testosterone replacement in androgen deficient HIV+ patients with an associated weight loss.",
                    "umls_id": "C0019682,C4084774",
                    "parsed_text": "HIV , Weight loss"
                }
            },
            {
                "compound_id": 6013,
                "inchl_key": "MUMGGOZAMZWBJJ-DYKIIFRCSA-N",
                "generic_name": "Testosterone",
                "designated_date": "02/05/1996",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Unimed Pharmaceuticals, Inc.|901 Sawyer Rd.|Marietta|Georgia|30062|United States",
                "orphan_designation": {
                    "original_text": "Treatment of weight loss in AIDS patients with HIV-associated wasting.",
                    "umls_id": "C0006625,C0019682,C4084774",
                    "parsed_text": "Wasting , HIV , Weight loss"
                }
            }
        ]
    },
    {
        "_id": "GFFXZLZWLOBBLO-ASKVSEFXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6435808,
                "inchl_key": "GFFXZLZWLOBBLO-ASKVSEFXSA-N",
                "generic_name": "Tezacitabine",
                "designated_date": "01/27/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sanofi-Aventis US, Inc.|9 Great valley Parkway|Malvern|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of adenocarcinoma of the esophagus and stomach",
                    "umls_id": "C0279628",
                    "parsed_text": "adenocarcinoma of the esophagus"
                }
            }
        ]
    },
    {
        "_id": "NZVYCXVTEHPMHE-ZSUJOUNUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16130571,
                "inchl_key": "NZVYCXVTEHPMHE-ZSUJOUNUSA-N",
                "generic_name": "thymalfasin",
                "designated_date": "05/03/1991",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SciClone Pharmaceuticals, Inc.|950 Tower Lane|Suite 900|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic active hepatitis B",
                    "umls_id": "C0744831",
                    "parsed_text": "Chronic active hepatitis B"
                }
            },
            {
                "compound_id": 16130571,
                "inchl_key": "NZVYCXVTEHPMHE-ZSUJOUNUSA-N",
                "generic_name": "Thymalfasin",
                "designated_date": "03/13/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SciClone Pharmaceuticals, Inc.|950 Tower Lane|Suite 900|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of stage IIb through Stage IV malignant melanoma",
                    "umls_id": "C0025202",
                    "parsed_text": "Malignant Melanoma"
                }
            },
            {
                "compound_id": 16130571,
                "inchl_key": "NZVYCXVTEHPMHE-ZSUJOUNUSA-N",
                "generic_name": "Thymalfasin",
                "designated_date": "03/06/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SciClone Pharmaceuticals, Inc.|950 Tower Lane|Suite 900|Foster city|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma.",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            },
            {
                "compound_id": 16130571,
                "inchl_key": "NZVYCXVTEHPMHE-ZSUJOUNUSA-N",
                "generic_name": "Thymalfasin",
                "designated_date": "01/08/1998",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SciClone Pharmaceuticals, Inc.|901 Mariner's Island Blvd.|San Mateo|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of DiGeorge anomaly with immune defects.",
                    "umls_id": "C0012236",
                    "parsed_text": "DiGeorge Anomaly"
                }
            }
        ]
    },
    {
        "_id": "YTGJWQPHMWSCST-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5483,
                "inchl_key": "YTGJWQPHMWSCST-UHFFFAOYSA-N",
                "generic_name": "Tiopronin",
                "trade_name": "Thiola",
                "designated_date": "01/17/1986",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "THIOLA is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone.",
                "marketing_approval_date": "\u00a006/28/2019\u00a0",
                "exclusivity_end_date": "\u00a006/28/2026\u00a0",
                "exclusivity_protected_indication": "Indicated in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in pediatric patients between 20 kg and 9 years of age with severe homozygous cystinuria, who are not responsive to these measures alone",
                "sponsor": "Mission Pharmacal Company|P.O. Box 786099|San Antonio|Texas|78278|United States",
                "orphan_designation": {
                    "original_text": "Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.",
                    "umls_id": "C0010691,C0022650",
                    "parsed_text": "Cystinuria , Nephrolithiasis"
                }
            },
            {
                "compound_id": 5483,
                "inchl_key": "YTGJWQPHMWSCST-UHFFFAOYSA-N",
                "generic_name": "Tiopronin",
                "trade_name": "Thiola",
                "designated_date": "01/17/1986",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Indicated for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria with urinary cystine greater than 500 mg/day, who are resistant to treatment with conservative measures of high fluid intake, alkali and diet modification or who have adverse reactions to d-penicillamine.",
                "marketing_approval_date": "\u00a008/11/1988\u00a0",
                "exclusivity_end_date": "\u00a008/11/1995\u00a0",
                "sponsor": "Mission Pharmacal Company|P.O. Box 786099|San Antonio|Texas|78278|United States",
                "orphan_designation": {
                    "original_text": "Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.",
                    "umls_id": "C0010691,C0022650",
                    "parsed_text": "Cystinuria , Nephrolithiasis"
                }
            },
            {
                "compound_id": 5483,
                "inchl_key": "YTGJWQPHMWSCST-UHFFFAOYSA-N",
                "generic_name": "Tiopronin",
                "trade_name": "Thiola",
                "designated_date": "01/17/1986",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "THIOLA EC is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone.",
                "marketing_approval_date": "\u00a006/28/2019\u00a0",
                "exclusivity_end_date": "\u00a006/28/2026\u00a0",
                "sponsor": "Mission Pharmacal Company|P.O. Box 786099|San Antonio|Texas|78278|United States",
                "orphan_designation": {
                    "original_text": "Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.",
                    "umls_id": "C0010691,C0022650",
                    "parsed_text": "Cystinuria , Nephrolithiasis"
                }
            }
        ]
    },
    {
        "_id": "MDCUNMLZLNGCQA-HWOAGHQOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44201346,
                "inchl_key": "MDCUNMLZLNGCQA-HWOAGHQOSA-N",
                "generic_name": "tiprelestat",
                "designated_date": "12/28/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Proteo Biotech AG|Am Kiel Kanal 44|Kiel|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "ORYDPOVDJJZGHQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135413511,
                "inchl_key": "ORYDPOVDJJZGHQ-UHFFFAOYSA-N",
                "generic_name": "tirapazamine",
                "designated_date": "11/30/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Teclison Limited|28 Baltusrol Way|Short Hills|New Jersey|7078|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            },
            {
                "compound_id": 135413511,
                "inchl_key": "ORYDPOVDJJZGHQ-UHFFFAOYSA-N",
                "generic_name": "tirapazamine",
                "designated_date": "10/23/2002",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sanofi-Aventis US, Inc.|11 Great Valley Parkway|P. O. Box 3026|Malvern|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of head and neck cancer",
                    "umls_id": "C3887461",
                    "parsed_text": "Head and Neck Cancer"
                }
            }
        ]
    },
    {
        "_id": "UOWZUVNAGUAEQC-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5803,
                "inchl_key": "UOWZUVNAGUAEQC-UHFFFAOYSA-N",
                "generic_name": "Tiratricol",
                "designated_date": "08/13/1991",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Laphal Laboratoires|48 Bis, Rue des Belles-Feuilles|Paris|France",
                "orphan_designation": {
                    "original_text": "For use in combination with levo-thyroxine to suppress thyroid stimulating hormone in patients with well-differentiated thyroid cancer who are intolerant to adequate doses of levo-thyroxine alone.",
                    "umls_id": "C1337013",
                    "parsed_text": "Well-Differentiated Thyroid Cancer"
                }
            },
            {
                "compound_id": 5803,
                "inchl_key": "UOWZUVNAGUAEQC-UHFFFAOYSA-N",
                "generic_name": "tiratricol",
                "designated_date": "01/16/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rare Thyroid Therapeutics|3 Teatergatan|SE-111 48|Stockholm|Sweden",
                "orphan_designation": {
                    "original_text": "Treatment of Monocarboxylate 8 Transporter (MCT8) Deficiency (Allan-Herndon-Dudley-Syndrome)",
                    "umls_id": "C0039082,C1420103",
                    "parsed_text": "Syndrome , MCT8"
                }
            }
        ]
    },
    {
        "_id": "GYHCTFXIZSNGJT-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 216237,
                "inchl_key": "GYHCTFXIZSNGJT-UHFFFAOYSA-N",
                "generic_name": "tolvaptan",
                "trade_name": "Jynarque",
                "designated_date": "04/06/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD)",
                "marketing_approval_date": "\u00a004/23/2018\u00a0",
                "exclusivity_end_date": "\u00a004/23/2025\u00a0",
                "exclusivity_protected_indication": "JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD)",
                "sponsor": "Otsuka Pharmaceutical Company, Ltd.|2-9, Kanda-Tsukasamachi|Tokyo|Japan",
                "orphan_designation": {
                    "original_text": "Treatment of autosomal dominant polycystic kidney disease",
                    "umls_id": "C0085413",
                    "parsed_text": "Autosomal dominant polycystic kidney disease"
                }
            }
        ]
    },
    {
        "_id": "GYDJEQRTZSCIOI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5526,
                "inchl_key": "GYDJEQRTZSCIOI-UHFFFAOYSA-N",
                "generic_name": "tranexamic acid",
                "trade_name": "Cyklokapron",
                "designated_date": "12/03/1985",
                "designation_status": "Designated/Approved/Withdrawn",
                "approved_labeled_indication": "Treatment of patients with hemophilia for short term use (2 to 8 days) before and after tooth extraction to reduce or prevent hemorrhage abd reduce the need for replacement therapy",
                "marketing_approval_date": "\u00a012/30/1986\u00a0",
                "exclusivity_end_date": "\u00a012/30/1993\u00a0",
                "sponsor": "Pharmacia Inc.|P.O. Box 16529|Columbus|Ohio|43216|United States",
                "orphan_designation": {
                    "original_text": "For use in patients with congenital coagulopathies undergoing surgical procedures, e.g. dental extractions",
                    "umls_id": "C0005779",
                    "parsed_text": "coagulopathies"
                }
            }
        ]
    },
    {
        "_id": "WBYWAXJHAXSJNI-VOTSOKGWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 444539,
                "inchl_key": "WBYWAXJHAXSJNI-VOTSOKGWSA-N",
                "generic_name": "Trans-Cinnamic Acid",
                "designated_date": "02/03/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Polaryx Therapeutics, Inc.|140 E. Ridgewood Avenue, Suite 415, South Tower|Paramus|New Jersey|7652|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Krabbe disease",
                    "umls_id": "C0023521",
                    "parsed_text": "Krabbe Disease"
                }
            },
            {
                "compound_id": 444539,
                "inchl_key": "WBYWAXJHAXSJNI-VOTSOKGWSA-N",
                "generic_name": "Trans-Cinnamic Acid",
                "designated_date": "11/24/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Polaryx Therapeutics, Inc.|140 E. Ridgewood Avenue, Suite 415, South Tower|Paramus|New Jersey|7652|United States",
                "orphan_designation": {
                    "original_text": "Treatment of GM2 gangliosidosis",
                    "umls_id": "C0268274",
                    "parsed_text": "GM2 Gangliosidosis"
                }
            },
            {
                "compound_id": 444539,
                "inchl_key": "WBYWAXJHAXSJNI-VOTSOKGWSA-N",
                "generic_name": "Trans-Cinnamic Acid",
                "designated_date": "11/24/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Polaryx Therapeutics, Inc.|140 E. Ridgewood Avenue|Suite 415, South Tower|Paramus|New Jersey|7652|United States",
                "orphan_designation": {
                    "original_text": "treatment for Niemann-Pick disease Type A and Type B",
                    "umls_id": "C0268242",
                    "parsed_text": "niemann-pick disease type a"
                }
            }
        ]
    },
    {
        "_id": "LUKBXSAWLPMMSZ-OWOJBTEDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 445154,
                "inchl_key": "LUKBXSAWLPMMSZ-OWOJBTEDSA-N",
                "generic_name": "trans-resveratrol",
                "designated_date": "08/16/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Jupiter Orphan Therapeutics|601 Heritage Drive|Jupiter|Florida|33458|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Friedreichs Ataxia (FRDA)",
                    "umls_id": "C0016719",
                    "parsed_text": "FRIEDREICHS ATAXIA"
                }
            }
        ]
    },
    {
        "_id": "HDTRYLNUVZCQOY-LIZSDCNHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 7427,
                "inchl_key": "HDTRYLNUVZCQOY-LIZSDCNHSA-N",
                "generic_name": "Trehalose",
                "designated_date": "04/29/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Seelos Therapeutics, Inc.|300 Park Avenue, 12th Floor|New York|New York|10022|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mucopolysaccharidosis type III (MPS III), or Sanfilippo syndrome",
                    "umls_id": "C0026706,C0086647",
                    "parsed_text": "Mucopolysaccharidosis type III , mps iii"
                }
            },
            {
                "compound_id": 7427,
                "inchl_key": "HDTRYLNUVZCQOY-LIZSDCNHSA-N",
                "generic_name": "trehalose",
                "designated_date": "10/25/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Seelos Therapeutics|300 Park Avenue|New York|New York|10022|United States",
                "orphan_designation": {
                    "original_text": "Treatment of occulopharyngeal muscular dystrophy",
                    "umls_id": "C0026850",
                    "parsed_text": "Muscular Dystrophy"
                }
            },
            {
                "compound_id": 7427,
                "inchl_key": "HDTRYLNUVZCQOY-LIZSDCNHSA-N",
                "generic_name": "trehalose",
                "designated_date": "11/18/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Seelos Therapeutics, Inc.|300 Park Avenue, 12th Floor|New York|New York|10022|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            },
            {
                "compound_id": 7427,
                "inchl_key": "HDTRYLNUVZCQOY-LIZSDCNHSA-N",
                "generic_name": "trehalose",
                "designated_date": "11/17/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Seelos Therapeutics, Inc.|300 Park Avenue|New York|New York|10022|United States",
                "orphan_designation": {
                    "original_text": "Treatment of spinal cerebellar ataxia type 3 (also known as SCA3 or Machado Joseph disease)",
                    "umls_id": "C0007758,C0024408",
                    "parsed_text": "Cerebellar Ataxia , SCA3"
                }
            },
            {
                "compound_id": 7427,
                "inchl_key": "HDTRYLNUVZCQOY-LIZSDCNHSA-N",
                "generic_name": "Trehalose",
                "designated_date": "10/21/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Beyond Batten Disease Foundation|P.O. Box 50221|Austin|Texas|78763|United States",
                "orphan_designation": {
                    "original_text": "Treatment of CLN Batten disease",
                    "umls_id": "C0751383",
                    "parsed_text": "Batten Disease"
                }
            }
        ]
    },
    {
        "_id": "SHGAZHPCJJPHSC-YCNIQYBTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 444795,
                "inchl_key": "SHGAZHPCJJPHSC-YCNIQYBTSA-N",
                "generic_name": "Tretinoin",
                "designated_date": "04/11/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Antigenics, Inc.|3 Forbes Road|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of T-cell non-Hodgkin's lymphoma",
                    "umls_id": "C0079772",
                    "parsed_text": "T-cell non-Hodgkin's lymphoma"
                }
            },
            {
                "compound_id": 444795,
                "inchl_key": "SHGAZHPCJJPHSC-YCNIQYBTSA-N",
                "generic_name": "Tretinoin",
                "trade_name": "Vesanoid",
                "designated_date": "10/24/1990",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Induction of remission in patients with acute promyelocytic leukemia who are refractory to or unable to tolerate anthracycline based cytotoxic chemotherapeutic regimens.",
                "marketing_approval_date": "\u00a011/22/1995\u00a0",
                "exclusivity_end_date": "\u00a011/22/2002\u00a0",
                "sponsor": "Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute promyelocytic leukemia.",
                    "umls_id": "C0023487",
                    "parsed_text": "Acute Promyelocytic Leukemia"
                }
            },
            {
                "compound_id": 444795,
                "inchl_key": "SHGAZHPCJJPHSC-YCNIQYBTSA-N",
                "generic_name": "Tretinoin",
                "designated_date": "01/14/1993",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Antigenics, Inc.|3 Forbes Road|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute and chronic leukemia.",
                    "umls_id": "C1279296",
                    "parsed_text": "Chronic leukemia"
                }
            }
        ]
    },
    {
        "_id": "PJHKBYALYHRYSK-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 69286,
                "inchl_key": "PJHKBYALYHRYSK-UHFFFAOYSA-N",
                "generic_name": "Triheptanoin",
                "designated_date": "02/01/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Baylor Research Institute|3330 Live Oak Blvd|Dallas|Texas|75204|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glycogen storage disorder II (Pompe disease)",
                    "umls_id": "C0017919,C0017921",
                    "parsed_text": "glycogen storage disorder , Pompe Disease"
                }
            },
            {
                "compound_id": 69286,
                "inchl_key": "PJHKBYALYHRYSK-UHFFFAOYSA-N",
                "generic_name": "triheptanoin",
                "trade_name": "Dojolvi",
                "designated_date": "04/15/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "DOJOLVI is indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).",
                "marketing_approval_date": "\u00a006/30/2020\u00a0",
                "exclusivity_end_date": "\u00a006/30/2027\u00a0",
                "exclusivity_protected_indication": "Indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).",
                "sponsor": "Ultragenyx Pharmaceutical, Inc.|60 Leveroni Court|Novato|California|94949|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fatty acid oxidation disorders",
                    "umls_id": "C1456270",
                    "parsed_text": "fatty acid oxidation disorder"
                }
            }
        ]
    },
    {
        "_id": "UHWVSEOVJBQKBE-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 21109,
                "inchl_key": "UHWVSEOVJBQKBE-UHFFFAOYSA-N",
                "generic_name": "Trimetazidine",
                "designated_date": "03/15/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Martin Pharmaceuticals, Inc.|233 Broadway|Suite 1750|New York|New York|10279|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute-on-chronic liver failure",
                    "umls_id": "C3850141",
                    "parsed_text": "Acute-On-Chronic Liver Failure"
                }
            },
            {
                "compound_id": 21109,
                "inchl_key": "UHWVSEOVJBQKBE-UHFFFAOYSA-N",
                "generic_name": "trimetazidine",
                "designated_date": "10/30/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Martin Pharmaceuticals, Inc.|233 Broadway|Suite 1750|New York|New York|10279|United States",
                "orphan_designation": {
                    "original_text": "Treatment of dilated cardiomyopathy",
                    "umls_id": "C0007193",
                    "parsed_text": "Dilated cardiomyopathy"
                }
            },
            {
                "compound_id": 21109,
                "inchl_key": "UHWVSEOVJBQKBE-UHFFFAOYSA-N",
                "generic_name": "trimetazidine",
                "designated_date": "08/07/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Martin Pharmaceuticals, Inc.|233 Broadway|Suite 1750|New York|New York|10279|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "ZCJXQWYMBJYJNB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 336805,
                "inchl_key": "ZCJXQWYMBJYJNB-UHFFFAOYSA-N",
                "generic_name": "Trimetrexate glucuronate",
                "designated_date": "01/13/1988",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medimmune Oncology, Inc.|One MedImmune Way|Gaithersburg|Maryland|20878|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with advanced non-small cell carcinoma of the lung.",
                    "umls_id": "C0007131",
                    "parsed_text": "Non-Small Cell Carcinoma of the Lung"
                }
            },
            {
                "compound_id": 336805,
                "inchl_key": "ZCJXQWYMBJYJNB-UHFFFAOYSA-N",
                "generic_name": "Trimetrexate glucuronate",
                "trade_name": "Neutrexin",
                "designated_date": "05/15/1986",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Concurrent leucovorin administration as an alternative therapy for the treatment of moderate to severe PCP in immunocompromised patients who are intolerant of, or are refractory to, trimethoprim sulfamethoxazole.",
                "marketing_approval_date": "\u00a012/17/1993\u00a0",
                "exclusivity_end_date": "\u00a012/17/2000\u00a0",
                "sponsor": "Medimmune Oncology, Inc.|One Tower Bridge|100 Front Street, Suite 400|West Conshohocken|Pennsylvania|19428|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pneumocystis carinii pneumonia in AIDS patients.",
                    "umls_id": "C1535939",
                    "parsed_text": "Pneumocystis carinii Pneumonia"
                }
            },
            {
                "compound_id": 336805,
                "inchl_key": "ZCJXQWYMBJYJNB-UHFFFAOYSA-N",
                "generic_name": "Trimetrexate glucuronate",
                "designated_date": "07/25/1985",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medimmune Oncology, Inc.|One MedImmune Way|Gaithersburg|Maryland|20878|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic adenocarcinoma.",
                    "umls_id": "C0281361",
                    "parsed_text": "Pancreatic adenocarcinoma"
                }
            }
        ]
    },
    {
        "_id": "ZCJXQWYMBJYJNB-LRDBBFHQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 54949,
                "inchl_key": "ZCJXQWYMBJYJNB-LRDBBFHQSA-N",
                "generic_name": "Trimetrexate glucuronate",
                "designated_date": "01/13/1988",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medimmune Oncology, Inc.|One MedImmune Way|Gaithersburg|Maryland|20878|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with advanced non-small cell carcinoma of the lung.",
                    "umls_id": "C0007131",
                    "parsed_text": "Non-Small Cell Carcinoma of the Lung"
                }
            },
            {
                "compound_id": 54949,
                "inchl_key": "ZCJXQWYMBJYJNB-LRDBBFHQSA-N",
                "generic_name": "Trimetrexate glucuronate",
                "trade_name": "Neutrexin",
                "designated_date": "05/15/1986",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Concurrent leucovorin administration as an alternative therapy for the treatment of moderate to severe PCP in immunocompromised patients who are intolerant of, or are refractory to, trimethoprim sulfamethoxazole.",
                "marketing_approval_date": "\u00a012/17/1993\u00a0",
                "exclusivity_end_date": "\u00a012/17/2000\u00a0",
                "sponsor": "Medimmune Oncology, Inc.|One Tower Bridge|100 Front Street, Suite 400|West Conshohocken|Pennsylvania|19428|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pneumocystis carinii pneumonia in AIDS patients.",
                    "umls_id": "C1535939",
                    "parsed_text": "Pneumocystis carinii Pneumonia"
                }
            },
            {
                "compound_id": 54949,
                "inchl_key": "ZCJXQWYMBJYJNB-LRDBBFHQSA-N",
                "generic_name": "Trimetrexate glucuronate",
                "designated_date": "07/25/1985",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medimmune Oncology, Inc.|One MedImmune Way|Gaithersburg|Maryland|20878|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic adenocarcinoma.",
                    "umls_id": "C0281361",
                    "parsed_text": "Pancreatic adenocarcinoma"
                }
            }
        ]
    },
    {
        "_id": "ODVKSTFPQDVPJZ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 105102,
                "inchl_key": "ODVKSTFPQDVPJZ-UHFFFAOYSA-N",
                "generic_name": "Ulinastatin",
                "designated_date": "06/12/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenefly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Kawasaki Disease",
                    "umls_id": "C0026691",
                    "parsed_text": "Kawasaki Disease"
                }
            }
        ]
    },
    {
        "_id": "IUVCFHHAEHNCFT-INIZCTEOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 72950888,
                "inchl_key": "IUVCFHHAEHNCFT-INIZCTEOSA-N",
                "generic_name": "umbralisib",
                "trade_name": "Ukoniq",
                "designated_date": "04/11/2019",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen.",
                "marketing_approval_date": "\u00a002/05/2021\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "TG Therapeutics, Inc.|2 Gansevoort Street|9th Floor|New York|New York|10014|United States",
                "orphan_designation": {
                    "original_text": "Treatment of extranodal marginal zone lymphoma",
                    "umls_id": "C1367654",
                    "parsed_text": "Marginal zone lymphoma"
                }
            },
            {
                "compound_id": 72950888,
                "inchl_key": "IUVCFHHAEHNCFT-INIZCTEOSA-N",
                "generic_name": "umbralisib",
                "trade_name": "Ukoniq",
                "designated_date": "03/04/2020",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.",
                "marketing_approval_date": "\u00a002/05/2021\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "TG Therapeutics, Inc.|2 Gansevoort Street|9th Floor|New York|New York|10014|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Follicular Lymphoma",
                    "umls_id": "C0024301",
                    "parsed_text": "follicular lymphoma"
                }
            },
            {
                "compound_id": 72950888,
                "inchl_key": "IUVCFHHAEHNCFT-INIZCTEOSA-N",
                "generic_name": "umbralisib",
                "trade_name": "Ukoniq",
                "designated_date": "04/11/2019",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen",
                "marketing_approval_date": "\u00a002/05/2021\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "TG Therapeutics, Inc.|2 Gansevoort Street|9th Floor|New York|New York|10014|United States",
                "orphan_designation": {
                    "original_text": "Treatment of nodal marginal zone lymphoma",
                    "umls_id": "C0242647",
                    "parsed_text": "Nodal marginal zone lymphoma"
                }
            },
            {
                "compound_id": 72950888,
                "inchl_key": "IUVCFHHAEHNCFT-INIZCTEOSA-N",
                "generic_name": "umbralisib",
                "trade_name": "Ukoniq",
                "designated_date": "04/11/2019",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen",
                "marketing_approval_date": "\u00a002/05/2021\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "TG Therapeutics, Inc.|2 Gansevoort Street|9th Floor|New York|New York|10014|United States",
                "orphan_designation": {
                    "original_text": "Treatment of splenic marginal zone lymphoma",
                    "umls_id": "C0349632",
                    "parsed_text": "Splenic marginal zone lymphoma"
                }
            }
        ]
    },
    {
        "_id": "XXUPXHKCPIKWLR-JHUOEJJVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5282175,
                "inchl_key": "XXUPXHKCPIKWLR-JHUOEJJVSA-N",
                "generic_name": "unoprostone isopropyl",
                "designated_date": "09/16/2010",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "R-Tech Ueno, Ltd.|Kobe Hybrid Business Center, 3F|Chuo-ku|Kobe City|Hyogo|Japan",
                "orphan_designation": {
                    "original_text": "Treatment of retinitis pigmentosa",
                    "umls_id": "C0035334",
                    "parsed_text": "Retinitis Pigmentosa"
                }
            }
        ]
    },
    {
        "_id": "RUDATBOHQWOJDD-UZVSRGJWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 31401,
                "inchl_key": "RUDATBOHQWOJDD-UZVSRGJWSA-N",
                "generic_name": "Ursodeoxycholic acid",
                "designated_date": "04/26/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "IntraBio Inc.|270 Devon Road|Tenafly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Niemann-Pick disease, type C",
                    "umls_id": "C0220756",
                    "parsed_text": "Niemann-Pick Disease, Type C"
                }
            },
            {
                "compound_id": 31401,
                "inchl_key": "RUDATBOHQWOJDD-UZVSRGJWSA-N",
                "generic_name": "Ursodiol",
                "designated_date": "02/19/1991",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Management of the clinical signs and symptoms associated with primary biliary cirrhosis.",
                    "umls_id": "C0008312",
                    "parsed_text": "Primary Biliary Cirrhosis"
                }
            },
            {
                "compound_id": 31401,
                "inchl_key": "RUDATBOHQWOJDD-UZVSRGJWSA-N",
                "generic_name": "Ursodiol",
                "trade_name": "URSO 250",
                "designated_date": "06/20/1991",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a012/10/1997\u00a0",
                "exclusivity_end_date": "\u00a012/10/2004\u00a0",
                "sponsor": "Aptalis Pharma US, Inc.|100 Somerset corporate Blvd|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with primary biliary cirrhosis",
                    "umls_id": "C0008312",
                    "parsed_text": "Primary Biliary Cirrhosis"
                }
            },
            {
                "compound_id": 31401,
                "inchl_key": "RUDATBOHQWOJDD-UZVSRGJWSA-N",
                "generic_name": "ursodiol",
                "designated_date": "10/23/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Asklepion Pharmaceuticals, LLC|5200 Maryland Way|Brentwood|Tennessee|37027|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis liver disease",
                    "umls_id": "C2827436",
                    "parsed_text": "Cystic Fibrosis Liver Disease"
                }
            }
        ]
    },
    {
        "_id": "FVJCUZCRPIMVLB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11528958,
                "inchl_key": "FVJCUZCRPIMVLB-UHFFFAOYSA-N",
                "generic_name": "verdiperstat",
                "designated_date": "02/15/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biohaven Pharmaceuticals, Inc.|215 Church Street|New Haven|Connecticut|6510|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple system atrophy (MSA).",
                    "umls_id": "C0393571",
                    "parsed_text": "Multiple System Atrophy"
                }
            }
        ]
    },
    {
        "_id": "DJWUNCQRNNEAKC-UHFFFAOYSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 11192,
                "inchl_key": "DJWUNCQRNNEAKC-UHFFFAOYSA-L",
                "generic_name": "Zinc acetate",
                "trade_name": "Galzin",
                "designated_date": "11/06/1985",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For maintenance treatment of patients with Wilson's disease who have been initially treated with a chelating agent.",
                "marketing_approval_date": "\u00a001/28/1997\u00a0",
                "exclusivity_end_date": "\u00a001/28/2004\u00a0",
                "sponsor": "Lemmon Company|1510 Delp Drive|Kulpsville|Pennsylvania|19443|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wilson's disease.",
                    "umls_id": "C0019202",
                    "parsed_text": "Wilson's Disease"
                }
            }
        ]
    },
    {
        "_id": "YFGBQHOOROIVKG-FKBYEOEOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 443363,
                "inchl_key": "YFGBQHOOROIVKG-FKBYEOEOSA-N",
                "generic_name": "[met5]-enkephalin",
                "designated_date": "01/24/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cytocom, Inc.|37 North Orange Avenue|Suite 607|Orlando|Florida|32801|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 443363,
                "inchl_key": "YFGBQHOOROIVKG-FKBYEOEOSA-N",
                "generic_name": "opioid growth factor",
                "designated_date": "04/16/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Primocure Pharma, Inc.|1732 1st Avenue|#23222|New York|New York|10128|United States",
                "orphan_designation": {
                    "original_text": "Treatment of liver and intrahepatic bile duct cancer",
                    "umls_id": "C0279000",
                    "parsed_text": "Liver and Intrahepatic Bile Duct Cancer"
                }
            }
        ]
    },
    {
        "_id": "PENDGIOBPJLVBT-WNGDBVLYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 146157949,
                "inchl_key": "PENDGIOBPJLVBT-WNGDBVLYSA-N",
                "generic_name": "cethromycin",
                "designated_date": "09/09/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Advanced Life Sciences, Inc.|1440 Davey Road|Woodridge|Illinois|60517|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of plague due to Yersinia pestis",
                    "umls_id": "C0032064",
                    "parsed_text": "Plague"
                }
            },
            {
                "compound_id": 146157949,
                "inchl_key": "PENDGIOBPJLVBT-WNGDBVLYSA-N",
                "generic_name": "cethromycin",
                "designated_date": "02/28/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Advanced LIfe Sciences, Inc.|1440 Davey Road|Woodridge|Illinois|60517|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of patients exposed to inhalation anthrax.",
                    "umls_id": "C0155866",
                    "parsed_text": "Inhalation anthrax"
                }
            },
            {
                "compound_id": 146157949,
                "inchl_key": "PENDGIOBPJLVBT-WNGDBVLYSA-N",
                "generic_name": "cethromycin",
                "designated_date": "09/09/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Advanced Life Sciences, Inc.|1440 Davey Road|Woodridge|Illinois|60517|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of tularemia due to Francisella tularensis.",
                    "umls_id": "C0041351",
                    "parsed_text": "Tularemia"
                }
            }
        ]
    },
    {
        "_id": "PENDGIOBPJLVBT-COVUKVLKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11354711,
                "inchl_key": "PENDGIOBPJLVBT-COVUKVLKSA-N",
                "generic_name": "cethromycin",
                "designated_date": "09/09/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Advanced Life Sciences, Inc.|1440 Davey Road|Woodridge|Illinois|60517|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of plague due to Yersinia pestis",
                    "umls_id": "C0032064",
                    "parsed_text": "Plague"
                }
            },
            {
                "compound_id": 11354711,
                "inchl_key": "PENDGIOBPJLVBT-COVUKVLKSA-N",
                "generic_name": "cethromycin",
                "designated_date": "02/28/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Advanced LIfe Sciences, Inc.|1440 Davey Road|Woodridge|Illinois|60517|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of patients exposed to inhalation anthrax.",
                    "umls_id": "C0155866",
                    "parsed_text": "Inhalation anthrax"
                }
            },
            {
                "compound_id": 11354711,
                "inchl_key": "PENDGIOBPJLVBT-COVUKVLKSA-N",
                "generic_name": "cethromycin",
                "designated_date": "09/09/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Advanced Life Sciences, Inc.|1440 Davey Road|Woodridge|Illinois|60517|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of tularemia due to Francisella tularensis.",
                    "umls_id": "C0041351",
                    "parsed_text": "Tularemia"
                }
            }
        ]
    },
    {
        "_id": "PENDGIOBPJLVBT-AMXFZXBBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 156417,
                "inchl_key": "PENDGIOBPJLVBT-AMXFZXBBSA-N",
                "generic_name": "cethromycin",
                "designated_date": "09/09/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Advanced Life Sciences, Inc.|1440 Davey Road|Woodridge|Illinois|60517|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of plague due to Yersinia pestis",
                    "umls_id": "C0032064",
                    "parsed_text": "Plague"
                }
            },
            {
                "compound_id": 156417,
                "inchl_key": "PENDGIOBPJLVBT-AMXFZXBBSA-N",
                "generic_name": "cethromycin",
                "designated_date": "02/28/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Advanced LIfe Sciences, Inc.|1440 Davey Road|Woodridge|Illinois|60517|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of patients exposed to inhalation anthrax.",
                    "umls_id": "C0155866",
                    "parsed_text": "Inhalation anthrax"
                }
            },
            {
                "compound_id": 156417,
                "inchl_key": "PENDGIOBPJLVBT-AMXFZXBBSA-N",
                "generic_name": "cethromycin",
                "designated_date": "09/09/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Advanced Life Sciences, Inc.|1440 Davey Road|Woodridge|Illinois|60517|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of tularemia due to Francisella tularensis.",
                    "umls_id": "C0041351",
                    "parsed_text": "Tularemia"
                }
            }
        ]
    },
    {
        "_id": "PENDGIOBPJLVBT-HMMOOPTJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5282045,
                "inchl_key": "PENDGIOBPJLVBT-HMMOOPTJSA-N",
                "generic_name": "cethromycin",
                "designated_date": "09/09/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Advanced Life Sciences, Inc.|1440 Davey Road|Woodridge|Illinois|60517|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of plague due to Yersinia pestis",
                    "umls_id": "C0032064",
                    "parsed_text": "Plague"
                }
            },
            {
                "compound_id": 5282045,
                "inchl_key": "PENDGIOBPJLVBT-HMMOOPTJSA-N",
                "generic_name": "cethromycin",
                "designated_date": "02/28/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Advanced LIfe Sciences, Inc.|1440 Davey Road|Woodridge|Illinois|60517|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of patients exposed to inhalation anthrax.",
                    "umls_id": "C0155866",
                    "parsed_text": "Inhalation anthrax"
                }
            },
            {
                "compound_id": 5282045,
                "inchl_key": "PENDGIOBPJLVBT-HMMOOPTJSA-N",
                "generic_name": "cethromycin",
                "designated_date": "09/09/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Advanced Life Sciences, Inc.|1440 Davey Road|Woodridge|Illinois|60517|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of tularemia due to Francisella tularensis.",
                    "umls_id": "C0041351",
                    "parsed_text": "Tularemia"
                }
            }
        ]
    },
    {
        "_id": "PENDGIOBPJLVBT-ONLVEXIXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 447451,
                "inchl_key": "PENDGIOBPJLVBT-ONLVEXIXSA-N",
                "generic_name": "cethromycin",
                "designated_date": "09/09/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Advanced Life Sciences, Inc.|1440 Davey Road|Woodridge|Illinois|60517|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of plague due to Yersinia pestis",
                    "umls_id": "C0032064",
                    "parsed_text": "Plague"
                }
            },
            {
                "compound_id": 447451,
                "inchl_key": "PENDGIOBPJLVBT-ONLVEXIXSA-N",
                "generic_name": "cethromycin",
                "designated_date": "02/28/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Advanced LIfe Sciences, Inc.|1440 Davey Road|Woodridge|Illinois|60517|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of patients exposed to inhalation anthrax.",
                    "umls_id": "C0155866",
                    "parsed_text": "Inhalation anthrax"
                }
            },
            {
                "compound_id": 447451,
                "inchl_key": "PENDGIOBPJLVBT-ONLVEXIXSA-N",
                "generic_name": "cethromycin",
                "designated_date": "09/09/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Advanced Life Sciences, Inc.|1440 Davey Road|Woodridge|Illinois|60517|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of tularemia due to Francisella tularensis.",
                    "umls_id": "C0041351",
                    "parsed_text": "Tularemia"
                }
            }
        ]
    },
    {
        "_id": "RUDATBOHQWOJDD-BSWAIDMHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10133,
                "inchl_key": "RUDATBOHQWOJDD-BSWAIDMHSA-N",
                "generic_name": "Chenodeoxycholic acid",
                "designated_date": "01/29/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Dr. Falk Pharma GmbH|Leinenweberstrasse 5|Freiburg|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of cerebrotendinous xanthomatosis",
                    "umls_id": "C0238052",
                    "parsed_text": "CEREBROTENDINOUS XANTHOMATOSIS"
                }
            },
            {
                "compound_id": 10133,
                "inchl_key": "RUDATBOHQWOJDD-BSWAIDMHSA-N",
                "generic_name": "chenodiol",
                "designated_date": "03/22/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Travere Therapeutics, Inc.|3611 Valley Centre Drive, Suite 300|San Diego|California|92130|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cerebrotendinous xanthomatosis",
                    "umls_id": "C0238052",
                    "parsed_text": "CEREBROTENDINOUS XANTHOMATOSIS"
                }
            },
            {
                "compound_id": 10133,
                "inchl_key": "RUDATBOHQWOJDD-BSWAIDMHSA-N",
                "generic_name": "chenodeoxycholic acid",
                "designated_date": "02/12/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Leadiant Biosciences, Inc.|9841 Washingtonian Boulevard|Suite 500|Gaithersburg|Maryland|20878|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cerebrotendinous xanthomatosis",
                    "umls_id": "C0238052",
                    "parsed_text": "CEREBROTENDINOUS XANTHOMATOSIS"
                }
            },
            {
                "compound_id": 10133,
                "inchl_key": "RUDATBOHQWOJDD-BSWAIDMHSA-N",
                "generic_name": "chenodiol",
                "trade_name": "Chenix",
                "designated_date": "09/21/1984",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a007/28/1983\u00a0",
                "exclusivity_end_date": "\u00a007/28/1990\u00a0",
                "sponsor": "Solvay|901 Sawyer Road|Marietta|Georgia|30062|United States",
                "orphan_designation": {
                    "original_text": "For patients with radiolucent stones in well opacifying gallbladders, in whom elective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age",
                    "umls_id": "C0442893",
                    "parsed_text": "Systemic disease"
                }
            }
        ]
    },
    {
        "_id": "KDLRVYVGXIQJDK-BVGIQVCNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 129627692,
                "inchl_key": "KDLRVYVGXIQJDK-BVGIQVCNSA-N",
                "generic_name": "Clindamycin",
                "designated_date": "10/28/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer Inc.|235 East 42nd Street|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Prevention of Pneumocystis carinii pneumonia in AIDS patients.",
                    "umls_id": "C1535939",
                    "parsed_text": "Pneumocystis carinii Pneumonia"
                }
            },
            {
                "compound_id": 129627692,
                "inchl_key": "KDLRVYVGXIQJDK-BVGIQVCNSA-N",
                "generic_name": "Clindamycin",
                "designated_date": "10/28/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacia & Upjohn|7000 Portage Road|Unit 0633-298-113|Kalamazoo|Michigan|49001|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.",
                    "umls_id": "C0276527,C1535939",
                    "parsed_text": "Pneumonia associated with AIDS , Pneumocystis carinii Pneumonia"
                }
            }
        ]
    },
    {
        "_id": "KDLRVYVGXIQJDK-NQQGAZBYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 129009913,
                "inchl_key": "KDLRVYVGXIQJDK-NQQGAZBYSA-N",
                "generic_name": "Clindamycin",
                "designated_date": "10/28/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer Inc.|235 East 42nd Street|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Prevention of Pneumocystis carinii pneumonia in AIDS patients.",
                    "umls_id": "C1535939",
                    "parsed_text": "Pneumocystis carinii Pneumonia"
                }
            },
            {
                "compound_id": 129009913,
                "inchl_key": "KDLRVYVGXIQJDK-NQQGAZBYSA-N",
                "generic_name": "Clindamycin",
                "designated_date": "10/28/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacia & Upjohn|7000 Portage Road|Unit 0633-298-113|Kalamazoo|Michigan|49001|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.",
                    "umls_id": "C0276527,C1535939",
                    "parsed_text": "Pneumonia associated with AIDS , Pneumocystis carinii Pneumonia"
                }
            }
        ]
    },
    {
        "_id": "KDLRVYVGXIQJDK-PSUNAQLJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 53245639,
                "inchl_key": "KDLRVYVGXIQJDK-PSUNAQLJSA-N",
                "generic_name": "Clindamycin",
                "designated_date": "10/28/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer Inc.|235 East 42nd Street|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Prevention of Pneumocystis carinii pneumonia in AIDS patients.",
                    "umls_id": "C1535939",
                    "parsed_text": "Pneumocystis carinii Pneumonia"
                }
            },
            {
                "compound_id": 53245639,
                "inchl_key": "KDLRVYVGXIQJDK-PSUNAQLJSA-N",
                "generic_name": "Clindamycin",
                "designated_date": "10/28/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacia & Upjohn|7000 Portage Road|Unit 0633-298-113|Kalamazoo|Michigan|49001|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.",
                    "umls_id": "C0276527,C1535939",
                    "parsed_text": "Pneumonia associated with AIDS , Pneumocystis carinii Pneumonia"
                }
            }
        ]
    },
    {
        "_id": "KDLRVYVGXIQJDK-NKPHASNASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 46783762,
                "inchl_key": "KDLRVYVGXIQJDK-NKPHASNASA-N",
                "generic_name": "Clindamycin",
                "designated_date": "10/28/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer Inc.|235 East 42nd Street|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Prevention of Pneumocystis carinii pneumonia in AIDS patients.",
                    "umls_id": "C1535939",
                    "parsed_text": "Pneumocystis carinii Pneumonia"
                }
            },
            {
                "compound_id": 46783762,
                "inchl_key": "KDLRVYVGXIQJDK-NKPHASNASA-N",
                "generic_name": "Clindamycin",
                "designated_date": "10/28/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacia & Upjohn|7000 Portage Road|Unit 0633-298-113|Kalamazoo|Michigan|49001|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.",
                    "umls_id": "C0276527,C1535939",
                    "parsed_text": "Pneumonia associated with AIDS , Pneumocystis carinii Pneumonia"
                }
            }
        ]
    },
    {
        "_id": "KDLRVYVGXIQJDK-ZNZDIMKLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 27281318,
                "inchl_key": "KDLRVYVGXIQJDK-ZNZDIMKLSA-N",
                "generic_name": "Clindamycin",
                "designated_date": "10/28/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer Inc.|235 East 42nd Street|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Prevention of Pneumocystis carinii pneumonia in AIDS patients.",
                    "umls_id": "C1535939",
                    "parsed_text": "Pneumocystis carinii Pneumonia"
                }
            },
            {
                "compound_id": 27281318,
                "inchl_key": "KDLRVYVGXIQJDK-ZNZDIMKLSA-N",
                "generic_name": "Clindamycin",
                "designated_date": "10/28/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacia & Upjohn|7000 Portage Road|Unit 0633-298-113|Kalamazoo|Michigan|49001|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.",
                    "umls_id": "C0276527,C1535939",
                    "parsed_text": "Pneumonia associated with AIDS , Pneumocystis carinii Pneumonia"
                }
            }
        ]
    },
    {
        "_id": "KDLRVYVGXIQJDK-ZUWRKQLMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 45357041,
                "inchl_key": "KDLRVYVGXIQJDK-ZUWRKQLMSA-N",
                "generic_name": "Clindamycin",
                "designated_date": "10/28/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer Inc.|235 East 42nd Street|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Prevention of Pneumocystis carinii pneumonia in AIDS patients.",
                    "umls_id": "C1535939",
                    "parsed_text": "Pneumocystis carinii Pneumonia"
                }
            },
            {
                "compound_id": 45357041,
                "inchl_key": "KDLRVYVGXIQJDK-ZUWRKQLMSA-N",
                "generic_name": "Clindamycin",
                "designated_date": "10/28/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacia & Upjohn|7000 Portage Road|Unit 0633-298-113|Kalamazoo|Michigan|49001|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.",
                    "umls_id": "C0276527,C1535939",
                    "parsed_text": "Pneumonia associated with AIDS , Pneumocystis carinii Pneumonia"
                }
            }
        ]
    },
    {
        "_id": "KDLRVYVGXIQJDK-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2786,
                "inchl_key": "KDLRVYVGXIQJDK-UHFFFAOYSA-N",
                "generic_name": "Clindamycin",
                "designated_date": "10/28/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer Inc.|235 East 42nd Street|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Prevention of Pneumocystis carinii pneumonia in AIDS patients.",
                    "umls_id": "C1535939",
                    "parsed_text": "Pneumocystis carinii Pneumonia"
                }
            },
            {
                "compound_id": 2786,
                "inchl_key": "KDLRVYVGXIQJDK-UHFFFAOYSA-N",
                "generic_name": "Clindamycin",
                "designated_date": "10/28/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacia & Upjohn|7000 Portage Road|Unit 0633-298-113|Kalamazoo|Michigan|49001|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.",
                    "umls_id": "C0276527,C1535939",
                    "parsed_text": "Pneumonia associated with AIDS , Pneumocystis carinii Pneumonia"
                }
            }
        ]
    },
    {
        "_id": "KDLRVYVGXIQJDK-NOWPCOIGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 29029,
                "inchl_key": "KDLRVYVGXIQJDK-NOWPCOIGSA-N",
                "generic_name": "Clindamycin",
                "designated_date": "10/28/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer Inc.|235 East 42nd Street|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Prevention of Pneumocystis carinii pneumonia in AIDS patients.",
                    "umls_id": "C1535939",
                    "parsed_text": "Pneumocystis carinii Pneumonia"
                }
            },
            {
                "compound_id": 29029,
                "inchl_key": "KDLRVYVGXIQJDK-NOWPCOIGSA-N",
                "generic_name": "Clindamycin",
                "designated_date": "10/28/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacia & Upjohn|7000 Portage Road|Unit 0633-298-113|Kalamazoo|Michigan|49001|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.",
                    "umls_id": "C0276527,C1535939",
                    "parsed_text": "Pneumonia associated with AIDS , Pneumocystis carinii Pneumonia"
                }
            }
        ]
    },
    {
        "_id": "KDLRVYVGXIQJDK-AWPVFWJPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 446598,
                "inchl_key": "KDLRVYVGXIQJDK-AWPVFWJPSA-N",
                "generic_name": "Clindamycin",
                "designated_date": "10/28/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer Inc.|235 East 42nd Street|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Prevention of Pneumocystis carinii pneumonia in AIDS patients.",
                    "umls_id": "C1535939",
                    "parsed_text": "Pneumocystis carinii Pneumonia"
                }
            },
            {
                "compound_id": 446598,
                "inchl_key": "KDLRVYVGXIQJDK-AWPVFWJPSA-N",
                "generic_name": "Clindamycin",
                "designated_date": "10/28/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacia & Upjohn|7000 Portage Road|Unit 0633-298-113|Kalamazoo|Michigan|49001|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.",
                    "umls_id": "C0276527,C1535939",
                    "parsed_text": "Pneumonia associated with AIDS , Pneumocystis carinii Pneumonia"
                }
            }
        ]
    },
    {
        "_id": "ZCIGNRJZKPOIKD-CQXVEOKZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25151504,
                "inchl_key": "ZCIGNRJZKPOIKD-CQXVEOKZSA-N",
                "generic_name": "cobicistat",
                "trade_name": "Tybost",
                "designated_date": "06/15/2017",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "TYBOST is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection in pediatric patients weighing at least 35 kg coadminstered with atazanavir or weighing at least 40 kg coadministered with darunavir.",
                "marketing_approval_date": "\u00a010/03/2019\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients",
                    "umls_id": "C0009450,C0019704",
                    "parsed_text": "Infection , Human immunodeficiency virus type 1"
                }
            },
            {
                "compound_id": 25151504,
                "inchl_key": "ZCIGNRJZKPOIKD-CQXVEOKZSA-N",
                "generic_name": "cobicistat",
                "trade_name": "Tybost",
                "designated_date": "06/15/2017",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "TYBOST is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir in combination with other antiretroviral agents in the treatment of HIV-1 infection in pediatric patients weighing at least 35 kg",
                "marketing_approval_date": "\u00a008/22/2019\u00a0",
                "exclusivity_end_date": "\u00a008/22/2026\u00a0",
                "exclusivity_protected_indication": "Indicated to increase systemic exposure of atazanavir in combination with other antiretroviral agents in the treatment of HIV-1 infection in pediatric patients weighing at least 35 kg.",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients",
                    "umls_id": "C0009450,C0019704",
                    "parsed_text": "Infection , Human immunodeficiency virus type 1"
                }
            }
        ]
    },
    {
        "_id": "MTSXPVSZJVNPBE-OCOINPOZSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 16218873,
                "inchl_key": "MTSXPVSZJVNPBE-OCOINPOZSA-M",
                "generic_name": "corifungin",
                "designated_date": "07/06/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sandler Center for Drug Discovery|University of CA, San Francisco|1700 4th Street|San Francisco|California|94158|United States",
                "orphan_designation": {
                    "original_text": "Treatment of visceral leishmaniasis",
                    "umls_id": "C0023290",
                    "parsed_text": "Visceral leishmaniasis"
                }
            },
            {
                "compound_id": 16218873,
                "inchl_key": "MTSXPVSZJVNPBE-OCOINPOZSA-M",
                "generic_name": "corifungin",
                "designated_date": "08/22/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ctr for Discovery & Innovation in Parasitic Diseas|University of CA, San Francisco|Byers Hall Room 508B, QB3|San Francisco|California|94158|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amebic meningoencephalitis.",
                    "umls_id": "C0487784",
                    "parsed_text": "Amebic Meningoencephalitis"
                }
            }
        ]
    },
    {
        "_id": "VLARUOGDXDTHEH-UHFFFAOYSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 27503,
                "inchl_key": "VLARUOGDXDTHEH-UHFFFAOYSA-L",
                "generic_name": "Cromolyn sodium",
                "trade_name": "Gastrocrom",
                "designated_date": "03/08/1984",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a012/22/1989\u00a0",
                "exclusivity_end_date": "\u00a012/22/1996\u00a0",
                "sponsor": "Fisons Corporation|755 Jefferson Rd., P.O. Box 1710|Rochester|New York|14603|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mastocytosis.",
                    "umls_id": "C0024899",
                    "parsed_text": "Mastocytosis"
                }
            }
        ]
    },
    {
        "_id": "PMATZTZNYRCHOR-RNWFWJGASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 138107778,
                "inchl_key": "PMATZTZNYRCHOR-RNWFWJGASA-N",
                "generic_name": "Cyclosporine A",
                "designated_date": "05/04/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|Batiment Genavenir IV|F-91058-Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Treatment of vernal keratoconjunctivitis",
                    "umls_id": "C0022577",
                    "parsed_text": "Vernal keratoconjunctivitis"
                }
            },
            {
                "compound_id": 138107778,
                "inchl_key": "PMATZTZNYRCHOR-RNWFWJGASA-N",
                "generic_name": "cyclosporine A",
                "designated_date": "09/30/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|Batiment Genavenir IV|F-91058-Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Prevention of corneal graft rejection",
                    "umls_id": "C0339303",
                    "parsed_text": "Corneal graft rejection"
                }
            },
            {
                "compound_id": 138107778,
                "inchl_key": "PMATZTZNYRCHOR-RNWFWJGASA-N",
                "generic_name": "cyclosporine A",
                "designated_date": "04/09/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|1 rue Pierre Fontaine|91058 Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Treatment of herpes simplex virus stromal keratitis",
                    "umls_id": "C0319157,C1318020",
                    "parsed_text": "virus , Stromal keratitis"
                }
            }
        ]
    },
    {
        "_id": "PMATZTZNYRCHOR-RYZPDLMBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 123134270,
                "inchl_key": "PMATZTZNYRCHOR-RYZPDLMBSA-N",
                "generic_name": "Cyclosporine A",
                "designated_date": "05/04/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|Batiment Genavenir IV|F-91058-Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Treatment of vernal keratoconjunctivitis",
                    "umls_id": "C0022577",
                    "parsed_text": "Vernal keratoconjunctivitis"
                }
            },
            {
                "compound_id": 123134270,
                "inchl_key": "PMATZTZNYRCHOR-RYZPDLMBSA-N",
                "generic_name": "cyclosporine A",
                "designated_date": "09/30/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|Batiment Genavenir IV|F-91058-Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Prevention of corneal graft rejection",
                    "umls_id": "C0339303",
                    "parsed_text": "Corneal graft rejection"
                }
            },
            {
                "compound_id": 123134270,
                "inchl_key": "PMATZTZNYRCHOR-RYZPDLMBSA-N",
                "generic_name": "cyclosporine A",
                "designated_date": "04/09/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|1 rue Pierre Fontaine|91058 Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Treatment of herpes simplex virus stromal keratitis",
                    "umls_id": "C0319157,C1318020",
                    "parsed_text": "virus , Stromal keratitis"
                }
            }
        ]
    },
    {
        "_id": "PMATZTZNYRCHOR-NFOUMSERSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16404350,
                "inchl_key": "PMATZTZNYRCHOR-NFOUMSERSA-N",
                "generic_name": "Cyclosporine A",
                "designated_date": "05/04/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|Batiment Genavenir IV|F-91058-Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Treatment of vernal keratoconjunctivitis",
                    "umls_id": "C0022577",
                    "parsed_text": "Vernal keratoconjunctivitis"
                }
            },
            {
                "compound_id": 16404350,
                "inchl_key": "PMATZTZNYRCHOR-NFOUMSERSA-N",
                "generic_name": "Cyclosporin A",
                "designated_date": "10/29/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Maas Biolab,LLC|Tecnology Ventures Corporation Technopolis|1155 University Blvd., SE|Albuquerque|New Mexico|87106|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis and its variants",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            },
            {
                "compound_id": 16404350,
                "inchl_key": "PMATZTZNYRCHOR-NFOUMSERSA-N",
                "generic_name": "cyclosporine A",
                "designated_date": "09/30/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|Batiment Genavenir IV|F-91058-Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Prevention of corneal graft rejection",
                    "umls_id": "C0339303",
                    "parsed_text": "Corneal graft rejection"
                }
            },
            {
                "compound_id": 16404350,
                "inchl_key": "PMATZTZNYRCHOR-NFOUMSERSA-N",
                "generic_name": "cyclosporine A",
                "designated_date": "04/09/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|1 rue Pierre Fontaine|91058 Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Treatment of herpes simplex virus stromal keratitis",
                    "umls_id": "C0319157,C1318020",
                    "parsed_text": "virus , Stromal keratitis"
                }
            }
        ]
    },
    {
        "_id": "PMATZTZNYRCHOR-QVSDIVLPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5497195,
                "inchl_key": "PMATZTZNYRCHOR-QVSDIVLPSA-N",
                "generic_name": "Cyclosporine A",
                "designated_date": "05/04/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|Batiment Genavenir IV|F-91058-Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Treatment of vernal keratoconjunctivitis",
                    "umls_id": "C0022577",
                    "parsed_text": "Vernal keratoconjunctivitis"
                }
            },
            {
                "compound_id": 5497195,
                "inchl_key": "PMATZTZNYRCHOR-QVSDIVLPSA-N",
                "generic_name": "Cyclosporine",
                "designated_date": "11/25/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "APT Pharmaceuticals, Inc.|700 Airport Blvd.|Suite 350|Burlingame|California|94010|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of organ rejection in patients receiving allogeneic lung transplant",
                    "umls_id": "C0815080",
                    "parsed_text": "organ rejection"
                }
            },
            {
                "compound_id": 5497195,
                "inchl_key": "PMATZTZNYRCHOR-QVSDIVLPSA-N",
                "generic_name": "cyclosporine",
                "designated_date": "02/17/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sigmoid Pharma Limited|Dublin City University|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Prophylaxis of graft-versus-host disease",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 5497195,
                "inchl_key": "PMATZTZNYRCHOR-QVSDIVLPSA-N",
                "generic_name": "Cyclosporin A",
                "designated_date": "10/29/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Maas Biolab,LLC|Tecnology Ventures Corporation Technopolis|1155 University Blvd., SE|Albuquerque|New Mexico|87106|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis and its variants",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            },
            {
                "compound_id": 5497195,
                "inchl_key": "PMATZTZNYRCHOR-QVSDIVLPSA-N",
                "generic_name": "cyclosporine A",
                "designated_date": "09/30/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|Batiment Genavenir IV|F-91058-Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Prevention of corneal graft rejection",
                    "umls_id": "C0339303",
                    "parsed_text": "Corneal graft rejection"
                }
            },
            {
                "compound_id": 5497195,
                "inchl_key": "PMATZTZNYRCHOR-QVSDIVLPSA-N",
                "generic_name": "cyclosporine",
                "designated_date": "02/17/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sigmoid Pharma Limited|Dublin City University|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Treatment of graft-versus-host disease",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 5497195,
                "inchl_key": "PMATZTZNYRCHOR-QVSDIVLPSA-N",
                "generic_name": "Cyclosporine",
                "designated_date": "11/25/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "APT Pharmaceuticals, Inc.|700 Airport Blvd.|Suite 350|Burlingame|California|94010|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute rejection in patients requiring allogenic lung transplants",
                    "umls_id": "C3273245",
                    "parsed_text": "Acute Rejection"
                }
            },
            {
                "compound_id": 5497195,
                "inchl_key": "PMATZTZNYRCHOR-QVSDIVLPSA-N",
                "generic_name": "cyclosporine A",
                "designated_date": "04/09/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|1 rue Pierre Fontaine|91058 Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Treatment of herpes simplex virus stromal keratitis",
                    "umls_id": "C0319157,C1318020",
                    "parsed_text": "virus , Stromal keratitis"
                }
            }
        ]
    },
    {
        "_id": "PMATZTZNYRCHOR-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2909,
                "inchl_key": "PMATZTZNYRCHOR-UHFFFAOYSA-N",
                "generic_name": "Cyclosporine A",
                "designated_date": "05/04/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|Batiment Genavenir IV|F-91058-Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Treatment of vernal keratoconjunctivitis",
                    "umls_id": "C0022577",
                    "parsed_text": "Vernal keratoconjunctivitis"
                }
            },
            {
                "compound_id": 2909,
                "inchl_key": "PMATZTZNYRCHOR-UHFFFAOYSA-N",
                "generic_name": "Cyclosporin A",
                "designated_date": "10/29/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Maas Biolab,LLC|Tecnology Ventures Corporation Technopolis|1155 University Blvd., SE|Albuquerque|New Mexico|87106|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis and its variants",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            },
            {
                "compound_id": 2909,
                "inchl_key": "PMATZTZNYRCHOR-UHFFFAOYSA-N",
                "generic_name": "cyclosporine A",
                "designated_date": "09/30/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|Batiment Genavenir IV|F-91058-Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Prevention of corneal graft rejection",
                    "umls_id": "C0339303",
                    "parsed_text": "Corneal graft rejection"
                }
            },
            {
                "compound_id": 2909,
                "inchl_key": "PMATZTZNYRCHOR-UHFFFAOYSA-N",
                "generic_name": "cyclosporine A",
                "designated_date": "04/09/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|1 rue Pierre Fontaine|91058 Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Treatment of herpes simplex virus stromal keratitis",
                    "umls_id": "C0319157,C1318020",
                    "parsed_text": "virus , Stromal keratitis"
                }
            }
        ]
    },
    {
        "_id": "PMATZTZNYRCHOR-NSJDOISKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71463825,
                "inchl_key": "PMATZTZNYRCHOR-NSJDOISKSA-N",
                "generic_name": "Cyclosporine A",
                "designated_date": "05/04/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|Batiment Genavenir IV|F-91058-Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Treatment of vernal keratoconjunctivitis",
                    "umls_id": "C0022577",
                    "parsed_text": "Vernal keratoconjunctivitis"
                }
            },
            {
                "compound_id": 71463825,
                "inchl_key": "PMATZTZNYRCHOR-NSJDOISKSA-N",
                "generic_name": "cyclosporine A",
                "designated_date": "09/30/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|Batiment Genavenir IV|F-91058-Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Prevention of corneal graft rejection",
                    "umls_id": "C0339303",
                    "parsed_text": "Corneal graft rejection"
                }
            },
            {
                "compound_id": 71463825,
                "inchl_key": "PMATZTZNYRCHOR-NSJDOISKSA-N",
                "generic_name": "cyclosporine A",
                "designated_date": "04/09/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|1 rue Pierre Fontaine|91058 Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Treatment of herpes simplex virus stromal keratitis",
                    "umls_id": "C0319157,C1318020",
                    "parsed_text": "virus , Stromal keratitis"
                }
            }
        ]
    },
    {
        "_id": "PMATZTZNYRCHOR-VPYFBNRVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 49867938,
                "inchl_key": "PMATZTZNYRCHOR-VPYFBNRVSA-N",
                "generic_name": "Cyclosporine A",
                "designated_date": "05/04/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|Batiment Genavenir IV|F-91058-Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Treatment of vernal keratoconjunctivitis",
                    "umls_id": "C0022577",
                    "parsed_text": "Vernal keratoconjunctivitis"
                }
            },
            {
                "compound_id": 49867938,
                "inchl_key": "PMATZTZNYRCHOR-VPYFBNRVSA-N",
                "generic_name": "Cyclosporin A",
                "designated_date": "10/29/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Maas Biolab,LLC|Tecnology Ventures Corporation Technopolis|1155 University Blvd., SE|Albuquerque|New Mexico|87106|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis and its variants",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            },
            {
                "compound_id": 49867938,
                "inchl_key": "PMATZTZNYRCHOR-VPYFBNRVSA-N",
                "generic_name": "cyclosporine A",
                "designated_date": "09/30/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|Batiment Genavenir IV|F-91058-Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Prevention of corneal graft rejection",
                    "umls_id": "C0339303",
                    "parsed_text": "Corneal graft rejection"
                }
            },
            {
                "compound_id": 49867938,
                "inchl_key": "PMATZTZNYRCHOR-VPYFBNRVSA-N",
                "generic_name": "cyclosporine A",
                "designated_date": "04/09/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|1 rue Pierre Fontaine|91058 Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Treatment of herpes simplex virus stromal keratitis",
                    "umls_id": "C0319157,C1318020",
                    "parsed_text": "virus , Stromal keratitis"
                }
            }
        ]
    },
    {
        "_id": "PMATZTZNYRCHOR-IMVLJIQESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5280754,
                "inchl_key": "PMATZTZNYRCHOR-IMVLJIQESA-N",
                "generic_name": "Cyclosporine A",
                "designated_date": "05/04/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|Batiment Genavenir IV|F-91058-Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Treatment of vernal keratoconjunctivitis",
                    "umls_id": "C0022577",
                    "parsed_text": "Vernal keratoconjunctivitis"
                }
            },
            {
                "compound_id": 5280754,
                "inchl_key": "PMATZTZNYRCHOR-IMVLJIQESA-N",
                "generic_name": "Cyclosporine",
                "designated_date": "11/25/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "APT Pharmaceuticals, Inc.|700 Airport Blvd.|Suite 350|Burlingame|California|94010|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of organ rejection in patients receiving allogeneic lung transplant",
                    "umls_id": "C0815080",
                    "parsed_text": "organ rejection"
                }
            },
            {
                "compound_id": 5280754,
                "inchl_key": "PMATZTZNYRCHOR-IMVLJIQESA-N",
                "generic_name": "cyclosporine",
                "designated_date": "02/17/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sigmoid Pharma Limited|Dublin City University|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Prophylaxis of graft-versus-host disease",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 5280754,
                "inchl_key": "PMATZTZNYRCHOR-IMVLJIQESA-N",
                "generic_name": "Cyclosporin A",
                "designated_date": "10/29/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Maas Biolab,LLC|Tecnology Ventures Corporation Technopolis|1155 University Blvd., SE|Albuquerque|New Mexico|87106|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis and its variants",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            },
            {
                "compound_id": 5280754,
                "inchl_key": "PMATZTZNYRCHOR-IMVLJIQESA-N",
                "generic_name": "cyclosporine A",
                "designated_date": "09/30/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|Batiment Genavenir IV|F-91058-Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Prevention of corneal graft rejection",
                    "umls_id": "C0339303",
                    "parsed_text": "Corneal graft rejection"
                }
            },
            {
                "compound_id": 5280754,
                "inchl_key": "PMATZTZNYRCHOR-IMVLJIQESA-N",
                "generic_name": "cyclosporine",
                "designated_date": "02/17/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sigmoid Pharma Limited|Dublin City University|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Treatment of graft-versus-host disease",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 5280754,
                "inchl_key": "PMATZTZNYRCHOR-IMVLJIQESA-N",
                "generic_name": "Cyclosporine",
                "designated_date": "11/25/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "APT Pharmaceuticals, Inc.|700 Airport Blvd.|Suite 350|Burlingame|California|94010|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute rejection in patients requiring allogenic lung transplants",
                    "umls_id": "C3273245",
                    "parsed_text": "Acute Rejection"
                }
            },
            {
                "compound_id": 5280754,
                "inchl_key": "PMATZTZNYRCHOR-IMVLJIQESA-N",
                "generic_name": "cyclosporine A",
                "designated_date": "04/09/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|1 rue Pierre Fontaine|91058 Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Treatment of herpes simplex virus stromal keratitis",
                    "umls_id": "C0319157,C1318020",
                    "parsed_text": "virus , Stromal keratitis"
                }
            }
        ]
    },
    {
        "_id": "PMATZTZNYRCHOR-CGLBZJNRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5284373,
                "inchl_key": "PMATZTZNYRCHOR-CGLBZJNRSA-N",
                "generic_name": "Cyclosporine A",
                "designated_date": "05/04/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|Batiment Genavenir IV|F-91058-Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Treatment of vernal keratoconjunctivitis",
                    "umls_id": "C0022577",
                    "parsed_text": "Vernal keratoconjunctivitis"
                }
            },
            {
                "compound_id": 5284373,
                "inchl_key": "PMATZTZNYRCHOR-CGLBZJNRSA-N",
                "generic_name": "Cyclosporine",
                "designated_date": "11/25/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "APT Pharmaceuticals, Inc.|700 Airport Blvd.|Suite 350|Burlingame|California|94010|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of organ rejection in patients receiving allogeneic lung transplant",
                    "umls_id": "C0815080",
                    "parsed_text": "organ rejection"
                }
            },
            {
                "compound_id": 5284373,
                "inchl_key": "PMATZTZNYRCHOR-CGLBZJNRSA-N",
                "generic_name": "cyclosporine",
                "designated_date": "02/17/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sigmoid Pharma Limited|Dublin City University|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Prophylaxis of graft-versus-host disease",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 5284373,
                "inchl_key": "PMATZTZNYRCHOR-CGLBZJNRSA-N",
                "generic_name": "Cyclosporin A",
                "designated_date": "10/29/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Maas Biolab,LLC|Tecnology Ventures Corporation Technopolis|1155 University Blvd., SE|Albuquerque|New Mexico|87106|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis and its variants",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            },
            {
                "compound_id": 5284373,
                "inchl_key": "PMATZTZNYRCHOR-CGLBZJNRSA-N",
                "generic_name": "cyclosporine A",
                "designated_date": "09/30/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|Batiment Genavenir IV|F-91058-Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Prevention of corneal graft rejection",
                    "umls_id": "C0339303",
                    "parsed_text": "Corneal graft rejection"
                }
            },
            {
                "compound_id": 5284373,
                "inchl_key": "PMATZTZNYRCHOR-CGLBZJNRSA-N",
                "generic_name": "cyclosporine",
                "designated_date": "02/17/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sigmoid Pharma Limited|Dublin City University|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Treatment of graft-versus-host disease",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 5284373,
                "inchl_key": "PMATZTZNYRCHOR-CGLBZJNRSA-N",
                "generic_name": "Cyclosporine",
                "designated_date": "11/25/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "APT Pharmaceuticals, Inc.|700 Airport Blvd.|Suite 350|Burlingame|California|94010|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute rejection in patients requiring allogenic lung transplants",
                    "umls_id": "C3273245",
                    "parsed_text": "Acute Rejection"
                }
            },
            {
                "compound_id": 5284373,
                "inchl_key": "PMATZTZNYRCHOR-CGLBZJNRSA-N",
                "generic_name": "cyclosporine A",
                "designated_date": "04/09/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santen SAS|1 rue Pierre Fontaine|91058 Evry cedex|France",
                "orphan_designation": {
                    "original_text": "Treatment of herpes simplex virus stromal keratitis",
                    "umls_id": "C0319157,C1318020",
                    "parsed_text": "virus , Stromal keratitis"
                }
            }
        ]
    },
    {
        "_id": "UFULAYFCSOUIOV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6058,
                "inchl_key": "UFULAYFCSOUIOV-UHFFFAOYSA-N",
                "generic_name": "Cysteamine",
                "designated_date": "05/01/1986",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Thoene, Jess G., M.D.|University of Michigan Medical School|300 NIB, 1192 SE|Ann Arbor|Michigan|48109|United States",
                "orphan_designation": {
                    "original_text": "Treatment of nephropathic cystinosis.",
                    "umls_id": "C0015624",
                    "parsed_text": "Nephropathic cystinosis"
                }
            },
            {
                "compound_id": 6058,
                "inchl_key": "UFULAYFCSOUIOV-UHFFFAOYSA-N",
                "generic_name": "Cysteamine",
                "trade_name": "Cystagon",
                "designated_date": "01/25/1991",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of nephropathic cystinosis in adults and children.",
                "marketing_approval_date": "\u00a008/15/1994\u00a0",
                "exclusivity_end_date": "\u00a008/15/2001\u00a0",
                "sponsor": "Mylan Laboratories, Inc.|781 Chestnut Ridge Road|P.O. Box 4310|Morgantown|West Virginia|26504|United States",
                "orphan_designation": {
                    "original_text": "Treatment of nephropathic cystinosis.",
                    "umls_id": "C0015624",
                    "parsed_text": "Nephropathic cystinosis"
                }
            },
            {
                "compound_id": 6058,
                "inchl_key": "UFULAYFCSOUIOV-UHFFFAOYSA-N",
                "generic_name": "cysteamine",
                "designated_date": "09/11/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Horizon Therapeutics USA, Inc.|150 S. Saunders Road|Lake Forest|Illinois|60045|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 6058,
                "inchl_key": "UFULAYFCSOUIOV-UHFFFAOYSA-N",
                "generic_name": "Cysteamine",
                "designated_date": "09/11/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NovaBiotics Ltd.|Cruickshank Building|Craibstone|Aberdeen|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            },
            {
                "compound_id": 6058,
                "inchl_key": "UFULAYFCSOUIOV-UHFFFAOYSA-N",
                "generic_name": "cysteamine",
                "designated_date": "08/06/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Raptor Pharmaceuticals, Inc.|9 Commercial Blvd.|Suite 200|Novato|California|94949|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuronal ceroid lipofuscinoses (Batten disease)",
                    "umls_id": "C0027877,C0751383",
                    "parsed_text": "neuronal ceroid lipofuscinoses , Batten Disease"
                }
            },
            {
                "compound_id": 6058,
                "inchl_key": "UFULAYFCSOUIOV-UHFFFAOYSA-N",
                "generic_name": "cysteamine",
                "designated_date": "05/09/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Horizon Therapeutics USA, Inc.|150 S. Saunders Road|Suite 100|Lake Forest|Illinois|60045|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Huntington's disease",
                    "umls_id": "C0020179",
                    "parsed_text": "Huntington's Disease"
                }
            }
        ]
    },
    {
        "_id": "WQZGKKKJIJFFOK-QTVWNMPRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 18950,
                "inchl_key": "WQZGKKKJIJFFOK-QTVWNMPRSA-N",
                "generic_name": "D-mannose",
                "designated_date": "01/14/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cerecor Inc.|1500 Liberty Ridge Drive|Suite 321|Wayne|Pennsylvania|19087|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Mannose Phosphate Isomerase Deficiency",
                    "umls_id": "C1291601,C1417244",
                    "parsed_text": "isomerase deficiency , mannose phosphate isomerase"
                }
            }
        ]
    },
    {
        "_id": "BFSMGDJOXZAERB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44462760,
                "inchl_key": "BFSMGDJOXZAERB-UHFFFAOYSA-N",
                "generic_name": "dabrafenib",
                "designated_date": "10/20/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|1 Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with BRAF mutation positive non-small cell lung cancer",
                    "umls_id": "C3539721",
                    "parsed_text": "Non-Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 44462760,
                "inchl_key": "BFSMGDJOXZAERB-UHFFFAOYSA-N",
                "generic_name": "dabrafenib",
                "designated_date": "02/08/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|1 Health Plaza|Bldg 337|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma with BRAF V600 mutation",
                    "umls_id": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            },
            {
                "compound_id": 44462760,
                "inchl_key": "BFSMGDJOXZAERB-UHFFFAOYSA-N",
                "generic_name": "dabrafenib",
                "trade_name": "TAFINLAR",
                "designated_date": "01/12/2011",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA approved test.",
                "marketing_approval_date": "\u00a005/29/2013\u00a0",
                "exclusivity_end_date": "\u00a005/29/2020\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA approved test.",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment BRAF V600 mutation positive Stage IIB through IV melanoma",
                    "umls_id": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "KSRLIXGNPXAZHD-DFPPEFKWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 136675526,
                "inchl_key": "KSRLIXGNPXAZHD-DFPPEFKWSA-N",
                "generic_name": "Dantrolene sodium",
                "designated_date": "12/14/1987",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Norwich Eaton Pharmaceuticals|P.O. Box 191|Norwich|New York|13815|United States",
                "orphan_designation": {
                    "original_text": "Treatment of the neuroleptic malignant syndrome.",
                    "umls_id": "C0027849",
                    "parsed_text": "Neuroleptic Malignant Syndrome"
                }
            },
            {
                "compound_id": 136675526,
                "inchl_key": "KSRLIXGNPXAZHD-DFPPEFKWSA-N",
                "generic_name": "Dantrolene sodium",
                "designated_date": "12/14/1987",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Norwich Eaton Pharmaceuticals|P.O. Box 191|Norwich|New York|13815|United States",
                "orphan_designation": {
                    "original_text": "Treatment of the neuroleptic malignant syndrome.",
                    "umls_id": "C0027849",
                    "parsed_text": "Neuroleptic Malignant Syndrome"
                }
            },
            {
                "compound_id": 136675526,
                "inchl_key": "KSRLIXGNPXAZHD-DFPPEFKWSA-N",
                "generic_name": "dantrolene sodium",
                "designated_date": "09/25/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eagle Pharmaceuticals, Inc.|50 Tice Blvd|Suite 315|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of heat stroke",
                    "umls_id": "C0038819",
                    "parsed_text": "Heat Stroke"
                }
            },
            {
                "compound_id": 136675526,
                "inchl_key": "KSRLIXGNPXAZHD-DFPPEFKWSA-N",
                "generic_name": "dantrolene sodium",
                "designated_date": "09/25/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eagle Pharmaceuticals, Inc.|50 Tice Blvd|Suite 315|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of heat stroke",
                    "umls_id": "C0038819",
                    "parsed_text": "Heat Stroke"
                }
            },
            {
                "compound_id": 136675526,
                "inchl_key": "KSRLIXGNPXAZHD-DFPPEFKWSA-N",
                "generic_name": "dantrolene sodium",
                "designated_date": "02/17/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Washington University in St. Louis|660 S. Euclid Avenue|Campus Box 8127|St. Louis|Missouri|63110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wolfram Syndrome",
                    "umls_id": "C0043207",
                    "parsed_text": "Wolfram Syndrome"
                }
            },
            {
                "compound_id": 136675526,
                "inchl_key": "KSRLIXGNPXAZHD-DFPPEFKWSA-N",
                "generic_name": "dantrolene sodium",
                "designated_date": "02/17/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Washington University in St. Louis|660 S. Euclid Avenue|Campus Box 8127|St. Louis|Missouri|63110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wolfram Syndrome",
                    "umls_id": "C0043207",
                    "parsed_text": "Wolfram Syndrome"
                }
            }
        ]
    },
    {
        "_id": "KSRLIXGNPXAZHD-DFPPEFKWSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 71563341,
                "inchl_key": "KSRLIXGNPXAZHD-DFPPEFKWSA-M",
                "generic_name": "Dantrolene sodium",
                "designated_date": "12/14/1987",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Norwich Eaton Pharmaceuticals|P.O. Box 191|Norwich|New York|13815|United States",
                "orphan_designation": {
                    "original_text": "Treatment of the neuroleptic malignant syndrome.",
                    "umls_id": "C0027849",
                    "parsed_text": "Neuroleptic Malignant Syndrome"
                }
            },
            {
                "compound_id": 71563341,
                "inchl_key": "KSRLIXGNPXAZHD-DFPPEFKWSA-M",
                "generic_name": "Dantrolene sodium",
                "designated_date": "12/14/1987",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Norwich Eaton Pharmaceuticals|P.O. Box 191|Norwich|New York|13815|United States",
                "orphan_designation": {
                    "original_text": "Treatment of the neuroleptic malignant syndrome.",
                    "umls_id": "C0027849",
                    "parsed_text": "Neuroleptic Malignant Syndrome"
                }
            },
            {
                "compound_id": 71563341,
                "inchl_key": "KSRLIXGNPXAZHD-DFPPEFKWSA-M",
                "generic_name": "dantrolene sodium",
                "designated_date": "09/25/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eagle Pharmaceuticals, Inc.|50 Tice Blvd|Suite 315|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of heat stroke",
                    "umls_id": "C0038819",
                    "parsed_text": "Heat Stroke"
                }
            },
            {
                "compound_id": 71563341,
                "inchl_key": "KSRLIXGNPXAZHD-DFPPEFKWSA-M",
                "generic_name": "dantrolene sodium",
                "designated_date": "09/25/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eagle Pharmaceuticals, Inc.|50 Tice Blvd|Suite 315|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of heat stroke",
                    "umls_id": "C0038819",
                    "parsed_text": "Heat Stroke"
                }
            },
            {
                "compound_id": 71563341,
                "inchl_key": "KSRLIXGNPXAZHD-DFPPEFKWSA-M",
                "generic_name": "dantrolene sodium",
                "designated_date": "02/17/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Washington University in St. Louis|660 S. Euclid Avenue|Campus Box 8127|St. Louis|Missouri|63110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wolfram Syndrome",
                    "umls_id": "C0043207",
                    "parsed_text": "Wolfram Syndrome"
                }
            },
            {
                "compound_id": 71563341,
                "inchl_key": "KSRLIXGNPXAZHD-DFPPEFKWSA-M",
                "generic_name": "dantrolene sodium",
                "designated_date": "02/17/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Washington University in St. Louis|660 S. Euclid Avenue|Campus Box 8127|St. Louis|Missouri|63110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wolfram Syndrome",
                    "umls_id": "C0043207",
                    "parsed_text": "Wolfram Syndrome"
                }
            }
        ]
    },
    {
        "_id": "OZOMQRBLCMDCEG-CHHVJCJISA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 5353563,
                "inchl_key": "OZOMQRBLCMDCEG-CHHVJCJISA-M",
                "generic_name": "Dantrolene sodium",
                "designated_date": "12/14/1987",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Norwich Eaton Pharmaceuticals|P.O. Box 191|Norwich|New York|13815|United States",
                "orphan_designation": {
                    "original_text": "Treatment of the neuroleptic malignant syndrome.",
                    "umls_id": "C0027849",
                    "parsed_text": "Neuroleptic Malignant Syndrome"
                }
            },
            {
                "compound_id": 5353563,
                "inchl_key": "OZOMQRBLCMDCEG-CHHVJCJISA-M",
                "generic_name": "dantrolene sodium",
                "designated_date": "09/25/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eagle Pharmaceuticals, Inc.|50 Tice Blvd|Suite 315|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of heat stroke",
                    "umls_id": "C0038819",
                    "parsed_text": "Heat Stroke"
                }
            },
            {
                "compound_id": 5353563,
                "inchl_key": "OZOMQRBLCMDCEG-CHHVJCJISA-M",
                "generic_name": "dantrolene sodium",
                "designated_date": "02/17/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Washington University in St. Louis|660 S. Euclid Avenue|Campus Box 8127|St. Louis|Missouri|63110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wolfram Syndrome",
                    "umls_id": "C0043207",
                    "parsed_text": "Wolfram Syndrome"
                }
            }
        ]
    },
    {
        "_id": "OZOMQRBLCMDCEG-VIZOYTHASA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 6604728,
                "inchl_key": "OZOMQRBLCMDCEG-VIZOYTHASA-M",
                "generic_name": "Dantrolene sodium",
                "designated_date": "12/14/1987",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Norwich Eaton Pharmaceuticals|P.O. Box 191|Norwich|New York|13815|United States",
                "orphan_designation": {
                    "original_text": "Treatment of the neuroleptic malignant syndrome.",
                    "umls_id": "C0027849",
                    "parsed_text": "Neuroleptic Malignant Syndrome"
                }
            },
            {
                "compound_id": 6604728,
                "inchl_key": "OZOMQRBLCMDCEG-VIZOYTHASA-M",
                "generic_name": "dantrolene sodium",
                "designated_date": "09/25/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eagle Pharmaceuticals, Inc.|50 Tice Blvd|Suite 315|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of heat stroke",
                    "umls_id": "C0038819",
                    "parsed_text": "Heat Stroke"
                }
            },
            {
                "compound_id": 6604728,
                "inchl_key": "OZOMQRBLCMDCEG-VIZOYTHASA-M",
                "generic_name": "dantrolene sodium",
                "designated_date": "02/17/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Washington University in St. Louis|660 S. Euclid Avenue|Campus Box 8127|St. Louis|Missouri|63110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wolfram Syndrome",
                    "umls_id": "C0043207",
                    "parsed_text": "Wolfram Syndrome"
                }
            }
        ]
    },
    {
        "_id": "KSRLIXGNPXAZHD-HAZZGOGXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 23707296,
                "inchl_key": "KSRLIXGNPXAZHD-HAZZGOGXSA-N",
                "generic_name": "Dantrolene sodium",
                "designated_date": "12/14/1987",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Norwich Eaton Pharmaceuticals|P.O. Box 191|Norwich|New York|13815|United States",
                "orphan_designation": {
                    "original_text": "Treatment of the neuroleptic malignant syndrome.",
                    "umls_id": "C0027849",
                    "parsed_text": "Neuroleptic Malignant Syndrome"
                }
            },
            {
                "compound_id": 23707296,
                "inchl_key": "KSRLIXGNPXAZHD-HAZZGOGXSA-N",
                "generic_name": "dantrolene sodium",
                "designated_date": "09/25/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eagle Pharmaceuticals, Inc.|50 Tice Blvd|Suite 315|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of heat stroke",
                    "umls_id": "C0038819",
                    "parsed_text": "Heat Stroke"
                }
            },
            {
                "compound_id": 23707296,
                "inchl_key": "KSRLIXGNPXAZHD-HAZZGOGXSA-N",
                "generic_name": "dantrolene sodium",
                "designated_date": "02/17/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Washington University in St. Louis|660 S. Euclid Avenue|Campus Box 8127|St. Louis|Missouri|63110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wolfram Syndrome",
                    "umls_id": "C0043207",
                    "parsed_text": "Wolfram Syndrome"
                }
            }
        ]
    },
    {
        "_id": "BDZCLIOURDFSFQ-HAZZGOGXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16219293,
                "inchl_key": "BDZCLIOURDFSFQ-HAZZGOGXSA-N",
                "generic_name": "Dantrolene sodium",
                "designated_date": "12/14/1987",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Norwich Eaton Pharmaceuticals|P.O. Box 191|Norwich|New York|13815|United States",
                "orphan_designation": {
                    "original_text": "Treatment of the neuroleptic malignant syndrome.",
                    "umls_id": "C0027849",
                    "parsed_text": "Neuroleptic Malignant Syndrome"
                }
            },
            {
                "compound_id": 16219293,
                "inchl_key": "BDZCLIOURDFSFQ-HAZZGOGXSA-N",
                "generic_name": "dantrolene sodium",
                "designated_date": "09/25/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eagle Pharmaceuticals, Inc.|50 Tice Blvd|Suite 315|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of heat stroke",
                    "umls_id": "C0038819",
                    "parsed_text": "Heat Stroke"
                }
            },
            {
                "compound_id": 16219293,
                "inchl_key": "BDZCLIOURDFSFQ-HAZZGOGXSA-N",
                "generic_name": "dantrolene sodium",
                "designated_date": "02/17/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Washington University in St. Louis|660 S. Euclid Avenue|Campus Box 8127|St. Louis|Missouri|63110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wolfram Syndrome",
                    "umls_id": "C0043207",
                    "parsed_text": "Wolfram Syndrome"
                }
            }
        ]
    },
    {
        "_id": "LTWQNYPDAUSXBC-CDJGKPBYSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 9568637,
                "inchl_key": "LTWQNYPDAUSXBC-CDJGKPBYSA-L",
                "generic_name": "Dantrolene sodium",
                "designated_date": "12/14/1987",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Norwich Eaton Pharmaceuticals|P.O. Box 191|Norwich|New York|13815|United States",
                "orphan_designation": {
                    "original_text": "Treatment of the neuroleptic malignant syndrome.",
                    "umls_id": "C0027849",
                    "parsed_text": "Neuroleptic Malignant Syndrome"
                }
            },
            {
                "compound_id": 9568637,
                "inchl_key": "LTWQNYPDAUSXBC-CDJGKPBYSA-L",
                "generic_name": "dantrolene sodium",
                "designated_date": "09/25/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eagle Pharmaceuticals, Inc.|50 Tice Blvd|Suite 315|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of heat stroke",
                    "umls_id": "C0038819",
                    "parsed_text": "Heat Stroke"
                }
            },
            {
                "compound_id": 9568637,
                "inchl_key": "LTWQNYPDAUSXBC-CDJGKPBYSA-L",
                "generic_name": "dantrolene sodium",
                "designated_date": "02/17/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Washington University in St. Louis|660 S. Euclid Avenue|Campus Box 8127|St. Louis|Missouri|63110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wolfram Syndrome",
                    "umls_id": "C0043207",
                    "parsed_text": "Wolfram Syndrome"
                }
            }
        ]
    },
    {
        "_id": "KSRLIXGNPXAZHD-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 32731,
                "inchl_key": "KSRLIXGNPXAZHD-UHFFFAOYSA-M",
                "generic_name": "Dantrolene sodium",
                "designated_date": "12/14/1987",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Norwich Eaton Pharmaceuticals|P.O. Box 191|Norwich|New York|13815|United States",
                "orphan_designation": {
                    "original_text": "Treatment of the neuroleptic malignant syndrome.",
                    "umls_id": "C0027849",
                    "parsed_text": "Neuroleptic Malignant Syndrome"
                }
            },
            {
                "compound_id": 32731,
                "inchl_key": "KSRLIXGNPXAZHD-UHFFFAOYSA-M",
                "generic_name": "dantrolene sodium",
                "designated_date": "09/25/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eagle Pharmaceuticals, Inc.|50 Tice Blvd|Suite 315|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of heat stroke",
                    "umls_id": "C0038819",
                    "parsed_text": "Heat Stroke"
                }
            },
            {
                "compound_id": 32731,
                "inchl_key": "KSRLIXGNPXAZHD-UHFFFAOYSA-M",
                "generic_name": "dantrolene sodium",
                "designated_date": "02/17/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Washington University in St. Louis|660 S. Euclid Avenue|Campus Box 8127|St. Louis|Missouri|63110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wolfram Syndrome",
                    "umls_id": "C0043207",
                    "parsed_text": "Wolfram Syndrome"
                }
            }
        ]
    },
    {
        "_id": "KSRLIXGNPXAZHD-HAZZGOGXSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 13271066,
                "inchl_key": "KSRLIXGNPXAZHD-HAZZGOGXSA-M",
                "generic_name": "Dantrolene sodium",
                "designated_date": "12/14/1987",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Norwich Eaton Pharmaceuticals|P.O. Box 191|Norwich|New York|13815|United States",
                "orphan_designation": {
                    "original_text": "Treatment of the neuroleptic malignant syndrome.",
                    "umls_id": "C0027849",
                    "parsed_text": "Neuroleptic Malignant Syndrome"
                }
            },
            {
                "compound_id": 13271066,
                "inchl_key": "KSRLIXGNPXAZHD-HAZZGOGXSA-M",
                "generic_name": "Dantrolene sodium",
                "designated_date": "12/14/1987",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Norwich Eaton Pharmaceuticals|P.O. Box 191|Norwich|New York|13815|United States",
                "orphan_designation": {
                    "original_text": "Treatment of the neuroleptic malignant syndrome.",
                    "umls_id": "C0027849",
                    "parsed_text": "Neuroleptic Malignant Syndrome"
                }
            },
            {
                "compound_id": 13271066,
                "inchl_key": "KSRLIXGNPXAZHD-HAZZGOGXSA-M",
                "generic_name": "dantrolene sodium",
                "designated_date": "09/25/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eagle Pharmaceuticals, Inc.|50 Tice Blvd|Suite 315|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of heat stroke",
                    "umls_id": "C0038819",
                    "parsed_text": "Heat Stroke"
                }
            },
            {
                "compound_id": 13271066,
                "inchl_key": "KSRLIXGNPXAZHD-HAZZGOGXSA-M",
                "generic_name": "dantrolene sodium",
                "designated_date": "09/25/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eagle Pharmaceuticals, Inc.|50 Tice Blvd|Suite 315|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of heat stroke",
                    "umls_id": "C0038819",
                    "parsed_text": "Heat Stroke"
                }
            },
            {
                "compound_id": 13271066,
                "inchl_key": "KSRLIXGNPXAZHD-HAZZGOGXSA-M",
                "generic_name": "dantrolene sodium",
                "designated_date": "02/17/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Washington University in St. Louis|660 S. Euclid Avenue|Campus Box 8127|St. Louis|Missouri|63110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wolfram Syndrome",
                    "umls_id": "C0043207",
                    "parsed_text": "Wolfram Syndrome"
                }
            },
            {
                "compound_id": 13271066,
                "inchl_key": "KSRLIXGNPXAZHD-HAZZGOGXSA-M",
                "generic_name": "dantrolene sodium",
                "designated_date": "02/17/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Washington University in St. Louis|660 S. Euclid Avenue|Campus Box 8127|St. Louis|Missouri|63110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wolfram Syndrome",
                    "umls_id": "C0043207",
                    "parsed_text": "Wolfram Syndrome"
                }
            }
        ]
    },
    {
        "_id": "ZBNZXTGUTAYRHI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3062316,
                "inchl_key": "ZBNZXTGUTAYRHI-UHFFFAOYSA-N",
                "generic_name": "dasatinib",
                "trade_name": "Sprycel",
                "designated_date": "11/28/2005",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adults with chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib",
                "marketing_approval_date": "\u00a006/28/2006\u00a0",
                "exclusivity_end_date": "\u00a006/28/2013\u00a0",
                "sponsor": "Bristol-Myers Squibb Company|3401 Princeton Pike, B-3043C|Lawrence Township|New Jersey|8648|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic myelogenous leukemia",
                    "umls_id": "C0023473",
                    "parsed_text": "Chronic myelogenous leukemia"
                }
            },
            {
                "compound_id": 3062316,
                "inchl_key": "ZBNZXTGUTAYRHI-UHFFFAOYSA-N",
                "generic_name": "Dasatinib",
                "trade_name": "Sprycel",
                "designated_date": "11/18/2005",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy",
                "marketing_approval_date": "\u00a006/28/2006\u00a0",
                "exclusivity_end_date": "\u00a006/28/2013\u00a0",
                "sponsor": "Bristol-Myers Squibb Company|P. O Box 5326|Mailstop C 4065|Princeton|New Jersey|8542|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Philadelphia-positive acute lymphoblastic leukemia",
                    "umls_id": "C1709527",
                    "parsed_text": "Philadelphia-positive acute lymphoblastic leukemia"
                }
            },
            {
                "compound_id": 3062316,
                "inchl_key": "ZBNZXTGUTAYRHI-UHFFFAOYSA-N",
                "generic_name": "Dasatinib",
                "designated_date": "10/26/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "IGIA Pharmaceuticals, Inc.|1125 Boone Aire Road|Florence|Kentucky|41042|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Noonan syndrome-associated hypertrophic cardiomyopathy",
                    "umls_id": "C0007194,C0028326",
                    "parsed_text": "Hypertrophic Cardiomyopathy , Noonan Syndrome"
                }
            },
            {
                "compound_id": 3062316,
                "inchl_key": "ZBNZXTGUTAYRHI-UHFFFAOYSA-N",
                "generic_name": "dasatinib",
                "trade_name": "Sprycel",
                "designated_date": "11/28/2005",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase",
                "marketing_approval_date": "\u00a011/09/2017\u00a0",
                "exclusivity_end_date": "\u00a011/09/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase",
                "sponsor": "Bristol-Myers Squibb Company|3401 Princeton Pike, B-3043C|Lawrence Township|New Jersey|8648|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic myelogenous leukemia",
                    "umls_id": "C0023473",
                    "parsed_text": "Chronic myelogenous leukemia"
                }
            },
            {
                "compound_id": 3062316,
                "inchl_key": "ZBNZXTGUTAYRHI-UHFFFAOYSA-N",
                "generic_name": "Dasatinib",
                "trade_name": "Sprycel",
                "designated_date": "11/18/2005",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "SPRYCEL (dasatinib) is indicated for the treatment of pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.",
                "marketing_approval_date": "\u00a012/21/2018\u00a0",
                "exclusivity_end_date": "\u00a012/21/2025\u00a0",
                "exclusivity_protected_indication": "SPRYCEL (dasatinib) is indicated for the treatment of pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.",
                "sponsor": "Bristol-Myers Squibb Company|P. O Box 5326|Mailstop C 4065|Princeton|New Jersey|8542|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Philadelphia-positive acute lymphoblastic leukemia",
                    "umls_id": "C1709527",
                    "parsed_text": "Philadelphia-positive acute lymphoblastic leukemia"
                }
            }
        ]
    },
    {
        "_id": "DWLTUUXCVGVRAV-XWRHUKJGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9832404,
                "inchl_key": "DWLTUUXCVGVRAV-XWRHUKJGSA-N",
                "generic_name": "davunetide",
                "designated_date": "12/07/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Allon Therapeutics, Inc.|506-1168 Hamilton Street|Vancouver|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of progressive supranuclear palsy.",
                    "umls_id": "C0038868",
                    "parsed_text": "Progressive supranuclear palsy"
                }
            },
            {
                "compound_id": 9832404,
                "inchl_key": "DWLTUUXCVGVRAV-XWRHUKJGSA-N",
                "generic_name": "davunetide",
                "designated_date": "02/22/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Coronis Neurosciences Ltd.|5 Golda Me'ir Street Lev-Hanevet Building|3rd Floor, Weizmann Science Park|Ness Ziona|Center District|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Activity-Dependent Neuroprotective Protein (ADNP) Syndrome",
                    "umls_id": "C0039082,C1423715",
                    "parsed_text": "Syndrome , ADNP"
                }
            }
        ]
    },
    {
        "_id": "UREBDLICKHMUKA-CXSFZGCWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5743,
                "inchl_key": "UREBDLICKHMUKA-CXSFZGCWSA-N",
                "generic_name": "dexamethasone",
                "designated_date": "02/26/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Fera Pharmaceuticals|134 Birch Hill Road|Locust Valley|New York|11560|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            },
            {
                "compound_id": 5743,
                "inchl_key": "UREBDLICKHMUKA-CXSFZGCWSA-N",
                "generic_name": "dexamethasone",
                "designated_date": "03/26/2018",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "HEMADY is indicated in combination with other anti-myeloma products for the treatment of adults with multiple myeloma",
                "marketing_approval_date": "\u00a010/03/2019\u00a0",
                "exclusivity_end_date": "\u00a010/03/2026\u00a0",
                "exclusivity_protected_indication": "Indicated in combination with other anti-myeloma products for the treatment of adults with multiple myeloma (MM).",
                "sponsor": "Dexcel Pharma Technologies Ltd|Dexcel Street|Or Akiva|Haifa District|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma (MM)",
                    "umls_id": "C0026764,C3538749",
                    "parsed_text": "Multiple Myeloma , Myeloma"
                }
            },
            {
                "compound_id": 5743,
                "inchl_key": "UREBDLICKHMUKA-CXSFZGCWSA-N",
                "generic_name": "dexamethasone",
                "designated_date": "01/26/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "TherOptix, Inc.|689 Main Street, #305|Walpole|Massachusetts|2081|United States",
                "orphan_designation": {
                    "original_text": "Prevention of Proliferative Vitreoretinopathy (PVR)",
                    "umls_id": "C0242852",
                    "parsed_text": "Proliferative vitreoretinopathy"
                }
            }
        ]
    },
    {
        "_id": "FASDKYOPVNHBLU-SSDOTTSWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 59868,
                "inchl_key": "FASDKYOPVNHBLU-SSDOTTSWSA-N",
                "generic_name": "Dexpramipexole",
                "designated_date": "04/22/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Knopp Biosciences LLC|2100 Wharton Street|Suite 615|Pittsburgh|Pennsylvania|15203|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hypereosinophilic syndrome (HES)",
                    "umls_id": "C0206141,C1540912",
                    "parsed_text": "Hypereosinophilic syndrome , Hypereosinophilic syndrome"
                }
            },
            {
                "compound_id": 59868,
                "inchl_key": "FASDKYOPVNHBLU-SSDOTTSWSA-N",
                "generic_name": "dexpramipexole",
                "designated_date": "10/11/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Knopp Biosciences LLC|2100 Wharton Street|Suite 615|Pittsburgh|Pennsylvania|15203|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "BMKDZUISNHGIBY-ZETCQYMHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71384,
                "inchl_key": "BMKDZUISNHGIBY-ZETCQYMHSA-N",
                "generic_name": "Dexrazoxane",
                "trade_name": "Zinecard",
                "designated_date": "12/17/1991",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative dose of 300mg/m2.",
                "marketing_approval_date": "\u00a005/26/1995\u00a0",
                "exclusivity_end_date": "\u00a005/26/2002\u00a0",
                "sponsor": "Pharmacia & Upjohn|7000 Portage Road|Kalamazoo|Michigan|49001|United States",
                "orphan_designation": {
                    "original_text": "For the prevention of cardiomyopathy associated with doxorubicin administration.",
                    "umls_id": "C0878544",
                    "parsed_text": "Cardiomyopathy"
                }
            },
            {
                "compound_id": 71384,
                "inchl_key": "BMKDZUISNHGIBY-ZETCQYMHSA-N",
                "generic_name": "dexrazoxane",
                "trade_name": "Totect(r)",
                "designated_date": "03/25/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of extravasation resulting from IV anthracycline chemotherapy",
                "marketing_approval_date": "\u00a009/06/2007\u00a0",
                "exclusivity_end_date": "\u00a009/06/2014\u00a0",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "Treatment of anthracycline extravasation during chemotherapy",
                    "umls_id": "C0015376",
                    "parsed_text": "Extravasation"
                }
            }
        ]
    },
    {
        "_id": "TYNLGDBUJLVSMA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 26248,
                "inchl_key": "TYNLGDBUJLVSMA-UHFFFAOYSA-N",
                "generic_name": "diacerein",
                "designated_date": "10/15/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Castle Creek Pharmaceuticals|1033 Skokie Blvd|Suite 600|Northbrook|Illinois|60062|United States",
                "orphan_designation": {
                    "original_text": "Treatment of epidermolysis bullosa",
                    "umls_id": "C0014527",
                    "parsed_text": "Epidermolysis Bullosa"
                }
            },
            {
                "compound_id": 26248,
                "inchl_key": "TYNLGDBUJLVSMA-UHFFFAOYSA-N",
                "generic_name": "Diacerein",
                "designated_date": "11/02/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "WORPHMED Srl|Via Malachia Marchesi de Taddei, 21|Milan|Lombardy|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of epidermolysis bullosa",
                    "umls_id": "C0014527",
                    "parsed_text": "Epidermolysis Bullosa"
                }
            }
        ]
    },
    {
        "_id": "WDJUZGPOPHTGOT-XUDUSOBPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 441207,
                "inchl_key": "WDJUZGPOPHTGOT-XUDUSOBPSA-N",
                "generic_name": "digitoxin",
                "designated_date": "10/18/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SimRx Advisors LLC|247 West 87th Street|Suite 7G|New York|New York|10024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcomas",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft Tissue Sarcomas"
                }
            },
            {
                "compound_id": 441207,
                "inchl_key": "WDJUZGPOPHTGOT-XUDUSOBPSA-N",
                "generic_name": "digitoxin",
                "designated_date": "11/02/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SimRx Advisors LLC|247 West 87th Street|Suite 7G|New York|New York|10024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "compound_id": 441207,
                "inchl_key": "WDJUZGPOPHTGOT-XUDUSOBPSA-N",
                "generic_name": "digitoxin",
                "designated_date": "05/27/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Silver Pharmaceuticals|350 Seven Locks Road|Suite 211|Rockville|Maryland|20854|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "PIQCTGMSNWUMAF-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135398510,
                "inchl_key": "PIQCTGMSNWUMAF-UHFFFAOYSA-N",
                "generic_name": "dovitinib",
                "designated_date": "09/26/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oncology Venture ApS|1 Venlighedsvej|Hrsholm|Denmark",
                "orphan_designation": {
                    "original_text": "Treatment of adenoid cystic carcinoma",
                    "umls_id": "C0010606",
                    "parsed_text": "Adenoid Cystic Carcinoma"
                }
            },
            {
                "compound_id": 135398510,
                "inchl_key": "PIQCTGMSNWUMAF-UHFFFAOYSA-N",
                "generic_name": "Dovitinib",
                "designated_date": "10/03/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "AOJJSUZBOXZQNB-TZSSRYMLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 31703,
                "inchl_key": "AOJJSUZBOXZQNB-TZSSRYMLSA-N",
                "generic_name": "doxorubicin",
                "designated_date": "04/06/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Louis D. Falo, Jr.|University of Pittsburgh, Dep. of Dermatology|3500 Fifth Avenue|Pittsburgh|Pennsylvania|15213|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cutaneous T-cell lymphoma",
                    "umls_id": "C0079773",
                    "parsed_text": "cutaneous T-cell lymphoma"
                }
            },
            {
                "compound_id": 31703,
                "inchl_key": "AOJJSUZBOXZQNB-TZSSRYMLSA-N",
                "generic_name": "doxorubicin",
                "designated_date": "08/25/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Delcath Systems, Inc.|1301 6th Avenue|43rd Floor|New York|New York|10019|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma.",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            }
        ]
    },
    {
        "_id": "QXWYKJLNLSIPIN-JGVFFNPUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 92974,
                "inchl_key": "QXWYKJLNLSIPIN-JGVFFNPUSA-N",
                "generic_name": "droxidopa",
                "trade_name": "NORTHERA",
                "designated_date": "01/17/2007",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of orthostatic dizziness, lightheadedness, or the \"feeling that you are about to black out\" in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.",
                "marketing_approval_date": "\u00a002/18/2014\u00a0",
                "exclusivity_end_date": "\u00a002/18/2021\u00a0",
                "exclusivity_protected_indication": "Treatment of orthostatic dizziness, lightheadedness, or the \"feeling that you are about to black out\" in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.",
                "sponsor": "Lundbeck LLC|3530 Toringdon Way, Suite 200|Charlotte|North Carolina|28277|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neurogenic symptomatic orthostatic hypotension in patients with primary autonomic failure, dopamine-beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy.",
                    "umls_id": "C0020651,C0259749,C0393911,C1291314",
                    "parsed_text": "ORTHOSTATIC HYPOTENSION , Autonomic neuropathy , Autonomic failure , hydroxylase deficiency"
                }
            }
        ]
    },
    {
        "_id": "SFVLTCAESLKEHH-WKAQUBQDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11764719,
                "inchl_key": "SFVLTCAESLKEHH-WKAQUBQDSA-N",
                "generic_name": "elamipretide",
                "designated_date": "09/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Stealth BioTherapeutics|275 Grove Street|Suite 3-107|Newton|Massachusetts|2466|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary mitochondrial myopathy",
                    "umls_id": "C0162670",
                    "parsed_text": "MITOCHONDRIAL MYOPATHY"
                }
            },
            {
                "compound_id": 11764719,
                "inchl_key": "SFVLTCAESLKEHH-WKAQUBQDSA-N",
                "generic_name": "elamipretide",
                "designated_date": "03/22/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Stealth BioTherapeutics|275 Grove Street|Suite 3-107|Newton|Massachusetts|2466|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Barth syndrome",
                    "umls_id": "C0574083",
                    "parsed_text": "Barth Syndrome"
                }
            },
            {
                "compound_id": 11764719,
                "inchl_key": "SFVLTCAESLKEHH-WKAQUBQDSA-N",
                "generic_name": "elamipretide",
                "designated_date": "04/02/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Stealth BioTherapeutics Inc.|275 Grove Street 3-107|Newton|Massachusetts|2466|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Lebers Hereditary Optic Neuropathy",
                    "umls_id": "C3887709",
                    "parsed_text": "Optic Neuropathy"
                }
            }
        ]
    },
    {
        "_id": "JYSJVJJVLNYRKL-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 53395169,
                "inchl_key": "JYSJVJJVLNYRKL-UHFFFAOYSA-N",
                "generic_name": "Elcatonin",
                "designated_date": "09/25/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Innapharma, Inc.|10 Mountainview Road|Upper Saddle River|New Jersey|7458|United States",
                "orphan_designation": {
                    "original_text": "Intrathecal treatment of intractable pain.",
                    "umls_id": "C0030200",
                    "parsed_text": "intractable pain"
                }
            }
        ]
    },
    {
        "_id": "WJIGGYYSZBWCGC-MRXNPFEDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25221720,
                "inchl_key": "WJIGGYYSZBWCGC-MRXNPFEDSA-N",
                "generic_name": "emixustat",
                "designated_date": "01/04/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Acucela Inc.|1301 2nd Avenue|Suite 4200|Seattle|Washington|98101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Stargardt disease (STGD)",
                    "umls_id": "C1412063,C1855465",
                    "parsed_text": "Stargardt disease , STGD"
                }
            }
        ]
    },
    {
        "_id": "ZMQMTKVVAMWKNY-YSXLEBCMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6918632,
                "inchl_key": "ZMQMTKVVAMWKNY-YSXLEBCMSA-N",
                "generic_name": "emodepside",
                "designated_date": "09/13/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bayer HealthCare Pharmaceuticals, Inc.|100 Bayer Boulevard|P. O. Box 915|Whippany|New Jersey|7981|United States",
                "orphan_designation": {
                    "original_text": "Treatment of onchocerhiasis (\"river blindness\") caused by the filarial nematode onchocerca volvulus",
                    "umls_id": "C0029002",
                    "parsed_text": "River Blindness"
                }
            }
        ]
    },
    {
        "_id": "HAYYBYPASCDWEQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25141092,
                "inchl_key": "HAYYBYPASCDWEQ-UHFFFAOYSA-N",
                "generic_name": "entrectinib",
                "designated_date": "12/22/2014",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|MS#241A|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuroblastoma",
                    "umls_id": "C0027819",
                    "parsed_text": "Neuroblastoma"
                }
            },
            {
                "compound_id": 25141092,
                "inchl_key": "HAYYBYPASCDWEQ-UHFFFAOYSA-N",
                "generic_name": "entrectinib",
                "trade_name": "ROZLYTREK",
                "designated_date": "02/03/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "ROZLYTREK is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.",
                "marketing_approval_date": "\u00a008/15/2019\u00a0",
                "exclusivity_end_date": "\u00a008/15/2026\u00a0",
                "exclusivity_protected_indication": "For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.",
                "sponsor": "Genentech, Inc.|1 DNA Way|MS#241A|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of TrkA-positive, TrkB-positive, TrkC-positive ROS1-positive or ALK-positive non-small cell lung cancer",
                    "umls_id": "C3539721",
                    "parsed_text": "Non-Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 25141092,
                "inchl_key": "HAYYBYPASCDWEQ-UHFFFAOYSA-N",
                "generic_name": "entrectinib",
                "trade_name": "ROZLYTREK",
                "designated_date": "07/05/2017",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "ROZLYTREK is indicated for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have either progressed following treatment or have no satisfactory alternative therapy",
                "marketing_approval_date": "\u00a008/15/2019\u00a0",
                "exclusivity_end_date": "\u00a008/15/2026\u00a0",
                "exclusivity_protected_indication": "For the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have either progressed following treatment or have no satisfactory alternative therapy.",
                "sponsor": "Genentech, Inc.|1 DNA Way|MS#241A|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of NTRK fusion-positive solid tumors",
                    "umls_id": "C0280100",
                    "parsed_text": "solid tumors"
                }
            }
        ]
    },
    {
        "_id": "YZSIZVRFVQKMJU-RDGPPVDQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135565889,
                "inchl_key": "YZSIZVRFVQKMJU-RDGPPVDQSA-N",
                "generic_name": "etarfolatide",
                "designated_date": "02/16/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Endocyte, Inc.|3000 Kent Ave.|Suite A1-100|West Lafayette|Indiana|47906|United States",
                "orphan_designation": {
                    "original_text": "For the identification of ovarian carcinomas",
                    "umls_id": "C1140680",
                    "parsed_text": "ovarian carcinomas"
                }
            }
        ]
    },
    {
        "_id": "RAJWOBJTTGJROA-QJISAEMRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 440114,
                "inchl_key": "RAJWOBJTTGJROA-QJISAEMRSA-N",
                "generic_name": "Etiocholanedione",
                "designated_date": "05/07/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SuperGen, Inc.|4140 Dublin Blvd.|Suite 200|Dublin|California|94568|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Prader-Willi syndrome.",
                    "umls_id": "C0032897",
                    "parsed_text": "Prader-Willi Syndrome"
                }
            },
            {
                "compound_id": 440114,
                "inchl_key": "RAJWOBJTTGJROA-QJISAEMRSA-N",
                "generic_name": "Etiocholanedione",
                "designated_date": "11/03/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SuperGen, Inc.|4140 Dublin Blvd.|Suite 200|Dublin|California|94568|United States",
                "orphan_designation": {
                    "original_text": "Treatment of aplastic anemia.",
                    "umls_id": "C0002874",
                    "parsed_text": "Aplastic Anemia"
                }
            }
        ]
    },
    {
        "_id": "HKVAMNSJSFKALM-GKUWKFKPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6442177,
                "inchl_key": "HKVAMNSJSFKALM-GKUWKFKPSA-N",
                "generic_name": "everolimus",
                "trade_name": "Afinitor",
                "designated_date": "06/08/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical resection",
                "marketing_approval_date": "\u00a010/29/2010\u00a0",
                "exclusivity_end_date": "\u00a010/29/2017\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza, 315/5450A|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)",
                    "umls_id": "C0041341,C0205768,C0206633,C0751674,C1832033,C2247022",
                    "parsed_text": "Tuberous Sclerosis Complex , Subependymal Giant Cell Astrocytoma , Angiomyolipoma , Lymphangioleiomyomatosis , Subependymal Giant Cell Astrocytoma , tuberous sclerosis complex"
                }
            },
            {
                "compound_id": 6442177,
                "inchl_key": "HKVAMNSJSFKALM-GKUWKFKPSA-N",
                "generic_name": "everolimus",
                "designated_date": "05/24/2011",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza, 315/5450A|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastric cancer",
                    "umls_id": "C0024623",
                    "parsed_text": "Gastric Cancer"
                }
            },
            {
                "compound_id": 6442177,
                "inchl_key": "HKVAMNSJSFKALM-GKUWKFKPSA-N",
                "generic_name": "everolimus",
                "trade_name": "Afinitor",
                "designated_date": "06/08/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the adjunctive treatment of adult and pediatric patients age 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures.",
                "marketing_approval_date": "\u00a004/10/2018\u00a0",
                "exclusivity_end_date": "\u00a004/10/2025\u00a0",
                "exclusivity_protected_indication": "For the adjunctive treatment of adult and pediatric patients age 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures.",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza, 315/5450A|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)",
                    "umls_id": "C0041341,C0205768,C0206633,C0751674,C1832033,C2247022",
                    "parsed_text": "Tuberous Sclerosis Complex , Subependymal Giant Cell Astrocytoma , Angiomyolipoma , Lymphangioleiomyomatosis , Subependymal Giant Cell Astrocytoma , tuberous sclerosis complex"
                }
            },
            {
                "compound_id": 6442177,
                "inchl_key": "HKVAMNSJSFKALM-GKUWKFKPSA-N",
                "generic_name": "everolimus",
                "designated_date": "09/16/2010",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza, 315/5450A|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Waldenstrom macroglobulinemia (also known as lymphoplasmacytic lymphoma)",
                    "umls_id": "C0024419,C0334633",
                    "parsed_text": "Waldenstrom Macroglobulinemia , Lymphoplasmacytic Lymphoma"
                }
            },
            {
                "compound_id": 6442177,
                "inchl_key": "HKVAMNSJSFKALM-GKUWKFKPSA-N",
                "generic_name": "everolimus",
                "trade_name": "Afinitor",
                "designated_date": "06/08/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery.",
                "marketing_approval_date": "\u00a004/26/2012\u00a0",
                "exclusivity_end_date": "\u00a004/26/2019\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza, 315/5450A|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)",
                    "umls_id": "C0041341,C0205768,C0206633,C0751674,C1832033,C2247022",
                    "parsed_text": "Tuberous Sclerosis Complex , Subependymal Giant Cell Astrocytoma , Angiomyolipoma , Lymphangioleiomyomatosis , Subependymal Giant Cell Astrocytoma , tuberous sclerosis complex"
                }
            },
            {
                "compound_id": 6442177,
                "inchl_key": "HKVAMNSJSFKALM-GKUWKFKPSA-N",
                "generic_name": "everolimus",
                "trade_name": "Afinitor",
                "designated_date": "02/14/2008",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease; and treatment of adult patients with progressive, well-differentiated, non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin, with unresectable, locally advanced or metastatic disease.",
                "marketing_approval_date": "\u00a002/26/2016\u00a0",
                "exclusivity_end_date": "\u00a002/26/2023\u00a0",
                "exclusivity_protected_indication": "Treatment of adult patients with progressive, well-differentiated, non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) (excluding pancreatic) or lung origin, with unresectable, locally advanced or metastatic disease.",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza, 315/5450A|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuroendocrine tumors",
                    "umls_id": "C0206754",
                    "parsed_text": "Neuroendocrine Tumors"
                }
            },
            {
                "compound_id": 6442177,
                "inchl_key": "HKVAMNSJSFKALM-GKUWKFKPSA-N",
                "generic_name": "everolimus",
                "designated_date": "06/02/2014",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza, 315/5450A|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diffuse large B-cell lymphoma",
                    "umls_id": "C1332201",
                    "parsed_text": "Diffuse Large B-Cell Lymphoma"
                }
            },
            {
                "compound_id": 6442177,
                "inchl_key": "HKVAMNSJSFKALM-GKUWKFKPSA-N",
                "generic_name": "everolimus",
                "designated_date": "07/23/2012",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza, 315/5450A|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            },
            {
                "compound_id": 6442177,
                "inchl_key": "HKVAMNSJSFKALM-GKUWKFKPSA-N",
                "generic_name": "everolimus",
                "trade_name": "Afinitor",
                "designated_date": "02/14/2008",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "0",
                "marketing_approval_date": "\u00a005/05/2011\u00a0",
                "exclusivity_end_date": "\u00a005/05/2018\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza, 315/5450A|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuroendocrine tumors",
                    "umls_id": "C0206754",
                    "parsed_text": "Neuroendocrine Tumors"
                }
            }
        ]
    },
    {
        "_id": "AINQERPKMNDVQT-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135565128,
                "inchl_key": "AINQERPKMNDVQT-UHFFFAOYSA-N",
                "generic_name": "fimaporfin",
                "designated_date": "09/27/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PCI Biotech AS|64 Ullernchausseen|Ullern|Oslo|Norway",
                "orphan_designation": {
                    "original_text": "Treatment of cholangiocarcinoma",
                    "umls_id": "C0206698",
                    "parsed_text": "Cholangiocarcinoma"
                }
            }
        ]
    },
    {
        "_id": "MKDNDKMECWBLOF-WDSKDSINSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44473414,
                "inchl_key": "MKDNDKMECWBLOF-WDSKDSINSA-N",
                "generic_name": "florilglutamic acid",
                "designated_date": "05/11/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Life Molecular Imaging SA|13 Route de l'Ecole|Matran|Fribourg|Switzerland",
                "orphan_designation": {
                    "original_text": "Diagnostic for the management of glioma",
                    "umls_id": "C0017638",
                    "parsed_text": "Glioma"
                }
            }
        ]
    },
    {
        "_id": "CPEUVMUXAHMANV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 35802,
                "inchl_key": "CPEUVMUXAHMANV-UHFFFAOYSA-N",
                "generic_name": "flubendazole",
                "designated_date": "10/25/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Janssen Research & Development, LLC|920 Route 202 South|Raritan|New Jersey|8869|United States",
                "orphan_designation": {
                    "original_text": "Treatment of onchocerciasis caused by Onchocerca volvulus",
                    "umls_id": "C0029001",
                    "parsed_text": "Onchocerciasis"
                }
            },
            {
                "compound_id": 35802,
                "inchl_key": "CPEUVMUXAHMANV-UHFFFAOYSA-N",
                "generic_name": "flubendazole",
                "designated_date": "01/23/2014",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Janssen Research & Development, LLC|920 Route 202 South|Raritan|New Jersey|8869|United States",
                "orphan_designation": {
                    "original_text": "Treatment of lymphatic filariasis caused by nematodes of the family Filariodidea, in children and adults.",
                    "umls_id": "C0013884",
                    "parsed_text": "Lymphatic Filariasis"
                }
            }
        ]
    },
    {
        "_id": "UUOUOERPONYGOS-CLCRDYEYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 91488,
                "inchl_key": "UUOUOERPONYGOS-CLCRDYEYSA-N",
                "generic_name": "Fluocinolone",
                "trade_name": "Retisert",
                "designated_date": "07/31/2000",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye",
                "marketing_approval_date": "\u00a004/08/2005\u00a0",
                "exclusivity_end_date": "\u00a004/08/2012\u00a0",
                "sponsor": "Bausch & Lomb Pharmaceuticals, Inc.|8500 Hidden River Parkway|Tampa|Florida|33637|United States",
                "orphan_designation": {
                    "original_text": "Treatment uveitis involving the posterior segment of the eye.",
                    "umls_id": "C0042164",
                    "parsed_text": "Uveitis"
                }
            }
        ]
    },
    {
        "_id": "LRNSXWGEKABTMP-XWLNNSFXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10307231,
                "inchl_key": "LRNSXWGEKABTMP-XWLNNSFXSA-N",
                "generic_name": "Folate Binding Protein Peptide: Glu-Ile-Trp-Thr-Phe-Ser-Thr-Lys-Val",
                "designated_date": "06/08/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Galena Biopharma, Inc.|Crow Canyon Place|Suite 380|San Ramon|California|94583|United States",
                "orphan_designation": {
                    "original_text": "Treatment (including prevention of recurrence) of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "FIDMEHCRMLKKPZ-YSMBQZINSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10186184,
                "inchl_key": "FIDMEHCRMLKKPZ-YSMBQZINSA-N",
                "generic_name": "fosbretabulin tromethamine",
                "designated_date": "12/29/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mateon Therapeutics, Inc.|701 Gateway Blvd|Suite 210|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuroendocrine tumors",
                    "umls_id": "C0206754",
                    "parsed_text": "Neuroendocrine Tumors"
                }
            },
            {
                "compound_id": 10186184,
                "inchl_key": "FIDMEHCRMLKKPZ-YSMBQZINSA-N",
                "generic_name": "fosbretabulin tromethamine",
                "designated_date": "06/08/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mateon Therapeutics, Inc.|701 Gateway Boulevard|Suite 210|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioma",
                    "umls_id": "C0017638",
                    "parsed_text": "Glioma"
                }
            }
        ]
    },
    {
        "_id": "XWLUWCNOOVRFPX-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 56339,
                "inchl_key": "XWLUWCNOOVRFPX-UHFFFAOYSA-N",
                "generic_name": "Fosphenytoin",
                "trade_name": "Cerebyx",
                "designated_date": "06/04/1991",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the control of generalized convulsive status epilepticus.",
                "marketing_approval_date": "\u00a008/05/1996\u00a0",
                "exclusivity_end_date": "\u00a008/05/2003\u00a0",
                "sponsor": "Warner-Lambert Company|2800 Plymouth Road|Ann Arbor|Michigan|48106|United States",
                "orphan_designation": {
                    "original_text": "For the acute treatment of patients with status epilepticus of the grand mal type.",
                    "umls_id": "C0014549,C0038220",
                    "parsed_text": "Grand mal , Status Epilepticus"
                }
            }
        ]
    },
    {
        "_id": "ZQGJCHHKJNSPMS-UHFFFAOYSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 24828759,
                "inchl_key": "ZQGJCHHKJNSPMS-UHFFFAOYSA-L",
                "generic_name": "fostamatinib disodium hexahydrate",
                "designated_date": "08/25/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.",
                "marketing_approval_date": "\u00a004/17/2018\u00a0",
                "exclusivity_end_date": "\u00a004/17/2025\u00a0",
                "exclusivity_protected_indication": "TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.",
                "sponsor": "Rigel Pharmaceuticals, Inc.|1180 Veterans Boulevard|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of immune thrombocytopenic purpura",
                    "umls_id": "C0398650",
                    "parsed_text": "Immune thrombocytopenic purpura"
                }
            }
        ]
    },
    {
        "_id": "JJICLMJFIKGAAU-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 23700083,
                "inchl_key": "JJICLMJFIKGAAU-UHFFFAOYSA-M",
                "generic_name": "Ganciclovir sodium",
                "trade_name": "Cytovene",
                "designated_date": "10/31/1985",
                "designation_status": "Designated/Approved/Withdrawn",
                "marketing_approval_date": "\u00a006/23/1989\u00a0",
                "exclusivity_end_date": "\u00a006/23/1996\u00a0",
                "sponsor": "Syntex (USA), Inc.|3401 Hillview Avenue|Palo Alto|California|94304|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cytomegalovirus retinitis in immunocompromised patients with AIDS.",
                    "umls_id": "C0001175,C0206178",
                    "parsed_text": "AIDS , Cytomegalovirus Retinitis"
                }
            }
        ]
    },
    {
        "_id": "IRSCQMHQWWYFCW-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135398740,
                "inchl_key": "IRSCQMHQWWYFCW-UHFFFAOYSA-N",
                "generic_name": "Gancyclovir",
                "designated_date": "06/07/1985",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Burroughs Wellcome Company|3030 Cornwallis Road|P.O. Box 12700|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe human cytomegalovirus infections in specific immunosuppressed patient populations.",
                    "umls_id": "C0010823",
                    "parsed_text": "Cytomegalovirus Infections"
                }
            },
            {
                "compound_id": 135398740,
                "inchl_key": "IRSCQMHQWWYFCW-UHFFFAOYSA-N",
                "generic_name": "ganciclovir",
                "trade_name": "Zirgan",
                "designated_date": "03/22/2007",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of acute herpetic keratitis (dendritic ulcers)",
                "marketing_approval_date": "\u00a009/15/2009\u00a0",
                "exclusivity_end_date": "\u00a009/15/2016\u00a0",
                "sponsor": "Sirion Therapeutics, Inc.|9314 East Broadway Avenue|Tampa|Florida|33619|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute herpetic keratitis (dendritic and geographic ulcers)",
                    "umls_id": "C0019357,C0041582",
                    "parsed_text": "Herpetic keratitis , Ulcers"
                }
            }
        ]
    },
    {
        "_id": "FHEAIOHRHQGZPC-KIWGSFCNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3081884,
                "inchl_key": "FHEAIOHRHQGZPC-KIWGSFCNSA-N",
                "generic_name": "glatiramer acetate",
                "trade_name": "Copaxone",
                "designated_date": "11/09/1987",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis.",
                "marketing_approval_date": "\u00a012/20/1996\u00a0",
                "exclusivity_end_date": "\u00a012/20/2003\u00a0",
                "sponsor": "Teva Pharmaceuticals USA|1510 Delp Drive|Kulpsville|Pennsylvania|19443|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple sclerosis",
                    "umls_id": "C0026769",
                    "parsed_text": "Multiple Sclerosis"
                }
            },
            {
                "compound_id": 3081884,
                "inchl_key": "FHEAIOHRHQGZPC-KIWGSFCNSA-N",
                "generic_name": "glatiramer acetate",
                "designated_date": "11/14/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Teva Neurosciences, Inc.|P. O. Box 1005|Horsham|Pennsylvania|19044|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis (ALS).",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "ZVVGTYQPRVEJOH-GGZXVAPBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 85471918,
                "inchl_key": "ZVVGTYQPRVEJOH-GGZXVAPBSA-N",
                "generic_name": "glecaprevir and pibrentasvir",
                "trade_name": "MAVYRET",
                "designated_date": "01/09/2017",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "MAVYRET is indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is also indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/",
                "marketing_approval_date": "\u00a004/30/2019\u00a0",
                "exclusivity_end_date": "\u00a004/30/2026\u00a0",
                "exclusivity_protected_indication": "For the treatment of pediatric patients 12 years and older or weighing at least 45 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A), and also for the treatment of pediatric patients 12 years and older or weighing at least 45 kg with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both.",
                "sponsor": "AbbVie, Inc.|1 Waukegan Road|North Chicago|Illinois|60044|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients with chronic hepatitis C virus infection",
                    "umls_id": "C0019196,C0524910",
                    "parsed_text": "Hepatitis C Virus Infection , chronic hepatitis c"
                }
            }
        ]
    },
    {
        "_id": "NGCGMRBZPXEPOZ-HBBGHHHDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11980076,
                "inchl_key": "NGCGMRBZPXEPOZ-HBBGHHHDSA-N",
                "generic_name": "Gonadorelin acetate",
                "trade_name": "Lutrepulse",
                "designated_date": "04/22/1987",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a010/10/1989\u00a0",
                "exclusivity_end_date": "\u00a010/10/1996\u00a0",
                "sponsor": "Ferring Laboratories, Inc.|400 Rella Boulevard, Suite 201|Suffern|New York|10901|United States",
                "orphan_designation": {
                    "original_text": "For induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion.",
                    "umls_id": "C0341862,C1689985",
                    "parsed_text": "Hypothalamic amenorrhea , Absence"
                }
            }
        ]
    },
    {
        "_id": "NTYJJOPFIAHURM-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 774,
                "inchl_key": "NTYJJOPFIAHURM-UHFFFAOYSA-N",
                "generic_name": "Histamine",
                "designated_date": "02/01/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EpiCept Corporation|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "For use as an adjunct to cytokine therapy in the treatment of malignant melanoma.",
                    "umls_id": "C0025202",
                    "parsed_text": "Malignant Melanoma"
                }
            },
            {
                "compound_id": 774,
                "inchl_key": "NTYJJOPFIAHURM-UHFFFAOYSA-N",
                "generic_name": "Histamine",
                "designated_date": "12/15/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EpiCept Corporation|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Adjunct to cytokine therapy in the treatment of acute myeloid leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "BVOZFCOTOYGLGD-VPQOAABJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24847767,
                "inchl_key": "BVOZFCOTOYGLGD-VPQOAABJSA-N",
                "generic_name": "hyaluronic acid",
                "designated_date": "03/19/2002",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CoTherix|5000 Shoreline Court|Suite 101|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency",
                    "umls_id": "C0034067,C0221757",
                    "parsed_text": "Emphysema , ALPHA-1 ANTITRYPSIN DEFICIENCY"
                }
            },
            {
                "compound_id": 24847767,
                "inchl_key": "BVOZFCOTOYGLGD-VPQOAABJSA-N",
                "generic_name": "hyaluronic acid",
                "designated_date": "01/18/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gerard M. Turino, MD|Division of Pulmonary, Critical Care & Sleep Medicine|Mt. Sinai Roosevelt Hospital Center|New York|New York|10019|United States",
                "orphan_designation": {
                    "original_text": "Treatment of emphysema due to alpha1-antitrypsin deficiency.",
                    "umls_id": "C0034067",
                    "parsed_text": "Emphysema"
                }
            }
        ]
    },
    {
        "_id": "DOMWKUIIPQCAJU-LJHIYBGHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 169870,
                "inchl_key": "DOMWKUIIPQCAJU-LJHIYBGHSA-N",
                "generic_name": "hydroxyprogesterone caproate",
                "trade_name": "Makena",
                "designated_date": "01/25/2007",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Makena auto-injector for subcutaneous injection is indicated to reduce the risk of preterm birth in women with singleton pregnancy who have a history of singleton spontaneous preterm birth.",
                "marketing_approval_date": "\u00a002/14/2018\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "AMAG Pharma USA, Inc.|1100 Winter Street|Waltham|Massachusetts|2154|United States",
                "orphan_designation": {
                    "original_text": "Prevention of preterm birth in singleton pregnancies",
                    "umls_id": "C0151526",
                    "parsed_text": "Preterm Birth"
                }
            },
            {
                "compound_id": 169870,
                "inchl_key": "DOMWKUIIPQCAJU-LJHIYBGHSA-N",
                "generic_name": "hydroxyprogesterone caproate",
                "trade_name": "Makena",
                "designated_date": "01/25/2007",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "To reduce the risk of preterm birth in women with singleton pregnancy who have a history of singleton spontaneous preterm birth",
                "marketing_approval_date": "\u00a002/03/2011\u00a0",
                "exclusivity_end_date": "\u00a002/03/2018\u00a0",
                "sponsor": "AMAG Pharma USA, Inc.|1100 Winter Street|Waltham|Massachusetts|2154|United States",
                "orphan_designation": {
                    "original_text": "Prevention of preterm birth in singleton pregnancies",
                    "umls_id": "C0151526",
                    "parsed_text": "Preterm Birth"
                }
            }
        ]
    },
    {
        "_id": "HWJPWWYTGBZDEG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 213043,
                "inchl_key": "HWJPWWYTGBZDEG-UHFFFAOYSA-N",
                "generic_name": "iclaprim",
                "designated_date": "09/14/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Motif Bio PLC|330 Madison Avenue|6th Floor|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Staphylococus aureus lung infections in patients with cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "YLMAHDNUQAMNNX-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 123596,
                "inchl_key": "YLMAHDNUQAMNNX-UHFFFAOYSA-N",
                "generic_name": "imatinib mesylate",
                "trade_name": "Gleevec",
                "designated_date": "11/01/2001",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Adjuvant treatment of adult patients following complete resection Kit (CD 117) positive gastrointestinal stromal tumors (GIST).",
                "marketing_approval_date": "\u00a012/19/2008\u00a0",
                "exclusivity_end_date": "\u00a012/19/2015\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza|Mail Code 105/1E870D|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastrointestinal stromal tumors",
                    "umls_id": "C0238198",
                    "parsed_text": "Gastrointestinal Stromal Tumors"
                }
            },
            {
                "compound_id": 123596,
                "inchl_key": "YLMAHDNUQAMNNX-UHFFFAOYSA-N",
                "generic_name": "imatinib mesylate",
                "trade_name": "Gleevec",
                "designated_date": "11/01/2001",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST)",
                "marketing_approval_date": "\u00a002/01/2002\u00a0",
                "exclusivity_end_date": "\u00a002/01/2009\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza|Mail Code 105/1E870D|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastrointestinal stromal tumors",
                    "umls_id": "C0238198",
                    "parsed_text": "Gastrointestinal Stromal Tumors"
                }
            },
            {
                "compound_id": 123596,
                "inchl_key": "YLMAHDNUQAMNNX-UHFFFAOYSA-N",
                "generic_name": "imatinib mesylate",
                "trade_name": "Gleevec",
                "designated_date": "12/19/2005",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP)",
                "marketing_approval_date": "\u00a010/19/2006\u00a0",
                "exclusivity_end_date": "\u00a010/19/2013\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|Mail Code 105/1E870D|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of dermatofibrosarcoma protuberans",
                    "umls_id": "C0206647",
                    "parsed_text": "Dermatofibrosarcoma Protuberans"
                }
            },
            {
                "compound_id": 123596,
                "inchl_key": "YLMAHDNUQAMNNX-UHFFFAOYSA-N",
                "generic_name": "Imatinib mesylate",
                "trade_name": "Gleevec",
                "designated_date": "10/05/2005",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements",
                "marketing_approval_date": "\u00a010/19/2006\u00a0",
                "exclusivity_end_date": "\u00a010/19/2013\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|Mail Code 105/1E870D|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myeloproliferative disorders/myelodysplastic syndromes associated with platelet-derived growth factor gene re-arrangements",
                    "umls_id": "C0027022,C0812325,C3463824",
                    "parsed_text": "Myeloproliferative Disorders , Growth Factor Gene , Myelodysplastic Syndromes"
                }
            },
            {
                "compound_id": 123596,
                "inchl_key": "YLMAHDNUQAMNNX-UHFFFAOYSA-N",
                "generic_name": "Imatinib mesylate",
                "trade_name": "Gleevec",
                "designated_date": "08/25/2005",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with hypereosinophic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFR} fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFR} fusion kinase negative or unknown",
                "marketing_approval_date": "\u00a010/19/2006\u00a0",
                "exclusivity_end_date": "\u00a010/19/2013\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|Mail Code 105/1E870D|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia",
                    "umls_id": "C0206141,C0346421",
                    "parsed_text": "Idiopathic Hypereosinophilic Syndrome , Chronic eosinophilic leukemia"
                }
            },
            {
                "compound_id": 123596,
                "inchl_key": "YLMAHDNUQAMNNX-UHFFFAOYSA-N",
                "generic_name": "imatinib mesylate",
                "designated_date": "06/15/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PHPrecisionMed, LLC|3621 Grove Street|Skokie|Illinois|60076|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            },
            {
                "compound_id": 123596,
                "inchl_key": "YLMAHDNUQAMNNX-UHFFFAOYSA-N",
                "generic_name": "Imatinib mesylate",
                "trade_name": "Gleevec",
                "designated_date": "09/09/2005",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with aggressive mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown",
                "marketing_approval_date": "\u00a010/19/2006\u00a0",
                "exclusivity_end_date": "\u00a010/19/2013\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|Mail Code 105/1E870D|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of systemic mastocytosis without the D816V c-kit mutation",
                    "umls_id": "C0221013",
                    "parsed_text": "Systemic mastocytosis"
                }
            }
        ]
    },
    {
        "_id": "ACRHBAYQBXXRTO-OAQYLSRUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 132999,
                "inchl_key": "ACRHBAYQBXXRTO-OAQYLSRUSA-N",
                "generic_name": "ivabradine",
                "trade_name": "CORLANOR",
                "designated_date": "03/23/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Corlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate.",
                "marketing_approval_date": "\u00a004/22/2019\u00a0",
                "exclusivity_end_date": "\u00a004/22/2026\u00a0",
                "exclusivity_protected_indication": "Corlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate.",
                "sponsor": "Amgen, Inc.,|1 Amgen Center Drive|Mail Stop 27-2-D|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients (0 through 16 years of age) with dilated cardiomyopathy.",
                    "umls_id": "C0007193",
                    "parsed_text": "Dilated cardiomyopathy"
                }
            },
            {
                "compound_id": 132999,
                "inchl_key": "ACRHBAYQBXXRTO-OAQYLSRUSA-N",
                "generic_name": "ivabradine",
                "designated_date": "07/09/2018",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Amgen, Inc.,|1 Amgen Center Drive|Mail Stop 27-2-D|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Treatment of post-cardiac transplant heart dysfunction",
                    "umls_id": "C0340515",
                    "parsed_text": "heart dysfunction"
                }
            }
        ]
    },
    {
        "_id": "YQEZLKZALYSWHR-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3821,
                "inchl_key": "YQEZLKZALYSWHR-UHFFFAOYSA-N",
                "generic_name": "ketamine",
                "designated_date": "02/01/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bexson Biomedical, Inc.|856 Chelham Way|Santa Barbara|California|93108|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Complex Regional Pain Syndrome",
                    "umls_id": "C0458219",
                    "parsed_text": "Complex regional pain syndrome"
                }
            }
        ]
    },
    {
        "_id": "XUJNEKJLAYXESH-REOHCLBHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5862,
                "inchl_key": "XUJNEKJLAYXESH-REOHCLBHSA-N",
                "generic_name": "L-cysteine",
                "designated_date": "05/16/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Brigham and Women's Hospital|Channing Laboratory|181 Longwood Ave.|Boston|Massachusetts|2115|United States",
                "orphan_designation": {
                    "original_text": "For the prevention and lessening of photosensitivity in erythropoietic protoporphyria.",
                    "umls_id": "C0162568,C0349506",
                    "parsed_text": "Erythropoietic Protoporphyria , Photosensitivity"
                }
            }
        ]
    },
    {
        "_id": "MWKYMZXCGYXLPL-ZDUSSCGKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 57495353,
                "inchl_key": "MWKYMZXCGYXLPL-ZDUSSCGKSA-N",
                "generic_name": "leniolisib",
                "designated_date": "01/30/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|1 Health Plaza Drive|Bld 125 2110C|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of activated P13Kdelta Syndrome/p110delta-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency",
                    "umls_id": "C0021051,C0497156",
                    "parsed_text": "Immunodeficiency , Lymphadenopathy"
                }
            }
        ]
    },
    {
        "_id": "VVIAGPKUTFNRDU-ABLWVSNPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135403648,
                "inchl_key": "VVIAGPKUTFNRDU-ABLWVSNPSA-N",
                "generic_name": "Leucovorin",
                "trade_name": "Leucovorin calcium",
                "designated_date": "12/08/1986",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.",
                "marketing_approval_date": "\u00a012/12/1991\u00a0",
                "exclusivity_end_date": "\u00a012/12/1998\u00a0",
                "sponsor": "Immunex Corporation|51 University Street|Seattle|Washington|98101|United States",
                "orphan_designation": {
                    "original_text": "For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.",
                    "umls_id": "C4721579",
                    "parsed_text": "Metastatic colorectal cancer"
                }
            }
        ]
    },
    {
        "_id": "RGLRXNKKBLIBQS-XNHQSDQCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 657180,
                "inchl_key": "RGLRXNKKBLIBQS-XNHQSDQCSA-N",
                "generic_name": "Leuprolide acetate",
                "trade_name": "Lupron Injection",
                "designated_date": "07/25/1988",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of children with central precocious puberty",
                "marketing_approval_date": "\u00a004/16/1993\u00a0",
                "exclusivity_end_date": "\u00a004/16/2000\u00a0",
                "sponsor": "Tap Pharmaceuticals, Inc.|2355 Waukegan Road|Deerfield|Illinois|60015|United States",
                "orphan_designation": {
                    "original_text": "Treatment of central precocious puberty",
                    "umls_id": "C0342543",
                    "parsed_text": "Central Precocious Puberty"
                }
            }
        ]
    },
    {
        "_id": "HPHUVLMMVZITSG-LURJTMIESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5284583,
                "inchl_key": "HPHUVLMMVZITSG-LURJTMIESA-N",
                "generic_name": "levetiracetam",
                "designated_date": "04/30/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "University of California|UCSD Medical Center 0935|La Jolla|California|92093|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neonatal seizures",
                    "umls_id": "C0159020",
                    "parsed_text": "Neonatal seizures"
                }
            }
        ]
    },
    {
        "_id": "WHXMKTBCFHIYNQ-SECBINFHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3033825,
                "inchl_key": "WHXMKTBCFHIYNQ-SECBINFHSA-N",
                "generic_name": "levosimendan",
                "designated_date": "04/10/2017",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orion Corporation|Orionintie 1|Espoo|Finland",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "MBBCVAKAJPKAKM-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9853053,
                "inchl_key": "MBBCVAKAJPKAKM-UHFFFAOYSA-N",
                "generic_name": "lomitapide",
                "trade_name": "Juxtapid",
                "designated_date": "10/23/2007",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).",
                "marketing_approval_date": "\u00a012/21/2012\u00a0",
                "exclusivity_end_date": "\u00a012/21/2019\u00a0",
                "sponsor": "Aegerion Pharmaceuticals, Inc.|101 Main St., Suite 1850|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of homozygous familial hypercholesterolemia",
                    "umls_id": "C0020445",
                    "parsed_text": "FAMILIAL HYPERCHOLESTEROLEMIA"
                }
            },
            {
                "compound_id": 9853053,
                "inchl_key": "MBBCVAKAJPKAKM-UHFFFAOYSA-N",
                "generic_name": "lomitapide",
                "designated_date": "03/03/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Amryt Pharmaceuticals DAC|45 Mespil Road|Dublin|4|Ireland",
                "orphan_designation": {
                    "original_text": "Treatment of Familial Chylomicronemia",
                    "umls_id": "C0023817",
                    "parsed_text": "Familial Chylomicronemia"
                }
            }
        ]
    },
    {
        "_id": "DHMTURDWPRKSOA-RUZDIDTESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 148195,
                "inchl_key": "DHMTURDWPRKSOA-RUZDIDTESA-N",
                "generic_name": "lonafarnib",
                "designated_date": "11/19/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eiger Biopharmaceuticals, Inc.|PO Box 430|San Carlos|California|94070|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Hepatitis Delta Virus (HDV)infection",
                    "umls_id": "C0009450,C0011220",
                    "parsed_text": "Infection , Hepatitis Delta Virus"
                }
            },
            {
                "compound_id": 148195,
                "inchl_key": "DHMTURDWPRKSOA-RUZDIDTESA-N",
                "generic_name": "lonafarnib",
                "trade_name": "ZOKINVY",
                "designated_date": "04/18/2011",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "in patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above (1) to reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS); and (2) for the treatment of processing-deficient Progeroid Laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation or homozygous or compound heterozygous ZMPSTE24 mutations",
                "marketing_approval_date": "\u00a011/20/2020\u00a0",
                "exclusivity_end_date": "\u00a011/20/2027\u00a0",
                "exclusivity_protected_indication": "in patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above: (1) to reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS); and (2) for the treatment of processing-deficient Progeroid Laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation or homozygous or compound heterozygous ZMPSTE24 mutations",
                "sponsor": "Eiger BioPharmaceuticals, Inc.|2155 Park Boulevard|Palo Alto|California|94306|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Hutchinson-Gilford progeria syndrome and progeroid laminopathies",
                    "umls_id": "C0033300",
                    "parsed_text": "Hutchinson-Gilford Progeria Syndrome"
                }
            }
        ]
    },
    {
        "_id": "XTTZERNUQAFMOF-QMMMGPOBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11658860,
                "inchl_key": "XTTZERNUQAFMOF-QMMMGPOBSA-N",
                "generic_name": "Lorcaserin",
                "designated_date": "08/31/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eisai Inc.|100 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Dravet syndrome",
                    "umls_id": "C0751122",
                    "parsed_text": "Dravet Syndrome"
                }
            },
            {
                "compound_id": 11658860,
                "inchl_key": "XTTZERNUQAFMOF-QMMMGPOBSA-N",
                "generic_name": "lorcaserin",
                "designated_date": "04/17/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Epygenix Therapeutics, Inc.|140 East Ridgewood Avenue|Suite 415 South Tower|Paramus|New Jersey|7652|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Dravet syndrome",
                    "umls_id": "C0751122",
                    "parsed_text": "Dravet Syndrome"
                }
            }
        ]
    },
    {
        "_id": "PSIFNNKUMBGKDQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3961,
                "inchl_key": "PSIFNNKUMBGKDQ-UHFFFAOYSA-N",
                "generic_name": "losartan",
                "designated_date": "12/12/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "National Marfan Foundation|22 Manhhasset Avenue|Port Washington|New York|11050|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Marfan Syndrome",
                    "umls_id": "C0024796",
                    "parsed_text": "Marfan Syndrome"
                }
            },
            {
                "compound_id": 3961,
                "inchl_key": "PSIFNNKUMBGKDQ-UHFFFAOYSA-N",
                "generic_name": "Losartan",
                "designated_date": "01/29/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "3R Pharma Consulting GmbH|3 Wildbader Stra\u07e5|Dobel|Baden-Wrttemberg|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of epidermolysis bullosa",
                    "umls_id": "C0014527",
                    "parsed_text": "Epidermolysis Bullosa"
                }
            }
        ]
    },
    {
        "_id": "YDDMIZRDDREKEP-HWTBNCOESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 57327016,
                "inchl_key": "YDDMIZRDDREKEP-HWTBNCOESA-N",
                "generic_name": "lurbinectedin",
                "designated_date": "08/20/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PharmaMar USA, Inc.|205 East 42nd St.|Suite 15003|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "compound_id": 57327016,
                "inchl_key": "YDDMIZRDDREKEP-HWTBNCOESA-N",
                "generic_name": "lurbinectedin",
                "trade_name": "Zepzelca",
                "designated_date": "08/01/2018",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Zepzelca (lurbinectedin) is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after prior platinum-based chemotherapy.",
                "marketing_approval_date": "\u00a006/15/2020\u00a0",
                "exclusivity_end_date": "\u00a006/15/2027\u00a0",
                "exclusivity_protected_indication": "For the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.",
                "sponsor": "Jazz Pharmaceuticals Ireland Limited|5th Floor Waterloo Exchange|Waterloo Road|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Treatment of small cell lung cancer (SCLC)",
                    "umls_id": "C0149925,C0262584,C3540630",
                    "parsed_text": "Small Cell Lung Cancer , SCLC , Small Cell Lung Cancer"
                }
            }
        ]
    },
    {
        "_id": "MXDPZUIOZWKRAA-PRDSJKGBSA-K",
        "Orphan Drug Designations": [
            {
                "compound_id": 132274234,
                "inchl_key": "MXDPZUIOZWKRAA-PRDSJKGBSA-K",
                "generic_name": "lutetium Lu 177 dotatate",
                "designated_date": "01/12/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of somatostatin receptor positive GEP-NETs including foregut, midgut, and hindgut neuroendocrine tumors in adults",
                "marketing_approval_date": "\u00a001/26/2018\u00a0",
                "exclusivity_end_date": "\u00a001/26/2025\u00a0",
                "exclusivity_protected_indication": "Treatment of somatostatin receptor positive GEP-NETs including foregut, midgut, and hindgut neuroendocrine tumors in adults",
                "sponsor": "Advanced Accelerator Applications|57 East Willow Street|Millburn|New Jersey|7041|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastro-entero-pancreatic neuroendocrine tumors",
                    "umls_id": "C0206754",
                    "parsed_text": "Neuroendocrine Tumors"
                }
            },
            {
                "compound_id": 132274234,
                "inchl_key": "MXDPZUIOZWKRAA-PRDSJKGBSA-K",
                "generic_name": "lutetium Lu 177 dotatate",
                "designated_date": "01/12/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of somatostatin receptor positive GEP-NETs including foregut, midgut, and hindgut neuroendocrine tumors in adults",
                "marketing_approval_date": "\u00a001/26/2018\u00a0",
                "exclusivity_end_date": "\u00a001/26/2025\u00a0",
                "exclusivity_protected_indication": "Treatment of somatostatin receptor positive GEP-NETs including foregut, midgut, and hindgut neuroendocrine tumors in adults",
                "sponsor": "Advanced Accelerator Applications|57 East Willow Street|Millburn|New Jersey|7041|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastro-entero-pancreatic neuroendocrine tumors",
                    "umls_id": "C0206754",
                    "parsed_text": "Neuroendocrine Tumors"
                }
            }
        ]
    },
    {
        "_id": "WVDSKQXKCDZXLH-OHIDFYLOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71526737,
                "inchl_key": "WVDSKQXKCDZXLH-OHIDFYLOSA-N",
                "generic_name": "macimorelin acetate",
                "trade_name": "Macrelin",
                "designated_date": "05/14/2007",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the diagnosis of adult growth hormone deficiency",
                "marketing_approval_date": "\u00a012/20/2017\u00a0",
                "exclusivity_end_date": "\u00a012/20/2024\u00a0",
                "exclusivity_protected_indication": "For the diagnosis of adult growth hormone deficiency.",
                "sponsor": "Strongbridge Ireland Ltd|10 Earlsfort Terrace|Dublin|County Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Diagnosis of growth hormone deficiency",
                    "umls_id": "C3714796",
                    "parsed_text": "Growth hormone deficiency"
                }
            }
        ]
    },
    {
        "_id": "FBPFZTCFMRRESA-KVTDHHQDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6251,
                "inchl_key": "FBPFZTCFMRRESA-KVTDHHQDSA-N",
                "generic_name": "MANNITOL",
                "trade_name": "Bronchitol",
                "designated_date": "02/11/2005",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. Use Bronchitol only for adults who have passed the Bronchitol Tolerance Test.",
                "marketing_approval_date": "\u00a010/30/2020\u00a0",
                "exclusivity_end_date": "\u00a010/30/2027\u00a0",
                "exclusivity_protected_indication": "as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis and who have passed the Bronchitol Tolerance Test",
                "sponsor": "Chiesi Farmaceutici S.p.A (Chiesi USA, Inc.)|175 Regency Woods Place|Suite 600|Cary|North Carolina|27518|United States",
                "orphan_designation": {
                    "original_text": "For use to facilitate clearance of mucus in patients with bronchiectasis and in patients with cystic fibrosis at risk for bronchiectasis",
                    "umls_id": "C0006267,C0010674",
                    "parsed_text": "Bronchiectasis , Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "FBOZXECLQNJBKD-ZDUSSCGKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 126941,
                "inchl_key": "FBOZXECLQNJBKD-ZDUSSCGKSA-N",
                "generic_name": "methotrexate",
                "designated_date": "03/25/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Antares Pharma, Inc|Princeton Crossroads Corporate Center|100 Princeton South Suite 300|Ewing,|New Jersey|8628|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ectopic pregnancy",
                    "umls_id": "C0032987",
                    "parsed_text": "Ectopic Pregnancy"
                }
            },
            {
                "compound_id": 126941,
                "inchl_key": "FBOZXECLQNJBKD-ZDUSSCGKSA-N",
                "generic_name": "methotrexate",
                "designated_date": "08/20/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orbona Pharma Ltd|Old Chambers|93-94 West Street|Farnham|Surrey|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of acute lymphoblastic leukemia",
                    "umls_id": "C0023449",
                    "parsed_text": "Acute lymphoblastic leukemia"
                }
            },
            {
                "compound_id": 126941,
                "inchl_key": "FBOZXECLQNJBKD-ZDUSSCGKSA-N",
                "generic_name": "methotrexate",
                "designated_date": "04/11/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Aldeyra Therapeutics, Inc.|131 Hartwell Avenue, Suite 320|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Prevention of proliferative vitreoretinopathy (PVR)",
                    "umls_id": "C0242852",
                    "parsed_text": "Proliferative vitreoretinopathy"
                }
            },
            {
                "compound_id": 126941,
                "inchl_key": "FBOZXECLQNJBKD-ZDUSSCGKSA-N",
                "generic_name": "Methotrexate",
                "designated_date": "08/28/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "The Universtiy of Kanasa Medical Center|3901 Rainbow Blvd|MSN 2012|Kanasa City|Kansas|66160|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Myasthenia Gravis",
                    "umls_id": "C0026896",
                    "parsed_text": "Myasthenia Gravis"
                }
            },
            {
                "compound_id": 126941,
                "inchl_key": "FBOZXECLQNJBKD-ZDUSSCGKSA-N",
                "generic_name": "methotrexate",
                "designated_date": "08/23/1993",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Wyeth-Ayerst Laboratories|P.O. Box 8299|Philadelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis.",
                    "umls_id": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            }
        ]
    },
    {
        "_id": "QXKHYNVANLEOEG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4114,
                "inchl_key": "QXKHYNVANLEOEG-UHFFFAOYSA-N",
                "generic_name": "methoxsalen",
                "designated_date": "05/12/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Therakos, Inc.|10 North High Street|Suite 300|West Chester|Pennsylvania|19380|United States",
                "orphan_designation": {
                    "original_text": "For the prevention of acute rejection of cardiac allografts",
                    "umls_id": "C3273245",
                    "parsed_text": "Acute Rejection"
                }
            },
            {
                "compound_id": 4114,
                "inchl_key": "QXKHYNVANLEOEG-UHFFFAOYSA-N",
                "generic_name": "Methoxsalen",
                "designated_date": "10/14/1998",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Therakos, Inc. (Mallinckrodt Hospital Products IP Limited)|1425 U.S. Route 206|Bedminster|New Jersey|7921|United States",
                "orphan_designation": {
                    "original_text": "For use in conjunction with the UVAR photopheresis system to treat graft versus host disease.",
                    "umls_id": "C0018133",
                    "parsed_text": "GRAFT VERSUS HOST DISEASE"
                }
            }
        ]
    },
    {
        "_id": "XDZAHHULFQIBFE-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24875489,
                "inchl_key": "XDZAHHULFQIBFE-UHFFFAOYSA-N",
                "generic_name": "methylparaben suberohydroxamic acid phenyl ester",
                "designated_date": "04/15/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medivir AB|Box 1086s|Huddinge|Sweden",
                "orphan_designation": {
                    "original_text": "Treatment of cutaneous T-cell lymphoma",
                    "umls_id": "C0079773",
                    "parsed_text": "cutaneous T-cell lymphoma"
                }
            }
        ]
    },
    {
        "_id": "VAOCPAMSLUNLGC-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4173,
                "inchl_key": "VAOCPAMSLUNLGC-UHFFFAOYSA-N",
                "generic_name": "metronidazole",
                "designated_date": "04/26/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "S.L.A. Pharma Limited (UK)|Elite House|Watford, Hertfordshire.|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of pouchitis",
                    "umls_id": "C0376620",
                    "parsed_text": "Pouchitis"
                }
            },
            {
                "compound_id": 4173,
                "inchl_key": "VAOCPAMSLUNLGC-UHFFFAOYSA-N",
                "generic_name": "metronidazole",
                "designated_date": "04/05/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Appili Therapeutics, Inc.|1344 Summer Street|Suite 415|Halifax|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of clostridium difficile infection in pediatric patients (0 through 16 years of age).",
                    "umls_id": "C0343386",
                    "parsed_text": "Clostridium difficile infection"
                }
            },
            {
                "compound_id": 4173,
                "inchl_key": "VAOCPAMSLUNLGC-UHFFFAOYSA-N",
                "generic_name": "Metronidazole",
                "designated_date": "10/24/1991",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Galderma Laboratories, Inc.|P.O. Box 331329|Fort Worth|Texas|76163|United States",
                "orphan_designation": {
                    "original_text": "Treatment of perioral dermatitis.",
                    "umls_id": "C0263449",
                    "parsed_text": "Perioral Dermatitis"
                }
            },
            {
                "compound_id": 4173,
                "inchl_key": "VAOCPAMSLUNLGC-UHFFFAOYSA-N",
                "generic_name": "metronidazole",
                "designated_date": "09/17/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Avivia Project BV|Leeuwenhoekweg 12|Schijndel|Netherlands",
                "orphan_designation": {
                    "original_text": "Treatment of pouchitis",
                    "umls_id": "C0376620",
                    "parsed_text": "Pouchitis"
                }
            }
        ]
    },
    {
        "_id": "BYBLEWFAAKGYCD-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4189,
                "inchl_key": "BYBLEWFAAKGYCD-UHFFFAOYSA-N",
                "generic_name": "miconazole",
                "designated_date": "05/22/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hill Dermaceuticals, Inc.|2650 S. Mellonville Ave.|Sanford|Florida|32773|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fungal otitis externa (otomycosis)",
                    "umls_id": "C0029895",
                    "parsed_text": "Fungal otitis externa"
                }
            }
        ]
    },
    {
        "_id": "VKHAHZOOUSRJNA-GCNJZUOMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 55245,
                "inchl_key": "VKHAHZOOUSRJNA-GCNJZUOMSA-N",
                "generic_name": "mifepristone",
                "designated_date": "01/14/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Corcept Therapeutics, Inc.|149 Commonwealth Drive|Menlo Park|California|94025|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer.",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "compound_id": 55245,
                "inchl_key": "VKHAHZOOUSRJNA-GCNJZUOMSA-N",
                "generic_name": "mifepristone",
                "trade_name": "Korlym",
                "designated_date": "07/05/2007",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "for the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.",
                "marketing_approval_date": "\u00a002/17/2012\u00a0",
                "exclusivity_end_date": "\u00a002/17/2019\u00a0",
                "sponsor": "Corcept Therapeutics, Inc.|149 Commonwealth Drive|Menlo Park|California|94025|United States",
                "orphan_designation": {
                    "original_text": "Treatment of the clinical manifestations of endogenous Cushing's syndrone",
                    "umls_id": "C0010481",
                    "parsed_text": "Cushing Syndrome"
                }
            },
            {
                "compound_id": 55245,
                "inchl_key": "VKHAHZOOUSRJNA-GCNJZUOMSA-N",
                "generic_name": "Mifepristone",
                "designated_date": "02/07/2005",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "HRA Pharma|15 , rue Beranger|75003|Paris|France",
                "orphan_designation": {
                    "original_text": "Treatment of Cushing's syndrome secondary to ectopic ACTH secretion",
                    "umls_id": "C0001231,C0039082",
                    "parsed_text": "Ectopic ACTH secretion , Syndrome"
                }
            }
        ]
    },
    {
        "_id": "UQRORFVVSGFNRO-UTINFBMNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 51634,
                "inchl_key": "UQRORFVVSGFNRO-UTINFBMNSA-N",
                "generic_name": "Miglustat",
                "designated_date": "02/02/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Edenbridge Pharmaceuticals LLC|169 Lackawanna Ave, Suite 110|Parsippany|New Jersey|7054|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Niemann-Pick Disease Type C",
                    "umls_id": "C0220756",
                    "parsed_text": "niemann-pick disease type c"
                }
            },
            {
                "compound_id": 51634,
                "inchl_key": "UQRORFVVSGFNRO-UTINFBMNSA-N",
                "generic_name": "miglustat",
                "designated_date": "11/12/2008",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Actelion Pharmaceuticals Ltd|Innovation Centre|Allschwil|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of the neurological manifestations of Niemann-Pick disease,type C.",
                    "umls_id": "C0027854,C0028064",
                    "parsed_text": "Neurological Manifestations , Niemann-Pick Disease"
                }
            },
            {
                "compound_id": 51634,
                "inchl_key": "UQRORFVVSGFNRO-UTINFBMNSA-N",
                "generic_name": "miglustat",
                "designated_date": "01/19/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Beyond Batten Disease Foundation|P.O. Box 50221|Austin|Texas|78763|United States",
                "orphan_designation": {
                    "original_text": "Treatment of CLN Batten Disease",
                    "umls_id": "C0751383",
                    "parsed_text": "Batten Disease"
                }
            },
            {
                "compound_id": 51634,
                "inchl_key": "UQRORFVVSGFNRO-UTINFBMNSA-N",
                "generic_name": "miglustat",
                "trade_name": "Zavesca",
                "designated_date": "05/29/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of mild to moderate Type I Gaucher disease in adults for whom enzyme replacement therapy is not a therapeutic option (e.g., due to constraints such as allergy, hypersensitivity, or poor venous access).",
                "marketing_approval_date": "\u00a007/31/2003\u00a0",
                "exclusivity_end_date": "\u00a007/31/2010\u00a0",
                "sponsor": "IC-MedTech Corporation|9902 Indian Creek Lane|San Diego|California|92021|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Gaucher disease.",
                    "umls_id": "C0017205",
                    "parsed_text": "Gaucher Disease"
                }
            }
        ]
    },
    {
        "_id": "WTJXVDPDEQKTCV-VQAITOIOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 54685925,
                "inchl_key": "WTJXVDPDEQKTCV-VQAITOIOSA-N",
                "generic_name": "Minocycline hydrochloride",
                "designated_date": "03/28/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Autoimmunity Research Foundation|Autoimmunity Research, Inc.|Thousand Oaks|California|91360|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sarcoidosis",
                    "umls_id": "C0036202",
                    "parsed_text": "Sarcoidosis"
                }
            },
            {
                "compound_id": 54685925,
                "inchl_key": "WTJXVDPDEQKTCV-VQAITOIOSA-N",
                "generic_name": "Minocycline HCl",
                "designated_date": "06/19/1992",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Lederle Laboratories Division|Division of American Cyanamid Company|401 N. Middletown Road|Pearl River|New York|10965|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic malignant pleural effusion.",
                    "umls_id": "C0080032",
                    "parsed_text": "malignant pleural effusion"
                }
            }
        ]
    },
    {
        "_id": "WOFMFGQZHJDGCX-ZULDAHANSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 441336,
                "inchl_key": "WOFMFGQZHJDGCX-ZULDAHANSA-N",
                "generic_name": "mometasone furoate",
                "designated_date": "06/26/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EsoCap AG|Malzgasse 9|Basel|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of eosinophilic esophagitis",
                    "umls_id": "C0341106",
                    "parsed_text": "Eosinophilic esophagitis"
                }
            }
        ]
    },
    {
        "_id": "ARIWANIATODDMH-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 14871,
                "inchl_key": "ARIWANIATODDMH-UHFFFAOYSA-N",
                "generic_name": "Monolaurin",
                "designated_date": "04/29/1993",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Glaxo Wellcome Inc.|5 Moore Drive|PO Box 13398|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Treatment of congenital primary ichthyosis.",
                    "umls_id": "C0020757",
                    "parsed_text": "Ichthyosis"
                }
            }
        ]
    },
    {
        "_id": "BLXXJMDCKKHMKV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4409,
                "inchl_key": "BLXXJMDCKKHMKV-UHFFFAOYSA-N",
                "generic_name": "nabumetone",
                "designated_date": "05/05/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cook Pharma|109 Graylyn Drive|Chapel Hill|North Carolina|27516|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric juvenile rheumatoid arthritis",
                    "umls_id": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            }
        ]
    },
    {
        "_id": "PBZBXDCHQQCLGL-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 138402875,
                "inchl_key": "PBZBXDCHQQCLGL-UHFFFAOYSA-M",
                "generic_name": "Nedaplatin",
                "designated_date": "08/05/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenefly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Small Cell Lung Cancer",
                    "umls_id": "C3540630",
                    "parsed_text": "Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 138402875,
                "inchl_key": "PBZBXDCHQQCLGL-UHFFFAOYSA-M",
                "generic_name": "nedaplatin",
                "designated_date": "08/31/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenafly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal cancer",
                    "umls_id": "C0014859",
                    "parsed_text": "esophageal cancer"
                }
            }
        ]
    },
    {
        "_id": "KLNFSAOEKUDMFA-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 154731013,
                "inchl_key": "KLNFSAOEKUDMFA-UHFFFAOYSA-M",
                "generic_name": "Nedaplatin",
                "designated_date": "08/05/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenefly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Small Cell Lung Cancer",
                    "umls_id": "C3540630",
                    "parsed_text": "Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 154731013,
                "inchl_key": "KLNFSAOEKUDMFA-UHFFFAOYSA-M",
                "generic_name": "nedaplatin",
                "designated_date": "08/31/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenafly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal cancer",
                    "umls_id": "C0014859",
                    "parsed_text": "esophageal cancer"
                }
            }
        ]
    },
    {
        "_id": "RPPDZANZFFUGHG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 46738098,
                "inchl_key": "RPPDZANZFFUGHG-UHFFFAOYSA-N",
                "generic_name": "Nedaplatin",
                "designated_date": "08/05/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenefly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Small Cell Lung Cancer",
                    "umls_id": "C3540630",
                    "parsed_text": "Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 46738098,
                "inchl_key": "RPPDZANZFFUGHG-UHFFFAOYSA-N",
                "generic_name": "nedaplatin",
                "designated_date": "08/31/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenafly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal cancer",
                    "umls_id": "C0014859",
                    "parsed_text": "esophageal cancer"
                }
            }
        ]
    },
    {
        "_id": "ZAXCMPAWRCMABN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25199925,
                "inchl_key": "ZAXCMPAWRCMABN-UHFFFAOYSA-N",
                "generic_name": "Nedaplatin",
                "designated_date": "08/05/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenefly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Small Cell Lung Cancer",
                    "umls_id": "C3540630",
                    "parsed_text": "Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 25199925,
                "inchl_key": "ZAXCMPAWRCMABN-UHFFFAOYSA-N",
                "generic_name": "Nedaplatin",
                "designated_date": "08/05/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenefly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Small Cell Lung Cancer",
                    "umls_id": "C3540630",
                    "parsed_text": "Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 25199925,
                "inchl_key": "ZAXCMPAWRCMABN-UHFFFAOYSA-N",
                "generic_name": "nedaplatin",
                "designated_date": "08/31/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenafly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal cancer",
                    "umls_id": "C0014859",
                    "parsed_text": "esophageal cancer"
                }
            },
            {
                "compound_id": 25199925,
                "inchl_key": "ZAXCMPAWRCMABN-UHFFFAOYSA-N",
                "generic_name": "nedaplatin",
                "designated_date": "08/31/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenafly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal cancer",
                    "umls_id": "C0014859",
                    "parsed_text": "esophageal cancer"
                }
            }
        ]
    },
    {
        "_id": "GRHLMSBCOPRFNA-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 131842090,
                "inchl_key": "GRHLMSBCOPRFNA-UHFFFAOYSA-M",
                "generic_name": "Nedaplatin",
                "designated_date": "08/05/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenefly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Small Cell Lung Cancer",
                    "umls_id": "C3540630",
                    "parsed_text": "Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 131842090,
                "inchl_key": "GRHLMSBCOPRFNA-UHFFFAOYSA-M",
                "generic_name": "nedaplatin",
                "designated_date": "08/31/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenafly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal cancer",
                    "umls_id": "C0014859",
                    "parsed_text": "esophageal cancer"
                }
            }
        ]
    },
    {
        "_id": "NOSYGQGJJZNNMA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9548889,
                "inchl_key": "NOSYGQGJJZNNMA-UHFFFAOYSA-N",
                "generic_name": "Nedaplatin",
                "designated_date": "08/05/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenefly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Small Cell Lung Cancer",
                    "umls_id": "C3540630",
                    "parsed_text": "Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 9548889,
                "inchl_key": "NOSYGQGJJZNNMA-UHFFFAOYSA-N",
                "generic_name": "nedaplatin",
                "designated_date": "08/31/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenafly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal cancer",
                    "umls_id": "C0014859",
                    "parsed_text": "esophageal cancer"
                }
            }
        ]
    },
    {
        "_id": "KLNFSAOEKUDMFA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24200453,
                "inchl_key": "KLNFSAOEKUDMFA-UHFFFAOYSA-N",
                "generic_name": "Nedaplatin",
                "designated_date": "08/05/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenefly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Small Cell Lung Cancer",
                    "umls_id": "C3540630",
                    "parsed_text": "Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 24200453,
                "inchl_key": "KLNFSAOEKUDMFA-UHFFFAOYSA-N",
                "generic_name": "Nedaplatin",
                "designated_date": "08/05/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenefly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Small Cell Lung Cancer",
                    "umls_id": "C3540630",
                    "parsed_text": "Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 24200453,
                "inchl_key": "KLNFSAOEKUDMFA-UHFFFAOYSA-N",
                "generic_name": "nedaplatin",
                "designated_date": "08/31/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenafly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal cancer",
                    "umls_id": "C0014859",
                    "parsed_text": "esophageal cancer"
                }
            },
            {
                "compound_id": 24200453,
                "inchl_key": "KLNFSAOEKUDMFA-UHFFFAOYSA-N",
                "generic_name": "nedaplatin",
                "designated_date": "08/31/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenafly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal cancer",
                    "umls_id": "C0014859",
                    "parsed_text": "esophageal cancer"
                }
            }
        ]
    },
    {
        "_id": "GYAVMUDJCHAASE-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 9796440,
                "inchl_key": "GYAVMUDJCHAASE-UHFFFAOYSA-M",
                "generic_name": "Nedaplatin",
                "designated_date": "08/05/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenefly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Small Cell Lung Cancer",
                    "umls_id": "C3540630",
                    "parsed_text": "Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 9796440,
                "inchl_key": "GYAVMUDJCHAASE-UHFFFAOYSA-M",
                "generic_name": "nedaplatin",
                "designated_date": "08/31/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenafly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal cancer",
                    "umls_id": "C0014859",
                    "parsed_text": "esophageal cancer"
                }
            }
        ]
    },
    {
        "_id": "JWNPDZNEKVCWMY-VQHVLOKHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9915743,
                "inchl_key": "JWNPDZNEKVCWMY-VQHVLOKHSA-N",
                "generic_name": "neratinib",
                "designated_date": "08/26/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Puma Biotechnology Inc.|10880 Wilshire Blvd., Suite 2150|Los Angeles|California|90024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of breast cancer patients with brain metastases",
                    "umls_id": "C0220650,C0678222",
                    "parsed_text": "brain metastases , Breast cancer"
                }
            }
        ]
    },
    {
        "_id": "ARFHIAQFJWUCFH-IZZDOVSWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6842999,
                "inchl_key": "ARFHIAQFJWUCFH-IZZDOVSWSA-N",
                "generic_name": "nifurtimox",
                "designated_date": "12/31/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MetronomX Therapeutics, LLC|7000 Fannin Street|Suite 1960|Houston|Texas|77030|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Chagas disease",
                    "umls_id": "C0041234",
                    "parsed_text": "Chagas Disease"
                }
            },
            {
                "compound_id": 6842999,
                "inchl_key": "ARFHIAQFJWUCFH-IZZDOVSWSA-N",
                "generic_name": "nifurtimox",
                "trade_name": "LAMPIT",
                "designated_date": "08/05/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "LAMPIT is indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi",
                "marketing_approval_date": "\u00a008/06/2020\u00a0",
                "exclusivity_end_date": "\u00a008/06/2027\u00a0",
                "exclusivity_protected_indication": "indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi",
                "sponsor": "Bayer HealthCare Pharmaceuticals, Inc.|100 BAYER BLVD|WHIPPANY|New Jersey|7981|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Chagas disease (American Typanosomiasis)caused by T. cruzi",
                    "umls_id": "C0041234",
                    "parsed_text": "Chagas Disease"
                }
            }
        ]
    },
    {
        "_id": "XHWRWCSCBDLOLM-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135400184,
                "inchl_key": "XHWRWCSCBDLOLM-UHFFFAOYSA-N",
                "generic_name": "nolatrexed",
                "designated_date": "10/18/2001",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EXIMIAS Pharmaceutical Corporation|1055 Westlakes Drive|Suite 200|Berwyn|Pennsylvania|19312|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            }
        ]
    },
    {
        "_id": "FDLYAMZZIXQODN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 23725625,
                "inchl_key": "FDLYAMZZIXQODN-UHFFFAOYSA-N",
                "generic_name": "olaparib",
                "trade_name": "Lynparza",
                "designated_date": "10/16/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FD",
                "marketing_approval_date": "\u00a005/08/2020\u00a0",
                "exclusivity_end_date": "\u00a005/08/2027\u00a0",
                "exclusivity_protected_indication": "LYNPARZA is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinumbased chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by genomic instability.",
                "sponsor": "AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P. O. Box 8355|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "compound_id": 23725625,
                "inchl_key": "FDLYAMZZIXQODN-UHFFFAOYSA-N",
                "generic_name": "olaparib",
                "trade_name": "Lynparza",
                "designated_date": "05/15/2018",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy. Select patients with gBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on FDA-approved companion diagnostic for Lynparza.",
                "marketing_approval_date": "\u00a012/19/2018\u00a0",
                "exclusivity_end_date": "\u00a012/19/2025\u00a0",
                "exclusivity_protected_indication": "Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy.",
                "sponsor": "AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P. O. Box 8355|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal cancer",
                    "umls_id": "C1514428",
                    "parsed_text": "Primary Peritoneal Cancer"
                }
            },
            {
                "compound_id": 23725625,
                "inchl_key": "FDLYAMZZIXQODN-UHFFFAOYSA-N",
                "generic_name": "olaparib",
                "trade_name": "Lynparza",
                "designated_date": "05/15/2018",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; and treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.",
                "marketing_approval_date": "\u00a008/17/2017\u00a0",
                "exclusivity_end_date": "\u00a008/17/2024\u00a0",
                "exclusivity_protected_indication": "Maintenance treatment of adult patients with recurrent primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",
                "sponsor": "AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P. O. Box 8355|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal cancer",
                    "umls_id": "C1514428",
                    "parsed_text": "Primary Peritoneal Cancer"
                }
            },
            {
                "compound_id": 23725625,
                "inchl_key": "FDLYAMZZIXQODN-UHFFFAOYSA-N",
                "generic_name": "olaparib",
                "trade_name": "Lynparza",
                "designated_date": "05/15/2018",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FD",
                "marketing_approval_date": "\u00a005/08/2020\u00a0",
                "exclusivity_end_date": "\u00a005/08/2027\u00a0",
                "exclusivity_protected_indication": "LYNPARZA is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinumbased chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by genomic instability.",
                "sponsor": "AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P. O. Box 8355|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal cancer",
                    "umls_id": "C1514428",
                    "parsed_text": "Primary Peritoneal Cancer"
                }
            },
            {
                "compound_id": 23725625,
                "inchl_key": "FDLYAMZZIXQODN-UHFFFAOYSA-N",
                "generic_name": "olaparib",
                "trade_name": "Lynparza",
                "designated_date": "05/15/2018",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FD",
                "marketing_approval_date": "\u00a005/08/2020\u00a0",
                "exclusivity_end_date": "\u00a005/08/2027\u00a0",
                "exclusivity_protected_indication": "LYNPARZA is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinumbased chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by genomic instability.",
                "sponsor": "AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P. O. Box 8355|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fallopian Tube Cancer",
                    "umls_id": "C0238122",
                    "parsed_text": "Fallopian Tube Cancer"
                }
            },
            {
                "compound_id": 23725625,
                "inchl_key": "FDLYAMZZIXQODN-UHFFFAOYSA-N",
                "generic_name": "olaparib",
                "trade_name": "Lynparza",
                "designated_date": "10/16/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy. Select patients with gBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on FDA-approved companion diagnostic for Lynparza.",
                "marketing_approval_date": "\u00a012/19/2018\u00a0",
                "exclusivity_end_date": "\u00a012/19/2025\u00a0",
                "exclusivity_protected_indication": "Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian cancer who are in complete or partial response to first-line platinum based chemotherapy.",
                "sponsor": "AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P. O. Box 8355|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "compound_id": 23725625,
                "inchl_key": "FDLYAMZZIXQODN-UHFFFAOYSA-N",
                "generic_name": "olaparib",
                "trade_name": "Lynparza",
                "designated_date": "05/15/2018",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy. Select patients with gBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on FDA-approved companion diagnostic for Lynparza.",
                "marketing_approval_date": "\u00a012/19/2018\u00a0",
                "exclusivity_end_date": "\u00a012/19/2025\u00a0",
                "exclusivity_protected_indication": "Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced fallopian tube cancer who are in complete or partial response to first-line platinum based chemotherapy.",
                "sponsor": "AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P. O. Box 8355|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fallopian Tube Cancer",
                    "umls_id": "C0238122",
                    "parsed_text": "Fallopian Tube Cancer"
                }
            },
            {
                "compound_id": 23725625,
                "inchl_key": "FDLYAMZZIXQODN-UHFFFAOYSA-N",
                "generic_name": "olaparib",
                "trade_name": "Lynparza",
                "designated_date": "10/16/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.",
                "marketing_approval_date": "\u00a008/17/2017\u00a0",
                "exclusivity_end_date": "\u00a008/17/2024\u00a0",
                "exclusivity_protected_indication": "Maintenance treatment of adult patients with recurrent epithelial ovarian cancer, who are in a complete or partial response to platinum-based chemotherapy.",
                "sponsor": "AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P. O. Box 8355|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "compound_id": 23725625,
                "inchl_key": "FDLYAMZZIXQODN-UHFFFAOYSA-N",
                "generic_name": "olaparib",
                "trade_name": "Lynparza",
                "designated_date": "05/15/2018",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; and treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.",
                "marketing_approval_date": "\u00a008/17/2017\u00a0",
                "exclusivity_end_date": "\u00a008/17/2024\u00a0",
                "exclusivity_protected_indication": "Maintenance treatment of adult patients with recurrent fallopian tube cancer who are in a complete or partial response to platinum-based chemotherapy.",
                "sponsor": "AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P. O. Box 8355|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fallopian Tube Cancer",
                    "umls_id": "C0238122",
                    "parsed_text": "Fallopian Tube Cancer"
                }
            },
            {
                "compound_id": 23725625,
                "inchl_key": "FDLYAMZZIXQODN-UHFFFAOYSA-N",
                "generic_name": "olaparib",
                "trade_name": "Lynparza",
                "designated_date": "10/11/2018",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
                "marketing_approval_date": "\u00a012/27/2019\u00a0",
                "exclusivity_end_date": "\u00a012/27/2026\u00a0",
                "exclusivity_protected_indication": "Indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",
                "sponsor": "AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P.O. Box 8355|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 23725625,
                "inchl_key": "FDLYAMZZIXQODN-UHFFFAOYSA-N",
                "generic_name": "olaparib",
                "trade_name": "Lynparza",
                "designated_date": "10/16/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy",
                "marketing_approval_date": "\u00a012/19/2014\u00a0",
                "exclusivity_end_date": "\u00a012/19/2021\u00a0",
                "exclusivity_protected_indication": "Use as monotherapy for patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy",
                "sponsor": "AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P. O. Box 8355|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "SUFPWYYDCOKDLL-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 91885568,
                "inchl_key": "SUFPWYYDCOKDLL-UHFFFAOYSA-N",
                "generic_name": "olorofim",
                "designated_date": "01/16/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "F2G Limited|Lankro Way|Eccles|Manchester|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of invasive aspergillosis",
                    "umls_id": "C0238013",
                    "parsed_text": "Invasive aspergillosis"
                }
            },
            {
                "compound_id": 91885568,
                "inchl_key": "SUFPWYYDCOKDLL-UHFFFAOYSA-N",
                "generic_name": "olorofim",
                "designated_date": "03/11/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "F2G Limited|Lankro Way|Eccles|Manchester|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of coccidioidomycosis",
                    "umls_id": "C0009186",
                    "parsed_text": "Coccidioidomycosis"
                }
            }
        ]
    },
    {
        "_id": "XNOPRXBHLZRZKH-DSZYJQQASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 439302,
                "inchl_key": "XNOPRXBHLZRZKH-DSZYJQQASA-N",
                "generic_name": "oxytocin",
                "designated_date": "11/24/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OT4B|109 Avenue de Lespinet|Toulouse|31400|France",
                "orphan_designation": {
                    "original_text": "Treatment of Prader-Willi syndrome",
                    "umls_id": "C0032897",
                    "parsed_text": "Prader-Willi Syndrome"
                }
            },
            {
                "compound_id": 439302,
                "inchl_key": "XNOPRXBHLZRZKH-DSZYJQQASA-N",
                "generic_name": "oxytocin",
                "designated_date": "06/15/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eric Hollander, MD|Montefiore Medical Center|Univ. Hosp for Albert Einstein College of Medicine|Bronx|New York|10467|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Prader-Willi syndrome",
                    "umls_id": "C0032897",
                    "parsed_text": "Prader-Willi Syndrome"
                }
            }
        ]
    },
    {
        "_id": "RCINICONZNJXQF-MZXODVADSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 36314,
                "inchl_key": "RCINICONZNJXQF-MZXODVADSA-N",
                "generic_name": "paclitaxel",
                "designated_date": "05/01/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SynCore Biotechnology Co., Ltd.|No. 84 Chung Shan Rd|Tung-Shan Shine I-Lan 269|Taiwan",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 36314,
                "inchl_key": "RCINICONZNJXQF-MZXODVADSA-N",
                "generic_name": "Paclitaxel",
                "trade_name": "Taxol",
                "designated_date": "03/25/1997",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the second line treatment of AIDS-related Kaposi's sarcoma.",
                "marketing_approval_date": "\u00a008/04/1997\u00a0",
                "exclusivity_end_date": "\u00a008/04/2004\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|5 Research Parkway|P.O. Box 5100|Wallingford|Connecticut|6492|United States",
                "orphan_designation": {
                    "original_text": "Treatment of AIDS-related Kaposi's sarcoma.",
                    "umls_id": "C0276535",
                    "parsed_text": "AIDS-related Kaposi's sarcoma"
                }
            },
            {
                "compound_id": 36314,
                "inchl_key": "RCINICONZNJXQF-MZXODVADSA-N",
                "generic_name": "Paclitaxel",
                "designated_date": "04/15/1997",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Baker Norton Pharmaceuticals, Inc.|4400 Biscayne Boulevard|Miami|Florida|33137|United States",
                "orphan_designation": {
                    "original_text": "Treatment of AIDS-related Kaposi's sarcoma.",
                    "umls_id": "C0276535",
                    "parsed_text": "AIDS-related Kaposi's sarcoma"
                }
            }
        ]
    },
    {
        "_id": "ZPUHVPYXSITYDI-ZYOSQDPASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134715513,
                "inchl_key": "ZPUHVPYXSITYDI-ZYOSQDPASA-N",
                "generic_name": "paclitaxel poliglumex",
                "designated_date": "09/20/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CTI BioPharma Corporation|3101 Western Ave|Suite 600|Seattle|Washington|98119|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioblastoma multiforme",
                    "umls_id": "C0017636",
                    "parsed_text": "Glioblastoma multiforme"
                }
            }
        ]
    },
    {
        "_id": "DIKSYHCCYVYKRO-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 54684617,
                "inchl_key": "DIKSYHCCYVYKRO-UHFFFAOYSA-N",
                "generic_name": "paquinimod",
                "designated_date": "01/17/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Active Biotech AB|Scheelevagen 22|SE-220 07|LUND|Sweden",
                "orphan_designation": {
                    "original_text": "Treatment of systemic sclerosis",
                    "umls_id": "C0036421",
                    "parsed_text": "Systemic sclerosis"
                }
            }
        ]
    },
    {
        "_id": "LMYRWZFENFIFIT-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6269,
                "inchl_key": "LMYRWZFENFIFIT-UHFFFAOYSA-N",
                "generic_name": "Para-toluenesulfonamide",
                "designated_date": "01/30/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PTS International Inc.|2211 Newoak Pk|San Antonio|Texas|78230|United States",
                "orphan_designation": {
                    "original_text": "Treatment of adenoid cystic carcinoma",
                    "umls_id": "C0010606",
                    "parsed_text": "Adenoid Cystic Carcinoma"
                }
            }
        ]
    },
    {
        "_id": "XDRYMKDFEDOLFX-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4735,
                "inchl_key": "XDRYMKDFEDOLFX-UHFFFAOYSA-N",
                "generic_name": "pentamidine",
                "designated_date": "08/12/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Verlyx Pharma, Inc.|555 Rene-Levesque West, 9th Floor|Montreal|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of liver and intrahepatic bile duct cancer",
                    "umls_id": "C0279000",
                    "parsed_text": "Liver and Intrahepatic Bile Duct Cancer"
                }
            },
            {
                "compound_id": 4735,
                "inchl_key": "XDRYMKDFEDOLFX-UHFFFAOYSA-N",
                "generic_name": "pentamidine",
                "designated_date": "08/12/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oncozyme Pharma, Inc.|555 Rene-Levesque West|Montreal|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "compound_id": 4735,
                "inchl_key": "XDRYMKDFEDOLFX-UHFFFAOYSA-N",
                "generic_name": "pentamidine",
                "designated_date": "09/13/2010",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oncozyme Pharma, Inc.|555 Rene-Levesque West - 9th Floor|Montreal|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer.",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "FCCNSUIJIOOXEZ-SJYYZXOBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 37720,
                "inchl_key": "FCCNSUIJIOOXEZ-SJYYZXOBSA-N",
                "generic_name": "pentosan polysulfate",
                "designated_date": "04/28/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Paradigm Biopharmaceuticals Ltd.|Level 2, 517 Flinders Lane|Melbourne|Victoria|Australia",
                "orphan_designation": {
                    "original_text": "Treatment of mucopolysaccharidosis type 1",
                    "umls_id": "C0026703",
                    "parsed_text": "Mucopolysaccharidosis"
                }
            }
        ]
    },
    {
        "_id": "SSJGXNSABQPEKM-SBUIBGKBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 56841989,
                "inchl_key": "SSJGXNSABQPEKM-SBUIBGKBSA-N",
                "generic_name": "peptide YY",
                "designated_date": "04/18/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mondobiotech Laboratories AG|Herrengasse 21|Furstentum Liechtenstein|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma.",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            }
        ]
    },
    {
        "_id": "OBKXEAXTFZPCHS-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4775,
                "inchl_key": "OBKXEAXTFZPCHS-UHFFFAOYSA-N",
                "generic_name": "Phenylbutyrate",
                "designated_date": "01/19/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Elan Drug Delivery, Inc.|1300 Gould Dr.|Gainesville|Georgia|30504|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute promyelocytic leukemia.",
                    "umls_id": "C0023487",
                    "parsed_text": "Acute Promyelocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "PHXJVRSECIGDHY-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24826799,
                "inchl_key": "PHXJVRSECIGDHY-UHFFFAOYSA-N",
                "generic_name": "ponatinib",
                "trade_name": "Iclusig",
                "designated_date": "11/20/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.",
                "marketing_approval_date": "\u00a012/14/2012\u00a0",
                "exclusivity_end_date": "\u00a012/14/2019\u00a0",
                "sponsor": "ARIAD Pharmaceuticals Inc.|26 Landsdowne Steet|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic myeloid leukemia",
                    "umls_id": "C0023473",
                    "parsed_text": "Chronic myeloid leukemia"
                }
            },
            {
                "compound_id": 24826799,
                "inchl_key": "PHXJVRSECIGDHY-UHFFFAOYSA-N",
                "generic_name": "ponatinib",
                "designated_date": "03/12/2015",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ARIAD Pharmaceuticals, Inc.|26 Landsdowne Street|Cambridge|Massachusetts|2339|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastrointestinal stromal tumors (GIST).",
                    "umls_id": "C0238198",
                    "parsed_text": "Gastrointestinal Stromal Tumors"
                }
            },
            {
                "compound_id": 24826799,
                "inchl_key": "PHXJVRSECIGDHY-UHFFFAOYSA-N",
                "generic_name": "ponatinib",
                "trade_name": "Iclusig",
                "designated_date": "11/20/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.",
                "marketing_approval_date": "\u00a012/14/2012\u00a0",
                "exclusivity_end_date": "\u00a012/14/2019\u00a0",
                "sponsor": "ARIAD Pharmaceuticals Inc.|26 Landsdowne Steet|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)",
                    "umls_id": "C1709527",
                    "parsed_text": "Philadelphia chromosome-positive acute lymphoblastic leukemia"
                }
            }
        ]
    },
    {
        "_id": "HRHKSTOGXBBQCB-VFWICMBZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 13116,
                "inchl_key": "HRHKSTOGXBBQCB-VFWICMBZSA-N",
                "generic_name": "Porfiromycin",
                "designated_date": "09/19/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Boehringer Ingelheim Pharmaceuticals, Inc.|900 Ridgebury Road|P. O. Box 368|Ridgefield|Connecticut|6877|United States",
                "orphan_designation": {
                    "original_text": "Treatment of head and neck cancer.",
                    "umls_id": "C3887461",
                    "parsed_text": "Head and Neck Cancer"
                }
            },
            {
                "compound_id": 13116,
                "inchl_key": "HRHKSTOGXBBQCB-VFWICMBZSA-N",
                "generic_name": "Porfiromycin",
                "designated_date": "03/13/1997",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Boehringer Ingelheim Pharmaceuticals, Inc.|900 Ridgebury Road|P. O. Box 368|Ridgefield|Connecticut|6877|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cervical cancer.",
                    "umls_id": "C4048328",
                    "parsed_text": "cervical cancer"
                }
            }
        ]
    },
    {
        "_id": "QEEAPRPFLLJWCF-UHFFFAOYSA-K",
        "Orphan Drug Designations": [
            {
                "compound_id": 13344,
                "inchl_key": "QEEAPRPFLLJWCF-UHFFFAOYSA-K",
                "generic_name": "Potassium citrate",
                "trade_name": "Urocit-K",
                "designated_date": "11/01/1984",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a008/30/1985\u00a0",
                "exclusivity_end_date": "\u00a008/30/1992\u00a0",
                "sponsor": "University of Texas Health Science Center at Dallas|5323 Harry Hines Blvd|Dallas|Texas|75235|United States",
                "orphan_designation": {
                    "original_text": "Prevention of uric acid nephrolithiasis.",
                    "umls_id": "C0558595",
                    "parsed_text": "Uric acid nephrolithiasis"
                }
            },
            {
                "compound_id": 13344,
                "inchl_key": "QEEAPRPFLLJWCF-UHFFFAOYSA-K",
                "generic_name": "Potassium citrate",
                "trade_name": "Urocit-K",
                "designated_date": "11/01/1984",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prevention of recurring calcium conating stines associated with a deficiency in the urine.",
                "marketing_approval_date": "\u00a008/07/1985\u00a0",
                "exclusivity_end_date": "\u00a008/07/1992\u00a0",
                "sponsor": "University of Texas Health Science Center at Dallas|5323 Harry Hines Blvd|Dallas|Texas|75235|United States",
                "orphan_designation": {
                    "original_text": "1. Prevention of calcium renal stones in patients with hypocitraturia 2. For avoidance of the complication of calcium stone formation in patients with uric lithiasis.",
                    "umls_id": "C0009566,C0022650,C0023869,C2673444",
                    "parsed_text": "Complication , renal stones , Lithiasis , Hypocitraturia"
                }
            }
        ]
    },
    {
        "_id": "OGSBUKJUDHAQEA-WMCAAGNKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 148121,
                "inchl_key": "OGSBUKJUDHAQEA-WMCAAGNKSA-N",
                "generic_name": "pralatrexate",
                "designated_date": "10/20/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Acrotech Biopharma LLC|279 Princeton Hightstown Road|East Windsor|New Jersey|8520|United States",
                "orphan_designation": {
                    "original_text": "Treatment of follicular lymphoma",
                    "umls_id": "C0024301",
                    "parsed_text": "follicular lymphoma"
                }
            },
            {
                "compound_id": 148121,
                "inchl_key": "OGSBUKJUDHAQEA-WMCAAGNKSA-N",
                "generic_name": "pralatrexate",
                "designated_date": "05/03/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Acrotech Biopharma LLC|279 Princeton Hightstown Road|East Windsor|New Jersey|8520|United States",
                "orphan_designation": {
                    "original_text": "Treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder",
                    "umls_id": "C0279680,C3160869",
                    "parsed_text": "Transitional Cell Carcinoma of the Urinary Bladder , Metastatic Transitional Cell Carcinoma"
                }
            },
            {
                "compound_id": 148121,
                "inchl_key": "OGSBUKJUDHAQEA-WMCAAGNKSA-N",
                "generic_name": "pralatrexate",
                "designated_date": "10/20/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Acrotech Biopharma LLC|279 Princeton Hightstown Road|East Windsor|New Jersey|8520|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diffuse large B-cell lymphoma",
                    "umls_id": "C1332201",
                    "parsed_text": "Diffuse Large B-Cell Lymphoma"
                }
            },
            {
                "compound_id": 148121,
                "inchl_key": "OGSBUKJUDHAQEA-WMCAAGNKSA-N",
                "generic_name": "pralatrexate",
                "trade_name": "Folotyn",
                "designated_date": "07/20/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with relapsed or refractory peripheral T-cell lymphoma",
                "marketing_approval_date": "\u00a009/24/2009\u00a0",
                "exclusivity_end_date": "\u00a009/24/2016\u00a0",
                "sponsor": "Acrotech Biopharma LLC|279 Princeton Hightstown Road|East Windsor|New Jersey|8520|United States",
                "orphan_designation": {
                    "original_text": "Treatment of T-cell lymphoma",
                    "umls_id": "C0079772",
                    "parsed_text": "T-Cell Lymphoma"
                }
            }
        ]
    },
    {
        "_id": "FSVJFNAIGNNGKK-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4891,
                "inchl_key": "FSVJFNAIGNNGKK-UHFFFAOYSA-N",
                "generic_name": "Praziquantel",
                "designated_date": "04/18/1988",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EM Pharmaceuticals, Inc.",
                "orphan_designation": {
                    "original_text": "Treatment of neurocysticercosis.",
                    "umls_id": "C0338437",
                    "parsed_text": "Neurocysticercosis"
                }
            }
        ]
    },
    {
        "_id": "HFVNWDWLWUCIHC-GUPDPFMOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 34457,
                "inchl_key": "HFVNWDWLWUCIHC-GUPDPFMOSA-N",
                "generic_name": "Prednimustine",
                "designated_date": "06/17/1985",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacia Inc.|P.O. Box 16529|Columbus|Ohio|43216|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant non-Hodgkin's lymphomas.",
                    "umls_id": "C0019829",
                    "parsed_text": "hodgkin's lymphomas"
                }
            }
        ]
    },
    {
        "_id": "ORMHJJCIJXWHFH-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9925625,
                "inchl_key": "ORMHJJCIJXWHFH-UHFFFAOYSA-N",
                "generic_name": "propofol hemisuccinate",
                "designated_date": "08/19/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EpaleX Corporation|305 Lytton Avenue|Palo Alto|California|94301|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute repetitive seizures",
                    "umls_id": "C0036572",
                    "parsed_text": "Seizures"
                }
            }
        ]
    },
    {
        "_id": "RZFNKJVCPDLQQA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2725002,
                "inchl_key": "RZFNKJVCPDLQQA-UHFFFAOYSA-N",
                "generic_name": "Quinacrine hydrochloride",
                "designated_date": "10/17/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Lyphomed, Inc.",
                "orphan_designation": {
                    "original_text": "For prevention of recurrence of pneumothorax in patients at high risk of recurrence.",
                    "umls_id": "C0032326",
                    "parsed_text": "Pneumothorax"
                }
            }
        ]
    },
    {
        "_id": "GPKJTRJOBQGKQK-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 237,
                "inchl_key": "GPKJTRJOBQGKQK-UHFFFAOYSA-N",
                "generic_name": "Quinacrine hydrochloride",
                "designated_date": "10/17/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Lyphomed, Inc.",
                "orphan_designation": {
                    "original_text": "For prevention of recurrence of pneumothorax in patients at high risk of recurrence.",
                    "umls_id": "C0032326",
                    "parsed_text": "Pneumothorax"
                }
            },
            {
                "compound_id": 237,
                "inchl_key": "GPKJTRJOBQGKQK-UHFFFAOYSA-N",
                "generic_name": "quinacrine",
                "designated_date": "09/28/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cleveland BioLabs, Inc & Incuron, LLC Joint Ventur|73 High Street|Buffalo|New York|14203|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            },
            {
                "compound_id": 237,
                "inchl_key": "GPKJTRJOBQGKQK-UHFFFAOYSA-N",
                "generic_name": "quinacrine",
                "designated_date": "09/10/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Collaborations Pharmaceuticals, Inc.|5616 Hilltop Needmore Rd,|Fuquay Varina|North Carolina|27526|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Ebola Infection",
                    "umls_id": "C0282687",
                    "parsed_text": "Ebola Infection"
                }
            }
        ]
    },
    {
        "_id": "UKZANTJXIMWQCH-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5351141,
                "inchl_key": "UKZANTJXIMWQCH-UHFFFAOYSA-N",
                "generic_name": "Quinacrine hydrochloride",
                "designated_date": "10/17/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Lyphomed, Inc.",
                "orphan_designation": {
                    "original_text": "For prevention of recurrence of pneumothorax in patients at high risk of recurrence.",
                    "umls_id": "C0032326",
                    "parsed_text": "Pneumothorax"
                }
            }
        ]
    },
    {
        "_id": "UDKVBVICMUEIKS-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6239,
                "inchl_key": "UDKVBVICMUEIKS-UHFFFAOYSA-N",
                "generic_name": "Quinacrine hydrochloride",
                "designated_date": "10/17/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Lyphomed, Inc.",
                "orphan_designation": {
                    "original_text": "For prevention of recurrence of pneumothorax in patients at high risk of recurrence.",
                    "umls_id": "C0032326",
                    "parsed_text": "Pneumothorax"
                }
            }
        ]
    },
    {
        "_id": "CBQGYUDMJHNJBX-MOPGFXCFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5311403,
                "inchl_key": "CBQGYUDMJHNJBX-MOPGFXCFSA-N",
                "generic_name": "reboxetine",
                "designated_date": "10/15/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Axsome Therapeutics, Inc.|25 Broadway, 9th Floor|Suite 2000|New York|New York|10004|United States",
                "orphan_designation": {
                    "original_text": "Treatment of narcolepsy",
                    "umls_id": "C0027404",
                    "parsed_text": "Narcolepsy"
                }
            }
        ]
    },
    {
        "_id": "CBQGYUDMJHNJBX-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3022645,
                "inchl_key": "CBQGYUDMJHNJBX-UHFFFAOYSA-N",
                "generic_name": "reboxetine",
                "designated_date": "10/15/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Axsome Therapeutics, Inc.|25 Broadway, 9th Floor|Suite 2000|New York|New York|10004|United States",
                "orphan_designation": {
                    "original_text": "Treatment of narcolepsy",
                    "umls_id": "C0027404",
                    "parsed_text": "Narcolepsy"
                }
            }
        ]
    },
    {
        "_id": "CBQGYUDMJHNJBX-OALUTQOASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 65856,
                "inchl_key": "CBQGYUDMJHNJBX-OALUTQOASA-N",
                "generic_name": "reboxetine",
                "designated_date": "10/15/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Axsome Therapeutics, Inc.|25 Broadway, 9th Floor|Suite 2000|New York|New York|10004|United States",
                "orphan_designation": {
                    "original_text": "Treatment of narcolepsy",
                    "umls_id": "C0027404",
                    "parsed_text": "Narcolepsy"
                }
            }
        ]
    },
    {
        "_id": "CBQGYUDMJHNJBX-RTBURBONSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 127151,
                "inchl_key": "CBQGYUDMJHNJBX-RTBURBONSA-N",
                "generic_name": "reboxetine",
                "designated_date": "10/15/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Axsome Therapeutics, Inc.|25 Broadway, 9th Floor|Suite 2000|New York|New York|10004|United States",
                "orphan_designation": {
                    "original_text": "Treatment of narcolepsy",
                    "umls_id": "C0027404",
                    "parsed_text": "Narcolepsy"
                }
            }
        ]
    },
    {
        "_id": "BXNMTOQRYBFHNZ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 159603,
                "inchl_key": "BXNMTOQRYBFHNZ-UHFFFAOYSA-N",
                "generic_name": "resiquimod",
                "designated_date": "05/24/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Galderma Research and Development, LLC|14501 North Freeway|Fort Worth|Texas|76177|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cutaneous T-cell lymphoma",
                    "umls_id": "C0079773",
                    "parsed_text": "cutaneous T-cell lymphoma"
                }
            }
        ]
    },
    {
        "_id": "WDZCUPBHRAEYDL-YUUOHQKVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 138404395,
                "inchl_key": "WDZCUPBHRAEYDL-YUUOHQKVSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "03/12/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel, Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 138404395,
                "inchl_key": "WDZCUPBHRAEYDL-YUUOHQKVSA-N",
                "generic_name": "Rifapentine",
                "trade_name": "Priftin",
                "designated_date": "06/09/1995",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a006/22/1998\u00a0",
                "exclusivity_end_date": "\u00a006/22/2005\u00a0",
                "sponsor": "Hoechst Marion Roussel|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary tuberculosis.",
                    "umls_id": "C0041327",
                    "parsed_text": "Pulmonary tuberculosis"
                }
            },
            {
                "compound_id": 138404395,
                "inchl_key": "WDZCUPBHRAEYDL-YUUOHQKVSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "06/09/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel , Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Mycobacterium avium complex in patients with AIDS.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            }
        ]
    },
    {
        "_id": "WDZCUPBHRAEYDL-RDKOBYJASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 137235501,
                "inchl_key": "WDZCUPBHRAEYDL-RDKOBYJASA-N",
                "generic_name": "Rifapentine",
                "designated_date": "03/12/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel, Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 137235501,
                "inchl_key": "WDZCUPBHRAEYDL-RDKOBYJASA-N",
                "generic_name": "Rifapentine",
                "trade_name": "Priftin",
                "designated_date": "06/09/1995",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a006/22/1998\u00a0",
                "exclusivity_end_date": "\u00a006/22/2005\u00a0",
                "sponsor": "Hoechst Marion Roussel|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary tuberculosis.",
                    "umls_id": "C0041327",
                    "parsed_text": "Pulmonary tuberculosis"
                }
            },
            {
                "compound_id": 137235501,
                "inchl_key": "WDZCUPBHRAEYDL-RDKOBYJASA-N",
                "generic_name": "Rifapentine",
                "designated_date": "06/09/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel , Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Mycobacterium avium complex in patients with AIDS.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            }
        ]
    },
    {
        "_id": "WDZCUPBHRAEYDL-LBJWSYCFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 137091916,
                "inchl_key": "WDZCUPBHRAEYDL-LBJWSYCFSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "03/12/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel, Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 137091916,
                "inchl_key": "WDZCUPBHRAEYDL-LBJWSYCFSA-N",
                "generic_name": "Rifapentine",
                "trade_name": "Priftin",
                "designated_date": "06/09/1995",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a006/22/1998\u00a0",
                "exclusivity_end_date": "\u00a006/22/2005\u00a0",
                "sponsor": "Hoechst Marion Roussel|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary tuberculosis.",
                    "umls_id": "C0041327",
                    "parsed_text": "Pulmonary tuberculosis"
                }
            },
            {
                "compound_id": 137091916,
                "inchl_key": "WDZCUPBHRAEYDL-LBJWSYCFSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "06/09/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel , Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Mycobacterium avium complex in patients with AIDS.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            }
        ]
    },
    {
        "_id": "WDZCUPBHRAEYDL-USLNORDZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 137030254,
                "inchl_key": "WDZCUPBHRAEYDL-USLNORDZSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "03/12/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel, Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 137030254,
                "inchl_key": "WDZCUPBHRAEYDL-USLNORDZSA-N",
                "generic_name": "Rifapentine",
                "trade_name": "Priftin",
                "designated_date": "06/09/1995",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a006/22/1998\u00a0",
                "exclusivity_end_date": "\u00a006/22/2005\u00a0",
                "sponsor": "Hoechst Marion Roussel|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary tuberculosis.",
                    "umls_id": "C0041327",
                    "parsed_text": "Pulmonary tuberculosis"
                }
            },
            {
                "compound_id": 137030254,
                "inchl_key": "WDZCUPBHRAEYDL-USLNORDZSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "06/09/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel , Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Mycobacterium avium complex in patients with AIDS.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            }
        ]
    },
    {
        "_id": "WDZCUPBHRAEYDL-QFWJEWEWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135887820,
                "inchl_key": "WDZCUPBHRAEYDL-QFWJEWEWSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "03/12/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel, Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 135887820,
                "inchl_key": "WDZCUPBHRAEYDL-QFWJEWEWSA-N",
                "generic_name": "Rifapentine",
                "trade_name": "Priftin",
                "designated_date": "06/09/1995",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a006/22/1998\u00a0",
                "exclusivity_end_date": "\u00a006/22/2005\u00a0",
                "sponsor": "Hoechst Marion Roussel|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary tuberculosis.",
                    "umls_id": "C0041327",
                    "parsed_text": "Pulmonary tuberculosis"
                }
            },
            {
                "compound_id": 135887820,
                "inchl_key": "WDZCUPBHRAEYDL-QFWJEWEWSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "06/09/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel , Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Mycobacterium avium complex in patients with AIDS.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            }
        ]
    },
    {
        "_id": "WDZCUPBHRAEYDL-FHDUCCPFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 136122663,
                "inchl_key": "WDZCUPBHRAEYDL-FHDUCCPFSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "03/12/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel, Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 136122663,
                "inchl_key": "WDZCUPBHRAEYDL-FHDUCCPFSA-N",
                "generic_name": "Rifapentine",
                "trade_name": "Priftin",
                "designated_date": "06/09/1995",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a006/22/1998\u00a0",
                "exclusivity_end_date": "\u00a006/22/2005\u00a0",
                "sponsor": "Hoechst Marion Roussel|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary tuberculosis.",
                    "umls_id": "C0041327",
                    "parsed_text": "Pulmonary tuberculosis"
                }
            },
            {
                "compound_id": 136122663,
                "inchl_key": "WDZCUPBHRAEYDL-FHDUCCPFSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "06/09/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel , Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Mycobacterium avium complex in patients with AIDS.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            }
        ]
    },
    {
        "_id": "WDZCUPBHRAEYDL-METIDKAPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135932821,
                "inchl_key": "WDZCUPBHRAEYDL-METIDKAPSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "03/12/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel, Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 135932821,
                "inchl_key": "WDZCUPBHRAEYDL-METIDKAPSA-N",
                "generic_name": "Rifapentine",
                "trade_name": "Priftin",
                "designated_date": "06/09/1995",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a006/22/1998\u00a0",
                "exclusivity_end_date": "\u00a006/22/2005\u00a0",
                "sponsor": "Hoechst Marion Roussel|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary tuberculosis.",
                    "umls_id": "C0041327",
                    "parsed_text": "Pulmonary tuberculosis"
                }
            },
            {
                "compound_id": 135932821,
                "inchl_key": "WDZCUPBHRAEYDL-METIDKAPSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "06/09/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel , Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Mycobacterium avium complex in patients with AIDS.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            }
        ]
    },
    {
        "_id": "WDZCUPBHRAEYDL-PWXWUWFUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135925739,
                "inchl_key": "WDZCUPBHRAEYDL-PWXWUWFUSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "03/12/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel, Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 135925739,
                "inchl_key": "WDZCUPBHRAEYDL-PWXWUWFUSA-N",
                "generic_name": "Rifapentine",
                "trade_name": "Priftin",
                "designated_date": "06/09/1995",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a006/22/1998\u00a0",
                "exclusivity_end_date": "\u00a006/22/2005\u00a0",
                "sponsor": "Hoechst Marion Roussel|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary tuberculosis.",
                    "umls_id": "C0041327",
                    "parsed_text": "Pulmonary tuberculosis"
                }
            },
            {
                "compound_id": 135925739,
                "inchl_key": "WDZCUPBHRAEYDL-PWXWUWFUSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "06/09/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel , Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Mycobacterium avium complex in patients with AIDS.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            }
        ]
    },
    {
        "_id": "WDZCUPBHRAEYDL-HJTBMZGUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135749824,
                "inchl_key": "WDZCUPBHRAEYDL-HJTBMZGUSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "03/12/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel, Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 135749824,
                "inchl_key": "WDZCUPBHRAEYDL-HJTBMZGUSA-N",
                "generic_name": "Rifapentine",
                "trade_name": "Priftin",
                "designated_date": "06/09/1995",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a006/22/1998\u00a0",
                "exclusivity_end_date": "\u00a006/22/2005\u00a0",
                "sponsor": "Hoechst Marion Roussel|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary tuberculosis.",
                    "umls_id": "C0041327",
                    "parsed_text": "Pulmonary tuberculosis"
                }
            },
            {
                "compound_id": 135749824,
                "inchl_key": "WDZCUPBHRAEYDL-HJTBMZGUSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "06/09/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel , Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Mycobacterium avium complex in patients with AIDS.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            }
        ]
    },
    {
        "_id": "WDZCUPBHRAEYDL-BGZYVKEHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 136246610,
                "inchl_key": "WDZCUPBHRAEYDL-BGZYVKEHSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "03/12/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel, Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 136246610,
                "inchl_key": "WDZCUPBHRAEYDL-BGZYVKEHSA-N",
                "generic_name": "Rifapentine",
                "trade_name": "Priftin",
                "designated_date": "06/09/1995",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a006/22/1998\u00a0",
                "exclusivity_end_date": "\u00a006/22/2005\u00a0",
                "sponsor": "Hoechst Marion Roussel|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary tuberculosis.",
                    "umls_id": "C0041327",
                    "parsed_text": "Pulmonary tuberculosis"
                }
            },
            {
                "compound_id": 136246610,
                "inchl_key": "WDZCUPBHRAEYDL-BGZYVKEHSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "06/09/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel , Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Mycobacterium avium complex in patients with AIDS.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            }
        ]
    },
    {
        "_id": "WDZCUPBHRAEYDL-LYDPARFQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135968625,
                "inchl_key": "WDZCUPBHRAEYDL-LYDPARFQSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "03/12/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel, Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 135968625,
                "inchl_key": "WDZCUPBHRAEYDL-LYDPARFQSA-N",
                "generic_name": "Rifapentine",
                "trade_name": "Priftin",
                "designated_date": "06/09/1995",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a006/22/1998\u00a0",
                "exclusivity_end_date": "\u00a006/22/2005\u00a0",
                "sponsor": "Hoechst Marion Roussel|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary tuberculosis.",
                    "umls_id": "C0041327",
                    "parsed_text": "Pulmonary tuberculosis"
                }
            },
            {
                "compound_id": 135968625,
                "inchl_key": "WDZCUPBHRAEYDL-LYDPARFQSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "06/09/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel , Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Mycobacterium avium complex in patients with AIDS.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            }
        ]
    },
    {
        "_id": "WDZCUPBHRAEYDL-NAFQJNKLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 136238508,
                "inchl_key": "WDZCUPBHRAEYDL-NAFQJNKLSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "03/12/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel, Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 136238508,
                "inchl_key": "WDZCUPBHRAEYDL-NAFQJNKLSA-N",
                "generic_name": "Rifapentine",
                "trade_name": "Priftin",
                "designated_date": "06/09/1995",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a006/22/1998\u00a0",
                "exclusivity_end_date": "\u00a006/22/2005\u00a0",
                "sponsor": "Hoechst Marion Roussel|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary tuberculosis.",
                    "umls_id": "C0041327",
                    "parsed_text": "Pulmonary tuberculosis"
                }
            },
            {
                "compound_id": 136238508,
                "inchl_key": "WDZCUPBHRAEYDL-NAFQJNKLSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "06/09/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel , Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Mycobacterium avium complex in patients with AIDS.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            }
        ]
    },
    {
        "_id": "WDZCUPBHRAEYDL-QEDJKGLXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 136073066,
                "inchl_key": "WDZCUPBHRAEYDL-QEDJKGLXSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "03/12/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel, Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 136073066,
                "inchl_key": "WDZCUPBHRAEYDL-QEDJKGLXSA-N",
                "generic_name": "Rifapentine",
                "trade_name": "Priftin",
                "designated_date": "06/09/1995",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a006/22/1998\u00a0",
                "exclusivity_end_date": "\u00a006/22/2005\u00a0",
                "sponsor": "Hoechst Marion Roussel|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary tuberculosis.",
                    "umls_id": "C0041327",
                    "parsed_text": "Pulmonary tuberculosis"
                }
            },
            {
                "compound_id": 136073066,
                "inchl_key": "WDZCUPBHRAEYDL-QEDJKGLXSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "06/09/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel , Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Mycobacterium avium complex in patients with AIDS.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            }
        ]
    },
    {
        "_id": "WDZCUPBHRAEYDL-PRHSTWAZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135659016,
                "inchl_key": "WDZCUPBHRAEYDL-PRHSTWAZSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "03/12/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel, Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 135659016,
                "inchl_key": "WDZCUPBHRAEYDL-PRHSTWAZSA-N",
                "generic_name": "Rifapentine",
                "trade_name": "Priftin",
                "designated_date": "06/09/1995",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a006/22/1998\u00a0",
                "exclusivity_end_date": "\u00a006/22/2005\u00a0",
                "sponsor": "Hoechst Marion Roussel|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary tuberculosis.",
                    "umls_id": "C0041327",
                    "parsed_text": "Pulmonary tuberculosis"
                }
            },
            {
                "compound_id": 135659016,
                "inchl_key": "WDZCUPBHRAEYDL-PRHSTWAZSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "06/09/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel , Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Mycobacterium avium complex in patients with AIDS.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            }
        ]
    },
    {
        "_id": "WDZCUPBHRAEYDL-GZAUEHORSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135403821,
                "inchl_key": "WDZCUPBHRAEYDL-GZAUEHORSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "03/12/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel, Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            },
            {
                "compound_id": 135403821,
                "inchl_key": "WDZCUPBHRAEYDL-GZAUEHORSA-N",
                "generic_name": "Rifapentine",
                "trade_name": "Priftin",
                "designated_date": "06/09/1995",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a006/22/1998\u00a0",
                "exclusivity_end_date": "\u00a006/22/2005\u00a0",
                "sponsor": "Hoechst Marion Roussel|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary tuberculosis.",
                    "umls_id": "C0041327",
                    "parsed_text": "Pulmonary tuberculosis"
                }
            },
            {
                "compound_id": 135403821,
                "inchl_key": "WDZCUPBHRAEYDL-GZAUEHORSA-N",
                "generic_name": "Rifapentine",
                "designated_date": "06/09/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoechst Marion Roussel , Inc.|P.O. Box 9627|Mail Station: H3-M2516|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Mycobacterium avium complex in patients with AIDS.",
                    "umls_id": "C0001175,C0026914",
                    "parsed_text": "AIDS , Mycobacterium avium Complex"
                }
            }
        ]
    },
    {
        "_id": "OWBFCJROIKNMGD-BQYQJAHWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6918736,
                "inchl_key": "OWBFCJROIKNMGD-BQYQJAHWSA-N",
                "generic_name": "rigosertib",
                "designated_date": "09/03/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Onconova Therapeutics, Inc.|375 Pheasant Run|Newtown|Pennsylvania|18940|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndromes",
                    "umls_id": "C3463824",
                    "parsed_text": "Myelodysplastic Syndromes"
                }
            },
            {
                "compound_id": 6918736,
                "inchl_key": "OWBFCJROIKNMGD-BQYQJAHWSA-N",
                "generic_name": "rigosertib",
                "designated_date": "03/18/2011",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Onconova Therapeutics, Inc|375 Pheasant Run|Newtown|Pennsylvania|18940|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer.",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 6918736,
                "inchl_key": "OWBFCJROIKNMGD-BQYQJAHWSA-N",
                "generic_name": "rigosertib",
                "designated_date": "03/16/2012",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Onconova Therapeutics, Inc.|375 Pheasant Run|Newton|Pennsylvania|18940|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "WPEWQEMJFLWMLV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11315474,
                "inchl_key": "WPEWQEMJFLWMLV-UHFFFAOYSA-N",
                "generic_name": "Rivoceranib",
                "designated_date": "02/02/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Elevar Therapeutics, Inc.|2825 E Cottonwood Pkwy, Suite 180|Salt Lake City|Utah|84121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Adenoid Cystic Carcinoma",
                    "umls_id": "C0010606",
                    "parsed_text": "Adenoid Cystic Carcinoma"
                }
            }
        ]
    },
    {
        "_id": "RZJQGNCSTQAWON-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5090,
                "inchl_key": "RZJQGNCSTQAWON-UHFFFAOYSA-N",
                "generic_name": "rofecoxib",
                "designated_date": "03/16/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MERCK & Co., Inc.|126 East Lincoln Ave.|Rahway|New Jersey|7065|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls_id": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "compound_id": 5090,
                "inchl_key": "RZJQGNCSTQAWON-UHFFFAOYSA-N",
                "generic_name": "rofecoxib",
                "designated_date": "09/26/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Tremeau Pharmaceuticals, Inc.|1 Broadway|14th Floor|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hemophilic arthropathy (HA)",
                    "umls_id": "C0263725",
                    "parsed_text": "Hemophilic arthropathy"
                }
            }
        ]
    },
    {
        "_id": "MUSGYEMSJUFFHT-UWABRSFTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 131634231,
                "inchl_key": "MUSGYEMSJUFFHT-UWABRSFTSA-N",
                "generic_name": "S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)",
                "designated_date": "10/09/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Amyndas Pharmaceuticals|Kyprou 27|Glyfada|16675|Greece",
                "orphan_designation": {
                    "original_text": "Treatment of paroxysmal nocturnal hemoglobinuria (PNH)",
                    "umls_id": "C0024790,C1418558",
                    "parsed_text": "Paroxysmal nocturnal hemoglobinuria , paroxysmal nocturnal hemoglobinuria"
                }
            }
        ]
    },
    {
        "_id": "ULRUOUDIQPERIJ-PQURJYPBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 91668186,
                "inchl_key": "ULRUOUDIQPERIJ-PQURJYPBSA-N",
                "generic_name": "sacituzumab govitecan",
                "designated_date": "11/27/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States",
                "orphan_designation": {
                    "original_text": "Treatment of small cell lung cancer",
                    "umls_id": "C3540630",
                    "parsed_text": "Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 91668186,
                "inchl_key": "ULRUOUDIQPERIJ-PQURJYPBSA-N",
                "generic_name": "sacituzumab govitecan",
                "designated_date": "10/08/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immunomedics, Inc.|300 The American Rd|Morris Plains|New Jersey|7950|United States",
                "orphan_designation": {
                    "original_text": "treatment of malignant glioma",
                    "umls_id": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            },
            {
                "compound_id": 91668186,
                "inchl_key": "ULRUOUDIQPERIJ-PQURJYPBSA-N",
                "generic_name": "sacituzumab govitecan",
                "designated_date": "05/29/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer.",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "IYETZZCWLLUHIJ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 92913,
                "inchl_key": "IYETZZCWLLUHIJ-UHFFFAOYSA-N",
                "generic_name": "Selegiline HCl",
                "trade_name": "Eldepryl",
                "designated_date": "11/07/1984",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a006/05/1989\u00a0",
                "exclusivity_end_date": "\u00a006/05/1996\u00a0",
                "sponsor": "Somerset Pharmaceuticals, Inc.|400 Morris Ave., Suite 7s|Denville|New Jersey|7834|United States",
                "orphan_designation": {
                    "original_text": "As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism.",
                    "umls_id": "C0030567,C0030568,C0030569",
                    "parsed_text": "Idiopathic Parkinson's disease , Postencephalitic Parkinsonism , Symptomatic parkinsonism"
                }
            }
        ]
    },
    {
        "_id": "IYETZZCWLLUHIJ-YDALLXLXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 199604,
                "inchl_key": "IYETZZCWLLUHIJ-YDALLXLXSA-N",
                "generic_name": "Selegiline HCl",
                "trade_name": "Eldepryl",
                "designated_date": "11/07/1984",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a006/05/1989\u00a0",
                "exclusivity_end_date": "\u00a006/05/1996\u00a0",
                "sponsor": "Somerset Pharmaceuticals, Inc.|400 Morris Ave., Suite 7s|Denville|New Jersey|7834|United States",
                "orphan_designation": {
                    "original_text": "As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism.",
                    "umls_id": "C0030567,C0030568,C0030569",
                    "parsed_text": "Idiopathic Parkinson's disease , Postencephalitic Parkinsonism , Symptomatic parkinsonism"
                }
            }
        ]
    },
    {
        "_id": "IYETZZCWLLUHIJ-UTONKHPSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 26758,
                "inchl_key": "IYETZZCWLLUHIJ-UTONKHPSSA-N",
                "generic_name": "Selegiline HCl",
                "trade_name": "Eldepryl",
                "designated_date": "11/07/1984",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a006/05/1989\u00a0",
                "exclusivity_end_date": "\u00a006/05/1996\u00a0",
                "sponsor": "Somerset Pharmaceuticals, Inc.|400 Morris Ave., Suite 7s|Denville|New Jersey|7834|United States",
                "orphan_designation": {
                    "original_text": "As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism.",
                    "umls_id": "C0030567,C0030568,C0030569",
                    "parsed_text": "Idiopathic Parkinson's disease , Postencephalitic Parkinsonism , Symptomatic parkinsonism"
                }
            }
        ]
    },
    {
        "_id": "CYOHGALHFOKKQC-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10127622,
                "inchl_key": "CYOHGALHFOKKQC-UHFFFAOYSA-N",
                "generic_name": "selumetinib",
                "designated_date": "02/14/2018",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "KOSELUGO is indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)",
                "marketing_approval_date": "\u00a004/10/2020\u00a0",
                "exclusivity_end_date": "\u00a004/10/2027\u00a0",
                "exclusivity_protected_indication": "Indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).",
                "sponsor": "AstraZeneca Pharmaceuticals LP|1800 Concord Pike|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Neurofibromatosis Type 1",
                    "umls_id": "C0027831",
                    "parsed_text": "Neurofibromatosis type 1"
                }
            },
            {
                "compound_id": 10127622,
                "inchl_key": "CYOHGALHFOKKQC-UHFFFAOYSA-N",
                "generic_name": "selumetinib",
                "designated_date": "04/15/2015",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P. O. Box 8355|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of uveal melanoma.",
                    "umls_id": "C0220633",
                    "parsed_text": "Uveal melanoma"
                }
            },
            {
                "compound_id": 10127622,
                "inchl_key": "CYOHGALHFOKKQC-UHFFFAOYSA-N",
                "generic_name": "selumetinib",
                "designated_date": "05/10/2016",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P.O. Box 8355|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Adjuvant treatment of patients with stage III or stage IV differentiated thyroid cancer.",
                    "umls_id": "C1337013",
                    "parsed_text": "Differentiated Thyroid Cancer"
                }
            }
        ]
    },
    {
        "_id": "VPVOXUSPXFPWBN-VKHMYHEASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135398579,
                "inchl_key": "VPVOXUSPXFPWBN-VKHMYHEASA-N",
                "generic_name": "sepiapterin",
                "designated_date": "03/04/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PTC Therapeutics, Inc.|100 Corporate Court|South Plainfield|New Jersey|7080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hyperphenylalaninemia",
                    "umls_id": "C0751435",
                    "parsed_text": "Hyperphenylalaninemia"
                }
            },
            {
                "compound_id": 135398579,
                "inchl_key": "VPVOXUSPXFPWBN-VKHMYHEASA-N",
                "generic_name": "sepiapterin",
                "designated_date": "02/19/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PTC Therapeutics, Inc. (PTC)|65 William Street, Suite 200|Wellesley|Massachusetts|2481|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary tetrahydrobiopterin deficiency",
                    "umls_id": "C0751436",
                    "parsed_text": "Tetrahydrobiopterin Deficiency"
                }
            }
        ]
    },
    {
        "_id": "HDHDTKMUACZDAA-PHNIDTBTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11993702,
                "inchl_key": "HDHDTKMUACZDAA-PHNIDTBTSA-N",
                "generic_name": "setmelanotide",
                "designated_date": "09/19/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rhythm Pharmaceuticals, Inc|222 Berkeley Street|Suite 1200|Boston|Massachusetts|2116|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Bardet-Biedl syndrome",
                    "umls_id": "C0752166",
                    "parsed_text": "Bardet-Biedl Syndrome"
                }
            },
            {
                "compound_id": 11993702,
                "inchl_key": "HDHDTKMUACZDAA-PHNIDTBTSA-N",
                "generic_name": "setmelanotide",
                "trade_name": "Imcivree",
                "designated_date": "11/27/2017",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).",
                "marketing_approval_date": "\u00a011/25/2020\u00a0",
                "exclusivity_end_date": "\u00a011/25/2027\u00a0",
                "exclusivity_protected_indication": "Chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).",
                "sponsor": "Rhythm Pharmaceuticals, Inc.|222 Berkeley St. Suite 1200|Boston|Massachusetts|2116|United States",
                "orphan_designation": {
                    "original_text": "Treatment of leptin receptor deficiency",
                    "umls_id": "C3554225",
                    "parsed_text": "LEPTIN RECEPTOR DEFICIENCY"
                }
            },
            {
                "compound_id": 11993702,
                "inchl_key": "HDHDTKMUACZDAA-PHNIDTBTSA-N",
                "generic_name": "setmelanotide",
                "trade_name": "Imcivree",
                "designated_date": "04/04/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).",
                "marketing_approval_date": "\u00a011/25/2020\u00a0",
                "exclusivity_end_date": "\u00a011/25/2027\u00a0",
                "exclusivity_protected_indication": "chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).",
                "sponsor": "Rhythm Pharmaceuticals, Inc.|222 Berkeley St. Suite 1200|Boston|Massachusetts|2116|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pro-opiomelanocortin (POMC) deficiency due to mutations in the POMC gene",
                    "umls_id": "C1337111",
                    "parsed_text": "POMC"
                }
            },
            {
                "compound_id": 11993702,
                "inchl_key": "HDHDTKMUACZDAA-PHNIDTBTSA-N",
                "generic_name": "setmelanotide",
                "designated_date": "09/21/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rhythm Metabolics, Inc.|855 Boylston Street|11th Floor|Boston|Massachusetts|2116|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Prader-Willi Syndrome.",
                    "umls_id": "C0032897",
                    "parsed_text": "Prader-Willi Syndrome"
                }
            }
        ]
    },
    {
        "_id": "MDTNUYUCUYPIHE-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11477084,
                "inchl_key": "MDTNUYUCUYPIHE-UHFFFAOYSA-N",
                "generic_name": "Sitaxsentan Sodium",
                "designated_date": "11/02/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer Global Research and Development|50 Pequot Avenue 6025-B4137|New London|Connecticut|6320|United States",
                "orphan_designation": {
                    "original_text": "For the treatment of pulmonary arterial hypertension in the absence of chronic obstructive pulmonary disease or congestive heart failure.",
                    "umls_id": "C0018802,C0024117,C3203102",
                    "parsed_text": "Congestive heart failure , CHRONIC OBSTRUCTIVE PULMONARY DISEASE , PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "URGAHOPLAPQHLN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 19758701,
                "inchl_key": "URGAHOPLAPQHLN-UHFFFAOYSA-N",
                "generic_name": "Sodium aluminosilicate",
                "designated_date": "03/04/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Westhaven Therapeutics Corporation|1825 K Street Northwest|Suite 510|Washington|District of Columbia|20006|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic hepatic encephalopathy",
                    "umls_id": "C4024937",
                    "parsed_text": "Chronic hepatic encephalopathy"
                }
            }
        ]
    },
    {
        "_id": "LUPNKHXLFSSUGS-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 517326,
                "inchl_key": "LUPNKHXLFSSUGS-UHFFFAOYSA-M",
                "generic_name": "Sodium dichloroacetate",
                "designated_date": "12/31/1997",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Questcor Pharmaceuticals, Inc.|3260 Whipple Rd.|Union City|California|94587|United States",
                "orphan_designation": {
                    "original_text": "Treatment of congenital lactic acidosis.",
                    "umls_id": "C4025276",
                    "parsed_text": "Congenital lactic acidosis"
                }
            },
            {
                "compound_id": 517326,
                "inchl_key": "LUPNKHXLFSSUGS-UHFFFAOYSA-M",
                "generic_name": "sodium dichloroacetate",
                "designated_date": "07/03/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EBD Group|2032 Corte del Nogal|Suite 120|Carlsbad|California|92011|United States",
                "orphan_designation": {
                    "original_text": "Use as an antidote in the management of systemic monochloroacetic acid poisoning",
                    "umls_id": "C4707283",
                    "parsed_text": "Systemic monochloroacetic acid poisoning"
                }
            },
            {
                "compound_id": 517326,
                "inchl_key": "LUPNKHXLFSSUGS-UHFFFAOYSA-M",
                "generic_name": "Sodium dichloroacetate",
                "designated_date": "06/11/1990",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Stacpoole, Peter W. M.D., Ph.D.|University of Florida|P.O. Box 100277|Gainesville|Florida|32610|United States",
                "orphan_designation": {
                    "original_text": "Treatment of homozygous familial hypercholesterolemia.",
                    "umls_id": "C0020445",
                    "parsed_text": "FAMILIAL HYPERCHOLESTEROLEMIA"
                }
            },
            {
                "compound_id": 517326,
                "inchl_key": "LUPNKHXLFSSUGS-UHFFFAOYSA-M",
                "generic_name": "Sodium dichloroacetate",
                "designated_date": "06/14/1999",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Questcor Pharmaceuticals, Inc.|3260 Whipple Rd.|Union City|California|94587|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe head injury.",
                    "umls_id": "C0018674",
                    "parsed_text": "HEAD INJURY"
                }
            },
            {
                "compound_id": 517326,
                "inchl_key": "LUPNKHXLFSSUGS-UHFFFAOYSA-M",
                "generic_name": "Sodium dichloroacetate",
                "designated_date": "11/10/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Stacpoole, Peter W. M.D., Ph.D.|University of Florida|P.O. Box 100277|Gainesville|Florida|32610|United States",
                "orphan_designation": {
                    "original_text": "Treatment of lactic acidosis in patients with severe malaria.",
                    "umls_id": "C0001125,C2747816",
                    "parsed_text": "LACTIC ACIDOSIS , Severe Malaria"
                }
            },
            {
                "compound_id": 517326,
                "inchl_key": "LUPNKHXLFSSUGS-UHFFFAOYSA-M",
                "generic_name": "Sodium dichloroacetate",
                "designated_date": "06/11/1990",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Stacpoole, Peter W. M.D., Ph.D.|University of Florida|P.O. Box 100277|Gainesville|Florida|32610|United States",
                "orphan_designation": {
                    "original_text": "Treatment of congenital lactic acidosis",
                    "umls_id": "C4025276",
                    "parsed_text": "Congenital lactic acidosis"
                }
            },
            {
                "compound_id": 517326,
                "inchl_key": "LUPNKHXLFSSUGS-UHFFFAOYSA-M",
                "generic_name": "sodium dichloroacetate",
                "designated_date": "11/29/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Peter W. Stackpoole, PhD, MD|University of FL College of Medicine|P. O. Box 100226|Gainesville|Florida|32611|United States",
                "orphan_designation": {
                    "original_text": "For pulmonary arterial hypertension.",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "XYGBKMMCQDZQOZ-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 23663870,
                "inchl_key": "XYGBKMMCQDZQOZ-UHFFFAOYSA-M",
                "generic_name": "sodium oxybate",
                "trade_name": "Xyrem",
                "designated_date": "11/07/1994",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Xyrem is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.",
                "marketing_approval_date": "\u00a010/26/2018\u00a0",
                "exclusivity_end_date": "\u00a010/26/2025\u00a0",
                "exclusivity_protected_indication": "Xyrem is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in pediatric patients 7 years of age and older with narcolepsy.",
                "sponsor": "Jazz Pharmaceuticals Ireland Limited|5th Floor Waterloo Exchange|Waterloo Road|Dublin 4|D04 E5W7|Ireland",
                "orphan_designation": {
                    "original_text": "Treatment of narcolepsy.",
                    "umls_id": "C0027404",
                    "parsed_text": "Narcolepsy"
                }
            },
            {
                "compound_id": 23663870,
                "inchl_key": "XYGBKMMCQDZQOZ-UHFFFAOYSA-M",
                "generic_name": "sodium oxybate",
                "trade_name": "Xyrem",
                "designated_date": "11/07/1994",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cataplexy associated with narcolepsy",
                "marketing_approval_date": "\u00a007/17/2002\u00a0",
                "exclusivity_end_date": "\u00a007/17/2009\u00a0",
                "sponsor": "Jazz Pharmaceuticals Ireland Limited|5th Floor Waterloo Exchange|Waterloo Road|Dublin 4|D04 E5W7|Ireland",
                "orphan_designation": {
                    "original_text": "Treatment of narcolepsy.",
                    "umls_id": "C0027404",
                    "parsed_text": "Narcolepsy"
                }
            },
            {
                "compound_id": 23663870,
                "inchl_key": "XYGBKMMCQDZQOZ-UHFFFAOYSA-M",
                "generic_name": "sodium oxybate",
                "trade_name": "Xyrem",
                "designated_date": "11/07/1994",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of excessive daytime sleepiness in patients with narcolepsy",
                "marketing_approval_date": "\u00a011/18/2005\u00a0",
                "exclusivity_end_date": "\u00a011/18/2012\u00a0",
                "sponsor": "Jazz Pharmaceuticals Ireland Limited|5th Floor Waterloo Exchange|Waterloo Road|Dublin 4|D04 E5W7|Ireland",
                "orphan_designation": {
                    "original_text": "Treatment of narcolepsy.",
                    "umls_id": "C0027404",
                    "parsed_text": "Narcolepsy"
                }
            }
        ]
    },
    {
        "_id": "VZZJRYRQSPEMTK-CALCHBBNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24775005,
                "inchl_key": "VZZJRYRQSPEMTK-CALCHBBNSA-N",
                "generic_name": "sonidegib",
                "designated_date": "03/23/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of medulloblastoma",
                    "umls_id": "C0025149",
                    "parsed_text": "Medulloblastoma"
                }
            }
        ]
    },
    {
        "_id": "MLDQJTXFUGDVEO-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 216239,
                "inchl_key": "MLDQJTXFUGDVEO-UHFFFAOYSA-N",
                "generic_name": "Sorafenib",
                "trade_name": "Nexavar",
                "designated_date": "04/20/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of unresectable hepatocellular carcinoma",
                "marketing_approval_date": "\u00a011/16/2007\u00a0",
                "exclusivity_end_date": "\u00a011/16/2014\u00a0",
                "sponsor": "Bayer Pharmaceuticals Corporation|400 Morgan Lane|West Haven|Connecticut|6516|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            },
            {
                "compound_id": 216239,
                "inchl_key": "MLDQJTXFUGDVEO-UHFFFAOYSA-N",
                "generic_name": "Sorafenib",
                "trade_name": "Nexavar",
                "designated_date": "10/08/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with advanced renal cell carcinoma",
                "marketing_approval_date": "\u00a012/20/2005\u00a0",
                "exclusivity_end_date": "\u00a012/20/2012\u00a0",
                "sponsor": "Bayer Pharmaceutical Corporation|400 Morgan Lane|West Haven|Connecticut|6516|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma.",
                    "umls_id": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            },
            {
                "compound_id": 216239,
                "inchl_key": "MLDQJTXFUGDVEO-UHFFFAOYSA-N",
                "generic_name": "sorafenib",
                "trade_name": "Nexavar",
                "designated_date": "12/12/2011",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DCT) that is refractory to radioactive iodine treatment.",
                "marketing_approval_date": "\u00a011/22/2013\u00a0",
                "exclusivity_end_date": "\u00a011/22/2020\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DCT) that is refractory to radioactive iodine treatment.",
                "sponsor": "Bayer HealthCare Pharmaceuticals, Inc.|100 Bayer Blvd.|PO Box 915|Whippany|New Jersey|7981|United States",
                "orphan_designation": {
                    "original_text": "Treatment of medullary thyroid cancer, anaplastic thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer",
                    "umls_id": "C0238461,C0238462,C0238463",
                    "parsed_text": "Cancer, Anaplastic Thyroid , medullary thyroid cancer , papillary thyroid cancer"
                }
            },
            {
                "compound_id": 216239,
                "inchl_key": "MLDQJTXFUGDVEO-UHFFFAOYSA-N",
                "generic_name": "sorafenib",
                "designated_date": "02/28/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bayer HealthCare Pharmaceuticals, Inc.|100 Bayer Boulevard|P.O. Box 915|Whippany|New Jersey|7981|United States",
                "orphan_designation": {
                    "original_text": "Treatment of desmoid tumors/aggressive fibromatosis",
                    "umls_id": "C0079218",
                    "parsed_text": "desmoid tumors"
                }
            },
            {
                "compound_id": 216239,
                "inchl_key": "MLDQJTXFUGDVEO-UHFFFAOYSA-N",
                "generic_name": "Sorafenib",
                "designated_date": "09/29/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bayer Pharmaceuticals Corp.|100 Bayer Blvd|P. O. Box 915|Whippany|New Jersey|7981|United States",
                "orphan_designation": {
                    "original_text": "Treatment of stage IIB through stage IV melanoma",
                    "umls_id": "C0278883",
                    "parsed_text": "stage iv melanoma"
                }
            }
        ]
    },
    {
        "_id": "IBLNKMRFIPWSOY-FNORWQNLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5311454,
                "inchl_key": "IBLNKMRFIPWSOY-FNORWQNLSA-N",
                "generic_name": "Stiripentol",
                "designated_date": "02/22/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biocodex|7 avenue Gallieni|Gentilly|Gentilly|94250|France",
                "orphan_designation": {
                    "original_text": "Treatment of Primary Hyperoxaluria",
                    "umls_id": "C0020501",
                    "parsed_text": "Primary Hyperoxaluria"
                }
            },
            {
                "compound_id": 5311454,
                "inchl_key": "IBLNKMRFIPWSOY-FNORWQNLSA-N",
                "generic_name": "stiripentol",
                "trade_name": "Diacomit",
                "designated_date": "10/30/2008",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "DIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients 2 years of age and older taking clobazam.",
                "marketing_approval_date": "\u00a008/20/2018\u00a0",
                "exclusivity_end_date": "\u00a008/20/2025\u00a0",
                "exclusivity_protected_indication": "DIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients 2 years of age and older taking clobazam.",
                "sponsor": "Biocodex|7, avenue Gallieni|94250|Gentilly|France",
                "orphan_designation": {
                    "original_text": "Treatment of Dravet syndrome",
                    "umls_id": "C0751122",
                    "parsed_text": "Dravet Syndrome"
                }
            }
        ]
    },
    {
        "_id": "ACTRVOBWPAIOHC-XIXRPRMCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2724354,
                "inchl_key": "ACTRVOBWPAIOHC-XIXRPRMCSA-N",
                "generic_name": "Succimer",
                "designated_date": "11/05/1990",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sanofi Winthrop, Inc.|90 Park Avenue|New York|New York|10016|United States",
                "orphan_designation": {
                    "original_text": "Prevention of cystine kidney stone formation in patients with homozygous cystinuria who are prone to stone development.",
                    "umls_id": "C0010691,C0022650",
                    "parsed_text": "Cystinuria , KIDNEY STONE"
                }
            },
            {
                "compound_id": 2724354,
                "inchl_key": "ACTRVOBWPAIOHC-XIXRPRMCSA-N",
                "generic_name": "Succimer",
                "designated_date": "03/22/1991",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sanofi Winthrop, Inc.|90 Park Avenue|New York|New York|10016|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mercury intoxication.",
                    "umls_id": "C0728899",
                    "parsed_text": "Intoxication"
                }
            },
            {
                "compound_id": 2724354,
                "inchl_key": "ACTRVOBWPAIOHC-XIXRPRMCSA-N",
                "generic_name": "Succimer",
                "trade_name": "Chemet capsules",
                "designated_date": "05/09/1984",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a001/30/1991\u00a0",
                "exclusivity_end_date": "\u00a001/30/1998\u00a0",
                "sponsor": "Bock Pharmacal Company|P.O. Box 419056|Saint Louis|Missouri|63141|United States",
                "orphan_designation": {
                    "original_text": "Treatment of lead poisoning in children.",
                    "umls_id": "C0149921",
                    "parsed_text": "lead poisoning in children"
                }
            }
        ]
    },
    {
        "_id": "YZPQNHUVIVIUCT-JTJNLBSYSA-F",
        "Orphan Drug Designations": [
            {
                "compound_id": 121494085,
                "inchl_key": "YZPQNHUVIVIUCT-JTJNLBSYSA-F",
                "generic_name": "Sucralfate",
                "designated_date": "07/15/1993",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Fuisz Technologies, Ltd.|14555 Avion at Lakeside|Chantilly|Virginia|20151|United States",
                "orphan_designation": {
                    "original_text": "Treatment of oral mucositis and stomatitis following radiation therapy for head and neck cancer.",
                    "umls_id": "C0038362,C1568868,C1578499,C3887461",
                    "parsed_text": "Oral mucositis , Oral Mucositis , Radiation Therapy , Head and Neck Cancer"
                }
            }
        ]
    },
    {
        "_id": "TTZSNFLLYPYKIL-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 52920501,
                "inchl_key": "TTZSNFLLYPYKIL-UHFFFAOYSA-N",
                "generic_name": "surufatinib",
                "designated_date": "11/21/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hutchison MediPharma Ltd.|Building 4, 720 Cailun Road|Zhangjiang Hi-Tech Park|Shanghai|China",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic neuroendocrine tumors",
                    "umls_id": "C0206754",
                    "parsed_text": "Neuroendocrine Tumors"
                }
            }
        ]
    },
    {
        "_id": "WOXKDUGGOYFFRN-IIBYNOLFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 110635,
                "inchl_key": "WOXKDUGGOYFFRN-IIBYNOLFSA-N",
                "generic_name": "tadalafil",
                "trade_name": "Adcirca",
                "designated_date": "12/18/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of pulmonary arterial hypertension (WHO Group I) to improve exercise ability",
                "marketing_approval_date": "\u00a005/22/2009\u00a0",
                "exclusivity_end_date": "\u00a005/22/2016\u00a0",
                "sponsor": "Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            },
            {
                "compound_id": 110635,
                "inchl_key": "WOXKDUGGOYFFRN-IIBYNOLFSA-N",
                "generic_name": "tadalafil",
                "designated_date": "05/04/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Duchenne Muscular Dystrophy (DMD)",
                    "umls_id": "C0013264",
                    "parsed_text": "DUCHENNE MUSCULAR DYSTROPHY"
                }
            }
        ]
    },
    {
        "_id": "MUTNCGKQJGXKEM-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 108143,
                "inchl_key": "MUTNCGKQJGXKEM-UHFFFAOYSA-N",
                "generic_name": "tamibarotene",
                "designated_date": "08/16/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Syros Pharmaceuticals, Inc.|620 Memorial Drive|Suite 300|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia (AML)",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "compound_id": 108143,
                "inchl_key": "MUTNCGKQJGXKEM-UHFFFAOYSA-N",
                "generic_name": "Tamibarotene",
                "designated_date": "10/11/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CytRx Corporation|11726 San Vicente Blvd.|Los Angeles|California|90049|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute promyelocytic leukemia (APL).",
                    "umls_id": "C0023487,C1859592",
                    "parsed_text": "Acute Promyelocytic Leukemia , APL"
                }
            }
        ]
    },
    {
        "_id": "AYUNIORJHRXIBJ-TXHRRWQRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6505803,
                "inchl_key": "AYUNIORJHRXIBJ-TXHRRWQRSA-N",
                "generic_name": "Tanespimycin",
                "designated_date": "09/09/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb|5 Research Parkway|P.O. Box 5100|Wallingford|Connecticut|6492|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "PTOIAAWZLUQTIO-GXFFZTMASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10220503,
                "inchl_key": "PTOIAAWZLUQTIO-GXFFZTMASA-N",
                "generic_name": "tasimelteon",
                "trade_name": "Hetlioz",
                "designated_date": "04/30/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in patients 16 years of age and older",
                "marketing_approval_date": "\u00a012/01/2020\u00a0",
                "exclusivity_end_date": "\u00a012/01/2027\u00a0",
                "exclusivity_protected_indication": "Treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in patients 16 years of age and older.",
                "sponsor": "Vanda Pharmaceuticals, Inc.|9605 Medical Center Drive|Rockville|Maryland|20850|United States",
                "orphan_designation": {
                    "original_text": "Treatment of the sleep disorder in Smith-Magenis syndrome associated with diurnal melatonin secretion.",
                    "umls_id": "C0795864,C0851578",
                    "parsed_text": "Smith-Magenis syndrome , Sleep disorder"
                }
            },
            {
                "compound_id": 10220503,
                "inchl_key": "PTOIAAWZLUQTIO-GXFFZTMASA-N",
                "generic_name": "tasimelteon",
                "trade_name": "Hetlioz LQ",
                "designated_date": "04/30/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in pediatric patients 3 to 15 years of age",
                "marketing_approval_date": "\u00a012/01/2020\u00a0",
                "exclusivity_end_date": "\u00a012/01/2027\u00a0",
                "exclusivity_protected_indication": "Treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in pediatric patients 3 to 15 years of age",
                "sponsor": "Vanda Pharmaceuticals, Inc.|9605 Medical Center Drive|Rockville|Maryland|20850|United States",
                "orphan_designation": {
                    "original_text": "Treatment of the sleep disorder in Smith-Magenis syndrome associated with diurnal melatonin secretion.",
                    "umls_id": "C0795864,C0851578",
                    "parsed_text": "Smith-Magenis syndrome , Sleep disorder"
                }
            }
        ]
    },
    {
        "_id": "QFLNTQDOVCLQKW-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 54718618,
                "inchl_key": "QFLNTQDOVCLQKW-UHFFFAOYSA-N",
                "generic_name": "tecarfarin",
                "designated_date": "03/07/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Espero BioPharma, Inc.|14286-19 Beach Blvd #270|Jacksonville|Florida|United States",
                "orphan_designation": {
                    "original_text": "Prevention of systemic thromboembolism of cardiac origin in patients with End Stage Renal Disease and atrial fibrillation",
                    "umls_id": "C0004238,C0022661,C0040038",
                    "parsed_text": "Atrial Fibrillation , End stage renal disease , Thromboembolism"
                }
            }
        ]
    },
    {
        "_id": "CSKDFZIMJXRJGH-VWLPUNTISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16124688,
                "inchl_key": "CSKDFZIMJXRJGH-VWLPUNTISA-N",
                "generic_name": "tecovirimat",
                "designated_date": "09/29/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SIGA Technologies, Inc.|4575 SW Research Way|Corvallis|Oregon|97333|United States",
                "orphan_designation": {
                    "original_text": "Treatment of orthopoxvirus infections.",
                    "umls_id": "C0206580,C3714514",
                    "parsed_text": "Orthopoxvirus , Infections"
                }
            },
            {
                "compound_id": 16124688,
                "inchl_key": "CSKDFZIMJXRJGH-VWLPUNTISA-N",
                "generic_name": "tecovirimat",
                "designated_date": "12/18/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SIGA Technologies, Inc.|4575 SW Research Way|Suite 230|Corvallis|Oregon|97333|United States",
                "orphan_designation": {
                    "original_text": "post exposure prophylaxis against smallpox",
                    "umls_id": "C0037356",
                    "parsed_text": "smallpox"
                }
            },
            {
                "compound_id": 16124688,
                "inchl_key": "CSKDFZIMJXRJGH-VWLPUNTISA-N",
                "generic_name": "tecovirimat",
                "trade_name": "TPOXX",
                "designated_date": "12/27/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "TPOXX is indicated for the treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg.",
                "marketing_approval_date": "\u00a007/13/2018\u00a0",
                "exclusivity_end_date": "\u00a007/13/2025\u00a0",
                "exclusivity_protected_indication": "TPOXX is indicated for the treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg.",
                "sponsor": "SIGA Technologies, Inc.|4575 SW Research Way|Suite 230|Corvallis|Oregon|97333|United States",
                "orphan_designation": {
                    "original_text": "Treatment of smallpox",
                    "umls_id": "C0037356",
                    "parsed_text": "smallpox"
                }
            }
        ]
    },
    {
        "_id": "OJICYBSWSZGRFB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 68234908,
                "inchl_key": "OJICYBSWSZGRFB-UHFFFAOYSA-N",
                "generic_name": "Telacebec",
                "designated_date": "01/13/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Qurient Co., Ltd.|C-dong 8th Floor 242, Pangyo-ro, Bundang-gu, Seongnam-si|Gyeonggi-do|Korea|463-400|South Korea",
                "orphan_designation": {
                    "original_text": "Treatment of Buruli ulcer",
                    "umls_id": "C0041582",
                    "parsed_text": "Ulcer"
                }
            }
        ]
    },
    {
        "_id": "PPJYSSNKSXAVDB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 65552,
                "inchl_key": "PPJYSSNKSXAVDB-UHFFFAOYSA-N",
                "generic_name": "Tetraiodothyroacetic acid",
                "designated_date": "05/01/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Danforth, Jr., MD, Elliot|University of Vermont|84 Beartown Rd.|Underhill|Vermont|5489|United States",
                "orphan_designation": {
                    "original_text": "Suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.",
                    "umls_id": "C0549473",
                    "parsed_text": "Cancer of the Thyroid"
                }
            }
        ]
    },
    {
        "_id": "WVTKBKWTSCPRNU-KYJUHHDHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 73078,
                "inchl_key": "WVTKBKWTSCPRNU-KYJUHHDHSA-N",
                "generic_name": "tetrandrine",
                "designated_date": "12/13/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Escend Pharmaceuticals, Inc.|3475 Edison Way|Suite R|Menlo Park|California|94025|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "compound_id": 73078,
                "inchl_key": "WVTKBKWTSCPRNU-KYJUHHDHSA-N",
                "generic_name": "tetrandrine",
                "designated_date": "05/19/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Escend Pharmaceuticals, Inc.|3475 Edison Way|Suite R|Menlo Park|California|94025|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic myeloid leukemia.",
                    "umls_id": "C0023473",
                    "parsed_text": "Chronic myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "UEJJHQNACJXSKW-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5426,
                "inchl_key": "UEJJHQNACJXSKW-UHFFFAOYSA-N",
                "generic_name": "Thalidomide",
                "designated_date": "11/15/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pediatric Pharmaceuticals, Inc.|718 Bradford Avenue|Westfield|New Jersey|7090|United States",
                "orphan_designation": {
                    "original_text": "Treatment and maintenance of reactional lepromatous leprosy.",
                    "umls_id": "C0023348",
                    "parsed_text": "Lepromatous leprosy"
                }
            },
            {
                "compound_id": 5426,
                "inchl_key": "UEJJHQNACJXSKW-UHFFFAOYSA-N",
                "generic_name": "thalidomide",
                "designated_date": "07/19/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PlumeStars s.r.l.|Via Lago Scuro11|Parma|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of hereditary hemorrhagic telangiectasia",
                    "umls_id": "C0039445",
                    "parsed_text": "hereditary hemorrhagic telangiectasia"
                }
            },
            {
                "compound_id": 5426,
                "inchl_key": "UEJJHQNACJXSKW-UHFFFAOYSA-N",
                "generic_name": "Thalidomide",
                "designated_date": "02/27/1998",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Celgene Corporation|P.O. Box 4914|7 Powder Horn Srive|Warren|New Jersey|7059|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary brain malignancies.",
                    "umls_id": "C0006826",
                    "parsed_text": "MALIGNANCIES"
                }
            },
            {
                "compound_id": 5426,
                "inchl_key": "UEJJHQNACJXSKW-UHFFFAOYSA-N",
                "generic_name": "thalidomide",
                "designated_date": "09/19/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pediatric Pharmaceuticals, Inc.|718 Bradford Avenue|Westfield|New Jersey|7090|United States",
                "orphan_designation": {
                    "original_text": "1. Treatment of graft versus host disease in patients receiving bone marrow transplantation 2. Prevention of graft versus host disease in patients receiving bone marrow transplantation",
                    "umls_id": "C0018133",
                    "parsed_text": "GRAFT VERSUS HOST DISEASE"
                }
            },
            {
                "compound_id": 5426,
                "inchl_key": "UEJJHQNACJXSKW-UHFFFAOYSA-N",
                "generic_name": "Thalidomide",
                "designated_date": "05/01/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Celgene Corporation|P.O. Box 4914|7 Powder Horn Srive|Warren|New Jersey|7059|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe recurrent aphthous stomatitis in severely, terminally immunocompromised patients.",
                    "umls_id": "C2937365",
                    "parsed_text": "Recurrent aphthous stomatitis"
                }
            },
            {
                "compound_id": 5426,
                "inchl_key": "UEJJHQNACJXSKW-UHFFFAOYSA-N",
                "generic_name": "Thalidomide",
                "designated_date": "05/15/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Andrulis Research Corporation|11800 Baltimore Avenue, Suite 113|Beltsville|Maryland|20705|United States",
                "orphan_designation": {
                    "original_text": "Treatment and prevention of recurrent aphthous ulcers in severely, terminally immunocompromised patients.",
                    "umls_id": "C2937365",
                    "parsed_text": "Recurrent aphthous ulcers"
                }
            },
            {
                "compound_id": 5426,
                "inchl_key": "UEJJHQNACJXSKW-UHFFFAOYSA-N",
                "generic_name": "thalidomide",
                "designated_date": "09/27/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndrome",
                    "umls_id": "C3463824",
                    "parsed_text": "MYELODYSPLASTIC SYNDROME"
                }
            },
            {
                "compound_id": 5426,
                "inchl_key": "UEJJHQNACJXSKW-UHFFFAOYSA-N",
                "generic_name": "Thalidomide",
                "designated_date": "03/05/1990",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Andrulis Research Corporation|11800 Baltimore Avenue, Suite 113|Beltsville|Maryland|20705|United States",
                "orphan_designation": {
                    "original_text": "Prevention of graft versus host disease.",
                    "umls_id": "C0018133",
                    "parsed_text": "GRAFT VERSUS HOST DISEASE"
                }
            },
            {
                "compound_id": 5426,
                "inchl_key": "UEJJHQNACJXSKW-UHFFFAOYSA-N",
                "generic_name": "Thalidomide",
                "trade_name": "Thalomid",
                "designated_date": "07/26/1995",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) and as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrences.",
                "marketing_approval_date": "\u00a007/16/1998\u00a0",
                "exclusivity_end_date": "\u00a007/16/2005\u00a0",
                "sponsor": "Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States",
                "orphan_designation": {
                    "original_text": "Treatment of erythema nodosum leprosum.",
                    "umls_id": "C0343467",
                    "parsed_text": "Erythema nodosum leprosum"
                }
            },
            {
                "compound_id": 5426,
                "inchl_key": "UEJJHQNACJXSKW-UHFFFAOYSA-N",
                "generic_name": "Thalidomide",
                "designated_date": "03/05/1990",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Andrulis Research Corporation|11800 Baltimore Avenue, Suite 113|Beltsville|Maryland|20705|United States",
                "orphan_designation": {
                    "original_text": "Treatment of graft versus host disease.",
                    "umls_id": "C0018133",
                    "parsed_text": "GRAFT VERSUS HOST DISEASE"
                }
            },
            {
                "compound_id": 5426,
                "inchl_key": "UEJJHQNACJXSKW-UHFFFAOYSA-N",
                "generic_name": "Thalidomide",
                "designated_date": "01/12/1993",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Celgene Corporation|P.O. Box 4914|7 Powder Horn Srive|Warren|New Jersey|7059|United States",
                "orphan_designation": {
                    "original_text": "Treatment of the clinical manifestations of mycobacterial infection caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria.",
                    "umls_id": "C0026918,C0041296,C1265234",
                    "parsed_text": "Mycobacterial infection , Infection caused by Mycobacterium tuberculosis , Non-Tuberculous Mycobacteria"
                }
            },
            {
                "compound_id": 5426,
                "inchl_key": "UEJJHQNACJXSKW-UHFFFAOYSA-N",
                "generic_name": "Thalidomide",
                "trade_name": "thalomid",
                "designated_date": "10/14/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with newly diagnosed multiple myeloma",
                "marketing_approval_date": "\u00a005/25/2006\u00a0",
                "exclusivity_end_date": "\u00a005/25/2013\u00a0",
                "sponsor": "Celgene Corporation|P.O. Box 4914|7 Powder Horn Srive|Warren|New Jersey|7059|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            },
            {
                "compound_id": 5426,
                "inchl_key": "UEJJHQNACJXSKW-UHFFFAOYSA-N",
                "generic_name": "Thalidomide",
                "designated_date": "07/29/1998",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Celgene Corporation|P.O. Box 4914|7 Powder Horn Srive|Warren|New Jersey|7059|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Kaposi's sarcoma.",
                    "umls_id": "C0036220",
                    "parsed_text": "Kaposi's Sarcoma"
                }
            },
            {
                "compound_id": 5426,
                "inchl_key": "UEJJHQNACJXSKW-UHFFFAOYSA-N",
                "generic_name": "Thalidomide",
                "designated_date": "04/06/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Celgene Corporation|P.O. Box 4914|7 Powder Horn Srive|Warren|New Jersey|7059|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Crohn's disease.",
                    "umls_id": "C0010346",
                    "parsed_text": "Crohn's Disease"
                }
            },
            {
                "compound_id": 5426,
                "inchl_key": "UEJJHQNACJXSKW-UHFFFAOYSA-N",
                "generic_name": "Thalidomide",
                "designated_date": "03/11/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Celgene Corporation|P.O. Box 4914|7 Powder Horn Srive|Warren|New Jersey|7059|United States",
                "orphan_designation": {
                    "original_text": "Treatment of HIV-associated wasting syndrome.",
                    "umls_id": "C0019682",
                    "parsed_text": "HIV"
                }
            }
        ]
    },
    {
        "_id": "PRDJGNVQBVXXEO-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 437740,
                "inchl_key": "PRDJGNVQBVXXEO-UHFFFAOYSA-N",
                "generic_name": "thioureidobutyronitrile",
                "designated_date": "07/14/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Innovation Pharmaceuticals, Inc.|100 Cummings Center|Suite 151-B|Beverly|Massachusetts|1915|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "compound_id": 437740,
                "inchl_key": "PRDJGNVQBVXXEO-UHFFFAOYSA-N",
                "generic_name": "thioureidobutyronitrile",
                "designated_date": "11/17/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Innovation Pharmaceuticals, Inc.|100 Cummings Center|Suite 151-B|Beverly|Massachusetts|1915|United States",
                "orphan_designation": {
                    "original_text": "Treatment of retinoblastoma.",
                    "umls_id": "C0035335",
                    "parsed_text": "Retinoblastoma"
                }
            },
            {
                "compound_id": 437740,
                "inchl_key": "PRDJGNVQBVXXEO-UHFFFAOYSA-N",
                "generic_name": "thioureidobutyronitrile",
                "designated_date": "01/20/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Innovation Pharmaceuticals, Inc.|100 Cummings Center|Suite 151-B|Beverly|Massachusetts|1915|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer.",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "PSWFFKRAVBDQEG-YGQNSOCVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 451417,
                "inchl_key": "PSWFFKRAVBDQEG-YGQNSOCVSA-N",
                "generic_name": "thymopentin",
                "designated_date": "02/04/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mondobiotech Laboratories AG|Herrengasse 21|Furstentum Liechtenstein|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of sarcoidosis.",
                    "umls_id": "C0036202",
                    "parsed_text": "Sarcoidosis"
                }
            }
        ]
    },
    {
        "_id": "UGPMCIBIHRSCBV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 45382195,
                "inchl_key": "UGPMCIBIHRSCBV-UHFFFAOYSA-N",
                "generic_name": "thymosin beta 4",
                "designated_date": "12/31/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ReGenTree, LLC|116 Village Blvd|Suite 200|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with neurotrophic keratopathy",
                    "umls_id": "C0339296",
                    "parsed_text": "Neurotrophic keratopathy"
                }
            },
            {
                "compound_id": 45382195,
                "inchl_key": "UGPMCIBIHRSCBV-UHFFFAOYSA-N",
                "generic_name": "Thymosin beta 4",
                "designated_date": "05/28/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Lenus Therapeutics, LLC|116 Village Blvd., Suite 200|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of epidermolysis bullosa",
                    "umls_id": "C0014527",
                    "parsed_text": "Epidermolysis Bullosa"
                }
            }
        ]
    },
    {
        "_id": "PMJIHLSCWIDGMD-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11313622,
                "inchl_key": "PMJIHLSCWIDGMD-UHFFFAOYSA-N",
                "generic_name": "Tideglusib",
                "designated_date": "06/19/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AMO Pharma Ltd.|Throwsters|The Street|Wonersh|England|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of myotonic dystrophy type 1 (DM1)",
                    "umls_id": "C0027126,C3250443",
                    "parsed_text": "Myotonic Dystrophy , DM1"
                }
            }
        ]
    },
    {
        "_id": "HJLSLZFTEKNLFI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5479,
                "inchl_key": "HJLSLZFTEKNLFI-UHFFFAOYSA-N",
                "generic_name": "Tinidazole",
                "trade_name": "Tindamax",
                "designated_date": "08/20/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of intestinal amebiasis and amebic liver abcess caused by E. histolytica in both adults and pediatric patients older than three years of age. It is not indicated for the treatment of asymptomatic cyst passage.",
                "marketing_approval_date": "\u00a005/17/2004\u00a0",
                "exclusivity_end_date": "\u00a005/17/2011\u00a0",
                "sponsor": "Presutti Laboratories, Inc.|1607 N. Douglas Ave.|Arlington Heights|Illinois|60004|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amebiasis",
                    "umls_id": "C0013370",
                    "parsed_text": "amebiasis"
                }
            },
            {
                "compound_id": 5479,
                "inchl_key": "HJLSLZFTEKNLFI-UHFFFAOYSA-N",
                "generic_name": "tinidazole",
                "trade_name": "Tindamax",
                "designated_date": "04/18/2002",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of giardiasis caused by G. duodenalis (also termed G. lamblia) in both adults and pediatric patients older than three years of age",
                "marketing_approval_date": "\u00a005/17/2004\u00a0",
                "exclusivity_end_date": "\u00a005/17/2011\u00a0",
                "sponsor": "Presutti Laboratories, Inc.|1607 N. Douglas Ave.|Arlington Heights|Illinois|60004|United States",
                "orphan_designation": {
                    "original_text": "Treatment of giardiasis",
                    "umls_id": "C0017536",
                    "parsed_text": "Giardiasis"
                }
            }
        ]
    },
    {
        "_id": "DWGQFQRWFYIINU-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134687437,
                "inchl_key": "DWGQFQRWFYIINU-UHFFFAOYSA-N",
                "generic_name": "tinostamustine hydrochloride",
                "designated_date": "04/02/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mundipharma EDO GmbH|74 Sankt Alban-Rheinweg|Basel|Basel-Stadt|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            },
            {
                "compound_id": 134687437,
                "inchl_key": "DWGQFQRWFYIINU-UHFFFAOYSA-N",
                "generic_name": "tinostamustine hydrochloride",
                "designated_date": "03/15/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mundipharma EDO GmbH|St. Alban-Rheinweg 74|Basel|Basel City|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of T-cell prolymphocytic leukemia",
                    "umls_id": "C2363142",
                    "parsed_text": "T-Cell Prolymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "PLHJCIYEEKOWNM-HHHXNRCGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 159324,
                "inchl_key": "PLHJCIYEEKOWNM-HHHXNRCGSA-N",
                "generic_name": "tipifarnib",
                "designated_date": "04/06/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kura Oncology|Clinical Development|55 Cambridge Parkway|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of T-cell lymphoma",
                    "umls_id": "C0079772",
                    "parsed_text": "T-Cell Lymphoma"
                }
            },
            {
                "compound_id": 159324,
                "inchl_key": "PLHJCIYEEKOWNM-HHHXNRCGSA-N",
                "generic_name": "tipifarnib",
                "designated_date": "06/22/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Paul Maher, MD|10644 Weymouth Street|Suite 104|Bethesda|Maryland|20814|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            },
            {
                "compound_id": 159324,
                "inchl_key": "PLHJCIYEEKOWNM-HHHXNRCGSA-N",
                "generic_name": "Tipifarnib",
                "designated_date": "07/06/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Johnson & Johnson Pharmaceutical Research & Dev.|920 U.S. Highway 202|Raritan|New Jersey|8869|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "UCEQXRCJXIVODC-PMACEKPBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11494412,
                "inchl_key": "UCEQXRCJXIVODC-PMACEKPBSA-N",
                "generic_name": "tivantinib",
                "designated_date": "10/16/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Daiichi Sankyo Pharma Development|399 Thornall Street|Edison|New Jersey|8837|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            }
        ]
    },
    {
        "_id": "LIRYPHYGHXZJBZ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11707110,
                "inchl_key": "LIRYPHYGHXZJBZ-UHFFFAOYSA-N",
                "generic_name": "trametinib",
                "trade_name": "MEKINIST",
                "designated_date": "12/20/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test.",
                "marketing_approval_date": "\u00a005/29/2013\u00a0",
                "exclusivity_end_date": "\u00a005/29/2020\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test.",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Stage IIb through Stage IV melanoma",
                    "umls_id": "C0278883",
                    "parsed_text": "stage iv melanoma"
                }
            }
        ]
    },
    {
        "_id": "PAJMKGZZBBTTOY-ZFORQUDYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6918140,
                "inchl_key": "PAJMKGZZBBTTOY-ZFORQUDYSA-N",
                "generic_name": "treprostinil",
                "trade_name": "Remodulin;Orenitram",
                "designated_date": "06/04/1997",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Orenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity.",
                "marketing_approval_date": "\u00a010/18/2019\u00a0",
                "exclusivity_end_date": "\u00a010/18/2026\u00a0",
                "exclusivity_protected_indication": "Indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression.",
                "sponsor": "United Therapeutics Corp.|55 T.W. Alexander Dr.|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension.",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            },
            {
                "compound_id": 6918140,
                "inchl_key": "PAJMKGZZBBTTOY-ZFORQUDYSA-N",
                "generic_name": "Treprostinil",
                "designated_date": "12/08/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "United Therapeutics Corporation|55 T.W. Alexander Drive|PO Box 14186|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Idiopathic Pulmonary Fibrosis",
                    "umls_id": "C1800706",
                    "parsed_text": "Idiopathic Pulmonary Fibrosis"
                }
            },
            {
                "compound_id": 6918140,
                "inchl_key": "PAJMKGZZBBTTOY-ZFORQUDYSA-N",
                "generic_name": "treprostinil",
                "designated_date": "06/08/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Aurora Research Institute, LLC|960 N 12th St|Discovery Lab|Milwaukee|Wisconsin|53233|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Systemic sclerosis",
                    "umls_id": "C0036421",
                    "parsed_text": "Systemic sclerosis"
                }
            },
            {
                "compound_id": 6918140,
                "inchl_key": "PAJMKGZZBBTTOY-ZFORQUDYSA-N",
                "generic_name": "treprostinil",
                "trade_name": "Remodulin;Orenitram",
                "designated_date": "06/04/1997",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Orenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity.",
                "marketing_approval_date": "\u00a012/20/2013\u00a0",
                "exclusivity_end_date": "\u00a012/20/2020\u00a0",
                "exclusivity_protected_indication": "For treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity.",
                "sponsor": "United Therapeutics Corp.|55 T.W. Alexander Dr.|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension.",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            },
            {
                "compound_id": 6918140,
                "inchl_key": "PAJMKGZZBBTTOY-ZFORQUDYSA-N",
                "generic_name": "treprostinil",
                "trade_name": "Remodulin;Orenitram",
                "designated_date": "06/04/1997",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of pulmonary arterial hypertension.",
                "marketing_approval_date": "\u00a005/21/2002\u00a0",
                "exclusivity_end_date": "\u00a005/21/2009\u00a0",
                "sponsor": "United Therapeutics Corp.|55 T.W. Alexander Dr.|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension.",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "NOYPYLRCIDNJJB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5583,
                "inchl_key": "NOYPYLRCIDNJJB-UHFFFAOYSA-N",
                "generic_name": "Trimetrexate",
                "designated_date": "08/10/2000",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medimmune Oncology, Inc.|One MedImmune Way|Gaithersburg|Maryland|20878|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic osteogenic sarcoma.",
                    "umls_id": "C0278512",
                    "parsed_text": "Metastatic Osteogenic Sarcoma"
                }
            }
        ]
    },
    {
        "_id": "VGGGPCQERPFHOB-RDBSUJKOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 72172,
                "inchl_key": "VGGGPCQERPFHOB-RDBSUJKOSA-N",
                "generic_name": "ubenimex",
                "designated_date": "11/19/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eiger BioPharmaceuticals, Inc.|350 Cambridge Avenue|Suite 350|Palo Alto|California|94306|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension.",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            },
            {
                "compound_id": 72172,
                "inchl_key": "VGGGPCQERPFHOB-RDBSUJKOSA-N",
                "generic_name": "Ubenimex",
                "designated_date": "08/07/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenafly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "compound_id": 72172,
                "inchl_key": "VGGGPCQERPFHOB-RDBSUJKOSA-N",
                "generic_name": "Ubenimex",
                "designated_date": "03/08/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical inc|161 Jefferson Ave.|tenafly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Chronic Myeloid Leukemia",
                    "umls_id": "C0023473",
                    "parsed_text": "Chronic myeloid leukemia"
                }
            },
            {
                "compound_id": 72172,
                "inchl_key": "VGGGPCQERPFHOB-RDBSUJKOSA-N",
                "generic_name": "Ubenimex",
                "designated_date": "06/12/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenefly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            }
        ]
    },
    {
        "_id": "ACTIUHUUMQJHFO-AMJCLVIFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5354031,
                "inchl_key": "ACTIUHUUMQJHFO-AMJCLVIFSA-N",
                "generic_name": "Ubiquinone",
                "designated_date": "12/14/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gel-Tec, Division of Tishcon Corp.|30 New York Avenue|P. O. Box 331|Westbury|New York|11590|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mitochondrial cytopathies.",
                    "umls_id": "C0162670",
                    "parsed_text": "mitochondrial cytopathies"
                }
            }
        ]
    },
    {
        "_id": "BNJNAEJASPUJTO-DUOHOMBCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 122706909,
                "inchl_key": "BNJNAEJASPUJTO-DUOHOMBCSA-N",
                "generic_name": "vadastuximab talirine",
                "designated_date": "11/10/2015",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "NIJJYAXOARWZEE-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3121,
                "inchl_key": "NIJJYAXOARWZEE-UHFFFAOYSA-N",
                "generic_name": "Valproic acid",
                "designated_date": "03/30/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Valcuria AB|Scheelev\u49e5n 2|Lund|Sk\u5ba5 l\u4b8d|Sweden",
                "orphan_designation": {
                    "original_text": "Treatment of diffuse large B-cell lymphoma",
                    "umls_id": "C1332201",
                    "parsed_text": "Diffuse Large B-Cell Lymphoma"
                }
            },
            {
                "compound_id": 3121,
                "inchl_key": "NIJJYAXOARWZEE-UHFFFAOYSA-N",
                "generic_name": "Valproate",
                "designated_date": "05/05/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neuropharm Ltd,|Fetcham Park House|Surrey|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of fragile X syndrome",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "SWXOGPJRIDTIRL-CISAEKETSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 133566183,
                "inchl_key": "SWXOGPJRIDTIRL-CISAEKETSA-N",
                "generic_name": "vapreotide",
                "designated_date": "03/06/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Debiopharm S.A.|17 rue des Terreaux|Lausanne|Switzerland",
                "orphan_designation": {
                    "original_text": "Prevention of early postoperative complications following pancreatic resection.",
                    "umls_id": "C0032787",
                    "parsed_text": "Postoperative Complications"
                }
            },
            {
                "compound_id": 133566183,
                "inchl_key": "SWXOGPJRIDTIRL-CISAEKETSA-N",
                "generic_name": "vapreotide",
                "designated_date": "01/10/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Debiovision, Inc.|666 Sherbrooke Street West|Suite 1400|Montreal|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal variceal hemorrhage patients with portal hypertension.",
                    "umls_id": "C0014852,C0020541,C0333106",
                    "parsed_text": "ESOPHAGEAL , Portal Hypertension , variceal hemorrhage"
                }
            },
            {
                "compound_id": 133566183,
                "inchl_key": "SWXOGPJRIDTIRL-CISAEKETSA-N",
                "generic_name": "Vapreotide",
                "designated_date": "04/06/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "H3 Pharma, Inc.|666 Sherbrooke Street West|Suite 1400|Montreal|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of symptomatic carcinoid tumors",
                    "umls_id": "C0007095",
                    "parsed_text": "Carcinoid Tumors"
                }
            },
            {
                "compound_id": 133566183,
                "inchl_key": "SWXOGPJRIDTIRL-CISAEKETSA-N",
                "generic_name": "vapreotide",
                "designated_date": "01/10/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Debiopharm S.A.|17 rue des Terreaux|Lausanne|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of gastrointestinal and pancreatic fistulas.",
                    "umls_id": "C0030290",
                    "parsed_text": "Pancreatic Fistulas"
                }
            },
            {
                "compound_id": 133566183,
                "inchl_key": "SWXOGPJRIDTIRL-CISAEKETSA-N",
                "generic_name": "vapreotide",
                "designated_date": "11/04/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "H3 Pharma, Inc.|666 Sherbrooke Street West,|Suite 1400|Montreal|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of acromegaly",
                    "umls_id": "C0001206",
                    "parsed_text": "Acromegaly"
                }
            }
        ]
    },
    {
        "_id": "SWXOGPJRIDTIRL-HFQRKYADSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5311370,
                "inchl_key": "SWXOGPJRIDTIRL-HFQRKYADSA-N",
                "generic_name": "vapreotide",
                "designated_date": "03/06/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Debiopharm S.A.|17 rue des Terreaux|Lausanne|Switzerland",
                "orphan_designation": {
                    "original_text": "Prevention of early postoperative complications following pancreatic resection.",
                    "umls_id": "C0032787",
                    "parsed_text": "Postoperative Complications"
                }
            },
            {
                "compound_id": 5311370,
                "inchl_key": "SWXOGPJRIDTIRL-HFQRKYADSA-N",
                "generic_name": "vapreotide",
                "designated_date": "01/10/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Debiovision, Inc.|666 Sherbrooke Street West|Suite 1400|Montreal|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal variceal hemorrhage patients with portal hypertension.",
                    "umls_id": "C0014852,C0020541,C0333106",
                    "parsed_text": "ESOPHAGEAL , Portal Hypertension , variceal hemorrhage"
                }
            },
            {
                "compound_id": 5311370,
                "inchl_key": "SWXOGPJRIDTIRL-HFQRKYADSA-N",
                "generic_name": "Vapreotide",
                "designated_date": "04/06/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "H3 Pharma, Inc.|666 Sherbrooke Street West|Suite 1400|Montreal|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of symptomatic carcinoid tumors",
                    "umls_id": "C0007095",
                    "parsed_text": "Carcinoid Tumors"
                }
            },
            {
                "compound_id": 5311370,
                "inchl_key": "SWXOGPJRIDTIRL-HFQRKYADSA-N",
                "generic_name": "vapreotide",
                "designated_date": "01/10/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Debiopharm S.A.|17 rue des Terreaux|Lausanne|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of gastrointestinal and pancreatic fistulas.",
                    "umls_id": "C0030290",
                    "parsed_text": "Pancreatic Fistulas"
                }
            },
            {
                "compound_id": 5311370,
                "inchl_key": "SWXOGPJRIDTIRL-HFQRKYADSA-N",
                "generic_name": "vapreotide",
                "designated_date": "11/04/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "H3 Pharma, Inc.|666 Sherbrooke Street West,|Suite 1400|Montreal|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of acromegaly",
                    "umls_id": "C0001206",
                    "parsed_text": "Acromegaly"
                }
            }
        ]
    },
    {
        "_id": "SWXOGPJRIDTIRL-KTJGOPLGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 70689318,
                "inchl_key": "SWXOGPJRIDTIRL-KTJGOPLGSA-N",
                "generic_name": "vapreotide",
                "designated_date": "03/06/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Debiopharm S.A.|17 rue des Terreaux|Lausanne|Switzerland",
                "orphan_designation": {
                    "original_text": "Prevention of early postoperative complications following pancreatic resection.",
                    "umls_id": "C0032787",
                    "parsed_text": "Postoperative Complications"
                }
            },
            {
                "compound_id": 70689318,
                "inchl_key": "SWXOGPJRIDTIRL-KTJGOPLGSA-N",
                "generic_name": "vapreotide",
                "designated_date": "01/10/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Debiovision, Inc.|666 Sherbrooke Street West|Suite 1400|Montreal|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal variceal hemorrhage patients with portal hypertension.",
                    "umls_id": "C0014852,C0020541,C0333106",
                    "parsed_text": "ESOPHAGEAL , Portal Hypertension , variceal hemorrhage"
                }
            },
            {
                "compound_id": 70689318,
                "inchl_key": "SWXOGPJRIDTIRL-KTJGOPLGSA-N",
                "generic_name": "Vapreotide",
                "designated_date": "04/06/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "H3 Pharma, Inc.|666 Sherbrooke Street West|Suite 1400|Montreal|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of symptomatic carcinoid tumors",
                    "umls_id": "C0007095",
                    "parsed_text": "Carcinoid Tumors"
                }
            },
            {
                "compound_id": 70689318,
                "inchl_key": "SWXOGPJRIDTIRL-KTJGOPLGSA-N",
                "generic_name": "vapreotide",
                "designated_date": "01/10/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Debiopharm S.A.|17 rue des Terreaux|Lausanne|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of gastrointestinal and pancreatic fistulas.",
                    "umls_id": "C0030290",
                    "parsed_text": "Pancreatic Fistulas"
                }
            },
            {
                "compound_id": 70689318,
                "inchl_key": "SWXOGPJRIDTIRL-KTJGOPLGSA-N",
                "generic_name": "vapreotide",
                "designated_date": "11/04/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "H3 Pharma, Inc.|666 Sherbrooke Street West,|Suite 1400|Montreal|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of acromegaly",
                    "umls_id": "C0001206",
                    "parsed_text": "Acromegaly"
                }
            }
        ]
    },
    {
        "_id": "SWXOGPJRIDTIRL-DLRASJFKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 45588099,
                "inchl_key": "SWXOGPJRIDTIRL-DLRASJFKSA-N",
                "generic_name": "vapreotide",
                "designated_date": "03/06/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Debiopharm S.A.|17 rue des Terreaux|Lausanne|Switzerland",
                "orphan_designation": {
                    "original_text": "Prevention of early postoperative complications following pancreatic resection.",
                    "umls_id": "C0032787",
                    "parsed_text": "Postoperative Complications"
                }
            },
            {
                "compound_id": 45588099,
                "inchl_key": "SWXOGPJRIDTIRL-DLRASJFKSA-N",
                "generic_name": "vapreotide",
                "designated_date": "01/10/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Debiovision, Inc.|666 Sherbrooke Street West|Suite 1400|Montreal|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal variceal hemorrhage patients with portal hypertension.",
                    "umls_id": "C0014852,C0020541,C0333106",
                    "parsed_text": "ESOPHAGEAL , Portal Hypertension , variceal hemorrhage"
                }
            },
            {
                "compound_id": 45588099,
                "inchl_key": "SWXOGPJRIDTIRL-DLRASJFKSA-N",
                "generic_name": "Vapreotide",
                "designated_date": "04/06/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "H3 Pharma, Inc.|666 Sherbrooke Street West|Suite 1400|Montreal|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of symptomatic carcinoid tumors",
                    "umls_id": "C0007095",
                    "parsed_text": "Carcinoid Tumors"
                }
            },
            {
                "compound_id": 45588099,
                "inchl_key": "SWXOGPJRIDTIRL-DLRASJFKSA-N",
                "generic_name": "vapreotide",
                "designated_date": "01/10/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Debiopharm S.A.|17 rue des Terreaux|Lausanne|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of gastrointestinal and pancreatic fistulas.",
                    "umls_id": "C0030290",
                    "parsed_text": "Pancreatic Fistulas"
                }
            },
            {
                "compound_id": 45588099,
                "inchl_key": "SWXOGPJRIDTIRL-DLRASJFKSA-N",
                "generic_name": "vapreotide",
                "designated_date": "11/04/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "H3 Pharma, Inc.|666 Sherbrooke Street West,|Suite 1400|Montreal|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of acromegaly",
                    "umls_id": "C0001206",
                    "parsed_text": "Acromegaly"
                }
            }
        ]
    },
    {
        "_id": "SWXOGPJRIDTIRL-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71306,
                "inchl_key": "SWXOGPJRIDTIRL-UHFFFAOYSA-N",
                "generic_name": "vapreotide",
                "designated_date": "03/06/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Debiopharm S.A.|17 rue des Terreaux|Lausanne|Switzerland",
                "orphan_designation": {
                    "original_text": "Prevention of early postoperative complications following pancreatic resection.",
                    "umls_id": "C0032787",
                    "parsed_text": "Postoperative Complications"
                }
            },
            {
                "compound_id": 71306,
                "inchl_key": "SWXOGPJRIDTIRL-UHFFFAOYSA-N",
                "generic_name": "vapreotide",
                "designated_date": "01/10/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Debiovision, Inc.|666 Sherbrooke Street West|Suite 1400|Montreal|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal variceal hemorrhage patients with portal hypertension.",
                    "umls_id": "C0014852,C0020541,C0333106",
                    "parsed_text": "ESOPHAGEAL , Portal Hypertension , variceal hemorrhage"
                }
            },
            {
                "compound_id": 71306,
                "inchl_key": "SWXOGPJRIDTIRL-UHFFFAOYSA-N",
                "generic_name": "Vapreotide",
                "designated_date": "04/06/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "H3 Pharma, Inc.|666 Sherbrooke Street West|Suite 1400|Montreal|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of symptomatic carcinoid tumors",
                    "umls_id": "C0007095",
                    "parsed_text": "Carcinoid Tumors"
                }
            },
            {
                "compound_id": 71306,
                "inchl_key": "SWXOGPJRIDTIRL-UHFFFAOYSA-N",
                "generic_name": "vapreotide",
                "designated_date": "01/10/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Debiopharm S.A.|17 rue des Terreaux|Lausanne|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of gastrointestinal and pancreatic fistulas.",
                    "umls_id": "C0030290",
                    "parsed_text": "Pancreatic Fistulas"
                }
            },
            {
                "compound_id": 71306,
                "inchl_key": "SWXOGPJRIDTIRL-UHFFFAOYSA-N",
                "generic_name": "vapreotide",
                "designated_date": "11/04/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "H3 Pharma, Inc.|666 Sherbrooke Street West,|Suite 1400|Montreal|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of acromegaly",
                    "umls_id": "C0001206",
                    "parsed_text": "Acromegaly"
                }
            }
        ]
    },
    {
        "_id": "SWXOGPJRIDTIRL-DOUNNPEJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6918026,
                "inchl_key": "SWXOGPJRIDTIRL-DOUNNPEJSA-N",
                "generic_name": "vapreotide",
                "designated_date": "03/06/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Debiopharm S.A.|17 rue des Terreaux|Lausanne|Switzerland",
                "orphan_designation": {
                    "original_text": "Prevention of early postoperative complications following pancreatic resection.",
                    "umls_id": "C0032787",
                    "parsed_text": "Postoperative Complications"
                }
            },
            {
                "compound_id": 6918026,
                "inchl_key": "SWXOGPJRIDTIRL-DOUNNPEJSA-N",
                "generic_name": "vapreotide",
                "designated_date": "01/10/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Debiovision, Inc.|666 Sherbrooke Street West|Suite 1400|Montreal|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal variceal hemorrhage patients with portal hypertension.",
                    "umls_id": "C0014852,C0020541,C0333106",
                    "parsed_text": "ESOPHAGEAL , Portal Hypertension , variceal hemorrhage"
                }
            },
            {
                "compound_id": 6918026,
                "inchl_key": "SWXOGPJRIDTIRL-DOUNNPEJSA-N",
                "generic_name": "Vapreotide",
                "designated_date": "04/06/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "H3 Pharma, Inc.|666 Sherbrooke Street West|Suite 1400|Montreal|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of symptomatic carcinoid tumors",
                    "umls_id": "C0007095",
                    "parsed_text": "Carcinoid Tumors"
                }
            },
            {
                "compound_id": 6918026,
                "inchl_key": "SWXOGPJRIDTIRL-DOUNNPEJSA-N",
                "generic_name": "vapreotide",
                "designated_date": "01/10/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Debiopharm S.A.|17 rue des Terreaux|Lausanne|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of gastrointestinal and pancreatic fistulas.",
                    "umls_id": "C0030290",
                    "parsed_text": "Pancreatic Fistulas"
                }
            },
            {
                "compound_id": 6918026,
                "inchl_key": "SWXOGPJRIDTIRL-DOUNNPEJSA-N",
                "generic_name": "vapreotide",
                "designated_date": "11/04/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "H3 Pharma, Inc.|666 Sherbrooke Street West,|Suite 1400|Montreal|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of acromegaly",
                    "umls_id": "C0001206",
                    "parsed_text": "Acromegaly"
                }
            }
        ]
    },
    {
        "_id": "JNAHVYVRKWKWKQ-CYBMUJFWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11960529,
                "inchl_key": "JNAHVYVRKWKWKQ-CYBMUJFWSA-N",
                "generic_name": "veliparib",
                "designated_date": "11/20/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AbbVie, Inc.|1 N. Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma in combination with DNA-damaging agents",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            },
            {
                "compound_id": 11960529,
                "inchl_key": "JNAHVYVRKWKWKQ-CYBMUJFWSA-N",
                "generic_name": "veliparib",
                "designated_date": "09/03/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AbbVie, Inc.|1 N. Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of epithelial ovarian cancer in combination with DNA-damaging agents",
                    "umls_id": "C4721610",
                    "parsed_text": "Epithelial Ovarian Cancer"
                }
            },
            {
                "compound_id": 11960529,
                "inchl_key": "JNAHVYVRKWKWKQ-CYBMUJFWSA-N",
                "generic_name": "veliparib",
                "designated_date": "11/03/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of squamous non-small cell lung cancer",
                    "umls_id": "C4509816",
                    "parsed_text": "Squamous non-small cell lung cancer"
                }
            },
            {
                "compound_id": 11960529,
                "inchl_key": "JNAHVYVRKWKWKQ-CYBMUJFWSA-N",
                "generic_name": "veliparib",
                "designated_date": "12/17/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of brain metastases when used in combination with DNA-damaging agents",
                    "umls_id": "C0220650",
                    "parsed_text": "brain metastases"
                }
            },
            {
                "compound_id": 11960529,
                "inchl_key": "JNAHVYVRKWKWKQ-CYBMUJFWSA-N",
                "generic_name": "veliparib",
                "designated_date": "05/09/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AbbVie, Inc.|1 N. Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioblastoma multiforme when used in combination with DNA-damaging agents",
                    "umls_id": "C0017636",
                    "parsed_text": "Glioblastoma multiforme"
                }
            }
        ]
    },
    {
        "_id": "WAEXFXRVDQXREF-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5311,
                "inchl_key": "WAEXFXRVDQXREF-UHFFFAOYSA-N",
                "generic_name": "vorinostat",
                "designated_date": "10/13/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Qameleon Therapeutics|Moslaan 32|1433 WJ|Kudelstaart|Noord-Holland|Netherlands",
                "orphan_designation": {
                    "original_text": "Treatment of advanced melanoma (stages IIb, IIc, III, and IV)",
                    "umls_id": "C4727838",
                    "parsed_text": "Advanced Melanoma"
                }
            },
            {
                "compound_id": 5311,
                "inchl_key": "WAEXFXRVDQXREF-UHFFFAOYSA-N",
                "generic_name": "vorinostat",
                "trade_name": "Zolinza",
                "designated_date": "03/16/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistant or recurrent disease on or following two systemic therapies.",
                "marketing_approval_date": "\u00a010/06/2006\u00a0",
                "exclusivity_end_date": "\u00a010/06/2013\u00a0",
                "sponsor": "Merck & Co., Inc.|P. O. Box 2000, RY 32-605|Rahway|New Jersey|7065|United States",
                "orphan_designation": {
                    "original_text": "Treatment of T-cell non-Hodgkin's lymphoma",
                    "umls_id": "C0079772",
                    "parsed_text": "T-cell non-Hodgkin's lymphoma"
                }
            },
            {
                "compound_id": 5311,
                "inchl_key": "WAEXFXRVDQXREF-UHFFFAOYSA-N",
                "generic_name": "vorinostat",
                "designated_date": "03/17/2004",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Merck & Co., Inc.|P. O. Box 2000, RY 32-605|Rahway|New Jersey|7065|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mesothelioma",
                    "umls_id": "C0025500",
                    "parsed_text": "Mesothelioma"
                }
            },
            {
                "compound_id": 5311,
                "inchl_key": "WAEXFXRVDQXREF-UHFFFAOYSA-N",
                "generic_name": "vorinostat",
                "designated_date": "06/12/2003",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Merck Research Laboratories|Merck & Co., Inc.|P. O. Box 2000, RY 33-212|Rahway|New Jersey|7065|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "XZAFZXJXZHRNAQ-STQMWFEESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9952884,
                "inchl_key": "XZAFZXJXZHRNAQ-STQMWFEESA-N",
                "generic_name": "vosaroxin",
                "designated_date": "10/28/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sunesis Pharmaceuticals, Inc.|395 Oyster Point Blvd|Suite 400|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "ZSSLCFLHEFXANG-GOSISDBHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25052630,
                "inchl_key": "ZSSLCFLHEFXANG-GOSISDBHSA-N",
                "generic_name": "Zamicastat",
                "designated_date": "07/15/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bial-Portela & C., S.A.|Av. da Siderurgia Nacional|4745-457 S. Mamede do Coronado|Coronado|Portugal",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension (PAH) (pulmonary hypertension WHO Group 1)",
                    "umls_id": "C0020542,C3203102",
                    "parsed_text": "Pulmonary Hypertension , PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "JDXCOXKBIGBZSK-PSNKNOTQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 133083018,
                "inchl_key": "JDXCOXKBIGBZSK-PSNKNOTQSA-N",
                "generic_name": "Zilucoplan",
                "designated_date": "08/26/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ra Pharmaceuticals, Inc.|87 Cambridge Park Drive|Cambridge|Massachusetts|2140|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myasthenia gravis",
                    "umls_id": "C0026896",
                    "parsed_text": "Myasthenia Gravis"
                }
            }
        ]
    },
    {
        "_id": "SGMZJAMFUVOLNK-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 6209,
                "inchl_key": "SGMZJAMFUVOLNK-UHFFFAOYSA-M",
                "generic_name": "Choline chloride",
                "designated_date": "02/10/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ArTara Therapeutics|1 Little West 12th Street|Suite 254|New York|New York|10014|United States",
                "orphan_designation": {
                    "original_text": "Treatment of choline deficiency, specifically the choline deficiency, hepatic steatosis, and cholestasis, associated with long-term parenteral nutrition.",
                    "umls_id": "C0008370,C0008412,C2711227",
                    "parsed_text": "Cholestasis , Choline Deficiency , Hepatic steatosis"
                }
            },
            {
                "compound_id": 6209,
                "inchl_key": "SGMZJAMFUVOLNK-UHFFFAOYSA-M",
                "generic_name": "Choline chloride",
                "designated_date": "07/20/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ArTara Therapeutics|1 Little West 12th Street|Suite 254|New York|New York|10014|United States",
                "orphan_designation": {
                    "original_text": "Prevention and/or treatment of choline deficiency in patients on long-term parenteral nutrition",
                    "umls_id": "C0008412",
                    "parsed_text": "Choline Deficiency"
                }
            }
        ]
    },
    {
        "_id": "QLMBAIRFQQLJJX-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 54909,
                "inchl_key": "QLMBAIRFQQLJJX-UHFFFAOYSA-N",
                "generic_name": "cicletanine hydrochloride",
                "designated_date": "06/24/2008",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment for pulmonary arterial hypertension.",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "CKLPLPZSUQEDRT-WPCRTTGESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44469321,
                "inchl_key": "CKLPLPZSUQEDRT-WPCRTTGESA-N",
                "generic_name": "cipargamin",
                "designated_date": "05/01/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|Bldg. 315 / 1650D|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 44469321,
                "inchl_key": "CKLPLPZSUQEDRT-WPCRTTGESA-N",
                "generic_name": "Cipargamin",
                "designated_date": "07/27/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Paul Maher, MD|10644 Weymouth Street|Suite 104|Bethesda|Maryland|20814|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            }
        ]
    },
    {
        "_id": "LFWCJABOXHSRGC-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6433095,
                "inchl_key": "LFWCJABOXHSRGC-UHFFFAOYSA-N",
                "generic_name": "clazosentan",
                "designated_date": "02/16/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Idorsia Pharmaceuticals US Inc.|1820 Chapel Avenue West|Suite 150|Cherry Hill|New Jersey|8002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cerebral vasospasm following subarachnoid hemorrhage",
                    "umls_id": "C0038525,C0265110",
                    "parsed_text": "Subarachnoid Hemorrhage , Cerebral Vasospasm"
                }
            }
        ]
    },
    {
        "_id": "WDQPAMHFFCXSNU-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2794,
                "inchl_key": "WDQPAMHFFCXSNU-UHFFFAOYSA-N",
                "generic_name": "clofazimine",
                "designated_date": "08/17/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MannKind Corporation|1 Casper Street|Danbury|Connecticut|6810|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pulmonary Nontuberculous Mycobacterial Infections",
                    "umls_id": "C0026918",
                    "parsed_text": "Mycobacterial infections"
                }
            },
            {
                "compound_id": 2794,
                "inchl_key": "WDQPAMHFFCXSNU-UHFFFAOYSA-N",
                "generic_name": "clofazimine",
                "designated_date": "06/25/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza|Bldg 135/409|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of active tuberculosis",
                    "umls_id": "C0041296",
                    "parsed_text": "Active Tuberculosis"
                }
            },
            {
                "compound_id": 2794,
                "inchl_key": "WDQPAMHFFCXSNU-UHFFFAOYSA-N",
                "generic_name": "Clofazimine",
                "trade_name": "Lamprene",
                "designated_date": "06/11/1984",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a012/15/1986\u00a0",
                "exclusivity_end_date": "\u00a012/15/1993\u00a0",
                "sponsor": "Novartis Pharmaceutical Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.",
                    "umls_id": "C0023348,C0343467",
                    "parsed_text": "Lepromatous leprosy , Erythema nodosum leprosum"
                }
            }
        ]
    },
    {
        "_id": "SDDSJMXGJNWMJY-BRHAQHMBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16757521,
                "inchl_key": "SDDSJMXGJNWMJY-BRHAQHMBSA-N",
                "generic_name": "cobiprostone",
                "designated_date": "11/14/2002",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sucampo Pharma Americas, LLC.|4520 East-West Highway|Suite 300|Bethesda|Maryland|20814|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "IXYNFLOLUBKHQU-FZCWJHTDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 121492440,
                "inchl_key": "IXYNFLOLUBKHQU-FZCWJHTDSA-N",
                "generic_name": "cobitolimod",
                "designated_date": "08/08/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "InDex Pharmaceuticals AB|23a Tomtebodav\u49e5n|Hagalund|Stockholms l\u4b8d|Sweden",
                "orphan_designation": {
                    "original_text": "Treatment of ulcerative colitis in pediatric patients",
                    "umls_id": "C0009324",
                    "parsed_text": "Ulcerative Colitis"
                }
            }
        ]
    },
    {
        "_id": "IAKHMKGGTNLKSZ-INIZCTEOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6167,
                "inchl_key": "IAKHMKGGTNLKSZ-INIZCTEOSA-N",
                "generic_name": "Colchicine",
                "designated_date": "12/09/1985",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacontrol Corporation|661 Palisade Ave., P.O. Box 931|Englewood Cliffs|New Jersey|7632|United States",
                "orphan_designation": {
                    "original_text": "For arresting the progression of neurologic disability caused by chronic progressive multiple sclerosis.",
                    "umls_id": "C0231170,C0242656,C0393665",
                    "parsed_text": "Disability , Progression , Chronic progressive multiple sclerosis"
                }
            },
            {
                "compound_id": 6167,
                "inchl_key": "IAKHMKGGTNLKSZ-INIZCTEOSA-N",
                "generic_name": "colchicine",
                "trade_name": "Colcrys",
                "designated_date": "09/25/2007",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of familial Mediterranean fever",
                "marketing_approval_date": "\u00a007/29/2009\u00a0",
                "exclusivity_end_date": "\u00a007/29/2016\u00a0",
                "sponsor": "AR Holding Company, Inc.|1100 Orthodox Street|Philadelphia|Pennsylvania|19124|United States",
                "orphan_designation": {
                    "original_text": "Treatment of familial Mediterranean fever",
                    "umls_id": "C0031069",
                    "parsed_text": "Familial Mediterranean Fever"
                }
            },
            {
                "compound_id": 6167,
                "inchl_key": "IAKHMKGGTNLKSZ-INIZCTEOSA-N",
                "generic_name": "Colchicine",
                "designated_date": "09/25/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AR Scientific, Inc.|1100 Orthodox Street|Philadelphia|Pennsylvania|19124|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Behcet's Syndrome",
                    "umls_id": "C0004943",
                    "parsed_text": "Behcet Syndrome"
                }
            }
        ]
    },
    {
        "_id": "DYNHJHQFHQTFTP-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10366136,
                "inchl_key": "DYNHJHQFHQTFTP-UHFFFAOYSA-N",
                "generic_name": "crenolanib",
                "designated_date": "10/31/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AROG Pharmaceuticals, LLC|12400 Coit Road|Suite 570|Dallas|Texas|75251|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelogenous leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            },
            {
                "compound_id": 10366136,
                "inchl_key": "DYNHJHQFHQTFTP-UHFFFAOYSA-N",
                "generic_name": "crenolanib",
                "designated_date": "03/18/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AROG Pharmaceuticals, LLC|12400 Coit Road|Suite 570|Dallas|Texas|75251|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcoma",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            },
            {
                "compound_id": 10366136,
                "inchl_key": "DYNHJHQFHQTFTP-UHFFFAOYSA-N",
                "generic_name": "crenolanib",
                "designated_date": "10/21/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AROG Pharmaceuticals, Inc.|5420 LBJ Freeway, Suite 410|Dallas|Texas|75240|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastric cancer, including cancer of the gastroesophageal junction",
                    "umls_id": "C0006826,C0024623",
                    "parsed_text": "Cancer , Gastric Cancer"
                }
            }
        ]
    },
    {
        "_id": "WQZGKKKJIJFFOK-SVZMEOIVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6036,
                "inchl_key": "WQZGKKKJIJFFOK-SVZMEOIVSA-N",
                "generic_name": "D-Galactose",
                "designated_date": "01/14/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cerecor Inc.|1500 Liberty Ridge Drive|Suite 321|Wayne|Pennsylvania|19087|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Phosphoglucomutase 1 Deficiency",
                    "umls_id": "C2752015",
                    "parsed_text": "PHOSPHOGLUCOMUTASE 1 DEFICIENCY"
                }
            }
        ]
    },
    {
        "_id": "PURKAOJPTOLRMP-ASMGOKTBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71470491,
                "inchl_key": "PURKAOJPTOLRMP-ASMGOKTBSA-N",
                "generic_name": "D9-ivacaftor",
                "designated_date": "01/18/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Vertex Pharmaceuticals, Inc.|50 Northern Avenue|Boston|Massachusetts|2210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis (CF)",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "RZRMFQMNPDPAIX-AJTOSFMRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 126961379,
                "inchl_key": "RZRMFQMNPDPAIX-AJTOSFMRSA-N",
                "generic_name": "dasiglucagon",
                "designated_date": "08/10/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Zealand Pharma A/S|36 Smedeland|Glostrup|Denmark",
                "orphan_designation": {
                    "original_text": "Treatment of hypoglycemia in patients with congenital hyperinsulinism (CH)",
                    "umls_id": "C0020615,C3888018",
                    "parsed_text": "Hypoglycemia , Congenital Hyperinsulinism"
                }
            }
        ]
    },
    {
        "_id": "UBQYURCVBFRUQT-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2973,
                "inchl_key": "UBQYURCVBFRUQT-UHFFFAOYSA-N",
                "generic_name": "deferoxamine",
                "designated_date": "03/15/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Theris Medical|604 Fifth Avenue|Suite D|Redwood City|California|94063|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sickle cell leg ulcers",
                    "umls_id": "C0023223",
                    "parsed_text": "Leg Ulcers"
                }
            }
        ]
    },
    {
        "_id": "WVYXNIXAMZOZFK-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 42616,
                "inchl_key": "WVYXNIXAMZOZFK-UHFFFAOYSA-N",
                "generic_name": "Diaziquone",
                "designated_date": "11/10/1983",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Warner-Lambert Company|2800 Plymouth Rd., P.O. Box 1047|Ann Arbor|Michigan|48106|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary brain malignancies (grade III and IV astrocytomas).",
                    "umls_id": "C0004114,C0006826",
                    "parsed_text": "Astrocytomas , MALIGNANCIES"
                }
            }
        ]
    },
    {
        "_id": "HJKBJIYDJLVSAO-UHFFFAOYSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 31195,
                "inchl_key": "HJKBJIYDJLVSAO-UHFFFAOYSA-L",
                "generic_name": "Disodium clodronate",
                "designated_date": "06/16/1993",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Discovery Experimental & Development, Inc.|29949 S.R. 54 West|Wesley Chapel|Florida|33543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hypercalcemia of malignancy.",
                    "umls_id": "C0149911",
                    "parsed_text": "Hypercalcemia of malignancy"
                }
            }
        ]
    },
    {
        "_id": "XLZOVRYBVCMCGL-BPNVQINPSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 49867944,
                "inchl_key": "XLZOVRYBVCMCGL-BPNVQINPSA-L",
                "generic_name": "disufenton sodium",
                "designated_date": "08/22/2016",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oblato, Inc.|116 Village Boulevard|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioblastoma multiforme",
                    "umls_id": "C0017636",
                    "parsed_text": "Glioblastoma multiforme"
                }
            },
            {
                "compound_id": 49867944,
                "inchl_key": "XLZOVRYBVCMCGL-BPNVQINPSA-L",
                "generic_name": "disufenton sodium",
                "designated_date": "08/22/2016",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oblato, Inc.|116 Village Boulevard|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioblastoma multiforme",
                    "umls_id": "C0017636",
                    "parsed_text": "Glioblastoma multiforme"
                }
            },
            {
                "compound_id": 49867944,
                "inchl_key": "XLZOVRYBVCMCGL-BPNVQINPSA-L",
                "generic_name": "Disufenton sodium",
                "designated_date": "08/14/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oblato, Inc.|116 Village Boulevard|Suite 200|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls_id": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            },
            {
                "compound_id": 49867944,
                "inchl_key": "XLZOVRYBVCMCGL-BPNVQINPSA-L",
                "generic_name": "Disufenton sodium",
                "designated_date": "08/14/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oblato, Inc.|116 Village Boulevard|Suite 200|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls_id": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            }
        ]
    },
    {
        "_id": "VBGWSQKGUZHFPS-ZVYAWBDLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 129628207,
                "inchl_key": "VBGWSQKGUZHFPS-ZVYAWBDLSA-N",
                "generic_name": "ecallantide",
                "trade_name": "Kalbitor",
                "designated_date": "02/04/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of acute attacks of hereditary angioedema in patients 16 years of age and older",
                "marketing_approval_date": "\u00a012/01/2009\u00a0",
                "exclusivity_end_date": "\u00a012/01/2016\u00a0",
                "sponsor": "Dyax Corporation|300 Shire Way|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of angioedema",
                    "umls_id": "C0002994",
                    "parsed_text": "Angioedema"
                }
            },
            {
                "compound_id": 129628207,
                "inchl_key": "VBGWSQKGUZHFPS-ZVYAWBDLSA-N",
                "generic_name": "ecallantide",
                "trade_name": "Kalbitor",
                "designated_date": "02/04/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older",
                "marketing_approval_date": "\u00a003/28/2014\u00a0",
                "exclusivity_end_date": "\u00a003/28/2021\u00a0",
                "exclusivity_protected_indication": "Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 through 15 years of age.",
                "sponsor": "Dyax Corporation|300 Shire Way|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of angioedema",
                    "umls_id": "C0002994",
                    "parsed_text": "Angioedema"
                }
            }
        ]
    },
    {
        "_id": "VBGWSQKGUZHFPS-FHVLXVBRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 118984459,
                "inchl_key": "VBGWSQKGUZHFPS-FHVLXVBRSA-N",
                "generic_name": "ecallantide",
                "trade_name": "Kalbitor",
                "designated_date": "02/04/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of acute attacks of hereditary angioedema in patients 16 years of age and older",
                "marketing_approval_date": "\u00a012/01/2009\u00a0",
                "exclusivity_end_date": "\u00a012/01/2016\u00a0",
                "sponsor": "Dyax Corporation|300 Shire Way|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of angioedema",
                    "umls_id": "C0002994",
                    "parsed_text": "Angioedema"
                }
            },
            {
                "compound_id": 118984459,
                "inchl_key": "VBGWSQKGUZHFPS-FHVLXVBRSA-N",
                "generic_name": "ecallantide",
                "trade_name": "Kalbitor",
                "designated_date": "02/04/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older",
                "marketing_approval_date": "\u00a003/28/2014\u00a0",
                "exclusivity_end_date": "\u00a003/28/2021\u00a0",
                "exclusivity_protected_indication": "Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 through 15 years of age.",
                "sponsor": "Dyax Corporation|300 Shire Way|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of angioedema",
                    "umls_id": "C0002994",
                    "parsed_text": "Angioedema"
                }
            }
        ]
    },
    {
        "_id": "VBGWSQKGUZHFPS-VGMMZINCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44152182,
                "inchl_key": "VBGWSQKGUZHFPS-VGMMZINCSA-N",
                "generic_name": "ecallantide",
                "trade_name": "Kalbitor",
                "designated_date": "02/04/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of acute attacks of hereditary angioedema in patients 16 years of age and older",
                "marketing_approval_date": "\u00a012/01/2009\u00a0",
                "exclusivity_end_date": "\u00a012/01/2016\u00a0",
                "sponsor": "Dyax Corporation|300 Shire Way|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of angioedema",
                    "umls_id": "C0002994",
                    "parsed_text": "Angioedema"
                }
            },
            {
                "compound_id": 44152182,
                "inchl_key": "VBGWSQKGUZHFPS-VGMMZINCSA-N",
                "generic_name": "ecallantide",
                "trade_name": "Kalbitor",
                "designated_date": "02/04/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older",
                "marketing_approval_date": "\u00a003/28/2014\u00a0",
                "exclusivity_end_date": "\u00a003/28/2021\u00a0",
                "exclusivity_protected_indication": "Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 through 15 years of age.",
                "sponsor": "Dyax Corporation|300 Shire Way|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of angioedema",
                    "umls_id": "C0002994",
                    "parsed_text": "Angioedema"
                }
            }
        ]
    },
    {
        "_id": "AUJXLBOHYWTPFV-BLWRDSOESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 138402870,
                "inchl_key": "AUJXLBOHYWTPFV-BLWRDSOESA-N",
                "generic_name": "echinomycin",
                "designated_date": "01/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OncoImmune, Inc.|502 E. Street, NE|Washington|District of Columbia|20002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of graft-versus-host disease (GVHD)",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 138402870,
                "inchl_key": "AUJXLBOHYWTPFV-BLWRDSOESA-N",
                "generic_name": "echinomycin",
                "designated_date": "05/21/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OncoImmune, Inc.|502 E. Street, NE|Washington|District of Columbia|20002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "AUJXLBOHYWTPFV-UJILECMYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134692670,
                "inchl_key": "AUJXLBOHYWTPFV-UJILECMYSA-N",
                "generic_name": "echinomycin",
                "designated_date": "01/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OncoImmune, Inc.|502 E. Street, NE|Washington|District of Columbia|20002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of graft-versus-host disease (GVHD)",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 134692670,
                "inchl_key": "AUJXLBOHYWTPFV-UJILECMYSA-N",
                "generic_name": "echinomycin",
                "designated_date": "05/21/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OncoImmune, Inc.|502 E. Street, NE|Washington|District of Columbia|20002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "AUJXLBOHYWTPFV-LDUXBRJQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 91826096,
                "inchl_key": "AUJXLBOHYWTPFV-LDUXBRJQSA-N",
                "generic_name": "echinomycin",
                "designated_date": "01/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OncoImmune, Inc.|502 E. Street, NE|Washington|District of Columbia|20002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of graft-versus-host disease (GVHD)",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 91826096,
                "inchl_key": "AUJXLBOHYWTPFV-LDUXBRJQSA-N",
                "generic_name": "echinomycin",
                "designated_date": "05/21/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OncoImmune, Inc.|502 E. Street, NE|Washington|District of Columbia|20002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "AUJXLBOHYWTPFV-MADNPERPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6917949,
                "inchl_key": "AUJXLBOHYWTPFV-MADNPERPSA-N",
                "generic_name": "echinomycin",
                "designated_date": "01/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OncoImmune, Inc.|502 E. Street, NE|Washington|District of Columbia|20002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of graft-versus-host disease (GVHD)",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 6917949,
                "inchl_key": "AUJXLBOHYWTPFV-MADNPERPSA-N",
                "generic_name": "echinomycin",
                "designated_date": "05/21/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OncoImmune, Inc.|502 E. Street, NE|Washington|District of Columbia|20002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "AUJXLBOHYWTPFV-MXGHYKICSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 23724556,
                "inchl_key": "AUJXLBOHYWTPFV-MXGHYKICSA-N",
                "generic_name": "echinomycin",
                "designated_date": "01/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OncoImmune, Inc.|502 E. Street, NE|Washington|District of Columbia|20002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of graft-versus-host disease (GVHD)",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 23724556,
                "inchl_key": "AUJXLBOHYWTPFV-MXGHYKICSA-N",
                "generic_name": "echinomycin",
                "designated_date": "05/21/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OncoImmune, Inc.|502 E. Street, NE|Washington|District of Columbia|20002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "AUJXLBOHYWTPFV-RQLJINDISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44448250,
                "inchl_key": "AUJXLBOHYWTPFV-RQLJINDISA-N",
                "generic_name": "echinomycin",
                "designated_date": "01/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OncoImmune, Inc.|502 E. Street, NE|Washington|District of Columbia|20002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of graft-versus-host disease (GVHD)",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 44448250,
                "inchl_key": "AUJXLBOHYWTPFV-RQLJINDISA-N",
                "generic_name": "echinomycin",
                "designated_date": "05/21/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OncoImmune, Inc.|502 E. Street, NE|Washington|District of Columbia|20002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "AUJXLBOHYWTPFV-CVLRASHMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 458034,
                "inchl_key": "AUJXLBOHYWTPFV-CVLRASHMSA-N",
                "generic_name": "echinomycin",
                "designated_date": "01/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OncoImmune, Inc.|502 E. Street, NE|Washington|District of Columbia|20002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of graft-versus-host disease (GVHD)",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 458034,
                "inchl_key": "AUJXLBOHYWTPFV-CVLRASHMSA-N",
                "generic_name": "echinomycin",
                "designated_date": "05/21/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OncoImmune, Inc.|502 E. Street, NE|Washington|District of Columbia|20002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "AUJXLBOHYWTPFV-VITLIGDRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6857732,
                "inchl_key": "AUJXLBOHYWTPFV-VITLIGDRSA-N",
                "generic_name": "echinomycin",
                "designated_date": "01/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OncoImmune, Inc.|502 E. Street, NE|Washington|District of Columbia|20002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of graft-versus-host disease (GVHD)",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 6857732,
                "inchl_key": "AUJXLBOHYWTPFV-VITLIGDRSA-N",
                "generic_name": "echinomycin",
                "designated_date": "05/21/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OncoImmune, Inc.|502 E. Street, NE|Washington|District of Columbia|20002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "AUJXLBOHYWTPFV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3197,
                "inchl_key": "AUJXLBOHYWTPFV-UHFFFAOYSA-N",
                "generic_name": "echinomycin",
                "designated_date": "01/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OncoImmune, Inc.|502 E. Street, NE|Washington|District of Columbia|20002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of graft-versus-host disease (GVHD)",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 3197,
                "inchl_key": "AUJXLBOHYWTPFV-UHFFFAOYSA-N",
                "generic_name": "echinomycin",
                "designated_date": "05/21/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OncoImmune, Inc.|502 E. Street, NE|Washington|District of Columbia|20002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "APFMVAHRFWBCDG-JUOYHRLASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 170317,
                "inchl_key": "APFMVAHRFWBCDG-JUOYHRLASA-N",
                "generic_name": "ecopipam hydrochloride",
                "designated_date": "09/29/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Emalex Biosciences, Inc.|1033 Skokie Bulevard, Suite 600|Northbrook|Illinois|60062|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients with Tourette's syndrome.",
                    "umls_id": "C0040517",
                    "parsed_text": "Tourette's Syndrome"
                }
            },
            {
                "compound_id": 170317,
                "inchl_key": "APFMVAHRFWBCDG-JUOYHRLASA-N",
                "generic_name": "ecopipam hydrochloride",
                "designated_date": "07/21/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Emalex Biosciences, Inc.|1033 Skokie Bulevard, Suite 600|Northbrook|Illinois|60062|United States",
                "orphan_designation": {
                    "original_text": "Symptomatic treatment of self injurious behaviors in patients with Lesch-Nyhan disease.",
                    "umls_id": "C0023374",
                    "parsed_text": "Lesch-Nyhan Disease"
                }
            }
        ]
    },
    {
        "_id": "QELUYTUMUWHWMC-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4021,
                "inchl_key": "QELUYTUMUWHWMC-UHFFFAOYSA-N",
                "generic_name": "edaravone",
                "designated_date": "03/12/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Treeway B.V.|Sevillaweg 142|Rotterdam|Netherlands",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            },
            {
                "compound_id": 4021,
                "inchl_key": "QELUYTUMUWHWMC-UHFFFAOYSA-N",
                "generic_name": "edaravone",
                "trade_name": "Radicava",
                "designated_date": "05/12/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of amyotrophic lateral sclerosis (ALS)",
                "marketing_approval_date": "\u00a005/05/2017\u00a0",
                "exclusivity_end_date": "\u00a005/05/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of amyotrophic lateral sclerosis (ALS)",
                "sponsor": "Mitsubishi Tanabe Pharma Corporation|17-10, Nihonbashi-Koamicho|Chuo-ku,|Tokyo|Japan",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "BKJIXTWSNXCKJH-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 300471,
                "inchl_key": "BKJIXTWSNXCKJH-UHFFFAOYSA-N",
                "generic_name": "Elesclomol",
                "designated_date": "12/18/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Synta Pharmaceuticals Corporation|45 Hartwell Ave.|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic melanoma in combination with paclitaxel",
                    "umls_id": "C0278883",
                    "parsed_text": "Metastatic melanoma"
                }
            }
        ]
    },
    {
        "_id": "SVOQIEJWJCQGDQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135449332,
                "inchl_key": "SVOQIEJWJCQGDQ-UHFFFAOYSA-N",
                "generic_name": "eltrombopag",
                "trade_name": "Promacta",
                "designated_date": "05/05/2008",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy",
                "marketing_approval_date": "\u00a011/20/2008\u00a0",
                "exclusivity_end_date": "\u00a011/20/2015\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic thrombocytopenia purpura",
                    "umls_id": "C0398650",
                    "parsed_text": "Idiopathic thrombocytopenia purpura"
                }
            },
            {
                "compound_id": 135449332,
                "inchl_key": "SVOQIEJWJCQGDQ-UHFFFAOYSA-N",
                "generic_name": "eltrombopag",
                "trade_name": "Promacta",
                "designated_date": "11/08/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.",
                "marketing_approval_date": "\u00a008/26/2014\u00a0",
                "exclusivity_end_date": "\u00a008/26/2021\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of aplastic anemia",
                    "umls_id": "C0002874",
                    "parsed_text": "Aplastic Anemia"
                }
            },
            {
                "compound_id": 135449332,
                "inchl_key": "SVOQIEJWJCQGDQ-UHFFFAOYSA-N",
                "generic_name": "eltrombopag",
                "trade_name": "Promacta",
                "designated_date": "11/08/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "PROMACTA is indicated in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia.",
                "marketing_approval_date": "\u00a011/16/2018\u00a0",
                "exclusivity_end_date": "\u00a011/16/2025\u00a0",
                "exclusivity_protected_indication": "PROMACTA is indicated in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia.",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of aplastic anemia",
                    "umls_id": "C0002874",
                    "parsed_text": "Aplastic Anemia"
                }
            }
        ]
    },
    {
        "_id": "DYLUUSLLRIQKOE-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 89683805,
                "inchl_key": "DYLUUSLLRIQKOE-UHFFFAOYSA-N",
                "generic_name": "enasidenib",
                "trade_name": "Idhifa",
                "designated_date": "06/12/2014",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test",
                "marketing_approval_date": "\u00a008/01/2017\u00a0",
                "exclusivity_end_date": "\u00a008/01/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test",
                "sponsor": "Celgene Corporation|9225 Indian Creek Parkway|Suite 900|Overland Park|Kansas|66210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelogenous leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "WSNVXWWLBYSQIM-DMHHVDOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 49855308,
                "inchl_key": "WSNVXWWLBYSQIM-DMHHVDOYSA-N",
                "generic_name": "Encaleret sulfate",
                "designated_date": "11/24/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Calcilytix Therapeutics, Inc.|101 Montgomery St., Suite 2000|San Francisco|California|94014|United States",
                "orphan_designation": {
                    "original_text": "Treatment for Autosomal Dominant Hypocalcemia (including ADh type 1 and ADH type 2).",
                    "umls_id": "C4048195",
                    "parsed_text": "Autosomal dominant hypocalcemia"
                }
            }
        ]
    },
    {
        "_id": "NOJBHZIZNPMQRT-CBASKZFISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 51049993,
                "inchl_key": "NOJBHZIZNPMQRT-CBASKZFISA-N",
                "generic_name": "Encaleret sulfate",
                "designated_date": "11/24/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Calcilytix Therapeutics, Inc.|101 Montgomery St., Suite 2000|San Francisco|California|94014|United States",
                "orphan_designation": {
                    "original_text": "Treatment for Autosomal Dominant Hypocalcemia (including ADh type 1 and ADH type 2).",
                    "umls_id": "C4048195",
                    "parsed_text": "Autosomal dominant hypocalcemia"
                }
            }
        ]
    },
    {
        "_id": "GVUGOAYIVIDWIO-UFWWTJHBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16143379,
                "inchl_key": "GVUGOAYIVIDWIO-UFWWTJHBSA-N",
                "generic_name": "Epidermal growth factor (human)",
                "designated_date": "03/06/1985",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ethicon, Inc.|P.O. Box 151|Somerville|New Jersey|8876|United States",
                "orphan_designation": {
                    "original_text": "For promotion of cutaneous wound healing in extreme burn treatment protocols.",
                    "umls_id": "C0564444",
                    "parsed_text": "Cutaneous wound"
                }
            }
        ]
    },
    {
        "_id": "GWBBVOVXJZATQQ-UHFFFAOYSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 23894,
                "inchl_key": "GWBBVOVXJZATQQ-UHFFFAOYSA-L",
                "generic_name": "Etidronate disodium",
                "designated_date": "05/02/1991",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MGI Pharma, Inc.|6300 West Old Shakoppe Rd.|Suite 110|Bloomington|Minnesota|55438|United States",
                "orphan_designation": {
                    "original_text": "Treatment of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition.",
                    "umls_id": "C0005944",
                    "parsed_text": "Metabolic Bone Disease"
                }
            },
            {
                "compound_id": 23894,
                "inchl_key": "GWBBVOVXJZATQQ-UHFFFAOYSA-L",
                "generic_name": "Etidronate disodium",
                "designated_date": "05/02/1991",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MGI Pharma, Inc.|6300 West Old Shakoppe Rd.|Suite 110|Bloomington|Minnesota|55438|United States",
                "orphan_designation": {
                    "original_text": "Prevention of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition.",
                    "umls_id": "C0005944",
                    "parsed_text": "Metabolic Bone Disease"
                }
            },
            {
                "compound_id": 23894,
                "inchl_key": "GWBBVOVXJZATQQ-UHFFFAOYSA-L",
                "generic_name": "Etidronate disodium",
                "trade_name": "Didronel",
                "designated_date": "03/21/1986",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a004/21/1987\u00a0",
                "exclusivity_end_date": "\u00a004/21/1994\u00a0",
                "sponsor": "MGI Pharma, Inc.|5775 West Old Shakoppe Rd.|Suite 100|Bloomington|Minnesota|55437|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.",
                    "umls_id": "C0149911",
                    "parsed_text": "Hypercalcemia of malignancy"
                }
            }
        ]
    },
    {
        "_id": "FCWSQAKOPTZCOD-SQYSSJHTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 101163123,
                "inchl_key": "FCWSQAKOPTZCOD-SQYSSJHTSA-N",
                "generic_name": "etoposide toniribate",
                "designated_date": "02/11/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mundipharma EDO GmbH|74 Sankt Alban-Rheinweg|Basel|Basel-Stadt|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of biliary tract cancer",
                    "umls_id": "C0750952",
                    "parsed_text": "Biliary Tract Cancer"
                }
            }
        ]
    },
    {
        "_id": "PCOBBVZJEWWZFR-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 121892,
                "inchl_key": "PCOBBVZJEWWZFR-UHFFFAOYSA-N",
                "generic_name": "ezogabine",
                "designated_date": "06/21/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Xenon Pharmaceuticals, Inc.|200-3650 Gilmore Way|Burnaby|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of KCNQ2 epileptic encephalopathy",
                    "umls_id": "C0543888",
                    "parsed_text": "Epileptic encephalopathy"
                }
            }
        ]
    },
    {
        "_id": "BWCJZAGTBVMMTO-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 139032792,
                "inchl_key": "BWCJZAGTBVMMTO-UHFFFAOYSA-N",
                "generic_name": "Fenobam hydrochloride",
                "designated_date": "11/20/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neuropharm, Ltd.|87 Church Street|Crowthorne, Berkshire|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of fragile X syndrome",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "KMUNHOKTIVSFRA-KXFIGUGUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135409256,
                "inchl_key": "KMUNHOKTIVSFRA-KXFIGUGUSA-N",
                "generic_name": "filociclovir",
                "designated_date": "11/29/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Microbiotix, Inc.|One Innovation Drive|Worcester|Massachusetts|1605|United States",
                "orphan_designation": {
                    "original_text": "Treatment of active cytomegalovirus infections",
                    "umls_id": "C0010823",
                    "parsed_text": "Cytomegalovirus Infections"
                }
            }
        ]
    },
    {
        "_id": "CXWRXYDTWCBSJF-DPTNTHPESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 59443782,
                "inchl_key": "CXWRXYDTWCBSJF-DPTNTHPESA-N",
                "generic_name": "firtecan pegol",
                "designated_date": "04/18/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Enzon Pharmaceuticals, Inc.|20 Kingsbridge Road|Piscataway|New Jersey|8854|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuroblastoma.",
                    "umls_id": "C0027819",
                    "parsed_text": "Neuroblastoma"
                }
            }
        ]
    },
    {
        "_id": "NCWZOASIUQVOFA-FWZJPQCDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11501341,
                "inchl_key": "NCWZOASIUQVOFA-FWZJPQCDSA-N",
                "generic_name": "florbetaben F18",
                "designated_date": "04/07/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Life Molecular Imaging SA|13 Route de l'Ecole|Matran|Fribourg|Switzerland",
                "orphan_designation": {
                    "original_text": "Diagnostic for the management of amyloid light chain (AL) amyloidosis",
                    "umls_id": "C4509023",
                    "parsed_text": "Light chain (AL) amyloidosis"
                }
            }
        ]
    },
    {
        "_id": "ZYULQCDNUYJBRI-HSGWXFLFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24989762,
                "inchl_key": "ZYULQCDNUYJBRI-HSGWXFLFSA-N",
                "generic_name": "flubrobenguane (18F)",
                "designated_date": "06/04/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Lantheus Medical Imaging, Inc.|331 Treble Cove Road|North Billerica|Massachusetts|1862|United States",
                "orphan_designation": {
                    "original_text": "Diagnostic for the management of neuroendocrine tumors",
                    "umls_id": "C0206754",
                    "parsed_text": "Neuroendocrine Tumors"
                }
            }
        ]
    },
    {
        "_id": "WMWTYOKRWGGJOA-CENSZEJFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 444036,
                "inchl_key": "WMWTYOKRWGGJOA-CENSZEJFSA-N",
                "generic_name": "fluticasone propionate",
                "designated_date": "01/19/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ellodi Pharmaceuticals|1200 Lenox Drive, Suite 100|Lawrenceville|New Jersey|8648|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric and adult eosinophilic esophagitis",
                    "umls_id": "C0341106",
                    "parsed_text": "Eosinophilic esophagitis"
                }
            },
            {
                "compound_id": 444036,
                "inchl_key": "WMWTYOKRWGGJOA-CENSZEJFSA-N",
                "generic_name": "fluticasone propionate",
                "designated_date": "12/29/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Banner Life Sciences, LLC|4125 Premier Drive|High Point|North Carolina|27265|United States",
                "orphan_designation": {
                    "original_text": "Treatment of eosinophilic esophagitis",
                    "umls_id": "C0341106",
                    "parsed_text": "Eosinophilic esophagitis"
                }
            }
        ]
    },
    {
        "_id": "WTCJDYDZHHFTEW-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24182261,
                "inchl_key": "WTCJDYDZHHFTEW-UHFFFAOYSA-N",
                "generic_name": "gallium citrate",
                "designated_date": "06/24/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Aridis Pharmaceuticals, Inc.|5941 Optical Court|San Jose|California|95138|United States",
                "orphan_designation": {
                    "original_text": "Treatment of lung infections in patients with cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "YEEGWNXDUZONAA-RYDPDVNUSA-K",
        "Orphan Drug Designations": [
            {
                "compound_id": 65430,
                "inchl_key": "YEEGWNXDUZONAA-RYDPDVNUSA-K",
                "generic_name": "gallium citrate",
                "designated_date": "06/24/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Aridis Pharmaceuticals, Inc.|5941 Optical Court|San Jose|California|95138|United States",
                "orphan_designation": {
                    "original_text": "Treatment of lung infections in patients with cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "YEEGWNXDUZONAA-UHFFFAOYSA-K",
        "Orphan Drug Designations": [
            {
                "compound_id": 34058,
                "inchl_key": "YEEGWNXDUZONAA-UHFFFAOYSA-K",
                "generic_name": "gallium citrate",
                "designated_date": "06/24/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Aridis Pharmaceuticals, Inc.|5941 Optical Court|San Jose|California|95138|United States",
                "orphan_designation": {
                    "original_text": "Treatment of lung infections in patients with cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "SJZRECIVHVDYJC-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10413,
                "inchl_key": "SJZRECIVHVDYJC-UHFFFAOYSA-N",
                "generic_name": "Gamma hydroxybutyrate",
                "designated_date": "12/03/1987",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biocraft Laboratories, Inc.|18-01 River Road|Fair Lawn|New Jersey|7410|United States",
                "orphan_designation": {
                    "original_text": "Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations and automatic behavior.",
                    "umls_id": "C0007384,C0027404,C0233773,C0456511,C1457887",
                    "parsed_text": "Cataplexy , Narcolepsy , Hypnagogic hallucinations , Sleep Paralysis , Symptoms"
                }
            },
            {
                "compound_id": 10413,
                "inchl_key": "SJZRECIVHVDYJC-UHFFFAOYSA-N",
                "generic_name": "Gamma-hydroxybutyric acid",
                "designated_date": "01/22/1985",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sigma Chemical Company",
                "orphan_designation": {
                    "original_text": "Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations, and automatic behavior.",
                    "umls_id": "C0007384,C0027404,C0233773,C0456511,C1457887",
                    "parsed_text": "Cataplexy , Narcolepsy , Hypnagogic hallucinations , Sleep Paralysis , Symptoms"
                }
            },
            {
                "compound_id": 10413,
                "inchl_key": "SJZRECIVHVDYJC-UHFFFAOYSA-N",
                "generic_name": "Gamma-hydroxybutyric acid",
                "designated_date": "07/31/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Jazz Pharmaceuticals Ireland Limited|5th Floor Waterloo Exchange|Waterloo Road|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic hypersomnia",
                    "umls_id": "C0751757",
                    "parsed_text": "Idiopathic Hypersomnia"
                }
            }
        ]
    },
    {
        "_id": "XGALLCVXEZPNRQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 123631,
                "inchl_key": "XGALLCVXEZPNRQ-UHFFFAOYSA-N",
                "generic_name": "gefitinib",
                "trade_name": "Iressa",
                "designated_date": "08/26/2014",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test",
                "marketing_approval_date": "\u00a007/13/2015\u00a0",
                "exclusivity_end_date": "\u00a007/13/2022\u00a0",
                "exclusivity_protected_indication": "For the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test",
                "sponsor": "AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P. O. Box 8355|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer",
                    "umls_id": "C3539721",
                    "parsed_text": "Non-Small Cell Lung Cancer"
                }
            }
        ]
    },
    {
        "_id": "SDUQYLNIPVEERB-QPPQHZFASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 60750,
                "inchl_key": "SDUQYLNIPVEERB-QPPQHZFASA-N",
                "generic_name": "gemcitabine",
                "designated_date": "12/30/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "TARIS Biomedical LLC|113 Hartwell Avenue|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of upper tract urothelial carcinoma",
                    "umls_id": "C0007138",
                    "parsed_text": "Urothelial carcinoma"
                }
            },
            {
                "compound_id": 60750,
                "inchl_key": "SDUQYLNIPVEERB-QPPQHZFASA-N",
                "generic_name": "gemcitabine",
                "designated_date": "01/11/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "InnoPharmax, Inc.|9F, No. 22, Lane 478|Rueiguang Road|Taipei|Neihu District|Taiwan",
                "orphan_designation": {
                    "original_text": "Treatment of cholangiocarcinoma.",
                    "umls_id": "C0206698",
                    "parsed_text": "Cholangiocarcinoma"
                }
            },
            {
                "compound_id": 60750,
                "inchl_key": "SDUQYLNIPVEERB-QPPQHZFASA-N",
                "generic_name": "Gemcitabine",
                "designated_date": "05/18/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RenovoRx|4546 El Camino Real|Suite 203|Los Altos|California|94022|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cholangiocarcinoma",
                    "umls_id": "C0206698",
                    "parsed_text": "Cholangiocarcinoma"
                }
            }
        ]
    },
    {
        "_id": "HEMJJKBWTPKOJG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3463,
                "inchl_key": "HEMJJKBWTPKOJG-UHFFFAOYSA-N",
                "generic_name": "gemfibrozil",
                "designated_date": "08/02/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Polaryx Therapeutics, Inc.|140 East Ridgewood Avenue|Suite 415, South Tower|Paramus|New Jersey|7652|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuronal ceroid lipofuscinoses",
                    "umls_id": "C0027877",
                    "parsed_text": "neuronal ceroid lipofuscinoses"
                }
            }
        ]
    },
    {
        "_id": "DOAUQKRTILFGHV-PDCMDPCFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 146170995,
                "inchl_key": "DOAUQKRTILFGHV-PDCMDPCFSA-N",
                "generic_name": "glepaglutide",
                "designated_date": "10/20/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Zealand Pharma A/S|36 Smedeland|Glostrup|Denmark",
                "orphan_designation": {
                    "original_text": "Treatment of short bowel syndrome",
                    "umls_id": "C0036992",
                    "parsed_text": "Short Bowel Syndrome"
                }
            }
        ]
    },
    {
        "_id": "FOHHNHSLJDZUGQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 37393,
                "inchl_key": "FOHHNHSLJDZUGQ-UHFFFAOYSA-N",
                "generic_name": "Halofantrine",
                "trade_name": "Halfan",
                "designated_date": "11/04/1991",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adults who can tolerate oral medication and who have mild to moderate malaria caused by Plasmodium falciparum or Plasmodium vivax.",
                "marketing_approval_date": "\u00a007/24/1992\u00a0",
                "exclusivity_end_date": "\u00a007/24/1999\u00a0",
                "sponsor": "SmithKline Beecham Pharmaceuticals|One Franklin Plaza|P.O. Box 7929|Philadelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mild to moderate acute malaria caused by susceptible strains of P. falciparum and P. vivax.",
                    "umls_id": "C2930826",
                    "parsed_text": "Acute malaria"
                }
            }
        ]
    },
    {
        "_id": "HQBGGOLLNATNQC-INZIHYEWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135564839,
                "inchl_key": "HQBGGOLLNATNQC-INZIHYEWSA-N",
                "generic_name": "Heme arginate",
                "designated_date": "03/01/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orphan Europe SARL|Immeuble Le Wilson|70 avenue du General de Gaulle,|Puteaux|France",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndromes.",
                    "umls_id": "C3463824",
                    "parsed_text": "Myelodysplastic Syndromes"
                }
            },
            {
                "compound_id": 135564839,
                "inchl_key": "HQBGGOLLNATNQC-INZIHYEWSA-N",
                "generic_name": "Heme arginate",
                "designated_date": "03/10/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orphan Europe SARL|Immeuble Le Wilson|70 avenue du General de Gaulle|Puteaux|France",
                "orphan_designation": {
                    "original_text": "Treatment of symptomatic stage of acute porphyria.",
                    "umls_id": "C0162565",
                    "parsed_text": "Acute Porphyria"
                }
            }
        ]
    },
    {
        "_id": "CZPDCEDNNVRQEX-INZIHYEWSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 154723996,
                "inchl_key": "CZPDCEDNNVRQEX-INZIHYEWSA-L",
                "generic_name": "Heme arginate",
                "designated_date": "03/01/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orphan Europe SARL|Immeuble Le Wilson|70 avenue du General de Gaulle,|Puteaux|France",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndromes.",
                    "umls_id": "C3463824",
                    "parsed_text": "Myelodysplastic Syndromes"
                }
            },
            {
                "compound_id": 154723996,
                "inchl_key": "CZPDCEDNNVRQEX-INZIHYEWSA-L",
                "generic_name": "Heme arginate",
                "designated_date": "03/10/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orphan Europe SARL|Immeuble Le Wilson|70 avenue du General de Gaulle|Puteaux|France",
                "orphan_designation": {
                    "original_text": "Treatment of symptomatic stage of acute porphyria.",
                    "umls_id": "C0162565",
                    "parsed_text": "Acute Porphyria"
                }
            }
        ]
    },
    {
        "_id": "MGQITOFVXOEWNL-INZIHYEWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3086464,
                "inchl_key": "MGQITOFVXOEWNL-INZIHYEWSA-N",
                "generic_name": "Heme arginate",
                "designated_date": "03/01/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orphan Europe SARL|Immeuble Le Wilson|70 avenue du General de Gaulle,|Puteaux|France",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndromes.",
                    "umls_id": "C3463824",
                    "parsed_text": "Myelodysplastic Syndromes"
                }
            },
            {
                "compound_id": 3086464,
                "inchl_key": "MGQITOFVXOEWNL-INZIHYEWSA-N",
                "generic_name": "Heme arginate",
                "designated_date": "03/10/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orphan Europe SARL|Immeuble Le Wilson|70 avenue du General de Gaulle|Puteaux|France",
                "orphan_designation": {
                    "original_text": "Treatment of symptomatic stage of acute porphyria.",
                    "umls_id": "C0162565",
                    "parsed_text": "Acute Porphyria"
                }
            }
        ]
    },
    {
        "_id": "ZRJBHWIHUMBLCN-JRYCNTDSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4369233,
                "inchl_key": "ZRJBHWIHUMBLCN-JRYCNTDSSA-N",
                "generic_name": "Huperzine A",
                "designated_date": "04/12/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biscayne Neurotherapeutics, Inc.|4770 Biscayne Boulevard|Suite 660|Miami|Florida|33137|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Dravet syndrome",
                    "umls_id": "C0751122",
                    "parsed_text": "Dravet Syndrome"
                }
            }
        ]
    },
    {
        "_id": "ZRJBHWIHUMBLCN-BMIGLBTASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 1633595,
                "inchl_key": "ZRJBHWIHUMBLCN-BMIGLBTASA-N",
                "generic_name": "Huperzine A",
                "designated_date": "04/12/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biscayne Neurotherapeutics, Inc.|4770 Biscayne Boulevard|Suite 660|Miami|Florida|33137|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Dravet syndrome",
                    "umls_id": "C0751122",
                    "parsed_text": "Dravet Syndrome"
                }
            }
        ]
    },
    {
        "_id": "ZRJBHWIHUMBLCN-HZRLMBICSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9794806,
                "inchl_key": "ZRJBHWIHUMBLCN-HZRLMBICSA-N",
                "generic_name": "Huperzine A",
                "designated_date": "04/12/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biscayne Neurotherapeutics, Inc.|4770 Biscayne Boulevard|Suite 660|Miami|Florida|33137|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Dravet syndrome",
                    "umls_id": "C0751122",
                    "parsed_text": "Dravet Syndrome"
                }
            }
        ]
    },
    {
        "_id": "JYGXADMDTFJGBT-VWUMJDOOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5754,
                "inchl_key": "JYGXADMDTFJGBT-VWUMJDOOSA-N",
                "generic_name": "hydrocortisone",
                "designated_date": "05/13/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "LABORATOIRE AGUETTANT|1, rue Alexander Fleming|Lyon|France",
                "orphan_designation": {
                    "original_text": "Prevention of bronchopulmonary dysplasia",
                    "umls_id": "C0006287",
                    "parsed_text": "Bronchopulmonary Dysplasia"
                }
            },
            {
                "compound_id": 5754,
                "inchl_key": "JYGXADMDTFJGBT-VWUMJDOOSA-N",
                "generic_name": "Hydrocortisone",
                "trade_name": "ALKINDI SPRINKLE",
                "designated_date": "05/13/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "ALKINDI SPRINKLE is indicated as replacement therapy in pediatric patients with adrenocortical insufficiency",
                "marketing_approval_date": "\u00a009/29/2020\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Eton Pharmaceuticals, Inc.|21925 West Field Parkway, Suite 235|Deer Park|Illinois|60010|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric adrenal insufficiency (0 through 16 years of age).",
                    "umls_id": "C0001623",
                    "parsed_text": "Adrenal Insufficiency"
                }
            }
        ]
    },
    {
        "_id": "ALEXXDVDDISNDU-JZYPGELDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5744,
                "inchl_key": "ALEXXDVDDISNDU-JZYPGELDSA-N",
                "generic_name": "hydrocortisone acetate",
                "designated_date": "06/27/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cristcot HCA, LLC|555 Virginia Road|Suite 202|Concord|Massachusetts|1742|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric ulcerative colitis",
                    "umls_id": "C2931173",
                    "parsed_text": "Pediatric ulcerative colitis"
                }
            }
        ]
    },
    {
        "_id": "IXZOHGPZAQLIBH-NRFANRHFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 67335295,
                "inchl_key": "IXZOHGPZAQLIBH-NRFANRHFSA-N",
                "generic_name": "iberdomide",
                "designated_date": "12/19/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "ZJVFLBOZORBYFE-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3671,
                "inchl_key": "ZJVFLBOZORBYFE-UHFFFAOYSA-N",
                "generic_name": "Ibudilast",
                "designated_date": "10/02/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MediciNova, Inc.|4275 Executive Square|Suite 300|La Jolla|California|92037|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Glioblastoma",
                    "umls_id": "C0017636",
                    "parsed_text": "Glioblastoma"
                }
            },
            {
                "compound_id": 3671,
                "inchl_key": "ZJVFLBOZORBYFE-UHFFFAOYSA-N",
                "generic_name": "ibudilast",
                "designated_date": "06/01/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MediciNova, Inc.|4275 Executive Square|Suite 300|La Jolla|California|92037|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Krabbe disease",
                    "umls_id": "C0023521",
                    "parsed_text": "Krabbe Disease"
                }
            },
            {
                "compound_id": 3671,
                "inchl_key": "ZJVFLBOZORBYFE-UHFFFAOYSA-N",
                "generic_name": "ibudilast",
                "designated_date": "10/06/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MediciNova, Inc.|4275 Executive Square|Suite 300|La Jolla|California|92037|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "JGPMMRGNQUBGND-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3686,
                "inchl_key": "JGPMMRGNQUBGND-UHFFFAOYSA-N",
                "generic_name": "idebenone",
                "designated_date": "03/25/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santhera Pharmaceuticals (Switzerland) Limited|Hammerstrass 49|CH-4410 Liestal|Liestal|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of Friedreich's ataxia",
                    "umls_id": "C0016719",
                    "parsed_text": "Friedreich's Ataxia"
                }
            },
            {
                "compound_id": 3686,
                "inchl_key": "JGPMMRGNQUBGND-UHFFFAOYSA-N",
                "generic_name": "idebenone",
                "designated_date": "02/16/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santhera Pharmaceuticals (Switzerland) Limited|Hammerstrass 49|CH-4410 Liestal|Liestal|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of Duchenne muscular dystrophy",
                    "umls_id": "C0013264",
                    "parsed_text": "DUCHENNE MUSCULAR DYSTROPHY"
                }
            },
            {
                "compound_id": 3686,
                "inchl_key": "JGPMMRGNQUBGND-UHFFFAOYSA-N",
                "generic_name": "idebenone",
                "designated_date": "10/31/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santhera Pharmaceuticals (Switzerland) Limited|Hammerstrass 49|CH-4410 Liestal|Liestal|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of Leber's hereditary optic neuropathy.",
                    "umls_id": "C0917796",
                    "parsed_text": "Leber's Hereditary Optic Neuropathy"
                }
            },
            {
                "compound_id": 3686,
                "inchl_key": "JGPMMRGNQUBGND-UHFFFAOYSA-N",
                "generic_name": "idebenone",
                "designated_date": "05/22/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santhera Pharmaceuticals (Switzerland) Ltd.|25 Hammerstrasse|Liestal|Basel-Landschaft|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of mitochondrial myopathy, encephalopathy, lactic acidosis with stroke-like episodes syndrome (MELAS)",
                    "umls_id": "C0001125,C0039082,C0085584,C0162670,C0162671,C1857287",
                    "parsed_text": "LACTIC ACIDOSIS , Syndrome , Encephalopathy , MITOCHONDRIAL MYOPATHY , MELAS , Stroke-like episodes"
                }
            }
        ]
    },
    {
        "_id": "XQFRJNBWHJMXHO-RRKCRQDMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5905,
                "inchl_key": "XQFRJNBWHJMXHO-RRKCRQDMSA-N",
                "generic_name": "Idoxuridine",
                "designated_date": "04/08/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NeoPharm, Inc.|225 East Deerpath, Suite 250|Lake Forest|Illinois|60045|United States",
                "orphan_designation": {
                    "original_text": "Treatment of nonparenchymatous sarcomas.",
                    "umls_id": "C1261473",
                    "parsed_text": "Sarcomas"
                }
            }
        ]
    },
    {
        "_id": "KTUFNOKKBVMGRW-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5291,
                "inchl_key": "KTUFNOKKBVMGRW-UHFFFAOYSA-N",
                "generic_name": "imatinib",
                "trade_name": "Gleevec",
                "designated_date": "10/11/2005",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy",
                "marketing_approval_date": "\u00a001/25/2013\u00a0",
                "exclusivity_end_date": "\u00a001/25/2020\u00a0",
                "exclusivity_protected_indication": "Treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|Mail Code 105/1E870D|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Philadelphia-positive acute lymphoblastic leukemia",
                    "umls_id": "C1709527",
                    "parsed_text": "Philadelphia-positive acute lymphoblastic leukemia"
                }
            },
            {
                "compound_id": 5291,
                "inchl_key": "KTUFNOKKBVMGRW-UHFFFAOYSA-N",
                "generic_name": "imatinib",
                "designated_date": "04/07/2010",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            },
            {
                "compound_id": 5291,
                "inchl_key": "KTUFNOKKBVMGRW-UHFFFAOYSA-N",
                "generic_name": "imatinib",
                "trade_name": "Gleevec",
                "designated_date": "10/11/2005",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL)",
                "marketing_approval_date": "\u00a010/19/2006\u00a0",
                "exclusivity_end_date": "\u00a010/19/2013\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|Mail Code 105/1E870D|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Philadelphia-positive acute lymphoblastic leukemia",
                    "umls_id": "C1709527",
                    "parsed_text": "Philadelphia-positive acute lymphoblastic leukemia"
                }
            },
            {
                "compound_id": 5291,
                "inchl_key": "KTUFNOKKBVMGRW-UHFFFAOYSA-N",
                "generic_name": "Imatinib",
                "designated_date": "12/21/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Aerovate Therapeutics, Inc|200 Berkeley Street, Floor 18|Boston|Massachusetts|2116|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pulmonary Arterial Hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            },
            {
                "compound_id": 5291,
                "inchl_key": "KTUFNOKKBVMGRW-UHFFFAOYSA-N",
                "generic_name": "Imatinib",
                "trade_name": "Gleevec",
                "designated_date": "01/31/2001",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy",
                "marketing_approval_date": "\u00a005/10/2001\u00a0",
                "exclusivity_end_date": "\u00a005/10/2008\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic myelogenous leukemia",
                    "umls_id": "C0023473",
                    "parsed_text": "Chronic myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "AMNXBQPRODZJQR-DITALETJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5745206,
                "inchl_key": "AMNXBQPRODZJQR-DITALETJSA-N",
                "generic_name": "Implitapide",
                "designated_date": "08/13/2004",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medical Research Laboratories International|2 Tesseneer Drive|Highland Heights|Kentucky|41076|United States",
                "orphan_designation": {
                    "original_text": "Treatment of homozygous familial hypercholesterolemia",
                    "umls_id": "C0020445",
                    "parsed_text": "FAMILIAL HYPERCHOLESTEROLEMIA"
                }
            },
            {
                "compound_id": 5745206,
                "inchl_key": "AMNXBQPRODZJQR-DITALETJSA-N",
                "generic_name": "Implitapide",
                "designated_date": "08/19/2004",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medical Research Laboratories International|2 Tesseneer Drive|Highland Heights|Kentucky|41076|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with Fredrickson type I or V hyperlipoproteinemia",
                    "umls_id": "C0023817",
                    "parsed_text": "Fredrickson type I or V hyperlipoproteinemia"
                }
            }
        ]
    },
    {
        "_id": "KLEGMTRDCCDFJK-XDQSQZFTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 121492004,
                "inchl_key": "KLEGMTRDCCDFJK-XDQSQZFTSA-N",
                "generic_name": "Inotersen",
                "trade_name": "TEGSEDI",
                "designated_date": "07/24/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "TEGSEDI is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.",
                "marketing_approval_date": "\u00a010/05/2018\u00a0",
                "exclusivity_end_date": "\u00a010/05/2025\u00a0",
                "exclusivity_protected_indication": "TEGSEDI is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.",
                "sponsor": "Akcea Therapeutics, Inc.|22 Boston Wharf Road|9th Floor|Boston|Massachusetts|2210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of transthyretin amyloidosis (ATTR amyloidosis)",
                    "umls_id": "C0002726,C2751492",
                    "parsed_text": "Amyloidosis , Transthyretin Amyloidosis"
                }
            }
        ]
    },
    {
        "_id": "PDWUPXJEEYOOTR-IUAIQHPESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135326,
                "inchl_key": "PDWUPXJEEYOOTR-IUAIQHPESA-N",
                "generic_name": "Iobenguane I 123",
                "trade_name": "Adreview",
                "designated_date": "12/01/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "To be used in the detection of primary or metastatic pheochromocytomas or neuroblastomas as an adjunct to other diagnostic tests",
                "marketing_approval_date": "\u00a009/19/2008\u00a0",
                "exclusivity_end_date": "\u00a009/19/2015\u00a0",
                "sponsor": "GE Healthcare, Inc.|101 Carnegie Center|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "For the diagnosis of neuroblastomas",
                    "umls_id": "C0027819",
                    "parsed_text": "Neuroblastomas"
                }
            },
            {
                "compound_id": 135326,
                "inchl_key": "PDWUPXJEEYOOTR-IUAIQHPESA-N",
                "generic_name": "Iobenguane I 123",
                "trade_name": "AdreView",
                "designated_date": "12/01/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "To be used in the detection of primary or metastatic pheochromocytomas or neuroblastomas as an adjunct to other diagnostic tests",
                "marketing_approval_date": "\u00a009/19/2008\u00a0",
                "exclusivity_end_date": "\u00a009/19/2015\u00a0",
                "sponsor": "GE Healthcare, Inc.|101 Carnegie Center|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "For the diagnosis of pheochromocytomas",
                    "umls_id": "C0031511",
                    "parsed_text": "Pheochromocytomas"
                }
            }
        ]
    },
    {
        "_id": "LWXUIUUOMSMZKJ-KLFWAVJMSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 72196309,
                "inchl_key": "LWXUIUUOMSMZKJ-KLFWAVJMSA-M",
                "generic_name": "isavuconazonium sulfate",
                "trade_name": "Cresemba",
                "designated_date": "05/06/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of invasive aspergillosis in patients 18 years of age and older",
                "marketing_approval_date": "\u00a003/06/2015\u00a0",
                "exclusivity_end_date": "\u00a003/06/2022\u00a0",
                "exclusivity_protected_indication": "Treatment of invasive aspergillosis in patients 18 years of age and older",
                "sponsor": "Astellas Pharma Global Development Inc.|1 Astellas Way|Northbrook|Illinois|60062|United States",
                "orphan_designation": {
                    "original_text": "Treatment of invasive aspergillosis",
                    "umls_id": "C0238013",
                    "parsed_text": "Invasive aspergillosis"
                }
            },
            {
                "compound_id": 72196309,
                "inchl_key": "LWXUIUUOMSMZKJ-KLFWAVJMSA-M",
                "generic_name": "isavuconazonium sulfate",
                "designated_date": "10/20/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Astellas Pharma Global Development, Inc.|1 Astellas Way|Northbrook|Illinois|60062|United States",
                "orphan_designation": {
                    "original_text": "Treatment of invasive candidiasis/candidemia",
                    "umls_id": "C0877445,C1609535",
                    "parsed_text": "Candidemia , Invasive Candidiasis"
                }
            },
            {
                "compound_id": 72196309,
                "inchl_key": "LWXUIUUOMSMZKJ-KLFWAVJMSA-M",
                "generic_name": "isavuconazonium sulfate",
                "trade_name": "Cresemba",
                "designated_date": "10/25/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of invasive mucormycosis in patients 18 years of age and older",
                "marketing_approval_date": "\u00a003/06/2015\u00a0",
                "exclusivity_end_date": "\u00a003/06/2022\u00a0",
                "exclusivity_protected_indication": "Treatment of invasive mucormycosis in patients 18 years of age and older",
                "sponsor": "Astellas Pharma Global Development Inc.|1 Astellas Way|Northbrook|Illinois|60062|United States",
                "orphan_designation": {
                    "original_text": "Treatment of zygomycosis",
                    "umls_id": "C0043541",
                    "parsed_text": "Zygomycosis"
                }
            }
        ]
    },
    {
        "_id": "MBOMYENWWXQSNW-AWEZNQCLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 56844015,
                "inchl_key": "MBOMYENWWXQSNW-AWEZNQCLSA-N",
                "generic_name": "ixazomib citrate",
                "trade_name": "Ninlaro",
                "designated_date": "02/18/2011",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy",
                "marketing_approval_date": "\u00a011/20/2015\u00a0",
                "exclusivity_end_date": "\u00a011/20/2022\u00a0",
                "exclusivity_protected_indication": "Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy",
                "sponsor": "Millennium Pharmaceuticals|40 Landsdowne St.|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "RHGKLRLOHDJJDR-BYPYZUCNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9750,
                "inchl_key": "RHGKLRLOHDJJDR-BYPYZUCNSA-N",
                "generic_name": "L-Citrulline",
                "designated_date": "11/03/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orpha Labs, AG|Haldenstrasse 5|Baar|CH-6340|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of Ornithine Transcarbamylase deficiency",
                    "umls_id": "C0268542",
                    "parsed_text": "Ornithine Transcarbamylase Deficiency"
                }
            },
            {
                "compound_id": 9750,
                "inchl_key": "RHGKLRLOHDJJDR-BYPYZUCNSA-N",
                "generic_name": "L-citrulline",
                "designated_date": "10/07/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Asklepion Pharmaceuticals, LLC|729 E. Pratt Street|Suite 360|Baltimore|Maryland|21202|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sickle cell disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            },
            {
                "compound_id": 9750,
                "inchl_key": "RHGKLRLOHDJJDR-BYPYZUCNSA-N",
                "generic_name": "L-citrulline",
                "designated_date": "01/09/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Asklepion Pharmaceuticals, LLC|729 East Pratt Street|Suite 360|Baltimore|Maryland|21202|United States",
                "orphan_designation": {
                    "original_text": "Prevention of clinical sequelae of acute lung injury induced by cardiopulmonary bypass in pediatric patients",
                    "umls_id": "C0242488",
                    "parsed_text": "Acute Lung Injury"
                }
            }
        ]
    },
    {
        "_id": "DYDCUQKUCUHJBH-REOHCLBHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 449215,
                "inchl_key": "DYDCUQKUCUHJBH-REOHCLBHSA-N",
                "generic_name": "L-cycloserine",
                "designated_date": "08/01/1989",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Lev, Meir M.D.|The City College, City University Of NY Medical Sc|Convent Avenue at 138 Street|New York|New York|10031|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Gaucher's disease.",
                    "umls_id": "C0017205",
                    "parsed_text": "Gaucher's Disease"
                }
            }
        ]
    },
    {
        "_id": "LLEUXCDZPQOJMY-AAEUAGOBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 100094,
                "inchl_key": "LLEUXCDZPQOJMY-AAEUAGOBSA-N",
                "generic_name": "L-glutamyl-L-tryptophan",
                "designated_date": "10/20/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Implicit Bioscience Pty Ltd|P. O. Box 2072.|Toowong Business Center|Australia",
                "orphan_designation": {
                    "original_text": "Treatment of AIDS-related Kaposi's sarcoma.",
                    "umls_id": "C0276535",
                    "parsed_text": "AIDS-related Kaposi's sarcoma"
                }
            }
        ]
    },
    {
        "_id": "PYZRQGJRPPTADH-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3878,
                "inchl_key": "PYZRQGJRPPTADH-UHFFFAOYSA-N",
                "generic_name": "Lamotrigine",
                "trade_name": "Lamictal",
                "designated_date": "08/23/1995",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Adjunctive treatment of Lennox-Gastaut syndrome in pediatric and adult patients.",
                "marketing_approval_date": "\u00a008/24/1998\u00a0",
                "exclusivity_end_date": "\u00a008/24/2005\u00a0",
                "sponsor": "Glaxo Wellcome Research and Development|5 Moore Drive|P.O. Box 13398|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Lennox-Gastaut syndrome.",
                    "umls_id": "C0238111",
                    "parsed_text": "Lennox-Gastaut syndrome"
                }
            }
        ]
    },
    {
        "_id": "PUDHBTGHUJUUFI-SCTWWAJVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6918011,
                "inchl_key": "PUDHBTGHUJUUFI-SCTWWAJVSA-N",
                "generic_name": "lanreotide acetate",
                "designated_date": "09/08/2011",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy",
                "marketing_approval_date": "\u00a009/15/2017\u00a0",
                "exclusivity_end_date": "\u00a009/15/2024\u00a0",
                "exclusivity_protected_indication": "treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy",
                "sponsor": "Ipsen Biopharmaceuticals, Inc.|106 Allen Road|Basking Ridge|New Jersey|7920|United States",
                "orphan_designation": {
                    "original_text": "Treatment of carcinoid syndrome",
                    "umls_id": "C0024586",
                    "parsed_text": "Carcinoid syndrome"
                }
            },
            {
                "compound_id": 6918011,
                "inchl_key": "PUDHBTGHUJUUFI-SCTWWAJVSA-N",
                "generic_name": "lanreotide acetate",
                "trade_name": "Somatuline Depot",
                "designated_date": "08/25/2011",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with unresectable,well- or moderately-differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival",
                "marketing_approval_date": "\u00a012/16/2014\u00a0",
                "exclusivity_end_date": "\u00a012/16/2021\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with unresectable,well- or moderately-differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival",
                "sponsor": "Ipsen Biopharmaceuticals, Inc.|106 Allen Road|Basking Ridge|New Jersey|7920|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuroendocrine tumors",
                    "umls_id": "C0206754",
                    "parsed_text": "Neuroendocrine Tumors"
                }
            }
        ]
    },
    {
        "_id": "PUDHBTGHUJUUFI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71349,
                "inchl_key": "PUDHBTGHUJUUFI-UHFFFAOYSA-N",
                "generic_name": "lanreotide acetate",
                "designated_date": "09/08/2011",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy",
                "marketing_approval_date": "\u00a009/15/2017\u00a0",
                "exclusivity_end_date": "\u00a009/15/2024\u00a0",
                "exclusivity_protected_indication": "treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy",
                "sponsor": "Ipsen Biopharmaceuticals, Inc.|106 Allen Road|Basking Ridge|New Jersey|7920|United States",
                "orphan_designation": {
                    "original_text": "Treatment of carcinoid syndrome",
                    "umls_id": "C0024586",
                    "parsed_text": "Carcinoid syndrome"
                }
            },
            {
                "compound_id": 71349,
                "inchl_key": "PUDHBTGHUJUUFI-UHFFFAOYSA-N",
                "generic_name": "lanreotide acetate",
                "trade_name": "Somatuline Depot",
                "designated_date": "08/25/2011",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with unresectable,well- or moderately-differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival",
                "marketing_approval_date": "\u00a012/16/2014\u00a0",
                "exclusivity_end_date": "\u00a012/16/2021\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with unresectable,well- or moderately-differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival",
                "sponsor": "Ipsen Biopharmaceuticals, Inc.|106 Allen Road|Basking Ridge|New Jersey|7920|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuroendocrine tumors",
                    "umls_id": "C0206754",
                    "parsed_text": "Neuroendocrine Tumors"
                }
            }
        ]
    },
    {
        "_id": "YCHYFHOSGQABSW-RTBURBONSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3083542,
                "inchl_key": "YCHYFHOSGQABSW-RTBURBONSA-N",
                "generic_name": "lenabasum",
                "designated_date": "07/18/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Corbus Pharmaceuticals, Inc.|500 River Ridge Drive|Second Floor|Norwood|Massachusetts|2062|United States",
                "orphan_designation": {
                    "original_text": "Treatment of dermatomyositis",
                    "umls_id": "C0011633",
                    "parsed_text": "Dermatomyositis"
                }
            }
        ]
    },
    {
        "_id": "UIARLYUEJFELEN-LROUJFHJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 126565,
                "inchl_key": "UIARLYUEJFELEN-LROUJFHJSA-N",
                "generic_name": "lestaurtinib",
                "designated_date": "03/24/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.|145 Brandywine Parkway|West Chester|Pennsylvania|19380|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "compound_id": 126565,
                "inchl_key": "UIARLYUEJFELEN-LROUJFHJSA-N",
                "generic_name": "lestaurtinib",
                "designated_date": "09/03/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.|145 Brandywine Parkway|West Chester|Pennsylvania|19380|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Philadelphia-negative classic myeloproliferative disorders",
                    "umls_id": "C0027022",
                    "parsed_text": "Myeloproliferative Disorders"
                }
            }
        ]
    },
    {
        "_id": "PHIQHXFUZVPYII-ZCFIWIBFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10917,
                "inchl_key": "PHIQHXFUZVPYII-ZCFIWIBFSA-N",
                "generic_name": "Levocarnitine",
                "trade_name": "Carnitor",
                "designated_date": "07/26/1984",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of primary systemic carnitine deficiency. (approved 12/27/85) Treatment of secondary carnitine deficiency. (approved 12/16/92)",
                "marketing_approval_date": "\u00a012/16/1992\u00a0",
                "exclusivity_end_date": "\u00a012/16/1999\u00a0",
                "sponsor": "Leadiant Biosciences, Inc.|9841 Washingtonian Blvd|Suite 500|Gaithersburg|Maryland|20878|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary and secondary carnitine deficiency of genetic origin.",
                    "umls_id": "C2025219",
                    "parsed_text": "Secondary carnitine deficiency"
                }
            },
            {
                "compound_id": 10917,
                "inchl_key": "PHIQHXFUZVPYII-ZCFIWIBFSA-N",
                "generic_name": "Levocarnitine",
                "trade_name": "Carnitor",
                "designated_date": "09/06/1988",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis.",
                "marketing_approval_date": "\u00a012/15/1999\u00a0",
                "exclusivity_end_date": "\u00a012/15/2006\u00a0",
                "sponsor": "Leadiant Biosciences, Inc.|9841 Washingtonian Blvd|Suite 500|Gaithersburg|Maryland|20878|United States",
                "orphan_designation": {
                    "original_text": "Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.",
                    "umls_id": "C0022661,C0342788",
                    "parsed_text": "End stage renal disease , Carnitine Deficiency"
                }
            },
            {
                "compound_id": 10917,
                "inchl_key": "PHIQHXFUZVPYII-ZCFIWIBFSA-N",
                "generic_name": "Levocarnitine",
                "trade_name": "Carnitor",
                "designated_date": "02/28/1984",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a004/10/1986\u00a0",
                "exclusivity_end_date": "\u00a004/10/1993\u00a0",
                "sponsor": "Leadiant Biosciences, Inc.|9841 Washingtonian Blvd|Suite 500|Gaithersburg|Maryland|20878|United States",
                "orphan_designation": {
                    "original_text": "Treatment of genetic carnitine deficiency.",
                    "umls_id": "C0342788",
                    "parsed_text": "Carnitine Deficiency"
                }
            },
            {
                "compound_id": 10917,
                "inchl_key": "PHIQHXFUZVPYII-ZCFIWIBFSA-N",
                "generic_name": "levocarnitine",
                "designated_date": "11/15/1989",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Leadiant Biosciences, Inc.|9841 Washingtonian Blvd|Suite 500|Gaithersburg|Maryland|20878|United States",
                "orphan_designation": {
                    "original_text": "1. Prevention of secondary carnitine deficiency in valproic acid toxicity 2. Treatment of secondary carnitine deficiency in valproic acid toxicity",
                    "umls_id": "C0600688,C2025219",
                    "parsed_text": "Toxicity , Secondary carnitine deficiency"
                }
            },
            {
                "compound_id": 10917,
                "inchl_key": "PHIQHXFUZVPYII-ZCFIWIBFSA-N",
                "generic_name": "Levocarnitine",
                "designated_date": "11/24/1986",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Leadiant Biosciences, Inc.|9841 Washingtonian Blvd|Suite 500|Gaithersburg|Maryland|20878|United States",
                "orphan_designation": {
                    "original_text": "Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.",
                    "umls_id": "C0022661,C0342788",
                    "parsed_text": "End stage renal disease , Carnitine Deficiency"
                }
            },
            {
                "compound_id": 10917,
                "inchl_key": "PHIQHXFUZVPYII-ZCFIWIBFSA-N",
                "generic_name": "Levocarnitine",
                "designated_date": "04/07/1997",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Leadiant Biosciences, Inc.|9841 Washingtonian Boulevard|Suite 500|Gaithersburg|Maryland|20878|United States",
                "orphan_designation": {
                    "original_text": "Treatment of zidovudine-induced mitochondrial myopathy.",
                    "umls_id": "C0162670",
                    "parsed_text": "MITOCHONDRIAL MYOPATHY"
                }
            },
            {
                "compound_id": 10917,
                "inchl_key": "PHIQHXFUZVPYII-ZCFIWIBFSA-N",
                "generic_name": "Levocarnitine",
                "designated_date": "11/22/1993",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Leadiant Biosciences, Inc.|9841 Washingtonian Blvd|Suite 500|Gaithersburg|Maryland|20878|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric cardiomyopathy.",
                    "umls_id": "C0878544",
                    "parsed_text": "Cardiomyopathy"
                }
            }
        ]
    },
    {
        "_id": "VVIAGPKUTFNRDU-STQMWFEESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135398559,
                "inchl_key": "VVIAGPKUTFNRDU-STQMWFEESA-N",
                "generic_name": "Levoleucovorin",
                "trade_name": "Fusilev",
                "designated_date": "08/01/1991",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Levoleucovorin rescue is indicated after high-dose methotrexate therapy in osteosarcoma. Levoleucovorin is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists",
                "marketing_approval_date": "\u00a003/07/2008\u00a0",
                "exclusivity_end_date": "\u00a003/07/2015\u00a0",
                "sponsor": "Acrotech Biopharma LLC|279 Princeton Hightstown Road|East Windsor|New Jersey|8520|United States",
                "orphan_designation": {
                    "original_text": "For use in conjunction with high-dose methotrexate in the treatment of osteosarcoma.",
                    "umls_id": "C0029463",
                    "parsed_text": "Osteosarcoma"
                }
            },
            {
                "compound_id": 135398559,
                "inchl_key": "VVIAGPKUTFNRDU-STQMWFEESA-N",
                "generic_name": "levoleucovorin",
                "trade_name": "Fusilev",
                "designated_date": "12/18/1990",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer",
                "marketing_approval_date": "\u00a004/29/2011\u00a0",
                "exclusivity_end_date": "\u00a004/29/2018\u00a0",
                "sponsor": "Acrotech Biopharma LLC|279 Princeton Hightstown Road|East Windsor|New Jersey|8520|United States",
                "orphan_designation": {
                    "original_text": "For use in combination chemotherapy with the approved agent 5-fluorouracil in the palliative treatment of metastatic adenocarcinoma of the colon and rectum",
                    "umls_id": "C0334277,C0338106",
                    "parsed_text": "Metastatic adenocarcinoma , adenocarcinoma of the colon"
                }
            }
        ]
    },
    {
        "_id": "NSMXQKNUPPXBRG-SECBINFHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 501254,
                "inchl_key": "NSMXQKNUPPXBRG-SECBINFHSA-N",
                "generic_name": "Lisofylline",
                "designated_date": "06/10/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cell Therapeutics, Inc.|501 Elliott Avenue West|Suite 400|Seattle|Washington|98119|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients undergoing induction therapy for acute myeloid leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "XGZVUEUWXADBQD-UHFFFAOYSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 11125,
                "inchl_key": "XGZVUEUWXADBQD-UHFFFAOYSA-L",
                "generic_name": "lithium carbonate",
                "designated_date": "03/29/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Lispiro LLC|4 Betsy Lane|Dover|Massachusetts|2030|United States",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic pulmonary fibrosis",
                    "umls_id": "C1800706",
                    "parsed_text": "Idiopathic Pulmonary Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "NGWSFRIPKNWYAO-SHTIJGAHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11347535,
                "inchl_key": "NGWSFRIPKNWYAO-SHTIJGAHSA-N",
                "generic_name": "marizomib",
                "designated_date": "09/21/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Celgene International II S?|Rue du Pre-Jorat 14|Couvet|Neuch\u2d25l|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma.",
                    "umls_id": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            },
            {
                "compound_id": 11347535,
                "inchl_key": "NGWSFRIPKNWYAO-SHTIJGAHSA-N",
                "generic_name": "marizomib",
                "designated_date": "12/13/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Celgene International II S?|4 Rue des Moulins|Couvet|Neuch\u2d25l|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "IMYZQPCYWPFTAG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4032,
                "inchl_key": "IMYZQPCYWPFTAG-UHFFFAOYSA-N",
                "generic_name": "Mecamylamine",
                "designated_date": "10/14/1998",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Targacept, Inc.|200 East First St.|Suite 300|Winston-Salem|North Carolina|27101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Tourette's syndrome.",
                    "umls_id": "C0040517",
                    "parsed_text": "Tourette's Syndrome"
                }
            }
        ]
    },
    {
        "_id": "SGDBTWWWUNNDEQ-LBPRGKRZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 460612,
                "inchl_key": "SGDBTWWWUNNDEQ-LBPRGKRZSA-N",
                "generic_name": "Melphalan",
                "trade_name": "Alkeran For Injection",
                "designated_date": "02/24/1992",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the palliative treatment of patients with multiple myeloma for whom oral melphalan is not appropriate.",
                "marketing_approval_date": "\u00a011/18/1992\u00a0",
                "exclusivity_end_date": "\u00a011/18/1999\u00a0",
                "sponsor": "Glaxo Wellcome Inc.|5 Moore Drive|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with multiple myeloma for whom oral therapy is inappropriate.",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            },
            {
                "compound_id": 460612,
                "inchl_key": "SGDBTWWWUNNDEQ-LBPRGKRZSA-N",
                "generic_name": "melphalan",
                "designated_date": "07/14/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Delcath Systems, Inc.|1633 Broadway|Suite 22C|New York|New York|10019|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cholangiocarcinoma.",
                    "umls_id": "C0206698",
                    "parsed_text": "Cholangiocarcinoma"
                }
            },
            {
                "compound_id": 460612,
                "inchl_key": "SGDBTWWWUNNDEQ-LBPRGKRZSA-N",
                "generic_name": "Melphalan",
                "designated_date": "03/03/1992",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Glaxo Wellcome Research and Development|5 Moore Drive|PO Box 13398|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "For use in hyperthermic regional limb perfusion to treat metastatic melanoma of the extremity.",
                    "umls_id": "C0015967,C0278883",
                    "parsed_text": "hyperthermic , Metastatic melanoma"
                }
            },
            {
                "compound_id": 460612,
                "inchl_key": "SGDBTWWWUNNDEQ-LBPRGKRZSA-N",
                "generic_name": "melphalan",
                "designated_date": "11/19/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EyePoint Pharmaceuticals, Inc.|480 Pleasant Street, B300|Watertown|Massachusetts|2472|United States",
                "orphan_designation": {
                    "original_text": "Treatment of retinoblastoma",
                    "umls_id": "C0035335",
                    "parsed_text": "Retinoblastoma"
                }
            },
            {
                "compound_id": 460612,
                "inchl_key": "SGDBTWWWUNNDEQ-LBPRGKRZSA-N",
                "generic_name": "melphalan",
                "designated_date": "11/19/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OncoTx, LLC|9 Brandeis Road|Newton|Massachusetts|2459|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Stage IIB through IV melanoma",
                    "umls_id": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "XDPFHGWVCTXHDX-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 23665888,
                "inchl_key": "XDPFHGWVCTXHDX-UHFFFAOYSA-M",
                "generic_name": "menadione sodium bisulfite",
                "designated_date": "05/14/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "IC-MedTech Corporation|9902 Indian Creek Lane|El Cajon|California|92021|United States",
                "orphan_designation": {
                    "original_text": "Treatment of autosomal dominant polycystic liver disease",
                    "umls_id": "C0158683",
                    "parsed_text": "Polycystic liver disease"
                }
            },
            {
                "compound_id": 23665888,
                "inchl_key": "XDPFHGWVCTXHDX-UHFFFAOYSA-M",
                "generic_name": "Menadione Sodium Bisulfite",
                "designated_date": "05/14/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "IC-MedTech Corporation|9902 Indian Creek Lane|El Cajon|California|92021|United States",
                "orphan_designation": {
                    "original_text": "For the treatment of autosomal dominant polycystic kidney disease",
                    "umls_id": "C0085413",
                    "parsed_text": "Autosomal dominant polycystic kidney disease"
                }
            }
        ]
    },
    {
        "_id": "DKHGMERMDICWDU-GHDNBGIDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5282367,
                "inchl_key": "DKHGMERMDICWDU-GHDNBGIDSA-N",
                "generic_name": "menatetrenone",
                "designated_date": "11/02/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NBI Pharmaceuticals, Inc.|1087 Stoneridge Drive|Bozeman|Montana|59718|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma (HCC).",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            },
            {
                "compound_id": 5282367,
                "inchl_key": "DKHGMERMDICWDU-GHDNBGIDSA-N",
                "generic_name": "menatetrenone",
                "designated_date": "03/17/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NBI Pharmaceuticals, Inc.|1087 Stoneridge Drive|Bozeman|Montana|59718|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "compound_id": 5282367,
                "inchl_key": "DKHGMERMDICWDU-GHDNBGIDSA-N",
                "generic_name": "menatetrenone",
                "designated_date": "11/02/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NBI Pharmaceuticals, Inc.|1087 Stoneridge Drive|Bozeman|Montana|59718|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute promyelocytic leukemia.",
                    "umls_id": "C0023487",
                    "parsed_text": "Acute Promyelocytic Leukemia"
                }
            },
            {
                "compound_id": 5282367,
                "inchl_key": "DKHGMERMDICWDU-GHDNBGIDSA-N",
                "generic_name": "menatetrenone",
                "designated_date": "02/04/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NBI Pharmaceuticals, Inc.|1087 Stoneridge Drive|Bozeman|Montana|59718|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndrome.",
                    "umls_id": "C3463824",
                    "parsed_text": "MYELODYSPLASTIC SYNDROME"
                }
            }
        ]
    },
    {
        "_id": "XOGTZOOQQBDUSI-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 23662354,
                "inchl_key": "XOGTZOOQQBDUSI-UHFFFAOYSA-M",
                "generic_name": "Mesna",
                "trade_name": "Mesnex",
                "designated_date": "11/14/1985",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a012/30/1988\u00a0",
                "exclusivity_end_date": "\u00a012/30/1995\u00a0",
                "sponsor": "Degussa Corporation|65 Challenger Road|Ridgefield Park|New Jersey|7660|United States",
                "orphan_designation": {
                    "original_text": "For use as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.",
                    "umls_id": "C0085692",
                    "parsed_text": "Hemorrhagic cystitis"
                }
            }
        ]
    },
    {
        "_id": "XZWYZXLIPXDOLR-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4091,
                "inchl_key": "XZWYZXLIPXDOLR-UHFFFAOYSA-N",
                "generic_name": "metformin",
                "designated_date": "05/29/2014",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EffRx Pharmaceuticals SA|Wolleraustrass 41 B|8807 Freienbach (SZ)|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric polycystic ovary syndrome",
                    "umls_id": "C0032460",
                    "parsed_text": "Polycystic Ovary Syndrome"
                }
            },
            {
                "compound_id": 4091,
                "inchl_key": "XZWYZXLIPXDOLR-UHFFFAOYSA-N",
                "generic_name": "metformin",
                "designated_date": "12/14/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Consorcio Centro de Investigaci\udb7a\udc02iom\u9929ca en Red, M.P. (CIBER)|Monforte de Lemos|3-5 Pabellon 11|Madrid|Comunidad de Madrid|Spain",
                "orphan_designation": {
                    "original_text": "Treatment of progressive myoclonus epilepsy type 2 (Lafora disease)",
                    "umls_id": "C0751778,C0751783",
                    "parsed_text": "progressive myoclonus epilepsy , Lafora Disease"
                }
            }
        ]
    },
    {
        "_id": "CXKWCBBOMKCUKX-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 6099,
                "inchl_key": "CXKWCBBOMKCUKX-UHFFFAOYSA-M",
                "generic_name": "methylene blue",
                "designated_date": "07/24/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Fera Pharmaceuticals, LLC|134 Birch Hill Road|Locust Valley|New York|11560|United States",
                "orphan_designation": {
                    "original_text": "Treatment of methemoglobinemia",
                    "umls_id": "C0025637",
                    "parsed_text": "Methemoglobinemia"
                }
            }
        ]
    },
    {
        "_id": "ZJIHMALTJRDNQI-OLALXQGDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11644097,
                "inchl_key": "ZJIHMALTJRDNQI-OLALXQGDSA-N",
                "generic_name": "migalastat hydrochloride",
                "trade_name": "GALAFOLD",
                "designated_date": "02/25/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "GALAFOLD is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data",
                "marketing_approval_date": "\u00a008/10/2018\u00a0",
                "exclusivity_end_date": "\u00a008/10/2025\u00a0",
                "exclusivity_protected_indication": "GALAFOLD is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data",
                "sponsor": "Amicus Therapeutics, Inc.|1 Cedarbrook Drive|Cranbury|New Jersey|8512|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fabry Disease",
                    "umls_id": "C0002986",
                    "parsed_text": "Fabry Disease"
                }
            }
        ]
    },
    {
        "_id": "RYAYYVTWKAOAJF-QISPRATLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 73297272,
                "inchl_key": "RYAYYVTWKAOAJF-QISPRATLSA-N",
                "generic_name": "milademetan",
                "designated_date": "02/13/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rain Therapeutics, Inc.|8000 Jarvis Rd., Suite 204|Newark|California|94560|United States",
                "orphan_designation": {
                    "original_text": "Treatment of liposarcoma",
                    "umls_id": "C0023827",
                    "parsed_text": "liposarcoma"
                }
            }
        ]
    },
    {
        "_id": "DGVCEXQFNYYRQI-BTJKTKAUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 46937352,
                "inchl_key": "DGVCEXQFNYYRQI-BTJKTKAUSA-N",
                "generic_name": "milciclib maleate",
                "designated_date": "09/20/2012",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Tiziana Life Sciences PLC|18 South Street|W1K 1DG|London|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of thymic epithelial tumors.",
                    "umls_id": "C1368683",
                    "parsed_text": "epithelial tumors"
                }
            }
        ]
    },
    {
        "_id": "OJLOPKGSLYJEMD-URPKTTJQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5282381,
                "inchl_key": "OJLOPKGSLYJEMD-URPKTTJQSA-N",
                "generic_name": "misoprostol",
                "designated_date": "01/10/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gynuity Health Projects, LLC|15 East 26th Street|New York|New York|10010|United States",
                "orphan_designation": {
                    "original_text": "Treatment of intrauterine fetal death not accompanied by complete expulsion of the products of conception in the second and third trimesters of pregnancy.",
                    "umls_id": "C0595939",
                    "parsed_text": "Intrauterine Fetal Death"
                }
            }
        ]
    },
    {
        "_id": "KKZJGLLVHKMTCM-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4212,
                "inchl_key": "KKZJGLLVHKMTCM-UHFFFAOYSA-N",
                "generic_name": "Mitoxantrone",
                "trade_name": "Novantrone",
                "designated_date": "08/13/1999",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly adnormal between relapses).",
                "marketing_approval_date": "\u00a010/13/2000\u00a0",
                "exclusivity_end_date": "\u00a010/13/2007\u00a0",
                "sponsor": "Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States",
                "orphan_designation": {
                    "original_text": "Treatment of progressive-relapsing multiple sclerosis.",
                    "umls_id": "C0026769",
                    "parsed_text": "Multiple Sclerosis"
                }
            },
            {
                "compound_id": 4212,
                "inchl_key": "KKZJGLLVHKMTCM-UHFFFAOYSA-N",
                "generic_name": "Mitoxantrone",
                "trade_name": "Novantrone",
                "designated_date": "08/13/1999",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly adnormal between relapses).",
                "marketing_approval_date": "\u00a010/13/2000\u00a0",
                "exclusivity_end_date": "\u00a010/13/2007\u00a0",
                "sponsor": "Serono, Inc.|One Technoloogy Place|Rockland|Massachusetts|2370|United States",
                "orphan_designation": {
                    "original_text": "Treatment of secondary-progressive multiple sclerosis.",
                    "umls_id": "C0393665",
                    "parsed_text": "Progressive multiple sclerosis"
                }
            },
            {
                "compound_id": 4212,
                "inchl_key": "KKZJGLLVHKMTCM-UHFFFAOYSA-N",
                "generic_name": "Mitoxantrone",
                "trade_name": "Novantrone",
                "designated_date": "08/21/1996",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with corticosteroids as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer.",
                "marketing_approval_date": "\u00a011/13/1996\u00a0",
                "exclusivity_end_date": "\u00a011/13/2003\u00a0",
                "sponsor": "Serono|One Technology Place|Rockland|Massachusetts|2370|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hormone refractory prostate cancer.",
                    "umls_id": "C1328504",
                    "parsed_text": "Hormone refractory prostate cancer"
                }
            }
        ]
    },
    {
        "_id": "YFGHCGITMMYXAQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4236,
                "inchl_key": "YFGHCGITMMYXAQ-UHFFFAOYSA-N",
                "generic_name": "Modafinil",
                "trade_name": "Provigil",
                "designated_date": "03/15/1993",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy.",
                "marketing_approval_date": "\u00a012/24/1998\u00a0",
                "exclusivity_end_date": "\u00a012/24/2005\u00a0",
                "sponsor": "Cephalon, Inc.|145 Brandywine Parkway|West Chester|Pennsylvania|19380|United States",
                "orphan_designation": {
                    "original_text": "Treatment of excessive daytime sleepiness in narcolepsy.",
                    "umls_id": "C0027404,C4551761",
                    "parsed_text": "Narcolepsy , Excessive daytime sleepiness"
                }
            }
        ]
    },
    {
        "_id": "GAKUNXBDVGLOFS-INJBRAEYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 87183232,
                "inchl_key": "GAKUNXBDVGLOFS-INJBRAEYSA-N",
                "generic_name": "mosedipimod",
                "designated_date": "12/19/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Enzychem Lifesciences Corporation|59, Bio valley-ro|Jecheon-si|Chungcheongbuk-do|South Korea",
                "orphan_designation": {
                    "original_text": "Treatment of acute radiation syndrome",
                    "umls_id": "C0520799",
                    "parsed_text": "Acute Radiation Syndrome"
                }
            }
        ]
    },
    {
        "_id": "GAKUNXBDVGLOFS-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 53827958,
                "inchl_key": "GAKUNXBDVGLOFS-UHFFFAOYSA-N",
                "generic_name": "mosedipimod",
                "designated_date": "12/19/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Enzychem Lifesciences Corporation|59, Bio valley-ro|Jecheon-si|Chungcheongbuk-do|South Korea",
                "orphan_designation": {
                    "original_text": "Treatment of acute radiation syndrome",
                    "umls_id": "C0520799",
                    "parsed_text": "Acute Radiation Syndrome"
                }
            }
        ]
    },
    {
        "_id": "GAKUNXBDVGLOFS-WCCXBCNRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 87183063,
                "inchl_key": "GAKUNXBDVGLOFS-WCCXBCNRSA-N",
                "generic_name": "mosedipimod",
                "designated_date": "12/19/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Enzychem Lifesciences Corporation|59, Bio valley-ro|Jecheon-si|Chungcheongbuk-do|South Korea",
                "orphan_designation": {
                    "original_text": "Treatment of acute radiation syndrome",
                    "umls_id": "C0520799",
                    "parsed_text": "Acute Radiation Syndrome"
                }
            }
        ]
    },
    {
        "_id": "GAKUNXBDVGLOFS-DUZKARGPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9960925,
                "inchl_key": "GAKUNXBDVGLOFS-DUZKARGPSA-N",
                "generic_name": "mosedipimod",
                "designated_date": "12/19/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Enzychem Lifesciences Corporation|59, Bio valley-ro|Jecheon-si|Chungcheongbuk-do|South Korea",
                "orphan_designation": {
                    "original_text": "Treatment of acute radiation syndrome",
                    "umls_id": "C0520799",
                    "parsed_text": "Acute Radiation Syndrome"
                }
            }
        ]
    },
    {
        "_id": "VAZLWPAHMORDGR-UHFFFAOYSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 393405,
                "inchl_key": "VAZLWPAHMORDGR-UHFFFAOYSA-L",
                "generic_name": "motexafin gadolinium",
                "designated_date": "01/27/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacyclics, LLC|995 E. Arques Avenue|Sunnyvale|California|94085|United States",
                "orphan_designation": {
                    "original_text": "For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors",
                    "umls_id": "C0220650,C0280100",
                    "parsed_text": "brain metastases , solid tumors"
                }
            },
            {
                "compound_id": 393405,
                "inchl_key": "VAZLWPAHMORDGR-UHFFFAOYSA-L",
                "generic_name": "motexafin gadolinium",
                "designated_date": "01/27/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacyclics, LLC|995 E. Arques Avenue|Sunnyvale|California|94085|United States",
                "orphan_designation": {
                    "original_text": "For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors",
                    "umls_id": "C0220650,C0280100",
                    "parsed_text": "brain metastases , solid tumors"
                }
            }
        ]
    },
    {
        "_id": "KHDBHVDCUGRVLA-UHFFFAOYSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 23724967,
                "inchl_key": "KHDBHVDCUGRVLA-UHFFFAOYSA-L",
                "generic_name": "motexafin gadolinium",
                "designated_date": "01/27/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacyclics, LLC|995 E. Arques Avenue|Sunnyvale|California|94085|United States",
                "orphan_designation": {
                    "original_text": "For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors",
                    "umls_id": "C0220650,C0280100",
                    "parsed_text": "brain metastases , solid tumors"
                }
            }
        ]
    },
    {
        "_id": "AARXZCZYLAFQQU-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 12047567,
                "inchl_key": "AARXZCZYLAFQQU-UHFFFAOYSA-N",
                "generic_name": "motexafin gadolinium",
                "designated_date": "01/27/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacyclics, LLC|995 E. Arques Avenue|Sunnyvale|California|94085|United States",
                "orphan_designation": {
                    "original_text": "For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors",
                    "umls_id": "C0220650,C0280100",
                    "parsed_text": "brain metastases , solid tumors"
                }
            },
            {
                "compound_id": 12047567,
                "inchl_key": "AARXZCZYLAFQQU-UHFFFAOYSA-N",
                "generic_name": "motexafin gadolinium",
                "designated_date": "01/27/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacyclics, LLC|995 E. Arques Avenue|Sunnyvale|California|94085|United States",
                "orphan_designation": {
                    "original_text": "For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors",
                    "umls_id": "C0220650,C0280100",
                    "parsed_text": "brain metastases , solid tumors"
                }
            }
        ]
    },
    {
        "_id": "IDRGFNPZDVBSSE-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 117909640,
                "inchl_key": "IDRGFNPZDVBSSE-UHFFFAOYSA-N",
                "generic_name": "N-(3-(2-(2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)quinazolin-8-yl)phenyl)acrylamide",
                "designated_date": "09/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Checkpoint Therapeutics, Inc.|2 Gansevoort Street|9th Floor|New York|New York|10014|United States",
                "orphan_designation": {
                    "original_text": "Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)",
                    "umls_id": "C0007131,C1414313,C3539721",
                    "parsed_text": "Non-Small Cell Lung Cancer , EPIDERMAL GROWTH FACTOR RECEPTOR , Non-Small Cell Lung Cancer"
                }
            }
        ]
    },
    {
        "_id": "LAMIXXKAWNLXOC-INIZCTEOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6918848,
                "inchl_key": "LAMIXXKAWNLXOC-INIZCTEOSA-N",
                "generic_name": "N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide",
                "designated_date": "01/13/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Recursion Pharmaceuticals Inc.|41 S. Rio Grande Street|Salt Lake City|Utah|84101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of meningioma",
                    "umls_id": "C0025286",
                    "parsed_text": "Meningioma"
                }
            },
            {
                "compound_id": 6918848,
                "inchl_key": "LAMIXXKAWNLXOC-INIZCTEOSA-N",
                "generic_name": "N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide",
                "designated_date": "01/13/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Recursion Pharmaceuticals Inc.|41 S. Rio Grande Street|Salt Lake City|Utah|84101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Schwannoma of the central nervous system",
                    "umls_id": "C0027809",
                    "parsed_text": "Schwannoma"
                }
            }
        ]
    },
    {
        "_id": "JLYAXFNOILIKPP-KXQOOQHDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24978538,
                "inchl_key": "JLYAXFNOILIKPP-KXQOOQHDSA-N",
                "generic_name": "navitoclax",
                "designated_date": "11/18/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Dept #PA72, Bldg. AP30-4|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelofibrosis",
                    "umls_id": "C0026987",
                    "parsed_text": "myelofibrosis"
                }
            }
        ]
    },
    {
        "_id": "OSZNNLWOYWAHSS-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 5824,
                "inchl_key": "OSZNNLWOYWAHSS-UHFFFAOYSA-M",
                "generic_name": "neostigmine methylsulfate",
                "designated_date": "02/17/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Luitpold Pharmaceuticals, Inc.|1000 Madison Ave|Norristown|Pennsylvania|19403|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Myasthenia Gravis",
                    "umls_id": "C0026896",
                    "parsed_text": "Myasthenia Gravis"
                }
            }
        ]
    },
    {
        "_id": "WWJFFVUVFNBJTN-VHDFTHOZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 102515122,
                "inchl_key": "WWJFFVUVFNBJTN-VHDFTHOZSA-N",
                "generic_name": "Nikkomycin Z",
                "designated_date": "02/14/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Valley Fever Center for Excellence (1-111 INF)|University of Arizona|Tucson|Alaska|85723|United States",
                "orphan_designation": {
                    "original_text": "Treatment of coccidioidomycosis",
                    "umls_id": "C0009186",
                    "parsed_text": "Coccidioidomycosis"
                }
            },
            {
                "compound_id": 102515122,
                "inchl_key": "WWJFFVUVFNBJTN-VHDFTHOZSA-N",
                "generic_name": "Nikkomycin Z",
                "designated_date": "02/14/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Valley Fever Center for Excellence (1-111 INF)|University of Arizona|Tucson|Alaska|85723|United States",
                "orphan_designation": {
                    "original_text": "Treatment of coccidioidomycosis",
                    "umls_id": "C0009186",
                    "parsed_text": "Coccidioidomycosis"
                }
            }
        ]
    },
    {
        "_id": "OUBCNLGXQFSTLU-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 115355,
                "inchl_key": "OUBCNLGXQFSTLU-UHFFFAOYSA-N",
                "generic_name": "Nitisinone",
                "trade_name": "Orfadin",
                "designated_date": "05/16/1995",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Adjunctive therapy to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1",
                "marketing_approval_date": "\u00a001/18/2002\u00a0",
                "exclusivity_end_date": "\u00a001/18/2009\u00a0",
                "sponsor": "Swedish Orphan Biovitrum AB|SE-112|75 Stockholm|Stockholm|Sweden",
                "orphan_designation": {
                    "original_text": "Treatment of tyrosinemia type 1.",
                    "umls_id": "C0268490",
                    "parsed_text": "Tyrosinemia Type 1"
                }
            },
            {
                "compound_id": 115355,
                "inchl_key": "OUBCNLGXQFSTLU-UHFFFAOYSA-N",
                "generic_name": "Nitisinone",
                "trade_name": "Orfadin",
                "designated_date": "05/16/1995",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.",
                "marketing_approval_date": "\u00a004/22/2016\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Swedish Orphan Biovitrum AB|SE-112|75 Stockholm|Stockholm|Sweden",
                "orphan_designation": {
                    "original_text": "Treatment of tyrosinemia type 1.",
                    "umls_id": "C0268490",
                    "parsed_text": "Tyrosinemia Type 1"
                }
            },
            {
                "compound_id": 115355,
                "inchl_key": "OUBCNLGXQFSTLU-UHFFFAOYSA-N",
                "generic_name": "nitisinone",
                "designated_date": "10/19/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Swedish Orphan Biovitrum (sobi)|Kungsgatan 37, 7th Floor|SE-111 56|Sweden",
                "orphan_designation": {
                    "original_text": "Treatment of alkaptonuria",
                    "umls_id": "C0002066",
                    "parsed_text": "Alkaptonuria"
                }
            }
        ]
    },
    {
        "_id": "XULSCZPZVQIMFM-IPZQJPLYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10153627,
                "inchl_key": "XULSCZPZVQIMFM-IPZQJPLYSA-N",
                "generic_name": "odevixibat",
                "designated_date": "01/16/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Albireo AB c/o Albireo Pharma, Inc.|10 Post Office Square|Suite 502|Boston|Massachusetts|2109|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Biliary Atresia",
                    "umls_id": "C0005411",
                    "parsed_text": "Biliary Atresia"
                }
            }
        ]
    },
    {
        "_id": "HYFHYPWGAURHIV-JFIAXGOJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 285033,
                "inchl_key": "HYFHYPWGAURHIV-JFIAXGOJSA-N",
                "generic_name": "omacetaxine mepesuccinate",
                "trade_name": "Synribo",
                "designated_date": "03/10/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI)",
                "marketing_approval_date": "\u00a010/26/2012\u00a0",
                "exclusivity_end_date": "\u00a010/26/2019\u00a0",
                "sponsor": "IVAX International GmbH|Alpenstrasse 2|8640 Rapperswil|Frazer|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of chronic myelogenous leukemia",
                    "umls_id": "C0023473",
                    "parsed_text": "Chronic myelogenous leukemia"
                }
            },
            {
                "compound_id": 285033,
                "inchl_key": "HYFHYPWGAURHIV-JFIAXGOJSA-N",
                "generic_name": "homoharringtonine",
                "designated_date": "02/08/2002",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "American BioScience, Inc.|2730 Wilshire Blvd. #110|Santa Monica|California|90403|United States",
                "orphan_designation": {
                    "original_text": "Treatment for chronic myelogenous leukemia",
                    "umls_id": "C0023473",
                    "parsed_text": "Chronic myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "USUZGMWDZDXMDG-CYBMUJFWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44139752,
                "inchl_key": "USUZGMWDZDXMDG-CYBMUJFWSA-N",
                "generic_name": "osilodrostat",
                "trade_name": "Isturisa",
                "designated_date": "09/13/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "ISTURISA is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushings disease for whom pituitary surgery is not an option or has not been curative.",
                "marketing_approval_date": "\u00a003/06/2020\u00a0",
                "exclusivity_end_date": "\u00a003/06/2027\u00a0",
                "exclusivity_protected_indication": "For the treatment of adult patients with Cushings disease for whom pituitary surgery is not an option or has not been curative.",
                "sponsor": "Recordati Rare Diseases, Inc|100 Corporate Drive|Lebanon|New Jersey|8833|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Cushing's disease",
                    "umls_id": "C0010481",
                    "parsed_text": "Cushing's disease"
                }
            }
        ]
    },
    {
        "_id": "SWMNGXODFOCPKQ-BTJKTKAUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 154731101,
                "inchl_key": "SWMNGXODFOCPKQ-BTJKTKAUSA-N",
                "generic_name": "Pafuramidine maleate",
                "designated_date": "05/14/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immtech Pharmaceuticsl, Inc.|150 Fairway Drive|Vernon Hills|Illinois|60061|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 154731101,
                "inchl_key": "SWMNGXODFOCPKQ-BTJKTKAUSA-N",
                "generic_name": "Pafuramidine maleate",
                "designated_date": "05/14/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immtech Pharmaceuticsl, Inc.|150 Fairway Drive|Vernon Hills|Illinois|60061|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 154731101,
                "inchl_key": "SWMNGXODFOCPKQ-BTJKTKAUSA-N",
                "generic_name": "Pafuramidine maleate",
                "designated_date": "05/14/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immtech Pharmaceuticsl, Inc.|150 Fairway Drive|Vernon Hills|Illinois|60061|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 154731101,
                "inchl_key": "SWMNGXODFOCPKQ-BTJKTKAUSA-N",
                "generic_name": "Pafuramidine maleate",
                "designated_date": "08/31/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immtech Pharmaceuticals, Inc.|150 Fairway Drive|Suite 150|Vernon Hills|Illinois|60061|United States",
                "orphan_designation": {
                    "original_text": "Treatment of human African trypanosomiasis (sleeping sickness)",
                    "umls_id": "C0041228",
                    "parsed_text": "African Trypanosomiasis"
                }
            },
            {
                "compound_id": 154731101,
                "inchl_key": "SWMNGXODFOCPKQ-BTJKTKAUSA-N",
                "generic_name": "Pafuramidine maleate",
                "designated_date": "08/31/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immtech Pharmaceuticals, Inc.|150 Fairway Drive|Suite 150|Vernon Hills|Illinois|60061|United States",
                "orphan_designation": {
                    "original_text": "Treatment of human African trypanosomiasis (sleeping sickness)",
                    "umls_id": "C0041228",
                    "parsed_text": "African Trypanosomiasis"
                }
            },
            {
                "compound_id": 154731101,
                "inchl_key": "SWMNGXODFOCPKQ-BTJKTKAUSA-N",
                "generic_name": "Pafuramidine maleate",
                "designated_date": "08/31/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immtech Pharmaceuticals, Inc.|150 Fairway Drive|Suite 150|Vernon Hills|Illinois|60061|United States",
                "orphan_designation": {
                    "original_text": "Treatment of human African trypanosomiasis (sleeping sickness)",
                    "umls_id": "C0041228",
                    "parsed_text": "African Trypanosomiasis"
                }
            },
            {
                "compound_id": 154731101,
                "inchl_key": "SWMNGXODFOCPKQ-BTJKTKAUSA-N",
                "generic_name": "pafuramidine maleate",
                "designated_date": "11/17/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immtech Pharmaceuticals, Inc.|150 Fairway Drive|Suite 150|Vernon Hills|Illinois|60061|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pneumocystis jiroveci pneumonia",
                    "umls_id": "C1535939",
                    "parsed_text": "Pneumocystis jiroveci pneumonia"
                }
            },
            {
                "compound_id": 154731101,
                "inchl_key": "SWMNGXODFOCPKQ-BTJKTKAUSA-N",
                "generic_name": "pafuramidine maleate",
                "designated_date": "11/17/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immtech Pharmaceuticals, Inc.|150 Fairway Drive|Suite 150|Vernon Hills|Illinois|60061|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pneumocystis jiroveci pneumonia",
                    "umls_id": "C1535939",
                    "parsed_text": "Pneumocystis jiroveci pneumonia"
                }
            },
            {
                "compound_id": 154731101,
                "inchl_key": "SWMNGXODFOCPKQ-BTJKTKAUSA-N",
                "generic_name": "pafuramidine maleate",
                "designated_date": "11/17/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immtech Pharmaceuticals, Inc.|150 Fairway Drive|Suite 150|Vernon Hills|Illinois|60061|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pneumocystis jiroveci pneumonia",
                    "umls_id": "C1535939",
                    "parsed_text": "Pneumocystis jiroveci pneumonia"
                }
            }
        ]
    },
    {
        "_id": "YTFHCXIPDIHOIA-DHZHZOJOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10295295,
                "inchl_key": "YTFHCXIPDIHOIA-DHZHZOJOSA-N",
                "generic_name": "palovarotene",
                "designated_date": "07/21/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ipsen Biopharmaceuticals, Inc.|One Main Street, 7th Floor|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fibrodysplasia ossificans progressiva",
                    "umls_id": "C0016037",
                    "parsed_text": "fibrodysplasia ossificans progressiva"
                }
            },
            {
                "compound_id": 10295295,
                "inchl_key": "YTFHCXIPDIHOIA-DHZHZOJOSA-N",
                "generic_name": "palovarotene",
                "designated_date": "11/06/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clementia Pharmaceuticals, Inc.|1000 De La Gauchetiere West, Suite 1200|Montreal|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of multiple osteochondromas",
                    "umls_id": "C0015306",
                    "parsed_text": "MULTIPLE OSTEOCHONDROMAS"
                }
            }
        ]
    },
    {
        "_id": "ZQPDJCIXJHUERQ-QWRGUYRKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 86677874,
                "inchl_key": "ZQPDJCIXJHUERQ-QWRGUYRKSA-N",
                "generic_name": "parsaclisib",
                "designated_date": "07/28/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Incyte Corporation|1801 Augustine Cut-Off|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of autoimmune hemolytic anemia",
                    "umls_id": "C0002880",
                    "parsed_text": "Autoimmune hemolytic anemia"
                }
            },
            {
                "compound_id": 86677874,
                "inchl_key": "ZQPDJCIXJHUERQ-QWRGUYRKSA-N",
                "generic_name": "parsaclisib",
                "designated_date": "10/07/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Incyte Corporation|1801 Augustine Cut-Off|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of nodal marginal zone lymphoma",
                    "umls_id": "C0242647",
                    "parsed_text": "Nodal marginal zone lymphoma"
                }
            },
            {
                "compound_id": 86677874,
                "inchl_key": "ZQPDJCIXJHUERQ-QWRGUYRKSA-N",
                "generic_name": "parsaclisib",
                "designated_date": "06/12/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Incyte Corporation|1801 Augustine Cut-Off|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mantle cell lymphoma",
                    "umls_id": "C4721414",
                    "parsed_text": "Mantle cell lymphoma"
                }
            },
            {
                "compound_id": 86677874,
                "inchl_key": "ZQPDJCIXJHUERQ-QWRGUYRKSA-N",
                "generic_name": "parsaclisib",
                "designated_date": "09/10/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Incyte Corporation|1801 Augustine Cut-Off|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of splenic marginal zone lymphoma",
                    "umls_id": "C0349632",
                    "parsed_text": "Splenic marginal zone lymphoma"
                }
            },
            {
                "compound_id": 86677874,
                "inchl_key": "ZQPDJCIXJHUERQ-QWRGUYRKSA-N",
                "generic_name": "Parsaclisib",
                "designated_date": "09/25/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Incyte Corporation|1801 Augustine Cut-Off|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Follicular Lymphoma",
                    "umls_id": "C0024301",
                    "parsed_text": "follicular lymphoma"
                }
            },
            {
                "compound_id": 86677874,
                "inchl_key": "ZQPDJCIXJHUERQ-QWRGUYRKSA-N",
                "generic_name": "parsaclisib",
                "designated_date": "10/09/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Incyte Corporation|1801 Augustine Cut-Off|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of extranodal marginal zone lymphoma",
                    "umls_id": "C1367654",
                    "parsed_text": "Marginal zone lymphoma"
                }
            }
        ]
    },
    {
        "_id": "FPVKHBSQESCIEP-JQCXWYLXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 439693,
                "inchl_key": "FPVKHBSQESCIEP-JQCXWYLXSA-N",
                "generic_name": "Pentostatin",
                "designated_date": "11/24/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SuperGen, Inc.|4140 Dublin Blvd.|Suite 200|Dublin|California|94568|United States",
                "orphan_designation": {
                    "original_text": "Treatment of peripheral T-cell lymphomas.",
                    "umls_id": "C0079774",
                    "parsed_text": "Peripheral T-Cell Lymphomas"
                }
            },
            {
                "compound_id": 439693,
                "inchl_key": "FPVKHBSQESCIEP-JQCXWYLXSA-N",
                "generic_name": "Pentostatin",
                "designated_date": "03/27/1998",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SuperGen, Inc.|4140 Dublin Blvd.|Suite 200|Dublin|California|94568|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cutaneous T-cell lymphoma.",
                    "umls_id": "C0079773",
                    "parsed_text": "cutaneous T-cell lymphoma"
                }
            },
            {
                "compound_id": 439693,
                "inchl_key": "FPVKHBSQESCIEP-JQCXWYLXSA-N",
                "generic_name": "Pentostatin",
                "designated_date": "01/29/1991",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SuperGen, Inc.|4140 Dublin Blvd.|Suite 200|Dublin|California|94568|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with chronic lymphocytic leukemia.",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "BYPFEZZEUUWMEJ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4740,
                "inchl_key": "BYPFEZZEUUWMEJ-UHFFFAOYSA-N",
                "generic_name": "pentoxifylline",
                "designated_date": "06/14/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Silk Road Therapeutics|641 S Street Northwest|3rd Floor|Washington|District of Columbia|20001|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Behcet's disease",
                    "umls_id": "C0004943",
                    "parsed_text": "Behcet Syndrome"
                }
            }
        ]
    },
    {
        "_id": "PRMWGUBFXWROHD-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9924495,
                "inchl_key": "PRMWGUBFXWROHD-UHFFFAOYSA-N",
                "generic_name": "perampanel",
                "designated_date": "12/07/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eisai, Inc.|155 Tice Blvd|Woodcliff|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Lennox-Gastaut Syndrome",
                    "umls_id": "C0238111",
                    "parsed_text": "Lennox-Gastaut syndrome"
                }
            }
        ]
    },
    {
        "_id": "JGWRKYUXBBNENE-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25151352,
                "inchl_key": "JGWRKYUXBBNENE-UHFFFAOYSA-N",
                "generic_name": "pexidartinib",
                "trade_name": "TURALIO",
                "designated_date": "02/14/2014",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "TURALIO is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.",
                "marketing_approval_date": "\u00a008/02/2019\u00a0",
                "exclusivity_end_date": "\u00a008/02/2026\u00a0",
                "exclusivity_protected_indication": "For the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery",
                "sponsor": "Daiichi Sankyo, Inc.|211 Mount Airy Road|Basking Ridge|New Jersey|7920|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pigmented villonodular synovitis/giant cell tumor of the tendon sheath",
                    "umls_id": "C0017525,C0039106",
                    "parsed_text": "Giant Cell Tumor , Pigmented villonodular synovitis"
                }
            }
        ]
    },
    {
        "_id": "YJGVMLPVUAXIQN-HAEOHBJNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 72435,
                "inchl_key": "YJGVMLPVUAXIQN-HAEOHBJNSA-N",
                "generic_name": "Picropodophyllin",
                "designated_date": "07/27/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MAX Kemikonsult AB|c/o Magnus Axelson|Hanna Nilssons vag 6, Lgh 1301|Jarfalla|Stockholms l\u4b8d|SE-176 68|Sweden",
                "orphan_designation": {
                    "original_text": "Treatment of glioma",
                    "umls_id": "C0017638",
                    "parsed_text": "Glioma"
                }
            }
        ]
    },
    {
        "_id": "QCHFTSOMWOSFHM-WPRPVWTQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5910,
                "inchl_key": "QCHFTSOMWOSFHM-WPRPVWTQSA-N",
                "generic_name": "Pilocarpine",
                "trade_name": "Salagen",
                "designated_date": "09/24/1990",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of symptoms of xerostomia from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck.",
                "marketing_approval_date": "\u00a003/22/1994\u00a0",
                "exclusivity_end_date": "\u00a003/22/2001\u00a0",
                "sponsor": "MGI Pharma, Inc.|5775 West Old Shakoppe Rd.|Suite 100|Bloomington|Minnesota|55437|United States",
                "orphan_designation": {
                    "original_text": "Treatment of xerostomia induced by radiation therapy for head and neck cancer.",
                    "umls_id": "C0043352,C3887461",
                    "parsed_text": "Xerostomia , Head and Neck Cancer"
                }
            }
        ]
    },
    {
        "_id": "RNAICSBVACLLGM-GNAZCLTHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5909,
                "inchl_key": "RNAICSBVACLLGM-GNAZCLTHSA-N",
                "generic_name": "Pilocarpine HCl",
                "trade_name": "Salagen",
                "designated_date": "02/28/1992",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of dry mouth in patients with Sjogren's syndrome.",
                "marketing_approval_date": "\u00a002/11/1998\u00a0",
                "exclusivity_end_date": "\u00a002/11/2005\u00a0",
                "sponsor": "MGI Pharma, Inc.|5775 West Old Shakoppe Rd.|Suite 100|Bloomington|Minnesota|55437|United States",
                "orphan_designation": {
                    "original_text": "Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.",
                    "umls_id": "C0022575,C0043352,C1527336",
                    "parsed_text": "Keratoconjunctivitis Sicca , Xerostomia , Sjogren Syndrome"
                }
            }
        ]
    },
    {
        "_id": "HYAFETHFCAUJAY-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4829,
                "inchl_key": "HYAFETHFCAUJAY-UHFFFAOYSA-N",
                "generic_name": "pioglitazone",
                "designated_date": "12/12/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Strekin AG|60C Hochbergerstrasse|Basel|Basel-Stadt|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of sudden sensorineural hearing loss",
                    "umls_id": "C4275242",
                    "parsed_text": "Sudden sensorineural hearing loss"
                }
            }
        ]
    },
    {
        "_id": "UUSZLLQJYRSZIS-LXNNNBEUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9812534,
                "inchl_key": "UUSZLLQJYRSZIS-LXNNNBEUSA-N",
                "generic_name": "plitidepsin",
                "designated_date": "09/30/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PharmaMar USA, Inc.|205 East 42nd St.|Suite 15003|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            },
            {
                "compound_id": 9812534,
                "inchl_key": "UUSZLLQJYRSZIS-LXNNNBEUSA-N",
                "generic_name": "Plitidepsin",
                "designated_date": "06/18/2004",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PharmaMar USA, Inc|University Park at M.I.T.|Sidney Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute lymphoblastic leukemia",
                    "umls_id": "C0023449",
                    "parsed_text": "Acute lymphoblastic leukemia"
                }
            }
        ]
    },
    {
        "_id": "RSQDGTJKZWTAGL-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 137321858,
                "inchl_key": "RSQDGTJKZWTAGL-UHFFFAOYSA-N",
                "generic_name": "Porfimer sodium",
                "designated_date": "11/15/1989",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "QLT Phototherapeutics, Inc.|Lederle Laboratories|401 North Middletown Road|Pearl River|New York|10965|United States",
                "orphan_designation": {
                    "original_text": "For the photodynamic therapy of patients with transitional cell carcinoma in situ of the urinary bladder.",
                    "umls_id": "C0334267,C4551642",
                    "parsed_text": "Transitional cell carcinoma in situ , Carcinoma in situ of the Urinary Bladder"
                }
            },
            {
                "compound_id": 137321858,
                "inchl_key": "RSQDGTJKZWTAGL-UHFFFAOYSA-N",
                "generic_name": "porfimer sodium",
                "designated_date": "12/02/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Concordia Laboratories, Inc., Sarl|8-10 Avenue de la Gare - L-1610|Luxembourg|Grand Duchy of Luxembourg|Luxembourg",
                "orphan_designation": {
                    "original_text": "Treatment of malignant mesothelioma",
                    "umls_id": "C0345967",
                    "parsed_text": "Malignant mesothelioma"
                }
            },
            {
                "compound_id": 137321858,
                "inchl_key": "RSQDGTJKZWTAGL-UHFFFAOYSA-N",
                "generic_name": "Porfimer sodium",
                "trade_name": "Photofrin",
                "designated_date": "06/06/1989",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Photodynamic therapy with PHOTOFRIN for the palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who cannot be satisfactorily treated with Nd:YAG laser therapy.",
                "marketing_approval_date": "\u00a012/27/1995\u00a0",
                "exclusivity_end_date": "\u00a012/27/2002\u00a0",
                "sponsor": "QLT Phototherapeutics, Inc.|Lederle Laboratories|401 North Middletown Road|Pearl River|New York|10965|United States",
                "orphan_designation": {
                    "original_text": "For the photodynamic therapy of patients with primary or recurrent obstructing (either partially or completely) esophageal carcinoma.",
                    "umls_id": "C0152018",
                    "parsed_text": "Esophageal carcinoma"
                }
            },
            {
                "compound_id": 137321858,
                "inchl_key": "RSQDGTJKZWTAGL-UHFFFAOYSA-N",
                "generic_name": "Porfimer sodium",
                "designated_date": "11/18/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Concordia Laboratories, Inc., Sarl|8-10 Avenue de la Gare - L-1610|Luxembourg|Grand Duchy of Luxembourg|Luxembourg",
                "orphan_designation": {
                    "original_text": "Treatment of cholangiocarcinoma",
                    "umls_id": "C0206698",
                    "parsed_text": "Cholangiocarcinoma"
                }
            }
        ]
    },
    {
        "_id": "RAGOYPUPXAKGKH-XAKZXMRKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 468595,
                "inchl_key": "RAGOYPUPXAKGKH-XAKZXMRKSA-N",
                "generic_name": "posaconazole",
                "designated_date": "07/16/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.|351 N. Sumneytown Pike|UG2CD-48|North Wales|Pennsylvania|19454|United States",
                "orphan_designation": {
                    "original_text": "Treatment of zygomycosis",
                    "umls_id": "C0043541",
                    "parsed_text": "Zygomycosis"
                }
            },
            {
                "compound_id": 468595,
                "inchl_key": "RAGOYPUPXAKGKH-XAKZXMRKSA-N",
                "generic_name": "posaconazole",
                "designated_date": "10/04/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Merck, Sharp & Dohme Corp.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States",
                "orphan_designation": {
                    "original_text": "Treatment of invasive aspergillosis",
                    "umls_id": "C0238013",
                    "parsed_text": "Invasive aspergillosis"
                }
            }
        ]
    },
    {
        "_id": "AUBOIOCYVHATDV-QYLLOTSKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134693628,
                "inchl_key": "AUBOIOCYVHATDV-QYLLOTSKSA-N",
                "generic_name": "pralmorelin hydrochloride",
                "designated_date": "10/18/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sella Pharmaceuticals, Inc.|412 Wister Road|Wynnewood|Pennsylvania|19096|United States",
                "orphan_designation": {
                    "original_text": "As a diagnostic agent for the detection of growth hormone deficiency",
                    "umls_id": "C3714796",
                    "parsed_text": "Growth hormone deficiency"
                }
            }
        ]
    },
    {
        "_id": "BKXVVCILCIUCLG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 54900,
                "inchl_key": "BKXVVCILCIUCLG-UHFFFAOYSA-N",
                "generic_name": "raloxifene hydrochloride",
                "designated_date": "08/20/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Consejo Superior de Investigaciones Cientificas|C/ Serrano 142|Madrid|Spain",
                "orphan_designation": {
                    "original_text": "Treatment of hereditary hemorrhagic telangiectasia",
                    "umls_id": "C0039445",
                    "parsed_text": "hereditary hemorrhagic telangiectasia"
                }
            }
        ]
    },
    {
        "_id": "PRFBWBYKWZVQJF-RRABGKBLSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 23668369,
                "inchl_key": "PRFBWBYKWZVQJF-RRABGKBLSA-M",
                "generic_name": "recilisib sodium",
                "designated_date": "06/01/2012",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Onconova Therapeutics, Inc.|375 Pheasant Run|Newtown|Pennsylvania|18940|United States",
                "orphan_designation": {
                    "original_text": "Prevention of acute radiation syndrome",
                    "umls_id": "C0520799",
                    "parsed_text": "Acute Radiation Syndrome"
                }
            },
            {
                "compound_id": 23668369,
                "inchl_key": "PRFBWBYKWZVQJF-RRABGKBLSA-M",
                "generic_name": "recilisib sodium",
                "designated_date": "09/04/2012",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Onconova Therapeutics, Inc.|375 Pheasant Run|Newton|Pennsylvania|18940|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute radiation syndrome",
                    "umls_id": "C0520799",
                    "parsed_text": "Acute Radiation Syndrome"
                }
            }
        ]
    },
    {
        "_id": "RWWYLEGWBNMMLJ-YSOARWBDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 121304016,
                "inchl_key": "RWWYLEGWBNMMLJ-YSOARWBDSA-N",
                "generic_name": "Remdesivir",
                "designated_date": "09/18/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Ebola virus disease",
                    "umls_id": "C0282687",
                    "parsed_text": "Ebola Virus Disease"
                }
            },
            {
                "compound_id": 121304016,
                "inchl_key": "RWWYLEGWBNMMLJ-YSOARWBDSA-N",
                "generic_name": "remdesivir",
                "designated_date": "03/23/2020",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of coronavirus disease 2019 (COVID-19)",
                    "umls_id": "C5203670",
                    "parsed_text": "COVID-19"
                }
            }
        ]
    },
    {
        "_id": "LEEIJTHMHDMWLJ-CQSZACIVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11703255,
                "inchl_key": "LEEIJTHMHDMWLJ-CQSZACIVSA-N",
                "generic_name": "resatorvid",
                "designated_date": "01/02/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Takeda Development Center Americas, Inc.|One Takeda Parkway|Deerfield|Illinois|60015|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute-on-chronic liver failure",
                    "umls_id": "C3850141",
                    "parsed_text": "Acute-On-Chronic Liver Failure"
                }
            }
        ]
    },
    {
        "_id": "FTALBRSUTCGOEG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5070,
                "inchl_key": "FTALBRSUTCGOEG-UHFFFAOYSA-N",
                "generic_name": "Riluzole",
                "designated_date": "10/15/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rhone-Poulenc Rorer Pharmaceuticals, Inc.|500 Arcola Road|PO Box 5096|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Huntington's disease.",
                    "umls_id": "C0020179",
                    "parsed_text": "Huntington's Disease"
                }
            },
            {
                "compound_id": 5070,
                "inchl_key": "FTALBRSUTCGOEG-UHFFFAOYSA-N",
                "generic_name": "Riluzole",
                "trade_name": "Rilutek",
                "designated_date": "03/16/1993",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with amyotrophic lateral sclerosis. Riluzole extends survival and/or time to tracheostomy.",
                "marketing_approval_date": "\u00a012/12/1995\u00a0",
                "exclusivity_end_date": "\u00a012/12/2002\u00a0",
                "sponsor": "Rhone-Poulenc Rorer Pharmaceuticals, Inc.|500 Arcola Road, P.O. Box 1200|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis.",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "CEFJVGZHQAGLHS-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71584930,
                "inchl_key": "CEFJVGZHQAGLHS-UHFFFAOYSA-N",
                "generic_name": "Ripretinib",
                "designated_date": "10/02/2014",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "QINLOCK (ripretinib) is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.",
                "marketing_approval_date": "\u00a005/15/2020\u00a0",
                "exclusivity_end_date": "\u00a005/15/2027\u00a0",
                "exclusivity_protected_indication": "Indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.",
                "sponsor": "Deciphera Pharmaceuticals, LLC|200 Smith Street|Waltham|Massachusetts|2451|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastrointestinal stromal tumors (GIST)",
                    "umls_id": "C0238198",
                    "parsed_text": "Gastrointestinal Stromal Tumors"
                }
            }
        ]
    },
    {
        "_id": "TZSZZENYCISATO-WIOPSUGQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 92045025,
                "inchl_key": "TZSZZENYCISATO-WIOPSUGQSA-N",
                "generic_name": "rodatristat ethyl",
                "designated_date": "10/06/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Altavant Sciences GmbH|8 Viaduktstrasse|Basel|Basel-Stadt|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension (PAH).",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "OHRURASPPZQGQM-QPJBHPOGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 154574495,
                "inchl_key": "OHRURASPPZQGQM-QPJBHPOGSA-N",
                "generic_name": "romidepsin",
                "trade_name": "Istodax",
                "designated_date": "09/30/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy",
                "marketing_approval_date": "\u00a011/05/2009\u00a0",
                "exclusivity_end_date": "\u00a011/05/2016\u00a0",
                "sponsor": "Celgene Corporation|One Broadway|14th Floor|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin T-cell lymphomas",
                    "umls_id": "C0079772",
                    "parsed_text": "T-Cell Lymphomas"
                }
            },
            {
                "compound_id": 154574495,
                "inchl_key": "OHRURASPPZQGQM-QPJBHPOGSA-N",
                "generic_name": "romidepsin",
                "trade_name": "Istodax",
                "designated_date": "09/30/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy",
                "marketing_approval_date": "\u00a006/16/2011\u00a0",
                "exclusivity_end_date": "\u00a006/16/2018\u00a0",
                "sponsor": "Celgene Corporation|One Broadway|14th Floor|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin T-cell lymphomas",
                    "umls_id": "C0079772",
                    "parsed_text": "T-Cell Lymphomas"
                }
            }
        ]
    },
    {
        "_id": "OHRURASPPZQGQM-WOADUJSRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 129905275,
                "inchl_key": "OHRURASPPZQGQM-WOADUJSRSA-N",
                "generic_name": "romidepsin",
                "trade_name": "Istodax",
                "designated_date": "09/30/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy",
                "marketing_approval_date": "\u00a011/05/2009\u00a0",
                "exclusivity_end_date": "\u00a011/05/2016\u00a0",
                "sponsor": "Celgene Corporation|One Broadway|14th Floor|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin T-cell lymphomas",
                    "umls_id": "C0079772",
                    "parsed_text": "T-Cell Lymphomas"
                }
            },
            {
                "compound_id": 129905275,
                "inchl_key": "OHRURASPPZQGQM-WOADUJSRSA-N",
                "generic_name": "romidepsin",
                "trade_name": "Istodax",
                "designated_date": "09/30/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy",
                "marketing_approval_date": "\u00a006/16/2011\u00a0",
                "exclusivity_end_date": "\u00a006/16/2018\u00a0",
                "sponsor": "Celgene Corporation|One Broadway|14th Floor|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin T-cell lymphomas",
                    "umls_id": "C0079772",
                    "parsed_text": "T-Cell Lymphomas"
                }
            }
        ]
    },
    {
        "_id": "OHRURASPPZQGQM-OYTWCIJESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 123135747,
                "inchl_key": "OHRURASPPZQGQM-OYTWCIJESA-N",
                "generic_name": "romidepsin",
                "trade_name": "Istodax",
                "designated_date": "09/30/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy",
                "marketing_approval_date": "\u00a011/05/2009\u00a0",
                "exclusivity_end_date": "\u00a011/05/2016\u00a0",
                "sponsor": "Celgene Corporation|One Broadway|14th Floor|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin T-cell lymphomas",
                    "umls_id": "C0079772",
                    "parsed_text": "T-Cell Lymphomas"
                }
            },
            {
                "compound_id": 123135747,
                "inchl_key": "OHRURASPPZQGQM-OYTWCIJESA-N",
                "generic_name": "romidepsin",
                "trade_name": "Istodax",
                "designated_date": "09/30/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy",
                "marketing_approval_date": "\u00a006/16/2011\u00a0",
                "exclusivity_end_date": "\u00a006/16/2018\u00a0",
                "sponsor": "Celgene Corporation|One Broadway|14th Floor|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin T-cell lymphomas",
                    "umls_id": "C0079772",
                    "parsed_text": "T-Cell Lymphomas"
                }
            }
        ]
    },
    {
        "_id": "OHRURASPPZQGQM-MWQPNCDWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 91110640,
                "inchl_key": "OHRURASPPZQGQM-MWQPNCDWSA-N",
                "generic_name": "romidepsin",
                "trade_name": "Istodax",
                "designated_date": "09/30/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy",
                "marketing_approval_date": "\u00a011/05/2009\u00a0",
                "exclusivity_end_date": "\u00a011/05/2016\u00a0",
                "sponsor": "Celgene Corporation|One Broadway|14th Floor|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin T-cell lymphomas",
                    "umls_id": "C0079772",
                    "parsed_text": "T-Cell Lymphomas"
                }
            },
            {
                "compound_id": 91110640,
                "inchl_key": "OHRURASPPZQGQM-MWQPNCDWSA-N",
                "generic_name": "romidepsin",
                "trade_name": "Istodax",
                "designated_date": "09/30/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy",
                "marketing_approval_date": "\u00a006/16/2011\u00a0",
                "exclusivity_end_date": "\u00a006/16/2018\u00a0",
                "sponsor": "Celgene Corporation|One Broadway|14th Floor|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin T-cell lymphomas",
                    "umls_id": "C0079772",
                    "parsed_text": "T-Cell Lymphomas"
                }
            }
        ]
    },
    {
        "_id": "OHRURASPPZQGQM-WDCUYUQDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 56840936,
                "inchl_key": "OHRURASPPZQGQM-WDCUYUQDSA-N",
                "generic_name": "romidepsin",
                "trade_name": "Istodax",
                "designated_date": "09/30/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy",
                "marketing_approval_date": "\u00a011/05/2009\u00a0",
                "exclusivity_end_date": "\u00a011/05/2016\u00a0",
                "sponsor": "Celgene Corporation|One Broadway|14th Floor|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin T-cell lymphomas",
                    "umls_id": "C0079772",
                    "parsed_text": "T-Cell Lymphomas"
                }
            },
            {
                "compound_id": 56840936,
                "inchl_key": "OHRURASPPZQGQM-WDCUYUQDSA-N",
                "generic_name": "romidepsin",
                "trade_name": "Istodax",
                "designated_date": "09/30/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy",
                "marketing_approval_date": "\u00a006/16/2011\u00a0",
                "exclusivity_end_date": "\u00a006/16/2018\u00a0",
                "sponsor": "Celgene Corporation|One Broadway|14th Floor|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin T-cell lymphomas",
                    "umls_id": "C0079772",
                    "parsed_text": "T-Cell Lymphomas"
                }
            }
        ]
    },
    {
        "_id": "OHRURASPPZQGQM-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3425,
                "inchl_key": "OHRURASPPZQGQM-UHFFFAOYSA-N",
                "generic_name": "romidepsin",
                "trade_name": "Istodax",
                "designated_date": "09/30/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy",
                "marketing_approval_date": "\u00a011/05/2009\u00a0",
                "exclusivity_end_date": "\u00a011/05/2016\u00a0",
                "sponsor": "Celgene Corporation|One Broadway|14th Floor|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin T-cell lymphomas",
                    "umls_id": "C0079772",
                    "parsed_text": "T-Cell Lymphomas"
                }
            },
            {
                "compound_id": 3425,
                "inchl_key": "OHRURASPPZQGQM-UHFFFAOYSA-N",
                "generic_name": "romidepsin",
                "trade_name": "Istodax",
                "designated_date": "09/30/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy",
                "marketing_approval_date": "\u00a006/16/2011\u00a0",
                "exclusivity_end_date": "\u00a006/16/2018\u00a0",
                "sponsor": "Celgene Corporation|One Broadway|14th Floor|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin T-cell lymphomas",
                    "umls_id": "C0079772",
                    "parsed_text": "T-Cell Lymphomas"
                }
            }
        ]
    },
    {
        "_id": "OHRURASPPZQGQM-QDBHDZETSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 57515973,
                "inchl_key": "OHRURASPPZQGQM-QDBHDZETSA-N",
                "generic_name": "romidepsin",
                "trade_name": "Istodax",
                "designated_date": "09/30/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy",
                "marketing_approval_date": "\u00a011/05/2009\u00a0",
                "exclusivity_end_date": "\u00a011/05/2016\u00a0",
                "sponsor": "Celgene Corporation|One Broadway|14th Floor|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin T-cell lymphomas",
                    "umls_id": "C0079772",
                    "parsed_text": "T-Cell Lymphomas"
                }
            },
            {
                "compound_id": 57515973,
                "inchl_key": "OHRURASPPZQGQM-QDBHDZETSA-N",
                "generic_name": "romidepsin",
                "trade_name": "Istodax",
                "designated_date": "09/30/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy",
                "marketing_approval_date": "\u00a006/16/2011\u00a0",
                "exclusivity_end_date": "\u00a006/16/2018\u00a0",
                "sponsor": "Celgene Corporation|One Broadway|14th Floor|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin T-cell lymphomas",
                    "umls_id": "C0079772",
                    "parsed_text": "T-Cell Lymphomas"
                }
            }
        ]
    },
    {
        "_id": "OHRURASPPZQGQM-GCCNXGTGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5352062,
                "inchl_key": "OHRURASPPZQGQM-GCCNXGTGSA-N",
                "generic_name": "romidepsin",
                "trade_name": "Istodax",
                "designated_date": "09/30/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy",
                "marketing_approval_date": "\u00a011/05/2009\u00a0",
                "exclusivity_end_date": "\u00a011/05/2016\u00a0",
                "sponsor": "Celgene Corporation|One Broadway|14th Floor|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin T-cell lymphomas",
                    "umls_id": "C0079772",
                    "parsed_text": "T-Cell Lymphomas"
                }
            },
            {
                "compound_id": 5352062,
                "inchl_key": "OHRURASPPZQGQM-GCCNXGTGSA-N",
                "generic_name": "romidepsin",
                "trade_name": "Istodax",
                "designated_date": "09/30/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy",
                "marketing_approval_date": "\u00a006/16/2011\u00a0",
                "exclusivity_end_date": "\u00a006/16/2018\u00a0",
                "sponsor": "Celgene Corporation|One Broadway|14th Floor|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin T-cell lymphomas",
                    "umls_id": "C0079772",
                    "parsed_text": "T-Cell Lymphomas"
                }
            }
        ]
    },
    {
        "_id": "POGQSBRIGCQNEG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 129228,
                "inchl_key": "POGQSBRIGCQNEG-UHFFFAOYSA-N",
                "generic_name": "rufinamide",
                "trade_name": "Banzel",
                "designated_date": "10/08/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Adjunctive therapy of seizures associated with Lennox-Gastaut syndrome.",
                "marketing_approval_date": "\u00a011/14/2008\u00a0",
                "exclusivity_end_date": "\u00a011/14/2015\u00a0",
                "sponsor": "Eisai, Inc.|300 Tice Blvd|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Lennox-Gastaut Syndrome.",
                    "umls_id": "C0238111",
                    "parsed_text": "Lennox-Gastaut syndrome"
                }
            }
        ]
    },
    {
        "_id": "WUILNKCFCLNXOK-CFBAGHHKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5469318,
                "inchl_key": "WUILNKCFCLNXOK-CFBAGHHKSA-N",
                "generic_name": "salirasib",
                "designated_date": "12/18/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kadmon Corporation, LLC|450 East 29th Street|5th Floor|New York|New York|10016|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer.",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "FSYKKLYZXJSNPZ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 1088,
                "inchl_key": "FSYKKLYZXJSNPZ-UHFFFAOYSA-N",
                "generic_name": "sarcosine",
                "designated_date": "10/12/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Guochuan Emil Tsai, MD, PhD|David Geffen School of Medicine, UCLA|1000 W., Carson St.|Torrance|California|90502|United States",
                "orphan_designation": {
                    "original_text": "Treatment of obsessive compulsive disorder in pediatric patients (0 to 16 years of age)",
                    "umls_id": "C0028768",
                    "parsed_text": "Obsessive compulsive disorder"
                }
            }
        ]
    },
    {
        "_id": "FCKJYANJHNLEEP-XRWYNYHCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5283748,
                "inchl_key": "FCKJYANJHNLEEP-XRWYNYHCSA-N",
                "generic_name": "Secalciferol",
                "designated_date": "07/26/1993",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Teva Pharmaceuticals USA|650 Cathill Rd.|Sellersville|Pennsylvania|18960|United States",
                "orphan_designation": {
                    "original_text": "Treatment of familial hypophosphatemic rickets.",
                    "umls_id": "C3536983",
                    "parsed_text": "Familial Hypophosphatemic Rickets"
                }
            }
        ]
    },
    {
        "_id": "QXWZQTURMXZVHJ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9913767,
                "inchl_key": "QXWZQTURMXZVHJ-UHFFFAOYSA-N",
                "generic_name": "selexipag",
                "designated_date": "10/02/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Janssen Research & Development LLC|1820 Chapel Ave West|Suite 300|Cherry Hill|New Jersey|8002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Chronic Thromboembolic Pulmonary Hypertension",
                    "umls_id": "C2363973",
                    "parsed_text": "Chronic thromboembolic pulmonary hypertension"
                }
            },
            {
                "compound_id": 9913767,
                "inchl_key": "QXWZQTURMXZVHJ-UHFFFAOYSA-N",
                "generic_name": "selexipag",
                "trade_name": "Uptravi",
                "designated_date": "04/30/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH",
                "marketing_approval_date": "\u00a012/21/2015\u00a0",
                "exclusivity_end_date": "\u00a012/21/2022\u00a0",
                "exclusivity_protected_indication": "For treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH",
                "sponsor": "Actelion Pharmaceuticals Ltd|Gewerbestrasse 16|Allschwil|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "GMBQZIIUCVWOCD-UQHLGXRBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 91439,
                "inchl_key": "GMBQZIIUCVWOCD-UQHLGXRBSA-N",
                "generic_name": "smilagenin",
                "designated_date": "07/21/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Junaxo, Inc.|First Canadian Place|Suite 5600|Toronto|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "VIDRYROWYFWGSY-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 66245,
                "inchl_key": "VIDRYROWYFWGSY-UHFFFAOYSA-N",
                "generic_name": "sotalol hydrochloride",
                "designated_date": "02/10/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Arbor Pharmaceuticals, LLC|980 Hammond Drive|Bldg Two, Suite 1250|Atlanta|Georgia|30328|United States",
                "orphan_designation": {
                    "original_text": "Treatment of life-threatening ventricular arrhythmias in pediatric patients",
                    "umls_id": "C3812282",
                    "parsed_text": "Ventricular Arrhythmias"
                }
            },
            {
                "compound_id": 66245,
                "inchl_key": "VIDRYROWYFWGSY-UHFFFAOYSA-N",
                "generic_name": "Sotalol HCl",
                "trade_name": "Betapace",
                "designated_date": "09/23/1988",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of life-threatening ventricular tachyarrhythmias",
                "marketing_approval_date": "\u00a010/30/1992\u00a0",
                "exclusivity_end_date": "\u00a010/30/1999\u00a0",
                "sponsor": "Berlex Laboratories, Inc.|300 Fairfield Road|Wayne|New Jersey|7470|United States",
                "orphan_designation": {
                    "original_text": "1. Treatment of life-threatening ventricular tachyarrhythmias 2. Prevention of life treatening ventricular tachyarrhythmias",
                    "umls_id": "C3827656",
                    "parsed_text": "Ventricular Tachyarrhythmias"
                }
            }
        ]
    },
    {
        "_id": "ZPYIELFRIYUVQP-BHBJEIPNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 72734342,
                "inchl_key": "ZPYIELFRIYUVQP-BHBJEIPNSA-N",
                "generic_name": "squalamine lactate",
                "designated_date": "05/11/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genaera Corporation|5110 Campus Drive|Plymouth Meeting|Pennsylvania|19462|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer refractory or resistant to standard chemotherapy",
                    "umls_id": "C0677936,C4721610",
                    "parsed_text": "cancer refractory , Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "JMNXSNUXDHHTKQ-QVMSTPCGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3036507,
                "inchl_key": "JMNXSNUXDHHTKQ-QVMSTPCGSA-N",
                "generic_name": "squalamine lactate",
                "designated_date": "05/11/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genaera Corporation|5110 Campus Drive|Plymouth Meeting|Pennsylvania|19462|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer refractory or resistant to standard chemotherapy",
                    "umls_id": "C0677936,C4721610",
                    "parsed_text": "cancer refractory , Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "QJJXYPPXXYFBGM-LFZNUXCKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 445643,
                "inchl_key": "QJJXYPPXXYFBGM-LFZNUXCKSA-N",
                "generic_name": "Tacrolimus",
                "designated_date": "04/06/1998",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Fujisawa USA, Inc.|3 Parkway North Center|Deerfield|Illinois|60015|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of graft-versus-host-disease.",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host-Disease"
                }
            },
            {
                "compound_id": 445643,
                "inchl_key": "QJJXYPPXXYFBGM-LFZNUXCKSA-N",
                "generic_name": "tacrolimus",
                "trade_name": "Envarsus XR",
                "designated_date": "12/20/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants",
                "marketing_approval_date": "\u00a007/10/2015\u00a0",
                "exclusivity_end_date": "\u00a007/10/2022\u00a0",
                "exclusivity_protected_indication": "Prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants",
                "sponsor": "Veloxis Pharmaceuticals, Inc.|1001 Winstead Drive|Suite 310|Cary|North Carolina|27513|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant",
                    "umls_id": "C0815080",
                    "parsed_text": "organ rejection"
                }
            },
            {
                "compound_id": 445643,
                "inchl_key": "QJJXYPPXXYFBGM-LFZNUXCKSA-N",
                "generic_name": "Tacrolimus",
                "designated_date": "06/03/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ophtho-Therapeutics, Inc.|324 S. Hyde Park Avenue|Tampa|Florida|33606|United States",
                "orphan_designation": {
                    "original_text": "Treatment of vernal keratoconjunctivitis",
                    "umls_id": "C0022577",
                    "parsed_text": "Vernal keratoconjunctivitis"
                }
            },
            {
                "compound_id": 445643,
                "inchl_key": "QJJXYPPXXYFBGM-LFZNUXCKSA-N",
                "generic_name": "tacrolimus",
                "trade_name": "Envarsus XR",
                "designated_date": "12/20/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "ENVARSUS XR is indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants.",
                "marketing_approval_date": "\u00a012/19/2018\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Veloxis Pharmaceuticals, Inc.|1001 Winstead Drive|Suite 310|Cary|North Carolina|27513|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant",
                    "umls_id": "C0815080",
                    "parsed_text": "organ rejection"
                }
            },
            {
                "compound_id": 445643,
                "inchl_key": "QJJXYPPXXYFBGM-LFZNUXCKSA-N",
                "generic_name": "tacrolimus",
                "designated_date": "05/04/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Stanford University School of Medicine|300 Pasteur Drive|Room H3143|Stanford|California|94305|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            },
            {
                "compound_id": 445643,
                "inchl_key": "QJJXYPPXXYFBGM-LFZNUXCKSA-N",
                "generic_name": "tacrolimus",
                "designated_date": "07/06/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Lipella Pharmaceuticals Inc.|400 N. Lexington Ave, LL105|Pittsburgh|Pennsylvania|15208|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hemorrhagic cystitis",
                    "umls_id": "C0085692",
                    "parsed_text": "Hemorrhagic cystitis"
                }
            },
            {
                "compound_id": 445643,
                "inchl_key": "QJJXYPPXXYFBGM-LFZNUXCKSA-N",
                "generic_name": "Tacrolimus",
                "trade_name": "Prograf",
                "designated_date": "06/06/2005",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prophylaxis of organ rejection in patients receiving allogenic heart transplants.",
                "marketing_approval_date": "\u00a003/29/2006\u00a0",
                "exclusivity_end_date": "\u00a003/29/2013\u00a0",
                "sponsor": "Astellas Pharma US, Inc.|Three Parkway North|Deerfield|Illinois|60015|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of organ rejection in patients receiving heart transplants.",
                    "umls_id": "C0815080",
                    "parsed_text": "organ rejection"
                }
            },
            {
                "compound_id": 445643,
                "inchl_key": "QJJXYPPXXYFBGM-LFZNUXCKSA-N",
                "generic_name": "tacrolimus",
                "designated_date": "03/16/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "VIVUS, Inc.|900 East Hamilton Avenue|Suite 550|Campbell|California|95008|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension.",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "DQJDBUPLRMRBAB-WZTVWXICSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24970412,
                "inchl_key": "DQJDBUPLRMRBAB-WZTVWXICSA-N",
                "generic_name": "tafamidis meglumine",
                "trade_name": "VYNDAQEL; VYNDAMAX",
                "designated_date": "02/17/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.",
                "marketing_approval_date": "\u00a005/03/2019\u00a0",
                "exclusivity_end_date": "\u00a005/03/2026\u00a0",
                "exclusivity_protected_indication": "VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.",
                "sponsor": "FoldRx Pharmaceuticals, Inc., a subsidiary of Pfizer Inc.|445 Eastern Point Road|Groton|Connecticut|6340|United States",
                "orphan_designation": {
                    "original_text": "Treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy.",
                    "umls_id": "C0268407",
                    "parsed_text": "Amyloid cardiomyopathy"
                }
            }
        ]
    },
    {
        "_id": "LBHLFPGPEGDCJG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 115358,
                "inchl_key": "LBHLFPGPEGDCJG-UHFFFAOYSA-N",
                "generic_name": "tafenoquine",
                "trade_name": "Krintafel",
                "designated_date": "01/15/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "KRINTAFEL is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection.",
                "marketing_approval_date": "\u00a007/20/2018\u00a0",
                "exclusivity_end_date": "\u00a007/20/2025\u00a0",
                "exclusivity_protected_indication": "KRINTAFEL is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection.",
                "sponsor": "GlaxoSmithKline Intellectual Property Development Ltd. England|980 Great West Road|Brentford, Middlesex|England|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            }
        ]
    },
    {
        "_id": "FKCMADOPPWWGNZ-YUMQZZPRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6918572,
                "inchl_key": "FKCMADOPPWWGNZ-YUMQZZPRSA-N",
                "generic_name": "Talabostat",
                "designated_date": "03/20/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "BioXcel Corporation|780 East Main Street|Suite 2|Branford|Connecticut|6405|United States",
                "orphan_designation": {
                    "original_text": "Treatment of stages IIb through IV melanoma",
                    "umls_id": "C0025202",
                    "parsed_text": "melanoma"
                }
            },
            {
                "compound_id": 6918572,
                "inchl_key": "FKCMADOPPWWGNZ-YUMQZZPRSA-N",
                "generic_name": "Talabostat",
                "designated_date": "03/16/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "BioXcel Corporation|780 East Main Street|Suite 2|Branford|Connecticut|6405|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 6918572,
                "inchl_key": "FKCMADOPPWWGNZ-YUMQZZPRSA-N",
                "generic_name": "Talabostat",
                "designated_date": "01/26/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "BioXcel Therapeutics|555 Long Wharf Drive, 5th Floor|New Haven|Connecticut|6511|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcoma",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            },
            {
                "compound_id": 6918572,
                "inchl_key": "FKCMADOPPWWGNZ-YUMQZZPRSA-N",
                "generic_name": "Talabostat",
                "designated_date": "08/21/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "BioXcel Therapeutics, Inc.|555 Long Wharf Drive|5th Floor|New Haven|Connecticut|6511|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelogenous leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "ONDYALNGTUAJDX-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 54682876,
                "inchl_key": "ONDYALNGTUAJDX-UHFFFAOYSA-N",
                "generic_name": "Tasquinimod",
                "designated_date": "04/10/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Active Biotech AB|Scheelev\u49e5n 22|P.O. Box 724|Lund|Sk\u5ba5 l\u4b8d|Sweden",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "XOAAWQZATWQOTB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 1123,
                "inchl_key": "XOAAWQZATWQOTB-UHFFFAOYSA-N",
                "generic_name": "taurine",
                "designated_date": "03/22/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Johan L. Van Hove, MD, PhD|Department of Pediatrics/University of Colorado De|13121 E. 17th Ave., P. O. Box 6508|Aurora|Colorado|80045|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystathionine beta-synthase deficient homocystinuria",
                    "umls_id": "C0019880",
                    "parsed_text": "Homocystinuria"
                }
            }
        ]
    },
    {
        "_id": "MREOOEFUTWFQOC-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 54715158,
                "inchl_key": "MREOOEFUTWFQOC-UHFFFAOYSA-M",
                "generic_name": "Tegafur/gimeracil/oteracil",
                "designated_date": "07/20/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Taiho Oncology, Inc.|101 Carnegie Center|Suite 101|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastric cancer",
                    "umls_id": "C0024623",
                    "parsed_text": "Gastric Cancer"
                }
            }
        ]
    },
    {
        "_id": "OMWCXCBGEFHCTN-FGYAAKKASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 46212391,
                "inchl_key": "OMWCXCBGEFHCTN-FGYAAKKASA-N",
                "generic_name": "tegavivint",
                "designated_date": "04/11/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Beta Cat Pharmaceuticals|2450 Holcombe Blvd, Suite J606|Houston|Texas|77021|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Desmoid Tumors",
                    "umls_id": "C0079218",
                    "parsed_text": "desmoid tumors"
                }
            }
        ]
    },
    {
        "_id": "BJNLLBUOHPVGFT-CAYRISATSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 133065662,
                "inchl_key": "BJNLLBUOHPVGFT-CAYRISATSA-N",
                "generic_name": "teicoplanin",
                "designated_date": "05/24/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neupharma srl|8 Piazza del Duomo|Imola|Emilia-Romagna|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis",
                    "umls_id": "C0010674,C0038172,C3714514",
                    "parsed_text": "Cystic Fibrosis , Staphylococcus aureus , Infections"
                }
            }
        ]
    },
    {
        "_id": "CBPNZQVSJQDFBE-RODMVNQKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 154827473,
                "inchl_key": "CBPNZQVSJQDFBE-RODMVNQKSA-N",
                "generic_name": "Temsirolimus",
                "trade_name": "Torisel",
                "designated_date": "12/16/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of advanced renal cell carcinoma",
                "marketing_approval_date": "\u00a005/30/2007\u00a0",
                "exclusivity_end_date": "\u00a005/30/2014\u00a0",
                "sponsor": "Wyeth Pharmaceuticals, Inc.|P. O. Box 8299|Phildelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls_id": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            }
        ]
    },
    {
        "_id": "CBPNZQVSJQDFBE-NUTFMQKQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 154575198,
                "inchl_key": "CBPNZQVSJQDFBE-NUTFMQKQSA-N",
                "generic_name": "Temsirolimus",
                "trade_name": "Torisel",
                "designated_date": "12/16/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of advanced renal cell carcinoma",
                "marketing_approval_date": "\u00a005/30/2007\u00a0",
                "exclusivity_end_date": "\u00a005/30/2014\u00a0",
                "sponsor": "Wyeth Pharmaceuticals, Inc.|P. O. Box 8299|Phildelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls_id": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            }
        ]
    },
    {
        "_id": "CBPNZQVSJQDFBE-LGVPMJLXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 152772378,
                "inchl_key": "CBPNZQVSJQDFBE-LGVPMJLXSA-N",
                "generic_name": "Temsirolimus",
                "trade_name": "Torisel",
                "designated_date": "12/16/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of advanced renal cell carcinoma",
                "marketing_approval_date": "\u00a005/30/2007\u00a0",
                "exclusivity_end_date": "\u00a005/30/2014\u00a0",
                "sponsor": "Wyeth Pharmaceuticals, Inc.|P. O. Box 8299|Phildelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls_id": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            }
        ]
    },
    {
        "_id": "CBPNZQVSJQDFBE-HELDCPHESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 137295275,
                "inchl_key": "CBPNZQVSJQDFBE-HELDCPHESA-N",
                "generic_name": "Temsirolimus",
                "trade_name": "Torisel",
                "designated_date": "12/16/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of advanced renal cell carcinoma",
                "marketing_approval_date": "\u00a005/30/2007\u00a0",
                "exclusivity_end_date": "\u00a005/30/2014\u00a0",
                "sponsor": "Wyeth Pharmaceuticals, Inc.|P. O. Box 8299|Phildelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls_id": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            }
        ]
    },
    {
        "_id": "CBPNZQVSJQDFBE-VYCIWTNRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 132274070,
                "inchl_key": "CBPNZQVSJQDFBE-VYCIWTNRSA-N",
                "generic_name": "Temsirolimus",
                "trade_name": "Torisel",
                "designated_date": "12/16/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of advanced renal cell carcinoma",
                "marketing_approval_date": "\u00a005/30/2007\u00a0",
                "exclusivity_end_date": "\u00a005/30/2014\u00a0",
                "sponsor": "Wyeth Pharmaceuticals, Inc.|P. O. Box 8299|Phildelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls_id": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            }
        ]
    },
    {
        "_id": "CBPNZQVSJQDFBE-QWRHTZMXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 86287409,
                "inchl_key": "CBPNZQVSJQDFBE-QWRHTZMXSA-N",
                "generic_name": "Temsirolimus",
                "trade_name": "Torisel",
                "designated_date": "12/16/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of advanced renal cell carcinoma",
                "marketing_approval_date": "\u00a005/30/2007\u00a0",
                "exclusivity_end_date": "\u00a005/30/2014\u00a0",
                "sponsor": "Wyeth Pharmaceuticals, Inc.|P. O. Box 8299|Phildelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls_id": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            }
        ]
    },
    {
        "_id": "CBPNZQVSJQDFBE-DZCFMHCPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71296107,
                "inchl_key": "CBPNZQVSJQDFBE-DZCFMHCPSA-N",
                "generic_name": "Temsirolimus",
                "trade_name": "Torisel",
                "designated_date": "12/16/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of advanced renal cell carcinoma",
                "marketing_approval_date": "\u00a005/30/2007\u00a0",
                "exclusivity_end_date": "\u00a005/30/2014\u00a0",
                "sponsor": "Wyeth Pharmaceuticals, Inc.|P. O. Box 8299|Phildelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls_id": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            }
        ]
    },
    {
        "_id": "CBPNZQVSJQDFBE-VBSVFFBFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 54608508,
                "inchl_key": "CBPNZQVSJQDFBE-VBSVFFBFSA-N",
                "generic_name": "Temsirolimus",
                "trade_name": "Torisel",
                "designated_date": "12/16/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of advanced renal cell carcinoma",
                "marketing_approval_date": "\u00a005/30/2007\u00a0",
                "exclusivity_end_date": "\u00a005/30/2014\u00a0",
                "sponsor": "Wyeth Pharmaceuticals, Inc.|P. O. Box 8299|Phildelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls_id": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            }
        ]
    },
    {
        "_id": "CBPNZQVSJQDFBE-MDHHOXSCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9876533,
                "inchl_key": "CBPNZQVSJQDFBE-MDHHOXSCSA-N",
                "generic_name": "Temsirolimus",
                "trade_name": "Torisel",
                "designated_date": "12/16/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of advanced renal cell carcinoma",
                "marketing_approval_date": "\u00a005/30/2007\u00a0",
                "exclusivity_end_date": "\u00a005/30/2014\u00a0",
                "sponsor": "Wyeth Pharmaceuticals, Inc.|P. O. Box 8299|Phildelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls_id": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            }
        ]
    },
    {
        "_id": "CBPNZQVSJQDFBE-GOFCWFHQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 145712265,
                "inchl_key": "CBPNZQVSJQDFBE-GOFCWFHQSA-N",
                "generic_name": "Temsirolimus",
                "trade_name": "Torisel",
                "designated_date": "12/16/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of advanced renal cell carcinoma",
                "marketing_approval_date": "\u00a005/30/2007\u00a0",
                "exclusivity_end_date": "\u00a005/30/2014\u00a0",
                "sponsor": "Wyeth Pharmaceuticals, Inc.|P. O. Box 8299|Phildelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls_id": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            }
        ]
    },
    {
        "_id": "CBPNZQVSJQDFBE-KFZNZFKNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71312019,
                "inchl_key": "CBPNZQVSJQDFBE-KFZNZFKNSA-N",
                "generic_name": "Temsirolimus",
                "trade_name": "Torisel",
                "designated_date": "12/16/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of advanced renal cell carcinoma",
                "marketing_approval_date": "\u00a005/30/2007\u00a0",
                "exclusivity_end_date": "\u00a005/30/2014\u00a0",
                "sponsor": "Wyeth Pharmaceuticals, Inc.|P. O. Box 8299|Phildelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls_id": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            }
        ]
    },
    {
        "_id": "CBPNZQVSJQDFBE-ZJEVVSOISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24847874,
                "inchl_key": "CBPNZQVSJQDFBE-ZJEVVSOISA-N",
                "generic_name": "Temsirolimus",
                "trade_name": "Torisel",
                "designated_date": "12/16/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of advanced renal cell carcinoma",
                "marketing_approval_date": "\u00a005/30/2007\u00a0",
                "exclusivity_end_date": "\u00a005/30/2014\u00a0",
                "sponsor": "Wyeth Pharmaceuticals, Inc.|P. O. Box 8299|Phildelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls_id": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            }
        ]
    },
    {
        "_id": "CBPNZQVSJQDFBE-DYFDTRMFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5938194,
                "inchl_key": "CBPNZQVSJQDFBE-DYFDTRMFSA-N",
                "generic_name": "Temsirolimus",
                "trade_name": "Torisel",
                "designated_date": "12/16/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of advanced renal cell carcinoma",
                "marketing_approval_date": "\u00a005/30/2007\u00a0",
                "exclusivity_end_date": "\u00a005/30/2014\u00a0",
                "sponsor": "Wyeth Pharmaceuticals, Inc.|P. O. Box 8299|Phildelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls_id": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            }
        ]
    },
    {
        "_id": "CBPNZQVSJQDFBE-UITOJQKMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 129317846,
                "inchl_key": "CBPNZQVSJQDFBE-UITOJQKMSA-N",
                "generic_name": "Temsirolimus",
                "trade_name": "Torisel",
                "designated_date": "12/16/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of advanced renal cell carcinoma",
                "marketing_approval_date": "\u00a005/30/2007\u00a0",
                "exclusivity_end_date": "\u00a005/30/2014\u00a0",
                "sponsor": "Wyeth Pharmaceuticals, Inc.|P. O. Box 8299|Phildelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls_id": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            }
        ]
    },
    {
        "_id": "CBPNZQVSJQDFBE-AQHKCTBXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71433778,
                "inchl_key": "CBPNZQVSJQDFBE-AQHKCTBXSA-N",
                "generic_name": "Temsirolimus",
                "trade_name": "Torisel",
                "designated_date": "12/16/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of advanced renal cell carcinoma",
                "marketing_approval_date": "\u00a005/30/2007\u00a0",
                "exclusivity_end_date": "\u00a005/30/2014\u00a0",
                "sponsor": "Wyeth Pharmaceuticals, Inc.|P. O. Box 8299|Phildelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls_id": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            }
        ]
    },
    {
        "_id": "CBPNZQVSJQDFBE-FAYWIXGWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 53486199,
                "inchl_key": "CBPNZQVSJQDFBE-FAYWIXGWSA-N",
                "generic_name": "Temsirolimus",
                "trade_name": "Torisel",
                "designated_date": "12/16/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of advanced renal cell carcinoma",
                "marketing_approval_date": "\u00a005/30/2007\u00a0",
                "exclusivity_end_date": "\u00a005/30/2014\u00a0",
                "sponsor": "Wyeth Pharmaceuticals, Inc.|P. O. Box 8299|Phildelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls_id": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            }
        ]
    },
    {
        "_id": "CBPNZQVSJQDFBE-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 148191,
                "inchl_key": "CBPNZQVSJQDFBE-UHFFFAOYSA-N",
                "generic_name": "Temsirolimus",
                "trade_name": "Torisel",
                "designated_date": "12/16/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of advanced renal cell carcinoma",
                "marketing_approval_date": "\u00a005/30/2007\u00a0",
                "exclusivity_end_date": "\u00a005/30/2014\u00a0",
                "sponsor": "Wyeth Pharmaceuticals, Inc.|P. O. Box 8299|Phildelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls_id": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            }
        ]
    },
    {
        "_id": "CBPNZQVSJQDFBE-HGVVHKDOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 23724530,
                "inchl_key": "CBPNZQVSJQDFBE-HGVVHKDOSA-N",
                "generic_name": "Temsirolimus",
                "trade_name": "Torisel",
                "designated_date": "12/16/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of advanced renal cell carcinoma",
                "marketing_approval_date": "\u00a005/30/2007\u00a0",
                "exclusivity_end_date": "\u00a005/30/2014\u00a0",
                "sponsor": "Wyeth Pharmaceuticals, Inc.|P. O. Box 8299|Phildelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls_id": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            }
        ]
    },
    {
        "_id": "CBPNZQVSJQDFBE-PXVOFZQNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 18293306,
                "inchl_key": "CBPNZQVSJQDFBE-PXVOFZQNSA-N",
                "generic_name": "Temsirolimus",
                "trade_name": "Torisel",
                "designated_date": "12/16/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of advanced renal cell carcinoma",
                "marketing_approval_date": "\u00a005/30/2007\u00a0",
                "exclusivity_end_date": "\u00a005/30/2014\u00a0",
                "sponsor": "Wyeth Pharmaceuticals, Inc.|P. O. Box 8299|Phildelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls_id": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            }
        ]
    },
    {
        "_id": "CBPNZQVSJQDFBE-FUXHJELOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6918289,
                "inchl_key": "CBPNZQVSJQDFBE-FUXHJELOSA-N",
                "generic_name": "Temsirolimus",
                "trade_name": "Torisel",
                "designated_date": "12/16/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of advanced renal cell carcinoma",
                "marketing_approval_date": "\u00a005/30/2007\u00a0",
                "exclusivity_end_date": "\u00a005/30/2014\u00a0",
                "sponsor": "Wyeth Pharmaceuticals, Inc.|P. O. Box 8299|Phildelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls_id": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            }
        ]
    },
    {
        "_id": "BENFXAYNYRLAIU-QSVFAHTRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 72081,
                "inchl_key": "BENFXAYNYRLAIU-QSVFAHTRSA-N",
                "generic_name": "Terlipressin",
                "designated_date": "03/06/1986",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ferring Pharmaceuticals Inc.|100 Interpace Parkway|Parsippany-Troy Hills|New Jersey|7054|United States",
                "orphan_designation": {
                    "original_text": "Treatment of bleeding esophageal varices.",
                    "umls_id": "C0014867",
                    "parsed_text": "Esophageal Varices"
                }
            },
            {
                "compound_id": 72081,
                "inchl_key": "BENFXAYNYRLAIU-QSVFAHTRSA-N",
                "generic_name": "terlipressin",
                "designated_date": "11/21/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "BioVie Inc.|100 Cummings Center|Suite 247-C|Beverly|Massachusetts|1915|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatorenal syndrome",
                    "umls_id": "C0019212",
                    "parsed_text": "Hepatorenal Syndrome"
                }
            },
            {
                "compound_id": 72081,
                "inchl_key": "BENFXAYNYRLAIU-QSVFAHTRSA-N",
                "generic_name": "terlipressin",
                "designated_date": "10/29/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mallinckrodt Hospital Products IP Limited|Perryville III Corporate Park|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Treatment of Hepatorenal Syndrome",
                    "umls_id": "C0019212",
                    "parsed_text": "Hepatorenal Syndrome"
                }
            },
            {
                "compound_id": 72081,
                "inchl_key": "BENFXAYNYRLAIU-QSVFAHTRSA-N",
                "generic_name": "terlipressin",
                "designated_date": "09/08/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bio Vie Inc.|100 Cummings Center|Suite 247-C|Beverly|Massachusetts|1915|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ascites due to all etiologies except cancer",
                    "umls_id": "C0003962",
                    "parsed_text": "Ascites"
                }
            }
        ]
    },
    {
        "_id": "MKJIEFSOBYUXJB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6018,
                "inchl_key": "MKJIEFSOBYUXJB-UHFFFAOYSA-N",
                "generic_name": "Tetrabenazine",
                "designated_date": "05/12/1998",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Prestwick Pharmaceuticals, Inc.|1825 K Street, NW|Suite 1475|Washington|District of Columbia|20006|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate/severe tardive dyskinesia.",
                    "umls_id": "C0686347",
                    "parsed_text": "Tardive Dyskinesia"
                }
            },
            {
                "compound_id": 6018,
                "inchl_key": "MKJIEFSOBYUXJB-UHFFFAOYSA-N",
                "generic_name": "Tetrabenazine",
                "trade_name": "Xenazine",
                "designated_date": "12/11/1997",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of chorea associated with Huntington's disease",
                "marketing_approval_date": "\u00a008/15/2008\u00a0",
                "exclusivity_end_date": "\u00a008/15/2015\u00a0",
                "sponsor": "Prestwick Pharmaceuticals, Inc|1825 K Street NW|Suite 1475|Washington|District of Columbia|20006|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Huntington's disease",
                    "umls_id": "C0020179",
                    "parsed_text": "Huntington's Disease"
                }
            },
            {
                "compound_id": 6018,
                "inchl_key": "MKJIEFSOBYUXJB-UHFFFAOYSA-N",
                "generic_name": "tetrabenazine",
                "designated_date": "07/01/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Valeant International (Barbados) SRL|Welches Christ Church|Barbados|Barbados",
                "orphan_designation": {
                    "original_text": "Treatment of Tourette's Syndrome in school-age children, ages 5-16",
                    "umls_id": "C0040517",
                    "parsed_text": "Tourette's Syndrome"
                }
            }
        ]
    },
    {
        "_id": "IKPNWIGTWUZCKM-JEDNCBNOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135242,
                "inchl_key": "IKPNWIGTWUZCKM-JEDNCBNOSA-N",
                "generic_name": "Tilarginine acetate",
                "designated_date": "04/11/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Arginox Pharmceuticals, Inc.|120 Constitution Drive|Menlo Park|California|94025|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cardiogenic shock",
                    "umls_id": "C0036980",
                    "parsed_text": "Cardiogenic shock"
                }
            }
        ]
    },
    {
        "_id": "DQHNAVOVODVIMG-RGECMCKFSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 5487426,
                "inchl_key": "DQHNAVOVODVIMG-RGECMCKFSA-M",
                "generic_name": "Tiotropium bromide",
                "designated_date": "01/08/2008",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Boehringer Ingelheim Pharmaceuticals, Inc.|P. O. Box 368|900 Ridgebury Road|Ridgefield|Connecticut|6877|United States",
                "orphan_designation": {
                    "original_text": "To improve pulmonary function in conjunction with standard therapy in the management of patients with cystic fibrosis",
                    "umls_id": "C0010674,C1547996",
                    "parsed_text": "Cystic Fibrosis , Pulmonary Function"
                }
            }
        ]
    },
    {
        "_id": "KPWYNAGOBXLMSE-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9893228,
                "inchl_key": "KPWYNAGOBXLMSE-UHFFFAOYSA-N",
                "generic_name": "tipelukast",
                "designated_date": "10/20/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MediciNova, Inc.|4275 Executive Square|Suite 300|La Jolla|California|92037|United States",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic pulmonary fibrosis",
                    "umls_id": "C1800706",
                    "parsed_text": "Idiopathic Pulmonary Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "ZWUKMNZJRDGCTQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 114869,
                "inchl_key": "ZWUKMNZJRDGCTQ-UHFFFAOYSA-N",
                "generic_name": "Tizanidine HCl",
                "designated_date": "01/31/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Athena Neurosciences, Inc.|800 Gateway Boulevard|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of spasticity associated with multiple sclerosis and spinal cord injury.",
                    "umls_id": "C0026769,C0026838,C0037929",
                    "parsed_text": "Multiple Sclerosis , Spasticity , Spinal Cord Injury"
                }
            }
        ]
    },
    {
        "_id": "YEZNLOUZAIOMLT-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 610479,
                "inchl_key": "YEZNLOUZAIOMLT-UHFFFAOYSA-N",
                "generic_name": "tolfenamic acid",
                "designated_date": "07/13/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Nasser H. Zawia|83 Castle Rocks Road|Warwick|Rhode Island|2886|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Frontotemporal Dementia",
                    "umls_id": "C0338451",
                    "parsed_text": "Frontotemporal dementia"
                }
            },
            {
                "compound_id": 610479,
                "inchl_key": "YEZNLOUZAIOMLT-UHFFFAOYSA-N",
                "generic_name": "tolfenamic acid",
                "designated_date": "07/13/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Nasser H. Zawia|83 Castle Rocks Road|Warwick|Rhode Island|2886|United States",
                "orphan_designation": {
                    "original_text": "Treatment of progressive supranuclear palsy",
                    "umls_id": "C0038868",
                    "parsed_text": "Progressive supranuclear palsy"
                }
            }
        ]
    },
    {
        "_id": "XFCLJVABOIYOMF-QPLCGJKRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3005573,
                "inchl_key": "XFCLJVABOIYOMF-QPLCGJKRSA-N",
                "generic_name": "Toremifene",
                "designated_date": "08/17/1993",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orion Corporation|Orionintie 1|Espoo|Finland",
                "orphan_designation": {
                    "original_text": "Treatment of desmoid tumors.",
                    "umls_id": "C0079218",
                    "parsed_text": "desmoid tumors"
                }
            },
            {
                "compound_id": 3005573,
                "inchl_key": "XFCLJVABOIYOMF-QPLCGJKRSA-N",
                "generic_name": "Toremifene",
                "trade_name": "Fareston",
                "designated_date": "09/19/1991",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of metastatic breast cancer in postmenopausal women with estrogen positive or receptor unknown tumors.",
                "marketing_approval_date": "\u00a005/29/1997\u00a0",
                "exclusivity_end_date": "\u00a005/29/2004\u00a0",
                "sponsor": "Orion Corporation|Orionintie 1|Espoo|Finland",
                "orphan_designation": {
                    "original_text": "Hormonal therapy of metastatic carcinoma of the breast.",
                    "umls_id": "C0678222,C1384494",
                    "parsed_text": "Carcinoma of the Breast , Metastatic Carcinoma"
                }
            }
        ]
    },
    {
        "_id": "HSWLVDBGZCETRH-UHFFFAOYSA-O",
        "Orphan Drug Designations": [
            {
                "compound_id": 132472120,
                "inchl_key": "HSWLVDBGZCETRH-UHFFFAOYSA-O",
                "generic_name": "trabedersen",
                "designated_date": "08/22/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oncotelic Inc.|29397 Agoura Road|Suite 107|Agoura Hills|California|91301|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Stage IIB through Stage IV malignant melanoma.",
                    "umls_id": "C0025202",
                    "parsed_text": "Malignant Melanoma"
                }
            },
            {
                "compound_id": 132472120,
                "inchl_key": "HSWLVDBGZCETRH-UHFFFAOYSA-O",
                "generic_name": "trabedersen",
                "designated_date": "07/21/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oncotelic Inc.|29397 Agoura Road|Suite 107|Agoura Hills|California|91301|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer.",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 132472120,
                "inchl_key": "HSWLVDBGZCETRH-UHFFFAOYSA-O",
                "generic_name": "trabedersen",
                "designated_date": "06/05/2002",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oncotelic Inc.|29397 Agoura Road|Suite 107|Agoura Hills|California|91301|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls_id": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            }
        ]
    },
    {
        "_id": "VLPFTAMPNXLGLX-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10850,
                "inchl_key": "VLPFTAMPNXLGLX-UHFFFAOYSA-N",
                "generic_name": "tricaprilin",
                "designated_date": "10/27/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cerecin, Inc.|44 Cook Street, Suite 100-71|Denver|Colorado|80206|United States",
                "orphan_designation": {
                    "original_text": "Treatment of infantile spasms also known as West's syndrome",
                    "umls_id": "C0037769,C3887898",
                    "parsed_text": "Infantile spasms , Infantile spasms"
                }
            }
        ]
    },
    {
        "_id": "MFBCDACCJCDGBA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11518241,
                "inchl_key": "MFBCDACCJCDGBA-UHFFFAOYSA-N",
                "generic_name": "trifarotene",
                "designated_date": "06/06/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mayne Pharma LLC.|1240 Sugg Parkway|Greenville|North Carolina|27834|United States",
                "orphan_designation": {
                    "original_text": "Treatment of congenital ichthyosis",
                    "umls_id": "C0079154",
                    "parsed_text": "congenital ichthyosis"
                }
            }
        ]
    },
    {
        "_id": "QNTNKSLOFHEFPK-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25201759,
                "inchl_key": "QNTNKSLOFHEFPK-UHFFFAOYSA-N",
                "generic_name": "ubiquinol",
                "designated_date": "04/12/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gel-Tec, Division of Tishcon Corp.|30 New York Avenue|P. O. Box 331|Westbury|New York|11590|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Huntington's Disease",
                    "umls_id": "C0020179",
                    "parsed_text": "Huntington's Disease"
                }
            }
        ]
    },
    {
        "_id": "QNTNKSLOFHEFPK-UPTCCGCDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9962735,
                "inchl_key": "QNTNKSLOFHEFPK-UPTCCGCDSA-N",
                "generic_name": "ubiquinol",
                "designated_date": "04/12/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gel-Tec, Division of Tishcon Corp.|30 New York Avenue|P. O. Box 331|Westbury|New York|11590|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Huntington's Disease",
                    "umls_id": "C0020179",
                    "parsed_text": "Huntington's Disease"
                }
            }
        ]
    },
    {
        "_id": "XSQUKJJJFZCRTK-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 1176,
                "inchl_key": "XSQUKJJJFZCRTK-UHFFFAOYSA-N",
                "generic_name": "urea",
                "designated_date": "11/07/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orenova Group, LLC|10 New King Street|Suite 106|White Plains|New York|10604|United States",
                "orphan_designation": {
                    "original_text": "Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis).",
                    "umls_id": "C0011606,C0079153,C0079154,C0079588,C0239849,C0265267,C0265962,C0265962,C0268238,C1955934,C3543867,C3665333",
                    "parsed_text": "Erythroderma , Epidermolytic hyperkeratosis , Lamellar ichthyosis , X-linked ichthyosis , Harlequin Ichthyosis , Child syndrome , Netherton Syndrome , Netherton Syndrome , Neutral lipid storage disease , Trichothiodystrophy , Collodion Baby , Kid syndrome"
                }
            }
        ]
    },
    {
        "_id": "ZDRRIRUAESZNIH-JLSAMJFVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 73759969,
                "inchl_key": "ZDRRIRUAESZNIH-JLSAMJFVSA-N",
                "generic_name": "Urofollitropin",
                "trade_name": "Metrodin",
                "designated_date": "11/25/1987",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a009/18/1986\u00a0",
                "exclusivity_end_date": "\u00a009/18/1993\u00a0",
                "sponsor": "EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States",
                "orphan_designation": {
                    "original_text": "For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.",
                    "umls_id": "C0032460",
                    "parsed_text": "Polycystic Ovarian Disease"
                }
            },
            {
                "compound_id": 73759969,
                "inchl_key": "ZDRRIRUAESZNIH-JLSAMJFVSA-N",
                "generic_name": "Urofollitropin",
                "designated_date": "12/05/1997",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States",
                "orphan_designation": {
                    "original_text": "For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism.",
                    "umls_id": "C0022735,C0281947,C3671958",
                    "parsed_text": "Hypogonadotropic Hypogonadism , pituitary dysfunction , Reproductive failure"
                }
            }
        ]
    },
    {
        "_id": "ZDRRIRUAESZNIH-BZGUUIOASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 75409771,
                "inchl_key": "ZDRRIRUAESZNIH-BZGUUIOASA-N",
                "generic_name": "Urofollitropin",
                "trade_name": "Metrodin",
                "designated_date": "11/25/1987",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a009/18/1986\u00a0",
                "exclusivity_end_date": "\u00a009/18/1993\u00a0",
                "sponsor": "EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States",
                "orphan_designation": {
                    "original_text": "For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.",
                    "umls_id": "C0032460",
                    "parsed_text": "Polycystic Ovarian Disease"
                }
            },
            {
                "compound_id": 75409771,
                "inchl_key": "ZDRRIRUAESZNIH-BZGUUIOASA-N",
                "generic_name": "Urofollitropin",
                "designated_date": "12/05/1997",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States",
                "orphan_designation": {
                    "original_text": "For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism.",
                    "umls_id": "C0022735,C0281947,C3671958",
                    "parsed_text": "Hypogonadotropic Hypogonadism , pituitary dysfunction , Reproductive failure"
                }
            }
        ]
    },
    {
        "_id": "ZDRRIRUAESZNIH-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 62819,
                "inchl_key": "ZDRRIRUAESZNIH-UHFFFAOYSA-N",
                "generic_name": "Urofollitropin",
                "trade_name": "Metrodin",
                "designated_date": "11/25/1987",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a009/18/1986\u00a0",
                "exclusivity_end_date": "\u00a009/18/1993\u00a0",
                "sponsor": "EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States",
                "orphan_designation": {
                    "original_text": "For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.",
                    "umls_id": "C0032460",
                    "parsed_text": "Polycystic Ovarian Disease"
                }
            },
            {
                "compound_id": 62819,
                "inchl_key": "ZDRRIRUAESZNIH-UHFFFAOYSA-N",
                "generic_name": "Urofollitropin",
                "designated_date": "12/05/1997",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States",
                "orphan_designation": {
                    "original_text": "For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism.",
                    "umls_id": "C0022735,C0281947,C3671958",
                    "parsed_text": "Hypogonadotropic Hypogonadism , pituitary dysfunction , Reproductive failure"
                }
            }
        ]
    },
    {
        "_id": "FJCDSQATIJKQKA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 54766013,
                "inchl_key": "FJCDSQATIJKQKA-UHFFFAOYSA-N",
                "generic_name": "Vactosertib",
                "designated_date": "09/28/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MedPacto, Inc|145 Gwanggyo-ro|Advanced Institutes of Convergence Technology, Building C, Room 506|Suwon|Gyeonggi-do|16229|Republic of Korea",
                "orphan_designation": {
                    "original_text": "Treatment of gastric cancer",
                    "umls_id": "C0024623",
                    "parsed_text": "Gastric Cancer"
                }
            },
            {
                "compound_id": 54766013,
                "inchl_key": "FJCDSQATIJKQKA-UHFFFAOYSA-N",
                "generic_name": "N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline",
                "designated_date": "06/14/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MedPacto, Inc.|145 Gwanggyo-ro|Advanced Institutes of Convergence Technology|Suwon|Gyeonggi-do|South Korea",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            }
        ]
    },
    {
        "_id": "VYUWDIKZJLOZJL-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11638255,
                "inchl_key": "VYUWDIKZJLOZJL-UHFFFAOYSA-N",
                "generic_name": "Varbulin",
                "designated_date": "11/05/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Myrexis, Inc.|305 Chipeta Way|Salt Lake City|Utah|84108|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioblastoma multiforme.",
                    "umls_id": "C0017636",
                    "parsed_text": "Glioblastoma multiforme"
                }
            }
        ]
    },
    {
        "_id": "GPXBXXGIAQBQNI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 42611257,
                "inchl_key": "GPXBXXGIAQBQNI-UHFFFAOYSA-N",
                "generic_name": "vemurafenib",
                "designated_date": "11/26/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|M/S 241B|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of anaplastic thyroid carcinoma and advanced papillary thyroid cancer whose tumors harbor a BRAF V600 mutation",
                    "umls_id": "C0027651,C0238461,C0238463",
                    "parsed_text": "Tumors , Anaplastic thyroid carcinoma , papillary thyroid cancer"
                }
            },
            {
                "compound_id": 42611257,
                "inchl_key": "GPXBXXGIAQBQNI-UHFFFAOYSA-N",
                "generic_name": "vemurafenib",
                "designated_date": "09/08/2014",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with non-small cell lung cancer (NSCLC) with BRAF V600 mutation",
                    "umls_id": "C0007131,C3539721",
                    "parsed_text": "Non-Small Cell Lung Cancer , Non-Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 42611257,
                "inchl_key": "GPXBXXGIAQBQNI-UHFFFAOYSA-N",
                "generic_name": "vemurafenib",
                "trade_name": "Zelboraf",
                "designated_date": "12/20/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of unresectable or metastatic melanoma with the BRAFV600E mutation as detected by an FDA-approved test.",
                "marketing_approval_date": "\u00a008/17/2011\u00a0",
                "exclusivity_end_date": "\u00a008/17/2018\u00a0",
                "sponsor": "Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with IIb to Stage IV melanoma positive for the BRAF(v600) mutation",
                    "umls_id": "C0025202",
                    "parsed_text": "melanoma"
                }
            },
            {
                "compound_id": 42611257,
                "inchl_key": "GPXBXXGIAQBQNI-UHFFFAOYSA-N",
                "generic_name": "vemurafenib",
                "trade_name": "Zelboraf",
                "designated_date": "08/02/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation",
                "marketing_approval_date": "\u00a011/06/2017\u00a0",
                "exclusivity_end_date": "\u00a011/06/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Erdheim-Chester Disease",
                    "umls_id": "C0878675",
                    "parsed_text": "Erdheim-Chester Disease"
                }
            },
            {
                "compound_id": 42611257,
                "inchl_key": "GPXBXXGIAQBQNI-UHFFFAOYSA-N",
                "generic_name": "vemurafenib",
                "designated_date": "08/26/2014",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|M/S 241B|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hairy cell leukemia (HCL).",
                    "umls_id": "C0023443",
                    "parsed_text": "Hairy Cell Leukemia"
                }
            }
        ]
    },
    {
        "_id": "ZVXLKCOOOKREJD-OERAVCCFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 154562176,
                "inchl_key": "ZVXLKCOOOKREJD-OERAVCCFSA-N",
                "generic_name": "viltolarsen",
                "trade_name": "VILTEPSO",
                "designated_date": "01/12/2017",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping",
                "marketing_approval_date": "\u00a008/12/2020\u00a0",
                "exclusivity_end_date": "\u00a008/12/2027\u00a0",
                "exclusivity_protected_indication": "VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping",
                "sponsor": "NS Pharma, Inc.|140 East Ridgewood Avenue, Suite 280S|Paramus|New Jersey|7652|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Duchenne Muscular Dystrophy",
                    "umls_id": "C0013264",
                    "parsed_text": "DUCHENNE MUSCULAR DYSTROPHY"
                }
            }
        ]
    },
    {
        "_id": "RNOAOAWBMHREKO-QFIPXVFZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135565884,
                "inchl_key": "RNOAOAWBMHREKO-QFIPXVFZSA-N",
                "generic_name": "zanubrutinib",
                "designated_date": "08/24/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "BeiGene USA, Inc.|2955 Campus Drive|Suite 200|San Mateo|California|94403|United States",
                "orphan_designation": {
                    "original_text": "Treatment of nodal marginal zone lymphoma",
                    "umls_id": "C0242647",
                    "parsed_text": "Nodal marginal zone lymphoma"
                }
            },
            {
                "compound_id": 135565884,
                "inchl_key": "RNOAOAWBMHREKO-QFIPXVFZSA-N",
                "generic_name": "Zanubrutinib",
                "designated_date": "06/29/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "BeiGene USA, Inc.|2955 Campus Drive|Suite 200|San Mateo|California|94403|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Waldenstrom's macroglobulinemia",
                    "umls_id": "C0024419",
                    "parsed_text": "Waldenstrom's Macroglobulinemia"
                }
            },
            {
                "compound_id": 135565884,
                "inchl_key": "RNOAOAWBMHREKO-QFIPXVFZSA-N",
                "generic_name": "Zanubrutinib",
                "designated_date": "07/20/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "BeiGene USA, Inc.|2955 Campus Drive|Suite 200|San Mateo|California|94403|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia.",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "compound_id": 135565884,
                "inchl_key": "RNOAOAWBMHREKO-QFIPXVFZSA-N",
                "generic_name": "zanubrutinib",
                "trade_name": "BRUKINSA",
                "designated_date": "06/23/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.",
                "marketing_approval_date": "\u00a011/14/2019\u00a0",
                "exclusivity_end_date": "\u00a011/14/2026\u00a0",
                "exclusivity_protected_indication": "Indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.",
                "sponsor": "BeiGene USA, Inc.|2955 Campus Drive|Suite 200|San Mateo|California|94403|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mantle cell lymphoma",
                    "umls_id": "C4721414",
                    "parsed_text": "Mantle cell lymphoma"
                }
            },
            {
                "compound_id": 135565884,
                "inchl_key": "RNOAOAWBMHREKO-QFIPXVFZSA-N",
                "generic_name": "zanubrutinib",
                "designated_date": "08/24/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "BeiGene USA, Inc.|2955 Campus Drive|Suite 200|San Mateo|California|94403|United States",
                "orphan_designation": {
                    "original_text": "Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue",
                    "umls_id": "C2200312",
                    "parsed_text": "marginal zone lymphoma of mucosa-associated lymphoid tissue"
                }
            },
            {
                "compound_id": 135565884,
                "inchl_key": "RNOAOAWBMHREKO-QFIPXVFZSA-N",
                "generic_name": "zanubrutinib",
                "designated_date": "08/24/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "BeiGene USA, Inc.|2955 Campus Drive|Suite 200|San Mateo|California|94403|United States",
                "orphan_designation": {
                    "original_text": "Treatment of splenic marginal zone lymphoma",
                    "umls_id": "C0349632",
                    "parsed_text": "Splenic marginal zone lymphoma"
                }
            }
        ]
    },
    {
        "_id": "QPAKKWCQMHUHNI-GQIQPHNSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 86278273,
                "inchl_key": "QPAKKWCQMHUHNI-GQIQPHNSSA-N",
                "generic_name": "chlorotoxin",
                "designated_date": "12/02/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eisai Inc.|155 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of stage IIb, IIc, III & IV melanoma",
                    "umls_id": "C0025202",
                    "parsed_text": "melanoma"
                }
            },
            {
                "compound_id": 86278273,
                "inchl_key": "QPAKKWCQMHUHNI-GQIQPHNSSA-N",
                "generic_name": "Chlorotoxin",
                "designated_date": "12/18/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eisai Inc.|155 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls_id": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            }
        ]
    },
    {
        "_id": "AMLYAMJWYAIXIA-VWNVYAMZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 176873,
                "inchl_key": "AMLYAMJWYAIXIA-VWNVYAMZSA-N",
                "generic_name": "cilengitide",
                "designated_date": "05/27/2005",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls_id": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            }
        ]
    },
    {
        "_id": "VNFPBHJOKIVQEB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2812,
                "inchl_key": "VNFPBHJOKIVQEB-UHFFFAOYSA-N",
                "generic_name": "Clotrimazole",
                "designated_date": "04/24/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Brugnara, Carlo M.D.|The Children's Hospital|300 Longwood Avenue, Bader 760|Boston|Massachusetts|2115|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sickle cell disease.",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            },
            {
                "compound_id": 2812,
                "inchl_key": "VNFPBHJOKIVQEB-UHFFFAOYSA-N",
                "generic_name": "Clotrimazole",
                "designated_date": "06/14/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AesRx, LLC|275 Grove Street|Suite 2-400|Newton|Massachusetts|2466|United States",
                "orphan_designation": {
                    "original_text": "Topical treatment of children and adults with pouchitis",
                    "umls_id": "C0376620",
                    "parsed_text": "Pouchitis"
                }
            },
            {
                "compound_id": 2812,
                "inchl_key": "VNFPBHJOKIVQEB-UHFFFAOYSA-N",
                "generic_name": "Clotrimazole",
                "designated_date": "03/13/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EnVivo Pharmaceuticals, Inc.|480 Arsenal Street|Watertown|Massachusetts|2472|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Huntington's disease",
                    "umls_id": "C0020179",
                    "parsed_text": "Huntington's Disease"
                }
            }
        ]
    },
    {
        "_id": "BSMCAPRUBJMWDF-KRWDZBQOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16222096,
                "inchl_key": "BSMCAPRUBJMWDF-KRWDZBQOSA-N",
                "generic_name": "cobimetinib",
                "designated_date": "01/31/2014",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation, in combination with vemurafenib. Limitations of Use: COTELLIC is not indicated for treatment of patients with wild-type BRAF melanoma.",
                "marketing_approval_date": "\u00a011/10/2015\u00a0",
                "exclusivity_end_date": "\u00a011/10/2022\u00a0",
                "exclusivity_protected_indication": "For the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation, in combination with vemurafenib. COTELLIC is not indicated for treatment of patients with wild-type BRAF melanoma",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 241A|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of stage IIb, IIc, III, and IV melanoma with BRAFV600 mutation",
                    "umls_id": "C0025202,C4553416",
                    "parsed_text": "melanoma , IIC"
                }
            }
        ]
    },
    {
        "_id": "RSGPTDNHQUJVBP-MDTVQASCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 129629077,
                "inchl_key": "RSGPTDNHQUJVBP-MDTVQASCSA-N",
                "generic_name": "copper histidinate",
                "designated_date": "05/14/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cyprium Therapeutics, Inc.|2 Gansevoort Street|9th Floor|New York|New York|10014|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Menkes disease",
                    "umls_id": "C0022716",
                    "parsed_text": "Menkes disease"
                }
            }
        ]
    },
    {
        "_id": "UUYDYUZBCIHUFZ-MDTVQASCSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 151722,
                "inchl_key": "UUYDYUZBCIHUFZ-MDTVQASCSA-L",
                "generic_name": "copper histidinate",
                "designated_date": "05/14/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cyprium Therapeutics, Inc.|2 Gansevoort Street|9th Floor|New York|New York|10014|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Menkes disease",
                    "umls_id": "C0022716",
                    "parsed_text": "Menkes disease"
                }
            }
        ]
    },
    {
        "_id": "ARUVKPQLZAKDPS-UHFFFAOYSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 24462,
                "inchl_key": "ARUVKPQLZAKDPS-UHFFFAOYSA-L",
                "generic_name": "copper sulfate",
                "designated_date": "10/26/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "iVeena Drug Delivery Systems, Inc.|391 Chipeta Way|Suite I|Salt Lake City|Utah|84108|United States",
                "orphan_designation": {
                    "original_text": "Treatment of keratoconus",
                    "umls_id": "C0022578",
                    "parsed_text": "Keratoconus"
                }
            }
        ]
    },
    {
        "_id": "PMATZTZNYRCHOR-SCYOXIPCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 123134263,
                "inchl_key": "PMATZTZNYRCHOR-SCYOXIPCSA-N",
                "generic_name": "Cyclosporine",
                "designated_date": "11/25/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "APT Pharmaceuticals, Inc.|700 Airport Blvd.|Suite 350|Burlingame|California|94010|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of organ rejection in patients receiving allogeneic lung transplant",
                    "umls_id": "C0815080",
                    "parsed_text": "organ rejection"
                }
            },
            {
                "compound_id": 123134263,
                "inchl_key": "PMATZTZNYRCHOR-SCYOXIPCSA-N",
                "generic_name": "cyclosporine",
                "designated_date": "02/17/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sigmoid Pharma Limited|Dublin City University|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Prophylaxis of graft-versus-host disease",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 123134263,
                "inchl_key": "PMATZTZNYRCHOR-SCYOXIPCSA-N",
                "generic_name": "cyclosporine",
                "designated_date": "02/17/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sigmoid Pharma Limited|Dublin City University|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Treatment of graft-versus-host disease",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 123134263,
                "inchl_key": "PMATZTZNYRCHOR-SCYOXIPCSA-N",
                "generic_name": "Cyclosporine",
                "designated_date": "11/25/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "APT Pharmaceuticals, Inc.|700 Airport Blvd.|Suite 350|Burlingame|California|94010|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute rejection in patients requiring allogenic lung transplants",
                    "umls_id": "C3273245",
                    "parsed_text": "Acute Rejection"
                }
            }
        ]
    },
    {
        "_id": "PMATZTZNYRCHOR-AVZWOAAISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 122172945,
                "inchl_key": "PMATZTZNYRCHOR-AVZWOAAISA-N",
                "generic_name": "Cyclosporine",
                "designated_date": "11/25/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "APT Pharmaceuticals, Inc.|700 Airport Blvd.|Suite 350|Burlingame|California|94010|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of organ rejection in patients receiving allogeneic lung transplant",
                    "umls_id": "C0815080",
                    "parsed_text": "organ rejection"
                }
            },
            {
                "compound_id": 122172945,
                "inchl_key": "PMATZTZNYRCHOR-AVZWOAAISA-N",
                "generic_name": "cyclosporine",
                "designated_date": "02/17/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sigmoid Pharma Limited|Dublin City University|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Prophylaxis of graft-versus-host disease",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 122172945,
                "inchl_key": "PMATZTZNYRCHOR-AVZWOAAISA-N",
                "generic_name": "cyclosporine",
                "designated_date": "02/17/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sigmoid Pharma Limited|Dublin City University|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Treatment of graft-versus-host disease",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 122172945,
                "inchl_key": "PMATZTZNYRCHOR-AVZWOAAISA-N",
                "generic_name": "Cyclosporine",
                "designated_date": "11/25/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "APT Pharmaceuticals, Inc.|700 Airport Blvd.|Suite 350|Burlingame|California|94010|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute rejection in patients requiring allogenic lung transplants",
                    "umls_id": "C3273245",
                    "parsed_text": "Acute Rejection"
                }
            }
        ]
    },
    {
        "_id": "PMATZTZNYRCHOR-SRFWORPQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25246316,
                "inchl_key": "PMATZTZNYRCHOR-SRFWORPQSA-N",
                "generic_name": "Cyclosporine",
                "designated_date": "11/25/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "APT Pharmaceuticals, Inc.|700 Airport Blvd.|Suite 350|Burlingame|California|94010|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of organ rejection in patients receiving allogeneic lung transplant",
                    "umls_id": "C0815080",
                    "parsed_text": "organ rejection"
                }
            },
            {
                "compound_id": 25246316,
                "inchl_key": "PMATZTZNYRCHOR-SRFWORPQSA-N",
                "generic_name": "cyclosporine",
                "designated_date": "02/17/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sigmoid Pharma Limited|Dublin City University|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Prophylaxis of graft-versus-host disease",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 25246316,
                "inchl_key": "PMATZTZNYRCHOR-SRFWORPQSA-N",
                "generic_name": "cyclosporine",
                "designated_date": "02/17/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sigmoid Pharma Limited|Dublin City University|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Treatment of graft-versus-host disease",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 25246316,
                "inchl_key": "PMATZTZNYRCHOR-SRFWORPQSA-N",
                "generic_name": "Cyclosporine",
                "designated_date": "11/25/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "APT Pharmaceuticals, Inc.|700 Airport Blvd.|Suite 350|Burlingame|California|94010|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute rejection in patients requiring allogenic lung transplants",
                    "umls_id": "C3273245",
                    "parsed_text": "Acute Rejection"
                }
            }
        ]
    },
    {
        "_id": "PMATZTZNYRCHOR-VJRYSDSKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24883466,
                "inchl_key": "PMATZTZNYRCHOR-VJRYSDSKSA-N",
                "generic_name": "Cyclosporine",
                "designated_date": "11/25/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "APT Pharmaceuticals, Inc.|700 Airport Blvd.|Suite 350|Burlingame|California|94010|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of organ rejection in patients receiving allogeneic lung transplant",
                    "umls_id": "C0815080",
                    "parsed_text": "organ rejection"
                }
            },
            {
                "compound_id": 24883466,
                "inchl_key": "PMATZTZNYRCHOR-VJRYSDSKSA-N",
                "generic_name": "cyclosporine",
                "designated_date": "02/17/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sigmoid Pharma Limited|Dublin City University|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Prophylaxis of graft-versus-host disease",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 24883466,
                "inchl_key": "PMATZTZNYRCHOR-VJRYSDSKSA-N",
                "generic_name": "Cyclosporin A",
                "designated_date": "10/29/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Maas Biolab,LLC|Tecnology Ventures Corporation Technopolis|1155 University Blvd., SE|Albuquerque|New Mexico|87106|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis and its variants",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            },
            {
                "compound_id": 24883466,
                "inchl_key": "PMATZTZNYRCHOR-VJRYSDSKSA-N",
                "generic_name": "cyclosporine",
                "designated_date": "02/17/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sigmoid Pharma Limited|Dublin City University|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Treatment of graft-versus-host disease",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 24883466,
                "inchl_key": "PMATZTZNYRCHOR-VJRYSDSKSA-N",
                "generic_name": "Cyclosporine",
                "designated_date": "11/25/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "APT Pharmaceuticals, Inc.|700 Airport Blvd.|Suite 350|Burlingame|California|94010|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute rejection in patients requiring allogenic lung transplants",
                    "umls_id": "C3273245",
                    "parsed_text": "Acute Rejection"
                }
            }
        ]
    },
    {
        "_id": "PMATZTZNYRCHOR-GNSAQUIPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 62280,
                "inchl_key": "PMATZTZNYRCHOR-GNSAQUIPSA-N",
                "generic_name": "Cyclosporine",
                "designated_date": "11/25/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "APT Pharmaceuticals, Inc.|700 Airport Blvd.|Suite 350|Burlingame|California|94010|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of organ rejection in patients receiving allogeneic lung transplant",
                    "umls_id": "C0815080",
                    "parsed_text": "organ rejection"
                }
            },
            {
                "compound_id": 62280,
                "inchl_key": "PMATZTZNYRCHOR-GNSAQUIPSA-N",
                "generic_name": "cyclosporine",
                "designated_date": "02/17/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sigmoid Pharma Limited|Dublin City University|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Prophylaxis of graft-versus-host disease",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 62280,
                "inchl_key": "PMATZTZNYRCHOR-GNSAQUIPSA-N",
                "generic_name": "cyclosporine",
                "designated_date": "02/17/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sigmoid Pharma Limited|Dublin City University|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Treatment of graft-versus-host disease",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 62280,
                "inchl_key": "PMATZTZNYRCHOR-GNSAQUIPSA-N",
                "generic_name": "Cyclosporine",
                "designated_date": "11/25/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "APT Pharmaceuticals, Inc.|700 Airport Blvd.|Suite 350|Burlingame|California|94010|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute rejection in patients requiring allogenic lung transplants",
                    "umls_id": "C3273245",
                    "parsed_text": "Acute Rejection"
                }
            }
        ]
    },
    {
        "_id": "PMATZTZNYRCHOR-KMSBSJHKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6435893,
                "inchl_key": "PMATZTZNYRCHOR-KMSBSJHKSA-N",
                "generic_name": "Cyclosporine",
                "designated_date": "11/25/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "APT Pharmaceuticals, Inc.|700 Airport Blvd.|Suite 350|Burlingame|California|94010|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of organ rejection in patients receiving allogeneic lung transplant",
                    "umls_id": "C0815080",
                    "parsed_text": "organ rejection"
                }
            },
            {
                "compound_id": 6435893,
                "inchl_key": "PMATZTZNYRCHOR-KMSBSJHKSA-N",
                "generic_name": "cyclosporine",
                "designated_date": "02/17/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sigmoid Pharma Limited|Dublin City University|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Prophylaxis of graft-versus-host disease",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 6435893,
                "inchl_key": "PMATZTZNYRCHOR-KMSBSJHKSA-N",
                "generic_name": "cyclosporine",
                "designated_date": "02/17/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sigmoid Pharma Limited|Dublin City University|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Treatment of graft-versus-host disease",
                    "umls_id": "C0018133",
                    "parsed_text": "Graft-Versus-Host Disease"
                }
            },
            {
                "compound_id": 6435893,
                "inchl_key": "PMATZTZNYRCHOR-KMSBSJHKSA-N",
                "generic_name": "Cyclosporine",
                "designated_date": "11/25/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "APT Pharmaceuticals, Inc.|700 Airport Blvd.|Suite 350|Burlingame|California|94010|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute rejection in patients requiring allogenic lung transplants",
                    "umls_id": "C3273245",
                    "parsed_text": "Acute Rejection"
                }
            }
        ]
    },
    {
        "_id": "KGPGQDLTDHGEGT-VBZOGQDBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 23724878,
                "inchl_key": "KGPGQDLTDHGEGT-VBZOGQDBSA-N",
                "generic_name": "dalbavancin",
                "designated_date": "03/30/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Durata Therapeutics International B.V.|Spaces Zuidas II, Kantoor 4.03|Amsterdam|Netherlands",
                "orphan_designation": {
                    "original_text": "Treatment of acute osteomyelitis in children (0 through 16 years of age)",
                    "umls_id": "C0158371",
                    "parsed_text": "Acute osteomyelitis"
                }
            }
        ]
    },
    {
        "_id": "KGPGQDLTDHGEGT-CUIWZYKSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 133268464,
                "inchl_key": "KGPGQDLTDHGEGT-CUIWZYKSSA-N",
                "generic_name": "dalbavancin",
                "designated_date": "03/30/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Durata Therapeutics International B.V.|Spaces Zuidas II, Kantoor 4.03|Amsterdam|Netherlands",
                "orphan_designation": {
                    "original_text": "Treatment of acute osteomyelitis in children (0 through 16 years of age)",
                    "umls_id": "C0158371",
                    "parsed_text": "Acute osteomyelitis"
                }
            }
        ]
    },
    {
        "_id": "KGPGQDLTDHGEGT-JCIKCJKQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16134410,
                "inchl_key": "KGPGQDLTDHGEGT-JCIKCJKQSA-N",
                "generic_name": "dalbavancin",
                "designated_date": "03/30/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Durata Therapeutics International B.V.|Spaces Zuidas II, Kantoor 4.03|Amsterdam|Netherlands",
                "orphan_designation": {
                    "original_text": "Treatment of acute osteomyelitis in children (0 through 16 years of age)",
                    "umls_id": "C0158371",
                    "parsed_text": "Acute osteomyelitis"
                }
            }
        ]
    },
    {
        "_id": "KGPGQDLTDHGEGT-FOPUKGCJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135659030,
                "inchl_key": "KGPGQDLTDHGEGT-FOPUKGCJSA-N",
                "generic_name": "dalbavancin",
                "designated_date": "03/30/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Durata Therapeutics International B.V.|Spaces Zuidas II, Kantoor 4.03|Amsterdam|Netherlands",
                "orphan_designation": {
                    "original_text": "Treatment of acute osteomyelitis in children (0 through 16 years of age)",
                    "umls_id": "C0158371",
                    "parsed_text": "Acute osteomyelitis"
                }
            }
        ]
    },
    {
        "_id": "KGPGQDLTDHGEGT-SZUNQUCBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16134627,
                "inchl_key": "KGPGQDLTDHGEGT-SZUNQUCBSA-N",
                "generic_name": "dalbavancin",
                "designated_date": "03/30/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Durata Therapeutics International B.V.|Spaces Zuidas II, Kantoor 4.03|Amsterdam|Netherlands",
                "orphan_designation": {
                    "original_text": "Treatment of acute osteomyelitis in children (0 through 16 years of age)",
                    "umls_id": "C0158371",
                    "parsed_text": "Acute osteomyelitis"
                }
            }
        ]
    },
    {
        "_id": "MQJKPEGWNLWLTK-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2955,
                "inchl_key": "MQJKPEGWNLWLTK-UHFFFAOYSA-N",
                "generic_name": "Dapsone",
                "designated_date": "11/07/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Jacobus Pharmaceutical Company, Inc.|37 Cleveland Lane|P.O. Box 5290|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of toxoplasmosis in severely immunocompromised patients with CD4 counts below 100.",
                    "umls_id": "C0040558",
                    "parsed_text": "Toxoplasmosis"
                }
            }
        ]
    },
    {
        "_id": "DPFYBZWSVVKNPZ-SYWJPMBBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 92043573,
                "inchl_key": "DPFYBZWSVVKNPZ-SYWJPMBBSA-N",
                "generic_name": "dextran 1",
                "designated_date": "03/21/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "BCY LifeSciences Inc.|160 Eglinton Ave. East|Suite 600|Toronto|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "LRCZQSDQZJBHAF-PUBGEWHCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6918473,
                "inchl_key": "LRCZQSDQZJBHAF-PUBGEWHCSA-N",
                "generic_name": "DHA-paclitaxel",
                "designated_date": "09/25/2001",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Luitpold Pharmaceuticals, Inc.|One Luitpold Drive|Shirley|New York|11976|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 6918473,
                "inchl_key": "LRCZQSDQZJBHAF-PUBGEWHCSA-N",
                "generic_name": "DHA-paclitaxel",
                "designated_date": "05/01/2003",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Luitpold Pharmaceuticals, Inc.|1000 Madison Ave|Norristown|Pennsylvania|19403|United States",
                "orphan_designation": {
                    "original_text": "Treatment of adenocarcinoma of the stomach or lower esophagus",
                    "umls_id": "C0278701",
                    "parsed_text": "adenocarcinoma of the stomach"
                }
            },
            {
                "compound_id": 6918473,
                "inchl_key": "LRCZQSDQZJBHAF-PUBGEWHCSA-N",
                "generic_name": "DHA-paclitaxel",
                "designated_date": "10/10/2002",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Luitpold Pharmaceuticals, Inc.|1000 Madison Ave|Norristown|Pennsylvania|19403|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic malignant melanoma",
                    "umls_id": "C0860594",
                    "parsed_text": "Metastatic malignant melanoma"
                }
            }
        ]
    },
    {
        "_id": "AAOVKJBEBIDNHE-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3016,
                "inchl_key": "AAOVKJBEBIDNHE-UHFFFAOYSA-N",
                "generic_name": "diazepam",
                "designated_date": "05/23/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Xeris Pharmaceutical, Inc.|180 North LaSalle Street|Suite 1800|Chicago|Illinois|60601|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Dravet syndrome",
                    "umls_id": "C0751122",
                    "parsed_text": "Dravet Syndrome"
                }
            }
        ]
    },
    {
        "_id": "YLLWQNAEYILHLV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25014811,
                "inchl_key": "YLLWQNAEYILHLV-UHFFFAOYSA-N",
                "generic_name": "diazoxide choline",
                "designated_date": "05/13/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Soleno Therapeutics, Inc.|1235 Radio Road|Suite 110|Redwood City|California|94065|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Prader-Willi Syndrome",
                    "umls_id": "C0032897",
                    "parsed_text": "Prader-Willi Syndrome"
                }
            }
        ]
    },
    {
        "_id": "JNODQFNWMXFMEV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 197033,
                "inchl_key": "JNODQFNWMXFMEV-UHFFFAOYSA-N",
                "generic_name": "dimebon",
                "designated_date": "05/12/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medivation, Inc.|201 Spear Street|San Francisco|California|94105|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Huntington's Disease.",
                    "umls_id": "C0020179",
                    "parsed_text": "Huntington's Disease"
                }
            }
        ]
    },
    {
        "_id": "SJVQHLPISAIATJ-ZDUSSCGKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 50905713,
                "inchl_key": "SJVQHLPISAIATJ-ZDUSSCGKSA-N",
                "generic_name": "duvelisib",
                "designated_date": "10/02/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Verastem, Inc.|117 Kendrick Street|Suite 500|Needham|Massachusetts|2494|United States",
                "orphan_designation": {
                    "original_text": "Treatment of T-Cell Lymphoma",
                    "umls_id": "C0079772",
                    "parsed_text": "T-Cell Lymphoma"
                }
            },
            {
                "compound_id": 50905713,
                "inchl_key": "SJVQHLPISAIATJ-ZDUSSCGKSA-N",
                "generic_name": "duvelisib",
                "trade_name": "COPIKTRA",
                "designated_date": "04/15/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies",
                "marketing_approval_date": "\u00a009/24/2018\u00a0",
                "exclusivity_end_date": "\u00a009/24/2025\u00a0",
                "exclusivity_protected_indication": "Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies",
                "sponsor": "Verastem, Inc.|117 Kendrick Street|Suite 500|Needham|Massachusetts|2494|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma",
                    "umls_id": "C0023434,C0855095",
                    "parsed_text": "Chronic Lymphocytic Leukemia , Small Lymphocytic Lymphoma"
                }
            },
            {
                "compound_id": 50905713,
                "inchl_key": "SJVQHLPISAIATJ-ZDUSSCGKSA-N",
                "generic_name": "duvelisib",
                "trade_name": "COPIKTRA",
                "designated_date": "08/01/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior therapies",
                "marketing_approval_date": "\u00a009/24/2018\u00a0",
                "exclusivity_end_date": "\u00a009/24/2025\u00a0",
                "exclusivity_protected_indication": "Treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior therapies",
                "sponsor": "Verastem, Inc.|117 Kendrick Street|Suite 500|Needham|Massachusetts|2494|United States",
                "orphan_designation": {
                    "original_text": "Treatment of follicular lymphoma",
                    "umls_id": "C0024301",
                    "parsed_text": "follicular lymphoma"
                }
            }
        ]
    },
    {
        "_id": "AOJJSUZBOXZQNB-VTZDEGQISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 41867,
                "inchl_key": "AOJJSUZBOXZQNB-VTZDEGQISA-N",
                "generic_name": "Epirubicin",
                "trade_name": "Ellence",
                "designated_date": "09/14/1999",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.",
                "marketing_approval_date": "\u00a009/15/1999\u00a0",
                "exclusivity_end_date": "\u00a009/15/2006\u00a0",
                "sponsor": "Pharmacia & Upjohn Company|0634-298-113|7000 Portage Rd.|Kalamazoo|Michigan|49001|United States",
                "orphan_designation": {
                    "original_text": "Treatment of breast cancer.",
                    "umls_id": "C0678222",
                    "parsed_text": "Breast cancer"
                }
            }
        ]
    },
    {
        "_id": "HGHOBRRUMWJWCU-FXQIFTODSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 219042,
                "inchl_key": "HGHOBRRUMWJWCU-FXQIFTODSA-N",
                "generic_name": "Epitalon",
                "designated_date": "09/02/2010",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "BioDiem Ltd|Level 10, South Tower|Victoria 3000|Melbourne|Australia",
                "orphan_designation": {
                    "original_text": "Treatment of retinitis pigmentosa",
                    "umls_id": "C0035334",
                    "parsed_text": "Retinitis Pigmentosa"
                }
            }
        ]
    },
    {
        "_id": "QAMYWGZHLCQOOJ-XXLUYSOPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 122362420,
                "inchl_key": "QAMYWGZHLCQOOJ-XXLUYSOPSA-N",
                "generic_name": "eribulin mesylate",
                "trade_name": "Halaven",
                "designated_date": "05/14/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen",
                "marketing_approval_date": "\u00a001/28/2016\u00a0",
                "exclusivity_end_date": "\u00a001/28/2023\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen",
                "sponsor": "Eisai Inc.|155 Tice Blvd|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcoma",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            }
        ]
    },
    {
        "_id": "QAMYWGZHLCQOOJ-ONAKUIRGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 117590636,
                "inchl_key": "QAMYWGZHLCQOOJ-ONAKUIRGSA-N",
                "generic_name": "eribulin mesylate",
                "trade_name": "Halaven",
                "designated_date": "05/14/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen",
                "marketing_approval_date": "\u00a001/28/2016\u00a0",
                "exclusivity_end_date": "\u00a001/28/2023\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen",
                "sponsor": "Eisai Inc.|155 Tice Blvd|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcoma",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            }
        ]
    },
    {
        "_id": "QAMYWGZHLCQOOJ-SLSRVFANSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 146158903,
                "inchl_key": "QAMYWGZHLCQOOJ-SLSRVFANSA-N",
                "generic_name": "eribulin mesylate",
                "trade_name": "Halaven",
                "designated_date": "05/14/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen",
                "marketing_approval_date": "\u00a001/28/2016\u00a0",
                "exclusivity_end_date": "\u00a001/28/2023\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen",
                "sponsor": "Eisai Inc.|155 Tice Blvd|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcoma",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            }
        ]
    },
    {
        "_id": "QAMYWGZHLCQOOJ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 22525136,
                "inchl_key": "QAMYWGZHLCQOOJ-UHFFFAOYSA-N",
                "generic_name": "eribulin mesylate",
                "trade_name": "Halaven",
                "designated_date": "05/14/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen",
                "marketing_approval_date": "\u00a001/28/2016\u00a0",
                "exclusivity_end_date": "\u00a001/28/2023\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen",
                "sponsor": "Eisai Inc.|155 Tice Blvd|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcoma",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            }
        ]
    },
    {
        "_id": "QAMYWGZHLCQOOJ-IJJXRQIPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 74891361,
                "inchl_key": "QAMYWGZHLCQOOJ-IJJXRQIPSA-N",
                "generic_name": "eribulin mesylate",
                "trade_name": "Halaven",
                "designated_date": "05/14/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen",
                "marketing_approval_date": "\u00a001/28/2016\u00a0",
                "exclusivity_end_date": "\u00a001/28/2023\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen",
                "sponsor": "Eisai Inc.|155 Tice Blvd|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcoma",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            }
        ]
    },
    {
        "_id": "QAMYWGZHLCQOOJ-WRNBYXCMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 17755248,
                "inchl_key": "QAMYWGZHLCQOOJ-WRNBYXCMSA-N",
                "generic_name": "eribulin mesylate",
                "trade_name": "Halaven",
                "designated_date": "05/14/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen",
                "marketing_approval_date": "\u00a001/28/2016\u00a0",
                "exclusivity_end_date": "\u00a001/28/2023\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen",
                "sponsor": "Eisai Inc.|155 Tice Blvd|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcoma",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            }
        ]
    },
    {
        "_id": "SUBDBMMJDZJVOS-XMMPIXPASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9579578,
                "inchl_key": "SUBDBMMJDZJVOS-XMMPIXPASA-N",
                "generic_name": "esomeprazole",
                "designated_date": "05/15/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Adare Pharmaceuticals US, L.P.|Princeton Pike Corporate Center|1200 Lenox Drive, Suite 100|Lawrenceville|New Jersey|8648|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Eosinophilic Esophagitis",
                    "umls_id": "C0341106",
                    "parsed_text": "Eosinophilic esophagitis"
                }
            }
        ]
    },
    {
        "_id": "SUBDBMMJDZJVOS-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4594,
                "inchl_key": "SUBDBMMJDZJVOS-UHFFFAOYSA-N",
                "generic_name": "esomeprazole",
                "designated_date": "05/15/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Adare Pharmaceuticals US, L.P.|Princeton Pike Corporate Center|1200 Lenox Drive, Suite 100|Lawrenceville|New Jersey|8648|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Eosinophilic Esophagitis",
                    "umls_id": "C0341106",
                    "parsed_text": "Eosinophilic esophagitis"
                }
            }
        ]
    },
    {
        "_id": "SUBDBMMJDZJVOS-DEOSSOPVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9568614,
                "inchl_key": "SUBDBMMJDZJVOS-DEOSSOPVSA-N",
                "generic_name": "esomeprazole",
                "designated_date": "05/15/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Adare Pharmaceuticals US, L.P.|Princeton Pike Corporate Center|1200 Lenox Drive, Suite 100|Lawrenceville|New Jersey|8648|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Eosinophilic Esophagitis",
                    "umls_id": "C0341106",
                    "parsed_text": "Eosinophilic esophagitis"
                }
            }
        ]
    },
    {
        "_id": "BFYIZQONLCFLEV-DAELLWKTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 60198,
                "inchl_key": "BFYIZQONLCFLEV-DAELLWKTSA-N",
                "generic_name": "Exemestane",
                "trade_name": "Aromasin",
                "designated_date": "09/19/1991",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.",
                "marketing_approval_date": "\u00a010/21/1999\u00a0",
                "exclusivity_end_date": "\u00a010/21/2006\u00a0",
                "sponsor": "Pharmacia & Upjohn|7000 Portage Road|Mail Stop: 0636-298-113|Kalamazoo|Michigan|49001|United States",
                "orphan_designation": {
                    "original_text": "Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.",
                    "umls_id": "C0012634,C0678222",
                    "parsed_text": "Disease , Breast cancer"
                }
            }
        ]
    },
    {
        "_id": "JOOXLOJCABQBSG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16722836,
                "inchl_key": "JOOXLOJCABQBSG-UHFFFAOYSA-N",
                "generic_name": "Fedratinib",
                "designated_date": "03/21/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Impact Biomedicines|12526 High Bluff Drive|Suite 260|San Diego|California|92130|United States",
                "orphan_designation": {
                    "original_text": "Treatment of polycythemia vera",
                    "umls_id": "C0032463",
                    "parsed_text": "Polycythemia Vera"
                }
            },
            {
                "compound_id": 16722836,
                "inchl_key": "JOOXLOJCABQBSG-UHFFFAOYSA-N",
                "generic_name": "Fedratinib",
                "trade_name": "INREBIC",
                "designated_date": "05/18/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "INREBIC is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).",
                "marketing_approval_date": "\u00a008/16/2019\u00a0",
                "exclusivity_end_date": "\u00a008/16/2026\u00a0",
                "exclusivity_protected_indication": "For the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).",
                "sponsor": "Impact Biomedicines, Inc. a wholly-owned subsidiary of Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States",
                "orphan_designation": {
                    "original_text": "Treatment of secondary and primary myelofibrosis",
                    "umls_id": "C0001815",
                    "parsed_text": "Primary Myelofibrosis"
                }
            }
        ]
    },
    {
        "_id": "IPVFGAYTKQKGBM-BYPJNBLXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 50313,
                "inchl_key": "IPVFGAYTKQKGBM-BYPJNBLXSA-N",
                "generic_name": "fialuridine",
                "designated_date": "07/24/1992",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oclassen Pharmaceuticals, Inc.|100 Pelican Way|San Rafael|California|94901|United States",
                "orphan_designation": {
                    "original_text": "Adjunctive treatment of chronic active hepatitis B.",
                    "umls_id": "C0744831",
                    "parsed_text": "Chronic active hepatitis B"
                }
            }
        ]
    },
    {
        "_id": "DVASNQYQOZHAJN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 41870,
                "inchl_key": "DVASNQYQOZHAJN-UHFFFAOYSA-N",
                "generic_name": "Flumecinol",
                "designated_date": "01/15/1985",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Farmacon, Inc.|Post House, Suite 213|1720 Post Road East|Westport|Connecticut|6880|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hyperbilirubinemia in newborn infants unresponsive to phototherapy.",
                    "umls_id": "C0020433",
                    "parsed_text": "Hyperbilirubinemia"
                }
            }
        ]
    },
    {
        "_id": "RTHCYVBBDHJXIQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3386,
                "inchl_key": "RTHCYVBBDHJXIQ-UHFFFAOYSA-N",
                "generic_name": "Fluoxetine",
                "designated_date": "04/30/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neuropharm, Ltd.|Felcham Park House|Surrey|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of autism.",
                    "umls_id": "C0004352",
                    "parsed_text": "Autism"
                }
            },
            {
                "compound_id": 3386,
                "inchl_key": "RTHCYVBBDHJXIQ-UHFFFAOYSA-N",
                "generic_name": "Fluoxetine",
                "designated_date": "04/14/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hollander, Eric MD|The Mount Sinai School of Medicine|One Gustave L. Levy Place|New York|New York|10029|United States",
                "orphan_designation": {
                    "original_text": "Treatment of body dysmorphic disorder in children and adolescents",
                    "umls_id": "C0005887",
                    "parsed_text": "Body dysmorphic disorder"
                }
            }
        ]
    },
    {
        "_id": "CZAKJJUNKNPTTO-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135894389,
                "inchl_key": "CZAKJJUNKNPTTO-UHFFFAOYSA-N",
                "generic_name": "fosdenopterin",
                "trade_name": "Nulibry",
                "designated_date": "11/05/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A",
                "marketing_approval_date": "\u00a002/26/2021\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Origin Biosciences, Inc.|75 Park Plaza|Boston|Massachusetts|2116|United States",
                "orphan_designation": {
                    "original_text": "Treatment of molybdenum cofactor deficiency type A (MoCD)",
                    "umls_id": "C0268119",
                    "parsed_text": "Molybdenum cofactor deficiency"
                }
            }
        ]
    },
    {
        "_id": "CZAKJJUNKNPTTO-AJFJRRQVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135463437,
                "inchl_key": "CZAKJJUNKNPTTO-AJFJRRQVSA-N",
                "generic_name": "fosdenopterin",
                "trade_name": "Nulibry",
                "designated_date": "11/05/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A",
                "marketing_approval_date": "\u00a002/26/2021\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Origin Biosciences, Inc.|75 Park Plaza|Boston|Massachusetts|2116|United States",
                "orphan_designation": {
                    "original_text": "Treatment of molybdenum cofactor deficiency type A (MoCD)",
                    "umls_id": "C0268119",
                    "parsed_text": "Molybdenum cofactor deficiency"
                }
            }
        ]
    },
    {
        "_id": "PZBPHYLKIMOZPR-ZWIFOJARSA-K",
        "Orphan Drug Designations": [
            {
                "compound_id": 145994621,
                "inchl_key": "PZBPHYLKIMOZPR-ZWIFOJARSA-K",
                "generic_name": "Gallium (68Ga) edotreotide",
                "designated_date": "07/01/2015",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Advanced Accelerator Applications, USA|57 East Willow Street|Millburn|New Jersey|7041|United States",
                "orphan_designation": {
                    "original_text": "Diagnostic for the clinical management of neuroendocrine tumors.",
                    "umls_id": "C0206754",
                    "parsed_text": "Neuroendocrine Tumors"
                }
            }
        ]
    },
    {
        "_id": "PZBPHYLKIMOZPR-FIYGWYQWSA-K",
        "Orphan Drug Designations": [
            {
                "compound_id": 71661158,
                "inchl_key": "PZBPHYLKIMOZPR-FIYGWYQWSA-K",
                "generic_name": "Gallium (68Ga) edotreotide",
                "designated_date": "07/01/2015",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Advanced Accelerator Applications, USA|57 East Willow Street|Millburn|New Jersey|7041|United States",
                "orphan_designation": {
                    "original_text": "Diagnostic for the clinical management of neuroendocrine tumors.",
                    "umls_id": "C0206754",
                    "parsed_text": "Neuroendocrine Tumors"
                }
            }
        ]
    },
    {
        "_id": "BRZYSWJRSDMWLG-JRRILZOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134688573,
                "inchl_key": "BRZYSWJRSDMWLG-JRRILZOYSA-N",
                "generic_name": "Geneticin",
                "designated_date": "06/06/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ProcesScience, Inc. (PSI)|117 Woodberry Lane|Fayetteville|New York|13066|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amoebiasis.",
                    "umls_id": "C0013370",
                    "parsed_text": "amoebiasis"
                }
            }
        ]
    },
    {
        "_id": "BRZYSWJRSDMWLG-OBOPTQIOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71684684,
                "inchl_key": "BRZYSWJRSDMWLG-OBOPTQIOSA-N",
                "generic_name": "Geneticin",
                "designated_date": "06/06/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ProcesScience, Inc. (PSI)|117 Woodberry Lane|Fayetteville|New York|13066|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amoebiasis.",
                    "umls_id": "C0013370",
                    "parsed_text": "amoebiasis"
                }
            }
        ]
    },
    {
        "_id": "BRZYSWJRSDMWLG-VVNRJQPTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 137967135,
                "inchl_key": "BRZYSWJRSDMWLG-VVNRJQPTSA-N",
                "generic_name": "Geneticin",
                "designated_date": "06/06/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ProcesScience, Inc. (PSI)|117 Woodberry Lane|Fayetteville|New York|13066|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amoebiasis.",
                    "umls_id": "C0013370",
                    "parsed_text": "amoebiasis"
                }
            }
        ]
    },
    {
        "_id": "BRZYSWJRSDMWLG-WFDQBLTDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6710770,
                "inchl_key": "BRZYSWJRSDMWLG-WFDQBLTDSA-N",
                "generic_name": "Geneticin",
                "designated_date": "06/06/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ProcesScience, Inc. (PSI)|117 Woodberry Lane|Fayetteville|New York|13066|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amoebiasis.",
                    "umls_id": "C0013370",
                    "parsed_text": "amoebiasis"
                }
            }
        ]
    },
    {
        "_id": "BRZYSWJRSDMWLG-NQRKCNNJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71308205,
                "inchl_key": "BRZYSWJRSDMWLG-NQRKCNNJSA-N",
                "generic_name": "Geneticin",
                "designated_date": "06/06/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ProcesScience, Inc. (PSI)|117 Woodberry Lane|Fayetteville|New York|13066|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amoebiasis.",
                    "umls_id": "C0013370",
                    "parsed_text": "amoebiasis"
                }
            }
        ]
    },
    {
        "_id": "BRZYSWJRSDMWLG-CAXSIQPQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2733531,
                "inchl_key": "BRZYSWJRSDMWLG-CAXSIQPQSA-N",
                "generic_name": "Geneticin",
                "designated_date": "06/06/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ProcesScience, Inc. (PSI)|117 Woodberry Lane|Fayetteville|New York|13066|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amoebiasis.",
                    "umls_id": "C0013370",
                    "parsed_text": "amoebiasis"
                }
            }
        ]
    },
    {
        "_id": "BRZYSWJRSDMWLG-KVXRWBJUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 447379,
                "inchl_key": "BRZYSWJRSDMWLG-KVXRWBJUSA-N",
                "generic_name": "Geneticin",
                "designated_date": "06/06/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ProcesScience, Inc. (PSI)|117 Woodberry Lane|Fayetteville|New York|13066|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amoebiasis.",
                    "umls_id": "C0013370",
                    "parsed_text": "amoebiasis"
                }
            }
        ]
    },
    {
        "_id": "BRZYSWJRSDMWLG-DJWUNRQOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 123865,
                "inchl_key": "BRZYSWJRSDMWLG-DJWUNRQOSA-N",
                "generic_name": "Geneticin",
                "designated_date": "06/06/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ProcesScience, Inc. (PSI)|117 Woodberry Lane|Fayetteville|New York|13066|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amoebiasis.",
                    "umls_id": "C0013370",
                    "parsed_text": "amoebiasis"
                }
            }
        ]
    },
    {
        "_id": "LZQXMCNBQHANEY-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 21195079,
                "inchl_key": "LZQXMCNBQHANEY-UHFFFAOYSA-N",
                "generic_name": "glucarpidase",
                "trade_name": "Voraxaze",
                "designated_date": "08/19/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of toxic (>1 micromole/liter) plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function.",
                "marketing_approval_date": "\u00a001/17/2012\u00a0",
                "exclusivity_end_date": "\u00a001/17/2019\u00a0",
                "sponsor": "BTG International Inc.|5214 Maryland Way|Suite 405|Brentwood|Tennessee|37027|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients at risk of methotrexate toxicity",
                    "umls_id": "C0568062",
                    "parsed_text": "Methotrexate Toxicity"
                }
            }
        ]
    },
    {
        "_id": "HLNZYALGGXMQQC-WFDKWETCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 138319140,
                "inchl_key": "HLNZYALGGXMQQC-WFDKWETCSA-N",
                "generic_name": "granaticin B",
                "designated_date": "03/07/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Belite Bio, LLC|3210 Merryfield Row|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Acute Lymphoblastic Leukemia (ALL)",
                    "umls_id": "C0023449,C3542401",
                    "parsed_text": "Acute lymphoblastic leukemia , Acute Lymphoblastic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "HLNZYALGGXMQQC-TVASSOHNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 136015147,
                "inchl_key": "HLNZYALGGXMQQC-TVASSOHNSA-N",
                "generic_name": "granaticin B",
                "designated_date": "03/07/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Belite Bio, LLC|3210 Merryfield Row|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Acute Lymphoblastic Leukemia (ALL)",
                    "umls_id": "C0023449,C3542401",
                    "parsed_text": "Acute lymphoblastic leukemia , Acute Lymphoblastic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "HLNZYALGGXMQQC-VHAJSWNUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 136018428,
                "inchl_key": "HLNZYALGGXMQQC-VHAJSWNUSA-N",
                "generic_name": "granaticin B",
                "designated_date": "03/07/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Belite Bio, LLC|3210 Merryfield Row|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Acute Lymphoblastic Leukemia (ALL)",
                    "umls_id": "C0023449,C3542401",
                    "parsed_text": "Acute lymphoblastic leukemia , Acute Lymphoblastic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "INJOMKTZOLKMBF-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3519,
                "inchl_key": "INJOMKTZOLKMBF-UHFFFAOYSA-N",
                "generic_name": "guanfacine",
                "designated_date": "08/05/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Watson Laboratories, Inc.|311 Bonnie Circle|P.O. Box 1900|Corona|California|91718|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fragile X syndrome.",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "JRTRSJGZMRQDHI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 92044406,
                "inchl_key": "JRTRSJGZMRQDHI-UHFFFAOYSA-N",
                "generic_name": "Heparin sodium",
                "designated_date": "06/29/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ockham Biotech Limited|Manor Farm|Swanwick|Hampshire|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            },
            {
                "compound_id": 92044406,
                "inchl_key": "JRTRSJGZMRQDHI-UHFFFAOYSA-N",
                "generic_name": "heparin sodium",
                "designated_date": "07/29/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Vectura Limited|One Prospect West|Chippenham|Wiltshire|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of Cystic Fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "WZHKXNSOCOQYQX-XFUHGIIQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44368295,
                "inchl_key": "WZHKXNSOCOQYQX-XFUHGIIQSA-N",
                "generic_name": "His-D-Trp-Ala-Trp-D-Phe-Lys NH2",
                "designated_date": "05/23/1990",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SmithKline Beecham Pharmaceuticals|One Franklin Plaza|Philadelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "For the long term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.",
                    "umls_id": "C0015544",
                    "parsed_text": "growth failure"
                }
            }
        ]
    },
    {
        "_id": "IHHXIUAEPKVVII-PTKYJSHISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9819903,
                "inchl_key": "IHHXIUAEPKVVII-PTKYJSHISA-N",
                "generic_name": "Ibuprofen lysine",
                "trade_name": "NeoProfen",
                "designated_date": "10/29/1996",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For closure of a clinically significant patent ductus arteriosus in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective",
                "marketing_approval_date": "\u00a004/13/2006\u00a0",
                "exclusivity_end_date": "\u00a004/13/2013\u00a0",
                "sponsor": "Lundbeck, Inc.|Four Parkway North|Deerfield|Illinois|60015|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patent ductus arteriosus",
                    "umls_id": "C0013274",
                    "parsed_text": "Patent ductus arteriosus"
                }
            }
        ]
    },
    {
        "_id": "IHHXIUAEPKVVII-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9863332,
                "inchl_key": "IHHXIUAEPKVVII-UHFFFAOYSA-N",
                "generic_name": "Ibuprofen lysine",
                "trade_name": "NeoProfen",
                "designated_date": "10/29/1996",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For closure of a clinically significant patent ductus arteriosus in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective",
                "marketing_approval_date": "\u00a004/13/2006\u00a0",
                "exclusivity_end_date": "\u00a004/13/2013\u00a0",
                "sponsor": "Lundbeck, Inc.|Four Parkway North|Deerfield|Illinois|60015|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patent ductus arteriosus",
                    "umls_id": "C0013274",
                    "parsed_text": "Patent ductus arteriosus"
                }
            }
        ]
    },
    {
        "_id": "IHHXIUAEPKVVII-ZSCHJXSPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9841440,
                "inchl_key": "IHHXIUAEPKVVII-ZSCHJXSPSA-N",
                "generic_name": "Ibuprofen lysine",
                "trade_name": "NeoProfen",
                "designated_date": "10/29/1996",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For closure of a clinically significant patent ductus arteriosus in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective",
                "marketing_approval_date": "\u00a004/13/2006\u00a0",
                "exclusivity_end_date": "\u00a004/13/2013\u00a0",
                "sponsor": "Lundbeck, Inc.|Four Parkway North|Deerfield|Illinois|60015|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patent ductus arteriosus",
                    "umls_id": "C0013274",
                    "parsed_text": "Patent ductus arteriosus"
                }
            }
        ]
    },
    {
        "_id": "HIFJCPQKFCZDDL-PNQLYJIOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134694981,
                "inchl_key": "HIFJCPQKFCZDDL-PNQLYJIOSA-N",
                "generic_name": "iloprost",
                "designated_date": "05/09/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eicos Sciences, Inc., a CiVi Biopharma, Inc. affiliated company|200 Four Falls Corporate Center|Suite 107|West Conshohocken|Pennsylvania|19528|United States",
                "orphan_designation": {
                    "original_text": "Treatment of systemic sclerosis",
                    "umls_id": "C0036421",
                    "parsed_text": "Systemic sclerosis"
                }
            },
            {
                "compound_id": 134694981,
                "inchl_key": "HIFJCPQKFCZDDL-PNQLYJIOSA-N",
                "generic_name": "iloprost",
                "designated_date": "04/06/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Algorithum Sciences, LLC|World Trade Center Delaware|702 West Street|Wilmington|Delaware|19801|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "HIFJCPQKFCZDDL-JYTNZNGZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 91746214,
                "inchl_key": "HIFJCPQKFCZDDL-JYTNZNGZSA-N",
                "generic_name": "iloprost",
                "designated_date": "05/09/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eicos Sciences, Inc., a CiVi Biopharma, Inc. affiliated company|200 Four Falls Corporate Center|Suite 107|West Conshohocken|Pennsylvania|19528|United States",
                "orphan_designation": {
                    "original_text": "Treatment of systemic sclerosis",
                    "umls_id": "C0036421",
                    "parsed_text": "Systemic sclerosis"
                }
            },
            {
                "compound_id": 91746214,
                "inchl_key": "HIFJCPQKFCZDDL-JYTNZNGZSA-N",
                "generic_name": "iloprost",
                "designated_date": "04/06/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Algorithum Sciences, LLC|World Trade Center Delaware|702 West Street|Wilmington|Delaware|19801|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "HIFJCPQKFCZDDL-QSGBCQANSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 20838499,
                "inchl_key": "HIFJCPQKFCZDDL-QSGBCQANSA-N",
                "generic_name": "iloprost",
                "designated_date": "05/09/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eicos Sciences, Inc., a CiVi Biopharma, Inc. affiliated company|200 Four Falls Corporate Center|Suite 107|West Conshohocken|Pennsylvania|19528|United States",
                "orphan_designation": {
                    "original_text": "Treatment of systemic sclerosis",
                    "umls_id": "C0036421",
                    "parsed_text": "Systemic sclerosis"
                }
            },
            {
                "compound_id": 20838499,
                "inchl_key": "HIFJCPQKFCZDDL-QSGBCQANSA-N",
                "generic_name": "iloprost",
                "designated_date": "04/06/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Algorithum Sciences, LLC|World Trade Center Delaware|702 West Street|Wilmington|Delaware|19801|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "HIFJCPQKFCZDDL-GBSCXWAGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 51397006,
                "inchl_key": "HIFJCPQKFCZDDL-GBSCXWAGSA-N",
                "generic_name": "iloprost",
                "designated_date": "05/09/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eicos Sciences, Inc., a CiVi Biopharma, Inc. affiliated company|200 Four Falls Corporate Center|Suite 107|West Conshohocken|Pennsylvania|19528|United States",
                "orphan_designation": {
                    "original_text": "Treatment of systemic sclerosis",
                    "umls_id": "C0036421",
                    "parsed_text": "Systemic sclerosis"
                }
            },
            {
                "compound_id": 51397006,
                "inchl_key": "HIFJCPQKFCZDDL-GBSCXWAGSA-N",
                "generic_name": "iloprost",
                "designated_date": "04/06/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Algorithum Sciences, LLC|World Trade Center Delaware|702 West Street|Wilmington|Delaware|19801|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "HIFJCPQKFCZDDL-NYBPDPFASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 54313,
                "inchl_key": "HIFJCPQKFCZDDL-NYBPDPFASA-N",
                "generic_name": "iloprost",
                "designated_date": "05/09/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eicos Sciences, Inc., a CiVi Biopharma, Inc. affiliated company|200 Four Falls Corporate Center|Suite 107|West Conshohocken|Pennsylvania|19528|United States",
                "orphan_designation": {
                    "original_text": "Treatment of systemic sclerosis",
                    "umls_id": "C0036421",
                    "parsed_text": "Systemic sclerosis"
                }
            },
            {
                "compound_id": 54313,
                "inchl_key": "HIFJCPQKFCZDDL-NYBPDPFASA-N",
                "generic_name": "iloprost",
                "designated_date": "04/06/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Algorithum Sciences, LLC|World Trade Center Delaware|702 West Street|Wilmington|Delaware|19801|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "HIFJCPQKFCZDDL-QYUAYYPJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 89077401,
                "inchl_key": "HIFJCPQKFCZDDL-QYUAYYPJSA-N",
                "generic_name": "iloprost",
                "designated_date": "05/09/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eicos Sciences, Inc., a CiVi Biopharma, Inc. affiliated company|200 Four Falls Corporate Center|Suite 107|West Conshohocken|Pennsylvania|19528|United States",
                "orphan_designation": {
                    "original_text": "Treatment of systemic sclerosis",
                    "umls_id": "C0036421",
                    "parsed_text": "Systemic sclerosis"
                }
            },
            {
                "compound_id": 89077401,
                "inchl_key": "HIFJCPQKFCZDDL-QYUAYYPJSA-N",
                "generic_name": "iloprost",
                "designated_date": "04/06/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Algorithum Sciences, LLC|World Trade Center Delaware|702 West Street|Wilmington|Delaware|19801|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "HIFJCPQKFCZDDL-CSAIKYROSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 53486260,
                "inchl_key": "HIFJCPQKFCZDDL-CSAIKYROSA-N",
                "generic_name": "iloprost",
                "designated_date": "05/09/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eicos Sciences, Inc., a CiVi Biopharma, Inc. affiliated company|200 Four Falls Corporate Center|Suite 107|West Conshohocken|Pennsylvania|19528|United States",
                "orphan_designation": {
                    "original_text": "Treatment of systemic sclerosis",
                    "umls_id": "C0036421",
                    "parsed_text": "Systemic sclerosis"
                }
            },
            {
                "compound_id": 53486260,
                "inchl_key": "HIFJCPQKFCZDDL-CSAIKYROSA-N",
                "generic_name": "iloprost",
                "designated_date": "04/06/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Algorithum Sciences, LLC|World Trade Center Delaware|702 West Street|Wilmington|Delaware|19801|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "HIFJCPQKFCZDDL-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 53394043,
                "inchl_key": "HIFJCPQKFCZDDL-UHFFFAOYSA-N",
                "generic_name": "iloprost",
                "designated_date": "05/09/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eicos Sciences, Inc., a CiVi Biopharma, Inc. affiliated company|200 Four Falls Corporate Center|Suite 107|West Conshohocken|Pennsylvania|19528|United States",
                "orphan_designation": {
                    "original_text": "Treatment of systemic sclerosis",
                    "umls_id": "C0036421",
                    "parsed_text": "Systemic sclerosis"
                }
            },
            {
                "compound_id": 53394043,
                "inchl_key": "HIFJCPQKFCZDDL-UHFFFAOYSA-N",
                "generic_name": "iloprost",
                "designated_date": "04/06/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Algorithum Sciences, LLC|World Trade Center Delaware|702 West Street|Wilmington|Delaware|19801|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "HIFJCPQKFCZDDL-SGSAMSKHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6435378,
                "inchl_key": "HIFJCPQKFCZDDL-SGSAMSKHSA-N",
                "generic_name": "iloprost",
                "designated_date": "05/09/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eicos Sciences, Inc., a CiVi Biopharma, Inc. affiliated company|200 Four Falls Corporate Center|Suite 107|West Conshohocken|Pennsylvania|19528|United States",
                "orphan_designation": {
                    "original_text": "Treatment of systemic sclerosis",
                    "umls_id": "C0036421",
                    "parsed_text": "Systemic sclerosis"
                }
            },
            {
                "compound_id": 6435378,
                "inchl_key": "HIFJCPQKFCZDDL-SGSAMSKHSA-N",
                "generic_name": "iloprost",
                "designated_date": "04/06/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Algorithum Sciences, LLC|World Trade Center Delaware|702 West Street|Wilmington|Delaware|19801|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "HIFJCPQKFCZDDL-ACWOEMLNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5311181,
                "inchl_key": "HIFJCPQKFCZDDL-ACWOEMLNSA-N",
                "generic_name": "iloprost",
                "designated_date": "05/09/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eicos Sciences, Inc., a CiVi Biopharma, Inc. affiliated company|200 Four Falls Corporate Center|Suite 107|West Conshohocken|Pennsylvania|19528|United States",
                "orphan_designation": {
                    "original_text": "Treatment of systemic sclerosis",
                    "umls_id": "C0036421",
                    "parsed_text": "Systemic sclerosis"
                }
            },
            {
                "compound_id": 5311181,
                "inchl_key": "HIFJCPQKFCZDDL-ACWOEMLNSA-N",
                "generic_name": "iloprost",
                "designated_date": "04/06/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Algorithum Sciences, LLC|World Trade Center Delaware|702 West Street|Wilmington|Delaware|19801|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "BIXBBIPTYBJTRY-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 68791,
                "inchl_key": "BIXBBIPTYBJTRY-UHFFFAOYSA-N",
                "generic_name": "Imexon",
                "designated_date": "11/08/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AmpliMed Corporation|2321 Camino La Zorrela|Tucson|Alaska|85718|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma.",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            },
            {
                "compound_id": 68791,
                "inchl_key": "BIXBBIPTYBJTRY-UHFFFAOYSA-N",
                "generic_name": "imexon",
                "designated_date": "08/12/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AmpliMed Corporation|4380 N. Campbell Ave.|Tucson|Alaska|85718|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer.",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "compound_id": 68791,
                "inchl_key": "BIXBBIPTYBJTRY-UHFFFAOYSA-N",
                "generic_name": "Imexon",
                "designated_date": "11/01/2003",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AmpliMed Corporation|4380 North Campbell Avenue|Suite 205|Tucson|Alaska|85718|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic adenocarcinoma",
                    "umls_id": "C0281361",
                    "parsed_text": "Pancreatic adenocarcinoma"
                }
            },
            {
                "compound_id": 68791,
                "inchl_key": "BIXBBIPTYBJTRY-UHFFFAOYSA-N",
                "generic_name": "Imexon",
                "designated_date": "08/03/2001",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AmpliMed Corporation|2321 Camino La Zorrela|Tucson|Alaska|85718|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic malignant melanoma",
                    "umls_id": "C0860594",
                    "parsed_text": "Metastatic malignant melanoma"
                }
            }
        ]
    },
    {
        "_id": "GAMYYCRTACQSBR-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 67504,
                "inchl_key": "GAMYYCRTACQSBR-UHFFFAOYSA-N",
                "generic_name": "Imidazopyridine",
                "designated_date": "07/22/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "1ST Biotherapeutics, Inc.|240 Pangyoyeok-ro A-306|Bundang-gu Seongnam-si|Gyeonggi-do|South Korea",
                "orphan_designation": {
                    "original_text": "Treatment of Amyotrophic Lateral Sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "HHGRMHMXKPQNGF-SAOVQBGCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134692690,
                "inchl_key": "HHGRMHMXKPQNGF-SAOVQBGCSA-N",
                "generic_name": "inecalcitol",
                "designated_date": "08/03/2015",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hybrigenics, S.A.|3-5 Impasse Reille|75014|Paris|France",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "compound_id": 134692690,
                "inchl_key": "HHGRMHMXKPQNGF-SAOVQBGCSA-N",
                "generic_name": "Inecalcitol",
                "designated_date": "05/14/2014",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hybrigenics, S.A.|3-5 Impasse Reille|75014|Paris|France",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "HHGRMHMXKPQNGF-VTQYNGMESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 131954606,
                "inchl_key": "HHGRMHMXKPQNGF-VTQYNGMESA-N",
                "generic_name": "inecalcitol",
                "designated_date": "08/03/2015",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hybrigenics, S.A.|3-5 Impasse Reille|75014|Paris|France",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "compound_id": 131954606,
                "inchl_key": "HHGRMHMXKPQNGF-VTQYNGMESA-N",
                "generic_name": "Inecalcitol",
                "designated_date": "05/14/2014",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hybrigenics, S.A.|3-5 Impasse Reille|75014|Paris|France",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "HHGRMHMXKPQNGF-AAMRAYDJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 146157506,
                "inchl_key": "HHGRMHMXKPQNGF-AAMRAYDJSA-N",
                "generic_name": "inecalcitol",
                "designated_date": "08/03/2015",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hybrigenics, S.A.|3-5 Impasse Reille|75014|Paris|France",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "compound_id": 146157506,
                "inchl_key": "HHGRMHMXKPQNGF-AAMRAYDJSA-N",
                "generic_name": "Inecalcitol",
                "designated_date": "05/14/2014",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hybrigenics, S.A.|3-5 Impasse Reille|75014|Paris|France",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "HHGRMHMXKPQNGF-ZKNOEPHOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 53877232,
                "inchl_key": "HHGRMHMXKPQNGF-ZKNOEPHOSA-N",
                "generic_name": "inecalcitol",
                "designated_date": "08/03/2015",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hybrigenics, S.A.|3-5 Impasse Reille|75014|Paris|France",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "compound_id": 53877232,
                "inchl_key": "HHGRMHMXKPQNGF-ZKNOEPHOSA-N",
                "generic_name": "Inecalcitol",
                "designated_date": "05/14/2014",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hybrigenics, S.A.|3-5 Impasse Reille|75014|Paris|France",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "HHGRMHMXKPQNGF-WEZTXPJVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9952841,
                "inchl_key": "HHGRMHMXKPQNGF-WEZTXPJVSA-N",
                "generic_name": "inecalcitol",
                "designated_date": "08/03/2015",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hybrigenics, S.A.|3-5 Impasse Reille|75014|Paris|France",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "compound_id": 9952841,
                "inchl_key": "HHGRMHMXKPQNGF-WEZTXPJVSA-N",
                "generic_name": "Inecalcitol",
                "designated_date": "05/14/2014",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hybrigenics, S.A.|3-5 Impasse Reille|75014|Paris|France",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "HHGRMHMXKPQNGF-WNSNRMDMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6915835,
                "inchl_key": "HHGRMHMXKPQNGF-WNSNRMDMSA-N",
                "generic_name": "inecalcitol",
                "designated_date": "08/03/2015",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hybrigenics, S.A.|3-5 Impasse Reille|75014|Paris|France",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "compound_id": 6915835,
                "inchl_key": "HHGRMHMXKPQNGF-WNSNRMDMSA-N",
                "generic_name": "Inecalcitol",
                "designated_date": "05/14/2014",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hybrigenics, S.A.|3-5 Impasse Reille|75014|Paris|France",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "PDWUPXJEEYOOTR-JRGAVVOBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71184,
                "inchl_key": "PDWUPXJEEYOOTR-JRGAVVOBSA-N",
                "generic_name": "Iobenguane I 131",
                "trade_name": "Azedra Ultratrace",
                "designated_date": "01/18/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "AZEDRA is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy.",
                "marketing_approval_date": "\u00a007/30/2018\u00a0",
                "exclusivity_end_date": "\u00a007/30/2025\u00a0",
                "exclusivity_protected_indication": "AZEDRA is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy.",
                "sponsor": "Progenics Pharmaceuticals, Inc.|One World Trade Center.|47th Floor, Suite J|New York|New York|10007|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuroendocrine tumors",
                    "umls_id": "C0206754",
                    "parsed_text": "Neuroendocrine Tumors"
                }
            },
            {
                "compound_id": 71184,
                "inchl_key": "PDWUPXJEEYOOTR-JRGAVVOBSA-N",
                "generic_name": "iobenguane I 131",
                "designated_date": "07/05/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Jubilant DraxImage, Inc.|Div. of Draxis Specialty Pharmaceuticals, Inc.|Kirkland|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of neuroendocrine tumors",
                    "umls_id": "C0206754",
                    "parsed_text": "Neuroendocrine Tumors"
                }
            }
        ]
    },
    {
        "_id": "AUGCSOFQTDKPSO-RGVLZGJSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16117309,
                "inchl_key": "AUGCSOFQTDKPSO-RGVLZGJSSA-N",
                "generic_name": "Ivaltinostat",
                "designated_date": "08/21/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CrystalGenomics, Inc.|5th F. Bldg.A, Korea Bio Park|700 Daewangpangyoro, Bundanggu, Seongnamsi|Gyeonggido|Korea|13488|Republic of Korea",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            },
            {
                "compound_id": 16117309,
                "inchl_key": "AUGCSOFQTDKPSO-RGVLZGJSSA-N",
                "generic_name": "Ivaltinostat",
                "designated_date": "01/08/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CrystalGenomics, Inc.|5th F. Bldg.A, Korea Bio Park|700 Daewangpangyoro, Bundanggu, Seongnamsi|Gyeonggido|Korea|13488|South Korea",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "BMLMGCPTLHPWPY-REOHCLBHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 72390,
                "inchl_key": "BMLMGCPTLHPWPY-REOHCLBHSA-N",
                "generic_name": "L-2-oxothiazolidine-4-carboxylic acid",
                "designated_date": "06/14/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Transcend Therapeutics, Inc.|640 Memorial Drive, 3rd Floor West|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of adult respiratory distress syndrome.",
                    "umls_id": "C0035222",
                    "parsed_text": "ADULT RESPIRATORY DISTRESS SYNDROME"
                }
            },
            {
                "compound_id": 72390,
                "inchl_key": "BMLMGCPTLHPWPY-REOHCLBHSA-N",
                "generic_name": "L-2-oxothiazolidine-4-carboxylic acid",
                "designated_date": "07/30/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Transcend Therapeutics, Inc.|640 Memorial Drive, 3rd Floor West|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis.",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "BMLMGCPTLHPWPY-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 65272,
                "inchl_key": "BMLMGCPTLHPWPY-UHFFFAOYSA-N",
                "generic_name": "L-2-oxothiazolidine-4-carboxylic acid",
                "designated_date": "06/14/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Transcend Therapeutics, Inc.|640 Memorial Drive, 3rd Floor West|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of adult respiratory distress syndrome.",
                    "umls_id": "C0035222",
                    "parsed_text": "ADULT RESPIRATORY DISTRESS SYNDROME"
                }
            },
            {
                "compound_id": 65272,
                "inchl_key": "BMLMGCPTLHPWPY-UHFFFAOYSA-N",
                "generic_name": "L-2-oxothiazolidine-4-carboxylic acid",
                "designated_date": "07/30/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Transcend Therapeutics, Inc.|640 Memorial Drive, 3rd Floor West|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis.",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "LRSYFEZBIMVWRY-VWMHFEHESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44247677,
                "inchl_key": "LRSYFEZBIMVWRY-VWMHFEHESA-N",
                "generic_name": "L-ornithine phenylacetate",
                "designated_date": "04/07/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ocera Therapeutics, Inc.|5001 South Miami Blvd|Suite 300|Durham|North Carolina|27703|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure or acute on chronic liver disase",
                    "umls_id": "C0019151,C0162557,C0220994",
                    "parsed_text": "Hepatic Encephalopathy , Acute liver failure , Hyperammonemia"
                }
            }
        ]
    },
    {
        "_id": "FNVKWTCPMNNIND-WDTSGDEMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71587496,
                "inchl_key": "FNVKWTCPMNNIND-WDTSGDEMSA-N",
                "generic_name": "L-tyrosine-L-serine-L-leucine",
                "designated_date": "09/10/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CMS Peptides Patent Holding Company Limited|Unit 2106, 21st Floor, Island Place Tower|510 King's Rd|North Point",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma.",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            }
        ]
    },
    {
        "_id": "JWHPPWBIIQMBQC-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 23697158,
                "inchl_key": "JWHPPWBIIQMBQC-UHFFFAOYSA-M",
                "generic_name": "laquinimod sodium",
                "designated_date": "01/31/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Active Biotech AB|Scheelevagen 22|Box 724|Lund|Scania|SE-220-07|Sweden",
                "orphan_designation": {
                    "original_text": "Treatment of Huntington's Disease",
                    "umls_id": "C0020179",
                    "parsed_text": "Huntington's Disease"
                }
            }
        ]
    },
    {
        "_id": "GSDSWSVVBLHKDQ-JTQLQIEISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 149096,
                "inchl_key": "GSDSWSVVBLHKDQ-JTQLQIEISA-N",
                "generic_name": "Levofloxacin",
                "designated_date": "02/27/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Horizon Therapeutics USA, Inc.|150 S. Saunders Road|Suite 100|Lake Forest|Illinois|60045|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis patients",
                    "umls_id": "C0004611,C0010674,C0033809,C0876973",
                    "parsed_text": "Bacteria , Cystic Fibrosis , Pseudomonas aeruginosa , Pulmonary infections"
                }
            }
        ]
    },
    {
        "_id": "VWBBRFHSPXRJQD-QNTKWALQSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 135564391,
                "inchl_key": "VWBBRFHSPXRJQD-QNTKWALQSA-L",
                "generic_name": "levomefolate calcium",
                "designated_date": "02/10/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cox Biosciences LLC|267 West 71st Street, #3F|New York|New York|10023|United States",
                "orphan_designation": {
                    "original_text": "Treatment of megaloblastic anemia caused by folate deficiency",
                    "umls_id": "C0002888,C0016412",
                    "parsed_text": "Megaloblastic anemia , Folate deficiency"
                }
            }
        ]
    },
    {
        "_id": "LKCWBDHBTVXHDL-CAIQVSFASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 456591,
                "inchl_key": "LKCWBDHBTVXHDL-CAIQVSFASA-N",
                "generic_name": "liposomal amikacin",
                "trade_name": "Arikayce",
                "designated_date": "03/25/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy",
                "marketing_approval_date": "\u00a009/28/2018\u00a0",
                "exclusivity_end_date": "\u00a009/28/2025\u00a0",
                "exclusivity_protected_indication": "Treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy",
                "sponsor": "Insmed Incorporated|10 Finderne Avenue|Building 10|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of infections caused by non-tuberculous mycobacteria",
                    "umls_id": "C1265234,C3714514",
                    "parsed_text": "Non-Tuberculous Mycobacteria , Infections"
                }
            },
            {
                "compound_id": 456591,
                "inchl_key": "LKCWBDHBTVXHDL-CAIQVSFASA-N",
                "generic_name": "liposomal amikacin",
                "designated_date": "08/25/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Insmed, Inc.|Princeton Corpoarate Plaza|Suite C|Monmouth Junction|New Jersey|8852|United States",
                "orphan_designation": {
                    "original_text": "Treatment of bronchiectasis in patients with Pseudomonas aeruginosa or other susceptible microbial pathogens",
                    "umls_id": "C0006267,C0033809",
                    "parsed_text": "Bronchiectasis , Pseudomonas aeruginosa"
                }
            },
            {
                "compound_id": 456591,
                "inchl_key": "LKCWBDHBTVXHDL-CAIQVSFASA-N",
                "generic_name": "liposomal amikacin",
                "designated_date": "03/09/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Insmed, Inc.|Princeton Corporate Plaza|9 Deer Park Drive, Suite C|Monmouth Junction|New Jersey|8852|United States",
                "orphan_designation": {
                    "original_text": "Treatment of bronchopulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients",
                    "umls_id": "C0010674,C0854135",
                    "parsed_text": "Cystic Fibrosis , Pseudomonas aeruginosa Infections"
                }
            }
        ]
    },
    {
        "_id": "JJOFNSLZHKIJEV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11192129,
                "inchl_key": "JJOFNSLZHKIJEV-UHFFFAOYSA-N",
                "generic_name": "Lodoxamide tromethamine",
                "trade_name": "Alomide Ophthalmic Solution",
                "designated_date": "10/16/1991",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, vernal keratitis.",
                "marketing_approval_date": "\u00a009/23/1993\u00a0",
                "exclusivity_end_date": "\u00a009/23/2000\u00a0",
                "sponsor": "Alcon Laboratories, Inc.|6201 South Freeway|Fort Worth|Texas|76134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of vernal keratoconjunctivitis.",
                    "umls_id": "C0022577",
                    "parsed_text": "Vernal keratoconjunctivitis"
                }
            }
        ]
    },
    {
        "_id": "WJEOLQLKVOPQFV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10074640,
                "inchl_key": "WJEOLQLKVOPQFV-UHFFFAOYSA-N",
                "generic_name": "masitinib",
                "designated_date": "09/14/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AB Science|3, avenue GeorgeV|75008|Paris|France",
                "orphan_designation": {
                    "original_text": "Treatment of mastocytosis",
                    "umls_id": "C0024899",
                    "parsed_text": "Mastocytosis"
                }
            },
            {
                "compound_id": 10074640,
                "inchl_key": "WJEOLQLKVOPQFV-UHFFFAOYSA-N",
                "generic_name": "masitinib",
                "designated_date": "07/21/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AB Science|3, avenue George V|Paris,|France",
                "orphan_designation": {
                    "original_text": "Treatment of patients with pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 10074640,
                "inchl_key": "WJEOLQLKVOPQFV-UHFFFAOYSA-N",
                "generic_name": "masitinib",
                "designated_date": "04/20/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AB Science|3, avenue George V|Paris|France",
                "orphan_designation": {
                    "original_text": "Treatment of malignant gastrointestinal stromal tumors",
                    "umls_id": "C0238198",
                    "parsed_text": "Gastrointestinal Stromal Tumors"
                }
            }
        ]
    },
    {
        "_id": "TXCWBWKVIZGWEQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25024769,
                "inchl_key": "TXCWBWKVIZGWEQ-UHFFFAOYSA-N",
                "generic_name": "masitinib mesylate",
                "designated_date": "09/14/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AB Science|3, avenue George V|Paris|France",
                "orphan_designation": {
                    "original_text": "Treatment of gastric cancer including cancer of the gastroesophageal junction",
                    "umls_id": "C0024623",
                    "parsed_text": "Gastric Cancer"
                }
            },
            {
                "compound_id": 25024769,
                "inchl_key": "TXCWBWKVIZGWEQ-UHFFFAOYSA-N",
                "generic_name": "masitinib mesylate",
                "designated_date": "03/18/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AB Science|3, avenuve George V|75008|Paris|France",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis.",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "PSGAAPLEWMOORI-PEINSRQWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6279,
                "inchl_key": "PSGAAPLEWMOORI-PEINSRQWSA-N",
                "generic_name": "Medroxyprogesterone acetate",
                "designated_date": "02/22/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ZaBeCor Pharmaceutical Company, LLC|821 Westview Street|Philadelphia|Pennsylvania|19119|United States",
                "orphan_designation": {
                    "original_text": "Treatment of immune thrombocytopenic purpura.",
                    "umls_id": "C0398650",
                    "parsed_text": "Immune thrombocytopenic purpura"
                }
            }
        ]
    },
    {
        "_id": "BKBBTCORRZMASO-ZOWNYOTGSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 24906323,
                "inchl_key": "BKBBTCORRZMASO-ZOWNYOTGSA-M",
                "generic_name": "Methotrexate sodium",
                "trade_name": "Methotrexate",
                "designated_date": "10/21/1985",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the use of high dose methotrexate with leucovorin rescue in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor.",
                "marketing_approval_date": "\u00a004/07/1988\u00a0",
                "exclusivity_end_date": "\u00a004/07/1995\u00a0",
                "sponsor": "Lederle Laboratories|Division of American Cyanamid Company|401 N. Middletown Road|Pearl River|New York|10965|United States",
                "orphan_designation": {
                    "original_text": "Treatment of osteogenic sarcoma.",
                    "umls_id": "C0029463",
                    "parsed_text": "Osteogenic sarcoma"
                }
            },
            {
                "compound_id": 24906323,
                "inchl_key": "BKBBTCORRZMASO-ZOWNYOTGSA-M",
                "generic_name": "Methotrexate sodium",
                "trade_name": "Methotrexate",
                "designated_date": "10/21/1985",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the use of high dose methotrexate with leucovorin rescue in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor.",
                "marketing_approval_date": "\u00a004/07/1988\u00a0",
                "exclusivity_end_date": "\u00a004/07/1995\u00a0",
                "sponsor": "Lederle Laboratories|Division of American Cyanamid Company|401 N. Middletown Road|Pearl River|New York|10965|United States",
                "orphan_designation": {
                    "original_text": "Treatment of osteogenic sarcoma.",
                    "umls_id": "C0029463",
                    "parsed_text": "Osteogenic sarcoma"
                }
            }
        ]
    },
    {
        "_id": "DASQOOZCTWOQPA-GXKRWWSZSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 11329481,
                "inchl_key": "DASQOOZCTWOQPA-GXKRWWSZSA-L",
                "generic_name": "Methotrexate sodium",
                "trade_name": "Methotrexate",
                "designated_date": "10/21/1985",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the use of high dose methotrexate with leucovorin rescue in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor.",
                "marketing_approval_date": "\u00a004/07/1988\u00a0",
                "exclusivity_end_date": "\u00a004/07/1995\u00a0",
                "sponsor": "Lederle Laboratories|Division of American Cyanamid Company|401 N. Middletown Road|Pearl River|New York|10965|United States",
                "orphan_designation": {
                    "original_text": "Treatment of osteogenic sarcoma.",
                    "umls_id": "C0029463",
                    "parsed_text": "Osteogenic sarcoma"
                }
            }
        ]
    },
    {
        "_id": "FJLBFSROUSIWMA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4174,
                "inchl_key": "FJLBFSROUSIWMA-UHFFFAOYSA-N",
                "generic_name": "metyrapone",
                "designated_date": "09/25/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "HRA Pharma Rare Diseases|200, Avenue de Paris|Chatillon|92320|France",
                "orphan_designation": {
                    "original_text": "Treatment of Cushing's syndrome",
                    "umls_id": "C0039082",
                    "parsed_text": "Syndrome"
                }
            }
        ]
    },
    {
        "_id": "NWIBSHFKIJFRCO-WUDYKRTCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5746,
                "inchl_key": "NWIBSHFKIJFRCO-WUDYKRTCSA-N",
                "generic_name": "mitomycin",
                "trade_name": "Jelmyto",
                "designated_date": "09/08/2014",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "JELMYTO is indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC)",
                "marketing_approval_date": "\u00a004/15/2020\u00a0",
                "exclusivity_end_date": "\u00a004/15/2027\u00a0",
                "exclusivity_protected_indication": "Indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC).",
                "sponsor": "UroGen Pharma, Ltd.|9 Ha'Ta'asiya St., POB 2397|Ra'anana|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of upper tract urothelial cell cancers (transitional cell carcinoma of the renal pelvis and ureter)",
                    "umls_id": "C1370932,C4087468",
                    "parsed_text": "carcinoma of the renal pelvis and ureter , Transitional Cell Carcinoma of the Renal Pelvis"
                }
            },
            {
                "compound_id": 5746,
                "inchl_key": "NWIBSHFKIJFRCO-WUDYKRTCSA-N",
                "generic_name": "mitomycin-C",
                "trade_name": "Mitosol",
                "designated_date": "01/08/2008",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "An adjunct to ab externo glaucoma surgery.",
                "marketing_approval_date": "\u00a002/07/2012\u00a0",
                "exclusivity_end_date": "\u00a002/07/2019\u00a0",
                "sponsor": "Mobius Therapeutics, LLC|1141 South 7th Street|St. Louis|Missouri|63104|United States",
                "orphan_designation": {
                    "original_text": "Treatment of refractory glaucoma as an adjunct to surgery",
                    "umls_id": "C0017601",
                    "parsed_text": "Glaucoma"
                }
            },
            {
                "compound_id": 5746,
                "inchl_key": "NWIBSHFKIJFRCO-WUDYKRTCSA-N",
                "generic_name": "Mitomycin-C",
                "designated_date": "08/20/1993",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "IOP Inc.|3100 Airway Avenue, Suite 106|Costa Mesa|California|92626|United States",
                "orphan_designation": {
                    "original_text": "Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.",
                    "umls_id": "C0017601",
                    "parsed_text": "Glaucoma"
                }
            },
            {
                "compound_id": 5746,
                "inchl_key": "NWIBSHFKIJFRCO-WUDYKRTCSA-N",
                "generic_name": "mitomycin",
                "designated_date": "01/13/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mobius Therapeutics, LLC|4041 Forest Park Avenue|St. Louis|Missouri|63108|United States",
                "orphan_designation": {
                    "original_text": "Prevention of recurrence of pterygium after its surgical excision.",
                    "umls_id": "C1867441",
                    "parsed_text": "Pterygium"
                }
            }
        ]
    },
    {
        "_id": "AZSRSNUQCUDCGG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 118607832,
                "inchl_key": "AZSRSNUQCUDCGG-UHFFFAOYSA-N",
                "generic_name": "mobocertinib",
                "designated_date": "12/17/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-small cell lung cancer with genetic alterations in EGFR including EGFR mutations and/or EGFR gene amplifications, HER2 mutations, or BRAF G466V mutations",
                    "umls_id": "C3539721",
                    "parsed_text": "Non-Small Cell Lung Cancer"
                }
            }
        ]
    },
    {
        "_id": "IDIIJJHBXUESQI-DFIJPDEKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 101526,
                "inchl_key": "IDIIJJHBXUESQI-DFIJPDEKSA-N",
                "generic_name": "moxifloxacin hydrochloride",
                "designated_date": "04/30/2014",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bayer HealthCare Pharmaceuticals, Inc.|100 Bayer Boulevard|P. O. Box 915|Whippany|New Jersey|7981|United States",
                "orphan_designation": {
                    "original_text": "Treatment of tuberculosis",
                    "umls_id": "C0041296",
                    "parsed_text": "Tuberculosis"
                }
            }
        ]
    },
    {
        "_id": "XIKSEDLKDYKPTO-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10038269,
                "inchl_key": "XIKSEDLKDYKPTO-UHFFFAOYSA-N",
                "generic_name": "N-(3,4-dihydroxyphenyl)-3,4-dihydroxybenzamide",
                "designated_date": "10/15/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ProtaMed, Inc.|14241 Woodinville Duvall Road, Suite # 370|Woodinville|Washington|98072|United States",
                "orphan_designation": {
                    "original_text": "Treatment of AL Amyloidosis",
                    "umls_id": "C0268381",
                    "parsed_text": "AL Amyloidosis"
                }
            }
        ]
    },
    {
        "_id": "XPEHHUISIBFLHX-QFWMXSHPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 121439966,
                "inchl_key": "XPEHHUISIBFLHX-QFWMXSHPSA-N",
                "generic_name": "N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)cyclobutyl)-3-phenylisoxazole-5-carboxamide",
                "designated_date": "03/07/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Proteostasis Therapeutics, Inc.|200 Technology Square|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "WXNXCEHXYPACJF-ZETCQYMHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 70912,
                "inchl_key": "WXNXCEHXYPACJF-ZETCQYMHSA-N",
                "generic_name": "N-Acetyl-Leucine",
                "designated_date": "10/02/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "IntraBio Inc.|270 Devon Road|Tenafly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Ataxia Telangiectasia",
                    "umls_id": "C0004135",
                    "parsed_text": "Ataxia Telangiectasia"
                }
            }
        ]
    },
    {
        "_id": "URCVCIZFVQDVPM-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3035714,
                "inchl_key": "URCVCIZFVQDVPM-UHFFFAOYSA-N",
                "generic_name": "N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide",
                "designated_date": "09/30/2004",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AbbVie, Inc.|1 N. Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuroblastoma",
                    "umls_id": "C0027819",
                    "parsed_text": "Neuroblastoma"
                }
            }
        ]
    },
    {
        "_id": "YZOQZEXYFLXNKA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10309114,
                "inchl_key": "YZOQZEXYFLXNKA-UHFFFAOYSA-N",
                "generic_name": "N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide",
                "designated_date": "08/13/2004",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer, Inc.|50 Pequot|6025-A3106|New London|Connecticut|6320|United States",
                "orphan_designation": {
                    "original_text": "Treatment of stages IIB-IV melanoma",
                    "umls_id": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "GDLPAGOVHZLZEK-JBUFHSOLSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 158780,
                "inchl_key": "GDLPAGOVHZLZEK-JBUFHSOLSA-L",
                "generic_name": "oglufanide disodium",
                "designated_date": "09/24/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Implicit Bioscience Pty Ltd|P. O. Box 2072|Toowong Business Center|Brisbane|Queensland|Australia",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "QJAGBAPUFWBVSD-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 86278354,
                "inchl_key": "QJAGBAPUFWBVSD-UHFFFAOYSA-N",
                "generic_name": "olaptesed pegol",
                "designated_date": "08/19/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Noxxon Pharma AG|Max-Dohrn0Strasse|Berlin|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of glioblastoma in conjunction with radiotherapy.",
                    "umls_id": "C0017636",
                    "parsed_text": "Glioblastoma"
                }
            }
        ]
    },
    {
        "_id": "HWXVIOGONBBTBY-ONEGZZNKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 46216796,
                "inchl_key": "HWXVIOGONBBTBY-ONEGZZNKSA-N",
                "generic_name": "pacritinib",
                "designated_date": "03/13/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CTI BioPharma Corporation|3101 Western Avenue|Suite 600|Seattle|Washington|98121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary myelofibrosis (MF), post-polycythemia vera MF, and post-essential thrombocythemia MF",
                    "umls_id": "C0001815,C0026987,C0032463,C0040028",
                    "parsed_text": "Primary Myelofibrosis , Myelofibrosis , Polycythemia Vera , ESSENTIAL THROMBOCYTHEMIA"
                }
            }
        ]
    },
    {
        "_id": "QXRSDHAAWVKZLJ-PVYNADRNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 448013,
                "inchl_key": "QXRSDHAAWVKZLJ-PVYNADRNSA-N",
                "generic_name": "patupilone",
                "designated_date": "02/02/2010",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary fallopian tube cancer.",
                    "umls_id": "C0238122",
                    "parsed_text": "Fallopian Tube Cancer"
                }
            },
            {
                "compound_id": 448013,
                "inchl_key": "QXRSDHAAWVKZLJ-PVYNADRNSA-N",
                "generic_name": "Patupilone",
                "designated_date": "10/04/2005",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceutical Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer.",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "GAQMWPRWVIGRRV-IVDGIBIRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 70683024,
                "inchl_key": "GAQMWPRWVIGRRV-IVDGIBIRSA-N",
                "generic_name": "Pegfilgrastim",
                "trade_name": "Neulasta",
                "designated_date": "11/20/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome)",
                "marketing_approval_date": "\u00a011/13/2015\u00a0",
                "exclusivity_end_date": "\u00a011/13/2022\u00a0",
                "exclusivity_protected_indication": "To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome)",
                "sponsor": "Amgen, Inc.|One Amgen Center Drive|M/S 17-1-C|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident",
                    "umls_id": "C0854467",
                    "parsed_text": "Myelosuppression"
                }
            }
        ]
    },
    {
        "_id": "YBVNFKZSMZGRAD-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 8813,
                "inchl_key": "YBVNFKZSMZGRAD-UHFFFAOYSA-N",
                "generic_name": "Pentamidine isethionate",
                "trade_name": "Nebupent",
                "designated_date": "01/12/1988",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a006/15/1989\u00a0",
                "exclusivity_end_date": "\u00a006/15/1996\u00a0",
                "sponsor": "Fujisawa USA, Inc.|3 Parkway North Center|Deerfield|Illinois|60015|United States",
                "orphan_designation": {
                    "original_text": "Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.",
                    "umls_id": "C1535939",
                    "parsed_text": "Pneumocystis carinii Pneumonia"
                }
            },
            {
                "compound_id": 8813,
                "inchl_key": "YBVNFKZSMZGRAD-UHFFFAOYSA-N",
                "generic_name": "Pentamidine isethionate",
                "designated_date": "10/29/1984",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Aventis Behring L.L.C.|1020 First Avenue|PO Box 61501|King of Prussia|Pennsylvania|19406|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pneumocystis carinii pneumonia.",
                    "umls_id": "C1535939",
                    "parsed_text": "Pneumocystis carinii Pneumonia"
                }
            },
            {
                "compound_id": 8813,
                "inchl_key": "YBVNFKZSMZGRAD-UHFFFAOYSA-N",
                "generic_name": "Pentamidine isethionate",
                "trade_name": "Pentam 300",
                "designated_date": "02/28/1984",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a010/16/1984\u00a0",
                "exclusivity_end_date": "\u00a010/16/1991\u00a0",
                "sponsor": "Fujisawa USA, Inc.|3 Parkway North Center|Deerfield|Illinois|60015|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pneumocystis carinii pneumonia.",
                    "umls_id": "C1535939",
                    "parsed_text": "Pneumocystis carinii Pneumonia"
                }
            }
        ]
    },
    {
        "_id": "RZPNFYXFSHGGBE-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2916,
                "inchl_key": "RZPNFYXFSHGGBE-UHFFFAOYSA-N",
                "generic_name": "Phosphocysteamine",
                "designated_date": "09/12/1988",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medea Research Laboratories|Port Jefferson Business Center|200 Wilson Street, Building D-6|Port Jefferson|New York|11776|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystinosis.",
                    "umls_id": "C4316899",
                    "parsed_text": "Cystinosis"
                }
            }
        ]
    },
    {
        "_id": "GMZVRMREEHBGGF-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4843,
                "inchl_key": "GMZVRMREEHBGGF-UHFFFAOYSA-N",
                "generic_name": "Piracetam",
                "designated_date": "10/02/1987",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "UCB Pharma, Inc.|1950 Lake Park Drive|Smyrna|Georgia|30080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myoclonus.",
                    "umls_id": "C0027066",
                    "parsed_text": "Myoclonus"
                }
            }
        ]
    },
    {
        "_id": "ONJQDTZCDSESIW-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 656641,
                "inchl_key": "ONJQDTZCDSESIW-UHFFFAOYSA-N",
                "generic_name": "polidocanol",
                "designated_date": "02/19/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Provensis Ltd|5 Fleet Place|London|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of congenital venous malformations",
                    "umls_id": "C2937220",
                    "parsed_text": "Venous malformations"
                }
            }
        ]
    },
    {
        "_id": "ACSROKXFXFNERX-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 51711,
                "inchl_key": "ACSROKXFXFNERX-UHFFFAOYSA-N",
                "generic_name": "Pramiracetam Sulfate",
                "designated_date": "11/04/1991",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cambridge Neuroscience, Inc.|1 Kendall Square, Bldg. 700|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "For the management of cognitive dysfunction and enhancement of antidepressant activity associated with electroconvulsive therapy.",
                    "umls_id": "C0338656",
                    "parsed_text": "Cognitive Dysfunction"
                }
            }
        ]
    },
    {
        "_id": "DGMKFQYCZXERLX-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4922,
                "inchl_key": "DGMKFQYCZXERLX-UHFFFAOYSA-N",
                "generic_name": "Proglumide",
                "designated_date": "07/23/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenefly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastric cancer",
                    "umls_id": "C0024623",
                    "parsed_text": "Gastric Cancer"
                }
            },
            {
                "compound_id": 4922,
                "inchl_key": "DGMKFQYCZXERLX-UHFFFAOYSA-N",
                "generic_name": "Proglumide",
                "designated_date": "09/09/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenefly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Chronic Pancreatitis",
                    "umls_id": "C0149521",
                    "parsed_text": "Chronic pancreatitis"
                }
            },
            {
                "compound_id": 4922,
                "inchl_key": "DGMKFQYCZXERLX-UHFFFAOYSA-N",
                "generic_name": "Proglumide",
                "designated_date": "06/16/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Jill P Smith, MD|Department of Medicine, Georgetown University|Building D Room 338|Washington|District of Columbia|20007|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "HSUDWURBWSUCOB-IBEPEKEJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44147881,
                "inchl_key": "HSUDWURBWSUCOB-IBEPEKEJSA-N",
                "generic_name": "Protaxel",
                "designated_date": "05/21/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biophysica, Inc.|2159 Avenida de la Playa|Suite B|La Jolla|California|92037|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "YKUQEKXHQFYULM-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 156867,
                "inchl_key": "YKUQEKXHQFYULM-UHFFFAOYSA-N",
                "generic_name": "Pyronaridine tetraphosphate",
                "designated_date": "02/11/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Collaborations Pharmaceuticals, Inc.|5616 Hilltop Needmore Rd,|Fuquay Varina|North Carolina|27526|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Malaria",
                    "umls_id": "C0024530",
                    "parsed_text": "Malaria"
                }
            },
            {
                "compound_id": 156867,
                "inchl_key": "YKUQEKXHQFYULM-UHFFFAOYSA-N",
                "generic_name": "pyronaridine tetraphosphate",
                "designated_date": "02/28/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Collaborations Pharmaceuticals, Inc.|5616 Hilltop Needmore Rd,|Fuquay Varina|North Carolina|27526|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Ebola infection",
                    "umls_id": "C0282687",
                    "parsed_text": "Ebola Infection"
                }
            }
        ]
    },
    {
        "_id": "CVWXJKQAOSCOAB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24889392,
                "inchl_key": "CVWXJKQAOSCOAB-UHFFFAOYSA-N",
                "generic_name": "quizartinib",
                "designated_date": "03/18/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Daiichi Sankyo, Inc.|211 Mount Airy Road|Basking Ridge|New Jersey|7920|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "PTFCDOFLOPIGGS-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 32051,
                "inchl_key": "PTFCDOFLOPIGGS-UHFFFAOYSA-N",
                "generic_name": "Recombinant human alpha-mannosidase",
                "designated_date": "02/02/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Chiesi USA, Inc.|175 Regency Woods Place|Suite 600|Cary|North Carolina|27518|United States",
                "orphan_designation": {
                    "original_text": "Treatment of alpha-mannosidosis",
                    "umls_id": "C0024748",
                    "parsed_text": "alpha-Mannosidosis"
                }
            }
        ]
    },
    {
        "_id": "WANIDIGFXJFFEL-SANMLTNESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 73051463,
                "inchl_key": "WANIDIGFXJFFEL-SANMLTNESA-N",
                "generic_name": "relacorilant",
                "designated_date": "10/15/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Corcept Therapeutics, Inc.|149 Commonwealth Drive|Menlo Park|California|94025|United States",
                "orphan_designation": {
                    "original_text": "Treatment of endogenous Cushing syndrome",
                    "umls_id": "C0010481",
                    "parsed_text": "Cushing Syndrome"
                }
            },
            {
                "compound_id": 73051463,
                "inchl_key": "WANIDIGFXJFFEL-SANMLTNESA-N",
                "generic_name": "relacorilant",
                "designated_date": "09/27/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Corcept Therapeutics, Inc.|149 Commonwealth Drive|Menlo Park|California|94025|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pancreatic Cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "VYGQUTWHTHXGQB-FFHKNEKCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5280531,
                "inchl_key": "VYGQUTWHTHXGQB-FFHKNEKCSA-N",
                "generic_name": "Retinol palmitate",
                "designated_date": "08/08/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orphanix GmbH|41 Peter-Rosegger-Stra\u07e5|Ried im Innkreis|Ober_xDE8F__xDD25_rreich|Austria",
                "orphan_designation": {
                    "original_text": "Prevention of bronchopulmonary dysplasia.",
                    "umls_id": "C0006287",
                    "parsed_text": "Bronchopulmonary Dysplasia"
                }
            },
            {
                "compound_id": 5280531,
                "inchl_key": "VYGQUTWHTHXGQB-FFHKNEKCSA-N",
                "generic_name": "vitamin A palmitate",
                "designated_date": "07/14/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Advent Therapeutics, Inc.|6500 Old Carversville Road|Lumberville|Pennsylvania|18933|United States",
                "orphan_designation": {
                    "original_text": "Prevention of bronchopulmonary dysplasia.",
                    "umls_id": "C0006287",
                    "parsed_text": "Bronchopulmonary Dysplasia"
                }
            }
        ]
    },
    {
        "_id": "WXXSNCNJFUAIDG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11304743,
                "inchl_key": "WXXSNCNJFUAIDG-UHFFFAOYSA-N",
                "generic_name": "riociguat",
                "designated_date": "07/24/2014",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bayer HealthCare Pharmaceuticals, Inc.|100 Bayer Blvd|P. O. Box 915|Whippany|New Jersey|7981|United States",
                "orphan_designation": {
                    "original_text": "Treatment of systemic sclerosis",
                    "umls_id": "C0036421",
                    "parsed_text": "Systemic sclerosis"
                }
            },
            {
                "compound_id": 11304743,
                "inchl_key": "WXXSNCNJFUAIDG-UHFFFAOYSA-N",
                "generic_name": "riociguat",
                "trade_name": "Adempas",
                "designated_date": "09/19/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adults with pulmonary arterial hypertension (PAH) WHO Group 1, to improve exercise capacity, WHO functional class and to delay clinical worsening.",
                "marketing_approval_date": "\u00a010/08/2013\u00a0",
                "exclusivity_end_date": "\u00a010/08/2020\u00a0",
                "exclusivity_protected_indication": "Treatment of adults with pulmonary arterial hypertension (PAH) WHO Group 1, to improve exercise capacity, WHO functional class and to delay clinical worsening.",
                "sponsor": "Bayer HealthCare Pharmaceuticals, Inc.|100 Bayer Blvd.|Whippany|New Jersey|7981|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension.",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            },
            {
                "compound_id": 11304743,
                "inchl_key": "WXXSNCNJFUAIDG-UHFFFAOYSA-N",
                "generic_name": "riociguat",
                "trade_name": "Adempas",
                "designated_date": "09/19/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) WHO Group 4, after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class",
                "marketing_approval_date": "\u00a010/08/2013\u00a0",
                "exclusivity_end_date": "\u00a010/08/2020\u00a0",
                "exclusivity_protected_indication": "Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) WHO Group 4, after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class",
                "sponsor": "Bayer HealthCare Pharmaceuticals, Inc.|100 Bayer Blvd.|Whippany|New Jersey|7981|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic thromboembolic pulmonary hypertension",
                    "umls_id": "C2363973",
                    "parsed_text": "Chronic thromboembolic pulmonary hypertension"
                }
            }
        ]
    },
    {
        "_id": "SGOOQMRIPALTEL-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 54676478,
                "inchl_key": "SGOOQMRIPALTEL-UHFFFAOYSA-N",
                "generic_name": "Roquinimex",
                "designated_date": "07/01/1993",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacia & Upjohn|7000 Portage Road|Kalamazoo|Michigan|49001|United States",
                "orphan_designation": {
                    "original_text": "To prolong time to relapse in leukemia patients who have undergone autologous bone marrow transplantation.",
                    "umls_id": "C0023418",
                    "parsed_text": "leukemia"
                }
            }
        ]
    },
    {
        "_id": "HMABYWSNWIZPAG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9931954,
                "inchl_key": "HMABYWSNWIZPAG-UHFFFAOYSA-N",
                "generic_name": "rucaparib",
                "trade_name": "Rubraca",
                "designated_date": "07/31/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "As monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies",
                "marketing_approval_date": "\u00a012/19/2016\u00a0",
                "exclusivity_end_date": "\u00a012/19/2023\u00a0",
                "exclusivity_protected_indication": "As monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies",
                "sponsor": "Clovis Oncology, Inc.|5500 Flatiron Parkway|Suite 100|Boulder|Colorado|80301|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "compound_id": 9931954,
                "inchl_key": "HMABYWSNWIZPAG-UHFFFAOYSA-N",
                "generic_name": "rucaparib",
                "trade_name": "Rubraca",
                "designated_date": "07/31/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.",
                "marketing_approval_date": "\u00a004/06/2018\u00a0",
                "exclusivity_end_date": "\u00a004/06/2025\u00a0",
                "exclusivity_protected_indication": "For the maintenance treatment of adult patients with recurrent epithelial ovarian cancer who are in complete or partial response to platinum-based chemotherapy.",
                "sponsor": "Clovis Oncology, Inc.|5500 Flatiron Parkway|Suite 100|Boulder|Colorado|80301|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "FUZYTVDVLBBXDL-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5113032,
                "inchl_key": "FUZYTVDVLBBXDL-UHFFFAOYSA-N",
                "generic_name": "selisistat",
                "designated_date": "12/07/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AOP Orphan Pharmaceuticals AG|91/llf Wilhelminenstra\u07e5|Wien|Wien|Austria",
                "orphan_designation": {
                    "original_text": "Treatment of Huntington's disease",
                    "umls_id": "C0020179",
                    "parsed_text": "Huntington's Disease"
                }
            }
        ]
    },
    {
        "_id": "BNRNXUUZRGQAQC-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135398744,
                "inchl_key": "BNRNXUUZRGQAQC-UHFFFAOYSA-N",
                "generic_name": "sildenafil",
                "designated_date": "07/28/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer, Inc.|Worldwide Regulatory strategy|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric (defined as children less than 17 years of age) pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "KIHYPELVXPAIDH-HNSNBQBZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44599207,
                "inchl_key": "KIHYPELVXPAIDH-HNSNBQBZSA-N",
                "generic_name": "siponimod",
                "designated_date": "07/10/2014",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of dermatomyositis",
                    "umls_id": "C0011633",
                    "parsed_text": "Dermatomyositis"
                }
            },
            {
                "compound_id": 44599207,
                "inchl_key": "KIHYPELVXPAIDH-HNSNBQBZSA-N",
                "generic_name": "Siponimod",
                "designated_date": "11/26/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of polymyositis",
                    "umls_id": "C0085655",
                    "parsed_text": "Polymyositis"
                }
            }
        ]
    },
    {
        "_id": "QNAZTOHXCZPOSA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9862248,
                "inchl_key": "QNAZTOHXCZPOSA-UHFFFAOYSA-N",
                "generic_name": "sobetirome",
                "designated_date": "04/29/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Naftali Kaminski, MD|Department of Medicine, Yale School of Medicine|300 Cedar Street|New Haven|Connecticut|6520|United States",
                "orphan_designation": {
                    "original_text": "Treatment of X-linked adrenoleukodystrophy",
                    "umls_id": "C0162309",
                    "parsed_text": "X-Linked Adrenoleukodystrophy"
                }
            }
        ]
    },
    {
        "_id": "NHXLMOGPVYXJNR-HVEUVEBASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44377662,
                "inchl_key": "NHXLMOGPVYXJNR-HVEUVEBASA-N",
                "generic_name": "Somatostatin",
                "designated_date": "12/22/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eumedica Pharmaceuticals A.G. (Schweiz)|Arnold Bocklin-Strasse 1|CH-4051|BASEL|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of bleeding esophageal varices.",
                    "umls_id": "C0014867",
                    "parsed_text": "Esophageal Varices"
                }
            },
            {
                "compound_id": 44377662,
                "inchl_key": "NHXLMOGPVYXJNR-HVEUVEBASA-N",
                "generic_name": "Somatostatin",
                "designated_date": "06/20/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ferring Laboratories, Inc.|400 Rella Boulevard, Suite 201|Suffern|New York|10901|United States",
                "orphan_designation": {
                    "original_text": "Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.",
                    "umls_id": "C0423772",
                    "parsed_text": "Cutaneous Fistulas"
                }
            }
        ]
    },
    {
        "_id": "NHXLMOGPVYXJNR-FMGBKAQLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44291156,
                "inchl_key": "NHXLMOGPVYXJNR-FMGBKAQLSA-N",
                "generic_name": "Somatostatin",
                "designated_date": "12/22/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eumedica Pharmaceuticals A.G. (Schweiz)|Arnold Bocklin-Strasse 1|CH-4051|BASEL|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of bleeding esophageal varices.",
                    "umls_id": "C0014867",
                    "parsed_text": "Esophageal Varices"
                }
            },
            {
                "compound_id": 44291156,
                "inchl_key": "NHXLMOGPVYXJNR-FMGBKAQLSA-N",
                "generic_name": "Somatostatin",
                "designated_date": "06/20/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ferring Laboratories, Inc.|400 Rella Boulevard, Suite 201|Suffern|New York|10901|United States",
                "orphan_designation": {
                    "original_text": "Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.",
                    "umls_id": "C0423772",
                    "parsed_text": "Cutaneous Fistulas"
                }
            }
        ]
    },
    {
        "_id": "NHXLMOGPVYXJNR-FQSIDJEASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71308696,
                "inchl_key": "NHXLMOGPVYXJNR-FQSIDJEASA-N",
                "generic_name": "Somatostatin",
                "designated_date": "12/22/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eumedica Pharmaceuticals A.G. (Schweiz)|Arnold Bocklin-Strasse 1|CH-4051|BASEL|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of bleeding esophageal varices.",
                    "umls_id": "C0014867",
                    "parsed_text": "Esophageal Varices"
                }
            },
            {
                "compound_id": 71308696,
                "inchl_key": "NHXLMOGPVYXJNR-FQSIDJEASA-N",
                "generic_name": "Somatostatin",
                "designated_date": "06/20/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ferring Laboratories, Inc.|400 Rella Boulevard, Suite 201|Suffern|New York|10901|United States",
                "orphan_designation": {
                    "original_text": "Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.",
                    "umls_id": "C0423772",
                    "parsed_text": "Cutaneous Fistulas"
                }
            }
        ]
    },
    {
        "_id": "NHXLMOGPVYXJNR-UYURUMNQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16161315,
                "inchl_key": "NHXLMOGPVYXJNR-UYURUMNQSA-N",
                "generic_name": "Somatostatin",
                "designated_date": "12/22/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eumedica Pharmaceuticals A.G. (Schweiz)|Arnold Bocklin-Strasse 1|CH-4051|BASEL|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of bleeding esophageal varices.",
                    "umls_id": "C0014867",
                    "parsed_text": "Esophageal Varices"
                }
            },
            {
                "compound_id": 16161315,
                "inchl_key": "NHXLMOGPVYXJNR-UYURUMNQSA-N",
                "generic_name": "Somatostatin",
                "designated_date": "06/20/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ferring Laboratories, Inc.|400 Rella Boulevard, Suite 201|Suffern|New York|10901|United States",
                "orphan_designation": {
                    "original_text": "Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.",
                    "umls_id": "C0423772",
                    "parsed_text": "Cutaneous Fistulas"
                }
            }
        ]
    },
    {
        "_id": "NHXLMOGPVYXJNR-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16129681,
                "inchl_key": "NHXLMOGPVYXJNR-UHFFFAOYSA-N",
                "generic_name": "Somatostatin",
                "designated_date": "12/22/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eumedica Pharmaceuticals A.G. (Schweiz)|Arnold Bocklin-Strasse 1|CH-4051|BASEL|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of bleeding esophageal varices.",
                    "umls_id": "C0014867",
                    "parsed_text": "Esophageal Varices"
                }
            },
            {
                "compound_id": 16129681,
                "inchl_key": "NHXLMOGPVYXJNR-UHFFFAOYSA-N",
                "generic_name": "Somatostatin",
                "designated_date": "06/20/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ferring Laboratories, Inc.|400 Rella Boulevard, Suite 201|Suffern|New York|10901|United States",
                "orphan_designation": {
                    "original_text": "Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.",
                    "umls_id": "C0423772",
                    "parsed_text": "Cutaneous Fistulas"
                }
            }
        ]
    },
    {
        "_id": "NHXLMOGPVYXJNR-ATOGVRKGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16129706,
                "inchl_key": "NHXLMOGPVYXJNR-ATOGVRKGSA-N",
                "generic_name": "Somatostatin",
                "designated_date": "12/22/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eumedica Pharmaceuticals A.G. (Schweiz)|Arnold Bocklin-Strasse 1|CH-4051|BASEL|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of bleeding esophageal varices.",
                    "umls_id": "C0014867",
                    "parsed_text": "Esophageal Varices"
                }
            },
            {
                "compound_id": 16129706,
                "inchl_key": "NHXLMOGPVYXJNR-ATOGVRKGSA-N",
                "generic_name": "Somatostatin",
                "designated_date": "06/20/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ferring Laboratories, Inc.|400 Rella Boulevard, Suite 201|Suffern|New York|10901|United States",
                "orphan_designation": {
                    "original_text": "Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.",
                    "umls_id": "C0423772",
                    "parsed_text": "Cutaneous Fistulas"
                }
            }
        ]
    },
    {
        "_id": "HMHVCUVYZFYAJI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5356,
                "inchl_key": "HMHVCUVYZFYAJI-UHFFFAOYSA-N",
                "generic_name": "sulthiame",
                "designated_date": "07/25/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Marathon Pharmaceuticals, LLC|1033 Skokie Blvd.,|Suite 600|Northbrook|Illinois|60062|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with benign epilepsy of childhood with centrotemporal spikes (BECTS) also known as rolandic epilepsy",
                    "umls_id": "C0376532,C2363129",
                    "parsed_text": "rolandic epilepsy , Benign Epilepsy Of Childhood With Centrotemporal Spikes"
                }
            }
        ]
    },
    {
        "_id": "GLXYOFXNKBTMQL-YKCHQESGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134687212,
                "inchl_key": "GLXYOFXNKBTMQL-YKCHQESGSA-N",
                "generic_name": "synthetic preImplantation factor",
                "designated_date": "05/08/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "BioIncept, LLC|140 East 40th Street|Suite 11E|New York|New York|10016|United States",
                "orphan_designation": {
                    "original_text": "Prevention of graft versus host disease",
                    "umls_id": "C0018133",
                    "parsed_text": "GRAFT VERSUS HOST DISEASE"
                }
            },
            {
                "compound_id": 134687212,
                "inchl_key": "GLXYOFXNKBTMQL-YKCHQESGSA-N",
                "generic_name": "Synthetic PreImplantation Factor",
                "designated_date": "12/19/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "BioIncept, LLC|140 East 40th Street|Suite 11E|New York|New York|10016|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Acute Radiation Syndrome",
                    "umls_id": "C0520799",
                    "parsed_text": "Acute Radiation Syndrome"
                }
            }
        ]
    },
    {
        "_id": "CILIXQOJUNDIDU-ASQIGDHWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16139605,
                "inchl_key": "CILIXQOJUNDIDU-ASQIGDHWSA-N",
                "generic_name": "Teduglutide",
                "designated_date": "12/08/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "9 Meters Biopharma Inc.|8480 Honeycutt Road, Suite 120|Raleigh|North Carolina|27615|United States",
                "orphan_designation": {
                    "original_text": "Prevention of acute graft versus host disease",
                    "umls_id": "C0856825",
                    "parsed_text": "Acute Graft Versus Host Disease"
                }
            }
        ]
    },
    {
        "_id": "MRGCZDWBFFUEES-CWBCWDDISA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 11583399,
                "inchl_key": "MRGCZDWBFFUEES-CWBCWDDISA-L",
                "generic_name": "temocillin sodium",
                "designated_date": "04/21/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Belpharma S.A.|5, Rue de Bonnevoie|L-2160|Luxembourg|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary infections caused by Burkholderia cepacia",
                    "umls_id": "C0085469,C0876973",
                    "parsed_text": "Burkholderia cepacia , Pulmonary infections"
                }
            }
        ]
    },
    {
        "_id": "LYPFDBRUNKHDGX-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 60751,
                "inchl_key": "LYPFDBRUNKHDGX-UHFFFAOYSA-N",
                "generic_name": "Temoporfin",
                "designated_date": "10/28/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biolitec Pharma Ireland Ltd.|United Drug House|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Palliative treatment of recurrent, refractory or second primary squamous cell carcinomas of the head and neck in patients considered to be incurable with surgery or radiotherapy.",
                    "umls_id": "C0007137",
                    "parsed_text": "Squamous Cell Carcinomas"
                }
            }
        ]
    },
    {
        "_id": "JOAHPSVPXZTVEP-YXJHDRRASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 443951,
                "inchl_key": "JOAHPSVPXZTVEP-YXJHDRRASA-N",
                "generic_name": "terguride",
                "designated_date": "05/17/2013",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medac GmbH|TheaterstraBe 6+|Wedel|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of systemic sclerosis",
                    "umls_id": "C0036421",
                    "parsed_text": "Systemic sclerosis"
                }
            },
            {
                "compound_id": 443951,
                "inchl_key": "JOAHPSVPXZTVEP-YXJHDRRASA-N",
                "generic_name": "terguride",
                "designated_date": "05/02/2008",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ErgoNex Pharma GmbH|Ruetistr. 20|CH-9050 Appenzell|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "OGBMKVWORPGQRR-UMXFMPSGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16133850,
                "inchl_key": "OGBMKVWORPGQRR-UMXFMPSGSA-N",
                "generic_name": "Teriparatide",
                "trade_name": "Parathar",
                "designated_date": "01/09/1987",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a012/23/1987\u00a0",
                "exclusivity_end_date": "\u00a012/23/1994\u00a0",
                "sponsor": "Rhone-Poulenc Rorer Pharmaceuticals, Inc.|500 Arcola Road|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism.",
                    "umls_id": "C0020598,C0020626,C0033835",
                    "parsed_text": "Hypocalcemia , Hypoparathyroidism , Pseudohypoparathyroidism"
                }
            },
            {
                "compound_id": 16133850,
                "inchl_key": "OGBMKVWORPGQRR-UMXFMPSGSA-N",
                "generic_name": "Teriparatide",
                "designated_date": "10/28/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biomeasure, Inc.|27 Maple St.|Milford|Massachusetts|1757|United States",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic osteoporosis.",
                    "umls_id": "C0158447",
                    "parsed_text": "Idiopathic osteoporosis"
                }
            },
            {
                "compound_id": 16133850,
                "inchl_key": "OGBMKVWORPGQRR-UMXFMPSGSA-N",
                "generic_name": "teriparatide",
                "designated_date": "04/18/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Entera Bio, Ltd.|Kiryat Hadassah Minrav Bldg, 5th Floor|P. O. Box 12117|Jeusalem|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of hypoparathyroidism",
                    "umls_id": "C0020626",
                    "parsed_text": "Hypoparathyroidism"
                }
            }
        ]
    },
    {
        "_id": "HVXKQKFEHMGHSL-GOOCMWNKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10458325,
                "inchl_key": "HVXKQKFEHMGHSL-GOOCMWNKSA-N",
                "generic_name": "Tesevatinib",
                "designated_date": "03/01/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kadmon Corporation, LLC|450 East 29th Street|New York|New York|10016|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with autosomal recessive polycystic kidney disease (ARPKD)",
                    "umls_id": "C0085548,C1418605",
                    "parsed_text": "Autosomal Recessive Polycystic Kidney Disease , ARPKD"
                }
            },
            {
                "compound_id": 10458325,
                "inchl_key": "HVXKQKFEHMGHSL-GOOCMWNKSA-N",
                "generic_name": "tesevatinib",
                "designated_date": "08/03/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kadmon Corporation, LLC|450 East 29th Street|New York|New York|10016|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-small cell lung cancer with epithelial growth factor receptor-activating mutations",
                    "umls_id": "C3539721",
                    "parsed_text": "Non-Small Cell Lung Cancer"
                }
            }
        ]
    },
    {
        "_id": "JICJBGPOMZQUBB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 68870,
                "inchl_key": "JICJBGPOMZQUBB-UHFFFAOYSA-N",
                "generic_name": "tianeptine",
                "designated_date": "03/08/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AMO Pharma Ltd.|Throwsters|The Street|Wonersh|England|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of Rett syndrome (RTT)",
                    "umls_id": "C0035372",
                    "parsed_text": "Rett Syndrome"
                }
            }
        ]
    },
    {
        "_id": "RSQGZEAXODVTOL-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 23729157,
                "inchl_key": "RSQGZEAXODVTOL-UHFFFAOYSA-N",
                "generic_name": "tirasemtiv",
                "designated_date": "03/02/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cytokinetics Inc.|280 East Grand Avenue|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis (ALS)",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "RMDMBHQVNHQDDD-VFWKRBOSSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 10287099,
                "inchl_key": "RMDMBHQVNHQDDD-VFWKRBOSSA-L",
                "generic_name": "trans sodium crocetinate",
                "designated_date": "12/03/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Diffusion Pharmaceuticals, LLC|1317 Carlton Ave|Suite 200|Charlottesville|Virginia|22902|United States",
                "orphan_designation": {
                    "original_text": "Treatment of brain metastasis",
                    "umls_id": "C0220650",
                    "parsed_text": "brain metastasis"
                }
            },
            {
                "compound_id": 10287099,
                "inchl_key": "RMDMBHQVNHQDDD-VFWKRBOSSA-L",
                "generic_name": "trans sodium crocetinate",
                "designated_date": "07/21/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Diffusion Pharmaceuticals, LLC|2020 Avon Court|Suite 4|Charlottesville|Virginia|22902|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioblastoma in conjunction with radiotherapy",
                    "umls_id": "C0017636",
                    "parsed_text": "Glioblastoma"
                }
            }
        ]
    },
    {
        "_id": "PHLBKPHSAVXXEF-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5533,
                "inchl_key": "PHLBKPHSAVXXEF-UHFFFAOYSA-N",
                "generic_name": "trazodone",
                "designated_date": "08/18/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Epygenix Therapeutics, Inc.|140 E. Ridgewood Avenue|Suite 415 South Tower|Paramus|New Jersey|7652|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Dravet syndrome",
                    "umls_id": "C0751122",
                    "parsed_text": "Dravet Syndrome"
                }
            }
        ]
    },
    {
        "_id": "ZBVJFYPGLGEMIN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25091037,
                "inchl_key": "ZBVJFYPGLGEMIN-UHFFFAOYSA-N",
                "generic_name": "Triptorelin pamoate",
                "designated_date": "08/10/1990",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Debio R.A. Inc.|7929 Westpark Drive, Suite 400|Mclean|Virginia|22102|United States",
                "orphan_designation": {
                    "original_text": "For use in the palliative treatment of advanced ovarian carcinoma of epithelial origin.",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian carcinoma"
                }
            },
            {
                "compound_id": 25091037,
                "inchl_key": "ZBVJFYPGLGEMIN-UHFFFAOYSA-N",
                "generic_name": "triptorelin pamoate",
                "trade_name": "Triptodur",
                "designated_date": "08/20/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of pediatric patients 2 years of age and older with central precocious puberty",
                "marketing_approval_date": "\u00a006/29/2017\u00a0",
                "exclusivity_end_date": "\u00a006/29/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of pediatric patients 2 years of age and older with central precocious puberty",
                "sponsor": "Arbor Pharmaceuticals, LLC|6 Concourse Parkway|Suite 1800|Atlanta|Georgia|30328|United States",
                "orphan_designation": {
                    "original_text": "Treatment of central precocious puberty",
                    "umls_id": "C0342543",
                    "parsed_text": "Central Precocious Puberty"
                }
            }
        ]
    },
    {
        "_id": "ZBVJFYPGLGEMIN-IKNXIQPFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 60196291,
                "inchl_key": "ZBVJFYPGLGEMIN-IKNXIQPFSA-N",
                "generic_name": "Triptorelin pamoate",
                "designated_date": "08/10/1990",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Debio R.A. Inc.|7929 Westpark Drive, Suite 400|Mclean|Virginia|22102|United States",
                "orphan_designation": {
                    "original_text": "For use in the palliative treatment of advanced ovarian carcinoma of epithelial origin.",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian carcinoma"
                }
            },
            {
                "compound_id": 60196291,
                "inchl_key": "ZBVJFYPGLGEMIN-IKNXIQPFSA-N",
                "generic_name": "triptorelin pamoate",
                "trade_name": "Triptodur",
                "designated_date": "08/20/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of pediatric patients 2 years of age and older with central precocious puberty",
                "marketing_approval_date": "\u00a006/29/2017\u00a0",
                "exclusivity_end_date": "\u00a006/29/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of pediatric patients 2 years of age and older with central precocious puberty",
                "sponsor": "Arbor Pharmaceuticals, LLC|6 Concourse Parkway|Suite 1800|Atlanta|Georgia|30328|United States",
                "orphan_designation": {
                    "original_text": "Treatment of central precocious puberty",
                    "umls_id": "C0342543",
                    "parsed_text": "Central Precocious Puberty"
                }
            }
        ]
    },
    {
        "_id": "ZBVJFYPGLGEMIN-OYLNGHKZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25074469,
                "inchl_key": "ZBVJFYPGLGEMIN-OYLNGHKZSA-N",
                "generic_name": "Triptorelin pamoate",
                "designated_date": "08/10/1990",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Debio R.A. Inc.|7929 Westpark Drive, Suite 400|Mclean|Virginia|22102|United States",
                "orphan_designation": {
                    "original_text": "For use in the palliative treatment of advanced ovarian carcinoma of epithelial origin.",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian carcinoma"
                }
            },
            {
                "compound_id": 25074469,
                "inchl_key": "ZBVJFYPGLGEMIN-OYLNGHKZSA-N",
                "generic_name": "triptorelin pamoate",
                "trade_name": "Triptodur",
                "designated_date": "08/20/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of pediatric patients 2 years of age and older with central precocious puberty",
                "marketing_approval_date": "\u00a006/29/2017\u00a0",
                "exclusivity_end_date": "\u00a006/29/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of pediatric patients 2 years of age and older with central precocious puberty",
                "sponsor": "Arbor Pharmaceuticals, LLC|6 Concourse Parkway|Suite 1800|Atlanta|Georgia|30328|United States",
                "orphan_designation": {
                    "original_text": "Treatment of central precocious puberty",
                    "umls_id": "C0342543",
                    "parsed_text": "Central Precocious Puberty"
                }
            }
        ]
    },
    {
        "_id": "BUSXWGRAOZQTEY-SDBXPKJASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11318905,
                "inchl_key": "BUSXWGRAOZQTEY-SDBXPKJASA-N",
                "generic_name": "Trofinetide",
                "designated_date": "02/11/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ACADIA Pharmaceuticals Inc.|3611 Valley Centre Drive|Suite 300|San Diego|California|92130|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Rett syndrome",
                    "umls_id": "C0035372",
                    "parsed_text": "Rett Syndrome"
                }
            },
            {
                "compound_id": 11318905,
                "inchl_key": "BUSXWGRAOZQTEY-SDBXPKJASA-N",
                "generic_name": "Trofinetide",
                "designated_date": "10/23/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ACADIA Pharmaceuticals Inc.|3611 Valley Centre Drive|Suite 300|San Diego|California|92130|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X Syndrome",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "ISAVYTVYFVQUDY-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 8814,
                "inchl_key": "ISAVYTVYFVQUDY-UHFFFAOYSA-N",
                "generic_name": "Tyloxapol",
                "designated_date": "03/08/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kennedy & Hoidal, M.D.'s|University of Utah Health Sciences Center|50 North Medical Drive, Room 4R240|Salt Lake City|Utah|84132|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis.",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "GWJOFBXSBDVUMH-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16219992,
                "inchl_key": "GWJOFBXSBDVUMH-UHFFFAOYSA-N",
                "generic_name": "Tyloxapol",
                "designated_date": "03/08/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kennedy & Hoidal, M.D.'s|University of Utah Health Sciences Center|50 North Medical Drive, Room 4R240|Salt Lake City|Utah|84132|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis.",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "MDYZKJNTKZIUSK-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71388,
                "inchl_key": "MDYZKJNTKZIUSK-UHFFFAOYSA-N",
                "generic_name": "Tyloxapol",
                "designated_date": "03/08/1995",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kennedy & Hoidal, M.D.'s|University of Utah Health Sciences Center|50 North Medical Drive, Room 4R240|Salt Lake City|Utah|84132|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis.",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "WYQFJHHDOKWSHR-MNOVXSKESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 58557659,
                "inchl_key": "WYQFJHHDOKWSHR-MNOVXSKESA-N",
                "generic_name": "upadacitinib",
                "designated_date": "08/16/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric systemic juvenile idiopathic arthritis",
                    "umls_id": "C1384600",
                    "parsed_text": "Systemic juvenile idiopathic arthritis"
                }
            },
            {
                "compound_id": 58557659,
                "inchl_key": "WYQFJHHDOKWSHR-MNOVXSKESA-N",
                "generic_name": "upadacitinib",
                "designated_date": "12/30/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AbbVie|1 North Waukegan Road|North Chicago|Illinois|60044|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric ulcerative colitis",
                    "umls_id": "C2931173",
                    "parsed_text": "Pediatric ulcerative colitis"
                }
            },
            {
                "compound_id": 58557659,
                "inchl_key": "WYQFJHHDOKWSHR-MNOVXSKESA-N",
                "generic_name": "upadacitinib",
                "designated_date": "09/18/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric (aged 0 through 16 years) juvenile idiopathic arthritis (JIA) ILAR categories excluding systemic JIA",
                    "umls_id": "C3495559,C3714757",
                    "parsed_text": "juvenile idiopathic arthritis , Juvenile idiopathic arthritis"
                }
            }
        ]
    },
    {
        "_id": "JZCILZBQRWUKME-SPOOISQMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 154731995,
                "inchl_key": "JZCILZBQRWUKME-SPOOISQMSA-N",
                "generic_name": "valine-valine-ganciclovir",
                "designated_date": "05/21/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Verenta Pharmaceuticals, Inc.|10901 Granada Lane|Suite 101|Leawood|Kansas|66211|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HSV1 and HSV2.",
                    "umls_id": "C0022568,C0022573",
                    "parsed_text": "Keratitis , Keratoconjunctivitis"
                }
            }
        ]
    },
    {
        "_id": "YFHRCLAKZBDRHN-MRXNPFEDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 60199242,
                "inchl_key": "YFHRCLAKZBDRHN-MRXNPFEDSA-N",
                "generic_name": "Venglustat",
                "designated_date": "08/26/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genzyme Corporation|500 Kendall Street|Cambridge|Massachusetts|1242|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fabry's disease",
                    "umls_id": "C0002986",
                    "parsed_text": "Fabry's Disease"
                }
            },
            {
                "compound_id": 60199242,
                "inchl_key": "YFHRCLAKZBDRHN-MRXNPFEDSA-N",
                "generic_name": "venglustat",
                "designated_date": "05/01/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genzyme Corporation, a SANOFI COMPANY|50 Binney Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Autosomal Dominant Polycystic Kidney Disease",
                    "umls_id": "C0085413",
                    "parsed_text": "Autosomal dominant polycystic kidney disease"
                }
            },
            {
                "compound_id": 60199242,
                "inchl_key": "YFHRCLAKZBDRHN-MRXNPFEDSA-N",
                "generic_name": "venglustat",
                "designated_date": "09/11/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genzyme|500 Kendall Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Gaucher disease",
                    "umls_id": "C0017205",
                    "parsed_text": "Gaucher Disease"
                }
            }
        ]
    },
    {
        "_id": "HJOCKFVCMLCPTP-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71424,
                "inchl_key": "HJOCKFVCMLCPTP-UHFFFAOYSA-N",
                "generic_name": "viloxazine HCL",
                "designated_date": "06/11/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Stuart Pharmaceuticals|Division of ICI Americas|Wilmington|Delaware|19897|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cataplexy and narcolepsy",
                    "umls_id": "C0751362",
                    "parsed_text": "Cataplexy and narcolepsy"
                }
            }
        ]
    },
    {
        "_id": "KUZYSQSABONDME-QRLOMCMNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25014653,
                "inchl_key": "KUZYSQSABONDME-QRLOMCMNSA-N",
                "generic_name": "vintafolide",
                "designated_date": "12/16/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Endocyte, Inc.|3000 Kent Avenue|Suite A1-100|West Lafayette|Indiana|47906|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "JESCETIFNOFKEU-SJORKVTESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16046068,
                "inchl_key": "JESCETIFNOFKEU-SJORKVTESA-N",
                "generic_name": "vixotrigine",
                "designated_date": "07/24/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biogen, Inc.|300 Binney Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of trigeminal neuralgia",
                    "umls_id": "C0040997",
                    "parsed_text": "Trigeminal Neuralgia"
                }
            }
        ]
    },
    {
        "_id": "XRASPMIURGNCCH-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 68740,
                "inchl_key": "XRASPMIURGNCCH-UHFFFAOYSA-N",
                "generic_name": "zoledronic acid",
                "designated_date": "05/06/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Axsome Therapeutics, Inc.|25 Broadway, 9th Floor|Suite 2000|New York|New York|10004|United States",
                "orphan_designation": {
                    "original_text": "Treatment of complex regional pain syndrome",
                    "umls_id": "C0458219",
                    "parsed_text": "Complex regional pain syndrome"
                }
            },
            {
                "compound_id": 68740,
                "inchl_key": "XRASPMIURGNCCH-UHFFFAOYSA-N",
                "generic_name": "Zoledronate",
                "trade_name": "Zometa, Zabel",
                "designated_date": "08/18/2000",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of hypercalcemia of malignancy.",
                "marketing_approval_date": "\u00a008/20/2001\u00a0",
                "exclusivity_end_date": "\u00a008/20/2008\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corp.|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of tumor induced hypercalcemia.",
                    "umls_id": "C0020437,C0027651",
                    "parsed_text": "Hypercalcemia , Tumor"
                }
            }
        ]
    },
    {
        "_id": "AUODDLQVRAJAJM-DOPPNGDLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 137705122,
                "inchl_key": "AUODDLQVRAJAJM-DOPPNGDLSA-N",
                "generic_name": "Clindamycin hydrochloride",
                "designated_date": "08/09/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Autoimmunity Research Foundation|Autoimmunity Research, Inc.|Thousand Oaks|California|91360|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sarcoidosis",
                    "umls_id": "C0036202",
                    "parsed_text": "Sarcoidosis"
                }
            }
        ]
    },
    {
        "_id": "AUODDLQVRAJAJM-OKBXBIFFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134693959,
                "inchl_key": "AUODDLQVRAJAJM-OKBXBIFFSA-N",
                "generic_name": "Clindamycin hydrochloride",
                "designated_date": "08/09/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Autoimmunity Research Foundation|Autoimmunity Research, Inc.|Thousand Oaks|California|91360|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sarcoidosis",
                    "umls_id": "C0036202",
                    "parsed_text": "Sarcoidosis"
                }
            }
        ]
    },
    {
        "_id": "AUODDLQVRAJAJM-PIPVPTKYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134129519,
                "inchl_key": "AUODDLQVRAJAJM-PIPVPTKYSA-N",
                "generic_name": "Clindamycin hydrochloride",
                "designated_date": "08/09/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Autoimmunity Research Foundation|Autoimmunity Research, Inc.|Thousand Oaks|California|91360|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sarcoidosis",
                    "umls_id": "C0036202",
                    "parsed_text": "Sarcoidosis"
                }
            }
        ]
    },
    {
        "_id": "AUODDLQVRAJAJM-ZSHBVFQLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 86222708,
                "inchl_key": "AUODDLQVRAJAJM-ZSHBVFQLSA-N",
                "generic_name": "Clindamycin hydrochloride",
                "designated_date": "08/09/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Autoimmunity Research Foundation|Autoimmunity Research, Inc.|Thousand Oaks|California|91360|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sarcoidosis",
                    "umls_id": "C0036202",
                    "parsed_text": "Sarcoidosis"
                }
            }
        ]
    },
    {
        "_id": "AUODDLQVRAJAJM-VSPYWEHYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 75534857,
                "inchl_key": "AUODDLQVRAJAJM-VSPYWEHYSA-N",
                "generic_name": "Clindamycin hydrochloride",
                "designated_date": "08/09/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Autoimmunity Research Foundation|Autoimmunity Research, Inc.|Thousand Oaks|California|91360|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sarcoidosis",
                    "umls_id": "C0036202",
                    "parsed_text": "Sarcoidosis"
                }
            }
        ]
    },
    {
        "_id": "AUODDLQVRAJAJM-FWTPQNFYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 46738091,
                "inchl_key": "AUODDLQVRAJAJM-FWTPQNFYSA-N",
                "generic_name": "Clindamycin hydrochloride",
                "designated_date": "08/09/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Autoimmunity Research Foundation|Autoimmunity Research, Inc.|Thousand Oaks|California|91360|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sarcoidosis",
                    "umls_id": "C0036202",
                    "parsed_text": "Sarcoidosis"
                }
            }
        ]
    },
    {
        "_id": "AUODDLQVRAJAJM-XNQAQEGKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44629924,
                "inchl_key": "AUODDLQVRAJAJM-XNQAQEGKSA-N",
                "generic_name": "Clindamycin hydrochloride",
                "designated_date": "08/09/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Autoimmunity Research Foundation|Autoimmunity Research, Inc.|Thousand Oaks|California|91360|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sarcoidosis",
                    "umls_id": "C0036202",
                    "parsed_text": "Sarcoidosis"
                }
            }
        ]
    },
    {
        "_id": "AUODDLQVRAJAJM-CTEDBMRYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16219133,
                "inchl_key": "AUODDLQVRAJAJM-CTEDBMRYSA-N",
                "generic_name": "Clindamycin hydrochloride",
                "designated_date": "08/09/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Autoimmunity Research Foundation|Autoimmunity Research, Inc.|Thousand Oaks|California|91360|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sarcoidosis",
                    "umls_id": "C0036202",
                    "parsed_text": "Sarcoidosis"
                }
            }
        ]
    },
    {
        "_id": "AUODDLQVRAJAJM-KBTFJHITSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 46781040,
                "inchl_key": "AUODDLQVRAJAJM-KBTFJHITSA-N",
                "generic_name": "Clindamycin hydrochloride",
                "designated_date": "08/09/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Autoimmunity Research Foundation|Autoimmunity Research, Inc.|Thousand Oaks|California|91360|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sarcoidosis",
                    "umls_id": "C0036202",
                    "parsed_text": "Sarcoidosis"
                }
            }
        ]
    },
    {
        "_id": "AUODDLQVRAJAJM-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 21872021,
                "inchl_key": "AUODDLQVRAJAJM-UHFFFAOYSA-N",
                "generic_name": "Clindamycin hydrochloride",
                "designated_date": "08/09/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Autoimmunity Research Foundation|Autoimmunity Research, Inc.|Thousand Oaks|California|91360|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sarcoidosis",
                    "umls_id": "C0036202",
                    "parsed_text": "Sarcoidosis"
                }
            }
        ]
    },
    {
        "_id": "AUODDLQVRAJAJM-SVLAMSDMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5702025,
                "inchl_key": "AUODDLQVRAJAJM-SVLAMSDMSA-N",
                "generic_name": "Clindamycin hydrochloride",
                "designated_date": "08/09/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Autoimmunity Research Foundation|Autoimmunity Research, Inc.|Thousand Oaks|California|91360|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sarcoidosis",
                    "umls_id": "C0036202",
                    "parsed_text": "Sarcoidosis"
                }
            }
        ]
    },
    {
        "_id": "AUODDLQVRAJAJM-GQYOKNPUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 441204,
                "inchl_key": "AUODDLQVRAJAJM-GQYOKNPUSA-N",
                "generic_name": "Clindamycin hydrochloride",
                "designated_date": "08/09/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Autoimmunity Research Foundation|Autoimmunity Research, Inc.|Thousand Oaks|California|91360|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sarcoidosis",
                    "umls_id": "C0036202",
                    "parsed_text": "Sarcoidosis"
                }
            }
        ]
    },
    {
        "_id": "AUODDLQVRAJAJM-PTTDBYGSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6419884,
                "inchl_key": "AUODDLQVRAJAJM-PTTDBYGSSA-N",
                "generic_name": "Clindamycin hydrochloride",
                "designated_date": "08/09/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Autoimmunity Research Foundation|Autoimmunity Research, Inc.|Thousand Oaks|California|91360|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sarcoidosis",
                    "umls_id": "C0036202",
                    "parsed_text": "Sarcoidosis"
                }
            }
        ]
    },
    {
        "_id": "AUODDLQVRAJAJM-XJQDNNTCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16051951,
                "inchl_key": "AUODDLQVRAJAJM-XJQDNNTCSA-N",
                "generic_name": "Clindamycin hydrochloride",
                "designated_date": "08/09/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Autoimmunity Research Foundation|Autoimmunity Research, Inc.|Thousand Oaks|California|91360|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sarcoidosis",
                    "umls_id": "C0036202",
                    "parsed_text": "Sarcoidosis"
                }
            }
        ]
    },
    {
        "_id": "CVSVTCORWBXHQV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 586,
                "inchl_key": "CVSVTCORWBXHQV-UHFFFAOYSA-N",
                "generic_name": "Creatine",
                "designated_date": "10/11/2005",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Marathon Pharmaceuticals, LLC|1033 Skokie Blvd|Suite 600|Northbrook|Illinois|60062|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Huntington's disease",
                    "umls_id": "C0020179",
                    "parsed_text": "Huntington's Disease"
                }
            },
            {
                "compound_id": 586,
                "inchl_key": "CVSVTCORWBXHQV-UHFFFAOYSA-N",
                "generic_name": "creatine",
                "designated_date": "02/12/2002",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Avicena Group, Inc.|580 California St.|Suite 1600|San Francisco|California|94104|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "CMSMOCZEIVJLDB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2907,
                "inchl_key": "CMSMOCZEIVJLDB-UHFFFAOYSA-N",
                "generic_name": "cyclophosphamide",
                "designated_date": "06/07/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Accentia Biopharmaceuticals, Inc.|324 South Hyde Avenue, Suite 350|Tampa|Florida|33606|United States",
                "orphan_designation": {
                    "original_text": "Treatment of systemic sclerosis.",
                    "umls_id": "C0036421",
                    "parsed_text": "Systemic sclerosis"
                }
            },
            {
                "compound_id": 2907,
                "inchl_key": "CMSMOCZEIVJLDB-UHFFFAOYSA-N",
                "generic_name": "cyclophosphamide",
                "designated_date": "06/17/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Accentia Biopharmaceuticals, Inc.|324 S. Hyde Park Avenue|Tampa|Florida|33606|United States",
                "orphan_designation": {
                    "original_text": "Prevention of graft versus host disease following allogeneic hematopoietic stem cell transplant",
                    "umls_id": "C0018133",
                    "parsed_text": "GRAFT VERSUS HOST DISEASE"
                }
            }
        ]
    },
    {
        "_id": "PMATZTZNYRCHOR-WIUPBDCUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 132274082,
                "inchl_key": "PMATZTZNYRCHOR-WIUPBDCUSA-N",
                "generic_name": "Cyclosporin A",
                "designated_date": "10/29/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Maas Biolab,LLC|Tecnology Ventures Corporation Technopolis|1155 University Blvd., SE|Albuquerque|New Mexico|87106|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis and its variants",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "PMATZTZNYRCHOR-ONJQHLSTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 129009974,
                "inchl_key": "PMATZTZNYRCHOR-ONJQHLSTSA-N",
                "generic_name": "Cyclosporin A",
                "designated_date": "10/29/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Maas Biolab,LLC|Tecnology Ventures Corporation Technopolis|1155 University Blvd., SE|Albuquerque|New Mexico|87106|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis and its variants",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "PMATZTZNYRCHOR-BMGRVWOJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71306795,
                "inchl_key": "PMATZTZNYRCHOR-BMGRVWOJSA-N",
                "generic_name": "Cyclosporin A",
                "designated_date": "10/29/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Maas Biolab,LLC|Tecnology Ventures Corporation Technopolis|1155 University Blvd., SE|Albuquerque|New Mexico|87106|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis and its variants",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "PMATZTZNYRCHOR-WCIOLWJGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5458585,
                "inchl_key": "PMATZTZNYRCHOR-WCIOLWJGSA-N",
                "generic_name": "Cyclosporin A",
                "designated_date": "10/29/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Maas Biolab,LLC|Tecnology Ventures Corporation Technopolis|1155 University Blvd., SE|Albuquerque|New Mexico|87106|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis and its variants",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "PMATZTZNYRCHOR-LQJDIJJQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 73896891,
                "inchl_key": "PMATZTZNYRCHOR-LQJDIJJQSA-N",
                "generic_name": "Cyclosporin A",
                "designated_date": "10/29/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Maas Biolab,LLC|Tecnology Ventures Corporation Technopolis|1155 University Blvd., SE|Albuquerque|New Mexico|87106|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis and its variants",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "TZXKOCQBRNJULO-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2972,
                "inchl_key": "TZXKOCQBRNJULO-UHFFFAOYSA-N",
                "generic_name": "deferiprone",
                "designated_date": "07/31/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Chiesi USA, Inc.|175 Regency Woods Place|Suite 600|Cary|North Carolina|27518|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Friedreich's ataxia",
                    "umls_id": "C0016719",
                    "parsed_text": "Friedreich's Ataxia"
                }
            },
            {
                "compound_id": 2972,
                "inchl_key": "TZXKOCQBRNJULO-UHFFFAOYSA-N",
                "generic_name": "deferiprone",
                "trade_name": "Ferriprox",
                "designated_date": "12/12/2001",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Ferriprox (deferiprone) is indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.",
                "marketing_approval_date": "\u00a005/19/2020\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Chiesi USA, Inc.|175 Regency Woods Place|Suite 600|Cary|North Carolina|27518|United States",
                "orphan_designation": {
                    "original_text": "Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy",
                    "umls_id": "C0018939,C0282193",
                    "parsed_text": "Hematologic Disorders , Iron Overload"
                }
            },
            {
                "compound_id": 2972,
                "inchl_key": "TZXKOCQBRNJULO-UHFFFAOYSA-N",
                "generic_name": "deferiprone",
                "trade_name": "Ferriprox",
                "designated_date": "12/12/2001",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate",
                "marketing_approval_date": "\u00a010/14/2011\u00a0",
                "exclusivity_end_date": "\u00a010/14/2018\u00a0",
                "sponsor": "Chiesi USA, Inc.|175 Regency Woods Place|Suite 600|Cary|North Carolina|27518|United States",
                "orphan_designation": {
                    "original_text": "Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy",
                    "umls_id": "C0018939,C0282193",
                    "parsed_text": "Hematologic Disorders , Iron Overload"
                }
            },
            {
                "compound_id": 2972,
                "inchl_key": "TZXKOCQBRNJULO-UHFFFAOYSA-N",
                "generic_name": "deferiprone",
                "designated_date": "06/15/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Chiesi USA, Inc.|175 Regency Woods Place|Suite 600|Cary|North Carolina|27518|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neurodegeneration with brain iron accumulation (NBIA)",
                    "umls_id": "C5194180",
                    "parsed_text": "Iron accumulation"
                }
            },
            {
                "compound_id": 2972,
                "inchl_key": "TZXKOCQBRNJULO-UHFFFAOYSA-N",
                "generic_name": "deferiprone",
                "designated_date": "09/01/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Chiesi USA, Inc.|175 Regency Woods Place|Suite 600|Cary|North Carolina|27518|United States",
                "orphan_designation": {
                    "original_text": "Treatment of superficial siderosis",
                    "umls_id": "C0037061",
                    "parsed_text": "Siderosis"
                }
            }
        ]
    },
    {
        "_id": "OEUUFNIKLCFNLN-LLVKDONJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135413558,
                "inchl_key": "OEUUFNIKLCFNLN-LLVKDONJSA-N",
                "generic_name": "Deferitrin",
                "designated_date": "04/14/2004",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genzyme Corporation|153 Second Avenue|Waltham|Massachusetts|2451|United States",
                "orphan_designation": {
                    "original_text": "Treatment of iron overload",
                    "umls_id": "C0282193",
                    "parsed_text": "Iron Overload"
                }
            }
        ]
    },
    {
        "_id": "LFQSCWFLJHTTHZ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 702,
                "inchl_key": "LFQSCWFLJHTTHZ-UHFFFAOYSA-N",
                "generic_name": "Dehydrated alcohol",
                "designated_date": "07/10/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eton Pharmaceuticals|21925 W. Field Pkwy|Suite 235|Deer Park|Illinois|60010|United States",
                "orphan_designation": {
                    "original_text": "Treatment of methanol poisoning",
                    "umls_id": "C0392621",
                    "parsed_text": "methanol poisoning"
                }
            },
            {
                "compound_id": 702,
                "inchl_key": "LFQSCWFLJHTTHZ-UHFFFAOYSA-N",
                "generic_name": "dehydrated alcohol",
                "designated_date": "03/16/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Luitpold Pharmaceuticals, Inc.|One Luitpold Drive|P. O. Box 9001|Shirley|New York|11967|United States",
                "orphan_designation": {
                    "original_text": "Treatment of trigeminal neuralgia",
                    "umls_id": "C0040997",
                    "parsed_text": "Trigeminal Neuralgia"
                }
            },
            {
                "compound_id": 702,
                "inchl_key": "LFQSCWFLJHTTHZ-UHFFFAOYSA-N",
                "generic_name": "dehydrated alcohol",
                "trade_name": "Ablysinol",
                "designated_date": "09/11/2013",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "ABLYSINOL is indicated to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy.",
                "marketing_approval_date": "\u00a006/21/2018\u00a0",
                "exclusivity_end_date": "\u00a006/21/2025\u00a0",
                "exclusivity_protected_indication": "ABLYSINOL is indicated to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy.",
                "sponsor": "Belcher Pharmaceuticals, LLC|6911 Bryan Dairy Road|Largo|Florida|33777|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hypertrophic obstructive cardiomyopathy",
                    "umls_id": "C4551472",
                    "parsed_text": "Hypertrophic obstructive cardiomyopathy"
                }
            }
        ]
    },
    {
        "_id": "SSNHGLKFJISNTR-FWUPRJFYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44148067,
                "inchl_key": "SSNHGLKFJISNTR-FWUPRJFYSA-N",
                "generic_name": "delta-9-tetrahydrocannabinol and cannabidiol",
                "designated_date": "03/07/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PhytoPain Pharma Inc.|9315-4466 Quebec Inc|1230 Boise Street|Boucherville|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of complex regional pain syndrome",
                    "umls_id": "C0458219",
                    "parsed_text": "Complex regional pain syndrome"
                }
            },
            {
                "compound_id": 44148067,
                "inchl_key": "SSNHGLKFJISNTR-FWUPRJFYSA-N",
                "generic_name": "delta-9-tetrahydrocannabinol and cannabidiol",
                "designated_date": "01/29/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MMJ International Holdings|1895 Preston White Drive|Suite 101|Reston|Virginia|20191|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Huntington's Disease",
                    "umls_id": "C0020179",
                    "parsed_text": "Huntington's Disease"
                }
            },
            {
                "compound_id": 44148067,
                "inchl_key": "SSNHGLKFJISNTR-FWUPRJFYSA-N",
                "generic_name": "delta-9-tetrahydrocannabinol and cannabidiol",
                "designated_date": "04/14/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Tetra Bio-Pharma Inc.|365 St.-Jean Street|Suite 122|Longueuil|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of Epidermolysis Bullosa",
                    "umls_id": "C0014527",
                    "parsed_text": "Epidermolysis Bullosa"
                }
            }
        ]
    },
    {
        "_id": "BIFMNMPSIYHKDN-FJXQXJEOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6918223,
                "inchl_key": "BIFMNMPSIYHKDN-FJXQXJEOSA-N",
                "generic_name": "dexrazoxane hydrochloride",
                "designated_date": "08/19/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Satiscor, LLC|45 Marine Road|Boston|Massachusetts|2127|United States",
                "orphan_designation": {
                    "original_text": "Prevention of cardiomyopathy for chilren and adolescents 0 through 16 years of age treated with anthracyclines",
                    "umls_id": "C0878544",
                    "parsed_text": "Cardiomyopathy"
                }
            }
        ]
    },
    {
        "_id": "GDLBFKVLRPITMI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3019,
                "inchl_key": "GDLBFKVLRPITMI-UHFFFAOYSA-N",
                "generic_name": "diazoxide",
                "designated_date": "12/03/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sedogen, LLC|1701 East Lake Avenue|Suite260|Glenview|Illinois|60025|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Prader Willi Syndrome",
                    "umls_id": "C0032897",
                    "parsed_text": "Prader Willi syndrome"
                }
            }
        ]
    },
    {
        "_id": "BXZVVICBKDXVGW-NKWVEPMBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135398739,
                "inchl_key": "BXZVVICBKDXVGW-NKWVEPMBSA-N",
                "generic_name": "Dideoxyinosine",
                "designated_date": "06/22/1988",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb|2400 West Lloyd Expressway|Evansville|Indiana|47721|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acquired immunodeficiency syndrome.",
                    "umls_id": "C0021051",
                    "parsed_text": "Immunodeficiency Syndrome"
                }
            }
        ]
    },
    {
        "_id": "NVKAWKQGWWIWPM-ABEVXSGRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10635,
                "inchl_key": "NVKAWKQGWWIWPM-ABEVXSGRSA-N",
                "generic_name": "Dihydrotestosterone",
                "designated_date": "02/05/1996",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Besins Internaitonal, US Inc.|610 Herndon Parkway|Suite 750|Herndon|Virginia|20170|United States",
                "orphan_designation": {
                    "original_text": "Treatment of weight loss in AIDS patients with HIV-associated wasting.",
                    "umls_id": "C0006625,C0019682,C4084774",
                    "parsed_text": "Wasting , HIV , Weight loss"
                }
            }
        ]
    },
    {
        "_id": "CTENFNNZBMHDDG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 65340,
                "inchl_key": "CTENFNNZBMHDDG-UHFFFAOYSA-N",
                "generic_name": "dopamine hydrochloride",
                "designated_date": "10/24/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Brepco Biopharma, Ltd.|1785 Old Mill Road|Bethlehem|Pennsylvania|18015|United States",
                "orphan_designation": {
                    "original_text": "Prevention of intraventricular hemorrhage in hypotensive premature neonates",
                    "umls_id": "C0151526,C0240059,C0857353",
                    "parsed_text": "Premature , Intraventricular hemorrhage , Hypotensive"
                }
            }
        ]
    },
    {
        "_id": "AVAACINZEOAHHE-VFZPANTDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 73303,
                "inchl_key": "AVAACINZEOAHHE-VFZPANTDSA-N",
                "generic_name": "Doripenem",
                "designated_date": "07/16/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Shionogi, Inc.|300 Campus Drive|Suite 300|Florham Park|New Jersey|7932|United States",
                "orphan_designation": {
                    "original_text": "Treatment of bronchopulmonary infection in patients with cystic fibrosis who are colonized with Pseudomonas aeruginosa or Burkholderia cepacia.",
                    "umls_id": "C0009450,C0010674",
                    "parsed_text": "Infection , Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "ZUJBBVJXXYRPFS-DYKIIFRCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71722017,
                "inchl_key": "ZUJBBVJXXYRPFS-DYKIIFRCSA-N",
                "generic_name": "dusquetide",
                "designated_date": "08/10/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Soligenix, Inc.|29 Emmons Drive|Suite B-10|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of macrophage activation syndrome",
                    "umls_id": "C1096155",
                    "parsed_text": "Macrophage Activation Syndrome"
                }
            }
        ]
    },
    {
        "_id": "ZJIHMALTJRDNQI-VFQQELCFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 13018787,
                "inchl_key": "ZJIHMALTJRDNQI-VFQQELCFSA-N",
                "generic_name": "duvoglustat hydrochloride",
                "designated_date": "06/18/2007",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Amicus Therapeutics, Inc|1 Cedarbrook Drive|Cranbury|New Jersey|8512|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pompe disease",
                    "umls_id": "C0017921",
                    "parsed_text": "Pompe Disease"
                }
            }
        ]
    },
    {
        "_id": "OVXQHPWHMXOFRD-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 10547,
                "inchl_key": "OVXQHPWHMXOFRD-UHFFFAOYSA-M",
                "generic_name": "echothiophate iodide",
                "designated_date": "06/02/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Makindus, Inc.|3805 Old Easton Road|Doylestown|Pennsylvania|18902|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Stargardt's disease",
                    "umls_id": "C0271093",
                    "parsed_text": "Stargardt's disease"
                }
            }
        ]
    },
    {
        "_id": "JQLBBYLGWHUHRW-KUBAVDMBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44626120,
                "inchl_key": "JQLBBYLGWHUHRW-KUBAVDMBSA-N",
                "generic_name": "Edasalonexent",
                "designated_date": "11/17/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Catabasis Pharmaceuticals, Inc.|One Kendall Square, Suite B14202|Suite B14202|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Duchenne muscular dystrophy",
                    "umls_id": "C0013264",
                    "parsed_text": "DUCHENNE MUSCULAR DYSTROPHY"
                }
            }
        ]
    },
    {
        "_id": "SCVHJVCATBPIHN-SJCJKPOMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 12000240,
                "inchl_key": "SCVHJVCATBPIHN-SJCJKPOMSA-N",
                "generic_name": "emricasan",
                "designated_date": "11/20/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Conatus Pharmaceuticals Inc.|16745 W. Bernardo Drive|Suite 200|San Diego|California|92127|United States",
                "orphan_designation": {
                    "original_text": "Treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end stage liver disease",
                    "umls_id": "C0016059,C0023890,C0745744",
                    "parsed_text": "Fibrosis , Cirrhosis , End Stage Liver Disease"
                }
            }
        ]
    },
    {
        "_id": "FBKMWOJEPMPVTQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135564890,
                "inchl_key": "FBKMWOJEPMPVTQ-UHFFFAOYSA-N",
                "generic_name": "epacadostat",
                "designated_date": "02/11/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Incyte Corporation|1801 Augustine Cut-Off|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of stage IIB-IV melanoma.",
                    "umls_id": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "PIWHBPJCPCXFEU-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 127893,
                "inchl_key": "PIWHBPJCPCXFEU-UHFFFAOYSA-N",
                "generic_name": "Epoetin alfa",
                "designated_date": "12/20/1993",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Johnson & Johnson Pharmaceutical Research & Dev.,|920 U.S. Highway|Route 202, P.O. Box 300|Raritan|New Jersey|8869|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndrome.",
                    "umls_id": "C3463824",
                    "parsed_text": "MYELODYSPLASTIC SYNDROME"
                }
            },
            {
                "compound_id": 127893,
                "inchl_key": "PIWHBPJCPCXFEU-UHFFFAOYSA-N",
                "generic_name": "Epoetin alfa",
                "trade_name": "Epogen",
                "designated_date": "04/10/1986",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of anemia associated with chronic renal failure, including patients on dialysis (end stage renal disesae) and patients not on dialysis",
                "marketing_approval_date": "\u00a006/01/1989\u00a0",
                "exclusivity_end_date": "\u00a006/01/1996\u00a0",
                "sponsor": "Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Treatment of anemia associated with end stage renal disease.",
                    "umls_id": "C0002871,C0022661",
                    "parsed_text": "Anemia , End stage renal disease"
                }
            },
            {
                "compound_id": 127893,
                "inchl_key": "PIWHBPJCPCXFEU-UHFFFAOYSA-N",
                "generic_name": "Epoetin alfa",
                "trade_name": "Epogen",
                "designated_date": "07/01/1991",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of AZT-induced anemia in HIV infected patients.",
                "marketing_approval_date": "\u00a012/31/1990\u00a0",
                "exclusivity_end_date": "\u00a012/31/1997\u00a0",
                "sponsor": "Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Treatment of anemia associated with HIV infection or HIV treatment.",
                    "umls_id": "C0002871,C0019693",
                    "parsed_text": "Anemia , HIV infection"
                }
            }
        ]
    },
    {
        "_id": "QGFORSXNKQLDNO-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 65632,
                "inchl_key": "QGFORSXNKQLDNO-UHFFFAOYSA-N",
                "generic_name": "erdosteine",
                "designated_date": "12/20/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Alitair Pharmaceuticals, Inc.|55 Madison Avenue|Suite 400|Morristown|New Jersey|7960|United States",
                "orphan_designation": {
                    "original_text": "Treatment of bronchiectasis.",
                    "umls_id": "C0006267",
                    "parsed_text": "Bronchiectasis"
                }
            }
        ]
    },
    {
        "_id": "XJDYQYNYISTAMO-GFDYFVENSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25063260,
                "inchl_key": "XJDYQYNYISTAMO-GFDYFVENSA-N",
                "generic_name": "ezatiostat hydrochloride",
                "designated_date": "01/09/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hessian Pharmaceuticals, Inc.|1111 Broadway, 3rd Floor|Suite 03-138|Oakland|California|94607|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndrome",
                    "umls_id": "C3463824",
                    "parsed_text": "MYELODYSPLASTIC SYNDROME"
                }
            }
        ]
    },
    {
        "_id": "WKGXYQFOCVYPAC-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3331,
                "inchl_key": "WKGXYQFOCVYPAC-UHFFFAOYSA-N",
                "generic_name": "Felbamate",
                "trade_name": "Felbatol",
                "designated_date": "01/24/1989",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "As adjunctive therapy in the treatment of partial and generalized seizures associated with the Lennox-Gastaut syndrome in children.",
                "marketing_approval_date": "\u00a007/29/1993\u00a0",
                "exclusivity_end_date": "\u00a007/29/2000\u00a0",
                "sponsor": "Wallace Laboratories|301B College Road East|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Lennox-Gastaut syndrome.",
                    "umls_id": "C0238111",
                    "parsed_text": "Lennox-Gastaut syndrome"
                }
            }
        ]
    },
    {
        "_id": "ZVGNESXIJDCBKN-DEIWUYIYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135391138,
                "inchl_key": "ZVGNESXIJDCBKN-DEIWUYIYSA-N",
                "generic_name": "fidaxomicin",
                "trade_name": "Dificid",
                "designated_date": "12/13/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "DIFICID is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD).",
                "marketing_approval_date": "\u00a001/24/2020\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc.|20 Weystrasse|Luzern|Luzern|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Clostridium difficile infection",
                    "umls_id": "C0343386",
                    "parsed_text": "Clostridium difficile infection"
                }
            }
        ]
    },
    {
        "_id": "ZVGNESXIJDCBKN-JMEUZRPYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 132472265,
                "inchl_key": "ZVGNESXIJDCBKN-JMEUZRPYSA-N",
                "generic_name": "fidaxomicin",
                "trade_name": "Dificid",
                "designated_date": "12/13/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "DIFICID is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD).",
                "marketing_approval_date": "\u00a001/24/2020\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc.|20 Weystrasse|Luzern|Luzern|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Clostridium difficile infection",
                    "umls_id": "C0343386",
                    "parsed_text": "Clostridium difficile infection"
                }
            }
        ]
    },
    {
        "_id": "ZVGNESXIJDCBKN-ZJHJTZDTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 131668620,
                "inchl_key": "ZVGNESXIJDCBKN-ZJHJTZDTSA-N",
                "generic_name": "fidaxomicin",
                "trade_name": "Dificid",
                "designated_date": "12/13/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "DIFICID is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD).",
                "marketing_approval_date": "\u00a001/24/2020\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc.|20 Weystrasse|Luzern|Luzern|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Clostridium difficile infection",
                    "umls_id": "C0343386",
                    "parsed_text": "Clostridium difficile infection"
                }
            }
        ]
    },
    {
        "_id": "ZVGNESXIJDCBKN-DBGJUELJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 117590639,
                "inchl_key": "ZVGNESXIJDCBKN-DBGJUELJSA-N",
                "generic_name": "fidaxomicin",
                "trade_name": "Dificid",
                "designated_date": "12/13/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "DIFICID is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD).",
                "marketing_approval_date": "\u00a001/24/2020\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc.|20 Weystrasse|Luzern|Luzern|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Clostridium difficile infection",
                    "umls_id": "C0343386",
                    "parsed_text": "Clostridium difficile infection"
                }
            }
        ]
    },
    {
        "_id": "ZVGNESXIJDCBKN-KFGPIHIUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 70678896,
                "inchl_key": "ZVGNESXIJDCBKN-KFGPIHIUSA-N",
                "generic_name": "fidaxomicin",
                "trade_name": "Dificid",
                "designated_date": "12/13/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "DIFICID is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD).",
                "marketing_approval_date": "\u00a001/24/2020\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc.|20 Weystrasse|Luzern|Luzern|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Clostridium difficile infection",
                    "umls_id": "C0343386",
                    "parsed_text": "Clostridium difficile infection"
                }
            }
        ]
    },
    {
        "_id": "ZVGNESXIJDCBKN-SZYXOGSFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 102580518,
                "inchl_key": "ZVGNESXIJDCBKN-SZYXOGSFSA-N",
                "generic_name": "fidaxomicin",
                "trade_name": "Dificid",
                "designated_date": "12/13/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "DIFICID is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD).",
                "marketing_approval_date": "\u00a001/24/2020\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc.|20 Weystrasse|Luzern|Luzern|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Clostridium difficile infection",
                    "umls_id": "C0343386",
                    "parsed_text": "Clostridium difficile infection"
                }
            }
        ]
    },
    {
        "_id": "ZVGNESXIJDCBKN-VUCVDCOISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 91885501,
                "inchl_key": "ZVGNESXIJDCBKN-VUCVDCOISA-N",
                "generic_name": "fidaxomicin",
                "trade_name": "Dificid",
                "designated_date": "12/13/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "DIFICID is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD).",
                "marketing_approval_date": "\u00a001/24/2020\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc.|20 Weystrasse|Luzern|Luzern|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Clostridium difficile infection",
                    "umls_id": "C0343386",
                    "parsed_text": "Clostridium difficile infection"
                }
            }
        ]
    },
    {
        "_id": "ZVGNESXIJDCBKN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 151383,
                "inchl_key": "ZVGNESXIJDCBKN-UHFFFAOYSA-N",
                "generic_name": "fidaxomicin",
                "trade_name": "Dificid",
                "designated_date": "12/13/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "DIFICID is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD).",
                "marketing_approval_date": "\u00a001/24/2020\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc.|20 Weystrasse|Luzern|Luzern|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Clostridium difficile infection",
                    "umls_id": "C0343386",
                    "parsed_text": "Clostridium difficile infection"
                }
            }
        ]
    },
    {
        "_id": "ZVGNESXIJDCBKN-LGPUCNCQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 46174142,
                "inchl_key": "ZVGNESXIJDCBKN-LGPUCNCQSA-N",
                "generic_name": "fidaxomicin",
                "trade_name": "Dificid",
                "designated_date": "12/13/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "DIFICID is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD).",
                "marketing_approval_date": "\u00a001/24/2020\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc.|20 Weystrasse|Luzern|Luzern|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Clostridium difficile infection",
                    "umls_id": "C0343386",
                    "parsed_text": "Clostridium difficile infection"
                }
            }
        ]
    },
    {
        "_id": "ZVGNESXIJDCBKN-UUEYKCAUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10034073,
                "inchl_key": "ZVGNESXIJDCBKN-UUEYKCAUSA-N",
                "generic_name": "fidaxomicin",
                "trade_name": "Dificid",
                "designated_date": "12/13/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "DIFICID is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD).",
                "marketing_approval_date": "\u00a001/24/2020\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc.|20 Weystrasse|Luzern|Luzern|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Clostridium difficile infection",
                    "umls_id": "C0343386",
                    "parsed_text": "Clostridium difficile infection"
                }
            }
        ]
    },
    {
        "_id": "LLXISKGBWFTGEI-FQEVSTJZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44224257,
                "inchl_key": "LLXISKGBWFTGEI-FQEVSTJZSA-N",
                "generic_name": "filanesib",
                "designated_date": "05/06/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Array BioPharma, Inc.|3200 Walnut Street|Boulder|Colorado|80301|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma.",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "NHTKGYOMICWFQZ-BBOXMAMFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134812042,
                "inchl_key": "NHTKGYOMICWFQZ-BBOXMAMFSA-N",
                "generic_name": "fosgemcitabine palabenamide",
                "designated_date": "06/11/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NuCana plc|3 Lochside Way|Edinburgh|Scotland|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of biliary tract cancer",
                    "umls_id": "C0750952",
                    "parsed_text": "Biliary Tract Cancer"
                }
            }
        ]
    },
    {
        "_id": "YKGYIDJEEQRWQH-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3447,
                "inchl_key": "YKGYIDJEEQRWQH-UHFFFAOYSA-N",
                "generic_name": "Gabexate",
                "designated_date": "09/18/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenafly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis",
                    "umls_id": "C0042384",
                    "parsed_text": "Vasculitis"
                }
            }
        ]
    },
    {
        "_id": "SDMBRCRVFFHJKR-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 157692,
                "inchl_key": "SDMBRCRVFFHJKR-UHFFFAOYSA-N",
                "generic_name": "gemcabene",
                "designated_date": "02/06/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NeuroBo Pharmaceuticals, Inc.|200 Berkeley Street|FL 19|Boston|Massachusetts|2116|United States",
                "orphan_designation": {
                    "original_text": "Treatment of homozygous familial hypercholesterolemia",
                    "umls_id": "C0020445",
                    "parsed_text": "FAMILIAL HYPERCHOLESTEROLEMIA"
                }
            }
        ]
    },
    {
        "_id": "ZNNLBTZKUZBEKO-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3488,
                "inchl_key": "ZNNLBTZKUZBEKO-UHFFFAOYSA-N",
                "generic_name": "Glyburide",
                "designated_date": "01/12/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biogen Chesapeake LLC|225 Binney Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe cerebral edema in patients with acute ischemic stroke",
                    "umls_id": "C0006114,C0948008",
                    "parsed_text": "Cerebral Edema , Ischemic stroke"
                }
            },
            {
                "compound_id": 3488,
                "inchl_key": "ZNNLBTZKUZBEKO-UHFFFAOYSA-N",
                "generic_name": "glyburide",
                "designated_date": "09/29/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Remedy Pharmaceuticals, Inc.|233 Broadway, Suite 1750|New York|New York|10279|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute spinal cord injury",
                    "umls_id": "C0878589",
                    "parsed_text": "acute spinal cord injury"
                }
            },
            {
                "compound_id": 3488,
                "inchl_key": "ZNNLBTZKUZBEKO-UHFFFAOYSA-N",
                "generic_name": "glyburide",
                "designated_date": "02/08/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Remedy Pharmaceuticals, Inc.|233 Broadway, Suite 1750|New York|New York|10279|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute subarachnoid hemorrhage",
                    "umls_id": "C0038525",
                    "parsed_text": "Subarachnoid Hemorrhage"
                }
            }
        ]
    },
    {
        "_id": "UEAYTGFTNACKMX-VMXHOPILSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9872764,
                "inchl_key": "UEAYTGFTNACKMX-VMXHOPILSA-N",
                "generic_name": "H-Leu-Pro-Pro-Ser-Arg-OH",
                "designated_date": "09/20/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immuno Tech, Inc.|6329 256th Street, NE|Arlington|Washington|98223|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Kaposi sarcoma",
                    "umls_id": "C0036220",
                    "parsed_text": "Kaposi Sarcoma"
                }
            }
        ]
    },
    {
        "_id": "HTTJABKRGRZYRN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 772,
                "inchl_key": "HTTJABKRGRZYRN-UHFFFAOYSA-N",
                "generic_name": "Heparin",
                "designated_date": "11/03/2005",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Vectura Group, Inc.|1 Prospect West|Wiltshire|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "XDXDZDZNSLXDNA-TZNDIEGXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 42890,
                "inchl_key": "XDXDZDZNSLXDNA-TZNDIEGXSA-N",
                "generic_name": "Idarubicin",
                "designated_date": "12/01/1992",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacia & Upjohn|7000 Portage Road|Unit 0633-298-113|Kalamazoo|Michigan|49001|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndromes.",
                    "umls_id": "C3463824",
                    "parsed_text": "Myelodysplastic Syndromes"
                }
            },
            {
                "compound_id": 42890,
                "inchl_key": "XDXDZDZNSLXDNA-TZNDIEGXSA-N",
                "generic_name": "Idarubicin",
                "designated_date": "12/02/1992",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmacia & Upjohn|7000 Portage Road|Unit 0633-298-113|Kalamazoo|Michigan|49001|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic myelogenous leukemia.",
                    "umls_id": "C0023473",
                    "parsed_text": "Chronic myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "TVTXCJFHQKSQQM-LJQIRTBHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 53358942,
                "inchl_key": "TVTXCJFHQKSQQM-LJQIRTBHSA-N",
                "generic_name": "idasanutlin",
                "designated_date": "11/29/2017",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoffmann-La Roche Inc.|430 East 29th Street|New York|New York|10016|United States",
                "orphan_designation": {
                    "original_text": "Treatment of polycythemia vera",
                    "umls_id": "C0032463",
                    "parsed_text": "Polycythemia Vera"
                }
            }
        ]
    },
    {
        "_id": "WFKAJVHLWXSISD-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 68424,
                "inchl_key": "WFKAJVHLWXSISD-UHFFFAOYSA-N",
                "generic_name": "Isobutyramide",
                "designated_date": "12/18/1992",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Perrine, Susan P., M.D.|Boston University|Cancer Research Center|Boston|Massachusetts|2118|United States",
                "orphan_designation": {
                    "original_text": "Treatment of beta-hemoglobinopathies and beta-thalassemia syndromes.",
                    "umls_id": "C0005283,C0019045",
                    "parsed_text": "BETA-THALASSEMIA , Hemoglobinopathies"
                }
            },
            {
                "compound_id": 68424,
                "inchl_key": "WFKAJVHLWXSISD-UHFFFAOYSA-N",
                "generic_name": "Isobutyramide",
                "designated_date": "05/25/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Alpha Therapeutic Corporation|5555 Valley Boulevard|Los Angeles|California|90032|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sickle cell disease and beta thalassemia.",
                    "umls_id": "C0002895,C0005283",
                    "parsed_text": "Sickle Cell Disease , beta Thalassemia"
                }
            }
        ]
    },
    {
        "_id": "KTBSXLIQKWEBRB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 53380437,
                "inchl_key": "KTBSXLIQKWEBRB-UHFFFAOYSA-N",
                "generic_name": "itacitinib",
                "designated_date": "04/17/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Incyte Corporation|1801 Augustine Cut-Off|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of graft versus host disease",
                    "umls_id": "C0018133",
                    "parsed_text": "GRAFT VERSUS HOST DISEASE"
                }
            }
        ]
    },
    {
        "_id": "PPHTXRNHTVLQED-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 172997,
                "inchl_key": "PPHTXRNHTVLQED-UHFFFAOYSA-N",
                "generic_name": "lixivaptan",
                "designated_date": "09/18/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Palladio Biosciences, Inc.|12 Penns Trail|Unit A|Newtown|Pennsylvania|18940|United States",
                "orphan_designation": {
                    "original_text": "Treatment of autosomal dominant polycystic kidney disease (ADPKD)",
                    "umls_id": "C0085413",
                    "parsed_text": "Autosomal dominant polycystic kidney disease"
                }
            }
        ]
    },
    {
        "_id": "KKYABQBFGDZVNQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11552706,
                "inchl_key": "KKYABQBFGDZVNQ-UHFFFAOYSA-N",
                "generic_name": "losmapimod",
                "designated_date": "01/27/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Fulcrum Therapeutics, Inc.|26 Landsdowne Street|5th Floor|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Facioscapulohumeral muscular dystrophy",
                    "umls_id": "C0238288",
                    "parsed_text": "Facioscapulohumeral muscular dystrophy"
                }
            }
        ]
    },
    {
        "_id": "UQRORFVVSGFNRO-XFWSIPNHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 501391,
                "inchl_key": "UQRORFVVSGFNRO-XFWSIPNHSA-N",
                "generic_name": "lucerastat",
                "designated_date": "10/29/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Idorsia Pharmaceuticals US Inc.|1820 Chapel Avenue West|Suite 150|Cherry Hill|New Jersey|8002|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fabry Disease.",
                    "umls_id": "C0002986",
                    "parsed_text": "Fabry Disease"
                }
            }
        ]
    },
    {
        "_id": "KJFBVJALEQWJBS-XUXIUFHCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 471161,
                "inchl_key": "KJFBVJALEQWJBS-XUXIUFHCSA-N",
                "generic_name": "maribavir",
                "designated_date": "02/01/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Takeda Phrmaceuticals USA, Inc.|650 East Kendall Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Prevention of cytomegalovirus viremia and disease in the populations at risk.",
                    "umls_id": "C0012634,C0877635",
                    "parsed_text": "Disease , Cytomegalovirus viremia"
                }
            },
            {
                "compound_id": 471161,
                "inchl_key": "KJFBVJALEQWJBS-XUXIUFHCSA-N",
                "generic_name": "maribavir",
                "designated_date": "06/07/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Takeda Pharmaceuticals USA, Inc.|650 East Kendall Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of clinically significant cytomegalovirus viremia and disease in at-risk patients.",
                    "umls_id": "C0012634,C0877635",
                    "parsed_text": "Disease , Cytomegalovirus viremia"
                }
            }
        ]
    },
    {
        "_id": "ZPXSCAKFGYXMGA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4020,
                "inchl_key": "ZPXSCAKFGYXMGA-UHFFFAOYSA-N",
                "generic_name": "mazindol",
                "designated_date": "07/06/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NLS-0 Pharma AG|10 Breitenweg|CH-6370|Stans NW|Nidwalden|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of narcolepsy",
                    "umls_id": "C0027404",
                    "parsed_text": "Narcolepsy"
                }
            },
            {
                "compound_id": 4020,
                "inchl_key": "ZPXSCAKFGYXMGA-UHFFFAOYSA-N",
                "generic_name": "Mazindol",
                "designated_date": "12/08/1986",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Collipp, Platon J. M.D.|176 Memorial Drive|Jesup|Georgia|31545|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Duchenne muscular dystrophy.",
                    "umls_id": "C0013264",
                    "parsed_text": "DUCHENNE MUSCULAR DYSTROPHY"
                }
            }
        ]
    },
    {
        "_id": "KBOPZPXVLCULAV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4075,
                "inchl_key": "KBOPZPXVLCULAV-UHFFFAOYSA-N",
                "generic_name": "mesalamine",
                "designated_date": "01/19/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Forest Laboratories, Inc.|Harborside Financial Center|Plaza V, Suite 1900|Jersey City|New Jersey|7311|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric ulcerative colitis",
                    "umls_id": "C2931173",
                    "parsed_text": "Pediatric ulcerative colitis"
                }
            }
        ]
    },
    {
        "_id": "CJCSPKMFHVPWAR-JTQLQIEISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 38853,
                "inchl_key": "CJCSPKMFHVPWAR-JTQLQIEISA-N",
                "generic_name": "methyldopa",
                "designated_date": "01/12/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "IM Therapeutics LLC|11001 West 120th Avenue|Suite 400|Broomfield|Colorado|80021|United States",
                "orphan_designation": {
                    "original_text": "Treatment of type 1 diabetes in DQ8 positive patients with residual beta cell function",
                    "umls_id": "C0011854",
                    "parsed_text": "Type 1 Diabetes"
                }
            }
        ]
    },
    {
        "_id": "MXWHMTNPTTVWDM-VEPASKNESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 76961227,
                "inchl_key": "MXWHMTNPTTVWDM-VEPASKNESA-N",
                "generic_name": "Mitoguazone",
                "designated_date": "03/18/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ILEX Oncology, Inc.|4545 Horizon Hill Blvd.|San Antonio|Texas|78229|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma.",
                    "umls_id": "C0001175,C0348394",
                    "parsed_text": "AIDS , Diffuse non-Hodgkin's lymphoma"
                }
            }
        ]
    },
    {
        "_id": "MXWHMTNPTTVWDM-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9991,
                "inchl_key": "MXWHMTNPTTVWDM-UHFFFAOYSA-N",
                "generic_name": "Mitoguazone",
                "designated_date": "03/18/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ILEX Oncology, Inc.|4545 Horizon Hill Blvd.|San Antonio|Texas|78229|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma.",
                    "umls_id": "C0001175,C0348394",
                    "parsed_text": "AIDS , Diffuse non-Hodgkin's lymphoma"
                }
            }
        ]
    },
    {
        "_id": "MXWHMTNPTTVWDM-XVVXZDBVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5363702,
                "inchl_key": "MXWHMTNPTTVWDM-XVVXZDBVSA-N",
                "generic_name": "Mitoguazone",
                "designated_date": "03/18/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ILEX Oncology, Inc.|4545 Horizon Hill Blvd.|San Antonio|Texas|78229|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma.",
                    "umls_id": "C0001175,C0348394",
                    "parsed_text": "AIDS , Diffuse non-Hodgkin's lymphoma"
                }
            }
        ]
    },
    {
        "_id": "MXWHMTNPTTVWDM-NXOFHUPFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5351154,
                "inchl_key": "MXWHMTNPTTVWDM-NXOFHUPFSA-N",
                "generic_name": "Mitoguazone",
                "designated_date": "03/18/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ILEX Oncology, Inc.|4545 Horizon Hill Blvd.|San Antonio|Texas|78229|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma.",
                    "umls_id": "C0001175,C0348394",
                    "parsed_text": "AIDS , Diffuse non-Hodgkin's lymphoma"
                }
            }
        ]
    },
    {
        "_id": "JJVZSYKFCOBILL-MKMRYRNGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 91865076,
                "inchl_key": "JJVZSYKFCOBILL-MKMRYRNGSA-N",
                "generic_name": "motixafortide",
                "designated_date": "09/05/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "BioLineRx, Ltd.|Modiin Technology Park|2 HaMaayan Street|Modiin|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "compound_id": 91865076,
                "inchl_key": "JJVZSYKFCOBILL-MKMRYRNGSA-N",
                "generic_name": "motixafortide",
                "designated_date": "02/01/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "BioLineRx, Ltd.|Modiin Technology Park|2 HaMaayan Street|Modiin|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "ALWKGYPQUAPLQC-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4456,
                "inchl_key": "ALWKGYPQUAPLQC-UHFFFAOYSA-N",
                "generic_name": "neostigmine",
                "designated_date": "03/18/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Luitpold Pharmaceuticals, Inc.|One Luitpold Drive|P. O. Box 9001|Shirley|New York|11967|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute colonic pseudo-obstruction",
                    "umls_id": "C0009377",
                    "parsed_text": "Colonic Pseudo-Obstruction"
                }
            }
        ]
    },
    {
        "_id": "PUUSSSIBPPTKTP-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71237,
                "inchl_key": "PUUSSSIBPPTKTP-UHFFFAOYSA-N",
                "generic_name": "neridronate",
                "designated_date": "03/25/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NovaPharm, LLC|526 Park Ridge Drive|Wayne|Pennsylvania|19087|United States",
                "orphan_designation": {
                    "original_text": "Treatment of complex regional pain syndrome (CRPS-1, CRPS-II, CRPS-NOS)",
                    "umls_id": "C0458219",
                    "parsed_text": "Complex regional pain syndrome"
                }
            }
        ]
    },
    {
        "_id": "YWQFJNWMWZMXRW-HXUWFJFHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 90445883,
                "inchl_key": "YWQFJNWMWZMXRW-HXUWFJFHSA-N",
                "generic_name": "olinciguat",
                "designated_date": "06/04/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cyclerion Therapeutics, Inc.|245 First Street|Riverview II, 18th Floor|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Sickle Cell Disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            }
        ]
    },
    {
        "_id": "DUYJMQONPNNFPI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71496458,
                "inchl_key": "DUYJMQONPNNFPI-UHFFFAOYSA-N",
                "generic_name": "osimertinib",
                "trade_name": "Tagrisso",
                "designated_date": "09/04/2014",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test",
                "marketing_approval_date": "\u00a012/18/2020\u00a0",
                "exclusivity_end_date": "\u00a012/18/2027\u00a0",
                "exclusivity_protected_indication": "adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test",
                "sponsor": "AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer",
                    "umls_id": "C1414313,C3539721",
                    "parsed_text": "EPIDERMAL GROWTH FACTOR RECEPTOR , Non-Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 71496458,
                "inchl_key": "DUYJMQONPNNFPI-UHFFFAOYSA-N",
                "generic_name": "osimertinib",
                "trade_name": "Tagrisso",
                "designated_date": "09/04/2014",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy",
                "marketing_approval_date": "\u00a011/13/2015\u00a0",
                "exclusivity_end_date": "\u00a011/13/2022\u00a0",
                "exclusivity_protected_indication": "For treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy",
                "sponsor": "AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer",
                    "umls_id": "C1414313,C3539721",
                    "parsed_text": "EPIDERMAL GROWTH FACTOR RECEPTOR , Non-Small Cell Lung Cancer"
                }
            },
            {
                "compound_id": 71496458,
                "inchl_key": "DUYJMQONPNNFPI-UHFFFAOYSA-N",
                "generic_name": "osimertinib",
                "trade_name": "Tagrisso",
                "designated_date": "09/04/2014",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "TAGRISSO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test",
                "marketing_approval_date": "\u00a004/18/2018\u00a0",
                "exclusivity_end_date": "\u00a004/18/2025\u00a0",
                "exclusivity_protected_indication": "TAGRISSO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test",
                "sponsor": "AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer",
                    "umls_id": "C1414313,C3539721",
                    "parsed_text": "EPIDERMAL GROWTH FACTOR RECEPTOR , Non-Small Cell Lung Cancer"
                }
            }
        ]
    },
    {
        "_id": "HXNFUBHNUDHIGC-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135398752,
                "inchl_key": "HXNFUBHNUDHIGC-UHFFFAOYSA-N",
                "generic_name": "Oxypurinol",
                "designated_date": "11/09/1998",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cardiome Pharma Corp.|3650 Westbrook Mall|Vancouver|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of hyperuricemia in patients intolerant to allopurinol.",
                    "umls_id": "C0740394",
                    "parsed_text": "Hyperuricemia"
                }
            }
        ]
    },
    {
        "_id": "BPKAHTKRCLCHEA-UBFJEZKGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5281104,
                "inchl_key": "BPKAHTKRCLCHEA-UBFJEZKGSA-N",
                "generic_name": "paricalcitol",
                "trade_name": "Zemplar",
                "designated_date": "10/27/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Indicated in adults and pediatric patients 10 years of age and older for the prevention and treatment of secondary hyperparathyroidism associated with Chronic kidney disease (CKD) Stages 3 and 4 and CKD Stage 5 in patients on hemodialysis or peritoneal dialysis",
                "marketing_approval_date": "\u00a010/18/2016\u00a0",
                "exclusivity_end_date": "\u00a010/18/2023\u00a0",
                "exclusivity_protected_indication": "Indicated in pediatric patients ages 10 -16 years for treatment of secondary hyperparathyroidism associated with Chronic kidney disease (CKD) Stages 3 and 4 and pediatric patients ages 10-16 years for treatment of secondary hyperparathyroidism associated with CKD Stage 5.",
                "sponsor": "Abbvie, inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric hyperparathyroidism",
                    "umls_id": "C0020502",
                    "parsed_text": "Hyperparathyroidism"
                }
            }
        ]
    },
    {
        "_id": "QXLQZLBNPTZMRK-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 436058,
                "inchl_key": "QXLQZLBNPTZMRK-UHFFFAOYSA-N",
                "generic_name": "Pegaspargase",
                "trade_name": "Oncaspar; Asparlas",
                "designated_date": "10/20/1989",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Combination chemotherapy for the treatment of patients with acute lymphoblastic leukemia who are hypersensitive to native forms of L-asparaginase.",
                "marketing_approval_date": "\u00a002/01/1994\u00a0",
                "exclusivity_end_date": "\u00a002/01/2001\u00a0",
                "sponsor": "Servier Pharmaceuticals LLC|200 Pier Four Blvd|Boston|Massachusetts|2210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute lymphocytic leukemia.",
                    "umls_id": "C0023449",
                    "parsed_text": "Acute lymphocytic leukemia"
                }
            },
            {
                "compound_id": 436058,
                "inchl_key": "QXLQZLBNPTZMRK-UHFFFAOYSA-N",
                "generic_name": "Pegaspargase",
                "trade_name": "Oncaspar; Asparlas",
                "designated_date": "10/20/1989",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "ASPARLAS is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.",
                "marketing_approval_date": "\u00a012/20/2018\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Servier Pharmaceuticals LLC|200 Pier Four Blvd|Boston|Massachusetts|2210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute lymphocytic leukemia.",
                    "umls_id": "C0023449",
                    "parsed_text": "Acute lymphocytic leukemia"
                }
            }
        ]
    },
    {
        "_id": "DOHVAKFYAHLCJP-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135413525,
                "inchl_key": "DOHVAKFYAHLCJP-UHFFFAOYSA-N",
                "generic_name": "Peldesine",
                "designated_date": "10/05/1993",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "BioCryst Pharmaceuticals, Inc.|2190 Parkway Lake Drive|Birmingham|Alabama|35244|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cutaneous T-cell lymphoma.",
                    "umls_id": "C0079773",
                    "parsed_text": "cutaneous T-cell lymphoma"
                }
            }
        ]
    },
    {
        "_id": "NEYNJQRKHLUJRU-DZUOILHNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9853654,
                "inchl_key": "NEYNJQRKHLUJRU-DZUOILHNSA-N",
                "generic_name": "pentagastrin",
                "designated_date": "04/21/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Exela Pharma Sciences, LLC|1245 Blowing Rock Blvd.|Lenoir|North Carolina|28645|United States",
                "orphan_designation": {
                    "original_text": "Diagnostic for the management of medullary thyroid cancer",
                    "umls_id": "C0238462",
                    "parsed_text": "medullary thyroid cancer"
                }
            },
            {
                "compound_id": 9853654,
                "inchl_key": "NEYNJQRKHLUJRU-DZUOILHNSA-N",
                "generic_name": "pentagastrin",
                "designated_date": "05/29/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AOP Orphan IP AG|Staedtle 28|P.O. Box 838|Vaduz|Liechtenstein",
                "orphan_designation": {
                    "original_text": "To aid in the diagnosis of medullary thyroid carcinoma",
                    "umls_id": "C0238462",
                    "parsed_text": "Medullary thyroid carcinoma"
                }
            }
        ]
    },
    {
        "_id": "CWRVKFFCRWGWCS-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5917,
                "inchl_key": "CWRVKFFCRWGWCS-UHFFFAOYSA-N",
                "generic_name": "pentetrazol",
                "designated_date": "09/09/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Balance Therapeutics, Inc.|1250 Bayhill Drive|Suite 125|San Bruno|California|94066|United States",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic hypersomnia",
                    "umls_id": "C0751757",
                    "parsed_text": "Idiopathic Hypersomnia"
                }
            },
            {
                "compound_id": 5917,
                "inchl_key": "CWRVKFFCRWGWCS-UHFFFAOYSA-N",
                "generic_name": "pentetrazol",
                "designated_date": "03/16/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Balance Therapeutics, Inc.|533 Airport Blvd.|Suite 400|Burlingame|California|94010|United States",
                "orphan_designation": {
                    "original_text": "Treatment of narcolepsy",
                    "umls_id": "C0027404",
                    "parsed_text": "Narcolepsy"
                }
            }
        ]
    },
    {
        "_id": "VPAWVRUHMJVRHU-GYKQLYQFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9690122,
                "inchl_key": "VPAWVRUHMJVRHU-GYKQLYQFSA-N",
                "generic_name": "Perfosfamide",
                "designated_date": "12/04/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Scios Nova, Inc.|2450 Bayshore Parkway|Mountain View|California|94043|United States",
                "orphan_designation": {
                    "original_text": "For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "VPAWVRUHMJVRHU-RWNHWRGESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6918238,
                "inchl_key": "VPAWVRUHMJVRHU-RWNHWRGESA-N",
                "generic_name": "Perfosfamide",
                "designated_date": "12/04/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Scios Nova, Inc.|2450 Bayshore Parkway|Mountain View|California|94043|United States",
                "orphan_designation": {
                    "original_text": "For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "VPAWVRUHMJVRHU-HYORBCNSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 70697640,
                "inchl_key": "VPAWVRUHMJVRHU-HYORBCNSSA-N",
                "generic_name": "Perfosfamide",
                "designated_date": "12/04/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Scios Nova, Inc.|2450 Bayshore Parkway|Mountain View|California|94043|United States",
                "orphan_designation": {
                    "original_text": "For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "VPAWVRUHMJVRHU-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 38347,
                "inchl_key": "VPAWVRUHMJVRHU-UHFFFAOYSA-N",
                "generic_name": "Perfosfamide",
                "designated_date": "12/04/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Scios Nova, Inc.|2450 Bayshore Parkway|Mountain View|California|94043|United States",
                "orphan_designation": {
                    "original_text": "For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "VPAWVRUHMJVRHU-VGDKGRGNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9554809,
                "inchl_key": "VPAWVRUHMJVRHU-VGDKGRGNSA-N",
                "generic_name": "Perfosfamide",
                "designated_date": "12/04/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Scios Nova, Inc.|2450 Bayshore Parkway|Mountain View|California|94043|United States",
                "orphan_designation": {
                    "original_text": "For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "JGSARLDLIJGVTE-MBNYWOFBSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 640429,
                "inchl_key": "JGSARLDLIJGVTE-MBNYWOFBSA-M",
                "generic_name": "picibanil",
                "designated_date": "05/15/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Royds Pharmaceuticals, Inc.|4365 Route 1 South|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with lymphatic malformations",
                    "umls_id": "C0398368",
                    "parsed_text": "lymphatic malformations"
                }
            },
            {
                "compound_id": 640429,
                "inchl_key": "JGSARLDLIJGVTE-MBNYWOFBSA-M",
                "generic_name": "picibanil",
                "designated_date": "03/17/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ArTara Therapeutics|1 Little West 12th Street|Suite 254|New York|New York|10014|United States",
                "orphan_designation": {
                    "original_text": "Treatment of lymphatic malformations",
                    "umls_id": "C0398368",
                    "parsed_text": "lymphatic malformations"
                }
            }
        ]
    },
    {
        "_id": "IIMIOEBMYPRQGU-UHFFFAOYSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 177358,
                "inchl_key": "IIMIOEBMYPRQGU-UHFFFAOYSA-L",
                "generic_name": "Picoplatin",
                "designated_date": "11/02/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Poniard Pharmaceuticals|300 Elliott Avenue West|Seattle|Washington|98119|United States",
                "orphan_designation": {
                    "original_text": "Treatment of small cell lung cancer",
                    "umls_id": "C3540630",
                    "parsed_text": "Small Cell Lung Cancer"
                }
            }
        ]
    },
    {
        "_id": "KMSKQZKKOZQFFG-MJKUFRJISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 137704806,
                "inchl_key": "KMSKQZKKOZQFFG-MJKUFRJISA-N",
                "generic_name": "Pirarubicin",
                "designated_date": "10/29/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hillstream BioPharma, Inc.|245 Main Street|Suite 204|Chester|New Jersey|7930|United States",
                "orphan_designation": {
                    "original_text": "Treatment of osteosarcoma",
                    "umls_id": "C0029463",
                    "parsed_text": "Osteosarcoma"
                }
            }
        ]
    },
    {
        "_id": "KMSKQZKKOZQFFG-ULRATTRFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134692159,
                "inchl_key": "KMSKQZKKOZQFFG-ULRATTRFSA-N",
                "generic_name": "Pirarubicin",
                "designated_date": "10/29/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hillstream BioPharma, Inc.|245 Main Street|Suite 204|Chester|New Jersey|7930|United States",
                "orphan_designation": {
                    "original_text": "Treatment of osteosarcoma",
                    "umls_id": "C0029463",
                    "parsed_text": "Osteosarcoma"
                }
            }
        ]
    },
    {
        "_id": "KMSKQZKKOZQFFG-CBFOJMSHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 131750285,
                "inchl_key": "KMSKQZKKOZQFFG-CBFOJMSHSA-N",
                "generic_name": "Pirarubicin",
                "designated_date": "10/29/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hillstream BioPharma, Inc.|245 Main Street|Suite 204|Chester|New Jersey|7930|United States",
                "orphan_designation": {
                    "original_text": "Treatment of osteosarcoma",
                    "umls_id": "C0029463",
                    "parsed_text": "Osteosarcoma"
                }
            }
        ]
    },
    {
        "_id": "KMSKQZKKOZQFFG-FQSDZSELSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 122173004,
                "inchl_key": "KMSKQZKKOZQFFG-FQSDZSELSA-N",
                "generic_name": "Pirarubicin",
                "designated_date": "10/29/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hillstream BioPharma, Inc.|245 Main Street|Suite 204|Chester|New Jersey|7930|United States",
                "orphan_designation": {
                    "original_text": "Treatment of osteosarcoma",
                    "umls_id": "C0029463",
                    "parsed_text": "Osteosarcoma"
                }
            }
        ]
    },
    {
        "_id": "KMSKQZKKOZQFFG-MJTHYZEOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6712062,
                "inchl_key": "KMSKQZKKOZQFFG-MJTHYZEOSA-N",
                "generic_name": "Pirarubicin",
                "designated_date": "10/29/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hillstream BioPharma, Inc.|245 Main Street|Suite 204|Chester|New Jersey|7930|United States",
                "orphan_designation": {
                    "original_text": "Treatment of osteosarcoma",
                    "umls_id": "C0029463",
                    "parsed_text": "Osteosarcoma"
                }
            }
        ]
    },
    {
        "_id": "KMSKQZKKOZQFFG-CBIZWKIZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 45358767,
                "inchl_key": "KMSKQZKKOZQFFG-CBIZWKIZSA-N",
                "generic_name": "Pirarubicin",
                "designated_date": "10/29/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hillstream BioPharma, Inc.|245 Main Street|Suite 204|Chester|New Jersey|7930|United States",
                "orphan_designation": {
                    "original_text": "Treatment of osteosarcoma",
                    "umls_id": "C0029463",
                    "parsed_text": "Osteosarcoma"
                }
            }
        ]
    },
    {
        "_id": "KMSKQZKKOZQFFG-NCXNULAVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6917695,
                "inchl_key": "KMSKQZKKOZQFFG-NCXNULAVSA-N",
                "generic_name": "Pirarubicin",
                "designated_date": "10/29/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hillstream BioPharma, Inc.|245 Main Street|Suite 204|Chester|New Jersey|7930|United States",
                "orphan_designation": {
                    "original_text": "Treatment of osteosarcoma",
                    "umls_id": "C0029463",
                    "parsed_text": "Osteosarcoma"
                }
            }
        ]
    },
    {
        "_id": "KMSKQZKKOZQFFG-YHKVCKOMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3033521,
                "inchl_key": "KMSKQZKKOZQFFG-YHKVCKOMSA-N",
                "generic_name": "Pirarubicin",
                "designated_date": "10/29/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hillstream BioPharma, Inc.|245 Main Street|Suite 204|Chester|New Jersey|7930|United States",
                "orphan_designation": {
                    "original_text": "Treatment of osteosarcoma",
                    "umls_id": "C0029463",
                    "parsed_text": "Osteosarcoma"
                }
            }
        ]
    },
    {
        "_id": "KMSKQZKKOZQFFG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4844,
                "inchl_key": "KMSKQZKKOZQFFG-UHFFFAOYSA-N",
                "generic_name": "Pirarubicin",
                "designated_date": "10/29/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hillstream BioPharma, Inc.|245 Main Street|Suite 204|Chester|New Jersey|7930|United States",
                "orphan_designation": {
                    "original_text": "Treatment of osteosarcoma",
                    "umls_id": "C0029463",
                    "parsed_text": "Osteosarcoma"
                }
            }
        ]
    },
    {
        "_id": "KMSKQZKKOZQFFG-YXRRJAAWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11296583,
                "inchl_key": "KMSKQZKKOZQFFG-YXRRJAAWSA-N",
                "generic_name": "Pirarubicin",
                "designated_date": "10/29/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hillstream BioPharma, Inc.|245 Main Street|Suite 204|Chester|New Jersey|7930|United States",
                "orphan_designation": {
                    "original_text": "Treatment of osteosarcoma",
                    "umls_id": "C0029463",
                    "parsed_text": "Osteosarcoma"
                }
            }
        ]
    },
    {
        "_id": "KMSKQZKKOZQFFG-HSUXVGOQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 636397,
                "inchl_key": "KMSKQZKKOZQFFG-HSUXVGOQSA-N",
                "generic_name": "Pirarubicin",
                "designated_date": "10/29/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hillstream BioPharma, Inc.|245 Main Street|Suite 204|Chester|New Jersey|7930|United States",
                "orphan_designation": {
                    "original_text": "Treatment of osteosarcoma",
                    "umls_id": "C0029463",
                    "parsed_text": "Osteosarcoma"
                }
            }
        ]
    },
    {
        "_id": "YIQPUIGJQJDJOS-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 65015,
                "inchl_key": "YIQPUIGJQJDJOS-UHFFFAOYSA-N",
                "generic_name": "plerixafor",
                "designated_date": "07/28/2011",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genzyme Corporation|500 Kendall Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "MRYYMYCQXMFJNE-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 136033680,
                "inchl_key": "MRYYMYCQXMFJNE-UHFFFAOYSA-N",
                "generic_name": "Poly-ICLC",
                "designated_date": "03/17/1997",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oncovir|3202 Cleveland Avenue N.W.|Washington|District of Columbia|20008|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary brain tumors.",
                    "umls_id": "C0750974",
                    "parsed_text": "primary brain tumors"
                }
            }
        ]
    },
    {
        "_id": "RJKFOVLPORLFTN-LEKSSAKUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5994,
                "inchl_key": "RJKFOVLPORLFTN-LEKSSAKUSA-N",
                "generic_name": "progesterone",
                "designated_date": "09/03/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "BHR Pharma, LLC|607 Herndon Parkway|Suite 110|Herndon|Virginia|20170|United States",
                "orphan_designation": {
                    "original_text": "For early intervention in the treatment of moderate to severe closed-head traumatic brain injury",
                    "umls_id": "C0876926",
                    "parsed_text": "Traumatic Brain Injury"
                }
            },
            {
                "compound_id": 5994,
                "inchl_key": "RJKFOVLPORLFTN-LEKSSAKUSA-N",
                "generic_name": "progesterone",
                "designated_date": "06/03/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "GLIA, LLC|134 Saint Botolph Street|Boston|Massachusetts|2115|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ocular graft versus host disease",
                    "umls_id": "C5203917",
                    "parsed_text": "Ocular Graft Versus Host Disease"
                }
            }
        ]
    },
    {
        "_id": "DJUFPMUQJKWIJB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 107771,
                "inchl_key": "DJUFPMUQJKWIJB-UHFFFAOYSA-N",
                "generic_name": "Pyronaridine",
                "designated_date": "10/21/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Collaborations Pharmaceuticals, Inc.|5616 Hilltop Needmore Rd,|Fuquay Varina|North Carolina|27526|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Chagas Disease",
                    "umls_id": "C0041234",
                    "parsed_text": "Chagas Disease"
                }
            }
        ]
    },
    {
        "_id": "LCTONWCANYUPML-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 107735,
                "inchl_key": "LCTONWCANYUPML-UHFFFAOYSA-M",
                "generic_name": "Pyruvate",
                "designated_date": "02/21/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cellular Sciences, Inc|84 park Avenue|P.O. Box 968|Flemington|New Jersey|8822|United States",
                "orphan_designation": {
                    "original_text": "Treatment of interstitial lung disease.",
                    "umls_id": "C0206062",
                    "parsed_text": "Interstitial lung disease"
                }
            }
        ]
    },
    {
        "_id": "NNYBQONXHNTVIJ-QGZVFWFLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 667528,
                "inchl_key": "NNYBQONXHNTVIJ-QGZVFWFLSA-N",
                "generic_name": "R-etodolac",
                "designated_date": "12/09/2002",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cephalon, Inc.|41 Moores Road|Frazer|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "NHTGHBARYWONDQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3125,
                "inchl_key": "NHTGHBARYWONDQ-UHFFFAOYSA-N",
                "generic_name": "Racemetyrosine",
                "designated_date": "07/31/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Tyme Technologies, Inc.|17 State Street|7th Floor|New York|New York|10004|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "GZUITABIAKMVPG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5035,
                "inchl_key": "GZUITABIAKMVPG-UHFFFAOYSA-N",
                "generic_name": "raloxifene",
                "trade_name": "Evista",
                "designated_date": "07/14/2005",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer",
                "marketing_approval_date": "\u00a009/13/2007\u00a0",
                "exclusivity_end_date": "\u00a009/13/2014\u00a0",
                "sponsor": "Eli Lilly and Company|Lilly Corporate Center|Drop Code 1853|Indianapolis|Indiana|46285|United States",
                "orphan_designation": {
                    "original_text": "Reduction of the risk of breast cancer in postmenopausal women",
                    "umls_id": "C0678222",
                    "parsed_text": "Breast cancer"
                }
            }
        ]
    },
    {
        "_id": "CKRVBMUJCFKRND-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 86287614,
                "inchl_key": "CKRVBMUJCFKRND-UHFFFAOYSA-N",
                "generic_name": "Redaporfin",
                "designated_date": "04/12/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Luzitin, S.A.|Edificio Bluepharma|S Martinho do Bispo|Coimbra|Coimbra District|Portugal",
                "orphan_designation": {
                    "original_text": "Treatment of cholangiocarcinoma",
                    "umls_id": "C0206698",
                    "parsed_text": "Cholangiocarcinoma"
                }
            }
        ]
    },
    {
        "_id": "FNHKPVJBJVTLMP-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11167602,
                "inchl_key": "FNHKPVJBJVTLMP-UHFFFAOYSA-N",
                "generic_name": "Regorafenib",
                "designated_date": "07/01/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bayer HealthCare Pharmaceuticals, Inc.|100 Bayer Boulevard|P.O. Box 915|Whippany|New Jersey|7981|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioblastoma multiforme",
                    "umls_id": "C0017636",
                    "parsed_text": "Glioblastoma multiforme"
                }
            },
            {
                "compound_id": 11167602,
                "inchl_key": "FNHKPVJBJVTLMP-UHFFFAOYSA-N",
                "generic_name": "regorafenib",
                "trade_name": "Stivarga",
                "designated_date": "06/04/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with sorafenib.",
                "marketing_approval_date": "\u00a004/27/2017\u00a0",
                "exclusivity_end_date": "\u00a004/27/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with sorafenib.",
                "sponsor": "Bayer HealthCare Pharmaceuticals, Inc.|100 Bayer Blvd|P. O. Box 915|Whippany|New Jersey|7981|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            },
            {
                "compound_id": 11167602,
                "inchl_key": "FNHKPVJBJVTLMP-UHFFFAOYSA-N",
                "generic_name": "regorafenib",
                "trade_name": "Stivarga",
                "designated_date": "01/12/2011",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.",
                "marketing_approval_date": "\u00a002/25/2013\u00a0",
                "exclusivity_end_date": "\u00a002/25/2020\u00a0",
                "exclusivity_protected_indication": "Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.",
                "sponsor": "Bayer HealthCare Pharmaceuticals, Inc.|P. O. Box 1000|Montvale|New Jersey|7045|United States",
                "orphan_designation": {
                    "original_text": "Treatment gastrointestinal stromal tumors",
                    "umls_id": "C0238198",
                    "parsed_text": "Gastrointestinal Stromal Tumors"
                }
            }
        ]
    },
    {
        "_id": "DSDNAKHZNJAGHN-WLJYXNHNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134688669,
                "inchl_key": "DSDNAKHZNJAGHN-WLJYXNHNSA-N",
                "generic_name": "resiniferatoxin",
                "designated_date": "05/13/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sorrento Theraeputics, Inc.|9380 Judicial Drive|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of intractable pain at end-stage disease",
                    "umls_id": "C0030200",
                    "parsed_text": "intractable pain"
                }
            }
        ]
    },
    {
        "_id": "DSDNAKHZNJAGHN-GGIHZKEUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44564218,
                "inchl_key": "DSDNAKHZNJAGHN-GGIHZKEUSA-N",
                "generic_name": "resiniferatoxin",
                "designated_date": "05/13/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sorrento Theraeputics, Inc.|9380 Judicial Drive|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of intractable pain at end-stage disease",
                    "umls_id": "C0030200",
                    "parsed_text": "intractable pain"
                }
            }
        ]
    },
    {
        "_id": "DSDNAKHZNJAGHN-YOHYOAFPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2733497,
                "inchl_key": "DSDNAKHZNJAGHN-YOHYOAFPSA-N",
                "generic_name": "resiniferatoxin",
                "designated_date": "05/13/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sorrento Theraeputics, Inc.|9380 Judicial Drive|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of intractable pain at end-stage disease",
                    "umls_id": "C0030200",
                    "parsed_text": "intractable pain"
                }
            }
        ]
    },
    {
        "_id": "DSDNAKHZNJAGHN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5148108,
                "inchl_key": "DSDNAKHZNJAGHN-UHFFFAOYSA-N",
                "generic_name": "resiniferatoxin",
                "designated_date": "05/13/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sorrento Theraeputics, Inc.|9380 Judicial Drive|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of intractable pain at end-stage disease",
                    "umls_id": "C0030200",
                    "parsed_text": "intractable pain"
                }
            }
        ]
    },
    {
        "_id": "DSDNAKHZNJAGHN-VQBCBPMFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6324660,
                "inchl_key": "DSDNAKHZNJAGHN-VQBCBPMFSA-N",
                "generic_name": "resiniferatoxin",
                "designated_date": "05/13/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sorrento Theraeputics, Inc.|9380 Judicial Drive|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of intractable pain at end-stage disease",
                    "umls_id": "C0030200",
                    "parsed_text": "intractable pain"
                }
            }
        ]
    },
    {
        "_id": "DSDNAKHZNJAGHN-IHCAYWNCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 104826,
                "inchl_key": "DSDNAKHZNJAGHN-IHCAYWNCSA-N",
                "generic_name": "resiniferatoxin",
                "designated_date": "05/13/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sorrento Theraeputics, Inc.|9380 Judicial Drive|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of intractable pain at end-stage disease",
                    "umls_id": "C0030200",
                    "parsed_text": "intractable pain"
                }
            }
        ]
    },
    {
        "_id": "DSDNAKHZNJAGHN-MXTYGGKSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5702546,
                "inchl_key": "DSDNAKHZNJAGHN-MXTYGGKSSA-N",
                "generic_name": "resiniferatoxin",
                "designated_date": "05/13/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sorrento Theraeputics, Inc.|9380 Judicial Drive|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of intractable pain at end-stage disease",
                    "umls_id": "C0030200",
                    "parsed_text": "intractable pain"
                }
            }
        ]
    },
    {
        "_id": "OAKGNIRUXAZDQF-DFZJEWIASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134694917,
                "inchl_key": "OAKGNIRUXAZDQF-DFZJEWIASA-N",
                "generic_name": "retaspimycin",
                "designated_date": "08/31/2007",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Infinity Pharmaceuticals, Inc.|780 Memorial Drive|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment for gastrointestinal stromal tumor",
                    "umls_id": "C0238198",
                    "parsed_text": "gastrointestinal stromal tumor"
                }
            }
        ]
    },
    {
        "_id": "OAKGNIRUXAZDQF-NTEXKKDHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 131801266,
                "inchl_key": "OAKGNIRUXAZDQF-NTEXKKDHSA-N",
                "generic_name": "retaspimycin",
                "designated_date": "08/31/2007",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Infinity Pharmaceuticals, Inc.|780 Memorial Drive|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment for gastrointestinal stromal tumor",
                    "umls_id": "C0238198",
                    "parsed_text": "gastrointestinal stromal tumor"
                }
            }
        ]
    },
    {
        "_id": "OAKGNIRUXAZDQF-RYORMVDLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 129894409,
                "inchl_key": "OAKGNIRUXAZDQF-RYORMVDLSA-N",
                "generic_name": "retaspimycin",
                "designated_date": "08/31/2007",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Infinity Pharmaceuticals, Inc.|780 Memorial Drive|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment for gastrointestinal stromal tumor",
                    "umls_id": "C0238198",
                    "parsed_text": "gastrointestinal stromal tumor"
                }
            }
        ]
    },
    {
        "_id": "OAKGNIRUXAZDQF-BGGMETADSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 131861370,
                "inchl_key": "OAKGNIRUXAZDQF-BGGMETADSA-N",
                "generic_name": "retaspimycin",
                "designated_date": "08/31/2007",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Infinity Pharmaceuticals, Inc.|780 Memorial Drive|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment for gastrointestinal stromal tumor",
                    "umls_id": "C0238198",
                    "parsed_text": "gastrointestinal stromal tumor"
                }
            }
        ]
    },
    {
        "_id": "OAKGNIRUXAZDQF-HTLBVUBBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 66577020,
                "inchl_key": "OAKGNIRUXAZDQF-HTLBVUBBSA-N",
                "generic_name": "retaspimycin",
                "designated_date": "08/31/2007",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Infinity Pharmaceuticals, Inc.|780 Memorial Drive|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment for gastrointestinal stromal tumor",
                    "umls_id": "C0238198",
                    "parsed_text": "gastrointestinal stromal tumor"
                }
            }
        ]
    },
    {
        "_id": "OAKGNIRUXAZDQF-TXHRRWQRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11534420,
                "inchl_key": "OAKGNIRUXAZDQF-TXHRRWQRSA-N",
                "generic_name": "retaspimycin",
                "designated_date": "08/31/2007",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Infinity Pharmaceuticals, Inc.|780 Memorial Drive|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment for gastrointestinal stromal tumor",
                    "umls_id": "C0238198",
                    "parsed_text": "gastrointestinal stromal tumor"
                }
            }
        ]
    },
    {
        "_id": "NZCRJKRKKOLAOJ-WSTNJLQSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135391139,
                "inchl_key": "NZCRJKRKKOLAOJ-WSTNJLQSSA-N",
                "generic_name": "Rifaximin",
                "designated_date": "10/28/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Salix Pharmaceuticals, Inc. (a division of Bausch Health US, LLC)|400 Somerset Corporate Boulevard|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "treatment of sickle cell disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            },
            {
                "compound_id": 135391139,
                "inchl_key": "NZCRJKRKKOLAOJ-WSTNJLQSSA-N",
                "generic_name": "rifaximin",
                "trade_name": "Xifaxan",
                "designated_date": "02/10/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age",
                "marketing_approval_date": "\u00a003/24/2010\u00a0",
                "exclusivity_end_date": "\u00a003/24/2017\u00a0",
                "sponsor": "Salix Pharmaceuticals, Inc.|400 Somerset Corporate Blvd|Somerset|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatic encephalopathy",
                    "umls_id": "C0019151",
                    "parsed_text": "Hepatic Encephalopathy"
                }
            }
        ]
    },
    {
        "_id": "NZCRJKRKKOLAOJ-UPMLHBPDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134754219,
                "inchl_key": "NZCRJKRKKOLAOJ-UPMLHBPDSA-N",
                "generic_name": "Rifaximin",
                "designated_date": "10/28/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Salix Pharmaceuticals, Inc. (a division of Bausch Health US, LLC)|400 Somerset Corporate Boulevard|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "treatment of sickle cell disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            },
            {
                "compound_id": 134754219,
                "inchl_key": "NZCRJKRKKOLAOJ-UPMLHBPDSA-N",
                "generic_name": "rifaximin",
                "trade_name": "Xifaxan",
                "designated_date": "02/10/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age",
                "marketing_approval_date": "\u00a003/24/2010\u00a0",
                "exclusivity_end_date": "\u00a003/24/2017\u00a0",
                "sponsor": "Salix Pharmaceuticals, Inc.|400 Somerset Corporate Blvd|Somerset|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatic encephalopathy",
                    "umls_id": "C0019151",
                    "parsed_text": "Hepatic Encephalopathy"
                }
            }
        ]
    },
    {
        "_id": "NZCRJKRKKOLAOJ-VJYREXROSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134754217,
                "inchl_key": "NZCRJKRKKOLAOJ-VJYREXROSA-N",
                "generic_name": "Rifaximin",
                "designated_date": "10/28/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Salix Pharmaceuticals, Inc. (a division of Bausch Health US, LLC)|400 Somerset Corporate Boulevard|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "treatment of sickle cell disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            },
            {
                "compound_id": 134754217,
                "inchl_key": "NZCRJKRKKOLAOJ-VJYREXROSA-N",
                "generic_name": "rifaximin",
                "trade_name": "Xifaxan",
                "designated_date": "02/10/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age",
                "marketing_approval_date": "\u00a003/24/2010\u00a0",
                "exclusivity_end_date": "\u00a003/24/2017\u00a0",
                "sponsor": "Salix Pharmaceuticals, Inc.|400 Somerset Corporate Blvd|Somerset|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatic encephalopathy",
                    "umls_id": "C0019151",
                    "parsed_text": "Hepatic Encephalopathy"
                }
            }
        ]
    },
    {
        "_id": "NZCRJKRKKOLAOJ-KPKMWDGOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 101307877,
                "inchl_key": "NZCRJKRKKOLAOJ-KPKMWDGOSA-N",
                "generic_name": "Rifaximin",
                "designated_date": "10/28/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Salix Pharmaceuticals, Inc. (a division of Bausch Health US, LLC)|400 Somerset Corporate Boulevard|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "treatment of sickle cell disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            },
            {
                "compound_id": 101307877,
                "inchl_key": "NZCRJKRKKOLAOJ-KPKMWDGOSA-N",
                "generic_name": "rifaximin",
                "trade_name": "Xifaxan",
                "designated_date": "02/10/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age",
                "marketing_approval_date": "\u00a003/24/2010\u00a0",
                "exclusivity_end_date": "\u00a003/24/2017\u00a0",
                "sponsor": "Salix Pharmaceuticals, Inc.|400 Somerset Corporate Blvd|Somerset|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatic encephalopathy",
                    "umls_id": "C0019151",
                    "parsed_text": "Hepatic Encephalopathy"
                }
            }
        ]
    },
    {
        "_id": "NZCRJKRKKOLAOJ-IEOSPBRCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 66577007,
                "inchl_key": "NZCRJKRKKOLAOJ-IEOSPBRCSA-N",
                "generic_name": "Rifaximin",
                "designated_date": "10/28/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Salix Pharmaceuticals, Inc. (a division of Bausch Health US, LLC)|400 Somerset Corporate Boulevard|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "treatment of sickle cell disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            },
            {
                "compound_id": 66577007,
                "inchl_key": "NZCRJKRKKOLAOJ-IEOSPBRCSA-N",
                "generic_name": "rifaximin",
                "trade_name": "Xifaxan",
                "designated_date": "02/10/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age",
                "marketing_approval_date": "\u00a003/24/2010\u00a0",
                "exclusivity_end_date": "\u00a003/24/2017\u00a0",
                "sponsor": "Salix Pharmaceuticals, Inc.|400 Somerset Corporate Blvd|Somerset|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatic encephalopathy",
                    "umls_id": "C0019151",
                    "parsed_text": "Hepatic Encephalopathy"
                }
            }
        ]
    },
    {
        "_id": "NZCRJKRKKOLAOJ-VXTOCXBKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 42608884,
                "inchl_key": "NZCRJKRKKOLAOJ-VXTOCXBKSA-N",
                "generic_name": "Rifaximin",
                "designated_date": "10/28/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Salix Pharmaceuticals, Inc. (a division of Bausch Health US, LLC)|400 Somerset Corporate Boulevard|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "treatment of sickle cell disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            },
            {
                "compound_id": 42608884,
                "inchl_key": "NZCRJKRKKOLAOJ-VXTOCXBKSA-N",
                "generic_name": "rifaximin",
                "trade_name": "Xifaxan",
                "designated_date": "02/10/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age",
                "marketing_approval_date": "\u00a003/24/2010\u00a0",
                "exclusivity_end_date": "\u00a003/24/2017\u00a0",
                "sponsor": "Salix Pharmaceuticals, Inc.|400 Somerset Corporate Blvd|Somerset|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatic encephalopathy",
                    "umls_id": "C0019151",
                    "parsed_text": "Hepatic Encephalopathy"
                }
            }
        ]
    },
    {
        "_id": "NZCRJKRKKOLAOJ-XWSQLESMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44384716,
                "inchl_key": "NZCRJKRKKOLAOJ-XWSQLESMSA-N",
                "generic_name": "Rifaximin",
                "designated_date": "10/28/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Salix Pharmaceuticals, Inc. (a division of Bausch Health US, LLC)|400 Somerset Corporate Boulevard|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "treatment of sickle cell disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            },
            {
                "compound_id": 44384716,
                "inchl_key": "NZCRJKRKKOLAOJ-XWSQLESMSA-N",
                "generic_name": "rifaximin",
                "trade_name": "Xifaxan",
                "designated_date": "02/10/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age",
                "marketing_approval_date": "\u00a003/24/2010\u00a0",
                "exclusivity_end_date": "\u00a003/24/2017\u00a0",
                "sponsor": "Salix Pharmaceuticals, Inc.|400 Somerset Corporate Blvd|Somerset|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatic encephalopathy",
                    "umls_id": "C0019151",
                    "parsed_text": "Hepatic Encephalopathy"
                }
            }
        ]
    },
    {
        "_id": "NZCRJKRKKOLAOJ-IIBMFGDOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 72111,
                "inchl_key": "NZCRJKRKKOLAOJ-IIBMFGDOSA-N",
                "generic_name": "Rifaximin",
                "designated_date": "10/28/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Salix Pharmaceuticals, Inc. (a division of Bausch Health US, LLC)|400 Somerset Corporate Boulevard|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "treatment of sickle cell disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            },
            {
                "compound_id": 72111,
                "inchl_key": "NZCRJKRKKOLAOJ-IIBMFGDOSA-N",
                "generic_name": "rifaximin",
                "trade_name": "Xifaxan",
                "designated_date": "02/10/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age",
                "marketing_approval_date": "\u00a003/24/2010\u00a0",
                "exclusivity_end_date": "\u00a003/24/2017\u00a0",
                "sponsor": "Salix Pharmaceuticals, Inc.|400 Somerset Corporate Blvd|Somerset|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatic encephalopathy",
                    "umls_id": "C0019151",
                    "parsed_text": "Hepatic Encephalopathy"
                }
            }
        ]
    },
    {
        "_id": "NZCRJKRKKOLAOJ-LXVXMSHWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71296876,
                "inchl_key": "NZCRJKRKKOLAOJ-LXVXMSHWSA-N",
                "generic_name": "Rifaximin",
                "designated_date": "10/28/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Salix Pharmaceuticals, Inc. (a division of Bausch Health US, LLC)|400 Somerset Corporate Boulevard|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "treatment of sickle cell disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            },
            {
                "compound_id": 71296876,
                "inchl_key": "NZCRJKRKKOLAOJ-LXVXMSHWSA-N",
                "generic_name": "rifaximin",
                "trade_name": "Xifaxan",
                "designated_date": "02/10/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age",
                "marketing_approval_date": "\u00a003/24/2010\u00a0",
                "exclusivity_end_date": "\u00a003/24/2017\u00a0",
                "sponsor": "Salix Pharmaceuticals, Inc.|400 Somerset Corporate Blvd|Somerset|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatic encephalopathy",
                    "umls_id": "C0019151",
                    "parsed_text": "Hepatic Encephalopathy"
                }
            }
        ]
    },
    {
        "_id": "NZCRJKRKKOLAOJ-KOPWYESNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 72698618,
                "inchl_key": "NZCRJKRKKOLAOJ-KOPWYESNSA-N",
                "generic_name": "Rifaximin",
                "designated_date": "10/28/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Salix Pharmaceuticals, Inc. (a division of Bausch Health US, LLC)|400 Somerset Corporate Boulevard|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "treatment of sickle cell disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            },
            {
                "compound_id": 72698618,
                "inchl_key": "NZCRJKRKKOLAOJ-KOPWYESNSA-N",
                "generic_name": "rifaximin",
                "trade_name": "Xifaxan",
                "designated_date": "02/10/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age",
                "marketing_approval_date": "\u00a003/24/2010\u00a0",
                "exclusivity_end_date": "\u00a003/24/2017\u00a0",
                "sponsor": "Salix Pharmaceuticals, Inc.|400 Somerset Corporate Blvd|Somerset|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatic encephalopathy",
                    "umls_id": "C0019151",
                    "parsed_text": "Hepatic Encephalopathy"
                }
            }
        ]
    },
    {
        "_id": "NZCRJKRKKOLAOJ-CPJOEXDVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 57507834,
                "inchl_key": "NZCRJKRKKOLAOJ-CPJOEXDVSA-N",
                "generic_name": "Rifaximin",
                "designated_date": "10/28/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Salix Pharmaceuticals, Inc. (a division of Bausch Health US, LLC)|400 Somerset Corporate Boulevard|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "treatment of sickle cell disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            },
            {
                "compound_id": 57507834,
                "inchl_key": "NZCRJKRKKOLAOJ-CPJOEXDVSA-N",
                "generic_name": "rifaximin",
                "trade_name": "Xifaxan",
                "designated_date": "02/10/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age",
                "marketing_approval_date": "\u00a003/24/2010\u00a0",
                "exclusivity_end_date": "\u00a003/24/2017\u00a0",
                "sponsor": "Salix Pharmaceuticals, Inc.|400 Somerset Corporate Blvd|Somerset|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatic encephalopathy",
                    "umls_id": "C0019151",
                    "parsed_text": "Hepatic Encephalopathy"
                }
            }
        ]
    },
    {
        "_id": "NZCRJKRKKOLAOJ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 53395233,
                "inchl_key": "NZCRJKRKKOLAOJ-UHFFFAOYSA-N",
                "generic_name": "Rifaximin",
                "designated_date": "10/28/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Salix Pharmaceuticals, Inc. (a division of Bausch Health US, LLC)|400 Somerset Corporate Boulevard|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "treatment of sickle cell disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            },
            {
                "compound_id": 53395233,
                "inchl_key": "NZCRJKRKKOLAOJ-UHFFFAOYSA-N",
                "generic_name": "rifaximin",
                "trade_name": "Xifaxan",
                "designated_date": "02/10/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age",
                "marketing_approval_date": "\u00a003/24/2010\u00a0",
                "exclusivity_end_date": "\u00a003/24/2017\u00a0",
                "sponsor": "Salix Pharmaceuticals, Inc.|400 Somerset Corporate Blvd|Somerset|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatic encephalopathy",
                    "umls_id": "C0019151",
                    "parsed_text": "Hepatic Encephalopathy"
                }
            }
        ]
    },
    {
        "_id": "NZCRJKRKKOLAOJ-HQDKJBBOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16667733,
                "inchl_key": "NZCRJKRKKOLAOJ-HQDKJBBOSA-N",
                "generic_name": "Rifaximin",
                "designated_date": "10/28/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Salix Pharmaceuticals, Inc. (a division of Bausch Health US, LLC)|400 Somerset Corporate Boulevard|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "treatment of sickle cell disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            },
            {
                "compound_id": 16667733,
                "inchl_key": "NZCRJKRKKOLAOJ-HQDKJBBOSA-N",
                "generic_name": "rifaximin",
                "trade_name": "Xifaxan",
                "designated_date": "02/10/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age",
                "marketing_approval_date": "\u00a003/24/2010\u00a0",
                "exclusivity_end_date": "\u00a003/24/2017\u00a0",
                "sponsor": "Salix Pharmaceuticals, Inc.|400 Somerset Corporate Blvd|Somerset|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatic encephalopathy",
                    "umls_id": "C0019151",
                    "parsed_text": "Hepatic Encephalopathy"
                }
            }
        ]
    },
    {
        "_id": "NZCRJKRKKOLAOJ-LGPAXTBISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 46783403,
                "inchl_key": "NZCRJKRKKOLAOJ-LGPAXTBISA-N",
                "generic_name": "Rifaximin",
                "designated_date": "10/28/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Salix Pharmaceuticals, Inc. (a division of Bausch Health US, LLC)|400 Somerset Corporate Boulevard|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "treatment of sickle cell disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            },
            {
                "compound_id": 46783403,
                "inchl_key": "NZCRJKRKKOLAOJ-LGPAXTBISA-N",
                "generic_name": "rifaximin",
                "trade_name": "Xifaxan",
                "designated_date": "02/10/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age",
                "marketing_approval_date": "\u00a003/24/2010\u00a0",
                "exclusivity_end_date": "\u00a003/24/2017\u00a0",
                "sponsor": "Salix Pharmaceuticals, Inc.|400 Somerset Corporate Blvd|Somerset|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatic encephalopathy",
                    "umls_id": "C0019151",
                    "parsed_text": "Hepatic Encephalopathy"
                }
            }
        ]
    },
    {
        "_id": "NZCRJKRKKOLAOJ-XRCRFVBUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6436173,
                "inchl_key": "NZCRJKRKKOLAOJ-XRCRFVBUSA-N",
                "generic_name": "Rifaximin",
                "designated_date": "10/28/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Salix Pharmaceuticals, Inc. (a division of Bausch Health US, LLC)|400 Somerset Corporate Boulevard|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "treatment of sickle cell disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            },
            {
                "compound_id": 6436173,
                "inchl_key": "NZCRJKRKKOLAOJ-XRCRFVBUSA-N",
                "generic_name": "rifaximin",
                "trade_name": "Xifaxan",
                "designated_date": "02/10/1998",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age",
                "marketing_approval_date": "\u00a003/24/2010\u00a0",
                "exclusivity_end_date": "\u00a003/24/2017\u00a0",
                "sponsor": "Salix Pharmaceuticals, Inc.|400 Somerset Corporate Blvd|Somerset|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatic encephalopathy",
                    "umls_id": "C0019151",
                    "parsed_text": "Hepatic Encephalopathy"
                }
            }
        ]
    },
    {
        "_id": "LCFFREMLXLZNHE-GBOLQPHISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 73388818,
                "inchl_key": "LCFFREMLXLZNHE-GBOLQPHISA-N",
                "generic_name": "rilzabrutinib",
                "designated_date": "10/15/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Principia Biopharma Inc.|400 East Jamie Court|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of immune thrombocytopenic purpura (ITP)",
                    "umls_id": "C0398650",
                    "parsed_text": "Immune thrombocytopenic purpura"
                }
            }
        ]
    },
    {
        "_id": "ASKZRYGFUPSJPN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 118513932,
                "inchl_key": "ASKZRYGFUPSJPN-UHFFFAOYSA-N",
                "generic_name": "risdiplam",
                "trade_name": "EVRYSDI",
                "designated_date": "01/04/2017",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older",
                "marketing_approval_date": "\u00a008/07/2020\u00a0",
                "exclusivity_end_date": "\u00a008/07/2027\u00a0",
                "exclusivity_protected_indication": "treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.",
                "sponsor": "Genentech, Inc., a Member of the Roche Group|1 DNA Way|South San Francisco|California|94080-4990|United States",
                "orphan_designation": {
                    "original_text": "Treatment of spinal muscular atrophy",
                    "umls_id": "C0026847",
                    "parsed_text": "Spinal Muscular Atrophy"
                }
            }
        ]
    },
    {
        "_id": "YUQCJZVVMQZBFE-JPUFUMQZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 145982170,
                "inchl_key": "YUQCJZVVMQZBFE-JPUFUMQZSA-N",
                "generic_name": "roneparstat",
                "designated_date": "03/19/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Leadiant Biosciences S.p.A|Via Sudafrica 20|Roma|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "BPRHUIZQVSMCRT-VEUZHWNKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 446157,
                "inchl_key": "BPRHUIZQVSMCRT-VEUZHWNKSA-N",
                "generic_name": "rosuvastatin",
                "trade_name": "Crestor",
                "designated_date": "02/14/2014",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "An adjunct to diet to reduce LDL-C, Total-C, nonHDL-C and ApoB in children and adolescents 7 to 17 years of age with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments (e.g., LDL apheresis).",
                "marketing_approval_date": "\u00a005/27/2016\u00a0",
                "exclusivity_end_date": "\u00a005/27/2023\u00a0",
                "exclusivity_protected_indication": "An adjunct to diet to reduce LDL-C, Total-C, nonHDL-C and ApoB in children and adolescents 7 to 17 years of age with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments (e.g., LDL apheresis).",
                "sponsor": "iPR Pharmaceuticals, Inc.|1 MedImmune Way|Gaithersburg|Maryland|20878|United States",
                "orphan_designation": {
                    "original_text": "For the treatment of pediatric homozygous familial hypercholesterolemia",
                    "umls_id": "C0020445",
                    "parsed_text": "FAMILIAL HYPERCHOLESTEROLEMIA"
                }
            }
        ]
    },
    {
        "_id": "NQUUPTGRJYIXSL-YPDXTJLXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 131954443,
                "inchl_key": "NQUUPTGRJYIXSL-YPDXTJLXSA-N",
                "generic_name": "rovalpituzumab tesirine",
                "designated_date": "12/22/2015",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of small cell lung cancer",
                    "umls_id": "C3540630",
                    "parsed_text": "Small Cell Lung Cancer"
                }
            }
        ]
    },
    {
        "_id": "VHXNKPBCCMUMSW-FQEVSTJZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 472335,
                "inchl_key": "VHXNKPBCCMUMSW-FQEVSTJZSA-N",
                "generic_name": "rubitecan",
                "designated_date": "07/17/2002",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SuperGen, Inc.|4140 Dublin Blvd.|Suite 200|Dublin|California|94568|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndrome",
                    "umls_id": "C0019682,C0021051",
                    "parsed_text": "Human Immunodeficiency Virus , Immunodeficiency Syndrome"
                }
            }
        ]
    },
    {
        "_id": "JFMWPOCYMYGEDM-XFULWGLBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25127112,
                "inchl_key": "JFMWPOCYMYGEDM-XFULWGLBSA-N",
                "generic_name": "ruxolitinib phosphate",
                "trade_name": "Jakafi",
                "designated_date": "09/05/2008",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis",
                "marketing_approval_date": "\u00a011/16/2011\u00a0",
                "exclusivity_end_date": "\u00a011/16/2018\u00a0",
                "sponsor": "Incyte Corporation|1801 Augustine Cut-Off|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelofibrosis",
                    "umls_id": "C0026987",
                    "parsed_text": "myelofibrosis"
                }
            },
            {
                "compound_id": 25127112,
                "inchl_key": "JFMWPOCYMYGEDM-XFULWGLBSA-N",
                "generic_name": "ruxolitinib phosphate",
                "designated_date": "03/22/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Incyte Corporation|1801 Augustine Cut-Off|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of essential thrombocythemia",
                    "umls_id": "C0040028",
                    "parsed_text": "ESSENTIAL THROMBOCYTHEMIA"
                }
            }
        ]
    },
    {
        "_id": "NXQKSXLFSAEQCZ-SFHVURJKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 137278711,
                "inchl_key": "NXQKSXLFSAEQCZ-SFHVURJKSA-N",
                "generic_name": "sotorasib",
                "designated_date": "05/01/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Amgen Inc.|1 Amgen Center Drive|Mail Stop 27-3-A|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Treatment of KRAS p.G12C-positive non-small cell lung cancer",
                    "umls_id": "C3539721",
                    "parsed_text": "Non-Small Cell Lung Cancer"
                }
            }
        ]
    },
    {
        "_id": "ACTOXUHEUCPTEW-IWJSIHOMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 153274329,
                "inchl_key": "ACTOXUHEUCPTEW-IWJSIHOMSA-N",
                "generic_name": "Spiramycin",
                "designated_date": "10/17/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rhone-Poulenc Rorer Pharmaceuticals|500 Arcola Road|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.",
                    "umls_id": "C0021051,C0030498,C0239055",
                    "parsed_text": "Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS"
                }
            }
        ]
    },
    {
        "_id": "ACTOXUHEUCPTEW-QTKFNTAMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135391165,
                "inchl_key": "ACTOXUHEUCPTEW-QTKFNTAMSA-N",
                "generic_name": "Spiramycin",
                "designated_date": "10/17/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rhone-Poulenc Rorer Pharmaceuticals|500 Arcola Road|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.",
                    "umls_id": "C0021051,C0030498,C0239055",
                    "parsed_text": "Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS"
                }
            }
        ]
    },
    {
        "_id": "ACTOXUHEUCPTEW-NHYPZVJXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134717663,
                "inchl_key": "ACTOXUHEUCPTEW-NHYPZVJXSA-N",
                "generic_name": "Spiramycin",
                "designated_date": "10/17/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rhone-Poulenc Rorer Pharmaceuticals|500 Arcola Road|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.",
                    "umls_id": "C0021051,C0030498,C0239055",
                    "parsed_text": "Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS"
                }
            }
        ]
    },
    {
        "_id": "ACTOXUHEUCPTEW-LFIIGWMYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134715567,
                "inchl_key": "ACTOXUHEUCPTEW-LFIIGWMYSA-N",
                "generic_name": "Spiramycin",
                "designated_date": "10/17/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rhone-Poulenc Rorer Pharmaceuticals|500 Arcola Road|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.",
                    "umls_id": "C0021051,C0030498,C0239055",
                    "parsed_text": "Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS"
                }
            }
        ]
    },
    {
        "_id": "ACTOXUHEUCPTEW-FCCRBRQASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134687906,
                "inchl_key": "ACTOXUHEUCPTEW-FCCRBRQASA-N",
                "generic_name": "Spiramycin",
                "designated_date": "10/17/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rhone-Poulenc Rorer Pharmaceuticals|500 Arcola Road|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.",
                    "umls_id": "C0021051,C0030498,C0239055",
                    "parsed_text": "Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS"
                }
            }
        ]
    },
    {
        "_id": "ACTOXUHEUCPTEW-VRCNPYAISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 131674879,
                "inchl_key": "ACTOXUHEUCPTEW-VRCNPYAISA-N",
                "generic_name": "Spiramycin",
                "designated_date": "10/17/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rhone-Poulenc Rorer Pharmaceuticals|500 Arcola Road|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.",
                    "umls_id": "C0021051,C0030498,C0239055",
                    "parsed_text": "Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS"
                }
            }
        ]
    },
    {
        "_id": "ACTOXUHEUCPTEW-SENNIVHBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 129627802,
                "inchl_key": "ACTOXUHEUCPTEW-SENNIVHBSA-N",
                "generic_name": "Spiramycin",
                "designated_date": "10/17/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rhone-Poulenc Rorer Pharmaceuticals|500 Arcola Road|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.",
                    "umls_id": "C0021051,C0030498,C0239055",
                    "parsed_text": "Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS"
                }
            }
        ]
    },
    {
        "_id": "ACTOXUHEUCPTEW-IMDCDJEBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 76324338,
                "inchl_key": "ACTOXUHEUCPTEW-IMDCDJEBSA-N",
                "generic_name": "Spiramycin",
                "designated_date": "10/17/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rhone-Poulenc Rorer Pharmaceuticals|500 Arcola Road|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.",
                    "umls_id": "C0021051,C0030498,C0239055",
                    "parsed_text": "Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS"
                }
            }
        ]
    },
    {
        "_id": "ACTOXUHEUCPTEW-HRAVRIHDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44629935,
                "inchl_key": "ACTOXUHEUCPTEW-HRAVRIHDSA-N",
                "generic_name": "Spiramycin",
                "designated_date": "10/17/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rhone-Poulenc Rorer Pharmaceuticals|500 Arcola Road|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.",
                    "umls_id": "C0021051,C0030498,C0239055",
                    "parsed_text": "Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS"
                }
            }
        ]
    },
    {
        "_id": "ACTOXUHEUCPTEW-GRWVDKKHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5353959,
                "inchl_key": "ACTOXUHEUCPTEW-GRWVDKKHSA-N",
                "generic_name": "Spiramycin",
                "designated_date": "10/17/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rhone-Poulenc Rorer Pharmaceuticals|500 Arcola Road|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.",
                    "umls_id": "C0021051,C0030498,C0239055",
                    "parsed_text": "Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS"
                }
            }
        ]
    },
    {
        "_id": "ACTOXUHEUCPTEW-OSLILNPBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 137704528,
                "inchl_key": "ACTOXUHEUCPTEW-OSLILNPBSA-N",
                "generic_name": "Spiramycin",
                "designated_date": "10/17/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rhone-Poulenc Rorer Pharmaceuticals|500 Arcola Road|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.",
                    "umls_id": "C0021051,C0030498,C0239055",
                    "parsed_text": "Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS"
                }
            }
        ]
    },
    {
        "_id": "ACTOXUHEUCPTEW-JNQYENBPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71729958,
                "inchl_key": "ACTOXUHEUCPTEW-JNQYENBPSA-N",
                "generic_name": "Spiramycin",
                "designated_date": "10/17/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rhone-Poulenc Rorer Pharmaceuticals|500 Arcola Road|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.",
                    "umls_id": "C0021051,C0030498,C0239055",
                    "parsed_text": "Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS"
                }
            }
        ]
    },
    {
        "_id": "ACTOXUHEUCPTEW-OBURPCBNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5356392,
                "inchl_key": "ACTOXUHEUCPTEW-OBURPCBNSA-N",
                "generic_name": "Spiramycin",
                "designated_date": "10/17/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rhone-Poulenc Rorer Pharmaceuticals|500 Arcola Road|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.",
                    "umls_id": "C0021051,C0030498,C0239055",
                    "parsed_text": "Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS"
                }
            }
        ]
    },
    {
        "_id": "ACTOXUHEUCPTEW-BWHGAVFKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5284619,
                "inchl_key": "ACTOXUHEUCPTEW-BWHGAVFKSA-N",
                "generic_name": "Spiramycin",
                "designated_date": "10/17/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rhone-Poulenc Rorer Pharmaceuticals|500 Arcola Road|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.",
                    "umls_id": "C0021051,C0030498,C0239055",
                    "parsed_text": "Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS"
                }
            }
        ]
    },
    {
        "_id": "ACTOXUHEUCPTEW-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5266,
                "inchl_key": "ACTOXUHEUCPTEW-UHFFFAOYSA-N",
                "generic_name": "Spiramycin",
                "designated_date": "10/17/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rhone-Poulenc Rorer Pharmaceuticals|500 Arcola Road|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.",
                    "umls_id": "C0021051,C0030498,C0239055",
                    "parsed_text": "Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS"
                }
            }
        ]
    },
    {
        "_id": "ACTOXUHEUCPTEW-BOISPSKTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5702243,
                "inchl_key": "ACTOXUHEUCPTEW-BOISPSKTSA-N",
                "generic_name": "Spiramycin",
                "designated_date": "10/17/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rhone-Poulenc Rorer Pharmaceuticals|500 Arcola Road|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.",
                    "umls_id": "C0021051,C0030498,C0239055",
                    "parsed_text": "Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS"
                }
            }
        ]
    },
    {
        "_id": "ACTOXUHEUCPTEW-CEUOBAOPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5289394,
                "inchl_key": "ACTOXUHEUCPTEW-CEUOBAOPSA-N",
                "generic_name": "Spiramycin",
                "designated_date": "10/17/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rhone-Poulenc Rorer Pharmaceuticals|500 Arcola Road|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.",
                    "umls_id": "C0021051,C0030498,C0239055",
                    "parsed_text": "Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS"
                }
            }
        ]
    },
    {
        "_id": "ACTOXUHEUCPTEW-KWBWCIJSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6440717,
                "inchl_key": "ACTOXUHEUCPTEW-KWBWCIJSSA-N",
                "generic_name": "Spiramycin",
                "designated_date": "10/17/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rhone-Poulenc Rorer Pharmaceuticals|500 Arcola Road|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.",
                    "umls_id": "C0021051,C0030498,C0239055",
                    "parsed_text": "Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS"
                }
            }
        ]
    },
    {
        "_id": "ACTOXUHEUCPTEW-JMRHEKERSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6419898,
                "inchl_key": "ACTOXUHEUCPTEW-JMRHEKERSA-N",
                "generic_name": "Spiramycin",
                "designated_date": "10/17/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rhone-Poulenc Rorer Pharmaceuticals|500 Arcola Road|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.",
                    "umls_id": "C0021051,C0030498,C0239055",
                    "parsed_text": "Immunodeficiency , parasitic , CHRONIC CRYPTOSPORIDIOSIS"
                }
            }
        ]
    },
    {
        "_id": "FIAFUQMPZJWCLV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5361,
                "inchl_key": "FIAFUQMPZJWCLV-UHFFFAOYSA-N",
                "generic_name": "suramin",
                "designated_date": "01/25/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PaxMedica, Inc.|50 Tice Blvd., Suite A26|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of human African trypanosomiasis",
                    "umls_id": "C0041228",
                    "parsed_text": "African Trypanosomiasis"
                }
            },
            {
                "compound_id": 5361,
                "inchl_key": "FIAFUQMPZJWCLV-UHFFFAOYSA-N",
                "generic_name": "Suramin",
                "designated_date": "05/06/1997",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Warner-Lambert Company|Parke-Davis Pharmaceutical Research Division|2800 Plymouth Road|Ann Arbor|Michigan|48105|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hormone-refractory prostate cancer.",
                    "umls_id": "C0376358",
                    "parsed_text": "Prostate Cancer"
                }
            }
        ]
    },
    {
        "_id": "QFCXANHHBCGMAS-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9808844,
                "inchl_key": "QFCXANHHBCGMAS-UHFFFAOYSA-N",
                "generic_name": "telatinib",
                "designated_date": "05/17/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ACT Biotech Inc.|717 market St #650|Suite 650|San Francisco|California|94103|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastric cancer",
                    "umls_id": "C0024623",
                    "parsed_text": "Gastric Cancer"
                }
            }
        ]
    },
    {
        "_id": "NRUKOCRGYNPUPR-CTWARWOPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 137701349,
                "inchl_key": "NRUKOCRGYNPUPR-CTWARWOPSA-N",
                "generic_name": "Teniposide",
                "trade_name": "Vumon for injection",
                "designated_date": "11/01/1984",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents.",
                "marketing_approval_date": "\u00a007/14/1992\u00a0",
                "exclusivity_end_date": "\u00a007/14/1999\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|5 Research Parkway|P.O. Box 5100|Wallingford|Connecticut|6492|United States",
                "orphan_designation": {
                    "original_text": "Treatment of refractory childhood acute lymphocytic leukemia.",
                    "umls_id": "C0023452",
                    "parsed_text": "Childhood Acute Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "NRUKOCRGYNPUPR-DYPKOKSYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134694361,
                "inchl_key": "NRUKOCRGYNPUPR-DYPKOKSYSA-N",
                "generic_name": "Teniposide",
                "trade_name": "Vumon for injection",
                "designated_date": "11/01/1984",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents.",
                "marketing_approval_date": "\u00a007/14/1992\u00a0",
                "exclusivity_end_date": "\u00a007/14/1999\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|5 Research Parkway|P.O. Box 5100|Wallingford|Connecticut|6492|United States",
                "orphan_designation": {
                    "original_text": "Treatment of refractory childhood acute lymphocytic leukemia.",
                    "umls_id": "C0023452",
                    "parsed_text": "Childhood Acute Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "NRUKOCRGYNPUPR-VEUOYOFCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 122172961,
                "inchl_key": "NRUKOCRGYNPUPR-VEUOYOFCSA-N",
                "generic_name": "Teniposide",
                "trade_name": "Vumon for injection",
                "designated_date": "11/01/1984",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents.",
                "marketing_approval_date": "\u00a007/14/1992\u00a0",
                "exclusivity_end_date": "\u00a007/14/1999\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|5 Research Parkway|P.O. Box 5100|Wallingford|Connecticut|6492|United States",
                "orphan_designation": {
                    "original_text": "Treatment of refractory childhood acute lymphocytic leukemia.",
                    "umls_id": "C0023452",
                    "parsed_text": "Childhood Acute Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "NRUKOCRGYNPUPR-OMLXZSNTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 90659141,
                "inchl_key": "NRUKOCRGYNPUPR-OMLXZSNTSA-N",
                "generic_name": "Teniposide",
                "trade_name": "Vumon for injection",
                "designated_date": "11/01/1984",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents.",
                "marketing_approval_date": "\u00a007/14/1992\u00a0",
                "exclusivity_end_date": "\u00a007/14/1999\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|5 Research Parkway|P.O. Box 5100|Wallingford|Connecticut|6492|United States",
                "orphan_designation": {
                    "original_text": "Treatment of refractory childhood acute lymphocytic leukemia.",
                    "umls_id": "C0023452",
                    "parsed_text": "Childhood Acute Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "NRUKOCRGYNPUPR-ANTWWVKXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 54610154,
                "inchl_key": "NRUKOCRGYNPUPR-ANTWWVKXSA-N",
                "generic_name": "Teniposide",
                "trade_name": "Vumon for injection",
                "designated_date": "11/01/1984",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents.",
                "marketing_approval_date": "\u00a007/14/1992\u00a0",
                "exclusivity_end_date": "\u00a007/14/1999\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|5 Research Parkway|P.O. Box 5100|Wallingford|Connecticut|6492|United States",
                "orphan_designation": {
                    "original_text": "Treatment of refractory childhood acute lymphocytic leukemia.",
                    "umls_id": "C0023452",
                    "parsed_text": "Childhood Acute Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "NRUKOCRGYNPUPR-DKQCQWADSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 129009948,
                "inchl_key": "NRUKOCRGYNPUPR-DKQCQWADSA-N",
                "generic_name": "Teniposide",
                "trade_name": "Vumon for injection",
                "designated_date": "11/01/1984",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents.",
                "marketing_approval_date": "\u00a007/14/1992\u00a0",
                "exclusivity_end_date": "\u00a007/14/1999\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|5 Research Parkway|P.O. Box 5100|Wallingford|Connecticut|6492|United States",
                "orphan_designation": {
                    "original_text": "Treatment of refractory childhood acute lymphocytic leukemia.",
                    "umls_id": "C0023452",
                    "parsed_text": "Childhood Acute Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "NRUKOCRGYNPUPR-ZVYBSHBNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 23724511,
                "inchl_key": "NRUKOCRGYNPUPR-ZVYBSHBNSA-N",
                "generic_name": "Teniposide",
                "trade_name": "Vumon for injection",
                "designated_date": "11/01/1984",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents.",
                "marketing_approval_date": "\u00a007/14/1992\u00a0",
                "exclusivity_end_date": "\u00a007/14/1999\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|5 Research Parkway|P.O. Box 5100|Wallingford|Connecticut|6492|United States",
                "orphan_designation": {
                    "original_text": "Treatment of refractory childhood acute lymphocytic leukemia.",
                    "umls_id": "C0023452",
                    "parsed_text": "Childhood Acute Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "NRUKOCRGYNPUPR-OQMCATNJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6708778,
                "inchl_key": "NRUKOCRGYNPUPR-OQMCATNJSA-N",
                "generic_name": "Teniposide",
                "trade_name": "Vumon for injection",
                "designated_date": "11/01/1984",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents.",
                "marketing_approval_date": "\u00a007/14/1992\u00a0",
                "exclusivity_end_date": "\u00a007/14/1999\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|5 Research Parkway|P.O. Box 5100|Wallingford|Connecticut|6492|United States",
                "orphan_designation": {
                    "original_text": "Treatment of refractory childhood acute lymphocytic leukemia.",
                    "umls_id": "C0023452",
                    "parsed_text": "Childhood Acute Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "NRUKOCRGYNPUPR-NFIYYIGVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5284623,
                "inchl_key": "NRUKOCRGYNPUPR-NFIYYIGVSA-N",
                "generic_name": "Teniposide",
                "trade_name": "Vumon for injection",
                "designated_date": "11/01/1984",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents.",
                "marketing_approval_date": "\u00a007/14/1992\u00a0",
                "exclusivity_end_date": "\u00a007/14/1999\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|5 Research Parkway|P.O. Box 5100|Wallingford|Connecticut|6492|United States",
                "orphan_designation": {
                    "original_text": "Treatment of refractory childhood acute lymphocytic leukemia.",
                    "umls_id": "C0023452",
                    "parsed_text": "Childhood Acute Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "NRUKOCRGYNPUPR-CRZAWEBOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 275784,
                "inchl_key": "NRUKOCRGYNPUPR-CRZAWEBOSA-N",
                "generic_name": "Teniposide",
                "trade_name": "Vumon for injection",
                "designated_date": "11/01/1984",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents.",
                "marketing_approval_date": "\u00a007/14/1992\u00a0",
                "exclusivity_end_date": "\u00a007/14/1999\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|5 Research Parkway|P.O. Box 5100|Wallingford|Connecticut|6492|United States",
                "orphan_designation": {
                    "original_text": "Treatment of refractory childhood acute lymphocytic leukemia.",
                    "umls_id": "C0023452",
                    "parsed_text": "Childhood Acute Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "NRUKOCRGYNPUPR-PSZSYXFXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 34698,
                "inchl_key": "NRUKOCRGYNPUPR-PSZSYXFXSA-N",
                "generic_name": "Teniposide",
                "trade_name": "Vumon for injection",
                "designated_date": "11/01/1984",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents.",
                "marketing_approval_date": "\u00a007/14/1992\u00a0",
                "exclusivity_end_date": "\u00a007/14/1999\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|5 Research Parkway|P.O. Box 5100|Wallingford|Connecticut|6492|United States",
                "orphan_designation": {
                    "original_text": "Treatment of refractory childhood acute lymphocytic leukemia.",
                    "umls_id": "C0023452",
                    "parsed_text": "Childhood Acute Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "NRUKOCRGYNPUPR-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5396,
                "inchl_key": "NRUKOCRGYNPUPR-UHFFFAOYSA-N",
                "generic_name": "Teniposide",
                "trade_name": "Vumon for injection",
                "designated_date": "11/01/1984",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents.",
                "marketing_approval_date": "\u00a007/14/1992\u00a0",
                "exclusivity_end_date": "\u00a007/14/1999\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|5 Research Parkway|P.O. Box 5100|Wallingford|Connecticut|6492|United States",
                "orphan_designation": {
                    "original_text": "Treatment of refractory childhood acute lymphocytic leukemia.",
                    "umls_id": "C0023452",
                    "parsed_text": "Childhood Acute Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "NRUKOCRGYNPUPR-QBPJDGROSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 452548,
                "inchl_key": "NRUKOCRGYNPUPR-QBPJDGROSA-N",
                "generic_name": "Teniposide",
                "trade_name": "Vumon for injection",
                "designated_date": "11/01/1984",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents.",
                "marketing_approval_date": "\u00a007/14/1992\u00a0",
                "exclusivity_end_date": "\u00a007/14/1999\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|5 Research Parkway|P.O. Box 5100|Wallingford|Connecticut|6492|United States",
                "orphan_designation": {
                    "original_text": "Treatment of refractory childhood acute lymphocytic leukemia.",
                    "umls_id": "C0023452",
                    "parsed_text": "Childhood Acute Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "XNSAINXGIQZQOO-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 32281,
                "inchl_key": "XNSAINXGIQZQOO-UHFFFAOYSA-N",
                "generic_name": "Thyrotropin alfa",
                "trade_name": "Thyrogen",
                "designated_date": "08/03/2001",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of metastatic thyroid cancer",
                "marketing_approval_date": "\u00a012/14/2007\u00a0",
                "exclusivity_end_date": "\u00a012/14/2014\u00a0",
                "sponsor": "Genzyme Corporation|One Kendall Square|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid",
                    "umls_id": "C0007097",
                    "parsed_text": "Carcinomas"
                }
            }
        ]
    },
    {
        "_id": "MIQPIUSUKVNLNT-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4659569,
                "inchl_key": "MIQPIUSUKVNLNT-UHFFFAOYSA-N",
                "generic_name": "Tolcapone",
                "designated_date": "12/24/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Corino Therapeutics, Inc.|57 West 57th Street|18th Floor|New York|New York|10019|United States",
                "orphan_designation": {
                    "original_text": "Treatment of transthyretin amyloidosis",
                    "umls_id": "C2751492",
                    "parsed_text": "Transthyretin Amyloidosis"
                }
            }
        ]
    },
    {
        "_id": "PPKXEPBICJTCRU-XMZRARIVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 63013,
                "inchl_key": "PPKXEPBICJTCRU-XMZRARIVSA-N",
                "generic_name": "Tramadol hydrochloride",
                "designated_date": "01/28/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "TheraQuest Biosciences, LLC|146 Medinah Drive|Blue Bell|Pennsylvania|19422|United States",
                "orphan_designation": {
                    "original_text": "Treatment of painful HIV-associated neuropathy",
                    "umls_id": "C0019682,C0442874",
                    "parsed_text": "HIV , Neuropathy"
                }
            },
            {
                "compound_id": 63013,
                "inchl_key": "PPKXEPBICJTCRU-XMZRARIVSA-N",
                "generic_name": "Tramadol hydrochloride",
                "designated_date": "04/26/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "TheraQuest Biosciences, LLC|146 Medinah Drive|Blue Bell|Pennsylvania|19422|United States",
                "orphan_designation": {
                    "original_text": "Management of postherpetic neuralgia",
                    "umls_id": "C0032768",
                    "parsed_text": "Postherpetic neuralgia"
                }
            }
        ]
    },
    {
        "_id": "NZHGWWWHIYHZNX-CSKARUKUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5282230,
                "inchl_key": "NZHGWWWHIYHZNX-CSKARUKUSA-N",
                "generic_name": "Tranilast",
                "designated_date": "12/02/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Angiogen Pharmaceuticals, Pty. Ltd.|Level 31, ABN AMRO Tower|88 Phillip Street|Sydney|Australia",
                "orphan_designation": {
                    "original_text": "For the treatment of maligant glioma",
                    "umls_id": "C0017638",
                    "parsed_text": "Glioma"
                }
            },
            {
                "compound_id": 5282230,
                "inchl_key": "NZHGWWWHIYHZNX-CSKARUKUSA-N",
                "generic_name": "tranilast",
                "designated_date": "12/23/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Altacor Ltd|St. John's Innovation Centre|Cambridge CB4 0WS|United Kingdom",
                "orphan_designation": {
                    "original_text": "Prevention of scarring following glaucoma filtration surgery",
                    "umls_id": "C0017601",
                    "parsed_text": "Glaucoma"
                }
            }
        ]
    },
    {
        "_id": "HOGVTUZUJGHKPL-HTVVRFAVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 65399,
                "inchl_key": "HOGVTUZUJGHKPL-HTVVRFAVSA-N",
                "generic_name": "triciribine",
                "designated_date": "02/01/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "VioQuest Pharmaceuticals, Inc.|180 Mt. Airy Road|Basking Ridge|New Jersey|7920|United States",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "XPVOJYDIBHYVFL-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5458180,
                "inchl_key": "XPVOJYDIBHYVFL-UHFFFAOYSA-N",
                "generic_name": "Trientine HCl",
                "trade_name": "Syprine",
                "designated_date": "12/24/1984",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a011/08/1985\u00a0",
                "exclusivity_end_date": "\u00a011/08/1992\u00a0",
                "sponsor": "Merck Sharp & Dohme Research|Division Of Merck And Company|West Point|Pennsylvania|19486|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with Wilson's disease who are intolerant, or inadequately responsive to penicillamine.",
                    "umls_id": "C0019202",
                    "parsed_text": "Wilson's Disease"
                }
            }
        ]
    },
    {
        "_id": "PGAVKCOVUIYSFO-XVFCMESISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6133,
                "inchl_key": "PGAVKCOVUIYSFO-XVFCMESISA-N",
                "generic_name": "Uridine 5'-triphosphate",
                "designated_date": "06/26/1996",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Inspire Pharmaceuticals, Inc.|4222 Emperor Boulevard, Suite 470|Durham|North Carolina|27703|United States",
                "orphan_designation": {
                    "original_text": "To facilitate the removal of lung secretions in the treatment of patients with primary ciliary dyskinesia.",
                    "umls_id": "C4551720",
                    "parsed_text": "Primary Ciliary Dyskinesia"
                }
            },
            {
                "compound_id": 6133,
                "inchl_key": "PGAVKCOVUIYSFO-XVFCMESISA-N",
                "generic_name": "Uridine 5'-triphosphate",
                "designated_date": "12/04/1995",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Inspire Pharmaceuticals, Inc.|4222 Emperor Boulevard, Suite 470|Durham|North Carolina|27703|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis.",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "FJLUJBDSFBGOPL-YOKUEUOXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44566638,
                "inchl_key": "FJLUJBDSFBGOPL-YOKUEUOXSA-N",
                "generic_name": "uttroside B",
                "designated_date": "01/19/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Q BioMed|366 Madison Ave|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            }
        ]
    },
    {
        "_id": "MYPYJXKWCTUITO-LYRMYLQWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 14969,
                "inchl_key": "MYPYJXKWCTUITO-LYRMYLQWSA-N",
                "generic_name": "vancomycin",
                "designated_date": "12/27/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Fera Pharmaceuticals, LLC|134 Birch Hill Road|Locust Valley|New York|11560|United States",
                "orphan_designation": {
                    "original_text": "Treatment of endophthalmitis",
                    "umls_id": "C0014236",
                    "parsed_text": "Endophthalmitis"
                }
            }
        ]
    },
    {
        "_id": "UWXSAYUXVSFDBQ-CYBMUJFWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 42642648,
                "inchl_key": "UWXSAYUXVSFDBQ-CYBMUJFWSA-N",
                "generic_name": "varlitinib",
                "designated_date": "06/20/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ASLAN Pharmaceuticals|10A Bukit Pasoh Road|Singapore",
                "orphan_designation": {
                    "original_text": "Treatment of gastric cancer.",
                    "umls_id": "C0024623",
                    "parsed_text": "Gastric Cancer"
                }
            },
            {
                "compound_id": 42642648,
                "inchl_key": "UWXSAYUXVSFDBQ-CYBMUJFWSA-N",
                "generic_name": "varlitinib",
                "designated_date": "08/05/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ASLAN Pharmaceuticals Pte, Ltd.|83 Clemenceau Avenue|#12-03|Singapore|Singapore",
                "orphan_designation": {
                    "original_text": "treatment of biliary tract cancer",
                    "umls_id": "C0750952",
                    "parsed_text": "Biliary Tract Cancer"
                }
            }
        ]
    },
    {
        "_id": "SQXUKOJKIWCALK-PKLMIRHRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 78425810,
                "inchl_key": "SQXUKOJKIWCALK-PKLMIRHRSA-N",
                "generic_name": "venglustat malate",
                "designated_date": "08/13/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genzyme Corporation, a SANOFI COMPANY|50 Binney Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of GM2 gangliosidosis",
                    "umls_id": "C0268274",
                    "parsed_text": "GM2 Gangliosidosis"
                }
            }
        ]
    },
    {
        "_id": "FWCVZAQENIZVMY-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71602803,
                "inchl_key": "FWCVZAQENIZVMY-UHFFFAOYSA-N",
                "generic_name": "Voxelotor",
                "trade_name": "OXBRYTA",
                "designated_date": "12/29/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "OXBRYTA is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.",
                "marketing_approval_date": "\u00a011/25/2019\u00a0",
                "exclusivity_end_date": "\u00a011/25/2026\u00a0",
                "exclusivity_protected_indication": "Indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.",
                "sponsor": "Global Blood Therapeutics, Inc.|171 Oyster Point Blvd|Suite 300|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sickle cell disease (SCD).",
                    "umls_id": "C0002895,C0085298",
                    "parsed_text": "Sickle Cell Disease , SCD"
                }
            }
        ]
    },
    {
        "_id": "WREGKURFCTUGRC-POYBYMJQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24066,
                "inchl_key": "WREGKURFCTUGRC-POYBYMJQSA-N",
                "generic_name": "Zalcitabine",
                "designated_date": "12/09/1986",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "National Cancer Institute, DCT|NIH, Executive Plaza North, Room 7-18|Bethesda|Maryland|20892|United States",
                "orphan_designation": {
                    "original_text": "Treatment of AIDS.",
                    "umls_id": "C0001175",
                    "parsed_text": "AIDS"
                }
            },
            {
                "compound_id": 24066,
                "inchl_key": "WREGKURFCTUGRC-POYBYMJQSA-N",
                "generic_name": "Zalcitabine",
                "trade_name": "Hivid",
                "designated_date": "06/28/1988",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Combination therapy with zidovudine is indicated for the treatment of adult patients with advanced HIV infection (CD4 count < 300) who have demonstrated malignant clinical or immunologic deterioration.",
                "marketing_approval_date": "\u00a006/19/1992\u00a0",
                "exclusivity_end_date": "\u00a006/19/1999\u00a0",
                "sponsor": "Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of AIDS.",
                    "umls_id": "C0001175",
                    "parsed_text": "AIDS"
                }
            }
        ]
    },
    {
        "_id": "HBOMLICNUCNMMY-XLPZGREQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 35370,
                "inchl_key": "HBOMLICNUCNMMY-XLPZGREQSA-N",
                "generic_name": "zidovudine",
                "trade_name": "Retrovir",
                "designated_date": "07/17/1985",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Management of certain adult patients with symptomatic HIV infection (AIDS and advanced ARC) who have a history of cytologically confirmed Pneumocytis carinii pneumonia (PCP) or an absolute CD4 (T4 helper/induccer) lymphocyte count of less than 200/mm in the peripheral blood before therapy is begun",
                "marketing_approval_date": "\u00a003/19/1987\u00a0",
                "exclusivity_end_date": "\u00a003/19/1994\u00a0",
                "sponsor": "Glaxo Wellcome Inc.|5 Moore Drive|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "Treatment of AIDS",
                    "umls_id": "C0001175",
                    "parsed_text": "AIDS"
                }
            }
        ]
    },
    {
        "_id": "REQQVBGILUTQNN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 90420193,
                "inchl_key": "REQQVBGILUTQNN-UHFFFAOYSA-N",
                "generic_name": "Ziritaxestat",
                "designated_date": "01/27/2020",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Galapagos NV|Generaal De Wittelaan|L11 A3|Mechelen|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of systemic sclerosis",
                    "umls_id": "C0036421",
                    "parsed_text": "Systemic sclerosis"
                }
            }
        ]
    },
    {
        "_id": "QGNJRVVDBSJHIZ-AQDFTDIISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10245972,
                "inchl_key": "QGNJRVVDBSJHIZ-AQDFTDIISA-N",
                "generic_name": "zuretinol acetate",
                "designated_date": "12/02/2010",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Retinagenix LLC|1815 Purdy Avenue|Miami Beach|Florida|33139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of retinitis pigmentosa",
                    "umls_id": "C0035334",
                    "parsed_text": "Retinitis Pigmentosa"
                }
            },
            {
                "compound_id": 10245972,
                "inchl_key": "QGNJRVVDBSJHIZ-AQDFTDIISA-N",
                "generic_name": "zuretinol acetate",
                "designated_date": "12/02/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Retinagenix Therapeutics, Inc.|421 Kipling Street|Palo Alto|California|94301|United States",
                "orphan_designation": {
                    "original_text": "Treatment of inherited retinal dystrophies caused by confirmed biallelic RPE65 or LRAT mutations",
                    "umls_id": "C0854723",
                    "parsed_text": "Retinal Dystrophies"
                }
            }
        ]
    },
    {
        "_id": "MYSWGUAQZAJSOK-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2764,
                "inchl_key": "MYSWGUAQZAJSOK-UHFFFAOYSA-N",
                "generic_name": "ciprofloxacin",
                "designated_date": "06/01/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Savara Inc.|6836 Bee Cave Road, Building 3, Suite 200|Austin|Texas|78746|United States",
                "orphan_designation": {
                    "original_text": "The management of bronchiectasis",
                    "umls_id": "C0006267",
                    "parsed_text": "Bronchiectasis"
                }
            }
        ]
    },
    {
        "_id": "LXZZYRPGZAFOLE-UHFFFAOYSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 5702198,
                "inchl_key": "LXZZYRPGZAFOLE-UHFFFAOYSA-L",
                "generic_name": "Cisplatin",
                "designated_date": "09/06/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Privo Technologies|13 Bristol Street|Unit #1|Cambridge|Massachusetts|2141|United States",
                "orphan_designation": {
                    "original_text": "Treatment of anal cancer",
                    "umls_id": "C0279637",
                    "parsed_text": "Anal Cancer"
                }
            }
        ]
    },
    {
        "_id": "PMHDSACGRKBACK-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4961254,
                "inchl_key": "PMHDSACGRKBACK-UHFFFAOYSA-N",
                "generic_name": "D-amino acid oxidase inhibitor",
                "designated_date": "12/06/2017",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Takeda Development Center Americas, Inc.|Takeda Parkway|Deerfield|Illinois|60015|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Friedreich's ataxia (FRDA)",
                    "umls_id": "C0016719",
                    "parsed_text": "Friedreich's Ataxia"
                }
            }
        ]
    },
    {
        "_id": "LVXJQMNHJWSHET-AATRIKPKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11511120,
                "inchl_key": "LVXJQMNHJWSHET-AATRIKPKSA-N",
                "generic_name": "dacomitinib",
                "trade_name": "VIZIMPRO",
                "designated_date": "03/03/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R",
                "marketing_approval_date": "\u00a009/27/2018\u00a0",
                "exclusivity_end_date": "\u00a009/27/2025\u00a0",
                "exclusivity_protected_indication": "For the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R",
                "sponsor": "Pfizer, Inc.|235 East 42nd Street|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-small cell lung cancer with EGFR, HER2, HER4, or DDR2 mutations.",
                    "umls_id": "C3539721",
                    "parsed_text": "Non-Small Cell Lung Cancer"
                }
            }
        ]
    },
    {
        "_id": "JGDXFQORBMPJGR-YUMQZZPRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11683005,
                "inchl_key": "JGDXFQORBMPJGR-YUMQZZPRSA-N",
                "generic_name": "Darinaparsin",
                "designated_date": "09/13/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Solasia Pharma K.K.|3F, Shiodome Building|Toyko 105-0022|Japan",
                "orphan_designation": {
                    "original_text": "Treatment of peripheral T-cell lymphoma.",
                    "umls_id": "C0079774",
                    "parsed_text": "Peripheral T-Cell Lymphoma"
                }
            }
        ]
    },
    {
        "_id": "GFJWACFSUSFUOG-ZJTJBYBXSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 23668320,
                "inchl_key": "GFJWACFSUSFUOG-ZJTJBYBXSA-M",
                "generic_name": "Dehydroepiandrosterone sulfate sodium",
                "designated_date": "01/29/1997",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmadigm, Inc.|2401 Foothill Drive|Salt Lake City|Utah|84109|United States",
                "orphan_designation": {
                    "original_text": "Treatment of serious burns requiring hospitalization.",
                    "umls_id": "C0006434",
                    "parsed_text": "Burns"
                }
            }
        ]
    },
    {
        "_id": "GJKXGJCSJWBJEZ-XRSSZCMZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25077495,
                "inchl_key": "GJKXGJCSJWBJEZ-XRSSZCMZSA-N",
                "generic_name": "Deslorelin",
                "designated_date": "11/05/1987",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Roberts Pharmaceutical Corp.|Meridian Center II|Four Industrial Way West|Eatontown|New Jersey|7724|United States",
                "orphan_designation": {
                    "original_text": "Treatment of central precocious puberty.",
                    "umls_id": "C0342543",
                    "parsed_text": "Central Precocious Puberty"
                }
            }
        ]
    },
    {
        "_id": "MLSVJHOYXJGGTR-GHZYFSNVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 146160431,
                "inchl_key": "MLSVJHOYXJGGTR-GHZYFSNVSA-N",
                "generic_name": "Desmopressin acetate",
                "designated_date": "01/22/1991",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with hemophilia A or von Willebrand's disease (type I) whose factor VIII coagulant activity level is greater than 5%.",
                "marketing_approval_date": "\u00a003/07/1994\u00a0",
                "exclusivity_end_date": "\u00a003/07/2001\u00a0",
                "sponsor": "Ferring Pharmaceuticals, Inc.|100 Interpace Parkway|Parsippany-Troy Hills|New Jersey|7054|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mild hemophilia A and von Willebrand's disease.",
                    "umls_id": "C0042974,C0272324",
                    "parsed_text": "von Willebrand's Disease , Mild hemophilia A"
                }
            }
        ]
    },
    {
        "_id": "MLSVJHOYXJGGTR-COZVRORISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 124080868,
                "inchl_key": "MLSVJHOYXJGGTR-COZVRORISA-N",
                "generic_name": "Desmopressin acetate",
                "designated_date": "01/22/1991",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with hemophilia A or von Willebrand's disease (type I) whose factor VIII coagulant activity level is greater than 5%.",
                "marketing_approval_date": "\u00a003/07/1994\u00a0",
                "exclusivity_end_date": "\u00a003/07/2001\u00a0",
                "sponsor": "Ferring Pharmaceuticals, Inc.|100 Interpace Parkway|Parsippany-Troy Hills|New Jersey|7054|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mild hemophilia A and von Willebrand's disease.",
                    "umls_id": "C0042974,C0272324",
                    "parsed_text": "von Willebrand's Disease , Mild hemophilia A"
                }
            }
        ]
    },
    {
        "_id": "MLSVJHOYXJGGTR-MOMGZFCSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16051969,
                "inchl_key": "MLSVJHOYXJGGTR-MOMGZFCSSA-N",
                "generic_name": "Desmopressin acetate",
                "designated_date": "01/22/1991",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with hemophilia A or von Willebrand's disease (type I) whose factor VIII coagulant activity level is greater than 5%.",
                "marketing_approval_date": "\u00a003/07/1994\u00a0",
                "exclusivity_end_date": "\u00a003/07/2001\u00a0",
                "sponsor": "Ferring Pharmaceuticals, Inc.|100 Interpace Parkway|Parsippany-Troy Hills|New Jersey|7054|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mild hemophilia A and von Willebrand's disease.",
                    "umls_id": "C0042974,C0272324",
                    "parsed_text": "von Willebrand's Disease , Mild hemophilia A"
                }
            }
        ]
    },
    {
        "_id": "MLSVJHOYXJGGTR-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 64758,
                "inchl_key": "MLSVJHOYXJGGTR-UHFFFAOYSA-N",
                "generic_name": "Desmopressin acetate",
                "designated_date": "01/22/1991",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with hemophilia A or von Willebrand's disease (type I) whose factor VIII coagulant activity level is greater than 5%.",
                "marketing_approval_date": "\u00a003/07/1994\u00a0",
                "exclusivity_end_date": "\u00a003/07/2001\u00a0",
                "sponsor": "Ferring Pharmaceuticals, Inc.|100 Interpace Parkway|Parsippany-Troy Hills|New Jersey|7054|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mild hemophilia A and von Willebrand's disease.",
                    "umls_id": "C0042974,C0272324",
                    "parsed_text": "von Willebrand's Disease , Mild hemophilia A"
                }
            }
        ]
    },
    {
        "_id": "MLSVJHOYXJGGTR-IFHOVBQLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9833407,
                "inchl_key": "MLSVJHOYXJGGTR-IFHOVBQLSA-N",
                "generic_name": "Desmopressin acetate",
                "designated_date": "01/22/1991",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with hemophilia A or von Willebrand's disease (type I) whose factor VIII coagulant activity level is greater than 5%.",
                "marketing_approval_date": "\u00a003/07/1994\u00a0",
                "exclusivity_end_date": "\u00a003/07/2001\u00a0",
                "sponsor": "Ferring Pharmaceuticals, Inc.|100 Interpace Parkway|Parsippany-Troy Hills|New Jersey|7054|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mild hemophilia A and von Willebrand's disease.",
                    "umls_id": "C0042974,C0272324",
                    "parsed_text": "von Willebrand's Disease , Mild hemophilia A"
                }
            }
        ]
    },
    {
        "_id": "MKJIEFSOBYUXJB-VFJJUKLQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 73437646,
                "inchl_key": "MKJIEFSOBYUXJB-VFJJUKLQSA-N",
                "generic_name": "deutetrabenazine",
                "designated_date": "01/13/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "TEVA Pharmaceuticals|3366 North Torrey Pines Court|Suite 225|LaJolla|California|92037|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Tourette syndrome in the pediatric population (defined as 0 through 16 years of age)",
                    "umls_id": "C0040517",
                    "parsed_text": "Tourette Syndrome"
                }
            }
        ]
    },
    {
        "_id": "PIMQWRZWLQKKBJ-SFHVURJKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 46926350,
                "inchl_key": "PIMQWRZWLQKKBJ-SFHVURJKSA-N",
                "generic_name": "dinaciclib",
                "designated_date": "08/25/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Merck Sharp & Dohme Ltd.|Hertford Road, Hoddesdon|Hertfordshire|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia.",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "FGXWKSZFVQUSTL-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3151,
                "inchl_key": "FGXWKSZFVQUSTL-UHFFFAOYSA-N",
                "generic_name": "domperidone",
                "designated_date": "09/02/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Thomas W. Hale, RPh, PhD|Texas Tech University Health Sciences Ctr.|1400 Coulter Suite 1400|Amarillo|Texas|79106|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hypoprolactinemia in breastfeeding mothers, and in some hypoprolactinemic conditions following the use of cabergoline or bromocriptine in mothers who wish to initiate or return to breastfeeding",
                    "umls_id": "C0271586",
                    "parsed_text": "Hypoprolactinemia"
                }
            }
        ]
    },
    {
        "_id": "FIITXXIVUIXYMI-RQJHMYQMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 164486,
                "inchl_key": "FIITXXIVUIXYMI-RQJHMYQMSA-N",
                "generic_name": "doranidazole",
                "designated_date": "11/30/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Shuttle Pharmaceuticals, Inc.|1 Research Court|Suite 450|Rockville|Maryland|20850|United States",
                "orphan_designation": {
                    "original_text": "radiosensitizer to be used during radiation treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "HWXIGFIVGWUZAO-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 50942,
                "inchl_key": "HWXIGFIVGWUZAO-UHFFFAOYSA-N",
                "generic_name": "doxofylline",
                "designated_date": "02/14/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Alitair Pharmaceuticals, Inc.|55 Madison Avenue|Suite 400|Morristown|New Jersey|7960|United States",
                "orphan_designation": {
                    "original_text": "Treatment of bronchiectasis",
                    "umls_id": "C0006267",
                    "parsed_text": "Bronchiectasis"
                }
            }
        ]
    },
    {
        "_id": "BNFRJXLZYUTIII-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 122335,
                "inchl_key": "BNFRJXLZYUTIII-UHFFFAOYSA-N",
                "generic_name": "efaproxiral",
                "designated_date": "07/28/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Allos Therapeutics, Inc.|11080 CirclePoint Road|Suite 200|Westminster|Colorado|80020|United States",
                "orphan_designation": {
                    "original_text": "Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancer",
                    "umls_id": "C0220650,C0678222",
                    "parsed_text": "brain metastases , Breast cancer"
                }
            }
        ]
    },
    {
        "_id": "FJZZPCZKBUKGGU-AUSIDOKSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 23652731,
                "inchl_key": "FJZZPCZKBUKGGU-AUSIDOKSSA-N",
                "generic_name": "eliglustat",
                "trade_name": "CERDELGA",
                "designated_date": "09/17/2008",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.",
                "marketing_approval_date": "\u00a008/19/2014\u00a0",
                "exclusivity_end_date": "\u00a008/19/2021\u00a0",
                "exclusivity_protected_indication": "Long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.",
                "sponsor": "Genzyme Corporation|500 Kendall Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Type I Gaucher disease",
                    "umls_id": "C0017205",
                    "parsed_text": "Gaucher Disease"
                }
            }
        ]
    },
    {
        "_id": "JUTBAVRYDAKVGQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 21133161,
                "inchl_key": "JUTBAVRYDAKVGQ-UHFFFAOYSA-N",
                "generic_name": "emeramide",
                "designated_date": "04/06/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NBMI Science Limited|c/o Philip Lee Solicitors|119 Burnside Drive|Nicholasville|Ireland",
                "orphan_designation": {
                    "original_text": "Treatment of mercury toxicity",
                    "umls_id": "C0600688",
                    "parsed_text": "Toxicity"
                }
            }
        ]
    },
    {
        "_id": "CMJCXYNUCSMDBY-ZDUSSCGKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 50922675,
                "inchl_key": "CMJCXYNUCSMDBY-ZDUSSCGKSA-N",
                "generic_name": "encorafenib",
                "designated_date": "11/19/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Array BioPharma, Inc.|125 Cambridge Park Drive|Suite 301|Cambridge|Massachusetts|2140|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Stage IIB-IV melanoma positive for BRAF mutation",
                    "umls_id": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "CIBHDGPIOICRGX-ZQCHCGQNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5311219,
                "inchl_key": "CIBHDGPIOICRGX-ZQCHCGQNSA-N",
                "generic_name": "enisoprost",
                "designated_date": "10/20/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "G.D. Searle & Company|4901 Searle Parkway|Skokie|Illinois|60077|United States",
                "orphan_designation": {
                    "original_text": "1. For use with cyclosporine in organ transplant recipients to reduce acute transplant rejection 2. For use in organ transplant patients to diminish the nephrotoxicity induced by cyclosporine.",
                    "umls_id": "C0595916",
                    "parsed_text": "nephrotoxicity"
                }
            }
        ]
    },
    {
        "_id": "CHNUOJQWGUIOLD-NFZZJPOKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 1549120,
                "inchl_key": "CHNUOJQWGUIOLD-NFZZJPOKSA-N",
                "generic_name": "epalrestat",
                "designated_date": "03/26/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Perlara PBC|2625 Alcatraz Ave, #435|Berkeley|California|94705|United States",
                "orphan_designation": {
                    "original_text": "Treatment of phosphomannomutase-2 deficiency, a congenital disorder of glycosylation",
                    "umls_id": "C0282577",
                    "parsed_text": "Congenital disorder of glycosylation"
                }
            }
        ]
    },
    {
        "_id": "MGNVWUDMMXZUDI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 428573,
                "inchl_key": "MGNVWUDMMXZUDI-UHFFFAOYSA-N",
                "generic_name": "eprodisate",
                "designated_date": "04/06/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "C. T. Development America, Inc.|663 Fifth Avenue|7th Floor|New York|New York|10022|United States",
                "orphan_designation": {
                    "original_text": "Treatment of secondary amyloidosis",
                    "umls_id": "C3536715",
                    "parsed_text": "Secondary amyloidosis"
                }
            }
        ]
    },
    {
        "_id": "GTTBEUCJPZQMDZ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 176871,
                "inchl_key": "GTTBEUCJPZQMDZ-UHFFFAOYSA-N",
                "generic_name": "Erlotinib Hydrochloride",
                "designated_date": "07/18/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant gliomas",
                    "umls_id": "C0555198",
                    "parsed_text": "malignant gliomas"
                }
            }
        ]
    },
    {
        "_id": "AJIPIJNNOJSSQC-NYLIRDPKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 27125,
                "inchl_key": "AJIPIJNNOJSSQC-NYLIRDPKSA-N",
                "generic_name": "estetrol",
                "designated_date": "03/28/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mithra Pharmaceuticals S.A.|5-7 Rue St Georges|Li\u89e5|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of neonatal hypoxic ischemic encephalopathy",
                    "umls_id": "C3898147",
                    "parsed_text": "Neonatal Hypoxic Ischemic Encephalopathy"
                }
            }
        ]
    },
    {
        "_id": "HTQBXNHDCUEHJF-JHBIHAKISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 138394057,
                "inchl_key": "HTQBXNHDCUEHJF-JHBIHAKISA-N",
                "generic_name": "exenatide",
                "designated_date": "05/16/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Alan Boyd Consultants Limited|Electra House|Crewe Business Park|Crewe|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic intracranial hypertension",
                    "umls_id": "C0033845",
                    "parsed_text": "Idiopathic Intracranial Hypertension"
                }
            }
        ]
    },
    {
        "_id": "HTQBXNHDCUEHJF-URRANESESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 56927919,
                "inchl_key": "HTQBXNHDCUEHJF-URRANESESA-N",
                "generic_name": "exenatide",
                "designated_date": "05/16/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Alan Boyd Consultants Limited|Electra House|Crewe Business Park|Crewe|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic intracranial hypertension",
                    "umls_id": "C0033845",
                    "parsed_text": "Idiopathic Intracranial Hypertension"
                }
            }
        ]
    },
    {
        "_id": "HTQBXNHDCUEHJF-XWLPCZSASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 45588096,
                "inchl_key": "HTQBXNHDCUEHJF-XWLPCZSASA-N",
                "generic_name": "exenatide",
                "designated_date": "05/16/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Alan Boyd Consultants Limited|Electra House|Crewe Business Park|Crewe|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic intracranial hypertension",
                    "umls_id": "C0033845",
                    "parsed_text": "Idiopathic Intracranial Hypertension"
                }
            }
        ]
    },
    {
        "_id": "DBGIVFWFUFKIQN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3337,
                "inchl_key": "DBGIVFWFUFKIQN-UHFFFAOYSA-N",
                "generic_name": "fenfluramine",
                "designated_date": "06/19/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Zogenix Inc.|5858 Horton Street|Suite 455|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Lennox-Gastaut syndrome",
                    "umls_id": "C0238111",
                    "parsed_text": "Lennox-Gastaut syndrome"
                }
            }
        ]
    },
    {
        "_id": "KKGQTZUTZRNORY-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 107970,
                "inchl_key": "KKGQTZUTZRNORY-UHFFFAOYSA-N",
                "generic_name": "fingolimod",
                "designated_date": "04/30/2010",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceutical Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic inflammatory demyelinating polyneuropathy",
                    "umls_id": "C0393819",
                    "parsed_text": "Chronic inflammatory demyelinating polyneuropathy"
                }
            }
        ]
    },
    {
        "_id": "RUPXJRIDSUCQAN-PQNNUJSWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 119058042,
                "inchl_key": "RUPXJRIDSUCQAN-PQNNUJSWSA-N",
                "generic_name": "givosiran",
                "trade_name": "GIVLAARI",
                "designated_date": "08/29/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP).",
                "marketing_approval_date": "\u00a011/20/2019\u00a0",
                "exclusivity_end_date": "\u00a011/20/2026\u00a0",
                "exclusivity_protected_indication": "Indicated for the treatment of adults with acute hepatic porphyria (AHP).",
                "sponsor": "Alnylam Pharmaceuticals, Inc.|101 Main Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute hepatic porphyria",
                    "umls_id": "C0268328",
                    "parsed_text": "Acute hepatic porphyria"
                }
            }
        ]
    },
    {
        "_id": "SFNSLLSYNZWZQG-VQIMIIECSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25166913,
                "inchl_key": "SFNSLLSYNZWZQG-VQIMIIECSA-N",
                "generic_name": "Glasdegib",
                "trade_name": "DAURISMO",
                "designated_date": "06/28/2017",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are >75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.",
                "marketing_approval_date": "\u00a011/21/2018\u00a0",
                "exclusivity_end_date": "\u00a011/21/2025\u00a0",
                "exclusivity_protected_indication": "DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are >75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.",
                "sponsor": "Pfizer, Inc.|445 Eastern Point Road|Groton|Connecticut|6340|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia (AML)",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "compound_id": 25166913,
                "inchl_key": "SFNSLLSYNZWZQG-VQIMIIECSA-N",
                "generic_name": "glasdegib",
                "designated_date": "10/20/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer, Inc.|445 Eastern Point Road|Groton|Connecticut|6340|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndrome",
                    "umls_id": "C3463824",
                    "parsed_text": "MYELODYSPLASTIC SYNDROME"
                }
            }
        ]
    },
    {
        "_id": "PSVUJBVBCOISSP-SPFKKGSWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 123628,
                "inchl_key": "PSVUJBVBCOISSP-SPFKKGSWSA-N",
                "generic_name": "glufosfamide",
                "designated_date": "09/18/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eleison Pharmaceuticals LLC|103 Carnegie Center|Suite 300|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "For treatment of pancreatic cancer.",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "LVZYXEALRXBLJZ-ISQYCPACSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71587831,
                "inchl_key": "LVZYXEALRXBLJZ-ISQYCPACSA-N",
                "generic_name": "imetelstat",
                "designated_date": "06/11/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Geron Corporation|919 E. Hillsdale Blvd., Suite 250|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelofibrosis",
                    "umls_id": "C0026987",
                    "parsed_text": "myelofibrosis"
                }
            },
            {
                "compound_id": 71587831,
                "inchl_key": "LVZYXEALRXBLJZ-ISQYCPACSA-N",
                "generic_name": "imetelstat",
                "designated_date": "12/23/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Geron Corporation|919 E. Hillsdale Blvd., Suite 250|Foster City|California|94404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndrome",
                    "umls_id": "C3463824",
                    "parsed_text": "MYELODYSPLASTIC SYNDROME"
                }
            }
        ]
    },
    {
        "_id": "YHTTWXCDIRTOQX-FQJIPJFPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134611625,
                "inchl_key": "YHTTWXCDIRTOQX-FQJIPJFPSA-N",
                "generic_name": "internalized-arginylglycylaspartic acid cyclic peptide",
                "designated_date": "01/29/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cend Therapeutics, Inc.|12544 High Bluff Drive, Suite 400|San Diego|California|92130|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "JOITUBWXBFATOR-HKBOAZHASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71587904,
                "inchl_key": "JOITUBWXBFATOR-HKBOAZHASA-N",
                "generic_name": "L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal",
                "designated_date": "01/18/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CepTor Corporation|200 International Circle|Hunt Valley|Maryland|21030|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Duchenne and Becker muscular dystrophy",
                    "umls_id": "C3542021",
                    "parsed_text": "Duchenne and Becker Muscular Dystrophy"
                }
            }
        ]
    },
    {
        "_id": "AYFVYJQAPQTCCC-GBXIJSLDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6288,
                "inchl_key": "AYFVYJQAPQTCCC-GBXIJSLDSA-N",
                "generic_name": "L-threonine",
                "designated_date": "07/24/1992",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Interneuron Pharmaceuticals, Inc.|99 Hayden Ave., Suite 200|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of spasticity associated with familial spastic paraparesis.",
                    "umls_id": "C0026838,C0037771",
                    "parsed_text": "Spasticity , spastic paraparesis"
                }
            },
            {
                "compound_id": 6288,
                "inchl_key": "AYFVYJQAPQTCCC-GBXIJSLDSA-N",
                "generic_name": "L-threonine",
                "designated_date": "02/06/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Tyson And Associates|12832 Chadron Avenue|Hawthorne|California|90250|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis.",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "NYNZQNWKBKUAII-KBXCAEBGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 46188928,
                "inchl_key": "NYNZQNWKBKUAII-KBXCAEBGSA-N",
                "generic_name": "Larotrectinib",
                "designated_date": "08/31/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bayer HealthCare Pharmaceuticals Inc.|100 Bayer Boulevard|Whippany|New Jersey|7981|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcoma.",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            },
            {
                "compound_id": 46188928,
                "inchl_key": "NYNZQNWKBKUAII-KBXCAEBGSA-N",
                "generic_name": "larotrectinib",
                "trade_name": "VITRAKVI",
                "designated_date": "05/09/2017",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity; and have no satisfactory alternative treatments or that have progressed following treatment.",
                "marketing_approval_date": "\u00a011/26/2018\u00a0",
                "exclusivity_end_date": "\u00a011/26/2025\u00a0",
                "exclusivity_protected_indication": "VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity; and have no satisfactory alternative treatments or that have progressed following treatment.",
                "sponsor": "Bayer HealthCare Pharmaceuticals Inc.|100 Bayer Boulevard|Whippany|New Jersey|7981|United States",
                "orphan_designation": {
                    "original_text": "Treatment of solid tumors with NTRK-fusion proteins",
                    "umls_id": "C0280100",
                    "parsed_text": "solid tumors"
                }
            }
        ]
    },
    {
        "_id": "FWYSMLBETOMXAG-QHCPKHFHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 45138674,
                "inchl_key": "FWYSMLBETOMXAG-QHCPKHFHSA-N",
                "generic_name": "letermovir",
                "trade_name": "PREVYMIS",
                "designated_date": "12/12/2011",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).",
                "marketing_approval_date": "\u00a011/08/2017\u00a0",
                "exclusivity_end_date": "\u00a011/08/2024\u00a0",
                "exclusivity_protected_indication": "Prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).",
                "sponsor": "Merck Sharpe & Dhome Corporation|P. O. Box 1000, UG2D-68|North Wales|Pennsylvania|19454|United States",
                "orphan_designation": {
                    "original_text": "Prevention of human cytomegalovirus viremia and disease in at risk populations",
                    "umls_id": "C0205725,C0877635",
                    "parsed_text": "Human cytomegalovirus , Cytomegalovirus viremia"
                }
            }
        ]
    },
    {
        "_id": "IVTMXOXVAHXCHI-YXLMWLKOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 104778,
                "inchl_key": "IVTMXOXVAHXCHI-YXLMWLKOSA-N",
                "generic_name": "levodopa and carbidopa",
                "trade_name": "Duopa",
                "designated_date": "01/18/2000",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of motor flucuations in patients with advanced Parkinson's disease",
                "marketing_approval_date": "\u00a001/09/2015\u00a0",
                "exclusivity_end_date": "\u00a001/09/2022\u00a0",
                "exclusivity_protected_indication": "Treatment of motor flucuations in patients with advanced Parkinson's disease",
                "sponsor": "AbbVie, Inc.|1 N. Waukegan Road|Building AP30-1|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of late stage Parkinson's disease",
                    "umls_id": "C0030567",
                    "parsed_text": "Parkinson's Disease"
                }
            }
        ]
    },
    {
        "_id": "RQZAXGRLVPAYTJ-GQFGMJRRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11683,
                "inchl_key": "RQZAXGRLVPAYTJ-GQFGMJRRSA-N",
                "generic_name": "Megestrol acetate",
                "trade_name": "Megace",
                "designated_date": "04/13/1988",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immune deficiency syndrome.",
                "marketing_approval_date": "\u00a009/10/1993\u00a0",
                "exclusivity_end_date": "\u00a009/10/2000\u00a0",
                "sponsor": "Bristol-Myers Squibb Pharmaceutical Research Institute|2400 West Lloyd Expressway|Evansville|Indiana|47721|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anorexia, cachexia, or significant weight loss (=/>10% of baseline body weight) and confirmed diagnosis of AIDS.",
                    "umls_id": "C0001175,C0006625,C4084774",
                    "parsed_text": "AIDS , Cachexia , Weight loss"
                }
            }
        ]
    },
    {
        "_id": "RYKKQQUKJJGFMN-HVDRVSQOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 115198,
                "inchl_key": "RYKKQQUKJJGFMN-HVDRVSQOSA-N",
                "generic_name": "metadoxine",
                "designated_date": "12/16/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Alcobra, Inc.|2 Weizman Street|Tel-Aviv|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Fragile X Syndrome",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "JVLBPIPGETUEET-GAAHOAFPSA-O",
        "Orphan Drug Designations": [
            {
                "compound_id": 5361918,
                "inchl_key": "JVLBPIPGETUEET-GAAHOAFPSA-O",
                "generic_name": "Methylnaltrexone",
                "designated_date": "06/17/1996",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Progenics Pharmaceuticals, Inc.|765 Old Saw Mill River Rd.|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic opioid-induced constipation unresponsive to conventional therapy.",
                    "umls_id": "C3160897",
                    "parsed_text": "Opioid-Induced Constipation"
                }
            }
        ]
    },
    {
        "_id": "NHTGHBARYWONDQ-JTQLQIEISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 441350,
                "inchl_key": "NHTGHBARYWONDQ-JTQLQIEISA-N",
                "generic_name": "metyrosine",
                "designated_date": "07/25/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cerberus Princeton, LLC|c/o Cerberus Capital Management L.P.|875 Third Avenue|New York|New York|10022|United States",
                "orphan_designation": {
                    "original_text": "Treatment of velocardiofacial syndrome associated psychosis.",
                    "umls_id": "C0012236,C0033975",
                    "parsed_text": "Velocardiofacial Syndrome , Psychosis"
                }
            }
        ]
    },
    {
        "_id": "ZHBJMVNZRZUQEP-KIKMAQITSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 46203139,
                "inchl_key": "ZHBJMVNZRZUQEP-KIKMAQITSA-L",
                "generic_name": "Minnelide",
                "designated_date": "02/18/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Minneamrita Therapeutics, LLC|6 Hickory Court|Rock Island|Illinois|61201|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "TZRFSLHOCZEXCC-HIVFKXHNSA-A",
        "Orphan Drug Designations": [
            {
                "compound_id": 71301230,
                "inchl_key": "TZRFSLHOCZEXCC-HIVFKXHNSA-A",
                "generic_name": "mipomersen",
                "trade_name": "KYNAMRO",
                "designated_date": "05/23/2006",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).",
                "marketing_approval_date": "\u00a001/29/2013\u00a0",
                "exclusivity_end_date": "\u00a001/29/2020\u00a0",
                "exclusivity_protected_indication": "Adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).",
                "sponsor": "Kastle Therapeutics, LLC|181 West Madison Street|Suite 3745|Chicago|Illinois|60602|United States",
                "orphan_designation": {
                    "original_text": "Treatment of homozygous familial hypercholesterolemia",
                    "umls_id": "C0020445",
                    "parsed_text": "FAMILIAL HYPERCHOLESTEROLEMIA"
                }
            }
        ]
    },
    {
        "_id": "HZQDCMWJEBCWBR-UUOKFMHZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 104762,
                "inchl_key": "HZQDCMWJEBCWBR-UUOKFMHZSA-N",
                "generic_name": "Mizoribine",
                "designated_date": "11/09/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|161 Jefferson Avenue|Tenafly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of membranous nephropathy",
                    "umls_id": "C0017665",
                    "parsed_text": "membranous nephropathy"
                }
            }
        ]
    },
    {
        "_id": "QJYMZHMIZZYHBI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 56841946,
                "inchl_key": "QJYMZHMIZZYHBI-UHFFFAOYSA-N",
                "generic_name": "monarsen",
                "designated_date": "11/14/2003",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bioline Rx, Ltd.|19 Hartum Street|P. O. Box 45158|Jerusalem|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of myasthenia gravis",
                    "umls_id": "C0026896",
                    "parsed_text": "Myasthenia Gravis"
                }
            }
        ]
    },
    {
        "_id": "RIIKDGPBTPECSW-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 124147085,
                "inchl_key": "RIIKDGPBTPECSW-UHFFFAOYSA-N",
                "generic_name": "N-(tert-butylcarbamoyl)-5-cyano-2-((4'-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)oxy)benzenesulfonamide",
                "designated_date": "03/01/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ATXA Therapeutics Limited|75 Avoca Avenue|Avoca Avenue|Blackrock|County Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "UJCHIZDEQZMODR-BYPYZUCNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10176265,
                "inchl_key": "UJCHIZDEQZMODR-BYPYZUCNSA-N",
                "generic_name": "N-acetyl cysteine amide",
                "designated_date": "12/31/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Nacuity Pharmaceuticals, Inc.|Fort Worth Club Building|306 W 17th Street|Fort Worth|Texas|76106|United States",
                "orphan_designation": {
                    "original_text": "Treatment of retinitis pigmentosa",
                    "umls_id": "C0035334",
                    "parsed_text": "Retinitis Pigmentosa"
                }
            }
        ]
    },
    {
        "_id": "AKFJWRDCWYYTIG-ZDUSSCGKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9884642,
                "inchl_key": "AKFJWRDCWYYTIG-ZDUSSCGKSA-N",
                "generic_name": "naproxcinod",
                "designated_date": "03/16/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Nicox SA|2105 route des Dolines|Drakkar bat D-CS 10313|Valbonne|France",
                "orphan_designation": {
                    "original_text": "Treatment of Duchenne muscular dystrophy.",
                    "umls_id": "C0013264",
                    "parsed_text": "DUCHENNE MUSCULAR DYSTROPHY"
                }
            }
        ]
    },
    {
        "_id": "ZBBHBTPTTSWHBA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4474,
                "inchl_key": "ZBBHBTPTTSWHBA-UHFFFAOYSA-N",
                "generic_name": "nicardipine",
                "designated_date": "11/26/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Collaborations Pharmaceuticals, Inc.|5616 Hilltop Needmore Rd,|Fuquay Varina|North Carolina|27526|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pitt-Hopkins Syndrome",
                    "umls_id": "C1970431",
                    "parsed_text": "PITT-HOPKINS SYNDROME"
                }
            }
        ]
    },
    {
        "_id": "HYIMSNHJOBLJNT-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4485,
                "inchl_key": "HYIMSNHJOBLJNT-UHFFFAOYSA-N",
                "generic_name": "Nifedipine",
                "designated_date": "06/13/1991",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Fleischmann, Jonathan M.D.|MetroHealth Medical Center|3395 Scranton Road|Cleveland|Ohio|44109|United States",
                "orphan_designation": {
                    "original_text": "Treatment of interstitial cystitis.",
                    "umls_id": "C0282488",
                    "parsed_text": "Interstitial Cystitis"
                }
            }
        ]
    },
    {
        "_id": "CPMDPSXJELVGJG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135423438,
                "inchl_key": "CPMDPSXJELVGJG-UHFFFAOYSA-N",
                "generic_name": "nintedanib",
                "trade_name": "OFEV",
                "designated_date": "07/06/2016",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "OFEV is indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD).",
                "marketing_approval_date": "\u00a009/06/2019\u00a0",
                "exclusivity_end_date": "\u00a009/06/2026\u00a0",
                "exclusivity_protected_indication": "Indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).",
                "sponsor": "Boehringer Ingelheim Pharmaceuticals, Inc.|900 Ridgebury Road|P. O. Box 368|Ridgefield|Connecticut|6877|United States",
                "orphan_designation": {
                    "original_text": "Treatment of systemic sclerosis (including the associated interstitial lung disease).",
                    "umls_id": "C0036421,C0206062",
                    "parsed_text": "Systemic sclerosis , Interstitial lung disease"
                }
            },
            {
                "compound_id": 135423438,
                "inchl_key": "CPMDPSXJELVGJG-UHFFFAOYSA-N",
                "generic_name": "nintedanib",
                "trade_name": "OFEV",
                "designated_date": "06/29/2011",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of idiopathic pulmonary fibrosis",
                "marketing_approval_date": "\u00a010/15/2014\u00a0",
                "exclusivity_end_date": "\u00a010/15/2021\u00a0",
                "exclusivity_protected_indication": "Treatment of idiopathic pulmonary fibrosis",
                "sponsor": "Boehringer Ingelheim Pharmaceuticals, Inc.|900 Ridgebury Road|P. O. Box 368|Ridgefield|Connecticut|6877|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with idiopathic pulmonary fibrosis.",
                    "umls_id": "C1800706",
                    "parsed_text": "Idiopathic Pulmonary Fibrosis"
                }
            },
            {
                "compound_id": 135423438,
                "inchl_key": "CPMDPSXJELVGJG-UHFFFAOYSA-N",
                "generic_name": "Nintedanib",
                "designated_date": "12/12/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Boehringer Ingelheim Pharmaceuticals, Inc.|900 Ridgebury Road|P. O. Box 368|Ridgefield|Connecticut|6877|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mesothelioma",
                    "umls_id": "C0025500",
                    "parsed_text": "Mesothelioma"
                }
            }
        ]
    },
    {
        "_id": "YQNQNVDNTFHQSW-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 41684,
                "inchl_key": "YQNQNVDNTFHQSW-UHFFFAOYSA-N",
                "generic_name": "nitazoxanide",
                "trade_name": "Alinia",
                "designated_date": "02/14/2002",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia",
                "marketing_approval_date": "\u00a011/22/2002\u00a0",
                "exclusivity_end_date": "\u00a011/22/2009\u00a0",
                "sponsor": "Romark Laboratories, L.C.|6200 Courtney Campbell Causeway|Suite 880|Tampa|Florida|33607|United States",
                "orphan_designation": {
                    "original_text": "Treatment of intestinal giardiasis",
                    "umls_id": "C0017536",
                    "parsed_text": "INTESTINAL GIARDIASIS"
                }
            },
            {
                "compound_id": 41684,
                "inchl_key": "YQNQNVDNTFHQSW-UHFFFAOYSA-N",
                "generic_name": "Nitazoxanide",
                "trade_name": "Alinia",
                "designated_date": "12/12/1996",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia",
                "marketing_approval_date": "\u00a011/22/2002\u00a0",
                "exclusivity_end_date": "\u00a011/22/2009\u00a0",
                "sponsor": "Romark Laboratories, L.C.|6200 Courtney Campbell Causeway|Suite 880|Tampa|Florida|33607|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cryptosporidiosis.",
                    "umls_id": "C0010418",
                    "parsed_text": "Cryptosporidiosis"
                }
            },
            {
                "compound_id": 41684,
                "inchl_key": "YQNQNVDNTFHQSW-UHFFFAOYSA-N",
                "generic_name": "nitazoxanide",
                "designated_date": "10/23/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Romark Laboratories, L.C.|6200 Courtney Campbell Causeway|Suite 880|Tampa|Florida|33607|United States",
                "orphan_designation": {
                    "original_text": "Treatment for intestinal amebiasis",
                    "umls_id": "C0013370",
                    "parsed_text": "Intestinal Amebiasis"
                }
            }
        ]
    },
    {
        "_id": "SLVOKEOPLJCHCQ-UHFFFAOYSA-O",
        "Orphan Drug Designations": [
            {
                "compound_id": 6710777,
                "inchl_key": "SLVOKEOPLJCHCQ-UHFFFAOYSA-O",
                "generic_name": "oleylphosphocholine",
                "designated_date": "10/25/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oblita Therapeutics bvba|Rogendijk 40|Zoersel|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of leishmaniasis",
                    "umls_id": "C0023281",
                    "parsed_text": "Leishmaniasis"
                }
            }
        ]
    },
    {
        "_id": "SLVOKEOPLJCHCQ-SEYXRHQNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9932595,
                "inchl_key": "SLVOKEOPLJCHCQ-SEYXRHQNSA-N",
                "generic_name": "oleylphosphocholine",
                "designated_date": "10/25/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oblita Therapeutics bvba|Rogendijk 40|Zoersel|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of leishmaniasis",
                    "umls_id": "C0023281",
                    "parsed_text": "Leishmaniasis"
                }
            }
        ]
    },
    {
        "_id": "HCDMJFOHIXMBOV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 86705695,
                "inchl_key": "HCDMJFOHIXMBOV-UHFFFAOYSA-N",
                "generic_name": "Pemigatinib",
                "trade_name": "PEMAZYRE",
                "designated_date": "03/12/2018",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "PEMAZYRE is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test",
                "marketing_approval_date": "\u00a004/17/2020\u00a0",
                "exclusivity_end_date": "\u00a004/17/2027\u00a0",
                "exclusivity_protected_indication": "For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.",
                "sponsor": "Incyte Corporation|1801 Augustine Cut-Off|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cholangiocarcinoma",
                    "umls_id": "C0206698",
                    "parsed_text": "Cholangiocarcinoma"
                }
            },
            {
                "compound_id": 86705695,
                "inchl_key": "HCDMJFOHIXMBOV-UHFFFAOYSA-N",
                "generic_name": "Pemigatinib",
                "designated_date": "08/21/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Incyte Corporation|1801 Augustine Cut-Off|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2",
                    "umls_id": "C0014457,C0027651",
                    "parsed_text": "Eosinophilia , Neoplasms"
                }
            }
        ]
    },
    {
        "_id": "UUBHZHZSIKRVIV-KCXSXWJSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6437836,
                "inchl_key": "UUBHZHZSIKRVIV-KCXSXWJSSA-N",
                "generic_name": "peretinoin",
                "designated_date": "09/23/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kowa Pharmaceutical Europe GmbH|Duiburger Landstassa|Dusseldorf|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            }
        ]
    },
    {
        "_id": "WTWWXOGTJWMJHI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9873,
                "inchl_key": "WTWWXOGTJWMJHI-UHFFFAOYSA-N",
                "generic_name": "Perflubron",
                "designated_date": "04/26/2001",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PFC Development/New Alliance Pharmaceutical|15021 Venture Blvd|Sherman Oaks|California|91403|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute respiratory distress disease (ARDS) in adults",
                    "umls_id": "C0012634,C0035222,C0748355",
                    "parsed_text": "Disease , ARDS , Acute respiratory distress"
                }
            }
        ]
    },
    {
        "_id": "ODUOJXZPIYUATO-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 107751,
                "inchl_key": "ODUOJXZPIYUATO-UHFFFAOYSA-N",
                "generic_name": "racecadotril",
                "designated_date": "04/13/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenefly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Microvillus inclusion disease",
                    "umls_id": "C0341306",
                    "parsed_text": "Microvillus inclusion disease"
                }
            }
        ]
    },
    {
        "_id": "HEBKCHPVOIAQTA-NGQZWQHPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6912,
                "inchl_key": "HEBKCHPVOIAQTA-NGQZWQHPSA-N",
                "generic_name": "ribitol",
                "designated_date": "01/16/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ML Bio Solutions, Inc.|1100 S. Mint Street, Suite 102|Charlotte|North Carolina|28203|United States",
                "orphan_designation": {
                    "original_text": "Treatment of limb-girdle muscular dystrophy type 2I",
                    "umls_id": "C0686353",
                    "parsed_text": "Limb-girdle muscular dystrophy"
                }
            }
        ]
    },
    {
        "_id": "DRFDPXKCEWYIAW-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 4194514,
                "inchl_key": "DRFDPXKCEWYIAW-UHFFFAOYSA-M",
                "generic_name": "risedronate sodium",
                "designated_date": "12/18/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Warner Chilcott Pharmaceuticals|100 Enterprise Drive|Roakaway|New Jersey|7866|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with osteogenesis imperfecta",
                    "umls_id": "C0029434",
                    "parsed_text": "Osteogenesis Imperfecta"
                }
            }
        ]
    },
    {
        "_id": "JUQLTPCYUFPYKE-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5074,
                "inchl_key": "JUQLTPCYUFPYKE-UHFFFAOYSA-N",
                "generic_name": "Ritanserin",
                "designated_date": "05/11/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "The University of Virginia/Benjamin Purow|1215 Lee Street|Charlottesville|Virginia|22908|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioblastoma",
                    "umls_id": "C0017636",
                    "parsed_text": "Glioblastoma"
                }
            }
        ]
    },
    {
        "_id": "HKFMQJUJWSFOLY-OAQYLSRUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6918388,
                "inchl_key": "HKFMQJUJWSFOLY-OAQYLSRUSA-N",
                "generic_name": "sarizotan",
                "designated_date": "07/07/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Newron Pharmaceuticals US, Inc.|89 Headquarter Plaza North|Suite 1438|Morristown|New Jersey|7960|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Rett syndrome.",
                    "umls_id": "C0035372",
                    "parsed_text": "Rett Syndrome"
                }
            }
        ]
    },
    {
        "_id": "ZJZDXGQUNVNYQP-MXEXKMKYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24894654,
                "inchl_key": "ZJZDXGQUNVNYQP-MXEXKMKYSA-N",
                "generic_name": "satoreotide tetraxetan",
                "designated_date": "09/24/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ipsen Biosciences, Inc.|650 East Kendall Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Management of gastroenteropancreatic neuroendocrine tumors",
                    "umls_id": "C0206754",
                    "parsed_text": "Neuroendocrine Tumors"
                }
            }
        ]
    },
    {
        "_id": "JWHYSEDOYMYMNM-QGZVFWFLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11236126,
                "inchl_key": "JWHYSEDOYMYMNM-QGZVFWFLSA-N",
                "generic_name": "seladelpar",
                "designated_date": "11/07/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CymaBay Therapeutics|7999 Gateway Boulevard|Suite 130|Newark|California|94560|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary biliary cholangitis",
                    "umls_id": "C0008312",
                    "parsed_text": "Primary Biliary Cholangitis"
                }
            }
        ]
    },
    {
        "_id": "AEQFSUDEHCCHBT-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 16760703,
                "inchl_key": "AEQFSUDEHCCHBT-UHFFFAOYSA-M",
                "generic_name": "sodium valproate",
                "designated_date": "08/05/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "The University of Birmingham|Birmingham Research Park - Vincent Drive|Birmingham|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of Wolfram syndrome",
                    "umls_id": "C0043207",
                    "parsed_text": "Wolfram Syndrome"
                }
            },
            {
                "compound_id": 16760703,
                "inchl_key": "AEQFSUDEHCCHBT-UHFFFAOYSA-M",
                "generic_name": "Valproate",
                "designated_date": "05/05/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neuropharm Ltd,|Fetcham Park House|Surrey|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of fragile X syndrome",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            },
            {
                "compound_id": 16760703,
                "inchl_key": "AEQFSUDEHCCHBT-UHFFFAOYSA-M",
                "generic_name": "sodium valproate",
                "designated_date": "03/09/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cereno Scientific AB|Pepparedsleden 1|M_xDE72__xDFA4_al|Sweden",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary arterial hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "UCTRAOBQFUDCSR-SECBINFHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10130337,
                "inchl_key": "UCTRAOBQFUDCSR-SECBINFHSA-N",
                "generic_name": "Solriamfetol",
                "trade_name": "Sunosi",
                "designated_date": "08/20/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "SUNOSI is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy",
                "marketing_approval_date": "\u00a006/17/2019\u00a0",
                "exclusivity_end_date": "\u00a006/17/2026\u00a0",
                "exclusivity_protected_indication": "To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy",
                "sponsor": "Jazz Pharmaceuticals Ireland Limited|5th Floor Waterloo Exchange|Waterloo Road|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Treatment of narcolepsy",
                    "umls_id": "C0027404",
                    "parsed_text": "Narcolepsy"
                }
            }
        ]
    },
    {
        "_id": "PWILYDZRJORZDR-MISYRCLQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 213054,
                "inchl_key": "PWILYDZRJORZDR-MISYRCLQSA-N",
                "generic_name": "soraprazan",
                "designated_date": "12/22/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Katairo GmbH|21 Lederstra\u07e5|Kusterdingen|Baden-Wrttemberg|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of Stargardt Disease (StD)",
                    "umls_id": "C0036916,C1412063",
                    "parsed_text": "STD , Stargardt disease"
                }
            }
        ]
    },
    {
        "_id": "SEEPANYCNGTZFQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5215,
                "inchl_key": "SEEPANYCNGTZFQ-UHFFFAOYSA-N",
                "generic_name": "Sulfadiazine",
                "designated_date": "03/14/1994",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Toxoplasmosis, as adjunctive with pyrimethamine",
                "marketing_approval_date": "\u00a007/29/1994\u00a0",
                "exclusivity_end_date": "\u00a007/29/2001\u00a0",
                "sponsor": "Eon Labs Manufacturing, Inc.|227-15 North Conduit Avenue|Laurelton|New York|11413|United States",
                "orphan_designation": {
                    "original_text": "For use in combination with pyrimethamine for the treatment of Toxoplasma gondii encephalitis in patients with and without AIDS.",
                    "umls_id": "C0001175,C0085315",
                    "parsed_text": "AIDS , toxoplasma gondii encephalitis"
                }
            }
        ]
    },
    {
        "_id": "GECHUMIMRBOMGK-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5336,
                "inchl_key": "GECHUMIMRBOMGK-UHFFFAOYSA-N",
                "generic_name": "Sulfapyridine",
                "designated_date": "09/10/1990",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Jacobus Pharmaceutical Company|37 Cleveland Lane|P.O. Box 5290|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of dermatitis herpetiformis.",
                    "umls_id": "C0011608",
                    "parsed_text": "Dermatitis Herpetiformis"
                }
            }
        ]
    },
    {
        "_id": "MLKXDPUZXIRXEP-MFOYZWKCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 1548887,
                "inchl_key": "MLKXDPUZXIRXEP-MFOYZWKCSA-N",
                "generic_name": "sulindac",
                "designated_date": "08/04/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Prolindox, Inc.|8008 Desmond Dr.|Boynton Beach|Florida|33472|United States",
                "orphan_designation": {
                    "original_text": "Treatment of retinitis pigmentosa",
                    "umls_id": "C0035334",
                    "parsed_text": "Retinitis Pigmentosa"
                }
            }
        ]
    },
    {
        "_id": "JCOHXVDKRMWUQP-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 23718384,
                "inchl_key": "JCOHXVDKRMWUQP-UHFFFAOYSA-M",
                "generic_name": "tasisulam sodium",
                "designated_date": "09/03/2009",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States",
                "orphan_designation": {
                    "original_text": "Treatment of melanoma stages IIB through IV",
                    "umls_id": "C0280209",
                    "parsed_text": "melanoma stages"
                }
            }
        ]
    },
    {
        "_id": "XSFPZBUIBYMVEA-CELUQASASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25253377,
                "inchl_key": "XSFPZBUIBYMVEA-CELUQASASA-N",
                "generic_name": "telotristat etiprate",
                "trade_name": "Xermelo",
                "designated_date": "03/09/2012",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.",
                "marketing_approval_date": "\u00a002/28/2017\u00a0",
                "exclusivity_end_date": "\u00a002/28/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.",
                "sponsor": "Lexicon Pharmaceuticals, Inc.|8800 Technology Forest Drive|The Woodlands|Texas|77381|United States",
                "orphan_designation": {
                    "original_text": "Treatment of carcinoid syndrome in patients with neuroendocrine tumors",
                    "umls_id": "C0024586,C0206754",
                    "parsed_text": "Carcinoid syndrome , Neuroendocrine Tumors"
                }
            }
        ]
    },
    {
        "_id": "FEQOLYDPQKHFTD-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 46932299,
                "inchl_key": "FEQOLYDPQKHFTD-UHFFFAOYSA-N",
                "generic_name": "tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride",
                "designated_date": "06/20/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Anavex Life Sciences Corp.|51 West 52nd Street|7th Floor|New York|New York|10019|United States",
                "orphan_designation": {
                    "original_text": "Treatment of infantile spasms",
                    "umls_id": "C3887898",
                    "parsed_text": "Infantile spasms"
                }
            }
        ]
    },
    {
        "_id": "MJUVRTYWUMPBTR-MRXNPFEDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 46199646,
                "inchl_key": "MJUVRTYWUMPBTR-MRXNPFEDSA-N",
                "generic_name": "Tezacaftor",
                "designated_date": "04/24/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Vertex Pharmaceuticals Inc.|50 Northern Avenue|Boston|Massachusetts|2210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls_id": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "SOVUOXKZCCAWOJ-HJYUBDRYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 54686904,
                "inchl_key": "SOVUOXKZCCAWOJ-HJYUBDRYSA-N",
                "generic_name": "tigecycline",
                "designated_date": "10/23/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Trillium Therapeutics, Inc.|96 Skyway Avenue|Toronto|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia.",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "FWFGIHPGRQZWIW-SQNIBIBYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 15547703,
                "inchl_key": "FWFGIHPGRQZWIW-SQNIBIBYSA-N",
                "generic_name": "Tosedostat",
                "designated_date": "12/10/2008",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CTI BioPharma Corporation|3101 Western Avenue|Suite 600|Seattle|Washington|98121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "PKVRCIRHQMSYJX-AIFWHQITSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 108150,
                "inchl_key": "PKVRCIRHQMSYJX-AIFWHQITSA-N",
                "generic_name": "trabectedin",
                "trade_name": "Yondelis",
                "designated_date": "09/30/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen",
                "marketing_approval_date": "\u00a010/23/2015\u00a0",
                "exclusivity_end_date": "\u00a010/23/2022\u00a0",
                "exclusivity_protected_indication": "For the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen",
                "sponsor": "Janssen Research & Development, LLC|920 Route 202 South|Raritan|New Jersey|8869|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcoma",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            },
            {
                "compound_id": 108150,
                "inchl_key": "PKVRCIRHQMSYJX-AIFWHQITSA-N",
                "generic_name": "trabectedin",
                "designated_date": "03/29/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Janssen Research & Development, LLC|920 Route 202 South|Raritan|New Jersey|8869|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "YCPOZVAOBBQLRI-PHDIDXHHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 95839,
                "inchl_key": "YCPOZVAOBBQLRI-PHDIDXHHSA-N",
                "generic_name": "Treosulfan",
                "designated_date": "05/16/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medac GmbH|Fehlandtstrasse 3|Hamburg|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer.",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "YCPOZVAOBBQLRI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9296,
                "inchl_key": "YCPOZVAOBBQLRI-UHFFFAOYSA-N",
                "generic_name": "Treosulfan",
                "designated_date": "05/16/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medac GmbH|Fehlandtstrasse 3|Hamburg|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer.",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "YCPOZVAOBBQLRI-WDSKDSINSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9882105,
                "inchl_key": "YCPOZVAOBBQLRI-WDSKDSINSA-N",
                "generic_name": "Treosulfan",
                "designated_date": "05/16/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Medac GmbH|Fehlandtstrasse 3|Hamburg|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer.",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "WYHIICXRPHEJKI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71433,
                "inchl_key": "WYHIICXRPHEJKI-UHFFFAOYSA-N",
                "generic_name": "trientine hydrochloride",
                "designated_date": "11/02/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cerberus Princeton, LLC|c/o Cerberus Capital Management L.P.|875 Third Avenue|New York|New York|10022|United States",
                "orphan_designation": {
                    "original_text": "Treatment of manganism",
                    "umls_id": "C0677050",
                    "parsed_text": "Manganism"
                }
            }
        ]
    },
    {
        "_id": "KSERXGMCDHOLSS-LJQANCHMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11719003,
                "inchl_key": "KSERXGMCDHOLSS-LJQANCHMSA-N",
                "generic_name": "Ulixertinib",
                "designated_date": "06/24/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "BioMed Valley Discoveries, Inc.|4435 Main Street|Suite 550|Kansas City|Missouri|64111|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Stage IIb through Stage IV BRAF mutant melanoma",
                    "umls_id": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "NIJJYAXOARWZEE-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 3549980,
                "inchl_key": "NIJJYAXOARWZEE-UHFFFAOYSA-M",
                "generic_name": "Valproate",
                "designated_date": "05/05/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neuropharm Ltd,|Fetcham Park House|Surrey|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of fragile X syndrome",
                    "umls_id": "C0016667",
                    "parsed_text": "Fragile X Syndrome"
                }
            }
        ]
    },
    {
        "_id": "UHTHHESEBZOYNR-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3081361,
                "inchl_key": "UHTHHESEBZOYNR-UHFFFAOYSA-N",
                "generic_name": "vandetanib",
                "trade_name": "CAPRELSA(r)",
                "designated_date": "10/21/2005",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of asymptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease",
                "marketing_approval_date": "\u00a004/06/2011\u00a0",
                "exclusivity_end_date": "\u00a004/06/2018\u00a0",
                "sponsor": "Genzyme Corporation|500 Kendall Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, and locally advanced and metastatic papillary thyroid carcinoma",
                    "umls_id": "C0206682,C0238461,C0238462,C0278851",
                    "parsed_text": "Follicular thyroid carcinoma , Carcinoma, Anaplastic Thyroid , Thyroid carcinoma, medullary , Metastatic papillary thyroid carcinoma"
                }
            }
        ]
    },
    {
        "_id": "SECKRCOLJRRGGV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135400189,
                "inchl_key": "SECKRCOLJRRGGV-UHFFFAOYSA-N",
                "generic_name": "vardenafil",
                "designated_date": "04/22/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Respira Therapeutics, Inc|5901 Indian School Road NE|#107|Albuquerque|New Mexico|87110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pulmonary Arterial Hypertension",
                    "umls_id": "C3203102",
                    "parsed_text": "PULMONARY ARTERIAL HYPERTENSION"
                }
            }
        ]
    },
    {
        "_id": "NJLRKAMQPVVOIU-IDLGWYNRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11980904,
                "inchl_key": "NJLRKAMQPVVOIU-IDLGWYNRSA-N",
                "generic_name": "verteporfin",
                "designated_date": "03/09/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Valeant Pharmaceuticals North America LLC|700 Route 202/206 North|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic or recurrent central serous chorioretinopathy",
                    "umls_id": "C0730328",
                    "parsed_text": "Central Serous Chorioretinopathy"
                }
            }
        ]
    },
    {
        "_id": "QCZAWDGAVJMPTA-RNFRBKRXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 117817422,
                "inchl_key": "QCZAWDGAVJMPTA-RNFRBKRXSA-N",
                "generic_name": "vorasidenib",
                "designated_date": "09/10/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Agios Pharmaceuticals, Inc.|88 Sidney Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioma",
                    "umls_id": "C0017638",
                    "parsed_text": "Glioma"
                }
            }
        ]
    },
    {
        "_id": "VQJFFWJUYDGTQZ-MGUDINDMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 54612642,
                "inchl_key": "VQJFFWJUYDGTQZ-MGUDINDMSA-N",
                "generic_name": "Zosuquidar trihydrochloride",
                "designated_date": "12/15/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kanisa Pharmaceuticals, Inc.|12264 El Camino Real|San Diego|California|2130|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "IHOVFYSQUDPMCN-XAKVHENESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3036703,
                "inchl_key": "IHOVFYSQUDPMCN-XAKVHENESA-N",
                "generic_name": "Zosuquidar trihydrochloride",
                "designated_date": "12/15/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kanisa Pharmaceuticals, Inc.|12264 El Camino Real|San Diego|California|2130|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "ZPFVQKPWGDRLHL-ZLYBXYBFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 153997,
                "inchl_key": "ZPFVQKPWGDRLHL-ZLYBXYBFSA-N",
                "generic_name": "Zosuquidar trihydrochloride",
                "designated_date": "12/15/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kanisa Pharmaceuticals, Inc.|12264 El Camino Real|San Diego|California|2130|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "VXBAJLGYBMTJCY-NSCUHMNNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16739650,
                "inchl_key": "VXBAJLGYBMTJCY-NSCUHMNNSA-N",
                "generic_name": "zotiraciclib",
                "designated_date": "11/21/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Adastra Pharmaceuticals Inc.|202 Carnegie Center, Suite 104|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioma",
                    "umls_id": "C0017638",
                    "parsed_text": "Glioma"
                }
            }
        ]
    },
    {
        "_id": "SCKYRAXSEDYPSA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2749,
                "inchl_key": "SCKYRAXSEDYPSA-UHFFFAOYSA-N",
                "generic_name": "Ciclopirox",
                "designated_date": "04/17/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Atlas Molecular Pharma S.L.|Parque Tecnol\udb5e\ude63o de Bizkaia|Building 800|Derio|Spain",
                "orphan_designation": {
                    "original_text": "Treatment of congenital erythropoietic porphyria",
                    "umls_id": "C0162530",
                    "parsed_text": "congenital erythropoietic porphyria"
                }
            }
        ]
    },
    {
        "_id": "NNUHKSNTEOVPHV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 145994613,
                "inchl_key": "NNUHKSNTEOVPHV-UHFFFAOYSA-N",
                "generic_name": "cobomarsen",
                "designated_date": "07/21/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "miRagen Therapeutics, Inc.|6200 Lookout Road|Suite 100|Boulder|Colorado|80301|United States",
                "orphan_designation": {
                    "original_text": "Treatment of T-cell lymphoma",
                    "umls_id": "C0079772",
                    "parsed_text": "T-Cell Lymphoma"
                }
            }
        ]
    },
    {
        "_id": "NNUHKSNTEOVPHV-XHZCTNOISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 126480232,
                "inchl_key": "NNUHKSNTEOVPHV-XHZCTNOISA-N",
                "generic_name": "cobomarsen",
                "designated_date": "07/21/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "miRagen Therapeutics, Inc.|6200 Lookout Road|Suite 100|Boulder|Colorado|80301|United States",
                "orphan_designation": {
                    "original_text": "Treatment of T-cell lymphoma",
                    "umls_id": "C0079772",
                    "parsed_text": "T-Cell Lymphoma"
                }
            }
        ]
    },
    {
        "_id": "OFEZSBMBBKLLBJ-BAJZRUMYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6303,
                "inchl_key": "OFEZSBMBBKLLBJ-BAJZRUMYSA-N",
                "generic_name": "Cordycepin",
                "designated_date": "07/05/2007",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OncoVista, Inc.|14785 Omicron Drive|San Antonio|Texas|78245|United States",
                "orphan_designation": {
                    "original_text": "Treatment of TdT-positive acute lymphocytic leukemia",
                    "umls_id": "C0023449",
                    "parsed_text": "Acute lymphocytic leukemia"
                }
            }
        ]
    },
    {
        "_id": "ZYGHJZDHTFUPRJ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 323,
                "inchl_key": "ZYGHJZDHTFUPRJ-UHFFFAOYSA-N",
                "generic_name": "Coumarin",
                "designated_date": "12/22/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Drossapharm LTD|Ariesheim|Basel|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma.",
                    "umls_id": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            }
        ]
    },
    {
        "_id": "ARQUTWAXTHJROR-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 18435899,
                "inchl_key": "ARQUTWAXTHJROR-UHFFFAOYSA-N",
                "generic_name": "crenolanib besylate",
                "designated_date": "12/20/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AROG Pharmaceuticals, LLC|Two Lincoln Centre|Suite 410|Dallas|Texas|75240|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls_id": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            }
        ]
    },
    {
        "_id": "UWFYSQMTEOIJJG-FDTZYFLXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9880,
                "inchl_key": "UWFYSQMTEOIJJG-FDTZYFLXSA-N",
                "generic_name": "Cyproterone acetate",
                "designated_date": "10/26/1984",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Berlex Laboratories, Inc.|300 Fairfield Road|Wayne|New Jersey|7470|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe hirsutism.",
                    "umls_id": "C0019572",
                    "parsed_text": "Hirsutism"
                }
            }
        ]
    },
    {
        "_id": "FWLMVFUGMHIOAA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25117126,
                "inchl_key": "FWLMVFUGMHIOAA-UHFFFAOYSA-N",
                "generic_name": "defactinib",
                "designated_date": "02/12/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Verastem, Inc.|117 Kendrick Street|Suite 500|Needham|Massachusetts|2494|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "CYQFCXCEBYINGO-IAGOWNOFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16078,
                "inchl_key": "CYQFCXCEBYINGO-IAGOWNOFSA-N",
                "generic_name": "delta-9-tetrahydrocannabinol",
                "designated_date": "11/27/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Tetra Bio-Pharma Inc.|365 St.-Jean Street|Suite 122|Longueuil|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of Hepatocellular Carcinoma",
                    "umls_id": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            },
            {
                "compound_id": 16078,
                "inchl_key": "CYQFCXCEBYINGO-IAGOWNOFSA-N",
                "generic_name": "Dronabinol",
                "trade_name": "Marinol",
                "designated_date": "01/15/1991",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of anorexia associated with weight loss in patients with AIDS.",
                "marketing_approval_date": "\u00a012/22/1992\u00a0",
                "exclusivity_end_date": "\u00a012/22/1999\u00a0",
                "sponsor": "Unimed Pharmaceuticals, Inc.|901 Sawyer Rd.|Marietta|Georgia|30062|United States",
                "orphan_designation": {
                    "original_text": "For the stimulation of appetite and prevention of weight loss in patients with a confirmed diagnosis of AIDS.",
                    "umls_id": "C0001175,C4084774",
                    "parsed_text": "AIDS , Weight loss"
                }
            }
        ]
    },
    {
        "_id": "LMBWSYZSUOEYSN-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 28343,
                "inchl_key": "LMBWSYZSUOEYSN-UHFFFAOYSA-M",
                "generic_name": "Diethyldithiocarbamate",
                "designated_date": "04/03/1986",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Connaught Laboratories|Route 611, P.O. Box 187|Swiftwater|Pennsylvania|18370|United States",
                "orphan_designation": {
                    "original_text": "Treatment of AIDS.",
                    "umls_id": "C0001175",
                    "parsed_text": "AIDS"
                }
            }
        ]
    },
    {
        "_id": "IAZDPXIOMUYVGZ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 679,
                "inchl_key": "IAZDPXIOMUYVGZ-UHFFFAOYSA-N",
                "generic_name": "Dimethylsulfoxide",
                "designated_date": "04/15/1997",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cancer Technologies, Inc.|7301 East 22nd Street|Suite 10E|Tucson|Alaska|85710|United States",
                "orphan_designation": {
                    "original_text": "Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.",
                    "umls_id": "C0037578",
                    "parsed_text": "SOFT TISSUE INJURY"
                }
            }
        ]
    },
    {
        "_id": "JAZBEHYOTPTENJ-JLNKQSITSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 446284,
                "inchl_key": "JAZBEHYOTPTENJ-JLNKQSITSA-N",
                "generic_name": "eicosapentaenoic acid",
                "designated_date": "03/08/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "S.L.A. Pharma Ltd. (UK)|Elite House|Leavesden, Watford|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of familial adenomatous polyposis",
                    "umls_id": "C0032580",
                    "parsed_text": "Familial Adenomatous Polyposis"
                }
            }
        ]
    },
    {
        "_id": "AFLFKFHDSCQHOL-IZZDOVSWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9864881,
                "inchl_key": "AFLFKFHDSCQHOL-IZZDOVSWSA-N",
                "generic_name": "elafibranor",
                "designated_date": "07/25/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genfit SA|Parc Eurasant\u9b20885 Avenue Eug\u8ba5 Avin\u994d|Loos|France",
                "orphan_designation": {
                    "original_text": "Treatment of Primary Biliary Cholangitis",
                    "umls_id": "C0008312",
                    "parsed_text": "Primary Biliary Cholangitis"
                }
            }
        ]
    },
    {
        "_id": "JFSOSUNPIXJCIX-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3025067,
                "inchl_key": "JFSOSUNPIXJCIX-UHFFFAOYSA-N",
                "generic_name": "eltoprazine HCl",
                "designated_date": "02/08/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Amarantus BioScience Holdings, Inc.|655 Montgomery St.|Suite 900|San Francisco|California|94111|United States",
                "orphan_designation": {
                    "original_text": "Treatment of levodopa-induced dyskinesia associated with Parkinson's disease.",
                    "umls_id": "C0013384,C0030567",
                    "parsed_text": "Dyskinesia , Parkinson's Disease"
                }
            }
        ]
    },
    {
        "_id": "ZVVAINSYJGRDTR-TYLGTTGKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 60767,
                "inchl_key": "ZVVAINSYJGRDTR-TYLGTTGKSA-N",
                "generic_name": "Enadoline hydrochloride",
                "designated_date": "01/28/1997",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Warner-Lambert Company|Parke-Davis Pharmaceutical Research Division|2800 Plymouth Road|Ann Arbor|Michigan|48105|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe head injury.",
                    "umls_id": "C0018674",
                    "parsed_text": "HEAD INJURY"
                }
            }
        ]
    },
    {
        "_id": "ANIAZGVDEUQPRI-ZJQCGQFWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71511839,
                "inchl_key": "ANIAZGVDEUQPRI-ZJQCGQFWSA-N",
                "generic_name": "etelcalcetide",
                "designated_date": "05/31/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Amgen, Inc.|1 Amgen Center Drive|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric hyperparathyroidism",
                    "umls_id": "C0020502",
                    "parsed_text": "Hyperparathyroidism"
                }
            }
        ]
    },
    {
        "_id": "HZAXFHJVJLSVMW-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 700,
                "inchl_key": "HZAXFHJVJLSVMW-UHFFFAOYSA-N",
                "generic_name": "ethanolamine",
                "designated_date": "01/17/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "QOL Medical, LLC|4445 North Highway A1A, 241|Vero Beach|Florida|32963|United States",
                "orphan_designation": {
                    "original_text": "Prophylactic use in pediatric patients (age 0 through 16 years) with esophageal varices that are at risk of bleeding to obliterate varices and to prevent bleeding",
                    "umls_id": "C0014867,C0042345",
                    "parsed_text": "Esophageal Varices , Varices"
                }
            }
        ]
    },
    {
        "_id": "CLQRMSBSMHXMMC-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 153980,
                "inchl_key": "CLQRMSBSMHXMMC-UHFFFAOYSA-N",
                "generic_name": "Ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate",
                "designated_date": "05/13/1998",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Tap Holdings Inc.|2355 Waukegan Road|Deerfield|Illinois|60015|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Crohn's disease.",
                    "umls_id": "C0010346",
                    "parsed_text": "Crohn's Disease"
                }
            }
        ]
    },
    {
        "_id": "SSQPWTVBQMWLSZ-AAQCHOMXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9831415,
                "inchl_key": "SSQPWTVBQMWLSZ-AAQCHOMXSA-N",
                "generic_name": "Ethyl eicosapentaenoate",
                "designated_date": "04/06/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Laxdale Ltd.|Kings Park House, Laurelhill Business Park|Polmaise Road|Stirling|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of Huntington's disease.",
                    "umls_id": "C0020179",
                    "parsed_text": "Huntington's Disease"
                }
            }
        ]
    },
    {
        "_id": "SELCJVNOEBVTAC-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71300725,
                "inchl_key": "SELCJVNOEBVTAC-UHFFFAOYSA-N",
                "generic_name": "etirinotecan pegol",
                "designated_date": "04/18/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Nektar Therapeutics|455 Mission Bay Blvd, South|San Francisco|California|94158|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer.",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "SELCJVNOEBVTAC-HLDPIHRNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 56935717,
                "inchl_key": "SELCJVNOEBVTAC-HLDPIHRNSA-N",
                "generic_name": "etirinotecan pegol",
                "designated_date": "04/18/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Nektar Therapeutics|455 Mission Bay Blvd, South|San Francisco|California|94158|United States",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer.",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "BFENHEAPFWQJFL-BTJKTKAUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 131801100,
                "inchl_key": "BFENHEAPFWQJFL-BTJKTKAUSA-N",
                "generic_name": "filgotinib maleate",
                "designated_date": "07/18/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gilead Sciences, Inc.|199 East Blaine Street|Seattle|Washington|98102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Crohn's disease",
                    "umls_id": "C2931133",
                    "parsed_text": "Pediatric Crohn's disease"
                }
            },
            {
                "compound_id": 131801100,
                "inchl_key": "BFENHEAPFWQJFL-BTJKTKAUSA-N",
                "generic_name": "filgotinib maleate",
                "designated_date": "10/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gilead Sciences, Inc.|199 East Blaine Street|Seattle|Washington|98102|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric ulcerative colitis (UC)",
                    "umls_id": "C0009324,C2931173",
                    "parsed_text": "Ulcerative Colitis , Pediatric ulcerative colitis"
                }
            }
        ]
    },
    {
        "_id": "PEDCQBHIVMGVHV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 753,
                "inchl_key": "PEDCQBHIVMGVHV-UHFFFAOYSA-N",
                "generic_name": "Glyceol",
                "designated_date": "02/22/1990",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Chugai Pharmaceutical Co., Ltd.",
                "orphan_designation": {
                    "original_text": "To decrease intracranial hypertension and/or alleviate cerebral edema in patients who may benefit from osmotherapy.",
                    "umls_id": "C0006114,C0151740",
                    "parsed_text": "Cerebral Edema , Intracranial Hypertension"
                }
            }
        ]
    },
    {
        "_id": "YUFWAVFNITUSHI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 56927696,
                "inchl_key": "YUFWAVFNITUSHI-UHFFFAOYSA-N",
                "generic_name": "Guanethidine monosulfate",
                "designated_date": "01/06/1986",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe reflex sympathetic dystrophy and causalgia.",
                    "umls_id": "C0007462,C0034931",
                    "parsed_text": "Causalgia , Reflex Sympathetic Dystrophy"
                }
            },
            {
                "compound_id": 56927696,
                "inchl_key": "YUFWAVFNITUSHI-UHFFFAOYSA-N",
                "generic_name": "Guanethidine monosulfate",
                "designated_date": "01/06/1986",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe reflex sympathetic dystrophy and causalgia.",
                    "umls_id": "C0007462,C0034931",
                    "parsed_text": "Causalgia , Reflex Sympathetic Dystrophy"
                }
            }
        ]
    },
    {
        "_id": "ACGDKVXYNVEAGU-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3518,
                "inchl_key": "ACGDKVXYNVEAGU-UHFFFAOYSA-N",
                "generic_name": "Guanethidine monosulfate",
                "designated_date": "01/06/1986",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe reflex sympathetic dystrophy and causalgia.",
                    "umls_id": "C0007462,C0034931",
                    "parsed_text": "Causalgia , Reflex Sympathetic Dystrophy"
                }
            }
        ]
    },
    {
        "_id": "SPCMQFLNOVTUBM-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 60150609,
                "inchl_key": "SPCMQFLNOVTUBM-UHFFFAOYSA-N",
                "generic_name": "hydromethylthionine mesylate",
                "designated_date": "11/20/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "TauRx Therapeutics Ltd|395 King Street|Aberdeen|Scotland|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of frontotemporal dementia",
                    "umls_id": "C0338451",
                    "parsed_text": "Frontotemporal dementia"
                }
            }
        ]
    },
    {
        "_id": "DQOCFCZRZOAIBN-BYFNXCQMSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 152743320,
                "inchl_key": "DQOCFCZRZOAIBN-BYFNXCQMSA-M",
                "generic_name": "Hydroxocobalamin",
                "trade_name": "Cyanokit",
                "designated_date": "11/25/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment on known or suspected cyanide poisoning",
                "marketing_approval_date": "\u00a012/15/2006\u00a0",
                "exclusivity_end_date": "\u00a012/15/2013\u00a0",
                "sponsor": "SERB, S.A.|480 Avenue Louise|Brussels|Brussels|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            },
            {
                "compound_id": 152743320,
                "inchl_key": "DQOCFCZRZOAIBN-BYFNXCQMSA-M",
                "generic_name": "Hydroxocobalamin",
                "designated_date": "09/22/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rare Disease Therapeutics, Inc.|12975 Brookprinter Pl|Suite 170|Poway|California|92064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            }
        ]
    },
    {
        "_id": "YOZNUFWCRFCGIH-UHFFFAOYSA-K",
        "Orphan Drug Designations": [
            {
                "compound_id": 146014417,
                "inchl_key": "YOZNUFWCRFCGIH-UHFFFAOYSA-K",
                "generic_name": "Hydroxocobalamin",
                "trade_name": "Cyanokit",
                "designated_date": "11/25/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment on known or suspected cyanide poisoning",
                "marketing_approval_date": "\u00a012/15/2006\u00a0",
                "exclusivity_end_date": "\u00a012/15/2013\u00a0",
                "sponsor": "SERB, S.A.|480 Avenue Louise|Brussels|Brussels|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            },
            {
                "compound_id": 146014417,
                "inchl_key": "YOZNUFWCRFCGIH-UHFFFAOYSA-K",
                "generic_name": "Hydroxocobalamin",
                "designated_date": "09/22/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rare Disease Therapeutics, Inc.|12975 Brookprinter Pl|Suite 170|Poway|California|92064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            }
        ]
    },
    {
        "_id": "ITFLMCXLENHUAD-PYFZXISVSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 134820153,
                "inchl_key": "ITFLMCXLENHUAD-PYFZXISVSA-L",
                "generic_name": "Hydroxocobalamin",
                "trade_name": "Cyanokit",
                "designated_date": "11/25/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment on known or suspected cyanide poisoning",
                "marketing_approval_date": "\u00a012/15/2006\u00a0",
                "exclusivity_end_date": "\u00a012/15/2013\u00a0",
                "sponsor": "SERB, S.A.|480 Avenue Louise|Brussels|Brussels|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            },
            {
                "compound_id": 134820153,
                "inchl_key": "ITFLMCXLENHUAD-PYFZXISVSA-L",
                "generic_name": "Hydroxocobalamin",
                "designated_date": "09/22/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rare Disease Therapeutics, Inc.|12975 Brookprinter Pl|Suite 170|Poway|California|92064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            }
        ]
    },
    {
        "_id": "ITFLMCXLENHUAD-WZHZPDAFSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 129893562,
                "inchl_key": "ITFLMCXLENHUAD-WZHZPDAFSA-M",
                "generic_name": "Hydroxocobalamin",
                "trade_name": "Cyanokit",
                "designated_date": "11/25/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment on known or suspected cyanide poisoning",
                "marketing_approval_date": "\u00a012/15/2006\u00a0",
                "exclusivity_end_date": "\u00a012/15/2013\u00a0",
                "sponsor": "SERB, S.A.|480 Avenue Louise|Brussels|Brussels|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            },
            {
                "compound_id": 129893562,
                "inchl_key": "ITFLMCXLENHUAD-WZHZPDAFSA-M",
                "generic_name": "Hydroxocobalamin",
                "designated_date": "09/22/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rare Disease Therapeutics, Inc.|12975 Brookprinter Pl|Suite 170|Poway|California|92064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            }
        ]
    },
    {
        "_id": "RHYVGCKRBKDRDX-UHFFFAOYSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 126480146,
                "inchl_key": "RHYVGCKRBKDRDX-UHFFFAOYSA-L",
                "generic_name": "Hydroxocobalamin",
                "trade_name": "Cyanokit",
                "designated_date": "11/25/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment on known or suspected cyanide poisoning",
                "marketing_approval_date": "\u00a012/15/2006\u00a0",
                "exclusivity_end_date": "\u00a012/15/2013\u00a0",
                "sponsor": "SERB, S.A.|480 Avenue Louise|Brussels|Brussels|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            },
            {
                "compound_id": 126480146,
                "inchl_key": "RHYVGCKRBKDRDX-UHFFFAOYSA-L",
                "generic_name": "Hydroxocobalamin",
                "designated_date": "09/22/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rare Disease Therapeutics, Inc.|12975 Brookprinter Pl|Suite 170|Poway|California|92064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            }
        ]
    },
    {
        "_id": "TUMIEHFYGNUNBB-JJUQEKPGSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 71774773,
                "inchl_key": "TUMIEHFYGNUNBB-JJUQEKPGSA-L",
                "generic_name": "Hydroxocobalamin",
                "trade_name": "Cyanokit",
                "designated_date": "11/25/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment on known or suspected cyanide poisoning",
                "marketing_approval_date": "\u00a012/15/2006\u00a0",
                "exclusivity_end_date": "\u00a012/15/2013\u00a0",
                "sponsor": "SERB, S.A.|480 Avenue Louise|Brussels|Brussels|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            },
            {
                "compound_id": 71774773,
                "inchl_key": "TUMIEHFYGNUNBB-JJUQEKPGSA-L",
                "generic_name": "Hydroxocobalamin",
                "designated_date": "09/22/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rare Disease Therapeutics, Inc.|12975 Brookprinter Pl|Suite 170|Poway|California|92064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            }
        ]
    },
    {
        "_id": "DQOCFCZRZOAIBN-WZHZPDAFSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 16056828,
                "inchl_key": "DQOCFCZRZOAIBN-WZHZPDAFSA-L",
                "generic_name": "Hydroxocobalamin",
                "trade_name": "Cyanokit",
                "designated_date": "11/25/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment on known or suspected cyanide poisoning",
                "marketing_approval_date": "\u00a012/15/2006\u00a0",
                "exclusivity_end_date": "\u00a012/15/2013\u00a0",
                "sponsor": "SERB, S.A.|480 Avenue Louise|Brussels|Brussels|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            },
            {
                "compound_id": 16056828,
                "inchl_key": "DQOCFCZRZOAIBN-WZHZPDAFSA-L",
                "generic_name": "Hydroxocobalamin",
                "trade_name": "Cyanokit",
                "designated_date": "11/25/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment on known or suspected cyanide poisoning",
                "marketing_approval_date": "\u00a012/15/2006\u00a0",
                "exclusivity_end_date": "\u00a012/15/2013\u00a0",
                "sponsor": "SERB, S.A.|480 Avenue Louise|Brussels|Brussels|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            },
            {
                "compound_id": 16056828,
                "inchl_key": "DQOCFCZRZOAIBN-WZHZPDAFSA-L",
                "generic_name": "Hydroxocobalamin",
                "trade_name": "Cyanokit",
                "designated_date": "11/25/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment on known or suspected cyanide poisoning",
                "marketing_approval_date": "\u00a012/15/2006\u00a0",
                "exclusivity_end_date": "\u00a012/15/2013\u00a0",
                "sponsor": "SERB, S.A.|480 Avenue Louise|Brussels|Brussels|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            },
            {
                "compound_id": 16056828,
                "inchl_key": "DQOCFCZRZOAIBN-WZHZPDAFSA-L",
                "generic_name": "Hydroxocobalamin",
                "designated_date": "09/22/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rare Disease Therapeutics, Inc.|12975 Brookprinter Pl|Suite 170|Poway|California|92064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            },
            {
                "compound_id": 16056828,
                "inchl_key": "DQOCFCZRZOAIBN-WZHZPDAFSA-L",
                "generic_name": "Hydroxocobalamin",
                "designated_date": "09/22/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rare Disease Therapeutics, Inc.|12975 Brookprinter Pl|Suite 170|Poway|California|92064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            },
            {
                "compound_id": 16056828,
                "inchl_key": "DQOCFCZRZOAIBN-WZHZPDAFSA-L",
                "generic_name": "Hydroxocobalamin",
                "designated_date": "09/22/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rare Disease Therapeutics, Inc.|12975 Brookprinter Pl|Suite 170|Poway|California|92064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            }
        ]
    },
    {
        "_id": "DQOCFCZRZOAIBN-JLKASCPDSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 6474319,
                "inchl_key": "DQOCFCZRZOAIBN-JLKASCPDSA-L",
                "generic_name": "Hydroxocobalamin",
                "trade_name": "Cyanokit",
                "designated_date": "11/25/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment on known or suspected cyanide poisoning",
                "marketing_approval_date": "\u00a012/15/2006\u00a0",
                "exclusivity_end_date": "\u00a012/15/2013\u00a0",
                "sponsor": "SERB, S.A.|480 Avenue Louise|Brussels|Brussels|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            },
            {
                "compound_id": 6474319,
                "inchl_key": "DQOCFCZRZOAIBN-JLKASCPDSA-L",
                "generic_name": "Hydroxocobalamin",
                "designated_date": "09/22/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rare Disease Therapeutics, Inc.|12975 Brookprinter Pl|Suite 170|Poway|California|92064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            }
        ]
    },
    {
        "_id": "DQOCFCZRZOAIBN-AZCDKEHOSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 146156970,
                "inchl_key": "DQOCFCZRZOAIBN-AZCDKEHOSA-L",
                "generic_name": "Hydroxocobalamin",
                "trade_name": "Cyanokit",
                "designated_date": "11/25/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment on known or suspected cyanide poisoning",
                "marketing_approval_date": "\u00a012/15/2006\u00a0",
                "exclusivity_end_date": "\u00a012/15/2013\u00a0",
                "sponsor": "SERB, S.A.|480 Avenue Louise|Brussels|Brussels|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            },
            {
                "compound_id": 146156970,
                "inchl_key": "DQOCFCZRZOAIBN-AZCDKEHOSA-L",
                "generic_name": "Hydroxocobalamin",
                "designated_date": "09/22/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rare Disease Therapeutics, Inc.|12975 Brookprinter Pl|Suite 170|Poway|California|92064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            }
        ]
    },
    {
        "_id": "DQOCFCZRZOAIBN-UVKKECPRSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 24892771,
                "inchl_key": "DQOCFCZRZOAIBN-UVKKECPRSA-L",
                "generic_name": "Hydroxocobalamin",
                "trade_name": "Cyanokit",
                "designated_date": "11/25/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment on known or suspected cyanide poisoning",
                "marketing_approval_date": "\u00a012/15/2006\u00a0",
                "exclusivity_end_date": "\u00a012/15/2013\u00a0",
                "sponsor": "SERB, S.A.|480 Avenue Louise|Brussels|Brussels|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            },
            {
                "compound_id": 24892771,
                "inchl_key": "DQOCFCZRZOAIBN-UVKKECPRSA-L",
                "generic_name": "Hydroxocobalamin",
                "designated_date": "09/22/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rare Disease Therapeutics, Inc.|12975 Brookprinter Pl|Suite 170|Poway|California|92064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            }
        ]
    },
    {
        "_id": "ITFLMCXLENHUAD-WZHZPDAFSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 70678542,
                "inchl_key": "ITFLMCXLENHUAD-WZHZPDAFSA-L",
                "generic_name": "Hydroxocobalamin",
                "trade_name": "Cyanokit",
                "designated_date": "11/25/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment on known or suspected cyanide poisoning",
                "marketing_approval_date": "\u00a012/15/2006\u00a0",
                "exclusivity_end_date": "\u00a012/15/2013\u00a0",
                "sponsor": "SERB, S.A.|480 Avenue Louise|Brussels|Brussels|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            },
            {
                "compound_id": 70678542,
                "inchl_key": "ITFLMCXLENHUAD-WZHZPDAFSA-L",
                "generic_name": "Hydroxocobalamin",
                "designated_date": "09/22/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rare Disease Therapeutics, Inc.|12975 Brookprinter Pl|Suite 170|Poway|California|92064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            }
        ]
    },
    {
        "_id": "DQOCFCZRZOAIBN-PMEYKKDOSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 50935334,
                "inchl_key": "DQOCFCZRZOAIBN-PMEYKKDOSA-L",
                "generic_name": "Hydroxocobalamin",
                "trade_name": "Cyanokit",
                "designated_date": "11/25/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment on known or suspected cyanide poisoning",
                "marketing_approval_date": "\u00a012/15/2006\u00a0",
                "exclusivity_end_date": "\u00a012/15/2013\u00a0",
                "sponsor": "SERB, S.A.|480 Avenue Louise|Brussels|Brussels|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            },
            {
                "compound_id": 50935334,
                "inchl_key": "DQOCFCZRZOAIBN-PMEYKKDOSA-L",
                "generic_name": "Hydroxocobalamin",
                "designated_date": "09/22/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rare Disease Therapeutics, Inc.|12975 Brookprinter Pl|Suite 170|Poway|California|92064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            }
        ]
    },
    {
        "_id": "DQOCFCZRZOAIBN-IQFXPAJWSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 45357193,
                "inchl_key": "DQOCFCZRZOAIBN-IQFXPAJWSA-L",
                "generic_name": "Hydroxocobalamin",
                "trade_name": "Cyanokit",
                "designated_date": "11/25/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment on known or suspected cyanide poisoning",
                "marketing_approval_date": "\u00a012/15/2006\u00a0",
                "exclusivity_end_date": "\u00a012/15/2013\u00a0",
                "sponsor": "SERB, S.A.|480 Avenue Louise|Brussels|Brussels|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            },
            {
                "compound_id": 45357193,
                "inchl_key": "DQOCFCZRZOAIBN-IQFXPAJWSA-L",
                "generic_name": "Hydroxocobalamin",
                "designated_date": "09/22/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rare Disease Therapeutics, Inc.|12975 Brookprinter Pl|Suite 170|Poway|California|92064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            }
        ]
    },
    {
        "_id": "YOZNUFWCRFCGIH-WZHZPDAFSA-K",
        "Orphan Drug Designations": [
            {
                "compound_id": 44475014,
                "inchl_key": "YOZNUFWCRFCGIH-WZHZPDAFSA-K",
                "generic_name": "Hydroxocobalamin",
                "trade_name": "Cyanokit",
                "designated_date": "11/25/2003",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment on known or suspected cyanide poisoning",
                "marketing_approval_date": "\u00a012/15/2006\u00a0",
                "exclusivity_end_date": "\u00a012/15/2013\u00a0",
                "sponsor": "SERB, S.A.|480 Avenue Louise|Brussels|Brussels|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            },
            {
                "compound_id": 44475014,
                "inchl_key": "YOZNUFWCRFCGIH-WZHZPDAFSA-K",
                "generic_name": "Hydroxocobalamin",
                "designated_date": "09/22/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rare Disease Therapeutics, Inc.|12975 Brookprinter Pl|Suite 170|Poway|California|92064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute cyanide poisoning",
                    "umls_id": "C0238080",
                    "parsed_text": "Cyanide poisoning"
                }
            }
        ]
    },
    {
        "_id": "YDOIFHVUBCIUHF-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3663,
                "inchl_key": "YDOIFHVUBCIUHF-UHFFFAOYSA-N",
                "generic_name": "hypericin",
                "designated_date": "02/07/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Soligenix, Inc.|29 Emmons Drive|Suite B-10|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cutaneous T-cell lymphoma",
                    "umls_id": "C0079773",
                    "parsed_text": "cutaneous T-cell lymphoma"
                }
            },
            {
                "compound_id": 3663,
                "inchl_key": "YDOIFHVUBCIUHF-UHFFFAOYSA-N",
                "generic_name": "Hypericin",
                "designated_date": "08/03/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "HyBiopharma, Inc.|2500 York Road|Suite 100|Jamison|Pennsylvania|18929|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioblastoma multiforme.",
                    "umls_id": "C0017636",
                    "parsed_text": "Glioblastoma multiforme"
                }
            }
        ]
    },
    {
        "_id": "DUGMCDWNXXFHDE-VZYDHVRKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6450830,
                "inchl_key": "DUGMCDWNXXFHDE-VZYDHVRKSA-N",
                "generic_name": "ibutamoren mesylate",
                "designated_date": "06/15/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Lumos Pharma|4200 Marathon Blvd.|Suite 200|Austin|Texas|78756|United States",
                "orphan_designation": {
                    "original_text": "Treatment of growth hormone deficiency",
                    "umls_id": "C3714796",
                    "parsed_text": "Growth hormone deficiency"
                }
            }
        ]
    },
    {
        "_id": "ZADWXFSZEAPBJS-SNVBAGLBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 405012,
                "inchl_key": "ZADWXFSZEAPBJS-SNVBAGLBSA-N",
                "generic_name": "indoximod",
                "designated_date": "10/26/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Lumos Pharma, Inc.|2503 South Loop Drive, Suite 5100|Ames|Iowa|50010|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Stage IIB to IV melanoma",
                    "umls_id": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "YLDCUKJMEKGGFI-QCSRICIXSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135449284,
                "inchl_key": "YLDCUKJMEKGGFI-QCSRICIXSA-N",
                "generic_name": "Inosine pranobex",
                "designated_date": "09/20/1988",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Newport Pharmaceuticals|897 West Sixteenth Street|Newport Beach|California|92663|United States",
                "orphan_designation": {
                    "original_text": "Treatment of subacute sclerosing panencephalitis.",
                    "umls_id": "C0038522",
                    "parsed_text": "Subacute Sclerosing Panencephalitis"
                }
            }
        ]
    },
    {
        "_id": "SHGAZHPCJJPHSC-XFYACQKRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5282379,
                "inchl_key": "SHGAZHPCJJPHSC-XFYACQKRSA-N",
                "generic_name": "isotretinoin",
                "designated_date": "04/10/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Timber Pharmaceuticals|50 Tice Blvd|Suite A35|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of congenital ichthyosis",
                    "umls_id": "C0079154",
                    "parsed_text": "congenital ichthyosis"
                }
            }
        ]
    },
    {
        "_id": "ZCVMWBYGMWKGHF-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3827,
                "inchl_key": "ZCVMWBYGMWKGHF-UHFFFAOYSA-N",
                "generic_name": "ketotifen",
                "designated_date": "02/25/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Valcrest Pharmaceuticals, LLC|520 White Plains Road|Suite 500|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mastocytosis",
                    "umls_id": "C0024899",
                    "parsed_text": "Mastocytosis"
                }
            }
        ]
    },
    {
        "_id": "DSBPAFWXMCKFIM-BSOLPCOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9844677,
                "inchl_key": "DSBPAFWXMCKFIM-BSOLPCOYSA-N",
                "generic_name": "L-threonyl-L-prolyl-L-prolyl-L-threonine",
                "designated_date": "04/26/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Nyxis Neurotherapies, Inc.|1801 Maple Avenue|Suite 4300|Evanston|Illinois|60201|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neuropathic pain associated with spinal cord injury",
                    "umls_id": "C0027796,C0037929",
                    "parsed_text": "Neuropathic Pain , Spinal Cord Injury"
                }
            }
        ]
    },
    {
        "_id": "JVTAAEKCZFNVCJ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 612,
                "inchl_key": "JVTAAEKCZFNVCJ-UHFFFAOYSA-N",
                "generic_name": "Lactic acid",
                "designated_date": "06/29/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Frontier Pharmaceutical, Inc.|SUNY Farmingdale|Conklin Hall|Farmingdale|New York|11735|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.",
                    "umls_id": "C0038363",
                    "parsed_text": "Aphthous Stomatitis"
                }
            }
        ]
    },
    {
        "_id": "PKCDDUHJAFVJJB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11640390,
                "inchl_key": "PKCDDUHJAFVJJB-UHFFFAOYSA-N",
                "generic_name": "linsitinib",
                "designated_date": "03/09/2012",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Astellas Pharma Global Development, Inc.|1 Astellas Way|Northbrook|Illinois|60062|United States",
                "orphan_designation": {
                    "original_text": "Treatment of adrenocortical carcinoma",
                    "umls_id": "C0206686",
                    "parsed_text": "Adrenocortical carcinoma"
                }
            }
        ]
    },
    {
        "_id": "IIXWYSCJSQVBQM-LLVKDONJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71731823,
                "inchl_key": "IIXWYSCJSQVBQM-LLVKDONJSA-N",
                "generic_name": "Lorlatinib",
                "trade_name": "LORBRENA",
                "designated_date": "06/23/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "LORBRENA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or alectinib as the first ALK inhibitor therapy for metastatic disease; or ceritinib as the first ALK inhibitor therapy for metastatic disease.",
                "marketing_approval_date": "\u00a011/02/2018\u00a0",
                "exclusivity_end_date": "\u00a011/02/2025\u00a0",
                "exclusivity_protected_indication": "LORBRENA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or alectinib as the first ALK inhibitor therapy for metastatic disease; or ceritinib as the first ALK inhibitor therapy for metastatic disease.",
                "sponsor": "Pfizer, Inc.|235 East 42nd Street (M/S 219/9/30)|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Treatment of anaplastic lymphoma kinase (ALK)-positive or ROS1-positive non-small cell lung cancer",
                    "umls_id": "C3539721",
                    "parsed_text": "Non-Small Cell Lung Cancer"
                }
            }
        ]
    },
    {
        "_id": "UFSKUSARDNFIRC-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16678941,
                "inchl_key": "UFSKUSARDNFIRC-UHFFFAOYSA-N",
                "generic_name": "Lumacaftor",
                "designated_date": "09/09/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Qanatpharma GmbH|Residenzstrasse 18|Munich|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of Subarachnoid Hemorrhage",
                    "umls_id": "C0038525",
                    "parsed_text": "Subarachnoid Hemorrhage"
                }
            }
        ]
    },
    {
        "_id": "CRXRROKIRDSTAH-ZUDQWMAJSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 134687480,
                "inchl_key": "CRXRROKIRDSTAH-ZUDQWMAJSA-L",
                "generic_name": "magnesium lysinate bis eicosapentaenoate",
                "designated_date": "12/23/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Thetis Pharmaceuticals|167 Old Post Road|2nd Floor|Southport|Connecticut|6890|United States",
                "orphan_designation": {
                    "original_text": "Treatment of familial adenomatous polyposis.",
                    "umls_id": "C0032580",
                    "parsed_text": "Familial Adenomatous Polyposis"
                }
            }
        ]
    },
    {
        "_id": "ZRVUJXDFFKFLMG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 54677470,
                "inchl_key": "ZRVUJXDFFKFLMG-UHFFFAOYSA-N",
                "generic_name": "meloxicam",
                "trade_name": "Mobic",
                "designated_date": "11/22/2002",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients 2 years of age or older",
                "marketing_approval_date": "\u00a008/11/2005\u00a0",
                "exclusivity_end_date": "\u00a008/11/2012\u00a0",
                "sponsor": "Boehringer Ingelheim Pharmaceuticals, Inc.|900 Ridgebury Road|P. O. Box 368|Ridgefield|Connecticut|6877|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls_id": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            }
        ]
    },
    {
        "_id": "QHADVLVFMKEIIP-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 44603533,
                "inchl_key": "QHADVLVFMKEIIP-UHFFFAOYSA-N",
                "generic_name": "merestinib",
                "designated_date": "04/10/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States",
                "orphan_designation": {
                    "original_text": "Treatment of biliary tract cancer",
                    "umls_id": "C0750952",
                    "parsed_text": "Biliary Tract Cancer"
                }
            }
        ]
    },
    {
        "_id": "MGCQZNBCJBRZDT-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 18340,
                "inchl_key": "MGCQZNBCJBRZDT-UHFFFAOYSA-N",
                "generic_name": "Midodrine HCl",
                "trade_name": "Amatine",
                "designated_date": "06/21/1985",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of symptomatic orthostatic hypotension.",
                "marketing_approval_date": "\u00a009/06/1996\u00a0",
                "exclusivity_end_date": "\u00a009/06/2003\u00a0",
                "sponsor": "Takeda Development Center Americas, Inc.|95 Hayden Avenue|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with symptomatic orthostatic hypotension.",
                    "umls_id": "C0020651",
                    "parsed_text": "ORTHOSTATIC HYPOTENSION"
                }
            }
        ]
    },
    {
        "_id": "ZVHNDZWQTBEVRY-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25062766,
                "inchl_key": "ZVHNDZWQTBEVRY-UHFFFAOYSA-N",
                "generic_name": "momelotinib",
                "designated_date": "08/05/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sierra Oncology, Inc.|46701 Commerce Center Drive|Plymouth|Michigan|48170|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelofibrosis",
                    "umls_id": "C0026987",
                    "parsed_text": "myelofibrosis"
                }
            }
        ]
    },
    {
        "_id": "PTKRPOIHIOAMPP-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 73334909,
                "inchl_key": "PTKRPOIHIOAMPP-UHFFFAOYSA-N",
                "generic_name": "N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl) pyridin-2-yl) Acetamide Besylate",
                "designated_date": "11/26/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kinex Pharmaceuticals, Inc.|701 Ellicott Street|Buffalo|New York|14203|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gliomas",
                    "umls_id": "C0017638",
                    "parsed_text": "gliomas"
                }
            }
        ]
    },
    {
        "_id": "RWHUEXWOYVBUCI-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25077649,
                "inchl_key": "RWHUEXWOYVBUCI-UHFFFAOYSA-N",
                "generic_name": "Nafarelin acetate",
                "trade_name": "Synarel Nasal Solution",
                "designated_date": "07/20/1988",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of central precocious puberty (gonadotropin-dependent precocious puberty) in children of both sexes.",
                "marketing_approval_date": "\u00a002/26/1992\u00a0",
                "exclusivity_end_date": "\u00a002/26/1999\u00a0",
                "sponsor": "Syntex (USA), Inc.|3401 Hillview Avenue|Palo Alto|California|94303|United States",
                "orphan_designation": {
                    "original_text": "Treatment of central precocious puberty.",
                    "umls_id": "C0342543",
                    "parsed_text": "Central Precocious Puberty"
                }
            }
        ]
    },
    {
        "_id": "FSBTYDWUUWLHBD-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25084011,
                "inchl_key": "FSBTYDWUUWLHBD-UHFFFAOYSA-N",
                "generic_name": "Nafarelin acetate",
                "trade_name": "Synarel Nasal Solution",
                "designated_date": "07/20/1988",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of central precocious puberty (gonadotropin-dependent precocious puberty) in children of both sexes.",
                "marketing_approval_date": "\u00a002/26/1992\u00a0",
                "exclusivity_end_date": "\u00a002/26/1999\u00a0",
                "sponsor": "Syntex (USA), Inc.|3401 Hillview Avenue|Palo Alto|California|94303|United States",
                "orphan_designation": {
                    "original_text": "Treatment of central precocious puberty.",
                    "umls_id": "C0342543",
                    "parsed_text": "Central Precocious Puberty"
                }
            }
        ]
    },
    {
        "_id": "GUJYDLHACHDKAJ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25077648,
                "inchl_key": "GUJYDLHACHDKAJ-UHFFFAOYSA-N",
                "generic_name": "Nafarelin acetate",
                "trade_name": "Synarel Nasal Solution",
                "designated_date": "07/20/1988",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of central precocious puberty (gonadotropin-dependent precocious puberty) in children of both sexes.",
                "marketing_approval_date": "\u00a002/26/1992\u00a0",
                "exclusivity_end_date": "\u00a002/26/1999\u00a0",
                "sponsor": "Syntex (USA), Inc.|3401 Hillview Avenue|Palo Alto|California|94303|United States",
                "orphan_designation": {
                    "original_text": "Treatment of central precocious puberty.",
                    "umls_id": "C0342543",
                    "parsed_text": "Central Precocious Puberty"
                }
            }
        ]
    },
    {
        "_id": "FSBTYDWUUWLHBD-UDXTWCDOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25079425,
                "inchl_key": "FSBTYDWUUWLHBD-UDXTWCDOSA-N",
                "generic_name": "Nafarelin acetate",
                "trade_name": "Synarel Nasal Solution",
                "designated_date": "07/20/1988",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of central precocious puberty (gonadotropin-dependent precocious puberty) in children of both sexes.",
                "marketing_approval_date": "\u00a002/26/1992\u00a0",
                "exclusivity_end_date": "\u00a002/26/1999\u00a0",
                "sponsor": "Syntex (USA), Inc.|3401 Hillview Avenue|Palo Alto|California|94303|United States",
                "orphan_designation": {
                    "original_text": "Treatment of central precocious puberty.",
                    "umls_id": "C0342543",
                    "parsed_text": "Central Precocious Puberty"
                }
            }
        ]
    },
    {
        "_id": "GUJYDLHACHDKAJ-CFWZQLQRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25079036,
                "inchl_key": "GUJYDLHACHDKAJ-CFWZQLQRSA-N",
                "generic_name": "Nafarelin acetate",
                "trade_name": "Synarel Nasal Solution",
                "designated_date": "07/20/1988",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of central precocious puberty (gonadotropin-dependent precocious puberty) in children of both sexes.",
                "marketing_approval_date": "\u00a002/26/1992\u00a0",
                "exclusivity_end_date": "\u00a002/26/1999\u00a0",
                "sponsor": "Syntex (USA), Inc.|3401 Hillview Avenue|Palo Alto|California|94303|United States",
                "orphan_designation": {
                    "original_text": "Treatment of central precocious puberty.",
                    "umls_id": "C0342543",
                    "parsed_text": "Central Precocious Puberty"
                }
            }
        ]
    },
    {
        "_id": "IXOXBSCIXZEQEQ-UHTZMRCNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3011155,
                "inchl_key": "IXOXBSCIXZEQEQ-UHTZMRCNSA-N",
                "generic_name": "nelarabine",
                "trade_name": "Arranon",
                "designated_date": "08/10/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens",
                "marketing_approval_date": "\u00a010/28/2005\u00a0",
                "exclusivity_end_date": "\u00a010/28/2012\u00a0",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma",
                    "umls_id": "C0023449,C0278721,C1961102",
                    "parsed_text": "Acute lymphoblastic leukemia , Lymphoblastic Lymphoma , Acute Lymphoblastic Leukemia"
                }
            },
            {
                "compound_id": 3011155,
                "inchl_key": "IXOXBSCIXZEQEQ-UHTZMRCNSA-N",
                "generic_name": "nelarabine",
                "designated_date": "09/02/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia.",
                    "umls_id": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "NQDJXKOVJZTUJA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4463,
                "inchl_key": "NQDJXKOVJZTUJA-UHFFFAOYSA-N",
                "generic_name": "nevirapine",
                "designated_date": "11/25/2009",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Auritec Pharmaceuticals|1434 6th Street|Santa Monica|California|90401|United States",
                "orphan_designation": {
                    "original_text": "Prevention of HIV infection in pediatric patients under the age of 16 years",
                    "umls_id": "C0019693",
                    "parsed_text": "HIV infection"
                }
            }
        ]
    },
    {
        "_id": "WWFDJIVIDXJAQR-FFWSQMGZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 131801471,
                "inchl_key": "WWFDJIVIDXJAQR-FFWSQMGZSA-N",
                "generic_name": "nusinersen",
                "trade_name": "Spinraza",
                "designated_date": "04/18/2011",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of spinal muscular atrophy in pediatric and adult patients",
                "marketing_approval_date": "\u00a012/23/2016\u00a0",
                "exclusivity_end_date": "\u00a012/23/2023\u00a0",
                "exclusivity_protected_indication": "Treatment of spinal muscular atrophy in pediatric and adult patients",
                "sponsor": "Biogen, Inc|225 Binney Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of spinal muscular atrophy",
                    "umls_id": "C0026847",
                    "parsed_text": "Spinal Muscular Atrophy"
                }
            }
        ]
    },
    {
        "_id": "GSDSWSVVBLHKDQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4583,
                "inchl_key": "GSDSWSVVBLHKDQ-UHFFFAOYSA-N",
                "generic_name": "Ofloxacin",
                "trade_name": "Ocuflox Ophthalmic Solution",
                "designated_date": "04/18/1991",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of bacterial corneal ulcers.",
                "marketing_approval_date": "\u00a005/22/1996\u00a0",
                "exclusivity_end_date": "\u00a005/22/2003\u00a0",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States",
                "orphan_designation": {
                    "original_text": "Treatment of bacterial corneal ulcers.",
                    "umls_id": "C0010043",
                    "parsed_text": "corneal ulcers"
                }
            }
        ]
    },
    {
        "_id": "BOWVQLFMWHZBEF-KTKRTIGZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5283454,
                "inchl_key": "BOWVQLFMWHZBEF-KTKRTIGZSA-N",
                "generic_name": "Oleoylethanolamide",
                "designated_date": "06/08/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NutriForward, LLC|1520 Luna Road, # 120|Carrollton|Texas|75006|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Prader-Willi syndrome",
                    "umls_id": "C0032897",
                    "parsed_text": "Prader-Willi Syndrome"
                }
            }
        ]
    },
    {
        "_id": "RJCWBNBKOKFWNY-IDPLTSGASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71811910,
                "inchl_key": "RJCWBNBKOKFWNY-IDPLTSGASA-N",
                "generic_name": "omaveloxolone",
                "designated_date": "06/19/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Reata Pharmaceuticals, Inc.|2801 Gateway Dr.|Suite 150|Irving|Texas|75063|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Friedreich's Ataxia",
                    "umls_id": "C0016719",
                    "parsed_text": "Friedreich's Ataxia"
                }
            },
            {
                "compound_id": 71811910,
                "inchl_key": "RJCWBNBKOKFWNY-IDPLTSGASA-N",
                "generic_name": "omaveloxolone",
                "designated_date": "09/05/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Reata Pharmaceuticals, Inc.|2801 Gateway Dr.|Suite 150|Irving|Texas|75063|United States",
                "orphan_designation": {
                    "original_text": "Treatment of stage IIb through IV malignant melanoma",
                    "umls_id": "C0025202",
                    "parsed_text": "Malignant Melanoma"
                }
            }
        ]
    },
    {
        "_id": "QLMMOGWZCFQAPU-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6419718,
                "inchl_key": "QLMMOGWZCFQAPU-UHFFFAOYSA-N",
                "generic_name": "omigapil",
                "designated_date": "06/24/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Santhera Pharmaceuticals (Switzerland) Limited|Hammerstrass 49|CH-4410 Liestal|Liestal|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of congenital muscular dystrophy.",
                    "umls_id": "C0699743",
                    "parsed_text": "Congenital muscular dystrophy"
                }
            }
        ]
    },
    {
        "_id": "DRMCATBEKSVAPL-BNTLRKBRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9887053,
                "inchl_key": "DRMCATBEKSVAPL-BNTLRKBRSA-N",
                "generic_name": "Oxaliplatin",
                "designated_date": "10/06/1992",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Debiopharm S.A.|17 Rue des Terreaux|Lausanne|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of ovarian cancer.",
                    "umls_id": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "XRVDGNKRPOAQTN-FQEVSTJZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 52938427,
                "inchl_key": "XRVDGNKRPOAQTN-FQEVSTJZSA-N",
                "generic_name": "ozanimod",
                "designated_date": "11/01/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Celgene International II Sarl|4 Rue des Moulins|Val-de-Travers|Neuch\u2d25l|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Crohns disease",
                    "umls_id": "C0010346",
                    "parsed_text": "Crohns Disease"
                }
            },
            {
                "compound_id": 52938427,
                "inchl_key": "XRVDGNKRPOAQTN-FQEVSTJZSA-N",
                "generic_name": "ozanimod",
                "designated_date": "12/29/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Celgene Corporation|3033 Science Park Road|Suite 300|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric (0 through 16 years of age) ulcerative colitis",
                    "umls_id": "C0009324",
                    "parsed_text": "Ulcerative Colitis"
                }
            }
        ]
    },
    {
        "_id": "BKCJZNIZRWYHBN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 100427,
                "inchl_key": "BKCJZNIZRWYHBN-UHFFFAOYSA-N",
                "generic_name": "Palifosfamide",
                "designated_date": "05/05/2008",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ZIOPHARM Oncology, Inc.|One First Avenue, Parris Building #34|Navy Yard Plaza|Boston|Massachusetts|2129|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcomas",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft Tissue Sarcomas"
                }
            }
        ]
    },
    {
        "_id": "GHILNKWBALQPDP-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 134168328,
                "inchl_key": "GHILNKWBALQPDP-UHFFFAOYSA-N",
                "generic_name": "Paltusotine",
                "designated_date": "07/07/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Crinetics Pharmaceuticals, Inc.|6197 Cornerstone Court East|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acromegaly",
                    "umls_id": "C0001206",
                    "parsed_text": "Acromegaly"
                }
            }
        ]
    },
    {
        "_id": "XQYZDYMELSJDRZ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4680,
                "inchl_key": "XQYZDYMELSJDRZ-UHFFFAOYSA-N",
                "generic_name": "papaverine",
                "designated_date": "08/03/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Nir Barak, MD|CO Noa Avtalion|161 Jefferson Avenue|Tenafly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mesenteric ischemia",
                    "umls_id": "C1412000",
                    "parsed_text": "Mesenteric Ischemia"
                }
            }
        ]
    },
    {
        "_id": "LGWACEZVCMBSKW-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 57384863,
                "inchl_key": "LGWACEZVCMBSKW-UHFFFAOYSA-N",
                "generic_name": "Paxalisib",
                "designated_date": "08/21/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kazia Therapeutics Limited|ACN 063 259 754|Level 24, 300 Barangaroo Avenue|Sydney|NSW|2000|Australia",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls_id": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            }
        ]
    },
    {
        "_id": "ZCTCZKWJFTYNMZ-WKUCUCPSSA-J",
        "Orphan Drug Designations": [
            {
                "compound_id": 135564527,
                "inchl_key": "ZCTCZKWJFTYNMZ-WKUCUCPSSA-J",
                "generic_name": "pemetrexed disodium",
                "trade_name": "Alimta",
                "designated_date": "08/28/2001",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery",
                "marketing_approval_date": "\u00a002/04/2004\u00a0",
                "exclusivity_end_date": "\u00a002/04/2011\u00a0",
                "sponsor": "Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant pleural mesothelioma",
                    "umls_id": "C0812413",
                    "parsed_text": "Malignant Pleural Mesothelioma"
                }
            }
        ]
    },
    {
        "_id": "PSXPIRGEVYHPKP-GXKRWWSZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135544142,
                "inchl_key": "PSXPIRGEVYHPKP-GXKRWWSZSA-N",
                "generic_name": "pemetrexed disodium",
                "trade_name": "Alimta",
                "designated_date": "08/28/2001",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery",
                "marketing_approval_date": "\u00a002/04/2004\u00a0",
                "exclusivity_end_date": "\u00a002/04/2011\u00a0",
                "sponsor": "Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant pleural mesothelioma",
                    "umls_id": "C0812413",
                    "parsed_text": "Malignant Pleural Mesothelioma"
                }
            }
        ]
    },
    {
        "_id": "NYDXNILOWQXUOF-GXKRWWSZSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 136253316,
                "inchl_key": "NYDXNILOWQXUOF-GXKRWWSZSA-M",
                "generic_name": "pemetrexed disodium",
                "trade_name": "Alimta",
                "designated_date": "08/28/2001",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery",
                "marketing_approval_date": "\u00a002/04/2004\u00a0",
                "exclusivity_end_date": "\u00a002/04/2011\u00a0",
                "sponsor": "Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant pleural mesothelioma",
                    "umls_id": "C0812413",
                    "parsed_text": "Malignant Pleural Mesothelioma"
                }
            }
        ]
    },
    {
        "_id": "QJVSMHJWAOSBMD-MYXYZBIASA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 135564751,
                "inchl_key": "QJVSMHJWAOSBMD-MYXYZBIASA-L",
                "generic_name": "pemetrexed disodium",
                "trade_name": "Alimta",
                "designated_date": "08/28/2001",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery",
                "marketing_approval_date": "\u00a002/04/2004\u00a0",
                "exclusivity_end_date": "\u00a002/04/2011\u00a0",
                "sponsor": "Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant pleural mesothelioma",
                    "umls_id": "C0812413",
                    "parsed_text": "Malignant Pleural Mesothelioma"
                }
            }
        ]
    },
    {
        "_id": "WBXPDJSOTKVWSJ-ZDUSSCGKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135410875,
                "inchl_key": "WBXPDJSOTKVWSJ-ZDUSSCGKSA-N",
                "generic_name": "pemetrexed disodium",
                "trade_name": "Alimta",
                "designated_date": "08/28/2001",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery",
                "marketing_approval_date": "\u00a002/04/2004\u00a0",
                "exclusivity_end_date": "\u00a002/04/2011\u00a0",
                "sponsor": "Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant pleural mesothelioma",
                    "umls_id": "C0812413",
                    "parsed_text": "Malignant Pleural Mesothelioma"
                }
            }
        ]
    },
    {
        "_id": "NYDXNILOWQXUOF-GXKRWWSZSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 135413520,
                "inchl_key": "NYDXNILOWQXUOF-GXKRWWSZSA-L",
                "generic_name": "pemetrexed disodium",
                "trade_name": "Alimta",
                "designated_date": "08/28/2001",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery",
                "marketing_approval_date": "\u00a002/04/2004\u00a0",
                "exclusivity_end_date": "\u00a002/04/2011\u00a0",
                "sponsor": "Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant pleural mesothelioma",
                    "umls_id": "C0812413",
                    "parsed_text": "Malignant Pleural Mesothelioma"
                }
            }
        ]
    },
    {
        "_id": "WLJVXDMOQOGPHL-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 999,
                "inchl_key": "WLJVXDMOQOGPHL-UHFFFAOYSA-N",
                "generic_name": "Phenylacetate",
                "designated_date": "03/06/1998",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Elan Drug Delivery, Inc.|1300 Gould Dr.|Gainesville|Georgia|30504|United States",
                "orphan_designation": {
                    "original_text": "For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.",
                    "umls_id": "C1578499,C4684861",
                    "parsed_text": "Radiation Therapy , Recurrent Malignant Glioma"
                }
            }
        ]
    },
    {
        "_id": "WLJVXDMOQOGPHL-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 4409936,
                "inchl_key": "WLJVXDMOQOGPHL-UHFFFAOYSA-M",
                "generic_name": "Phenylacetate",
                "designated_date": "03/06/1998",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Elan Drug Delivery, Inc.|1300 Gould Dr.|Gainesville|Georgia|30504|United States",
                "orphan_designation": {
                    "original_text": "For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.",
                    "umls_id": "C1578499,C4684861",
                    "parsed_text": "Radiation Therapy , Recurrent Malignant Glioma"
                }
            }
        ]
    },
    {
        "_id": "JALHGCPDPSNJNY-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10158453,
                "inchl_key": "JALHGCPDPSNJNY-UHFFFAOYSA-N",
                "generic_name": "prasugrel hydrochloride",
                "designated_date": "05/26/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eli Lilly|Lilly Corporate Center|Indianapolis|Indiana|46285|United States",
                "orphan_designation": {
                    "original_text": "Treatment of sickle cell disease",
                    "umls_id": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            }
        ]
    },
    {
        "_id": "ZLHZLMOSPGACSZ-NSHDSACASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 456199,
                "inchl_key": "ZLHZLMOSPGACSZ-NSHDSACASA-N",
                "generic_name": "Pretomanid",
                "trade_name": "Pretomanid",
                "designated_date": "07/05/2007",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Pretomanid tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug resistant (XDR) or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).",
                "marketing_approval_date": "\u00a008/14/2019\u00a0",
                "exclusivity_end_date": "\u00a008/14/2026\u00a0",
                "exclusivity_protected_indication": "As part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug resistant (XDR) or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).",
                "sponsor": "Global Alliance for TB Drug Development|40 Wall Street|24th Floor|New York|New York|10005|United States",
                "orphan_designation": {
                    "original_text": "Treatment of tuberculosis",
                    "umls_id": "C0041296",
                    "parsed_text": "Tuberculosis"
                }
            }
        ]
    },
    {
        "_id": "UKUYYHVRVSDDQG-UBXFZUKZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 86566352,
                "inchl_key": "UKUYYHVRVSDDQG-UBXFZUKZSA-N",
                "generic_name": "Pro-Pro-Thr-Val-Pro-Thr-Arg",
                "designated_date": "07/27/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ProGeLife S.A.S|8 Rue Sainte-Barbe|Marseille|Provence-Alpes-C_xDC92__xDD60_d'Azur|France",
                "orphan_designation": {
                    "original_text": "Treatment of xeroderma pigmentosum",
                    "umls_id": "C0043346",
                    "parsed_text": "Xeroderma Pigmentosum"
                }
            }
        ]
    },
    {
        "_id": "LNFCWEXGZIEGJW-TXSVMFMRSA-O",
        "Orphan Drug Designations": [
            {
                "compound_id": 78318119,
                "inchl_key": "LNFCWEXGZIEGJW-TXSVMFMRSA-O",
                "generic_name": "Rezafungin",
                "designated_date": "02/08/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cidara Therapeutics, Inc.|6310 Nancy Ridge Drive|Suite 101|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of candidemia and invasive candidiasis infections caused by susceptible Candida spp.",
                    "umls_id": "C0877445,C1609535",
                    "parsed_text": "Candidemia , Invasive Candidiasis"
                }
            }
        ]
    },
    {
        "_id": "IXSVOCGZBUJEPI-HTQYORAHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135431094,
                "inchl_key": "IXSVOCGZBUJEPI-HTQYORAHSA-N",
                "generic_name": "Rifalazil",
                "designated_date": "04/13/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PathoGenesis Corporation|201 Elliott Avenue West|Suite 150|Seattle|Washington|98119|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary tuberculosis.",
                    "umls_id": "C0041327",
                    "parsed_text": "Pulmonary tuberculosis"
                }
            }
        ]
    },
    {
        "_id": "HUFOZJXAKZVRNJ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 57335384,
                "inchl_key": "HUFOZJXAKZVRNJ-UHFFFAOYSA-N",
                "generic_name": "rociletinib",
                "designated_date": "05/14/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clovis Oncology, Inc.|5500 Flatiron Parkway|Suite 100|Boulder|Colorado|80301|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-small cell lung cancer and mutations in the epidermal growth factor receptor",
                    "umls_id": "C1414313,C3539721",
                    "parsed_text": "EPIDERMAL GROWTH FACTOR RECEPTOR , Non-Small Cell Lung Cancer"
                }
            }
        ]
    },
    {
        "_id": "FNKQXYHWGSIFBK-RPDRRWSUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135398654,
                "inchl_key": "FNKQXYHWGSIFBK-RPDRRWSUSA-N",
                "generic_name": "sapropterin",
                "trade_name": "Kuvan",
                "designated_date": "01/29/2004",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet.",
                "marketing_approval_date": "\u00a012/13/2007\u00a0",
                "exclusivity_end_date": "\u00a012/13/2014\u00a0",
                "sponsor": "BioMarin Pharmaceutical, Inc.|105 Digital Drive|Novato|California|94949|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hyperphenylalaninemia",
                    "umls_id": "C0751435",
                    "parsed_text": "Hyperphenylalaninemia"
                }
            }
        ]
    },
    {
        "_id": "UJYFZCVPOSZDMK-YPPDDXJESA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 121000421,
                "inchl_key": "UJYFZCVPOSZDMK-YPPDDXJESA-L",
                "generic_name": "saroglitazar magnesium",
                "designated_date": "01/26/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Zydus Discovery DMCC|Unit no 909, Armada 2|Plot no : JLT-PH2-P2A,|Dubai|United Arab Emirates",
                "orphan_designation": {
                    "original_text": "Treatment of Primary Biliary Cholangitis",
                    "umls_id": "C0008312",
                    "parsed_text": "Primary Biliary Cholangitis"
                }
            }
        ]
    },
    {
        "_id": "RGYQPQARIQKJKH-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 58496428,
                "inchl_key": "RGYQPQARIQKJKH-UHFFFAOYSA-N",
                "generic_name": "Setanaxib",
                "designated_date": "10/16/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genkyotex SA|218 Route Marie Curie, Technopole dArchamps, Forum 2|Archamps|74160|France",
                "orphan_designation": {
                    "original_text": "treatment of primary biliary cholangitis",
                    "umls_id": "C0008312",
                    "parsed_text": "Primary Biliary Cholangitis"
                }
            }
        ]
    },
    {
        "_id": "MUOKSQABCJCOPU-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24748573,
                "inchl_key": "MUOKSQABCJCOPU-UHFFFAOYSA-N",
                "generic_name": "Silmitasertib",
                "designated_date": "12/22/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Senhwa Biosciences, Inc.|No. 205-1, Peihsin Road|Section 3|New Taipei City|Hsintien District|Taiwan",
                "orphan_designation": {
                    "original_text": "Treatment of cholangiocarcinoma",
                    "umls_id": "C0206698",
                    "parsed_text": "Cholangiocarcinoma"
                }
            }
        ]
    },
    {
        "_id": "UPUIQOIQVMNQAP-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 23665770,
                "inchl_key": "UPUIQOIQVMNQAP-UHFFFAOYSA-M",
                "generic_name": "Sodium tetradecyl sulfate",
                "designated_date": "06/10/1986",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Elkins-Sinn, Inc.|2 Esterbrook Lane|Cherry Hill|New Jersey|8003|United States",
                "orphan_designation": {
                    "original_text": "Treatment of bleeding esophageal varices.",
                    "umls_id": "C0014867",
                    "parsed_text": "Esophageal Varices"
                }
            }
        ]
    },
    {
        "_id": "LXMSZDCAJNLERA-ZHYRCANASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5833,
                "inchl_key": "LXMSZDCAJNLERA-ZHYRCANASA-N",
                "generic_name": "spironolactone",
                "designated_date": "05/22/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CMP Pharma, Inc.|PO Box 147|8026 US Highway 264A|Farmville|North Carolina|27828|United States",
                "orphan_designation": {
                    "original_text": "Use in pediatric patients with primary hyperaldosteronism",
                    "umls_id": "C1384514",
                    "parsed_text": "Primary Hyperaldosteronism"
                }
            }
        ]
    },
    {
        "_id": "HDXDQPRPFRKGKZ-INIZCTEOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 86291103,
                "inchl_key": "HDXDQPRPFRKGKZ-INIZCTEOSA-N",
                "generic_name": "tenalisib",
                "designated_date": "04/04/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rhizen Pharmaceuticals SA|40 Rue Fritz-Courvoisier|La Chaux-de-Fonds|Neuch\u2d25l|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of Cutaneous T-Cell Lymphoma",
                    "umls_id": "C0079773",
                    "parsed_text": "cutaneous T-cell lymphoma"
                }
            }
        ]
    },
    {
        "_id": "SCTJKHUUZLXJIP-RUZDIDTESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 23628250,
                "inchl_key": "SCTJKHUUZLXJIP-RUZDIDTESA-N",
                "generic_name": "tenofovir exalidex",
                "designated_date": "02/20/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ContraVir Pharmaceuticals, Inc.|399 Thornall Street|First Floor|Edison|New Jersey|8837|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric chronic hepatitis B infection (age 0 through 11 years of age)",
                    "umls_id": "C0019163,C0524909",
                    "parsed_text": "Hepatitis B infection , chronic hepatitis b"
                }
            }
        ]
    },
    {
        "_id": "BSVYJQAWONIOOU-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 33958,
                "inchl_key": "BSVYJQAWONIOOU-UHFFFAOYSA-N",
                "generic_name": "tilorone dihydrochloride",
                "designated_date": "02/07/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Collaborations Pharmaceuticals, Inc.|840 Main Campus Drive|Lab 3510|Raleigh|North Carolina|27606|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Ebola infection",
                    "umls_id": "C0282687",
                    "parsed_text": "Ebola Infection"
                }
            }
        ]
    },
    {
        "_id": "DMAHZCZCPVOYGS-ZLSDMPCXSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 135565472,
                "inchl_key": "DMAHZCZCPVOYGS-ZLSDMPCXSA-L",
                "generic_name": "tin ethyl etiopurpurin",
                "designated_date": "01/16/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Adgero Biopharmaceuticals, Inc|4365 US Highway 1|Suite 211|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of basal cell carcinoma nevus syndrome (BCCNS)",
                    "umls_id": "C0007117,C0027962",
                    "parsed_text": "Basal cell carcinoma , Nevus"
                }
            }
        ]
    },
    {
        "_id": "NLVFBUXFDBBNBW-PBSUHMDJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 36294,
                "inchl_key": "NLVFBUXFDBBNBW-PBSUHMDJSA-N",
                "generic_name": "Tobramycin",
                "designated_date": "06/18/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Novartis Pharmaceuticals Corp.|One Health Plaza|Office 315|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.",
                    "umls_id": "C0006267",
                    "parsed_text": "Bronchiectasis"
                }
            }
        ]
    },
    {
        "_id": "KJADKKWYZYXHBB-XBWDGYHZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5284627,
                "inchl_key": "KJADKKWYZYXHBB-XBWDGYHZSA-N",
                "generic_name": "Topiramate",
                "trade_name": "Topamax",
                "designated_date": "11/25/1992",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "As adjunctive therapy in patients two years and older with siezures associated with Lennox-Gastaut syndrome.",
                "marketing_approval_date": "\u00a008/28/2001\u00a0",
                "exclusivity_end_date": "\u00a008/28/2008\u00a0",
                "sponsor": "Johnson & Johnson Pharmaceutical R & D, LLC|Route 202, P.O. Box 300|Raritan|New Jersey|8869|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Lennox-Gastaut syndrome.",
                    "umls_id": "C0238111",
                    "parsed_text": "Lennox-Gastaut syndrome"
                }
            }
        ]
    },
    {
        "_id": "NQPDXQQQCQDHHW-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 50248,
                "inchl_key": "NQPDXQQQCQDHHW-UHFFFAOYSA-N",
                "generic_name": "triclabendazole",
                "designated_date": "06/27/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Tropicalis Pharmaceuticals, LLC|22345 Bracketts Road|Excelsior|Minnesota|55331|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fascioliasis",
                    "umls_id": "C0015652",
                    "parsed_text": "Fascioliasis"
                }
            },
            {
                "compound_id": 50248,
                "inchl_key": "NQPDXQQQCQDHHW-UHFFFAOYSA-N",
                "generic_name": "triclabendazole",
                "trade_name": "Egaten",
                "designated_date": "04/17/2017",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "EGATEN is indicated for the treatment of fascioliasis in patients 6 years of age and older.",
                "marketing_approval_date": "\u00a002/13/2019\u00a0",
                "exclusivity_end_date": "\u00a002/13/2026\u00a0",
                "exclusivity_protected_indication": "EGATEN is indicated for the treatment of fascioliasis in patients 6 years of age and older.",
                "sponsor": "Novartis Pharmaceuticals Corporation|1 Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fascioliasis",
                    "umls_id": "C0015652",
                    "parsed_text": "Fascioliasis"
                }
            }
        ]
    },
    {
        "_id": "LQCLVBQBTUVCEQ-DURLPPERSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 133562799,
                "inchl_key": "LQCLVBQBTUVCEQ-DURLPPERSA-N",
                "generic_name": "Troleandomycin",
                "designated_date": "09/21/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Szefler, Stanley M. M.D.|National Jewish Center for Immunology and Respirat|1400 Jackson Street|Denver|Colorado|80206|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe steroid-requiring asthma.",
                    "umls_id": "C0004096",
                    "parsed_text": "Asthma"
                }
            }
        ]
    },
    {
        "_id": "LQCLVBQBTUVCEQ-ISONCDLBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 146158448,
                "inchl_key": "LQCLVBQBTUVCEQ-ISONCDLBSA-N",
                "generic_name": "Troleandomycin",
                "designated_date": "09/21/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Szefler, Stanley M. M.D.|National Jewish Center for Immunology and Respirat|1400 Jackson Street|Denver|Colorado|80206|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe steroid-requiring asthma.",
                    "umls_id": "C0004096",
                    "parsed_text": "Asthma"
                }
            }
        ]
    },
    {
        "_id": "LQCLVBQBTUVCEQ-BFKGUNNCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6713914,
                "inchl_key": "LQCLVBQBTUVCEQ-BFKGUNNCSA-N",
                "generic_name": "Troleandomycin",
                "designated_date": "09/21/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Szefler, Stanley M. M.D.|National Jewish Center for Immunology and Respirat|1400 Jackson Street|Denver|Colorado|80206|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe steroid-requiring asthma.",
                    "umls_id": "C0004096",
                    "parsed_text": "Asthma"
                }
            }
        ]
    },
    {
        "_id": "LQCLVBQBTUVCEQ-CLPGKMRCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5289436,
                "inchl_key": "LQCLVBQBTUVCEQ-CLPGKMRCSA-N",
                "generic_name": "Troleandomycin",
                "designated_date": "09/21/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Szefler, Stanley M. M.D.|National Jewish Center for Immunology and Respirat|1400 Jackson Street|Denver|Colorado|80206|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe steroid-requiring asthma.",
                    "umls_id": "C0004096",
                    "parsed_text": "Asthma"
                }
            }
        ]
    },
    {
        "_id": "LQCLVBQBTUVCEQ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 418931,
                "inchl_key": "LQCLVBQBTUVCEQ-UHFFFAOYSA-N",
                "generic_name": "Troleandomycin",
                "designated_date": "09/21/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Szefler, Stanley M. M.D.|National Jewish Center for Immunology and Respirat|1400 Jackson Street|Denver|Colorado|80206|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe steroid-requiring asthma.",
                    "umls_id": "C0004096",
                    "parsed_text": "Asthma"
                }
            }
        ]
    },
    {
        "_id": "LQCLVBQBTUVCEQ-RFHKDOLOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6708521,
                "inchl_key": "LQCLVBQBTUVCEQ-RFHKDOLOSA-N",
                "generic_name": "Troleandomycin",
                "designated_date": "09/21/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Szefler, Stanley M. M.D.|National Jewish Center for Immunology and Respirat|1400 Jackson Street|Denver|Colorado|80206|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe steroid-requiring asthma.",
                    "umls_id": "C0004096",
                    "parsed_text": "Asthma"
                }
            }
        ]
    },
    {
        "_id": "LQCLVBQBTUVCEQ-MCQAQMIOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5284630,
                "inchl_key": "LQCLVBQBTUVCEQ-MCQAQMIOSA-N",
                "generic_name": "Troleandomycin",
                "designated_date": "09/21/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Szefler, Stanley M. M.D.|National Jewish Center for Immunology and Respirat|1400 Jackson Street|Denver|Colorado|80206|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe steroid-requiring asthma.",
                    "umls_id": "C0004096",
                    "parsed_text": "Asthma"
                }
            }
        ]
    },
    {
        "_id": "LQCLVBQBTUVCEQ-GSELTXNRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 17675,
                "inchl_key": "LQCLVBQBTUVCEQ-GSELTXNRSA-N",
                "generic_name": "Troleandomycin",
                "designated_date": "09/21/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Szefler, Stanley M. M.D.|National Jewish Center for Immunology and Respirat|1400 Jackson Street|Denver|Colorado|80206|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe steroid-requiring asthma.",
                    "umls_id": "C0004096",
                    "parsed_text": "Asthma"
                }
            }
        ]
    },
    {
        "_id": "LQCLVBQBTUVCEQ-QTFUVMRISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 202225,
                "inchl_key": "LQCLVBQBTUVCEQ-QTFUVMRISA-N",
                "generic_name": "Troleandomycin",
                "designated_date": "09/21/1989",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Szefler, Stanley M. M.D.|National Jewish Center for Immunology and Respirat|1400 Jackson Street|Denver|Colorado|80206|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe steroid-requiring asthma.",
                    "umls_id": "C0004096",
                    "parsed_text": "Asthma"
                }
            }
        ]
    },
    {
        "_id": "RXRGZNYSEHTMHC-BQBZGAKWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 454194,
                "inchl_key": "RXRGZNYSEHTMHC-BQBZGAKWSA-N",
                "generic_name": "Troxacitabine",
                "designated_date": "04/04/2005",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Structural GenomiX, Inc. (SGX)|10505 Roselle Street|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "SDEAXTCZPQIFQM-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 51039094,
                "inchl_key": "SDEAXTCZPQIFQM-UHFFFAOYSA-N",
                "generic_name": "tucatinib",
                "designated_date": "06/05/2017",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.",
                "marketing_approval_date": "\u00a004/17/2020\u00a0",
                "exclusivity_end_date": "\u00a004/17/2027\u00a0",
                "exclusivity_protected_indication": "For use in combination with trastuzumab and capecitabine for treatment of adult patients with metastatic HER2-positive breast cancer and brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.",
                "sponsor": "Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States",
                "orphan_designation": {
                    "original_text": "Treatment of breast cancer patients with brain metastases.",
                    "umls_id": "C0220650,C0678222",
                    "parsed_text": "brain metastases , Breast cancer"
                }
            },
            {
                "compound_id": 51039094,
                "inchl_key": "SDEAXTCZPQIFQM-UHFFFAOYSA-N",
                "generic_name": "tucatinib",
                "designated_date": "09/18/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States",
                "orphan_designation": {
                    "original_text": "Treatment of HER2+ colorectal cancer",
                    "umls_id": "C0009404",
                    "parsed_text": "Colorectal Cancer"
                }
            }
        ]
    },
    {
        "_id": "GEJDGVNQKABXKG-CFKGEZKQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24795069,
                "inchl_key": "GEJDGVNQKABXKG-CFKGEZKQSA-N",
                "generic_name": "valbenazine",
                "designated_date": "10/19/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neurocrine Biosciences, Inc.|12780 El Camino Real|San Diego|California|92130|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients with Tourette syndrome (TS).",
                    "umls_id": "C0040517",
                    "parsed_text": "Tourette Syndrome"
                }
            }
        ]
    },
    {
        "_id": "ZYTXTXAMMDTYDQ-DGEXFFLYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3035000,
                "inchl_key": "ZYTXTXAMMDTYDQ-DGEXFFLYSA-N",
                "generic_name": "vamorolone",
                "designated_date": "12/02/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ReveraGen Biopharma|155 Gibbs Road, Suite 433|Rockville|Maryland|20850|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Duchenne muscular dystrophy",
                    "umls_id": "C0013264",
                    "parsed_text": "DUCHENNE MUSCULAR DYSTROPHY"
                }
            }
        ]
    },
    {
        "_id": "SXNJFOWDRLKDSF-XKHVUIRMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 10461508,
                "inchl_key": "SXNJFOWDRLKDSF-XKHVUIRMSA-N",
                "generic_name": "volasertib",
                "designated_date": "04/14/2014",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Boehringer Ingelheim Pharmaceuticals, Inc.|900 Ridgebury Road|P. O. Box 368|Ridgefield|Connecticut|6877|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "compound_id": 10461508,
                "inchl_key": "SXNJFOWDRLKDSF-XKHVUIRMSA-N",
                "generic_name": "Volasertib",
                "designated_date": "10/08/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oncoheroes Biosciences Inc.|43 Kent Street, #1|Brookline|Massachusetts|2445|United States",
                "orphan_designation": {
                    "original_text": "treatment of soft tissue sarcoma",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            }
        ]
    },
    {
        "_id": "CFMRIVODIXTERW-BDTNDASRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11553430,
                "inchl_key": "CFMRIVODIXTERW-BDTNDASRSA-N",
                "generic_name": "[(1S,2S,5S)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-6,6-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol",
                "designated_date": "04/13/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Tetra Bio-Pharma Inc.|365 St.-Jean Street|Suite 122|Longueuil|Canada",
                "orphan_designation": {
                    "original_text": "Prevention of proliferative vitreoretinopathy",
                    "umls_id": "C0242852",
                    "parsed_text": "Proliferative vitreoretinopathy"
                }
            }
        ]
    },
    {
        "_id": "ICKFFNBDFNZJSX-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25295,
                "inchl_key": "ICKFFNBDFNZJSX-UHFFFAOYSA-N",
                "generic_name": "chloropyramine",
                "designated_date": "10/22/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CurFAKtor Pharmaceuticals, LLC|14 Rock Dove Lane|Orchard Park|New York|14127|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "YASYEJJMZJALEJ-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 22230,
                "inchl_key": "YASYEJJMZJALEJ-UHFFFAOYSA-N",
                "generic_name": "citric acid monohydrate",
                "designated_date": "06/21/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Versantis AG|7 Otto-Stern-Weg|HPL D16.2|Zrich|Zrich|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of acute-on-chronic liver failure",
                    "umls_id": "C3850141",
                    "parsed_text": "Acute-On-Chronic Liver Failure"
                }
            }
        ]
    },
    {
        "_id": "CJXAEXPPLWQRFR-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2782,
                "inchl_key": "CJXAEXPPLWQRFR-UHFFFAOYSA-N",
                "generic_name": "clemizole",
                "designated_date": "04/19/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Epygenix Therapeutics, Inc.|140 East Ridgewood Avenue|Suite 415 South Tower|Paramus|New Jersey|7652|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Dravet syndrome",
                    "umls_id": "C0751122",
                    "parsed_text": "Dravet Syndrome"
                }
            }
        ]
    },
    {
        "_id": "GJSURZIOUXUGAL-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2803,
                "inchl_key": "GJSURZIOUXUGAL-UHFFFAOYSA-N",
                "generic_name": "Clonidine",
                "trade_name": "Duraclon",
                "designated_date": "01/24/1989",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone.",
                "marketing_approval_date": "\u00a010/02/1996\u00a0",
                "exclusivity_end_date": "\u00a010/02/2003\u00a0",
                "sponsor": "Roxane Laboratories, Inc.|PO Box 16532|Columbus|Ohio|43216|United States",
                "orphan_designation": {
                    "original_text": "For continous epidural administration as adjunctive therapy with intraspinal opiates for the treatment of pain in cancer patients tolerant to, or unresponsive to, intraspinal opiates.",
                    "umls_id": "C0006826,C0030193",
                    "parsed_text": "Cancer , Pain"
                }
            }
        ]
    },
    {
        "_id": "UOMKBIIXHQIERR-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 38072,
                "inchl_key": "UOMKBIIXHQIERR-UHFFFAOYSA-N",
                "generic_name": "cridanimod",
                "designated_date": "01/12/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Xenetic Biosciences, Inc.|99 Hayden Avenue|Suite 230|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy.",
                    "umls_id": "C0476089",
                    "parsed_text": "Endometrial Cancer"
                }
            }
        ]
    },
    {
        "_id": "AMHZIUVRYRVYBA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 2896,
                "inchl_key": "AMHZIUVRYRVYBA-UHFFFAOYSA-N",
                "generic_name": "cyclocreatine",
                "designated_date": "06/18/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Lumos Pharma|4200 Marathon Blvd.|Suite 200|Austin|Texas|78756|United States",
                "orphan_designation": {
                    "original_text": "Treatment of creatine transporter deficiency",
                    "umls_id": "C1845862",
                    "parsed_text": "Creatine transporter deficiency"
                }
            }
        ]
    },
    {
        "_id": "USSIQXCVUWKGNF-KRWDZBQOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 643985,
                "inchl_key": "USSIQXCVUWKGNF-KRWDZBQOSA-N",
                "generic_name": "d-methadone",
                "designated_date": "06/02/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Relmada Therapeutics, Inc.|750 Third Avenue|9th Floor|New York|New York|10017|United States",
                "orphan_designation": {
                    "original_text": "Treatment of postherpetic neuralgia",
                    "umls_id": "C0032768",
                    "parsed_text": "Postherpetic neuralgia"
                }
            }
        ]
    },
    {
        "_id": "VQODGRNSFPNSQE-CXSFZGCWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9400,
                "inchl_key": "VQODGRNSFPNSQE-CXSFZGCWSA-N",
                "generic_name": "dexamethasone phosphate",
                "designated_date": "12/02/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EyeGate Pharmaceuticals, Inc.|100 Beaver Street|Waltham|Massachusetts|2453|United States",
                "orphan_designation": {
                    "original_text": "Treatment of corneal graft rejection.",
                    "umls_id": "C0339303",
                    "parsed_text": "Corneal graft rejection"
                }
            }
        ]
    },
    {
        "_id": "SSQJFGMEZBFMNV-PMACEKPBSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 107778,
                "inchl_key": "SSQJFGMEZBFMNV-PMACEKPBSA-N",
                "generic_name": "dexanabinol",
                "designated_date": "08/11/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmos Corporation|99 Wood Avenue|Suite 311|Iselin|New Jersey|8830|United States",
                "orphan_designation": {
                    "original_text": "For the attenuation or amelioration of the long-term neurological sequelae associated with moderate and severe traumatic brain injury",
                    "umls_id": "C0543419,C0876926",
                    "parsed_text": "Sequelae , Traumatic Brain Injury"
                }
            }
        ]
    },
    {
        "_id": "DPFYBZWSVVKNPZ-AQWIXGDGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71315856,
                "inchl_key": "DPFYBZWSVVKNPZ-AQWIXGDGSA-N",
                "generic_name": "Dextran 70",
                "designated_date": "03/05/1990",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Holles Laboratories, Inc.|30 Forest Notch|Cohasset|Massachusetts|2025|United States",
                "orphan_designation": {
                    "original_text": "Treatment of recurrent corneal erosion unresponsive to conventional therapy.",
                    "umls_id": "C0155119",
                    "parsed_text": "Recurrent corneal erosion"
                }
            }
        ]
    },
    {
        "_id": "GJQPMPFPNINLKP-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3038,
                "inchl_key": "GJQPMPFPNINLKP-UHFFFAOYSA-N",
                "generic_name": "dichlorphenamide",
                "designated_date": "09/02/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of primary hyperkalemic periodic paralysis, primary hypokalemic period paralysis, and related variants",
                "marketing_approval_date": "\u00a008/07/2015\u00a0",
                "exclusivity_end_date": "\u00a008/07/2022\u00a0",
                "exclusivity_protected_indication": "Treatment of primary hyperkalemic periodic paralysis, primary hypokalemic period paralysis, and related variants",
                "sponsor": "Strongbridge US Inc.|900 Northbrook Drives|Suite 200|trevose|Pennsylvania|19053|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary periodic paralyses",
                    "umls_id": "C0522224",
                    "parsed_text": "Paralyses"
                }
            }
        ]
    },
    {
        "_id": "WYQPLTPSGFELIB-JTQPXKBDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 443936,
                "inchl_key": "WYQPLTPSGFELIB-JTQPXKBDSA-N",
                "generic_name": "difluprednate",
                "trade_name": "Durezol",
                "designated_date": "09/30/2008",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of endogenous anterior uveitis",
                "marketing_approval_date": "\u00a006/13/2012\u00a0",
                "exclusivity_end_date": "\u00a006/13/2019\u00a0",
                "sponsor": "Alcon Pharmaceuticals. Ltd.|Route Des Arsenaux 41|(P.O. Box 61)|Fribourg|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of endogenous and traumatic anterior uveitis and panuveitis.",
                    "umls_id": "C0030343,C4325554",
                    "parsed_text": "Panuveitis , Traumatic anterior uveitis"
                }
            }
        ]
    },
    {
        "_id": "GZSOSUNBTXMUFQ-YFAPSIMESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5281613,
                "inchl_key": "GZSOSUNBTXMUFQ-YFAPSIMESA-N",
                "generic_name": "diosmin",
                "designated_date": "05/15/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Primus Pharmaceuticals, Inc.|7373 North Scottsdale Road|Suite B-200|Scottsdale|Alaska|85253|United States",
                "orphan_designation": {
                    "original_text": "Treatment of systemic sclerosis",
                    "umls_id": "C0036421",
                    "parsed_text": "Systemic sclerosis"
                }
            }
        ]
    },
    {
        "_id": "DNUXJWBKTMJNEP-JVSLBXKQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 131842305,
                "inchl_key": "DNUXJWBKTMJNEP-JVSLBXKQSA-N",
                "generic_name": "Disaccharide tripeptide glycerol dipalmitoyl",
                "designated_date": "03/01/1990",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ImmunoTherapeutics, Inc.|3505 Riverview Circle|Moorhead|Minnesota|56560|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pulmonary and hepatic metastases in patients with colorectal adenocarcinoma.",
                    "umls_id": "C0494165,C1319315",
                    "parsed_text": "hepatic metastases , Colorectal Adenocarcinoma"
                }
            }
        ]
    },
    {
        "_id": "XWHPUCFOTRBMGS-UHFFFAOYSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 23724874,
                "inchl_key": "XWHPUCFOTRBMGS-UHFFFAOYSA-L",
                "generic_name": "Disodium clodronate tetrahydrate",
                "designated_date": "03/05/1990",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Anthra Pharmaceuticals, Inc.|103 Carnegie Center, Suite 102|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of increased bone resorption due to malignancy.",
                    "umls_id": "C0006826",
                    "parsed_text": "Malignancy"
                }
            }
        ]
    },
    {
        "_id": "VKDGNNYJFSHYKD-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 57004,
                "inchl_key": "VKDGNNYJFSHYKD-UHFFFAOYSA-N",
                "generic_name": "Eflornithine HCl",
                "designated_date": "04/18/1986",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Marion Merrell Dow, Inc.|P.O. Box 9627|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pneumocystis carinii pneumonia in AIDS patients.",
                    "umls_id": "C1535939",
                    "parsed_text": "Pneumocystis carinii Pneumonia"
                }
            },
            {
                "compound_id": 57004,
                "inchl_key": "VKDGNNYJFSHYKD-UHFFFAOYSA-N",
                "generic_name": "eflornithine HCL",
                "designated_date": "04/07/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cancer Prevention Pharmaceuticals, Inc.|1760 East River Road|Suite 250|Tucson|Alaska|85718|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastric cancer",
                    "umls_id": "C0024623",
                    "parsed_text": "Gastric Cancer"
                }
            },
            {
                "compound_id": 57004,
                "inchl_key": "VKDGNNYJFSHYKD-UHFFFAOYSA-N",
                "generic_name": "Eflornithine HCl",
                "trade_name": "Ornidyl",
                "designated_date": "04/23/1986",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a011/28/1990\u00a0",
                "exclusivity_end_date": "\u00a011/28/1997\u00a0",
                "sponsor": "Hoechst Marion Roussel|P.O. Box 9627|Kansas City|Missouri|64134|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Trypanosoma brucei gambiense infection (sleeping sickness).",
                    "umls_id": "C0009450,C0041218,C0041228",
                    "parsed_text": "Infection , Trypanosoma brucei gambiense , Sleeping sickness"
                }
            }
        ]
    },
    {
        "_id": "FLFGNMFWNBOBGE-FNNZEKJRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6438895,
                "inchl_key": "FLFGNMFWNBOBGE-FNNZEKJRSA-N",
                "generic_name": "elacytarabine",
                "designated_date": "06/18/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clavis Pharma ASA|Parkveien 53 B|Oslo|Norway",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia (AML)",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "WSEVKKHALHSUMB-RYVRVIGHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 129012199,
                "inchl_key": "WSEVKKHALHSUMB-RYVRVIGHSA-N",
                "generic_name": "exendin-(9-39)",
                "designated_date": "06/01/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "The Children's Hospital of Philadelphia|Children's Hospital of Phil. Research Institute|Abramson Research Center|Philadelphia|Pennsylvania|19104|United States",
                "orphan_designation": {
                    "original_text": "Treatment of congential hyperinsulinenic hypoglycemia and other causes of hyperinsulinemic hypoglycemia in adults and children",
                    "umls_id": "C0020615,C3888018",
                    "parsed_text": "Hypoglycemia , Hyperinsulinemic Hypoglycemia"
                }
            }
        ]
    },
    {
        "_id": "MVGSNCBCUWPVDA-MFOYZWKCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5472495,
                "inchl_key": "MVGSNCBCUWPVDA-MFOYZWKCSA-N",
                "generic_name": "Exisulind",
                "designated_date": "02/14/1994",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OSI Pharmaceuticals, Inc.|41 Pinelawn Road|Melville|New York|11747|United States",
                "orphan_designation": {
                    "original_text": "For the suppression and control of colonic adenomatous polyps in the inherited disease adenomatous polyposis coli.",
                    "umls_id": "C0032580,C0206677",
                    "parsed_text": "Adenomatous Polyposis Coli , Adenomatous Polyps"
                }
            }
        ]
    },
    {
        "_id": "GKDRMWXFWHEQQT-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11671467,
                "inchl_key": "GKDRMWXFWHEQQT-UHFFFAOYSA-N",
                "generic_name": "fostamatinib",
                "designated_date": "01/31/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rigel Pharmaceuticals, INc.|1180 Veterans Blvd|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of autoimmune hemolytic anemia (AIHA)",
                    "umls_id": "C0002880",
                    "parsed_text": "Autoimmune hemolytic anemia"
                }
            }
        ]
    },
    {
        "_id": "TZDUHAJSIBHXDL-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9883933,
                "inchl_key": "TZDUHAJSIBHXDL-UHFFFAOYSA-N",
                "generic_name": "gabapentin enacarbil",
                "trade_name": "Horizant",
                "designated_date": "06/07/2011",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Management of postherpetic neuralgia in adults.",
                "marketing_approval_date": "\u00a006/06/2012\u00a0",
                "exclusivity_end_date": "\u00a006/06/2019\u00a0",
                "sponsor": "Arbor Pharmaceuticals, LLC|6 Concourse Parkway|Suite 1800|Atlanta|Georgia|30328|United States",
                "orphan_designation": {
                    "original_text": "Treatment of postherpetic neuralgia",
                    "umls_id": "C0032768",
                    "parsed_text": "Postherpetic neuralgia"
                }
            }
        ]
    },
    {
        "_id": "YALNUENQHAQXEA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9804992,
                "inchl_key": "YALNUENQHAQXEA-UHFFFAOYSA-N",
                "generic_name": "Givinostat",
                "designated_date": "09/28/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Italfarmaco SpA|54 Via dei Lavoratori|Cinisello Balsamo|Lombardia|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of polycythemia vera (PV)",
                    "umls_id": "C0032463",
                    "parsed_text": "Polycythemia Vera"
                }
            },
            {
                "compound_id": 9804992,
                "inchl_key": "YALNUENQHAQXEA-UHFFFAOYSA-N",
                "generic_name": "givinostat",
                "designated_date": "04/12/2013",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Italfarmaco SpA|Via dei Lavoratori, 54|20092 Cinisello Balsamo|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy",
                    "umls_id": "C0013264,C0917713",
                    "parsed_text": "DUCHENNE MUSCULAR DYSTROPHY , Becker Muscular Dystrophy"
                }
            }
        ]
    },
    {
        "_id": "QBKSWRVVCFFDOT-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3503,
                "inchl_key": "QBKSWRVVCFFDOT-UHFFFAOYSA-N",
                "generic_name": "Gossypol",
                "designated_date": "10/22/1990",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Reidenberg, Marcus M. M.D.|The New York Hospital - Cornell Medical Center|525 East 68th Street, Box 70|New York|New York|10021|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cancer of the adrenal cortex.",
                    "umls_id": "C0206686",
                    "parsed_text": "cancer of the adrenal cortex"
                }
            }
        ]
    },
    {
        "_id": "GUWXKKAWLCENJA-WGWHJZDNSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135564655,
                "inchl_key": "GUWXKKAWLCENJA-WGWHJZDNSA-N",
                "generic_name": "guadecitabine",
                "designated_date": "09/29/2015",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Astex Pharmaceuticals, Inc.|4420 Rosewood Drive|Suite 200|Pleasanton|California|94588|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "AXSPHUWXYSZPBG-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 55361,
                "inchl_key": "AXSPHUWXYSZPBG-UHFFFAOYSA-N",
                "generic_name": "gusperimus trihydrochloride",
                "designated_date": "06/29/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Nordic Group B.V.|Siriusdreef 22|2132 WT Hoofdorp|Netherlands",
                "orphan_designation": {
                    "original_text": "Treatment of Wegener's granulomatosis",
                    "umls_id": "C3495801",
                    "parsed_text": "Wegener's Granulomatosis"
                }
            }
        ]
    },
    {
        "_id": "LVASCWIMLIKXLA-CABCVRRESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 456390,
                "inchl_key": "LVASCWIMLIKXLA-CABCVRRESA-N",
                "generic_name": "Halofuginone",
                "designated_date": "02/07/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Collgard Biopharmaceuticals Ltd.|Textile House, 2 Koifman St.|Tel-Aviv|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of systemic sclerosis.",
                    "umls_id": "C0036421",
                    "parsed_text": "Systemic sclerosis"
                }
            }
        ]
    },
    {
        "_id": "LVASCWIMLIKXLA-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 62894,
                "inchl_key": "LVASCWIMLIKXLA-UHFFFAOYSA-N",
                "generic_name": "Halofuginone",
                "designated_date": "02/07/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Collgard Biopharmaceuticals Ltd.|Textile House, 2 Koifman St.|Tel-Aviv|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of systemic sclerosis.",
                    "umls_id": "C0036421",
                    "parsed_text": "Systemic sclerosis"
                }
            }
        ]
    },
    {
        "_id": "LVASCWIMLIKXLA-LSDHHAIUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 400772,
                "inchl_key": "LVASCWIMLIKXLA-LSDHHAIUSA-N",
                "generic_name": "Halofuginone",
                "designated_date": "02/07/2000",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Collgard Biopharmaceuticals Ltd.|Textile House, 2 Koifman St.|Tel-Aviv|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of systemic sclerosis.",
                    "umls_id": "C0036421",
                    "parsed_text": "Systemic sclerosis"
                }
            }
        ]
    },
    {
        "_id": "DHZIAGCFFSRULK-UHFFFAOYSA-H",
        "Orphan Drug Designations": [
            {
                "compound_id": 91667962,
                "inchl_key": "DHZIAGCFFSRULK-UHFFFAOYSA-H",
                "generic_name": "hexasodium phytate",
                "designated_date": "12/02/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Laboratoris Sanifit, S.L.|Parc Bit - Building Disset - Office D3|07121 Palma de Mallorca|Spain",
                "orphan_designation": {
                    "original_text": "Treatment of calciphylaxis",
                    "umls_id": "C0006666",
                    "parsed_text": "Calciphylaxis"
                }
            }
        ]
    },
    {
        "_id": "HYFHYPWGAURHIV-PWNJXPRTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71296925,
                "inchl_key": "HYFHYPWGAURHIV-PWNJXPRTSA-N",
                "generic_name": "homoharringtonine",
                "designated_date": "02/08/2002",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "American BioScience, Inc.|2730 Wilshire Blvd. #110|Santa Monica|California|90403|United States",
                "orphan_designation": {
                    "original_text": "Treatment for chronic myelogenous leukemia",
                    "umls_id": "C0023473",
                    "parsed_text": "Chronic myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "HYFHYPWGAURHIV-RZCBTRPQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 56841046,
                "inchl_key": "HYFHYPWGAURHIV-RZCBTRPQSA-N",
                "generic_name": "homoharringtonine",
                "designated_date": "02/08/2002",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "American BioScience, Inc.|2730 Wilshire Blvd. #110|Santa Monica|California|90403|United States",
                "orphan_designation": {
                    "original_text": "Treatment for chronic myelogenous leukemia",
                    "umls_id": "C0023473",
                    "parsed_text": "Chronic myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "HYFHYPWGAURHIV-BRXDYEKISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5458297,
                "inchl_key": "HYFHYPWGAURHIV-BRXDYEKISA-N",
                "generic_name": "homoharringtonine",
                "designated_date": "02/08/2002",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "American BioScience, Inc.|2730 Wilshire Blvd. #110|Santa Monica|California|90403|United States",
                "orphan_designation": {
                    "original_text": "Treatment for chronic myelogenous leukemia",
                    "umls_id": "C0023473",
                    "parsed_text": "Chronic myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "HYFHYPWGAURHIV-JCNWCSDUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 45356872,
                "inchl_key": "HYFHYPWGAURHIV-JCNWCSDUSA-N",
                "generic_name": "homoharringtonine",
                "designated_date": "02/08/2002",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "American BioScience, Inc.|2730 Wilshire Blvd. #110|Santa Monica|California|90403|United States",
                "orphan_designation": {
                    "original_text": "Treatment for chronic myelogenous leukemia",
                    "umls_id": "C0023473",
                    "parsed_text": "Chronic myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "HYFHYPWGAURHIV-ZEDNPHJLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 72332,
                "inchl_key": "HYFHYPWGAURHIV-ZEDNPHJLSA-N",
                "generic_name": "homoharringtonine",
                "designated_date": "02/08/2002",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "American BioScience, Inc.|2730 Wilshire Blvd. #110|Santa Monica|California|90403|United States",
                "orphan_designation": {
                    "original_text": "Treatment for chronic myelogenous leukemia",
                    "umls_id": "C0023473",
                    "parsed_text": "Chronic myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "HYFHYPWGAURHIV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3628,
                "inchl_key": "HYFHYPWGAURHIV-UHFFFAOYSA-N",
                "generic_name": "homoharringtonine",
                "designated_date": "02/08/2002",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "American BioScience, Inc.|2730 Wilshire Blvd. #110|Santa Monica|California|90403|United States",
                "orphan_designation": {
                    "original_text": "Treatment for chronic myelogenous leukemia",
                    "umls_id": "C0023473",
                    "parsed_text": "Chronic myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "RPTUSVTUFVMDQK-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3637,
                "inchl_key": "RPTUSVTUFVMDQK-UHFFFAOYSA-N",
                "generic_name": "Hydralazine",
                "designated_date": "04/09/2004",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bioniche Pharma USA LLC|272 E. Deerpath Road|Suite 304|Lake Forest|Illinois|60045|United States",
                "orphan_designation": {
                    "original_text": "Treatment of severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure greater than or equal to 160) associated with severe preeclampsia/eclampsia of pregnancy",
                    "umls_id": "C0013537,C0341950,C1963138",
                    "parsed_text": "Eclampsia , Severe Preeclampsia , Hypertension"
                }
            }
        ]
    },
    {
        "_id": "KZIMLUFVKJLCCH-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9942657,
                "inchl_key": "KZIMLUFVKJLCCH-UHFFFAOYSA-N",
                "generic_name": "imidazolyl ethanamide pentandioic acid",
                "designated_date": "09/17/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Myelo Therapeutics GmbH|Rheinsberger Str. 7|Berlin|Berlin|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of Acute Radiation Syndrome",
                    "umls_id": "C0520799",
                    "parsed_text": "Acute Radiation Syndrome"
                }
            }
        ]
    },
    {
        "_id": "NMHJRGCKGFRFAQ-ZKFIMABGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 450505,
                "inchl_key": "NMHJRGCKGFRFAQ-ZKFIMABGSA-N",
                "generic_name": "Iobenguane Sulfate I 131",
                "designated_date": "11/14/1984",
                "designation_status": "Designated/Approved/Withdrawn",
                "approved_labeled_indication": "Adjunctive diagnostic agent in the localization of primary or metastatic pheochromocytomas.",
                "marketing_approval_date": "\u00a003/25/1994\u00a0",
                "exclusivity_end_date": "\u00a003/25/2001\u00a0",
                "sponsor": "University of Michigan|UH B1 H410/0028|1500 E. Medical Center Drive|Ann Arbor|Michigan|48109|United States",
                "orphan_designation": {
                    "original_text": "For use as a diagnostic adjunct in patients with pheochromocytoma.",
                    "umls_id": "C0031511",
                    "parsed_text": "Pheochromocytoma"
                }
            }
        ]
    },
    {
        "_id": "XNACDNPGABUBFR-GNPGNDBSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 76971242,
                "inchl_key": "XNACDNPGABUBFR-GNPGNDBSSA-N",
                "generic_name": "Iobenguane Sulfate I 131",
                "designated_date": "11/14/1984",
                "designation_status": "Designated/Approved/Withdrawn",
                "approved_labeled_indication": "Adjunctive diagnostic agent in the localization of primary or metastatic pheochromocytomas.",
                "marketing_approval_date": "\u00a003/25/1994\u00a0",
                "exclusivity_end_date": "\u00a003/25/2001\u00a0",
                "sponsor": "University of Michigan|UH B1 H410/0028|1500 E. Medical Center Drive|Ann Arbor|Michigan|48109|United States",
                "orphan_designation": {
                    "original_text": "For use as a diagnostic adjunct in patients with pheochromocytoma.",
                    "umls_id": "C0031511",
                    "parsed_text": "Pheochromocytoma"
                }
            }
        ]
    },
    {
        "_id": "GRZXWCHAXNAUHY-NSISKUIASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24788740,
                "inchl_key": "GRZXWCHAXNAUHY-NSISKUIASA-N",
                "generic_name": "Ipatasertib",
                "designated_date": "04/30/2014",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "For the treatment of gastric cancer including cancer of the gastro-esophageal junction.",
                    "umls_id": "C0024623",
                    "parsed_text": "Gastric Cancer"
                }
            }
        ]
    },
    {
        "_id": "XMAYWYJOQHXEEK-ZZHFZYNASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 73951506,
                "inchl_key": "XMAYWYJOQHXEEK-ZZHFZYNASA-N",
                "generic_name": "Ketoconazole",
                "designated_date": "03/27/1991",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmedic Company|28101 Ballard Road|Lake Forest|Illinois|60045|United States",
                "orphan_designation": {
                    "original_text": "For use with cyclosporine A to diminish the nephrotoxicity induced by cyclosporine in organ transplantation.",
                    "umls_id": "C0595916",
                    "parsed_text": "nephrotoxicity"
                }
            }
        ]
    },
    {
        "_id": "XMAYWYJOQHXEEK-ANWICMFUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16757695,
                "inchl_key": "XMAYWYJOQHXEEK-ANWICMFUSA-N",
                "generic_name": "Ketoconazole",
                "designated_date": "03/27/1991",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmedic Company|28101 Ballard Road|Lake Forest|Illinois|60045|United States",
                "orphan_designation": {
                    "original_text": "For use with cyclosporine A to diminish the nephrotoxicity induced by cyclosporine in organ transplantation.",
                    "umls_id": "C0595916",
                    "parsed_text": "nephrotoxicity"
                }
            }
        ]
    },
    {
        "_id": "XMAYWYJOQHXEEK-NASUQTAISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5702077,
                "inchl_key": "XMAYWYJOQHXEEK-NASUQTAISA-N",
                "generic_name": "Ketoconazole",
                "designated_date": "03/27/1991",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmedic Company|28101 Ballard Road|Lake Forest|Illinois|60045|United States",
                "orphan_designation": {
                    "original_text": "For use with cyclosporine A to diminish the nephrotoxicity induced by cyclosporine in organ transplantation.",
                    "umls_id": "C0595916",
                    "parsed_text": "nephrotoxicity"
                }
            }
        ]
    },
    {
        "_id": "XMAYWYJOQHXEEK-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3823,
                "inchl_key": "XMAYWYJOQHXEEK-UHFFFAOYSA-N",
                "generic_name": "Ketoconazole",
                "designated_date": "03/27/1991",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmedic Company|28101 Ballard Road|Lake Forest|Illinois|60045|United States",
                "orphan_designation": {
                    "original_text": "For use with cyclosporine A to diminish the nephrotoxicity induced by cyclosporine in organ transplantation.",
                    "umls_id": "C0595916",
                    "parsed_text": "nephrotoxicity"
                }
            }
        ]
    },
    {
        "_id": "XMAYWYJOQHXEEK-OZXSUGGESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 456201,
                "inchl_key": "XMAYWYJOQHXEEK-OZXSUGGESA-N",
                "generic_name": "Ketoconazole",
                "designated_date": "03/27/1991",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pharmedic Company|28101 Ballard Road|Lake Forest|Illinois|60045|United States",
                "orphan_designation": {
                    "original_text": "For use with cyclosporine A to diminish the nephrotoxicity induced by cyclosporine in organ transplantation.",
                    "umls_id": "C0595916",
                    "parsed_text": "nephrotoxicity"
                }
            }
        ]
    },
    {
        "_id": "LDCYZAJDBXYCGN-VIFPVBQESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 439280,
                "inchl_key": "LDCYZAJDBXYCGN-VIFPVBQESA-N",
                "generic_name": "L-5-hydroxytryptophan",
                "designated_date": "01/20/1999",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Watson Laboratories, Inc.|311 Bonnie Circle|P.O. Box 1900|Corona|California|91718|United States",
                "orphan_designation": {
                    "original_text": "Treatment of tetrahydrobiopterin deficiency.",
                    "umls_id": "C0751436",
                    "parsed_text": "Tetrahydrobiopterin Deficiency"
                }
            }
        ]
    },
    {
        "_id": "FIBJDTSHOUXTKV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 139600825,
                "inchl_key": "FIBJDTSHOUXTKV-UHFFFAOYSA-N",
                "generic_name": "Lepirudin",
                "trade_name": "Refluden",
                "designated_date": "02/13/1997",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For anticoagulation in patients with heparin-induced thrombocytopenia and associated thromboembolic disease in order to prevent further thromboembolic complications.",
                "marketing_approval_date": "\u00a003/06/1998\u00a0",
                "exclusivity_end_date": "\u00a003/06/2005\u00a0",
                "sponsor": "Hoechst Marion Roussel|Frankfurt am Main|P.O. Box 1140|Marburg|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of heparin-associated thrombocytopenia type II.",
                    "umls_id": "C0040034",
                    "parsed_text": "Thrombocytopenia"
                }
            }
        ]
    },
    {
        "_id": "FIBJDTSHOUXTKV-BRHMIFOHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 118856773,
                "inchl_key": "FIBJDTSHOUXTKV-BRHMIFOHSA-N",
                "generic_name": "Lepirudin",
                "trade_name": "Refluden",
                "designated_date": "02/13/1997",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For anticoagulation in patients with heparin-induced thrombocytopenia and associated thromboembolic disease in order to prevent further thromboembolic complications.",
                "marketing_approval_date": "\u00a003/06/1998\u00a0",
                "exclusivity_end_date": "\u00a003/06/2005\u00a0",
                "sponsor": "Hoechst Marion Roussel|Frankfurt am Main|P.O. Box 1140|Marburg|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of heparin-associated thrombocytopenia type II.",
                    "umls_id": "C0040034",
                    "parsed_text": "Thrombocytopenia"
                }
            }
        ]
    },
    {
        "_id": "VVIAGPKUTFNRDU-ABLWVSNPSA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 135823198,
                "inchl_key": "VVIAGPKUTFNRDU-ABLWVSNPSA-L",
                "generic_name": "Leucovorin calcium",
                "designated_date": "06/23/1988",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Glaxo Wellcome Research and Development|5 Moore Drive|PO Box 13398|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.",
                    "umls_id": "C4721579",
                    "parsed_text": "Metastatic colorectal cancer"
                }
            }
        ]
    },
    {
        "_id": "KVUAALJSMIVURS-ZEDZUCNESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135436482,
                "inchl_key": "KVUAALJSMIVURS-ZEDZUCNESA-N",
                "generic_name": "Leucovorin calcium",
                "designated_date": "06/23/1988",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Glaxo Wellcome Research and Development|5 Moore Drive|PO Box 13398|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.",
                    "umls_id": "C4721579",
                    "parsed_text": "Metastatic colorectal cancer"
                }
            }
        ]
    },
    {
        "_id": "DZNHRKNLTYYMQA-ZIGBGYJWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135738681,
                "inchl_key": "DZNHRKNLTYYMQA-ZIGBGYJWSA-N",
                "generic_name": "Leucovorin calcium",
                "designated_date": "06/23/1988",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Glaxo Wellcome Research and Development|5 Moore Drive|PO Box 13398|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.",
                    "umls_id": "C4721579",
                    "parsed_text": "Metastatic colorectal cancer"
                }
            }
        ]
    },
    {
        "_id": "KVUAALJSMIVURS-ZEDZUCNESA-L",
        "Orphan Drug Designations": [
            {
                "compound_id": 135883785,
                "inchl_key": "KVUAALJSMIVURS-ZEDZUCNESA-L",
                "generic_name": "Leucovorin calcium",
                "designated_date": "06/23/1988",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Glaxo Wellcome Research and Development|5 Moore Drive|PO Box 13398|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.",
                    "umls_id": "C4721579",
                    "parsed_text": "Metastatic colorectal cancer"
                }
            },
            {
                "compound_id": 135883785,
                "inchl_key": "KVUAALJSMIVURS-ZEDZUCNESA-L",
                "generic_name": "Leucovorin calcium",
                "designated_date": "06/23/1988",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Glaxo Wellcome Research and Development|5 Moore Drive|PO Box 13398|Research Triangle Park|North Carolina|27709|United States",
                "orphan_designation": {
                    "original_text": "For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.",
                    "umls_id": "C4721579",
                    "parsed_text": "Metastatic colorectal cancer"
                }
            }
        ]
    },
    {
        "_id": "CZGVOBIGEBDYTP-VSGBNLITSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 53492727,
                "inchl_key": "CZGVOBIGEBDYTP-VSGBNLITSA-N",
                "generic_name": "linerixibat",
                "designated_date": "09/18/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "GlaxoSmithKline|1250 South Collegeville Road|Building 4, Mail Stop 4400|Collegeville|Pennsylvania|19426|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Primary Biliary Cholangitis",
                    "umls_id": "C0008312",
                    "parsed_text": "Primary Biliary Cholangitis"
                }
            }
        ]
    },
    {
        "_id": "VDCRFBBZFHHYGT-IOSLPCCCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135410906,
                "inchl_key": "VDCRFBBZFHHYGT-IOSLPCCCSA-N",
                "generic_name": "Loxoribine",
                "designated_date": "02/24/1992",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "R. W. Johnson Pharmaceutical Research Institute|Route 202, P.O. Box 300|Raritan|New Jersey|8869|United States",
                "orphan_designation": {
                    "original_text": "Treatment of common variable immunodeficiency.",
                    "umls_id": "C2936664",
                    "parsed_text": "Common Variable Immunodeficiency"
                }
            }
        ]
    },
    {
        "_id": "PBUUPFTVAPUWDE-HSLMEMBISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5362269,
                "inchl_key": "PBUUPFTVAPUWDE-HSLMEMBISA-N",
                "generic_name": "Mafosfamide",
                "designated_date": "01/21/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Baxter Healthcare Corporation|Route 120 & Wilson Road|Round Lake|Illinois|60073|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neoplastic meningitis",
                    "umls_id": "C0220654",
                    "parsed_text": "neoplastic meningitis"
                }
            }
        ]
    },
    {
        "_id": "PBUUPFTVAPUWDE-UGZDLDLSSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 76968809,
                "inchl_key": "PBUUPFTVAPUWDE-UGZDLDLSSA-N",
                "generic_name": "Mafosfamide",
                "designated_date": "01/21/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Baxter Healthcare Corporation|Route 120 & Wilson Road|Round Lake|Illinois|60073|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neoplastic meningitis",
                    "umls_id": "C0220654",
                    "parsed_text": "neoplastic meningitis"
                }
            }
        ]
    },
    {
        "_id": "PBUUPFTVAPUWDE-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 104746,
                "inchl_key": "PBUUPFTVAPUWDE-UHFFFAOYSA-N",
                "generic_name": "Mafosfamide",
                "designated_date": "01/21/2003",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Baxter Healthcare Corporation|Route 120 & Wilson Road|Round Lake|Illinois|60073|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neoplastic meningitis",
                    "umls_id": "C0220654",
                    "parsed_text": "neoplastic meningitis"
                }
            }
        ]
    },
    {
        "_id": "OPXLLQIJSORQAM-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4030,
                "inchl_key": "OPXLLQIJSORQAM-UHFFFAOYSA-N",
                "generic_name": "mebendazole",
                "trade_name": "VERMOX 500 mg chewable tablets",
                "designated_date": "09/03/2014",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of patients one year of age and older withgastrointestinal infections caused by Ascaris lumbricoides (roundworm) and Trichuris trichiura (whipworm)",
                "marketing_approval_date": "\u00a010/19/2016\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Janssen Pharmaceutical Research & Development, LLC|920 Route 202 South|Raritan|New Jersey|8869|United States",
                "orphan_designation": {
                    "original_text": "Treatment of single or mixed gastrointestinal infestations by Trichuris trichiura (whipworm), Ascaris lumbricoides (large roundworm), and Ancylostoma duodenale and Nectar americanus (hookworm).",
                    "umls_id": "C0040954",
                    "parsed_text": "whipworm"
                }
            }
        ]
    },
    {
        "_id": "YQZNKYXGZSVEHI-VXKWHMMOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9935639,
                "inchl_key": "YQZNKYXGZSVEHI-VXKWHMMOSA-N",
                "generic_name": "melphalan flufenamide",
                "trade_name": "Pepaxto",
                "designated_date": "03/16/2015",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment (in combination with dexamethasone) of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38 directed monoclonal antibody.",
                "marketing_approval_date": "\u00a002/26/2021\u00a0",
                "exclusivity_end_date": "\u00a0\u00a0",
                "sponsor": "Oncopeptides AB|Vastra Tradgardsgatan 15|Stockholm|Sweden",
                "orphan_designation": {
                    "original_text": "Treatment of plasma cell myeloma, also referred to as multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Plasma cell myeloma"
                }
            }
        ]
    },
    {
        "_id": "DMJNNHOOLUXYBV-PQTSNVLCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 441130,
                "inchl_key": "DMJNNHOOLUXYBV-PQTSNVLCSA-N",
                "generic_name": "Meropenem",
                "designated_date": "04/27/2000",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AstraZeneca Pharmaceuticals|1800 Concord Pike|PO Box 15437|Wilmington|Delaware|19850|United States",
                "orphan_designation": {
                    "original_text": "Management of acute pulmonary exacerbations, in cystic fibrosis patients, due to respiratory tract infection with susceptible organisms.",
                    "umls_id": "C0010674,C0035243",
                    "parsed_text": "Cystic Fibrosis , Respiratory Tract Infection"
                }
            }
        ]
    },
    {
        "_id": "BMGQWWVMWDBQGC-IIFHNQTCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9829523,
                "inchl_key": "BMGQWWVMWDBQGC-IIFHNQTCSA-N",
                "generic_name": "midostaurin",
                "trade_name": "Rydapt",
                "designated_date": "07/07/2009",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.",
                "marketing_approval_date": "\u00a004/28/2017\u00a0",
                "exclusivity_end_date": "\u00a004/28/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza, 105/3W038|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "compound_id": 9829523,
                "inchl_key": "BMGQWWVMWDBQGC-IIFHNQTCSA-N",
                "generic_name": "midostaurin",
                "trade_name": "Rydapt",
                "designated_date": "04/30/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL)",
                "marketing_approval_date": "\u00a004/28/2017\u00a0",
                "exclusivity_end_date": "\u00a004/28/2024\u00a0",
                "exclusivity_protected_indication": "Treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL)",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza, 105/3W038|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mastocytosis",
                    "umls_id": "C0024899",
                    "parsed_text": "Mastocytosis"
                }
            }
        ]
    },
    {
        "_id": "PZRHRDRVRGEVNW-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4197,
                "inchl_key": "PZRHRDRVRGEVNW-UHFFFAOYSA-N",
                "generic_name": "milrinone",
                "designated_date": "01/08/2018",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Baker Heart and Diabetes Institute|75 Commercial Road|PO Box 6492|Melbourne|Victoria|3004|Australia",
                "orphan_designation": {
                    "original_text": "Treatment of right heart failure (RHF) in left ventricular assist device (LVAD) patients",
                    "umls_id": "C0235527",
                    "parsed_text": "Right heart failure"
                }
            }
        ]
    },
    {
        "_id": "ABASMUXUCSQFKC-PKEKLUKKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 121490254,
                "inchl_key": "ABASMUXUCSQFKC-PKEKLUKKSA-N",
                "generic_name": "mongersen",
                "designated_date": "07/20/2015",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Crohn's disease",
                    "umls_id": "C2931133",
                    "parsed_text": "Pediatric Crohn's disease"
                }
            }
        ]
    },
    {
        "_id": "GHBFNMLVSPCDGN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3033877,
                "inchl_key": "GHBFNMLVSPCDGN-UHFFFAOYSA-N",
                "generic_name": "Monooctanoin",
                "trade_name": "Moctanin",
                "designated_date": "05/30/1984",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "\u00a010/31/1985\u00a0",
                "exclusivity_end_date": "\u00a010/31/1992\u00a0",
                "sponsor": "Ethitek Pharmaceuticals, Inc.|7855 Gross Point Road, Unit L|Skokie|Illinois|60077|United States",
                "orphan_designation": {
                    "original_text": "For dissolution of cholesterol gallstones retained in the common bile duct.",
                    "umls_id": "C0856727",
                    "parsed_text": "Cholesterol gallstones"
                }
            }
        ]
    },
    {
        "_id": "YZBLFMPOMVTDJY-JLOCULIASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 154825546,
                "inchl_key": "YZBLFMPOMVTDJY-JLOCULIASA-N",
                "generic_name": "moxidectin",
                "designated_date": "09/29/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "marketing_approval_date": "\u00a006/13/2018\u00a0",
                "exclusivity_end_date": "\u00a006/13/2025\u00a0",
                "exclusivity_protected_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "sponsor": "Medicines Development Limited|Level 1, 18 Kevanagh Street|Southbank VIC 3006|Melbourne|Australia",
                "orphan_designation": {
                    "original_text": "Treatment of onchocerciasis volvulus in children and adults",
                    "umls_id": "C0029001,C0042961",
                    "parsed_text": "Onchocerciasis , Volvulus"
                }
            }
        ]
    },
    {
        "_id": "YZBLFMPOMVTDJY-HFVHDGGLSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 153640463,
                "inchl_key": "YZBLFMPOMVTDJY-HFVHDGGLSA-N",
                "generic_name": "moxidectin",
                "designated_date": "09/29/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "marketing_approval_date": "\u00a006/13/2018\u00a0",
                "exclusivity_end_date": "\u00a006/13/2025\u00a0",
                "exclusivity_protected_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "sponsor": "Medicines Development Limited|Level 1, 18 Kevanagh Street|Southbank VIC 3006|Melbourne|Australia",
                "orphan_designation": {
                    "original_text": "Treatment of onchocerciasis volvulus in children and adults",
                    "umls_id": "C0029001,C0042961",
                    "parsed_text": "Onchocerciasis , Volvulus"
                }
            }
        ]
    },
    {
        "_id": "YZBLFMPOMVTDJY-IRFODQMOSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 131954608,
                "inchl_key": "YZBLFMPOMVTDJY-IRFODQMOSA-N",
                "generic_name": "moxidectin",
                "designated_date": "09/29/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "marketing_approval_date": "\u00a006/13/2018\u00a0",
                "exclusivity_end_date": "\u00a006/13/2025\u00a0",
                "exclusivity_protected_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "sponsor": "Medicines Development Limited|Level 1, 18 Kevanagh Street|Southbank VIC 3006|Melbourne|Australia",
                "orphan_designation": {
                    "original_text": "Treatment of onchocerciasis volvulus in children and adults",
                    "umls_id": "C0029001,C0042961",
                    "parsed_text": "Onchocerciasis , Volvulus"
                }
            }
        ]
    },
    {
        "_id": "YZBLFMPOMVTDJY-LRWNSQJFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 139031013,
                "inchl_key": "YZBLFMPOMVTDJY-LRWNSQJFSA-N",
                "generic_name": "moxidectin",
                "designated_date": "09/29/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "marketing_approval_date": "\u00a006/13/2018\u00a0",
                "exclusivity_end_date": "\u00a006/13/2025\u00a0",
                "exclusivity_protected_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "sponsor": "Medicines Development Limited|Level 1, 18 Kevanagh Street|Southbank VIC 3006|Melbourne|Australia",
                "orphan_designation": {
                    "original_text": "Treatment of onchocerciasis volvulus in children and adults",
                    "umls_id": "C0029001,C0042961",
                    "parsed_text": "Onchocerciasis , Volvulus"
                }
            }
        ]
    },
    {
        "_id": "YZBLFMPOMVTDJY-XHQXRQCGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 91885488,
                "inchl_key": "YZBLFMPOMVTDJY-XHQXRQCGSA-N",
                "generic_name": "moxidectin",
                "designated_date": "09/29/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "marketing_approval_date": "\u00a006/13/2018\u00a0",
                "exclusivity_end_date": "\u00a006/13/2025\u00a0",
                "exclusivity_protected_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "sponsor": "Medicines Development Limited|Level 1, 18 Kevanagh Street|Southbank VIC 3006|Melbourne|Australia",
                "orphan_designation": {
                    "original_text": "Treatment of onchocerciasis volvulus in children and adults",
                    "umls_id": "C0029001,C0042961",
                    "parsed_text": "Onchocerciasis , Volvulus"
                }
            }
        ]
    },
    {
        "_id": "YZBLFMPOMVTDJY-AMFIFCOJSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 86287400,
                "inchl_key": "YZBLFMPOMVTDJY-AMFIFCOJSA-N",
                "generic_name": "moxidectin",
                "designated_date": "09/29/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "marketing_approval_date": "\u00a006/13/2018\u00a0",
                "exclusivity_end_date": "\u00a006/13/2025\u00a0",
                "exclusivity_protected_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "sponsor": "Medicines Development Limited|Level 1, 18 Kevanagh Street|Southbank VIC 3006|Melbourne|Australia",
                "orphan_designation": {
                    "original_text": "Treatment of onchocerciasis volvulus in children and adults",
                    "umls_id": "C0029001,C0042961",
                    "parsed_text": "Onchocerciasis , Volvulus"
                }
            }
        ]
    },
    {
        "_id": "YZBLFMPOMVTDJY-UBOCAARVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9604461,
                "inchl_key": "YZBLFMPOMVTDJY-UBOCAARVSA-N",
                "generic_name": "moxidectin",
                "designated_date": "09/29/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "marketing_approval_date": "\u00a006/13/2018\u00a0",
                "exclusivity_end_date": "\u00a006/13/2025\u00a0",
                "exclusivity_protected_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "sponsor": "Medicines Development Limited|Level 1, 18 Kevanagh Street|Southbank VIC 3006|Melbourne|Australia",
                "orphan_designation": {
                    "original_text": "Treatment of onchocerciasis volvulus in children and adults",
                    "umls_id": "C0029001,C0042961",
                    "parsed_text": "Onchocerciasis , Volvulus"
                }
            }
        ]
    },
    {
        "_id": "YZBLFMPOMVTDJY-KAAHEXRMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 137701808,
                "inchl_key": "YZBLFMPOMVTDJY-KAAHEXRMSA-N",
                "generic_name": "moxidectin",
                "designated_date": "09/29/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "marketing_approval_date": "\u00a006/13/2018\u00a0",
                "exclusivity_end_date": "\u00a006/13/2025\u00a0",
                "exclusivity_protected_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "sponsor": "Medicines Development Limited|Level 1, 18 Kevanagh Street|Southbank VIC 3006|Melbourne|Australia",
                "orphan_designation": {
                    "original_text": "Treatment of onchocerciasis volvulus in children and adults",
                    "umls_id": "C0029001,C0042961",
                    "parsed_text": "Onchocerciasis , Volvulus"
                }
            }
        ]
    },
    {
        "_id": "YZBLFMPOMVTDJY-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 72728820,
                "inchl_key": "YZBLFMPOMVTDJY-UHFFFAOYSA-N",
                "generic_name": "moxidectin",
                "designated_date": "09/29/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "marketing_approval_date": "\u00a006/13/2018\u00a0",
                "exclusivity_end_date": "\u00a006/13/2025\u00a0",
                "exclusivity_protected_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "sponsor": "Medicines Development Limited|Level 1, 18 Kevanagh Street|Southbank VIC 3006|Melbourne|Australia",
                "orphan_designation": {
                    "original_text": "Treatment of onchocerciasis volvulus in children and adults",
                    "umls_id": "C0029001,C0042961",
                    "parsed_text": "Onchocerciasis , Volvulus"
                }
            }
        ]
    },
    {
        "_id": "YZBLFMPOMVTDJY-RWJZGKSFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71312368,
                "inchl_key": "YZBLFMPOMVTDJY-RWJZGKSFSA-N",
                "generic_name": "moxidectin",
                "designated_date": "09/29/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "marketing_approval_date": "\u00a006/13/2018\u00a0",
                "exclusivity_end_date": "\u00a006/13/2025\u00a0",
                "exclusivity_protected_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "sponsor": "Medicines Development Limited|Level 1, 18 Kevanagh Street|Southbank VIC 3006|Melbourne|Australia",
                "orphan_designation": {
                    "original_text": "Treatment of onchocerciasis volvulus in children and adults",
                    "umls_id": "C0029001,C0042961",
                    "parsed_text": "Onchocerciasis , Volvulus"
                }
            }
        ]
    },
    {
        "_id": "YZBLFMPOMVTDJY-DSNUORPKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6436009,
                "inchl_key": "YZBLFMPOMVTDJY-DSNUORPKSA-N",
                "generic_name": "moxidectin",
                "designated_date": "09/29/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "marketing_approval_date": "\u00a006/13/2018\u00a0",
                "exclusivity_end_date": "\u00a006/13/2025\u00a0",
                "exclusivity_protected_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "sponsor": "Medicines Development Limited|Level 1, 18 Kevanagh Street|Southbank VIC 3006|Melbourne|Australia",
                "orphan_designation": {
                    "original_text": "Treatment of onchocerciasis volvulus in children and adults",
                    "umls_id": "C0029001,C0042961",
                    "parsed_text": "Onchocerciasis , Volvulus"
                }
            }
        ]
    },
    {
        "_id": "YZBLFMPOMVTDJY-BFPKLJSTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9571036,
                "inchl_key": "YZBLFMPOMVTDJY-BFPKLJSTSA-N",
                "generic_name": "moxidectin",
                "designated_date": "09/29/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "marketing_approval_date": "\u00a006/13/2018\u00a0",
                "exclusivity_end_date": "\u00a006/13/2025\u00a0",
                "exclusivity_protected_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "sponsor": "Medicines Development Limited|Level 1, 18 Kevanagh Street|Southbank VIC 3006|Melbourne|Australia",
                "orphan_designation": {
                    "original_text": "Treatment of onchocerciasis volvulus in children and adults",
                    "umls_id": "C0029001,C0042961",
                    "parsed_text": "Onchocerciasis , Volvulus"
                }
            }
        ]
    },
    {
        "_id": "YZBLFMPOMVTDJY-CBYMMZEQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16760141,
                "inchl_key": "YZBLFMPOMVTDJY-CBYMMZEQSA-N",
                "generic_name": "moxidectin",
                "designated_date": "09/29/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "marketing_approval_date": "\u00a006/13/2018\u00a0",
                "exclusivity_end_date": "\u00a006/13/2025\u00a0",
                "exclusivity_protected_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "sponsor": "Medicines Development Limited|Level 1, 18 Kevanagh Street|Southbank VIC 3006|Melbourne|Australia",
                "orphan_designation": {
                    "original_text": "Treatment of onchocerciasis volvulus in children and adults",
                    "umls_id": "C0029001,C0042961",
                    "parsed_text": "Onchocerciasis , Volvulus"
                }
            }
        ]
    },
    {
        "_id": "YZBLFMPOMVTDJY-LSGXYNIPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9832912,
                "inchl_key": "YZBLFMPOMVTDJY-LSGXYNIPSA-N",
                "generic_name": "moxidectin",
                "designated_date": "09/29/2010",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "marketing_approval_date": "\u00a006/13/2018\u00a0",
                "exclusivity_end_date": "\u00a006/13/2025\u00a0",
                "exclusivity_protected_indication": "Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older",
                "sponsor": "Medicines Development Limited|Level 1, 18 Kevanagh Street|Southbank VIC 3006|Melbourne|Australia",
                "orphan_designation": {
                    "original_text": "Treatment of onchocerciasis volvulus in children and adults",
                    "umls_id": "C0029001,C0042961",
                    "parsed_text": "Onchocerciasis , Volvulus"
                }
            }
        ]
    },
    {
        "_id": "CDAISMWEOUEBRE-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 892,
                "inchl_key": "CDAISMWEOUEBRE-UHFFFAOYSA-N",
                "generic_name": "myo-inositol",
                "designated_date": "04/07/2005",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Abbott Nutrition|Abbott Laboratories|625 Cleveland Ave.|Columbus|Ohio|43215|United States",
                "orphan_designation": {
                    "original_text": "Prevention of retinopathy of prematurity in preterm infants at risk for developing retinopathy of prematurity",
                    "umls_id": "C0035344",
                    "parsed_text": "Retinopathy of Prematurity"
                }
            }
        ]
    },
    {
        "_id": "OVRNDRQMDRJTHS-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 899,
                "inchl_key": "OVRNDRQMDRJTHS-UHFFFAOYSA-N",
                "generic_name": "N-Acetylglucosamine",
                "designated_date": "09/23/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Wellesley Therapeutics, Inc.|200 Gerrard St., East|Toronto|Ontario|M5A 2E6|Canada",
                "orphan_designation": {
                    "original_text": "Treatment for Duchenne Muscular Dystrophy",
                    "umls_id": "C0013264",
                    "parsed_text": "DUCHENNE MUSCULAR DYSTROPHY"
                }
            }
        ]
    },
    {
        "_id": "OVRNDRQMDRJTHS-RTRLPJTCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 439174,
                "inchl_key": "OVRNDRQMDRJTHS-RTRLPJTCSA-N",
                "generic_name": "N-Acetylglucosamine",
                "designated_date": "09/23/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Wellesley Therapeutics, Inc.|200 Gerrard St., East|Toronto|Ontario|M5A 2E6|Canada",
                "orphan_designation": {
                    "original_text": "Treatment for Duchenne Muscular Dystrophy",
                    "umls_id": "C0013264",
                    "parsed_text": "DUCHENNE MUSCULAR DYSTROPHY"
                }
            }
        ]
    },
    {
        "_id": "OVRNDRQMDRJTHS-FMDGEEDCSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 24139,
                "inchl_key": "OVRNDRQMDRJTHS-FMDGEEDCSA-N",
                "generic_name": "N-Acetylglucosamine",
                "designated_date": "09/23/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Wellesley Therapeutics, Inc.|200 Gerrard St., East|Toronto|Ontario|M5A 2E6|Canada",
                "orphan_designation": {
                    "original_text": "Treatment for Duchenne Muscular Dystrophy",
                    "umls_id": "C0013264",
                    "parsed_text": "DUCHENNE MUSCULAR DYSTROPHY"
                }
            }
        ]
    },
    {
        "_id": "ACPCMBPQKQTAQY-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 67027333,
                "inchl_key": "ACPCMBPQKQTAQY-UHFFFAOYSA-N",
                "generic_name": "N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea",
                "designated_date": "10/23/2007",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AbbVie, Inc.|1 N. Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelogenous leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "MQQNFDZXWVTQEH-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4413,
                "inchl_key": "MQQNFDZXWVTQEH-UHFFFAOYSA-N",
                "generic_name": "Nafamostat",
                "designated_date": "05/11/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenefly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "UZHSEJADLWPNLE-GRGSLBFTSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5284596,
                "inchl_key": "UZHSEJADLWPNLE-GRGSLBFTSA-N",
                "generic_name": "naloxone",
                "designated_date": "11/23/2010",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Elorac, Inc.|100 Fairway Drive|Vernon Hills|Illinois|60061|United States",
                "orphan_designation": {
                    "original_text": "Topical treatment of pruritus associated with mycosis fungoides",
                    "umls_id": "C0026948,C0033774",
                    "parsed_text": "Mycosis Fungoides , Pruritus"
                }
            }
        ]
    },
    {
        "_id": "QAGYKUNXZHXKMR-HKWSIXNMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 64143,
                "inchl_key": "QAGYKUNXZHXKMR-HKWSIXNMSA-N",
                "generic_name": "nelfinavir",
                "designated_date": "02/14/2017",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Swiss Group for Clinical Cancer Research (SAKK)|Effingerstrasse 33|Bern|Bern|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls_id": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "JLEBZPBDRKPWTD-TURQNECASA-O",
        "Orphan Drug Designations": [
            {
                "compound_id": 439924,
                "inchl_key": "JLEBZPBDRKPWTD-TURQNECASA-O",
                "generic_name": "nicotinamide riboside",
                "designated_date": "01/25/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Rejuvenation Therapeutics|774 Mays Boulevard|10-509 PMB|Incline Village|Nevada|89451|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome (MELAS)",
                    "umls_id": "C0001125,C0039082,C0162671,C1852373,C1857287",
                    "parsed_text": "LACTIC ACIDOSIS , Syndrome , MELAS , Mitochondrial encephalopathy , Stroke-like episodes"
                }
            }
        ]
    },
    {
        "_id": "AKNNEGZIBPJZJG-MSOLQXFVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 275196,
                "inchl_key": "AKNNEGZIBPJZJG-MSOLQXFVSA-N",
                "generic_name": "noscapine",
                "designated_date": "12/29/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "KineMed Inc.|5980 Horton Street|Suite 470|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis.",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "TZKBVRDEOITLRB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 51038269,
                "inchl_key": "TZKBVRDEOITLRB-UHFFFAOYSA-N",
                "generic_name": "olverembatinib",
                "designated_date": "04/22/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ascentage Pharma Group Inc.|800 King Farm Blvd., Suite 300|Rockville|Maryland|20850|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic myeloid leukemia",
                    "umls_id": "C0023473",
                    "parsed_text": "Chronic myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "MZPVEMOYADUARK-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 91667513,
                "inchl_key": "MZPVEMOYADUARK-UHFFFAOYSA-N",
                "generic_name": "Orelabrutinib",
                "designated_date": "12/30/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "InnoCare Pharma Inc.|103 Carnegie Center, Suite 209|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Mantle Cell Lymphoma",
                    "umls_id": "C4721414",
                    "parsed_text": "Mantle cell lymphoma"
                }
            }
        ]
    },
    {
        "_id": "UQCNKQCJZOAFTQ-ISWURRPUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5284604,
                "inchl_key": "UQCNKQCJZOAFTQ-ISWURRPUSA-N",
                "generic_name": "Oxymorphone",
                "designated_date": "03/19/1985",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "DuPont Merck Pharmaceutical Company|P.O. Box 80027|Wilmington|Delaware|19880|United States",
                "orphan_designation": {
                    "original_text": "For relief of severe intractable pain in narcotic-tolerant patients.",
                    "umls_id": "C0030200",
                    "parsed_text": "intractable pain"
                }
            }
        ]
    },
    {
        "_id": "NPOCDVAOUKODSQ-ZDUSSCGKSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 86278362,
                "inchl_key": "NPOCDVAOUKODSQ-ZDUSSCGKSA-N",
                "generic_name": "pegvaliase-pqpz",
                "trade_name": "PALYNZIQ",
                "designated_date": "03/08/1995",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Palynziq is indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management",
                "marketing_approval_date": "\u00a005/24/2018\u00a0",
                "exclusivity_end_date": "\u00a005/24/2025\u00a0",
                "exclusivity_protected_indication": "Palynziq is indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management",
                "sponsor": "BioMarin Pharmaceutical Inc.|105 Digital Drive|Novato|California|94949|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hyperphenylalaninemia",
                    "umls_id": "C0751435",
                    "parsed_text": "Hyperphenylalaninemia"
                }
            }
        ]
    },
    {
        "_id": "YEHCICAEULNIGD-MZMPZRCHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 47811,
                "inchl_key": "YEHCICAEULNIGD-MZMPZRCHSA-N",
                "generic_name": "Pergolide",
                "designated_date": "11/20/1997",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sallee, Floyd R. M.D., Ph.D.|Cincinnati Children's Hospital Medical Center|3333 Burnet Ave.|Cincinnati|Ohio|45229|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Tourette's syndrome.",
                    "umls_id": "C0040517",
                    "parsed_text": "Tourette's Syndrome"
                }
            }
        ]
    },
    {
        "_id": "JDZOTSLZMQDFLG-BTJKTKAUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5284439,
                "inchl_key": "JDZOTSLZMQDFLG-BTJKTKAUSA-N",
                "generic_name": "perhexiline maleate",
                "designated_date": "06/14/2012",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Heart Metabolics, Limited.|88 Harcourt Street|Dublin|Ireland",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe symptomatic hypertrophic cardiomyopathy",
                    "umls_id": "C0007194",
                    "parsed_text": "Hypertrophic Cardiomyopathy"
                }
            }
        ]
    },
    {
        "_id": "KQOXLKOJHVFTRN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 1684,
                "inchl_key": "KQOXLKOJHVFTRN-UHFFFAOYSA-N",
                "generic_name": "pleconaril",
                "designated_date": "12/22/2014",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NES Therapeutics, Inc.|7 Ardsley Ct.|Princeton|New Jersey|8550|United States",
                "orphan_designation": {
                    "original_text": "Treatment of symptomatic enteroviral infection in the neonate",
                    "umls_id": "C0014378,C0854706",
                    "parsed_text": "Enteroviral infection , infection in the neonate"
                }
            }
        ]
    },
    {
        "_id": "VAZJLPXFVQHDFB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 20977,
                "inchl_key": "VAZJLPXFVQHDFB-UHFFFAOYSA-N",
                "generic_name": "polyhexanide",
                "designated_date": "11/06/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Societ\u0809ndustria Farmaceutica Italiana S.p.A.|36 Via Ercole Patti|Lavinaio|Sicilia|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of Acanthamoeba keratitis",
                    "umls_id": "C0000880",
                    "parsed_text": "Acanthamoeba Keratitis"
                }
            }
        ]
    },
    {
        "_id": "FASDKYOPVNHBLU-ZETCQYMHSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 119570,
                "inchl_key": "FASDKYOPVNHBLU-ZETCQYMHSA-N",
                "generic_name": "pramipexole",
                "designated_date": "01/31/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Boehringer-Ingelheim Pharmaceuticals, Inc.|900 Ridgebury Road|Ridgefield|Connecticut|6877|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Tourette's syndrome in pediatric patients",
                    "umls_id": "C0040517",
                    "parsed_text": "Tourette's Syndrome"
                }
            }
        ]
    },
    {
        "_id": "GJOHLWZHWQUKAU-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6135,
                "inchl_key": "GJOHLWZHWQUKAU-UHFFFAOYSA-N",
                "generic_name": "Primaquine phosphate",
                "designated_date": "07/23/1993",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sanofi Winthrop, Inc.|90 Park Avenue|New York|New York|10016|United States",
                "orphan_designation": {
                    "original_text": "For use in combination with clindamycin hydrochloride in the treatment of Pneumocystis carinii pneumonia associated with AIDS.",
                    "umls_id": "C0276527,C1535939",
                    "parsed_text": "Pneumonia associated with AIDS , Pneumocystis carinii Pneumonia"
                }
            }
        ]
    },
    {
        "_id": "DERJYEZSLHIUKF-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9703,
                "inchl_key": "DERJYEZSLHIUKF-UHFFFAOYSA-N",
                "generic_name": "Procarbazine HCl",
                "designated_date": "08/08/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Leadiant Biosciences, Inc.|9841 Washingtonian Boulevard|Suite 500|Gaithersburg|Maryland|20878|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls_id": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            }
        ]
    },
    {
        "_id": "WKSAUQYGYAYLPV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 4993,
                "inchl_key": "WKSAUQYGYAYLPV-UHFFFAOYSA-N",
                "generic_name": "pyrimethamine",
                "designated_date": "08/16/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ExSAR Corporation|11 Deer Park Drive|Monmouth Junction|New Jersey|8852|United States",
                "orphan_designation": {
                    "original_text": "Treatment of GM-2 gangliosidoses (Tay-Sachs disease and Sandhoff disease).",
                    "umls_id": "C0017083,C0036161,C0039373",
                    "parsed_text": "Gangliosidoses , Sandhoff Disease , Tay-Sachs Disease"
                }
            }
        ]
    },
    {
        "_id": "MQXWPWOCXGARRK-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 67454400,
                "inchl_key": "MQXWPWOCXGARRK-UHFFFAOYSA-N",
                "generic_name": "Reldesemtiv",
                "designated_date": "12/11/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Cytokinetics, Inc.|280 East Grand Avenue|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Amyotrophic lateral sclerosis",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "PWOQRKCAHTVFLB-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 22420,
                "inchl_key": "PWOQRKCAHTVFLB-UHFFFAOYSA-N",
                "generic_name": "Revimmune",
                "designated_date": "02/18/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Accentia Biopharmaceuticals|324 South Hyde Park Avenue #350|Tampa|Florida|33606|United States",
                "orphan_designation": {
                    "original_text": "Treatment of autoimmune hemolytic anemia.",
                    "umls_id": "C0002880",
                    "parsed_text": "Autoimmune hemolytic anemia"
                }
            }
        ]
    },
    {
        "_id": "BUROJSBIWGDYCN-MWBWAFHZSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 137704508,
                "inchl_key": "BUROJSBIWGDYCN-MWBWAFHZSA-N",
                "generic_name": "ridaforolimus",
                "designated_date": "08/12/2005",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Merck Sharp & Dohme Corp.|Merck & Co., Inc. Subsidiary|P. Box 1000, UG-2C50|North Wales|Oregon|19454|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcoma",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            }
        ]
    },
    {
        "_id": "BUROJSBIWGDYCN-BPIPWEEESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 137303705,
                "inchl_key": "BUROJSBIWGDYCN-BPIPWEEESA-N",
                "generic_name": "ridaforolimus",
                "designated_date": "08/12/2005",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Merck Sharp & Dohme Corp.|Merck & Co., Inc. Subsidiary|P. Box 1000, UG-2C50|North Wales|Oregon|19454|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcoma",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            }
        ]
    },
    {
        "_id": "BUROJSBIWGDYCN-GAFNQWMWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 133268486,
                "inchl_key": "BUROJSBIWGDYCN-GAFNQWMWSA-N",
                "generic_name": "ridaforolimus",
                "designated_date": "08/12/2005",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Merck Sharp & Dohme Corp.|Merck & Co., Inc. Subsidiary|P. Box 1000, UG-2C50|North Wales|Oregon|19454|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcoma",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            }
        ]
    },
    {
        "_id": "BUROJSBIWGDYCN-AFTOUBNRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 87423409,
                "inchl_key": "BUROJSBIWGDYCN-AFTOUBNRSA-N",
                "generic_name": "ridaforolimus",
                "designated_date": "08/12/2005",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Merck Sharp & Dohme Corp.|Merck & Co., Inc. Subsidiary|P. Box 1000, UG-2C50|North Wales|Oregon|19454|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcoma",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            }
        ]
    },
    {
        "_id": "BUROJSBIWGDYCN-QSRQGROMSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 86289926,
                "inchl_key": "BUROJSBIWGDYCN-QSRQGROMSA-N",
                "generic_name": "ridaforolimus",
                "designated_date": "08/12/2005",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Merck Sharp & Dohme Corp.|Merck & Co., Inc. Subsidiary|P. Box 1000, UG-2C50|North Wales|Oregon|19454|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcoma",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            }
        ]
    },
    {
        "_id": "BUROJSBIWGDYCN-OZFXDLPUSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 74787553,
                "inchl_key": "BUROJSBIWGDYCN-OZFXDLPUSA-N",
                "generic_name": "ridaforolimus",
                "designated_date": "08/12/2005",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Merck Sharp & Dohme Corp.|Merck & Co., Inc. Subsidiary|P. Box 1000, UG-2C50|North Wales|Oregon|19454|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcoma",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            }
        ]
    },
    {
        "_id": "BUROJSBIWGDYCN-QVXCGEACSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71308311,
                "inchl_key": "BUROJSBIWGDYCN-QVXCGEACSA-N",
                "generic_name": "ridaforolimus",
                "designated_date": "08/12/2005",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Merck Sharp & Dohme Corp.|Merck & Co., Inc. Subsidiary|P. Box 1000, UG-2C50|North Wales|Oregon|19454|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcoma",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            }
        ]
    },
    {
        "_id": "BUROJSBIWGDYCN-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71433797,
                "inchl_key": "BUROJSBIWGDYCN-UHFFFAOYSA-N",
                "generic_name": "ridaforolimus",
                "designated_date": "08/12/2005",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Merck Sharp & Dohme Corp.|Merck & Co., Inc. Subsidiary|P. Box 1000, UG-2C50|North Wales|Oregon|19454|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcoma",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            }
        ]
    },
    {
        "_id": "BUROJSBIWGDYCN-QHPXJTPRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 25199957,
                "inchl_key": "BUROJSBIWGDYCN-QHPXJTPRSA-N",
                "generic_name": "ridaforolimus",
                "designated_date": "08/12/2005",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Merck Sharp & Dohme Corp.|Merck & Co., Inc. Subsidiary|P. Box 1000, UG-2C50|North Wales|Oregon|19454|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcoma",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            }
        ]
    },
    {
        "_id": "BUROJSBIWGDYCN-GAUTUEMISA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11520894,
                "inchl_key": "BUROJSBIWGDYCN-GAUTUEMISA-N",
                "generic_name": "ridaforolimus",
                "designated_date": "08/12/2005",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Merck Sharp & Dohme Corp.|Merck & Co., Inc. Subsidiary|P. Box 1000, UG-2C50|North Wales|Oregon|19454|United States",
                "orphan_designation": {
                    "original_text": "Treatment of soft tissue sarcoma",
                    "umls_id": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            }
        ]
    },
    {
        "_id": "GROMEQPXDKRRIE-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 9799487,
                "inchl_key": "GROMEQPXDKRRIE-UHFFFAOYSA-N",
                "generic_name": "rimeporide",
                "designated_date": "09/19/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EspeRare Foundation|14, Ch des Aulx|Plan-les-Ouates|Gen\u8da5|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of Duchenne muscular dystrophy",
                    "umls_id": "C0013264",
                    "parsed_text": "DUCHENNE MUSCULAR DYSTROPHY"
                }
            }
        ]
    },
    {
        "_id": "KNUXHTWUIVMBBY-JRJYXWDASA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135537060,
                "inchl_key": "KNUXHTWUIVMBBY-JRJYXWDASA-N",
                "generic_name": "Rintatolimod",
                "designated_date": "12/17/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AIM ImmunoTech Inc.|2117 SW Highway 484|Ocala|Florida|34473|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pancreatic Cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "FZVMMANVVHMVBM-OIXLVLAFSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 70693548,
                "inchl_key": "FZVMMANVVHMVBM-OIXLVLAFSA-N",
                "generic_name": "rusalatide acetate",
                "designated_date": "09/07/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Chrysalis BioTherapeutics, Inc.|2200 Market Street|Suite 609|Galveston|Texas|77550|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute radiation syndrome (ARS)",
                    "umls_id": "C0520799",
                    "parsed_text": "Acute Radiation Syndrome"
                }
            }
        ]
    },
    {
        "_id": "AHMIRVCNZZUANP-LPBAWZRYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 91668177,
                "inchl_key": "AHMIRVCNZZUANP-LPBAWZRYSA-N",
                "generic_name": "rusalatide acetate",
                "designated_date": "09/07/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Chrysalis BioTherapeutics, Inc.|2200 Market Street|Suite 609|Galveston|Texas|77550|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute radiation syndrome (ARS)",
                    "umls_id": "C0520799",
                    "parsed_text": "Acute Radiation Syndrome"
                }
            }
        ]
    },
    {
        "_id": "KQXDHUJYNAXLNZ-XQSDOZFQSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 3085092,
                "inchl_key": "KQXDHUJYNAXLNZ-XQSDOZFQSA-N",
                "generic_name": "Salinomycin",
                "designated_date": "12/12/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hillstream Biopharma, Inc.|245 Main Street|Suite 204|Chester|New Jersey|7930|United States",
                "orphan_designation": {
                    "original_text": "Treatment of small cell lung cancer",
                    "umls_id": "C3540630",
                    "parsed_text": "Small Cell Lung Cancer"
                }
            }
        ]
    },
    {
        "_id": "GMBQZIIUCVWOCD-WWASVFFGSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 92095,
                "inchl_key": "GMBQZIIUCVWOCD-WWASVFFGSA-N",
                "generic_name": "sarsasapogenin",
                "designated_date": "06/18/2004",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Phytopharm plc|Corpus Christi House|Godmanchester|Cambridgeshire|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis (ALS)",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "BTGNGJJLZOIYID-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 107706,
                "inchl_key": "BTGNGJJLZOIYID-UHFFFAOYSA-N",
                "generic_name": "Sivelestat",
                "designated_date": "01/27/2021",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical|c/o Noa Avtalion|161 Jefferson Avenue|Tenafly|New Jersey|07670-1627|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Acute Radiation Syndrome",
                    "umls_id": "C0520799",
                    "parsed_text": "Acute Radiation Syndrome"
                }
            },
            {
                "compound_id": 107706,
                "inchl_key": "BTGNGJJLZOIYID-UHFFFAOYSA-N",
                "generic_name": "sivelestat",
                "designated_date": "06/05/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RNR BioMedical Inc.|c/o Noa Avtalion|161 Jefferson Av|Tenefly|New Jersey|7670|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastric cancer",
                    "umls_id": "C0024623",
                    "parsed_text": "Gastric Cancer"
                }
            }
        ]
    },
    {
        "_id": "QUMMZNCRRKUJLQ-ZMGJSDJYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 71680544,
                "inchl_key": "QUMMZNCRRKUJLQ-ZMGJSDJYSA-M",
                "generic_name": "Sodium (4Z,7Z,10R,11E,13E,15Z,17S,19Z) 10,17-dihydroxy-docosa-4,7,11,13,15,19-hexaenoate",
                "designated_date": "03/30/2020",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Anida Pharma Inc.|155 Brookline Street, Suite 005|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Prevention of retinopathy of prematurity",
                    "umls_id": "C0035344",
                    "parsed_text": "Retinopathy of Prematurity"
                }
            }
        ]
    },
    {
        "_id": "UKLNMMHNWFDKNT-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 23668197,
                "inchl_key": "UKLNMMHNWFDKNT-UHFFFAOYSA-M",
                "generic_name": "sodium chlorite",
                "designated_date": "08/22/2011",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neuraltus Pharmaceuticals, Inc.|1111 Bayhill Drive|Suite 210|San Bruno|California|94066|United States",
                "orphan_designation": {
                    "original_text": "For slowing the progression of amyotrophic lateral sclerosis.",
                    "umls_id": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "GCQYYIHYQMVWLT-HQNLTJAPSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5282192,
                "inchl_key": "GCQYYIHYQMVWLT-HQNLTJAPSA-N",
                "generic_name": "Sorivudine",
                "designated_date": "11/09/1995",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb|5 Research Parkway|P.O. Box 5100|Wallingford|Connecticut|6492|United States",
                "orphan_designation": {
                    "original_text": "Treatment of herpes zoster (shingles) in immunocompromised patients",
                    "umls_id": "C0019360,C4553551",
                    "parsed_text": "Zoster , Shingles"
                }
            }
        ]
    },
    {
        "_id": "TXEIIPDJKFWEEC-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 11001318,
                "inchl_key": "TXEIIPDJKFWEEC-UHFFFAOYSA-N",
                "generic_name": "tafamidis",
                "designated_date": "05/23/2006",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Pfizer, Inc.|P. O. Box 8299|Philadelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of familial amyloid polyneuropathy",
                    "umls_id": "C0206245",
                    "parsed_text": "Familial Amyloid Polyneuropathy"
                }
            }
        ]
    },
    {
        "_id": "NYQPLPNEESYGNO-IBGZPJMESA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 130731,
                "inchl_key": "NYQPLPNEESYGNO-IBGZPJMESA-N",
                "generic_name": "Talotrexin",
                "designated_date": "05/08/2006",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hana Biosciences, Inc.|7000 Shoreline Court|Suite 370|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute lymphoblastic leukemia",
                    "umls_id": "C0023449",
                    "parsed_text": "Acute lymphoblastic leukemia"
                }
            }
        ]
    },
    {
        "_id": "MODVSQKJJIBWPZ-VLLPJHQWSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 6918574,
                "inchl_key": "MODVSQKJJIBWPZ-VLLPJHQWSA-N",
                "generic_name": "tesetaxel",
                "designated_date": "12/22/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genta Inc.|200 Connell Drive|Berkeley Heights|New Jersey|7922|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastric cancer",
                    "umls_id": "C0024623",
                    "parsed_text": "Gastric Cancer"
                }
            },
            {
                "compound_id": 6918574,
                "inchl_key": "MODVSQKJJIBWPZ-VLLPJHQWSA-N",
                "generic_name": "tesetaxel",
                "designated_date": "11/21/2008",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genta, Inc.|200 Connell Drive|Berkley Heights|New Jersey|7922|United States",
                "orphan_designation": {
                    "original_text": "Treatment of stages IIB, IIC, III, and stage IV melanoma",
                    "umls_id": "C0278883,C4521788,C4553416",
                    "parsed_text": "stage iv melanoma , IIB , IIC"
                }
            }
        ]
    },
    {
        "_id": "JTVPZMFULRWINT-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5467,
                "inchl_key": "JTVPZMFULRWINT-UHFFFAOYSA-N",
                "generic_name": "Tiapride",
                "designated_date": "04/21/1998",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Sanofi-Synthelabo, Inc.|9 Great Valley Parkway|PO Box 3026|Malvern|Pennsylvania|19355|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Tourette's syndrome.",
                    "umls_id": "C0040517",
                    "parsed_text": "Tourette's Syndrome"
                }
            }
        ]
    },
    {
        "_id": "URLYINUFLXOMHP-HTVVRFAVSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 43860,
                "inchl_key": "URLYINUFLXOMHP-HTVVRFAVSA-N",
                "generic_name": "Triciribine phosphate",
                "designated_date": "04/24/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Prescient Therapeutics LTD|2644 North Kitty Hawk Drive|Palm Springs|California|92262|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia",
                    "umls_id": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "OKHMDSCYUWAQPT-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 71434,
                "inchl_key": "OKHMDSCYUWAQPT-UHFFFAOYSA-N",
                "generic_name": "trientine tetrahydrochloride",
                "designated_date": "03/10/2016",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orphalan|226 boulevard Voltaire|Paris|75011|France",
                "orphan_designation": {
                    "original_text": "treatment of Wilsons disease",
                    "umls_id": "C0019202",
                    "parsed_text": "Wilsons Disease"
                }
            }
        ]
    },
    {
        "_id": "IYFNEFQTYQPVOC-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 135413547,
                "inchl_key": "IYFNEFQTYQPVOC-UHFFFAOYSA-N",
                "generic_name": "udenafil",
                "designated_date": "08/31/2015",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mezzion Pharma Co. Ltd.|3rd Floor C & H Building|Gangnam-gu 135-879|Seoul|South Korea",
                "orphan_designation": {
                    "original_text": "Treatment of single ventricle congenital heart disease with Fontan physiology",
                    "umls_id": "C0152021,C0152424",
                    "parsed_text": "Congenital heart disease , Single ventricle"
                }
            }
        ]
    },
    {
        "_id": "HUASEDVYRABWCV-NDEPHWFRSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 90937527,
                "inchl_key": "HUASEDVYRABWCV-NDEPHWFRSA-N",
                "generic_name": "upamostat",
                "designated_date": "10/16/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RedHill Biopharma Ltd.|21 Ha'arba'a Street|Tel Aviv-Yafo|Tel Aviv District|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 90937527,
                "inchl_key": "HUASEDVYRABWCV-NDEPHWFRSA-N",
                "generic_name": "upamostat",
                "designated_date": "10/16/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RedHill Biopharma Ltd.|21 Ha'arba'a Street|Tel Aviv-Yafo|Tel Aviv District|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "compound_id": 90937527,
                "inchl_key": "HUASEDVYRABWCV-NDEPHWFRSA-N",
                "generic_name": "upamostat",
                "designated_date": "10/16/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RedHill Biopharma Ltd.|21 Ha'arba'a Street|Tel Aviv-Yafo|Tel Aviv District|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "HUASEDVYRABWCV-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 72754524,
                "inchl_key": "HUASEDVYRABWCV-UHFFFAOYSA-N",
                "generic_name": "upamostat",
                "designated_date": "10/16/2017",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "RedHill Biopharma Ltd.|21 Ha'arba'a Street|Tel Aviv-Yafo|Tel Aviv District|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls_id": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "ZOCKGBMQLCSHFP-KQRAQHLDSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 454216,
                "inchl_key": "ZOCKGBMQLCSHFP-KQRAQHLDSA-N",
                "generic_name": "Valrubicin",
                "trade_name": "Valstar",
                "designated_date": "05/23/1994",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For intravesical therapy of BCG-refractory carcinoma in situ of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.",
                "marketing_approval_date": "\u00a009/25/1998\u00a0",
                "exclusivity_end_date": "\u00a009/25/2005\u00a0",
                "sponsor": "Anthra Pharmaceuticals, Inc.|103 Carnegie Center, Suite 102|Princeton|New Jersey|8540|United States",
                "orphan_designation": {
                    "original_text": "Treatment of carcinoma in situ of the urinary bladder.",
                    "umls_id": "C4551642",
                    "parsed_text": "Carcinoma in situ of the Urinary Bladder"
                }
            }
        ]
    },
    {
        "_id": "BHLXTPHDSZUFHR-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 155815,
                "inchl_key": "BHLXTPHDSZUFHR-UHFFFAOYSA-N",
                "generic_name": "Varespladib",
                "designated_date": "03/25/2019",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ophirex, Inc.|5643 Paradise Dr #2|Corte Madera|California|94925|United States",
                "orphan_designation": {
                    "original_text": "Treatment of snakebite",
                    "umls_id": "C0037379",
                    "parsed_text": "Snakebite"
                }
            }
        ]
    },
    {
        "_id": "XZZUHXILQXLTGV-UHFFFAOYSA-M",
        "Orphan Drug Designations": [
            {
                "compound_id": 23674730,
                "inchl_key": "XZZUHXILQXLTGV-UHFFFAOYSA-M",
                "generic_name": "varespladib sodium",
                "designated_date": "11/19/2007",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Anthera Pharmaceuticals, Inc.|25801 Industrial Blvd.|Suite B|Hayward|California|94545|United States",
                "orphan_designation": {
                    "original_text": "Prevention of acute chest syndrome in at-risk patients with sickle cell disease",
                    "umls_id": "C0002895,C0742343",
                    "parsed_text": "Sickle Cell Disease , Acute Chest Syndrome"
                }
            }
        ]
    },
    {
        "_id": "VBUWHHLIZKOSMS-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 16129679,
                "inchl_key": "VBUWHHLIZKOSMS-UHFFFAOYSA-N",
                "generic_name": "Vasoactive intestinal polypeptide",
                "designated_date": "06/23/1993",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Research Triangle Pharmaceuticals|200 Westpark Corporate Center|4364 South Alston Avenue|Durham|North Carolina|27713|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute esophageal food impaction.",
                    "umls_id": "C1695984",
                    "parsed_text": "Esophageal food impaction"
                }
            }
        ]
    },
    {
        "_id": "PJDFLNIOAUIZSL-UHFFFAOYSA-N",
        "Orphan Drug Designations": [
            {
                "compound_id": 5665,
                "inchl_key": "PJDFLNIOAUIZSL-UHFFFAOYSA-N",
                "generic_name": "vigabatrin",
                "trade_name": "Sabril",
                "designated_date": "06/12/2000",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For infantile spasms (IS) - 1 month to 2 years of age.",
                "marketing_approval_date": "\u00a008/21/2009\u00a0",
                "exclusivity_end_date": "\u00a008/21/2016\u00a0",
                "sponsor": "H. Lundbeck A/S|Four Parkway North|Deerfield|Illinois|60015|United States",
                "orphan_designation": {
                    "original_text": "Treatment of infantile spasms.",
                    "umls_id": "C3887898",
                    "parsed_text": "Infantile spasms"
                }
            }
        ]
    }
]